PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Kakizaki, K; Yamauchi, H				Kakizaki, K; Yamauchi, H			Hepatic venous obstruction by a membranes web	NEW ENGLAND JOURNAL OF MEDICINE			English	Article											Kakizaki, K (corresponding author), SENDAI NATL HOSP,SENDAI,MIYAGI 983,JAPAN.								0	0	0	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 9	1996	334	19					1237	1237		10.1056/NEJM199605093341905	http://dx.doi.org/10.1056/NEJM199605093341905			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UJ054	8606719				2022-12-28	WOS:A1996UJ05400005
J	Lowe, LA; Supp, DM; Sampath, K; Yokoyama, T; Wright, CVE; Potter, SS; Overbeek, P; Kuehn, MR				Lowe, LA; Supp, DM; Sampath, K; Yokoyama, T; Wright, CVE; Potter, SS; Overbeek, P; Kuehn, MR			Conserved left-right asymmetry of nodal expression and alterations in murine situs inversus	NATURE			English	Article							MOUSE; LATERALITY; SIDEDNESS; REVERSAL	VERTEBRATES have characteristic and conserved left-right (L-R) visceral asymmetries, for example the left-sided heart. In humans, alterations of L-R development can have serious clinical implications, including cardiac defects(1). Although little is known about how the embryonic L-R axis is established, a recent study in the chick embryo revealed L-R asymmetric expression of several previously cloned genes, including Cnr-1 (for chicken nodal-related-1), and indicated how this L-R molecular asymmetry might be important for subsequent visceral morphogenesis(2). Here we show that nodal(3) is asymmetrically expressed in mice at similar stages, as is Xnr-1 (for Xenopus nodal related-1)(4) in frogs. We also examine nodal expression in two mouse mutations that perturb L-R development, namely situs inversus viscerum (iv)(5), in which assignment of L-R asymmetry is apparently random and individuals develop either normally or are mirror-image-reverse (situs inversus), and inversion of embryonic turning (inv)(6), in which all individuals develop with situs inversus. In both, nodal expression is strikingly affected, being reversed or converted to symmetry. These results further support a key role for nodal and nodal-related genes in interpreting and relaying L-R patterning information in vertebrates. To our knowledge, our results provide the first direct evidence that iv and inv normally function well before the appearance of morphological L-R asymmetry.	NCI,EXPTL IMMUNOL BRANCH,NIH,BETHESDA,MD 20892; UNIV CINCINNATI,CHILDRENS HOSP RES FDN,DIV DEV BIOL,CINCINNATI,OH 45229; VANDERBILT UNIV,SCH MED,DEPT CELL BIOL,NASHVILLE,TN 37232; BAYLOR COLL MED,DEPT CELL BIOL,HOUSTON,TX 77030	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Research Foundation; University System of Ohio; University of Cincinnati; Vanderbilt University; Baylor College of Medicine			Supp, Dorothy/ABQ-7999-2022; Kuehn, Michael R/A-4573-2014	Supp, Dorothy/0000-0002-2429-6630; Kuehn, Michael R/0000-0002-7703-9160; Sampath, Karuna/0000-0002-0729-1977; Overbeek, Paul/0000-0001-9784-2084				BROWN NA, 1990, DEVELOPMENT, V109, P1; BROWN NA, 1989, DEVELOPMENT, V107, P637; BURN J, 1991, CIBA F SYMP, V162, P282; CONLON FL, 1994, DEVELOPMENT, V120, P1919; DANOS MC, 1995, DEVELOPMENT, V121, P1467; FUJINAGA M, 1994, DEV BIOL, V162, P558, DOI 10.1006/dbio.1994.1109; FUJINAGA M, 1991, TERATOLOGY, V44, P453, DOI 10.1002/tera.1420440411; HARLAND RM, 1991, METHOD CELL BIOL, V36, P685; HENRIQUE D, 1995, NATURE, V375, P787, DOI 10.1038/375787a0; HOGAN B, 1994, MANIPULATING MOUSE E, P357; JONES CM, 1995, DEVELOPMENT, V121, P3651; KLAR AJS, 1994, TRENDS GENET, V10, P392, DOI 10.1016/0168-9525(94)90055-8; LAYTON WM, 1976, J HERED, V67, P336, DOI 10.1093/oxfordjournals.jhered.a108749; LEVIN M, 1995, CELL, V82, P803, DOI 10.1016/0092-8674(95)90477-8; METZLER M, 1994, EMBO J, V13, P2056, DOI 10.1002/j.1460-2075.1994.tb06480.x; PANSERA F, 1994, MED HYPOTHESES, V42, P283, DOI 10.1016/0306-9877(94)90134-1; SEO JW, 1992, CIRCULATION, V86, P642, DOI 10.1161/01.CIR.86.2.642; SMITH WC, 1995, CELL, V82, P37, DOI 10.1016/0092-8674(95)90050-0; VANDERHOEVEN F, 1994, DEVELOPMENT, V120, P2601; YOKOYAMA T, 1993, SCIENCE, V260, P679, DOI 10.1126/science.8480178; YOST HJ, 1995, CELL, V82, P689, DOI 10.1016/0092-8674(95)90464-6; YOST HJ, 1990, DEVELOPMENT, V110, P865; YOST HJ, 1992, NATURE, V357, P158, DOI 10.1038/357158a0; ZHOU XL, 1993, NATURE, V361, P543, DOI 10.1038/361543a0	24	402	418	0	34	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAY 9	1996	381	6578					158	161		10.1038/381158a0	http://dx.doi.org/10.1038/381158a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UK139	8610013	Green Submitted			2022-12-28	WOS:A1996UK13900050
J	Malaviya, R; Ikeda, T; Ross, E; Abraham, SN				Malaviya, R; Ikeda, T; Ross, E; Abraham, SN			Mast cell modulation of neutrophil influx and bacterial clearance at sites of infection through TNF-alpha	NATURE			English	Article							TUMOR-NECROSIS-FACTOR; KLEBSIELLA-PNEUMONIAE; MICE; INFLAMMATION; RECRUITMENT; PERITONITIS; MOUSE	ALTHOUGH mast cells have been implicated in a variety of inflammatory conditions including immediate hypersensitivity and interstitial cystitis,(1,2) their physiological role in the body is unknown. We investigated the role of mast cells in host defence against bacterial infections using a well characterized mast-cell-deficiency mouse model(3,4). We report here that mast cells, which are selectively located at portals of bacterial entry, are important to host defence. Mast-cell-deficient WBB6F1-W/W-v mice (W/W-v) were up to 20-fold less efficient in clearing enterobacteria than WBB6F1+/+ (+/+)mice or mast-cell-reconstituted W/W-v (W/W-v + MC) mice. With higher bacterial inocula, only W/W-v mice died (80%). The limited bacterial clearance in W/W-v mice directly correlated with impaired neutrophil influx. The mast-cell chemoattractant TNF-alpha was implicated in the neutrophil response because TNF-alpha was locally released only in +/+ and W/W-v + MC mice, TNF-alpha-specific antibodies blocked over 70% of the neutrophil influx, and purified mast cells released TNF-alpha upon incubation with bacteria. Additionally, the type-1 fimbrial subunit, FimH, was the necessary enterobacterial component for mast-cell activation and neutrophil influx because an isogenic FimH(-) mutant evoked a limited neutrophil response in +/+ mice compared to wild-type bacteria.	WASHINGTON UNIV,BARNES JEWISH HOSP,SCH MED,DEPT PATHOL,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT PATHOL,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT MOLEC MICROBIOL,ST LOUIS,MO 63110; AZABU UNIV,DEPT VET MICROBIOL,KANAGAWA,JAPAN	Barnes-Jewish Hospital; Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Azabu University								ABRAHAM SN, 1988, NATURE, V336, P682, DOI 10.1038/336682a0; ARNOLD JW, 1993, MICROB PATHOGENESIS, V14, P217, DOI 10.1006/mpat.1993.1021; BIENENSTOCK J, 1982, J ALLERGY CLIN IMMUN, V70, P407, DOI 10.1016/0091-6749(82)90001-X; BRADLEY PP, 1982, J INVEST DERMATOL, V78, P206, DOI 10.1111/1523-1747.ep12506462; ECHTENACHER B, 1990, J IMMUNOL, V145, P3762; ESPOSITO AL, 1987, AM REV RESPIR DIS, V135, P676; GALLI SJ, 1993, NEW ENGL J MED, V328, P257; GERLACH GF, 1989, J BACTERIOL, V171, P1262, DOI 10.1128/jb.171.3.1262-1270.1989; GORDON JR, 1991, J EXP MED, V174, P103, DOI 10.1084/jem.174.1.103; KITAMURA Y, 1978, BLOOD, V52, P447; KITAMURA Y, 1979, J EXP MED, V150, P482, DOI 10.1084/jem.150.3.482; MADISON B, 1994, INFECT IMMUN, V62, P843, DOI 10.1128/IAI.62.3.843-848.1994; MALAVIYA R, 1994, J CLIN INVEST, V93, P1645, DOI 10.1172/JCI117146; MALAVIYA R, 1994, J IMMUNOL, V152, P1907; Malaviya R, 1996, J IMMUNOL, V156, P1490; MALONE DG, 1988, ANN ALLERGY, V61, P27; NAKANO T, 1985, J EXP MED, V162, P1025, DOI 10.1084/jem.162.3.1025; NATANSON C, 1994, ANN INTERN MED, V120, P771, DOI 10.7326/0003-4819-120-9-199405010-00009; OFEK I, 1993, INFECT IMMUN, V61, P4208, DOI 10.1128/IAI.61.10.4208-4216.1993; SHEEHAN KCF, 1989, J IMMUNOL, V142, P3884; SUZUKI N, 1993, AM J RESP CELL MOL, V9, P475, DOI 10.1165/ajrcmb/9.5.475; VASSALLI P, 1992, ANNU REV IMMUNOL, V10, P411, DOI 10.1146/annurev.iy.10.040192.002211; WERSHIL BK, 1991, J CLIN INVEST, V87, P446, DOI 10.1172/JCI115016; ZHANG Y, 1992, SCIENCE, V258, P1957, DOI 10.1126/science.1470922	24	911	943	0	26	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAY 2	1996	381	6577					77	80		10.1038/381077a0	http://dx.doi.org/10.1038/381077a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UJ053	8609993				2022-12-28	WOS:A1996UJ05300060
J	Haddad, KM; Cassel, CK; Berenson, RA; Bertram, PD; Altus, P; McLean, A; LavizzoMourey, RJ; Fogarty, WM; Gullen, DJ; Gary, NE; Latos, DL; HerbertCarter, J; Webster, J; Honsiger, R				Haddad, KM; Cassel, CK; Berenson, RA; Bertram, PD; Altus, P; McLean, A; LavizzoMourey, RJ; Fogarty, WM; Gullen, DJ; Gary, NE; Latos, DL; HerbertCarter, J; Webster, J; Honsiger, R			Voluntary purchasing pools: A market model for improving access, quality, and cost in health care	ANNALS OF INTERNAL MEDICINE			English	Article								States and small businesses have been rapidly establishing voluntary health care purchasing pools during the past few yea rs. Purchasing pools can decrease health care costs, improve access for some small businesses and individual persons, allow greater choice among health care plans, and provide continuity of care. Purchasing pools also help to even the balance of power in the health care marketplace, which has come increasingly under the control of huge proprietary managed care corporations. This position paper of the American College of Physicians discusses how a system of well-designed voluntary purchasing pools can help protect the integrity of health care in the emerging managed care marketplace.										*AM AC ACT, 1993, HLTH RISK ASS HLTH R; CURTIS RE, 1994, SUBSIDIES MEANT HLTH; ENTHOVEN AC, 1993, HEALTH AFFAIR, V12, P24, DOI 10.1377/hlthaff.12.suppl_1.24; ENTHOVEN AC, 1993, HEALTH AFFAIR, V12, P27, DOI 10.1377/hlthaff.12.3.27; GLASSBERG T, 1993, GOVERNORS GUIDE FORM; HALL WJ, 1993, HEALTH AFFAIR, V12, P58, DOI 10.1377/hlthaff.12.1.58; HOY EW, 1994, HLTH REFORM ALLOW PE; *I HLTH POL SOL, 1994, COMP SMALL EMPL PURC; *I HLTH POL SOL, 1995, KEY STAT PURCH COOP; *KAIS FAM FDN, 1994, KAIS KPMG PET MARW E; *KAIS FAM FDN COMM, 1993, HLTH INS SURV; KRONICK R, 1994, RISK ADJUSTMENT VULN; LADENHEIM K, 1994, HLTH CARE REFORM 50; MOORE M, 1993, GOVENORS GUIDE FORMI; *PHYS PAYM REV COM, 1994, ANN REP C; *PHYS PAYM REV COM, 1995, ANN REP C; Scott HD, 1992, ANN INTERN MED, V117, P511, DOI 10.7326/0003-4819-117-6-511; STONE DA, 1994, POLITICS HLTH CARE R; *US GEN ACC OFF, 1993, ACC HLTH INS PUBL PR; WICKS EK, DESIGNING PURCHASING; WOOLSEY C, 1992, BUSINESS INSURANCE, V25, P1; ZELMAN WA, 1993, HEALTH AFFAIR, V12, P49, DOI 10.1377/hlthaff.12.suppl_1.49; 1996, IN PRESS ANN INTERN	23	3	3	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572	0003-4819			ANN INTERN MED	Ann. Intern. Med.	MAY 1	1996	124	9					845	853						9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	UG254	8610956				2022-12-28	WOS:A1996UG25400011
J	OShaughnessy, JA				OShaughnessy, JA			Chemoprevention of breast cancer	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							TAMOXIFEN TREATMENT; ADJUVANT TAMOXIFEN; CARCINOMA INSITU; RISK; EXPRESSION; RECEPTOR; TUMORS; WOMEN; TRIAL; RAT				OShaughnessy, JA (corresponding author), NCI, MED BRANCH, NATL INST HLTH, BLDG 10, ROOM 12N226, BETHESDA, MD 20892 USA.							ALPERS CE, 1985, HUM PATHOL, V16, P796, DOI 10.1016/S0046-8177(85)80251-3; ANZANO MA, 1994, CANCER RES, V54, P4614; BACUS SS, 1990, MOL CARCINOGEN, V3, P350, DOI 10.1002/mc.2940030607; BOONE CW, 1993, J CELL BIOCHEM, P37; BURING JE, 1994, P CHEM AG DRUG DEV S; BUTTA A, 1992, CANCER RES, V52, P4261; CHRISTOV K, 1994, J CELL BIOCHEM, P165; CLAUS EB, 1994, CANCER, V73, P643, DOI 10.1002/1097-0142(19940201)73:3<643::AID-CNCR2820730323>3.0.CO;2-5; DEPALO G, 1995, J NATL CANCER I, V87, P146, DOI 10.1093/jnci/87.2.146; DRAPER MW, IN PRESS P 4 INT S O; DUPONT WD, 1985, NEW ENGL J MED, V312, P146, DOI 10.1056/NEJM198501173120303; DUPONT WD, 1989, HUM PATHOL, V20, P723, DOI 10.1016/0046-8177(89)90063-4; ERIKSSON ET, 1994, HUM PATHOL, V25, P1228, DOI 10.1016/0046-8177(94)90040-X; Ernster VL, 1996, JAMA-J AM MED ASSOC, V275, P913, DOI 10.1001/jama.275.12.913; FABIAN CJ, 1993, J CELL BIOCHEM, P153; FISHER B, 1989, NEW ENGL J MED, V320, P479, DOI 10.1056/NEJM198902233200802; FORNANDER T, 1989, LANCET, V1, P117; FRYKBERG ER, 1987, SURG GYNECOL OBSTET, V164, P285; GAIL MH, 1989, J NATL CANCER I, V81, P1879, DOI 10.1093/jnci/81.24.1879; GLICK AB, 1991, DEVELOPMENT, V111, P1081; JIRTLE RL, 1993, CANCER RES, V53, P3849; JORDAN VC, 1994, P CHEM AG DRUG DEV S, P28; KELLOFF GJ, 1993, J CELL BIOCHEM, P2; KHAN SA, 1994, CANCER RES, V54, P993; LOTAN R, 1995, NEW ENGL J MED, V332, P1405, DOI 10.1056/NEJM199505253322103; LOVE RR, 1992, NEW ENGL J MED, V326, P852, DOI 10.1056/NEJM199203263261302; MCCONATHA JT, 1993, PSYCHOL WOMEN QUART, V17, P253, DOI 10.1177/036168439301700208; MCDONALD CC, 1991, BRIT MED J, V303, P435, DOI 10.1136/bmj.303.6800.435; MCKENNA PG, 1988, BRIT J CANCER, V57, P619, DOI 10.1038/bjc.1988.141; MCKITTRICK R, 1995, P AN M AM SOC CLIN, V14, pA348; MESSINA MJ, 1994, NUTR CANCER, V21, P113, DOI 10.1080/01635589409514310; OSBORNE MP, 1993, J NATL CANCER I, V85, P1917, DOI 10.1093/jnci/85.23.1917; PAVELIC ZP, 1992, CANCER RES, V52, P2597; PIKE MC, 1993, J CELL BIOCHEM, P26; Powles T, 1996, J CLIN ONCOL, V14, P78, DOI 10.1200/JCO.1996.14.1.78; RATKO TA, 1989, CANCER RES, V49, P4472; ROSE DP, 1986, CANCER-AM CANCER SOC, V58, P2363, DOI 10.1002/1097-0142(19861201)58:11<2363::AID-CNCR2820581102>3.0.CO;2-#; Russo I H, 1993, Eur J Cancer Prev, V2 Suppl 3, P101; RUSSO IH, 1978, J NATL CANCER I, V61, P1439; RUSSO J, 1991, PROG EXP TUMOR RES, V33, P175; RUSSO J, 1982, IRCS MED SCI-BIOCHEM, V10, P935; STEWART HJ, 1987, LANCET, V2, P171; SWISSHELM K, 1994, CELL GROWTH DIFFER, V5, P133; TORRISI R, 1993, CANCER RES, V53, P4769; VANLEEUWEN FE, 1994, LANCET, V343, P448, DOI 10.1016/S0140-6736(94)92692-1; VOGEL VG, 1991, PREV MED, V20, P86, DOI 10.1016/0091-7435(91)90009-S; VOGEL VG, 1993, J CELL BIOCHEM, P257; WEINSTATSASLOW D, 1995, NAT MED, V1, P1257, DOI 10.1038/nm1295-1257; YEE D, 1989, MOL ENDOCRINOL, V3, P509, DOI 10.1210/mend-3-3-509; YOUNES M, 1995, P AM ASSOC CANC RES, V36, pA3726	50	24	25	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 1	1996	275	17					1349	1353		10.1001/jama.275.17.1349	http://dx.doi.org/10.1001/jama.275.17.1349			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UG612	8614122				2022-12-28	WOS:A1996UG61200033
J	Tosini, G; Menaker, M				Tosini, G; Menaker, M			Circadian rhythms in cultured mammalian retina	SCIENCE			English	Article							SUPRACHIASMATIC NUCLEUS; SYSTEM; MELATONIN; PINEAL; CLOCK; LESIONS; LIGHT	Many retinal functions are circadian, but in most instances the location of the clock that drives the rhythm is not known. Cultured neural retinas of the golden hamster (Mesocricetus auratus) exhibited circadian rhythms of melatonin synthesis for at least 5 days at 27 degrees C. The rhythms were entrained by light cycles applied in vitro and were free-running in constant darkness. Retinas from hamsters homozygous for the circadian mutation tau, which shortens the free-running period of the circadian activity rhythm by 4 hours, showed a shortened free-running period of melatonin synthesis. The mammalian retina contains a genetically programmed circadian oscillator that regulates its synthesis of melatonin.	UNIV VIRGINIA, DEPT BIOL, CHARLOTTESVILLE, VA 22903 USA; UNIV VIRGINIA, NATL SCI FDN CTR BIOL TIMING, CHARLOTTESVILLE, VA 22903 USA	University of Virginia; National Science Foundation (NSF); NSF - Center for Biological Timing; University of Virginia			Jansen, Heiko T./A-5770-2008	Jansen, Heiko T./0000-0003-0178-396X; tosini, gianluca/0000-0003-3645-4533	NICHD NIH HHS [HD13162] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD013162] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		CAHILL GM, 1995, PROG RETIN EYE RES, V14, P267, DOI 10.1016/1350-9462(94)00001-Y; CAHILL GM, 1991, J NEUROSCI, V11, P2959; FALCON J, 1991, CELL TISSUE RES, V265, P601, DOI 10.1007/BF00340884; JANIK DS, 1990, J COMP PHYSIOL A, V166, P811; JOHNSON ML, 1985, METHOD ENZYMOL, V117, P301; MENAKER M, 1983, P NATL ACAD SCI-BIOL, V80, P6119, DOI 10.1073/pnas.80.19.6119; MENAKER M, IN PRESS 6 SAPP S BI; OOKASOUDA S, 1993, NEUROSCI LETT, V164, P33, DOI 10.1016/0304-3940(93)90850-K; RALPH MR, 1988, SCIENCE, V241, P1225, DOI 10.1126/science.3413487; RALPH MR, 1990, SCIENCE, V247, P975, DOI 10.1126/science.2305266; REME CE, 1991, J BIOL RHYTHM, V6, P5, DOI 10.1177/074873049100600104; ROLLAG MD, 1976, ENDOCRINOLOGY, V98, P482, DOI 10.1210/endo-98-2-482; Straume M, 1991, TOPICS FLUORESCENCE, P177, DOI DOI 10.1007/B112907; TAKAHASHI JS, 1989, RECENT PROG HORM RES, V45, P279; TAKAHASHI JS, 1982, J NEUROSCI, V2, P815; TERMAN JS, 1993, BRAIN RES, V605, P256; TERMAN M, 1985, ANN NY ACAD SCI, V453, P147, DOI 10.1111/j.1749-6632.1985.tb11807.x; WELSH DK, 1995, NEURON, V14, P697, DOI 10.1016/0896-6273(95)90214-7	18	588	597	0	35	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 19	1996	272	5260					419	421		10.1126/science.272.5260.419	http://dx.doi.org/10.1126/science.272.5260.419			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UG252	8602533				2022-12-28	WOS:A1996UG25200050
J	Naldini, L; Blomer, U; Gallay, P; Ory, D; Mulligan, R; Gage, FH; Verma, IM; Trono, D				Naldini, L; Blomer, U; Gallay, P; Ory, D; Mulligan, R; Gage, FH; Verma, IM; Trono, D			In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector	SCIENCE			English	Article							VIRUS TYPE-1 RNA; RETROVIRAL VECTORS; HUMAN-LYMPHOCYTES; MAMMALIAN-CELLS; HIGH-TITER; INFECTION; DNA; EXPRESSION; PROTEIN; TROPISM	A retroviral vector system based on the human immunodeficiency virus (HIV) was developed that, in contrast to a murine leukemia virus-based counterpart, transduced heterologous sequences into HeLa cells and rat fibroblasts blocked in the cell cycle, as well as into human primary macrophages. Additionally, the HIV vector could mediate stable in vivo gene transfer into terminally differentiated neurons. The ability of HIV-based viral vectors to deliver genes in vivo into nondividing cells could increase the applicability of retroviral vectors in human gene therapy.	SALK INST BIOL STUDIES,LA JOLLA,CA 92037; WHITEHEAD INST BIOMED RES,CAMBRIDGE,MA 02142	Salk Institute; Massachusetts Institute of Technology (MIT); Whitehead Institute			Naldini, Luigi/E-9083-2012	NALDINI, Luigi/0000-0002-7835-527X	NIAID NIH HHS [AI37510] Funding Source: Medline; NIA NIH HHS [AG08514, AG10435] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI037510] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG008514, P01AG010435, R37AG008514] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		AIKEN C, 1995, J VIROL, V69, P5048, DOI 10.1128/JVI.69.8.5048-5056.1995; ALDOVINI A, 1990, J VIROL, V64, P1920, DOI 10.1128/JVI.64.5.1920-1926.1990; ANSARILARI MA, 1995, VIROLOGY, V211, P332, DOI 10.1006/viro.1995.1412; BERKOWITZ RD, 1995, VIROLOGY, V212, P718, DOI 10.1006/viro.1995.1530; BUCHSCHACHER GL, 1992, J VIROL, V66, P2731, DOI 10.1128/JVI.66.5.2731-2739.1992; BUKRINSKY MI, 1993, NATURE, V365, P666, DOI 10.1038/365666a0; BURNS JC, 1993, P NATL ACAD SCI USA, V90, P8033, DOI 10.1073/pnas.90.17.8033; BYRNES JJ, 1984, MOL CELL BIOCHEM, V62, P13; CARROLL R, 1994, J VIROL, V68, P6047, DOI 10.1128/JVI.68.9.6047-6051.1994; CHARNEAU P, 1994, J MOL BIOL, V241, P651, DOI 10.1006/jmbi.1994.1542; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; COHEN A, 1983, J BIOL CHEM, V258, P2334; CRYSTAL RG, 1995, SCIENCE, V270, P404, DOI 10.1126/science.270.5235.404; FINER MH, 1994, BLOOD, V83, P43; Gallay P, 1996, J VIROL, V70, P1027, DOI 10.1128/JVI.70.2.1027-1032.1996; GALLAY P, 1995, CELL, V80, P379, DOI 10.1016/0092-8674(95)90488-3; GALLAY P, 1995, CELL, V83, P569, DOI 10.1016/0092-8674(95)90097-7; GALLAY P, UNPUB; HEINZINGER NK, 1994, P NATL ACAD SCI USA, V91, P7311, DOI 10.1073/pnas.91.15.7311; HUBERMAN JA, 1981, CELL, V23, P647, DOI 10.1016/0092-8674(81)90426-8; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KAYE JF, 1995, J VIROL, V69, P6588, DOI 10.1128/JVI.69.10.6588-6592.1995; KIM HJ, 1994, VIROLOGY, V198, P336, DOI 10.1006/viro.1994.1037; KNOWLES RM, 1995, NEW ENGL J MED, V333, P823; LANDAU NR, 1992, J VIROL, V66, P5110, DOI 10.1128/JVI.66.8.5110-5113.1992; LANDAU NR, 1991, J VIROL, V65, P162, DOI 10.1128/JVI.65.1.162-169.1991; Leavitt AD, 1996, J VIROL, V70, P721, DOI 10.1128/JVI.70.2.721-728.1996; LEIDEN JM, 1995, NEW ENGL J MED, V333, P871, DOI 10.1056/NEJM199509283331310; LEVER A, 1989, J VIROL, V63, P4085, DOI 10.1128/JVI.63.9.4085-4087.1989; LEWIS P, 1992, EMBO J, V11, P3053, DOI 10.1002/j.1460-2075.1992.tb05376.x; LEWIS PF, 1994, J VIROL, V68, P510, DOI 10.1128/JVI.68.1.510-516.1994; LUBAN J, 1994, J VIROL, V68, P3784, DOI 10.1128/JVI.68.6.3784-3793.1994; LUSSO P, 1990, SCIENCE, V247, P848, DOI 10.1126/science.2305256; MCCORMICK PJ, 1983, BIOCHIM BIOPHYS ACTA, V755, P36; MEYERHANS A, 1994, J VIROL, V68, P535, DOI 10.1128/JVI.68.1.535-540.1994; MILLER AD, 1993, METHOD ENZYMOL, V217, P581; MILLER DG, 1990, MOL CELL BIOL, V10, P4239, DOI 10.1128/MCB.10.8.4239; MILLER MD, 1994, J EXP MED, V179, P101, DOI 10.1084/jem.179.1.101; MULLEN RJ, 1992, DEVELOPMENT, V116, P201; MULLIGAN RC, 1993, SCIENCE, V260, P926, DOI 10.1126/science.8493530; NAIDINI L, UNPUB; NALDININ L, UNPUB; NOLAN GP, 1988, P NATL ACAD SCI USA, V85, P2603, DOI 10.1073/pnas.85.8.2603; PAGE KA, 1990, J VIROL, V64, P5270, DOI 10.1128/JVI.64.11.5270-5276.1990; PAROLIN C, 1994, J VIROL, V68, P3888, DOI 10.1128/JVI.68.6.3888-3895.1994; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; POZNANSKY M, 1991, J VIROL, V65, P532, DOI 10.1128/JVI.65.1.532-536.1991; RATNER L, 1985, NATURE, V313, P277, DOI 10.1038/313277a0; RICHARDSON JH, 1995, J GEN VIROL, V76, P691, DOI 10.1099/0022-1317-76-3-691; RICHARDSON JH, 1993, J VIROL, V67, P3997, DOI 10.1128/JVI.67.7.3997-4005.1993; ROE TY, 1993, EMBO J, V12, P2099, DOI 10.1002/j.1460-2075.1993.tb05858.x; SCHARFMANN R, 1991, P NATL ACAD SCI USA, V88, P4626, DOI 10.1073/pnas.88.11.4626; SCHUITEMAKER H, 1994, EMBO J, V13, P5929, DOI 10.1002/j.1460-2075.1994.tb06938.x; SHIMADA T, 1991, J CLIN INVEST, V88, P1043, DOI 10.1172/JCI115365; SONEOKA Y, 1995, NUCLEIC ACIDS RES, V23, P628, DOI 10.1093/nar/23.4.628; SPECTOR DH, 1990, J VIROL, V64, P2298, DOI 10.1128/JVI.64.5.2298-2308.1990; SPINA CA, 1994, J EXP MED, V179, P115, DOI 10.1084/jem.179.1.115; TRONO D, 1989, CELL, V59, P113, DOI 10.1016/0092-8674(89)90874-X; VERMA IM, 1994, MOL MED, V1, P2; VICENZI E, 1994, J VIROL, V68, P7879, DOI 10.1128/JVI.68.12.7879-7890.1994; VONSCHWEDLER U, 1994, P NATL ACAD SCI USA, V91, P6992, DOI 10.1073/pnas.91.15.6992; WEINBERG JB, 1991, J EXP MED, V174, P1477, DOI 10.1084/jem.174.6.1477; WILLIAMS RS, 1995, NAT MED, V1, P1137, DOI 10.1038/nm1195-1137; YEE JK, 1994, P NATL ACAD SCI USA, V91, P9564, DOI 10.1073/pnas.91.20.9564; ZACK JA, 1992, J VIROL, V66, P1717, DOI 10.1128/JVI.66.3.1717-1725.1992; ZACK JA, 1990, CELL, V61, P213, DOI 10.1016/0092-8674(90)90802-L	66	3774	4306	6	400	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 12	1996	272	5259					263	267		10.1126/science.272.5259.263	http://dx.doi.org/10.1126/science.272.5259.263			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UE729	8602510				2022-12-28	WOS:A1996UE72900040
J	Lu, KP; Hanes, SD; Hunter, T				Lu, KP; Hanes, SD; Hunter, T			A human peptidyl-prolyl isomerase essential for regulation of mitosis	NATURE			English	Article							PROTEIN-KINASE; ASPERGILLUS-NIDULANS; YEAST; GENE; INDUCTION; NIMA	THE NIMA kinase is essential for progression through mitosis in Aspergillus nidulans(1-6), and there is evidence for a similar pathway in other eukaryotic cells(5-8). Here we describe the human protein Pin1, a peptidyl-prolyl cis/trans isomerase (PPIase) that interacts with NIMA. PPIases are important in protein folding, assembly and/or transport(9-13), but none has so far been shown to be required for cell viability(9-11). Pin1 is nuclear PPIase containing a WW protein interaction domain, and is structurally and functionally related to Ess1/Ptf1, an essential protein in budding yeast(14,15). PPIase activity is necessary for Ess1/Pin1 function in yeast. Depletion of Pin1/Ess1 from yeast or HeLa cells induces mitotic arrest, whereas HeLa cells overexpressing Pin1 arrest in the G2 phase of the cell cycle. Pin1 is thus an essential PPIase that regulates mitosis presumably by interacting with MMA and attenuating its mitosis-promoting activity.	NEW YORK STATE DEPT HLTH, WADSWORTH CTR, LAB DEV GENET, ALBANY, NY 12201 USA	State University of New York (SUNY) System; Wadsworth Center	Lu, KP (corresponding author), SALK INST BIOL STUDIES, MOLEC BIOL & VIROL LAB, 10010 N TORREY PINES RD, LA JOLLA, CA 92037 USA.							CHEN HI, 1995, P NATL ACAD SCI USA, V92, P7819, DOI 10.1073/pnas.92.17.7819; DAVIS ES, 1992, P NATL ACAD SCI USA, V89, P11169, DOI 10.1073/pnas.89.23.11169; FISCHER G, 1994, ANGEW CHEM INT EDIT, V63, P67; FRY AM, 1995, CURR BIOL, V5, P1122, DOI 10.1016/S0960-9822(95)00227-2; FU XD, 1995, RNA, V1, P663; FU XD, 1990, NATURE, V343, P437, DOI 10.1038/343437a0; GUI JF, 1994, NATURE, V369, P678, DOI 10.1038/369678a0; HANES SD, 1989, YEAST, V5, P55, DOI 10.1002/yea.320050108; HANI J, 1995, FEBS LETT, V365, P198, DOI 10.1016/0014-5793(95)00471-K; HANNON GJ, 1993, GENE DEV, V7, P2378, DOI 10.1101/gad.7.12a.2378; HARPER JW, 1993, CELL, V75, P805; HEITMAN J, 1992, NEW BIOL, V4, P448; Heitman Joseph, 1993, Methods (Orlando), V5, P176, DOI 10.1006/meth.1993.1022; LOUVION JF, 1993, GENE, V131, P129, DOI 10.1016/0378-1119(93)90681-R; Lu K P, 1995, Prog Cell Cycle Res, V1, P187; LU KP, 1995, CELL, V81, P413, DOI 10.1016/0092-8674(95)90394-1; LU KP, 1994, EMBO J, V13, P2103, DOI 10.1002/j.1460-2075.1994.tb06486.x; LU KP, 1993, J BIOL CHEM, V268, P8769; Maleszka R, 1996, P NATL ACAD SCI USA, V93, P447, DOI 10.1073/pnas.93.1.447; OCONNELL MJ, 1994, EMBO J, V13, P4926, DOI 10.1002/j.1460-2075.1994.tb06820.x; OSMANI AH, 1991, CELL, V67, P283, DOI 10.1016/0092-8674(91)90180-7; OSMANI SA, 1988, CELL, V53, P237, DOI 10.1016/0092-8674(88)90385-6; PU RT, 1995, EMBO J, V14, P995, DOI 10.1002/j.1460-2075.1995.tb07080.x; RAHFELD JU, 1994, FEBS LETT, V343, P65, DOI 10.1016/0014-5793(94)80608-X; ROBERTS CJ, 1991, METHOD ENZYMOL, V194, P644; RUDD KE, 1995, TRENDS BIOCHEM SCI, V20, P12, DOI 10.1016/S0968-0004(00)88940-9; SCHREIBER SL, 1991, SCIENCE, V251, P283, DOI 10.1126/science.1702904; SPECTOR DL, 1993, REV CELL BIOL, V9, P265; SUDOL M, 1995, FEBS LETT, V369, P67, DOI 10.1016/0014-5793(95)00550-S; TAKEUCHI M, 1993, MOL BIOL CELL, V4, P247, DOI 10.1091/mbc.4.3.247	30	784	833	1	66	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 11	1996	380	6574					544	547						4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UE663	8606777				2022-12-28	WOS:A1996UE66300055
J	Garber, AM; Browner, WS; Hulley, SB				Garber, AM; Browner, WS; Hulley, SB			Cholesterol screening in asymptomatic adults, revisited	ANNALS OF INTERNAL MEDICINE			English	Review							CORONARY HEART-DISEASE; DENSITY LIPOPROTEIN CHOLESTEROL; PRIMARY-PREVENTION TRIAL; MIDDLE-AGED MEN; SERUM-CHOLESTEROL; SECONDARY PREVENTION; BLOOD CHOLESTEROL; RISK-FACTORS; FOLLOW-UP; PRIMARY HYPERCHOLESTEROLEMIA	Objective: io assess the role of serum lipid levels as screening tests in adults. Design: Pooled analysis of clinical trials, supplemented by analysis of data from the Framingham Heart Study, to estimate the effect of cholesterol reduction in patient groups stratified by cardiac risk. Study Selection: Published randomized controlled trials of cholesterol reduction, meta-analyses of such trials, prospective cohort studies of the association between cholesterol levels and morbidity and death related to coronary heart disease, and cost-effectiveness analyses of cholesterol reduction. Data Analysis: Two-stage logistic regression on cardiac risk factors and outcomes in the Framingham Heart Study. The first stage predicted the risk for death from coronary heart disease using standard risk factors but not cholesterol; the second stage predicted the risk for death from coronary heart disease and all causes as functions of age and cholesterol level, stratified by the risk predicted from the first stage. Results: Randomized clinical trials show that cholesterol reduction confers survival benefits in patients with symptomatic coronary disease. In asymptomatic middle-aged men, who are at lower risk for death from coronary disease, cholesterol reduction prevents coronary disease but has not been shown to prolong life. The risk model based on analysis of the da a from the Framingham Heart Study is consistent with the randomized trial data and shows that in the demographic groups excluded from trials, the hypothetical benefits of cholesterol reduction are greatest when the underlying risk for coronary disease is greatest. Conclusions: Screening with total cholesterol levels is most likely to be useful when done in populations at high short-term risk for dying of coronary heart disease, such as survivors of myocardial infarction and middle-aged men with multiple cardiac risk factors. In these populations, cholesterol reduction appears to be both effective and cost-effective. In other populations, the benefits of reduction are much smaller or are uncertain.	UNIV CALIF SAN FRANCISCO, SAN FRANCISCO, CA 94143 USA; DEPT VET AFFAIRS MED CTR, SAN FRANCISCO, CA USA; VET AFFAIRS PALO ALTO HLTH CARE SYST, PALO ALTO, CA USA	University of California System; University of California San Francisco; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Palo Alto Health Care System			Garber, Alan M/F-1476-2010		NHLBI NIH HHS [R01 HL46297] Funding Source: Medline; NIA NIH HHS [R29 AG07651] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL046297] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R29AG007651] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ACHESON J, 1972, ATHEROSCLEROSIS, V15, P177, DOI 10.1016/0021-9150(72)90067-6; ANDERSON KM, 1987, JAMA-J AM MED ASSOC, V257, P2176, DOI 10.1001/jama.257.16.2176; [Anonymous], 1991, BMJ, V303, P893; [Anonymous], 1965, LANCET, V2, P501; [Anonymous], 1968, LANCET, V2, P693; [Anonymous], 1975, JAMA-J AM MED ASSOC, V231, P360; [Anonymous], 1996, GUIDE CLIN PREVENTIV; [Anonymous], COMMON SCREENING TES; AVINS AL, 1993, CIRCULATION, V87, P300, DOI 10.1161/circ.87.1.8419022; BARRATT A, 1994, AM J PUBLIC HEALTH, V84, P779, DOI 10.2105/AJPH.84.5.779; Begg T B, 1971, Minerva Med, V62, P3469; BETTERIDGE DJ, 1993, POSTGRAD MED J, V69, P359, DOI 10.1136/pgmj.69.811.359; Beurden E. van, 1990, Health Education Research, V5, P445, DOI 10.1093/her/5.4.445; BLANKENHORN DH, 1987, JAMA-J AM MED ASSOC, V257, P3233, DOI 10.1001/jama.257.23.3233; BRADFORD RH, 1991, ARCH INTERN MED, V151, P43, DOI 10.1001/archinte.151.1.43; BRENSIKE JF, 1984, CIRCULATION, V69, P313, DOI 10.1161/01.CIR.69.2.313; BRETT AS, 1991, AM J MED, V91, P642, DOI 10.1016/0002-9343(91)90218-M; BROWN G, 1990, NEW ENGL J MED, V323, P1289, DOI 10.1056/NEJM199011083231901; BROWN MS, 1994, HARRISONS PRINCIPLES; BUCHWALD H, 1990, NEW ENGL J MED, V323, P946, DOI 10.1056/NEJM199010043231404; BURR ML, 1989, LANCET, V2, P757; CANNER PL, 1986, J AM COLL CARDIOL, V8, P1245, DOI 10.1016/S0735-1097(86)80293-5; CARLSON LA, 1988, ACTA MED SCAND, V223, P405; CORTI MC, 1995, JAMA-J AM MED ASSOC, V274, P539, DOI 10.1001/jama.274.7.539; COULTER A, 1995, BRIT MED J, V310, P1099; CRIQUI MH, 1993, NEW ENGL J MED, V328, P1220, DOI 10.1056/NEJM199304293281702; CRIQUI MH, 1991, ANN INTERN MED, V115, P973, DOI 10.7326/0003-4819-115-12-973; DAMMERMAN M, 1995, CIRCULATION, V91, P505, DOI 10.1161/01.CIR.91.2.505; DAVIS CE, 1990, JAMA-J AM MED ASSOC, V264, P3044, DOI 10.1001/jama.264.23.3044; Dawber TR., 1980, FRAMINGHAM STUDY EPI, DOI DOI 10.4159/HARVARD.9780674492097; DAYTON S, 1969, CIRCULATION       S2, V40, P1; DEWAR HA, 1972, BRIT MED J, V1, P506, DOI 10.1136/bmj.1.5798.506-a; DITSCHUNEIT HH, 1991, EUR J CLIN PHARMACOL, V40, pS27, DOI 10.1007/BF01409404; DORR AE, 1978, J CHRON DIS, V31, P5, DOI 10.1016/0021-9681(78)90076-0; ELTON PJ, 1994, J EPIDEMIOL COMMUN H, V48, P22, DOI 10.1136/jech.48.1.22; FRANTZ ID, 1989, ARTERIOSCLEROSIS, V9, P129, DOI 10.1161/01.ATV.9.1.129; FRICK MH, 1993, ANN MED, V25, P41, DOI 10.3109/07853899309147855; FRICK MH, 1987, NEW ENGL J MED, V317, P1237, DOI 10.1056/NEJM198711123172001; FURBERG CD, 1994, CIRCULATION, V90, P1679, DOI 10.1161/01.CIR.90.4.1679; GARBER AM, 1994, BRIT MED J, V309, P2, DOI 10.1136/bmj.309.6946.2; GARBER AM, 1991, ARCH INTERN MED, V151, P1089, DOI 10.1001/archinte.151.6.1089; GARBER AM, 1989, ANN INTERN MED, V110, P622, DOI 10.7326/0003-4819-110-8-622; GARBER AM, 1994, INT STAT REV, V62, P203, DOI 10.2307/1403509; GARDNER MJ, 1973, J CHRON DIS, V26, P781, DOI 10.1016/0021-9681(73)90013-1; GOLDMAN L, 1992, CIRCULATION, V85, P1960, DOI 10.1161/01.CIR.85.5.1960; GOLDMAN L, 1991, JAMA-J AM MED ASSOC, V265, P1145, DOI 10.1001/jama.265.9.1145; GORDON DJ, 1989, AM J CARDIOL, V63, pH48; GORDON DJ, 1989, CIRCULATION, V79, P8, DOI 10.1161/01.CIR.79.1.8; GORDON DJ, 1986, CIRCULATION, V74, P1217, DOI 10.1161/01.CIR.74.6.1217; GOULD AL, 1995, CIRCULATION, V91, P2274, DOI 10.1161/01.CIR.91.8.2274; GROSS L, 1973, J AM GERIATR SOC, V21, P552, DOI 10.1111/j.1532-5415.1973.tb01662.x; GRUNDY SM, 1993, JAMA-J AM MED ASSOC, V269, P3015, DOI 10.1001/jama.269.23.3015; HAMILTON VH, 1995, JAMA-J AM MED ASSOC, V273, P1032, DOI 10.1001/jama.273.13.1032; HARRIS T, 1992, J CLIN EPIDEMIOL, V45, P595, DOI 10.1016/0895-4356(92)90131-6; HARROLD BP, 1969, DIABETES, V18, P285, DOI 10.2337/diab.18.5.285; HJERMANN I, 1981, LANCET, V2, P1303; HOLME I, 1990, CIRCULATION, V82, P1916, DOI 10.1161/01.CIR.82.6.1916; HOLME I, 1993, BRIT HEART J, V69, pS42; HULLEY SB, 1992, CIRCULATION, V86, P1026, DOI 10.1161/01.CIR.86.3.1026; HULLEY SB, 1993, JAMA-J AM MED ASSOC, V269, P1416, DOI 10.1001/jama.269.11.1416; HULLEY SB, 1992, BRIT MED J, V304, P394, DOI 10.1136/bmj.304.6824.394; HULLEY SB, 1994, JAMA-J AM MED ASSOC, V272, P1372, DOI 10.1001/jama.272.17.1372; HUNNINGHAKE DB, 1993, NEW ENGL J MED, V328, P1213, DOI 10.1056/NEJM199304293281701; HUNNINGHAKE DB, 1990, ATHEROSCLEROSIS, V85, P81, DOI 10.1016/0021-9150(90)90185-L; IRIBARREN C, 1995, JAMA-J AM MED ASSOC, V273, P1926, DOI 10.1001/jama.273.24.1926; JACOBS D, 1992, CIRCULATION, V86, P1046, DOI 10.1161/01.CIR.86.3.1046; JONES PH, 1991, CLIN CARDIOL, V14, P146, DOI 10.1002/clc.4960140211; KANE JP, 1990, JAMA-J AM MED ASSOC, V264, P3007, DOI 10.1001/jama.264.23.3007; KANNEL WB, 1987, NIH872703 NAT HEART; KJELSBERG MO, 1982, JAMA-J AM MED ASSOC, V248, P1465; KLAG MJ, 1993, NEW ENGL J MED, V328, P313, DOI 10.1056/NEJM199302043280504; KRONMAL RA, 1993, ARCH INTERN MED, V153, P1065, DOI 10.1001/archinte.153.9.1065; KRUMHOLZ HM, 1994, JAMA-J AM MED ASSOC, V272, P1335, DOI 10.1001/jama.272.17.1335; LAW MR, 1994, BMJ-BRIT MED J, V308, P367, DOI 10.1136/bmj.308.6925.367; LAW MR, 1994, BRIT MED J, V308, P373, DOI 10.1136/bmj.308.6925.373; Leren P, 1966, Acta Med Scand Suppl, V466, P1; LOGAN AG, 1993, CAN MED ASSOC J, V148, P521; MANNINEN V, 1992, CIRCULATION, V85, P37, DOI 10.1161/01.CIR.85.1.37; Manolio T A, 1992, Ann Epidemiol, V2, P161, DOI 10.1016/1047-2797(92)90051-Q; MARMORSTON J, 1962, P SOC EXP BIOL MED, V110, P400; MCCAUGHAN D, 1981, ARCH INTERN MED, V141, P1428, DOI 10.1001/archinte.141.11.1428; MCNAMARA JR, 1995, CLIN CHEM, V41, P232; MIETTINEN TA, 1985, JAMA-J AM MED ASSOC, V254, P2097, DOI 10.1001/jama.254.15.2097; MULDOON MF, 1990, BMJ-BRIT MED J, V301, P309, DOI 10.1136/bmj.301.6747.309; NEIL HAW, 1995, BMJ-BRIT MED J, V310, P569, DOI 10.1136/bmj.310.6979.569; Newman TB, 1996, JAMA-J AM MED ASSOC, V275, P55, DOI 10.1001/jama.275.1.55; OLIVER M F, 1978, British Heart Journal, V40, P1069, DOI 10.1136/hrt.40.10.1069; OLIVER MF, 1961, LANCET, V2, P499; ORNISH D, 1990, LANCET, V336, P129, DOI 10.1016/0140-6736(90)91656-U; PEDERSEN TR, 1994, LANCET, V344, P1383; POCOCK SJ, 1989, BMJ-BRIT MED J, V298, P998, DOI 10.1136/bmj.298.6679.998; RAMSAY LE, 1991, BMJ-BRIT MED J, V303, P953, DOI 10.1136/bmj.303.6808.953; RAVNSKOV U, 1992, BMJ-BRIT MED J, V305, P15, DOI 10.1136/bmj.305.6844.15; RIFKIND BM, 1984, JAMA-J AM MED ASSOC, V251, P351; ROBERTSON I, 1992, BRIT J GEN PRACT, V42, P469; ROSE G, 1986, LANCET, V1, P869; ROSE GA, 1965, BMJ-BRIT MED J, V1, P1531, DOI 10.1136/bmj.1.5449.1531; ROSSER WW, 1993, FAM PRACT, V10, P431, DOI 10.1093/fampra/10.4.431; ROSSOUW JE, 1990, NEW ENGL J MED, V323, P1112, DOI 10.1056/NEJM199010183231606; SAHNI R, 1991, AM HEART J, V121, P1600, DOI 10.1016/0002-8703(91)90002-Y; SCHOCH HK, 1968, ADV EXP MED BIOL, V4, P405; SHEPHERD J, 1995, NEW ENGL J MED, V333, P1301, DOI 10.1056/NEJM199511163332001; SILBERBERG JS, 1991, MED J AUSTRALIA, V155, P665, DOI 10.5694/j.1326-5377.1991.tb93956.x; SIMON JA, 1993, CARDIOVASC RISK FACT, V3, P305; SINGH RB, 1992, BRIT MED J, V304, P1015, DOI 10.1136/bmj.304.6833.1015; SMITH GD, 1993, BMJ-BRIT MED J, V306, P1367, DOI 10.1136/bmj.306.6889.1367; SOX HC, 1990, COMMON DIAGNOSTIC TE; STAMLER J, 1963, JAMA-J AM MED ASSOC, V183, P632; TAYLOR WC, 1987, ANN INTERN MED, V106, P605, DOI 10.7326/0003-4819-106-4-605; The Coronary Drug Project, 1973, JAMA-J AM MED ASSOC, V226, P652; WATTS GF, 1992, LANCET, V339, P563, DOI 10.1016/0140-6736(92)90863-X; WILHELMSEN L, 1986, EUR HEART J, V7, P279, DOI 10.1093/oxfordjournals.eurheartj.a062065; WILSON PWF, 1988, ARTERIOSCLEROSIS, V8, P737, DOI 10.1161/01.ATV.8.6.737; Woodhill J M, 1978, Adv Exp Med Biol, V109, P317; 1992, OCCAS PAP R COLL GEN, V52, P1; 1988, CAN MED ASSOC J, V139, P1; 1971, BRIT MED J, V790, P767; 1994, FAMILY HEART STUDY G, V308, P313; 1972, JAMA-J AM MED ASSOC, V220, P996; 1970, JAMA-J AM MED ASSOC, V214, P1303; 1990, J CLIN EPIDEMIOL, V43, P1028	121	105	105	0	10	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 1	1996	124	5					518	531		10.7326/0003-4819-124-5-199603010-00013	http://dx.doi.org/10.7326/0003-4819-124-5-199603010-00013			14	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TW773	8602715				2022-12-28	WOS:A1996TW77300013
J	Chelala, C				Chelala, C			Relations between the United States and Cuba - A proposal for action	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																		DELONG DM, 1995, ANN INTERN MED, V123, P734, DOI 10.7326/0003-4819-123-9-199511010-00027; DILLON S, 1995, NY TIEMS        0522, pA1; KUNTZ D, 1994, INT J HEALTH SERV, V24, P161, DOI 10.2190/L6VN-57RR-AFLK-XW90; ROMAN GC, 1995, ANN INTERN MED, V122, P530, DOI 10.7326/0003-4819-122-7-199504010-00009; 1993, EPIDEMIC NEUROPATHY; 1995, NEW ENGL J MED, V333, P1176; 1994, MMWR-MORBID MORTAL W, V43, P183	7	5	5	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 21	1996	275	7					559	560						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TV569	8606479				2022-12-28	WOS:A1996TV56900035
J	Hoge, CW; Shlim, DR; Echeverria, P; Rajah, R; Herrmann, JE; Cross, JH				Hoge, CW; Shlim, DR; Echeverria, P; Rajah, R; Herrmann, JE; Cross, JH			Epidemiology of diarrhea among expatriate residents living in a highly endemic environment	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ENTEROPATHOGENIC ESCHERICHIA-COLI; TRAVELERS DIARRHEA; MONOCLONAL-ANTIBODIES; CAMPYLOBACTER-JEJUNI; FOREIGN RESIDENTS; ANTIGEN-DETECTION; UNITED-STATES; MEXICO; CELLS; GASTROENTERITIS	Objective.-To determine the etiology of diarrhea among expatriate residents living in a developing country and identify risk factors for travelers' diarrhea that are difficult to evaluate in tourist populations. Design.-Clinic-based case-control study. Setting.-Primary care travel medicine clinic in Kathmandu, Nepal. Participants.-A total of 69 expatriate residents with diarrhea, compared with 120 tourists with diarrhea, and 112 asymptomatic resident and tourist controls, selected systematically during a 1-year period. Main Outcome Measures.-Risk factors for diarrhea assessed by questionnaire and pathogen prevalence assessed by microbiologic analysis of stool specimens. Results.-The dominant risk factors for diarrhea among expatriate residents included younger age (P=.003), shorter duration of stay in Nepal (P<.001), and eating out in restaurants ((=.01). Eating raw vegetables, salads, fresh fruit, or ice served in restaurants was not significantly associated with diarrhea. Longer duration of residence was linearly correlated with protection. Enteric pathogens were identified in 44 (64%) of 69 residents with diarrhea compared with 100 (83%) of 120 tourists with diarrhea, with enterotoxigenic Escherichia coli, Campylobacter, and Shigella predominant for both groups. Pathogens were also found in stools;from 32 (37%) of 87 asymptomatic resident controls and 13 (52%) of 25 tourist controls. The attack rate of diarrhea among expatriates was estimated to be 49% (95% confidence interval, 37% to 61%) per month during the first 2 years of residence. The highest-risk months were April through July. Conclusions.-Diarrhea among expatriates in a highly endemic environment is a persistent risk. The extremely high prevalence of enteric pathogens among asymptomatic persons reflects widespread exposure. The most important risk factors for travelers' diarrhea are difficult to modify, including younger age, duration of stay, eating in restaurants, and seasonality. Preventive dietary recommendations may not be fully protective, suggesting that pretravel advice should emphasize empiric treatment in addition to strategies to avoid exposure.	ARMED FORCES RES INST MED SCI,DEPT BACTERIOL IMMUNOL & MOLEC GENET,BANGKOK 10400,THAILAND; CIWEC CLIN,KATMANDU,NEPAL; UNIV MASSACHUSETTS,MED CTR,DIV INFECT DIS,WORCESTER,MA; UNIFORMED SERV UNIV HLTH SCI,BETHESDA,MD 20814	United States Department of Defense; United States Army; Walter Reed Army Institute of Research (WRAIR); Armed Forces Research Institute of Medical Science (AFRIMS); University of Massachusetts System; University of Massachusetts Worcester; Uniformed Services University of the Health Sciences - USA								BLACK RE, 1990, REV INFECT DIS, V12, pS73; CHANG TW, 1978, ANN INTERN MED, V89, P428, DOI 10.7326/0003-4819-89-3-428_2; CROSS J H, 1968, Chinese Journal of Microbiology, V1, P117; DEAN AG, 1972, J INFECT DIS, V125, P407, DOI 10.1093/infdis/125.4.407; Dean AG, 1994, EPI INFO VERSION 6 0; DUPONT HL, 1977, AM J EPIDEMIOL, V105, P37, DOI 10.1093/oxfordjournals.aje.a112353; ECHEVERRIA P, 1991, J INFECT DIS, V164, P550, DOI 10.1093/infdis/164.3.550; ECHEVERRIA P, 1990, P95; ENG TR, 1993, MORBIDITY MORTALITY; ERICSSON CD, 1980, GASTROENTEROLOGY, V79, P812; HABERBERGER RL, 1994, AM J TROP MED HYG, V51, P870, DOI 10.4269/ajtmh.1994.51.870; HERRMANN JE, 1987, J INFECT DIS, V155, P1167, DOI 10.1093/infdis/155.6.1167; HERRMANN JE, 1990, J INFECT DIS, V161, P226, DOI 10.1093/infdis/161.2.226; HOGE CW, 1993, LANCET, V341, P1175, DOI 10.1016/0140-6736(93)91002-4; JERSE AE, 1990, P NATL ACAD SCI USA, V87, P7839, DOI 10.1073/pnas.87.20.7839; KNUTTON S, 1991, INFECT IMMUN, V59, P365, DOI 10.1128/IAI.59.1.365-371.1991; KOLLARITSCH H, 1989, EUR J EPIDEMIOL, V5, P74, DOI 10.1007/BF00145049; KOZICKI M, 1985, INT J EPIDEMIOL, V14, P169, DOI 10.1093/ije/14.1.169; MERSON MH, 1976, NEW ENGL J MED, V294, P1299, DOI 10.1056/NEJM197606102942401; NATARO JP, 1987, PEDIATR INFECT DIS J, V6, P829, DOI 10.1097/00006454-198709000-00008; OKHUYSEN PC, 1992, MED CLIN N AM, V6, P1357; ORSKOV F, 1975, ACTA PATH MICRO IM B, V83, P595; PICKERING LK, 1977, J INFECT DIS, V135, P1003, DOI 10.1093/infdis/135.6.1003; RYDER RW, 1981, J INFECT DIS, V144, P442, DOI 10.1093/infdis/144.5.442; SACK DA, 1975, INFECT IMMUN, V11, P334, DOI 10.1128/IAI.11.2.334-336.1975; STEELE TW, 1984, PATHOLOGY, V16, P263, DOI 10.3109/00313028409068535; STEFFEN R, 1986, REV INFECT DIS, V8, pS122; STEFFEN R, 1983, JAMA-J AM MED ASSOC, V249, P1176; TAYLOR DN, 1988, JAMA-J AM MED ASSOC, V260, P1245, DOI 10.1001/jama.260.9.1245; TAYLOR DN, 1986, REV INFECT DIS, V8, pS136; TJOA WS, 1977, AM J EPIDEMIOL, V106, P61, DOI 10.1093/oxfordjournals.aje.a112433; WANG WLL, 1983, J CLIN MICROBIOL, V18, P803, DOI 10.1128/JCM.18.4.803-807.1983; 1992, WKLY EPIDEMIOL REC, V67, P273	33	77	77	1	9	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 21	1996	275	7					533	538		10.1001/jama.275.7.533	http://dx.doi.org/10.1001/jama.275.7.533			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TV569	8606474				2022-12-28	WOS:A1996TV56900030
J	Nunnari, J; Walter, P				Nunnari, J; Walter, P			Regulation of organelle biogenesis	CELL			English	Review							SIGNAL RECOGNITION PARTICLE; PHOSPHOLIPID BIOSYNTHETIC-ENZYMES; CELL-FREE SYSTEM; SACCHAROMYCES-CEREVISIAE; ENDOPLASMIC-RETICULUM; CITRATE SYNTHASE; PEROXISOME PROLIFERATION; TRANSMEMBRANE PROTEIN; CONTACT SITES; ALPHA-FACTOR		UNIV CALIF SAN FRANCISCO,SCH MED,DEPT BIOCHEM & BIOPHYS,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco								ARDAIL D, 1993, J BIOL CHEM, V268, P25985; ARNOLD CE, 1994, J BIOL CHEM, V269, P30412; BLOBEL G, 1980, P NATL ACAD SCI-BIOL, V77, P1496, DOI 10.1073/pnas.77.3.1496; BLOBEL G, 1971, RIBOSOME MEMBRANE IN, P193; Blobel G., 1971, BIOMEMBRANE, P193; BOLENDER RP, 1974, J CELL BIOL, V61, P269, DOI 10.1083/jcb.61.2.269; BROWN RE, 1992, BIOCHIM BIOPHYS ACTA, V1113, P375, DOI 10.1016/0304-4157(92)90007-W; CHELSTOWSKA A, 1995, J BIOL CHEM, V270, P18141, DOI 10.1074/jbc.270.30.18141; COX JS, 1993, CELL, V73, P1197, DOI 10.1016/0092-8674(93)90648-A; DAUM G, 1990, EXPERIENTIA, V46, P586, DOI 10.1007/BF01939697; DENIS CL, 1983, MOL CELL BIOL, V3, P360, DOI 10.1128/MCB.3.3.360; EINERHAND AWC, 1992, CELL BIOCHEM FUNCT, V10, P185, DOI 10.1002/cbf.290100308; EINERHAND AWC, 1993, EUR J BIOCHEM, V214, P323, DOI 10.1111/j.1432-1033.1993.tb17927.x; FILIPITS M, 1993, GENE, V132, P49, DOI 10.1016/0378-1119(93)90513-3; FORSBURG SL, 1989, ANNU REV CELL BIOL, V5, P153, DOI 10.1146/annurev.cb.05.110189.001101; GRATZER S, 1995, J CELL BIOL, V129, P25, DOI 10.1083/jcb.129.1.25; GREEN S, 1994, MOL CELL ENDOCRINOL, V100, P149, DOI 10.1016/0303-7207(94)90294-1; HACHIYA N, 1995, NATURE, V376, P705, DOI 10.1038/376705a0; HANN BC, 1991, CELL, V67, P131, DOI 10.1016/0092-8674(91)90577-L; HANSEN W, 1986, CELL, V45, P397, DOI 10.1016/0092-8674(86)90325-9; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; HOOD DA, 1994, CAN J APPL PHYSIOL, V19, P12, DOI 10.1139/h94-002; JELSEMA CL, 1978, J BIOL CHEM, V253, P7960; JOHNSTON M, 1992, MOL CELLULAR BIOL YE, P193; KIEBLER M, 1993, CELL, V74, P483, DOI 10.1016/0092-8674(93)80050-O; KOS W, 1995, IN PRESS BIOCH BIOPH; KOZUTSUMI Y, 1988, NATURE, V332, P462, DOI 10.1038/332462a0; LEWIN AS, 1990, MOL CELL BIOL, V10, P1399, DOI 10.1128/MCB.10.4.1399; LIAO XS, 1993, CELL, V72, P61, DOI 10.1016/0092-8674(93)90050-Z; LIAO XS, 1991, MOL CELL BIOL, V11, P38, DOI 10.1128/MCB.11.1.38; LITHGOW T, 1994, P NATL ACAD SCI USA, V91, P11973, DOI 10.1073/pnas.91.25.11973; LITHGOW T, 1995, TRENDS BIOCHEM SCI, V20, P98, DOI 10.1016/S0968-0004(00)88972-0; MORI K, 1992, EMBO J, V11, P2583, DOI 10.1002/j.1460-2075.1992.tb05323.x; MORI K, 1993, CELL, V74, P743; NIKAWA JI, 1992, MOL MICROBIOL, V6, P1441, DOI 10.1111/j.1365-2958.1992.tb00864.x; NORMINGTON K, 1989, CELL, V57, P1223, DOI 10.1016/0092-8674(89)90059-7; OGG SC, 1992, MOL BIOL CELL, V3, P895, DOI 10.1091/mbc.3.8.895; PALADE G, 1975, SCIENCE, V189, P347, DOI 10.1126/science.1096303; PALADE GE, 1983, METHOD ENZYMOL, V96, P29; PFANNER N, 1994, TRENDS BIOCHEM SCI, V19, P368, DOI 10.1016/0968-0004(94)90113-9; PLAUTAUF F, 1992, MOL CELLULAR BIOL YE, P415; PURDUE PE, 1994, J BIOL CHEM, V269, P30065; RACHUBINSKI RA, 1995, CELL, V83, P525, DOI 10.1016/0092-8674(95)90091-8; RAPOPORT TA, 1992, SCIENCE, V258, P931, DOI 10.1126/science.1332192; RESENDEZ E, 1988, MOL CELL BIOL, V8, P4579, DOI 10.1128/MCB.8.10.4579; ROSE MD, 1989, CELL, V57, P1211, DOI 10.1016/0092-8674(89)90058-5; ROTHBLATT JA, 1986, CELL, V44, P619, DOI 10.1016/0092-8674(86)90271-0; RUSINOL AE, 1994, J BIOL CHEM, V269, P27494; RYAN KR, 1995, CELL, V83, P517, DOI 10.1016/0092-8674(95)90089-6; Shamu Caroline E., 1994, Trends in Cell Biology, V4, P56, DOI 10.1016/0962-8924(94)90011-6; SHIU RP, 1971, P NATL ACAD SCI USA, V74, P3840; SHYJAN AW, 1993, CURR BIOL, V3, P398, DOI 10.1016/0960-9822(93)90212-7; SIMBENI R, 1991, J BIOL CHEM, V266, P10047; SIMON M, 1991, MOL CELL BIOL, V11, P699, DOI 10.1128/MCB.11.2.699; SIMON M, 1992, YEAST, V8, P303, DOI 10.1002/yea.320080407; SOLLNER T, 1990, CELL, V62, P107, DOI 10.1016/0092-8674(90)90244-9; SUBRAMANI S, 1993, ANNU REV CELL BIOL, V9, P445, DOI 10.1146/annurev.cb.09.110193.002305; SUISSA M, 1984, EMBO J, V3, P1773, DOI 10.1002/j.1460-2075.1984.tb02045.x; TROTTER PJ, 1994, BBA-LIPID LIPID MET, V1213, P241, DOI 10.1016/0005-2760(94)00073-5; van Meer G, 1993, CURR OPIN CELL BIOL, V5, P661, DOI 10.1016/0955-0674(93)90137-F; VANCE JE, 1988, J BIOL CHEM, V263, P5898; VANCE JE, 1990, J BIOL CHEM, V265, P7248; VANDENBOSCH H, 1992, ANNU REV BIOCHEM, V61, P157, DOI 10.1146/annurev.bi.61.070192.001105; VEENHUIS M, 1987, YEAST, V3, P77, DOI 10.1002/yea.320030204; VOELKER DR, 1993, J BIOL CHEM, V268, P7069; VOELKER DR, 1985, J BIOL CHEM, V260, P4671; VOELKER DR, 1990, J BIOL CHEM, V265, P14340; WALTER P, 1994, ANNU REV CELL BIOL, V10, P87, DOI 10.1146/annurev.cb.10.110194.000511; WANG TW, 1994, J BIOL CHEM, V269, P24480; WATERS MG, 1986, J CELL BIOL, V102, P1543, DOI 10.1083/jcb.102.5.1543; WIRTZ K, 1990, ANN REV BIOCH, V60, P73; WOLIN SL, 1989, J CELL BIOL, V109, P2617, DOI 10.1083/jcb.109.6.2617; WRIGHT R, 1990, New Biologist, V2, P915; ZINSER E, 1991, J BACTERIOL, V173, P2026, DOI 10.1128/jb.173.6.2026-2034.1991	74	81	84	1	7	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 9	1996	84	3					389	394		10.1016/S0092-8674(00)81283-0	http://dx.doi.org/10.1016/S0092-8674(00)81283-0			6	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TV708	8608592	Bronze			2022-12-28	WOS:A1996TV70800007
J	Moons, MAW; Peters, L; Bartelds, AIM; Kerssens, JJ				Moons, MAW; Peters, L; Bartelds, AIM; Kerssens, JJ			Concerns about AIDS in general practice	BRITISH MEDICAL JOURNAL			English	Article							HIV		NETHERLANDS INST PRIMARY HLTH CARE,3500 BN UTRECHT,NETHERLANDS									Bartelds A I, 1993, Gesundheitswesen, V55, P3; BARTELDS AIM, 1994, CONTINUOUS MORBIDITY; MILNE RIG, 1988, BRIT MED J, V296, P533, DOI 10.1136/bmj.296.6621.533; SINGH S, 1993, BRIT J GEN PRACT, V43, P182; 1988, J R COLL GEN PRACT, V38, P219	5	3	3	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 3	1996	312	7026					285	286						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TU507	8611785	Green Published			2022-12-28	WOS:A1996TU50700023
J	Breslow, JL				Breslow, JL			Mouse models of atherosclerosis	SCIENCE			English	Article							TRANSGENIC MICE; APOLIPOPROTEIN-E; HYPERCHOLESTEROLEMIA; SUSCEPTIBILITY; ATHEROGENESIS; PROTEIN	As a species the mouse is highly resistant to atherosclerosis. However, through induced mutations it has been possible to develop lines of mice that are susceptible to this disease. For example, mice that are deficient in apolipoprotein E, a ligand important in lipoprotein clearance, develop atherosclerotic lesions resembling those observed in humans. These lesions are exacerbated when the mice are fed a high-cholesterol, high-fat, Western-type diet. Other promising models are mice that are deficient in the low density lipoprotein receptor and transgenic mice that express human apolipoprotein B and transdominant mutant forms of apolipoprotein E. These models are now being used to study the pathogenesis of atherosclerotic lesions, as well as the influence of genetics, environment, hormones, and drugs on lesion development.			Breslow, JL (corresponding author), ROCKEFELLER UNIV, BIOCHEM GENET & METAB LAB, NEW YORK, NY 10021 USA.							BELLOSTA S, 1995, J CLIN INVEST, V96, P2170, DOI 10.1172/JCI118271; BOISVERT WA, 1995, J CLIN INVEST, V96, P1118, DOI 10.1172/JCI118098; CALLOW MJ, 1995, J CLIN INVEST, V96, P1639, DOI 10.1172/JCI118203; FAZIO S, 1994, ARTERIOSCLER THROMB, V14, P1873, DOI 10.1161/01.ATV.14.11.1873; HAYEK T, 1995, J CLIN INVEST, V96, P2071, DOI 10.1172/JCI118255; ISHIBASHI S, 1994, J CLIN INVEST, V93, P1885, DOI 10.1172/JCI117179; LAWN RM, 1992, NATURE, V360, P670, DOI 10.1038/360670a0; LIAO F, 1993, J CLIN INVEST, V91, P2572, DOI 10.1172/JCI116495; LINTON MF, 1995, SCIENCE, V267, P1034, DOI 10.1126/science.7863332; MANCINI FP, 1995, ARTERIOSCL THROM VAS, V15, P1911, DOI 10.1161/01.ATV.15.11.1911; MAROTTI KR, 1993, NATURE, V364, P73, DOI 10.1038/364073a0; NAKASHIMA Y, 1994, ARTERIOSCLER THROMB, V14, P133, DOI 10.1161/01.ATV.14.1.133; PAIGEN B, 1987, P NATL ACAD SCI USA, V84, P3763, DOI 10.1073/pnas.84.11.3763; PAIGEN B, 1985, ATHEROSCLEROSIS, V57, P65, DOI 10.1016/0021-9150(85)90138-8; PALINSKI W, 1995, ARTERIOSCL THROM VAS, V15, P1569, DOI 10.1161/01.ATV.15.10.1569; PALINSKI W, 1994, ARTERIOSCLER THROMB, V14, P605, DOI 10.1161/01.ATV.14.4.605; PASZTY C, 1994, J CLIN INVEST, V94, P899, DOI 10.1172/JCI117412; PLUMP AS, 1994, P NATL ACAD SCI USA, V91, P9607, DOI 10.1073/pnas.91.20.9607; PLUMP AS, 1992, CELL, V71, P343, DOI 10.1016/0092-8674(92)90362-G; PLUMP AS, 1993, CIRCULATION, V88, pA9; PURCELLHUYNH DA, 1995, J CLIN INVEST, V95, P2246, DOI 10.1172/JCI117915; REDDICK RL, 1994, ARTERIOSCLER THROMB, V14, P141, DOI 10.1161/01.ATV.14.1.141; RUBIN EM, 1991, NATURE, V353, P265, DOI 10.1038/353265a0; SCHULTZ JR, 1993, NATURE, V365, P762, DOI 10.1038/365762a0; SHIMANO H, 1995, J CLIN INVEST, V95, P469, DOI 10.1172/JCI117687; SMITH JD, 1995, P NATL ACAD SCI USA, V92, P8264, DOI 10.1073/pnas.92.18.8264; TANGIRALA RK, 1995, J LIPID RES, V36, P2320; TANGIRALA RK, 1995, ARTERIOSCL THROM VAS, V15, P1625, DOI 10.1161/01.ATV.15.10.1625; VANREE JH, 1994, ATHEROSCLEROSIS, V111, P25, DOI 10.1016/0021-9150(94)90188-0; VANVLIJMEN BJM, 1994, J CLIN INVEST, V93, P1403, DOI 10.1172/JCI117117; WARDEN CH, 1993, SCIENCE, V261, P469, DOI 10.1126/science.8332912; ZHANG SH, 1992, SCIENCE, V258, P468, DOI 10.1126/science.1411543; ZHANG SH, 1994, J CLIN INVEST, V94, P937, DOI 10.1172/JCI117460	33	553	582	0	37	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 3	1996	272	5262					685	688		10.1126/science.272.5262.685	http://dx.doi.org/10.1126/science.272.5262.685			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UJ051	8614828				2022-12-28	WOS:A1996UJ05100036
J	Keating, MT; Sanguinetti, MC				Keating, MT; Sanguinetti, MC			Molecular genetic insights into cardiovascular disease	SCIENCE			English	Article							FAMILIAL HYPERTROPHIC CARDIOMYOPATHY; IDIOPATHIC DILATED CARDIOMYOPATHY; CARNITINE PALMITOYLTRANSFERASE-II; SUPRAVALVULAR AORTIC-STENOSIS; HEAVY-CHAIN GENE; LONG-QT SYNDROME; MARFAN-SYNDROME; MISSENSE MUTATION; MITOCHONDRIAL-DNA; DEFICIENCY	The recent application of molecular genetic tools to inherited forms of cardiovascular disease has provided important insight into the molecular mechanisms underlying cardiac arrhythmias, cardiomyopathies, and vascular diseases. These studies point to defects in ion channels, contractile proteins, structural proteins, and signaling molecules as key players in disease pathogenesis. Genetic testing is now available for a subset of inherited cardiovascular diseases, and new mechanism-based therapies may be available in the near future. This remarkable progress and the implications it may have for more common forms of cardiovascular disease are reviewed here.	UNIV UTAH, DIV CARDIOL, SALT LAKE CITY, UT 84112 USA; UNIV UTAH, ECCLES PROGRAM HUMAN MOL BIOL & GENET, SALT LAKE CITY, UT 84112 USA	Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah	Keating, MT (corresponding author), UNIV UTAH, HOWARD HUGHES MED INST, ECCLES INST HUMAN GENET, SALT LAKE CITY, UT 84112 USA.		Sanguinetti, Michael/AAN-2615-2020					*AM HEART ASS, 1996, HEART STROK FACTS S; ANAN R, 1994, J CLIN INVEST, V93, P280, DOI 10.1172/JCI116957; [Anonymous], 1989, NEW ENGL J MED, V321, P406; BENNETT PB, 1995, NATURE, V376, P683, DOI 10.1038/376683a0; Bione S, 1996, NAT GENET, V12, P385, DOI 10.1038/ng0496-385; BONNE G, 1995, NAT GENET, V11, P438, DOI 10.1038/ng1295-438; CODD MB, 1989, CIRCULATION, V80, P564, DOI 10.1161/01.CIR.80.3.564; COMPTON SJ, IN PRESS CIRCULATION; CURRAN ME, 1995, CELL, V80, P795, DOI 10.1016/0092-8674(95)90358-5; CURRAN ME, 1993, CELL, V73, P159, DOI 10.1016/0092-8674(93)90168-P; DAMMERMAN M, 1995, CIRCULATION, V91, P505, DOI 10.1161/01.CIR.91.2.505; DIETZ HC, 1995, HUM MOL GENET, V4, P1799, DOI 10.1093/hmg/4.suppl_1.1799; DIETZ HC, 1991, NATURE, V352, P337, DOI 10.1038/352337a0; DUMAINE R, IN PRESS CIRC RES; EPSTEIN ND, 1992, CIRCULATION, V86, P345, DOI 10.1161/01.CIR.86.2.345; EWART AK, 1993, NAT GENET, V5, P11, DOI 10.1038/ng0993-11; EWART AK, 1993, P NATL ACAD SCI USA, V90, P3226, DOI 10.1073/pnas.90.8.3226; FANANAPAZIR L, 1994, CIRCULATION, V89, P22, DOI 10.1161/01.CIR.89.1.22; FRANCKE U, 1995, AM J HUM GENET, V56, P1287; GEISTERFERLOWRA.AA, IN PRESS SCIENCE; GEISTERFERLOWRANCE AAT, 1990, CELL, V62, P999, DOI 10.1016/0092-8674(90)90274-I; GUTTMACHER AE, 1995, NEW ENGL J MED, V333, P918, DOI 10.1056/NEJM199510053331407; HUG G, 1991, NEW ENGL J MED, V325, P1862, DOI 10.1056/NEJM199112263252607; KANNEL WB, 1987, AM HEART J, V113, P799, DOI 10.1016/0002-8703(87)90722-8; KASS S, 1994, NAT GENET, V7, P546, DOI 10.1038/ng0894-546; KEATING M, 1991, SCIENCE, V252, P704, DOI 10.1126/science.1673802; KONTUSAARI S, 1990, J CLIN INVEST, V86, P1465, DOI 10.1172/JCI114863; KRAJINOVIC M, 1995, AM J HUM GENET, V57, P846; KUIVANIEMI H, 1991, J CLIN INVEST, V88, P1441, DOI 10.1172/JCI115452; LEE B, 1991, NATURE, V352, P330, DOI 10.1038/352330a0; MASLEN CL, 1991, NATURE, V352, P334, DOI 10.1038/352334a0; MCALLISTER KA, 1994, NAT GENET, V8, P345, DOI 10.1038/ng1294-345; MCALLISTER KA, 1994, J MED GENET, V31, P927, DOI 10.1136/jmg.31.12.927; MICHELS VV, 1992, NEW ENGL J MED, V326, P77, DOI 10.1056/NEJM199201093260201; MUNTONI F, 1993, NEW ENGL J MED, V329, P921, DOI 10.1056/NEJM199309233291304; NARCISI P, 1993, AM J MED GENET, V46, P278, DOI 10.1002/ajmg.1320460308; Olson TM, 1996, J CLIN INVEST, V97, P528, DOI 10.1172/JCI118445; Pyeritz RE, 1992, HEART DIS TXB CARDIO, P1622; ROCCHICCIOLI F, 1990, PEDIATR RES, V28, P657, DOI 10.1203/00006450-199012000-00023; SANGUINETTI MC, 1995, CELL, V81, P299, DOI 10.1016/0092-8674(95)90340-2; Sanguinetti MC, 1996, P NATL ACAD SCI USA, V93, P2208, DOI 10.1073/pnas.93.5.2208; SCHOTT JJ, 1995, AM J HUM GENET, V57, P1114; SCHWARTZ PJ, 1995, CIRCULATION, V92, P3381, DOI 10.1161/01.CIR.92.12.3381; SUOMALAINEN A, 1992, LANCET, V340, P1319, DOI 10.1016/0140-6736(92)92496-3; SWEENEY HL, 1994, J BIOL CHEM, V269, P1603; TARONI F, 1992, P NATL ACAD SCI USA, V89, P8429, DOI 10.1073/pnas.89.18.8429; TAYLOR SI, 1995, METABOLIC MOL BASES, V1, P843; THIERFELDER L, 1994, CELL, V77, P701, DOI 10.1016/0092-8674(94)90054-X; TOWBIN JA, 1993, CIRCULATION, V87, P1854, DOI 10.1161/01.CIR.87.6.1854; TROMP G, 1993, J CLIN INVEST, V91, P2539, DOI 10.1172/JCI116490; VINCENT GM, 1992, NEW ENGL J MED, V327, P846, DOI 10.1056/NEJM199209173271204; WANG Q, 1995, CELL, V80, P805, DOI 10.1016/0092-8674(95)90359-3; Wang Q, 1996, NAT GENET, V12, P17, DOI 10.1038/ng0196-17; WATKINS H, 1995, NAT GENET, V11, P434, DOI 10.1038/ng1295-434; WATKINS H, 1992, NEW ENGL J MED, V326, P1108, DOI 10.1056/NEJM199204233261703; ZEVIANI M, 1991, LANCET, V338, P143, DOI 10.1016/0140-6736(91)90136-D	56	138	145	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 3	1996	272	5262					681	685		10.1126/science.272.5262.681	http://dx.doi.org/10.1126/science.272.5262.681			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UJ051	8614827				2022-12-28	WOS:A1996UJ05100035
J	Ferris, JP; Hill, AR; Liu, RH; Orgel, LE				Ferris, JP; Hill, AR; Liu, RH; Orgel, LE			Synthesis of long prebiotic oligomers on mineral surfaces	NATURE			English	Article								MOST theories of the origin of biological organization assume that polymers with lengths in the range of 30-60 monomers are needed to make a genetic system viable(1). But it has not proved possible to synthesize plausibly prebiotic polymers this long by condensation in aqueous solution, because hydrolysis competes with polymerization. The potential of mineral surfaces to facilitate prebiotic polymerization was pointed out long ago(2). Here we describe a system that models prebiotic polymerization by the oligomerization of activated monomers-both nucleotides and amino acids. We find that whereas the reactions in solution produce only short oligomers (the longest typically being a 10-mer), the presence of mineral surfaces (montmorillonite for nucleotides, illite and hydroxylapatite for amino acids) induces the formation of oligomers up to 55 monomers long. These are formed by successive 'feedings' with the monomers; polymerization takes place on the mineral surfaces in a manner akin to solid-phase synthesis of biopolymers(3,4).	SALK INST BIOL STUDIES,SAN DIEGO,CA 92186	Salk Institute	Ferris, JP (corresponding author), RENSSELAER POLYTECH INST,DEPT CHEM,TROY,NY 12180, USA.							ACEVEDO OL, 1986, NATURE, V321, P790, DOI 10.1038/321790a0; BERNAL JD, 1951, PHYSICAL BASIS LIFE; EHLER KW, 1976, BIOCHIM BIOPHYS ACTA, V434, P233, DOI 10.1016/0005-2795(76)90055-6; FERRIS JP, 1993, J AM CHEM SOC, V115, P12270, DOI 10.1021/ja00079a006; GIBBS D, 1980, J MOL EVOL, V15, P347, DOI 10.1007/BF01733141; HOLM NG, 1993, ORIGINS LIFE EVOL B, V23, P195, DOI 10.1007/BF01581839; KAWAMURA K, 1994, J AM CHEM SOC, V116, P7564, DOI 10.1021/ja00096a013; SCHWARTZ AW, 1985, J MOL EVOL, V21, P299, DOI 10.1007/BF02102362; Szostak J.W., 1993, RNA WORLD, P511	9	612	626	6	215	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAY 2	1996	381	6577					59	61		10.1038/381059a0	http://dx.doi.org/10.1038/381059a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UJ053	8609988	Green Submitted			2022-12-28	WOS:A1996UJ05300053
J	Liu, LX; Weller, PF				Liu, LX; Weller, PF			Drug therapy - Antiparasitic drugs	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							ISOSPORA-BELLI INFECTION; ACQUIRED IMMUNODEFICIENCY SYNDROME; MANSONELLA-PERSTANS FILARIASIS; CUTANEOUS LARVA MIGRANS; ALBENDAZOLE THERAPY; CONTROLLED TRIAL; MICROSPORIDIAL KERATOCONJUNCTIVITIS; CEREBRAL CYSTICERCOSIS; BRAIN CYSTICERCOSIS; TOPICAL FUMAGILLIN		BETH ISRAEL HOSP, DIV INFECT DIS, BOSTON, MA 02215 USA; HARVARD UNIV, SCH MED, DEPT MED, BOSTON, MA USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School								ABIOSE A, 1993, LANCET, V341, P130, DOI 10.1016/0140-6736(93)90002-X; ADAMS EJ, 1994, J NUTR, V124, P1199, DOI 10.1093/jn/124.8.1199; ALBONICO M, 1994, T ROY SOC TROP MED H, V88, P585, DOI 10.1016/0035-9203(94)90174-0; AMMANN RW, 1994, HEPATOLOGY, V19, P735, DOI 10.1002/hep.1840190328; ANDREWS JRH, 1994, T ROY SOC TROP MED H, V88, P200, DOI 10.1016/0035-9203(94)90295-X; APT W, 1995, AM J TROP MED HYG, V52, P532, DOI 10.4269/ajtmh.1995.52.532; ARCHIBALD LK, 1993, Q J MED, V86, P191; ASMUTH DM, 1994, CLIN INFECT DIS, V18, P819, DOI 10.1093/clinids/18.5.819; AUBIN F, 1995, NEW ENGL J MED, V332, P612, DOI 10.1056/NEJM199503023320917; AWADZI K, 1994, TROP MED PARASITOL, V45, P203; BASTID C, 1994, DIGEST DIS SCI, V39, P1576, DOI 10.1007/BF02088067; BEAUVAIS B, 1994, ANTIMICROB AGENTS CH, V38, P2440, DOI 10.1128/AAC.38.10.2440; BISSUEL F, 1994, CLIN INFECT DIS, V18, P447, DOI 10.1093/clinids/18.3.447; BISSUEL F, 1994, J INFECT DIS, V170, P749, DOI 10.1093/infdis/170.3.749; BITTENCOURT PRM, 1992, NEUROLOGY, V42, P492, DOI 10.1212/WNL.42.3.492; BLANSHARD C, 1992, AIDS, V6, P311, DOI 10.1097/00002030-199203000-00008; BRINDLEY PJ, 1990, EXP PARASITOL, V71, P245, DOI 10.1016/0014-4894(90)90028-B; CAMPBELL WC, 1991, ANNU REV MICROBIOL, V45, P445, DOI 10.1146/annurev.mi.45.100191.002305; CARPIO A, 1995, ARCH INTERN MED, V155, P1982, DOI 10.1001/archinte.155.18.1982; CAUMES E, 1993, AM J TROP MED HYG, V49, P641, DOI 10.4269/ajtmh.1993.49.641; CLINE BL, 1992, AM J TROP MED HYG, V47, P512, DOI 10.4269/ajtmh.1992.47.512; COOK GC, 1992, J INFECTION, V25, P1, DOI 10.1016/0163-4453(92)93369-2; CROSS J H, 1987, Southeast Asian Journal of Tropical Medicine and Public Health, V18, P507; CRUZ M, 1991, T ROY SOC TROP MED H, V85, P244, DOI 10.1016/0035-9203(91)90041-V; CULLY DF, 1994, NATURE, V371, P707, DOI 10.1038/371707a0; DACHMAN WD, 1994, J INFECT DIS, V169, P689, DOI 10.1093/infdis/169.3.689; DATRY A, 1994, T ROY SOC TROP MED H, V88, P344, DOI 10.1016/0035-9203(94)90110-4; DAVIES HD, 1993, ARCH DERMATOL, V129, P588, DOI 10.1001/archderm.129.5.588; DAY TA, 1992, PARASITOL TODAY, V8, P342, DOI 10.1016/0169-4758(92)90070-I; DEHOVITZ JA, 1986, NEW ENGL J MED, V315, P87, DOI 10.1056/NEJM198607103150203; DELBRUTTO OH, 1992, ARCH NEUROL-CHICAGO, V49, P535, DOI 10.1001/archneur.1992.00530290123021; DELBRUTTO OH, 1990, J NEUROSURG, V72, P816, DOI 10.3171/jns.1990.72.5.0816; DELBRUTTO OH, 1993, CLIN INFECT DIS, V17, P730, DOI 10.1093/clinids/17.4.730; DIESENHOUSE MC, 1993, AM J OPHTHALMOL, V115, P293, DOI 10.1016/S0002-9394(14)73578-0; DIETERICH DT, 1994, J INFECT DIS, V169, P178, DOI 10.1093/infdis/169.1.178; DUNNE CL, 1991, T ROY SOC TROP MED H, V85, P550, DOI 10.1016/0035-9203(91)90255-W; FLISSER A, 1993, LANCET, V342, P748, DOI 10.1016/0140-6736(93)91743-6; GANN PH, 1994, J INFECT DIS, V169, P1076, DOI 10.1093/infdis/169.5.1076; GILGRANDE LA, 1993, LANCET, V342, P1269, DOI 10.1016/0140-6736(93)92361-V; GLAZIOU P, 1993, TROP MED PARASITOL, V44, P331; GREENE BM, 1991, J INFECT DIS, V163, P376, DOI 10.1093/infdis/163.2.376; GROVE DI, 1982, T ROY SOC TROP MED H, V76, P114, DOI 10.1016/0035-9203(82)90034-7; HALL A, 1993, T ROY SOC TROP MED H, V87, P84, DOI 10.1016/0035-9203(93)90435-S; HALL A, 1994, T ROY SOC TROP MED H, V88, P110, DOI 10.1016/0035-9203(94)90525-8; HAQUE MA, 1993, J INVERTEBR PATHOL, V62, P171, DOI 10.1006/jipa.1993.1092; HOGE CW, 1995, LANCET, V345, P691, DOI 10.1016/S0140-6736(95)90868-4; Hoge CW, 1995, LANCET, V345, P1060; HORTON RJ, 1989, T ROY SOC TROP MED H, V83, P97, DOI 10.1016/0035-9203(89)90724-4; Jongsuksuntigul Praphasri, 1993, Southeast Asian Journal of Tropical Medicine and Public Health, V24, P724; JUNG H, 1992, J CLIN PHARMACOL, V32, P28, DOI 10.1002/j.1552-4604.1992.tb03783.x; JUNG H, 1990, J NEUROL, V237, P279, DOI 10.1007/BF00314741; KAZURA J, 1993, AM J TROP MED HYG, V49, P804, DOI 10.4269/ajtmh.1993.49.804; KHUROO MS, 1993, GASTROENTEROLOGY, V104, P1452, DOI 10.1016/0016-5085(93)90355-G; KLION AD, 1993, J INFECT DIS, V168, P202, DOI 10.1093/infdis/168.1.202; KOLLARITSCH H, 1993, T ROY SOC TROP MED H, V87, P689, DOI 10.1016/0035-9203(93)90296-3; KOUDELA B, 1994, J EUKARYOT MICROBIOL, V41, pS49; KRAIVICHIAN P, 1992, T ROY SOC TROP MED H, V86, P418, DOI 10.1016/0035-9203(92)90248-B; KREPEL HP, 1993, T ROY SOC TROP MED H, V87, P87, DOI 10.1016/0035-9203(93)90437-U; LACEY E, 1990, PARASITOL TODAY, V6, P112, DOI 10.1016/0169-4758(90)90227-U; LACEY E, 1994, ACTA TROP, V56, P245, DOI 10.1016/0001-706X(94)90066-3; LATHAM MC, 1990, AM J TROP MED HYG, V43, P170, DOI 10.4269/ajtmh.1990.43.170; LIU YH, 1991, CHINESE MED J-PEKING, V104, P27; MADICO G, 1993, LANCET, V342, P122, DOI 10.1016/0140-6736(93)91330-O; MAK JW, 1993, AM J TROP MED HYG, V48, P591, DOI 10.4269/ajtmh.1993.48.591; MARTINPREVEL Y, 1993, AM J TROP MED HYG, V48, P186, DOI 10.4269/ajtmh.1993.48.186; MCCOWEN MC, 1951, SCIENCE, V113, P202, DOI 10.1126/science.113.2930.202; MENEGHELLI U G, 1986, Arquivos de Gastroenterologia, V23, P177; MOLINA JM, 1995, J INFECT DIS, V171, P245, DOI 10.1093/infdis/171.1.245; NAHMIAS J, 1994, ANN TROP MED PARASIT, V88, P295, DOI 10.1080/00034983.1994.11812870; NAQUIRA C, 1989, AM J TROP MED HYG, V40, P304, DOI 10.4269/ajtmh.1989.40.304; NOKES C, 1992, P ROY SOC B-BIOL SCI, V247, P77, DOI 10.1098/rspb.1992.0011; NUTMAN TB, 1987, J INFECT DIS, V156, P662, DOI 10.1093/infdis/156.4.662; OOSTBURG BFJ, 1992, TROP GEOGR MED, V44, P154; ORTEGA YR, 1993, NEW ENGL J MED, V328, P1308, DOI 10.1056/NEJM199305063281804; OTTESEN EA, 1990, NEW ENGL J MED, V322, P1113, DOI 10.1056/NEJM199004193221604; PACQUE M, 1991, AM J MED, V90, P590, DOI 10.1016/S0002-9343(05)80010-5; PACQUE M, 1990, LANCET, V336, P1486, DOI 10.1016/0140-6736(90)93187-T; PAPE JW, 1994, ANN INTERN MED, V121, P654, DOI 10.7326/0003-4819-121-9-199411010-00004; PAPE JW, 1989, NEW ENGL J MED, V320, P1044, DOI 10.1056/NEJM198904203201604; ROSBERGER DF, 1993, CORNEA, V12, P261, DOI 10.1097/00003226-199305000-00013; SHANDERA WX, 1994, MEDICINE, V73, P37, DOI 10.1097/00005792-199401000-00004; SOTELO J, 1990, J NEUROL, V237, P69, DOI 10.1007/BF00314663; TAKAYANAGUI OM, 1992, ARCH NEUROL-CHICAGO, V49, P290, DOI 10.1001/archneur.1992.00530270106026; TORRES JR, 1993, CLIN INFECT DIS, V17, P900, DOI 10.1093/clinids/17.5.900; VANDENENDEN E, 1992, ANN SOC BELG MED TR, V72, P215; VANDENENDEN E, 1993, T ROY SOC TROP MED H, V87, P90, DOI 10.1016/0035-9203(93)90438-V; VAZQUEZ ML, 1987, NEUROLOGY, V37, P1561, DOI 10.1212/WNL.37.9.1561; VAZQUEZ V, 1992, NEW ENGL J MED, V327, P696, DOI 10.1056/NEJM199209033271005; WEBER R, 1994, CLIN INFECT DIS, V19, P342, DOI 10.1093/clinids/19.2.342; WEBER R, 1994, CLIN INFECT DIS, V19, P517, DOI 10.1093/clinids/19.3.517; WEISS LM, 1988, ANN INTERN MED, V109, P474, DOI 10.7326/0003-4819-109-6-474; WEISS LM, 1994, J EUKARYOT MICROBIOL, V41, pS65; WEN H, 1993, BRIT J CLIN PHARMACO, V35, P565, DOI 10.1111/j.1365-2125.1993.tb04182.x; WHITE AC, 1994, J INFECT DIS, V170, P419, DOI 10.1093/infdis/170.2.419; WHITWORTH JAG, 1991, LANCET, V338, P1100, DOI 10.1016/0140-6736(91)91963-U; WILKINS JH, 1994, EYE, V8, P703, DOI 10.1038/eye.1994.177; WILSON JF, 1992, CLIN INFECT DIS, V15, P234, DOI 10.1093/clinids/15.2.234; World Health Organization, 1995, WHO MODEL PRESCRIBIN, V2nd; WYLER DJ, 1993, NEW ENGL J MED, V329, P31, DOI 10.1056/NEJM199307013290107; 1995, MED LETT DRUGS THER, V37, P99	100	103	111	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 2	1996	334	18					1178	1184		10.1056/NEJM199605023341808	http://dx.doi.org/10.1056/NEJM199605023341808			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UG831	8602186				2022-12-28	WOS:A1996UG83100008
J	Olschewski, H; Walmrath, D; Schermuly, R; Ghofrani, A; Grimminger, F; Seeger, W				Olschewski, H; Walmrath, D; Schermuly, R; Ghofrani, A; Grimminger, F; Seeger, W			Aerosolized prostacyclin and iloprost in severe pulmonary hypertension	ANNALS OF INTERNAL MEDICINE			English	Article							NITRIC-OXIDE; EPOPROSTENOL; SURVIVAL	Objective: To compare the effects of aerosolization of prostacyclin and its stable analog iloprost with those of nasal oxygen, inhaled nitric oxide, and intravenous prostacyclin on hemodynamics and gas exchange in patients with severe pulmonary hypertension. Design: Open uncontrolled trial. Setting: Justus-Liebig-University, Giessen, Germany. Patients: 4 patients with primary pulmonary hypertension and 2 patients with severe pulmonary hypertension associated with calcinosis, the Raynaud phenomenon, esophageal dysfunction, sclerodactyly, and telangiectasia (the CREST syndrome). All were classified as New York Heart Association class III or class IV. Intervention: Short-term applications of O-2, inhaled nitric oxide, intravenous prostacyclin, aerosolized prostacyclin, and aerosolized iloprost during repeated catheter investigation of the right side of the heart within a 1-month period. One patient had long-term therapy with inhaled iloprost. Results: Aerosolized prostacyclin decreased pulmonary artery pressure in 6 patients from (mean +/- SE) 62.3 +/- 4.1 mm Hg to 50.8 +/- 5.5 mm Hg and reduced pulmonary vascular resistance from 1721 +/- 253 dyne/s . cm(-5) to 1019 +/- 203 dyne/s . cm(-5), and it increased cardiac output from 2.75 +/- 0.21 L/min to 4.11 +/- 0.54 L/min, mixed venous oxygen saturation from 51.1% +/- 3.4% to 66.3% +/- 4.1%, and arterial oxygen saturation from 90.6% +/- 2.7% to 93.8% +/- 23% (P < 0.05 for all changes). Mean systemic arterial pressure was only slightly affected. The responses lasted for 10 to 30 minutes after inhalation was terminated. Aerosolized iloprost had an identical efficacy profile but was associated with a longer duration of the pulmonary vasodilatory effect (60 min to 120 min). In comparison, intravenous prostacyclin reduced pulmonary vascular resistance with corresponding efficacy but produced a more pronounced decline in systemic artery pressure and no clinically significant decrease in pulmonary artery pressure. Nitric oxide and O-2 were less potent pulmonary vasodilators in these patients. In one patient, 1 year of therapy with aerosolized iloprost (100 mu g/d in six aerosol doses) resulted in sustained efficacy of the inhaled vasodilator regimen and clinical improvement. Conclusion: Aerosolization of prostacyclin or its stable analog iloprost causes selective pulmonary vasodilatation, increases cardiac output, and improves venous and arterial oxygenation in patients with severe pulmonary hypertension. Thus, it may offer a new strategy for treatment of this disease.	UNIV GIESSEN, DEPT MED, D-35392 GIESSEN, GERMANY	Justus Liebig University Giessen			Ghofrani, Ardeschir/AAD-5293-2020; Ghofrani, Hossein Ardeschir/AAD-2856-2022; Olschewski, Horst/L-3547-2019	Ghofrani, Ardeschir/0000-0002-2029-4419; Olschewski, Horst/0000-0002-2834-7466; Seeger, Werner/0000-0003-1946-0894; Grimminger, Friedrich/0000-0001-8725-6276; Schermuly, Ralph/0000-0002-5167-6970				BARST RJ, 1994, ANN INTERN MED, V121, P409, DOI 10.7326/0003-4819-121-6-199409150-00003; DALONZO GE, 1991, ANN INTERN MED, V115, P343, DOI 10.7326/0003-4819-115-5-343; HIGENBOTTAM T, 1987, AM REV RESPIR DIS, V136, P782, DOI 10.1164/ajrccm/136.3.782; HIGENBOTTAM T, 1984, LANCET, V1, P1046; PEPKEZABA J, 1991, LANCET, V338, P1173, DOI 10.1016/0140-6736(91)92033-X; RICH S, 1992, NEW ENGL J MED, V327, P76, DOI 10.1056/NEJM199207093270203; RUBIN LJ, 1990, ANN INTERN MED, V112, P485, DOI 10.7326/0003-4819-112-7-485; WALMRATH D, 1993, LANCET, V342, P961, DOI 10.1016/0140-6736(93)92004-D; WELTE M, 1993, EUR SURG RES, V25, P329, DOI 10.1159/000129297; ZAPOL WM, 1994, AM J RESP CRIT CARE, V149, P1375, DOI 10.1164/ajrccm.149.5.8173780	10	324	342	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 1	1996	124	9					820	824		10.7326/0003-4819-124-9-199605010-00006	http://dx.doi.org/10.7326/0003-4819-124-9-199605010-00006			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UG254	8610951				2022-12-28	WOS:A1996UG25400006
J	Gao, JM; Mammen, M; Whitesides, GM				Gao, JM; Mammen, M; Whitesides, GM			Evaluating electrostatic contributions to binding with the use of protein charge ladders	SCIENCE			English	Article								Electrostatic interactions between charges on ligands and charges on proteins that are remote from the binding interface can influence the free energy of binding (Delta G(b)). The binding affinities between charged ligands and the members of a charge ladder of bovine carbonic anhydrase (CAII) constructed by random acetylation of the amino groups on its surface were measured by affinity capillary electrophoresis (ACE). The values of Delta G(b) derived from this analysis correlated approximately linearly with the charge. Opposite charges on the ligand and the members of the charge ladder of CAII were stabilizing; like charges were destabilizing. The combination of ACE and protein charge ladders provides a tool for quantitatively examining the contributions of electrostatics to free energies of molecular recognition in biology.	HARVARD UNIV,DEPT CHEM,CAMBRIDGE,MA 02138	Harvard University					NIGMS NIH HHS [GM51559] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051559] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAMSON HA, 1942, ELECTROPHORESIS PROT, pCH5; BASAK SK, 1995, ANAL BIOCHEM, V226, P51, DOI 10.1006/abio.1995.1190; CHU YH, 1995, ACCOUNTS CHEM RES, V28, P461, DOI 10.1021/ar00059a004; DODGSON SJ, 1991, CARBONIC ANHYDRASES; GAO JM, 1994, P NATL ACAD SCI USA, V91, P12027, DOI 10.1073/pnas.91.25.12027; HONIG B, 1995, SCIENCE, V268, P1144, DOI 10.1126/science.7761829; Ise N, 1996, ACCOUNTS CHEM RES, V29, P3, DOI 10.1021/ar950019k; LILJAS A, 1972, NATURE-NEW BIOL, V235, P131, DOI 10.1038/newbio235131a0; LUMB KJ, 1995, SCIENCE, V268, P436, DOI 10.1126/science.7716550; NOVOTNY J, 1992, PROG BIOPHYS MOL BIO, V58, P203, DOI 10.1016/0079-6107(92)90006-R; Schmitz KS, 1996, ACCOUNTS CHEM RES, V29, P7, DOI 10.1021/ar950129r; THOMAS PG, 1985, NATURE, V318, P375, DOI 10.1038/318375a0	12	82	84	0	25	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 26	1996	272	5261					535	537		10.1126/science.272.5261.535	http://dx.doi.org/10.1126/science.272.5261.535			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UG826	8614800				2022-12-28	WOS:A1996UG82600040
J	Lehman, A; Black, R; Ecker, JR				Lehman, A; Black, R; Ecker, JR			HOOKLESS1, an ethylene response gene, is required for differential cell elongation in the Arabidopsis hypocotyl	CELL			English	Article							NUCLEOTIDE-SEQUENCE; T-DNA; PLANTS; AUXIN; ACETYLTRANSFERASE; EXPRESSION; MUTANTS; GROWTH; MUTAGENESIS; THALIANA	Bending in plant tissues results from differential cell elongation. We have characterized Arabidopsis ''hookless'' mutants that are defective in differential growth in the hypocotyl. HOOKLESS1 was cloned and its predicted protein shows similarity to a diverse group of N-acetyltransferases. HOOKLESS1 mRNA is increased by treatment with ethylene and decreased in the ethylene-insensitive mutant ein2. High level expression of HOOKLESS1 mRNA results in constitutive hook curvature. The morphology of the hookless hypocotyl is phenocopied by inhibitors of auxin transport or by high levels of endogenous or exogenous auxin. Spatial patterns of expression of two immediate early auxin-responsive genes are altered in hookless1 mutants, suggesting that the ethylene response gene HOOKLESS1 controls differential cell growth by regulating auxin activity.	UNIV PENN,INST PLANT SCI,DEPT BIOL,PHILADELPHIA,PA 19104; PENN STATE UNIV,DEPT BIOL,MEDIA,PA 19603	University of Pennsylvania; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University			Ecker, Joseph R/B-9144-2008	Ecker, Joseph R/0000-0001-5799-5895				ABEL S, 1995, J MOL BIOL, V251, P533, DOI 10.1006/jmbi.1995.0454; ABELES FB, 1992, IN PRESS ETHYLENE PL; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ANZAI H, 1990, NUCLEIC ACIDS RES, V18, P1890, DOI 10.1093/nar/18.7.1890; BECHTOLD N, 1993, CR ACAD SCI III-VIE, V316, P1194; BLACK RC, 1986, PLANT PHYSIOL, V80, P145, DOI 10.1104/pp.80.1.145; BOERJAN W, 1995, PLANT CELL, V7, P1405, DOI 10.1105/tpc.7.9.1405; CASERO RA, 1991, J BIOL CHEM, V266, P810; CELENZA JL, 1995, GENE DEV, V9, P2131, DOI 10.1101/gad.9.17.2131; CHAUDHURY AM, 1993, PLANT J, V4, P907, DOI 10.1046/j.1365-313X.1993.04060907.x; Cleland R. E., 1987, Plant hormones and their role in plant growth and development., P132; COON SL, 1995, SCIENCE, V270, P1681, DOI 10.1126/science.270.5242.1681; COX KH, 1988, PLANT MOL BIOL PRACT, P1; DARWIN C, 1896, POWER MOVEMENT PLANT, P87; DAVIE JR, 1994, J CELL BIOCHEM, V55, P98, DOI 10.1002/jcb.240550112; DRIESSEN HPC, 1985, CRIT REV BIOCHEM MOL, V18, P281, DOI 10.3109/10409238509086784; ECKER JR, 1995, SCIENCE, V268, P667, DOI 10.1126/science.7732375; EDWARDS K, 1991, NUCLEIC ACIDS RES, V19, P1349, DOI 10.1093/nar/19.6.1349; FELDMANN KA, 1991, PLANT J, V1, P71, DOI 10.1111/j.1365-313X.1991.00071.x; FIRN RD, 1980, ANNU REV PLANT PHYS, V31, P131, DOI 10.1146/annurev.pp.31.060180.001023; GIL P, 1994, PLANT PHYSIOL, V104, P777, DOI 10.1104/pp.104.2.777; GIL P, 1996, IN PRESS EMBO J; GUZMAN P, 1990, PLANT CELL, V2, P513, DOI 10.1105/tpc.2.6.513; HEIM U, 1989, NUCLEIC ACIDS RES, V17, P7103, DOI 10.1093/nar/17.17.7103; HOBBIE L, 1994, PLANT CELL ENVIRON, V17, P525, DOI 10.1111/j.1365-3040.1994.tb00147.x; HORINOUCHI S, 1987, J BACTERIOL, V169, P1929, DOI 10.1128/jb.169.5.1929-1937.1987; HOU YM, 1993, PLANT CELL, V5, P329, DOI 10.1105/tpc.5.3.329; JORGENSEN RA, 1995, SCIENCE, V268, P686, DOI 10.1126/science.268.5211.686; KANG BG, 1967, SCIENCE, V156, P958, DOI 10.1126/science.156.3777.958; KERK NM, 1995, DEVELOPMENT, V121, P2825; KIEBER JJ, 1993, CELL, V72, P427, DOI 10.1016/0092-8674(93)90119-B; King JJ, 1995, PLANT CELL, V7, P2023, DOI 10.1105/tpc.7.12.2023; KRUGEL H, 1993, GENE, V127, P127, DOI 10.1016/0378-1119(93)90627-F; LEYSER HMO, 1993, NATURE, V364, P161, DOI 10.1038/364161a0; LI Y, 1994, PLANT MOL BIOL, V24, P715, DOI 10.1007/BF00029853; LI Y, 1991, PLANT CELL, V3, P1167, DOI 10.1105/tpc.3.11.1167; LINCOLN C, 1990, PLANT CELL, V2, P1071, DOI 10.1105/tpc.2.11.1071; Lomax Terri L., 1995, P509; MORGAN DG, 1964, NATURE, V201, P476, DOI 10.1038/201476a0; MULLEN JR, 1989, EMBO J, V8, P2067, DOI 10.1002/j.1460-2075.1989.tb03615.x; OELLER PW, 1993, J MOL BIOL, V233, P789, DOI 10.1006/jmbi.1993.1555; OHMETAKAGI M, 1995, PLANT CELL, V7, P173, DOI 10.1105/tpc.7.2.173; PRUITT RE, 1986, J MOL BIOL, V187, P169, DOI 10.1016/0022-2836(86)90226-3; Reinecke D. M., 1987, Plant hormones and their role in plant growth and development., P24; ROMAN G, 1995, GENETICS, V139, P1393; RUBERY PH, 1990, SYM SOC EXP BIOL, V44, P119; RYAN KA, 1993, P NATL ACAD SCI USA, V90, P8609, DOI 10.1073/pnas.90.18.8609; SCHARDL CL, 1987, GENE, V61, P1, DOI 10.1016/0378-1119(87)90359-3; SCHWARK A, 1993, J PLANT PHYSIOL, V142, P585, DOI 10.1016/S0176-1617(11)80403-7; SCHWARK A, 1992, J PLANT PHYSIOL, V140, P562, DOI 10.1016/S0176-1617(11)80790-X; SILK WK, 1978, AM J BOT, V65, P310, DOI 10.2307/2442271; SMITH H, 1995, ANNU REV PLANT PHYS, V46, P289, DOI 10.1146/annurev.pp.46.060195.001445; Tamas I. A., 1987, Plant hormones and their role in plant growth and development., P393; TENOVER FC, 1988, J BACTERIOL, V170, P471, DOI 10.1128/jb.170.1.471-473.1988; TERCERO JC, 1992, J BIOL CHEM, V267, P20270; TIMPTE C, 1995, PLANT J, V8, P561, DOI 10.1046/j.1365-313X.1995.8040561.x; TRIBIOLI C, 1994, HUM MOL GENET, V3, P1061, DOI 10.1093/hmg/3.7.1061; WYATT RE, 1993, PLANT MOL BIOL, V22, P731, DOI 10.1007/BF00027361; YOSHIKAWA A, 1987, MOL GEN GENET, V209, P481, DOI 10.1007/BF00331153; ZIMMER W, 1991, MOL GEN GENET, V229, P41, DOI 10.1007/BF00264211	60	330	349	7	49	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 19	1996	85	2					183	194		10.1016/S0092-8674(00)81095-8	http://dx.doi.org/10.1016/S0092-8674(00)81095-8			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UG255	8612271	hybrid			2022-12-28	WOS:A1996UG25500007
J	Sawle, G				Sawle, G			Visual vertigo	LANCET			English	Editorial Material											Sawle, G (corresponding author), QUEENS MED CTR,DIV CLIN NEUROL,NOTTINGHAM,ENGLAND.							BRONSTEIN AM, 1995, J NEUROL NEUROSUR PS, V59, P472, DOI 10.1136/jnnp.59.5.472; FURMAN JM, 1994, BAILLIERE CLIN NEUR, V3, P510; RUDGE P, 1995, J NEUROL NEUROSUR PS, V59, P568, DOI 10.1136/jnnp.59.6.568	3	2	2	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 13	1996	347	9007					986	987		10.1016/S0140-6736(96)90140-3	http://dx.doi.org/10.1016/S0140-6736(96)90140-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UF380	8606609				2022-12-28	WOS:A1996UF38000005
J	Zopf, D; Roth, S				Zopf, D; Roth, S			Oligosaccharide anti-infective agents	LANCET			English	Review							ESCHERICHIA-COLI; HUMAN-MILK; EPITHELIAL-CELLS; INFLUENZA-VIRUS; GLYCOPROTEIN; GLYCOLIPIDS; ADHESION				Zopf, D (corresponding author), NEOSE TECHNOL INC, 102 WITMER RD, HORSHAM, PA 19044 USA.							ANDERSSON B, 1986, J INFECT DIS, V153, P232, DOI 10.1093/infdis/153.2.232; CACALANO G, 1992, J CLIN INVEST, V89, P1866, DOI 10.1172/JCI115791; CARLSON SE, 1985, AM J CLIN NUTR, V41, P720, DOI 10.1093/ajcn/41.4.720; COPPA GV, 1990, LANCET, V335, P569, DOI 10.1016/0140-6736(90)90350-E; CUNDELL DR, 1994, MICROB PATHOGENESIS, V17, P361, DOI 10.1006/mpat.1994.1082; CUNDELL DR, 1995, INFECT IMMUN, V63, P757, DOI 10.1128/IAI.63.3.757-761.1995; GIBBONS RJ, 1992, INFECT DIS, P7; GOTTSCHALK A, 1972, GLYCOPROTEINS THEI A, V5, P15; Hirst GK, 1941, SCIENCE, V94, P22, DOI 10.1126/science.94.2427.22; HULTGREN SJ, 1991, ANNU REV MICROBIOL, V45, P383, DOI 10.1146/annurev.micro.45.1.383; KARLSSON KA, 1992, APMIS, V100, P71; KRIVAN HC, 1988, P NATL ACAD SCI USA, V85, P6157, DOI 10.1073/pnas.85.16.6157; KUNZ C, 1993, ACTA PAEDIATR, V82, P903, DOI 10.1111/j.1651-2227.1993.tb12597.x; KYOGASHIMA M, 1989, ARCH BIOCHEM BIOPHYS, V270, P391, DOI 10.1016/0003-9861(89)90042-8; MOURICOUT M, 1990, INFECT IMMUN, V58, P98, DOI 10.1128/IAI.58.1.98-106.1990; Ofek I., 1990, CURR TOP MICROBIOL, V151, P91; Ofek I., 1994, BACTERIAL ADHESION C; RENNER B, 1993, NEW PERSPECTIVES INF; ROBERTS JA, 1984, J UROLOGY, V131, P163, DOI 10.1016/S0022-5347(17)50251-7; SPALTENSTEIN A, 1991, J AM CHEM SOC, V113, P686, DOI 10.1021/ja00002a053; STAPLETON A, 1992, J CLIN INVEST, V90, P965, DOI 10.1172/JCI115973; STRONGE WJ, 1990, INT J IMPACT ENG, V9, P1, DOI 10.1016/0734-743X(90)90018-Q; TOMASZ A, 1994, NEW ENGL J MED, V330, P1247, DOI 10.1056/NEJM199404283301725; WATKINS W, 1972, GLYCOPROTEINS THEI B, V5, P843; WEISER JN, 1994, INFECT IMMUN, V62, P2582, DOI 10.1128/IAI.62.6.2582-2589.1994; WICK MJ, 1991, CELL, V67, P651; WILEY DC, 1987, ANNU REV BIOCHEM, V56, P365, DOI 10.1146/annurev.bi.56.070187.002053; [No title captured]	28	265	287	2	28	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	APR 13	1996	347	9007					1017	1021		10.1016/S0140-6736(96)90150-6	http://dx.doi.org/10.1016/S0140-6736(96)90150-6			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UF380	8606566				2022-12-28	WOS:A1996UF38000015
J	Langdon, LO; Toskes, PP; Kimball, HR				Langdon, LO; Toskes, PP; Kimball, HR			Future roles and training of internal medicine subspecialists	ANNALS OF INTERNAL MEDICINE			English	Article								While fellowship training programs are being reduced in size to better conform to societal needs, the training of subspecialist basic scientists and clinical investigators must be protected to ensure continued discovery and the scholarly application of knowledge to patient care. Fewer subspecialist clinicians must be appropriately trained to serve as consultants, as principal care providers, and as scholarly leaders and educators in their subspecialties. This article describes the recommendations of the American Board of internal Medicine for subspecialty training. To encourage physicians to choose careers as investigators, overlapping but different training paths are delineated for subspecialist clinicians and investigators. More didactic coursework is recommended for both paths. To maximize the contribution of fewer subspecialists, it is essential to provide rigorous training that is appropriately relevant and realistically matched with career opportunities.	UNIV FLORIDA, COLL MED, DIV GASTROENTEROL HEPATOL & NUTR, GAINESVILLE, FL 32610 USA; UNIV ALABAMA, BIRMINGHAM, AL USA; OREGON HLTH SCI UNIV, PORTLAND, OR 97201 USA; CEDARS SINAI MED CTR, LOS ANGELES, CA 90048 USA; UNIV MIAMI, SCH MED, MIAMI, FL USA; SAN FRANCISCO GEN HOSP, SAN FRANCISCO, CA 94110 USA; LONG ISL JEWISH MED CTR, NEW HYDE PK, NY 11042 USA; VET ADM MED CTR, DALLAS, TX 75216 USA; UNIV CHICAGO, MED CTR, CHICAGO, IL 60637 USA; UNIV CALIF SAN DIEGO, SCH MED, SAN DIEGO, CA 92103 USA; NEW ENGLAND JOURNAL MED, BOSTON, MA USA; UNIV PENN, MED CTR, PHILADELPHIA, PA 19104 USA; TUFTS UNIV, SCH MED, BOSTON, MA 02111 USA; CASE WESTERN RESERVE UNIV, SCH MED, CLEVELAND, OH USA; MONTEFIORE MED CTR, BRONX, NY 10467 USA; INDIANA UNIV, SCH MED, INDIANAPOLIS, IN USA	State University System of Florida; University of Florida; University of Alabama System; University of Alabama Birmingham; Oregon Health & Science University; Cedars Sinai Medical Center; University of Miami; San Francisco General Hospital Medical Center; Northwell Health; US Department of Veterans Affairs; Veterans Health Administration (VHA); University of Chicago; University of Chicago Medical Center; University of California System; University of California San Diego; University of Pennsylvania; Tufts University; Case Western Reserve University; Montefiore Medical Center; Yeshiva University; Albert Einstein College of Medicine; Indiana University System; Indiana University-Purdue University Indianapolis	Langdon, LO (corresponding author), AMER BOARD INTERNAL MED, 3624 MARKET ST, PHILADELPHIA, PA 19104 USA.							AHRENS EH, 1992, CRISIS CLIN RES OVER, P45; AIKEN LH, 1979, NEW ENGL J MED, V300, P1363, DOI 10.1056/NEJM197906143002404; *AM BOARD INT MED, 1995, POL PROC; DIAL TH, 1996, HLTH AFF MILWOOD, V14, P168; KASSIRER JP, 1994, NEW ENGL J MED, V331, P1370, DOI 10.1056/NEJM199411173312010; KASSIRER JP, 1994, NEW ENGL J MED, V331, P1151, DOI 10.1056/NEJM199410273311709; KIMBALL HR, 1994, AM J MED, V96, P559, DOI 10.1016/0002-9343(94)90097-3; LEVEY GS, 1988, ANN INTERN MED, V109, P414, DOI 10.7326/0003-4819-109-5-414; Neilson EG, 1995, J INVEST MED, V43, P534; NORCINI JJ, 1995, ACAD MED, V70, P512, DOI 10.1097/00001888-199506000-00012; *U CHIC NAT STUD I, 1994, DIR TRAIN PROGR INT; VANSELOW NA, 1995, JAMA-J AM MED ASSOC, V273, P192, DOI 10.1001/jama.273.3.192; WEINER JP, 1994, JAMA-J AM MED ASSOC, V272, P222; [No title captured]; 1994, AM J MED, V97, pR6	15	47	47	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 1	1996	124	7					686	691		10.7326/0003-4819-124-7-199604010-00011	http://dx.doi.org/10.7326/0003-4819-124-7-199604010-00011			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UB513	8607599				2022-12-28	WOS:A1996UB51300011
J	Grellier, P; Chanson, P; Casadevall, N; Abboud, S; Schaison, G				Grellier, P; Chanson, P; Casadevall, N; Abboud, S; Schaison, G			Remission of polycythemia vera after surgical cure of acromegaly	ANNALS OF INTERNAL MEDICINE			English	Article							COLONY FORMATION INVITRO		HOP BICETRE, SERV ENDOCRINOL & MALAD REPROD, F-94275 LE KREMLIN BICETRE, FRANCE; UNIV TEXAS, HLTH SCI CTR, DEPT MED NEPHROL, SAN ANTONIO, TX 78248 USA; HOP RAY POINCARE, SERV HEMATOL, F-92380 GARCHES, FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bicetre - APHP; UDICE-French Research Universities; Universite Paris Saclay; University of Texas System; University of Texas Health San Antonio; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Raymond-Poincare - APHP			Chanson, Philippe/F-8511-2013	Chanson, Philippe/0000-0001-5096-5722	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR042306] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR42306] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ADAMSON JW, 1976, NEW ENGL J MED, V295, P913, DOI 10.1056/NEJM197610212951702; CHANSON P, 1990, ANN INTERN MED, V113, P921, DOI 10.7326/0003-4819-113-12-921; CLAUSTRES M, 1987, J CLIN ENDOCR METAB, V65, P78, DOI 10.1210/jcem-65-1-78; CONGOTE LF, 1987, IN VITRO CELL DEV B, V23, P361, DOI 10.1007/BF02620993; CORREA PN, 1994, BLOOD, V83, P99; KURTZ A, 1988, P NATL ACAD SCI USA, V85, P7825, DOI 10.1073/pnas.85.20.7825; LEMOINE F, 1986, BLOOD, V68, P996; MUTA K, 1994, J CLIN INVEST, V94, P34, DOI 10.1172/JCI117327; RATAJCZAK MZ, 1994, J CLIN INVEST, V94, P320, DOI 10.1172/JCI117324; STRAUCH G, 1977, ACTA ENDOCRINOL-COP, V85, P465, DOI 10.1530/acta.0.0850465; VALLA D, 1985, ANN INTERN MED, V103, P329, DOI 10.7326/0003-4819-103-3-329	11	11	11	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 1	1996	124	5					495	496		10.7326/0003-4819-124-5-199603010-00006	http://dx.doi.org/10.7326/0003-4819-124-5-199603010-00006			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TW773	8602708				2022-12-28	WOS:A1996TW77300006
J	Todorov, P; Cariuk, P; McDevitt, T; Coles, B; Fearon, K; Tisdale, M				Todorov, P; Cariuk, P; McDevitt, T; Coles, B; Fearon, K; Tisdale, M			Characterization of a cancer cachectic factor	NATURE			English	Article							LEUKEMIA-INHIBITORY FACTOR; TUMOR NECROSIS FACTOR; CACHEXIA; MICE; MECHANISM; MUSCLE; CELLS; MODEL	CANCER cachexia is a syndrome of progressive wasting which has been suggested to be mediated by tumour-necrosis factor-alpha (ref. 1), interleukins 1 and 6 (ref. 2), interferon-gamma (ref. 3) and leukaemia-inhibitory factor(4). It has proved difficult to correlate levels of tumour-necrosis factor-alpha and interleukin-6 with cancer cachexia(5,6), and the weight loss induced by leukaemia-inhibitory factor may be due to toxicity(7). In the murine adenocarcinoma MAC16, cachexia is mediated by circulatory catabolic factors(8,9), which we have now isolated using an antibody cloned from splenocytes of mice transplanted with the MAC16 tumour, with a delayed cachexia(10). The material is a proteoglycan of relative molecular mass 24K which produces cachexia in vivo by inducing catabolism of skeletal muscle. The 24K material was also present in urine of cachectic cancer patients, but was absent from normal subjects, patients with weight loss due to trauma, and cancer patients with little or no weight loss. This suggests that cachexia in mice and humans may be produced by the same material.	UNIV ASTON,INST PHARMACEUT SCI,CRC,NUTR BIOCHEM RES GRP,BIRMINGHAM B4 7ET,W MIDLANDS,ENGLAND; UNIV COLL & MIDDLESEX SCH MED,DEPT BIOCHEM,CRC,MOLEC TOXICOL GRP,LONDON W1P 6D8,ENGLAND; UNIV EDINBURGH,ROYAL INFIRM,DEPT SURG,EDINBURGH EH3 9YW,MIDLOTHIAN,SCOTLAND	Aston University; University of Birmingham; University of London; University College London; Royal Infirmary of Edinburgh; University of Edinburgh								BECK SA, 1987, CANCER RES, V47, P5919; BECK SA, 1991, CANCER RES, V51, P6089; BEUTLER B, 1986, NATURE, V320, P584, DOI 10.1038/320584a0; BIBBY MC, 1987, J NATL CANCER I, V78, P539; GARCIAMARTINEZ C, 1994, CANCER LETT, V76, P1, DOI 10.1016/0304-3835(94)90126-0; GOLDBERG AL, 1988, J CLIN INVEST, V81, P1378, DOI 10.1172/JCI113466; MATTHYS P, 1991, INT J CANCER, V49, P77, DOI 10.1002/ijc.2910490115; MCDEVITT TM, 1992, BRIT J CANCER, V66, P815, DOI 10.1038/bjc.1992.366; MCDEVITT TM, 1995, J CANCER RES, V55, P1458; METCALF D, 1990, BLOOD, V76, P50; MORI M, 1991, CANCER RES, V51, P6656; PLUMB JA, 1991, CLIN NUTR, V10, P23, DOI 10.1016/0261-5614(91)90077-P; SMITH KL, 1993, BRIT J CANCER, V68, P314, DOI 10.1038/bjc.1993.334; SOCHER SH, 1988, J NATL CANCER I, V80, P595, DOI 10.1093/jnci/80.8.595; SODA K, 1994, JPN J CANCER RES, V85, P1124, DOI 10.1111/j.1349-7006.1994.tb02917.x; STRASSMANN G, 1992, J CLIN INVEST, V89, P1681, DOI 10.1172/JCI115767; YOSHIZAWA N, 1992, J IMMUNOL, V148, P3110	17	340	361	0	16	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	FEB 22	1996	379	6567					739	742		10.1038/379739a0	http://dx.doi.org/10.1038/379739a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TW567	8602222				2022-12-28	WOS:A1996TW56700056
J	Lauffenburger, DA; Horwitz, AF				Lauffenburger, DA; Horwitz, AF			Cell migration: A physically integrated molecular process	CELL			English	Review							MYOSIN-II; POLYMORPHONUCLEAR LEUKOCYTES; TYROSINE PHOSPHORYLATION; EXTRACELLULAR-MATRIX; DICTYOSTELIUM AMEBAE; FOCAL ADHESIONS; LIVING CELLS; FREE CALCIUM; ACTIN; MOTILITY		MIT,DEPT CHEM ENGN,CAMBRIDGE,MA 02139; UNIV ILLINOIS,DEPT CELL & STRUCT BIOL,URBANA,IL 61801	Massachusetts Institute of Technology (MIT); University of Illinois System; University of Illinois Urbana-Champaign	Lauffenburger, DA (corresponding author), MIT,CTR BIOMED ENGN,77 MASSACHUSETTS AVE,CAMBRIDGE,MA 02139, USA.				NIGMS NIH HHS [GM23244, GM53905] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM023244, R01GM053905, R01GM023244] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDRE E, 1989, J CELL BIOL, V108, P985, DOI 10.1083/jcb.108.3.985; BARD JB, 1975, J CELL BIOL, V67, P100; BILOZUR ME, 1989, CELL MOTIL CYTOSKEL, V14, P469, DOI 10.1002/cm.970140405; BOFELDT KE, 1994, J CLIN INVEST, V93, P1266; BOUDREAU N, 1995, TRENDS CELL BIOL, V5, P1, DOI 10.1016/S0962-8924(00)88924-2; BRETSCHER MS, 1992, EMBO J, V11, P405, DOI 10.1002/j.1460-2075.1992.tb05068.x; BURRIDGE K, 1992, J CELL BIOL, V119, P893, DOI 10.1083/jcb.119.4.893; BURRIDGE K, 1988, ANNU REV CELL BIOL, V4, P487, DOI 10.1146/annurev.cb.04.110188.002415; CANO ML, 1991, J CELL BIOL, V115, P677, DOI 10.1083/jcb.115.3.677; CHEN HC, 1995, J BIOL CHEM, V270, P16995, DOI 10.1074/jbc.270.28.16995; CHEN HC, 1994, P NATL ACAD SCI USA, V91, P10148, DOI 10.1073/pnas.91.21.10148; CHEN P, 1994, J CELL BIOL, V127, P847, DOI 10.1083/jcb.127.3.847; CHEN WT, 1981, J CELL BIOL, V90, P187, DOI 10.1083/jcb.90.1.187; COATES TD, 1992, J CELL BIOL, V117, P765, DOI 10.1083/jcb.117.4.765; CONDEELIS J, 1993, ANNU REV CELL BIOL, V9, P411, DOI 10.1146/annurev.cb.09.110193.002211; CONRAD PA, 1993, J CELL BIOL, V120, P1381, DOI 10.1083/jcb.120.6.1381; COOPER JA, 1987, J CELL BIOL, V104, P491, DOI 10.1083/jcb.104.3.491; COOPER JA, 1991, ANNU REV PHYSIOL, V53, P585, DOI 10.1146/annurev.ph.53.030191.003101; CORTESE JD, 1989, P NATL ACAD SCI USA, V86, P5773, DOI 10.1073/pnas.86.15.5773; COX D, 1992, J CELL BIOL, V116, P943, DOI 10.1083/jcb.116.4.943; COX D, 1995, J CELL BIOL, V128, P819, DOI 10.1083/jcb.128.5.819; CROWLEY E, 1995, J CELL BIOL, V131, P525, DOI 10.1083/jcb.131.2.525; CUNNINGHAM CC, 1991, SCIENCE, V251, P1233, DOI 10.1126/science.1848726; CUNNINGHAM CC, 1992, SCIENCE, V255, P325, DOI 10.1126/science.1549777; DAVIS S, 1991, SCIENCE, V252, P712, DOI 10.1126/science.1708917; DIMILLA PA, 1993, J CELL BIOL, V122, P729, DOI 10.1083/jcb.122.3.729; DIMILLA PA, 1991, BIOPHYS J, V60, P15, DOI 10.1016/S0006-3495(91)82027-6; DINUBILE MJ, 1995, MOL BIOL CELL, V6, P1659, DOI 10.1091/mbc.6.12.1659; DUBAND JL, 1991, J CELL SCI, V98, P517; EVANS E, 1993, J CELL BIOL, V122, P1295, DOI 10.1083/jcb.122.6.1295; FECHHEIMER M, 1993, J CELL BIOL, V123, P1, DOI 10.1083/jcb.123.1.1; FELDER S, 1990, J CELL BIOL, V111, P2513, DOI 10.1083/jcb.111.6.2513; FUKUI Y, 1989, NATURE, V341, P328, DOI 10.1038/341328a0; GINSBERG MH, 1995, ANNU REV CELL DEV BI, V11, P549; HAHN K, 1992, NATURE, V359, P736, DOI 10.1038/359736a0; HALL A, 1994, ANNU REV CELL BIOL, V10, P31, DOI 10.1146/annurev.cb.10.110194.000335; HARRIS AK, 1980, SCIENCE, V208, P177, DOI 10.1126/science.6987736; HARTWIG JH, 1995, CELL, V82, P643, DOI 10.1016/0092-8674(95)90036-5; Heidemann S R, 1991, Curr Opin Neurobiol, V1, P339, DOI 10.1016/0959-4388(91)90050-H; HENDEY B, 1992, SCIENCE, V258, P296, DOI 10.1126/science.1384129; HUG C, 1995, CELL, V81, P591, DOI 10.1016/0092-8674(95)90080-2; HUTTENLOCHER A, 1995, CURR OPIN CELL BIOL, V7, P607; IZZARD CS, 1988, CELL MOTIL CYTOSKEL, V10, P137, DOI 10.1002/cm.970100118; IZZARD CS, 1980, J CELL SCI, V42, P81; JANMEY PA, 1994, ANNU REV PHYSIOL, V56, P169, DOI 10.1146/annurev.ph.56.030194.001125; JAY PY, 1992, NATURE, V356, P438, DOI 10.1038/356438a0; JAY PY, 1995, J CELL SCI, V108, P387; KASSNER PD, 1995, MOL BIOL CELL, V6, P661, DOI 10.1091/mbc.6.6.661; KEELY PJ, 1995, J CELL SCI, V108, P595; KOLEGA J, 1986, J CELL BIOL, V102, P1400, DOI 10.1083/jcb.102.4.1400; KOVACSOVICS TJ, 1995, J BIOL CHEM, V270, P11358, DOI 10.1074/jbc.270.19.11358; KOZMA R, 1995, MOL CELL BIOL, V15, P1942; KUNDRA V, 1994, NATURE, V367, P474, DOI 10.1038/367474a0; KUO SC, 1993, BIOPHYS J, V65, P2191, DOI 10.1016/S0006-3495(93)81277-3; LAFFAFIAN I, 1995, J CELL SCI, V108, P3199; LATHAM VM, 1994, J CELL BIOL, V126, P1211, DOI 10.1083/jcb.126.5.1211; LAUFFENBURGER DA, 1963, RECEPTORS MODELS BIN; LAWSON MA, 1995, NATURE, V377, P75, DOI 10.1038/377075a0; LEE J, 1994, J CELL BIOL, V127, P1957, DOI 10.1083/jcb.127.6.1957; LIN CH, 1995, NEURON, V14, P763, DOI 10.1016/0896-6273(95)90220-1; LO SH, 1994, BIOESSAYS, V16, P817, DOI 10.1002/bies.950161108; MARKS PW, 1991, J CELL BIOL, V112, P149, DOI 10.1083/jcb.112.1.149; Matsudaira Paul, 1994, Seminars in Cell Biology, V5, P165, DOI 10.1006/scel.1994.1021; Maxfield Frederick R., 1993, Trends in Cell Biology, V3, P386, DOI 10.1016/0962-8924(93)90088-I; MIURA Y, 1993, J BIOL CHEM, V268, P510; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; Oliver Tim, 1994, Seminars in Cell Biology, V5, P139, DOI 10.1006/scel.1994.1018; PALECEK S, 1996, IN PRESS J CELL SCI; PASTERNAK C, 1989, NATURE, V341, P549, DOI 10.1038/341549a0; PATERSON HF, 1990, J CELL BIOL, V111, P1001, DOI 10.1083/jcb.111.3.1001; PESKIN CS, 1993, BIOPHYS J, V65, P316, DOI 10.1016/S0006-3495(93)81035-X; REGEN CM, 1992, J CELL BIOL, V119, P1347, DOI 10.1083/jcb.119.5.1347; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; RUBINO S, 1984, J CELL BIOL, V98, P382, DOI 10.1083/jcb.98.2.382; Schafer DA, 1995, ANNU REV CELL DEV BI, V11, P497, DOI 10.1146/annurev.cellbio.11.1.497; SCHALLER MD, 1995, MOL CELL BIOL, V15, P2635; SCHALLER MD, 1994, CURR OPIN CELL BIOL, V6, P705, DOI 10.1016/0955-0674(94)90097-3; Schmidt C. E., 1995, Journal of Cellular Engineering Incorporating Molecular Engineering, V1, P3; SCHMIDT CE, 1993, J CELL BIOL, V123, P977, DOI 10.1083/jcb.123.4.977; SCHMIDT CE, 1995, J NEUROSCI, V15, P3400; SCHWARTZ MA, 1994, MOL BIOL CELL, V5, P389, DOI 10.1091/mbc.5.4.389; Sheetz Michael P., 1994, Seminars in Cell Biology, V5, P149, DOI 10.1006/scel.1994.1019; SIMON SI, 1990, BIOPHYS J, V58, P319, DOI 10.1016/S0006-3495(90)82379-1; STOSSEL TP, 1993, SCIENCE, V260, P1086, DOI 10.1126/science.8493552; SULLIVAN SJ, 1984, J CELL BIOL, V99, P1461, DOI 10.1083/jcb.99.4.1461; SUN HQ, 1995, CURR OPIN CELL BIOL, V7, P102, DOI 10.1016/0955-0674(95)80051-4; THERIOT JA, 1991, NATURE, V352, P126, DOI 10.1038/352126a0; Theriot Julie A., 1994, Seminars in Cell Biology, V5, P193, DOI 10.1006/scel.1994.1024; TITUS MA, 1993, MOL BIOL CELL, V4, P233, DOI 10.1091/mbc.4.2.233; TURNER CE, 1994, J CELL SCI, V107, P1583; TURNER CE, 1994, BIOESSAYS, V16, P47, DOI 10.1002/bies.950160107; WANG YL, 1987, J CELL BIOL, V105, P2811, DOI 10.1083/jcb.105.6.2811; WENNSTROM S, 1994, ONCOGENE, V9, P651; WESSELS D, 1988, DEV BIOL, V128, P164, DOI 10.1016/0012-1606(88)90279-5; WESSELS D, 1991, CELL MOTIL CYTOSKEL, V20, P301, DOI 10.1002/cm.970200406; WILSON AK, 1991, J CELL BIOL, V114, P277, DOI 10.1083/jcb.114.2.277; WITKE W, 1995, CELL, V81, P41, DOI 10.1016/0092-8674(95)90369-0; WOLENSKI JS, 1995, TRENDS CELL BIOL, V5, P310, DOI 10.1016/S0962-8924(00)89053-4; WU DY, 1993, J CELL BIOL, V123, P653, DOI 10.1083/jcb.123.3.653; YONEMURA S, 1992, J CELL SCI, V102, P301; YUMURA S, 1984, J CELL BIOL, V99, P894, DOI 10.1083/jcb.99.3.894; ZHELEV DV, 1995, BIOPHYS J, V68, P2004, DOI 10.1016/S0006-3495(95)80377-2	103	3187	3251	7	453	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 9	1996	84	3					359	369		10.1016/S0092-8674(00)81280-5	http://dx.doi.org/10.1016/S0092-8674(00)81280-5			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TV708	8608589	Bronze			2022-12-28	WOS:A1996TV70800004
J	Yan, RQ; Small, S; Desplan, C; Dearolf, CR; Darnell, JE				Yan, RQ; Small, S; Desplan, C; Dearolf, CR; Darnell, JE			Identification of a Stat gene that functions in Drosophila development	CELL			English	Article							REGULATORY ELEMENTS; EXPRESSION; PROTEIN; SEGMENTATION; PHOSPHORYLATION; TRANSCRIPTION; PROMOTER; PATTERN; LETHAL; EMBRYO	A Drosophila Stat gene (D-Stat) with a zygotic segmental expression pattern was identified. This protein becomes phosphorylated on Tyr-704 when coexpressed in Schneider cells with a Drosophila janus kinase (JAK), Hopscotch (HOP). The phosphorylated protein binds specifically to the consensus sequence TTCCCGGAA. Suppressor mutations of hop(Tum-1), a dominant hyperactive allele of hop whose phenotype is hematocyte overproduction and tumor formation, were selected. One of these mutants, stat(HJ), mapped to the same chromosomal region (92E) as does D-Stat, had an incompletely penetrant pair rule phenotype, and exhibited aberrant expression of the pair rule gene even skipped (eve) at the cellular blastoderm stage. Two D-STAT-binding sites were identified within the eve stripe 3 enhancer region. Mutations in either of the STAT-binding sites greatly decreased the stripe 3 expression in transgenic flies. Clearly, the JAK-STAT pathway is connected to Drosophila early development.	NYU,DEPT BIOL,NEW YORK,NY 10003; ROCKEFELLER UNIV,HOWARD HUGHES MED INST,NEW YORK,NY 10021; HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DEV GENET GRP,BOSTON,MA 02115; HARVARD UNIV,SCH MED,CANC BIOL SECT,JOINT CTR RADIAT THERAPY,BOSTON,MA 02115	New York University; Howard Hughes Medical Institute; Rockefeller University; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School	Yan, RQ (corresponding author), ROCKEFELLER UNIV,MOLEC CELL BIOL LAB,NEW YORK,NY 10021, USA.			Desplan, Claude/0000-0002-6914-1413; Yan, Riqiang/0000-0001-7195-7617	NIAID NIH HHS [AI32489, AI34420] Funding Source: Medline; NIGMS NIH HHS [GM1946] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI034420, R37AI034420, R01AI032489] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BANG AG, 1992, GENE DEV, V6, P1752, DOI 10.1101/gad.6.9.1752; BINARI R, 1994, GENE DEV, V8, P300, DOI 10.1101/gad.8.3.300; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; FRASCH M, 1987, EMBO J, V6, P749, DOI 10.1002/j.1460-2075.1987.tb04817.x; GERGEN JP, 1988, GENE DEV, V2, P1179, DOI 10.1101/gad.2.9.1179; GOTO T, 1989, CELL, V57, P413, DOI 10.1016/0092-8674(89)90916-1; GREENLUND AC, 1994, EMBO J, V13, P1591, DOI 10.1002/j.1460-2075.1994.tb06422.x; GUYER NB, 1995, IN PRESS J IMMUNOL; HANRATTY WP, 1993, MOL GEN GENET, V238, P33, DOI 10.1007/BF00279527; HANRATTY WP, 1981, DEV BIOL, V83, P238, DOI 10.1016/0012-1606(81)90470-X; HARDING K, 1989, EMBO J, V8, P1205, DOI 10.1002/j.1460-2075.1989.tb03493.x; HARRISON DA, 1995, EMBO J, V14, P2857, DOI 10.1002/j.1460-2075.1995.tb07285.x; HORVATH CM, 1995, GENE DEV, V9, P984, DOI 10.1101/gad.9.8.984; IHLE JN, 1995, NATURE, V377, P591, DOI 10.1038/377591a0; INGHAM PW, 1985, NATURE, V318, P439, DOI 10.1038/318439a0; JIANG J, 1991, GENE DEV, V5, P1881, DOI 10.1101/gad.5.10.1881; LARNER AC, 1993, SCIENCE, V261, P1730, DOI 10.1126/science.8378773; LAWRENCE PA, 1987, NATURE, V328, P440, DOI 10.1038/328440a0; LEVY DE, 1989, GENE DEV, V3, P1362, DOI 10.1101/gad.3.9.1362; LONCAR D, 1995, P NATL ACAD SCI USA, V92, P8154, DOI 10.1073/pnas.92.18.8154; LUO H, 1995, EMBO J, V14, P1412, DOI 10.1002/j.1460-2075.1995.tb07127.x; MACDONALD PM, 1986, CELL, V47, P721, DOI 10.1016/0092-8674(86)90515-5; PERRIMON N, 1986, DEV BIOL, V118, P28, DOI 10.1016/0012-1606(86)90070-9; PIRROTTA V, 1985, EMBO J, V4, P3501, DOI 10.1002/j.1460-2075.1985.tb04109.x; POLLOCK R, 1990, NUCLEIC ACIDS RES, V18, P6197, DOI 10.1093/nar/18.21.6197; QUELLE FW, IN PRESS J BIOL CHEM; QURESHI SA, 1995, P NATL ACAD SCI USA, V92, P3829, DOI 10.1073/pnas.92.9.3829; SADOWSKI HB, 1993, SCIENCE, V261, P1739, DOI 10.1126/science.8397445; Sambrook J, 1989, MOL CLONING LABORATO; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; SEIDEL HM, 1995, P NATL ACAD SCI USA, V92, P3041, DOI 10.1073/pnas.92.7.3041; SHUAI K, 1994, CELL, V76, P821, DOI 10.1016/0092-8674(94)90357-3; SIMPSONBROSE M, 1994, CELL, V78, P855, DOI 10.1016/S0092-8674(94)90622-X; SMALL S, 1991, GENE DEV, V5, P827, DOI 10.1101/gad.5.5.827; SMALL S, 1992, EMBO J, V11, P4047, DOI 10.1002/j.1460-2075.1992.tb05498.x; SMALL S, 1996, IN PRESS DEV BIOL; Spradling AC, 1986, DROSOPHILA PRACTICAL, P175; STANOJEVIC D, 1989, NATURE, V341, P331, DOI 10.1038/341331a0; STANOJEVIC D, 1991, SCIENCE, V254, P1385, DOI 10.1126/science.1683715; STJOHNSTON D, 1992, CELL, V68, P201; TANAKA N, 1994, P NATL ACAD SCI USA, V91, P7271, DOI 10.1073/pnas.91.15.7271; TJIAN R, 1994, CELL, V77, P5, DOI 10.1016/0092-8674(94)90227-5; VOLBERG T, 1992, EMBO J, V11, P1733, DOI 10.1002/j.1460-2075.1992.tb05225.x; WAGNER BJ, 1990, EMBO J, V9, P4477, DOI 10.1002/j.1460-2075.1990.tb07898.x; Wieschaus E., 1986, P199; YAN RQ, 1995, NUCLEIC ACIDS RES, V23, P459, DOI 10.1093/nar/23.3.459; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422; ZHONG Z, 1994, P NATL ACAD SCI USA, V91, P4806, DOI 10.1073/pnas.91.11.4806; ZHONG Z, 1995, STAT UNDERSTANDING S	50	313	324	1	16	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 9	1996	84	3					421	430		10.1016/S0092-8674(00)81287-8	http://dx.doi.org/10.1016/S0092-8674(00)81287-8			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TV708	8608596	Bronze			2022-12-28	WOS:A1996TV70800011
J	Davenport, M				Davenport, M			ABC of general surgery in children - Problems with the penis and prepuce	BRITISH MEDICAL JOURNAL			English	Article											Davenport, M (corresponding author), UNIV LONDON KINGS COLL HOSP,DEPT PAEDIAT SURG,LONDON,ENGLAND.								0	13	14	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 3	1996	312	7026					299	301						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TU507	8611792	Green Published			2022-12-28	WOS:A1996TU50700033
J	Grosskurth, H; Mayaud, P; Mosha, F; Todd, J; Senkoro, K; Newell, J; Gabone, R; Changalucha, J; West, B; Hayes, R; Mabey, D				Grosskurth, H; Mayaud, P; Mosha, F; Todd, J; Senkoro, K; Newell, J; Gabone, R; Changalucha, J; West, B; Hayes, R; Mabey, D			Asymptomatic gonorrhoea and chlamydial infection in rural Tanzanian men	BRITISH MEDICAL JOURNAL			English	Article							SEXUALLY-TRANSMITTED DISEASES; GONOCOCCAL INFECTIONS; RISK-FACTORS; EPIDEMIOLOGY; URETHRITIS; TRANSMISSION; TRACHOMATIS	Objective-To measure the prevalence of urethritis due to Neisseria gonorrhoeae and Chlamydia trachomatis in rural Tanzanian men. Design-About 500 men aged 15-54 years were selected from each of 12 rural communities by random cluster sampling; interviewed concerning past or present symptoms of sexually transmitted diseases; and asked to provide a first catch urine specimen, which was tested for pyuria with a leucocyte esterase dipstick test. Subjects with symptoms or with a positive result on testing were examined, and urethral swabs were taken for detection of N gonorrhoeae by gram stain and of C trachomatis by antigen detection immunoassay. Setting-Mwanza region, north western Tanzania. Subjects-5876 men aged 15-54 years. Main outcome measures-Prevalence of urethral symptoms, observed urethral discharge, pyuria, urethritis (>4 pus cells per high power field on urethral smear), N gonorrhoeae infection (intracellular gram negative diplococci), and C trachomatis infection (IDEIA antigen detection assay). Results-1618 (28%) subjects reported ever having had a urethral discharge. Current discharge was reported by 149 (2.5%) and observed on examination in 207 (3.5%). Gonorrhoea was found in 128 subjects (2.2%) and chlamydial infection in 39 (0.7%). Only 24 of 158 infected subjects complained of urethral discharge at the time of interview (15%). Conclusion-Infection with N gonorrhoeae and C trachomatis is commonly asymptomatic among men in this rural African population. This has important implications for the design of control programmes for sexually transmitted disease.	UNIV LONDON LONDON SCH HYG & TROP MED,LONDON WC1E 7HT,ENGLAND; NATL INST MED RES,MWANZA,TANZANIA	University of London; London School of Hygiene & Tropical Medicine; National Institute of Medical Research				Todd, Jim/0000-0001-5918-4914; MAYAUD, Philippe/0000-0001-5730-947X; Hayes, Richard/0000-0002-1729-9892; Grosskurth, Heiner/0000-0001-9960-7280				Arya O P, 1977, Trop Doct, V7, P51; ARYA OP, 1973, B WORLD HEALTH ORGAN, V49, P587; BARONGO LR, 1992, AIDS, V6, P1521, DOI 10.1097/00002030-199212000-00016; DESCHRYVER A, 1990, B WORLD HEALTH ORGAN, V68, P639; HANDSFIELD HH, 1974, NEW ENGL J MED, V290, P117, DOI 10.1056/NEJM197401172900301; LAGA M, 1993, AIDS, V7, P95, DOI 10.1097/00002030-199301000-00015; MAHEY DCW, 1994, GENITOURIN MED, V70, P1; MAYAUD P, 1992, GENITOURIN MED, V68, P361; MAYAUD P, 1993, 10TH P INT M ISSTDR; MCNAGNY SE, 1992, J INFECT DIS, V165, P573, DOI 10.1093/infdis/165.3.573; MEHEUS A, 1980, INT J EPIDEMIOL, V9, P239, DOI 10.1093/ije/9.3.239; NDOYE I, 1993, 10TH P INT M ISSTDR; OBRIEN SF, 1988, AM J PUBLIC HEALTH, V78, P1583, DOI 10.2105/AJPH.78.12.1583; PLUMMER FA, 1991, J INFECT DIS, V163, P233, DOI 10.1093/infdis/163.2.233; RIETMEIJER CAM, 1991, SEX TRANSM DIS, V18, P28, DOI 10.1097/00007435-199101000-00007; SCHACHTER J, 1994, CHLAMYDIAL INFECTION, P293; SCHULZ K, 1987, GENITOURIN MED, V62, P320; SHAFER MA, 1989, JAMA-J AM MED ASSOC, V262, P2562, DOI 10.1001/jama.262.18.2562; VANDYCK E, 1989, WHOVDT443; VUYLSTEKE B, 1993, CLIN INFECT DIS, V17, P82, DOI 10.1093/clinids/17.1.82; WEST B, 1995, GENITOURIN MED, V71, P9; 1993, INVESTING HLTH; 1993, WHOGPASTD931	23	64	65	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 3	1996	312	7026					277	280						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TU507	8611782	Green Published			2022-12-28	WOS:A1996TU50700020
J	Dybowski, R; Weller, P; Chang, R; Gant, V				Dybowski, R; Weller, P; Chang, R; Gant, V			Prediction of outcome in critically ill patients using artificial neural network synthesised by genetic algorithm	LANCET			English	Article							SEPSIS; SCORE	Background Decisions about which patients to admit to intensive care and how long to keep them there are difficult. A flexible computer-based mathematical model which is sensitive to the complexity of intensive care medicine, and which accurately models prognosis, seems highly desirable. Methods We have created, optimised by genetic algorithms, trained, and evaluated the performance of an artificial neural network (ANN) in the clinical setting of systemic inflammatory response syndrome and haemodynamic shock. 258 patients were selected from an intensive care database of 4484 patients al a London teaching hospital and randomised to a network training set (168) and a test set (90). The outcome evaluated was death during that hospital admission and the performance of the neural net was compared (by receiver operating characteristic [ROC] curves and by Brier scores) with that of a logistic regression model. Findings Artificial neural network performance increased with successive generations; the best-performing ANN was created after 7 generations and predicted outcome more accurately than the logistic regression model (ROC curve area 0.863 vs 0.753). Interpretation In this study, ANNs have lent themselves particularly well to modelling a complex clinical situation; we suggest that this relates to their inherently flexible nature which accommodates interactions between the clinical input fields. In addition, we have demonstrated the value of a second computational technique (genetic algorithms) in ''tuning'' ANN performance. These techniques can potentially be implemented in individual intensive care units; the outcome models which they will generate will be sensitive to local practice. Analysis of such accurate clinical outcome models may empower clinicians with a hitherto unappreciated degree of insight into those elements of their clinical practice which are most relevant to their patients' outcome.	CITY UNIV LONDON,DEPT SYST SCI,LONDON EC1V 0HB,ENGLAND; UNIV LONDON ST GEORGES HOSP,LONDON,ENGLAND	City University London; St Georges University London	Dybowski, R (corresponding author), UMDS,DIV INFECT,INFECT & IMMUN LAB,ST THOMAS HOSP CAMPUS,LAMBETH PALACE RD,LONDON SE1 7EH,ENGLAND.							ABRAHAM E, 1994, JAMA-J AM MED ASSOC, V271, P1876, DOI 10.1001/jama.271.23.1876; ATKINSON S, 1994, LANCET, V344, P1203, DOI 10.1016/S0140-6736(94)90514-2; BAXT WG, 1995, LANCET, V346, P1135, DOI 10.1016/S0140-6736(95)91804-3; BAXT WG, 1994, CANCER LETT, V77, P85, DOI 10.1016/0304-3835(94)90090-6; BONE RC, 1991, ANN INTERN MED, V115, P457, DOI 10.7326/0003-4819-115-6-457; Breiman L., 1984, CLASSIFICATION REGRE; BUCHMAN TG, 1994, CRIT CARE MED, V22, P750, DOI 10.1097/00003246-199405000-00008; CROSS SS, 1995, LANCET, V346, P1075, DOI 10.1016/S0140-6736(95)91746-2; Doig G S, 1993, Proc Annu Symp Comput Appl Med Care, P361; DYBOWSKI R, 1995, LANCET, V346, P1203, DOI 10.1016/S0140-6736(95)92904-5; HART A, 1990, MED INFORM, V15, P229, DOI 10.3109/14639239009025270; HOSMER DW, 1989, APPL LOGISTIC REGRES; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; KNAUS WA, 1993, JAMA-J AM MED ASSOC, V270, P1233, DOI 10.1001/jama.270.10.1233; KNAUS WA, 1991, CHEST, V100, P1619, DOI 10.1378/chest.100.6.1619; LEGALL JR, 1993, JAMA-J AM MED ASSOC, V270, P2957, DOI 10.1001/jama.270.24.2957; LEMESHOW S, 1993, JAMA-J AM MED ASSOC, V270, P2478, DOI 10.1001/jama.270.20.2478; LONG WJ, 1993, COMPUT BIOMED RES, V26, P74, DOI 10.1006/cbmr.1993.1005; METZ CE, 1978, SEMIN NUCL MED, V8, P283, DOI 10.1016/S0001-2998(78)80014-2; MILLER GF, 1989, 3RD P INT C GEN ALG, P379; MONTANA DJ, 1989, P 11 INT JOINT C ART, P762; NARAYANAN MN, 1993, METHOD INFORM MED, V32, P55, DOI 10.1055/s-0038-1634888; RIPLEY BD, 1994, J R STAT SOC B, V56, P409; SAHASAKUL Y, 1990, BRIT HEART J, V64, P182; WARREN HS, 1992, NEW ENGL J MED, V326, P1153, DOI 10.1056/NEJM199204233261711; WYATT J, 1995, LANCET, V346, P1175, DOI 10.1016/S0140-6736(95)92893-6; YATES JF, 1982, ORGAN BEHAV HUM PERF, V30, P132, DOI 10.1016/0030-5073(82)90237-9	27	161	167	0	16	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 27	1996	347	9009					1146	1150		10.1016/S0140-6736(96)90609-1	http://dx.doi.org/10.1016/S0140-6736(96)90609-1			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UG755	8609749				2022-12-28	WOS:A1996UG75500011
J	Morrison, PJ				Morrison, PJ			Anticipating more anticipation	LANCET			English	Editorial Material							REPEAT				Morrison, PJ (corresponding author), BELFAST CITY HOSP,NO IRELAND REG GENET CTR,BELFAST BT9 7AB,ANTRIM,NORTH IRELAND.							Campuzano V, 1996, SCIENCE, V271, P1423, DOI 10.1126/science.271.5254.1423; HARLEY HG, 1993, AM J HUM GENET, V52, P1164; MORRISON PJ, 1993, LANCET, V342, P385; Morrison PJ, 1996, J MED GENET, V33, P504, DOI 10.1136/jmg.33.6.504; ODONOVAN MC, 1995, NAT GENET, V10, P379; Polito JMII, 1996, LANCET, V347, P798, DOI 10.1016/S0140-6736(96)90870-3	6	3	3	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 27	1996	347	9009					1132	1132		10.1016/S0140-6736(96)90605-4	http://dx.doi.org/10.1016/S0140-6736(96)90605-4			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UG755	8609745				2022-12-28	WOS:A1996UG75500007
J	Rockall, TA; Logan, RFA; Devlin, HB; Northfield, TC				Rockall, TA; Logan, RFA; Devlin, HB; Northfield, TC			Selection of patients for early discharge or outpatient care after acute upper gastrointestinal haemorrhage	LANCET			English	Article								Background Acute upper gastrointestinal haemorrhage is a common medical emergency and hospital admission has usually been regarded as obligatory until the risk of further haemorrhage has receded. This policy means that some patients at low risk stay in hospital for longer than is necessary especially when delayed. We attempted to negligible risk of further bleeding or death and for whom early discharge or even outpatient management would be possible with no adverse effect on standards of care. Methods We used a validated risk scoring system based on age (score 0-2), presence of shock (0-2), comorbidity (0-3), diagnosis (0-2), and endoscopic stigmata of recent haemorrhage (0-2); the maximum possible score was 11. We studied patients identified through the UK National Audit of acute upper gastrointestinal haemorrhage; they had been admitted with upper gastrointestinal haemorrhage to hospitals in the UK during 4 months of 1993. This analysis was based on the 2531 patients from the national audit who underwent endoscopy after an acute admission. Findings 744 (29.4%) of the 2531 patients scored 2 or less on the risk score. Of these patients only 32 (4.3% [95% CI 3.0-6.0] rebled and only one (0.1% [0.006-0.75] died). Thus, the risk score identifies patients at low risk of rebleeding or death. The median hospital stay for these patients was 4 days; duration of hospital stay increased with risk score. Within risk score categories of 5 or less, there was a trend of increasing hospital stay as the time between admission and endoscopy increased. Interpretation Our risk score identifies a large proportion of patients with acute upper gastrointestinal haemorrhage who are at low risk of further bleeding or death. Early endoscopy and discharge of such patients could allow substantial resource savings.	QUEENS MED CTR,NOTTINGHAM NG7 2UH,ENGLAND; ST GEORGE HOSP,SCH MED,LONDON,ENGLAND	University of Nottingham; St Georges University London	Rockall, TA (corresponding author), ROYAL COLL SURGEONS ENGLAND,AUDIT UNIT,LONDON WC2A 3PN,ENGLAND.							LONGSTRETH GF, 1995, LANCET, V345, P108, DOI 10.1016/S0140-6736(95)90068-3; ROCKALL TA, 1995, BRIT MED J, V311, P222, DOI 10.1136/bmj.311.6999.222; Rockall TA, 1996, GUT, V38, P316, DOI 10.1136/gut.38.3.316; ROCKALL TA, 1995, LANCET, V346, P346, DOI 10.1016/S0140-6736(95)92227-X	4	249	262	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 27	1996	347	9009					1138	1140		10.1016/S0140-6736(96)90607-8	http://dx.doi.org/10.1016/S0140-6736(96)90607-8			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UG755	8609747				2022-12-28	WOS:A1996UG75500009
J	Nyberg, L; McIntosh, AR; Houle, S; Nilsson, LG; Tulving, E				Nyberg, L; McIntosh, AR; Houle, S; Nilsson, LG; Tulving, E			Activation of medial temporal structures during episodic memory retrieval	NATURE			English	Article							HIPPOCAMPUS; AMNESIA	MEDIAL temporal lobe structures have been implicated in human episodic memory. Patients with medial temporal lesions show memory deficits(1-3), and functional neuroimaging studies have revealed activation in this region during episodic encoding and retrieval when data are averaged over a sample of subjects(4-7). The relevance of such observations for memory performance has remained unclear, however. Here we have used positron emission tomography (PET) to examine cerebral blood how related to verbal episodic retrieval. We observed strong positive correlations between retrieval and blood flow in left medial temporal structures in individual normal human subjects. In addition, multivariate analysis showed that regions in the left medial temporal lobe were dominant components of a pattern of brain regions that distinguished a high-retrieval condition from conditions of lower retrieval. These results suggest that medial temporal activity is related to retrieval success rather than retrieval attempt, possibly by reflecting reactivation of stored patterns.	UMEA UNIV,DEPT PSYCHOL,S-90187 UMEA,SWEDEN; CLARKE INST PSYCHIAT,PET CTR,TORONTO,ON M5T 1R8,CANADA; UNIV STOCKHOLM,DEPT PSYCHOL,S-10691 STOCKHOLM,SWEDEN	Umea University; University of Toronto; University Toronto Affiliates; Centre for Addiction & Mental Health - Canada; Stockholm University	Nyberg, L (corresponding author), BAYCREST CTR GERIATR CARE,ROTMAN RES INST,3560 BATHURST ST,N YORK,ON M6A 2E1,CANADA.		Nyberg, Lars/C-2514-2009; Nyberg, Lars/M-5986-2019; McIntosh, Anthony R/G-4955-2011	Nyberg, Lars/0000-0002-3367-1746; Nyberg, Lars/0000-0002-3367-1746; Houle, Sylvain/0000-0002-4231-6316; McIntosh, Anthony/0000-0002-1784-5662				AMARAL DG, 1990, DISCUSSIONS NEUROSCI; BOOKSTEIN FL, 1990, COMMUN STAT THEORY, V19, P765, DOI 10.1080/03610929008830231; Edgington E. S., 1987, RANDOMIZATION TESTS; FLETCHER PC, 1995, BRAIN, V118, P401, DOI 10.1093/brain/118.2.401; Friston K., 1994, HUM BRAIN MAPP, V2, P189, DOI [DOI 10.1002/HBM.460020402, 10.1002/hbm.460020402]; GRADY CL, 1995, SCIENCE, V269, P218, DOI 10.1126/science.7618082; GRAF P, 1985, J EXP PSYCHOL LEARN, V11, P386, DOI 10.1037/0278-7393.11.2.386; Grafton S T, 1994, Hum Brain Mapp, V1, P221, DOI 10.1002/hbm.460010307; GRASBY PM, 1993, NEUROSCI LETT, V163, P185, DOI 10.1016/0304-3940(93)90378-X; HAIST F, 1992, J EXP PSYCHOL LEARN, V18, P691, DOI 10.1037/0278-7393.18.4.691; Haxby JV, 1996, P NATL ACAD SCI USA, V93, P922, DOI 10.1073/pnas.93.2.922; HERSCOVITCH P, 1983, J NUCL MED, V24, P782; Kosslyn SM, 1996, J COGNITIVE NEUROSCI, V8, P78, DOI 10.1162/jocn.1996.8.1.78; Markowitsch HJ, 1995, BRAIN RES REV, V21, P117, DOI 10.1016/0165-0173(95)00007-0; MCCLELLAND JL, 1995, PSYCHOL REV, V102, P419, DOI 10.1037/0033-295X.102.3.419; PRESS GA, 1989, NATURE, V341, P54, DOI 10.1038/341054a0; Schacter DL, 1996, P NATL ACAD SCI USA, V93, P321, DOI 10.1073/pnas.93.1.321; SCHACTER DL, 1995, NATURE, V376, P587, DOI 10.1038/376587a0; SCOVILLE WB, 1957, J NEUROL NEUROSUR PS, V20, P11, DOI 10.1136/jnnp.20.1.11; SMITH M, 1989, HDB NEUROPSYCHOLOGY, V3; SQUIRE LR, 1991, SCIENCE, V253, P1380, DOI 10.1126/science.1896849; SQUIRE LR, 1992, P NATL ACAD SCI USA, V89, P1837, DOI 10.1073/pnas.89.5.1837; TALAIRACH J, 1988, STEREOTAXIC ATLAS HU; Victor M, 1990, J Cogn Neurosci, V2, P246, DOI 10.1162/jocn.1990.2.3.246; ZOLAMORGAN S, 1986, J NEUROSCI, V6, P2950	25	306	311	0	22	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	APR 25	1996	380	6576					715	717		10.1038/380715a0	http://dx.doi.org/10.1038/380715a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UG827	8614466				2022-12-28	WOS:A1996UG82700052
J	Yates, JRW				Yates, JRW			Recent advances - Medical genetics	BMJ-BRITISH MEDICAL JOURNAL			English	Article											Yates, JRW (corresponding author), ADDENBROOKES HOSP NHS TRUST, DEPT MED GENET, CAMBRIDGE CB2 2QQ, ENGLAND.							AHN J, 1995, NAT GENET, V11, P137, DOI 10.1038/ng1095-137; BASSI MT, 1995, NAT GENET, V10, P13, DOI 10.1038/ng0595-13; BELLUS GA, 1995, NAT GENET, V10, P357, DOI 10.1038/ng0795-357; BELLUS GA, 1995, AM J HUM GENET, V56, P368; BENNETT ST, 1995, NAT GENET, V9, P284, DOI 10.1038/ng0395-284; BONNE G, 1995, NAT GENET, V11, P438, DOI 10.1038/ng1295-438; BONNEMANN CG, 1995, NAT GENET, V11, P266, DOI 10.1038/ng1195-266; BRAHE C, 1995, LANCET, V346, P741, DOI 10.1016/S0140-6736(95)91507-9; BRIGGS MD, 1995, NAT GENET, V10, P330, DOI 10.1038/ng0795-330; COLLINS FS, 1995, NAT GENET, V9, P347, DOI 10.1038/ng0495-347; COPEMAN JB, 1995, NAT GENET, V9, P80, DOI 10.1038/ng0195-80; CURRAN ME, 1995, CELL, V80, P795, DOI 10.1016/0092-8674(95)90358-5; DAVIES JL, 1994, NATURE, V371, P130, DOI 10.1038/371130a0; DRYJA TP, 1995, P NATL ACAD SCI USA, V92, P10177, DOI 10.1073/pnas.92.22.10177; DRYJA TP, 1995, HUM MOL GENET, V4, P1739, DOI 10.1093/hmg/4.suppl_1.1739; EASTON DF, 1995, AM J HUM GENET, V56, P265; EASTON DF, 1994, INT J RADIAT BIOL, V66, pS177, DOI 10.1080/09553009414552011; ELLIS NA, 1995, CELL, V83, P655, DOI 10.1016/0092-8674(95)90105-1; FIELD LL, 1994, NAT GENET, V8, P189, DOI 10.1038/ng1094-189; FitzGerald MG, 1996, NEW ENGL J MED, V334, P143, DOI 10.1056/NEJM199601183340302; FORD D, 1995, AM J HUM GENET, V57, P1457; FORREST S, 1995, NAT GENET, V10, P375, DOI 10.1038/ng0895-375; FRANCIS F, 1995, NAT GENET, V11, P130, DOI 10.1038/ng1095-130; GARDNER RJ, 1995, AM J HUM GENET, V57, P311; GAYTHER SA, 1995, NAT GENET, V11, P428, DOI 10.1038/ng1295-428; GIBBONS RJ, 1995, CELL, V80, P837, DOI 10.1016/0092-8674(95)90287-2; GOLDMUNTZ E, 1993, J MED GENET, V30, P807, DOI 10.1136/jmg.30.10.807; HASHIMOTO L, 1994, NATURE, V371, P161, DOI 10.1038/371161a0; HELBLINGLECLERC A, 1995, NAT GENET, V11, P216, DOI 10.1038/ng1095-216; HOGERVORST FBL, 1995, NAT GENET, V10, P208, DOI 10.1038/ng0695-208; HUANG SH, 1995, NAT GENET, V11, P468, DOI 10.1038/ng1295-468; LAJEUNIE E, 1995, NAT GENET, V9, P108, DOI 10.1038/ng0295-108; Langston AA, 1996, NEW ENGL J MED, V334, P137, DOI 10.1056/NEJM199601183340301; LEFEBVRE S, 1995, CELL, V80, P155, DOI 10.1016/0092-8674(95)90460-3; LERNER TJ, 1995, CELL, V82, P949, DOI 10.1016/0092-8674(95)90274-0; LEVYLAHAD E, 1995, SCIENCE, V269, P973, DOI 10.1126/science.7638622; LIM LE, 1995, NAT GENET, V11, P257, DOI 10.1038/ng1195-257; LIU B, 1995, NAT MED, V1, P348, DOI 10.1038/nm0495-348; LUCASSEN AM, 1995, HUM MOL GENET, V4, P501, DOI 10.1093/hmg/4.4.501; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; MUENKE M, 1994, NAT GENET, V8, P269, DOI 10.1038/ng1194-269; NOGUCHI S, 1995, SCIENCE, V270, P819, DOI 10.1126/science.270.5237.819; REARDON W, 1994, NAT GENET, V8, P98, DOI 10.1038/ng0994-98; RICHARD I, 1995, CELL, V81, P27, DOI 10.1016/0092-8674(95)90368-2; ROEST PAM, 1993, HUM MOL GENET, V2, P1719, DOI 10.1093/hmg/2.10.1719; ROGAEV EI, 1995, NATURE, V376, P775, DOI 10.1038/376775a0; ROUSSEAU F, 1994, NATURE, V371, P252, DOI 10.1038/371252a0; ROY N, 1995, CELL, V80, P167, DOI 10.1016/0092-8674(95)90461-1; RUTLAND P, 1995, NAT GENET, V9, P173, DOI 10.1038/ng0295-173; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; SCHELL U, 1995, HUM MOL GENET, V4, P323, DOI 10.1093/hmg/4.3.323; SCHIAFFINO MV, 1995, HUM MOL GENET, V4, P2319, DOI 10.1093/hmg/4.12.2319; SCOTT HS, 1995, NAT GENET, V11, P465, DOI 10.1038/ng1295-465; SHATTUCKEIDENS D, 1995, JAMA-J AM MED ASSOC, V273, P535, DOI 10.1001/jama.273.7.535; SHERRINGTON R, 1995, NATURE, V375, P754, DOI 10.1038/375754a0; SHIANG R, 1994, CELL, V78, P335, DOI 10.1016/0092-8674(94)90302-6; STRUEWING JP, 1995, NAT GENET, V11, P198, DOI 10.1038/ng1095-198; SZABO CI, 1995, HUM MOL GENET, V4, P1811, DOI 10.1093/hmg/4.suppl_1.1811; TAVORMINA PL, 1995, NAT GENET, V9, P321, DOI 10.1038/ng0395-321; VANDERLUIJT R, 1994, GENOMICS, V20, P1, DOI 10.1006/geno.1994.1119; VANOMMEN GJB, 1995, CURR OPIN GENET DEV, V5, P304, DOI 10.1016/0959-437X(95)80043-3; WANG Q, 1995, CELL, V80, P805, DOI 10.1016/0092-8674(95)90359-3; WATKINS H, 1995, NAT GENET, V11, P434, DOI 10.1038/ng1295-434; WELL D, 1995, NATURE, V374, P60, DOI 10.1038/374060a0; WILKIE AOM, 1995, NAT GENET, V9, P165, DOI 10.1038/ng0295-165; WOOSTER R, 1995, NATURE, V378, P789, DOI 10.1038/378789a0	66	9	9	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	APR 20	1996	312	7037					1021	1025						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UG610	8616352				2022-12-28	WOS:A1996UG61000031
J	Souer, E; vanHouwelingen, A; Kloos, D; Mol, J; Koes, R				Souer, E; vanHouwelingen, A; Kloos, D; Mol, J; Koes, R			The no apical meristem gene of petunia is required for pattern formation in embryos and flowers and is expressed at meristem and primordia boundaries	CELL			English	Article							ARABIDOPSIS-THALIANA; ANTIRRHINUM-MAJUS; HOMEOTIC GENES; MORPHOGENESIS; MUTAGENESIS; MUTATIONS; PROTEINS; SEQUENCE	Petunia embryos carrying the no epical meristem (nam) mutation fail to develop a shoot apical meristem. Occasional shoots on nam(-) seedlings bear flowers that develop ten instead of five primordia in the second whorl. Double mutants with the homeotic gene green petals show that nam acts independently of organ identity in whorl 2 and now also affects primordium number in whorl 3. The nam gene was isolated by transposon tagging. The encoded protein shares a conserved N-terminal domain with several other proteins of unknown function and thus represents a novel class of proteins. Strikingly, nam mRNA accumulates in cells at the boundaries of meristems and primordia. These data indicate a role for nam in determining positions of meristems and primordia.			Souer, E (corresponding author), VRIJE UNIV AMSTERDAM,BIOCENTRUM,INST MOLEC BIOL SCI,DEPT GENET,DE BOELELAAN 1087,1081 HV AMSTERDAM,NETHERLANDS.			Souer, Erik/0000-0003-4459-2485; Koes, Ronald/0000-0003-3793-5072				ANGENENT GC, 1995, PLANT CELL, V7, P1569, DOI 10.1105/tpc.7.10.1569; ANGENENT GC, 1995, PLANT CELL, V7, P507, DOI 10.1105/tpc.7.5.507; BAIROCH A, 1992, NUCLEIC ACIDS RES, V20, P2013, DOI 10.1093/nar/20.suppl.2013; BARTON MK, 1993, DEVELOPMENT, V119, P823; BERNIER G, 1988, ANNU REV PLANT PHYS, V39, P175, DOI 10.1146/annurev.arplant.39.1.175; BOWMAN JL, 1991, DEVELOPMENT, V112, P1; CANAS LA, 1994, PLANT J, V6, P597, DOI 10.1046/j.1365-313X.1994.6040597.x; CLARK SE, 1993, DEVELOPMENT, V119, P397; COEN ES, 1991, NATURE, V353, P31, DOI 10.1038/353031a0; DOODEMAN M, 1984, THEOR APPL GENET, V67, P357, DOI 10.1007/BF00272875; ERRAMPALLI D, 1991, PLANT CELL, V3, P149, DOI 10.1105/tpc.3.2.149; FELDMANN KA, 1991, PLANT J, V1, P71, DOI 10.1111/j.1365-313X.1991.00071.x; GERATS AGM, 1990, PLANT CELL, V2, P1121, DOI 10.1105/tpc.2.11.1121; GOLDBERG RB, 1994, SCIENCE, V266, P605, DOI 10.1126/science.266.5185.605; HAUGHN GW, 1995, CAN J BOT, V73, P959, DOI 10.1139/b95-105; HENIKOFF S, 1991, NUCLEIC ACIDS RES, V19, P6565, DOI 10.1093/nar/19.23.6565; HERNANDEZ LF, 1993, PLANT CELL, V5, P1725, DOI 10.1105/tpc.5.12.1725; HERNANDEZ LF, 1991, PLANTA, V185, P139, DOI 10.1007/BF00194054; HOFTE H, 1993, PLANT J, V4, P1051, DOI 10.1046/j.1365-313X.1993.04061051.x; HUIJSER P, 1992, EMBO J, V11, P1239, DOI 10.1002/j.1460-2075.1992.tb05168.x; JURGENS G, 1994, ANNU REV GENET, V28, P351, DOI 10.1146/annurev.ge.28.120194.002031; JURGENS G, 1995, CELL, V81, P467, DOI 10.1016/0092-8674(95)90065-9; Jurgens G, 1991, DEVELOPMENT S, V1, P27; KOES R, 1995, P NATL ACAD SCI USA, V92, P8149, DOI 10.1073/pnas.92.18.8149; KUSH A, 1993, PLANT PHYSIOL, V102, P1051, DOI 10.1104/pp.102.3.1051; Long JA, 1996, NATURE, V379, P66, DOI 10.1038/379066a0; MAYER U, 1991, NATURE, V353, P402, DOI 10.1038/353402a0; NAGATO Y, 1989, THEOR APPL GENET, V78, P11, DOI 10.1007/BF00299746; NEWMAN T, 1994, PLANT PHYSIOL, V106, P1241, DOI 10.1104/pp.106.4.1241; SAKAI H, 1995, NATURE, V378, P199, DOI 10.1038/378199a0; SASAKI T, 1994, PLANT J, V6, P615, DOI 10.1046/j.1365-313X.1994.6040615.x; SCHULTZ EA, 1993, DEVELOPMENT, V119, P745; SCHWARZSOMMER Z, 1990, SCIENCE, V250, P931, DOI 10.1126/science.250.4983.931; SHERIDAN WF, 1993, PLANT J, V3, P347, DOI 10.1111/j.1365-313X.1993.tb00186.x; SHEVELL DE, 1994, CELL, V77, P1051, DOI 10.1016/0092-8674(94)90444-8; SOUER E, 1995, PLANT J, V7, P677, DOI 10.1046/j.1365-313X.1995.7040677.x; VANDERKROL AR, 1993, GENE DEV, V7, P1214, DOI 10.1101/gad.7.7a.1214; Vincent CA, 1995, CURR BIOL, V5, P1449, DOI 10.1016/S0960-9822(95)00282-X; WEIGEL D, 1994, CELL, V78, P203, DOI 10.1016/0092-8674(94)90291-7; WEST MAL, 1993, PLANT CELL, V5, P1361, DOI 10.1105/tpc.5.10.1361	40	706	896	10	128	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 19	1996	85	2					159	170		10.1016/S0092-8674(00)81093-4	http://dx.doi.org/10.1016/S0092-8674(00)81093-4			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UG255	8612269	Bronze			2022-12-28	WOS:A1996UG25500005
J	Taunton, J; Hassig, CA; Schreiber, SL				Taunton, J; Hassig, CA; Schreiber, SL			A mammalian histone deacetylase related to the yeast transcriptional regulator Rpd3p	SCIENCE			English	Article							SACCHAROMYCES-CEREVISIAE; ACETYLATION; NUCLEOSOME; ACTIVATION; LOCI	Trapoxin is a microbially derived cyclotetrapeptide that inhibits histone deacetylation in vivo and causes mammalian cells to arrest in the cell cycle. A trapoxin affinity matrix was used to isolate two nuclear proteins that copurified with histone deacetylase activity. Both proteins were identified by peptide microsequencing, and a complementary DNA encoding the histone deacetylase catalytic subunit (HD1) was cloned from a human Jurkat T cell library. As the predicted protein is very similar to the yeast transcriptional regulator Rpd3p, these results support a role for histone deacetylase as a key regulator of eukaryotic transcription.	HARVARD UNIV,HOWARD HUGHES MED INST,DEPT CHEM & BIOL CHEM,CAMBRIDGE,MA 02138; HARVARD UNIV,HOWARD HUGHES MED INST,DEPT MOLEC & CELLULAR BIOL,CAMBRIDGE,MA 02138	Harvard University; Howard Hughes Medical Institute; Harvard University; Howard Hughes Medical Institute								APARICIO OM, 1991, CELL, V66, P1279, DOI 10.1016/0092-8674(91)90049-5; BOWDISH KS, 1993, MOL CELL BIOL, V13, P2172, DOI 10.1128/MCB.13.4.2172; BRAUNSTEIN M, 1993, GENE DEV, V7, P592, DOI 10.1101/gad.7.4.592; CLIPSTONE NA, 1992, NATURE, V357, P695, DOI 10.1038/357695a0; HECHT A, 1995, CELL, V80, P583, DOI 10.1016/0092-8674(95)90512-X; JOHNSON LM, 1990, P NATL ACAD SCI USA, V87, P6286, DOI 10.1073/pnas.87.16.6286; KIJIMA M, 1993, J BIOL CHEM, V268, P22429; KLEFF S, 1995, J BIOL CHEM, V270, P24674, DOI 10.1074/jbc.270.42.24674; LEE DY, 1993, CELL, V72, P73, DOI 10.1016/0092-8674(93)90051-Q; MCKENZIE EA, 1993, MOL GEN GENET, V240, P374, DOI 10.1007/BF00280389; MEGEE PC, 1990, SCIENCE, V247, P841, DOI 10.1126/science.2106160; NASMYTH K, 1987, CELL, V48, P579, DOI 10.1016/0092-8674(87)90236-4; NEER EJ, 1994, NATURE, V371, P297, DOI 10.1038/371297a0; PARK EC, 1990, MOL CELL BIOL, V10, P4932, DOI 10.1128/MCB.10.9.4932; QIAN YW, 1993, NATURE, V364, P648, DOI 10.1038/364648a0; STILLMAN DJ, 1994, GENETICS, V136, P781; TAUNTON J, UNPUB; TURNER BM, 1993, CELL, V75, P5, DOI 10.1016/S0092-8674(05)80078-9; VIDAL M, 1991, MOL CELL BIOL, V11, P6317, DOI 10.1128/MCB.11.12.6317; YOSHIDA M, 1995, BIOESSAYS, V17, P423, DOI 10.1002/bies.950170510	20	1463	1587	3	124	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 19	1996	272	5260					408	411		10.1126/science.272.5260.408	http://dx.doi.org/10.1126/science.272.5260.408			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UG252	8602529				2022-12-28	WOS:A1996UG25200046
J	Allain, FHT; Gubser, CC; Howe, PWA; Nagai, K; Neuhaus, D; Varani, G				Allain, FHT; Gubser, CC; Howe, PWA; Nagai, K; Neuhaus, D; Varani, G			Specificity of ribonucleoprotein interaction determined by RNA folding during complex formation	NATURE			English	Article							SMALL NUCLEAR RIBONUCLEOPROTEIN; U1A PROTEIN; CRYSTAL-STRUCTURE; PREMESSENGER RNA; NMR-SPECTROSCOPY; BINDING DOMAIN; POLYADENYLATION; CONFORMATION	Many proteins involved in pre-mRNA processing contain one or more copies of a 70-90-amino-acid alpha beta module called the ribonucleoprotein domain(1-4). RNA maturation depends on the specific recognition by ribonucleoproteins of RNA elements within pre-mRNAs and small nuclear RNAs. The human U1A protein binds an RNA hairpin during splicing(5-8), and regulates its own expression by binding an internal loop(9) in the 3'-untranslated region of its pre mRNA, preventing polyadenylation3. Here we report the nuclear magnetic resonance structure of the complex between the regulatory element of the U1A 3'-untranslated region (UTR)(9-11) and the U1A protein RNA-binding domain. Specific intermolecular recognition requires the interaction of the variable loops of the ribonucleoprotein domain with the well-structured helical regions of the RNA. Formation of the complex then orders the flexible RNA single-stranded loop against the protein beta-sheet surface, and reorganizes the carboxy-terminal region of the protein to maximize surface complementarity and functional group recognition.	MRC,MOLEC BIOL LAB,CAMBRIDGE CB2 1QB,ENGLAND	MRC Laboratory Molecular Biology								ABOULELA F, 1995, J MOL BIOL, V253, P313, DOI 10.1006/jmbi.1995.0555; ALLAIN FHT, 1995, J MOL BIOL, V250, P333, DOI 10.1006/jmbi.1995.0381; AVIS J, 1996, J MOL BIOL; BOELENS WC, 1993, CELL, V72, P881, DOI 10.1016/0092-8674(93)90577-D; BRUNGER AT, 1990, XPLOR 3 1 SYSTEM XRA; BURD CG, 1994, SCIENCE, V265, P615, DOI 10.1126/science.8036511; DIAMOND R, 1995, ACTA CRYSTALLOGR D, V51, P127, DOI 10.1107/S0907444994010723; GERCHMAN SE, 1994, PROTEIN EXPRES PURIF, V5, P242, DOI 10.1006/prep.1994.1037; GORLACH M, 1994, J BIOL CHEM, V269, P23074; Gubser CC, 1996, BIOCHEMISTRY-US, V35, P2253, DOI 10.1021/bi952319f; GUNDERSON SI, 1994, CELL, V76, P531, DOI 10.1016/0092-8674(94)90116-3; HALL KB, 1992, NUCLEIC ACIDS RES, V20, P4283, DOI 10.1093/nar/20.16.4283; HOFFMAN DW, 1991, P NATL ACAD SCI USA, V88, P2495, DOI 10.1073/pnas.88.6.2495; HOWE PWA, 1994, EMBO J, V13, P3873, DOI 10.1002/j.1460-2075.1994.tb06698.x; JESSEN TH, 1991, EMBO J, V10, P3447, DOI 10.1002/j.1460-2075.1991.tb04909.x; KIM JL, 1993, NATURE, V365, P520, DOI 10.1038/365520a0; KIM YC, 1993, NATURE, V365, P512, DOI 10.1038/365512a0; LAIRDOFFRINGA IA, 1995, P NATL ACAD SCI USA, V92, P11859, DOI 10.1073/pnas.92.25.11859; Liljas A, 1995, CURR OPIN STRUC BIOL, V5, P721, DOI 10.1016/0959-440X(95)80003-4; LOVE JJ, 1995, NATURE, V376, P791, DOI 10.1038/376791a0; NAGAI K, 1990, NATURE, V348, P515, DOI 10.1038/348515a0; OTTING G, 1990, Q REV BIOPHYS, V23, P39, DOI 10.1017/S0033583500005412; OUBRIDGE C, 1994, NATURE, V372, P432, DOI 10.1038/372432a0; PUGLISI JD, 1992, SCIENCE, V257, P76, DOI 10.1126/science.1621097; QUERY CC, 1989, CELL, V57, P89, DOI 10.1016/0092-8674(89)90175-X; SCHERLY D, 1990, NATURE, V345, P502, DOI 10.1038/345502a0; SPOLAR RS, 1994, SCIENCE, V263, P777, DOI 10.1126/science.8303294; VANGELDER CWG, 1993, EMBO J, V12, P5191, DOI 10.1002/j.1460-2075.1993.tb06214.x; WEEKS KM, 1995, CELL, V82, P221, DOI 10.1016/0092-8674(95)90309-7; WERNER MH, 1995, CELL, V81, P705, DOI 10.1016/0092-8674(95)90532-4	30	233	237	0	14	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	APR 18	1996	380	6575					646	650		10.1038/380646a0	http://dx.doi.org/10.1038/380646a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UF741	8602269				2022-12-28	WOS:A1996UF74100052
J	Wennberg, DE; Kellett, MA; Dickens, JD; Malenka, DJ; Keilson, LM; Keller, RB				Wennberg, DE; Kellett, MA; Dickens, JD; Malenka, DJ; Keilson, LM; Keller, RB			The association between local diagnostic testing intensity and invasive cardiac procedures	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ACUTE MYOCARDIAL-INFARCTION; NEW-YORK-STATE; CORONARY-ARTERY DISEASE; RACIAL-DIFFERENCES; ANGIOGRAPHY; APPROPRIATENESS; SURGERY; CARE; REVASCULARIZATION; CATHETERIZATION	Objective.-To determine the extent to which geographic variation in invasive cardiac procedures can be explained by the variable use of diagnostic testing. Design.-A population-based cohort study using Medicare Part B data (physician services). Setting and Subjects.-Procedure data for all Medicare beneficiaries in northern New England. Main Outcome Measures.-Twelve coronary angiography service areas were constructed for Medicare beneficiaries in northern New England. Age- and sex-adjusted utilization rates were developed for three procedure categories: total stress test, coronary angiography, and revascularization. Total stress tests were further stratified into nonimaging and imaging procedures leg, thallium). Tests performed in follow-up to invasive procedures were excluded leg, stress test following revascularizations). Linear regression was used to assess the relationship between procedure categories. Results.-A tight positive relationship was found between total stress test rates and the rates of subsequent coronary angiography (R(2)=0.61, P<.005). Most of the variance was explained by imaging stress tests (R(2)=0.50, P<.02), A strong relationship was found between coronary angiography and revascularization (R(2)=0.82, P<.001). Finally, a clear relationship between total stress tests and subsequent revascularizations was also found (R(2)=0.55, P<.006). Conclusion.-The population-based rates of diagnostic testing largely explained the variance associated with subsequent therapeutic interventions. Our results suggest that local testing intensity is an important determinant of the variable use of invasive cardiac procedures.	MAINE MED CTR,DEPT MED,DIV CARDIOL,PORTLAND,ME 04107; MAINE MED ASSESSMENT FDN,AUGUSTA,ME; DARTMOUTH HITCHCOCK MED CTR,CARDIOL SECT,DEPT MED,LEBANON,NH	Maine Medical Center; Dartmouth College	Wennberg, DE (corresponding author), MAINE MED CTR,DEPT MED,DIV HLTH SERV RES,22 BRAMHALL ST,PORTLAND,ME 04107, USA.				AHRQ HHS [HS06813-04] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		*AM MED ASS, 1992, PHYS CURR PROC TERM; AYANIAN JZ, 1993, JAMA-J AM MED ASSOC, V269, P2642, DOI 10.1001/jama.269.20.2642; BARNES BA, 1985, JAMA-J AM MED ASSOC, V254, P371, DOI 10.1001/jama.254.3.371; BERNSTEIN SJ, 1993, JAMA-J AM MED ASSOC, V269, P766, DOI 10.1001/jama.269.6.766; BLACK WC, 1993, NEW ENGL J MED, V328, P1237, DOI 10.1056/NEJM199304293281706; Draper NR, 1981, PROBABILITY MATH STA; EVERY NR, 1993, NEW ENGL J MED, V329, P546, DOI 10.1056/NEJM199308193290807; GITTELSOHN AM, 1991, AM J PUBLIC HEALTH, V81, P1435, DOI 10.2105/AJPH.81.11.1435; GRABOYS TB, 1992, JAMA-J AM MED ASSOC, V268, P2537, DOI 10.1001/jama.268.18.2537; GRAY D, 1990, LANCET, V335, P1317, DOI 10.1016/0140-6736(90)91196-H; HILBORNE LH, 1993, JAMA-J AM MED ASSOC, V269, P761, DOI 10.1001/jama.269.6.761; Kahn H.A., 1983, STAT METHODS EPIDEMI; KLEINBAUM DG, 1988, APPLIED REGRESSION A; KOSTIS JB, 1994, CIRCULATION, V90, P1715, DOI 10.1161/01.CIR.90.4.1715; LACROIX AZ, 1990, CIRCULATION, V81, P437, DOI 10.1161/01.CIR.81.2.437; LANGA KM, 1993, NEW ENGL J MED, V329, P1784, DOI 10.1056/NEJM199312093292407; LEAPE LL, 1993, JAMA-J AM MED ASSOC, V269, P753, DOI 10.1001/jama.269.6.753; LEAPE LL, 1990, JAMA-J AM MED ASSOC, V263, P669, DOI 10.1001/jama.263.5.669; MARK DB, 1994, NEW ENGL J MED, V330, P1101, DOI 10.1056/NEJM199404213301601; MASSIE BM, 1979, AM J CARDIOL, V44, P616, DOI 10.1016/0002-9149(79)90278-9; MAYNARD C, 1992, ARCH INTERN MED, V152, P972, DOI 10.1001/archinte.152.5.972; MCCLELLAN M, 1994, JAMA-J AM MED ASSOC, V272, P859, DOI 10.1001/jama.272.11.859; MOLD JW, 1986, NEW ENGL J MED, V314, P512, DOI 10.1056/NEJM198602203140809; POLLOCK SG, 1992, CIRCULATION, V85, P237, DOI 10.1161/01.CIR.85.1.237; ROULEAU JL, 1993, NEW ENGL J MED, V328, P779, DOI 10.1056/NEJM199303183281108; *SAS I INC, 1989, SAS STAT US GUID VER, V2, P891; STEINGART RM, 1991, NEW ENGL J MED, V325, P226, DOI 10.1056/NEJM199107253250402; WASSERTHEILSMOLLER S, 1987, J CHRON DIS, V40, P385, DOI 10.1016/0021-9681(87)90172-X; WENNBERG J, 1982, SCI AM, V246, P120, DOI 10.1038/scientificamerican0482-120; WHITTLE J, 1993, NEW ENGL J MED, V329, P621, DOI 10.1056/NEJM199308263290907; 1994, MMWR MORBID MORTAL W, V44, P61	31	100	103	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 17	1996	275	15					1161	1164		10.1001/jama.275.15.1161	http://dx.doi.org/10.1001/jama.275.15.1161			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UE625	8609682				2022-12-28	WOS:A1996UE62500026
J	Donnan, GA				Donnan, GA			Posterior leucoencephalopathy syndrome	LANCET			English	Editorial Material							CYCLOSPORINE				Donnan, GA (corresponding author), AUSTIN & REPATRIAT MED CTR,DEPT NEUROL,MELBOURNE,VIC,AUSTRALIA.			Donnan, Geoffrey/0000-0001-6324-3403				BENIGNI A, 1992, TRANSPLANTATION, V54, P775, DOI 10.1097/00007890-199211000-00002; BYROM FB, 1954, LANCET, V2, P201; DAHMUS MA, 1992, AM J OBSTET GYNECOL, V167, P935, DOI 10.1016/S0002-9378(12)80015-9; FISHER M, 1985, ANN NEUROL, V18, P268, DOI 10.1002/ana.410180219; Hinchey J, 1996, NEW ENGL J MED, V334, P494, DOI 10.1056/NEJM199602223340803; Hughes EC., 1972, OBSTET GYNECOLOGIC T; HUGHES RL, 1990, NEW ENGL J MED, V323, P420; Oppenheimer BS, 1928, ARCH INTERN MED, V41, P264, DOI 10.1001/archinte.1928.00130140126010; ROBERTSON DM, 1970, AM J PATHOL, V59, P115; WILL AD, 1987, NEUROLOGY, V37, P1555, DOI 10.1212/WNL.37.9.1555	10	12	12	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 13	1996	347	9007					988	988		10.1016/S0140-6736(96)90142-7	http://dx.doi.org/10.1016/S0140-6736(96)90142-7			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UF380	8606611				2022-12-28	WOS:A1996UF38000007
J	Kersh, GJ; Allen, PM				Kersh, GJ; Allen, PM			Essential flexibility in the T-cell recognition of antigen	NATURE			English	Article							RECEPTOR LIGAND; PEPTIDE; COMPLEX; TCR; PROLIFERATION; ANTAGONISTS; ACTIVATION; SEPARATION; INHIBITION; ANERGY	alpha beta T cells specifically recognize a ligand composed of a peptide bound to a self-major-histocompatibility-complex molecule, but the recognition of slightly altered ligands by T cells can lead to a partial activation. This flexibility is crucial for T-cell development and can have both beneficial and harmful effects on peripheral T cells.	WASHINGTON UNIV,SCH MED,DEPT PATHOL,ST LOUIS,MO 63110	Washington University (WUSTL)	Kersh, GJ (corresponding author), WASHINGTON UNIV,SCH MED,CTR IMMUNOL,660 S EUCLID AVE,ST LOUIS,MO 63110, USA.							ALEXANDER J, 1993, J IMMUNOL, V150, P1; ALLEN PM, 1994, NATURE, V369, P355, DOI 10.1038/369355a0; ASHTONRICKARDT PG, 1994, IMMUNOL TODAY, V15, P362, DOI 10.1016/0167-5699(94)90174-0; ASHTONRICKARDT PG, 1994, CELL, V76, P651, DOI 10.1016/0092-8674(94)90505-3; BARTLETT J, 1901, FAMILIAR QUOTATIONS; BERTOLETTI A, 1994, NATURE, V369, P407, DOI 10.1038/369407a0; BHARDWAJ V, 1993, J IMMUNOL, V151, P5000; BJORKMAN PJ, 1987, NATURE, V329, P506, DOI 10.1038/329506a0; CAO WX, 1995, NATURE, V378, P295, DOI 10.1038/378295a0; CHAN AC, 1994, ANNU REV IMMUNOL, V12, P555, DOI 10.1146/annurev.iy.12.040194.003011; CHAN AC, 1992, CELL, V71, P649, DOI 10.1016/0092-8674(92)90598-7; CORR M, 1994, SCIENCE, V265, P946, DOI 10.1126/science.8052850; DAVENPORT MP, 1995, IMMUNOL TODAY, V16, P432, DOI 10.1016/0167-5699(95)80020-4; DAVIS MM, 1988, NATURE, V334, P395, DOI 10.1038/334395a0; DEMAGISTRIS MT, 1992, CELL, V68, P625, DOI 10.1016/0092-8674(92)90139-4; EVAVOLD BD, 1995, IMMUNITY, V2, P655, DOI 10.1016/1074-7613(95)90010-1; EVAVOLD BD, 1993, J IMMUNOL, V150, P3131; EVAVOLD BD, 1991, SCIENCE, V252, P1308, DOI 10.1126/science.1833816; EVAVOLD BD, 1993, IMMUNOL TODAY, V14, P602, DOI 10.1016/0167-5699(93)90200-5; EVAVOLD BD, 1993, P NATL ACAD SCI USA, V91, P2300; FRANCO A, 1994, EUR J IMMUNOL, V24, P940, DOI 10.1002/eji.1830240424; FREMONT DH, 1992, SCIENCE, V257, P919, DOI 10.1126/science.1323877; GERMAIN RN, 1995, IMMUNOLOGIST, V3, P113; HOGQUIST KA, 1994, CELL, V76, P17, DOI 10.1016/0092-8674(94)90169-4; JAMESON SC, 1994, NATURE, V369, P750, DOI 10.1038/369750a0; JAMESON SC, 1993, J EXP MED, V177, P1541, DOI 10.1084/jem.177.6.1541; JAMESON SC, 1995, IMMUNITY, V2, P1, DOI 10.1016/1074-7613(95)90074-8; JANEWAY CA, 1989, COLD SH Q B, V54, P657; JANEWAY CA, 1995, IMMUNOL TODAY, V16, P223, DOI 10.1016/0167-5699(95)80163-4; JENKINS MK, 1987, J EXP MED, V165, P302, DOI 10.1084/jem.165.2.302; KISIELOW P, 1995, ADV IMMUNOL, V58, P87, DOI 10.1016/S0065-2776(08)60620-3; KLENERMAN P, 1994, NATURE, V369, P403, DOI 10.1038/369403a0; KUCHROO VK, 1994, J IMMUNOL, V153, P3326; MADDEN DR, 1991, NATURE, V353, P321, DOI 10.1038/353321a0; MADRENAS J, 1995, SCIENCE, V267, P515, DOI 10.1126/science.7824949; MARRACK P, 1993, SCI AM, V269, P86; MATSUI K, 1991, SCIENCE, V254, P1788, DOI 10.1126/science.1763329; MATSUI K, 1994, P NATL ACAD SCI USA, V91, P12862, DOI 10.1073/pnas.91.26.12862; MCKEITHAN TW, 1995, P NATL ACAD SCI USA, V92, P5042, DOI 10.1073/pnas.92.11.5042; MEIER UC, 1995, SCIENCE, V270, P1360, DOI 10.1126/science.270.5240.1360; NICHOLSON LB, 1995, IMMUNITY, V3, P397, DOI 10.1016/1074-7613(95)90169-8; PASTOR MI, 1995, IMMUNOL TODAY, V16, P159, DOI 10.1016/0167-5699(95)80134-0; PERLMUTTER RM, 1993, ANNU REV IMMUNOL, V11, P451, DOI 10.1146/annurev.iy.11.040193.002315; PFEIFFER C, 1995, J EXP MED, V181, P1569, DOI 10.1084/jem.181.4.1569; PIRCHER H, 1991, NATURE, V351, P482, DOI 10.1038/351482a0; RACIOPPI L, 1993, J EXP MED, V177, P1047, DOI 10.1084/jem.177.4.1047; RACKE MK, 1994, J EXP MED, V180, P1961, DOI 10.1084/jem.180.5.1961; ROBEY E, 1994, ANNU REV IMMUNOL, V12, P675, DOI 10.1146/annurev.iy.12.040194.003331; SAMELSON LE, 1992, J BIOL CHEM, V267, P24913; SCHWARTZ RH, 1990, SCIENCE, V248, P1349, DOI 10.1126/science.2113314; SEBZDA E, 1994, SCIENCE, V263, P1615, DOI 10.1126/science.8128249; SETTE A, 1994, ANNU REV IMMUNOL, V12, P413, DOI 10.1146/annurev.immunol.12.1.413; SLOANLANCASTER J, 1994, J EXP MED, V180, P1195, DOI 10.1084/jem.180.4.1195; SLOANLANCASTER J, 1994, CELL, V79, P913, DOI 10.1016/0092-8674(94)90080-9; SLOANLANCASTER J, 1993, NATURE, V363, P156, DOI 10.1038/363156a0; SLOANLANCASTER J, IN PRESS A REV IMMUN; SMILEK DE, 1991, P NATL ACAD SCI USA, V88, P9633, DOI 10.1073/pnas.88.21.9633; SNOKE K, 1993, J IMMUNOL, V151, P6815; STERN LJ, 1994, NATURE, V368, P215, DOI 10.1038/368215a0; SYKULEV Y, 1994, IMMUNITY, V1, P15, DOI 10.1016/1074-7613(94)90005-1; VALITUTTI S, 1995, NATURE, V375, P148, DOI 10.1038/375148a0; VALITUTTI S, 1995, J EXP MED, V181, P577, DOI 10.1084/jem.181.2.577; VASQUEZ NJ, 1994, IMMUNITY, V1, P45, DOI 10.1016/1074-7613(94)90008-6; WAUBEN MHM, 1992, J EXP MED, V176, P667, DOI 10.1084/jem.176.3.667; WEBER S, 1992, NATURE, V356, P793, DOI 10.1038/356793a0; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; WINDHAGEN A, 1995, IMMUNITY, V2, P373, DOI 10.1016/1074-7613(95)90145-0; WUCHERPFENNIG KW, 1995, CELL, V80, P695, DOI 10.1016/0092-8674(95)90348-8; YAGI J, 1990, INT IMMUNOL, V2, P83, DOI 10.1093/intimm/2.1.83	69	289	291	0	10	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	APR 11	1996	380	6574					495	498		10.1038/380495a0	http://dx.doi.org/10.1038/380495a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UE663	8606766				2022-12-28	WOS:A1996UE66300040
J	Bond, CM; Bradley, C				Bond, CM; Bradley, C			Over the counter drugs - The interface between the community pharmacist and patients .3.	BRITISH MEDICAL JOURNAL			English	Article								Pharmacists play an important part in primary health care, and their accessibility is a key factor. Their NHS payments relate predominantly to the dispensing of prescribed medicines; to recognise the service element of their advisory role, an NHS funded professional fee could be built into the cost structure for pharmacy medicines. The increased number of medicines available over the counter has need for training for counter assistants; it will become compulsory in July 1996, and some family health services authorities are providing this. The shift to care in the community could mean that pharmacists will have an even greater role in the primary health care team. Encouraging the public to seek advice from the community pharmacist may lead to a greater proportion of visits to doctors resulting from referrals from the pharmacist. Joint development by pharmacists and doctors of guidelines for advice on, and recommendation of, over the counter medicines is needed.	UNIV BIRMINGHAM,SCH MED,DEPT GEN PRACTICE,BIRMINGHAM B15 2TT,W MIDLANDS,ENGLAND	University of Birmingham	Bond, CM (corresponding author), UNIV ABERDEEN,DEPT GEN PRACTICE,ABERDEEN,SCOTLAND.							BLENKINSOPP A, 1994, OTCS PRESCRIPTION HE; Bond C M, 1995, Health Bull (Edinb), V53, P26; Bond CM, 1995, INT J PHARM PRACT, V3, P85; BOND CM, 1992, PHARM J, V249, pR6; *COMM INQ PHARM, 1986, REP NUFF FDN; DARRACOTT R, 1995, PHARM J, V254, P497; Eaton G, 1979, Sociol Health Illn, V1, P69, DOI 10.1111/1467-9566.ep11006781; EVANS D, 1994, PHARM J, V252, P631; FLINT JF, 1995, PHARM J, V254, P28; GOODBURN E, 1991, BMJ-BRIT MED J, V302, P440, DOI 10.1136/bmj.302.6774.440; HARGIE ODW, 1987, INT PHARM J, V1, P175; Jepson M, 1991, CONSUMER EXPECTATION; KRSKA J, 1994, PHARM J, V252, P936; National Audit Office, 1992, COMM PHARM ENGL; *ROYAL PHARM SOC, 1992, PHARM CAR FUT ROL CO; TAPSTER JV, 1994, PHARM J, V253, P112; 1987, CM249	17	35	35	0	7	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 23	1996	312	7033					758	760						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UC166	8605465				2022-12-28	WOS:A1996UC16600039
J	Goldstein, ST; Juranek, DD; Ravenholt, O; Hightower, AW; Martin, DG; Mesnik, JL; Griffiths, SD; Bryant, AJ; Reich, RR; Herwaldt, BL				Goldstein, ST; Juranek, DD; Ravenholt, O; Hightower, AW; Martin, DG; Mesnik, JL; Griffiths, SD; Bryant, AJ; Reich, RR; Herwaldt, BL			Cryptosporidiosis: An outbreak associated with drinking water despite state-of-the-art water treatment	ANNALS OF INTERNAL MEDICINE			English	Article							SUPPLIES; GIARDIA	Objective: To determine the magnitude and source of an outbreak of cryptosporidiosis among persons with human immunodeficiency virus (HIV) infection and to determine whether the outbreak extended into the immunocompetent population. Design: Matched case-control study and environmental investigation. Setting: Clark County, Nevada. Participants: Adults with HIV infection (36 case-patients with laboratory-confirmed Cryptosporidium parvum infection and 107 controls), matched by physician or clinic and by CD4(+) cell count category. Measurements: Potential risk factors for infection, death rates, and data on water quality. Results: Review of surveillance and microbiology records identified 3 cases of cryptosporidiosis in 1992 (the first year that cryptosporidiosis was reportable in Nevada), 23 cases in 1993, and 78 cases in the first quarter of 1994. Of the 78 laboratory-confirmed cases in the first quarter of 1994, 61 (78.2%) were in HIV-infected adults. Of these 61 adults, 32 (52.5%) had died by 30 June 1994; at least 20 of the 32 (62.5%) had cryptosporidiosis listed on their death certificates. In the case-control study, persons who drank any unboiled tap water were four times more likely than persons who drank only bottled water to have had cryptosporidiosis (odds ratio, 4.22 [95% CI, 1.22 to 14.65]; P = 0.02). For persons with CD4(+) cell counts less than 100 cells/mm(3), the association between tap water and cryptosporidiosis was even stronger (odds ratio, 13.52 [CI, 1.78 to 102.92]; P = 0.01). Additional data indicate that this outbreak also affected persons who were not infected with HIV. No elevated turbidity values or coliform counts and no Cryptosporidium oocysts were found in testing of source (Lake Mead) or finished (treated) water during the study period, but so-called presumptive oocysts were intermittently found after the investigation in samples of source water, filter backwash, and finished water. Conclusions: A cryptosporidiosis outbreak was associated with municipal drinking water, despite state-of-the-art water treatment and water quality better than that required by current federal standards. This outbreak highlights the importance of surveillance for cryptosporidiosis and the need for guidelines for the prevention of waterborne-Cryptosporidium infection among HIV-infected persons.	CDCP, DIV PARASIT DIS, ATLANTA, GA 30341 USA; CLARK CTY DIST HLTH DEPT, LAS VEGAS, NV 89106 USA; CDCP, DIV VIRAL & RICKETTSIAL DIS, HEPATITIS BRANCH, ATLANTA, GA 30333 USA	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA								BADENOCH J, 1990, CRYPTOSPORIDIUM WATE; Boyce TG, 1996, PEDIATR INFECT DIS J, V15, P87, DOI 10.1097/00006454-199601000-00019; Centers for Disease Control and Prevention (CDC), 1994, MMWR Morb Mortal Wkly Rep, V43, P661; CIESIELSKI C, 1995, 2ND NAT C HUM RETR R; CLANCY JL, 1994, J AM WATER WORKS ASS, V86, P89; CURRENT WL, 1991, CLIN MICROBIOL REV, V4, P325, DOI 10.1128/CMR.4.3.325-358.1991; DUPONT HL, 1995, NEW ENGL J MED, V332, P855, DOI 10.1056/NEJM199503303321304; HAAS CN, 1994, 1994 P ANN C AM WAT, P517; HAYES EB, 1989, NEW ENGL J MED, V320, P1372, DOI 10.1056/NEJM198905253202103; JURANEK DD, 1995, CLIN INFECT DIS, V21, pS57, DOI 10.1093/clinids/21.Supplement_1.S57; KLEINBAUM DG, 1982, EPIDEMIOLOGIC RES PR, P159; LECHAVALLIER MW, 1994, PREVENTING WATERBORN, P2; LECHEVALLIER MW, 1991, APPL ENVIRON MICROB, V57, P2617, DOI 10.1128/AEM.57.9.2617-2621.1991; LECHEVALLIER MW, 1991, APPL ENVIRON MICROB, V57, P2610, DOI 10.1128/AEM.57.9.2610-2616.1991; MACKENZIE WR, 1994, NEW ENGL J MED, V331, P161, DOI 10.1056/NEJM199407213310304; Moore Anne C., 1993, Morbidity and Mortality Weekly Report, V42, P1; MUSIAL CE, 1987, APPL ENVIRON MICROB, V53, P687, DOI 10.1128/AEM.53.4.687-692.1987; ODONOGHUE PJ, 1995, INT J PARASITOL, V25, P139, DOI 10.1016/0020-7519(94)E0059-V; SORVILLO F, 1994, EPIDEMIOL INFECT, V113, P313, DOI 10.1017/S0950268800051748; SORVILLO FJ, 1994, AM J TROP MED HYG, V51, P326, DOI 10.4269/ajtmh.1994.51.326; Van Loon Frederik P. L., 1995, Morbidity and Mortality Weekly Report, V44, P1; 1993, 1993 BOOK ASTM STAND, P899; 1989, FED REGISTER, V54, P27486	23	168	174	0	18	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 1	1996	124	5					459	+		10.7326/0003-4819-124-5-199603010-00001	http://dx.doi.org/10.7326/0003-4819-124-5-199603010-00001			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TW773	8602703				2022-12-28	WOS:A1996TW77300001
J	Frain, JP; Frain, AE; Carr, PH				Frain, JP; Frain, AE; Carr, PH			Experience of medical senior house officers in preparing discharge summaries	BRITISH MEDICAL JOURNAL			English	Article									DARLINGTON MEM HOSP,DEPT MED,DARLINGTON DL3 6HX,DURHAM,ENGLAND; NETHERLAW SURG,DARLINGTON,DURHAM,ENGLAND									HARDING J, 1987, J ROY COLL GEN PRACT, V37, P494; MAGEEAN RJ, 1986, BRIT MED J, V293, P1283, DOI 10.1136/bmj.293.6557.1283; SOLOMON JK, 1995, J ROY COLL PHYS LOND, V29, P307	3	16	16	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 10	1996	312	7027					350	350						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TV698	8611833				2022-12-28	WOS:A1996TV69800025
J	Lattimer, V; Smith, H; Hungin, P; Glasper, A; George, S				Lattimer, V; Smith, H; Hungin, P; Glasper, A; George, S			Future provision of out of hours primary medical care: A survey with two general practitioner research networks	BRITISH MEDICAL JOURNAL			English	Article							TELEPHONE; ADVICE; CALLS	Objective-To ascertain general practitioners' views about the future provision of out of hours primary medical care. Design-Self completing postal questionnaire survey. Setting-Wessex and north east England. Subjects-116 general practitioners in the Wessex Primary Care Research Network and 83 in the Northern Primary Care Research Network. Main outcome measures-Intention to reduce or opt out of on call; plans for changing out of hours arrangements; the three most important changes needed to out of hours care; willingness to try, and perceived strengths and limitations of, three alternative out of hours care models-primary care emergency centres, telephone triage services, and cooperatives. Results-The overall response rate was 74% Wessex research network 77% (89/116), northern research network 71% (59/83)). Eighty three per cent of respondents (123/148) were willing to try at least one service model, primary care emergency centres being the most popular option. Key considerations were the potential for a model to reduce time on call and workload, to maintain continuity of care, and to fit the practice context. Sixty one per cent (91/148) hoped to reduce time on call and 25% (37/148) hoped to opt out completely. Conclusion-General practitioners were keen to try alternative arrangements for out of hours care delivery, despite the lack of formal trials. The increased flexibility in funding brought about by the recent agreement between the General Medical Services Committee and the Department of Health is likely to lead to a proliferation of different schemes. Careful monitoring will be necessary, and formal trials of new service models are needed urgently.	UNIV SOUTHAMPTON,WESSEX INST PUBL HLTH MED,SOUTHAMPTON GEN HOSP,SOUTHAMPTON SO16 6YD,HANTS,ENGLAND; ALDERMOOR HLTH CTR,SOUTHAMPTON SO16 5ST,HANTS,ENGLAND; CTR HLTH,STOCKTON ON TEES TS16 9EA,CLEVELAND,ENGLAND; UNIV SOUTHAMPTON,SCH NURSING & MIDWIFERY,SOUTHAMPTON GEN HOSP,SOUTHAMPTON SO16 6YD,HANTS,ENGLAND	University of Southampton; University of Southampton			Smith, Helen E/M-2449-2016	Smith, Helen E/0000-0003-1883-6124				ALLEN D, 1988, PRACTITIONER, V232, P1380; Angel S., 1990, HLTH VISITOR, V63, P226; [Anonymous], 1992, ANN REPORT; BAKER D, 1994, BRIT J GEN PRACT, V44, P68; BAKER M, 1995, BRIT J GEN PRACT, V45, P405; BEECHAM L, 1993, BRIT MED J, V307, P1375; COHEN J, 1987, FAM PRACT, V4, P81, DOI 10.1093/fampra/4.2.81; CRAGG DK, 1994, BRIT MED J, V309, P1627, DOI 10.1136/bmj.309.6969.1627; DEAN AG, 1994, EPI INFO VERSIION 6; DORRELL S, 1995, OUT HOURS; FIELD PA, 1985, NURSING RES APPLICAT; HALLAM L, 1994, BRIT MED J, V308, P249, DOI 10.1136/bmj.308.6923.249; HALLAM L, 1994, BRIT MED J, V309, P1621, DOI 10.1136/bmj.309.6969.1621; LATTIMER V, 1995, HEALTH SOC CARE COMM, V3, P58; LOWY A, 1994, J PUBLIC HEALTH MED, V16, P134, DOI 10.1093/oxfordjournals.pubmed.a042947; MACPHERSON I, 1995, FAM PRACT, V12, P335, DOI 10.1093/fampra/12.3.335; MARKLUND B, 1989, FAM PRACT, V6, P42, DOI 10.1093/fampra/6.1.42; MARSH GN, 1987, J ROY COLL GEN PRACT, V37, P301; WHEELER S, 1993, TELEPHONE TRIAGE THE; WILKINS VC, 1993, J NURS ADMIN, V23, P26, DOI 10.1097/00005110-199303000-00008; WILLIAMS BT, 1985, BRIT MED J, V291, P1689, DOI 10.1136/bmj.291.6510.1689; 1994, HLTH SERVICE INDICAT; [No title captured]; 1995, ANAL FELLOWS MEMBERS; 1992, YOUR CHOICES FUTURE; 1994, REGIONAL TRENDS, V29; 1992, HOSPITALS HLTH SERVI	27	32	32	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 10	1996	312	7027					352	356						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TV698	8611835				2022-12-28	WOS:A1996TV69800027
J	Gumbiner, BM				Gumbiner, BM			Cell adhesion: The molecular basis of tissue architecture and morphogenesis	CELL			English	Review							EXTRACELLULAR-MATRIX; REARRANGEMENT; PROTEINS; SURFACE; GROWTH				Gumbiner, BM (corresponding author), MEM SLOAN KETTERING CANC CTR,CELLULAR BIOCHEM & BIOPHYS PROGRAM,1275 YORK AVE,NEW YORK,NY 10021, USA.		Penney, Bethany J/B-3124-2010		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM037432, R01GM037432] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM37432] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALON R, 1995, NATURE, V374, P539, DOI 10.1038/374539a0; ALON R, 1995, J CELL BIOL, V128, P1243, DOI 10.1083/jcb.128.6.1243; BERGELSON JM, 1995, CURR BIOL, V5, P615, DOI 10.1016/S0960-9822(95)00124-2; Bernfield M, 1984, ROLE EXTRACELLULAR M, P542; BERNFIELD M, 1993, DEVELOPMENT S, V119, P205; BIRCHMEIER W, 1994, BBA-REV CANCER, V1198, P11, DOI 10.1016/0304-419X(94)90003-5; BRADLEY RS, 1993, J CELL BIOL, V123, P1857, DOI 10.1083/jcb.123.6.1857; BURRIDGE K, 1992, J CELL BIOL, V119, P893, DOI 10.1083/jcb.119.4.893; CAMPBELL KP, 1995, CELL, V80, P675, DOI 10.1016/0092-8674(95)90344-5; CHEN YP, 1994, J BIOL CHEM, V269, P18307; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; DRUBIN DG, 1996, CELL, V84, P336; DSOUZA SE, 1994, CELL, V79, P659, DOI 10.1016/0092-8674(94)90551-7; DUDEN R, 1988, J CELL BIOL, V107, P1049, DOI 10.1083/jcb.107.3.1049; FLEMING TP, 1988, ANNU REV CELL BIOL, V4, P459, DOI 10.1146/annurev.cellbio.4.1.459; FUCHS E, 1994, CURR OPIN GENET DEV, V4, P725, DOI 10.1016/0959-437X(94)90140-X; FURUSE M, 1994, J CELL BIOL, V127, P1617, DOI 10.1083/jcb.127.6.1617; Garrod DR, 1993, CURR OPIN CELL BIOL, V5, P30, DOI 10.1016/S0955-0674(05)80005-5; Ginsberg Mark H., 1992, Current Opinion in Cell Biology, V4, P766, DOI 10.1016/0955-0674(92)90099-X; GUMBINER B, 1987, AM J PHYSIOL, V253, pC749, DOI 10.1152/ajpcell.1987.253.6.C749; GUMBINER BM, 1993, NEURON, V11, P551, DOI 10.1016/0896-6273(93)90068-3; GUMBINER BM, IN PRESS CURR OPIN C, V7; HALL ZW, 1995, SCIENCE, V269, P362, DOI 10.1126/science.7618101; HEASMAN J, 1994, CELL, V79, P791, DOI 10.1016/0092-8674(94)90069-8; HENDEY B, 1992, SCIENCE, V258, P296, DOI 10.1126/science.1384129; HINCK L, 1994, J CELL BIOL, V124, P729, DOI 10.1083/jcb.124.5.729; HIROKAWA N, 1981, J CELL BIOL, V91, P399, DOI 10.1083/jcb.91.2.399; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; HYNES RO, 1992, CELL, V68, P303, DOI 10.1016/0092-8674(92)90472-O; JULIANO RL, 1993, J CELL BIOL, V120, P577, DOI 10.1083/jcb.120.3.577; Kapfhammer Josef P., 1992, Current Opinion in Cell Biology, V4, P863, DOI 10.1016/0955-0674(92)90112-P; KELLER R, 1987, ZOOL SCI, V4, P763; KELLER RE, 1987, DEV BIOL, V120, P12, DOI 10.1016/0012-1606(87)90099-6; Kemler R, 1989, CURR OPIN CELL BIOL, V1, P892, DOI 10.1016/0955-0674(89)90055-0; KIM SK, 1995, IN PRESS CURR OPIN C, V7; KINCH MS, 1995, J CELL BIOL, V130, P461, DOI 10.1083/jcb.130.2.461; KLEIN G, 1988, CELL, V55, P331, DOI 10.1016/0092-8674(88)90056-6; KOLODKIN AL, 1993, CELL, V75, P1389, DOI 10.1016/0092-8674(93)90625-Z; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; LAURE L, 1994, P NATL ACAD SCI USA, V91, P8263; LEE CH, 1995, IN PRESS DEV BIOL; LEE JO, 1995, CELL, V80, P631, DOI 10.1016/0092-8674(95)90517-0; MADARA JL, 1988, CELL, V53, P497, DOI 10.1016/0092-8674(88)90562-4; MCNAMEE HP, 1993, J CELL BIOL, V121, P673, DOI 10.1083/jcb.121.3.673; Mitchison TJ, 1996, CELL, V84, P371, DOI 10.1016/S0092-8674(00)81281-7; MIYAMOTO S, 1995, SCIENCE, V267, P883, DOI 10.1126/science.7846531; MONTESANO R, 1991, CELL, V67, P901, DOI 10.1016/0092-8674(91)90363-4; Mosher Deane F., 1992, Current Opinion in Cell Biology, V4, P810, DOI 10.1016/0955-0674(92)90104-K; NAGAFUCHI A, 1994, J CELL BIOL, V127, P235, DOI 10.1083/jcb.127.1.235; NAKAGAWA S, 1995, DEVELOPMENT, V121, P1321; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; OBERLENDER SA, 1994, DEVELOPMENT, V120, P177; OLSEN BR, 1995, IN PRESS CURR OPIN C; OVERDUIN M, 1995, SCIENCE, V267, P386, DOI 10.1126/science.7824937; PFIFER M, 1995, TRENDS CELL BIOL, V5, P224; PORTER BE, 1995, DEV BIOL, V167, P609, DOI 10.1006/dbio.1995.1052; RIMM DL, 1995, P NATL ACAD SCI USA, V92, P8813, DOI 10.1073/pnas.92.19.8813; RUOSLAHTI E, 1994, CELL, V77, P477, DOI 10.1016/0092-8674(94)90209-7; Sastry SK, 1993, CURR OPIN CELL BIOL, V5, P819, DOI 10.1016/0955-0674(93)90031-K; SCHLAEPFER DD, 1994, NATURE, V372, P786; SCHWARTZ MA, 1995, IN PRESS ANN REV CEL; SHAPIRO L, 1995, NATURE, V374, P327, DOI 10.1038/374327a0; SHATTIL SJ, 1994, CURR OPIN CELL BIOL, V6, P695, DOI 10.1016/0955-0674(94)90096-5; SONDEREGGER P, 1992, J CELL BIOL, V119, P1387, DOI 10.1083/jcb.119.6.1387; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; STANLEY JR, 1995, J EXP MED, V181, P1, DOI 10.1084/jem.181.1.1; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; Takeichi M, 1993, CURR OPIN CELL BIOL, V5, P806, DOI 10.1016/0955-0674(93)90029-P; TROYANOVSKY SM, 1993, CELL, V72, P561, DOI 10.1016/0092-8674(93)90075-2; Turner CE, 1991, CURR OPIN CELL BIOL, V3, P849, DOI 10.1016/0955-0674(91)90059-8; WATABE M, 1994, J CELL BIOL, V127, P247, DOI 10.1083/jcb.127.1.247; ZHU XY, 1995, MOL BIOL CELL, V6, P273, DOI 10.1091/mbc.6.3.273	72	2826	2903	4	337	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 9	1996	84	3					345	357		10.1016/S0092-8674(00)81279-9	http://dx.doi.org/10.1016/S0092-8674(00)81279-9			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TV708	8608588	Bronze			2022-12-28	WOS:A1996TV70800003
J	Kumar, NM; Gilula, NB				Kumar, NM; Gilula, NB			The gap junction communication channel	CELL			English	Review							MEMBRANE CHANNEL; PROTEIN; ANTIBODIES; LIVER; PHOSPHORYLATION; CONNEXIN43; TOPOLOGY; EMBRYO; CELLS				Kumar, NM (corresponding author), SCRIPPS RES INST, DEPT CELL BIOL, 10666 N TORREY PINES RD, LA JOLLA, CA 92037 USA.							BERGOFFEN J, 1993, SCIENCE, V262, P2039, DOI 10.1126/science.8266101; BRISSETTE JL, 1994, P NATL ACAD SCI USA, V91, P6453, DOI 10.1073/pnas.91.14.6453; BRITZCUNNINGHAM SH, 1995, NEW ENGL J MED, V332, P1323, DOI 10.1056/NEJM199505183322002; BRUZZONE R, 1994, NEURON, V13, P1253, DOI 10.1016/0896-6273(94)90063-9; BRUZZONE R, 1993, MOL BIOL CELL, V4, P7, DOI 10.1091/mbc.4.1.7; BUEHLER LK, 1995, BIOPHYS J, V68, P1767, DOI 10.1016/S0006-3495(95)80353-X; CASCIO M, 1995, J BIOL CHEM, V270, P18643, DOI 10.1074/jbc.270.31.18643; DERMIETZEL R, 1993, TRENDS NEUROSCI, V16, P186, DOI 10.1016/0166-2236(93)90151-B; ELFGANG C, 1995, J CELL BIOL, V129, P805, DOI 10.1083/jcb.129.3.805; FALK MM, 1994, J CELL BIOL, V127, P343, DOI 10.1083/jcb.127.2.343; GOLIGER JA, 1994, DEV DYNAM, V200, P1, DOI 10.1002/aja.1002000102; GUERRIER D, 1995, J CELL SCI, V108, P2609; HURTLEY SM, 1989, ANNU REV CELL BIOL, V5, P277, DOI 10.1146/annurev.cb.05.110189.001425; KAM E, 1986, J INVEST DERMATOL, V87, P748, DOI 10.1111/1523-1747.ep12456937; KANNO Y, 1995, PROGR CELL RES, V4; KISTLER J, 1993, J STRUCT BIOL, V110, P28, DOI 10.1006/jsbi.1993.1002; KREN BT, 1993, J CELL BIOL, V123, P707, DOI 10.1083/jcb.123.3.707; Kumar N M, 1992, Semin Cell Biol, V3, P3; KUMAR NM, 1995, J CELL SCI, V108, P3725; LAIRD DW, 1992, DEV DYNAM, V195, P153, DOI 10.1002/aja.1001950302; Leclerc Catherine, 1994, P45; LEE SW, 1992, J CELL BIOL, V118, P1213, DOI 10.1083/jcb.118.5.1213; LEUBE RE, 1995, J CELL SCI, V108, P883; LO CW, 1979, CELL, V18, P411, DOI 10.1016/0092-8674(79)90060-6; LOEWENSTEIN WR, 1981, PHYSIOL REV, V61, P829, DOI 10.1152/physrev.1981.61.4.829; MEHTA PP, 1991, J MEMBRANE BIOL, V124, P207, DOI 10.1007/BF01994355; MESNIL M, 1995, CANCER RES, V55, P629; MEYER RA, 1992, J CELL BIOL, V119, P179, DOI 10.1083/jcb.119.1.179; MILKS LC, 1988, EMBO J, V7, P2967, DOI 10.1002/j.1460-2075.1988.tb03159.x; MOON RT, 1993, DEVELOPMENT S, V119, P85; Musil Linda S., 1994, P173; MUSIL LS, 1991, J CELL BIOL, V115, P1357, DOI 10.1083/jcb.115.5.1357; MUSIL LS, 1990, J CELL BIOL, V111, P2077, DOI 10.1083/jcb.111.5.2077; MUSIL LS, 1993, CELL, V74, P1065, DOI 10.1016/0092-8674(93)90728-9; NEDERGAARD M, 1994, SCIENCE, V263, P1768, DOI 10.1126/science.8134839; NICHOLSON B, 1987, NATURE, V329, P732, DOI 10.1038/329732a0; PARPURA V, 1994, NATURE, V369, P744, DOI 10.1038/369744a0; PAUL DL, 1995, CURR OPIN CELL BIOL, V7, P665, DOI 10.1016/0955-0674(95)80108-1; PAUL DL, 1995, DEVELOPMENT, V121, P371; RAHMAN S, 1993, J BIOL CHEM, V268, P1260; REAUME AG, 1995, SCIENCE, V267, P1831, DOI 10.1126/science.7892609; RISEK B, 1994, DEV BIOL, V164, P183, DOI 10.1006/dbio.1994.1190; ROOK MB, 1990, J MEMBRANE BIOL, V118, P179, DOI 10.1007/BF01868475; SAEZ JC, 1989, P NATL ACAD SCI USA, V86, P2708, DOI 10.1073/pnas.86.8.2708; SANDERSON MJ, 1994, MOL CELL ENDOCRINOL, V98, P173, DOI 10.1016/0303-7207(94)90136-8; Spray David C., 1994, P195; SPRAY DC, 1991, BRAIN RES, V568, P1, DOI 10.1016/0006-8993(91)91373-9; SPRAY DC, 1995, TRENDS NEUROSCI, V18, P256, DOI 10.1016/0166-2236(95)93911-G; STAUFFER KA, 1995, J BIOL CHEM, V270, P6768; STAUFFER KA, 1991, J CELL BIOL, V115, P141, DOI 10.1083/jcb.115.1.141; STEINBERG TH, 1994, EMBO J, V13, P744, DOI 10.1002/j.1460-2075.1994.tb06316.x; SULLIVAN R, 1995, J CELL BIOL, V130, P419, DOI 10.1083/jcb.130.2.419; TIBBITTS TT, 1990, BIOPHYS J, V57, P1025, DOI 10.1016/S0006-3495(90)82621-7; TRAUB O, 1989, J CELL BIOL, V108, P1039, DOI 10.1083/jcb.108.3.1039; VEENSTRA RD, 1995, CIRC RES, V77, P1156, DOI 10.1161/01.RES.77.6.1156; WARNER AE, 1984, NATURE, V311, P127, DOI 10.1038/311127a0; WHITE TW, 1995, MOL BIOL CELL, V6, P459, DOI 10.1091/mbc.6.4.459; WHITE TW, 1994, J CELL BIOL, V125, P8979; WOLBURG H, 1995, INT REV CYTOL, V157, P315, DOI 10.1016/S0074-7696(08)62161-0; YEAGER M, 1992, J MOL BIOL, V223, P929, DOI 10.1016/0022-2836(92)90253-G; YOST HJ, 1995, CELL, V82, P689, DOI 10.1016/0092-8674(95)90464-6	61	1562	1617	5	105	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 9	1996	84	3					381	388		10.1016/S0092-8674(00)81282-9	http://dx.doi.org/10.1016/S0092-8674(00)81282-9			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TV708	8608591	Bronze			2022-12-28	WOS:A1996TV70800006
J	Glanz, K; Yang, H				Glanz, K; Yang, H			Communicating about risk of infectious diseases	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PERCEPTIONS; RADON				Glanz, K (corresponding author), UNIV HAWAII,CANC RES CTR HAWAII,PREVENT & CONTROL PROGRAM,1236 LAUHALA ST,HONOLULU,HI 96813, USA.							ALLEN FW, 1987, SCI TECHNOL HUM VAL, V12, P138; Centers for Disease Control and Prevention, 1994, ADDRESSING EMERGING; CHALK R, 1987, SCI TECHNOL HUM VAL, V12, P11; DUTTON DB, 1987, SCI TECHNOL HUM VAL, V12, P48; FISCHHOFF B, 1987, SCI TECHNOL HUM VAL, V12, P13; Garrett L., 1994, COMING PLAGUE NEWLY; GLANZ K, 1990, HLTH BEHAVIOR HLTH E; GOODMAN RA, 1994, PRINCIPLES PRACTICE, P150; Hovland C.I., 1953, COMMUN PERSUATION; KULIK JA, 1987, HEALTH PSYCHOL, V6, P15, DOI 10.1037/0278-6133.6.1.15; Lederberg J., 1992, EMERGING INFECTIONS; McGuire William, 1985, HDB SOCIAL PSYCHOL P, P233; MCLEROY K R, 1989, Health Education Research, V4, P169, DOI 10.1093/her/4.2.169; PLOUGH A, 1987, SCI TECHNOL HUM VAL, V12, P4; SANDMAN PM, 1993, HEALTH EDUC QUART, V20, P471, DOI 10.1177/109019819302000408; SHORT JF, 1984, AM SOCIOL REV, V49, P711, DOI 10.2307/2095526; SLOVIC P, 1987, SCIENCE, V236, P280, DOI 10.1126/science.3563507; Slovic P., 1981, ASSESSMENT PERCEPTIO; van der Veide F, 1992, PSYCHOL HEALTH, V6, P23, DOI DOI 10.1080/08870449208402018; WEINSTEIN ND, 1993, HEALTH PSYCHOL, V12, P324, DOI 10.1037/0278-6133.12.4.324; WEINSTEIN ND, 1993, RISK ANAL, V13, P103, DOI 10.1111/j.1539-6924.1993.tb00733.x; WEINSTEIN ND, 1988, AM J PUBLIC HEALTH, V78, P796, DOI 10.2105/AJPH.78.7.796; WEINSTEIN ND, 1992, HEALTH PSYCHOL, V11, P170, DOI 10.1037/0278-6133.11.3.170; WEINSTEIN ND, 1984, HEALTH PSYCHOL, V3, P431, DOI 10.1037/0278-6133.3.5.431; 1989, IMPROVING RISK COMMU; 1994, MMWR-MORBID MORTAL W, V43, P1	27	23	23	0	5	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 17	1996	275	3					253	256		10.1001/jama.275.3.253	http://dx.doi.org/10.1001/jama.275.3.253			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	TP282	8604182				2022-12-28	WOS:A1996TP28200037
J	Hennessy, TW; Hedberg, CW; Slutsker, L; White, KE; BesserWiek, JM; Moen, ME; Feldman, J; Coleman, WW; Edmonson, LM; MacDonald, KL; Osterholm, MT; Belongia, E; Boxrud, D; Boyer, W; Danila, R; Korlath, J; Leano, F; Mills, W; Soler, J; Sullivan, M; Deling, M; Geisen, P; Kontz, C; Elfering, K; Krueger, W; Masso, T; Mitchell, MF; Vought, K; Duran, A; Harrell, F; Jirele, K; Krivitsky, A; Manresa, H; Mars, R; Nierman, M; Schwab, A; Sedzielarz, F; Tillman, F; Wagner, D; Wieneke, D; Price, C				Hennessy, TW; Hedberg, CW; Slutsker, L; White, KE; BesserWiek, JM; Moen, ME; Feldman, J; Coleman, WW; Edmonson, LM; MacDonald, KL; Osterholm, MT; Belongia, E; Boxrud, D; Boyer, W; Danila, R; Korlath, J; Leano, F; Mills, W; Soler, J; Sullivan, M; Deling, M; Geisen, P; Kontz, C; Elfering, K; Krueger, W; Masso, T; Mitchell, MF; Vought, K; Duran, A; Harrell, F; Jirele, K; Krivitsky, A; Manresa, H; Mars, R; Nierman, M; Schwab, A; Sedzielarz, F; Tillman, F; Wagner, D; Wieneke, D; Price, C			A national outbreak of Salmonella enteritidis infections from ice cream	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							FOODBORNE OUTBREAK; UNITED-STATES; RAW-MILK; CONSUMPTION; GASTROENTERITIS; TRANSMISSION	Background. In September 1994, the Minnesota Department of Health detected an increase in the number of reports of Salmonella enteritidis infections. After a case-control study implicated a nationally distributed brand of ice cream (Schwan's) in the outbreak, the product was recalled and further epidemiologic and microbiologic investigations were conducted. Methods. We defined an outbreak-associated case of S. enteritidis infection as one in which S. enteritidis was cultured from a person who became ill in September or October 1994. We established national surveillance and surveyed customers of the implicated manufacturer, The steps involved in the manufacture of ice cream associated with cases of S. enteritidis infection were compared with those of products not known to be associated with infection matched for the date of manufacture. Cultures for bacteria were obtained from ice cream samples, the ice cream plant, and tanker trailers that had transported the ice cream base (premix) to the plant. Results. estimate that S. enteritidis gastroenteritis developed in 224,000 persons in the United States after they ate Schwan's ice cream. The attack rate for consumers was 6.6 percent. Ice cream associated with infection contained a higher percentage of premix that had been transported by tanker trailers that had carried nonpasteurized eggs immediately before (P = 0.02). S. enteritidis was isolated from 8 of 266 ice cream products (3 percent), but not from environmental samples obtained from the ice cream plant (n = 157) or tanker trailers (n = 204). Conclusions. This nationwide outbreak of salmonellosis was most likely the result of contamination of pasteurized ice cream premix during transport in tanker trailers that had previously carried nonpasteurized liquid eggs containing S. enteritidis. To prevent further outbreaks, food products not destined for repasteurization should be transported in dedicated containers.	MINNESOTA DEPT HLTH,ACUTE DIS EPIDEMIOL SECT,MINNEAPOLIS,MN 55440; MINNESOTA DEPT HLTH,PUBL HLTH LAB,MINNEAPOLIS,MN 55440; MINNESOTA DEPT HLTH,EXECUT OFF,MINNEAPOLIS,MN 55440; CTR DIS CONTROL & PREVENT,DIV FIELD EPIDEMIOL,ATLANTA,GA 30341; CTR DIS CONTROL & PREVENT,EPIDEM INTELLIGENCE SERV,ATLANTA,GA 30341; CTR DIS CONTROL & PREVENT,FOODBORNE & DIARRHEAL DIS BRANCH,NATL CTR INFECT DIS,ATLANTA,GA 30341; MINNESOTA DEPT AGR,DIV DAIRY & FOOD INSPECT,ST PAUL,MN; US FDA,MINNEAPOLIS,MN; OLMSTED CTY HLTH DEPT,ROCHESTER,MN; US FDA,CHICAGO,IL	Minnesota Department of Health (MHD); Minnesota Department of Health (MHD); Minnesota Department of Health (MHD); Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; US Food & Drug Administration (FDA); US Food & Drug Administration (FDA)				Belongia, Edward/0000-0001-7478-0415				BELONGIA EA, 1991, J INFECT DIS, V164, P338, DOI 10.1093/infdis/164.2.338; BELONGIA EA, 1990, NEW ENGL J MED, V323, P357, DOI 10.1056/NEJM199008093230601; BLASER MJ, 1982, REV INFECT DIS, V4, P1096; *CDCP, 1995, SALM SURV ANN TAB SU; CHALKER RB, 1988, REV INFECT DIS, V10, P111; Ewing WH, 1986, IDENTIFICATION ENTER; GRASMICK A, 1992, CLIN MICROBIOLOGY PR, V1; HEDBERG CW, 1992, JAMA-J AM MED ASSOC, V268, P3203, DOI 10.1001/jama.268.22.3203; HEDBERG CW, 1993, J INFECT DIS, V167, P107, DOI 10.1093/infdis/167.1.107; HEDBERG CW, 1991, J INFECT DIS, V164, P1135, DOI 10.1093/infdis/164.6.1135; HEDBERG CW, 1992, JAMA-J AM MED ASSOC, V268, P3208, DOI 10.1001/jama.268.22.3208; HEDBERG CW, 1987, NEW ENGL J MED, V316, P993, DOI 10.1056/NEJM198704163161605; HICKMANBRENNER FW, 1991, J CLIN MICROBIOL, V29, P2817, DOI 10.1128/JCM.29.12.2817-2823.1991; HOLMBERG SD, 1984, NEW ENGL J MED, V311, P617, DOI 10.1056/NEJM198409063111001; KORLATH JA, 1985, J INFECT DIS, V152, P592, DOI 10.1093/infdis/152.3.592; KURITSKY JN, 1984, ANN INTERN MED, V100, P519, DOI 10.7326/0003-4819-100-4-519; MISHU B, 1994, J INFECT DIS, V169, P547, DOI 10.1093/infdis/169.3.547; OSTERHOLM MT, 1981, NEW ENGL J MED, V304, P24, DOI 10.1056/NEJM198101013040106; OSTERHOLM MT, 1980, AM J EPIDEMIOL, V112, P8, DOI 10.1093/oxfordjournals.aje.a112978; OSTERHOLM MT, 1986, JAMA-J AM MED ASSOC, V256, P484, DOI 10.1001/jama.256.4.484; TAYLOR A, 1974, AM J EPIDEMIOL, V100, P150, DOI 10.1093/oxfordjournals.aje.a112017; *US FDA, 1992, BACT AN MAN; WHITE KE, 1986, AM J EPIDEMIOL, V124, P120, DOI 10.1093/oxfordjournals.aje.a114356; 1994, MMWR-MORBID MORTAL W, V43, P740; 1988, JAMA-J AM MED ASSOC, V259, P2103; 1994, MMWR-MORBID MORTAL W, V43, P669	26	234	241	0	28	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 16	1996	334	20					1281	1286		10.1056/NEJM199605163342001	http://dx.doi.org/10.1056/NEJM199605163342001			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UK880	8609944				2022-12-28	WOS:A1996UK88000001
J	Driver, J				Driver, J			Enhancement of selective listening by illusory mislocation of speech sounds due to lip-reading	NATURE			English	Article								MECHANISMS of human attention allow selective processing of just the relevant events among the many stimuli bombarding our senses(1). Most laboratory studies examine attention within just a single sense, but in the real world many important events are specified multimodally, as in verbal communication. Speech comprises visual lip movements as well as sounds, and lip-reading contributes to speech perception. even for listeners with good hearing, by a process of audiovisual integration(2). Such examples raise the problem of how we coordinate our spatial attention across the sensory modalities, to select sights and sounds from a common source for further processing. Here we show that this problem is alleviated by allowing some cross-modal matching before attentional selection is completed. Cross modal matching can lead to an illusion, whereby sounds are mislocated at their apparent visual source(3); this crossmodal illusion can enhance selective spatial attention to speech sounds.			Driver, J (corresponding author), UNIV LONDON BIRKBECK COLL,DEPT PSYCHOL,MALET ST,LONDON WC1E 7HX,ENGLAND.		Driver, Jon/A-4779-2010					BERTELSON P, 1976, PERCEPT PSYCHOPHYS, V19, P531, DOI 10.3758/BF03211222; Blauert J., 1983, SPATIAL HEARING; CHERRY EC, 1953, J ACOUST SOC AM, V25, P975, DOI 10.1121/1.1907229; DRIVER J, 1994, ATTENTION PERFORM, V15, P311; MASSARO DW, 1995, CURR DIR PSYCHOL SCI, V4, P104, DOI 10.1111/1467-8721.ep10772401; MASSARO DW, 1987, PERSPECTIVES PERCEPT, P273; Massaro DW, 1987, SPEECH PERCEPTION EA; MCGURK H, 1976, NATURE, V263, P747; Naatanen R., 2018, ATTENTION BRAIN FUNC; RADEAU M, 1994, CAH PSYCHOL COGN, V13, P3; REISBERG D, 1978, ACTA PSYCHOL, V42, P331, DOI 10.1016/0001-6918(78)90007-0; WITKIN HA, 1952, J EXP PSYCHOL, V43, P58, DOI 10.1037/h0055889	12	197	200	1	45	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAY 2	1996	381	6577					66	68		10.1038/381066a0	http://dx.doi.org/10.1038/381066a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	UJ053	8609989				2022-12-28	WOS:A1996UJ05300056
J	Fine, KD				Fine, KD			The prevalence of occult gastrointestinal bleeding in celiac sprue	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							GLUTEN-FREE DIET; IRON-DEFICIENCY; REFRACTORY SPRUE; DISEASE; DIARRHEA; CHILDREN; ANEMIA	Background. Iron deficiency complicating celiac sprue is usually attributed to the malabsorption of dietary iron or the loss of iron from the intestinal mucosa, There has been little investigation of the role of intestinal loss of blood in patients with this condition, The purpose of this study was to determine the prevalence of occult gastrointestinal bleeding in patients with celiac sprue. Methods. We tested one 48- or 72-hour stool collection from each of 8 patients with partial villous atrophy and 28 patients with total villous atrophy using a guaiac-impregnated card (Hemoccult). Serving as controls were 18 normal subjects, each studied before and during laxative-induced diarrhea; 17 patients with idiopathic chronic diarrhea; 63 patients with microscopic colitis; 23 patients with pancreatic steatorrhea; and 7 patients with treated celiac sprue who had normal intestinal histologic features, All the patients underwent a diagnostic workup that included esophagogastroduodenoscopy, colonoscopy, and barium radiography of the small bower. Results. Positive Hemoccult tests were infrequent in each of the control groups, occurring in 0 to 8 percent of the subjects, whereas 2 of the 8 patients with partial villous atrophy (25 percent) and 15 of the 28 patients with total villous atrophy (54 percent) had positive tests, When the patients with total villous atrophy were classified according to their subsequent responses to a gluten-free diet, 7 of the 17 who were responsive to gluten withdrawal (41 percent) were Hemoccult-positive, as compared with 8 of the 11 who did not respond to the diet (73 percent). Conclusions. Occult gastrointestinal bleeding can be detected in about half of patients with celiac sprue and should be added to the list of factors that can contribute to iron deficiency in patients with this disorder. (C) 1996, Massachusetts Medical Society.			Fine, KD (corresponding author), BAYLOR UNIV, MED CTR, DEPT GASTROINTESTINAL RES, 3500 GASTON AVE, DALLAS, TX 75246 USA.				NIDDK NIH HHS [5-R01-DK37172-05] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK037172] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AFZALPURKAR RG, 1992, NEW ENGL J MED, V327, P1849, DOI 10.1056/NEJM199212243272605; BADENOCH J, 1954, BLOOD, V9, P123, DOI 10.1182/blood.V9.2.123.123; BADENOCH J, 1960, LANCET, V1, P192; BONAMICO M, 1987, J PEDIATR GASTR NUTR, V6, P702, DOI 10.1097/00005176-198709000-00007; BRADY CE, 1994, J CLIN GASTROENTEROL, V18, P130, DOI 10.1097/00004836-199403000-00010; COOKE WT, 1984, COELIAC DISEASE, P128; COOPER BT, 1987, Q J MED, V63, P269; DEPLA ACTM, 1990, HEPATO-GASTROENTEROL, V37, P90; DUBOIS RN, 1989, JAMA-J AM MED ASSOC, V262, P935, DOI 10.1001/jama.262.7.935; GIULIANI ER, 1961, J NUCL MED, V2, P297; GOSTOUT CJ, 1993, GASTROINTEST ENDOSC, V39, P76, DOI 10.1016/S0016-5107(93)70018-8; HOFFBRAND AV, 1974, CLIN GASTROENTEROL, V3, P71; HOLMES GKT, 1989, GUT, V30, P333, DOI 10.1136/gut.30.3.333; HOLMES GKT, 1992, DYN NUTR R, V2, P105; KAGNOFF MF, 1991, TXB GASTROENTEROLOGY, P1503; KILPATRICK ZM, 1969, J AMER MED ASSOC, V208, P999, DOI 10.1001/jama.208.6.999; KOSNAI I, 1979, ARCH DIS CHILD, V54, P375, DOI 10.1136/adc.54.5.375; MARSH MN, 1993, EUR J GASTROEN HEPAT, V5, P784; MCGUIGAN JE, 1964, GASTROENTEROLOGY, V47, P636; SIMON JB, 1985, GASTROENTEROLOGY, V88, P820, DOI 10.1016/0016-5085(85)90158-1; STEVENS D, 1979, ARCH DIS CHILD, V54, P648, DOI 10.1136/adc.54.8.648; SUTTON DR, 1970, LANCET, V2, P387; SYLWESTROWICZ T, 1989, AM J GASTROENTEROL, V84, P763; TRIER JS, 1978, GASTROENTEROLOGY, V75, P307; WEBB MGT, 1967, BMJ-BRIT MED J, V2, P151, DOI 10.1136/bmj.2.5545.151; WHITEHEAD R, 1965, J CLIN PATHOL, V18, P110, DOI 10.1136/jcp.18.1.110	26	100	104	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 2	1996	334	18					1163	1167		10.1056/NEJM199605023341804	http://dx.doi.org/10.1056/NEJM199605023341804			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UG831	8602182				2022-12-28	WOS:A1996UG83100004
J	Rossi, F; Labourier, E; Forne, T; Divita, G; Derancourt, J; Riou, JF; Antoine, E; Cathala, G; Brunel, C; Tazi, J				Rossi, F; Labourier, E; Forne, T; Divita, G; Derancourt, J; Riou, JF; Antoine, E; Cathala, G; Brunel, C; Tazi, J			Specific phosphorylation of SR proteins by mammalian DNA topoisomerase I	NATURE			English	Article							SPLICING FACTOR; CONSERVED FAMILY; RNA; DOMAINS; REGULATORS; EXPRESSION; PARTICLES; CLONING; U1-70K	SEVERAL metazoan splicing factors are characterized by ribonucleoprotein (RNP) consensus sequences and arginine-serine repeats (RS domain)(1-8) which are essential for their function in splicing(5,9,10). These include members of the SR-protein family (SC35, SF2/ASF), the U1 small nuclear (sn)RNP protein (U1-70K) and the U2 snRNP auxiliary factor (U2AF). SR proteins are phosphorylated in vivo(11) and the phosphorylation state of U1-70K's RS domain influences its splicing activity(12). Here we report the purification of a protein kinase that is specific for SR proteins and show that it is DNA topoisomerase I. This enzyme lacks a canonical ATP-binding motif hut hinds ATP with a dissociation constant of 50 nM. Camptothecin and derivatives, known to be specific inhibitors of DNA topoisomerase I, strongly inhibit the kinase activity in the presence of DNA and affect the phosphorylation state of SR proteins. Thus, DNA topoisomerase I may well be one of the SR protein kinases operating in vivo.	CNRS,CTR RECH BIOCHIM MACROMOLEC,LP 9008,INSERM,U249,F-34033 MONTPELLIER 1,FRANCE; RHONE POULENC RORER SA,CTR RECH VITRY ALFORTVILLE,UNITE CANCEROL,DEPT BIOL,F-94403 VITRY,FRANCE	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; Sanofi-Aventis			DIVITA, GILLES/AAV-9214-2021; Forne, Thierry/D-3718-2013	Forne, Thierry/0000-0002-9179-1551; riou, jean-francois/0000-0002-0055-6506; Labourier, Emmanuel/0000-0001-8010-0674; Tazi, Jamal/0000-0002-1949-8748				BACH M, 1990, METHOD ENZYMOL, V181, P232; BJORNSTI MA, 1989, CANCER RES, V49, P6318; CACERES JF, 1993, EMBO J, V12, P4715, DOI 10.1002/j.1460-2075.1993.tb06160.x; COTWILL K, 1996, EMBO J, V15, P265; DARPA P, 1988, P NATL ACAD SCI USA, V85, P2543, DOI 10.1073/pnas.85.8.2543; DIVITA G, 1993, J BIOL CHEM, V268, P13178; FROELICHAMMON SJ, 1995, J BIOL CHEM, V270, P21429, DOI 10.1074/jbc.270.37.21429; FU XD, 1995, RNA, V1, P663; FU XD, 1992, SCIENCE, V256, P535, DOI 10.1126/science.1373910; GE H, 1991, CELL, V66, P373, DOI 10.1016/0092-8674(91)90626-A; GUI JF, 1994, NATURE, V369, P678, DOI 10.1038/369678a0; GUPTA M, 1995, BBA-GENE STRUCT EXPR, V1262, P1, DOI 10.1016/0167-4781(95)00029-G; HSIANG YH, 1985, J BIOL CHEM, V260, P4873; KRAINER AR, 1991, CELL, V66, P383, DOI 10.1016/0092-8674(91)90627-B; LEE MP, 1993, P NATL ACAD SCI USA, V90, P6656, DOI 10.1073/pnas.90.14.6656; MENNO A, 1993, NATURE, V365, P227; Moore M., 1993, RNA WORLD, P303; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; OFARRELL PZ, 1977, CELL, V12, P133; RITTINGER K, 1995, P NATL ACAD SCI USA, V92, P8046, DOI 10.1073/pnas.92.17.8046; ROTH MB, 1991, J CELL BIOL, V115, P587, DOI 10.1083/jcb.115.3.587; TAZI J, 1993, NATURE, V363, P283, DOI 10.1038/363283a0; VELLARD M, 1992, P NATL ACAD SCI USA, V89, P2511, DOI 10.1073/pnas.89.7.2511; WANG JC, 1985, ANNU REV BIOCHEM, V54, P665, DOI 10.1146/annurev.biochem.54.1.665; WOPPMANN A, 1993, NUCLEIC ACIDS RES, V21, P2815, DOI 10.1093/nar/21.12.2815; ZAHLER AM, 1992, GENE DEV, V6, P837, DOI 10.1101/gad.6.5.837; ZAMORE PD, 1992, NATURE, V355, P609, DOI 10.1038/355609a0; ZHELKOVSKY AM, 1994, PROTEIN EXPRES PURIF, V5, P364, DOI 10.1006/prep.1994.1053; ZIEVE G, 1981, J MOL BIOL, V145, P501, DOI 10.1016/0022-2836(81)90542-8; ZUO P, 1993, EMBO J, V12, P4727, DOI 10.1002/j.1460-2075.1993.tb06161.x	30	279	281	0	9	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAY 2	1996	381	6577					80	82		10.1038/381080a0	http://dx.doi.org/10.1038/381080a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UJ053	8609994				2022-12-28	WOS:A1996UJ05300061
J	Baker, RJ; VanDenBussche, RA; Wright, AJ; Wiggins, LE; Hamilton, MJ; Reat, EP; Smith, MH; Lomakin, MD; Chesser, RK				Baker, RJ; VanDenBussche, RA; Wright, AJ; Wiggins, LE; Hamilton, MJ; Reat, EP; Smith, MH; Lomakin, MD; Chesser, RK			RETRACTED: High levels of genetic change in rodents of Chernobyl (Retracted article. See vol 390, pg 100, 1997)	NATURE			English	Article; Retracted Publication							MUTATIONS	BASE-PAIR substitution rates for the mitochondrial cytochrome b gene of free-living, native populations of voles collected next to reactor 4 at Chernobyl, Ukraine, were estimated by two independent methods to be in excess of 10(-4) nucleotides per site per generation. These estimates are hundreds of times greater than those typically found in mitochondria of vertebrates, suggesting that the environment resulting from this nuclear power plant disaster is having a measurable genetic impact on the organisms of that region. Despite these DNA changes, vole populations thrive and reproduce in the radioactive regions around the Chernobyl reactor.	SAVANNAH RIVER ECOL LAB, AIKEN, SC 29802 USA; INT RES & DEV AGCY, KIEV 252001, UKRAINE	United States Department of Energy (DOE); Savannah River Ecology Laboratory	Baker, RJ (corresponding author), TEXAS TECH UNIV, DEPT BIOL SCI, LUBBOCK, TX 79409 USA.			Van Den Bussche, Ronald/0000-0002-6481-3209				Baker RJ, 1996, J MAMMAL, V77, P155, DOI 10.2307/1382717; BAKER RJ, 1994, J MAMMAL, V75, P321, DOI 10.2307/1382550; *BROOKH NAT LAB, 1961, FUND ASP RAD; HOLLAENDER A, 1954, RAD BIOL, V1; IRWIN DM, 1991, J MOL EVOL, V32, P128, DOI 10.1007/BF02515385; KIMURA M, 1973, GENETICS, V73, P19; LI WH, 1991, FUNDAMENTALS MOL EVO, P67; LONGMIRE JL, 1992, AUK, V109, P522; Maddison W.P., 1992, ANAL PHYLOGENY CHARA; MEDVEDEV Z, 1990, LEGACY CHEMOBYL, P74; Mourad R., 1987, Transactions of the American Nuclear Society, V54, P226; Neel J V, 1991, CHILDREN ATOMIC BOMB; NEEL JV, 1986, P NATL ACAD SCI USA, V83, P389, DOI 10.1073/pnas.83.2.389; POWERS DA, 1987, NUCL SAFETY, V28, P10; SAVCHENKO VK, 1995, ECOLOGY CHEM CATASTR; Schull WJ, 1995, EFFECTS ATOMIC RAD H; SICH AR, 1994, NUCL SAFETY, V35, P1; SMITH MF, 1991, MOL BIOL EVOL, V8, P85; SOMMER SS, 1992, FASEB J, V6, P2767, DOI 10.1096/fasebj.6.10.1634040; STAMATOYANNOPOULOS G, 1982, HUM GENET, V60, P181, DOI 10.1007/BF00569709; SUGG DW, 1995, ENVIRON TOXICOL CHEM, V14, P661, DOI 10.1002/etc.5620140414; Swofford D. L., 1991, PAUP PHYLOGENETIC AN; VOGEL F, 1986, HUMAN GENETICS PROBL, P433; WETTSTEIN PJ, 1995, MOL PHYLOGENET EVOL, V4, P150, DOI 10.1006/mpev.1995.1015	24	57	60	0	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 25	1996	380	6576					707	708						2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UG827	8614463				2022-12-28	WOS:A1996UG82700049
J	Khunti, K				Khunti, K			A method of creating a death register for general practice	BRITISH MEDICAL JOURNAL			English	Article							AUDIT				Khunti, K (corresponding author), UNIV LEICESTER,ELI LILLY NATL CLIN AUDIT CTR,DEPT GEN PRACTICE & PRIMARY HLTH CARE,LEICESTER LE5 4PW,LEICS,ENGLAND.		/ABC-9527-2021	Khunti, Kamlesh/0000-0003-2343-7099				BERLIN A, 1993, BRIT J GEN PRACT, V43, P70; BLACK DA, 1984, BMJ-BRIT MED J, V288, P1127, DOI 10.1136/bmj.288.6424.1127; HART JT, 1987, BRIT MED J, V294, P871, DOI 10.1136/bmj.294.6576.871; NEVILLE RG, 1987, J ROY COLL GEN PRACT, V37, P496	4	11	11	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 13	1996	312	7036					952	952						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UF659	8616311				2022-12-28	WOS:A1996UF65900023
J	Senard, JM; Montastruc, P; Herxheimer, A				Senard, JM; Montastruc, P; Herxheimer, A			Early warnings about drugs - From the stock market	LANCET			English	Editorial Material											Senard, JM (corresponding author), FAC MED TOULOUSE,SERV PHARMACOL MED & CLIN,TOULOUSE,FRANCE.			Senard, Jean-Michel/0000-0001-7679-1281				COSNARD D, 1993, ECHOS           1026, P12; HALAAS JL, 1995, SCIENCE, V269, P543, DOI 10.1126/science.7624777; NODELANGLOIS F, 1995, LIBERATION      0729, P20; 1995, SCRIP, V2048, P16; 1993, INVESTIR, V1032, P18; 1994, ECHOS           0817, P7; 1995, INVESTIR, V1095, P14	7	7	7	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 13	1996	347	9007					987	988		10.1016/S0140-6736(96)90141-5	http://dx.doi.org/10.1016/S0140-6736(96)90141-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UF380	8606610				2022-12-28	WOS:A1996UF38000006
J	Spector, TD; Cicuttini, F; Baker, J; Loughlin, J; Hart, D				Spector, TD; Cicuttini, F; Baker, J; Loughlin, J; Hart, D			Genetic influences on osteoarthritis in women: A twin study	BRITISH MEDICAL JOURNAL			English	Article							NUTRITION EXAMINATION SURVEY; KNEE OSTEO-ARTHRITIS; GENERAL-POPULATION; NATIONAL-HEALTH; CHINGFORD; OBESITY	Objectives-To assess the relative contribution of genetic and environmental factors to common forms of osteoarthritis of the hands and knees. Design-Classic twin study with unselected twins who were screened radiologically for osteoarthritis. Subjects-130 identical and 120 non-identical female twins aged 48-70 recruited from a London based twin register and through a national media campaign. Main outcome measures-Similarity in identical compared with non-identical twin pairs for radiographic changes at the interphalangeal and first carpometacarpal joints of the hands and the tibiofemoral joint and patellofemoral joint of the knee expressed as intraclass correlations. Results-The intraclass correlations of radiographic osteophytes and narrowing at most sites and the presence of Heberden's nodes and knee pain were higher in the identical pairs. The intraclass correlation of the total radiographic osteoarthritis score in identical pairs (rMZ) was 0.64 (SE 0.05) compared with 0.38 (0.08) in non-identical pairs. The proportion of genetic variance of total osteoarthritis score (osteophytes and narrowing) with modelling techniques was estimated at 0.54 (95% confidence interval 0.43 to 0.65) and ranged from 0.39 to 0.65 for different sites and features (P<0.001) after adjustment for age and weight. Conclusions-These results demonstrate for the first time a clear genetic effect for radiographic osteoarthritis of the hand and knee in women, with a genetic influence ranging from 39-65%, independent of known environmental or demographic confounders. The results of this study should lead to further work on isolating the gene or genes involved in the pathogenesis of this common disabling disease.	INST MOLEC MED,COLLAGEN GENET UNIT,OXFORD,ENGLAND	University of Oxford	Spector, TD (corresponding author), ST THOMAS HOSP,DEPT RHEUMATOL,LONDON SE1 7EH,ENGLAND.		Spector, Tim D/F-6533-2012; Cicuttini, Flavia/H-4978-2014	Cicuttini, Flavia/0000-0002-8200-1618; Loughlin, John/0000-0003-2018-3361				ALLAKOKKO L, 1990, P NATL ACAD SCI USA, V87, P6565; ANDERSON JJ, 1988, AM J EPIDEMIOL, V128, P179, DOI 10.1093/oxfordjournals.aje.a114939; Burnett S, 1994, RADIOGRAPHIC ATLAS O; COOPER C, 1994, J RHEUMATOL, V21, P307; DAVIS MA, 1991, J RHEUMATOL, V18, P591; DONNER A, 1995, GENET EPIDEMIOL, V12, P267, DOI 10.1002/gepi.1370120304; FELSON DT, 1988, ANN INTERN MED, V109, P18, DOI 10.7326/0003-4819-109-1-18; FELSON DT, 1987, ARTHRITIS RHEUM, V30, P914, DOI 10.1002/art.1780300811; HART D, 1994, ANN RHEUM DIS, V53, P220, DOI 10.1136/ard.53.4.220; HART DJ, 1993, J RHEUMATOL, V20, P331; HART DJ, 1991, ANN RHEUM DIS, V50, P467, DOI 10.1136/ard.50.7.467; HART DJ, 1993, ANN RHEUM DIS, V52, P93, DOI 10.1136/ard.52.2.93; HELLER RF, 1988, GENET EPIDEMIOL, V5, P311, DOI 10.1002/gepi.1370050503; HOCHBERG MC, 1989, SEMIN ARTHRITIS RHEU, V18, P4, DOI 10.1016/0049-0172(89)90008-5; KELLGREN JH, 1958, ANN RHEUM DIS, V17, P388, DOI 10.1136/ard.17.4.388; KELLGREN JH, 1963, ANN RHEUM DIS, V22, P237, DOI 10.1136/ard.22.4.237; KELSEY JL, 1988, ANN REV PUBLIC HLTH, V9, P48; KNOWLTON RG, 1990, NEW ENGL J MED, V322, P526, DOI 10.1056/NEJM199002223220807; LAWRENCE JS, 1977, RHEUMATISM POPULATIO, P144; MACALINDON TE, 1992, ANN RHEUM DIS, V51, P844; MARTIN NG, 1975, ANN HUM GENET, V39, P213, DOI 10.1111/j.1469-1809.1975.tb00124.x; PALOTIE A, 1989, LANCET, V1, P924; PEYRON JG, 1992, OSTEOARTHRITIS DIAGN, P15; PHILLIPS DIW, 1993, LANCET, V341, P1008, DOI 10.1016/0140-6736(93)91086-2; PUN YL, 1994, ARTHRITIS RHEUM, V37, P264, DOI 10.1002/art.1780370216; SANDLAND G, 1989, STAT MED, V8, P825; SILMAN AJ, 1993, BRIT J RHEUMATOL, V32, P903; SILMAN AJ, 1993, EPIDEMIOLOGY RHEUMAT, P257; SPECTOR JD, 1992, ANN RHEUM DIS, V51, P1105; Spector T D, 1993, Osteoarthritis Cartilage, V1, P203, DOI 10.1016/S1063-4584(05)80325-5; SPECTOR TD, 1993, ANN RHEUM DIS, V52, P790, DOI 10.1136/ard.52.11.790; Stecher RM, 1941, AM J MED SCI, V201, P801, DOI 10.1097/00000441-194106000-00004; WILLIAMS CJ, 1992, COMPUT METH PROG BIO, V38, P167, DOI 10.1016/0169-2607(92)90084-K	33	476	488	22	94	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 13	1996	312	7036					940	943						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UF659	8616305				2022-12-28	WOS:A1996UF65900017
J	McArdle, JMC; George, WD; McArdle, CS; Smith, DC; Moodie, AR; Hughson, AVM; Murray, GD				McArdle, JMC; George, WD; McArdle, CS; Smith, DC; Moodie, AR; Hughson, AVM; Murray, GD			Psychological support for patients undergoing breast cancer surgery: A randomised study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							MASTECTOMY; MORBIDITY; CONSERVATION; CHEMOTHERAPY; INTERVENTION	Objective-To evaluate the effect of support from a nurse specialising in breast care and a voluntary support organisation on prevalence of psychological morbidity after surgery for breast cancer. Design-Prospective randomised study. Setting-Three teaching hospitals in Glasgow with established breast clinics. Subjects-272 women aged less than 70 years undergoing surgery for breast cancer. Interventions-Patients were randomly allocated to receive routine care hem ward staff, routine care plus support from breast care nurse, routine care plus support from voluntary organisation, or routine care plus support hem nurse and organisation. Main outcome measures-Prevalence of psychological morbidity as assessed by self rating scales: 28 item general health questionnaire and its subscales, and hospital anxiety and depression scale. Measurements were made at first postoperative clinic visit and at three, six, and 12 months after surgery. Results-On each self rating scale, psychological morbidity tended to fall over the 12 month period. For each scale, scores were consistently lower in patients offered support from breast care nurse alone compared with the other groups, which were similar to each other. Differences were significant or nearly so: P values were 0.015 (28 item general health questionnaire), 0.027 (anxiety and insomnia), 0.072 (severe depression), 0.053 (somatic symptoms), 0.031 (social dysfunction), 0.093 (hospital anxiety), and 0.003 (hospital depression). Conclusion-Support hem breast care nurse can significantly reduce psychological morbidity, as measured by self rating scales, in women undergoing breast cancer surgery.	LEVERNDALE HOSP, DIV PSYCHIAT, GLASGOW G53 7TU, LANARK, SCOTLAND; UNIV GLASGOW, ROYAL INFIRM, DEPT SURG, GLASGOW G31 2ER, LANARK, SCOTLAND; UNIV GLASGOW, WESTERN INFIRM, DEPT SURG, GLASGOW G11 6NT, LANARK, SCOTLAND; VICTORIA INFIRM, DIV SURG, GLASGOW G42 9TY, LANARK, SCOTLAND; TAK TENT, GLASGOW G12 6SQ, LANARK, SCOTLAND; UNIV GLASGOW, ROBERTSON CTR BIOSTAT, GLASGOW G12 8QQ, LANARK, SCOTLAND	Royal Infirmary of Edinburgh; University of Glasgow; University of Glasgow; University of Glasgow				Murray, Gordon/0000-0001-9866-4734				Berne E., 1975, T ANAL PSYCHOTHERAPY; CALMAN KC, 1984, PRACTITIONER, V228, P585; FALLOWFIELD LJ, 1986, BMJ-BRIT MED J, V293, P1331, DOI 10.1136/bmj.293.6558.1331; GOLDBERG DP, 1979, MANUAL GENERAL HLTH; GORDON WA, 1980, J CONSULT CLIN PSYCH, V48, P743, DOI 10.1037/0022-006X.48.6.743; HUGHSON AVM, 1987, BMJ-BRIT MED J, V294, P1515, DOI 10.1136/bmj.294.6586.1515; HUGHSON AVM, 1986, BMJ-BRIT MED J, V293, P1268, DOI 10.1136/bmj.293.6557.1268; HUGHSON AVM, 1988, J PSYCHOSOM RES, V32, P393, DOI 10.1016/0022-3999(88)90022-0; MAGUIRE GP, 1978, BMJ-BRIT MED J, V1, P963, DOI 10.1136/bmj.1.6118.963; MAGUIRE P, 1980, BMJ-BRIT MED J, V281, P1454, DOI 10.1136/bmj.281.6253.1454; MATTHEWS JNS, 1990, BRIT MED J, V300, P230, DOI 10.1136/bmj.300.6719.230; MCARDLE JM, 1990, BRIT J SURG, V77, P1221, DOI 10.1002/bjs.1800771110; WATSON M, 1983, PSYCHOL MED, V13, P839, DOI 10.1017/S0033291700051552; WATSON M, 1988, COUNS PSYCHOL, V1, P23; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	15	144	145	0	10	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 30	1996	312	7034					813	816						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	UD378	8608288				2022-12-28	WOS:A1996UD37800023
J	Cho, MK; Bero, LA				Cho, MK; Bero, LA			The quality of drug studies published in symposium proceedings	ANNALS OF INTERNAL MEDICINE			English	Article							CLINICAL-TRIALS; PUBLICATION BIAS; JOURNALS; DECADES	Objective: To compare the quality, relevance, and structure of drug studies published in symposium proceedings that are sponsored by drug companies with 1) articles from symposia with other sponsors and 2) articles in the peer-reviewed parent journals of symposium proceedings; and to study the relation between drug company sponsorship and study outcome. Design: Cross-sectional studies of clinical drug studies published in symposium proceedings or their parent medical journals. Measurements: The proportion of articles with no methods sections (which are necessary to assess quality); methodologic quality and clinical relevance scores; and the proportion of articles with outcomes favoring the drug of interest. Results: Symposia sponsored by single drug companies had more articles without methods sections (10%; 108 of 1064) than did symposia that had other sponsors (3%; 58 of 2314) or symposia that had no mentioned sponsor (2%; 29 of 1663) (P < 0.001). The mean methodologic quality and relevance scores of articles were similar both by type of sponsorship and between articles published in symposia sponsored by single drug companies and articles from the parent journals. Significantly more articles with drug company support (98%; 39 of 40) than without drug company support (79%; 89 of 112) had outcomes favoring the drug of interest (P = 0.01). Conclusions: Articles in symposia sponsored by single drug companies were similar in quality and clinical relevance to articles with other sponsors and to articles published in the parent journals. Articles with drug company support are more likely than articles without drug company support to have outcomes favoring the drug of interest.	UNIV CALIF SAN FRANCISCO, SAN FRANCISCO, CA 94143 USA	University of California System; University of California San Francisco	Cho, MK (corresponding author), UNIV PENN, CTR BIOETH, 3401 MARKET ST, SUITE 320, PHILADELPHIA, PA 19104 USA.							ANDREW E, 1990, EUR J RADIOL, V10, P92, DOI 10.1016/0720-048X(90)90114-Q; ANDREW E, 1994, JAMA-J AM MED ASSOC, V272, P1926, DOI 10.1001/jama.1994.03520240054041; AVORN J, 1982, AM J MED, V73, P4, DOI 10.1016/0002-9343(82)90911-1; BERO LA, 1992, NEW ENGL J MED, V327, P1135, DOI 10.1056/NEJM199210153271606; CHO MK, 1994, JAMA-J AM MED ASSOC, V272, P101, DOI 10.1001/jama.272.2.101; COLDITZ GA, 1989, STAT MED, V8, P441, DOI 10.1002/sim.4780080408; DAVIDSON RA, 1986, J GEN INTERN MED, V1, P155, DOI 10.1007/BF02602327; DERSIMONIAN R, 1982, NEW ENGL J MED, V306, P1332, DOI 10.1056/NEJM198206033062204; DICKERSIN K, 1992, JAMA-J AM MED ASSOC, V267, P374, DOI 10.1001/jama.267.3.374; DICKERSIN K, 1987, CONTROL CLIN TRIALS, V8, P343, DOI 10.1016/0197-2456(87)90155-3; DIEPPE PA, 1993, LANCET, V341, P353, DOI 10.1016/0140-6736(93)90147-9; EASTERBROOK PJ, 1991, LANCET, V337, P867, DOI 10.1016/0140-6736(91)90201-Y; GOTZ ME, 1993, NEUROCHEM INT, V22, P255, DOI 10.1016/0197-0186(93)90053-8; GOTZSCHE PC, 1987, BRIT MED J, V295, P654, DOI 10.1136/bmj.295.6599.654; Haggard E.A., 1958, INTRACLASS CORRELATI; HEMMINKI E, 1982, METHOD INFORM MED, V21, P81; HEMMINKI E, 1980, BRIT MED J, V280, P833, DOI 10.1136/bmj.280.6217.833; MANNING PR, 1980, ANN INTERN MED, V92, P690, DOI 10.7326/0003-4819-92-5-690; RENNIE D, 1990, AM J ROENTGENOL, V155, P889, DOI 10.2214/ajr.155.4.2119127; ROCHON PA, 1994, JAMA-J AM MED ASSOC, V272, P108, DOI 10.1001/jama.272.2.108; ROCHON PA, 1994, ARCH INTERN MED, V154, P157, DOI 10.1001/archinte.154.2.157; ROSENTHAL R, 1980, NEW DIRECTIONS METHO, V5, P33; Siegel S., 1988, NONPARAMETRIC STAT B; SIMES RJ, 1986, J CLIN ONCOL, V4, P1529, DOI 10.1200/JCO.1986.4.10.1529; 1990, OFFICES DRUG EVALUAT	25	203	204	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 1	1996	124	5					485	+		10.7326/0003-4819-124-5-199603010-00004	http://dx.doi.org/10.7326/0003-4819-124-5-199603010-00004			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TW773	8602706				2022-12-28	WOS:A1996TW77300004
J	Olliaro, P; Cattani, J; Wirth, D				Olliaro, P; Cattani, J; Wirth, D			Malaria, the submerged disease	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							RESISTANT FALCIPARUM-MALARIA; ANTIMALARIAL DRUG; WEST-AFRICA; MEFLOQUINE; HALOFANTRINE		HARVARD UNIV, SCH PUBL HLTH, DEPT TROP PUBL HLTH, BOSTON, MA 02115 USA	Harvard University; Harvard T.H. Chan School of Public Health	Olliaro, P (corresponding author), UNDP, WORLD BANK, WHO, SPECIAL PROGRAMME RES DEV & RES TRAINING TROP DIS, 20 AVE APPIA, CH-1211 GENEVA 27, SWITZERLAND.							ALONSO PL, 1991, LANCET, V337, P1499, DOI 10.1016/0140-6736(91)93194-E; ALONSO PL, 1994, LANCET, V344, P1175, DOI 10.1016/S0140-6736(94)90505-3; [Anonymous], 1993, WORLD DEV REPORT 199; [Anonymous], 1995, WHO MODEL PRESCRIBIN; BASCO LK, 1991, TROP MED PARASITOL, V42, P413; BJORKMAN A, 1990, T ROY SOC TROP MED H, V84, P177, DOI 10.1016/0035-9203(90)90246-B; BRASSEUR P, 1992, AM J TROP MED HYG, V46, P8, DOI 10.4269/ajtmh.1992.46.8; CANFIELD CJ, 1995, EXP PARASITOL, V80, P373, DOI 10.1006/expr.1995.1049; CANFIELD CJ, 1993, AM J TROP MED HYG, V49, P121, DOI 10.4269/ajtmh.1993.49.121; CANFIELD CJ, 1995, AM J TROP MED HYG, V53, P87; CHILDS GE, 1991, AM J TROP MED HYG, V44, P553, DOI 10.4269/ajtmh.1991.44.553; DALESSANDRO U, 1995, LANCET, V345, P479, DOI 10.1016/S0140-6736(95)90582-0; DALESSANDRO U, 1995, LANCET, V346, P462, DOI 10.1016/S0140-6736(95)91321-1; FOSTER S, 1991, SOC SCI MED, V32, P1201, DOI 10.1016/0277-9536(91)90035-B; FRYAUFF DJ, 1995, LANCET, V346, P1190, DOI 10.1016/S0140-6736(95)92898-7; FU S, 1991, PARASITOL TODAY, V7, P310, DOI 10.1016/0169-4758(91)90267-R; GABALDON A, 1978, AM J TROP MED HYG, V27, P653, DOI 10.4269/ajtmh.1978.27.653; GARNER P, 1994, B WORLD HEALTH ORGAN, V72, P89; GREENWOOD BM, 1991, MALARIA : WAITING FOR THE VACCINE, P83; GREENWOOD BM, 1987, T ROY SOC TROP MED H, V81, P478, DOI 10.1016/0035-9203(87)90170-2; HIEN TT, 1993, LANCET, V341, P603; KITRON U, 1987, INT J HEALTH SERV, V17, P295, DOI 10.2190/68UG-BAWQ-YXCT-HFKT; LAYTON M, 1995, LANCET, V346, P729, DOI 10.1016/S0140-6736(95)91503-6; LOOAREESUWAN S, 1992, LANCET, V339, P821, DOI 10.1016/0140-6736(92)90276-9; LOOAREESUWAN S, IN PRESS AM J TROP M; Looareesuwan Sornchai, 1992, Southeast Asian Journal of Tropical Medicine and Public Health, V23, P621; MAURICE J, 1995, SCIENCE, V267, P320, DOI 10.1126/science.7824925; MCCOMBIE SC, 1994, WHO2TDRSERRP941 SPEC; MENON A, 1988, J TROP MED HYG, V91, P49; MURRAY CJL, 1994, B WORLD HEALTH ORGAN, V72, P447; MURRAY CJL, 1994, B WORLD HEALTH ORGAN, V72, P495; MURRAY CJL, 1994, B WORLD HEALTH ORGAN, V72, P429; NOSTEN F, 1991, LANCET, V337, P1140, DOI 10.1016/0140-6736(91)92798-7; Oaks Jr S. C., 1991, MALARIA OBSTACLES OP, P45; Olliaro PL, 1995, B WORLD HEALTH ORGAN, V73, P565; PHILLIPSHOWARD PA, 1990, BMJ-BRIT MED J, V300, P499, DOI 10.1136/bmj.300.6723.499; PUKRITTAYAKAMEE S, 1994, T ROY SOC TROP MED H, V88, P324, DOI 10.1016/0035-9203(94)90102-3; RINGWALD P, IN PRESS LANCET; STONE R, 1995, SCIENCE, V267, P957, DOI 10.1126/science.7863337; TERKUILE FO, 1993, LANCET, V341, P1044, DOI 10.1016/0140-6736(93)92409-M; VALERO MV, 1993, LANCET, V341, P705, DOI 10.1016/0140-6736(93)90483-W; WEISS WR, 1995, J INFECT DIS, V171, P1569, DOI 10.1093/infdis/171.6.1569; WERNSDORFER WH, 1991, PARASITOL TODAY, V7, P297, DOI 10.1016/0169-4758(91)90262-M; WHITE NJ, 1992, J ANTIMICROB CHEMOTH, V30, P571, DOI 10.1093/jac/30.5.571; ZUCKER JR, 1993, INFECT DIS CLIN N AM, V7, P547; 1995, CONTROL TROPICAL DIS; 1994, WHOMAL941070; 1994, WHOMAL941067; [No title captured]; 1995, MMWR CDC SURVEI SSS5, V44; 1990, MMWR-MORBID MORTAL W, V40, P106; 1994, INT TRAVEL HLTH VACC, P67; 1994, T R SOC TROP MED S2, V88, P1; 1993, WHO TECHNICAL REPORT, V839	54	108	112	0	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 17	1996	275	3					230	233		10.1001/jama.275.3.230	http://dx.doi.org/10.1001/jama.275.3.230			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TP282	8604177				2022-12-28	WOS:A1996TP28200032
J	Yasui, K; Ohta, K; Kobayashi, M; Aizawa, T; Komiyama, A				Yasui, K; Ohta, K; Kobayashi, M; Aizawa, T; Komiyama, A			Successful treatment of Behcet disease with pentoxifylline	ANNALS OF INTERNAL MEDICINE			English	Article							HUMAN POLYMORPHONUCLEAR LEUKOCYTES; SUPEROXIDE PRODUCTION; ACTIVATION; MOVEMENT; AGENTS		SHINSHU UNIV, SCH MED, DEPT OPHTHALMOL, MATSUMOTO, NAGANO 390, JAPAN; SHINSHU UNIV, SCH MED, DEPT INTERNAL MED 2, MATSUMOTO, NAGANO 390, JAPAN; SHINSHU UNIV, SCH MED, DEPT GERIATR, MATSUMOTO, NAGANO 390, JAPAN	Shinshu University; Shinshu University; Shinshu University	Yasui, K (corresponding author), SHINSHU UNIV, SCH MED, DEPT PEDIAT, ASAHI 3-1-1, MATSUMOTO, NAGANO 390, JAPAN.							AKTULGA E, 1980, HAEMATOLOGICA, V65, P399; BUESCHER ES, 1990, INFECT IMMUN, V58, P3002, DOI 10.1128/IAI.58.9.3002-3008.1990; COHEN HJ, 1978, J CLIN INVEST, V61, P1081, DOI 10.1172/JCI109007; CRADDOCK PR, 1979, SEMIN HEMATOL, V16, P140; HILL HR, 1987, AM J PATHOL, V128, P307; KITAGAWA S, 1982, BIOCHIM BIOPHYS ACTA, V719, P589, DOI 10.1016/0304-4165(82)90249-5; LINGENFELSER T, 1992, ANN INTERN MED, V116, P651, DOI 10.7326/0003-4819-116-8-651; MATSUMURA N, 1975, LANCET, V2, P813; NELSON RD, 1975, J IMMUNOL, V115, P1650; YASUI K, 1994, INFECT IMMUN, V62, P922, DOI 10.1128/IAI.62.3.922-927.1994; YAZICI H, 1991, DRUGS, V42, P796, DOI 10.2165/00003495-199142050-00006	11	69	69	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 15	1996	124	10					891	893		10.7326/0003-4819-124-10-199605150-00005	http://dx.doi.org/10.7326/0003-4819-124-10-199605150-00005			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UJ801	8610918				2022-12-28	WOS:A1996UJ80100005
J	Tan, S; Hunziker, Y; Sargent, DF; Richmond, TJ				Tan, S; Hunziker, Y; Sargent, DF; Richmond, TJ			Crystal structure of a yeast TFIIA/TBP/DNA complex	NATURE			English	Article							RNA POLYMERASE-II; TRANSCRIPTION FACTOR-IIA; TATA-BINDING PROTEIN; SACCHAROMYCES-CEREVISIAE; TFIIA; INITIATION; SUBUNITS; IDENTIFICATION; GENES; EXPRESSION	The X-ray crystal structure of the transcription factor IIA (TFIIA) in complex with the TATA-box-binding protein (TBP) and TATA-element DNA is presented at 2.5 Angstrom resolution. TFIIA is composed of a beta-barrel and a four-helix bundle motif that together have a boot-like appearance. The beta-barrel extends the TBP beta-sheet and bridges over the DNA major groove immediately upstream of the TATE box. The four-helix bundle contributes substantially to the surface of the complex available for interaction with additional transcription factors.	ETH HONGGERBERG,INST MOLEK BIOL & BIOPHYS,CH-8093 ZURICH,SWITZERLAND	Swiss Federal Institutes of Technology Domain; ETH Zurich								AUBLE DT, 1993, GENE DEV, V7, P844, DOI 10.1101/gad.7.5.844; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; BRUNGER AT, 1992, XPLOR VERSION 3 1; BURATOWSKI S, 1992, SCIENCE, V255, P1130, DOI 10.1126/science.1546314; BURATOWSKI S, 1989, CELL, V56, P549, DOI 10.1016/0092-8674(89)90578-3; CHASMAN DI, 1993, P NATL ACAD SCI USA, V90, P8174, DOI 10.1073/pnas.90.17.8174; CONAWAY RC, 1993, ANNU REV BIOCHEM, V62, P161; CORTES P, 1992, MOL CELL BIOL, V12, P413, DOI 10.1128/MCB.12.1.413; COULOMBE B, 1994, J BIOL CHEM, V269, P19962; DEJONG J, 1995, P NATL ACAD SCI USA, V92, P3313, DOI 10.1073/pnas.92.8.3313; DEJONG J, 1993, GENE DEV, V7, P2220, DOI 10.1101/gad.7.11.2220; FERRIN TE, 1988, J MOL GRAPHICS, V6, P13, DOI 10.1016/0263-7855(88)80054-7; GE H, 1994, CELL, V78, P513, DOI 10.1016/0092-8674(94)90428-6; HAHN S, 1989, EMBO J, V8, P3379, DOI 10.1002/j.1460-2075.1989.tb08501.x; HANSEN SK, 1995, CELL, V82, P565, DOI 10.1016/0092-8674(95)90029-2; HORI R, 1994, CURR OPIN GENET DEV, V4, P236, DOI 10.1016/S0959-437X(05)80050-4; IMBALZANO AN, 1994, J BIOL CHEM, V269, P8280; INOSTROZA JA, 1992, CELL, V70, P477; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KANG JJ, 1995, MOL CELL BIOL, V15, P1234; KIM JL, 1993, NATURE, V365, P520, DOI 10.1038/365520a0; KIM YC, 1993, NATURE, V365, P512, DOI 10.1038/365512a0; LAVERY R, 1988, J BIOMOL STRUCT DYN, V6, P63, DOI 10.1080/07391102.1988.10506483; LEE DK, 1992, MOL CELL BIOL, V12, P5189, DOI 10.1128/MCB.12.11.5189; LI WZ, 1991, MOL CELL BIOL, V11, P666, DOI 10.1128/MCB.11.2.666; MA DM, 1993, GENE DEV, V7, P2246, DOI 10.1101/gad.7.11.2246; MALDONADO E, 1995, CURR OPIN CELL BIOL, V7, P352, DOI 10.1016/0955-0674(95)80090-5; MATSUI T, 1980, J BIOL CHEM, V255, P1992; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; NIKOLOV DB, 1995, NATURE, V377, P119, DOI 10.1038/377119a0; NIKOLOV DB, 1992, NATURE, V360, P40, DOI 10.1038/360040a0; Otwinowski Z, 1991, P CCP4 STUD WEEK IS, P80; OZER J, 1994, GENE DEV, V8, P2324, DOI 10.1101/gad.8.19.2324; PARKS TD, 1994, ANAL BIOCHEM, V216, P413, DOI 10.1006/abio.1994.1060; RANISH JA, 1992, SCIENCE, V255, P1127, DOI 10.1126/science.1546313; RANISH JA, 1991, J BIOL CHEM, V266, P19320; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; REINBERG D, 1987, J BIOL CHEM, V262, P3322; SAYRE MH, 1992, J BIOL CHEM, V267, P23376; SHYKIND BM, 1995, GENE DEV, V9, P1354, DOI 10.1101/gad.9.11.1354; STARGELL LA, 1995, SCIENCE, V269, P75, DOI 10.1126/science.7604282; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; SUN XQ, 1994, GENE DEV, V8, P2336, DOI 10.1101/gad.8.19.2336; Tang H, 1996, P NATL ACAD SCI USA, V93, P1119, DOI 10.1073/pnas.93.3.1119; TRONRUD DE, 1992, ACTA CRYSTALLOGR A, V48, P912, DOI 10.1107/S0108767392005415; WANG WD, 1992, GENE DEV, V6, P1716, DOI 10.1101/gad.6.9.1716; YOKOMORI K, 1993, GENE DEV, V7, P2235, DOI 10.1101/gad.7.11.2235; YOKOMORI K, 1994, GENE DEV, V8, P2313, DOI 10.1101/gad.8.19.2313; Zeidler MP, 1996, GENE DEV, V10, P50, DOI 10.1101/gad.10.1.50	50	257	262	0	9	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAY 9	1996	381	6578					127	134		10.1038/381127a0	http://dx.doi.org/10.1038/381127a0			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UK139	8610010				2022-12-28	WOS:A1996UK13900040
J	Yellon, DM; Baxter, GF; Marber, MS				Yellon, DM; Baxter, GF; Marber, MS			Angina reassessed: Pain or protector?	LANCET			English	Review							WARM-UP PHENOMENON; MYOCARDIAL-INFARCTION; SUBLETHAL ISCHEMIA; STABLE ANGINA; CARDIAC PAIN; ADAPTATION; ADENOSINE; PECTORIS; INJURY; STRESS		UNITED MED & DENT SCH, GUYS & ST THOMAS HOSP, DEPT CARDIOL, LONDON SE1 9RT, ENGLAND	Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London	Yellon, DM (corresponding author), UCL HOSP & MED SCH, DEPT ACAD & CLIN CARDIOL, LONDON WC1E 6DB, ENGLAND.		marber, michael/AAW-7916-2021; Yellon, Derek M/ABD-5110-2021	Yellon, Derek/0000-0001-7791-9320; Baxter, Gary/0000-0002-7887-6841				[Anonymous], 1988, LANCET, V2, P349; [Anonymous], 1986, Lancet, V2, P57; ANZAI T, 1995, J AM COLL CARDIOL, V26, P319, DOI 10.1016/0735-1097(95)80002-X; ANZAI T, 1994, AM J CARDIOL, V74, P755, DOI 10.1016/0002-9149(94)90428-6; BAXTER GF, 1994, CIRCULATION, V90, P2993, DOI 10.1161/01.CIR.90.6.2993; BAXTER GF, 1995, BRIT J PHARMACOL, V115, P222, DOI 10.1111/j.1476-5381.1995.tb15866.x; BAXTER GF, 1995, CIRCULATION S1, V92, P389; BAXTER GF, 1996, MYOCARDIAL PRECONDIT; BEHAR S, 1992, AM HEART J, V123, P1481, DOI 10.1016/0002-8703(92)90798-Z; COHEN MV, 1993, LANCET, V342, P6, DOI 10.1016/0140-6736(93)91878-P; CORTINA A, 1985, J AM COLL CARDIOL, V5, P619, DOI 10.1016/S0735-1097(85)80386-7; CREA F, 1992, J AM COLL CARDIOL, V20, P1498, DOI 10.1016/0735-1097(92)90442-P; CRIBIER A, 1992, J AM COLL CARDIOL, V20, P578, DOI 10.1016/0735-1097(92)90011-B; DAS DK, 1995, J MOL CELL CARDIOL, V27, P181, DOI 10.1016/S0022-2828(08)80017-X; DEUTSCH E, 1990, CIRCULATION, V82, P2044, DOI 10.1161/01.CIR.82.6.2044; FISHER L, 1983, CIRCULATION, V68, P939, DOI 10.1161/01.CIR.68.5.939; FURBERG CD, 1995, CIRCULATION, V92, P1326, DOI 10.1161/01.CIR.92.5.1326; GASPARDONE A, 1995, J AM COLL CARDIOL, V25, P251, DOI 10.1016/0735-1097(94)00352-Q; HELD PH, 1994, CORONARY ARTERY DIS, V5, P21, DOI 10.1097/00019501-199401000-00004; HOSHIDA S, 1993, AM J PHYSIOL, V264, pH33, DOI 10.1152/ajpheart.1993.264.1.H33; HULTGREN HN, 1984, AM J CARDIOL, V54, P988, DOI 10.1016/S0002-9149(84)80131-9; JENKINS DP, 1995, PHARM RES-DORDR, V31, P1; KLONER RA, 1995, CIRCULATION, V91, P37, DOI 10.1161/01.CIR.91.1.37; KLONER RA, 1994, J AM COLL CARDIOL, V24, P1133, DOI 10.1016/0735-1097(94)90880-X; KNATTERUD GL, 1971, J AMER MED ASSOC, V217, P777, DOI 10.1001/jama.217.6.777; KUZUYA T, 1993, CIRC RES, V72, P1293, DOI 10.1161/01.RES.72.6.1293; LIU GS, 1991, CIRCULATION, V84, P350, DOI 10.1161/01.CIR.84.1.350; MARBER MS, 1995, CIRCULATION, V92, P1061; MARBER MS, 1994, BRIT HEART J, V72, P213; MARBER MS, 1993, CIRCULATION, V88, P1264, DOI 10.1161/01.CIR.88.3.1264; MELLER ST, 1992, NEUROSCIENCE, V48, P501, DOI 10.1016/0306-4522(92)90398-L; MURRY CE, 1986, CIRCULATION, V74, P1124, DOI 10.1161/01.CIR.74.5.1124; NAKAGAWA Y, 1995, J AM COLL CARDIOL, V25, P1076, DOI 10.1016/0735-1097(94)00542-X; OKAZAKI Y, 1993, J AM COLL CARDIOL, V21, P1597, DOI 10.1016/0735-1097(93)90374-A; OTTANI F, 1995, CIRCULATION, V91, P291, DOI 10.1161/01.CIR.91.2.291; PARRATT JR, 1994, CARDIOVASC RES, V28, P783, DOI 10.1093/cvr/28.6.783; Przyklenk K, 1996, BASIC RES CARDIOL, V91, P41; SMITH SC, 1995, CIRCULATION, V92, P2; SPEECHLYDICK ME, 1995, CIRC RES, V77, P1030, DOI 10.1161/01.RES.77.5.1030; TOMAI F, 1994, CIRCULATION, V90, P700, DOI 10.1161/01.CIR.90.2.700; TOPOL EJ, 1991, CIRCULATION, V83, P1084, DOI 10.1161/01.CIR.83.3.1084; Wayne EJ, 1934, CLIN SCI, V1, P287; WILLIAMS DO, 1985, CIRCULATION, V71, P687, DOI 10.1161/01.CIR.71.4.687; YELLON DM, 1990, CARDIOSCIENCE, V1, P89; YELLON DM, 1995, J MOL CELL CARDIOL, V27, P1023, DOI 10.1016/0022-2828(95)90071-3	45	27	27	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	APR 27	1996	347	9009					1159	1162		10.1016/S0140-6736(96)90613-3	http://dx.doi.org/10.1016/S0140-6736(96)90613-3			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UG755	8609753				2022-12-28	WOS:A1996UG75500015
J	Glazewski, S; Chen, CM; Silva, A; Fox, K				Glazewski, S; Chen, CM; Silva, A; Fox, K			Requirement for alpha-CaMKII in experience-dependent plasticity of the barrel cortex	SCIENCE			English	Article							LONG-TERM POTENTIATION; II MUTANT MICE; PROTEIN-KINASE; GENE-EXPRESSION; STRIATE CORTEX; CALMODULIN; HISTOCHEMISTRY; SYSTEM; BRAIN	The mammalian sensory neocortex exhibits experience-dependent plasticity such that neurons modify their response properties according to changes in sensory experience. The synaptic plasticity mechanism of long-term potentiation requiring calcium-calmodulin-dependent kinase type II (CaMKII) could underlie experience-dependent plasticity. Plasticity in adult mice can be induced by changes in the patterns of tactile input to the barrel cortex. This response is strongly depressed in adult mice that lack the gene encoding alpha-CaMKII, although adolescent animals are unaffected. Thus, alpha-CaMKII is necessary either for the induction or for the expression of plasticity in adult mice.	UNIV MINNESOTA,DEPT PHYSIOL,MINNEAPOLIS,MN 55455; COLD SPRING HARBOR LAB,COLD SPRING HARBOR,NY 11724	University of Minnesota System; University of Minnesota Twin Cities; Cold Spring Harbor Laboratory			Fox, Kevin/E-8836-2010	Fox, Kevin/0000-0002-2563-112X	PHS HHS [27759] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ARMSTRONGJAMES M, 1987, J COMP NEUROL, V263, P265, DOI 10.1002/cne.902630209; BENSON DL, 1992, NEUROSCIENCE, V46, P825, DOI 10.1016/0306-4522(92)90188-8; BURGIN KE, 1990, J NEUROSCI, V10, P1788; BUTLER LS, 1995, P NATL ACAD SCI USA, V92, P6852, DOI 10.1073/pnas.92.15.6852; CASTROALAMANCOS MA, 1995, J NEUROSCI, V15, P5324; CHEN C, 1994, SCIENCE, V266, P291, DOI 10.1126/science.7939668; CLARK SA, 1988, NATURE, V332, P444, DOI 10.1038/332444a0; FOX K, 1994, J NEUROSCI, V14, P7665; FOX K, 1992, J NEUROSCI, V12, P1286; GLAZEWSKI S, 1996, J NEUROPHYSIOL, V74, P1714; Gordon J. A., 1994, Society for Neuroscience Abstracts, V20, P465; Hand PJ, 1982, CHANGING CONCEPTS NE, P49; HENDRY SHC, 1986, P NATL ACAD SCI USA, V83, P1536, DOI 10.1073/pnas.83.5.1536; KENNEDY MB, 1983, P NATL ACAD SCI-BIOL, V80, P7357, DOI 10.1073/pnas.80.23.7357; KOMATSU Y, 1988, J NEUROPHYSIOL, V59, P124, DOI 10.1152/jn.1988.59.1.124; KOSSUT M, 1992, PROG NEUROBIOL, V39, P389, DOI 10.1016/0301-0082(92)90013-5; LI XR, 1995, J COMP NEUROL, V357, P465, DOI 10.1002/cne.903570310; LISMAN J, 1994, TRENDS NEUROSCI, V17, P406, DOI 10.1016/0166-2236(94)90014-0; LISMAN JE, 1985, P NATL ACAD SCI USA, V82, P3055, DOI 10.1073/pnas.82.9.3055; MALENKA RC, 1989, NATURE, V340, P554, DOI 10.1038/340554a0; MALINOW R, 1989, SCIENCE, V245, P862, DOI 10.1126/science.2549638; MERZENICH MM, 1983, NEUROSCIENCE, V8, P33, DOI 10.1016/0306-4522(83)90024-6; MILLER SG, 1986, CELL, V44, P861, DOI 10.1016/0092-8674(86)90008-5; MOGILNER A, 1993, P NATL ACAD SCI USA, V90, P3593, DOI 10.1073/pnas.90.8.3593; NEVE RL, 1989, P NATL ACAD SCI USA, V86, P4781, DOI 10.1073/pnas.86.12.4781; SCHLAGGAR BL, 1993, NATURE, V364, P623, DOI 10.1038/364623a0; SILVA AJ, 1992, SCIENCE, V257, P206, DOI 10.1126/science.1321493; SILVA AJ, 1992, SCIENCE, V257, P201, DOI 10.1126/science.1378648; VIDEEN TO, 1986, BRAIN RES, V371, P1, DOI 10.1016/0006-8993(86)90803-6; WONGRILEY M, 1979, BRAIN RES, V171, P11, DOI 10.1016/0006-8993(79)90728-5; WOOLSEY TA, 1976, J COMP NEUROL, V170, P53, DOI 10.1002/cne.901700105	31	126	127	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 19	1996	272	5260					421	423		10.1126/science.272.5260.421	http://dx.doi.org/10.1126/science.272.5260.421			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UG252	8602534				2022-12-28	WOS:A1996UG25200051
J	Dorfman, L; Schauffler, HH; Wilkerson, J; Feinson, J				Dorfman, L; Schauffler, HH; Wilkerson, J; Feinson, J			Local television news coverage of President Clinton's introduction of the Health Security Act	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								Objective.-To investigate how local television news reported on health system reform during the week President Clinton presented his health system reform bill. Design.-Retrospective content analysis of the 1342-page Health Security Act of 1993, the printed text of President Clinton's speech before Congress on September 22, 1993, and a sample of local television news stories on health system reform broadcast during the week of September 19 through 25, 1993. Setting.-The state of California. Results.-During the week, 316 television news stories on health system reform were aired during the 166 local news broadcasts sampled. Health system reform was the second most frequently reported topic, second to stories on violent crime. News stories on health system reform averaged 1 minute 38 seconds in length, compared with 57 seconds for violent crime. Fifty-seven percent of the local news stories focused on interest group politics. Compared with the content of the Health Security Act, local news broadcasts devoted a significantly greater portion of their stories to financing, eligibility, and preventive services. Local news stories gave significantly less attention to cost-saving mechanisms, longterm care benefits, and changes in Medicare and Medicaid, and less than 2% of stories mentioned quality assurance mechanisms, malpractice reform, or new public health initiatives. Of the 316 televised news stories, 53 reported on the president's speech, covering many of the same topics emphasized in the speech (financing, organization and administration, and eligibility) and de-emphasizing many of the same topics (Medicare and Medicaid, quality assurance, and malpractice reform), Two percent of the president's speech covered partisan politics; 45% of the local news stories on the speech featured challenges from partisan politicians. Conclusions.-Although health system reform was the focus of a large number of local television news stories during the week, in-depth explanation was scarce. In general, the news stories provided superficial coverage framed largely in terms of the risks and costs of reform to specific stakeholders.	UNIV CALIF BERKELEY,SCH PUBL HLTH,DIV HLTH POLICY & ADM,BERKELEY,CA 94720; UNIV WASHINGTON,DEPT POLIT SCI,SEATTLE,WA 98195	University of California System; University of California Berkeley; University of Washington; University of Washington Seattle	Dorfman, L (corresponding author), BERKELEY MEDIA STUDIES GRP,2140 SHATTUCK AVE,SUITE 804,BERKELEY,CA 94704, USA.							Ansolabehere Stephen, 1993, MEDIA GAME AM POLITI; DAN BB, 1992, JAMA-J AM MED ASSOC, V268, P1026, DOI 10.1001/jama.268.8.1026; DAVIS RM, 1988, JAMA-J AM MED ASSOC, V259, P1036, DOI 10.1001/jama.259.7.1036; DORFMAN L, 1994, THESIS U CALIFORNIA; FINNEGAN JR, 1993, JOURNALISM QUART, V700, P569; Fishman, 1980, MANUF NEWS; Gans, 2004, DECIDING WHATS NEWS; GREENBERG M, 1990, AM J EPIDEMIOL, V132, pS192; Iyengar S., 1991, IS ANYONE RESPONSIBL; JAMIESON KH, 1994, NEWSPAPER TELEVISION; KANISS P, 1991, MKAING LOCAL NEWS; Kinder D.R., 1987, NEWS MATTERS AGENDA; LIEBERMAN T, 1994, COLUMBIA JOURNAL MAR, P20; LIEBERMAN T, 1994, COLUMBIA JOURNAL MAR; LIEBERMAN T, 1993, COLUMBIA JOURNAL SEP, P33; MCCOMBS ME, 1972, PUBLIC OPIN QUART, V36, P176, DOI 10.1086/267990; ROGERS E, 1988, COMMUNICATION YB; *ROP STARCH WORLDW, 1994, 3910 ROP STARCH WORL, P22; *ROP STARCH WORLDW, 1995, AM WATCH, P17; Smith E. R., 1991, WHAT COLOR IS NEWS E; Tuchman G., 1978, MAKING NEWS; 1993, COLUMBIA JOURNALIS S; 1995, COLUMBIA JOURNALIS S; 1993, NY TIMES        0923, pA24; 1993, TYNDALL REPORT, V6, P3	25	4	4	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 17	1996	275	15					1201	1205		10.1001/jama.275.15.1201	http://dx.doi.org/10.1001/jama.275.15.1201			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UE625	8609691				2022-12-28	WOS:A1996UE62500035
J	Sakaguchi, S; Katamine, S; Nishida, N; Moriuchi, R; Shigematsu, K; Sugimoto, T; Nakatani, A; Kataoka, Y; Houtani, T; Shirabe, S; Okada, H; Hasegawa, S; Miyamoto, T; Noda, T				Sakaguchi, S; Katamine, S; Nishida, N; Moriuchi, R; Shigematsu, K; Sugimoto, T; Nakatani, A; Kataoka, Y; Houtani, T; Shirabe, S; Okada, H; Hasegawa, S; Miyamoto, T; Noda, T			Loss of cerebellar Purkinje cells in aged mice homozygous for a disrupted Prp gene	NATURE			English	Article							PROTEIN; SCRAPIE; BRAIN	PRION protein (PrP) is a glycoprotein constitutively expressed on the neuronal cell surface. A protease-resistant isoform of prion protein is implicated in the pathogenesis of a series of transmissible spongiform encephalopathies(1). We have developed a line of mice homozygous for a disrupted PrP gene in which the whole PrP-coding sequence is replaced by a drug-resistant gene(2). In keeping with pre,ious results(3-8), we find that homozygous loss of the PrP gene has no deleterious effect on the development of these mice and renders them resistant to prion(2). The PrP-null mice grew normally after birth, but at about 70 weeks of age all began to show progressive symptoms of ataxia. Impaired motor coordination in these ataxic mice was evident in a rotorod test. Pathological examination revealed an extensive loss of Purkinje cells in the vast majority of cerebellar folia, suggesting that PrP plays a role in the long-term survival of Purkinje neurons.	NAGASAKI UNIV,SCH MED,DEPT BACTERIOL,NAGASAKI 852,JAPAN; NAGASAKI UNIV,SCH MED,DEPT PATHOL,NAGASAKI 852,JAPAN; NAGASAKI UNIV,SCH MED,DEPT PHARMACOL,NAGASAKI 852,JAPAN; NAGASAKI UNIV,SCH MED,DEPT INTERNAL MED 1,NAGASAKI 852,JAPAN; KANSAI MED UNIV,DEPT ANAT,MORIGUCHI,OSAKA 570,JAPAN; JAPANESE FDN CANC RES,INST CANC,DEPT CELL BIOL,TOKYO 170,JAPAN	Nagasaki University; Nagasaki University; Nagasaki University; Nagasaki University; Kansai Medical University; Japanese Foundation for Cancer Research			Noda, Tetsuo/B-1667-2016; hasegawa, sumitaka/A-4020-2012					BUELER H, 1993, CELL, V73, P1339, DOI 10.1016/0092-8674(93)90360-3; BUELER H, 1994, MOL MED, V1, P19; BUELER H, 1992, NATURE, V356, P577, DOI 10.1038/356577a0; COLLINGE J, 1994, NATURE, V370, P295, DOI 10.1038/370295a0; DEARMOND SJ, 1987, NEUROLOGY, V37, P1271, DOI 10.1212/WNL.37.8.1271; FORLONI G, 1993, NATURE, V362, P543, DOI 10.1038/362543a0; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; MANSON JC, 1994, NEURODEGENERATION, V3, P331; MANSON JC, 1994, MOL NEUROBIOL, V8, P121, DOI 10.1007/BF02780662; MATTSON MP, 1990, NEURON, V4, P105, DOI 10.1016/0896-6273(90)90447-N; MCMAHON AP, 1990, CELL, V62, P1073, DOI 10.1016/0092-8674(90)90385-R; PRUSINER SB, 1994, ANNU REV MICROBIOL, V48, P655, DOI 10.1146/annurev.mi.48.100194.003255; PRUSINER SB, 1993, P NATL ACAD SCI USA, V90, P10608, DOI 10.1073/pnas.90.22.10608; SAKAGUCHI S, 1995, J VIROL, V69, P7586, DOI 10.1128/JVI.69.12.7586-7592.1995; WHITTINGTON MA, 1995, NAT GENET, V9, P197, DOI 10.1038/ng0295-197	15	400	408	1	12	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	APR 11	1996	380	6574					528	531		10.1038/380528a0	http://dx.doi.org/10.1038/380528a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UE663	8606772				2022-12-28	WOS:A1996UE66300050
J	Dawson, C; Whitfield, H				Dawson, C; Whitfield, H			ABC of urology - Urological emergencies in general practice	BRITISH MEDICAL JOURNAL			English	Article									CENT MIDDLESEX HOSP,LONDON NW10 7NS,ENGLAND; INST UROL & NEPHROL,LONDON,ENGLAND	Imperial College London; University of London; University College London	Dawson, C (corresponding author), EDITH CAVELL HOSP,PETERBOROUGH,ENGLAND.							DAWSON C, 1994, SURGERY, V12, P73; PRYOR JP, 1994, CURRENT OPINION UROL, V4, P343	2	19	19	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 30	1996	312	7034					838	840						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UD378	8608297				2022-12-28	WOS:A1996UD37800034
J	Foster, C				Foster, C			Commentary: Ethics of clinical research without patients' consent	BRITISH MEDICAL JOURNAL			English	Editorial Material								What makes a research project ethical? A series of criteria need to be satisfied. Difficulties arise when only some of them can be satisfied or, as in the case of this trial, when two of them are mutually exclusive. The criteria are that the research is aimed at obtaining a desirable end, that the research subjects will not be harmed by being in the trial, and that the research subjects are consulted before being enrolled into the research.			Foster, C (corresponding author), UNIV LONDON KINGS COLL,CTR MED LAW & ETH,LONDON WC2R 2LS,ENGLAND.								0	5	5	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 30	1996	312	7034					817	817						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UD378	8608289	Green Published			2022-12-28	WOS:A1996UD37800024
J	Dawson, C; Whitfield, H				Dawson, C; Whitfield, H			ABC of urology - Bladder outflow obstruction	BRITISH MEDICAL JOURNAL			English	Article							PSA		CENT MIDDLESEX HOSP,LONDON NW10 7NS,ENGLAND; INST UROL & NEPHROL,LONDON,ENGLAND	Imperial College London; University of London; University College London	Dawson, C (corresponding author), EDITH CAVELL HOSP,PETERBOROUGH,ENGLAND.							CARTER HB, 1993, UROL CLIN N AM, V20, P665; DEGEERTER P, 1993, EUROPEAN UROLOGY UPD, V2, P146; DENIS LJ, 1995, BRIT J UROL, V76, P17; PARTIN AW, 1994, J UROLOGY, V152, P1358, DOI 10.1016/S0022-5347(17)32422-9; SEAMAN E, 1993, UROL CLIN N AM, V20, P653	5	3	3	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 23	1996	312	7033					767	770						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UC166	8605468				2022-12-28	WOS:A1996UC16600042
J	Hamilton, BA; Frankel, WN; Kerrebrock, AW; Hawkins, TL; FitzHugh, W; Kusumi, K; Russell, LB; Mueller, KL; vanBerkel, V; Birren, BW; Kruglyak, L; Lander, ES				Hamilton, BA; Frankel, WN; Kerrebrock, AW; Hawkins, TL; FitzHugh, W; Kusumi, K; Russell, LB; Mueller, KL; vanBerkel, V; Birren, BW; Kruglyak, L; Lander, ES			Disruption of the nuclear hormone receptor ROR alpha in staggerer mice	NATURE			English	Article							MUTANT MICE; PURKINJE-CELLS; MULTIPLE INNERVATION; CEREBELLAR CORTEX; CLIMBING FIBERS; MOUSE; ABNORMALITIES	HOMOZYGOUS staggerer (sg) mice show a characteristic severe cerebellar ataxia due to a cell-autonomous defect in the development of Purkinje cells(1,2). These cells show immature morphology, synaptic arrangement, biochemical properties and gene expression, and are reduced in numbers(3-12). In addition, sg heterozygotes show accelerated dendritic atrophy and cell loss(13), suggesting that sg has a role in mature Purkinje cells. Effects of this mutation on cerebellar development have been studied for 25 years, but its molecular basis has remained unknown, We have genetically mapped staggerer to an interval of 160 kilobases on mouse chromosome 9 which was found to contain the gene encoding ROR alpha, a member of the nuclear hormone-receptor superfamily. Staggerer mice were found to carry a deletion within the ROR alpha gene that prevents translation of the ligand-binding homology domain. We propose a model based on these results, in which ROR alpha interacts with the thyroid hormone signalling pathway to induce Purkinje-cell maturation.	JACKSON LAB, BAR HARBOR, ME 04609 USA; MIT, DEPT BIOL, CAMBRIDGE, MA 02139 USA; OAK RIDGE NATL LAB, DIV BIOL, OAK RIDGE, TN 37831 USA	Jackson Laboratory; Massachusetts Institute of Technology (MIT); United States Department of Energy (DOE); Oak Ridge National Laboratory	Hamilton, BA (corresponding author), WHITEHEAD INST BIOMED RES, 9 CAMBRIDGE CTR, CAMBRIDGE, MA 02142 USA.		Kusumi, Kenro/J-2626-2012; van Berkel, Victor/AAC-1956-2021	Kusumi, Kenro/0000-0002-1458-4540; Hamilton, Bruce/0000-0001-5599-9139				BECKERANDRE M, 1993, BIOCHEM BIOPH RES CO, V194, P1371, DOI 10.1006/bbrc.1993.1976; CREPEL F, 1980, NATURE, V283, P483, DOI 10.1038/283483a0; DIETRICH WF, 1994, NAT GENET, V7, P220, DOI 10.1038/ng0694supp-220; EDELMAN GM, 1982, P NATL ACAD SCI-BIOL, V79, P7036, DOI 10.1073/pnas.79.22.7036; FORMAN BM, 1994, MOL ENDOCRINOL, V8, P1253, DOI 10.1210/me.8.9.1253; FORMAN BM, 1995, CELL, V81, P541, DOI 10.1016/0092-8674(95)90075-6; GIGUERE V, 1994, GENE DEV, V8, P538, DOI 10.1101/gad.8.5.538; GIGUERE V, 1995, MOL CELL BIOL, V15, P2517; HATTEN ME, 1978, NATURE, V276, P504, DOI 10.1038/276504a0; HATTEN ME, 1995, ANNU REV NEUROSCI, V18, P385, DOI 10.1146/annurev.ne.18.030195.002125; HERRUP K, 1979, BRAIN RES, V172, P1, DOI 10.1016/0006-8993(79)90891-6; HERRUP K, 1979, BRAIN RES, V178, P443, DOI 10.1016/0006-8993(79)90705-4; Herrup K, 1983, Brain Res, V313, P267; HERRUP K, 1981, DEV BRAIN RES, V1, P475, DOI 10.1016/0165-3806(81)90002-X; KUSUMI K, 1993, MAMM GENOME, V4, P391, DOI 10.1007/BF00360591; LANDIS DMD, 1978, J COMP NEUROL, V179, P831, DOI 10.1002/cne.901790408; LEGRAND J, 1979, TRENDS NEUROSCI, V2, P234, DOI 10.1016/0166-2236(79)90091-2; MARIANI J, 1980, J NEUROBIOL, V11, P41, DOI 10.1002/neu.480110106; MCBROOM LDB, 1995, MOL CELL BIOL, V15, P796; MESSER A, 1988, J NEUROCHEM, V51, P888, DOI 10.1111/j.1471-4159.1988.tb01825.x; Sambrook J, 1989, MOL CLONING LABORATO; SIDMAN RL, 1962, SCIENCE, V137, P610, DOI 10.1126/science.137.3530.610; SOTELO C, 1975, ADV NEUROL, V12, P335; SOTELO C, 1974, BRAIN RES, V67, P519, DOI 10.1016/0006-8993(74)90499-5; TINI M, 1995, J BIOL CHEM, V270, P20156, DOI 10.1074/jbc.270.34.20156; TINI M, 1994, MOL ENDOCRINOL, V8, P1494, DOI 10.1210/me.8.11.1494; TRENKNER E, 1979, NATURE, V277, P566, DOI 10.1038/277566a0; TRENKNER E, 1986, J NEUROSCI, V6, P1733; ZANJANI HS, 1992, DEV BRAIN RES, V67, P153, DOI 10.1016/0165-3806(92)90216-J; ZHOU L, 1994, J BIOL CHEM, V269, P13346	30	412	425	1	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 22	1996	379	6567					736	739		10.1038/379736a0	http://dx.doi.org/10.1038/379736a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TW567	8602221				2022-12-28	WOS:A1996TW56700055
J	Durbin, JE; Hackenmiller, R; Simon, MC; Levy, DE				Durbin, JE; Hackenmiller, R; Simon, MC; Levy, DE			Targeted disruption of the mouse STAT1 results in compromised innate immunity to viral disease	CELL			English	Article							GAMMA SIGNAL-TRANSDUCTION; DNA-BINDING PROTEINS; MUTANT-CELL LINE; INTERFERON-GAMMA; TRANSCRIPTION FACTOR; TYROSINE PHOSPHORYLATION; GROWTH-FACTOR; GENE; INDUCTION; IRF-1	The STAT1 transcription factor is activated in response to many cytokines and growth factors. To study the requirement for STAT1 in vivo, we disrupted the Stat1 gene in embryonic stem (ES) cells and in mice. Stat1(-/-) ES cells were unresponsive to interferon (IFN), but retained responsiveness to leukemia inhibitory factor (LIF) and remained LIF dependent for undifferentiated growth. Stat1(-/-) animals were born at normal frequencies and displayed no gross developmental defects. However, these animals failed to thrive and were extremely susceptible to viral disease. Cells and tissues from Stat1(-/-) mice were unresponsive to IFN, but remained responsive to all other cytokines tested. Thus, STAT1 appears to be specific for IFN pathways that are essential for viability in the face of otherwise innocuous pathogens.	NYU,SCH MED,DEPT PATHOL,NEW YORK,NY 10016; NYU,SCH MED,KAPLAN CANC CTR,NEW YORK,NY 10016; UNIV CHICAGO,DEPT MED,CHICAGO,IL 60637; UNIV CHICAGO,HOWARD HUGHES MED INST,CHICAGO,IL 60637	New York University; New York University; University of Chicago; Howard Hughes Medical Institute; University of Chicago			Levy, David/AAG-6202-2019; Simon, Celeste/AAG-3941-2021; Levy, David/GPS-4945-2022	Levy, David/0000-0002-7320-7788; 				BHAT GJ, 1994, J BIOL CHEM, V269, P31443; BLUYSSEN HAR, 1995, P NATL ACAD SCI USA, V92, P5645, DOI 10.1073/pnas.92.12.5645; BOULTON TG, 1995, P NATL ACAD SCI USA, V92, P6915, DOI 10.1073/pnas.92.15.6915; BRADLEY A, 1984, NATURE, V309, P255, DOI 10.1038/309255a0; CAMPBELL GS, 1995, J BIOL CHEM, V270, P3974, DOI 10.1074/jbc.270.8.3974; COMPTON SR, 1993, LAB ANIM SCI, V43, P15; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DAVID M, 1994, P NATL ACAD SCI USA, V91, P7174, DOI 10.1073/pnas.91.15.7174; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FUJITA T, 1988, EMBO J, V7, P3397, DOI 10.1002/j.1460-2075.1988.tb03213.x; FUJITA T, 1989, NATURE, V337, P270, DOI 10.1038/337270a0; GREENLUND AC, 1994, EMBO J, V13, P1591, DOI 10.1002/j.1460-2075.1994.tb06422.x; GUSCHIN D, 1995, EMBO J, V14, P1421, DOI 10.1002/j.1460-2075.1995.tb07128.x; HAVELL EA, 1972, ANTIMICROB AGENTS CH, V2, P476, DOI 10.1128/AAC.2.6.476; HEIM MH, 1995, SCIENCE, V267, P1347, DOI 10.1126/science.7871432; HORVATH CM, 1995, GENE DEV, V9, P984, DOI 10.1101/gad.9.8.984; HUANG S, 1993, SCIENCE, V259, P1742, DOI 10.1126/science.8456301; HUME DA, 1995, J INTERF CYTOK RES, V15, P279, DOI 10.1089/jir.1995.15.279; IHLE JN, 1995, TRENDS GENET, V11, P69, DOI 10.1016/S0168-9525(00)89000-9; KAWAKAMI T, 1995, FEBS LETT, V358, P225, DOI 10.1016/0014-5793(94)01426-2; LAMB P, 1995, NUCLEIC ACIDS RES, V23, P3283, DOI 10.1093/nar/23.16.3283; LARNER AC, 1993, SCIENCE, V261, P1730, DOI 10.1126/science.8378773; Leaman DW, 1996, MOL CELL BIOL, V16, P369; LEVEEN P, 1994, GENE DEV, V8, P1875, DOI 10.1101/gad.8.16.1875; LEVY D, 1990, New Biologist, V2, P923; LEVY DE, 1995, SEMIN VIROL, V6, P181, DOI 10.1006/smvy.1995.0023; LORD KA, 1990, ONCOGENE, V5, P387; MARRERO MB, 1995, NATURE, V375, P247, DOI 10.1038/375247a0; MORTENSEN RM, 1992, MOL CELL BIOL, V12, P2391, DOI 10.1128/MCB.12.5.2391; MULLER M, 1993, NATURE, V366, P129, DOI 10.1038/366129a0; MULLER M, 1993, EMBO J, V12, P4221, DOI 10.1002/j.1460-2075.1993.tb06106.x; MULLER U, 1994, SCIENCE, V264, P1918, DOI 10.1126/science.8009221; PINE R, 1990, MOL CELL BIOL, V10, P2448, DOI 10.1128/MCB.10.6.2448; PINE R, 1994, EMBO J, V13, P158, DOI 10.1002/j.1460-2075.1994.tb06245.x; RAZ R, 1994, J BIOL CHEM, V269, P24391; RUFFJAMISON S, 1993, SCIENCE, V261, P1733, DOI 10.1126/science.8378774; SADOWSKI HB, 1993, SCIENCE, V261, P1739, DOI 10.1126/science.8397445; SCHIJNS VECJ, 1994, J IMMUNOL, V153, P2029; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; SCHINDLER C, 1992, SCIENCE, V257, P809, DOI 10.1126/science.1496401; SCHINDLER U, 1995, IMMUNITY, V2, P689, DOI 10.1016/1074-7613(95)90013-6; SEIDEL HM, 1995, P NATL ACAD SCI USA, V92, P3041, DOI 10.1073/pnas.92.7.3041; SHUAI K, 1994, CELL, V76, P821, DOI 10.1016/0092-8674(94)90357-3; SIBILIA M, 1995, SCIENCE, V269, P234, DOI 10.1126/science.7618085; SILVENNOINEN O, 1993, NATURE, V366, P583, DOI 10.1038/366583a0; SILVENNOINEN O, 1993, SCIENCE, V261, P1736, DOI 10.1126/science.8378775; SIMON MC, 1992, NAT GENET, V1, P92, DOI 10.1038/ng0592-92; SIMS SH, 1993, MOL CELL BIOL, V13, P690, DOI 10.1128/MCB.13.1.690; SMITH AL, 1991, ARCH VIROL, V121, P89, DOI 10.1007/BF01316746; STAHL N, 1995, SCIENCE, V267, P1349, DOI 10.1126/science.7871433; STEINHOFF U, 1995, J VIROL, V69, P2153, DOI 10.1128/JVI.69.4.2153-2158.1995; THREADGILL DW, 1995, SCIENCE, V269, P230, DOI 10.1126/science.7618084; TODARO GJ, 1963, J CELL BIOL, V17, P299, DOI 10.1083/jcb.17.2.299; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; VANDENBROEK MF, 1995, J VIROL, V69, P4792, DOI 10.1128/JVI.69.8.4792-4796.1995; VEALS SA, 1993, MOL CELL BIOL, V13, P196, DOI 10.1128/MCB.13.1.196; WAKSMAN G, 1992, NATURE, V358, P646, DOI 10.1038/358646a0; WATLING D, 1993, NATURE, V366, P166, DOI 10.1038/366166a0; WIKTORJEDRZEJCZ.W, 1990, P NATL ACAD SCI USA, V87, P7828; Wurst W., 1993, Gene targeting: a practical approach., P33; YOSHIDA H, 1990, NATURE, V345, P442, DOI 10.1038/345442a0; ZHANG XK, 1995, SCIENCE, V267, P1990, DOI 10.1126/science.7701321	62	1280	1321	0	22	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 9	1996	84	3					443	450		10.1016/S0092-8674(00)81289-1	http://dx.doi.org/10.1016/S0092-8674(00)81289-1			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TV708	8608598	hybrid			2022-12-28	WOS:A1996TV70800013
J	Warren, G; Wickner, W				Warren, G; Wickner, W			Organelle inheritance	CELL			English	Review							NUCLEAR-ENVELOPE; CELL-CYCLE; SACCHAROMYCES-CEREVISIAE; ENDOPLASMIC-RETICULUM; GOLGI-APPARATUS; ANIMAL-CELLS; HELA-CELLS; COMPLEX; PATHWAY; MUTANTS		DARTMOUTH COLL, SCH MED, DEPT BIOCHEM, HANOVER, NH 03755 USA	Dartmouth College	Warren, G (corresponding author), IMPERIAL CANC RES FUND, CELL BIOL LAB, 44 LINCOLNS INN FIELDS, LONDON WC2A 3PX, ENGLAND.							ACHARYA U, 1995, CELL, V82, P895, DOI 10.1016/0092-8674(95)90269-4; ALLAN VJ, 1991, J CELL BIOL, V113, P347, DOI 10.1083/jcb.113.2.347; BIRKY CW, 1983, INT REV CYTOL, P49; BIRKY CW, 1983, SCIENCE, V222, P468, DOI 10.1126/science.6353578; Byers B, 1981, MOL BIOL YEAST SACCH, P59; CALVAYRAC R, 1974, PROTOPLASMA, V80, P355, DOI 10.1007/BF01276351; CHALFIE M, 1994, SCIENCE, V263, P802, DOI 10.1126/science.8303295; CHAPMAN RE, 1994, EMBO J, V13, P4896, DOI 10.1002/j.1460-2075.1994.tb06817.x; CHAPPELL TG, 1989, J CELL BIOL, V109, P2693, DOI 10.1083/jcb.109.6.2693; COLMAN A, 1985, J CELL BIOL, V101, P313, DOI 10.1083/jcb.101.1.313; CONRADT B, 1994, J CELL BIOL, V126, P99, DOI 10.1083/jcb.126.1.99; CONRADT B, 1992, J CELL BIOL, V119, P1469, DOI 10.1083/jcb.119.6.1469; CORTHESYTHEULAZ I, 1992, J CELL BIOL, V118, P1333, DOI 10.1083/jcb.118.6.1333; Cox L S, 1994, Subcell Biochem, V22, P263; FOISNER R, 1993, CELL, V73, P1267, DOI 10.1016/0092-8674(93)90355-T; FORBES DJ, 1992, ANNU REV CELL BIOL, V8, P495, DOI 10.1146/annurev.cb.08.110192.002431; GERACE L, 1988, ANNU REV CELL BIOL, V4, P335, DOI 10.1146/annurev.cb.04.110188.002003; GRIFFING LR, 1991, J ELECTRON MICR TECH, V17, P179, DOI 10.1002/jemt.1060170206; HAAS A, 1994, J CELL BIOL, V126, P87, DOI 10.1083/jcb.126.1.87; HAAS A, 1995, EMBO J, V14, P5258, DOI 10.1002/j.1460-2075.1995.tb00210.x; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; HEPLER PK, 1984, INT REV CYTOL, V90, P169, DOI 10.1016/S0074-7696(08)61490-4; HO WC, 1989, EUR J CELL BIOL, V48, P250; JOHNSON BF, 1979, EXP CELL RES, V123, P253, DOI 10.1016/0014-4827(79)90466-X; KOCH GLE, 1987, J CELL SCI, V87, P535; KONSTANTINOV K, 1995, CLIN IMMUNOL IMMUNOP, V74, P89, DOI 10.1006/clin.1995.1013; LATTERICH M, 1995, CELL, V82, P885, DOI 10.1016/0092-8674(95)90268-6; LUCOCQ JM, 1989, J CELL BIOL, V109, P463, DOI 10.1083/jcb.109.2.463; LUCOCQ JM, 1987, J CELL BIOL, V104, P865, DOI 10.1083/jcb.104.4.865; MANIOTIS A, 1991, CELL, V67, P495, DOI 10.1016/0092-8674(91)90524-3; MAUL GR, 1977, INT REV CYTOL      S, V6, P75; MCCONNELL SJ, 1990, J CELL BIOL, V111, P967, DOI 10.1083/jcb.111.3.967; MCCONNELL SJ, 1993, SCIENCE, V260, P687, DOI 10.1126/science.8480179; MCINTOSH JR, 1989, MITOSIS SCI, V246, P622; MISTELI T, 1995, J CELL BIOL, V130, P1027, DOI 10.1083/jcb.130.5.1027; MISTELI T, 1995, J CELL SCI, V108, P2715; MISTELI T, 1994, J CELL BIOL, V125, P269, DOI 10.1083/jcb.125.2.269; NEWPORT J, 1992, J CELL BIOL, V116, P295, DOI 10.1083/jcb.116.2.295; NEWPORT JW, 1987, ANNU REV BIOCHEM, V56, P535; NEWPORT JW, 1990, J CELL BIOL, V111, P2247, DOI 10.1083/jcb.111.6.2247; NIGG E A, 1992, Current Opinion in Cell Biology, V4, P105, DOI 10.1016/0955-0674(92)90066-L; Nigg EA, 1993, CURR OPIN CELL BIOL, V5, P187, DOI 10.1016/0955-0674(93)90101-U; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; PAIEMENT J, 1984, EXP CELL RES, V151, P354, DOI 10.1016/0014-4827(84)90386-0; PORTER KR, 1960, J BIOPHYS BIOCHEM CY, V7, P167, DOI 10.1083/jcb.7.1.167; PREUSS D, 1992, MOL BIOL CELL, V3, P789, DOI 10.1091/mbc.3.7.789; PYPAERT M, 1993, J CELL SCI, V104, P811; RABOUILLE C, 1995, CELL, V82, P905, DOI 10.1016/0092-8674(95)90270-8; RABOUILLE C, 1995, J CELL BIOL, V129, P605, DOI 10.1083/jcb.129.3.605; RAPPAPORT R, 1986, INT REV CYTOL, V105, P245, DOI 10.1016/S0074-7696(08)61065-7; RAYMOND CK, 1992, MOL BIOL CELL, V3, P1389, DOI 10.1091/mbc.3.12.1389; RIZZUTO R, 1995, CURR BIOL, V5, P635, DOI 10.1016/S0960-9822(95)00128-X; Robinow C, 1989, MOL BIOL FISSION YEA, P273; ROTHMAN JE, 1994, CURR BIOL, V4, P220, DOI 10.1016/S0960-9822(00)00051-8; SHAW JM, 1991, EMBO J, V10, P1741, DOI 10.1002/j.1460-2075.1991.tb07698.x; STEINMAN RM, 1976, J CELL BIOL, V68, P665, DOI 10.1083/jcb.68.3.665; Stevens B., 1981, MOL BIOL YEAST SACCH, V11, P471; STICK R, 1983, CELL, V33, P949, DOI 10.1016/0092-8674(83)90038-7; STROME S, 1993, CELL, V72, P3, DOI 10.1016/0092-8674(93)90041-N; WARREN G, 1993, ANNU REV BIOCHEM, V62, P323, DOI 10.1146/annurev.bi.62.070193.001543; WARREN G, 1995, TRENDS CELL BIOL, V5, P413, DOI 10.1016/S0962-8924(00)89094-7; WEISMAN LS, 1988, SCIENCE, V241, P589, DOI 10.1126/science.3041591; WEISMAN LS, 1987, J CELL BIOL, V105, P1539, DOI 10.1083/jcb.105.4.1539; WEISMAN LS, 1990, P NATL ACAD SCI USA, V87, P1076, DOI 10.1073/pnas.87.3.1076; Wiese C, 1993, CURR OPIN CELL BIOL, V5, P387, DOI 10.1016/0955-0674(93)90002-8; Wilson EB, 1931, J MORPHOL, V52, P429, DOI 10.1002/jmor.1050520205; Wilson EB, 1916, P NATL ACAD SCI USA, V2, P321, DOI 10.1073/pnas.2.6.321; Wilson EB., 1925, CELL DEV HEREDITY, V3rd edition; WORMAN HJ, 1988, P NATL ACAD SCI USA, V85, P8531, DOI 10.1073/pnas.85.22.8531; XU Z, 1995, IN PRESS J CELL BIOL; Yaffe M P, 1991, Trends Cell Biol, V1, P160, DOI 10.1016/0962-8924(91)90017-4; YEH E, 1995, J CELL BIOL, V130, P687, DOI 10.1083/jcb.130.3.687; ZELIGS JD, 1979, J ULTRA MOL STRUCT R, V66, P53, DOI 10.1016/S0022-5320(79)80065-9; Zerial M, 1993, CURR OPIN CELL BIOL, V5, P613, DOI 10.1016/0955-0674(93)90130-I; ZORN GA, 1979, CELL, V18, P659, DOI 10.1016/0092-8674(79)90121-1	75	205	211	1	8	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 9	1996	84	3					395	400		10.1016/S0092-8674(00)81284-2	http://dx.doi.org/10.1016/S0092-8674(00)81284-2			6	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TV708	8608593	hybrid			2022-12-28	WOS:A1996TV70800008
J	Weissman, JS; Rye, HS; Fenton, WA; Beechem, JM; Horwich, AL				Weissman, JS; Rye, HS; Fenton, WA; Beechem, JM; Horwich, AL			Characterization of the active intermediate of a GroEL-GroES-mediated protein folding reaction	CELL			English	Article							RHODANESE; CYCLE	Recent studies of GroE-mediated protein folding indicate that substrate proteins are productively released from a cis ternary complex in which the nonnative substrate is sequestered within the GroEL channel underneath GroES. Here, we examine whether protein folding can occur in this space. Stopped-flow fluorescence anisotropy of a pyrene-rhodanese-GroEL complex indicates that addition of GroES and ATP (but not ADP) leads to a rapid change in substrate flexibility at GroEL. Strikingly, when GroES release is blocked by the use of either a nonhydrolyzable ATP analog or a single-ring GroEL mutant, substrates complete folding while remaining associated with chaperonin. We conclude that the cis ternary complex, in the presence of ATP, is the active state intermediate in the GroE-mediated folding reaction: folding is initiated in this state and for some substrates may be completed prior to the timed release of GroES triggered by ATP hydrolysis.	YALE UNIV,SCH MED,HOWARD HUGHES MED INST,NEW HAVEN,CT 06510; VANDERBILT UNIV,DEPT MOLEC PHYSIOL & BIOPHYS,NASHVILLE,TN 37232	Howard Hughes Medical Institute; Yale University; Vanderbilt University	Weissman, JS (corresponding author), YALE UNIV,SCH MED,DEPT GENET,NEW HAVEN,CT 06510, USA.			Rye, Hays/0000-0002-9420-3137; Weissman, Jonathan/0000-0003-2445-670X				AGARD DA, 1993, SCIENCE, V260, P1903, DOI 10.1126/science.8100365; Azem A, 1995, P NATL ACAD SCI USA, V92, P12021, DOI 10.1073/pnas.92.26.12021; BEECHEM JM, 1992, METHOD ENZYMOL, V210, P37; BRAIG K, 1994, NATURE, V371, P578, DOI 10.1038/371578a0; BURSTON SG, 1995, J MOL BIOL, V249, P138, DOI 10.1006/jmbi.1995.0285; CHEN S, 1994, NATURE, V371, P261, DOI 10.1038/371261a0; CORRALES FJ, 1995, P NATL ACAD SCI USA, V92, P5326, DOI 10.1073/pnas.92.12.5326; CUBITT AB, 1995, TRENDS BIOCHEM SCI, V20, P448, DOI 10.1016/S0968-0004(00)89099-4; ELLIS RJ, 1994, CURR BIOL, V4, P633; FENTON WA, 1994, NATURE, V371, P614, DOI 10.1038/371614a0; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; HAYERHARTL MK, 1995, SCIENCE, V269, P836, DOI 10.1126/science.7638601; HENDRICK JP, 1993, ANNU REV BIOCHEM, V62, P349, DOI 10.1146/annurev.bi.62.070193.002025; HORWICH AL, 1993, CELL, V74, P909, DOI 10.1016/0092-8674(93)90470-B; HUMMEL JP, 1962, BIOCHIM BIOPHYS ACTA, V63, P530, DOI 10.1016/0006-3002(62)90124-5; ITZHAKI LS, 1995, BIOCHEMISTRY-US, V34, P14581, DOI 10.1021/bi00044a037; JACKSON GS, 1993, BIOCHEMISTRY-US, V32, P2554, DOI 10.1021/bi00061a013; KANDROR O, 1994, J BIOL CHEM, V269, P23575; LANDRY SJ, 1994, ANNU REV BIOPH BIOM, V23, P645, DOI 10.1146/annurev.bb.23.060194.003241; Llorca O, 1996, J BIOL CHEM, V271, P68, DOI 10.1074/jbc.271.1.68; MARTIN J, 1991, NATURE, V352, P36, DOI 10.1038/352036a0; MARTIN J, 1993, NATURE, V366, P228, DOI 10.1038/366228a0; MENDOZA JA, 1991, J BIOL CHEM, V266, P13044; OTTO MR, 1994, BIOPHYS J, V67, P2511, DOI 10.1016/S0006-3495(94)80741-6; PERALTA D, 1994, FEBS LETT, V339, P45, DOI 10.1016/0014-5793(94)80381-1; PEREZHOWARD GM, 1995, BIOCHEMISTRY-US, V34, P8005, DOI 10.1021/bi00025a006; RANSON NA, 1995, J MOL BIOL, V250, P581, DOI 10.1006/jmbi.1995.0399; RAO BDN, 1980, BIOPHYS J, V32, P630, DOI 10.1016/S0006-3495(80)84999-X; ROUSSEAU DL, 1995, BIOCHEMISTRY-US, V34, P14508, DOI 10.1021/bi00044a029; SCHMIDT M, 1994, J BIOL CHEM, V269, P10304; SCHRODER H, 1993, EMBO J, V12, P4137, DOI 10.1002/j.1460-2075.1993.tb06097.x; SMITH KE, 1995, J BIOL CHEM, V270, P21517, DOI 10.1074/jbc.270.37.21517; TAGUCHI H, 1995, FEBS LETT, V359, P195, DOI 10.1016/0014-5793(95)00041-7; TANDON S, 1989, J BIOL CHEM, V264, P9859; TIAN GL, 1995, NATURE, V375, P250, DOI 10.1038/375250a0; TODD MJ, 1994, SCIENCE, V265, P659, DOI 10.1126/science.7913555; TODD MJ, 1995, BIOCHEMISTRY-US, V34, P14932, DOI 10.1021/bi00045a038; WARD WW, 1982, BIOCHEMISTRY-US, V21, P4535, DOI 10.1021/bi00262a003; WEISSMAN JS, 1994, CELL, V78, P693, DOI 10.1016/0092-8674(94)90533-9; WEISSMAN JS, 1995, CELL, V83, P577, DOI 10.1016/0092-8674(95)90098-5; YEE DP, 1994, J MOL BIOL, V241, P557, DOI 10.1006/jmbi.1994.1531; ZHENG XX, 1993, J BIOL CHEM, V268, P7489	42	344	347	0	13	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 9	1996	84	3					481	490		10.1016/S0092-8674(00)81293-3	http://dx.doi.org/10.1016/S0092-8674(00)81293-3			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TV708	8608602	hybrid			2022-12-28	WOS:A1996TV70800017
J	Hilleman, MR				Hilleman, MR			Cooperation between government and industry in combating a perceived emerging pandemic - The 1976 swine influenza vaccination program	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											Hilleman, MR (corresponding author), MERCK SHARP & DOHME LTD,RES LABS,MERCK INST THERAPEUT RES,WP53C-350,W POINT,PA 19486, USA.							HILLEMAN M R, 1958, Mil Med, V123, P23; LANGMUIR AD, 1979, J ROY SOC MED, V72, P660, DOI 10.1177/014107687907200908; Neustadt RE, 1978, SWINE FLU AFFAIR DEC, DOI [10.17226/12660, DOI 10.17226/12660]; OSBORN JE, 1977, HIST SCI POLITICS IN; SCHONBERGER LB, 1979, AM J EPIDEMIOL, V110, P1005; Silverstein ArthurM., 1981, PURE POLITICS IMPURE; SOFRANOK TJ, 1991, AM J EPIDEMIOL, V133, P940; WEBSTER RG, 1994, SEMIN VIROL, V5, P103, DOI 10.1006/smvy.1994.1011; 1976, L94380 PUB; 1976, L94266 PUB, P890	10	10	10	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 17	1996	275	3					241	243		10.1001/jama.275.3.241	http://dx.doi.org/10.1001/jama.275.3.241			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TP282	8604179				2022-12-28	WOS:A1996TP28200034
J	Allender, PS; Cutler, JA; Follmann, D; Cappuccio, FP; Pryer, J; Elliott, P				Allender, PS; Cutler, JA; Follmann, D; Cappuccio, FP; Pryer, J; Elliott, P			Dietary calcium and blood pressure: A meta-analysis of randomized clinical trials	ANNALS OF INTERNAL MEDICINE			English	Review							ORAL CALCIUM; DOUBLE-BLIND; CONTROLLED INTERVENTION; ESSENTIAL-HYPERTENSION; NORMOTENSIVE SUBJECTS; MILD HYPERTENSION; SUPPLEMENTATION; CROSSOVER; MEN	Purpose: To assess the effect of dietary calcium supplementation on blood pressure. Data Sources: Published reports of trials studying the effect of dietary calcium supplementation on blood pressure were identified by a search of previous reviews, a MEDLINE search, a manual review of journal articles, and a review of abstracts from scientific meetings. Study Selection: Randomized clinical trials in which dietary calcium intake varied by intervention group were selected. Multifactorial trials were not included. Data Synthesis: Data from 28 active treatment arms or strata from 22 randomized clinical trials were pooled using a weighted average method, with weights proportional to the inverse of the variance of the treatment effect. The total sample comprised 1231 persons. Because trials of both normotensive and hypertensive persons were included, subgroup analyses could be done. Pooled estimates of the effect of calcium supplementation on blood pressure were -0.18 mm Hg for diastolic blood pressure (95% CI, -0.75 to 0.40 mm Hg) and -0.89 mm Hg for systolic blood pressure (CI, -1.74 to -0.05 mm Hg). Pooled estimates for systolic blood pressure were -0.53 mm Hg (CI, -1.56 to 0.49 mm Hg) for trials of normotensive persons and -1.68 mm Hg (CI, -3.18 to -0.18 mm Hg) for trials of hypertensive persons. Diastolic blood pressure was not significantly affected in either subgroup. Conclusion: The pooled estimate shows a statistically significant decrease of systolic blood pressure with calcium supplementation, both for hypertensive persons and for the overall sample. However, the effect is too small to support the use of calcium supplementation for preventing or treating hypertension.	UNIV LONDON LONDON SCH HYG & TROP MED, DEPT PUBL HLTH & POLICY, LONDON WC1E 7HT, ENGLAND	University of London; London School of Hygiene & Tropical Medicine	Allender, PS (corresponding author), NHLBI, DIV EPIDEMIOL & CLIN APPLICAT,2 ROCKLEDGE CTR, ROOM 8132,6701 ROCKLEDGE DR, MSC 7, BETHESDA, MD 20892 USA.			Cappuccio, Francesco Paolo/0000-0002-7842-5493				BELIZAN JM, 1983, JAMA-J AM MED ASSOC, V249, P1161, DOI 10.1001/jama.249.9.1161; BIERENBAUM ML, 1988, AM J HYPERTENS, V1, pS149, DOI 10.1093/ajh/1.3.149S; BLOOMFIELD RL, 1986, J HYPERTENS, V4, pS351; CAPPUCCIO FP, 1995, AM J EPIDEMIOL, V142, P935, DOI 10.1093/oxfordjournals.aje.a117741; CAPPUCCIO FP, 1986, CLIN SCI, V71, P453, DOI 10.1042/cs0710453; CAPPUCCIO FP, 1989, J HYPERTENS, V7, P941, DOI 10.1097/00004872-198912000-00003; CAPPUCCIO FP, 1987, J HYPERTENS, V5, P67, DOI 10.1097/00004872-198702000-00010; CUTLER JA, 1990, AM J HYPERTENS, V3, pS137, DOI 10.1093/ajh/3.8.137; FOLLMANN D, 1992, J CLIN EPIDEMIOL, V45, P769, DOI 10.1016/0895-4356(92)90054-Q; GALLOE AM, 1993, J HUM HYPERTENS, V7, P43; GROBBEE DE, 1986, LANCET, V2, P703; HATTON DC, 1994, HYPERTENSION, V23, P513, DOI 10.1161/01.HYP.23.4.513; Hedges L, 1985, STATISTICAL METHODS; JOHNSON NE, 1985, AM J CLIN NUTR, V42, P12, DOI 10.1093/ajcn/42.1.12; LASARIDIS AN, 1987, J HYPERTENS       S5, V5, pS307; LEVINE RL, 1992, CLIN APPL NUTR, V2, P30; LYLE RM, 1987, JAMA-J AM MED ASSOC, V257, P1772, DOI 10.1001/jama.257.13.1772; MCCARRON DA, 1985, ANN INTERN MED, V103, P825, DOI 10.7326/0003-4819-103-6-825; MEESE RB, 1987, AM J MED SCI, V294, P219, DOI 10.1097/00000441-198710000-00001; *NAT HEART LUNG BL, 1991, REP TASK FORC RES HY; Neri L C, 1978, Ann N Y Acad Sci, V304, P203, DOI 10.1111/j.1749-6632.1978.tb25595.x; NOWSON C, 1996, J HYPERTENS, V4, pS673; PRYER J, 1995, J HUM HYPERTENS, V9, P597; SAITO K, 1989, HYPERTENSION, V13, P219, DOI 10.1161/01.HYP.13.3.219; SCHROEDER HA, 1960, JAMA-J AM MED ASSOC, V172, P1902, DOI 10.1001/jama.1960.03020170028007; SIANI A, 1988, J HYPERTENS, V6, P253, DOI 10.1097/00004872-198803000-00011; SIANI A, 1987, J HYPERTENS       S5, V5, pS311; STITT FW, 1973, LANCET, V1, P122; STRAZZULLO P, 1986, HYPERTENSION, V8, P1084, DOI 10.1161/01.HYP.8.11.1084; SUNDERRAJAN S, 1984, CIRCULATION, V70, P130; Tanji J L, 1991, J Am Board Fam Pract, V4, P145; THOMSEN K, 1987, ACTA MED SCAND, V222, P51; VANBERESTEIJN ECH, 1990, J INTERN MED, V228, P477, DOI 10.1111/j.1365-2796.1990.tb00266.x; VANBERESTEYN ECH, 1986, AM J CLIN NUTR, V44, P883, DOI 10.1093/ajcn/44.6.883; VINSON JA, 1987, NUTR REP INT, V36, P497; WEINBERGER MH, 1993, AM J HYPERTENS, V6, P799, DOI 10.1093/ajh/6.9.799; WHELTON PK, 1992, JAMA-J AM MED ASSOC, V267, P1213, DOI 10.1001/jama.1992.03480090061028; ZOCCALI C, 1986, J HYPERTENS, V4, pS676; 1994, JAMA-J AM MED ASSOC, V24, P1942	39	233	236	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 1	1996	124	9					825	831		10.7326/0003-4819-124-9-199605010-00007	http://dx.doi.org/10.7326/0003-4819-124-9-199605010-00007			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UG254	8610952				2022-12-28	WOS:A1996UG25400007
J	Davis, RM; Genel, M; Howe, JP; Karlan, MS; Kennedy, WR; Numann, PJ; Riggs, JA; Skelton, WD; Slanetz, PJ; Spillman, MA; Williams, M; Young, DC; Allen, JR; Rinaldi, RC; Ayesse, MC; ONeill, JF				Davis, RM; Genel, M; Howe, JP; Karlan, MS; Kennedy, WR; Numann, PJ; Riggs, JA; Skelton, WD; Slanetz, PJ; Spillman, MA; Williams, M; Young, DC; Allen, JR; Rinaldi, RC; Ayesse, MC; ONeill, JF			Health care needs of gay men and lesbians in the United States	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							HUMAN-IMMUNODEFICIENCY-VIRUS; SEXUALLY-TRANSMITTED DISEASES; HOMOSEXUAL MEN; BISEXUAL MEN; RISK-FACTORS; HEPATITIS-C; HIV TRANSMISSION; OVARIAN-CANCER; MALE-CHILDREN; CONDOM USE		AMER MED ASSOC, COUNCIL SCI AFFAIRS, CHICAGO, IL 60610 USA	American Medical Association								*AM MED ASS, 1994, AMA POL COMP; Arday D. R., 1993, Tobacco Control, V2, P156, DOI 10.1136/tc.2.2.156; Auerbach J, 1994, AIDS BEHAV INTEGRATE; BARTHOLOW BN, 1994, CHILD ABUSE NEGLECT, V18, P747; BEACH RK, 1993, PEDIATRICS, V92, P631; Berger BJ, 1995, CLIN INFECT DIS, V21, P1402, DOI 10.1093/clinids/21.6.1402; BEVIER PJ, 1995, AM J PUBLIC HEALTH, V85, P1366, DOI 10.2105/AJPH.85.10.1366; BHUGRA D, 1989, PSYCHIAT B, V13, P426; BILLY JOG, 1993, FAM PLANN PERSPECT, V25, P52, DOI 10.2307/2136206; BINSON D, 1995, J SEX RES, V32, P245, DOI 10.1080/00224499509551795; BLACK CA, 1993, ADOLESCENCE, V28, P123; BLOOMFIELD K, 1993, DRUG ALCOHOL DEPEN, V33, P257, DOI 10.1016/0376-8716(93)90112-4; BOEKELOO BO, 1991, AM J PUBLIC HEALTH, V81, P1645, DOI 10.2105/AJPH.81.12.1645; BOOTH M, 1989, BRIT J CANCER, V60, P592, DOI 10.1038/bjc.1989.320; BOWMAN CA, 1992, COLUMBIA LAW REV, V92, P1164, DOI 10.2307/1122980; BRADFORD J, 1994, J CONSULT CLIN PSYCH, V62, P228, DOI 10.1037/0022-006X.62.2.228; BREESE PL, 1995, SEX TRANSM DIS, V22, P7, DOI 10.1097/00007435-199501000-00002; BYERS T, 1985, AM J EPIDEMIOL, V121, P664, DOI 10.1093/aje/121.5.664; CABAJ RP, 1992, SUBSTANCE ABUSE COMP, P852; Catalan J, 1995, AIDS CARE, V7, pS117; CATANIA JA, 1992, AM J PUBLIC HEALTH, V82, P284, DOI 10.2105/AJPH.82.2.284; CHAIMOWITZ GA, 1991, CAN J PSYCHIAT, V36, P206, DOI 10.1177/070674379103600309; CHAISSON RE, 1994, JAMA-J AM MED ASSOC, V272, P564, DOI 10.1001/jama.272.7.564; CHU SY, 1994, JAMA-J AM MED ASSOC, V272, P433, DOI 10.1001/jama.272.6.433b; CHU SY, 1990, AM J PUBLIC HEALTH, V80, P1380, DOI 10.2105/AJPH.80.11.1380; CHU SY, 1994, 10 INT C AIDS AUG 7; COCHRAN SD, 1988, WESTERN J MED, V149, P616; COCHRAN SD, 1994, AM J PSYCHIAT, V151, P524, DOI 10.1176/ajp.151.4.524; COHEN H, 1993, J ACQ IMMUN DEF SYND, V6, P1173; COHEN JB, 1993, SAN FRAN EPIDEMIOL B, V9, P25; CRAMER DW, 1983, JNCI-J NATL CANCER I, V71, P711; CUNNINGHAM RN, 1994, CHILD ABUSE NEGLECT, V18, P233, DOI 10.1016/0145-2134(94)90108-2; DALEY J, 1992, PRIMARY CARE, V19, P203; DALING JR, 1982, JAMA-J AM MED ASSOC, V247, P1988; DAVIDSON L, 1989, REPORT SECRETARYS TA, V2, P89; DENENBERG R, 1995, WOMEN HEALTH ISS, V5, P81, DOI 10.1016/1049-3867(95)00030-8; DOLL LS, 1992, J SEX RES, V29, P1, DOI 10.1080/00224499209551630; DOLL LS, 1992, CHILD ABUSE NEGLECT, V16, P855, DOI 10.1016/0145-2134(92)90087-8; ENDE J, 1984, ARCH INTERN MED, V144, P558, DOI 10.1001/archinte.144.3.558; FALCO KL, 1991, PSYCHOTHERAPY LESBIA; FAY RE, 1989, SCIENCE, V243, P338, DOI 10.1126/science.2911744; FEINLEIB MR, 1989, REPORT SECRETARYS TA, V3, P89; FERGUSON KJ, 1991, ARCH INTERN MED, V151, P561, DOI 10.1001/archinte.151.3.561; FISCUS SA, 1994, SEX TRANSM DIS, V21, P155, DOI 10.1097/00007435-199405000-00005; FITZPATRICK R, 1994, BRIT J GEN PRACT, V44, P80; FROST JC, 1989, AIDS PRIMARY CARE PR, P45; GARCIA D, 1993, 9 INT C AIDS JUN 6 1; GERBERT B, 1990, AM J PUBLIC HEALTH, V80, P467, DOI 10.2105/AJPH.80.4.467; HAIDEMAN DC, 1994, J CONSULT CLIN PSYCH, V62, P221; HALL JM, 1993, J PSYCHOACTIVE DRUGS, V25, P109, DOI 10.1080/02791072.1993.10472240; Harrison A E, 1996, Fam Med, V28, P10; HART GJ, 1993, AIDS, V7, P863, DOI 10.1097/00002030-199306000-00016; HEIN K, 1995, PEDIATRICS, V95, P96; HITCHCOCK JM, 1992, NURS RES, V41, P178; HUNTER J, 1993, 9 INT C AIDS JUN 6 1; Johnson AM, 1994, SEXUAL ATTITUDES LIF; Johnson M C, 1988, Iowa Med, V78, P118; JOHNSON SR, 1987, J REPROD MED, V32, P805; JONES DJ, 1992, BRIT MED J, V305, P820, DOI 10.1136/bmj.305.6857.820; KALICHMAN SC, 1995, J SEX RES, V32, P45, DOI 10.1080/00224499509551773; KELLY CE, 1992, PHAROS           WIN, P2; KELLY JA, 1992, ARCH INTERN MED, V152, P2293, DOI 10.1001/archinte.152.11.2293; Kelsey J L, 1979, Epidemiol Rev, V1, P74; Kennedy M B, 1995, J Am Med Womens Assoc (1972), V50, P103; KINSEY AC, 1949, SEXUAL BEHAVIOR HUMA; Koziol D E, 1993, Ann Epidemiol, V3, P434, DOI 10.1016/1047-2797(93)90073-D; Laumann E. O., 1994, SOCIAL ORG SEXUALITY; LEE NC, 1987, NEW ENGL J MED, V317, P509; LEVER J, 1992, J SEX RES, V29, P141, DOI 10.1080/00224499209551640; LEWIS C E, 1990, Journal of General Internal Medicine, V5, pS78, DOI 10.1007/BF02600848; LO B, 1989, AIDS PRIMARY CARE PR, P193; MARCELLIN P, 1993, LIVER, V13, P319; MARMOR M, 1986, ANN INTERN MED, V105, P969, DOI 10.7326/0003-4819-105-6-969_1; MCCANCE KL, 1991, AM J PREV MED, V7, P141, DOI 10.1016/S0749-3797(18)30929-2; MCCOLL P, 1994, BRIT MED J, V308, P550, DOI 10.1136/bmj.308.6928.550; MELBYE M, 1994, LANCET, V343, P636, DOI 10.1016/S0140-6736(94)92636-0; *NAT I DRUG AB, 1988, SUBST AB COUNS AG AI; ODETS W, 1995, SHADOW EPIDEMIC BEIN, P101; OHANLAN KA, 1995, CURR PROB OBST GYN F, V18, P93; ONEILL JF, 1992, PRIMARY CARE, V19, P191; OSMOND DH, 1994, AM J PUBLIC HEALTH, V84, P1933, DOI 10.2105/AJPH.84.12.1933; OSMOND DH, 1993, J INFECT DIS, V167, P66, DOI 10.1093/infdis/167.1.66; Ostrow D G, 1993, J Subst Abuse, V5, P311, DOI 10.1016/0899-3289(93)90001-R; OSTROW DG, 1994, PSYCHIAT CLIN N AM, V17, P69; OSTROW DG, 1995, AM J EPIDEMIOL, V142, P875, DOI 10.1093/oxfordjournals.aje.a117727; OSTROW DG, 1992, COMPREHENSIVE HIV AI, V1; PALEFSKY JM, 1993, HOSP PHYSICIAN   JAN, P35; PAUL JP, 1993, AIDS EDUC PREV, V5, P11; QUARANTA JF, 1994, J MED VIROL, V42, P29, DOI 10.1002/jmv.1890420106; QUINN TC, 1983, NEW ENGL J MED, V309, P576, DOI 10.1056/NEJM198309083091002; Rankow E J, 1995, Womens Health Issues, V5, P123, DOI 10.1016/1049-3867(95)00042-3; REARDON J, 1994, 10 INT C AIDS AUG 7; REMAFEDI G, 1990, MED CLIN N AM, V74, P1169, DOI 10.1016/S0025-7125(16)30509-0; REMAFEDI G, 1991, PEDIATRICS, V87, P869; REMAFEDI G, 1994, PEDIATRICS, V94, P163; RICH JD, 1993, CLIN INFECT DIS, V17, P1003, DOI 10.1093/clinids/17.6.1003; Robertson M M, 1992, Health Care Women Int, V13, P155; ROBERTSON P, 1981, SEX TRANSM DIS, V8, P75, DOI 10.1097/00007435-198104000-00008; ROMPALO A, 1990, MED CLIN N AM, V74, P1633, DOI 10.1016/S0025-7125(16)30499-0; ROTHERAMBORUS MJ, 1994, J SEX RES, V31, P47, DOI 10.1080/00224499409551729; SABATINI MT, 1984, AIDS RES, V1, P135; SAVINWILLIAMS RC, 1994, J CONSULT CLIN PSYCH, V62, P261, DOI 10.1037/0022-006X.62.2.261; Schatz B, 1994, ANTIGAY DISCRIMINATI; SCHWARTZ GR, 1994, JAMA-J AM MED ASSOC, V271, P712; SEAGE GR, 1992, AM J EPIDEMIOL, V135, P1; SEIDMAN SN, 1994, AM J PSYCHIAT, V151, P330; SEIDMAN SN, 1994, SEX TRANSM DIS, V21, P173, DOI 10.1097/00007435-199405000-00008; SHERRARD J, 1992, BRIT MED J, V305, P1436, DOI 10.1136/bmj.305.6866.1436; SIMKIN RJ, 1993, CAN J OBSTET GYNECOL, V5, P485; SIMON P, 1994, 10 INT C AIDS AUG 7; SKINNER WF, 1994, AM J PUBLIC HEALTH, V84, P1307, DOI 10.2105/AJPH.84.8.1307; SMITH EM, 1985, AM J PUBLIC HEALTH, V75, P1085, DOI 10.2105/AJPH.75.9.1085; STEIN TS, 1993, REV PSYCHIAT, V12, P9; STEINBROOK R, 1986, NEW ENGL J MED, V314, P457, DOI 10.1056/NEJM198602133140730; STEVENS PE, 1991, INT J HEALTH SERV, V21, P291, DOI 10.2190/R2AW-MTCR-U0Q7-XMMY; STEVENS PE, 1993, AM J ORTHOPSYCHIAT, V63, P289, DOI 10.1037/h0079436; STOKES JP, 1993, J SEX RES, V30, P203, DOI 10.1080/00224499309551704; TANFER K, 1993, FAM PLANN PERSPECT, V25, P83, DOI 10.2307/2136210; TRIPPET SE, 1993, LESBIAN HLTH WHAT AR, P55; WATKINS B, 1992, J CHILD PSYCHOL PSYC, V33, P197, DOI 10.1111/j.1469-7610.1992.tb00862.x; WEINSTOCK HS, 1993, JAMA-J AM MED ASSOC, V269, P392; WHITE J, 1993, J GEN INTERN MED, V8, P41, DOI 10.1007/BF02600295; WILSON H, 1994, 10 INT C AIDS AUG 7; YOUNG RM, 1992, AIDS PUBLIC POL J, V7, P72; 1995, MMWR-MORBID MORTAL W, V44, P401; 1995, HIV AIDS SURVEILL RE, V7, P1	126	70	70	0	5	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 1	1996	275	17					1354	1359		10.1001/jama.1996.03530410068036	http://dx.doi.org/10.1001/jama.1996.03530410068036			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	UG612	8614123				2022-12-28	WOS:A1996UG61200034
J	Safrin, S; Finkelstein, DM; Feinberg, JD; Frame, P; Simpson, G; Wu, A; Cheung, T; Soeiro, R; Hojczyk, P; Black, JR				Safrin, S; Finkelstein, DM; Feinberg, JD; Frame, P; Simpson, G; Wu, A; Cheung, T; Soeiro, R; Hojczyk, P; Black, JR			Comparison of three regimens for treatment of mild to moderate Pneumocystis carinii pneumonia in patients with AIDS - A double-blind, randomized trial of oral trimethoprim-sulfamethoxazole, dapsone-trimethoprim, and clindamycin-primaquine	ANNALS OF INTERNAL MEDICINE			English	Article						pneumonia, Pneumocystis carinii; trimethoprim-sulfamethoxazole combination; dapsone; clindamycin; primaquine	ACQUIRED-IMMUNODEFICIENCY-SYNDROME; PENTAMIDINE; THERAPY; QUESTIONNAIRE	Objective: To compare the tolerability and efficacy of three oral regimens for the treatment of patients with the acquired immunodeficiency syndrome (AIDS) and Pneumocystis carinii pneumonia. Design: A randomized, double-blind study. Setting: 24 U.S. academic medical centers. Patients: 181 patients with morphologically confirmed P. carinii pneumonia and alveolar-arterial oxygen differences (PAO(2)-PaO2) of 45 mm Hg or less. Intervention: Patients were randomly assigned to receive trimethoprim-sulfamethoxazole, dapsone-trimethoprim, or clindamycin-primaquine for 21 days. Patients with a PaO2-PaO2 of 35 to 45 mm Hg at study entry also received prednisone. Measurements: Serial clinical and laboratory evaluations for therapeutic response and toxicity. Therapeutic failure at day 21 was defined by any of the following: increase in PAO(2)-PaO2 of greater than 20 mm Hg; no remission of baseline signs and symptoms; and change in antipneumocystis therapy for reasons other than toxicity, intubation, or death. Dose-limiting toxicity was defined as discontinuation of therapy by the primary physician because of one or more adverse reactions. Results: No statistically significant differences were seen among treatment groups in the proportions of patients who had dose-limiting toxicity (P = 0.2), therapeutic failure (P > 0.2), or a complete course of therapy (P > 0.2). Survival during therapy or for 2 months thereafter did not differ among the three groups (P > 0.2). However, elevation of serum aminotransferase levels to more than five times the baseline levels was more frequent in the trimethoprim-sulfamethoxazole group (P = 0.003), and one or more serious hematologic toxicities (neutropenia, anemia, thrombocytopenia, or methemoglobinemia) occurred more frequently in the clindamycin-primaquine group (P = 0.01). Conclusions: The rates of dose-limiting toxicity, therapeutic failure, and survival did not differ among patients with AIDS who were receiving oral trimethoprim-sulfamethoxazole, dapsone-trimethoprim, or clindamycin-primaquine for mild to moderate P. carinii pneumonia. However, the limited sample size prevents the unequivocal demonstration of the equality of these three regimens. Differences in expected categories of toxicities associated with each regimen should guide the clinician in choosing first-line therapy, particularly for patients with baseline hepatic insufficiency or myelosuppression.	HARVARD UNIV, SCH PUBL HLTH, BOSTON, MA 02111 USA; UNIV CINCINNATI, HOLMES HOSP, CINCINNATI, OH 45267 USA; UNIV CINCINNATI, MED CTR, CINCINNATI, OH 45267 USA; MT SINAI MED CTR, BALTIMORE, MD 21205 USA; ALBERT EINSTEIN COLL MED, DEPT MED, BRONX, NY 10461 USA; UNIV CALIF LOS ANGELES, LOS ANGELES, CA 90024 USA; UNIV CALIF SAN FRANCISCO, SAN FRANCISCO, CA 94143 USA; METHODIST HOSP INDIANA, INDIANAPOLIS, IN 46202 USA; FRONTIER SCI TECHNOL & RES FDN, AMHERST, NY USA	Harvard University; Harvard T.H. Chan School of Public Health; University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati; Yeshiva University; Albert Einstein College of Medicine; University of California System; University of California Los Angeles; University of California System; University of California San Francisco; Indiana University System; Frontier Science Foundation					AHRQ HHS [HS07824] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		BLACK JR, 1994, CLIN INFECT DIS, V18, P905, DOI 10.1093/clinids/18.6.905; BOWDEN FJ, 1986, LANCET, V1, P853; GARAY SM, 1989, CHEST, V95, P769, DOI 10.1378/chest.95.4.769; HLATKY MA, 1989, AM J CARDIOL, V64, P651, DOI 10.1016/0002-9149(89)90496-7; HUGHES W, 1993, NEW ENGL J MED, V328, P1521, DOI 10.1056/NEJM199305273282103; KAY R, 1990, SOUTHERN MED J, V83, P403, DOI 10.1097/00007611-199004000-00010; KLEIN NC, 1992, AIDS, V6, P301, DOI 10.1097/00002030-199203000-00007; LEE BL, 1989, ANN INTERN MED, V110, P606, DOI 10.7326/0003-4819-110-8-606; LEOUNG GS, 1986, ANN INTERN MED, V105, P45, DOI 10.7326/0003-4819-105-1-45; MASUR H, 1990, NEW ENGL J MED, V323, P1500, DOI 10.1056/NEJM199011223232131; MEDINA I, 1990, NEW ENGL J MED, V323, P776, DOI 10.1056/NEJM199009203231202; *NAT CTR INF DIS, 1994, HIV AIDS SURV REP, P1; QUEENER SF, 1988, ANTIMICROB AGENTS CH, V32, P807, DOI 10.1128/AAC.32.6.807; RIES PW, 1986, NATL HLTH SURVEY SER, V10; RUBIN HR, 1992, 8 INT C AIDS 3 STD W; RUF B, 1991, EUR J CLIN MICROBIOL, V10, P207, DOI 10.1007/BF01964466; SAFRIN S, 1994, J INFECT DIS, V170, P912, DOI 10.1093/infdis/170.4.912; SAFRIN S, 1994, PNEUMOCYSTIS CARINII, P2270; SATTLER FR, 1988, ANN INTERN MED, V109, P280, DOI 10.7326/0003-4819-109-4-280; SATTLER FR, 1994, J INFECT DIS, V170, P165, DOI 10.1093/infdis/170.1.165; STEVENS RC, 1991, ANTIMICROB AGENTS CH, V35, P1884, DOI 10.1128/AAC.35.9.1884; Stewart AL, 1992, MEASURING FUNCTIONIN; TOMA E, 1991, EUR J CLIN MICROBIOL, V10, P210, DOI 10.1007/BF01964467; TOMA E, 1993, CLIN INFECT DIS, V17, P178, DOI 10.1093/clinids/17.2.178; TOMA E, 1989, LANCET, V1, P1046, DOI 10.1016/S0140-6736(89)92446-X; WHARTON JM, 1986, ANN INTERN MED, V105, P37, DOI 10.7326/0003-4819-105-1-37; WU AW, 1991, MED CARE, V29, P786, DOI 10.1097/00005650-199108000-00011	28	131	137	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 1	1996	124	9					792	+		10.7326/0003-4819-124-9-199605010-00003	http://dx.doi.org/10.7326/0003-4819-124-9-199605010-00003			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UG254	8610948				2022-12-28	WOS:A1996UG25400003
J	Buckley, NA; Smith, AJ				Buckley, NA; Smith, AJ			Evidence-based medicine in toxicology: Where is the evidence?	LANCET			English	Editorial Material											Buckley, NA (corresponding author), UNIV NEWCASTLE,DISCIPLINE CLIN PHARMACOL,FAC MED,UNIV DR,CALLAGHAN,NSW 2308,AUSTRALIA.		Smith, Ashley/GZB-0298-2022; Buckley, Nicholas A/D-4030-2012	Buckley, Nicholas A/0000-0002-6326-4711				Baselt R.C., 1989, DISPOSITION TOXIC DR; BUCKLEY NA, 1995, J TOXICOL-CLIN TOXIC, V33, P199, DOI 10.3109/15563659509017984; BUCKLEY NA, 1994, LANCET, V343, P159, DOI 10.1016/S0140-6736(94)90940-7; BUCKLEY NA, 1995, BMJ-BRIT MED J, V310, P219, DOI 10.1136/bmj.310.6974.219; BUCKLEY NA, 1994, MED J AUSTRALIA, V160, P188, DOI 10.5694/j.1326-5377.1994.tb126600.x; BUCKLEY NA, 1995, MED J AUSTRALIA, V162, P190, DOI 10.5694/j.1326-5377.1995.tb126020.x; CHALMERS I, 1994, BMJ-BRIT MED J, V309, P862, DOI 10.1136/bmj.309.6958.862; DEBARD ML, 1981, CLIN TOXICOL, V18, P1117, DOI 10.3109/15563658108990341; Ellenhorn M.J., 1988, MED TOXICOLOGY DIAGN; FISHER WL, 1993, HDB MED TOXICOLOGY; HOOPER RG, 1979, JACEP-J AM COLL EMER, V8, P98, DOI 10.1016/S0361-1124(79)80150-1; JACOBSEN D, 1984, HUM TOXICOL, V3, P93, DOI 10.1177/096032718400300203; KOPPEL C, 1987, J TOXICOL-CLIN TOXIC, V25, P53; KOPPEL C, 1987, HUM TOXICOL, V6, P355, DOI 10.1177/096032718700600503; MATTHEW H, 1968, BMJ-BRIT MED J, V2, P101, DOI 10.1136/bmj.2.5597.101; NORMANN S, 1992, POISINDEX R SYSTEM, V86; POND SM, 1995, MED J AUSTRALIA, V162, P174, DOI 10.5694/j.1326-5377.1995.tb126015.x; RESCH F, 1982, KLIN PADIATR, V194, P42, DOI 10.1055/s-2008-1033768; SACKETT DL, 1989, CLIN EPIDEMIOLOGY BA; von Muhlendahl K E, 1978, Monatsschr Kinderheilkd, V126, P123; WEISSMAN RS, 1994, GOLDFRANKS TOXICOLOG; WINEK CL, 1977, CLIN TOXICOL, V11, P287, DOI 10.3109/15563657708989842; WYNGAARDEN JB, 1951, JAMA-J AM MED ASSOC, V145, P277, DOI 10.1001/jama.1951.02920230001001	23	16	16	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 27	1996	347	9009					1167	1169		10.1016/S0140-6736(96)90615-7	http://dx.doi.org/10.1016/S0140-6736(96)90615-7			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UG755	8609755				2022-12-28	WOS:A1996UG75500017
J	Habib, FM; Springall, DR; Davies, GJ; Oakley, CM; Yacoub, MH; Polak, JM				Habib, FM; Springall, DR; Davies, GJ; Oakley, CM; Yacoub, MH; Polak, JM			Tumour necrosis factor and inducible nitric oxide synthase in dilated cardiomyopathy	LANCET			English	Article							CONGESTIVE-HEART-FAILURE; IMMUNE-RESPONSE; FACTOR-ALPHA; MYOCARDITIS; RNA	Background Two important features of dilated cardiomyopathy (DCM) are low myocardial contractility and risk of thromboembolism. Nitric oxide (NO) exerts a negative inotropic effect on the myocardium and is produced by NO-synthase, an inducible form of which (iNOS) is stimulated by tumour necrosis factor (TNF-alpha). Accordingly, we hypothesised that locally produced TNF-alpha might contribute to the pathogenesis and complications of DCM by inducing iNOS in the heart. Methods iNOS and TNF-alpha were quantified by histochemistry and computerised image analysis in explanted heart tissues or myocardial biopsy material from patients with DCM (n=21) or ischaemic heart disease (IHD; n=10) and from normal donor hearts (n=9). Findings Immunoreactivity for iNOS was strong in myocytes of DCM hearts, particularly in areas adjacent to the endocardium, and moderately intense in blood vessels of DCM and IHD hearts, The median optical density of the immunostaining for iNOS was greater in cardiac myocytes of patients with DCM (0.86, range 0.21 to 1.29) than in those from patients with IHD (0.20, range 0.095 to 0.26) (p<0.01) or controls (0.01, range 0.001 to 0.02) (p<0.001). Staining for TNF-alpha was observed in the vascular endothelium and smooth muscle cells of patients with DCM but not in IHD or control tissues. Interpretation The localisation of iNOS and TNF-alpha within cardiac tissues in DCM suggests that TNF-alpha contributes to both the low contractility and the tendency to thromboembolism in these patients.	HAMMERSMITH HOSP,ROYAL POSTGRAD MED SCH,DEPT HISTOCHEM,LONDON W12 0HS,ENGLAND; HAMMERSMITH HOSP,ROYAL POSTGRAD MED SCH,DEPT CARDIOL,LONDON,ENGLAND; HAREFIELD HOSP,HEART SCI CTR,HAREFIELD UB9 6JH,MIDDX,ENGLAND	Imperial College London; Imperial College London; Royal Brompton & Harefield NHS Foundation Trust; Harefield Hospital								ARBUSTINI E, 1989, AM J CARDIOL, V64, P991, DOI 10.1016/0002-9149(89)90796-0; BOWLES NE, 1989, CIRCULATION, V80, P1128, DOI 10.1161/01.CIR.80.5.1128; BOWLES NE, 1986, LANCET, V1, P1120; CAFORIO ALP, 1990, J AM COLL CARDIOL, V15, P1527, DOI 10.1016/0735-1097(90)92821-I; DEBELDER AJ, 1993, LANCET, V341, P84, DOI 10.1016/0140-6736(93)92559-C; DREXLER H, 1993, AM HEART J, V126, P761, DOI 10.1016/0002-8703(93)90926-Z; DUNKMAN WB, 1993, CIRCULATION, V87, P94; FINKEL MS, 1992, SCIENCE, V257, P387, DOI 10.1126/science.1631560; HABIB F, 1994, LANCET, V344, P371, DOI 10.1016/S0140-6736(94)91402-8; KAPADIA S, 1995, J CLIN INVEST, V96, P1042, DOI 10.1172/JCI118090; KATZ SD, 1993, CIRCULATION, V88, P55, DOI 10.1161/01.CIR.88.1.55; KIRCHHOFER D, 1994, J CLIN INVEST, V93, P2073, DOI 10.1172/JCI117202; KRONCKE KD, 1995, BIOL CHEM H-S, V376, P327; LATIF N, 1993, J AM COLL CARDIOL, V22, P1378, DOI 10.1016/0735-1097(93)90546-D; LEVINE B, 1990, NEW ENGL J MED, V323, P236, DOI 10.1056/NEJM199007263230405; MATSUMORI A, 1994, CIRCULATION, V89, P955, DOI 10.1161/01.CIR.89.3.955; MCBRIDE JT, 1995, IMAGE ANAL HISTOLOGY; MCMURRAY J, 1991, BRIT HEART J, V66, P356; MONCADA S, 1991, PHARMACOL REV, V43, P109; MUNKVAD S, 1991, LYMPHOKINE CYTOK RES, V10, P325; MUNTONI F, 1993, NEW ENGL J MED, V329, P921, DOI 10.1056/NEJM199309233291304; PINSKY DJ, 1995, J CLIN INVEST, V95, P677, DOI 10.1172/JCI117713; SCHULZ R, 1992, BRIT J PHARMACOL, V105, P575, DOI 10.1111/j.1476-5381.1992.tb09021.x; SEKO Y, 1993, J CLIN INVEST, V91, P1327, DOI 10.1172/JCI116333; TORREAMIONE G, 1995, CIRCULATION, V92, P1487, DOI 10.1161/01.CIR.92.6.1487; UNGUREANULONGROIS D, 1995, CIRC RES, V77, P494, DOI 10.1161/01.RES.77.3.494; WALLEY KR, 1994, J APPL PHYSIOL, V76, P1060, DOI 10.1152/jappl.1994.76.3.1060; WOODRUFF JF, 1980, AM J PATHOL, V101, P425; YOKOYAMA T, 1993, J CLIN INVEST, V92, P2303, DOI 10.1172/JCI116834; YOSHIZUMI M, 1993, CIRC RES, V73, P205, DOI 10.1161/01.RES.73.1.205	30	293	303	1	6	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 27	1996	347	9009					1151	1155		10.1016/S0140-6736(96)90610-8	http://dx.doi.org/10.1016/S0140-6736(96)90610-8			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UG755	8609750				2022-12-28	WOS:A1996UG75500012
J	Singh, UK; Sinha, R; Suman, S				Singh, UK; Sinha, R; Suman, S			An unsteady 12-year-old	LANCET			English	Article											Singh, UK (corresponding author), PATNA MED COLL,DEPT PEDIAT,PATNA 800016,BIHAR,INDIA.							GARCIA HH, 1993, LANCET, V341, P197, DOI 10.1016/0140-6736(93)90064-N; Kalra Veena, 1994, Indian Journal of Pediatrics, V61, P33, DOI 10.1007/BF02753555; LOPEZHERNANDEZ A, 1983, CYSTICERCOSIS CENTRA, P69; PURI V, 1991, Indian Pediatrics, V28, P1309	4	3	3	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 27	1996	347	9009					1158	1158		10.1016/S0140-6736(96)90612-1	http://dx.doi.org/10.1016/S0140-6736(96)90612-1			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UG755	8609752				2022-12-28	WOS:A1996UG75500014
J	Normandeau, M; Taylor, AP; Dewdney, PE				Normandeau, M; Taylor, AP; Dewdney, PE			A galactic chimney in the Perseus arm of the Milky Way	NATURE			English	Article							H-I SHELLS; O-STARS; TERMINAL VELOCITIES; INTERSTELLAR-MEDIUM; MOLECULAR CLOUD; STELLAR WINDS; MASS-LOSS; EVOLUTION; SUPERSHELLS; COMPLEX	GALAXIES are surrounded by large haloes of hot gas(1) which must be replenished as the gas cools, This has led to the concept(2) of galactic 'chimneys'-cavities in the interstellar medium, created by multiple supernova explosions, that can act as conduits for the efficient transport of hot gas from a galaxy's disk to its halo. Here we present a high-resolution map of atomic hydrogen in the Perseus arm of our Galaxy, which shows clear evidence for the existence of such a chimney, This chimney appears to have been formed by the energetic winds from a cluster of young massive stars, and may currently have reached the stage of blowing out into the halo.	NATL RES COUNCIL CANADA,DOMINION RADIO ASTROPHYS OBSERV,OTTAWA,ON,CANADA	National Research Council Canada	Normandeau, M (corresponding author), UNIV CALGARY,DEPT PHYS & ASTRON,2500 UNIV DR NW,CALGARY,AB T2N 3E7,CANADA.							Alter G., 1970, CATALOGUE STAR CLUST; BURKI G, 1979, ASTRON ASTROPHYS, V79, P613; CHIOSI C, 1978, ASTRON ASTROPHYS, V63, P103; DEANDRES FL, 1982, ASTRON ASTROPHYS, V107, P43; DICKEL HR, 1980, ASTROPHYS J, V238, P829, DOI 10.1086/158044; DIGEL SW, IN PRESS ASTROPHYS; GOUDIS C, 1979, ASTROPHYS SPACE SCI, V61, P417, DOI 10.1007/BF00640542; GROENEWEGEN MAT, 1989, ASTRON ASTROPHYS, V221, P78; HARRIS GLH, 1976, ASTROPHYS J SUPPL S, V30, P451, DOI 10.1086/190368; HEILES C, 1987, ASTROPHYS J, V315, P555, DOI 10.1086/165158; Heiles C., 1974, Astronomy and Astrophysics Supplement Series, V14, P1; HEILES C, 1979, ASTROPHYS J, V229, P533, DOI 10.1086/156986; HEILES C, 1984, ASTROPHYS J SUPPL S, V55, P585, DOI 10.1086/190970; HOWARTH ID, 1989, ASTROPHYS J SUPPL S, V69, P527, DOI 10.1086/191321; JOSHI UC, 1983, J ROY ASTRON SOC CAN, V77, P40; LADA CJ, 1978, ASTROPHYS J, V226, pL39, DOI 10.1086/182826; LAMERS HJGLM, 1993, ASTROPHYS J, V412, P771, DOI 10.1086/172960; MACLOW M, 1988, ASTROPHYS J, V337, P776; MATHYS G, 1987, ASTRON ASTROPHYS SUP, V71, P201; NORMAN CA, 1989, ASTROPHYS J, V345, P372, DOI 10.1086/167912; PRINJA RK, 1990, ASTROPHYS J, V361, P607, DOI 10.1086/169224; TENORIOTAGLE G, 1988, ANNU REV ASTRON ASTR, V26, P145; THRONSON HA, 1985, ASTROPHYS J, V297, P662, DOI 10.1086/163565; TOMISAKA K, 1986, PUBL ASTRON SOC JPN, V38, P697; Vogler A, 1996, ASTRON ASTROPHYS, V305, P74; Weaver H., 1973, Astronomy and Astrophysics Supplement Series, V8, P1; WEAVER R, 1977, ASTROPHYS J, V218, P377, DOI 10.1086/155692	27	117	119	0	1	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	APR 25	1996	380	6576					687	689		10.1038/380687a0	http://dx.doi.org/10.1038/380687a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UG827	8614462				2022-12-28	WOS:A1996UG82700041
J	Gelber, RD; Cole, BF; Goldhirsch, A; Rose, C; Fisher, B; Osborne, CK; Boccardo, F; Gray, R; Gordon, NH; Bengtsson, NO; Sevelda, P				Gelber, RD; Cole, BF; Goldhirsch, A; Rose, C; Fisher, B; Osborne, CK; Boccardo, F; Gray, R; Gordon, NH; Bengtsson, NO; Sevelda, P			Adjuvant chemotherapy plus tamoxifen compared with tamoxifen alone for postmenopausal breast cancer: Meta-analysis of quality-adjusted survival	LANCET			English	Article							TRIAL; LIFE	Background Adjuvant tamoxifen for early breast cancer provides an improvement in relapse-free (RFS) and overall survival (OS), especially for older women. We carried out a meta-analysis to find out whether the benefit of adding chemotherapy to tamoxifen outweighs its costs in terms of toxic effects for postmenopausal patients. Methods The meta-analysis of quality-adjusted survival was based on data from 3920 patients aged 50 years or older with node-positive breast cancer randomly assigned in nine trials that compared combination chemotherapy plus tamoxifen with tamoxifen alone. The nine trials were included in the worldwide overview conducted by the early breast. cancer trialists' collaborative group (EBCTCG). The quality-adjusted time without symptoms or toxicity (Q-TWiST) method was used to provide treatment comparisons incorporating differences in quality of life associated with subjective toxic effects of treatment and symptoms of disease relapse. Findings Within 7 years of follow-up the modest benefit of increased RFS and OS for patients who received chemotherapy just balanced the costs in terms of acute toxic side-effects. Chemotherapy-treated patients gained an average of 5 . 4 months of RFS and 2 months of OS (neither statistically significant), but had to receive cytotoxic treatment for between 2 and 24 months to achieve these gains. No values of preference weights for time spent undergoing chemotherapy and time after relapse gave significantly more Q-TWiST with chemotherapy plus tamoxifen than with tamoxifen alone. Interpretation Within 7 years of follow-up, adjuvant significant advantage in relapse-free survival, but the effect on overall survival was not significant. The question of whether the observed benefit for chemotherapy outweighs the costs in terms of toxic effects demands an answer before the regimen is used for all postmenopausal patients who require adjuvant systemic therapy. Our evaluation of chemotherapy effectiveness in postmenopausal patients was based on a meta-analysis of quality-adjusted survival. We analysed data from all trials on combination chemotherapy plus tamoxifen versus tamoxifen alone included in the EBCTCG overview update. Treatment effects were estimated exclusively for patients aged 50 years or older. We provided an additional type of analysis that incorproated features of quality of life into the treatment comparison.	HARVARD UNIV,SCH MED,SCH PUBL HLTH,DANA FARBER CANC INST,CTR OUTCOMES & POLICY RES,BOSTON,MA 02115; BROWN UNIV,DEPT COMMUNITY HLTH,PROVIDENCE,RI 02912; BROWN UNIV,DIV APPL MATH,PROVIDENCE,RI 02912; OSPED CIV,DIV ONCOL,LUGANO,SWITZERLAND; ODENSE UNIV HOSP,DIV ONCOL R,DK-5000 ODENSE,DENMARK; UNIV PITTSBURGH,DEPT SURG,PITTSBURGH,PA 15260; UNIV TEXAS,HLTH SCI CTR,DEPT MED,SAN ANTONIO,TX 78284; IST NAZL RIC CANC,I-16132 GENOA,ITALY; RADCLIFFE INFIRM,CLIN TRIAL SERV UNIT,OXFORD OX2 6HE,ENGLAND; CASE WESTERN RESERVE UNIV,UNIV HOSP CLEVELAND,CLEVELAND,OH 44106; REG SJUKHUSET,DEPT ONCOL,UMEA,SWEDEN; UNIV HOSP,VIENNA,AUSTRIA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard T.H. Chan School of Public Health; Brown University; Brown University; University of Southern Denmark; Odense University Hospital; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of Texas System; University of Texas Health San Antonio; University of Genoa; IRCCS AOU San Martino IST; Radcliffe Infirmary; University of Oxford; Case Western Reserve University; Case Western Reserve University Hospital; University Hospitals of Cleveland; University Hospital Vienna	Gelber, RD (corresponding author), HARVARD UNIV,SCH MED,SCH PUBL HLTH,DANA FARBER CANC INST,DIV BIOSTAT,BOSTON,MA 02115, USA.		Boccardo, Francesco Mario/AAF-2654-2019	Boccardo, Francesco Mario/0000-0002-5392-4077; Gray, Richard/0000-0003-4440-574X	NCI NIH HHS [CA-06516] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA006516] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BOCCARDO F, 1990, J CLIN ONCOL, V8, P1310, DOI 10.1200/JCO.1990.8.8.1310; CASTIGLIONEGERTSCH M, 1994, ANN ONCOL, V5, P717, DOI 10.1093/oxfordjournals.annonc.a058976; COATES AS, 1992, INTRO NEW TREATMENTS; COLE BF, 1995, STAT MED, V14, P1771, DOI 10.1002/sim.4780141606; FISHER B, 1990, J CLIN ONCOL, V8, P1005, DOI 10.1200/JCO.1990.8.6.1005; FISHER B, 1986, J CLIN ONCOL, V4, P459, DOI 10.1200/JCO.1986.4.4.459; Gelber R D, 1995, Cancer J Sci Am, V1, P114; GELBER RD, 1991, ANN INTERN MED, V114, P621, DOI 10.7326/0003-4819-114-8-621; GELBER RD, 1995, AM STAT, V49, P161, DOI 10.2307/2684631; GELBER RD, 1992, NATL CANCER I MONOGR, V11, P127; GLASZIOU PP, 1990, STAT MED, V9, P1259, DOI 10.1002/sim.4780091106; GOLDHIRSCH A, 1994, NEW ENGL J MED, V330, P1308, DOI 10.1056/NEJM199405053301811; GOLDHIRSCH A, 1989, J CLIN ONCOL, V7, P36, DOI 10.1200/JCO.1989.7.1.36; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KAUFMANN M, 1987, ADJUVANT THERAPY CAN, V5, P337; LARSSON LG, 1987, TRIALS ADJUVANT HORM; Osborne CK, 1994, LONG TERM TAMOXIFEN, P181; OVERGAARD M, 1990, INT J RADIAT ONCOL, V19, P1121, DOI 10.1016/0360-3016(90)90214-5; PEARSON OH, 1989, CANCER-AM CANCER SOC, V64, P1819, DOI 10.1002/1097-0142(19891101)64:9<1819::AID-CNCR2820640910>3.0.CO;2-N; RIVKIN SE, 1994, J CLIN ONCOL, V12, P2078, DOI 10.1200/JCO.1994.12.10.2078; SCHUMACHER M, 1994, J CLIN ONCOL, V12, P2086, DOI 10.1200/JCO.1994.12.10.2086; SENANAYAKE F, 1984, LANCET, V2, P1148; SEVELDA P, 1988, ADJUVANT THERAPY PRI, V64; SIMES RJ, 1989, P AN M AM SOC CLIN, V8, P52; TANCINI G, 1983, J CLIN ONCOL, V1, P2, DOI 10.1200/JCO.1983.1.1.2; TORRANCE GW, 1987, J CHRON DIS, V40, P593, DOI 10.1016/0021-9681(87)90019-1; Weinstein MC, 1980, CLIN DECISION ANAL; WEISBERG S, 1985, APPLIED LINEAR REGRE; WOOD WC, 1994, NEW ENGL J MED, V330, P1253, DOI 10.1056/NEJM199405053301801; 1984, LANCET, V1, P1256; 1992, LANCET, V339, P71	31	101	105	0	7	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 20	1996	347	9008					1066	1071		10.1016/S0140-6736(96)90277-9	http://dx.doi.org/10.1016/S0140-6736(96)90277-9			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UG042	8602056				2022-12-28	WOS:A1996UG04200010
J	Pritchard, KI				Pritchard, KI			Postmenopausal breast cancer: Is the short-term pain worth the long-term gain?	LANCET			English	Editorial Material									UNIV TORONTO,TORONTO,ON,CANADA	University of Toronto	Pritchard, KI (corresponding author), TORONTO SUNNYBROOK REG CANC CTR,DIV MED ONCOL HAEMATOL,TORONTO,ON,CANADA.							FISHER B, 1990, J CLIN ONCOL, V8, P1483, DOI 10.1200/JCO.1990.8.9.1483; 1992, LANCET, V339, P71	2	1	1	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 20	1996	347	9008					1057	1058		10.1016/S0140-6736(96)90271-8	http://dx.doi.org/10.1016/S0140-6736(96)90271-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UG042	8602051				2022-12-28	WOS:A1996UG04200004
J	Herwaldt, BL; Persing, DH; Precigout, EA; Goff, WL; Mathiesen, DA; Taylor, PW; Eberhard, ML; Gorenflot, AF				Herwaldt, BL; Persing, DH; Precigout, EA; Goff, WL; Mathiesen, DA; Taylor, PW; Eberhard, ML; Gorenflot, AF			A fatal case of babesiosis in Missouri: Identification of another piroplasm that infects humans	ANNALS OF INTERNAL MEDICINE			English	Article						babesiosis; Missouri; Babesia divergens; Babesia microti; tick-borne diseases	DEER ODOCOILEUS-VIRGINIANUS; SHEEP OVIS-CANADENSIS; BIGHORN SHEEP; MONOCLONAL-ANTIBODIES; DIFFERENT HOSTS; DIVERGENS; GERBIL; BOVIS; PROTECTION; RESPONSES	Objective: To characterize the etiologic agent (MO1) of the first reported cas Design: Case report, serologic testing, animal inoculations, and molecular studies. Setting: Southeastern Missouri. Patient: A 73-year-old man who had had a splenectomy and had a fatal case of babesiosis. Measurements: Serum specimens from the patient were assayed by indirect immunofluorescent antibody testing and immunoprecipitation for reactivity with antigens from various Babesia species. Whole blood obtained from the patient before treatment was inoculated into hamsters and jirds and into calves and bighorn sheep that had had splenectomy and were immunosuppressed with dexamethasone. Piroplasm-specific nuclear small-subunit ribosomal DNA was recovered from the patient's blood by using broad-range amplification with the polymerase chain reaction; a 144 base-pair region of the amplification product was sequenced; and phylogenetic analysis was done to compare MO1 with various Babesia species. Results: Indirect immunofluorescent antibody testing showed that the patient's serum had strong reactivity with Babesia divergens, which causes babesiosis in cattle and humans in Europe, but that it had minimal reactivity with B. microti and WA1, which are the piroplasms previously known to cause zoonotic babesiosis in the United States. Immunoprecipitations showed that MO1 is more closely related to B. divergens than to B. canis (a canine parasite). None of the experimentally inoculated animals became demonstrably parasitemic. Phylogenetic analyses, after DNA sequencing, showed that MO1 is most closely related to B. divergens (100% similarity). Conclusions: Although MO1 is probably distinct from B. divergens, the two share morphologic, antigenic, and genetic characteristics; MO1 probably represents a Babesia species not previously recognized to have infected humans. Medical personnel should be aware that patients in the United States can have life-threatening babesiosis even though they are seronegative to B. microti and WA1 antigen.	MAYO CLIN & MAYO FDN, DEPT LAB MED & PATHOL, DIV EXPTL PATHOL, ROCHESTER, MN 55905 USA; MAYO CLIN & MAYO FDN, DEPT MED, DIV INFECT DIS, ROCHESTER, MN 55905 USA; UNIV MONTPELLIER, F-34059 MONTPELLIER, FRANCE; USDA, PULLMAN, WA USA; CAPE GIRARDEAU PHYSICIAN ASSOCIATES, CAPE GIRARDEAU, MO USA	Mayo Clinic; Mayo Clinic; Universite de Montpellier; United States Department of Agriculture (USDA)	Herwaldt, BL (corresponding author), CTR DIS CONTROL & PREVENT, DIV PARASIT DIS, MAILSTOP F-22, 4770 BUFORD HIGHWAY NE, ATLANTA, GA 30341 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI032403, P01AI030548] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR041497] Funding Source: NIH RePORTER; NIAID NIH HHS [AI30548, AI32403] Funding Source: Medline; NIAMS NIH HHS [AR41497] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BRASSEUR P, 1992, MEM I OSWALDO CRUZ, V87, P131, DOI 10.1590/S0074-02761992000700019; CARCY B, 1991, BIOL CELL, V72, P93, DOI 10.1016/0248-4900(91)90083-Y; CHISHOLM ES, 1978, AM J TROP MED HYG, V27, P14, DOI 10.4269/ajtmh.1978.27.14; GOFF WL, 1986, EXP PARASITOL, V62, P202, DOI 10.1016/0014-4894(86)90024-X; GOFF WL, 1988, INT J PARASITOL, V18, P775, DOI 10.1016/0020-7519(88)90118-X; GOFF WL, 1988, INFECT IMMUN, V56, P2363, DOI 10.1128/IAI.56.9.2363-2368.1988; GOFF WL, 1982, VET PARASITOL, V11, P109, DOI 10.1016/0304-4017(82)90032-2; GOFF WL, 1993, J EUKARYOT MICROBIOL, V40, P237, DOI 10.1111/j.1550-7408.1993.tb04909.x; GOFF WL, 1993, P 9 INT VET HEM DIS; GORENFLOT A, 1990, INFECT IMMUN, V58, P4076, DOI 10.1128/IAI.58.12.4076-4082.1990; GORENFLOT A, 1991, PARASITOL RES, V77, P3, DOI 10.1007/BF00934377; HERWALDT BL, 1995, AM J TROP MED HYG, V53, P146, DOI 10.4269/ajtmh.1995.53.146; HOLMAN PJ, 1988, J PARASITOL, V74, P111, DOI 10.2307/3282486; HOLMAN PJ, 1994, THESIS TEXAS A M U; KOCAN A A, 1991, Bulletin of the Society for Vector Ecology, V16, P94; KOCK MD, 1987, J WILDLIFE DIS, V23, P641, DOI 10.7589/0090-3558-23.4.641; LEWIS D, 1979, NATURE, V278, P170, DOI 10.1038/278170a0; PANCHOLI P, 1995, J INFECT DIS, V172, P1007, DOI 10.1093/infdis/172.4.1007; PERSING DH, 1995, NEW ENGL J MED, V332, P298, DOI 10.1056/NEJM199502023320504; PHILLIPS RS, 1987, RES VET SCI, V42, P96, DOI 10.1016/S0034-5288(18)30662-3; PRECIGOUT E, 1991, INFECT IMMUN, V59, P2799, DOI 10.1128/IAI.59.8.2799-2805.1991; PURNELL RE, 1976, VET REC, V99, P415, DOI 10.1136/vr.99.21.415; QUICK RE, 1993, ANN INTERN MED, V119, P284, DOI 10.7326/0003-4819-119-4-199308150-00006; SCHETTERS TPM, 1992, PARASITE IMMUNOL, V14, P295, DOI 10.1111/j.1365-3024.1992.tb00469.x; Swofford D. L., 1991, PAUP PHYLOGENETIC AN; Telford S. R. III, 1993, PARASIT PROTOZOA, V5, P1; THOMFORD JW, 1994, J INFECT DIS, V169, P1050, DOI 10.1093/infdis/169.5.1050; TIBBITTS T, 1992, J WILDLIFE DIS, V28, P125, DOI 10.7589/0090-3558-28.1.125; WALDRUP KA, 1989, J WILDLIFE DIS, V25, P194, DOI 10.7589/0090-3558-25.2.194; WINGER CM, 1987, PARASITOLOGY, V94, P17, DOI 10.1017/S0031182000053415	30	169	182	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 1	1996	124	7					643	+		10.7326/0003-4819-124-7-199604010-00004	http://dx.doi.org/10.7326/0003-4819-124-7-199604010-00004			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UB513	8607592				2022-12-28	WOS:A1996UB51300004
J	TalarWilliams, C; Hijazi, YM; Walther, MM; Linehan, WM; Hallahan, CW; Lubensky, L; Kerr, CS; Hoffman, GS; Fauci, AS; Sneller, MC				TalarWilliams, C; Hijazi, YM; Walther, MM; Linehan, WM; Hallahan, CW; Lubensky, L; Kerr, CS; Hoffman, GS; Fauci, AS; Sneller, MC			Cyclophosphamide-induced cystitis and bladder cancer in patients with wegener granulomatosis	ANNALS OF INTERNAL MEDICINE			English	Article							ULCERATIVE-COLITIS; RHEUMATOID-ARTHRITIS; TOXICITY	Objective: To describe the incidence of, clinical manifestations of, and risk factors for cyclophosphamide-induced urinary bladder toxicity in patients treated for nonmalignant disease. Design: Retrospective analysis of patients followed at the National Institutes of Allergy and Infectious Diseases from 1967 to 1993. Setting: The Warren G. Magnuson Clinical Center of the National Institutes of Health (NIH). Patients: 145 patients who received cyclophosphamide for the treatment of Wegener granulomatosis and were followed for 0.5 to 27 years (median, 8.5 years), for a total of 1333 patient-years. Measurements: Clinical characteristics, cystoscopic findings, results of cytologic examination of urine, surgical pathology. and total dose and duration of cyclophosphamide therapy were recorded and analyzed using a computer-based information retrieval system. Results: Nonglomerular hematuria occurred in 73 of 145 patients treated with cyclophosphamide (50%). Sixty of the 73 patients with nonglomerular hematuria (82%) had cystoscopy at the NIH. Forty-two of the 60 patients (70%) who had cystoscopy had macroscopic changes consistent with cyclophosphamide-induced bladder injury. Seven patients (5%) developed transitional-cell carcinoma of the urinary bladder. In 6 of these 7 patients, the total cumulative cyclophosphamide dose exceeded 100 g, and the cumulative duration of cyclophosphamide therapy exceeded 2.7 years. Before they were given a diagnosis of bladder cancer, all 7 patients had had one or more episodes of microscopic or gross nonglomerular hematuria. In contrast, none of the 72 patients who had never had nonglomerular hematuria developed bladder cancer. Cox proportional hazards regression analysis showed that only microscopic nonglomerular hematuria was a significant risk factor for the development of bladder cancer (P < 0.01). Conclusion: Long-term oral cyclophosphamide therapy is associated with substantial urotoxicity, including the development of transitional-cell carcinoma of the urinary bladder. In this cohort of patients, the estimated incidence of bladder cancer after the first exposure to cyclophosphamide was 5% at 10 years and 16% at 15 years. Nonglomerular hematuria was a frequent manifestation of cyclophosphamide-induced cystitis, and it identified a subgroup of patients at high risk for the development of bladder cancer.	NIAID,NIH,IMMUNOREGULAT LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)								BAKER GL, 1987, AM J MED, V83, P1, DOI 10.1016/0002-9343(87)90490-6; COLEMAN DV, 1975, ACTA CYTOL, V19, P93; COX DR, 1972, J R STAT SOC B, V34, P187; COX PJ, 1979, BIOCHEM PHARMACOL, V28, P2045, DOI 10.1016/0006-2952(79)90222-3; CROWLEY J, 1977, J AM STAT ASSOC, V72, P27, DOI 10.2307/2286902; FAUCI AS, 1973, MEDICINE, V52, P535, DOI 10.1097/00005792-197311000-00002; FAUCI AS, 1983, ANN INTERN MED, V98, P76, DOI 10.7326/0003-4819-98-1-76; FORNI AM, 1964, CANCER, V17, P1348, DOI 10.1002/1097-0142(196410)17:10<1348::AID-CNCR2820171017>3.0.CO;2-0; FRAISER LH, 1991, DRUGS, V42, P781, DOI 10.2165/00003495-199142050-00005; GYDE SN, 1988, GUT, V29, P206, DOI 10.1136/gut.29.2.206; HOFFMAN GS, 1992, ANN INTERN MED, V116, P488, DOI 10.7326/0003-4819-116-6-488; JEWELL DP, 1993, GASTROINTESTINAL DIS, P105; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KORELITZ BI, 1995, BOCKUS GASTROENTEROL, P1364; LENNARDJONES JE, 1990, GUT, V31, P800, DOI 10.1136/gut.31.7.800; LOFBERG R, 1990, GASTROENTEROLOGY, V99, P1021; PEDERSENBJERGAARD J, 1988, NEW ENGL J MED, V318, P1028, DOI 10.1056/NEJM198804213181604; PLOTZ PH, 1979, ANN INTERN MED, V91, P221, DOI 10.7326/0003-4819-91-2-221; REZA MJ, 1975, ARTHRITIS RHEUM, V18, P501, DOI 10.1002/art.1780180513; RIES LAG, 1994, NIH942789 PUB; SIMES RJ, 1986, BIOMETRIKA, V73, P751, DOI 10.2307/2336545; SNELLER MC, 1995, ARTHRITIS RHEUM, V38, P608, DOI 10.1002/art.1780380505; STILLWELL TJ, 1988, ARTHRITIS RHEUM, V31, P465, DOI 10.1002/art.1780310402; WEISS MA, 1989, PATHOLOGY URINARY BL, P245	24	379	393	0	5	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572	0003-4819			ANN INTERN MED	Ann. Intern. Med.	MAR 1	1996	124	5					477	&		10.7326/0003-4819-124-5-199603010-00003	http://dx.doi.org/10.7326/0003-4819-124-5-199603010-00003			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TW773	8602705				2022-12-28	WOS:A1996TW77300003
J	Tamai, H; Sudo, T; Kimura, A; Mukuta, T; Matsubayashi, S; Kuma, K; Nagataki, S; Sasazuki, T				Tamai, H; Sudo, T; Kimura, A; Mukuta, T; Matsubayashi, S; Kuma, K; Nagataki, S; Sasazuki, T			Association between the DRB1*08032 histocompatibility antigen and methimazole-induced agranulocytosis in Japanese patients with graves disease	ANNALS OF INTERNAL MEDICINE			English	Article							PROPYLTHIOURACIL-INDUCED AGRANULOCYTOSIS; INSULIN AUTOIMMUNE SYNDROME; COLONY-STIMULATING FACTOR; LUPUS-LIKE SYNDROME; MHC CLASS-II; ANTITHYROID DRUGS; IMMUNE-RESPONSE; HLA; SUSCEPTIBILITY; GENES	Objective: To determine the association between HLA class II genes and methimazole-induced agranulocytosis in patients with Graves disease. Design: Case-control study. Setting: Kuma Hospital, which specializes in thyroid diseases, in Kobe, Japan. Subjects: 24 patients with Graves disease who had methimazole-induced agranulocytosis diagnosed by peripheral granulocyte counts of less than 0.5 x 10(9)/L, and 68 patients with Graves disease treated with methimazole, who were free from agranulocytosis. Controls were 525 healthy, unrelated Japanese student volunteers at Kyushu University in Japan. Measurements: All HLA class II genes were analyzed for polymorphisms at the DNA level by using the polymerase chain reaction sequence-specific oligonucleotide probes method. The allele frequencies in the agranulocytotic Graves disease group were compared with those in the nonagranulocytotic Graves disease and control groups. Results: A strong positive association was seen in DRB1*08032 between the agranulocytotic group and both the control and nonagranulocytotic Graves disease groups. Conclusion: The HLA DRB1*08032 allele was strongly associated with susceptibility to methimazole-induced agranulocytosis, suggesting that cellular autoimmunity may be involved in its development.	KYUSHU UNIV, MED INST BIOREGULAT, DEPT GENET, HIGASHI KU, FUKUOKA 812, JAPAN; TOKYO MED & DENT UNIV, MED RES INST,DEPT TISSUE PHYSIOL,DIV ADULT DIS, CHIYODA KU, TOKYO 101, JAPAN; KUMA HOSP, CHUOU KU, KOBE, HYOGO 650, JAPAN; NAGASAKI UNIV, SCH MED, DEPT INTERNAL MED 1, NAGASAKI 852, JAPAN	Kyushu University; Tokyo Medical & Dental University (TMDU); Kuma Hospital; Nagasaki University	Tamai, H (corresponding author), KYUSHU UNIV, FAC MED, DEPT PSYCHOSOMAT MED, HIGASHI KU, 3-1-1 MAIDASHI, FUKUOKA 812, JAPAN.			nagataki, shigenobu/0000-0002-9974-3554				AMRHEIN JA, 1970, J PEDIATR-US, V76, P54, DOI 10.1016/S0022-3476(70)80130-5; BERKMAN EM, 1983, TRANSFUSION, V23, P135, DOI 10.1046/j.1537-2995.1983.23283172851.x; BILEZIKIAN SB, 1976, JOHNS HOPKINS MED J, V138, P124; BODMER JG, 1995, TISSUE ANTIGENS, V46, P1; BROWN JH, 1993, NATURE, V364, P33, DOI 10.1038/364033a0; CHICZ RM, 1993, J EXP MED, V178, P27, DOI 10.1084/jem.178.1.27; COOPER DS, 1983, ANN INTERN MED, V98, P26, DOI 10.7326/0003-4819-98-1-26; COOPER DS, 1984, NEW ENGL J MED, V311, P1353, DOI 10.1056/NEJM198411223112106; DONG RP, 1992, HUM IMMUNOL, V35, P165, DOI 10.1016/0198-8859(92)90101-R; FIBBE WE, 1986, BRIT J HAEMATOL, V64, P363, DOI 10.1111/j.1365-2141.1986.tb04130.x; FU XT, 1995, J EXP MED, V181, P915, DOI 10.1084/jem.181.3.915; GEORGE AJT, 1995, IMMUNOL TODAY, V16, P209, DOI 10.1016/0167-5699(95)80158-8; GUFFY MM, 1984, ARCH INTERN MED, V144, P1687, DOI 10.1001/archinte.144.8.1687; HAMMER J, 1993, CELL, V74, P197, DOI 10.1016/0092-8674(93)90306-B; HEINRICH B, 1989, ANN INTERN MED, V111, P621, DOI 10.7326/0003-4819-111-7-621_2; Imanish T, 1992, HLA 1991, V1, P1065; KIMURA A, 1992, TISSUE ANTIGENS, V40, P5, DOI 10.1111/j.1399-0039.1992.tb01951.x; Kimura A., 1991, HLA 1991 P 11 INT HI, VVolume 1, P397; KRIEGER JI, 1991, J IMMUNOL, V146, P2331; MARSHALL KW, 1994, J IMMUNOL, V152, P4946; MATSUSHITA S, 1994, J EXP MED, V180, P873, DOI 10.1084/jem.180.3.873; MCDEVITT HO, 1980, NEW ENGL J MED, V303, P1514, DOI 10.1056/NEJM198012253032606; MCGAVACK TH, 1954, AM J MED, V17, P36, DOI 10.1016/0002-9343(54)90141-2; McIntyre P A, 1971, Trans Assoc Am Physicians, V84, P217; MOORE FD, 1946, JAMA-J AM MED ASSOC, V130, P315, DOI 10.1001/jama.1946.02870060001001; RAMMENSEE HG, 1995, IMMUNOGENETICS, V41, P178, DOI 10.1007/BF00172063; RENOUX G, 1980, DRUGS, V20, P89, DOI 10.2165/00003495-198020020-00001; ROSOVE MH, 1977, WESTERN J MED, V126, P339; SASAZUKI T, 1983, IMMUNOL REV, V70, P51, DOI 10.1111/j.1600-065X.1983.tb00709.x; SATO K, 1985, J ENDOCRINOL INVEST, V8, P551, DOI 10.1007/BF03348560; TAKAYAMAHASUMI S, 1990, DIABETES RES CLIN PR, V10, P211, DOI 10.1016/0168-8227(90)90063-Y; TAMAI H, 1994, J CLIN ENDOCR METAB, V78, P94, DOI 10.1210/jc.78.1.94; TAMAI H, 1989, CLIN ENDOCRINOL, V30, P525, DOI 10.1111/j.1365-2265.1989.tb01424.x; TAMAI H, 1993, J CLIN ENDOCR METAB, V77, P1356, DOI 10.1210/jc.77.5.1356; TIWARI JL, HLA DISEASE ASS, P214; TODD JA, 1988, SCIENCE, V240, P1003, DOI 10.1126/science.3368786; TOTH EL, 1988, AM J MED, V85, P725; TROTTER W. R., 1962, JOUR NEW DRUGS, V2, P333, DOI 10.1177/009127006200200603; UCHIGATA Y, 1992, LANCET, V340, P1467, DOI 10.1016/0140-6736(92)92654-X; UNO H, 1981, NATURE, V292, P768, DOI 10.1038/292768a0; WADE WF, 1993, IMMUNOL TODAY, V14, P539, DOI 10.1016/0167-5699(93)90184-M; WALL JR, 1984, J CLIN ENDOCR METAB, V58, P868, DOI 10.1210/jcem-58-5-868; WALZER RA, 1963, JAMA-J AM MED ASSOC, V184, P743, DOI 10.1001/jama.1963.03700230043006; WEITZMAN SA, 1978, LANCET, V1, P1068	44	53	67	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 1	1996	124	5					490	494		10.7326/0003-4819-124-5-199603010-00005	http://dx.doi.org/10.7326/0003-4819-124-5-199603010-00005			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TW773	8602707				2022-12-28	WOS:A1996TW77300005
J	Davenport, M				Davenport, M			ABC of general surgery in children - Lumps and swellings of the head and neck	BRITISH MEDICAL JOURNAL			English	Article											Davenport, M (corresponding author), UNIV LONDON KINGS COLL HOSP,DEPT PAEDIAT SURG,LONDON,ENGLAND.								0	32	32	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 10	1996	312	7027					368	371						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TV698	8611838				2022-12-28	WOS:A1996TV69800031
J	Bossingham, DH; Simpson, FG				Bossingham, DH; Simpson, FG			Lesson of the week - Acute laryngeal obstruction in rheumatoid arthritis	BRITISH MEDICAL JOURNAL			English	Article									CAIRNS BASE HOSP,CAIRNS,QLD 4870,AUSTRALIA									BOLLIGER CT, 1993, CHEST, V104, P1302, DOI 10.1378/chest.104.4.1302; DARKE CS, 1958, BRIT MED J, V2, P1279; GETERUD A, 1986, J RHEUMATOL, V13, P948; GETERUD A, 1991, THESIS U GOTEBORG; LOFGREN RH, 1962, NEW ENGL J MED, V267, P193, DOI 10.1056/NEJM196207262670407; PINALS RS, 1966, BRIT MED J, V1, P842, DOI 10.1136/bmj.1.5491.842; TENHOLTER JBM, 1988, CLIN RHEUMATOL, V7, P288, DOI 10.1007/BF02204472	7	8	8	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 3	1996	312	7026					295	296						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TU507	8611789				2022-12-28	WOS:A1996TU50700029
J	Goldmann, DA; Weinstein, RA; Wenzel, RP; Tablan, OC; Duma, RJ; Gaynes, RP; Schlosser, J; Martone, WJ				Goldmann, DA; Weinstein, RA; Wenzel, RP; Tablan, OC; Duma, RJ; Gaynes, RP; Schlosser, J; Martone, WJ			Strategies to prevent and control the emergence and spread of antimicrobial-resistant microorganisms in hospitals - A challenge to hospital leadership	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							INTENSIVE-CARE UNIT; COAGULASE-NEGATIVE STAPHYLOCOCCI; SPECTRUM BETA-LACTAMASES; NOSOCOMIAL INFECTIONS; PSEUDOMONAS-AERUGINOSA; ENTEROCOCCUS-FAECALIS; HANDWASHING PRACTICES; MUPIROCIN RESISTANCE; EDUCATIONAL OUTREACH; AGENTS	Objective-To provide hospital leaders with strategic goals or actions likely to have a significant impact on antimicrobial resistance, outline outcome and process measures for evaluating progress toward each goal, describe potential barriers to success, and suggest countermeasures and novel improvement strategies. Participants.-A multidisciplinary group of experts was drawn from the following areas: hospital epidemiology and Infection control, infectious diseases (including graduate training programs), clinical practice (including nursing, surgery, internal medicine, and pediatrics), pharmacy, administration, quality improvement, appropriateness evaluation, behavior modification, practice guideline development, medical informatics, and outcomes research, Representatives from appropriate federal agencies, the Joint Commission on Accreditation of Healthcare Organizations, and the pharmaceutical industry also participated. Evidence.-Published literature, guidelines, expert opinion, and practical experience regarding efforts to improve antibiotic utilization and prevent and control the emergence and dissemination of antimicrobial-resistant microorganisms in hospitals. Consensus Process.-Participants were divided into two quality improvement teams: one focusing on improving antimicrobial usage and the other on preventing and controlling transmission of resistant microorganisms. The teams modeled the process a hospital might use to develop and implement a strategic plan to combat antimicrobial resistance. Conclusions.-Ten strategic goals and related process and outcome measures were agreed on, The five strategic goals to optimize antimicrobial use were as follows: optimizing antimicrobial prophylaxis for operative procedures; optimizing choice and duration of empiric therapy; improving antimicrobial prescribing by educational and administrative means, monitoring and providing feedback regarding antibiotic resistance; and defining and implementing health care delivery system guidelines for important types of antimicrobial use, The five strategic goals to detect, report, and prevent transmission of antimicrobial resistant organisms were as follows. to develop a system to recognize and report trends in antimicrobial resistance within the institution; develop a system to rapidly detect and report resistant microorganisms in individual patients and ensure a rapid response by caregivers; increase adherence to basic infection control policies and procedures; incorporate the detection, prevention, and control of antimicrobial resistance into institutional strategic goals and provide the required resources; and develop a plan for identifying, transferring, discharging, and readmitting patients colonized with specific antimicrobial-resistant pathogens.	CHILDRENS HOSP,DEPT QUAL IMPROVEMENT,BOSTON,MA 02115; COOK CTY HOSP,DIV INFECT DIS,CHICAGO,IL 60612; UNIV IOWA HOSP & CLIN,DIV GEN MED,IOWA CITY,IA 52242; CTR DIS CONTROL & PREVENT,HOSP INFECT PROGRAM,NATL CTR INFECT DIS,ATLANTA,GA 30341; NATL FDN INFECT DIS,BETHESDA,MD; CAMBRIDGE HOSP,BOSTON,MA; INST HEALTHCARE IMPROVEMENT,BOSTON,MA	Harvard University; Boston Children's Hospital; John H Stroger Junior Hospital Cook County; University of Iowa; Centers for Disease Control & Prevention - USA; Harvard University; Cambridge Health Alliance; Cambridge Hospital; Institute for Healthcare Improvement	Goldmann, DA (corresponding author), CHILDRENS HOSP,DIV INFECT DIS,DEPT MED,300 LONGWOOD AVE,BOSTON,MA 02115, USA.							ALBERT RK, 1981, NEW ENGL J MED, V304, P146; ALLEN KD, 1987, J HOSP INFECT, V10, P156, DOI 10.1016/0195-6701(87)90142-3; AVORN J, 1983, NEW ENGL J MED, V308, P1457, DOI 10.1056/NEJM198306163082406; AVORN J, 1987, REV INFECT DIS, V9, pS286; BAILLIE L, 1987, J HOSP INFECT, V10, P83, DOI 10.1016/0195-6701(87)90037-5; BILLSTEIN SA, 1994, ANTIMICROB AGENTS CH, V38, P2679, DOI 10.1128/AAC.38.12.2679; BOYCE JM, 1994, J CLIN MICROBIOL, V32, P1148, DOI 10.1128/JCM.32.5.1148-1153.1994; COHEN ML, 1992, SCIENCE, V257, P1050, DOI 10.1126/science.257.5073.1050; CONLY JM, 1989, AM J INFECT CONTROL, V17, P330, DOI 10.1016/0196-6553(89)90002-3; CONNOLLY S, 1993, J MED MICROBIOL, V39, P450, DOI 10.1099/00222615-39-6-450; DANCE DAB, 1987, J HOSP INFECT, V10, P10, DOI 10.1016/0195-6701(87)90027-2; DELLINGER EP, 1994, CLIN INFECT DIS, V18, P422, DOI 10.1093/clinids/18.3.422; DOEBBELING BN, 1992, NEW ENGL J MED, V327, P88, DOI 10.1056/NEJM199207093270205; DUBBERT PM, 1990, INFECT CONT HOSP EP, V11, P191; DURBIN WA, 1981, JAMA-J AM MED ASSOC, V246, P1796, DOI 10.1001/jama.246.16.1796; EHRENKRANZ NJ, 1991, INFECT CONT HOSP EP, V12, P654, DOI 10.2307/30146898; EVANS RS, 1993, M D COMPUT, V10, P17; EVANS RS, 1994, ADV EXP MED BIOL, V349, P87; EVANS RS, 1990, DICP ANN PHARMAC, V24, P351, DOI 10.1177/106002809002400401; EVERITT DE, 1990, INFECT CONT HOSP EP, V11, P578; Field MJ., 1992, GUIDELINES CLIN PRAC; FLYNN DM, 1988, J HOSP INFECT, V11, P367, DOI 10.1016/0195-6701(88)90212-5; GAILLARD JL, 1990, JPEN-PARENTER ENTER, V14, P593, DOI 10.1177/0148607190014006593; GARNER JS, IN PRESS HOSP EPIDEM; GOLDMANN D, 1992, NEW ENGL J MED, V327, P120, DOI 10.1056/NEJM199207093270211; GOLDMANN DA, 1981, J INFECT DIS, V144, P449, DOI 10.1093/infdis/144.5.449; GOLDMANN DA, 1978, J PEDIATR-US, V93, P288, DOI 10.1016/S0022-3476(78)80523-X; GORMAN LJ, 1993, J HOSP INFECT, V23, P27, DOI 10.1016/0195-6701(93)90127-L; GROSS PA, 1994, CLIN INFECT DIS, V18, P428, DOI 10.1093/clinids/18.3.428; HALEY RW, 1982, J INFECT DIS, V145, P875, DOI 10.1093/infdis/145.6.875; HARTSTEIN AI, 1988, AM J MED, V85, P624, DOI 10.1016/S0002-9343(88)80233-X; HILL MN, 1988, AM J PUBLIC HEALTH, V78, P1190, DOI 10.2105/AJPH.78.9.1190; HUYCKE MM, 1991, ANTIMICROB AGENTS CH, V35, P1626, DOI 10.1128/AAC.35.8.1626; JARLIER V, 1988, REV INFECT DIS, V10, P867; JARVIS WR, 1994, LANCET, V344, P1312; JOHANSON WG, 1969, NEW ENGL J MED, V281, P1137, DOI 10.1056/NEJM196911202812101; JOHANSON WG, 1972, ANN INTERN MED, V77, P701, DOI 10.7326/0003-4819-77-5-701; KOSECOFF J, 1987, JAMA-J AM MED ASSOC, V258, P2708, DOI 10.1001/jama.258.19.2708; KUNIN CM, 1987, REV INFECT DIS, V9, pS270; LANGLEY GJ, 1994, QUAL PROG, V27, P81; LARSON E, 1991, INFECT CONT HOSP EP, V12, P422; LARSON E, 1988, AM J INFECT CONTROL, V16, P253, DOI 10.1016/S0196-6553(88)80005-1; LOHR JA, 1991, AM J DIS CHILD, V145, P1198, DOI 10.1001/archpedi.1991.02160100130037; LYNCH P, 1987, ANN INTERN MED, V107, P243, DOI 10.7326/0003-4819-107-2-243; MAKI DG, 1982, NEW ENGL J MED, V307, P1562, DOI 10.1056/NEJM198212163072507; MAKI DG, 1990, 30TH INT C ANT AG CH; MARR JJ, 1988, J INFECT DIS, V157, P869, DOI 10.1093/infdis/157.5.869; MURRAY BE, 1990, CLIN MICROBIOL REV, V3, P46, DOI 10.1128/CMR.3.1.46-65.1990; NAGUIB MH, 1993, CHEMOTHERAPY, V39, P400, DOI 10.1159/000238984; OLSON B, 1985, J INFECT DIS, V152, P769, DOI 10.1093/infdis/152.4.769; OSANO E, 1994, ANTIMICROB AGENTS CH, V38, P71, DOI 10.1128/AAC.38.1.71; PANLILIO AL, 1992, INFECT CONT HOSP EP, V13, P582; PESTOTNIK SL, 1990, AM J MED, V88, P43, DOI 10.1016/0002-9343(90)90126-X; RANSON MR, 1990, J HOSP INFECT, V15, P95, DOI 10.1016/0195-6701(90)90025-J; REICHLER MR, 1995, J INFECT DIS, V171, P1491, DOI 10.1093/infdis/171.6.1491; RICE LB, 1990, ANTIMICROB AGENTS CH, V34, P2193, DOI 10.1128/AAC.34.11.2193; RILEY LW, 1984, J INFECT DIS, V150, P236, DOI 10.1093/infdis/150.2.236; RUHNKE M, 1994, J CLIN MICROBIOL, V32, P2092, DOI 10.1128/JCM.32.9.2092-2098.1994; RYDBERG J, 1994, SCAND J INFECT DIS, V26, P317, DOI 10.3109/00365549409011801; SCHABERG DR, 1992, ANTIMICROB AGENTS CH, V36, P2533, DOI 10.1128/AAC.36.11.2533; Soumerai S B, 1990, Qual Assur Health Care, V2, P37; SOUMERAI SB, 1993, MED CARE, V31, P552, DOI 10.1097/00005650-199306000-00009; SOUMERAI SB, 1986, MED CARE, V24, P313, DOI 10.1097/00005650-198604000-00003; SOUMERAI SB, 1990, JAMA-J AM MED ASSOC, V263, P549, DOI 10.1001/jama.263.4.549; SOUMERAI SB, 1987, MED CARE, V25, P210, DOI 10.1097/00005650-198703000-00005; SPAFFORD PS, 1994, J PEDIATR-US, V125, P259, DOI 10.1016/S0022-3476(94)70208-X; SPROAT LJ, 1994, J HOSP INFECT, V26, P137, DOI 10.1016/0195-6701(94)90057-4; UDO EE, 1994, J HOSP INFECT, V26, P157, DOI 10.1016/0195-6701(94)90038-8; WADE JJ, 1991, J HOSP INFECT, V18, P211, DOI 10.1016/0195-6701(91)90145-X; WATANABE N, 1992, J ANTIMICROB CHEMOTH, V30, P633, DOI 10.1093/jac/30.5.633; WEINSTEIN RA, 1981, AM J MED, V70, P449; WEINSTEIN RA, 1991, AM J MED, V30, P2525; WELLS VD, 1992, ANN INTERN MED, V116, P285, DOI 10.7326/0003-4819-116-4-285; WINGARD JR, 1994, CLIN INFECT DIS, V19, pS49, DOI 10.1093/clinids/19.Supplement_1.S49; WOODWARD RS, 1987, AM J MED, V83, P817, DOI 10.1016/0002-9343(87)90636-X; ZERVOS MJ, 1987, ANN INTERN MED, V106, P687, DOI 10.7326/0003-4819-106-5-687; 1995, INFECT CONT HOSP EP, V16, P105; 1988, MMWR-MORBID MORTAL W, V37, P377; 1992, QUALITY IMPROVEMENT; 1993, MMWR-MORBID MORTAL W, V42, P597; 1992, INFECT CONT HOSP EP, V13, P599	81	601	626	0	95	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 17	1996	275	3					234	240		10.1001/jama.275.3.234	http://dx.doi.org/10.1001/jama.275.3.234			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TP282	8604178				2022-12-28	WOS:A1996TP28200033
J	Goodman, RB; Lakshminarayan, S				Goodman, RB; Lakshminarayan, S			Inflammatory autobullectomy	NEW ENGLAND JOURNAL OF MEDICINE			English	Article											Goodman, RB (corresponding author), VET AFFAIRS MED CTR,SEATTLE,WA 98108, USA.								0	5	7	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 23	1996	334	21					1372	1373		10.1056/NEJM199605233342105	http://dx.doi.org/10.1056/NEJM199605233342105			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UL251	8614423				2022-12-28	WOS:A1996UL25100005
J	Owens, DK; Holodniy, M; Garber, AM; Scott, J; Sonnad, S; Moses, L; Kinosian, B; Schwartz, JS				Owens, DK; Holodniy, M; Garber, AM; Scott, J; Sonnad, S; Moses, L; Kinosian, B; Schwartz, JS			Polymerase chain reaction for the diagnosis of HIV infection in adults - A meta-analysis with recommendations for clinical practice and study design	ANNALS OF INTERNAL MEDICINE			English	Review						human immunodeficiency virus; human immunodeficiency virus infections; polymerase chain reaction; meta-analysis; sensitivity and specificity	HUMAN-IMMUNODEFICIENCY-VIRUS; BLOOD MONONUCLEAR-CELLS; SERONEGATIVE HOMOSEXUAL MEN; INTRAVENOUS-DRUG-USERS; AT-RISK INDIVIDUALS; AMPLIFIED VIRAL-DNA; TYPE-1 INFECTION; PERIPHERAL-BLOOD; PROVIRAL DNA; GENE AMPLIFICATION	Purpose: To do a meta-analysis of studies that have evaluated the sensitivity and specificity of polymerase chain reaction (PCR) assay for the diagnosis of human immunodeficiency virus (HIV) infection in adults. Evaluating the performance of PCR is difficult because in certain clinical situations, the sensitivity or specificity of PCR may exceed those of the current reference standard tests (enzyme immunoassay followed by confirmatory Western blot analysis). Therefore, an additional goal was to develop recommendations for 1) the design of future evaluative studies of PCR and 2) the use of PCR in persons with suspected HIV infection. Data Sources: Studies published between 1988 and 1994 that were identified in a search of 17 computer databases, including MEDLINE, and abstracts identified from conference proceedings. Study Selection: Studies were included if DNA amplification by PCR was done on peripheral blood mononuclear cells from adults. Ninety-six studies met the inclusion criteria. Data Extraction: Data were extracted independently by two reviewers. Study design was assessed independently by two investigators blinded to study results. Results: Reported sensitivities for PCR range from 10% to 100%, and specificities range from 40% to 100%. A summary receiver-operating characteristic curve based on all 96 studies has a maximum joint sensitivity and specificity (upper left point on the curve, where sensitivity equals specificity) of 97.0% to 98.1%. If the threshold value that defines a positive PCR result is chosen so that sensitivity is higher than 98.1%, specificity will decrease to less than 98.1%. Conversely, if the threshold value that defines a positive PCR result is chosen so that specificity is greater than 98.1%, sensitivity will decrease to less than 98.1%. If sensitivity and specificity are chosen to be equal, the corresponding false-positive rate is 1.9% to 3.0%. At the maximum joint sensitivity and specificity, the positive predictive value of PCR ranges from 34% to 85% as the prevalence of HIV increases from 1.0% to 10%. We identified seven areas in which study design could be modified to 1) reduce susceptibility to bias in estimates of the sensitivity and specificity of PCR and 2) to increase the generalizability of the study results. These modifications will also help to overcome methodologic problems created by the lack of a reference standard test. Conclusions: The PCR assay is not sufficiently accurate to be used for the diagnosis of HIV infection without confirmation. Use of PCR for the diagnosis of HIV in adults should be limited to situations in which antibody tests are known to be insufficient. Future studies of PCR performance should be sufficiently large and should use adequate reference standard tests and standardized methods for the performance of PCR. Specimens should be evaluated by persons blinded to clinical status and to the results of other diagnostic tests for HIV infection.	STANFORD UNIV, DEPT HLTH RES & POLICY, STANFORD, CA 94305 USA; DEPT VET AFFAIRS MED CTR, PHILADELPHIA, PA 19104 USA; UNIV PENN, PHILADELPHIA, PA 19104 USA	Stanford University; University of Pennsylvania; Pennsylvania Medicine; US Department of Veterans Affairs; Veterans Health Administration (VHA); Philadelphia Veterans Affairs Medical Center; University of Pennsylvania	Owens, DK (corresponding author), VET AFFAIRS PALO ALTO HLTH CARE SYST, GEN INTERNAL MED SECT 111A, 3801 MIRANDA AVE, PALO ALTO, CA 94304 USA.		Garber, Alan M/F-1476-2010	Holodniy, Mark/0000-0002-6655-7982	NIAID NIH HHS [AI27762-04] Funding Source: Medline; PHS HHS [IIR91-044.A] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P30AI027762] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABBOTT MA, 1988, J INFECT DIS, V158, P1158, DOI 10.1093/infdis/158.6.1158; AIUTI F, 1993, VACCINE, V11, P538, DOI 10.1016/0264-410X(93)90226-N; ALBERT J, 1990, J CLIN MICROBIOL, V28, P1560, DOI 10.1128/JCM.28.7.1560-1564.1990; ALTER HJ, 1990, NEW ENGL J MED, V323, P1312, DOI 10.1056/NEJM199011083231905; [Anonymous], 1982, JACKKNIFE BOOTSTRAP; ARKIN CF, 1990, JAMA-J AM MED ASSOC, V263, P275, DOI 10.1001/jama.263.2.275; AYEHUNIE S, 1990, J ACQ IMMUN DEF SYND, V3, P975; BAGNARELLI P, 1991, J VIROL METHODS, V32, P31, DOI 10.1016/0166-0934(91)90182-Y; BAILLY E, 1992, TRANSFUSION, V32, P104, DOI 10.1046/j.1537-2995.1992.32292180136.x; BOURNIQUE B, 1992, MOL CELL PROBE, V6, P443, DOI 10.1016/0890-8508(92)90040-5; BRETTLER DB, 1992, BLOOD, V80, P2396; BRUISTEN SM, 1991, VOX SANG, V61, P24, DOI 10.1111/j.1423-0410.1991.tb00922.x; BRUISTEN SM, 1992, J INFECT DIS, V166, P620, DOI 10.1093/infdis/166.3.620; BUSCH MP, 1991, NEW ENGL J MED, V325, P1, DOI 10.1056/NEJM199107043250101; CASSOL S, 1991, MOL CELL PROBE, V5, P157, DOI 10.1016/0890-8508(91)90011-8; CASSOL S, 1991, J CLIN MICROBIOL, V29, P667, DOI 10.1128/JCM.29.4.667-671.1991; CELUM CL, 1991, J INFECT DIS, V164, P656, DOI 10.1093/infdis/164.4.656; CHADWICK EG, 1989, J INFECT DIS, V160, P954, DOI 10.1093/infdis/160.6.954; CONWAY B, 1990, J ACQ IMMUN DEF SYND, V3, P1059; COUTLEE F, 1990, AIDS RES HUM RETROV, V6, P775, DOI 10.1089/aid.1990.6.775; COUTLEE F, 1994, AM J MED, V96, P42, DOI 10.1016/0002-9343(94)90114-7; COUTLEE F, 1991, J CLIN MICROBIOL, V29, P2461; DAHLEN PO, 1991, J CLIN MICROBIOL, V29, P798; DANNATT AHG, 1992, CLIN LAB HAEMATOL, V14, P1; DAWOOD MR, 1992, J CLIN MICROBIOL, V30, P2279, DOI 10.1128/JCM.30.9.2279-2283.1992; DEFER C, 1992, AIDS, V6, P659, DOI 10.1097/00002030-199207000-00007; DELASALLE C, 1991, ANN HEMATOL, V62, P165, DOI 10.1007/BF01703142; DOCK NL, 1991, ARCH INTERN MED, V151, P525, DOI 10.1001/archinte.151.3.525; EBLE BE, 1992, TRANSFUSION, V32, P503, DOI 10.1046/j.1537-2995.1992.32692367191.x; ENSOLI F, 1990, MOL CELL PROBE, V4, P153, DOI 10.1016/0890-8508(90)90016-S; ENSOLI F, 1991, AIDS, V5, P1195, DOI 10.1097/00002030-199110000-00007; ENSOLI F, 1991, 7 INT C AIDS FLOR 16, P302; FARZADEGAN H, 1993, J INFECT DIS, V168, P327, DOI 10.1093/infdis/168.2.327; FERRERLECOEUR F, 1991, THROMB HAEMOSTASIS, V65, P478; Fleiss JL, 1981, STAT METHODS RATES P; GENESCA J, 1990, J INFECT DIS, V162, P1025, DOI 10.1093/infdis/162.5.1025; GIBBONS J, 1990, BLOOD, V76, P1924; GIBSON KM, 1991, J VIROL METHODS, V32, P277, DOI 10.1016/0166-0934(91)90058-8; GUPTA P, 1992, AIDS, V6, P143, DOI 10.1097/00002030-199202000-00001; HART C, 1988, LANCET, V2, P596; HE YL, 1993, J CLIN MICROBIOL, V31, P1040, DOI 10.1128/JCM.31.5.1040-1047.1993; HENRARD DR, 1993, TRANSFUSION, V33, P405, DOI 10.1046/j.1537-2995.1993.33593255601.x; HEWLETT IK, 1990, J ACQ IMMUN DEF SYND, V3, P714; HOFFMAN RM, 1991, SPINE, V16, P623, DOI 10.1097/00007632-199106000-00005; HOLODNIY M, 1991, J CLIN MICROBIOL, V29, P676, DOI 10.1128/JCM.29.4.676-679.1991; HOLODNIY M, 1993, J ACQ IMMUN DEF SYND, V6, P366; HORSBURGH CR, 1989, LANCET, V2, P637; HORSBURGH CR, 1990, J INFECT DIS, V162, P542, DOI 10.1093/infdis/162.2.542; HURLBUT TA, 1991, AM J CLIN PATHOL, V96, P582, DOI 10.1093/ajcp/96.5.582; IMAGAWA DT, 1989, NEW ENGL J MED, V320, P1458, DOI 10.1056/NEJM198906013202205; JACKSON JB, 1988, JAMA-J AM MED ASSOC, V260, P2236; JACKSON JB, 1993, J CLIN MICROBIOL, V31, P3123, DOI 10.1128/JCM.31.12.3123-3128.1993; JACKSON JB, 1990, J CLIN MICROBIOL, V28, P16, DOI 10.1128/JCM.28.1.16-19.1990; JACKSON JB, 1990, NEW ENGL J MED, V322, P217, DOI 10.1056/NEJM199001253220402; JEHUDACOHEN T, 1990, P NATL ACAD SCI USA, V87, P3972, DOI 10.1073/pnas.87.10.3972; JEHUDACOHEN T, 1992, SCAND J IMMUNOL, V36, P81, DOI 10.1111/j.1365-3083.1992.tb01625.x; KELEN GD, 1993, ANN EMERG MED, V22, P769, DOI 10.1016/S0196-0644(05)80789-9; KELSEY JL, 1986, METHODS OBSERVATIONA; KEMP DJ, 1990, GENE, V94, P223, DOI 10.1016/0378-1119(90)90391-4; KENT DL, 1992, AM J ROENTGENOL, V158, P1135, DOI 10.2214/ajr.158.5.1533084; KENT DL, 1992, INVEST RADIOL, V27, P245, DOI 10.1097/00004424-199203000-00014; KUMAR R, 1989, AIDS RES HUM RETROV, V5, P345, DOI 10.1089/aid.1989.5.345; KUNAKORN M, 1993, AIDS, V7, P1681, DOI 10.1097/00002030-199312000-00025; KWOK S, 1989, HIV DETECTION GENETI, P243; LANDESMAN S, 1991, JAMA-J AM MED ASSOC, V266, P3443, DOI 10.1001/jama.266.24.3443; LEE TH, 1991, AIDS, V5, P683, DOI 10.1097/00002030-199106000-00007; LEE TH, 1991, AIDS, V5, P1201, DOI 10.1097/00002030-199110000-00008; LEFRERE JJ, 1990, VOX SANG, V59, P218, DOI 10.1111/j.1423-0410.1990.tb00240.x; LEFRERE JJ, 1990, LANCET, V335, P1400, DOI 10.1016/0140-6736(90)91277-H; LEFRERE JJ, 1990, LANCET, V336, P1386, DOI 10.1016/0140-6736(90)92947-G; LEFRERE JJ, 1991, NOUV REV FR HEMATOL, V33, P245; LEFRERE JJ, 1991, TRANSFUSION, V31, P205, DOI 10.1046/j.1537-2995.1991.31391165168.x; LI JJ, 1990, LANCET, V335, P1590; LIFSON AR, 1990, J INFECT DIS, V161, P436, DOI 10.1093/infdis/161.3.436; LITTENBERG B, 1992, J GEN INTERN MED, V7, P158, DOI 10.1007/BF02598005; LOCHE M, 1988, LANCET, V2, P418; LUCOTTE G, 1989, MOL CELL PROBE, V3, P299, DOI 10.1016/0890-8508(89)90010-8; LUQUE F, 1993, EUR J CLIN MICROBIOL, V12, P663, DOI 10.1007/BF02009376; LYNCH CE, 1992, J ACQ IMMUN DEF SYND, V5, P433; MACDONALD KL, 1989, ANN INTERN MED, V110, P617, DOI 10.7326/0003-4819-110-8-617; MARIOTTI M, 1990, AIDS, V4, P633, DOI 10.1097/00002030-199007000-00004; MARIOTTI M, 1993, AIDS, V7, P1680, DOI 10.1097/00002030-199312000-00024; MOODLEY D, 1993, AIDS, V7, P1538, DOI 10.1097/00002030-199311000-00027; MOSES LE, 1993, STAT MED, V12, P1293, DOI 10.1002/sim.4780121203; MOSES LE, 1986, THINK EXPLAIN STAT; MULLIS K, 1986, COLD SPRING HARB SYM, V51, P263, DOI 10.1101/SQB.1986.051.01.032; MUSHLIN AI, 1993, JAMA-J AM MED ASSOC, V269, P3146, DOI 10.1001/jama.269.24.3146; Nandi J., 1993, National Medical Journal of India, V6, P156; NIELSEN C, 1991, J ACQ IMMUN DEF SYND, V4, P1107; OU CY, 1988, SCIENCE, V239, P295, DOI 10.1126/science.3336784; OU CY, 1990, AIDS RES HUM RETROV, V6, P1323, DOI 10.1089/aid.1990.6.1323; OWENS DK, 1990, MED INFORMATICS COMP, P70; PALENICEK J, 1992, J ACQ IMMUN DEF SYND, V5, P1204; PAN LZ, 1991, J INFECT DIS, V164, P962, DOI 10.1093/infdis/164.5.962; PERRIN LH, 1990, BLOOD, V76, P641; PHILBRICK JT, 1980, AM J CARDIOL, V46, P807, DOI 10.1016/0002-9149(80)90432-4; QUIROS E, 1993, EUR J EPIDEMIOL, V9, P426, DOI 10.1007/BF00157401; RANSOHOFF DF, 1978, NEW ENGL J MED, V299, P926, DOI 10.1056/NEJM197810262991705; RAPIER JM, 1993, CLIN CHEM, V39, P244; ROBINS J, 1986, BIOMETRICS, V42, P311, DOI 10.2307/2531052; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; SAUVAIGO S, 1993, J CLIN MICROBIOL, V31, P1066, DOI 10.1128/JCM.31.5.1066-1074.1993; SCARLATTI G, 1991, AIDS, V5, P1173, DOI 10.1097/00002030-199110000-00003; SCHECHTER MT, 1991, AIDS, V5, P373, DOI 10.1097/00002030-199104000-00003; SCHMIDT BL, 1991, J VIROL METHODS, V32, P233, DOI 10.1016/0166-0934(91)90054-4; SCHWARTZ JS, 1988, JAMA-J AM MED ASSOC, V259, P2574, DOI 10.1001/jama.259.17.2574; SEVALL JS, 1993, CLIN CHEM, V39, P433; SHEPPARD HW, 1991, J ACQ IMMUN DEF SYND, V4, P277; SHEPPARD HW, 1991, J ACQ IMMUN DEF SYND, V4, P819; SIMMONDS P, 1990, J VIROL, V64, P864, DOI 10.1128/JVI.64.2.864-872.1990; SONNERBORG A, 1990, J MED VIROL, V31, P234, DOI 10.1002/jmv.1890310311; WAGES JM, 1991, J MED VIROL, V33, P58, DOI 10.1002/jmv.1890330112; WHETSELL AJ, 1992, J CLIN MICROBIOL, V30, P845, DOI 10.1128/JCM.30.4.845-853.1992; WILLERFORD DM, 1993, J INFECT DIS, V167, P1414, DOI 10.1093/infdis/167.6.1414; WOLINSKY SM, 1989, ANN INTERN MED, V111, P961, DOI 10.7326/0003-4819-111-12-961; WORMSER GP, 1989, NEW ENGL J MED, V321, P1681, DOI 10.1056/NEJM198912143212413; YAGI MJ, 1991, J INFECT DIS, V164, P183, DOI 10.1093/infdis/164.1.183; YERLY S, 1991, J INFECT DIS, V164, P965, DOI 10.1093/infdis/164.5.965; YOUNG KKY, 1990, AIDS, V4, P389, DOI 10.1097/00002030-199005000-00002; YOURNO J, 1992, J CLIN MICROBIOL, V30, P2887, DOI 10.1128/JCM.30.11.2887-2892.1992; ZACHAR V, 1991, J VIROL METHODS, V33, P391, DOI 10.1016/0166-0934(91)90039-3; ZAZZI M, 1992, J MED VIROL, V38, P172, DOI 10.1002/jmv.1890380304; ZAZZI M, 1993, AIDS RES HUM RETROV, V9, P315, DOI 10.1089/aid.1993.9.315; 1990, MMWR-MORBID MORTAL W, V39, P380	124	44	45	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 1	1996	124	9					803	+		10.7326/0003-4819-124-9-199605010-00004	http://dx.doi.org/10.7326/0003-4819-124-9-199605010-00004			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UG254	8610949				2022-12-28	WOS:A1996UG25400004
J	BenShlomo, Y; White, IR; Marmot, M				BenShlomo, Y; White, IR; Marmot, M			Does the variation in the socioeconomic characteristics of an area affect mortality?	BRITISH MEDICAL JOURNAL			English	Article									UNIV LONDON LONDON SCH HYG & TROP MED, MED STAT UNIT, LONDON WC1E 7HT, ENGLAND	University of London; London School of Hygiene & Tropical Medicine	BenShlomo, Y (corresponding author), UCL, SCH MED, INT CTR HLTH & SOC, DEPT EPIDEMIOL & PUBL HLTH, LONDON WC1E 6BT, ENGLAND.		Marmot, M G/Y-3920-2019; Ben-Shlomo, Yoav/ABD-2004-2021	Marmot, M G/0000-0002-2431-6419; Ben-Shlomo, Yoav/0000-0001-6648-3007; White, Ian/0000-0002-6718-7661	Medical Research Council [G8802774] Funding Source: Medline	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		EAMES M, 1993, BRIT MED J, V307, P1097, DOI 10.1136/bmj.307.6912.1097; HAAN M, 1987, AM J EPIDEMIOL, V125, P989, DOI 10.1093/oxfordjournals.aje.a114637; Putnam R.D., 1994, MAKING DEMOCRACY WOR, DOI DOI 10.2307/206637; SLOGGETT A, 1994, BRIT MED J, V309, P1470, DOI 10.1136/bmj.309.6967.1470; WILKINSON RG, 1992, BRIT MED J, V304, P165, DOI 10.1136/bmj.304.6820.165	5	129	129	0	3	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	APR 20	1996	312	7037					1013	1014						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UG610	8616348				2022-12-28	WOS:A1996UG61000026
J	Choi, OH; Kim, JH; Kinet, JP				Choi, OH; Kim, JH; Kinet, JP			Calcium mobilization via sphingosine kinase in signalling by the Fc epsilon RI antigen receptor	NATURE			English	Article							CELL; TRANSDUCTION; PLATELETS	Calcium mobilization through antigen receptors, including high-affinity IgE receptors (Fc epsilon RI), is thought to be mediated by inositol-1,4,5-trisphosphate production (InsP(3))(1-4). Here we show that antigen clustering of Fc epsilon RI on the rat mast-cell line (RBC 2H3) activates a sphingosine kinase (SK) and produces sphingosine-l-phosphate (S1P), an alternative second messenger for intracellular calcium mobilization, The sphingosine analogue, D-L-threo-dihydrosphingosine (DHS), inhibits the SK enzyme competitively with a dissociation constant, K-i, of 5 to 18 mu M. This inhibition substantially suppresses the Fc epsilon RI-mediated calcium signal, but leaves intact the syk tyrosine kinase activation and the small InsP(3) production. The entire InsP(3)-dependent pathway activated by a transfected G-protein coupled receptor, used here as a positive control, also remained intact. Thus Fc epsilon RI principally utilizes a SK pathway to mobilize calcium.	BETH ISRAEL HOSP,LAB ALLERGY & IMMUNOL,BOSTON,MA 02215; HARVARD UNIV,SCH MED,DEPT PATHOL,BOSTON,MA 02215	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School	Choi, OH (corresponding author), NIAID,LAB ALLERG DIS,NIH,ROCKVILLE,MD 20852, USA.							BEAVEN MA, 1993, IMMUNOL TODAY, V14, P222, DOI 10.1016/0167-5699(93)90167-J; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BUEHRER BM, 1992, J BIOL CHEM, V267, P3154; BUEHRER BM, 1993, ADV LIPID RES, V26, P59; CHOI OH, 1993, J IMMUNOL, V151, P5586; GHOSH TK, 1994, J BIOL CHEM, V269, P22628; JONES SVP, 1991, FEBS LETT, V289, P47, DOI 10.1016/0014-5793(91)80905-I; JOUVIN MHE, 1994, J BIOL CHEM, V269, P5918; KINDMAN LA, 1994, J BIOL CHEM, V269, P13088; KOLANUS W, 1993, CELL, V74, P171, DOI 10.1016/0092-8674(93)90304-9; LOUIE DD, 1976, J BIOL CHEM, V251, P4557; MATTIE M, 1994, J BIOL CHEM, V269, P3181; OLIVERA A, 1993, NATURE, V365, P557, DOI 10.1038/365557a0; SCHARENBERG AM, 1995, EMBO J, V14, P3385, DOI 10.1002/j.1460-2075.1995.tb07344.x; STOFFEL W, 1973, H-S Z PHYSIOL CHEM, V354, P1311, DOI 10.1515/bchm2.1973.354.2.1311; STOFFEL W, 1973, H-S Z PHYSIOL CHEM, V354, P562, DOI 10.1515/bchm2.1973.354.1.562; TAKATA M, 1994, EMBO J, V13, P1341, DOI 10.1002/j.1460-2075.1994.tb06387.x	17	372	385	0	11	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	APR 18	1996	380	6575					634	636						3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UF741	8602265				2022-12-28	WOS:A1996UF74100048
J	Shimoda, K; vanDeursen, J; Sangster, MY; Sarawar, SR; Carson, RT; Tripp, RA; Chu, C; Quelle, FW; Nosaka, T; Vignali, DAA; Doherty, PC; Grosveld, G; Paul, WE; Ihle, JN				Shimoda, K; vanDeursen, J; Sangster, MY; Sarawar, SR; Carson, RT; Tripp, RA; Chu, C; Quelle, FW; Nosaka, T; Vignali, DAA; Doherty, PC; Grosveld, G; Paul, WE; Ihle, JN			Lack of IL-4-induced Th2 response and IgE class switching in mice with disrupted Stat6 gene	NATURE			English	Article							IL-4; GENERATION; INVIVO; CELLS	Signal transducers and activators of transcription (Stats) are activated by tyrosine phosphorylation in response to cytokines, and are thought to mediate many of their functional responses(1-4) Stat6 is activated in response to interleukin (IL)-4 (refs 5,6) and may contribute to various functions including mitogenesis, T-helper cell differentiation and immunoglobulin isotype switching(7). To evaluate the role of Stat6, we generated Stat6-null mice (Stat6(-/-)) by gene disruption in embryonic stem cells. The mice were viable, indicating the lack of a non-redundant function in normal development. Although naive lymphoid cell development was normal, Stat6(-/-) mice were deficient in IL-4-mediated functions including Th2 helper T-cell differentiation, expression of cell surface markers, and immunoglobulin class switching to IgE. In contrast, IL-4-mediated proliferation was only partly affected.	ST JUDE CHILDRENS RES HOSP, DEPT BIOCHEM, MEMPHIS, TN 38105 USA; ST JUDE CHILDRENS RES HOSP, DEPT GENET, MEMPHIS, TN 38105 USA; ST JUDE CHILDRENS RES HOSP, DEPT IMMUNOL, MEMPHIS, TN 38105 USA; NIAID, IMMUNOL LAB, NIH, BETHESDA, MD 20892 USA	St Jude Children's Research Hospital; St Jude Children's Research Hospital; St Jude Children's Research Hospital; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)			Tripp, Ralph/F-5218-2011; Doherty, Peter Charles/C-4185-2013	Tripp, Ralph/0000-0002-2924-9956; Quelle, Frederick/0000-0002-1184-6170; Doherty, Peter Charles/0000-0002-5028-3489; Sangster, Mark/0000-0002-1599-5894				COFFMAN RL, 1993, ADV IMMUNOL, V54, P229, DOI 10.1016/S0065-2776(08)60536-2; COFFMAN RL, 1986, J IMMUNOL, V136, P4538; COVFFMAN RL, 1996, J IMMUNOL, V136, P4538; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Durbin JE, 1996, CELL, V84, P443, DOI 10.1016/S0092-8674(00)81289-1; HOUR J, 1994, SCIENCE, V265, P1701; IHLE JN, 1995, NATURE, V377, P591, DOI 10.1038/377591a0; Ihle JN, 1996, CELL, V84, P331, DOI 10.1016/S0092-8674(00)81277-5; JACOBSON NG, 1995, J EXP MED, V181, P1755, DOI 10.1084/jem.181.5.1755; KATONA IM, 1991, J IMMUNOL, V146, P4215; KOHLER I, 1993, EUR J IMMUNOL, V23, P3066, DOI 10.1002/eji.1830231204; KOPF M, 1993, NATURE, V362, P245, DOI 10.1038/362245a0; KOTANIDES H, 1993, SCIENCE, V262, P1265, DOI 10.1126/science.7694370; KRETSOVALI A, 1995, NUCLEIC ACIDS RES, V23, P2919, DOI 10.1093/nar/23.15.2919; KUHN R, 1991, SCIENCE, V254, P707, DOI 10.1126/science.1948049; LEGROS G, 1990, J EXP MED, V172, P921, DOI 10.1084/jem.172.3.921; LIN JX, 1995, IMMUNITY, V2, P331, DOI 10.1016/1074-7613(95)90141-8; Meraz MA, 1996, CELL, V84, P431, DOI 10.1016/S0092-8674(00)81288-X; NOSAKA T, 1995, SCIENCE, V270, P800, DOI 10.1126/science.270.5237.800; PAUL WE, 1994, CELL, V76, P241, DOI 10.1016/0092-8674(94)90332-8; QUELLE FW, 1995, MOL CELL BIOL, V15, P3336; RICHARDSML, 1994, J IMMUNOL, V22, P3453; Ryan JJ, 1996, IMMUNITY, V4, P123, DOI 10.1016/S1074-7613(00)80677-9; SCHINDLER C, 1994, EMBO J, V13, P1350, DOI 10.1002/j.1460-2075.1994.tb06388.x; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; SEDER RA, 1994, ANNU REV IMMUNOL, V12, P635, DOI 10.1146/annurev.iy.12.040194.003223; SNAPPER CM, 1988, P NATL ACAD SCI USA, V85, P6107, DOI 10.1073/pnas.85.16.6107; SWAIN SL, 1990, J IMMUNOL, V145, P3796; Wang HY, 1996, IMMUNITY, V4, P113, DOI 10.1016/S1074-7613(00)80676-7	29	1072	1096	0	29	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 18	1996	380	6575					630	633		10.1038/380630a0	http://dx.doi.org/10.1038/380630a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UF741	8602264				2022-12-28	WOS:A1996UF74100047
J	Sugita, Y				Sugita, Y			Global plasticity in adult visual cortex following reversal of visual input	NATURE			English	Article							CONNECTIONS; MOTION	THE reversal or displacement of the retinal image by prism spectacles leads to extreme disruption of visually guided behaviour, but after an extended period of visual transformation normal behaviour is gradually restored. It is unclear whether this adaptation involves a change in visual perception(1-5), the learning of new motor responses(6), a modification of the sensorimotor control system(7) or a proprioceptive change in the perceived positions of the body parts(8). Here I describe the effects of visual field reversal on neuronal activity in the monkey visual cortex After a few months of wearing reversing spectacles, some cells in the primary visual cortex began to respond to stimuli presented not only in the contralateral visual field but also in the ipsilateral field. These cells were not selective for orientation or direction of motion, but responded well to a light flash. This result suggests that adaptation to visual field reversal is mediated, at least in part, by a large-scale functional reorganization at an early stage the visual processing pathway.			Sugita, Y (corresponding author), TOYOHASHI UNIV TECHNOL,LAB NEURAL SYST,TOYOHASHI,AICHI 441,JAPAN.							BISHOP PO, 1962, J PHYSIOL-LONDON, V163, P466, DOI 10.1113/jphysiol.1962.sp006990; CUSICK CG, 1984, J COMP NEUROL, V230, P311, DOI 10.1002/cne.902300302; DAY RH, 1967, PSYCHOL BULL, V67, P307, DOI 10.1037/h0024482; GILBERT CD, 1992, NATURE, V356, P150, DOI 10.1038/356150a0; HARRIS CS, 1963, SCIENCE, V140, P812, DOI 10.1126/science.140.3568.812; HELD R, 1963, SCIENCE, V142, P455, DOI 10.1126/science.142.3591.455; Kohler I, 1964, PSYCHOL ISSUES, V3, P1; SHIMOJO S, 1981, PERCEPTION, V10, P391, DOI 10.1068/p100391; SPATZ WB, 1984, NEUROSCI LETT, V48, P49, DOI 10.1016/0304-3940(84)90287-8; Stratton G. M., 1897, PSYCHOL REV, V4, P463, DOI [10.1037/h0075482, DOI 10.1037/H0071173]; Stratton G.M., 1897, PSYCHOL REV, V4, P341, DOI [DOI 10.1037/H0075482, 10.1037/h0075482]; SUGITA Y, 1994, PERCEPT MOTOR SKILL, V79, P1047, DOI 10.2466/pms.1994.79.2.1047; SUGITA Y, 1991, NEUROREPORT, V2, P751, DOI 10.1097/00001756-199112000-00005; TANAKA K, 1993, J NEUROPHYSIOL, V69, P128, DOI 10.1152/jn.1993.69.1.128; Taylor J. g., 1962, BEHAV BASIS PERCEPTI; VANESSEN DC, 1983, TRENDS NEUROSCI, V6, P370, DOI 10.1016/0166-2236(83)90167-4	16	60	60	0	6	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	APR 11	1996	380	6574					523	526		10.1038/380523a0	http://dx.doi.org/10.1038/380523a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	UE663	8606770				2022-12-28	WOS:A1996UE66300048
J	Pullinger, R				Pullinger, R			Lesson of the Week - Something in the air: Survival after dramatic, unsuspected case of accidental carbon monoxide poisoning	BRITISH MEDICAL JOURNAL			English	Article											Pullinger, R (corresponding author), JOHN RADCLIFFE HOSP,DEPT ACCID & EMERGENCY MED,OXFORD OX3 9DU,ENGLAND.							ALAN H, 1992, ARCH EMERG MED, V9, P65; COBB N, 1991, JAMA-J AM MED ASSOC, V266, P659, DOI 10.1001/jama.266.5.659; DOLAN MC, 1987, ANN EMERG MED, V16, P782, DOI 10.1016/S0196-0644(87)80575-9; FOUTCH RG, 1988, AM J EMERG MED, V6, P596, DOI 10.1016/0735-6757(88)90099-X; GAJDOS P, 1991, ARCH ENVIRON HEALTH, V46, P373, DOI 10.1080/00039896.1991.9934405; GASMAN JD, 1990, WESTERN J MED, V153, P656; GUJER HR, 1982, SOZ PRAVENTIV MED, V27, P39, DOI 10.1007/BF02075607; HAMPSON NB, 1994, JAMA-J AM MED ASSOC, V271, P52, DOI 10.1001/jama.271.1.52; HECKERLING PS, 1987, AM J EMERG MED, V5, P201, DOI 10.1016/0735-6757(87)90320-2; JELINEK G, 1994, S PACIFIC UNDERWATER, V24, P126; MILIS L, 1989, Archives Belges de Medecine Sociale Hygiene Medecine du Travail et Medecine Legale, V47, P24; STERNBACH G, 1991, WESTERN J MED, V154, P737; Taudorf K, 1983, Ugeskr Laeger, V145, P3593; Thomsen J L, 1983, Ugeskr Laeger, V145, P3598; WHARTON M, 1989, JAMA-J AM MED ASSOC, V262, P771; 1966, ANESTH ANALG, V45, P664	16	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 6	1996	312	7035					897	898						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UE371	8611885				2022-12-28	WOS:A1996UE37100031
J	Dowswell, T; Thornton, JG; Hewison, J; Lilford, RJL				Dowswell, T; Thornton, JG; Hewison, J; Lilford, RJL			Should there be a trial of home versus hospital delivery in the United Kingdom? Measuring outcomes other than safety is feasible	BRITISH MEDICAL JOURNAL			English	Article											Dowswell, T (corresponding author), UNIV LEEDS,INST EPIDEMIOL & HLTH SERV,LEEDS LS2 9LN,W YORKSHIRE,ENGLAND.		Thornton, Jim/B-8336-2008	Thornton, Jim/0000-0001-9764-6876				CAMPBELL R, 1986, BRIT J OBSTET GYNAEC, V93, P675, DOI 10.1111/j.1471-0528.1986.tb07965.x; CUNNINGHAM JD, 1993, SOC SCI MED, V36, P475, DOI 10.1016/0277-9536(93)90409-W; *DEP HLTH EXP MAT, 1993, REP 1; *HOUS COMM HLTH CO, 1992, WINT REP; *ROY COLL OBST GYN, 1992, RESP REP HOUS COMM H	5	38	39	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 23	1996	312	7033					753	753						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UC166	8605464				2022-12-28	WOS:A1996UC16600032
J	Paterson, CR; Ogston, SA; Henry, RM				Paterson, CR; Ogston, SA; Henry, RM			Life expectancy in osteogenesis imperfecta	BRITISH MEDICAL JOURNAL			English	Article									UNIV DUNDEE,NINEWELLS HOSP & MED SCH,DEPT EPIDEMIOL & PUBL HLTH,DUNDEE DD1 9SY,SCOTLAND; UNIV STRATHCLYDE,DEPT MANAGEMENT SCI,GLASGOW G1 1XH,LANARK,SCOTLAND	University of Dundee; University of Strathclyde	Paterson, CR (corresponding author), UNIV DUNDEE,NINEWELLS HOSP & MED SCH,DEPT BIOCHEM MED,DUNDEE DD1 9SY,SCOTLAND.							BAKER RJ, 1978, GLIM SYSTEM; MATTEI JP, 1994, CLIN RHEUMATOL, V13, P447; PATERSON CR, 1987, ACTA PAEDIATR SCAND, V76, P548, DOI 10.1111/j.1651-2227.1987.tb10519.x; SILLENCE D, 1981, CLIN ORTHOPAEDICS, V159, P11; 1983, MORTALITY STATISTICS	5	44	44	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 10	1996	312	7027					351	351						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TV698	8611834				2022-12-28	WOS:A1996TV69800026
J	Alexander, DA; Naji, AA; Pinion, SB; Mollison, J; Kitchener, HC; Parkin, DE; Abramovich, DR; Russell, IT				Alexander, DA; Naji, AA; Pinion, SB; Mollison, J; Kitchener, HC; Parkin, DE; Abramovich, DR; Russell, IT			Randomised trial comparing hysterectomy with endometrial ablation for dysfunctional uterine bleeding: Psychiatric and psychosocial aspects	BRITISH MEDICAL JOURNAL			English	Article							PREMENSTRUAL SYMPTOMS; PERSONALITY; MORBIDITY	Objective-To compare in psychiatric and psychosocial terms the outcome of hysterectomy and endometrial ablation for the treatment of dysfunctional uterine bleeding. Design-Prospective randomised controlled trial. Setting-Obstetrics and gynaecology department of a large teaching hospital. Subjects-204 women with dysfunctional bleeding for whom hysterectomy would have been the preferred treatment were recruited over 24 months and randomly allocated to hysterectomy (99 women) or to hysteroscopic surgery (transcervical resection (52 women) or laser ablation (53 women)). Main outcome measures-Mental state, marital relationship, psychosocial and sexual adjustment in assessments conducted before the operation and one month, six months, and 12 months later. Results-Both treatments significantly reduced the anxiety and depression present before the operation, and there were no differences in mental health between the groups at 12 months. Hysterectomy did not lead to postoperative psychiatric illness, Sexual interest after the operation did not vary with treatment, Overall, 46 out of 185 (25%) women reported a loss of sexual interest and 50 out of 185 (27%) reported increased sexual interest. Marital relationships were unaffected by surgery. Personality and duration of dysfunctional uterine bleeding played no significant part in determining outcome. Conclusions-Hysteroscopic surgery and hysterectomy have a similar effect on psychiatric and psychosocial outcomes, There is no evidence that hysterectomy leads to postoperative psychiatric illness.	ABERDEEN ROYAL INFIRM,ABERDEEN AB9 2ZD,SCOTLAND; UNIV ABERDEEN,SCH MED,HLTH SERV RES UNIT,ABERDEEN AB9 2ZD,SCOTLAND	University of Aberdeen; University of Aberdeen	Alexander, DA (corresponding author), UNIV ABERDEEN,SCH MED,DEPT MENTAL HLTH,ABERDEEN AB9 2ZD,SCOTLAND.		Russell, Ian T/H-1181-2012					ALEXANDER DA, 1986, J ROY COLL GEN PRACT, V36, P10; ALEXANDER DA, 1993, POLICES STRESS WORK; ANDERSEN TF, 1993, ACTA OBSTET GYN SCAN, V72, P570, DOI 10.3109/00016349309058166; BALLINGER CB, 1977, BRIT J PSYCHIAT, V131, P83, DOI 10.1192/bjp.131.1.83; CARLSON KJ, 1993, NEW ENGL J MED, V328, P856; CHYNOWETH R, 1977, AUST NZ J OBSTET GYN, V17, P40, DOI 10.1111/j.1479-828X.1977.tb02667.x; DERAGOTIS LR, 1986, J PSYCHOSOM RES, V30, P77; DRELLICH M, 1958, J NERV MENT DIS, V27, P332; DWYER N, 1993, BRIT J OBSTET GYNAEC, V100, P237, DOI 10.1111/j.1471-0528.1993.tb15237.x; Eysenck H.J., 1975, MANUAL EYSENCK PERSO; GATH D, 1982, BRIT J PSYCHIAT, V140, P335, DOI 10.1192/bjp.140.4.335; HUFNAGEL V, 1990, NO MORE HYSTERECTOMI; MICHAELIS W, 1971, J GENET PSYCHOL, V118, P223, DOI 10.1080/00221325.1971.10532611; PINION SB, 1994, BRIT MED J, V309, P979, DOI 10.1136/bmj.309.6960.979; RICHARDS DH, 1974, LANCET, V2, P983; Rust J, 1986, SEXUAL MARITAL THERA, V1, P34; RYAN MM, 1989, BRIT J PSYCHIAT, V154, P516, DOI 10.1192/bjp.154.4.516; SPITZER RL, 1983, STRUCTURED CLIN INTE; TAYLOR RJ, 1991, BRIT J GEN PRACT, V41, P55; TRELOAR SA, 1992, AM J OBSTET GYNECOL, V167, P82, DOI 10.1016/S0002-9378(11)91632-9; TSOI MM, 1984, BRIT J CLIN PSYCHOL, V23, P151, DOI 10.1111/j.2044-8260.1984.tb00640.x; UTIAN W H, 1975, International Journal of Gynecology and Obstetrics, V13, P97; VONKRAFFTEBING R, 1988, LEHRBUCH PSYCHIATRIE; WINGO PA, 1985, AM J OBSTET GYNECOL, V152, P803, DOI 10.1016/S0002-9378(85)80067-3; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x; ZUSSMAN L, 1981, AM J OBSTET GYNECOL, V140, P725, DOI 10.1016/0002-9378(81)90730-4; 1987, DIAGNOSTIC STATISTIC	27	91	98	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 3	1996	312	7026					280	284						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	TU507	8611783				2022-12-28	WOS:A1996TU50700021
J	Gao, JH; Parsons, LM; Bower, JM; Xiong, JH; Li, JQ; Fox, PT				Gao, JH; Parsons, LM; Bower, JM; Xiong, JH; Li, JQ; Fox, PT			Cerebellum implicated in sensory acquisition and discrimination rather than motor control	SCIENCE			English	Article							CORTICOPONTINE PROJECTION; ORGANIZATION; MOVEMENT; MONKEY; CORTEX	Recent evidence that the cerebellum is involved in perception and cognition challenges the prevailing view that its primary function is fine motor control. A new alternative hypothesis is that the lateral cerebellum is not activated by the control of movement per se, but is strongly engaged during the acquisition and discrimination of sensory information. Magnetic resonance imaging of the lateral cerebellar output (dentate) nucleus during passive and active sensory tasks confirmed this hypothesis. These findings suggest that the lateral cerebellum may be active during motor, perceptual, and cognitive performances specifically because of the requirement to process sensory data.	UNIV TEXAS, HLTH SCI CTR, SCH MED, RES IMAGING CTR, SAN ANTONIO, TX 78284 USA; CALTECH, PASADENA, CA 91125 USA	University of Texas System; University of Texas Health San Antonio; California Institute of Technology			Fox, Peter/B-4725-2010; Li, Jinqi/F-7778-2010; Bower, James/F-8343-2010	Fox, Peter/0000-0002-0465-2028; Parsons, Lawrence/0000-0001-7498-8742; Xiong, Jinhu/0000-0001-5262-5756	NIDA NIH HHS [P20 DA52176-01] Funding Source: Medline; NIMH NIH HHS [MH/DA52145] Funding Source: Medline	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Baddeley A.D., 1986, WORKING MEMORY THOUG; BOWEN J, 1995, HUMAN BRAIN MAPPING, V2, P255, DOI DOI 10.1002/HBM.460020407; BOWER JM, 1990, J COMP NEUROL, V302, P768, DOI 10.1002/cne.903020409; BOWER JM, 1992, BEHAV BRAIN SCI, V15, P714; BOWER JM, IN PRESS BEHAV BRAIN; BOWER JM, IN PRESS PROG BRAIN; Brodal A, 1981, NEUROLOGICAL ANATOMY; BRODAL P, 1978, BRAIN, V101, P251, DOI 10.1093/brain/101.2.251; Brooks VB, 1981, HDB PHYSL NERVOUS SY, V2, P877; DRAYER B, 1986, AM J ROENTGENOL, V147, P103, DOI 10.2214/ajr.147.1.103; ELLERMAN JM, 1994, NMR BIOMED, V7, P63, DOI 10.1002/nbm.1940070110; FIEZ JA, 1992, BRAIN, V115, P155, DOI 10.1093/brain/115.1.155; FOX PT, 1985, P NATL ACAD SCI USA, V82, P7462, DOI 10.1073/pnas.82.21.7462; Gao J.-H., 1995, Society for Neuroscience Abstracts, V21, P270; GLICKSTEIN M, 1985, J COMP NEUROL, V235, P343, DOI 10.1002/cne.902350306; Holmes G, 1939, BRAIN, V62, P1, DOI 10.1093/brain/62.1.1; Ito M, 1984, CEREBELLUM NEURAL CO; Ivry R B, 1989, J Cogn Neurosci, V1, P136, DOI 10.1162/jocn.1989.1.2.136; KIM SG, 1994, SCIENCE, V265, P949, DOI 10.1126/science.8052851; LEINER HC, 1995, HUMAN BRAIN MAPPING, V2, P244; MIDDLETON FA, 1994, SCIENCE, V266, P458, DOI 10.1126/science.7939688; Parsons L. M., 1995, Society for Neuroscience Abstracts, V21, P272; PARSONS LM, 1995, NATURE, V375, P54, DOI 10.1038/375054a0; PAULIN MG, 1993, BRAIN BEHAV EVOLUT, V41, P39, DOI 10.1159/000113822; Petersen S E, 1989, J Cogn Neurosci, V1, P153, DOI 10.1162/jocn.1989.1.2.153; SABATINI U, 1993, J CEREBR BLOOD F MET, V13, P639, DOI 10.1038/jcbfm.1993.82; SCHMAHMANN JD, 1990, J COMP NEUROL, V295, P299, DOI 10.1002/cne.902950212; SCHMAHMANN JD, 1991, ARCH NEUROL-CHICAGO, V48, P1178, DOI 10.1001/archneur.1991.00530230086029; SCHMAHMANN JD, IN PRESS; SEITZ RJ, 1990, NEUROREPORT, V1, P17; STRICK PL, 1983, J NEUROSCI, V3, P2007; THACH WT, 1978, J NEUROPHYSIOL, V41, P654, DOI 10.1152/jn.1978.41.3.654; THACH WT, 1992, ANNU REV NEUROSCI, V15, P403, DOI 10.1146/annurev.neuro.15.1.403; VANKAN PLE, 1993, J NEUROPHYSIOL, V69, P57, DOI 10.1152/jn.1993.69.1.57; Welker W, 1987, NEW CONCEPTS CEREBEL, P239; WILSON FAW, 1993, SCIENCE, V260, P1955, DOI 10.1126/science.8316836; Xiong JH, 1995, HUM BRAIN MAPP, V3, P287, DOI 10.1002/hbm.460030404	37	533	547	0	27	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 26	1996	272	5261					545	547		10.1126/science.272.5261.545	http://dx.doi.org/10.1126/science.272.5261.545			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UG826	8614803				2022-12-28	WOS:A1996UG82600043
J	Banatvala, JE				Banatvala, JE			HIV testing over Easter	LANCET			English	Editorial Material											Banatvala, JE (corresponding author), GUYS & ST THOMAS NHS TRUST,LONDON,ENGLAND.							*NHS EX, 1995, STRAT REV PATH SERV	1	3	3	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 20	1996	347	9008					1058	1059		10.1016/S0140-6736(96)90272-X	http://dx.doi.org/10.1016/S0140-6736(96)90272-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UG042	8602052				2022-12-28	WOS:A1996UG04200005
J	Essen, LO; Perisic, O; Cheung, R; Katan, M; Williams, RL				Essen, LO; Perisic, O; Cheung, R; Katan, M; Williams, RL			Crystal structure of a mammalian phosphoinositide-specific phospholipase C delta	NATURE			English	Article							BACILLUS-CEREUS; BOVINE BRAIN; PHOSPHATIDYLINOSITOL; REFINEMENT; C-DELTA-1; PROGRAM	Mammalian phosphoinositide-specific phospholipase C enzymes (PI-PLC) act as signal transducers that generate two second messengers, inositol-1,4,5-trisphosphate and diacylglycerol. The 2.4-Angstrom structure of phospholipase C delta 1 reveals a multidomain protein incorporating modules shared by many signalling proteins. The structure suggests a mechanism for membrane attachment and Ca2+-dependent hydrolysis of second-messenger precursors. The regulation and reversible membrane association of PI-PLC may serve as a model for understanding other multidomain enzymes involved in phospholipid signalling.	UNIV CAMBRIDGE, CTR MRC, CTR PROT RES, CAMBRIDGE CB2 2QH, ENGLAND; INST CANC RES, CHESTER BEATTY LABS, CRC, CTR CELL & MOL BIOL, LONDON SW3 6JB, ENGLAND	University of Cambridge; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK			Essen, Lars-Oliver/L-3862-2016	Essen, Lars-Oliver/0000-0003-4272-4026; Perisic, Olga/0000-0002-3842-2896; Williams, Roger/0000-0001-7754-4207	Medical Research Council [MC_U105184308] Funding Source: Medline	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Abrahams JP, 1996, ACTA CRYSTALLOGR D, V52, P30, DOI 10.1107/S0907444995008754; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BRUZIK KS, 1992, BIOCHEMISTRY-US, V31, P5183, DOI 10.1021/bi00137a014; BURKHARD R, 1993, J MOL BIOL, V232, P584; CCP4, 1979, CCP4 SUITE PROGRAMS; CHENG HF, 1995, J BIOL CHEM, V270, P5495, DOI 10.1074/jbc.270.10.5495; CIFUENTES ME, 1993, J BIOL CHEM, V268, P11586; DEKKER LV, 1995, CURR OPIN STRUC BIOL, V5, P396, DOI 10.1016/0959-440X(95)80103-0; DRAYER AL, 1992, J BIOL CHEM, V267, P18387; ELLIS MV, 1993, EUR J BIOCHEM, V213, P339, DOI 10.1111/j.1432-1033.1993.tb17767.x; ELLIS MV, 1995, BIOCHEM J, V307, P69, DOI 10.1042/bj3070069; ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071; FERGUSON KM, 1995, CELL, V83, P1037, DOI 10.1016/0092-8674(95)90219-8; FLICK JS, 1993, MOL CELL BIOL, V13, P5861, DOI 10.1128/MCB.13.9.5861; GAGNE SM, 1995, NAT STRUCT BIOL, V2, P784, DOI 10.1038/nsb0995-784; GRIFFITH OH, 1991, METHOD ENZYMOL, V197, P493; HEINZ DW, 1995, EMBO J, V14, P3855, DOI 10.1002/j.1460-2075.1995.tb00057.x; HERZBERG O, 1986, J BIOL CHEM, V261, P2638; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KAWASAKI H, 1994, PROTEIN PROFILE, V1, P343; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KUBONIWA H, 1995, NAT STRUCT BIOL, V2, P768, DOI 10.1038/nsb0995-768; LEE SB, 1995, CURR OPIN CELL BIOL, V7, P183, DOI 10.1016/0955-0674(95)80026-3; Leslie AGW, 1992, JOINT CCP4 ESF EACMB; LIN GL, 1990, BIOCHEMISTRY-US, V29, P277; MEADOR WE, 1993, SCIENCE, V262, P1718, DOI 10.1126/science.8259515; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; NAKASHIMA S, 1995, BIOCHEM BIOPH RES CO, V211, P364, DOI 10.1006/bbrc.1995.1822; Nicholls A., 1992, GRASP GRAPHICAL REPR; Paterson HF, 1995, BIOCHEM J, V312, P661, DOI 10.1042/bj3120661; QUIOCHO FA, 1989, T AM CRYST ASS, V25, P23; REBECCHI M, 1992, BIOCHEMISTRY-US, V31, P12748, DOI 10.1021/bi00166a006; RHEE SG, 1989, SCIENCE, V244, P546, DOI 10.1126/science.2541501; RHEE SG, 1992, J BIOL CHEM, V267, P12393; RYU SH, 1987, P NATL ACAD SCI USA, V84, P6649, DOI 10.1073/pnas.84.19.6649; SCHEDLER DJA, 1992, DISS ABSTR INT B, V53, P4118; SEITZ SP, 1992, BIOORG MED CHEM LETT, V2, P171, DOI 10.1016/S0960-894X(01)80444-3; SERUNIAN LA, 1989, J BIOL CHEM, V264, P17809; SHELDRICK GM, 1990, ACTA CRYSTALLOGR A, V46, P467, DOI 10.1107/S0108767390000277; SHI JR, 1995, PLANT J, V8, P381, DOI 10.1046/j.1365-313X.1995.08030381.x; SIMOES AP, 1995, FEBS LETT, V365, P155; SMITH MR, 1994, P NATL ACAD SCI USA, V91, P6554, DOI 10.1073/pnas.91.14.6554; SUTTON RB, 1995, CELL, V80, P929, DOI 10.1016/0092-8674(95)90296-1; SWAIRJO MA, 1995, NAT STRUCT BIOL, V2, P968, DOI 10.1038/nsb1195-968; TAYLOR SJ, 1991, NATURE, V350, P516, DOI 10.1038/350516a0; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; TRONRUD DE, 1987, ACTA CRYSTALLOGR A, V43, P489, DOI 10.1107/S0108767387099124; VOLWERK JJ, 1990, BIOCHEMISTRY-US, V29, P8056, DOI 10.1021/bi00487a010; YAGISAWA H, 1994, J BIOL CHEM, V269, P20179; ZHANG M, 1995, NAT STRUCT BIOL, V2, P758, DOI 10.1038/nsb0995-758	50	505	516	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 18	1996	380	6575					595	602		10.1038/380595a0	http://dx.doi.org/10.1038/380595a0			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UF741	8602259				2022-12-28	WOS:A1996UF74100036
J	Kwok, RPS; Laurance, ME; Lundblad, JR; Goldman, PS; Shih, HM; Connor, LM; Marriott, SJ; Goodman, RH				Kwok, RPS; Laurance, ME; Lundblad, JR; Goldman, PS; Shih, HM; Connor, LM; Marriott, SJ; Goodman, RH			Control of cAMP-regulated enhancers by the viral transactivator Tax through CREB and the co-activator CBP	NATURE			English	Article							VIRUS TYPE-I; LONG TERMINAL REPEAT; TRANSCRIPTIONAL ACTIVATION; PROTEIN; BINDING; ELEMENT; GENE; SEQUENCES	The Tax protein of human T-lymphotrophic virus (HTLV)-1 activates expression of the HTLV-1 long terminal repeat through a DNA element that resembles the cellular cyclic AMP-regulated enhancer (CRE)(1,2). Tax contains a transcriptional activation domain(3), but its ability to activate gene expression depends on interactions with cellular CRE-binding proteins such as CREB. Whether Tax can activate the expression of cellular CRE-containing genes has been controversial. Here we show that Tax can activate both the HTLV-1 and consensus cellular CREs, and propose that this activation may occur through mechanisms that are differentially dependent on CREB phosphorylation. Tax not only increases the binding of CREB to the viral CRE but also recruits the transcriptional co-activator CBP4,5 in a manner independent of CREB phosphorylation. In contrast, association of Tax with the cellular CRE occurs through CBP which, in turn, is recruited only in the presence of phosphorylated CREB.	OREGON HLTH SCI UNIV,VOLLUM INST,PORTLAND,OR 97201; BAYLOR COLL MED,DIV MOLEC VIROL,HOUSTON,TX 77030	Oregon Health & Science University; Baylor College of Medicine			Shih, Hsiu-Ming/S-7023-2018					BRAUWEILER A, 1995, J BIOL CHEM, V270, P12814, DOI 10.1074/jbc.270.21.12814; BREEDEN L, 1985, COLD SPRING HARB SYM, V50, P643, DOI 10.1101/SQB.1985.050.01.078; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; FELBER BK, 1985, SCIENCE, V229, P54; FRANKLIN AA, 1993, J BIOL CHEM, V268, P21225; FUJII M, 1991, ONCOGENE, V6, P2349; FUJISAWA J, 1985, P NATL ACAD SCI USA, V82, P2277, DOI 10.1073/pnas.82.8.2277; GITLIN SD, 1993, J VIROL, V67, P7307, DOI 10.1128/JVI.67.12.7307-7316.1993; JAMESON DM, 1995, METHOD ENZYMOL, V246, P283; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; Langton B., 1988, MED VIROL, V8, P295; LORIAUX MM, 1993, P NATL ACAD SCI USA, V90, P9046, DOI 10.1073/pnas.90.19.9046; LUNDBLAD JR, 1995, NATURE, V374, P85, DOI 10.1038/374085a0; MONTMINY MR, 1986, P NATL ACAD SCI USA, V83, P6682, DOI 10.1073/pnas.83.18.6682; PACAUCCARALERTKUN S, 1994, MOL CELL BIOL, V14, P456, DOI 10.1128/MCB.14.1.456; PASKALIS H, 1986, P NATL ACAD SCI USA, V83, P6558, DOI 10.1073/pnas.83.17.6558; PERINI G, 1995, NATURE, V376, P602, DOI 10.1038/376602a0; ROSEN CA, 1985, P NATL ACAD SCI USA, V82, P6502, DOI 10.1073/pnas.82.19.6502; SMITH MR, 1991, J CLIN INVEST, V88, P1038, DOI 10.1172/JCI115364; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WAGNER S, 1993, SCIENCE, V262, P395, DOI 10.1126/science.8211160; WATERMAN ML, 1988, MOL ENDOCRINOL, V2, P14, DOI 10.1210/mend-2-1-14; YIN MJ, 1995, J VIROL, V69, P3420, DOI 10.1128/JVI.69.6.3420-3432.1995; ZHAO LJ, 1992, P NATL ACAD SCI USA, V89, P7070, DOI 10.1073/pnas.89.15.7070	24	300	302	0	5	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	APR 18	1996	380	6575					642	646		10.1038/380642a0	http://dx.doi.org/10.1038/380642a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UF741	8602268				2022-12-28	WOS:A1996UF74100051
J	Schreibmayer, W; Dessauer, CW; Vorobiov, D; Gilman, AG; Lester, HA; Davidson, N; Dascal, N				Schreibmayer, W; Dessauer, CW; Vorobiov, D; Gilman, AG; Lester, HA; Davidson, N; Dascal, N			Inhibition of an inwardly rectifying K+ channel by G-protein alpha-subunits	NATURE			English	Article							BETA-GAMMA; RECEPTORS; EXPRESSION	Cholinergic muscarinic, serotonergic, opioid and several other G-protein-coupled neurotransmitter receptors activate inwardly rectifying K+ channels of the GIRK family, slowing the heartbeat and decreasing the excitability of neuronal cells'. Inhibitory modulation of GIRKs by G-protein-coupled receptors may have important implications in cardiac and brain physiology, Previously G alpha and G beta gamma subunits of heterotrimeric G proteins have both been implicated in channel opening(2,3), but recent studies attribute this role primarily to the G beta gamma dimer that activates GIRKs in a membrane-delimited fashion, probably by direct binding to the channel protein(4-8). We report here that free GTP gamma S-activated G(alpha i1), but not G(alpha i2) or G(alpha i3), potently inhibits G(beta 1 gamma 2)-induced GIRK activity in excised membrane patches of Xenopus oocytes expressing GIRK1. High-affinity but partial inhibition is produced by G(alpha s)-GTP gamma S. G(alpha i1)-GTP gamma S also inhibits G(beta 1 gamma 2)-activated GIRK in atrial myocytes. Antagonistic interactions between G(alpha) and G(beta gamma) may be among the mechanisms determining specificity of G protein coupling to GIRKs.	GRAZ UNIV,INST MED PHYS & BIOPHYS,A-8010 GRAZ,AUSTRIA; UNIV TEXAS,SW MED SCH,DEPT PHARMACOL,DALLAS,TX 75235; TEL AVIV UNIV,SACKLER SCH MED,DEPT PHYSIOL & PHARMACOL,IL-69978 RAMAT AVIV,ISRAEL; CALTECH,DIV BIOL,PASADENA,CA 91125	University of Graz; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Tel Aviv University; Sackler Faculty of Medicine; California Institute of Technology			Dascal, Nathan/O-3915-2015	Dascal, Nathan/0000-0002-5397-4146; Schreibmayer, Wolfgang/0000-0002-4631-7922				ASHFORD MLJ, 1994, NATURE, V370, P456, DOI 10.1038/370456a0; BREITWIESER GE, 1985, NATURE, V317, P538, DOI 10.1038/317538a0; CASEY PJ, 1994, CURR OPIN CELL BIOL, V6, P219, DOI 10.1016/0955-0674(94)90139-2; CLAPHAM DE, 1993, NATURE, V365, P403, DOI 10.1038/365403a0; DASCAL N, 1993, P NATL ACAD SCI USA, V90, P10235, DOI 10.1073/pnas.90.21.10235; Dascal N., 1992, METHODS MOL BIOL VOL, VVolume 13, P205; DOUPNIK CA, 1995, CURR OPIN NEUROBIOL, V5, P268, DOI 10.1016/0959-4388(95)80038-7; DUPRAT F, 1995, BIOCHEM BIOPH RES CO, V212, P657, DOI 10.1006/bbrc.1995.2019; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; HEDIN KE, IN PRESS NEURON; Hille B., 1992, IONIC CHANNELS EXCIT; HUANG CL, 1995, NEURON, V15, P1133, DOI 10.1016/0896-6273(95)90101-9; INABOBE A, 1995, BIOCHEM BIOPH RES CO, V212, P1022; INIGUEZLLUHI JA, 1992, J BIOL CHEM, V267, P23409; ITO H, 1992, J GEN PHYSIOL, V99, P961, DOI 10.1085/jgp.99.6.961; KOZASA T, 1995, J BIOL CHEM, V270, P1734, DOI 10.1074/jbc.270.4.1734; KRAPIVINSKY G, 1995, NATURE, V374, P135, DOI 10.1038/374135a0; KUBO Y, 1993, NATURE, V364, P802, DOI 10.1038/364802a0; LIM NF, 1995, J GEN PHYSIOL, V105, P421, DOI 10.1085/jgp.105.3.421; LINDER ME, 1991, J BIOL CHEM, V266, P4654; LOGOTHETIS DE, 1987, NATURE, V325, P321, DOI 10.1038/325321a0; MATESIC DF, 1991, MOL PHARMACOL, V40, P347; NORTH RA, 1987, P NATL ACAD SCI USA, V84, P5487, DOI 10.1073/pnas.84.15.5487; PFAFFINGER PJ, 1985, NATURE, V317, P538; REUVENY E, 1994, NATURE, V370, P143, DOI 10.1038/370143a0; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; TAUSSIG R, 1993, SCIENCE, V261, P218, DOI 10.1126/science.8327893; TRAUTWEIN W, 1990, REV PHYSL, V52, P257; WICKMAN KD, 1994, NATURE, V368, P255, DOI 10.1038/368255a0; YATANI A, 1987, SCIENCE, V238, P1288, DOI 10.1126/science.2446390	30	97	99	0	5	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	APR 18	1996	380	6575					624	627		10.1038/380624a0	http://dx.doi.org/10.1038/380624a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UF741	8602262				2022-12-28	WOS:A1996UF74100045
J	Hu, H; Aro, A; Payton, M; Korrick, S; Sparrow, D; Weiss, ST; Rotnitzky, A				Hu, H; Aro, A; Payton, M; Korrick, S; Sparrow, D; Weiss, ST; Rotnitzky, A			The relationship of bone and blood lead to hypertension - The normative aging study	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							X-RAY-FLUORESCENCE; PRESSURE RELATIONS; ALCOHOL INTAKE; CONFOUNDERS; HEMOGLOBIN; EXPOSURE; BURDEN	Objective.-To test the hypothesis that long-term lead accumulation, as reflected by levels of lead in bone (as opposed to blood, which reflects recent lead exposure), is associated with an increased odds of developing hypertension. Design.-Case-control study of participants in the Veterans Administration (now Department of Veterans Affairs) Normative Aging Study, a 30-year longitudinal study of men. Participants.-Of 1171 active subjects who were seen between August 1991 and December 1994, 590 (50%) participated in this investigation and had data on all variables of interest. Main Outcome Measures.-Hypertension was defined as taking daily medication for the treatment of hypertension or systolic blood pressure higher than 160 mm Hg or diastolic blood pressure of 96 mm Hg or higher during the time of examination. Levels of lead in the tibia (representing cortical bone) and the patella (representing trabecular bone) were measured in vivo with a K x-ray fluorescence (KXRF) instrument. Levels of lead in blood were measured by graphite furnace atomic absorption spectroscopy. Results.-Blood lead levels were low, ranging from less than 0.05 to 1.35 mu mol/L (<1 to 28 mu g/dL), with a mean (SD) of 0.30 (0.20) mu mol/L (6.3 [4.1] mu g/dL). Bone lead levels were similar to those described in other general populations. In comparison to nonhypertensives, mean levels of lead in blood and both tibia and patella bone lead levels were significantly higher in hypertensive subjects. In a logistic regression model of hypertensive status that began with age, race, body mass index, family history of hypertension, history of ethanol ingestion, pack-years of smoking, dietary sodium intake, dietary calcium intake, blood lead, tibia lead, and patella lead, the variables that remained after backward elimination were body mass index, family history of hypertension, and level of lead in the tibia. An increase from the midpoint of the lowest quintile to the midpoint of the highest quintile of tibia lead from 8 to 37 mu g per gram of bone mineral was associated with an increased odds ratio of hypertension of 1.5. Conclusion.-Our findings suggest that long-term lead accumulation, as reflected by levels of lead in bone, may be an independent risk factor for developing hypertension in men in the general population.	HARVARD UNIV,SCH PUBL HLTH,DEPT ENVIRONM HLTH,OCCUPAT HLTH PROGRAM,BOSTON,MA 02115; HARVARD UNIV,SCH PUBL HLTH,DEPT BIOSTAT,BOSTON,MA 02115; DEPT VET AFFAIRS,NORMAT AGING STUDY,BOSTON,MA	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health	Hu, H (corresponding author), HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,CHANNING LAB,DEPT MED,180 LONGWOOD AVE,BOSTON,MA 02115, USA.				NIEHS NIH HHS [NIEHS ES 05257-01A1, NIEHS 2 P30 ES 00002, NIEHS P42-ES05947] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P42ES005947, P30ES000002, R01ES005257] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BARRY PSI, 1970, BRIT J IND MED, V27, P339; BATUMAN V, 1983, NEW ENGL J MED, V309, P17, DOI 10.1056/NEJM198307073090104; Bell B, 1972, AGING HUM DEVELOP, V3, P4; Burger D E, 1990, Basic Life Sci, V55, P287; Centers for Disease Control, 1991, PREV LEAD POIS YOUNG; COCHRAN WG, 1968, TECHNOMETRICS, V10, P637, DOI 10.2307/1267450; FERRIS BG, 1978, AM REV RESPIR DIS, V118, P1; FINE BP, 1988, TOXICOL APPL PHARM, V93, P388, DOI 10.1016/0041-008X(88)90041-5; GORDON CL, 1993, BRIT J IND MED, V50, P637; GRANDJEAN P, 1989, AM J EPIDEMIOL, V129, P732, DOI 10.1093/oxfordjournals.aje.a115188; HENSE HW, 1994, EPIDEMIOLOGY, V5, P120, DOI 10.1097/00001648-199401000-00018; HERTZPICCIOTTO I, 1993, EPIDEMIOL REV, V15, P352, DOI 10.1093/oxfordjournals.epirev.a036125; HU H, 1989, ENVIRON RES, V49, P295, DOI 10.1016/S0013-9351(89)80074-X; HU H, 1994, JAMA-J AM MED ASSOC, V272, P1512, DOI 10.1001/jama.272.19.1512; HU H, 1990, ARCH ENVIRON HEALTH, V45, P335, DOI 10.1080/00039896.1990.10118752; JONES KW, 1987, INVITRO BOD COMPOSIT, V363, P373; KIM R, 1995, PHYS MED BIOL, V40, P1475, DOI 10.1088/0031-9155/40/9/007; KOPP SJ, 1988, ENVIRON HEALTH PERSP, V78, P91, DOI 10.2307/3430507; LANDRIGAN PJ, 1994, JAMA-J AM MED ASSOC, V271, P239, DOI 10.1001/jama.271.3.239; LANDRIGAN PJ, 1991, ENVIRON HEALTH PERSP, V91, P81, DOI 10.2307/3430987; MANTON WI, 1985, BRIT J IND MED, V42, P168; PERRY HM, 1988, ENVIRON HEALTH PERSP, V78, P107, DOI 10.2307/3430509; PIRKLE JL, 1985, AM J EPIDEMIOL, V121, P246, DOI 10.1093/oxfordjournals.aje.a113995; RABINOWITZ MB, 1991, ENVIRON HEALTH PERSP, V91, P33, DOI 10.2307/3430979; RABINOWITZ MB, 1976, J CLIN INVEST, V58, P260, DOI 10.1172/JCI108467; ROSNER B, 1983, TECHNOMETRICS, V25, P165, DOI 10.2307/1268549; SALTZMAN BE, 1990, ENVIRON RES, V52, P126, DOI 10.1016/S0013-9351(05)80248-8; SCHROEDER HA, 1968, ARCH ENVIRON HEALTH, V17, P965, DOI 10.1080/00039896.1968.10665354; SCHWARTZ J, 1995, ARCH ENVIRON HEALTH, V50, P31, DOI 10.1080/00039896.1995.9955010; SHARP DS, 1990, AM J EPIDEMIOL, V131, P1098, DOI 10.1093/oxfordjournals.aje.a115603; SHARP DS, 1987, MED TOXICOL ADV DRUG, V2, P210, DOI 10.1007/BF03259865; SHARP DS, 1990, AM J EPIDEMIOL, V131, P845, DOI 10.1093/oxfordjournals.aje.a115575; SILBERGELD EK, 1991, ENVIRON HEALTH PERSP, V91, P63, DOI 10.2307/3430984; SOMERVAILLE LJ, 1985, PHYS MED BIOL, V30, P929, DOI 10.1088/0031-9155/30/9/005; TYROLER HA, 1988, ENVIRON HEALTH PERSP, V78, P3, DOI 10.2307/3430491; WARD KD, 1994, INT J OBESITY, V18, P137; WILLETT WC, 1988, AM J EPIDEMIOL, V127, P188, DOI 10.1093/oxfordjournals.aje.a114780	37	242	252	1	11	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 17	1996	275	15					1171	1176		10.1001/jama.275.15.1171	http://dx.doi.org/10.1001/jama.275.15.1171			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UE625	8609684				2022-12-28	WOS:A1996UE62500028
J	Huston, P; Moher, D				Huston, P; Moher, D			Redundancy, disaggregation, and the integrity of medical research	LANCET			English	Article							MULTIPLE PUBLICATION; TRIALS		LOEB MED RES INST,CLIN EPIDEMIOL UNIT,OTTAWA,ON,CANADA; UNIV OTTAWA,DEPT MED,OTTAWA,ON,CANADA; UNIV OTTAWA,DEPT EPIDEMIOL & COMMUNITY MED,OTTAWA,ON,CANADA	University of Ottawa; Ottawa Hospital Research Institute; University of Ottawa; University of Ottawa	Huston, P (corresponding author), UNIV OTTAWA,DEPT FAMILY MED,POB 8650,OTTAWA,ON K1G 0G8,CANADA.			Moher, David/0000-0003-2434-4206; Huston, Patricia/0000-0002-2927-1176				CHOUINARD G, 1993, J CLIN PSYCHOPHARM, V13, P25; COHEN LJ, 1994, PHARMACOTHERAPY, V14, P253; GOTZSCHE PC, 1989, EUR J CLIN PHARMACOL, V36, P429, DOI 10.1007/BF00558064; GOTZSCHE PC, 1989, CONTROL CLIN TRIALS, V10, P31, DOI 10.1016/0197-2456(89)90017-2; HEINRICH K, 1994, PROG NEURO-PSYCHOPH, V18, P129, DOI 10.1016/0278-5846(94)90029-9; HUTH EJ, 1986, ANN INTERN MED, V104, P257, DOI 10.7326/0003-4819-104-2-257; HUTTUNEN MO, 1995, ACTA PSYCHIAT SCAND, V91, P271, DOI 10.1111/j.1600-0447.1995.tb09781.x; KASSIRER JP, 1995, NEW ENGL J MED, V333, P449, DOI 10.1056/NEJM199508173330709; KLEIN MC, 1995, CAN MED ASSOC J, V153, P769; KLEISER E, 1995, J CLIN PSYCHOPHARM S, V15, pS45; LEIZOROVICZ A, 1992, LANCET, V340, P1102, DOI 10.1016/0140-6736(92)93126-8; LINDSTROM E, 1994, PHARMACOPSYCHIATRY, V27, P108, DOI 10.1055/s-2007-1014288; Mahoney M.J., 1977, COGNITIVE THER RES, V1, P161, DOI [10.1007/BF01173636, DOI 10.1007/BF01173636]; MARDER S, RISBEL7; MARDER S, 1992, RISINT3; Marder S R, 1992, Clin Neuropharmacol, V15 Suppl 1 Pt A, p92A; MARDER SR, 1994, AM J PSYCHIAT, V151, P825; MCEVOY JP, 1994, J CLIN PSYCHIAT, V55, P18; MCMILLEN JI, 1982, CURR THER RES CLIN E, V31, P813; MCMILLEN JI, 1977, CURR THER RES CLIN E, V22, P266; MEIBACH RC, 1993, SCHIZOPHR RES, V9, P245; MULLERSPAHN R, 1992, CLIN NEUROPHARMAC S1, V15, pA90; PEUSKENS J, 1995, BRIT J PSYCHIAT, V166, P712, DOI 10.1192/bjp.166.6.712; PEUSKENS J, 1992, RISONT2; RENNIE D, 1994, JAMA-J AM MED ASSOC, V271, P469, DOI 10.1001/jama.271.6.469; SCHULZ KF, 1995, JAMA-J AM MED ASSOC, V274, P1456; SCHULZ KF, 1995, JAMA-J AM MED ASSOC, V273, P408, DOI 10.1001/jama.273.5.408; ZINNER H, 1991, BIOL PSYCHIAT, V29, P247; 1993, JAMA-J AM MED ASSOC, V269, P2282	29	123	126	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 13	1996	347	9007					1024	1026		10.1016/S0140-6736(96)90153-1	http://dx.doi.org/10.1016/S0140-6736(96)90153-1			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UF380	8606568				2022-12-28	WOS:A1996UF38000017
J	MacSween, RM; Williams, HC				MacSween, RM; Williams, HC			Lesson of the week - Seabather's eruption - A case of Caribbean itch	BRITISH MEDICAL JOURNAL			English	Article											MacSween, RM (corresponding author), QUEENS MED CTR,DEPT DERMATOL,NOTTINGHAM NG7 2UH,ENGLAND.			williams, hywel/0000-0002-5646-3093				BURNETT JW, 1986, J AM ACAD DERMATOL, V14, P100, DOI 10.1016/S0190-9622(86)70013-3; BURNETT JW, 1995, TOXICON, V33, P99, DOI 10.1016/0041-0101(94)00145-X; FREUDENTHAL AR, 1993, NEW ENGL J MED, V329, P542, DOI 10.1056/NEJM199308193290805; KOKELJ F, 1995, J AM ACAD DERMATOL, V33, P307, DOI 10.1016/0190-9622(95)90267-8; LOTAN A, 1995, NATURE, V375, P456, DOI 10.1038/375456a0; SAMS WM, 1949, ARCH DERMATOL SYPH, V60, P227, DOI 10.1001/archderm.1949.01530020095013; TOMCHIK RS, 1993, JAMA-J AM MED ASSOC, V269, P1669, DOI 10.1001/jama.269.13.1669; WONG DE, 1994, J AM ACAD DERMATOL, V30, P399, DOI 10.1016/S0190-9622(94)70046-X	8	12	12	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 13	1996	312	7036					957	958						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UF659	8616313	Green Published			2022-12-28	WOS:A1996UF65900025
J	Lasic, DD				Lasic, DD			Doxorubicin in sterically stabilized liposomes	NATURE			English	Article							LONG-CIRCULATING LIPOSOMES; CLEARANCE											BANGHAM AD, 1995, BIOESSAYS, V17, P1081, DOI 10.1002/bies.950171213; BLUME G, 1990, BIOCHIM BIOPHYS ACTA, V1029, P91, DOI 10.1016/0005-2736(90)90440-Y; CEH B, 1995, LANGMUIR, V11, P3356, DOI 10.1021/la00009a016; DAEMEN T, 1995, INT J CANCER, V61, P716, DOI 10.1002/ijc.2910610520; DEGENNES PG, 1987, ADV COLLOID INTERFAC, V27, P189, DOI 10.1016/0001-8686(87)85003-0; GABIZON A, 1994, CANCER RES, V54, P987; GABIZON A, 1994, ACTA ONCOL, V33, P779, DOI 10.3109/02841869409083948; GREGORIADIS G, 1980, FEBS LETT, V119, P43, DOI 10.1016/0014-5793(80)80994-X; HARAN G, 1993, BIOCHIM BIOPHYS ACTA, V1151, P201, DOI 10.1016/0005-2736(93)90105-9; ISRAELACHVILI JN, 1985, SURFACE INTERPARTICL; KLIBANOV AL, 1990, FEBS LETT, V268, P235, DOI 10.1016/0014-5793(90)81016-H; KUHL TL, 1994, BIOPHYS J, V66, P1479, DOI 10.1016/S0006-3495(94)80938-5; LASIC DD, 1992, FEBS LETT, V312, P255, DOI 10.1016/0014-5793(92)80947-F; LASIC DD, 1995, SCIENCE, V267, P1275, DOI 10.1126/science.7871422; LASIC DD, 1991, BIOCHIM BIOPHYS ACTA, V1070, P187, DOI 10.1016/0005-2736(91)90162-2; LASIC DD, 1994, ANGEW CHEM INT EDIT, V33, P1685, DOI 10.1002/anie.199416851; LASIC DD, 1995, BBA-BIOMEMBRANES, V1239, P145, DOI 10.1016/0005-2736(95)00159-Z; LASIC DD, 1993, LIPOSOMES PHYSICS AP; LASIC DD, 1995, CHEM REV, V96, P1601; Lasic DD, 1995, STEALTH LIPOSOMES; MAYHEW EG, 1992, INT J CANCER, V51, P302, DOI 10.1002/ijc.2910510221; Needham D., 1992, J LIPOSOME RES, V2, P411, DOI [10.3109/08982109209010218, DOI 10.3109/08982109209010218]; PAPAHADJOPOULOS D, 1991, P NATL ACAD SCI USA, V88, P11640; SENIOR J, 1991, BIOCHIM BIOPHYS ACTA, V1062, P77, DOI 10.1016/0005-2736(91)90337-8; UZIELY B, 1995, J CLIN ONCOL, V13, P1777, DOI 10.1200/JCO.1995.13.7.1777; VAAGE J, 1992, INT J CANCER, V51, P942, DOI 10.1002/ijc.2910510618; WILLIAMS SS, 1993, CANCER RES, V53, P3964; Zheng S., 2008, LIPOSOME ENCAPSULATE, V3, P575, DOI [proxy.lib.ohio-state.edu/10.3109/08982109309150740, DOI 10.3109/08982109309150740]	28	253	265	3	49	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	APR 11	1996	380	6574					561	562		10.1038/380561a0	http://dx.doi.org/10.1038/380561a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UE663	8606781				2022-12-28	WOS:A1996UE66300061
J	Guttman, A				Guttman, A			High-resolution carbohydrate profiling by capillary gel electrophoresis	NATURE			English	Article								Capillary gel electrophoresis with laser-induced fluorescent detection has been found to be a powerful separation and characterization tool for fluorescently labelled carbohydrates.			Guttman, A (corresponding author), BECKMAN INSTRUMENTS INC,2500 HARBOUR BLVD,FULLERTON,CA 92634, USA.		Guttman, András/GLT-9077-2022					CHIESA C, 1993, J CHROMATOGR, V645, P337, DOI 10.1016/0021-9673(93)83394-8; EVANGELISTA RA, 1995, ANAL CHEM, V67, P2239, DOI 10.1021/ac00109a051; GUTTMAN A, 1995, ELECTROPHORESIS, V16, P1906, DOI 10.1002/elps.11501601314; Guttman A, 1996, ANAL BIOCHEM, V233, P234, DOI 10.1006/abio.1996.0034; Guttman A, 1996, ELECTROPHORESIS, V17, P412, DOI 10.1002/elps.1150170221; JACKSON P, 1994, ANAL BIOCHEM, V216, P243, DOI 10.1006/abio.1994.1038; TOWNSEND RR, 1995, CARBOHYDRATE ANAL; VARKI A, 1993, GLYCOBIOLOGY, V3, P97, DOI 10.1093/glycob/3.2.97	8	111	113	0	25	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	APR 4	1996	380	6573					461	462		10.1038/380461a0	http://dx.doi.org/10.1038/380461a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UD590	8602248				2022-12-28	WOS:A1996UD59000069
J	Fauci, AS; Pantaleo, G; Stanley, S; Weissman, D				Fauci, AS; Pantaleo, G; Stanley, S; Weissman, D			Immunopathogenic mechanisms of HIV infection	ANNALS OF INTERNAL MEDICINE			English	Editorial Material							HUMAN-IMMUNODEFICIENCY-VIRUS; BLOOD DENDRITIC CELLS; SCID-HU MOUSE; CD4+ T-CELLS; BONE-MARROW; TYPE-1; LYMPHOCYTES; THYMUS; MODEL; AIDS	A complex array of multiphasic and multifactorial immunopathogenic mechanisms are involved in the establishment and progression of human immunodeficiency virus (HIV) disease. After primary infection, acute viremia occurs with wide dissemination of HIV. During this early viremic phase, the virus is trapped within the processes of follicular dendritic cells in the germinal centers of lymphoid tissue. Also, during this phase of primary infection, some patients show major expansions of certain subsets of CD8(+) T cells that are identified by the expression of a particular variable region of the beta chain of the T-cell receptor. These expansions are manifestations of responses to HIV that may be important in controlling the progression of HIV infection. in addition, inappropriate immune activation and elevated secretion of certain proinflammatory cytokines occur during HIV infection; these cytokines play a role in the regulation of HIV expression in the tissues. Infection of progenitor cells in bone marrow and the thymus contribute to the lack of regeneration of immuno-competent cells. Dendritic cells are involved in the initiation and propagation of HIV infection in CD4(+) T cells. In studies of long-term nonprogressors-persons who have stable CD4(+) T-cell counts and no HIV disease progression despite years of HIV infection-preserved lymph node architecture, low viral burden, and viral expression were found.					Pantaleo, Giuseppe/K-6163-2016					ALDROVANDI GM, 1993, NATURE, V363, P732, DOI 10.1038/363732a0; ASCHER MS, 1988, CLIN EXP IMMUNOL, V73, P165; BONYHADI ML, 1993, NATURE, V363, P728, DOI 10.1038/363728a0; CAMERON PU, 1992, CLIN EXP IMMUNOL, V88, P226, DOI 10.1111/j.1365-2249.1992.tb03066.x; CAMERON PU, 1992, SCIENCE, V257, P383, DOI 10.1126/science.1352913; CAO YZ, 1995, NEW ENGL J MED, V332, P201, DOI 10.1056/NEJM199501263320401; CLARK SJ, 1991, NEW ENGL J MED, V324, P954, DOI 10.1056/NEJM199104043241404; DAAR ES, 1991, NEW ENGL J MED, V324, P961, DOI 10.1056/NEJM199104043241405; EMBRETSON J, 1993, NATURE, V362, P359, DOI 10.1038/362359a0; FAUCI AS, 1991, ANN INTERN MED, V114, P678, DOI 10.7326/0003-4819-114-8-678; FAUCI AS, 1993, SCIENCE, V262, P1011, DOI 10.1126/science.8235617; FAUCI AS, 1988, SCIENCE, V239, P617, DOI 10.1126/science.3277274; FAUCI AS, 1995, P ASSOC AM PHYSICIAN, V107, P151; FOLKS TM, 1988, SCIENCE, V242, P919, DOI 10.1126/science.2460922; FOLKS TM, 1987, SCIENCE, V238, P800, DOI 10.1126/science.3313729; FOLKS TM, 1989, P NATL ACAD SCI USA, V86, P2365, DOI 10.1073/pnas.86.7.2365; FOX CH, 1991, J INFECT DIS, V164, P1051, DOI 10.1093/infdis/164.6.1051; GRAZIOSI C, 1994, SCIENCE, V265, P248, DOI 10.1126/science.8023143; HARPER ME, 1986, P NATL ACAD SCI USA, V83, P772, DOI 10.1073/pnas.83.3.772; HEATH SL, 1995, NATURE, V377, P740, DOI 10.1038/377740a0; HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0; KARHUMAKI E, 1993, CLIN EXP IMMUNOL, V91, P482; KINTER AL, 1995, J IMMUNOL, V154, P2448; KIRCHHOFF F, 1995, NEW ENGL J MED, V332, P228, DOI 10.1056/NEJM199501263320405; KOUP RA, 1994, J VIROL, V68, P4650, DOI 10.1128/JVI.68.7.4650-4655.1994; LANGHOFF E, 1991, P NATL ACAD SCI USA, V88, P7998, DOI 10.1073/pnas.88.18.7998; LIFSON AR, 1991, J INFECT DIS, V163, P959, DOI 10.1093/infdis/163.5.959; MACATONIA SE, 1990, IMMUNOLOGY, V71, P38; MACATONIA SE, 1992, IMMUNOLOGY, V75, P576; MCCUNE JM, 1988, SCIENCE, V241, P1632, DOI 10.1126/science.2971269; MCWILLIAM AS, 1994, J EXP MED, V179, P1331, DOI 10.1084/jem.179.4.1331; ODOHERTY U, 1993, J EXP MED, V178, P1067, DOI 10.1084/jem.178.3.1067; PANTALEO G, 1990, J IMMUNOL, V144, P1696; PANTALEO G, 1993, NEW ENGL J MED, V328, P327, DOI 10.1056/NEJM199302043280508; PANTALEO G, 1994, NATURE, V370, P463, DOI 10.1038/370463a0; PANTALEO G, 1995, NEW ENGL J MED, V332, P209, DOI 10.1056/NEJM199501263320402; PANTALEO G, 1994, IMMUNOL REV, V140, P105, DOI 10.1111/j.1600-065X.1994.tb00867.x; PANTALEO G, 1993, NATURE, V362, P355, DOI 10.1038/362355a0; PANTALEO G, 1995, ANNU REV IMMUNOL, V13, P487, DOI 10.1146/annurev.immunol.13.1.487; PIATAK M, 1993, SCIENCE, V259, P1749, DOI 10.1126/science.8096089; POLI G, 1994, P NATL ACAD SCI USA, V91, P108, DOI 10.1073/pnas.91.1.108; Poli G, 1993, Semin Immunol, V5, P165, DOI 10.1006/smim.1993.1020; POPE M, 1994, CELL, V78, P389, DOI 10.1016/0092-8674(94)90418-9; SAFRIT JT, 1994, J EXP MED, V179, P463, DOI 10.1084/jem.179.2.463; SCHRAGER LK, 1995, NATURE, V377, P680, DOI 10.1038/377680a0; SCHUURMAN HJ, 1989, AM J PATHOL, V134, P1329; STANLEY SK, 1993, J EXP MED, V178, P1151, DOI 10.1084/jem.178.4.1151; STANLEY SK, 1992, J IMMUNOL, V149, P689; STEINMAN RM, 1991, ANNU REV IMMUNOL, V9, P271, DOI 10.1146/annurev.iy.09.040191.001415; THOMAS R, 1993, J IMMUNOL, V150, P821; TINDALL B, 1991, AIDS, V5, P1, DOI 10.1097/00002030-199101000-00001; WEI XP, 1995, NATURE, V373, P117, DOI 10.1038/373117a0; WEISSMAN D, 1995, J IMMUNOL, V155, P4111; WEISSMAN D, 1995, P NATL ACAD SCI USA, V92, P826, DOI 10.1073/pnas.92.3.826; ZHOU LJ, 1992, J IMMUNOL, V149, P735; ZON LI, 1987, BRIT J HAEMATOL, V66, P251, DOI 10.1111/j.1365-2141.1987.tb01307.x	56	321	348	0	29	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 1	1996	124	7					654	663		10.7326/0003-4819-124-7-199604010-00006	http://dx.doi.org/10.7326/0003-4819-124-7-199604010-00006			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UB513	8607594				2022-12-28	WOS:A1996UB51300006
J	Seaman, J; Mercer, AJ; Sondorp, HE; Herwaldt, BL				Seaman, J; Mercer, AJ; Sondorp, HE; Herwaldt, BL			Epidemic visceral leishmaniasis in southern Sudan: Treatment of severely debilitated patients under wartime conditions and with limited resources	ANNALS OF INTERNAL MEDICINE			English	Article							KALA-AZAR; SODIUM STIBOGLUCONATE; PARASITIC DISEASE; MALNUTRITION; RISK; POPULATION; INFECTION; ADULTS	Objectives: 1) To determine the proportions of patients with visceral leishmaniasis who had various treatment outcomes when cared for under wartime conditions and with limited resources and 2) to identify patient characteristics associated with the outcomes. Design: Cohort study. Setting: Medicins sans Frontieres-Holland's treatment center in Duar, Western Upper Nile province, an area in southern Sudan that has been severely affected by Sudan's civil war and a massive epidemic of visceral leishmaniasis. Patients: 3076 consecutive patients who had visceral leishmaniasis, were admitted to the treatment center the first year the center was operational (August 1990 to July 1991), and were treated with the pentavalent antimonial compound sodium stibogluconate. Measurements: Patient characteristics on admission and four mutually exclusive treatment outcomes (default during first admission, death during first admission, discharge and readmission for retreatment [relapse], and discharge and no readmission for retreatment [successful treatment]). Results: The patients had a median age of 15 years and were notably anemic (median hemoglobin level, 77 g/L) and malnourished (median body mass index of adults [greater than or equal to 18 years of age], 15.2 kg/m(2)); most (91.0%) had been sick less than 5 months. Although patients could not be monitored after treatment to document cure, most (2562 [83.3%]) were successfully treated; 336 (10.9%) died during their first admission, and 79 are known to have relapsed (3.0% of those discharged alive [that is, those whose final treatment outcome was successful treatment or relapse]). In univariable analysis, young and older age (<5 or greater than or equal to 45 years of age), long duration of illness (greater than or equal to 5 months), markedly low hemoglobin level or body mass index, large spleen, high parasite density, and vomiting at least once during the treatment course were associated with death. In multiple logistic regression analysis of data for a subgroup of 1207 adults (those who did not default or relapse and for whom data were recorded on age, sex, duration of illness, hemoglobin level, body mass index, and spleen size), the approximate risk ratios for death were 2.2 (95% CI, 1.4 to 3.6) for those with a long duration of illness, 3.6 (CI, 2.1 to 5.9) for those 45 years of age or older, 4.6 (CI, 2.2 to 9.4) for those with a hemoglobin level less than 60 g/L, and 12.2 (CI, 3.2 to 47.2) for those with a body mass index less than 12 kg/m(2). Conclusion: Despite the severe debility of the patients and the exceptionally difficult circumstances under which they were treated, most fared remarkably well.	CTR DIS CONTROL & PREVENT, DIV PARASIT DIS, ATLANTA, GA 30341 USA; MED SANS FRONTIERES HOLLAND, AMSTERDAM, NETHERLANDS	Centers for Disease Control & Prevention - USA								ASHFORD RW, 1992, T ROY SOC TROP MED H, V86, P379, DOI 10.1016/0035-9203(92)90229-6; ASHFORD RW, 1992, PARASITOL TODAY, V8, P104, DOI 10.1016/0169-4758(92)90249-2; BADARO R, 1986, J INFECT DIS, V154, P639, DOI 10.1093/infdis/154.4.639; BAKER RJ, 1978, GLIM MANUAL RELEASE; CAMPOS N, 1989, AM J EPIDEMIOL, V129, P439, DOI 10.1093/oxfordjournals.aje.a115148; CERF BJ, 1987, J INFECT DIS, V156, P1030, DOI 10.1093/infdis/156.6.1030; CHULAY JD, 1983, AM J TROP MED HYG, V32, P475, DOI 10.4269/ajtmh.1983.32.475; DEBEER P, 1990, LANCET, V335, P224, DOI 10.1016/0140-6736(90)90313-T; DEBEER P, 1991, AM J TROP MED HYG, V44, P283, DOI 10.4269/ajtmh.1991.44.283; DYE C, 1993, P ROY SOC B-BIOL SCI, V254, P33, DOI 10.1098/rspb.1993.0123; GASSER RA, 1994, CLIN INFECT DIS, V18, P83, DOI 10.1093/clinids/18.1.83; GOLDEN MHN, 1993, LANCET, V342, P360, DOI 10.1016/0140-6736(93)91491-4; HARITH AE, 1986, T ROY SOC TROP MED H, V80, P583, DOI 10.1016/0035-9203(86)90149-5; HARRISON LH, 1986, REV INFECT DIS, V8, P447; HENRY CJK, 1990, EUR J CLIN NUTR, V44, P329; HERWALDT BL, 1992, AM J TROP MED HYG, V46, P296, DOI 10.4269/ajtmh.1992.46.296; HOOGSTRAAL H, 1969, AM J TROP MED HYG, V18, P1091, DOI 10.4269/ajtmh.1969.18.1091; JAMES WPT, 1988, EUR J CLIN NUTR, V42, P969; LIGHTNER LK, 1983, AM J TROP MED HYG, V32, P296, DOI 10.4269/ajtmh.1983.32.296; MANSONBAHR PE, 1987, MANSONS TROPICAL DIS, P43; MENGESHA B, 1978, TROP GEOGR MED, V30, P199; PEARSON RD, 1992, AM J TROP MED HYG, V47, P8, DOI 10.4269/ajtmh.1992.47.8; PEREA WA, 1991, T ROY SOC TROP MED H, V85, P48, DOI 10.1016/0035-9203(91)90152-O; SEAMAN J, 1993, J INFECT DIS, V168, P715, DOI 10.1093/infdis/168.3.715; SEAMAN J, 1995, CLIN INFECT DIS, V21, P188, DOI 10.1093/clinids/21.1.188; SEAMAN J, 1992, ANN TROP MED PARASIT, V86, P481, DOI 10.1080/00034983.1992.11812697; SEAMAN J, IN PRESS INT J EPIDE; THAKUR CP, 1991, AM J TROP MED HYG, V45, P435, DOI 10.4269/ajtmh.1991.45.435; THAKUR CP, 1984, T ROY SOC TROP MED H, V78, P391, DOI 10.1016/0035-9203(84)90131-7; *UN, 1985, WORLD POP PROSP EST; ZIJLSTRA EE, 1992, J TROP PEDIATRICS, V38, P17, DOI 10.1093/tropej/38.1.17; ZIJLSTRA EE, 1991, T ROY SOC TROP MED H, V85, P365, DOI 10.1016/0035-9203(91)90293-8; 1991, TROPICALDIS RES NEWS, V37, P1; 1991, TROPICAL DIS RES NEW, V37, P1	34	88	94	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 1	1996	124	7					664	672		10.7326/0003-4819-124-7-199604010-00007	http://dx.doi.org/10.7326/0003-4819-124-7-199604010-00007			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UB513	8607595				2022-12-28	WOS:A1996UB51300007
J	Druey, KM; Blumer, KJ; Kang, VH; Kehrl, JH				Druey, KM; Blumer, KJ; Kang, VH; Kehrl, JH			Inhibition of C-protein-mediated MAP kinase activation by a new mammalian gene family	NATURE			English	Article							PHEROMONE RESPONSE PATHWAY; ALPHA-FACTOR PHEROMONES; SACCHAROMYCES-CEREVISIAE; G1 ARREST; A-FACTOR; DESENSITIZATION; PHOSPHORYLATION; RECEPTOR	A GENERAL property of signal transduction pathways is that prolonged stimulation decreases responsiveness, a phenomenon termed desensitization. Yeast cells stimulated with mating pheromone activate a heterotrimeric G-protein-linked, MAP-kinase-dependent signalling pathway that induces G1-phase cell-cycle arrest and morphological differentiation (reviewed in refs 1, 2). Eventually the cells desensitize to pheromone and resume growth(3). Genetic studies have demonstrated the relative importance of a desensitization mechanism that uses the SST2 gene product, Sst2p(4-7). Here we identify a mammalian gene family termed RGS (for regulator of G-protein signalling) that encodes structural and functional homologues of Sst2p. Introduction of RGS family members into yeast blunts signal transduction through the pheromone-response pathway. Like SST2 (refs 8-10), they negatively regulate this pathway at a point upstream or at the level of the G protein. The RGS family members also markedly impair MAP kinase activation by mammalian G-protein-linked receptors, indicating the existence and importance of an SST2-like desensitization mechanism in mammalian cells.	NIAID, IMMUNOREGULAT LAB, BETHESDA, MD 20892 USA; WASHINGTON UNIV, SCH MED, DEPT CELL BIOL & PHYSIOL, ST LOUIS, MO 63110 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Washington University (WUSTL)			Kehrl, John/AAE-6292-2019; Blumer, Kendall J/C-5268-2012	Kehrl, John/0000-0002-6526-159X				ADAMS TH, 1992, MOL CELL BIOL, V12, P3827, DOI 10.1128/MCB.12.9.3827; BLINDER D, 1989, MOL CELL BIOL, V9, P3720, DOI 10.1128/MCB.9.9.3720; CAIRNS BR, 1992, GENE DEV, V6, P1305, DOI 10.1101/gad.6.7.1305; CHAN RK, 1982, MOL CELL BIOL, V2, P21, DOI 10.1128/MCB.2.1.21; CHAN RK, 1982, MOL CELL BIOL, V2, P11, DOI 10.1128/MCB.2.1.11; DEVRIES L, 1995, P NATL ACAD SCI USA, V92, P11916, DOI 10.1073/pnas.92.25.11916; DIETZEL C, 1987, MOL CELL BIOL, V7, P4169, DOI 10.1128/MCB.7.12.4169; DOHLMAN HG, 1995, MOL CELL BIOL, V15, P3635; DOHMEN RJ, 1991, P NATL ACAD SCI USA, V88, P7351, DOI 10.1073/pnas.88.16.7351; FRANKLIN RA, 1993, J IMMUNOL, V151, P1802; HASSON MS, 1994, MOL CELL BIOL, V14, P1054, DOI 10.1128/MCB.14.2.1054; HONG JX, 1993, J IMMUNOL, V150, P3895; Koelle MR, 1996, CELL, V84, P115, DOI 10.1016/S0092-8674(00)80998-8; KURJAN J, 1993, ANNU REV GENET, V27, P147; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; MADURA K, 1994, SCIENCE, V265, P1454, DOI 10.1126/science.8073290; MAZER BD, 1992, J CLIN INVEST, V90, P759, DOI 10.1172/JCI115948; MOORE SA, 1984, J BIOL CHEM, V259, P1004; MURPHY PM, 1991, SCIENCE, V253, P1280, DOI 10.1126/science.1891716; NEWTON JS, 1993, BIOCHIM BIOPHYS ACTA, V1216, P314, DOI 10.1016/0167-4781(93)90163-8; SIDEROVSKI DP, 1994, DNA CELL BIOL, V13, P125, DOI 10.1089/dna.1994.13.125; SPRAGUE GF, 1992, PHEROMONE RESPONSE S, P657; STEVEN BJ, 1989, MOL GEN GENET, V219, P421, DOI 10.1007/BF00259615; THEVENIN C, 1993, J BIOL CHEM, V268, P5949; VANLINT J, 1993, MOL CELL BIOCHEM, V128, P171, DOI 10.1007/BF01076768; WEINER JL, 1993, J BIOL CHEM, V268, P8070; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0	28	415	433	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 22	1996	379	6567					742	746		10.1038/379742a0	http://dx.doi.org/10.1038/379742a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TW567	8602223	Green Submitted			2022-12-28	WOS:A1996TW56700057
J	Gharib, H				Gharib, H			Subclinical hyperthyroidism	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter											Gharib, H (corresponding author), MAYO CLIN & MAYO FDN,DIV ENDOCRINOL METAB & MED,ROCHESTER,MN 55905, USA.							ROSS DS, 1991, ADV ENDOCRINOL METAB, V2, P89; SAWIN CT, 1994, NEW ENGL J MED, V331, P1249, DOI 10.1056/NEJM199411103311901	2	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 21	1996	275	7					513	513						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TV569	8606463				2022-12-28	WOS:A1996TV56900010
J	Barza, M; Ioannidis, JPA; Cappelleri, JC; Lau, J				Barza, M; Ioannidis, JPA; Cappelleri, JC; Lau, J			Single or multiple daily doses of aminoglycosides: A meta-analysis	BRITISH MEDICAL JOURNAL			English	Article							GRAM-NEGATIVE INFECTIONS; FEBRILE NEUTROPENIC PATIENTS; DAILY NETILMICIN REGIMENS; URINARY-TRACT INFECTION; COMPARATIVE TRIAL; DOSAGE REGIMEN; PSEUDOMONAS-AERUGINOSA; COMBINATION THERAPY; ADAPTIVE RESISTANCE; GENTAMICIN THERAPY	Objective-To assess relative efficacy and toxicity of aminoglycosides given by single daily dose compared with multiple daily doses. Design-Meta-analysis of 21 randomised trials identified through MEDLARS (1966 to January 1995). Data were overviewed with fixed effects and random effects models and with meta-regression analysis. Subjects-Total of 3091 patients with bacterial infection, most without pre-existing renal disease. Interventions-Patients were randomised to receive aminoglycosides once daily or multiple times daily with similar total daily dose. Main outcome measures-Clinical failure of treatment, nephrotoxicity, ototoxicity, and mortality. Results-Single daily dose regimen produced a non-significant decrease in risk of antibiotic failures (random effects risk ratio 0.83 (95% confidence interval 0.57 to 1.21)). Benefit of once daily dosing was greater when the percentage of pseudomonas isolates in a trial was larger. Once daily administration reduced risk of nephrotoxicity (fixed effects risk ratio 0.74 (0.54 to 1.00)). Similar trends were noted for patients with febrile neutropenia and for children. There was no significant difference in ototoxicity between the two dosing regimens, but the power of the pooled trials to detect a meaningful difference was low. There was no significant difference in mortality. Conclusions-Once daily administration of aminoglycosides in patients without pre-existing renal impairment is as effective as multiple daily dosing, has a lower risk of nephrotoxicity, and no greater risk of ototoxicity. Given the additional convenience and reduced cost, once daily dosing should be the preferred mode of administration.	TUFTS UNIV,NEW ENGLAND MED CTR HOSP,SCH MED,DIV CLIN CARE RES,BOSTON,MA 02111	Tufts Medical Center; Tufts University	Barza, M (corresponding author), TUFTS UNIV,SCH MED,NEW ENGLAND MED CTR HOSP,DIV GEOG MED & INFECT DIS,BOSTON,MA 02111, USA.		Ioannidis, John P. A./G-9836-2011		AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [R01HS007782] Funding Source: NIH RePORTER; AHRQ HHS [R01 HS07782] Funding Source: Medline	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		ANDERSON ET, 1976, AM J MED, V61, P493, DOI 10.1016/0002-9343(76)90328-4; ARONOFF GR, 1983, ANTIMICROB AGENTS CH, V23, P74, DOI 10.1128/AAC.23.1.74; BAMONTE F, 1990, CHEMOTHERAPY, V36, P41, DOI 10.1159/000238747; BENNETT WM, 1979, J INFECT DIS, V140, P576, DOI 10.1093/infdis/140.4.576; BLASER J, 1987, ANTIMICROB AGENTS CH, V31, P1054, DOI 10.1128/AAC.31.7.1054; Bracken Michael B., 1992, P13; BRUMMETT RE, 1978, J ANTIMICROB CHEMOTH, V4, P73, DOI 10.1093/jac/4.suppl_A.73; Chalmers T C, 1993, Stat Methods Med Res, V2, P161; COHEN B, 1985, CURR THER RES CLIN E, V38, P880; DACOSTA PM, 1992, HEPATO-GASTROENTEROL, V39, P350; DAIKOS GL, 1990, J INFECT DIS, V162, P414, DOI 10.1093/infdis/162.2.414; DAIKOS GL, 1991, ANTIMICROB AGENTS CH, V35, P117, DOI 10.1128/AAC.35.1.117; DAVIS RR, 1984, J ANTIMICROB CHEMOTH, V14, P291, DOI 10.1093/jac/14.3.291; DEBROE ME, 1986, AM J MED, V80, P115, DOI 10.1016/0002-9343(86)90488-2; DEVRIES PJ, 1990, EUR J CLIN MICROBIOL, V9, P161; FELD R, 1984, ARCH INTERN MED, V144, P1005, DOI 10.1001/archinte.144.5.1005; Fleiss J L, 1993, Stat Methods Med Res, V2, P121, DOI 10.1177/096228029300200202; GALLOE AM, 1993, LANCET, V341, P1152, DOI 10.1016/0140-6736(93)93170-6; GERBER A U, 1988, Journal of Drug Development, V1, P17; GERBER AU, 1985, J ANTIMICROB CHEMOTH, V15, P201, DOI 10.1093/jac/15.suppl_A.201; GERBER AU, 1989, EUR J CLIN MICROBIOL, V8, P233, DOI 10.1007/BF01965266; GIAMARELLOU H, 1991, J ANTIMICROB CHEMOTH, V27, P73, DOI 10.1093/jac/27.suppl_C.73; GIBSON J, 1993, INT J HEMATOL, V58, P63; GILBERT DN, 1991, ANTIMICROB AGENTS CH, V35, P399, DOI 10.1128/AAC.35.3.399; GONZALEZ P, 1993, LANCET, V341, P895; HANSEN M, 1988, Journal of Drug Development, V1, P119; HERSCOVICI L, 1988, SCAND J INFECT DIS, V20, P205, DOI 10.3109/00365548809032439; HOLLENDER LF, 1989, J ANTIMICROB CHEMOTH, V23, P773, DOI 10.1093/jac/23.5.773; HUY PTB, 1986, J CLIN INVEST, V77, P1492, DOI 10.1172/JCI112463; HUY PTB, 1988, J DRUG DEV S3, V1, P93; KAPUSNIK JE, 1988, J INFECT DIS, V158, P7, DOI 10.1093/infdis/158.1.7; KLASTERSKY J, 1977, J CLIN PHARMACOL, V17, P520, DOI 10.1002/j.1552-4604.1977.tb05645.x; LABOVITZ E, 1974, ANTIMICROB AGENTS CH, V6, P465, DOI 10.1128/AAC.6.4.465; MALLER R, 1993, J ANTIMICROB CHEMOTH, V31, P939, DOI 10.1093/jac/31.6.939; MARIK PE, 1991, J ANTIMICROB CHEMOTH, V28, P753, DOI 10.1093/jac/28.5.753; MAURACHER EH, 1989, CLIN THER, V11, P604; MCCORMACK JP, 1992, CLIN INFECT DIS, V14, P320, DOI 10.1093/clinids/14.1.320; MOORE RD, 1984, J INFECT DIS, V149, P443, DOI 10.1093/infdis/149.3.443; MORDENTI JJ, 1985, J ANTIMICROB CHEMOTH, V15, P313, DOI 10.1093/jac/15.suppl_A.313; MUIJSKEN M A, 1988, Journal of Drug Development, V1, P145; NOONE P, 1974, BRIT MED J, V1, P477, DOI 10.1136/bmj.1.5906.477; NORDSTROM L, 1991, J HOSP INFECT, V18, P117, DOI 10.1016/0195-6701(91)90013-X; NORDSTROM L, 1990, J ANTIMICROB CHEMOTH, V25, P159, DOI 10.1093/jac/25.1.159; Oakes M, 1993, Stat Methods Med Res, V2, P147; OLIER B, 1983, CHEMOTHERAPY, V29, P385, DOI 10.1159/000238225; PECHERE JC, 1984, 24TH INT C ANT AG CH; POWELL SH, 1983, J INFECT DIS, V147, P918, DOI 10.1093/infdis/147.5.918; PRINS JM, 1993, LANCET, V341, P335, DOI 10.1016/0140-6736(93)90137-6; REINER NE, 1978, J ANTIMICROB CHEMOTH, V4, P85, DOI 10.1093/jac/4.suppl_A.85; ROOSENDAAL R, 1989, EUR J CLIN MICROBIOL, V8, P878, DOI 10.1007/BF01963774; ROZDZINSKI E, 1993, J ANTIMICROB CHEMOTH, V31, P585, DOI 10.1093/jac/31.4.585; STURM AW, 1989, J INFECT DIS, V159, P931, DOI 10.1093/infdis/159.5.931; TERBRAAK EW, 1990, AM J MED, V89, P58, DOI 10.1016/0002-9343(90)90099-Y; Thompson S G, 1993, Stat Methods Med Res, V2, P173, DOI 10.1177/096228029300200205; TULKENS P M, 1988, Journal of Drug Development, V1, P71; VANDERAUWERA P, 1991, ANTIMICROB AGENTS CH, V35, P640, DOI 10.1128/AAC.35.4.640; VANHAEVERBEEK M, 1993, INT J CLIN PHARM TH, V31, P153; VERPOOTEN GA, 1989, CLIN PHARMACOL THER, V45, P22, DOI 10.1038/clpt.1989.4; VIGANO A, 1992, ANTIMICROB AGENTS CH, V36, P1499, DOI 10.1128/AAC.36.7.1499; VOGELMAN B, 1988, J INFECT DIS, V157, P287, DOI 10.1093/infdis/157.2.287; WOOD CA, 1988, J INFECT DIS, V158, P13, DOI 10.1093/infdis/158.1.13; YOURASSOWSKY E, 1990, CHEMOTHERAPY, V36, P1, DOI 10.1159/000238741; 1988, SAS GUIDE PERSONAL C; 1993, ANN INTERN MED, V119, P584	64	318	330	0	12	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 10	1996	312	7027					338	344						7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TV698	8611830				2022-12-28	WOS:A1996TV69800021
J	Herron, C				Herron, C			Smallpox - 26 years ago	NEW ENGLAND JOURNAL OF MEDICINE			English	Article																			0	1	1	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 16	1996	334	20					1304	1304		10.1056/NEJM199605163342005	http://dx.doi.org/10.1056/NEJM199605163342005			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UK880	8609948				2022-12-28	WOS:A1996UK88000005
J	Wrenn, K				Wrenn, K			Annual meeting: Perspectives	ANNALS OF INTERNAL MEDICINE			English	Editorial Material											Wrenn, K (corresponding author), VANDERBILT UNIV, MED CTR, 703 OXFORD HOUSE, NASHVILLE, TN 37232 USA.		Wrenn, Keith/AAI-7651-2020						0	0	0	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 15	1996	124	10					924	924		10.7326/0003-4819-124-10-199605150-00012	http://dx.doi.org/10.7326/0003-4819-124-10-199605150-00012			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UJ801	8610925				2022-12-28	WOS:A1996UJ80100012
J	Heynen, AJ; Abraham, WC; Bear, MF				Heynen, AJ; Abraham, WC; Bear, MF			Bidirectional modification of CA1 synapses in the adult hippocampus in vivo	NATURE			English	Article							LONG-TERM POTENTIATION; AREA CA1; DEPRESSION	MEMORIES are believed to be stored by synaptic modifications. One type of activity-dependent synaptic modification, long-term potentiation (LTP), has received considerable attention as a possible memory mechanism, particularly in hippocampus(1). However, use-dependent decreases in synaptic strength can store information as well. A form of homosynaptic long-term depression (LTD) has been described and widely studied in the CA1 region of the developing hippocampus in vitro(2-4). However, the relevance of this model of LTD to memory has been questioned because of failures to replicate it in the adult brain in vitro(5) and, more recently, in vivo(6). Here we re-examine this important issue and find that homosynaptic LTD can in fact be elicited in the adult hippocampus in vivo, that it has all the properties described in immature CA1 in vitro, and that LTD and LTP are reversible modifications of the same Schaffer collateral synapses. Thus homosynaptic LTD is not peculiar to brain slices, nor is it only of developmental significance. Rather, our data suggest that the mechanisms of LTP and LTD may be equal partners in the mnemonic operations of hippocampal neural networks.	BROWN UNIV,DEPT NEUROSCI,PROVIDENCE,RI 02912; BROWN UNIV,HOWARD HUGHES MED INST,PROVIDENCE,RI 02912; UNIV OTAGO,DEPT PSYCHOL,DUNEDIN,NEW ZEALAND; UNIV OTAGO,NEUROSCI RES CTR,DUNEDIN,NEW ZEALAND	Brown University; Brown University; Howard Hughes Medical Institute; University of Otago; University of Otago				Bear, Mark/0000-0002-9903-2541				ABRAHAM WC, 1988, BRAIN RES, V462, P40, DOI 10.1016/0006-8993(88)90582-3; BASHIR ZI, 1994, EXP BRAIN RES, V100, P437, DOI 10.1007/BF02738403; Bear Mark F., 1994, Current Opinion in Neurobiology, V4, P389, DOI 10.1016/0959-4388(94)90101-5; BIENENSTOCK EL, 1982, J NEUROSCI, V2, P32, DOI 10.1523/jneurosci.02-01-00032.1982; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; BREESE CR, 1989, J NEUROSCI, V9, P1097; DUDEK SM, 1992, P NATL ACAD SCI USA, V89, P4363, DOI 10.1073/pnas.89.10.4363; ERRINGTON ML, 1995, J NEUROPHYSIOL, V74, P1793, DOI 10.1152/jn.1995.74.4.1793; KERR DS, 1995, P NATL ACAD SCI USA, V92, P11637, DOI 10.1073/pnas.92.25.11637; MULKEY RM, 1992, NEURON, V9, P967, DOI 10.1016/0896-6273(92)90248-C; THIELS E, 1994, J NEUROPHYSIOL, V71, P3009; WILSON MA, 1993, SCIENCE, V261, P1055, DOI 10.1126/science.8351520	12	149	152	0	8	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAY 9	1996	381	6578					163	166		10.1038/381163a0	http://dx.doi.org/10.1038/381163a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UK139	8610015				2022-12-28	WOS:A1996UK13900052
J	Normand, SLT; Glickman, ME; Sharma, RGVRK; McNeil, BJ				Normand, SLT; Glickman, ME; Sharma, RGVRK; McNeil, BJ			Using admission characteristics to predict short-term mortality from myocardial infarction in elderly patients - Results from the Cooperative Cardiovascular Project	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							OUTCOMES; DISEASE; RISK; CARE	Objective.-To develop a prediction model of death within 30 days of hospital admission for Medicare patients with acute myocardial infarction that would permit use of risk-adjusted mortality rates as hospital quality measures. Design.-Retrospective cohort study using data created from medical charts and administrative flies. Setting.-All acute care hospitals in Alabama, Connecticut, Iowa, or Wisconsin. Patients.-A cohort of 14 581 patients with acute myocardial infarction covered by Medicare in 1993. Results.-The unadjusted 30-day mortality rate was 21%, ranging from 18% in Connecticut to 23% in Alabama. The 4 largest contributors to variability in mortality rates were mean arterial pressure, age, respiratory rate, and serum urea nitrogen level. The area under the receiver operator characteristic curve was 0.79 in a developmental sample of 10 936 patients and 0.78 in a validation sample of 3645 patients. Based on admission variables, we were able to explain 27% of the variability in 30-day mortality rates. During the index admission, aspirin, beta-blockers, angiotensin-converting enzyme inhibitors, and thrombolytic agents were used in 72%, 39%, 32%, and 15% of patients, respectively. Explained variation increased by 6 percentage points to 33% when drug therapies and revascularization procedures performed during the index admission were added to the model predictors, Conclusions.-Short-term mortality remains high for elderly patients with acute myocardial infarction, and a large percentage of variation remains unexplained after controlling for admission severity. Part of the unexplained variability can be explained by the location of the admitting hospital; some of the remaining unexplained variation may reflect differences in quality of care or unmeasured differences in disease severity. Researchers should develop quality indicators based on process measures for acute myocardial infarction and should incorporate these measures into mortality models to determine whether quality accounts for variation in 30-day mortality rates beyond that explained by clinical status at admission.	HARVARD UNIV,SCH PUBL HLTH,DEPT BIOSTAT,BOSTON,MA 02115; BOSTON UNIV,DEPT MATH,BOSTON,MA 02215; DEPT VET AFFAIRS MED CTR,DIV CARDIOL,BROCKTON,MA; BRIGHAM & WOMENS HOSP,DEPT RADIOL,BOSTON,MA 02115	Harvard University; Harvard T.H. Chan School of Public Health; Boston University; Harvard University; Brigham & Women's Hospital	Normand, SLT (corresponding author), HARVARD UNIV,SCH MED,DEPT HLTH CARE POLICY,PARCEL B,1ST FLOOR,25 SHATTUCK ST,BOSTON,MA 02115, USA.			Glickman, Mark/0000-0003-3993-2801	AHRQ HHS [R01-HS08071, R01-HS06341] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		AYANIAN JZ, 1993, JAMA-J AM MED ASSOC, V269, P2642, DOI 10.1001/jama.269.20.2642; BERGER CJ, 1992, JAMA-J AM MED ASSOC, V268, P1545, DOI 10.1001/jama.268.12.1545; Codman EA, 1916, SURG GYNECOL OBSTET, V22, P119; CORTI MC, 1994, JAMA-J AM MED ASSOC, V272, P1036, DOI 10.1001/jama.272.13.1036; CRAWFORD SL, 1995, J CLIN EPIDEMIOL, V48, P209, DOI 10.1016/0895-4356(94)00124-9; DALEY J, 1988, JAMA-J AM MED ASSOC, V260, P3617, DOI 10.1001/jama.260.24.3617; ELLERBECK EF, 1995, JAMA-J AM MED ASSOC, V273, P1509, DOI 10.1001/jama.273.19.1509; FIRSHEIN J, 1993, F GRAYS MED HLTH, V47, P3; Fleiss J. L., 1981, STAT METHODS RATES P, V2, P22; HANLEY JA, 1982, RADIOLOGY, V143, P29, DOI 10.1148/radiology.143.1.7063747; JENCKS SF, 1988, JAMA-J AM MED ASSOC, V260, P3611, DOI 10.1001/jama.260.24.3611; KRAKAUER H, 1993, INQUIRY-J HEALTH CAR, V30, P115; LANDWEHR JM, 1984, J AM STAT ASSOC, V79, P61, DOI 10.2307/2288334; LEE KL, 1995, CIRCULATION, V91, P1659, DOI 10.1161/01.CIR.91.6.1659; LITTLE RJ, 1987, STAT ANAL MISSING DA, P9; NAGELKERKE NJ, 1991, BIOMETRIKA, V3, P691; NORMAND SLT, 1995, J CLIN EPIDEMIOL, V48, P229, DOI 10.1016/0895-4356(94)00126-B; PARSONNET V, 1989, CIRCULATION, V79, P3; PASHOS CL, 1993, JAMA-J AM MED ASSOC, V270, P1832, DOI 10.1001/jama.270.15.1832; *SAS I INC, 1990, SAS STAT US GUID VER, P2; UDVARHELYI IS, 1992, JAMA-J AM MED ASSOC, V268, P2530, DOI 10.1001/jama.268.18.2530; *US DEP HLTH HUM S, 1992, MED HOSP INF 1992; VLADECK BC, 1988, HEALTH AFFAIR, V7, P122, DOI 10.1377/hlthaff.7.1.122	24	116	120	3	7	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 1	1996	275	17					1322	1328		10.1001/jama.275.17.1322	http://dx.doi.org/10.1001/jama.275.17.1322			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UG612	8614117				2022-12-28	WOS:A1996UG61200028
J	Pahor, M; Guralnik, JM; Furberg, CD; Carbonin, P; Havlik, RJ				Pahor, M; Guralnik, JM; Furberg, CD; Carbonin, P; Havlik, RJ			Risk of gastrointestinal haemorrhage with calcium antagonists in hypertensive persons over 67 years old	LANCET			English	Article							PLATELET-AGGREGATION; CLINICAL-TRIAL; DIHYDROPYRIDINES; HEMORRHAGE	Background Calcium antagonists are used frequently in management of hypertension, In addition to their cardiovascular effects, these drugs inhibit platelet aggregation. Therefore we examined whether the use of calcium antagonists was associated with an increased risk of gastrointestinal haemorrhage (GIH). Methods A prospective cohort study was conducted from 1985 through 1992 on 1636 hypertensive persons aged greater than or equal to 68 years living in three communities. The participants were taking beta-blockers, angiotensin-converting enzyme (ACE) inhibitors, or calcium antagonists; those taking combinations of these drugs were excluded, The incidence of GIH was assessed by surveying hospital discharge deaths. Age, gender, disability, arterial pressure, other drugs, and comorbid conditions were examined as confounders. Findings Compared with beta-blockers (4819 person-years, 65 events), after adjustment for confounders the relative risk for GIH associated with ACE inhibitors (772 person-years, 13 events) was 1 . 23 (95% CI 0 . 66-2 . 28) and with calcium antagonists (1510 person-years, 42 events) it was 1 . 86 (1 . 22-2 . 82). The risks for verapamil, diltiazem, and nifedipine did not differ significantly. The results were unchanged when the analyses were restricted to severe events (GIH in conjunction with blood transfusion or death). Interpretation Calcium antagonists were associated with an increased risk of GIH in this population. Therefore caution is needed in prescription of these agents to old patients who have other risk factors for gastrointestinal bleeding.	NIA,EPIDEMIOL DEMOG & BIOMETRY PROGRAM,BETHESDA,MD 20892; WAKE FOREST UNIV,BOWMAN GRAY SCH MED,DEPT PUBL HLTH SCI,WINSTON SALEM,NC 27103	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); Wake Forest University; Wake Forest Baptist Medical Center	Pahor, M (corresponding author), UNIV CATTOLICA SACRO CUORE,IST MED INTERNA & GERIATRIA,LARGO F VITO 1,I-00168 ROME,ITALY.							BERKELS R, 1994, THROMB HAEMOSTASIS, V72, P309; BLACHE D, 1992, PHARMACOLOGY, V45, P250, DOI 10.1159/000139008; CONN HO, 1991, HEPATOLOGY, V13, P902, DOI 10.1002/hep.1840130517; CORNONIHUNTLEY J, 1993, AGING-CLIN EXP RES, V5, P27; COX DR, 1972, J R STAT SOC B, V34, P187; CUTLER S J, 1958, J Chronic Dis, V8, P699, DOI 10.1016/0021-9681(58)90126-7; Dahlof B, 1993, Blood Press, V2, P136, DOI 10.3109/08037059309077541; DAVIS BR, IN PRESS AM J HYPERT; FURBERG CD, 1995, CIRCULATION, V92, P1326, DOI 10.1161/01.CIR.92.5.1326; GILBERT DA, 1990, GASTROINTEST ENDOSC, V36, pS8; GORE JM, 1991, CIRCULATION, V83, P448, DOI 10.1161/01.CIR.83.2.448; HUDSON N, 1995, GUT, V37, P177, DOI 10.1136/gut.37.2.177; KARIO K, 1995, J HUM HYPERTENS, V9, P206; KATZ S, 1963, JAMA-J AM MED ASSOC, V185, P94, DOI DOI 10.1001/JAMA.1963.03060120024016; KONRADDALHOFF I, 1991, EUR J CLIN PHARMACOL, V41, P313, DOI 10.1007/BF00314958; LANDRY JA, 1988, GERONTOLOGIST, V28, P672, DOI 10.1093/geront/28.5.672; PAHOR M, 1995, J AM GERIATR SOC, V43, P1191, DOI 10.1111/j.1532-5415.1995.tb07393.x; PAHOR M, 1994, EUR J EPIDEMIOL, V10, P405, DOI 10.1007/BF01719664; PAHOR M, 1994, J AM GERIATR SOC, V42, P816, DOI 10.1111/j.1532-5415.1994.tb06552.x; PAHOR M, 1994, JAMA-J AM MED ASSOC, V272, P595, DOI 10.1001/jama.272.8.595; PALES J, 1991, BIOCHIM BIOPHYS ACTA, V1064, P169, DOI 10.1016/0005-2736(91)90298-M; *PHS HLTH CAR FIN, 1980, INT CLASS DIS; PSATY BM, 1992, J CLIN EPIDEMIOL, V45, P683, DOI 10.1016/0895-4356(92)90143-B; ROSE GA, 1982, CARDIOVASCULAR SURVE, P162; ROSOW I, 1966, J GERONTOL, V21, P556, DOI 10.1093/geronj/21.4.556; *SPSS, 1993, SPSS ADV STAT REF GU; WAGENKNECHT LE, 1995, BRIT MED J, V310, P776, DOI 10.1136/bmj.310.6982.776; WALLEN NH, 1995, AM J CARDIOL, V75, P1, DOI 10.1016/S0002-9149(99)80516-5; ZUCKER ML, 1993, THROMB HAEMOSTASIS, V70, P332; 1977, JAMA-J AM MED ASSOC, V237, P2385	30	215	217	1	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 20	1996	347	9008					1061	1065		10.1016/S0140-6736(96)90276-7	http://dx.doi.org/10.1016/S0140-6736(96)90276-7			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UG042	8602055				2022-12-28	WOS:A1996UG04200009
J	Remarque, EJ; Cools, HJM; Boere, TJ; vanderKlis, RJ; Masurel, N; Ligthart, GJ				Remarque, EJ; Cools, HJM; Boere, TJ; vanderKlis, RJ; Masurel, N; Ligthart, GJ			Functional disability and antibody response to influenza vaccine in elderly patients in a Dutch nursing home	BRITISH MEDICAL JOURNAL			English	Article									LEIDEN UNIV,DEPT GEN PRACTICE,SECT DUTCH NURSING HOME MED,2301 RC LEIDEN,NETHERLANDS; ERASMUS UNIV ROTTERDAM,DEPT VIROL,WHO NATL INFLUENZA CTR NETHERLANDS,3000 DR ROTTERDAM,NETHERLANDS	Leiden University; Leiden University - Excl LUMC; Erasmus University Rotterdam	Remarque, EJ (corresponding author), UNIV LEIDEN HOSP,DEPT PATHOL,SECT GERONTOL,BLDG 1 P3-Q,POB 9600,2300 RC LEIDEN,NETHERLANDS.		Remarque, Edmond J/B-2217-2010; Remarque, Ed/AAE-8643-2020					BEYER WEP, 1989, VACCINE, V7, P385, DOI 10.1016/0264-410X(89)90150-3; GROSS PA, 1989, VACCINE, V7, P303, DOI 10.1016/0264-410X(89)90190-4; KATZ S, 1970, GERONTOLOGIST, V10, P20, DOI 10.1093/geront/10.1_Part_1.20; POTTER CW, 1979, BRIT MED BULL, V35, P69, DOI 10.1093/oxfordjournals.bmb.a071545; REMARQUE EJ, 1993, VACCINE, V11, P649, DOI 10.1016/0264-410X(93)90311-K	5	32	35	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 20	1996	312	7037					1015	1015						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UG610	8616350				2022-12-28	WOS:A1996UG61000028
J	Dodds, PN; Clarke, AE; Newbigin, E				Dodds, PN; Clarke, AE; Newbigin, E			A molecular perspective on pollination in flowering plants	CELL			English	Review							SELF-INCOMPATIBILITY; KINASE GENE				Dodds, PN (corresponding author), UNIV MELBOURNE, SCH BOT, PLANT CELL BIOL RES CTR, PARKVILLE, VIC 3052, AUSTRALIA.		; Dodds, Peter/D-1181-2009	Newbigin, Ed/0000-0002-9644-302X; Dodds, Peter/0000-0003-0620-5923				CHEUNG AY, 1995, P NATL ACAD SCI USA, V92, P3077, DOI 10.1073/pnas.92.8.3077; De Nettancourt D, 1974, Theor Appl Genet, V44, P278, DOI 10.1007/BF00278744; DICKINSON H, 1995, PLANT REPROD, V8, P1; Dickinson HG, 1994, CUR TOP PL, V12, P45; DODDS PN, 1993, PLANT CELL, V5, P1771, DOI 10.1105/tpc.5.12.1771; DOUGHTY J, 1993, P NATL ACAD SCI USA, V90, P467, DOI 10.1073/pnas.90.2.467; FERRARI TE, 1981, PLANT PHYSIOL, V67, P270, DOI 10.1104/pp.67.2.270; GOLZ JF, 1995, CURR OPIN GENET DEV, V5, P640, DOI 10.1016/0959-437X(95)80033-6; GORING DR, 1993, PLANT CELL, V5, P531, DOI 10.1105/tpc.5.5.531; HUANG S, 1994, PLANT CELL, V6, P1021, DOI 10.1105/tpc.6.7.1021; LEE HS, 1994, NATURE, V367, P560, DOI 10.1038/367560a0; MARTIN GB, 1993, SCIENCE, V262, P1432, DOI 10.1126/science.7902614; MCCLURE BA, 1990, NATURE, V347, P757, DOI 10.1038/347757a0; MURFETT J, 1994, NATURE, V367, P563, DOI 10.1038/367563a0; NASRALLAH JB, 1993, PLANT CELL, V5, P1325, DOI 10.2307/3869785; NEWBIGIN E, 1993, PLANT CELL, V5, P1315, DOI 10.1105/tpc.5.10.1315; ROYO J, 1994, P NATL ACAD SCI USA, V91, P6511, DOI 10.1073/pnas.91.14.6511; STRAUB J, 1947, Z NATURFORSCH B, V2, P433; TORIYAMA K, 1991, THEOR APPL GENET, V81, P769, DOI 10.1007/BF00224988; TUPY J, 1977, BIOL PLANTARUM, V19, P226, DOI 10.1007/BF02923116; WALKER JC, 1994, PLANT MOL BIOL, V26, P1599, DOI 10.1007/BF00016492; ZHANG XS, 1993, PLANT CELL, V5, P403, DOI 10.1105/tpc.5.4.403	22	52	56	1	6	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	APR 19	1996	85	2					141	144		10.1016/S0092-8674(00)81090-9	http://dx.doi.org/10.1016/S0092-8674(00)81090-9			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UG255	8612266	Bronze			2022-12-28	WOS:A1996UG25500002
J	Albukrek, D; Moran, DS; Epstein, Y				Albukrek, D; Moran, DS; Epstein, Y			A depressed workman with heatstroke	LANCET			English	Article									IDF MED CORPS,INST MIL PHYSIOL,TEL HASHOMER,ISRAEL; CHAIM SHEBA MED CTR,HELLER INST MED RES,IL-52621 TEL HASHOMER,ISRAEL	Chaim Sheba Medical Center								BALDESSARINI R J, 1990, P383; EPSTEIN Y, 1989, MED SCI SPORTS EXERC, V22, P29; FAVA M, 1994, AM J PSYCHIAT, V151, P1372; MYERS RD, 1974, TEMPERATURE REGULATI, P32; SCOTT IM, 1984, BRAIN RES, V306, P157, DOI 10.1016/0006-8993(84)90364-0	5	4	4	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 13	1996	347	9007					1016	1016		10.1016/S0140-6736(96)90149-X	http://dx.doi.org/10.1016/S0140-6736(96)90149-X			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UF380	8606565				2022-12-28	WOS:A1996UF38000014
J	Marubini, E; Mariani, L; Salvadori, B; Veronesi, U; Saccozzi, R; Merson, M; Zucali, R; Rilke, F				Marubini, E; Mariani, L; Salvadori, B; Veronesi, U; Saccozzi, R; Merson, M; Zucali, R; Rilke, F			Results of a breast-cancer-surgery trial compared with observational data from routine practice	LANCET			English	Article							RANDOMIZED TRIAL; AXILLARY DISSECTION; MASTECTOMY; QUADRANTECTOMY; RADIOTHERAPY	Background The strength of randomised controlled trials (RCTs) is that they allow investigators to draw reliable inferences about treatment differences; physicians can then make a choice between different options. Their weakness is that they are conducted on a set of patients who cannot be regarded as a random sample from the population that will be treated outside the trial. Observational data collected in a prospective clinical database may provide more realistic estimates. Methods At the Istituto Nazionale dei Tumori of Milan an RCT was started in 1973 (MI1) in which Halsted mastectomy was compared with quadrantectomy plus axillary dissection and radiotherapy (QUART), a breast conserving treatment, for ''early-stage'' primary breast cancer. In addition, a prospective clinical database was established to collect, in standard format, information on ail women undergoing breast conservation thereafter and followed up at the institute. 1760 women were treated with QUART, 350 of them being accrued in the years 1973-80 in the context of the MI1 trial. The remaining 1408 received QUART after the MI1 trial, up to December, 1984. Results In the years after the trial, the criteria for use of QUART became more liberal. However, after adjustment for baseline characteristics, out-trial patients fared no worse than trial patients in terms of survival or distant metastasis. Out-trial patients did have a slightly higher rate of local recurrence, probably because of subtle and multiple changes in the surgical procedures since the time of the trial. Interpretation The results of QUART in out-trial patients resembled those reported from research settings. In this instance, the results of clinical trials did not exaggerate the benefits obtainable in routine practice.	IST NAZL STUDIO & CURA TUMORI,MILAN,ITALY; EUROPEAN INST ONCOL,MILAN,ITALY	Fondazione IRCCS Istituto Nazionale Tumori Milan; IRCCS European Institute of Oncology (IEO)	Marubini, E (corresponding author), UNIV MILAN,IST STAT MED & BIOMETRIA,VIA VENEZIAN 1,I-20133 MILAN,ITALY.		Mariani, Luigi/AAB-9464-2019; Mariani, Luigi/C-2580-2017	Mariani, Luigi/0000-0001-6208-4084				BADER J, 1987, International Journal of Radiation Oncology, Biology, Physics, V13, P160; BARTELINK H, 1988, 7TH P ANN M EUR SOC, P211; BLICHERTTOFT M, 1988, ACTA ONCOL, V27, P671, DOI 10.3109/02841868809091767; BLICHERTTOFT M, 1990, BR J CANCER S12, V62, P15; BONADONNA G, 1977, CANCER-AM CANCER SOC, V39, P2904, DOI 10.1002/1097-0142(197706)39:6<2904::AID-CNCR2820390677>3.0.CO;2-8; BYAR DP, 1980, BIOMETRICS, V36, P337, DOI 10.2307/2529989; COX DR, 1972, J R STAT SOC B, V34, P187; FISHER B, 1985, NEW ENGL J MED, V312, P665, DOI 10.1056/NEJM198503143121101; FISHER B, 1995, NEW ENGL J MED, V333, P1456, DOI 10.1056/NEJM199511303332203; GREEN SB, 1984, STAT MED, V3, P361, DOI 10.1002/sim.4780030413; HABIBOLLAHI F, 1987, P AN M AM SOC CLIN, V6, pA231; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; Marubini E, 1995, ANAL SURVIVAL DATA C; SARRAZIN D, 1989, RADIOTHER ONCOL, V14, P177, DOI 10.1016/0167-8140(89)90165-5; *SAS I, 1985, SAS US GUID; van Dongen J A, 1992, J Natl Cancer Inst Monogr, P15; VERONESI U, 1986, EUR J CANCER CLIN ON, V22, P1085, DOI 10.1016/0277-5379(86)90011-8; VERONESI U, 1990, EUR J CANCER, V26, P671, DOI 10.1016/0277-5379(90)90114-9; VERONESI U, 1990, EUR J CANCER, V26, P668, DOI 10.1016/0277-5379(90)90113-8; VERONESI U, 1981, NEW ENGL J MED, V305, P6, DOI 10.1056/NEJM198107023050102	20	28	28	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 13	1996	347	9007					1000	1003		10.1016/S0140-6736(96)90145-2	http://dx.doi.org/10.1016/S0140-6736(96)90145-2			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UF380	8606561				2022-12-28	WOS:A1996UF38000010
J	Leclerc, JR; Geerts, WH; Desjardins, L; Laflamme, GH; lEsperance, B; Demers, C; Kassis, J; Cruickshank, M; Whitman, L; Delorme, F				Leclerc, JR; Geerts, WH; Desjardins, L; Laflamme, GH; lEsperance, B; Demers, C; Kassis, J; Cruickshank, M; Whitman, L; Delorme, F			Prevention of venous thromboembolism after knee arthroplasty - A randomized, double-blind trial comparing enoxaparin with warfarin	ANNALS OF INTERNAL MEDICINE			English	Article						knee prosthesis; enoxaparin; warfarin; thromboembolism; pulmonary embolism	DEEP-VEIN THROMBOSIS; MOLECULAR-WEIGHT HEPARIN; ELECTIVE HIP-SURGERY; REPLACEMENT; PROPHYLAXIS; CALF	Objective: To compare the effectiveness and safety of fixed-dose enoxaparin and adjusted-dose warfarin in preventing venous thromboembolism after knee arthroplasty. Design: A randomized, double-blind controlled trial. Setting: 8 university hospitals. Patients: 670 consecutive patients who had knee arthroplasty. Intervention: Patients were randomly assigned to receive enoxaparin (30 mg subcutaneously every 12 hours) or adjusted-dose warfarin (international normalized ratio, 2.0 to 3.0). Both regimens were started after surgery. Measurements: The primary end point was the incidence of deep venous thrombosis in patients with adequate bilateral venograms; the secondary end point was hemorrhage. Results: Among the 417 patients with adequate venograms, 109 of 211 warfarin recipients (51.7%) had deep venous thrombosis compared with 76 of 206 enoxaparin recipients (36.9%) (P = 0.003). The absolute risk difference was 14.8% in favor of enoxaparin (95% CI, 5.3% to 24.1%). Twenty-two warfarin recipients (10.4%) and 24 enoxaparin recipients (11.7%) had proximal venous thrombosis (P > 0.2). The absolute risk difference was 1.2% in favor of warfarin (CI, -7.2% to 4.8%). The incidence of major bleeding was 1.8% (6 of 334 patients) in the warfarin group and 2.1% (7 of 336 patients) in the enoxaparin group (P > 0.2). The absolute risk difference was 0.3% in favor of warfarin (CI, -2.4% to 1.8%). Conclusions: A postoperative, fixed-dose enoxaparin regimen is more effective than adjusted-dose warfarin in preventing total deep venous thrombosis after knee arthroplasty. No differences were seen in the incidence of proximal venous thrombosis or clinically overt hemorrhage.	UNIV MONTREAL, DEPT PATHOL, MONTREAL, PQ H3C 3J7, CANADA; UNIV LAVAL, ST FOY, PQ G1K 7P4, CANADA; MCGILL UNIV, MONTREAL, PQ, CANADA; UNIV TORONTO, TORONTO, ON, CANADA; UNIV WESTERN ONTARIO, LONDON, ON, CANADA	Universite de Montreal; Laval University; McGill University; University of Toronto; Western University (University of Western Ontario)								[Anonymous], 1994, J Bone Joint Surg Am, V76, P1174; BERGQVIST D, 1988, WORLD J SURG, V12, P349, DOI 10.1007/BF01655669; COHEN SH, 1973, J BONE JOINT SURG AM, VA 55, P106, DOI 10.2106/00004623-197355010-00010; COLWELL CW, 1994, J BONE JOINT SURG AM, V76A, P3, DOI 10.2106/00004623-199401000-00002; CUSHNER FD, 1991, CLIN ORTHOP RELAT R, V269, P98; FAUNO P, 1994, J BONE JOINT SURG AM, V76A, P1814, DOI 10.2106/00004623-199412000-00007; FRANCIS CW, 1990, J BONE JOINT SURG AM, V72A, P976, DOI 10.2106/00004623-199072070-00003; FRANCIS CW, 1983, JAMA-J AM MED ASSOC, V249, P374, DOI 10.1001/jama.249.3.374; FRANCIS CW, 1988, CLIN ORTHOP RELAT R, V232, P271; HAAS SB, 1990, J BONE JOINT SURG AM, V72A, P27, DOI 10.2106/00004623-199072010-00005; HEIT J, 1995, THROMB HAEMOSTASIS, V73, P978; HODGE WA, 1991, CLIN ORTHOP RELAT R, V271, P101; HULL R, 1979, THROMB RES, V16, P37, DOI 10.1016/0049-3848(79)90267-6; HULL R, 1993, NEW ENGL J MED, V329, P1370, DOI 10.1056/NEJM199311043291902; KHAW FM, 1993, J BONE JOINT SURG BR, V75, P940, DOI 10.1302/0301-620X.75B6.8245087; LECLERC JR, 1992, THROMB HAEMOSTASIS, V67, P417; LEVINE MN, 1991, ANN INTERN MED, V114, P545, DOI 10.7326/0003-4819-114-7-545; LIEBERMAN JR, 1994, J BONE JOINT SURG AM, V76A, P1239, DOI 10.2106/00004623-199408000-00015; LOTKE PA, 1984, J BONE JOINT SURG AM, V66A, P202, DOI 10.2106/00004623-198466020-00006; MCKENNA R, 1976, J BONE JOINT SURG AM, V58, P928, DOI 10.2106/00004623-197658070-00006; MCKENNA R, 1980, BRIT MED J, V280, P514, DOI 10.1136/bmj.280.6213.514; OBRIEN PC, 1979, BIOMETRICS, V35, P549, DOI 10.2307/2530245; SEAGROATT V, 1991, BRIT MED J, V303, P1431, DOI 10.1136/bmj.303.6815.1431; SPIRO TE, 1994, BLOOD, V84, pA246; SPIRO TE, 1994, ANN INTERN MED, V121, P81, DOI 10.7326/0003-4819-121-2-199407150-00001; STRANDNESS DE, 1983, JAMA-J AM MED ASSOC, V250, P1289, DOI 10.1001/jama.250.10.1289; STRINGER MD, 1989, J BONE JOINT SURG BR, V71, P492, DOI 10.1302/0301-620X.71B3.2785998; STULBERG BN, 1984, J BONE JOINT SURG AM, V66A, P194, DOI 10.2106/00004623-198466020-00005; TURPIE AGG, 1986, NEW ENGL J MED, V315, P925, DOI 10.1056/NEJM198610093151503; WELLS PS, 1995, ANN INTERN MED, V122, P47, DOI 10.7326/0003-4819-122-1-199501010-00008	30	212	215	0	6	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 1	1996	124	7					619	+		10.7326/0003-4819-124-7-199604010-00001	http://dx.doi.org/10.7326/0003-4819-124-7-199604010-00001			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UB513	8607589				2022-12-28	WOS:A1996UB51300001
J	Neuenschwander, S; Singer, W				Neuenschwander, S; Singer, W			Long-range synchronization of oscillatory light responses in the cat retina and lateral geniculate nucleus	NATURE			English	Article							CROSS-CORRELATION ANALYSIS; GANGLION-CELLS; VISUAL-CORTEX; DISCHARGE; NEURONS	VISUAL responses in the retina and the lateral geniculate nucleus (LGN) exhibit oscillatory patterning within a broad range of frequencies(1-9). Oscillatory activity is often associated with the synchronization of spatially distributed responses(10). Here we demonstrate, with simultaneous multi-electrode recordings from the retina and the LGN, that stationary and moving light stimuli evoke in retinal ganglion cells oscillatory responses in the frequency range of 61 to 114 Hz that become synchronized over distances larger than 20 degrees of visual angle across the nasal and temporal halves of the retina. This temporal patterning of retinal responses is transmitted reliably by LGN neurons, such that stimuli crossing the vertical meridian evoke synchronous responses in the LGNs of both hemispheres. The oscillatory responses are not phase-locked to the stimulus onset, indicating that synchronization results from horizontal interactions in the retina, The occurrence of synchronization depends on global stimulus properties such as size and continuity, suggesting that temporal correlation among responses of spatially segregated ganglion cells can be exploited to convey information relevant for perceptual grouping.	MAX PLANCK INST HIRNFORSCH, D-60528 FRANKFURT, GERMANY	Max Planck Society			Singer, Wolf/D-6874-2012	NEUENSCHWANDER, Sergio/0000-0001-7493-121X				ARNETT D, 1981, J PHYSIOL-LONDON, V317, P29, DOI 10.1113/jphysiol.1981.sp013812; ARNETT DW, 1978, EXP BRAIN RES, V32, P49; ARNETT DW, 1975, EXP BRAIN RES, V24, P111; BISHOP PO, 1964, J PHYSIOL-LONDON, V170, P598, DOI 10.1113/jphysiol.1964.sp007352; COOK JE, 1995, MICROSC RES TECHNIQ, V31, P408, DOI 10.1002/jemt.1070310510; DEVRIES SH, 1993, CELL S, V10, P1390; DOTY RW, 1963, J PHYSIOL-LONDON, V168, P205, DOI 10.1113/jphysiol.1963.sp007187; ENGEL AK, 1991, SCIENCE, V252, P1177, DOI 10.1126/science.252.5009.1177; ENGEL AK, 1990, EUR J NEUROSCI, V2, P588, DOI 10.1111/j.1460-9568.1990.tb00449.x; GERSTEIN GL, 1972, BIOPHYS J, V12, P453, DOI 10.1016/S0006-3495(72)86097-1; GHOSE GM, 1992, J NEUROPHYSIOL, V68, P1558, DOI 10.1152/jn.1992.68.5.1558; ITO H, 1994, SOC NEUR ABSTR, V20; KONIG P, 1994, J NEUROSCI METH, V54, P31, DOI 10.1016/0165-0270(94)90157-0; LAUFER M, 1967, VISION RES, V7, P215, DOI 10.1016/0042-6989(67)90086-7; MASTRONARDE DN, 1989, TRENDS NEUROSCI, V12, P75, DOI 10.1016/0166-2236(89)90140-9; NUNEZ A, 1992, NEUROSCIENCE, V51, P269, DOI 10.1016/0306-4522(92)90314-R; PEICHL L, 1979, J PHYSIOL-LONDON, V291, P117, DOI 10.1113/jphysiol.1979.sp012803; PERKEL DH, 1967, BIOPHYS J, V7, P419, DOI 10.1016/S0006-3495(67)86597-4; ROBSON JG, 1987, J OPT SOC AM A, V4, P2301, DOI 10.1364/JOSAA.4.002301; RODIECK RW, 1967, J NEUROPHYSIOL, V30, P1043, DOI 10.1152/jn.1967.30.5.1043; SILLITO AM, 1994, NATURE, V369, P479, DOI 10.1038/369479a0; SINGER W, 1995, ANNU REV NEUROSCI, V18, P555, DOI 10.1146/annurev.neuro.18.1.555; STEVENS JK, 1976, J NEUROPHYSIOL, V39, P239, DOI 10.1152/jn.1976.39.2.239; VANEY DI, 1994, PROG RETIN EYE RES, V13, P301, DOI 10.1016/1350-9462(94)90014-0; WASSLE H, 1991, PHYSIOL REV, V71, P447, DOI 10.1152/physrev.1991.71.2.447; WORGOTTER F, 1995, VISUAL NEUROSCI, V12, P469, DOI 10.1017/S0952523800008373	26	240	246	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 22	1996	379	6567					728	733		10.1038/379728a0	http://dx.doi.org/10.1038/379728a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TW567	8602219				2022-12-28	WOS:A1996TW56700053
J	Nickens, HW; Cohen, JJ				Nickens, HW; Cohen, JJ			On affirmative action	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									ASSOC AMER MED COLL,WASHINGTON,DC 20037; COMMUN & MINOR PROGRAMS,WASHINGTON,DC 20037	Association of American Medical Colleges								COOPER JAD, 1978, J MED EDUC, V53, P776; Fraser S., 1995, BELL CURVE WARS RACE; Herrstein Richard J., 1994, BELL CURVE INTELLIGE; MORRISSEY J, 1995, MOD HEALTHCARE  0821, V25, P76; MORRISSEY J, 1995, MOD HEALTHCARE  0821, V25, P78; MOY E, 1995, JAMA-J AM MED ASSOC, V273, P1515, DOI 10.1001/jama.273.19.1515; Nickens H, 1994, MORE MINORITIES HLTH, P1; Nickens H W, 1992, JAMA, V267, P2395, DOI 10.1001/jama.267.17.2390; NICKENS HW, 1991, WESTERN J MED, V155, P27; NICKENS HW, 1995, HEALTH SERV RES, V30, P151; NICKENS HW, 1994, NEW ENGL J MED, V331, P472, DOI 10.1056/NEJM199408183310712; NICKENS HW, 1992, JAMA-J AM MED ASSOC, V267, P2395; PRICE P B, 1964, J Med Educ, V39, P203; STEELE CM, 1995, J PERS SOC PSYCHOL, V69, P797, DOI 10.1037/0022-3514.69.5.797; TRACEY TJ, 1984, MEAS EVAL GUID, V16, P171, DOI 10.1080/00256307.1984.12022352; WRIGHT P, 1995, ACAD MANAGE J, V38, P272, DOI 10.2307/256736; 1965, FULFILL THESE RIGHTS, V2, P636; 1995, PROJECT 3000 2000 PR; 1995, FACTS APPLICANTS MAT; 1992, POPULATION PROJECTIO, pR18; 1995, UNPUB USE SOCIOECONO; 1970, REPORT ASS AM MED CO; 1994, MINORITY STUDENTS ME, V8; 1993, COLLEGE BOUND SENIOR, P7; 1996, CHRONICLE HIGHE 0202, pA26	25	18	18	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 21	1996	275	7					572	574		10.1001/jama.275.7.572	http://dx.doi.org/10.1001/jama.275.7.572			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TV569	8606482				2022-12-28	WOS:A1996TV56900038
J	Hou, XS; Melnick, MB; Perrimon, N				Hou, XS; Melnick, MB; Perrimon, N			marelle acts downstream of the Drosophila HOP/JAK kinase and encodes a protein similar to the mammalian STATs	CELL			English	Article							GAMMA SIGNAL-TRANSDUCTION; TYROSINE KINASE; JAK2; DNA; SEQUENCE; EMBRYO; STRIPE; GENE; MELANOGASTER; SEGMENTATION	We have identified a putative Drosophila STAT protein named Marelle that exhibits mutant phenotypes identical to mutations in the Hopscotch/JAK kinase. We show that a reduction in the amount of marelle gene activity suppresses the phenotype associated with a gain-of-function mutation in hopscotch and enhances the phenotype associated with a weak hopscotch mutation. We propose that Hopscotch activates Marelle to regulate transcription of target genes such as the pair rule gene even-skipped. Our results demonstrate the existence of an invertebrate JAK/STAT system.	HARVARD UNIV,SCH MED,DEPT GENET,BOSTON,MA 02115	Harvard University; Harvard Medical School	Hou, XS (corresponding author), HARVARD UNIV,SCH MED,HOWARD HUGHES MED INST,BOSTON,MA 02115, USA.			Perrimon, Norbert/0000-0001-7542-472X				ANDERSON KV, 1984, NATURE, V311, P223, DOI 10.1038/311223a0; ARGETSINGER LS, 1993, CELL, V74, P237, DOI 10.1016/0092-8674(93)90415-M; BINARI R, 1994, GENE DEV, V8, P300, DOI 10.1101/gad.8.3.300; BLACKMAN RK, 1987, CELL, V49, P497, DOI 10.1016/0092-8674(87)90452-1; BLALOCK JE, 1994, IMMUNOL TODAY, V15, P504, DOI 10.1016/0167-5699(94)90205-4; BROWN NH, 1988, J MOL BIOL, V203, P425, DOI 10.1016/0022-2836(88)90010-1; CAVENER DR, 1987, NUCLEIC ACIDS RES, V15, P1353, DOI 10.1093/nar/15.4.1353; CHOU TB, 1992, GENETICS, V131, P643; CHOU TB, 1993, DEVELOPMENT, V119, P1359; CORWIN HO, 1976, MOL GEN GENET, V144, P345, DOI 10.1007/BF00341734; DELSAL G, 1989, BIOTECHNIQUES, V7, P514; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GOTO T, 1989, CELL, V57, P413, DOI 10.1016/0092-8674(89)90916-1; GOUILLEUX F, 1994, EMBO J, V13, P4361, DOI 10.1002/j.1460-2075.1994.tb06756.x; GOUILLEUX F, 1995, EMBO J, V14, P2005, DOI 10.1002/j.1460-2075.1995.tb07192.x; HARRISON DA, 1995, EMBO J, V14, P2857, DOI 10.1002/j.1460-2075.1995.tb07285.x; HORVATH CM, 1995, GENE DEV, V9, P984, DOI 10.1101/gad.9.8.984; HOU JZ, 1995, IMMUNITY, V2, P321, DOI 10.1016/1074-7613(95)90140-X; HOU JZ, 1994, SCIENCE, V265, P1701, DOI 10.1126/science.8085155; HOU XS, 1995, CELL, V81, P63, DOI 10.1016/0092-8674(95)90371-2; IHLE JN, 1995, TRENDS GENET, V11, P69, DOI 10.1016/S0168-9525(00)89000-9; IHLE JN, 1995, NATURE, V377, P591, DOI 10.1038/377591a0; IHLE JN, 1994, TRENDS BIOCHEM SCI, V19, P222, DOI 10.1016/0968-0004(94)90026-4; KRIEG PA, 1987, METHOD ENZYMOL, V155, P397; LINDSLEY D, 1990, DROS INF SERV, P68; LUO H, 1995, EMBO J, V14, P1412, DOI 10.1002/j.1460-2075.1995.tb07127.x; MULLER M, 1993, NATURE, V366, P129, DOI 10.1038/366129a0; NARAZAKI M, 1994, P NATL ACAD SCI USA, V91, P2285, DOI 10.1073/pnas.91.6.2285; OCONNELL P, 1984, NUCLEIC ACIDS RES, V12, P5495, DOI 10.1093/nar/12.13.5495; PALLARD C, 1995, EMBO J, V14, P2847, DOI 10.1002/j.1460-2075.1995.tb07284.x; PANKRATZ MJ, 1990, CELL, V61, P309, DOI 10.1016/0092-8674(90)90811-R; PERRIMON N, 1986, DEV BIOL, V118, P28, DOI 10.1016/0012-1606(86)90070-9; QUELLE FW, 1994, MOL CELL BIOL, V14, P4335, DOI 10.1128/MCB.14.7.4335; ROBERTSON HM, 1988, GENETICS, V118, P461; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; SILVENNOINEN O, 1993, P NATL ACAD SCI USA, V90, P8429, DOI 10.1073/pnas.90.18.8429; SMALL S, 1991, GENE DEV, V5, P827, DOI 10.1101/gad.5.5.827; SMALL S, 1996, IN PRESS DEV BIOL; SMALL S, 1992, EMBO J, V11, P4077; SMITH AG, 1992, DEV BIOL, V151, P339, DOI 10.1016/0012-1606(92)90174-F; SPRADLING AC, 1995, P NATL ACAD SCI USA, V92, P10824, DOI 10.1073/pnas.92.24.10824; STANOJEVIC D, 1989, NATURE, V341, P331, DOI 10.1038/341331a0; STANOJEVIC D, 1991, SCIENCE, V254, P1385, DOI 10.1126/science.1683715; TANIGUCHI T, 1995, SCIENCE, V268, P251, DOI 10.1126/science.7716517; THUMMEL CS, 1988, GENE, V74, P445, DOI 10.1016/0378-1119(88)90177-1; WAKAO H, 1992, J BIOL CHEM, V267, P16365; WAKAO H, 1994, EMBO J, V13, P2183; WATLING D, 1993, NATURE, V366, P166, DOI 10.1038/366166a0; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; Wieschaus E., 1986, P199; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L	54	305	318	0	9	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 9	1996	84	3					411	419		10.1016/S0092-8674(00)81286-6	http://dx.doi.org/10.1016/S0092-8674(00)81286-6			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TV708	8608595	Bronze			2022-12-28	WOS:A1996TV70800010
J	Ihle, JN				Ihle, JN			STATs: Signal transducers and activators of transcription	CELL			English	Review											Ihle, JN (corresponding author), ST JUDE CHILDRENS RES HOSP, DEPT BIOCHEM, 332 N LAUDERDALE ST, MEMPHIS, TN 38105 USA.							BHAT GJ, 1994, J BIOL CHEM, V269, P31443; CARNELL JE, 1994, SCIENCE, V264, P1415; COPELAND NG, 1995, GENOMICS, V29, P225, DOI 10.1006/geno.1995.1235; DAVID M, 1995, SCIENCE, V269, P1721, DOI 10.1126/science.7569900; DURBIN JE, 1996, CELL, V18, P336; GRUSBY MJ, 1990, P NATL ACAD SCI USA, V87, P6897, DOI 10.1073/pnas.87.17.6897; HEIM MH, 1995, SCIENCE, V267, P1347, DOI 10.1126/science.7871432; Hou XS, 1996, CELL, V84, P411, DOI 10.1016/S0092-8674(00)81286-6; IHLE JN, 1995, TRENDS GENET, V11, P69, DOI 10.1016/S0168-9525(00)89000-9; IHLE JN, 1995, NATURE, V377, P591, DOI 10.1038/377591a0; IHLE JN, 1995, ANNU REV IMMUNOL, V13, P369, DOI 10.1146/annurev.iy.13.040195.002101; MARRERO MB, 1995, NATURE, V375, P247, DOI 10.1038/375247a0; Meraz MA, 1996, CELL, V84, P431, DOI 10.1016/S0092-8674(00)81288-X; QUELLE FW, 1996, IN PRESS MOL CELL BI; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; STAHL N, 1995, SCIENCE, V267, P1349, DOI 10.1126/science.7871433; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; Yan RQ, 1996, CELL, V84, P421, DOI 10.1016/S0092-8674(00)81287-8; YU CL, 1995, SCIENCE, V269, P81, DOI 10.1126/science.7541555; ZHANG Z, 1995, SCIENCE, V267, P1990	20	1250	1295	0	15	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	FEB 9	1996	84	3					331	334		10.1016/S0092-8674(00)81277-5	http://dx.doi.org/10.1016/S0092-8674(00)81277-5			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TV708	8608586	Bronze			2022-12-28	WOS:A1996TV70800001
J	Kurz, A; Sessler, DI; Lenhardt, R				Kurz, A; Sessler, DI; Lenhardt, R			Perioperative normothermia to reduce the incidence of surgical-wound infection and shorten hospitalization	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							TISSUE OXYGEN; RISK; HYPOTHERMIA; TEMPERATURE; ANESTHESIA; PERFUSION; KINETICS; COLLAGEN; SURGERY; HUMANS	Background. Mild perioperative hypothermia, which is common during major surgery, may promote surgical-wound infection by triggering thermoregulatory vasoconstriction, which decreases subcutaneous oxygen tension. Reduced levels of oxygen in tissue impair oxidative killing by neutrophils and decrease the strength of the healing wound by reducing the deposition of collagen, Hypothermia also directly impairs immune function. We tested the hypothesis that hypothermia both increases susceptibility to surgical-wound infection and lengthens hospitalization. Methods. Two hundred patients undergoing colorectal surgery were randomly assigned to routine intraoperative thermal care (the hypothermia group) or additional warming (the normothermia group). The patients' anesthetic care was standardized, and they were all given cefamandole and metronidazole. in a double-blind protocol, their wounds were evaluated daily until discharge from the hospital and in the clinic after two weeks; wounds containing culture-positive pus were considered infected. The patients' surgeons remained unaware of the patients' group assignments. Results. The mean (+/-SD) final intraoperative core temperature was 34.7+/-0.6 degrees C in the hypothermia group and 36.6+/-0.5 degrees C in the normothermia group (P<0.001), Surgical-wound infections were found in 18 of 96 patients assigned to hypothermia (19 percent) but in only 6 of 104 patients assigned to normothermia (6 percent, P = 0.009). The sutures were removed one day later in the patients assigned to hypothermia than in those assigned to normothermia (P = 0.002), and the duration of hospitalization was prolonged by 2.6 days (approximately 20 percent) in the hypothermia group (P = 0.01). Conclusions. Hypothermia itself may delay healing and predispose patients to wound infections, Maintaining normothermia intraoperatively is likely to decrease the incidence of infectious complications in patients undergoing colorectal resection and to shorten their hospitalizations. (C) 1996, Massachusetts Medical Society.	UNIV CALIF SAN FRANCISCO,DEPT ANESTHESIA,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,THERMOREGULAT RES LAB,SAN FRANCISCO,CA 94143; UNIV VIENNA,DEPT ANESTHESIOL,VIENNA,AUSTRIA; UNIV VIENNA,DEPT GEN INTENS CARE,VIENNA,AUSTRIA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of Vienna; University of Vienna			Sessler, Daniel/D-3504-2011	Sessler, Daniel/0000-0001-9932-3077; Kurz, Andrea/0000-0001-5887-3099	NIGMS NIH HHS [GM49670, GM27345] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049670, P50GM027345] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANNADATA R, 1995, ANESTHESIOLOGY, V83, P1205, DOI 10.1097/00000542-199512000-00011; BABIOR BM, 1990, SEMIN HEMATOL, V27, P247; BREMMELGAARD A, 1989, J HOSP INFECT, V13, P1, DOI 10.1016/0195-6701(89)90090-X; BYRNE DJ, 1989, BIOMED PHARMACOTHER, V43, P669, DOI 10.1016/0753-3322(89)90085-1; CHANG N, 1982, PLAST RECONSTR SURG, V70, P1; CLASSEN DC, 1992, NEW ENGL J MED, V326, P281, DOI 10.1056/NEJM199201303260501; CULVER DH, 1991, AM J MED, V91, pS152, DOI 10.1016/0002-9343(91)90361-Z; DEJONG L, 1984, BIOCHIM BIOPHYS ACTA, V787, P105; FLEMING TR, 1984, CONTROL CLIN TRIALS, V5, P348, DOI 10.1016/S0197-2456(84)80014-8; FRANK SM, 1992, ANESTHESIOLOGY, V77, P252, DOI 10.1097/00000542-199208000-00005; FRANK SM, 1995, ANESTHESIOLOGY, V82, P83, DOI 10.1097/00000542-199501000-00012; HALEY RW, 1985, AM J EPIDEMIOL, V121, P206, DOI 10.1093/oxfordjournals.aje.a113991; HOHN DC, 1976, SURG FORUM, V27, P18; HUNT TK, 1972, SURG GYNECOL OBSTETR, V135, P561; JENSEN JA, 1991, ARCH SURG-CHICAGO, V126, P1131; JENSEN LS, 1992, BRIT J SURG, V79, P513, DOI 10.1002/bjs.1800790613; JONSSON K, 1988, ANN SURG, V208, P783; JONSSON K, 1987, BRIT J SURG, V74, P263, DOI 10.1002/bjs.1800740413; JONSSON K, 1991, ANN SURG, V214, P605, DOI 10.1097/00000658-199111000-00011; KNIGHTON DR, 1984, ARCH SURG-CHICAGO, V119, P199; KURZ A, 1993, ANESTH ANALG, V77, P89; LEIJH PCJ, 1979, IMMUNOLOGY, V37, P453; MACKOWIAK PA, 1981, REV INFECT DIS, V3, P508; MADER JT, 1980, J INFECT DIS, V142, P915, DOI 10.1093/infdis/142.6.915; MATSUKAWA T, 1995, ANESTHESIOLOGY, V82, P662, DOI 10.1097/00000542-199503000-00008; MATSUKAWA T, 1995, ANESTHESIOLOGY, V82, P1169, DOI 10.1097/00000542-199505000-00012; MICHELSON AD, 1994, THROMB HAEMOSTASIS, V71, P633; MILES AA, 1957, BRIT J EXP PATHOL, V38, P79; MOUDGIL GC, 1981, CAN ANAESTH SOC J, V28, P232, DOI 10.1007/BF03005506; OZAKI M, 1995, ANESTH ANALG, V80, P1212, DOI 10.1097/00000539-199506000-00025; PROCKOP DJ, 1979, NEW ENGL J MED, V301, P13, DOI 10.1056/NEJM197907053010104; RABKIN J M, 1986, Surgical Forum (Chicago), V37, P592; ROHRER MJ, 1992, CRIT CARE MED, V20, P1402, DOI 10.1097/00003246-199210000-00007; RUBINSTEIN EH, 1990, ANESTHESIOLOGY, V73, P541, DOI 10.1097/00000542-199009000-00027; Schmied H, 1996, LANCET, V347, P289, DOI 10.1016/S0140-6736(96)90466-3; SESSLER DI, 1991, ANESTHESIOLOGY, V75, P594, DOI 10.1097/00000542-199110000-00009; Sheffield C W, 1994, Wound Repair Regen, V2, P48, DOI 10.1046/j.1524-475X.1994.20108.x; SHEFFIELD CW, 1994, ACTA ANAESTH SCAND, V38, P201, DOI 10.1111/j.1399-6576.1994.tb03873.x; SHEFFIELD CW, IN PRESS WOUND REPAI; STOPINSKI J, 1993, J CHIR-PARIS, V130, P422; VANOSS CJ, 1980, J RETICULOENDOTH SOC, V27, P561	41	1709	1803	1	58	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 9	1996	334	19					1209	1215		10.1056/NEJM199605093341901	http://dx.doi.org/10.1056/NEJM199605093341901			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UJ054	8606715	Bronze			2022-12-28	WOS:A1996UJ05400001
J	Lifton, RP				Lifton, RP			Molecular genetics of human blood pressure variation	SCIENCE			English	Article							APPARENT MINERALOCORTICOID EXCESS; GLUCOCORTICOID-REMEDIABLE ALDOSTERONISM; HUMAN ESSENTIAL-HYPERTENSION; FAMILIAL AGGREGATION; RENIN GENE; RATS; EXPRESSION; SYNTHASE; LINKAGE; PSEUDOHYPOALDOSTERONISM	Hypertension is a common multifactorial vascular disorder of largely unknown cause. Recognition that hypertension is in part genetically determined has motivated studies to identify mutations that confer susceptibility. Thus far, mutations in at least 10 genes have been shown to alter blood pressure; most of these are rare mutations imparting large quantitative effects that either raise or lower blood pressure. These mutations alter blood pressure through a common pathway, changing salt and water reabsorption in the kidney. These findings demonstrate the utility of molecular genetic approaches to the understanding of blood pressure variation and may provide insight into the physiologic mechanisms underlying common forms of hypertension.	YALE UNIV, SCH MED, DEPT MED, BOYER CTR MOLEC MED, NEW HAVEN, CT 06510 USA; YALE UNIV, SCH MED, DEPT GENET, NEW HAVEN, CT 06510 USA	Yale University; Yale University	Lifton, RP (corresponding author), YALE UNIV, SCH MED, HOWARD HUGHES MED INST, 295 CONGRESS AVE, NEW HAVEN, CT 06510 USA.							ARRIZA JR, 1987, SCIENCE, V230, P268; BETTINELLI A, 1992, J PEDIATR-US, V120, P38, DOI 10.1016/S0022-3476(05)80594-3; BIRON P, 1976, CAN MED ASSOC J, V115, P773; BONNARDEAUX A, 1994, HYPERTENSION, V24, P63, DOI 10.1161/01.HYP.24.1.63; BOTEROVELEZ M, 1994, NEW ENGL J MED, V330, P178, DOI 10.1056/NEJM199401203300305; CANESSA CM, 1994, NATURE, V367, P463, DOI 10.1038/367463a0; CANNESSA CM, 1993, NATURE, V361, P467; Chang SS, 1996, NAT GENET, V12, P248, DOI 10.1038/ng0396-248; CHEEK DB, 1958, ARCH DIS CHILD, V33, P252, DOI 10.1136/adc.33.169.252; CHRISTIAN JC, 1985, CHILDRENS BLOOD PRES, P51; CURNOW KM, 1993, P NATL ACAD SCI USA, V90, P4552, DOI 10.1073/pnas.90.10.4552; DAHL LK, 1975, CIRC RES, V36, P692, DOI 10.1161/01.RES.36.6.692; DAVIES JL, 1994, NATURE, V371, P130, DOI 10.1038/371130a0; DENTON D, 1995, NAT MED, V1, P1009, DOI 10.1038/nm1095-1009; DILLON MJ, 1980, ARCH DIS CHILD, V55, P427, DOI 10.1136/adc.55.6.427; DIMARTINONARDI J, 1987, CLIN ENDOCRINOL, V27, P49, DOI 10.1111/j.1365-2265.1987.tb00838.x; DUBAY C, 1993, NAT GENET, V3, P354, DOI 10.1038/ng0493-354; EDWARDS C R W, 1985, Journal of Endocrinology, V104, P53; FUNDER JW, 1988, SCIENCE, V242, P583, DOI 10.1126/science.2845584; GAMBA G, 1993, P NATL ACAD SCI USA, V90, P2749, DOI 10.1073/pnas.90.7.2749; GAMBA G, 1994, J BIOL CHEM, V269, P17713; Gitelman H J, 1966, Trans Assoc Am Physicians, V79, P221; GROBBEE DE, 1994, TXB HYPERTENSION, P539; GUYTON AC, 1991, SCIENCE, V252, P1813, DOI 10.1126/science.2063193; HANSSON JH, 1995, P NATL ACAD SCI USA, V92, P11495, DOI 10.1073/pnas.92.25.11495; HANSSON JH, 1995, NAT GENET, V11, P76, DOI 10.1038/ng0995-76; HASHIMOTO L, 1994, NATURE, V371, P161, DOI 10.1038/371161a0; HASTBACKA J, 1992, NAT GENET, V2, P204, DOI 10.1038/ng1192-204; HERMUS A, 1991, HORM METAB RES, V23, P572, DOI 10.1055/s-2007-1003757; HILBERT P, 1991, NATURE, V353, P521, DOI 10.1038/353521a0; JACOB HJ, 1991, CELL, V67, P213, DOI 10.1016/0092-8674(91)90584-L; JEUNEMAITRE X, 1992, CELL, V71, P169, DOI 10.1016/0092-8674(92)90275-H; JEUNEMAITRE X, 1992, HUM GENET, V88, P301; JEUNEMAITRE X, 1992, NAT GENET, V1, P72, DOI 10.1038/ng0492-72; JEUNEMAITRE X, 1994, NAT GENET, V24, P63; KARL M, 1993, J CLIN ENDOCR METAB, V76, P683, DOI 10.1210/jc.76.3.683; KATER CE, 1994, ENDOCRIN METAB CLIN, V23, P341, DOI 10.1016/S0889-8529(18)30101-4; KAWAMOTO T, 1990, BIOCHEM BIOPH RES CO, V173, P309, DOI 10.1016/S0006-291X(05)81058-7; KIM HS, 1995, P NATL ACAD SCI USA, V92, P2735, DOI 10.1073/pnas.92.7.2735; LIDDLE GW, 1963, T ASSOC AM PHYSICIAN, V76, P199; LIFTON RP, 1992, NAT GENET, V2, P66, DOI 10.1038/ng0992-66; LIFTON RP, 1992, NATURE, V355, P262, DOI 10.1038/355262a0; LIFTON RP, 1991, HYPERTENSION, V1, P8; LONGINI IM, 1984, AM J EPIDEMIOL, V120, P131, DOI 10.1093/oxfordjournals.aje.a113862; MORNET E, 1989, J BIOL CHEM, V264, P20961; MUNE T, 1995, NAT GENET, V10, P394, DOI 10.1038/ng0895-394; NABIKA T, 1995, HYPERTENSION, V25, P6, DOI 10.1161/01.HYP.25.1.6; NEW MI, 1977, J CLIN ENDOCR METAB, V44, P924, DOI 10.1210/jcem-44-5-924; NEW MI, 1967, J CLIN ENDOCR METAB, V27, P300, DOI 10.1210/jcem-27-2-300; OBERFIELD SE, 1983, J CLIN ENDOCR METAB, V56, P332, DOI 10.1210/jcem-56-2-332; OGISHIMA T, 1991, J BIOL CHEM, V266, P10731; PASCOE L, 1992, P NATL ACAD SCI USA, V89, P8327, DOI 10.1073/pnas.89.17.8327; PERUSSE L, 1991, AM J HUM GENET, V49, P94; POPOW C, 1988, ACTA PAEDIATR SCAND, V77, P136, DOI 10.1111/j.1651-2227.1988.tb10612.x; PUFFENBERGER EG, 1994, HUM MOL GENET, V3, P1217; RAPP JP, 1989, SCIENCE, V243, P542, DOI 10.1126/science.2563177; RETTIG R, 1993, J HYPERTENS, V11, P883, DOI 10.1097/00004872-199309000-00001; RICE T, 1990, AM J HUM GENET, V46, P37; RICH GM, 1992, ANN INTERN MED, V116, P813, DOI 10.7326/0003-4819-116-10-813; SCHILD L, 1995, P NATL ACAD SCI USA, V92, P5699, DOI 10.1073/pnas.92.12.5699; SHACKLETON CHL, 1990, ENDOCRINE HYPERTENSI, P155; SHIMKETS RA, 1994, CELL, V79, P407, DOI 10.1016/0092-8674(94)90250-X; Simon DB, 1996, NAT GENET, V12, P24, DOI 10.1038/ng0196-24; SMITHIES O, 1995, P NATL ACAD SCI USA, V92, P5266, DOI 10.1073/pnas.92.12.5266; SNYDER PM, 1995, CELL, V83, P969, DOI 10.1016/0092-8674(95)90212-0; STEWART PM, 1987, LANCET, V2, P821; Strautnieks SS, 1996, HUM MOL GENET, V5, P293, DOI 10.1093/hmg/5.2.293; SUTHERLAND DJ, 1966, CAN MED ASSOC J, V95, P1109; ULICK S, 1979, J CLIN ENDOCR METAB, V49, P757, DOI 10.1210/jcem-49-5-757; ULICK S, 1990, J CLIN ENDOCR METAB, V71, P1151, DOI 10.1210/jcem-71-5-1151; ULICK S, 1992, J CLIN ENDOCR METAB, V74, P963, DOI 10.1210/jc.74.5.963; WEINBERGER MH, 1986, HYPERTENSION, V8, P127, DOI 10.1161/01.HYP.8.6_Pt_2.II127; WHITE PC, 1994, ENDOCRIN METAB CLIN, V23, P325, DOI 10.1016/S0889-8529(18)30100-2; WILSON RC, 1995, J CLIN ENDOCR METAB, V80, P2263, DOI 10.1210/jc.80.7.2263; 1994, SCIENCE, V265, P2049	75	509	526	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 3	1996	272	5262					676	680		10.1126/science.272.5262.676	http://dx.doi.org/10.1126/science.272.5262.676			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UJ051	8614826				2022-12-28	WOS:A1996UJ05100034
J	Chiu, BCH; Cerhan, JR; Folsom, AR; Sellers, TA; Kushi, LH; Wallace, RB; Zheng, W; Potter, JD				Chiu, BCH; Cerhan, JR; Folsom, AR; Sellers, TA; Kushi, LH; Wallace, RB; Zheng, W; Potter, JD			Diet and risk of non-Hodgkin lymphoma in older women	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							FOOD FREQUENCY QUESTIONNAIRE; PEYER PATCHES; CANCER; MICE; FAT; 2-AMINO-1-METHYL-6-PHENYLIMIDAZO<4,5-B>PYRIDINE; REPRODUCIBILITY; CARCINOGENESIS	Objective.-To test whether high dietary intakes of fat, protein, and milk are associated with the development of non-Hodgkin lymphoma in older women. Design.-Prospective cohort study with a 7-year follow-up period. Setting.-General community. Participants.-Sample of 35 156 Iowa women aged 55 to 69 years with no prior history of cancer who returned the 1986 baseline questionnaire. Main Outcome Measure.-Non-Hodgkin lymphoma (104 incident cases). Main Results.-After controlling for age, marital status, residence, total energy intake, and transfusion history, the relative risks (RRs) for the highest tertile of intake compared with the lowest were 2.00 (95% confidence interval [CI], 1.21-3.30; P for trend=.01) for animal fat, 1.69 (95% CI, 1.07-2.67; P for trend=.02) for saturated fat, and 1.90 (95% CI, 1.18-3.04; P for trend=.01) for monounsaturated fat, and there was no association with vegetable fat or polyunsaturated fat. Greater intake of animal protein (RR=1.52; 95% CI, 0.94-2.44; P for trend=.08), but not vegetable protein, was associated with elevated risk, and this was mainly explained by greater consumption of red meat (RR=1.98; 95% CI, 1.13-3.47; P for trend=.02) and hamburger in particular (RR=2.35; 95% CI, 1.23-4.48; P for trend=.02). Milk and dairy product consumption were not associated with elevated risk. There was also a decreased risk of non-Hodgkin lymphoma with greater consumption of fruits (RR=0.64; 95% CI, 0.40-1.05; P for trend=.07). Conclusions.-A high-meat diet and a high intake of fat from animal sources is associated with an increased risk of non-Hodgkin lymphoma in older women.	UNIV IOWA, COLL MED, DEPT PREVENT MED & ENVIRONM HLTH, IOWA CITY, IA 52242 USA; UNIV MINNESOTA, SCH PUBL HLTH, DIV EPIDEMIOL, MINNEAPOLIS, MN 55455 USA; FRED HUTCHINSON CANC RES CTR, SEATTLE, WA 98104 USA	University of Iowa; University of Minnesota System; University of Minnesota Twin Cities; Fred Hutchinson Cancer Center			Zheng, Wei/O-3351-2013; zhang, weihua/GXV-1334-2022	Zheng, Wei/0000-0003-1226-070X; Cerhan, James/0000-0002-7482-178X; Potter, John/0000-0001-5439-1500; Kushi, Lawrence/0000-0001-9136-1175	NATIONAL CANCER INSTITUTE [R01CA039742] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA39742] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BALLESTER OF, 1993, J AM GERIATR SOC, V41, P1245, DOI 10.1111/j.1532-5415.1993.tb07310.x; BISGARD KM, 1994, AM J EPIDEMIOL, V139, P990, DOI 10.1093/oxfordjournals.aje.a116948; BOST KL, 1986, CARCINOGENESIS, V7, P1257, DOI 10.1093/carcin/7.8.1257; BOST KL, 1986, CARCINOGENESIS, V7, P1251, DOI 10.1093/carcin/7.8.1251; CANTOR KP, 1988, AM J PUBLIC HEALTH, V78, P570, DOI 10.2105/AJPH.78.5.570; CARROLL KK, 1986, CANCER, V58, P1818, DOI 10.1002/1097-0142(19861015)58:8+<1818::AID-CNCR2820581406>3.0.CO;2-4; CERHAN JR, 1993, ANN INTERN MED, V119, P8, DOI 10.7326/0003-4819-119-1-199307010-00002; CINADER B, 1983, IMMUNOL LETT, V6, P331, DOI 10.1016/0165-2478(83)90077-9; COX DR, 1972, J R STAT SOC B, V34, P187; CUNNINGHAM AS, 1976, LANCET, V2, P1184; DAVIS DAP, 1994, FUND APPL TOXICOL, V23, P81, DOI 10.1006/faat.1994.1082; DAVIS S, 1992, CANCER RES, V52, pS5492; ERICKSON KL, 1986, INT J IMMUNOPHARMACO, V8, P529, DOI 10.1016/0192-0561(86)90023-8; ESUMI H, 1989, JPN J CANCER RES, V80, P1176, DOI 10.1111/j.1349-7006.1989.tb01651.x; FOLSOM AR, 1990, AM J EPIDEMIOL, V131, P794, DOI 10.1093/oxfordjournals.aje.a115570; FOLSOM AR, IN PRESS J OCCUP ENV; FRANCESCHI S, 1989, NUTR CANCER, V12, P333, DOI 10.1080/01635588909514034; FRIEDMAN A, 1994, CHEM IMMUNOL, V58, P259; LYNCH CF, 1994, AM J PUBLIC HEALTH, V84, P469, DOI 10.2105/AJPH.84.3.469; MALVY DJM, 1993, INT J EPIDEMIOL, V22, P761, DOI 10.1093/ije/22.5.761; MOWAT AM, 1987, IMMUNOL TODAY, V8, P93, DOI 10.1016/0167-5699(87)90853-X; MUNGER RG, 1992, AM J EPIDEMIOL, V136, P192, DOI 10.1093/oxfordjournals.aje.a116485; NIGG HN, 1990, EFFECTS PESTICIDES H, P35; OHGAKI H, 1987, CARCINOGENESIS, V8, P665, DOI 10.1093/carcin/8.5.665; PEARCE N, 1992, CANCER RES, V52, pS5496; RABKIN CS, 1993, SEMIN HEMATOL, V30, P286; Ries L, 1994, NIH PUBLICATION, V94-2789; STEINMETZ KA, 1994, AM J EPIDEMIOL, V139, P1; TURTELTAUB KW, 1992, CANCER RES, V52, P4682; URSIN G, 1990, BRIT J CANCER, V61, P454, DOI 10.1038/bjc.1990.100; VITALE JJ, 1981, CANCER RES, V41, P3706; WARD MH, 1994, CANCER CAUSE CONTROL, V5, P422, DOI 10.1007/BF01694756; WEISENBURGER DD, 1994, ANN ONCOL, V5, pS19, DOI 10.1093/annonc/5.suppl_1.S19; WILLETT W, 1986, AM J EPIDEMIOL, V124, P17, DOI 10.1093/oxfordjournals.aje.a114366; WILLETT WC, 1985, AM J EPIDEMIOL, V122, P51, DOI 10.1093/oxfordjournals.aje.a114086; World Health Organization, 1976, INT CLASS DIS; YESS NJ, 1991, J ASSOC OFF ANA CHEM, V74, P273; ZAHM SH, 1993, ARCH ENVIRON HEALTH, V48, P353, DOI 10.1080/00039896.1993.9936725	38	115	115	0	7	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 1	1996	275	17					1315	1321		10.1001/jama.275.17.1315	http://dx.doi.org/10.1001/jama.275.17.1315			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UG612	8614116				2022-12-28	WOS:A1996UG61200027
J	Goodman, R; Graham, P				Goodman, R; Graham, P			Psychiatric problems in children with hemiplegia: Cross sectional epidemiological survey	BRITISH MEDICAL JOURNAL			English	Article							DISORDER; PREVALENCE	Objective-To examine the prevalence and predictors of psychiatric problems in children with hemiplegia. Design-Cross sectional questionnaire survey of an epidemiological sample with individual assessments of a representative subgroup, The questionnaire survey was repeated on school age subjects four years later. Subjects-428 hemiplegic children aged 2 1/2-16 years, of whom 149 (aged 6-10 years) were individually assessed. Main outcome measures-Psychiatric symptom scores and the occurrence of psychiatric disorder. Results-Psychiatric disorders affected 61% (95% confidence interval 53% to 69%) of subjects as judged by individual assessments and 54% (49% to 59%) and 42% (37% to 47%) as judged from parent and teacher questionnaires, respectively, Few affected children had been in contact with child mental health services, The strongest consistent predictor of psychiatric problems was intelligence quotient (IQ), which was highly correlated with an index of neurological severity; age, sex, and laterality of lesion had little or no predictive power. Conclusion-Though most hemiplegic children have considerable emotional or behavioural difficulties, these psychological complications commonly go unrecognised or untreated, Comprehensive health provision for children with chronic neurodevelopmental disorders such as hemiplegia should be psychologically as well as physically oriented.	INST CHILD HLTH,BEHAV SCI UNIT,LONDON WC1N 1EH,ENGLAND	University of London; University College London	Goodman, R (corresponding author), INST PSYCHIAT,DEPT CHILD & ADOLESCENT PSYCHIAT,DE CRESPIGNY PK,LONDON SE5 8AF,ENGLAND.				Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		American Psychiatric Association, 2000, DSM 4 DIAGN STAT MAN, V4th ed., DOI DOI 10.1001/JAMA.1994.03520100096; BRANDENBURG NA, 1990, J AM ACAD CHILD PSY, V29, P76, DOI 10.1097/00004583-199001000-00013; BRESLAU N, 1985, J AM ACAD CHILD PSY, V24, P87, DOI 10.1016/S0002-7138(09)60415-5; BROWN G, 1981, PSYCHOL MED, V11, P63, DOI 10.1017/S0033291700053289; GOODMAN R, 1994, J CHILD PSYCHOL PSYC, V35, P1483, DOI 10.1111/j.1469-7610.1994.tb01289.x; GOODMAN R, 1995, J CHILD PSYCHOL PSYC, V36, P409, DOI 10.1111/j.1469-7610.1995.tb01299.x; Goodman R, 1996, J CHILD PSYCHOL PSYC, V37, P369, DOI 10.1111/j.1469-7610.1996.tb01418.x; Goodman R, 1996, DEV MED CHILD NEUROL, V38, P156; GOODMAN R, 1995, EUR CHILD ADOLES PSY, V4, P187, DOI 10.1007/BF01980457; GOODMAN R, 1994, CHILD ADOLESCENT PSY, P49; GOODMAN R, IN PRESS DEV MED CHI; KORNHUBER HH, 1985, EUR ARCH PSY CLIN N, V235, P129, DOI 10.1007/BF00380981; MCGUIRE J, 1986, J CHILD PSYCHOL PSYC, V27, P7, DOI 10.1111/j.1469-7610.1986.tb00618.x; Richman N., 1977, EPIDEMIOLOGICAL APPR, P125; RUTTER M, 1975, BRIT J PSYCHIAT, V126, P493, DOI 10.1192/bjp.126.6.493; RUTTER M, 1967, J CHILD PSYCHOL PSYC, V8, P1, DOI 10.1111/j.1469-7610.1967.tb02175.x; RUTTER M, 1968, BRIT J PSYCHIAT, V114, P563, DOI 10.1192/bjp.114.510.563; RUTTER M, 1970, ED HLTH BEHAVIOR; Rutter M., 1970, CLIN DEV MED, V35; SEIDEL UP, 1975, DEV MED CHILD NEUROL, V17, P563; TAYLOR E, 1986, BRIT J PSYCHIAT, V149, P760, DOI 10.1192/bjp.149.6.760; Wechsler DW., 1999, INTELLIGENCE SCALE C; WHO, 2012, ICD 10 CLASS MENT BE	23	100	100	0	7	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 27	1996	312	7038					1065	1069						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	UH816	8616413				2022-12-28	WOS:A1996UH81600024
J	Bothwell, M				Bothwell, M			p75(NTR): Receptor after all	SCIENCE			English	Editorial Material							NERVE GROWTH-FACTOR; AFFINITY NGF RECEPTOR; SCHWANN-CELLS; EXPRESSION; INDUCTION; BINDING				Bothwell, M (corresponding author), WASEDA UNIV,DEPT PHYSIOL & BIOPHYS,SEATTLE,WA 98192, USA.							ANTON ES, 1994, P NATL ACAD SCI USA, V91, P2795, DOI 10.1073/pnas.91.7.2795; Baker SJ, 1996, ONCOGENE, V12, P1; BARBACID M, 1994, J NEUROBIOL, V25, P1386, DOI 10.1002/neu.480251107; BARRETT GL, 1994, P NATL ACAD SCI USA, V91, P6501, DOI 10.1073/pnas.91.14.6501; BEUTLER B, 1994, SCIENCE, V264, P667, DOI 10.1126/science.8171316; Carter BD, 1996, SCIENCE, V272, P542, DOI 10.1126/science.272.5261.542; DAVIES AM, 1993, NEURON, V11, P565, DOI 10.1016/0896-6273(93)90069-4; DOBROWSKY RT, 1994, SCIENCE, V265, P1596, DOI 10.1126/science.8079174; DOBROWSKY RT, 1995, J BIOL CHEM, V270, P22135, DOI 10.1074/jbc.270.38.22135; HANTZOPOULOS PA, 1994, NEURON, V13, P187, DOI 10.1016/0896-6273(94)90469-3; HEMPSTEAD BL, 1991, NATURE, V350, P678, DOI 10.1038/350678a0; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; JOHNSON D, 1986, CELL, V47, P545, DOI 10.1016/0092-8674(86)90619-7; KLEIN R, 1994, FASEB J, V8, P738, DOI 10.1096/fasebj.8.10.8050673; LEE KF, 1992, CELL, V69, P737, DOI 10.1016/0092-8674(92)90286-L; LEE KF, 1994, SCIENCE, V263, P1447, DOI 10.1126/science.8128229; Pronk GJ, 1996, SCIENCE, V271, P808, DOI 10.1126/science.271.5250.808; RABIZADEH S, 1993, SCIENCE, V261, P345, DOI 10.1126/science.8332899; RADEKE MJ, 1987, NATURE, V325, P593, DOI 10.1038/325593a0; RODRIGUEZTEBAR A, 1990, NEURON, V4, P487, DOI 10.1016/0896-6273(90)90107-Q; RODRIGUEZTEBAR A, 1993, EUR J BIOCHEM, V211, P789, DOI 10.1111/j.1432-1033.1993.tb17610.x; ROSS AH, 1984, P NATL ACAD SCI-BIOL, V81, P6681, DOI 10.1073/pnas.81.21.6681; ROTHE M, 1995, SCIENCE, V269, P1424, DOI 10.1126/science.7544915; SEILHEIMER B, 1987, EMBO J, V6, P1611, DOI 10.1002/j.1460-2075.1987.tb02408.x; TANIUCHI M, 1986, P NATL ACAD SCI USA, V83, P4094, DOI 10.1073/pnas.83.11.4094; VONBARTHELD CS, 1994, NEURON, V12, P639, DOI 10.1016/0896-6273(94)90219-4; VONBARTHELD CS, 1996, IN PRESS J NEUROSCI; WOLF DE, 1995, J BIOL CHEM, V270, P2133, DOI 10.1074/jbc.270.5.2133; YAN Q, 1987, DEV BIOL, V121, P139, DOI 10.1016/0012-1606(87)90147-3	29	121	124	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 26	1996	272	5261					506	507		10.1126/science.272.5261.506	http://dx.doi.org/10.1126/science.272.5261.506			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UG826	8614797				2022-12-28	WOS:A1996UG82600030
J	Schneider, BL; Yang, QH; Futcher, AB				Schneider, BL; Yang, QH; Futcher, AB			Linkage of replication to start by the Cdk inhibitor Sic1	SCIENCE			English	Article							PROTEIN-KINASE ACTIVITY; SACCHAROMYCES-CEREVISIAE; YEAST; CYCLINS; CLB5; DNA	In Saccharomyces cerevisiae, three G(1) cyclins (Clns) are important for Start, the event committing cells to division. Sic1, an inhibitor of Clb-Cdc28 kinases, became phosphorylated at Start, and this phosphorylation depended on the activity of Clns. Sic1 was subsequently lost, which depended on the activity of Clns and the ubiquitin-conjugating enzyme Cdc34. Inactivation of Sic1 was the only nonredundant essential function of Clns, because a sic1 deletion rescued the inviability of the cln1 cln2 cln3 triple mutant. In sic1 mutants, DNA replication became uncoupled from budding. Thus, Sic1 may be a substrate of Cln-Cdc28 complexes, and phosphorylation and proteolysis of Sic1 may regulate commitment to replication at Start.	SUNY STONY BROOK, GRAD PROGRAM GENET, STONY BROOK, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Schneider, BL (corresponding author), COLD SPRING HARBOR LAB, POB 100, COLD SPRING HARBOR, NY 11724 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM039978] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM39978] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CROSS F, UNPUB COMMUNICATION; CROSS FR, COMMUNICATION; DIRICK L, 1995, EMBO J, V14, P4803, DOI 10.1002/j.1460-2075.1995.tb00162.x; DONOVAN JD, 1994, GENE DEV, V8, P1640, DOI 10.1101/gad.8.14.1640; EPSTEIN CB, 1994, MOL CELL BIOL, V14, P2041, DOI 10.1128/MCB.14.3.2041; EPSTEIN CB, 1992, GENE DEV, V6, P1695, DOI 10.1101/gad.6.9.1695; GARRELS J, UNPUB; MEASDAY V, 1994, SCIENCE, V266, P1391, DOI 10.1126/science.7973731; MENDENHALL MD, 1987, CELL, V50, P927, DOI 10.1016/0092-8674(87)90519-8; MENDENHALL MD, 1993, SCIENCE, V259, P216, DOI 10.1126/science.8421781; Nasmyth K, 1993, CURR OPIN CELL BIOL, V5, P166, DOI 10.1016/0955-0674(93)90099-C; NUGROHO TT, 1994, MOL CELL BIOL, V14, P3320, DOI 10.1128/MCB.14.5.3320; REED SI, 1985, P NATL ACAD SCI USA, V82, P4055, DOI 10.1073/pnas.82.12.4055; SCHNEIDER BL, UNPUB; SCHWOB E, 1994, CELL, V79, P233, DOI 10.1016/0092-8674(94)90193-7; SCHWOB E, 1993, GENE DEV, V7, P1160, DOI 10.1101/gad.7.7a.1160; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; SHERR CJ, 1995, TRENDS BIOCHEM SCI, V20, P187, DOI 10.1016/S0968-0004(00)89005-2; THOMAS BJ, 1989, CELL, V56, P619, DOI 10.1016/0092-8674(89)90584-9; TYERS M, 1993, EMBO J, V12, P1955, DOI 10.1002/j.1460-2075.1993.tb05845.x; YAGLOM J, 1995, MOL CELL BIOL, V15, P731	21	195	197	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 26	1996	272	5261					560	562		10.1126/science.272.5261.560	http://dx.doi.org/10.1126/science.272.5261.560			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UG826	8614808				2022-12-28	WOS:A1996UG82600048
J	Miles, MM; Shaw, RJ				Miles, MM; Shaw, RJ			Effect of inadvertent intradermal administration of high dose percutaneous BCG vaccine	BRITISH MEDICAL JOURNAL			English	Article									PARKSIDE HLTH COMMUNITY TRUST,LONDON W9 3XZ,ENGLAND; ST MARYS HOSP,CHEST & ALLERGY CLIN,LONDON W2 1NY,ENGLAND	Imperial College London								*DEP HLTH, 1992, IMM INF DIS, P76; HALL C, 1994, INDEPENDENT     1125, P4; 1990, BRIT MED J, V30, P995	3	3	3	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 20	1996	312	7037					1014	1014						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UG610	8616349				2022-12-28	WOS:A1996UG61000027
J	Li, JM; Nagpal, P; Vitart, V; McMorris, TC; Chory, J				Li, JM; Nagpal, P; Vitart, V; McMorris, TC; Chory, J			A role for brassinosteroids in light-dependent development of Arabidopsis	SCIENCE			English	Article							ARTIFICIAL CHROMOSOME LIBRARY; PLANT-GROWTH; GENE	Although steroid hormones are important for animal development, the physiological role of plant steroids is unknown. The Arabidopsis DET2 gene encodes a protein that shares significant sequence identity with mammalian steroid 5 alpha-reductases. A mutation of glutamate 204, which is absolutely required for the activity of human steroid reductase, abolishes the in vivo activity of DET2 and leads to defects in light-regulated development that can be ameliorated by application of a plant steroid, brassinolide. Thus, DET2 may encode a reductase in the brassinolide biosynthetic pathway, and brassinosteroids may constitute a distinct dass of phytohormones with an important role in light-regulated development of higher plants.	SALK INST BIOL STUDIES, PLANT BIOL LAB, LA JOLLA, CA 92037 USA; UNIV CALIF SAN DIEGO, DEPT CHEM, LA JOLLA, CA 92037 USA	Salk Institute; University of California System; University of California San Diego			Li, Jianming/O-1772-2014	Li, Jianming/0000-0003-3231-0778; Nagpal, Punita/0000-0003-2257-9183; Vitart, Veronique/0000-0002-4991-3797				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Arteca Richard N., 1995, P206; BECHTOLD N, 1993, CR ACAD SCI III-VIE, V316, P1194; BELL CJ, 1994, GENOMICS, V19, P137, DOI 10.1006/geno.1994.1023; BENT AF, 1994, SCIENCE, V265, P1856, DOI 10.1126/science.8091210; BOWLER C, 1994, PLANT CELL, V6, P1529, DOI 10.1105/tpc.6.11.1529; CHORY J, 1993, TRENDS GENET, V9, P167, DOI 10.1016/0168-9525(93)90163-C; CHORY J, 1991, PLANT CELL, V3, P445, DOI 10.1105/tpc.3.5.445; CHORY J, 1994, PLANT PHYSIOL, V104, P339, DOI 10.1104/pp.104.2.339; Davies Peter J., 1995, P1; DEGREEF JA, 1983, PHOTOMORPHOGENESIS, P401; Dellaporta SL, 1983, PLANT MOL BIOL REP, V1, P19, DOI DOI 10.1007/BF02712670; ECKER J R, 1990, Methods (Orlando), V1, P186, DOI 10.1016/S1046-2023(05)80134-3; FUJIOKA S, 1995, BIOSCI BIOTECH BIOCH, V59, P1973, DOI 10.1271/bbb.59.1973; GEUNS JMC, 1978, PHYTOCHEMISTRY, V17, P1, DOI 10.1016/S0031-9422(00)89671-5; GRILL E, 1991, MOL GEN GENET, V226, P484, DOI 10.1007/BF00260662; HIGGINS DG, 1989, COMPUT APPL BIOSCI, V5, P151; KIEBER JJ, 1993, CELL, V72, P427, DOI 10.1016/0092-8674(93)90119-B; KONIECZNY A, 1993, PLANT J, V4, P403, DOI 10.1046/j.1365-313X.1993.04020403.x; Li J. P. H., UNPUB; MANDAVA NB, 1988, ANNU REV PLANT PHYS, V39, P23, DOI 10.1146/annurev.arplant.39.1.23; MCNELLIS TW, 1995, PLANT CELL, V7, P1749, DOI 10.1105/tpc.7.11.1749; MILLAR AJ, 1995, SCIENCE, V267, P1163, DOI 10.1126/science.7855596; OLSZEWSKI NE, 1988, NUCLEIC ACIDS RES, V16, P10765, DOI 10.1093/nar/16.22.10765; RUSSELL DW, 1994, ANNU REV BIOCHEM, V63, P25, DOI 10.1146/annurev.bi.63.070194.000325; WARD ER, 1990, PLANT MOL BIOL, V14, P561, DOI 10.1007/BF00027501; WILSON JD, 1993, ENDOCR REV, V14, P577, DOI 10.1210/er.14.5.577	27	672	723	12	144	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 19	1996	272	5260					398	401		10.1126/science.272.5260.398	http://dx.doi.org/10.1126/science.272.5260.398			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UG252	8602526				2022-12-28	WOS:A1996UG25200043
J	Tobler, I; Gaus, SE; Deboer, T; Achermann, P; Fischer, M; Rulicke, T; Moser, M; Oesch, B; McBride, PA; Manson, JC				Tobler, I; Gaus, SE; Deboer, T; Achermann, P; Fischer, M; Rulicke, T; Moser, M; Oesch, B; McBride, PA; Manson, JC			Altered circadian activity rhythms and sleep in mice devoid of prion protein	NATURE			English	Article							FATAL FAMILIAL INSOMNIA; GENE; SCRAPIE; NUCLEI; RATS; EEG	There is a wealth of data supporting a central role for the prion protein (PrP) in the neurodegenerative prion diseases of both humans and other species(1), yet the normal function of PrP, which is expressed at the cell surface of neurons and glial cells(2,3), is unknown. It has been speculated that neuropathology may be due to loss of normal function of PrP (ref. 4). Here we show that in mice devoid of PrP there is an alteration in both circadian activity rhythms and sleep patterns. To our knowledge, this is the first null mutation that has been shown to affect sleep regulation and our results indicate that the pathology of at least one of the inherited prion diseases, fatal familial insomnia(5), where there is a profound alteration in sleep and the daily rhythms of many hormones(6-10), may be related to the normal function of the prion protein.	UNIV ZURICH,DEPT 1,INST MOLEC BIOL,CH-8093 ZURICH,SWITZERLAND; UNIV ZURICH HOSP,CENT BIOL LAB,CH-8091 ZURICH,SWITZERLAND; UNIV ZURICH,BRAIN RES INST,CH-8029 ZURICH,SWITZERLAND; BBSRC,INST ANIM HLTH,EDINBURGH EH9 3JF,MIDLOTHIAN,SCOTLAND; MRC,NEUROPATHOGENESIS UNIT,EDINBURGH EH9 3JF,MIDLOTHIAN,SCOTLAND	University of Zurich; University of Zurich; University Zurich Hospital; University of Zurich; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Pirbright Institute; Roslin Institute; University of Edinburgh	Tobler, I (corresponding author), UNIV ZURICH,INST PHARMACOL,WINTERTHURERSTR 190,CH-8057 ZURICH,SWITZERLAND.		Achermann, Peter/N-1215-2014	Achermann, Peter/0000-0002-0208-3511				Borbely AA, 1994, PRINCIPLES PRACTICE, P309; BUELER H, 1992, NATURE, V356, P577, DOI 10.1038/356577a0; BULT A, 1993, BRAIN RES BULL, V32, P623, DOI 10.1016/0361-9230(93)90164-7; COLLINGE J, 1994, NATURE, V370, P295, DOI 10.1038/370295a0; DEBOER T, 1994, J COMP PHYSIOL A, V174, P145; DEBOER T, 1995, BRAIN RES, V670, P153, DOI 10.1016/0006-8993(94)01299-W; FISCHER M, IN PRESS EMBO J; FRANKEN P, 1991, AM J PHYSIOL, V261, pR198, DOI 10.1152/ajpregu.1991.261.1.R198; FRIEDMAN.JK, 1974, PHYSIOL BEHAV, V12, P169, DOI 10.1016/0031-9384(74)90169-3; GAMBETTI P, 1995, BRAIN PATHOL, V5, P43, DOI 10.1111/j.1750-3639.1995.tb00576.x; LUGARESI E, 1986, NEW ENGL J MED, V315, P997, DOI 10.1056/NEJM198610163151605; Manson J., 1992, Neurodegeneration, V1, P45; MANSON JC, 1995, NEURODEGENERATION, V4, P113; MANSON JC, 1994, MOL NEUROBIOL, V8, P121, DOI 10.1007/BF02780662; MEDORI R, 1992, NEW ENGL J MED, V326, P444, DOI 10.1056/NEJM199202133260704; MONTAGNA P, 1995, ADV NEUROIMMUNOL, V5, P13, DOI 10.1016/0960-5428(94)00042-M; MOSER M, 1995, NEURON, V14, P509, DOI 10.1016/0896-6273(95)90307-0; PORTALUPPI F, 1994, J CLIN ENDOCR METAB, V78, P1075, DOI 10.1210/jc.78.5.1075; POSSIDENTE B, 1988, BEHAV GENET, V18, P109, DOI 10.1007/BF01067080; PRUSINER SB, 1991, SCIENCE, V252, P1515, DOI 10.1126/science.1675487; REDER AT, 1995, NEUROLOGY, V45, P1068, DOI 10.1212/WNL.45.6.1068; SCHWARTZ WJ, 1990, J NEUROSCI, V10, P3685; TOBLER I, 1986, ELECTROEN CLIN NEURO, V64, P74, DOI 10.1016/0013-4694(86)90044-1; VALATX JL, 1974, BRAIN RES, V69, P315, DOI 10.1016/0006-8993(74)90009-2; VALATX JL, 1972, NATURE, V238, P226, DOI 10.1038/238226a0; VITATERNA MH, 1994, SCIENCE, V264, P719, DOI 10.1126/science.8171325; WESTAWAY D, 1986, NUCLEIC ACIDS RES, V14, P2035, DOI 10.1093/nar/14.5.2035	28	509	524	0	26	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	APR 18	1996	380	6575					639	642		10.1038/380639a0	http://dx.doi.org/10.1038/380639a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UF741	8602267				2022-12-28	WOS:A1996UF74100050
J	Doerner, P; Jorgensen, JE; You, R; Steppuhn, J; Lamb, C				Doerner, P; Jorgensen, JE; You, R; Steppuhn, J; Lamb, C			Control of root growth and development by cyclin expression	NATURE			English	Article							ARABIDOPSIS-THALIANA; CELL-PROLIFERATION; GENE; FIBROBLASTS; ONCOGENE; G(1)	ROOT development is plastic, with post-embryonic organogenesis being mediated by meristems(1), Although cell division is intrinsic to meristem initiation, maintenance and proliferative growth, the role of the cell cycle in regulating growth and development is unclear, To address this question, we examined the expression of cdc2 and eye genes, which encode the catalytic and regulatory subunits, respectively, of cyclin-dependent protein kinases that control progression through the cell cycle(2). Unlike cdc2, which is expressed not only in apical meristems but also before lateral root initiation(3) in quiescent, pericycle cells arrested in the G2 phase of the cell cycle(4), cyc1At transcripts accumulate specifically in dividing cells immediately before cytokinesis. Ectopic expression of cyc1At under the control of the cdc2aAt promoter in Arabidopsis plants markedly accelerates growth without altering the pattern of lateral root development or inducing neoplasia. Thus cyclin expression is a limiting factor for growth, which in turn drives indeterminate development of the root system.			Doerner, P (corresponding author), SALK INST BIOL STUDIES,PLANT BIOL LAB,10010 N TORREY PINES RD,LA JOLLA,CA 92037, USA.			Doerner, Peter/0000-0001-7218-8469				Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BECHTOLD N, 1993, CR ACAD SCI III-VIE, V316, P1194; BECKER D, 1992, PLANT MOL BIOL, V20, P1195, DOI 10.1007/BF00028908; BLAKELY LM, 1979, PLANT SCI LETT, V14, P79, DOI 10.1016/0304-4211(79)90158-5; CELENZA JL, 1995, GENE DEV, V9, P2131, DOI 10.1101/gad.9.17.2131; DOLAN L, 1993, DEVELOPMENT, V119, P71; DREW MC, 1975, NEW PHYTOL, V75, P479, DOI 10.1111/j.1469-8137.1975.tb01409.x; DREWS GN, 1991, CELL, V65, P991, DOI 10.1016/0092-8674(91)90551-9; FERREIRA PCG, 1994, PLANT CELL, V6, P1763, DOI 10.1105/tpc.6.12.1763; FOBERT PR, 1994, EMBO J, V13, P616, DOI 10.1002/j.1460-2075.1994.tb06299.x; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; HEMERLY A, 1992, P NATL ACAD SCI USA, V89, P3295, DOI 10.1073/pnas.89.8.3295; HEMERLY A, 1995, EMBO J, V14, P3295; HEMERLY AS, 1993, PLANT CELL, V5, P1711, DOI 10.1105/tpc.5.12.1711; HIRAYAMA T, 1991, GENE, V105, P159, DOI 10.1016/0378-1119(91)90146-3; KONCZ C, 1986, MOL GEN GENET, V204, P383, DOI 10.1007/BF00331014; MARTINEZ MC, 1992, P NATL ACAD SCI USA, V89, P7360, DOI 10.1073/pnas.89.16.7360; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; MURASHIGE T, 1962, PHYSIOL PLANTARUM, V15, P473, DOI 10.1111/j.1399-3054.1962.tb08052.x; MURRAY A, 1993, CELL CYCLE; NORRIS SR, 1993, PLANT MOL BIOL, V21, P895, DOI 10.1007/BF00027120; OHTSUBO M, 1993, SCIENCE, V259, P1908, DOI 10.1126/science.8384376; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; RESNITZKY D, 1995, MOL CELL BIOL, V15, P3463; ROSENBERG CL, 1991, P NATL ACAD SCI USA, V88, P9638, DOI 10.1073/pnas.88.21.9638; SKAPEK SX, 1995, SCIENCE, V267, P1022, DOI 10.1126/science.7863328; STEEVES TA, 1989, PATTERNS PLANT DEV, P1; WANG TC, 1994, NATURE, V369, P669, DOI 10.1038/369669a0; WITHERS DA, 1991, MOL CELL BIOL, V11, P4846, DOI 10.1128/MCB.11.10.4846	30	309	336	1	27	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	APR 11	1996	380	6574					520	523		10.1038/380520a0	http://dx.doi.org/10.1038/380520a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UE663	8606769				2022-12-28	WOS:A1996UE66300047
J	Polson, AG; Bass, BL; Casey, JL				Polson, AG; Bass, BL; Casey, JL			RNA editing of hepatitis delta virus antigenome by dsRNA-adenosine deaminase	NATURE			English	Article							UNWINDING ACTIVITY; MAMMALIAN-CELLS; GENOME; REPLICATION; EXPRESSION; MECHANISM	HEPATITIS delta virus (HDV) is a subviral human pathogen that requires hepatitis B virus (HBV) for packaging(1,2). Concurrent infection by HBV and HDV increases the risk of severe liver disease compared to infection with HBV alone(3). The HDV genome is a closed circular RNA of about 1,700 bases which is replicated through an RNA intermediate, the antigenome(4). Both RNAs cars be folded into highly base-paired, rod-shaped structures, similar to the plant viroid RNAs(5). Two forms of the sole HDV protein, hepatitis delta antigen, are derived from a single open reading frame by RNA editing; the enzymes responsible for the editing have not been characterized, Here we report that the purified enzyme dsRAD (for double-stranded-RNA-adenosine deaminase) can edit HDV antigenomic RNA in vitro. Most important, we observe that mutations in critical sequences of the antigenome have identical effects on in vitro and in vivo editing, suggesting that dsRAD, or a closely related enzyme, is responsible for editing HDV RNA in vivo.	UNIV UTAH,HOWARD HUGHES MED INST,SALT LAKE CITY,UT 84112; GEORGETOWN UNIV,MED CTR,DIV MOL VIROL & IMMUNOL,ROCKVILLE,MD 20852	Howard Hughes Medical Institute; Utah System of Higher Education; University of Utah; Georgetown University	Polson, AG (corresponding author), UNIV UTAH,DEPT BIOCHEM,6110A EIHG,BLDG 533,SALT LAKE CITY,UT 84112, USA.			Casey, John/0000-0003-0396-9856				BASS BL, 1988, CELL, V55, P1089, DOI 10.1016/0092-8674(88)90253-X; BASS BL, 1987, CELL, V48, P607, DOI 10.1016/0092-8674(87)90239-X; BASS BL, 1993, RNA WORLD, P383; CASEY JL, 1995, J VIROL, V69, P7593, DOI 10.1128/JVI.69.12.7593-7600.1995; CASEY JL, 1992, P NATL ACAD SCI USA, V89, P7149, DOI 10.1073/pnas.89.15.7149; CHAO M, 1990, J VIROL, V64, P5066, DOI 10.1128/JVI.64.10.5066-5069.1990; HOUGH RF, 1994, J BIOL CHEM, V269, P9933; Hurst SR, 1995, RNA, V1, P1051; KUO MYP, 1989, J VIROL, V63, P1945, DOI 10.1128/JVI.63.5.1945-1950.1989; LAI MMC, 1995, ANNU REV BIOCHEM, V64, P259, DOI 10.1146/annurev.bi.64.070195.001355; LOMELI H, 1994, SCIENCE, V266, P1709, DOI 10.1126/science.7992055; LUO GX, 1990, J VIROL, V64, P1021, DOI 10.1128/JVI.64.3.1021-1027.1990; MELCHER T, 1995, J BIOL CHEM, V270, P8566, DOI 10.1074/jbc.270.15.8566; Melcher T, 1996, NATURE, V379, P460, DOI 10.1038/379460a0; NETTER HJ, 1995, J VIROL, V69, P1687, DOI 10.1128/JVI.69.3.1687-1692.1995; POLSON AG, 1994, EMBO J, V13, P5701, DOI 10.1002/j.1460-2075.1994.tb06908.x; RIZZETTO M, 1983, HEPATOLOGY, V3, P729; RUETER SM, 1995, SCIENCE, V267, P1491, DOI 10.1126/science.7878468; RYU WS, 1992, J VIROL, V66, P2310, DOI 10.1128/JVI.66.4.2310-2315.1992; SACCOMANNO L, 1994, MOL CELL BIOL, V14, P5425, DOI 10.1128/MCB.14.8.5425; TANG JR, 1994, J MED VIROL, V42, P1, DOI 10.1002/jmv.1890420102; WAGNER RW, 1989, P NATL ACAD SCI USA, V86, P2647, DOI 10.1073/pnas.86.8.2647; WAGNER RW, 1988, MOL CELL BIOL, V8, P770, DOI 10.1128/MCB.8.2.770; WANG KS, 1986, NATURE, V323, P508, DOI 10.1038/323508a0; WU JC, 1991, J VIROL, V65, P1099, DOI 10.1128/JVI.65.3.1099-1104.1991; YANG JH, 1995, NATURE, V374, P77, DOI 10.1038/374077a0; ZHENG HQ, 1992, J VIROL, V66, P4693, DOI 10.1128/JVI.66.8.4693-4697.1992	27	256	264	0	13	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	APR 4	1996	380	6573					454	456						3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UD590	8602246				2022-12-28	WOS:A1996UD59000066
J	RiveraPomar, R; Niessing, D; SchmidtOtt, U; Gehring, WJ; Jackle, H				RiveraPomar, R; Niessing, D; SchmidtOtt, U; Gehring, WJ; Jackle, H			RNA binding and translational suppression by bicoid	NATURE			English	Article							SEGMENTATION GENE HUNCHBACK; DROSOPHILA EMBRYOS; BODY PATTERN; GRADIENT; PROTEIN; TRANSCRIPTION; EXPRESSION; KRUPPEL; LOCALIZATION; ANTERIOR	THE anterior determinant bicoid (bcd) of Drosophila is a homeodomain protein. It forms an anterior-to-posterior gradient in the embryo and activates, in a concentration-dependent manner, several zygotic segmentation genes during blastoderm formation(1-4). Its posterior counterpart, the homeodomain transcription factor caudal (cad)(5-7), forms a concentration gradient in the opposite direction, emanating from evenly distributed messenger RNA in the egg. In embryos lacking bcd activity as a result of mutation, the cad gradient fails to form and cad becomes evenly distributed throughout the embryo(8). This suggests that bcd may act in the region-specific control of cad mRNA translation. Here we report that bcd binds through its homeodomain to cad mRNA in vitro, and exerts translational control through a bcd-binding region of cad mRNA.	UNIV BASEL,BIOZENTRUM,CH-4056 BASEL,SWITZERLAND	University of Basel	RiveraPomar, R (corresponding author), MAX PLANCK INST BIOPHYS CHEM,ABT MOLEK ENTWICKLUNGSBIOL,FASSBERG,D-37077 GOTTINGEN,GERMANY.		Niessing, Dierk/AAE-4936-2022; Niessing, Dierk/M-4619-2014	Niessing, Dierk/0000-0002-5589-369X; Niessing, Dierk/0000-0002-5589-369X				BERLETH T, 1988, EMBO J, V7, P1749, DOI 10.1002/j.1460-2075.1988.tb03004.x; DRIEVER W, 1988, CELL, V54, P83, DOI 10.1016/0092-8674(88)90182-1; DRIEVER W, 1989, NATURE, V337, P138, DOI 10.1038/337138a0; DRIEVER W, 1989, THESIS EBERHARD KARL; HESS MA, 1994, J BIOL CHEM, V269, P10913; HUISKAMP M, 1988, NATURE, V338, P629; KERRIGAN LA, 1991, J BIOL CHEM, V266, P574; LEHMANN R, 1987, NATURE, V329, P167, DOI 10.1038/329167a0; MACDONALD PM, 1986, NATURE, V324, P537, DOI 10.1038/324537a0; MLODZIK M, 1987, CELL, V48, P465, DOI 10.1016/0092-8674(87)90197-8; MLODZIK M, 1987, DEVELOPMENT, V101, P421; MLODZIK M, 1985, EMBO J, V4, P2961, DOI 10.1002/j.1460-2075.1985.tb04030.x; MULLER M, 1988, EMBO J, V7, P4299, DOI 10.1002/j.1460-2075.1988.tb03328.x; MURATA Y, 1995, CELL, V80, P747, DOI 10.1016/0092-8674(95)90353-4; Pankratz Michael J., 1993, P467; PIELER T, 1993, TRENDS BIOCHEM SCI, V18, P226, DOI 10.1016/0968-0004(93)90194-R; REBAGLIATI M, 1989, CELL, V58, P231, DOI 10.1016/0092-8674(89)90834-9; RIVERAPOMAR R, 1995, NATURE, V376, P253, DOI 10.1038/376253a0; RUDEN DM, 1995, DEVELOPMENT, V121, P63; SAUER F, 1993, NATURE, V364, P454, DOI 10.1038/364454a0; SAUER F, 1991, NATURE, V353, P563, DOI 10.1038/353563a0; SIMPSONBROSE M, 1994, CELL, V78, P855, DOI 10.1016/S0092-8674(94)90622-X; SOELLER WC, 1988, GENE DEV, V2, P68, DOI 10.1101/gad.2.1.68; STJOHNSTON RD, 1992, CELL, V68, P201; STRUHL G, 1989, NATURE, V338, P741, DOI 10.1038/338741a0; STRUHL G, 1989, CELL, V57, P1259, DOI 10.1016/0092-8674(89)90062-7; TAUTZ D, 1988, NATURE, V332, P281, DOI 10.1038/332281a0; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; WHARTON RP, 1991, CELL, V67, P955, DOI 10.1016/0092-8674(91)90368-9	29	250	254	1	13	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	FEB 22	1996	379	6567					746	749		10.1038/379746a0	http://dx.doi.org/10.1038/379746a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TW567	8602224				2022-12-28	WOS:A1996TW56700058
J	Dusheiko, GM; Khakoo, S; Soni, P; Grellier, L				Dusheiko, GM; Khakoo, S; Soni, P; Grellier, L			Fortnightly review a rational approach to the management of hepatitis C infection	BMJ-BRITISH MEDICAL JOURNAL			English	Article							RECOMBINANT INTERFERON-ALFA; ALPHA-INTERFERON; CONTROLLED TRIAL; VIRUS; ANTIBODIES; THERAPY; HCV				Dusheiko, GM (corresponding author), UNIV LONDON ROYAL FREE HOSP, SCH MED, DEPT MED, LONDON NW3 2QG, ENGLAND.		Dusheiko, Geoffrey M/C-7677-2010	Khakoo, Salim/0000-0002-4057-9091				ATTILI AF, 1994, J HEPATOL, V20, P315, DOI 10.1016/S0168-8278(94)80001-4; BELOQUI O, 1993, J INTERFERON RES, V13, P279, DOI 10.1089/jir.1993.13.279; CARELLA C, 1995, HORM RES, V44, P110, DOI 10.1159/000184606; CHEMELLO L, 1995, HEPATOLOGY, V22, P700, DOI 10.1016/0270-9139(95)90286-4; CLEMENTE MG, 1994, J PEDIATR-US, V125, P123, DOI 10.1016/S0022-3476(94)70138-5; DAVIS GL, 1989, NEW ENGL J MED, V321, P1501, DOI 10.1056/NEJM198911303212203; DIBISCEGLIE AM, 1992, GASTROENTEROLOGY, V102, P2108, DOI 10.1016/0016-5085(92)90339-Z; DIBISCEGLIE AM, 1989, NEW ENGL J MED, V321, P1506, DOI 10.1056/NEJM198911303212204; Dusheiko G, 1994, J Viral Hepat, V1, P3, DOI 10.1111/j.1365-2893.1994.tb00057.x; DUSHEIKO G, 1996, IN PRESS J HEPATOLOG; DUSHEIKO GM, 1990, LANCET, V336, P503, DOI 10.1016/0140-6736(90)92049-N; ELGOHARY A, 1995, ACTA TROP, V59, P155, DOI 10.1016/0001-706X(95)00075-P; Enomoto N, 1996, NEW ENGL J MED, V334, P77, DOI 10.1056/NEJM199601113340203; EYSTER ME, 1991, ANN INTERN MED, V115, P764, DOI 10.7326/0003-4819-115-10-764; FERNANDEZ H, 1986, European Journal of Epidemiology, V2, P1, DOI 10.1007/BF00152711; FERRARI C, 1994, HEPATOLOGY, V19, P286; GARCIABUEY L, 1995, GASTROENTEROLOGY, V108, P1770, DOI 10.1016/0016-5085(95)90139-6; GIRELLI CM, 1995, AM J GASTROENTEROL, V90, P170; HAYASHI H, 1994, AM J GASTROENTEROL, V89, P986; KANAI K, 1995, BIOMED PHARMACOTHER, V49, P65, DOI 10.1016/0753-3322(96)82588-1; LENZI M, 1991, LANCET, V338, P277, DOI 10.1016/0140-6736(91)90418-O; LESNIEWSKI R, 1995, J MED VIROL, V45, P415, DOI 10.1002/jmv.1890450411; LOK ASF, 1990, HEPATOLOGY, V12, P1266, DOI 10.1002/hep.1840120603; MAYET WJ, 1989, HEPATOLOGY, V10, P24, DOI 10.1002/hep.1840100106; MIYAKAWA H, 1993, ALCOHOL ALCOHOLISM, V28, P85, DOI 10.1093/alcalc/28.Supplement_1A.85; NISHIGUCHI S, 1995, LANCET, V346, P1051, DOI 10.1016/S0140-6736(95)91739-X; ORITO E, 1995, J MED VIROL, V46, P109, DOI 10.1002/jmv.1890460205; POYNARD T, 1995, NEW ENGL J MED, V332, P1457, DOI 10.1056/NEJM199506013322201; REICHARD O, 1994, HEPATOLOGY, V19, P280; RENAULT PF, 1989, SEMIN LIVER DIS, V9, P273, DOI 10.1055/s-2008-1040523; SAWADA M, 1993, ALCOHOL ALCOHOLISM, V28, P85, DOI 10.1093/alcalc/28.Supplement_1B.85; SHINDO M, 1995, ANN INTERN MED, V122, P586, DOI 10.7326/0003-4819-122-8-199504150-00005; SIMMONDS P, 1994, HEPATOLOGY, V19, P1321, DOI 10.1016/0270-9139(94)90887-7; SIMMONDS P, IN PRESS J HEPATOL; SUZUKI T, 1995, J MED VIROL, V46, P162, DOI 10.1002/jmv.1890460215; TAKANO S, 1994, HEPATOLOGY, V20, P558, DOI 10.1016/0270-9139(94)90088-4; THALER MM, 1991, LANCET, V338, P17, DOI 10.1016/0140-6736(91)90006-B; VANTHIEL DH, 1994, J HEPATOL, V20, P410, DOI 10.1016/S0168-8278(94)80017-0; VARAGONA G, 1992, EUR J GASTROEN HEPAT, V4, P707; WEINER AJ, 1994, VIRAL HEPATITIS LIVE, P463; YAMADA G, 1992, DIGEST DIS SCI, V37, P1926, DOI 10.1007/BF01308091; ZANETTI AR, 1995, LANCET, V345, P289, DOI 10.1016/S0140-6736(95)90277-5; ZUMBUSCHENFELDE KHM, 1995, J HEPATOL, V22, P93	43	35	36	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 10	1996	312	7027					357	364						8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TV698	8611836	Green Published			2022-12-28	WOS:A1996TV69800029
J	Moormeier, J				Moormeier, J			Breast cancer in black women	ANNALS OF INTERNAL MEDICINE			English	Review							ESTROGEN REPLACEMENT THERAPY; LATE-STAGE DIAGNOSIS; PROGESTERONE RECEPTORS; WHITE WOMEN; SOCIOECONOMIC-STATUS; RACIAL-DIFFERENCES; CERVICAL-CANCER; NATIONAL SURVEY; UNITED-STATES; SOCIAL-CLASS	Purpose: To review the current knowledge about breast cancer in black women-including epidemiology, risk factors, screening practices, pathology, clinical manifestations, treatment, and outcome-with emphasis on issues that might explain why the survival rate in this population of women is lower than that in white women. Data Sources: The MEDLINE database from 1966 to 1995 and the bibliographies of all related articles. Study Selection: Review articles and clinical studies related to all aspects of breast cancer in black women. Data Synthesis: The incidence of breast cancer is lower in black women (95.8 cases per 100 000 women) than in white women (112.7 cases per 100 000 women). Differences in reproductive factors may partially explain the lower risk for breast cancer among black women in the United States. Breast tumors in black women are consistently diagnosed at a more advanced stage of disease: Forty-two percent of black women present with cancer confined to the breast compared with 53% of white women. In addition, the cancers of black women tend to be more poorly differentiated and are less likely to be estrogen receptor positive. Treatment of breast cancer in black women appears to be similar to that in white women, but little is known about systemic therapy choices and efficacy. Overall, despite their lower risk for breast cancer, black women have a mortality rate from breast cancer similar to that of white women because they have a lower 5-year disease-specific survival rate (64% in black women compared with 80% in white women). Conclusions: The discrepancy in survival rate between black and white women exists because black women have tumors that are more advanced at the time of diagnosis, because tumor biology in black women is different from that in white women (in particular, black women have a higher frequency of poorly differentiated tumors and a lower frequency of hormone receptor-positive tumors), and because of confounding comorbid conditions and socioeconomic factors. Current efforts to improve survival rates in black women with breast cancer should focus on community education, screening efforts, and early detection. As more information is gained about breast cancer treatment in black women, this may also be an important area for intervention.			Moormeier, J (corresponding author), UNIV MISSOURI, SCH MED, 2411 HOLMES ST, KANSAS CITY, MO 64108 USA.							Ackermann S P, 1992, MMWR CDC Surveill Summ, V41, P17; AMOS CI, 1991, CANCER RES, V51, P1793; AUSTIN H, 1979, INT J CANCER, V24, P541, DOI 10.1002/ijc.2910240504; AYANIAN JZ, 1993, NEW ENGL J MED, V329, P326, DOI 10.1056/NEJM199307293290507; BACQUET CR, 1986, NIH PUBLICATION; BAIN RP, 1986, J CHRON DIS, V39, P631, DOI 10.1016/0021-9681(86)90188-8; BASSETT MT, 1986, AM J PUBLIC HEALTH, V76, P1400, DOI 10.2105/AJPH.76.12.1400; BERG JW, 1977, CANCER, V39, P467, DOI 10.1002/1097-0142(197702)39:2<467::AID-CNCR2820390215>3.0.CO;2-B; BEVERLY LN, 1987, AM J PUBLIC HEALTH, V77, P351, DOI 10.2105/AJPH.77.3.351; BLASZYK H, 1994, LANCET, V343, P1195, DOI 10.1016/S0140-6736(94)92403-1; BODIAN CA, 1993, EPIDEMIOL REV, V15, P177, DOI 10.1093/oxfordjournals.epirev.a036103; BORING CC, 1994, CA-CANCER J CLIN, V44, P7, DOI 10.3322/canjclin.44.1.7; BURACK RC, 1989, AM J PUBLIC HEALTH, V79, P721, DOI 10.2105/AJPH.79.6.721; CALLE EE, 1993, AM J PUBLIC HEALTH, V83, P53, DOI 10.2105/AJPH.83.1.53; CAPLAN LS, 1992, J GERONTOL, V47, P101; CHAMBERLAIN JS, 1993, AM J HUM GENET, V52, P792; CHEN VW, 1994, CANCER EPIDEM BIOMAR, V3, P127; CHEVALLIER B, 1988, CANCER-AM CANCER SOC, V62, P2517, DOI 10.1002/1097-0142(19881215)62:12<2517::AID-CNCR2820621211>3.0.CO;2-9; CLARK GM, 1989, NEW ENGL J MED, V320, P627, DOI 10.1056/NEJM198903093201003; COATES RJ, 1992, JNCI-J NATL CANCER I, V84, P938, DOI 10.1093/jnci/84.12.938; COATES RJ, 1990, J NATL CANCER I, V82, P1684, DOI 10.1093/jnci/82.21.1684; COLDITZ GA, 1995, NEW ENGL J MED, V332, P1589, DOI 10.1056/NEJM199506153322401; CONTESSO G, 1987, J CLIN ONCOL, V5, P1378, DOI 10.1200/JCO.1987.5.9.1378; CROWE JP, 1986, SURGERY, V100, P599; DAWSON DA, 1990, FAM PLANN PERSPECT, V22, P169, DOI 10.2307/2135608; DAYAL HH, 1982, J CHRON DIS, V35, P675, DOI 10.1016/0021-9681(82)90020-0; DEVESA SS, 1980, JNCI-J NATL CANCER I, V65, P515; DIEHR P, 1989, MED CARE, V27, P942, DOI 10.1097/00005650-198910000-00005; DUPONT WD, 1991, ARCH INTERN MED, V151, P67, DOI 10.1001/archinte.151.1.67; ELEY JW, 1994, JAMA-J AM MED ASSOC, V272, P947, DOI 10.1001/jama.272.12.947; ELIAS EG, 1994, J SURG ONCOL, V55, P37, DOI 10.1002/jso.2930550111; ELLEDGE RM, 1994, J NATL CANCER I, V86, P705, DOI 10.1093/jnci/86.9.705; FARLEY TA, 1989, AM J PUBLIC HEALTH, V79, P1508, DOI 10.2105/AJPH.79.11.1508; FLETCHER SW, 1993, JNCI-J NATL CANCER I, V85, P112, DOI 10.1093/jnci/85.2.112; FLETCHER SW, 1993, J NATL CANCER I, V85, P1644, DOI 10.1093/jnci/85.20.1644; FREEMAN HP, 1989, CANCER, V63, P2562, DOI 10.1002/1097-0142(19890615)63:12<2562::AID-CNCR2820631234>3.0.CO;2-0; FUNDERBURK WW, 1972, SURG GYNECOL OBSTETR, V135, P58; GARBER JE, 1991, BREAST DIS, P152; GARRETT PA, 1993, CANCER EPIDEM BIOMAR, V2, P131; GORDON NH, 1992, AM J EPIDEMIOL, V135, P609, DOI 10.1093/oxfordjournals.aje.a116340; GRAY GE, 1980, J NATL CANCER I, V64, P461; HAYWARD RA, 1988, ARCH INTERN MED, V148, P1177, DOI 10.1001/archinte.148.5.1177; HOSKINS KF, 1995, JAMA-J AM MED ASSOC, V273, P577, DOI 10.1001/jama.273.7.577; HUNTER CP, 1993, J NATL CANCER I, V85, P1129, DOI 10.1093/jnci/85.14.1129; HUSEBY RA, 1988, J CLIN ONCOL, V6, P83, DOI 10.1200/JCO.1988.6.1.83; KATZ SJ, 1994, JAMA-J AM MED ASSOC, V272, P530, DOI 10.1001/jama.272.7.530; KELLERMANN AL, 1994, NEW ENGL J MED, V330, P1426; KELSEY JL, 1993, EPIDEMIOL REV, V15, P36, DOI 10.1093/oxfordjournals.epirev.a036115; KIEFE CI, 1994, ARCH INTERN MED, V154, P1217, DOI 10.1001/archinte.154.11.1217; KIMMICK G, 1991, CANCER, V67, P2850, DOI 10.1002/1097-0142(19910601)67:11<2850::AID-CNCR2820671124>3.0.CO;2-S; KOVI J, 1989, PATHOL ANNU, V24, P199; KRIEGER N, 1990, AM J EPIDEMIOL, V131, P804, DOI 10.1093/oxfordjournals.aje.a115571; LACKLAND DT, 1991, SOUTHERN MED J, V84, P862, DOI 10.1097/00007611-199107000-00010; LAMBE M, 1994, NEW ENGL J MED, V331, P5, DOI 10.1056/NEJM199407073310102; LANE DS, 1992, AM J PUBLIC HEALTH, V82, P199, DOI 10.2105/AJPH.82.2.199; LEDOUSSAL V, 1989, CANCER, V64, P1914, DOI 10.1002/1097-0142(19891101)64:9<1914::AID-CNCR2820640926>3.0.CO;2-G; LESSER ML, 1981, CANCER, V48, P299, DOI 10.1002/1097-0142(19810715)48:2<299::AID-CNCR2820480215>3.0.CO;2-2; MacMahon B, 1966, Vital Health Stat 11, P1; MACMAHON B, 1973, VITAL HLTH STAT, V11, P11; MAKUC DM, 1989, AM J PUBLIC HEALTH, V79, P21, DOI 10.2105/AJPH.79.1.21; MANDELBLATT J, 1993, AM J PREV MED, V9, P133, DOI 10.1016/S0749-3797(18)30728-1; MANDELBLATT J, 1991, AM J PUBLIC HEALTH, V81, P646, DOI 10.2105/AJPH.81.5.646; MAYBERRY RM, 1992, AM J EPIDEMIOL, V136, P1445, DOI 10.1093/oxfordjournals.aje.a116465; MCWHORTER WP, 1989, CANCER, V63, P982, DOI 10.1002/1097-0142(19890301)63:5<982::AID-CNCR2820630533>3.0.CO;2-I; MCWHORTER WP, 1987, AM J PUBLIC HEALTH, V77, P1515, DOI 10.2105/AJPH.77.12.1515; MILLER BA, 1993, NIH PUBLICATION; MOHLA S, 1982, CANCER-AM CANCER SOC, V50, P552, DOI 10.1002/1097-0142(19820801)50:3<552::AID-CNCR2820500328>3.0.CO;2-G; MUSS HB, 1992, CANCER-AM CANCER SOC, V70, P2460, DOI 10.1002/1097-0142(19921115)70:10<2460::AID-CNCR2820701012>3.0.CO;2-A; NATARAJAN N, 1985, CANCER-AM CANCER SOC, V56, P1704, DOI 10.1002/1097-0142(19851001)56:7<1704::AID-CNCR2820560740>3.0.CO;2-L; NEMOTO T, 1980, CANCER, V45, P2917, DOI 10.1002/1097-0142(19800615)45:12<2917::AID-CNCR2820451203>3.0.CO;2-M; NEVILLE AM, 1992, J CLIN ONCOL, V10, P696, DOI 10.1200/JCO.1992.10.5.696; OLUWOLE SF, 1979, AM J SURG, V137, P786, DOI 10.1016/0002-9610(79)90094-1; OMALLEY MS, 1987, JAMA-J AM MED ASSOC, V257, P2197; ORGAN CH, 1983, J NATL MED ASSOC, V75, P701; OWNBY HE, 1985, J NATL CANCER I, V75, P55; PEGORARO RJ, 1986, CANCER RES, V46, P2117; PIERCE L, 1992, CANCER-AM CANCER SOC, V69, P2831, DOI 10.1002/1097-0142(19920601)69:11<2831::AID-CNCR2820691132>3.0.CO;2-J; PIKE MC, 1993, EPIDEMIOL REV, V15, P17, DOI 10.1093/oxfordjournals.epirev.a036102; ROSEN PP, 1989, J CLIN ONCOL, V7, P1239, DOI 10.1200/JCO.1989.7.9.1239; SAVAGE N, 1981, S AFR MED J, V59, P623; SCHATZKIN A, 1987, J NATL CANCER I, V78, P213; SCHWARTZ AG, 1991, AM J EPIDEMIOL, V134, P1325, DOI 10.1093/oxfordjournals.aje.a116035; SHATTUCKEIDENS D, 1995, JAMA-J AM MED ASSOC, V273, P535, DOI 10.1001/jama.273.7.535; SHIAO YH, 1995, CANCER RES, V55, P1485; SIGURDSSON H, 1990, NEW ENGL J MED, V322, P1045, DOI 10.1056/NEJM199004123221505; SIMON MS, 1992, CANCER, V69, P466, DOI 10.1002/1097-0142(19920115)69:2<466::AID-CNCR2820690232>3.0.CO;2-7; SKINNER CS, 1994, AM J PUBLIC HEALTH, V84, P43, DOI 10.2105/AJPH.84.1.43; SPRATLEY E, 1977, VITAL HLTH STAT, V27, P1; STEINBERG KK, 1991, JAMA-J AM MED ASSOC, V265, P1985, DOI 10.1001/jama.265.15.1985; SUTHERLAND CM, 1986, CANCER-AM CANCER SOC, V57, P622, DOI 10.1002/1097-0142(19860201)57:3<622::AID-CNCR2820570338>3.0.CO;2-C; SWANSON GM, 1990, CANCER-AM CANCER SOC, V66, P1297, DOI 10.1002/1097-0142(19900915)66:6<1297::AID-CNCR2820660633>3.0.CO;2-M; SWANSON GM, 1993, CANCER, V72, P788, DOI 10.1002/1097-0142(19930801)72:3<788::AID-CNCR2820720326>3.0.CO;2-C; THOMAS DB, 1993, JNCI-J NATL CANCER I, V85, P359, DOI 10.1093/jnci/85.5.359; VERNON SW, 1992, CANCER, V69, P165, DOI 10.1002/1097-0142(19920101)69:1<165::AID-CNCR2820690128>3.0.CO;2-F; VERNON SW, 1985, CANCER-AM CANCER SOC, V55, P1563, DOI 10.1002/1097-0142(19850401)55:7<1563::AID-CNCR2820550726>3.0.CO;2-1; WELLS BL, 1992, AM J PUBLIC HEALTH, V82, P1383, DOI 10.2105/AJPH.82.10.1383; ZELEN M, 1990, P AN M AM SOC CLIN, V9, P59; 1981, CA CANC J CLIN, V31, P212	98	105	106	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 15	1996	124	10					897	905		10.7326/0003-4819-124-10-199605150-00007	http://dx.doi.org/10.7326/0003-4819-124-10-199605150-00007			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UJ801	8610920				2022-12-28	WOS:A1996UJ80100007
J	Scally, G				Scally, G			Physicians can't heal themselves	LANCET			English	Editorial Material											Scally, G (corresponding author), NHS EXECUT S&W,BRISTOL,AVON,ENGLAND.							BOK S, 1993, CAMB Q HEALTHC ETHIC, V2, P341; Femino J, 1994, R I Med, V77, P345; HARRISON D, 1994, ADDICTION, V89, P1613, DOI 10.1111/j.1360-0443.1994.tb03762.x; McKevitt C, 1996, DOCTORS HLTH NEEDS S; *NHS EX, 1994, OCC HLTH SERV NHS ST; *NUFF PROV HOSP TR, 1996, TAK CAR DOCT HLTH RE; PULLEN D, 1995, MED J AUSTRALIA, V162, P481, DOI 10.5694/j.1326-5377.1995.tb140011.x; WHITLEY TW, 1994, ANN EMERG MED, V23, P1068, DOI 10.1016/S0196-0644(94)70105-9	8	5	5	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 20	1996	347	9008					1059	1059		10.1016/S0140-6736(96)90273-1	http://dx.doi.org/10.1016/S0140-6736(96)90273-1			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UG042	8602053				2022-12-28	WOS:A1996UG04200006
J	Toburen, LH				Toburen, LH			Electromagnetic fields, radon, and cancer	LANCET			English	Editorial Material									NATL RES COUNCIL,BOARD RADIAT EFFECTS RES,WASHINGTON,DC 20418	National Academies of Sciences, Engineering & Medicine	Toburen, LH (corresponding author), E CAROLINA UNIV,DEPT PHYS,GREENVILLE,NC 27858, USA.							Henshaw DL, 1996, INT J RADIAT BIOL, V69, P25, DOI 10.1080/095530096146156; *NAT RES COUNC COM, 1988, HLTH RISK RAD OTH IN; *NAT RES COUNC COM, 1994, HLTH EFFECTS EXPOSUR	3	1	1	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 20	1996	347	9008					1059	1060		10.1016/S0140-6736(96)90274-3	http://dx.doi.org/10.1016/S0140-6736(96)90274-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UG042	8602054				2022-12-28	WOS:A1996UG04200007
J	Kahmann, R; Bolker, M				Kahmann, R; Bolker, M			Self nonself recognition in fungi: Old mysteries and simple solutions	CELL			English	Review							MATING-TYPE LOCUS; USTILAGO-MAYDIS; U-MAYDIS; A-ALPHA; ALLELES; SPECIFICITY; PROTEINS				Kahmann, R (corresponding author), UNIV MUNICH,INST GENET & MIKROBIOL,MARIA WARD STR 1A,D-80638 MUNICH,GERMANY.			Bolker, Michael/0000-0002-7366-3855				BANHAM AH, 1995, PLANT CELL, V7, P773, DOI 10.1105/tpc.7.6.773; BANUETT F, 1992, TRENDS GENET, V8, P174, DOI 10.1016/0168-9525(92)90091-H; BOLKER M, 1992, CELL, V68, P441, DOI 10.1016/0092-8674(92)90182-C; CASSELTON LA, 1994, MYCOTA, V1, P307; GILLISSEN B, 1992, CELL, V68, P1; HERSKOWITZ I, 1989, NATURE, V342, P749, DOI 10.1038/342749a0; KAMPER J, 1995, CELL, V81, P73, DOI 10.1016/0092-8674(95)90372-0; Kniep H, 1920, VERH PHYS MED GES WU, V46, P1; KRONSTAD JW, 1990, GENE DEV, V4, P1384, DOI 10.1101/gad.4.8.1384; KRONSTAD JW, 1989, P NATL ACAD SCI USA, V86, P978, DOI 10.1073/pnas.86.3.978; KUES U, 1994, PLANT CELL, V6, P1467, DOI 10.1105/tpc.6.10.1467; KUES U, 1992, GENE DEV, V6, P568, DOI 10.1101/gad.6.4.568; LI T, 1995, SCIENCE, V270, P262, DOI 10.1126/science.270.5234.262; MAGAE Y, 1995, BIOCHEM BIOPH RES CO, V211, P1071, DOI 10.1006/bbrc.1995.1920; OSHEA EK, 1992, CELL, V68, P699, DOI 10.1016/0092-8674(92)90145-3; PUHALLA JE, 1970, GENET RES, V16, P229, DOI 10.1017/S0016672300002457; SCHULZ B, 1990, CELL, V60, P295, DOI 10.1016/0092-8674(90)90744-Y; STANKIS MM, 1992, P NATL ACAD SCI USA, V89, P7169, DOI 10.1073/pnas.89.15.7169; WENDLAND J, 1995, EMBO J, V14, P5271, DOI 10.1002/j.1460-2075.1995.tb00211.x; YEE AR, 1993, P NATL ACAD SCI USA, V90, P664, DOI 10.1073/pnas.90.2.664	20	36	37	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 19	1996	85	2					145	148		10.1016/S0092-8674(00)81091-0	http://dx.doi.org/10.1016/S0092-8674(00)81091-0			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UG255	8612267	Bronze			2022-12-28	WOS:A1996UG25500003
J	Savilahti, H; Mizuuchi, K				Savilahti, H; Mizuuchi, K			Mu transpositional recombination: Donor DNA cleavage and strand transfer in trans by the Mu transposase	CELL			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; POLYNUCLEOTIDYL TRANSFER; INTEGRASE PROTEIN; INVITRO PROCEEDS; BACTERIOPHAGE-MU; SITE; MECHANISM; DOMAINS; IDENTIFICATION; COMPLEX	Central to the Mu transpositional recombination are the two chemical steps; donor DNA cleavage and strand transfer. These reactions occur within the Mu transpososome that contains two Mu DNA end segments bound to a tetramer of MuA, the transposase. To investigate which MuA-monomer catalyzes which chemical reaction, we made transpososomes containing wild-type and active site mutant MuA. By preloading the MuA variants onto Mu end DNA fragments of different length prior to transpososome assembly, we could track the catalysis by MuA bound to each Mu end segment. The donor DNA end that underwent the chemical reaction was identified. Both the donor DNA cleavage and strand transfer were catalyzed in trans by the MuA monomers bound to the partner Mu end. This arrangement explains why the transpososome assembly is a prerequisite for the chemical steps.	NIDDKD, MOLEC BIOL LAB, NIH, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)				Savilahti, Harri/0000-0002-6246-2572				ARCISZEWSKA LK, 1991, NUCLEIC ACIDS RES, V19, P5021, DOI 10.1093/nar/19.18.5021; BAINTON R, 1991, CELL, V65, P805, DOI 10.1016/0092-8674(91)90388-F; BAKER TA, 1992, GENE DEV, V6, P2221, DOI 10.1101/gad.6.11.2221; BAKER TA, 1993, CELL, V74, P723, DOI 10.1016/0092-8674(93)90519-V; BAKER TA, 1994, P NATL ACAD SCI USA, V91, P6654, DOI 10.1073/pnas.91.14.6654; BAKER TA, 1994, GENE DEV, V8, P2416, DOI 10.1101/gad.8.20.2416; Berg DE, 1989, MOBILE DNA; Bolland S, 1996, CELL, V84, P223, DOI 10.1016/S0092-8674(00)80977-0; BOOCOCK MR, 1995, EMBO J, V14, P5129, DOI 10.1002/j.1460-2075.1995.tb00195.x; BROWN PO, 1990, CURR TOP MICROBIOL, V157, P19; BUJACZ G, 1995, J MOL BIOL, V253, P333, DOI 10.1006/jmbi.1995.0556; Bujacz G, 1996, STRUCTURE, V4, P89, DOI 10.1016/S0969-2126(96)00012-3; BUSHMAN FD, 1993, P NATL ACAD SCI USA, V90, P3428, DOI 10.1073/pnas.90.8.3428; CHOW SA, 1992, SCIENCE, V255, P723, DOI 10.1126/science.1738845; CRAIG NL, 1995, SCIENCE, V270, P253, DOI 10.1126/science.270.5234.253; CRAIGIE R, 1985, CELL, V41, P867, DOI 10.1016/S0092-8674(85)80067-2; CRAIGIE R, 1987, CELL, V51, P493, DOI 10.1016/0092-8674(87)90645-3; DYDA F, 1994, SCIENCE, V266, P1981, DOI 10.1126/science.7801124; ENGELMAN A, 1993, EMBO J, V12, P3269, DOI 10.1002/j.1460-2075.1993.tb05996.x; ENGELMAN A, 1992, J VIROL, V66, P6361, DOI 10.1128/JVI.66.11.6361-6369.1992; ENGELMAN A, 1991, CELL, V67, P1211, DOI 10.1016/0092-8674(91)90297-C; FAYET O, 1990, MOL MICROBIOL, V4, P1771, DOI 10.1111/j.1365-2958.1990.tb00555.x; Haniford DB, 1992, CURR OPIN GENET DEV, V2, P698, DOI 10.1016/S0959-437X(05)80129-7; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; Jenkins TM, 1996, J BIOL CHEM, V271, P7712, DOI 10.1074/jbc.271.13.7712; JOHNSON R, 1996, DNA PROTEIN STRUCTUR, P141; KAUFMAN PD, 1992, CELL, V69, P27, DOI 10.1016/0092-8674(92)90116-T; KIM K, 1995, J BIOL CHEM, V270, P1472, DOI 10.1074/jbc.270.3.1472; Kleckner N, 1996, CURR TOP MICROBIOL, V204, P49; KRUKLITIS R, 1994, J BIOL CHEM, V269, P16469; KULKOSKY J, 1992, MOL CELL BIOL, V12, P2331, DOI 10.1128/MCB.12.5.2331; LAVOIE BD, 1991, EMBO J, V10, P3051, DOI 10.1002/j.1460-2075.1991.tb07856.x; MIZUCHI M, 1996, CELL, V83, P375; MIZUUCHI K, 1991, CELL, V66, P129, DOI 10.1016/0092-8674(91)90145-O; MIZUUCHI K, 1992, J BIOL CHEM, V267, P21273; MIZUUCHI K, 1992, ANNU REV BIOCHEM, V61, P1011; MIZUUCHI M, 1992, CELL, V70, P303, DOI 10.1016/0092-8674(92)90104-K; MIZUUCHI M, 1991, P NATL ACAD SCI USA, V88, P9031, DOI 10.1073/pnas.88.20.9031; NAKAYAMA C, 1987, P NATL ACAD SCI USA, V84, P1809, DOI 10.1073/pnas.84.7.1809; RICE P, 1995, CELL, V82, P209, DOI 10.1016/0092-8674(95)90308-9; RICE PA, 1994, STRUCTURE, V2, P371, DOI 10.1016/S0969-2126(00)00039-3; ROWLAND SJ, 1990, MOL MICROBIOL, V4, P961, DOI 10.1111/j.1365-2958.1990.tb00669.x; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SANDERSON MR, 1990, CELL, V63, P1323, DOI 10.1016/0092-8674(90)90427-G; SAVILAHTI H, 1995, EMBO J, V14, P4893, DOI 10.1002/j.1460-2075.1995.tb00170.x; STARK WM, 1995, TRENDS GENET, V11, P121; STARK WM, 1992, TRENDS GENET, V8, P432, DOI 10.1016/0168-9525(92)90176-5; SURETTE MG, 1987, CELL, V49, P253, DOI 10.1016/0092-8674(87)90566-6; VANGENT DC, 1993, EMBO J, V12, P3261, DOI 10.1002/j.1460-2075.1993.tb05995.x; VANGENT DC, 1996, IN PRESS SCIENCE; VANLUENEN HGAM, 1994, CELL, V79, P293, DOI 10.1016/0092-8674(94)90198-8; VARMUS H, 1989, MOBILE DNA, P53; VINK C, 1991, NUCLEIC ACIDS RES, V19, P6691, DOI 10.1093/nar/19.24.6691; WU ZG, 1995, EMBO J, V14, P3835, DOI 10.1002/j.1460-2075.1995.tb00053.x; YANG JY, 1995, EMBO J, V14, P2374, DOI 10.1002/j.1460-2075.1995.tb07232.x; YANG W, 1995, CELL, V82, P193, DOI 10.1016/0092-8674(95)90307-0; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; ZOU AH, 1991, J BIOL CHEM, V266, P20478	59	81	89	0	4	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 19	1996	85	2					271	280		10.1016/S0092-8674(00)81103-4	http://dx.doi.org/10.1016/S0092-8674(00)81103-4			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UG255	8612279	Bronze			2022-12-28	WOS:A1996UG25500015
J	Smith, JJ; Travis, SM; Greenberg, EP; Welsh, MJ				Smith, JJ; Travis, SM; Greenberg, EP; Welsh, MJ			Cystic fibrosis airway epithelia fail to kill bacteria because of abnormal airway surface fluid	CELL			English	Article							ELECTROLYTE TRANSPORT; LUNG-DISEASE; CELLS; EXPRESSION; CULTURES; SITE	Despite an increased understanding of the cellular and molecular biology of the CFTR Cl- channel, it is not known how defective Cl- transport across airway epithelia causes chronic bacterial infections in cystic fibrosis (CF) airways. Here, we show that common CF pathogens were killed when added to the apical surface of normal airway epithelia. In contrast, these bacteria multiplied on CF epithelia. We found that bactericidal activity was present in airway surface fluid of both normal and CF epithelia. However, because bacterial killing required a low NaCl concentration and because CF surface fluid has a high NaCl concentration, CF epithelia failed to kill bacteria. This defect was corrected by reducing the NaCl concentration on CF epithelia. These data explain how the loss of CFTR Cl- channels may lead to lung disease and suggest new approaches to therapy.	UNIV IOWA,COLL MED,DEPT INTERNAL MED,IOWA CITY,IA 52242; UNIV IOWA,COLL MED,DEPT MICROBIOL,IOWA CITY,IA 52242; UNIV IOWA,COLL MED,DEPT PHYSIOL & BIOPHYS,IOWA CITY,IA 52242; UNIV IOWA,COLL MED,HOWARD HUGHES MED INST,IOWA CITY,IA 52242	University of Iowa; University of Iowa; University of Iowa; Howard Hughes Medical Institute; University of Iowa	Smith, JJ (corresponding author), UNIV IOWA,COLL MED,DEPT PEDIAT,IOWA CITY,IA 52242, USA.			Welsh, Michael/0000-0002-1646-6206; Greenberg, Everett/0000-0001-9474-8041	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL042385] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL42385] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BALOUGH K, 1995, PEDIATR PULM, V20, P63, DOI 10.1002/ppul.1950200203; BOUCHER RC, 1983, LUNG, V161, P1, DOI 10.1007/BF02713837; BREEZE RG, 1977, AM REV RESPIR DIS, V116, P705, DOI 10.1164/arrd.1977.116.4.705; COLLINS FS, 1992, SCIENCE, V256, P774, DOI 10.1126/science.1375392; DAVIS PB, 1993, CYSTIC FIBROSIS, P193; DEKOSTER JA, 1995, AM IND HYG ASSOC J, V56, P573, DOI 10.1202/0002-8894(1995)056<0573:BCINCA>2.0.CO;2; DIAMOND G, 1993, P NATL ACAD SCI USA, V90, P4596, DOI 10.1073/pnas.90.10.4596; ENGELHARDT JF, 1992, NAT GENET, V2, P240, DOI 10.1038/ng1192-240; FICK RB, 1981, J CLIN INVEST, V68, P899, DOI 10.1172/JCI110345; GILLJAM H, 1989, SCAND J CLIN LAB INV, V49, P121, DOI 10.3109/00365518909105409; GOLDSTEIN IM, 1994, TXB RESPIRATORY MED, P402; HUXLEY EJ, 1978, AM J MED, V64, P564, DOI 10.1016/0002-9343(78)90574-0; IMUNDO L, 1995, P NATL ACAD SCI USA, V92, P3019, DOI 10.1073/pnas.92.7.3019; JIANG CW, 1993, SCIENCE, V262, P424, DOI 10.1126/science.8211164; JORIS L, 1993, AM REV RESPIR DIS, V148, P1633, DOI 10.1164/ajrccm/148.6_Pt_1.1633; KHAN TZ, 1995, AM J RESP CRIT CARE, V151, P1075; KNOWLES MR, 1990, NEW ENGL J MED, V322, P1189, DOI 10.1056/NEJM199004263221704; KNOWLES MR, 1991, NEW ENGL J MED, V325, P533, DOI 10.1056/NEJM199108223250802; Konstan M.W., 1993, CYSTIC FIBROSIS, V64, P219; LARIVEE P, 1994, AIRWAY SECRETION PHY, P469; LEHRER RI, 1993, ANNU REV IMMUNOL, V11, P105, DOI 10.1146/annurev.iy.11.040193.000541; LEVINE SJ, 1995, AM J RESP CELL MOL, V12, P196, DOI 10.1165/ajrcmb.12.2.7865217; MARTIN E, 1995, J LEUKOCYTE BIOL, V58, P128, DOI 10.1002/jlb.58.2.128; Pier GB, 1996, SCIENCE, V271, P64, DOI 10.1126/science.271.5245.64; Pilewski J M, 1995, Curr Opin Pulm Med, V1, P435, DOI 10.1097/00063198-199511000-00002; QUINTON PM, 1990, FASEB J, V4, P2709, DOI 10.1096/fasebj.4.10.2197151; QUINTON PM, 1994, AM J RESP CRIT CARE, V149, P6, DOI 10.1164/ajrccm.149.1.8111599; RAMSEY BW, 1991, AM REV RESPIR DIS, V144, P331, DOI 10.1164/ajrccm/144.2.331; REGNIS JA, 1994, AM J RESP CRIT CARE, V150, P66, DOI 10.1164/ajrccm.150.1.8025774; RIORDAN JR, 1993, ANNU REV PHYSIOL, V55, P609, DOI 10.1146/annurev.ph.55.030193.003141; SAIMAN L, 1993, J CLIN INVEST, V92, P1875, DOI 10.1172/JCI116779; SANCHIS J, 1973, NEW ENGL J MED, V288, P651, DOI 10.1056/NEJM197303292881304; SHEPPARD DN, 1994, AM J PHYSIOL, V266, pL405, DOI 10.1152/ajplung.1994.266.4.L405; SMITH JJ, 1994, J CLIN INVEST, V93, P1307, DOI 10.1172/JCI117087; SMITH JJ, 1993, J CLIN INVEST, V91, P1590, DOI 10.1172/JCI116365; Taussig LM, 1984, CYSTIC FIBROSIS, P338; Welsh MJ, 1995, METABOLIC MOL BASES, V3, P3799; WILMOTT RW, 1990, AM REV RESPIR DIS, V142, P365, DOI 10.1164/ajrccm/142.2.365; Wine JJ, 1995, CURR BIOL, V5, P1357, DOI 10.1016/S0960-9822(95)00269-7; YAMAYA M, 1992, AM J PHYSIOL, V262, pL713, DOI 10.1152/ajplung.1992.262.6.L713; YEATES DB, 1976, ARCH DIS CHILD, V51, P28, DOI 10.1136/adc.51.1.28; ZABNER J, 1994, HUM GENE THER, V5, P585, DOI 10.1089/hum.1994.5.5-585	42	790	817	0	69	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 19	1996	85	2					229	236		10.1016/S0092-8674(00)81099-5	http://dx.doi.org/10.1016/S0092-8674(00)81099-5			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UG255	8612275	Bronze			2022-12-28	WOS:A1996UG25500011
J	Burns, H				Burns, H			Disease management and the drug industry: Carve out or carve up?	LANCET			English	Editorial Material											Burns, H (corresponding author), GREATER GLASGOW HLTH BOARD,GLASGOW G1 1ET,LANARK,SCOTLAND.							*BOST CONS GROUP, 1995, PROM DIS MAN, P15; HUNTER D, 1995, HLTH SERVICE J  1005, P22; *NHA WZ, 1994, EL9494 NHS EX; Zalta E, 1994, Med Interface, V7, P66	4	17	17	1	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 13	1996	347	9007					1021	1023		10.1016/S0140-6736(96)90151-8	http://dx.doi.org/10.1016/S0140-6736(96)90151-8			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UF380	8606567				2022-12-28	WOS:A1996UF38000016
J	Lichtenstein, P; Olausson, PO; Kallen, AJB				Lichtenstein, P; Olausson, PO; Kallen, AJB			Twin births to mothers who are twins: A registry based study	BRITISH MEDICAL JOURNAL			English	Article							GENE	Objectives-To estimate the risk of having twin infants for mothers who are twins; to investigate the genetic influence on twinning. Design-Retrospective study of multiple births in two nationwide registries. Setting-Sweden. Subjects-Multiple births among 31586 deliveries between 1973 and 1991 to women who were twins. Main outcome measures-Numbers of monozygotic and dizygotic twin births expected and estimated. Results-Women who are dizygotic twins have a moderately increased risk of having twins (relative risk 1.30, 95% confidence interval 1.14 to 1.49) which seems to be completely the result of dizygotic twinning. When a mother is a monozygotic twin, her risk of having twins of the same sex is significantly increased (1.47; 1.10 to 1.97). This is the result of an excess of monozygotic twins (39 pairs estimated, 18 expected). Conclusion-Women who are twins have an increased risk of giving birth to twins. Genetic components of monozygotic and dizygotic twinning seem to be independent.	NATL BOARD HLTH & WELF,CTR EPIDEMIOL,S-10630 STOCKHOLM,SWEDEN; LUND UNIV,TORNBALD INST,S-22362 LUND,SWEDEN	National Board of Health & Welfare; Lund University	Lichtenstein, P (corresponding author), KAROLINSKA INST,INST ENVIRONM MED,BOX 210,S-17177 STOCKHOLM,SWEDEN.			lichtenstein, paul/0000-0003-3037-5287				Bulmer M. G., 1970, BIOL TWINNING MAN; CARMELLI D, 1978, TWIN RES, V3, P81; CEDERLOEF R, 1961, ACTA GENET STAT MED, V11, P338; CEDERLOF R, 1978, TWIN RES, V3, P189; CNATTINGIUS S, 1990, SCAND J SOC MED, V18, P143, DOI 10.1177/140349489001800209; CRUMPACKER DW, 1979, ACTA GENET MED GEMEL, V28, P173, DOI 10.1017/S0001566000009041; DAVIS GH, 1991, BIOL REPROD, V44, P620, DOI 10.1095/biolreprod44.4.620; Derom R, 1995, MULTIPLE PREGNANCY E, P145; JAMES WH, 1992, ACTA GENET MED GEMEL, V41, P33, DOI 10.1017/S0001566000002488; Medlund P, 1976, Acta Med Scand Suppl, V600, P1; MILLHAM S, 1964, LANCET, V2, P566; MONTGOMERY GW, 1993, NAT GENET, V4, P410, DOI 10.1038/ng0893-410; NYLANDER PP, 1970, ACTA GENET MED GEMEL, V19, P36, DOI 10.1017/S1120962300024951; PARAZZINI F, 1993, ACTA OBSTET GYN SCAN, V72, P177, DOI 10.3109/00016349309013368; PARISI P, 1983, NATURE, V304, P626, DOI 10.1038/304626a0; PHILIPPE P, 1985, AM J MED GENET, V20, P97, DOI 10.1002/ajmg.1320200112; SARNA S, 1978, HUM HERED, V28, P241, DOI 10.1159/000152964; WEINBERG W, 1902, PFLUGERS ARCH GES PH, V88, P346; Weinberg Wilhelm, 1909, ARCH RASSEN GES BIOL, V6, P322; Weinberg Wilhelm, 1909, ARCH RASSEN GES BIOL, V6, P470; Weinberg Wilhelm, 1909, ARCH RASSEN GES BIOL, V6, P609; WYSHAK G, 1965, AM J PUBLIC HEALTH N, V55, P1586, DOI 10.2105/AJPH.55.10.1586	22	30	30	0	6	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 6	1996	312	7035					879	881						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UE371	8611875				2022-12-28	WOS:A1996UE37100020
J	Thomas, SM; Davies, ARW; Birtwistle, NJ; Crowther, SM; Burke, JF				Thomas, SM; Davies, ARW; Birtwistle, NJ; Crowther, SM; Burke, JF			Ownership of the human genome	NATURE			English	Editorial Material									UNIV SUSSEX,DEPT BIOCHEM,BRIGHTON BN1 9RF,E SUSSEX,ENGLAND	University of Sussex	Thomas, SM (corresponding author), UNIV SUSSEX,SCI POLICY RES UNIT,BRIGHTON BN1 9RF,E SUSSEX,ENGLAND.							COLETURNER R, 1995, SCIENCE, V270, P52, DOI 10.1126/science.270.5233.52; DIXON D, 1995, NATURE, V378, P425; DIXON D, 1996, NATURE, V379, P574; *EUR COMM, 1994, EUR15897 EUR COMM; *OFF TECHN ASS, 1992, BIOT GLOB EC; SWINBANKS D, 1994, NATURE, V371, P731; THOMAS SM, 1995, RES POLICY, V24, P645, DOI 10.1016/S0048-7333(98)80001-2	7	28	28	0	4	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	APR 4	1996	380	6573					387	388		10.1038/380387a0	http://dx.doi.org/10.1038/380387a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UD590	8602236				2022-12-28	WOS:A1996UD59000035
J	Sumner, AE; Chin, MM; Abrahm, JL; Berry, GT; Gracely, EJ; Allen, RH; Stabler, SP				Sumner, AE; Chin, MM; Abrahm, JL; Berry, GT; Gracely, EJ; Allen, RH; Stabler, SP			Elevated methylmalonic acid and total homocysteine levels show high prevalence of vitamin B-12 deficiency after gastric surgery	ANNALS OF INTERNAL MEDICINE			English	Article							CHROMATOGRAPHY MASS-SPECTROMETRY; COBALAMIN DEFICIENCY; FOLATE-DEFICIENCY; NORMAL SERUM; MALABSORPTION; URINE; QUANTITATION; PLASMA; RISK	Objective: To determine the prevalence of vitamin B-12 deficiency in patients who have had gastric surgery. Design: Cross-sectional study. Setting: Philadelphia Veterans Affairs Medical Center. Participants: 61 patients who had had gastric surgery and 107 controls. Measurements: Serum levels of vitamin B-12 folate, methylmalonic acid, and total homocysteine measured before and after treatment in participants with vitamin B-12 deficiency. Vitamin B-12 deficiency was defined as one of the following: 1) a serum vitamin B-12 level less than 221 pmol/L and an elevated methylmalonic acid level; 2) a serum vitamin B-12 level less than 221 pmol/L and an elevated total homocysteine level that decreased with vitamin B-12 treatment; or 3) in patients unavailable for treatment, a serum vitamin B-12 level less than 221 pmol/L, a folate level greater than 9 nmol/L, and an elevated total homocysteine level. Results: Study patients and controls were similar in age, sex, and racial distribution. Nineteen patients (31%) and 2 controls (2%) had vitamin B-12 deficiency (P < 0.001). Twelve (63%) of the 19 vitamin B-12-deficient patients had elevated total homocysteine levels. In all participants with vitamin B-12 deficiency who received treatment (15 of 21). methylmalonic acid and total homocysteine levels decreased substantially, confirming the deficiency before treatment. Conclusion: Patients who have had gastric surgery have a high prevalence of vitamin B-12 deficiency. Prompt recognition and treatment of the deficiency with resultant normalization of elevated total homocysteine and methylmalonic acid levels may prevent the development of cardiovascular, hematologic, and neurologic abnormalities. Our data support both frequent screening and vitamin B-12 replacement therapy in patients who have had gastric surgery and have serum vitamin B-12 levels less than 221 pmol/L.	HAHNEMANN UNIV, PHILADELPHIA COLL PHARM & SCI, PHILADELPHIA, PA 19104 USA; CHILDRENS HOSP PHILADELPHIA, DIV BIOCHEM DEV & MOLEC DIS, PHILADELPHIA, PA 19104 USA; UNIV COLORADO, HLTH SCI CTR, DIV HEMATOL, DENVER, CO 80262 USA	Drexel University; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Sumner, AE (corresponding author), MED COLL PENN, PHILADELPHIA VET AFFAIRS MED CTR, 3300 HENRY AVE, PHILADELPHIA, PA 19129 USA.		Gracely, Ed/B-7188-2014	Gracely, Ed/0000-0002-8344-3223; Berry, Gerard/0000-0001-5299-3313	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK021365] Funding Source: NIH RePORTER; NIA NIH HHS [AG00532, AG0983] Funding Source: Medline; NIDDK NIH HHS [DK-21365] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALLEN RH, 1993, METABOLISM, V42, P978, DOI 10.1016/0026-0495(93)90010-L; ALLEN RH, 1990, AM J HEMATOL, V34, P90, DOI 10.1002/ajh.2830340204; BADENOCH J, 1955, BRIT J HAEMATOL, V1, P339, DOI 10.1111/j.1365-2141.1955.tb05518.x; BAKER H, 1979, J AM GERIATR SOC, V27, P444, DOI 10.1111/j.1532-5415.1979.tb01724.x; CARMEL R, 1988, ARCH INTERN MED, V148, P1715, DOI 10.1001/archinte.148.8.1715; CLARKE R, 1991, NEW ENGL J MED, V324, P1149, DOI 10.1056/NEJM199104253241701; DELER DJ, 1963, LANCET, V2, P162; DOSCHERHOLMEN A, 1973, GASTROENTEROLOGY, V64, P913; HEALTON EB, 1991, MEDICINE, V70, P229, DOI 10.1097/00005792-199107000-00001; HINES JD, 1967, AM J MED, V43, P555, DOI 10.1016/0002-9343(67)90179-9; KARNAZE DS, 1990, ARCH NEUROL-CHICAGO, V47, P1008, DOI 10.1001/archneur.1990.00530090082017; KLIPSTEIN FA, 1962, ANN INTERN MED, V57, P133, DOI 10.7326/0003-4819-57-1-133; KOLHOUSE JF, 1978, NEW ENGL J MED, V299, P785, DOI 10.1056/NEJM197810122991501; LINDENBAUM J, 1988, NEW ENGL J MED, V318, P1720, DOI 10.1056/NEJM198806303182604; MACLEAN LD, 1957, NEW ENGL J MED, V257, P262, DOI 10.1056/NEJM195708082570603; MAHMUD MB, 1971, J AMER MED ASSOC, V216, P1167; MANSOOR MA, 1995, ARTERIOSCL THROM VAS, V15, P232, DOI 10.1161/01.ATV.15.2.232; MARCELL PD, 1985, ANAL BIOCHEM, V150, P58, DOI 10.1016/0003-2697(85)90440-3; MARCUARD SP, 1994, ANN INTERN MED, V120, P211, DOI 10.7326/0003-4819-120-3-199402010-00006; MARTIN DC, 1992, J AM GERIATR SOC, V40, P168, DOI 10.1111/j.1532-5415.1992.tb01939.x; MOLINOFF PB, 1990, PEPTIC ULCER DISEASE; PENNYPACKER LC, 1992, J AM GERIATR SOC, V40, P1197, DOI 10.1111/j.1532-5415.1992.tb03641.x; Rowlands RA, 1932, LANCET, V2, P1202; RYGVOLD O, 1974, SCAND J GASTROENTERO, V9, P57; SAVAGE DG, 1994, AM J MED, V96, P239, DOI 10.1016/0002-9343(94)90149-X; SCHADE SG, 1967, AM J CLIN NUTR, V20, P636, DOI 10.1093/ajcn/20.6.636; SELHUB J, 1995, NEW ENGL J MED, V332, P286, DOI 10.1056/NEJM199502023320502; STABLER SP, 1988, J CLIN INVEST, V81, P466, DOI 10.1172/JCI113343; STABLER SP, 1993, BLOOD, V81, P3404; STABLER SP, 1986, J CLIN INVEST, V77, P1606, DOI 10.1172/JCI112476; STABLER SP, 1987, ANAL BIOCHEM, V162, P185, DOI 10.1016/0003-2697(87)90026-1; STAMPFER MJ, 1992, JAMA-J AM MED ASSOC, V268, P877, DOI 10.1001/jama.268.7.877; STEINBERG WM, 1980, DIGEST DIS SCI, V25, P188, DOI 10.1007/BF01308137; STREETER AM, 1974, AM J SURG, V128, P340, DOI 10.1016/0002-9610(74)90169-X; TALSTAD I, 1975, SCAND J GASTROENTERO, V10, P1; YALE CE, 1993, AM J HEMATOL, V42, P63, DOI 10.1002/ajh.2830420113	36	84	86	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 1	1996	124	5					469	+		10.7326/0003-4819-124-5-199603010-00002	http://dx.doi.org/10.7326/0003-4819-124-5-199603010-00002			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TW773	8602704				2022-12-28	WOS:A1996TW77300002
J	Hynynen, M; Kuitunen, A; Salmenpera, M				Hynynen, M; Kuitunen, A; Salmenpera, M			Surgical bleeding and calcium antagonists	BRITISH MEDICAL JOURNAL			English	Letter							BYPASS				Hynynen, M (corresponding author), UNIV HELSINKI HOSP,DEPT ANAESTHESIA,SF-00290 HELSINKI,FINLAND.							KUITUNEN A, 1993, ACTA ANAESTH SCAND, V37, P652, DOI 10.1111/j.1399-6576.1993.tb03783.x; KUITUNEN A, 1993, BRIT J ANAESTH, V70, P173, DOI 10.1093/bja/70.2.173; KUITUNEN A, 1995, BR J ANAESTH S2, V74, pA66; KUITUNEN AH, 1992, ANN CHIR GYNAECOL FE, V81, P11; MARTIN DE, 1995, PRACTICAL APPROACH C, P27; WAGENKNECHT LE, 1995, BRIT MED J, V310, P776, DOI 10.1136/bmj.310.6982.776	6	7	7	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 3	1996	312	7026					313	313						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TU507	8611807				2022-12-28	WOS:A1996TU50700058
J	Scholes, D; Stergachis, A; Heidrich, FE; Andrilla, H; Holmes, KK; Stamm, WE				Scholes, D; Stergachis, A; Heidrich, FE; Andrilla, H; Holmes, KK; Stamm, WE			Prevention of pelvic inflammatory disease by screening for cervical chlamydial infection	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SEXUALLY-TRANSMITTED DISEASES; FAMILY-PLANNING CLINICS; TRACHOMATIS INFECTION; COST-EFFECTIVENESS; DIAGNOSTIC MODEL; WOMEN; CRITERIA; PATHOGENESIS; POPULATION; CARE	Background. Chlamydia trachomatis is a frequent cause of pelvic inflammatory disease, However, there is little information from clinical studies about whether screening women for cervical chlamydial infection can reduce the incidence of this serious illness. Methods. We conducted a randomized, controlled trial to determine whether selective testing for cervical chlamydial infection prevented pelvic inflammatory disease. Women who were at high risk for disease were identified by means of a questionnaire mailed to all women enrollees in a health maintenance organization who were 18 to 34 years of age. Eligible respondents were randomly assigned to undergo testing for C. trachomatis or to receive usual care; both groups were followed for one year, Possible cases of pelvic inflammatory disease were identified through a variety of data bases and were confirmed by review of the women's medical records, We used an intention-to-screen analysis to compare the incidence of pelvic inflammatory disease in the two groups of women. Results. Of the 2607 eligible women, 1009 were randomly assigned to screening and 1598 to usual care. A total of 645 women in the screening group (64 percent) were tested for chlamydia; 7 percent tested positive and were treated. At the end of the follow-up period, there had been 9 verified cases of pelvic inflammatory disease among the women in the screening group and 33 cases among the women receiving usual care (relative risk, 0.44; 95 percent confidence interval, 0.20 to 0.90), We found similar results when we used logistic-regression analysis to control for potentially confounding variables. Conclusions. A strategy of identifying, testing, and treating women at increased risk for cervical chlamydial infection was associated with a reduced incidence of pelvic inflammatory disease. (C) 1996, Massachusetts Medical Society.	GRP HLTH COOPERAT PUGET SOUND,DEPT FAMILY PRACTICE,SEATTLE,WA 98101; UNIV WASHINGTON,SCH PUBL HLTH & COMMUNITY MED,DEPT EPIDEMIOL,SEATTLE,WA 98195; UNIV WASHINGTON,SCH MED,DEPT MED,SEATTLE,WA 98195; UNIV WASHINGTON,SCH PHARM,DEPT PHARM,SEATTLE,WA 98195	Group Health Cooperative; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Scholes, D (corresponding author), GRP HLTH COOPERAT PUGET SOUND,CTR HLTH STUDIES,1730 MINOR AVE,SUITE 1600,SEATTLE,WA 98101, USA.		, Holmes/K-6215-2019		NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI024756] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-24756] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADDISS DG, 1991, JAMA-J AM MED ASSOC, V265, P1951; BUHAUG H, 1990, BRIT J GEN PRACT, V40, P142; BUHAUG H, 1989, MED CARE, V27, P833, DOI 10.1097/00005650-198908000-00007; CATES W, 1990, EPIDEMIOL REV, V12, P199, DOI 10.1093/oxfordjournals.epirev.a036054; CATES W, 1994, ANN NY ACAD SCI, V709, P179, DOI 10.1111/j.1749-6632.1994.tb30397.x; *DEP HLTH HUM SERV, 1991, DHHS PUBL; HAGER WD, 1983, OBSTET GYNECOL, V61, P113; HANDSFIELD HH, 1986, JAMA-J AM MED ASSOC, V255, P1730, DOI 10.1001/jama.255.13.1730; JOHNSON BA, 1990, JAMA-J AM MED ASSOC, V264, P3161, DOI 10.1001/jama.264.24.3161; KAHN JG, 1991, JAMA-J AM MED ASSOC, V266, P2594, DOI 10.1001/jama.266.18.2594; MALOTTE CK, 1990, AM J PUBLIC HEALTH, V80, P469, DOI 10.2105/AJPH.80.4.469; NETTLEMAN MD, 1986, ANN INTERN MED, V105, P189, DOI 10.7326/0003-4819-105-2-189; PHILLIPS RS, 1987, ANN INTERN MED, V107, P188, DOI 10.7326/0003-4819-107-2-188; PHILLIPS RS, 1989, AM J MED, V86, P515, DOI 10.1016/0002-9343(89)90377-X; RICE PA, 1991, JAMA-J AM MED ASSOC, V266, P2587, DOI 10.1001/jama.266.18.2587; ROLFS RT, 1991, SEX TRANSM DIS, V18, P131, DOI 10.1097/00007435-199118020-00015; Saunders KW, 1994, PHARMACOEPIDEM DR S, P171; STAMM WE, 1983, J CLIN MICROBIOL, V17, P666, DOI 10.1128/JCM.17.4.666-668.1983; Stamm WE, 1990, SEXUALLY TRANSMITTED, P181; STERGACHIS A, 1993, AM J EPIDEMIOL, V138, P143, DOI 10.1093/oxfordjournals.aje.a116840; TAPLIN SH, 1990, CANCER, V66, P812, DOI 10.1002/1097-0142(19900815)66:4<812::AID-CNCR2820660436>3.0.CO;2-1; TRACHTENBERG AI, 1988, OBSTET GYNECOL, V71, P101; VINCELETTE J, 1991, CAN MED ASSOC J, V144, P713; WASHINGTON AE, 1991, JAMA-J AM MED ASSOC, V266, P2574, DOI 10.1001/jama.266.18.2574; Webster Linda A., 1993, Morbidity and Mortality Weekly Report, V42, P21; WESTROM L, 1993, GENITOURIN MED, V69, P9; 1991, SEX TRANSM DIS, V18, P46; [No title captured]; 1993, MMWR-MORBID MORTAL W, V42, P1	29	650	665	0	16	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 23	1996	334	21					1362	1366		10.1056/NEJM199605233342103	http://dx.doi.org/10.1056/NEJM199605233342103			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UL251	8614421				2022-12-28	WOS:A1996UL25100003
J	Komaromy, M; Grumbach, K; Drake, M; Vranizan, K; Lurie, N; Keane, D; Bindman, AB				Komaromy, M; Grumbach, K; Drake, M; Vranizan, K; Lurie, N; Keane, D; Bindman, AB			The role of black and Hispanic physicians in providing health care for underserved populations	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MEDICAL-SCHOOLS	Background. Patients who are members of minority groups may be more likely than others to consult physicians of the same race or ethnic group, but little is known about the relation between patients' race or ethnic group and the supply of physicians or the likelihood that minority-group physicians will care for poor or black and Hispanic patients. Methods. We analyzed data on physicians' practice locations and the racial and ethnic makeup and socioeconomic status of communities in California in 1990. We also surveyed 718 primary care physicians from 51 California communities in 1993 to examine the relation between the physicians' race or ethnic group and the characteristics of the patients they served. Results. Communities with high proportions of black and Hispanic residents were four times as likely as others to have a shortage of physicians, regardless of community income. Black physicians practiced In areas where the percentage of black residents was nearly five times as high, on average, as in areas where other physicians practiced. Hispanic physicians practiced in areas where the percentage of Hispanic residents was twice as high as in areas where other physicians practiced. After we controlled for the racial and ethnic makeup of the community, black physicians cared for significantly more black patients (absolute difference, 25 percentage points; P<0.001) and Hispanic physicians for significantly more Hispanic patients (absolute difference, 21 percentage points; P<0.001) than did other physicians, Black physicians cared for more patients covered by Medicaid (P=0.001) and Hispanic physicians for more uninsured patients (P=0.03) than did other physicians. Conclusions. Black and Hispanic physicians have a unique and important role in caring for poor, black, and Hispanic patients in California. Dismantling affirmative-action programs, as is currently proposed, may threaten health care for both poor people and members of minority groups.	UNIV CALIF SAN FRANCISCO, DIV GEN INTERNAL MED, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, INST HLTH POLICY STUDIES, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DEPT FAMILY & COMMUNITY MED, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, MED EFFECTIVENESS RES CTR DIVERSE POPULAT, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, OFF ASSOCIATE DEAN MED SCH ADMISS, SAN FRANCISCO, CA 94143 USA; SAN FRANCISCO GEN HOSP, DIV GEN INTERNAL MED, SAN FRANCISCO, CA 94110 USA; SAN FRANCISCO GEN HOSP, PRIMARY CARE RES CTR, SAN FRANCISCO, CA 94110 USA; UNIV MINNESOTA, SCH MED, MINNEAPOLIS, MN 55455 USA; UNIV MINNESOTA, SCH PUBL HLTH, MINNEAPOLIS, MN 55455 USA; HENNEPIN CTY MED CTR, MINNEAPOLIS, MN USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; San Francisco General Hospital Medical Center; San Francisco General Hospital Medical Center; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; Hennepin County Medical Center			Grumbach, Kevin/L-9222-2016; Komaromy, Miriam/AAV-4820-2020		AHRQ HHS [HS07373] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		*ASS AM MED COLL, 1994, MIN STUD MED ED FACT, V8; BINDMAN AB, 1995, JAMA-J AM MED ASSOC, V274, P305, DOI 10.1001/jama.274.4.305; CARLISLE DM, 1995, AM J PUBLIC HEALTH, V85, P352, DOI 10.2105/AJPH.85.3.352; CORNELIUS L, 1991, NATL MED EXPENDITURE, V11; CUNNINGHAM P, 1993, NATL MED EXPENDITURE, V16; FORD ES, 1995, HEALTH SERV RES, V30, P237; KEITH SN, 1985, NEW ENGL J MED, V313, P1519, DOI 10.1056/NEJM198512123132406; KINDIG DA, 1989, HEALTH AFFAIR, V8, P63, DOI 10.1377/hlthaff.8.2.63; KLETKE PR, 1985, HEALTH SERV RES, V20, P503; KOMAROMY M, IN PRESS MED CARE; Lee R C, 1991, J Rural Health, V7, P437; MOY E, 1995, JAMA-J AM MED ASSOC, V273, P1515, DOI 10.1001/jama.273.19.1515; NICKENS HW, 1994, NEW ENGL J MED, V331, P472, DOI 10.1056/NEJM199408183310712; ROBACK J, 1993, PHYSICIAN CHARACTERI; SHEA S, 1985, NEW ENGL J MED, V313, P933, DOI 10.1056/NEJM198510103131506; WILLIAMS DJ, 1994, 1994 I GOALS RANKING; 1995, SAN FRANCISCO C 0721, P1	17	603	602	0	9	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 16	1996	334	20					1305	1310		10.1056/NEJM199605163342006	http://dx.doi.org/10.1056/NEJM199605163342006			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	UK880	8609949	Bronze			2022-12-28	WOS:A1996UK88000006
J	Py, B; Higgins, CF; Krisch, HM; Carpousis, AJ				Py, B; Higgins, CF; Krisch, HM; Carpousis, AJ			A DEAD-box RNA helicase in the Escherichia coli RNA degradosome	NATURE			English	Article							MESSENGER-RNA; RIBOSOMAL-RNA; PROTEIN; DEGRADATION; DECAY; GENE; INVITRO; MUTANT; INVIVO; ATPASE	THE Escherichia coli RNA degradosome is a multi-enzyme complex that contains the exoribonuclease polynucleotide phosphorylase (PNPase) and the endoribonuclease RNase E(1,2). Both enzymes are important in RNA processing and messenger RNA degradation(3-14). Here we report that enolase and RhlB are two other major components of the degradosome. Enolase is a glycolytic enzyme with an unknown role in RNA metabolism. RhlB is a member of the DEAD-box family of ATP-dependent RNA helicases, which are found in both prokaryotes and eukaryote(15-26). We show that the degradosome has an ATP-dependent activity that aids the degradation of structured RNA by PNPase. Incubation of the degradosome with affinity-purified antibody against RhlB inhibited the ATP-stimulated RNA degradation. These results suggest that RhlB acts by unwinding RNA structures that impede the processive activity of PNPase. RhlB is thus an important enzyme in mRNA turnover.	UNIV OXFORD, NUFFIELD DEPT CLIN BIOCHEM, OXFORD OX3 9DU, ENGLAND; UNIV OXFORD, JOHN RADCLIFFE HOSP, INST MOLEC MED, IMPERIAL CANC RES FUND LABS, OXFORD OX3 9DU, ENGLAND; CNRS, LAB MICROBIOL & GENET MOLEC, UPR 9007, F-31062 TOULOUSE, FRANCE	University of Oxford; Cancer Research UK; University of Oxford; Centre National de la Recherche Scientifique (CNRS)			Carpousis, Agamemnon/S-2098-2019	Carpousis, Agamemnon/0000-0002-1774-2102				BOUVET P, 1992, NATURE, V360, P488, DOI 10.1038/360488a0; CARPOUSIS AJ, 1994, CELL, V76, P889, DOI 10.1016/0092-8674(94)90363-8; CAUSTON H, 1994, MOL MICROBIOL, V14, P731, DOI 10.1111/j.1365-2958.1994.tb01310.x; CHIFFLET S, 1988, ANAL BIOCHEM, V168, P1, DOI 10.1016/0003-2697(88)90002-4; CORMACK RS, 1993, P NATL ACAD SCI USA, V90, P9006, DOI 10.1073/pnas.90.19.9006; DONOVAN WP, 1986, P NATL ACAD SCI USA, V83, P120, DOI 10.1073/pnas.83.1.120; Fuller-Pace Frances V., 1994, Trends in Cell Biology, V4, P271, DOI 10.1016/0962-8924(94)90210-0; FULLERPACE FV, 1993, EMBO J, V12, P3619, DOI 10.1002/j.1460-2075.1993.tb06035.x; GHORA BK, 1978, CELL, V15, P1055, DOI 10.1016/0092-8674(78)90289-1; GRIFO JA, 1984, J BIOL CHEM, V259, P8648; HIRLING H, 1989, NATURE, V339, P562, DOI 10.1038/339562a0; IOST I, 1994, NATURE, V372, P193, DOI 10.1038/372193a0; KALMAN M, 1991, NEW BIOL, V3, P886; KLEIN M, 1994, EMBL DATA BANK; LIANG L, 1994, DEVELOPMENT, V120, P1201; LINCHAO S, 1991, CELL, V65, P1233, DOI 10.1016/0092-8674(91)90018-T; MCLAREN RS, 1991, J MOL BIOL, V221, P81, DOI 10.1016/0022-2836(91)90806-H; MUDD EA, 1990, GENE DEV, V4, P873, DOI 10.1101/gad.4.5.873; MUDD EA, 1990, MOL MICROBIOL, V4, P2127, DOI 10.1111/j.1365-2958.1990.tb00574.x; NEWBURY SF, 1987, CELL, V51, P1131, DOI 10.1016/0092-8674(87)90599-X; NISHI K, 1988, NATURE, V336, P496, DOI 10.1038/336496a0; ONO M, 1979, J MOL BIOL, V129, P343, DOI 10.1016/0022-2836(79)90500-X; PAUSE A, 1992, EMBO J, V11, P2643, DOI 10.1002/j.1460-2075.1992.tb05330.x; PY B, 1994, MOL MICROBIOL, V14, P717, DOI 10.1111/j.1365-2958.1994.tb01309.x; ROZEN F, 1990, MOL CELL BIOL, V10, P1134, DOI 10.1128/MCB.10.3.1134; SCHMID SR, 1992, MOL MICROBIOL, V6, P283, DOI 10.1111/j.1365-2958.1992.tb01470.x; SCHWER B, 1991, NATURE, V349, P494, DOI 10.1038/349494a0; SPRING TG, 1975, METHOD ENZYMOL, V62, P323; TOMCSANYI T, 1985, J MOL BIOL, V185, P713, DOI 10.1016/0022-2836(85)90056-7; XU FF, 1995, NATURE, V374, P180, DOI 10.1038/374180a0	30	454	457	0	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 9	1996	381	6578					169	172		10.1038/381169a0	http://dx.doi.org/10.1038/381169a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UK139	8610017				2022-12-28	WOS:A1996UK13900054
J	Nakano, T; Kodama, H; Honjo, T				Nakano, T; Kodama, H; Honjo, T			In vitro development of primitive and definitive erythrocytes from different precursors	SCIENCE			English	Article							HEMATOPOIETIC PROGENITOR CELLS; C-KIT; DEVELOPING MOUSE; STEM-CELLS; YOLK-SAC; EXPRESSION; INVITRO; BLOOD; CULTURE; EMBRYO	During mouse embryogenesis the production of ''primitive'' erythrocytes (EryP) precedes the production of ''definitive'' erythrocytes (EryD) in parallel with the transition of the hematopoietic site from the yolk sac to the fetal liver. On a macrophage colony-stimulating factor-deficient stromal cell line OP9, mouse embryonic stem cells were shown to give rise to EryP and EryD sequentially with a time course similar to that seen in murine ontogeny. Studies of the different growth factor requirements and limiting dilution analysis of precursor frequencies indicate that most EryP and EryD probably developed from different precursors by way of distinct differentiation pathways.	KYOTO UNIV,FAC ENGN,DEPT MED CHEM,SAKYO KU,KYOTO 606,JAPAN; OHU UNIV,SCH DENT,DEPT ANAT,KORIYAMA,FUKUSHIMA 963,JAPAN	Kyoto University			Honjo, Tasuku/N-4470-2016					BREIVIK H, 1971, J CELL PHYSIOL, V78, P73, DOI 10.1002/jcp.1040780111; COOPER MC, 1974, P NATL ACAD SCI USA, V71, P1677, DOI 10.1073/pnas.71.5.1677; CRAIG ML, 1964, DEV BIOL, V10, P191, DOI 10.1016/0012-1606(64)90040-5; DOETSCHMAN TC, 1985, J EMBRYOL EXP MORPH, V87, P27; DZIERZAK E, 1995, TRENDS GENET, V11, P359, DOI 10.1016/S0168-9525(00)89107-6; INGRAM VM, 1972, NATURE, V235, P338, DOI 10.1038/235338a0; JOYNER AL, 1993, GENE TARGETING; KELLER G, 1993, MOL CELL BIOL, V13, P473, DOI 10.1128/MCB.13.1.473; KODAMA H, 1994, EXP HEMATOL, V22, P979; LEDER A, 1992, DEVELOPMENT, V116, P1041; LINDENBAUM MH, 1990, GENE DEV, V4, P2075, DOI 10.1101/gad.4.12a.2075; MEDVINSKY AL, 1993, NATURE, V364, P64, DOI 10.1038/364064a0; MIWA Y, 1991, DEVELOPMENT, V111, P543; MOORE MAS, 1970, BRIT J HAEMATOL, V18, P279, DOI 10.1111/j.1365-2141.1970.tb01443.x; MULLER AM, 1994, IMMUNITY, V1, P291, DOI 10.1016/1074-7613(94)90081-7; NAKANO T, 1994, SCIENCE, V265, P1098, DOI 10.1126/science.8066449; Nakano T, 1995, Semin Immunol, V7, P197, DOI 10.1016/1044-5323(95)90047-0; NAKANO T, UNPUB; NOCKA K, 1989, GENE DEV, V3, P816, DOI 10.1101/gad.3.6.816; OGAWA M, 1991, J EXP MED, V174, P63, DOI 10.1084/jem.174.1.63; OGAWA M, 1993, DEVELOPMENT, V117, P1089; PESCHLE C, 1985, NATURE, V313, P235, DOI 10.1038/313235a0; RUGH R, 1968, MOUSE; Sambrook J., 2002, MOL CLONING LAB MANU; STAMATOYANNOPOU.G, 1994, MOL BASIS BLOOD DIS; SUDA T, 1985, J CELL PHYSIOL, V124, P182, DOI 10.1002/jcp.1041240203; WEISS MJ, 1994, GENE DEV, V8, P1184, DOI 10.1101/gad.8.10.1184; WONG PMC, 1983, BLOOD, V62, P1280; WONG PMC, 1986, BLOOD, V67, P716; WU H, 1995, CELL, V83, P59, DOI 10.1016/0092-8674(95)90234-1	30	185	194	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 3	1996	272	5262					722	724		10.1126/science.272.5262.722	http://dx.doi.org/10.1126/science.272.5262.722			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UJ051	8614833				2022-12-28	WOS:A1996UJ05100051
J	Durand, GM; Kovalchuk, Y; Konnerth, A				Durand, GM; Kovalchuk, Y; Konnerth, A			Long-term potentiation and functional synapse induction in developing hippocampus	NATURE			English	Article							EXCITATORY SYNAPSES; DENTATE GYRUS; RAT; SLICES; RECEPTORS; REGION	LONG-TERM potentiation (LTP) is a cellular mechanism that potentially underlies learning and memory(1). To test the hypothesis that LTP is involved in activity-dependent synapse formation, we combined whole-cell recordings and confocal microscopy to investigate hippocampal glutamatergic synapses at their earliest stages of development. Here we report that, during the first postnatal week, the hippocampal glutamatergic network becomes gradually functional owing to the transformation of precursor, pure NMDA (N-methyl-D-aspartate)-receptor-based synaptic contacts into conducting AMPA (alpha-amino-3-hydroxyd-methylisoxazole-4-proprionate)/NMDA-receptor-type synapses. This functional synapse induction is caused by an associative form of LTP, so it is input-specific and easily triggered experimentally by pairing presynaptic stimulation with postsynaptic depolarization. Our results challenge previous views that LTP occurs in the hippocampus only at later stages of development(2-6) and that its induction requires dendritic spines(7). They also provide direct evidence that LTP is important for the activity-dependent formation of conducting glutamatergic synapses in the developing mammalian brain.	UNIV SAARLAND, INST PHYSIOL, D-66421 HOMBURG, GERMANY	Saarland University								BAUDRY M, 1981, DEV BRAIN RES, V1, P37, DOI 10.1016/0165-3806(81)90092-4; BAYER SA, 1980, J COMP NEUROL, V190, P87, DOI 10.1002/cne.901900107; BEKENSTEIN JW, 1991, DEV BRAIN RES, V63, P245, DOI 10.1016/0165-3806(91)90084-V; BEKKERS JM, 1989, NATURE, V341, P230, DOI 10.1038/341230a0; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; BOLSHAKOV VY, 1994, SCIENCE, V264, P1148, DOI 10.1126/science.7909958; DUDEK SM, 1993, J NEUROSCI, V13, P2910; EDWARDS FA, 1989, PFLUG ARCH EUR J PHY, V414, P600, DOI 10.1007/BF00580998; EILERS J, 1995, NATURE, V373, P155, DOI 10.1038/373155a0; EILERS J, 1995, P NATL ACAD SCI USA, V92, P10272, DOI 10.1073/pnas.92.22.10272; GUSTAFSSON B, 1988, TRENDS NEUROSCI, V11, P156, DOI 10.1016/0166-2236(88)90142-7; HARNS KM, 1984, J PHYSIOL-LONDON, V346, P27; HARRIS KM, 1994, ANNU REV NEUROSCI, V17, P341, DOI 10.1146/annurev.ne.17.030194.002013; HEBB DO, 1949, ORG BEHAVIOR; HESTRIN S, 1990, J PHYSIOL-LONDON, V422, P203, DOI 10.1113/jphysiol.1990.sp017980; ISAAC JTR, 1995, NEURON, V15, P427, DOI 10.1016/0896-6273(95)90046-2; KONNERTH A, 1990, PFLUG ARCH EUR J PHY, V417, P285, DOI 10.1007/BF00370994; KONNERTH A, 1990, TRENDS NEUROSCI, V13, P321, DOI 10.1016/0166-2236(90)90137-Y; LIAO DZ, 1995, NATURE, V375, P400, DOI 10.1038/375400a0; LYNCH G, 1983, NATURE, V305, P719, DOI 10.1038/305719a0; MALENKA RC, 1988, SCIENCE, V242, P81, DOI 10.1126/science.2845577; PARTIN KM, 1993, NEURON, V11, P1069, DOI 10.1016/0896-6273(93)90220-L; STEWARD O, 1991, J COMP NEUROL, V314, P545, DOI 10.1002/cne.903140311; WONG LA, 1993, MOL PHARMACOL, V44, P504; YUSTE R, 1995, NATURE, V375, P682, DOI 10.1038/375682a0	25	644	663	1	25	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 2	1996	381	6577					71	75		10.1038/381071a0	http://dx.doi.org/10.1038/381071a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UJ053	8609991				2022-12-28	WOS:A1996UJ05300058
J	Newburger, JW				Newburger, JW			Treatment of Kawasaki disease	LANCET			English	Editorial Material							INTRAVENOUS GAMMA-GLOBULIN				Newburger, JW (corresponding author), CHILDRENS HOSP, DEPT CARDIOL, BOSTON, MA 02115 USA.		Nakashima, Lynne/I-1708-2019	Nakashima, Lynne/0000-0002-0712-7958				Burns JC, 1995, INT CONGR SER, V1093, P296; DAJANI AS, 1994, CIRCULATION, V89, P916, DOI 10.1161/01.CIR.89.2.916; DURONGPISITKUL K, 1995, PEDIATRICS, V96, P1057; FURUSHO K, 1984, LANCET, V2, P1055; HARADA K, 1993, P 4 INT S KAW DIS DA, P459; KATO H, 1982, AM J CARDIOL, V49, P1758, DOI 10.1016/0002-9149(82)90256-9; KLASSEN TP, 1993, J PEDIATR-US, V122, P538, DOI 10.1016/S0022-3476(05)83532-2; NEWBURGER JW, 1986, NEW ENGL J MED, V315, P341, DOI 10.1056/NEJM198608073150601; Rosenfeld EA, 1995, INT CONGR SER, V1093, P291; SCHNEIDER L, 1994, MMWR-MORBID MORTAL W, V43, P505; Silverman ED, 1995, INT CONGR SER, V1093, P301; TAUBERT KA, 1991, J PEDIATR-US, V119, P279, DOI 10.1016/S0022-3476(05)80742-5	12	25	27	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	APR 27	1996	347	9009					1128	1128		10.1016/S0140-6736(96)90600-5	http://dx.doi.org/10.1016/S0140-6736(96)90600-5			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UG755	8609740				2022-12-28	WOS:A1996UG75500002
J	Muragaki, Y; Mundlos, S; Upton, J; Olsen, BR				Muragaki, Y; Mundlos, S; Upton, J; Olsen, BR			Altered growth and branching patterns in synpolydactyly caused by mutations in HOXD13	SCIENCE			English	Article							GENE; LIMB; EXPRESSION; REPRESSION; PROTEINS; HOXD-13; LOCUS	Hox genes regulate patterning during limb development. It is believed that they function in the determination of the timing and extent of local growth rates. Here, it is demonstrated that synpolydactyly, an inherited human abnormality of the hands and feet, is caused by expansions of a polyalanine stretch in the amino-terminal region of HOXD13. The homozygous phenotype includes the transformation of metacarpal and metatarsal bones to short carpal- and tarsal-like bones. The mutations identify the polyalanine stretch outside of the DNA binding domain of HOXD13 as a region necessary for proper protein function.	HARVARD UNIV,BETH ISRAEL HOSP,SCH MED,DEPT SURG,DIV PLAST SURG,BOSTON,MA 02115; HARVARD UNIV,CHILDRENS HOSP,SCH MED,BOSTON,MA 02115	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Boston Children's Hospital; Harvard Medical School	Muragaki, Y (corresponding author), HARVARD UNIV,SCH MED,DEPT CELL BIOL,BOSTON,MA 02115, USA.		Mundlos, Stefan/ABH-9585-2020		NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R37AR036819, R01AR036819, R01AR036820, R37AR036820] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR36820, AR36819] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		CARROLL SB, 1995, NATURE, V376, P479, DOI 10.1038/376479a0; DESPOSITO M, 1991, GENOMICS, V10, P43, DOI 10.1016/0888-7543(91)90482-T; DOLLE P, 1994, DEVELOPMENT, P143; DOLLE P, 1991, MECH DEVELOP, V36, P3, DOI 10.1016/0925-4773(91)90067-G; DOLLE P, 1993, CELL, V75, P431, DOI 10.1016/0092-8674(93)90378-4; GEHRING WJ, 1994, CELL, V78, P211, DOI 10.1016/0092-8674(94)90292-5; HAN KY, 1993, EMBO J, V12, P2723, DOI 10.1002/j.1460-2075.1993.tb05934.x; HAN KY, 1993, GENE DEV, V7, P491, DOI 10.1101/gad.7.3.491; HAYASHI S, 1990, CELL, V63, P883, DOI 10.1016/0092-8674(90)90492-W; IZPISUABELMONTE JC, 1991, NATURE, V350, P585, DOI 10.1038/350585a0; JAYNES JB, 1988, NATURE, V336, P744, DOI 10.1038/336744a0; LICHT JD, 1990, NATURE, V346, P76, DOI 10.1038/346076a0; MORGAN BA, 1992, NATURE, V358, P236, DOI 10.1038/358236a0; MORGAN BA, 1994, DEVELOPMENT, P181; MURAGAKI Y, UNPUB; Polymeropoulos M. H., 1995, American Journal of Human Genetics, V57, pA200; ROBERTS DJ, 1994, AM J HUM GENET, V55, P1; ROGINA B, 1993, NUCLEIC ACIDS RES, V21, P1316, DOI 10.1093/nar/21.5.1316; ROSEN DR, 1993, HUM MOL GENET, V2, P617, DOI 10.1093/hmg/2.5.617; SARFARAZI M, 1995, HUM MOL GENET, V4, P1453, DOI 10.1093/hmg/4.8.1453; SAYLI BS, 1994, J MED GENET, V32, P421; SHUBIN NH, 1986, EVOL BIOL, V20, P319; SMITH DL, 1994, EMBO J, V13, P2378, DOI 10.1002/j.1460-2075.1994.tb06521.x; SORDINO P, 1995, NATURE, V375, P678, DOI 10.1038/375678a0; YOKOUCHI Y, 1995, GENE DEV, V9, P2509, DOI 10.1101/gad.9.20.2509; YOKOUCHI Y, 1991, NATURE, V353, P443, DOI 10.1038/353443a0	26	457	479	1	16	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 26	1996	272	5261					548	551		10.1126/science.272.5261.548	http://dx.doi.org/10.1126/science.272.5261.548			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UG826	8614804				2022-12-28	WOS:A1996UG82600044
J	Minor, DL; Kim, PS				Minor, DL; Kim, PS			Context-dependent secondary structure formation of a designed protein sequence	NATURE			English	Article							DIFFERENT CONFORMATIONS; PENTAPEPTIDES	PROTEIN secondary structures have been viewed as fundamental building blocks for protein folding, structure and design. Previous studies indicate that the propensities of individual amino acids to form particular secondary structures are the result of a combination of local conformational preferences(1,2) and non-local factors(3-7). To examine the extent to which non-local factors influence the formation of secondary structural elements, we have designed an 11-amino-acid sequence (dubbed the 'chameleon' sequence) that folds as an alpha-helix when in one position but as a beta-sheet when in another position of the primary sequence of the IgG-binding domain of protein G (GB1). Both proteins, chameleon-alpha and chameleon-beta, are folded into structures similar to native GB1, as judged hy several biophysical criteria. Our results demonstrate that non-local interactions can determine the secondary structure of peptide sequences of substantial length. They also support views of protein folding that favour tertiary interactions as dominant determinants of structure (for example, see refs 8,9).	MIT,WHITEHEAD INST BIOMED RES,HOWARD HUGHES MED INST,DEPT BIOL,CAMBRIDGE,MA 02142; MIT,WHITEHEAD INST BIOMED RES,HOWARD HUGHES MED INST,DEPT CHEM,CAMBRIDGE,MA 02142	Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT); Whitehead Institute; Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT); Whitehead Institute								ACHARI A, 1992, BIOCHEMISTRY-US, V31, P10449, DOI 10.1021/bi00158a006; ALEXANDER P, 1992, BIOCHEMISTRY-US, V31, P3597, DOI 10.1021/bi00129a007; ARGOS P, 1987, J MOL BIOL, V197, P331, DOI 10.1016/0022-2836(87)90127-6; BAI YW, 1993, PROTEINS, V17, P75, DOI 10.1002/prot.340170110; BRYSON JW, 1995, SCIENCE, V270, P935, DOI 10.1126/science.270.5238.935; BULLOUGH PA, 1994, NATURE, V371, P37, DOI 10.1038/371037a0; CARR CM, 1993, CELL, V73, P823, DOI 10.1016/0092-8674(93)90260-W; CHAKRABARTTY A, 1995, ADV PROTEIN CHEM, V46, P141, DOI 10.1016/S0065-3233(08)60334-4; CHOU PY, 1974, BIOCHEMISTRY-US, V13, P211, DOI 10.1021/bi00699a001; COHEN BI, 1993, PROTEIN SCI, V2, P2134, DOI 10.1002/pro.5560021213; DILL KA, 1995, PROTEIN SCI, V4, P561; DYSON HJ, 1991, ANNU REV BIOPHYS BIO, V20, P519; FAHNESTOCK SR, 1990, BACTERIAL IMMUNOGLOB; GARRATT RC, 1985, FEBS LETT, V188, P59, DOI 10.1016/0014-5793(85)80874-7; GOLDSMITH EJ, 1994, STRUCTURE, V2, P241, DOI 10.1016/S0969-2126(00)00025-3; GRONENBOM AM, 1993, J MOL BIOL, V223, P331; GRONENBORN AM, 1991, SCIENCE, V253, P657, DOI 10.1126/science.1871600; HEINZ DW, 1993, NATURE, V361, P561, DOI 10.1038/361561a0; KABSCH W, 1984, P NATL ACAD SCI-BIOL, V81, P1075, DOI 10.1073/pnas.81.4.1075; Laue T. M., 1994, MODERN ANAL ULTRACEN; LUMB KJ, 1995, BIOCHEMISTRY-US, V34, P8642, DOI 10.1021/bi00027a013; LUMB KJ, 1994, BIOCHEMISTRY-US, V33, P7361, DOI 10.1021/bi00189a042; MINOR DL, 1994, NATURE, V367, P660, DOI 10.1038/367660a0; MINOR DL, 1994, NATURE, V371, P264, DOI 10.1038/371264a0; ORBAN J, 1995, BIOCHEMISTRY-US, V34, P15291, DOI 10.1021/bi00046a038; PRIVALOV PL, 1989, ANNU REV BIOPHYS BIO, V18, P47, DOI 10.1146/annurev.biophys.18.1.47; SMITH CK, 1995, SCIENCE, V270, P980, DOI 10.1126/science.270.5238.980; WILSON IA, 1985, P NATL ACAD SCI USA, V82, P5255, DOI 10.1073/pnas.82.16.5255; Woody R., 1985, PEPTIDES; Wuthrich K., 1986, NMR PROTEINS NUCL AC; XIONG HY, 1995, P NATL ACAD SCI USA, V92, P6349, DOI 10.1073/pnas.92.14.6349	31	341	349	1	32	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	APR 25	1996	380	6576					730	734		10.1038/380730a0	http://dx.doi.org/10.1038/380730a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UG827	8614471				2022-12-28	WOS:A1996UG82700057
J	Kononen, M; Waltimo, A; Nystrom, M				Kononen, M; Waltimo, A; Nystrom, M			Does clicking in adolescence lead to painful temporomandibular joint locking?	LANCET			English	Article							DYSFUNCTION	Background It has been assumed that clicking of the temporomandibular joint (TMJ) may predispose to closed locking. Although jaw clicking is a common complaint, locking of the TMJ is rare. Methods To assess whether clicking is a reliable predictor of locking, we examined longitudinally over 9 years the variation of reported and recorded TMJ clicking in 128 young Finnish adults. Subjects were interviewed and examined at the ages of 14, 15, 18, and 23 years. Findings Reported and recorded TMJ clicking both increased significantly with age, varying from 11% to 31% and from 11% to 34%, respectively. However, clicking showed no predictable pattern, and only a few subjects consistently reported clicking (2%) or had it recorded (2%). None developed locking. Interpretation Because none of the young adults developed locking of the TMJ, we suggest treatment for clicking should be conservative.	UNIV HELSINKI,DEPT PEDODONT & ORTHODONT,HELSINKI,FINLAND	University of Helsinki	Kononen, M (corresponding author), UNIV HELSINKI,DEPT PROSTH DENT,POB 41,SF-00014 HELSINKI,FINLAND.							Annandale T, 1887, LANCET, V129, P411; BROOKE RI, 1988, ORAL SURG ORAL MED O, V65, P668, DOI 10.1016/0030-4220(88)90005-9; DOLWICK MF, 1983, J PROSTHET DENT, V49, P415, DOI 10.1016/0022-3913(83)90287-1; Dworkin Samuel F., 1992, Journal of Craniomandibular Disorders, V6, P301; GREENE CS, 1988, J AM DENT ASSOC, V117, P461, DOI 10.1016/S0002-8177(88)73018-4; GROSS A, 1983, J AM DENT ASSOC, V107, P932, DOI 10.14219/jada.archive.1983.0354; Kononen Mauno, 1993, Journal of Orofacial Pain, V7, P329; RANDOLPH CS, 1990, AM J ORTHOD DENTOFAC, V77, P77; WANMAN A, 1990, ORAL SURG ORAL MED O, V69, P2, DOI 10.1016/0030-4220(90)90259-U	9	72	73	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 20	1996	347	9008					1080	1081		10.1016/S0140-6736(96)90280-9	http://dx.doi.org/10.1016/S0140-6736(96)90280-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UG042	8602059				2022-12-28	WOS:A1996UG04200013
J	Takeda, K; Tanaka, T; Shi, W; Matsumoto, M; Minami, M; Kashiwamura, S; Nakanishi, K; Yoshida, N; Kishimoto, T; Akira, S				Takeda, K; Tanaka, T; Shi, W; Matsumoto, M; Minami, M; Kashiwamura, S; Nakanishi, K; Yoshida, N; Kishimoto, T; Akira, S			Essential role of Stat6 in IL-4 signalling	NATURE			English	Article							RESTING B-CELLS; INTERLEUKIN-4; EXPRESSION; LIPOPOLYSACCHARIDE; LYMPHOKINE; RECEPTOR	Interleukin-4(IL-4) is a pleiotropic lymphokine which plays an important role in the immune system(1). IL-4 activates two distinct signalling pathways through tyrosine phosphorylation of Stat6, a signal transducer and activator of transcription, and of a 170K protein called 4PS(2-7). To investigate the functional role of Stat6 in IL-4 signalling, we generated mice deficient in Stat6 by gene targeting. We report here that in the mutant mice, expression of CD23 and major histocompatibility complex (MHC) class II in resting B cells was not enhanced in response to IL-4. IL-4-induced B-cell proliferation costimulated by anti-IgM antibody was abolished. The T-cell proliferative response was also notably reduced. Furthermore, production of Th2 cytokines from T cells as well as IgE and IgG1 responses after nematode infection were profoundly reduced. These findings agreed with those obtained in IL4-deficient mice(8,9) or using antibodies to IL-4(10) and the IL-4 receptor(11). We conclude that Stat6 plays a central role in exerting IL-4-mediated biological responses.	OSAKA UNIV, INST MOLEC & CELLULAR BIOL, SUITA, OSAKA 565, JAPAN; OSAKA UNIV, SCH MED, DEPT MED 3, SUITA, OSAKA 565, JAPAN; HYOGO MED UNIV, DEPT IMMUNOL & MED ZOOL, NISHINOMIYA, HYOGO 663, JAPAN; OSAKA MED CTR MATERNAL & CHILD HLTH, RES INST, IZUMI, OSAKA 59002, JAPAN	Osaka University; Osaka University; Hyogo College of Medicine; University of Hyogo			Akira, Shizuo/C-3134-2009; Takeda, Kiyoshi/C-9331-2009; Kishimoto, Tadamitsu/C-8470-2009; Tanaka, Takashi/O-8254-2015					CONRAD DH, 1988, J IMMUNOL, V141, P1091; FINKELMAN FD, 1986, P NATL ACAD SCI USA, V83, P9675, DOI 10.1073/pnas.83.24.9675; FINKELMAN FD, 1990, ANNU REV IMMUNOL, V8, P303, DOI 10.1146/annurev.iy.08.040190.001511; FUJII H, 1995, P NATL ACAD SCI USA, V92, P5482, DOI 10.1073/pnas.92.12.5482; HOU JZ, 1994, SCIENCE, V265, P1701, DOI 10.1126/science.8085155; HULI J, 1987, J EXP MED, V165, P157, DOI 10.1084/jem.165.1.157; KEEGAN AD, 1994, IMMUNOL TODAY, V15, P423, DOI 10.1016/0167-5699(94)90272-0; KEEGAN AD, 1994, CELL, V76, P811, DOI 10.1016/0092-8674(94)90356-5; KIKUTANI H, 1986, CELL, V47, P657, DOI 10.1016/0092-8674(86)90508-8; KOPF M, 1993, NATURE, V362, P245, DOI 10.1038/362245a0; KOTANIDES H, 1995, J BIOL CHEM, V270, P19481, DOI 10.1074/jbc.270.33.19481; KUHN R, 1991, SCIENCE, V254, P707, DOI 10.1126/science.1948049; LIN JX, 1995, IMMUNITY, V2, P331, DOI 10.1016/1074-7613(95)90141-8; MOSMANN TR, 1986, J IMMUNOL, V136, P2348; NOELLE R, 1984, P NATL ACAD SCI-BIOL, V81, P6149, DOI 10.1073/pnas.81.19.6149; PAUL WE, 1991, BLOOD, V77, P1859; PEMIS A, 1995, P NATL ACAD SCI USA, V92, P7971; QUELLE FW, 1995, MOL CELL BIOL, V15, P3336; RABIN EM, 1985, P NATL ACAD SCI USA, V82, P2935, DOI 10.1073/pnas.82.9.2935; RABIN EM, 1986, J EXP MED, V164, P517, DOI 10.1084/jem.164.2.517; ROEHM NW, 1984, J EXP MED, V160, P679, DOI 10.1084/jem.160.3.679; ROTHMAN P, 1993, RES IMMUNOL, V144, P579, DOI 10.1016/S0923-2494(05)80006-9; STREET NE, 1990, J IMMUNOL, V144, P1629; SUN XJ, 1995, NATURE, V377, P173, DOI 10.1038/377173a0; TANAKA T, 1995, CELL, V80, P353, DOI 10.1016/0092-8674(95)90418-2; WANG LM, 1992, EMBO J, V11, P4899, DOI 10.1002/j.1460-2075.1992.tb05596.x; WANG LM, 1993, SCIENCE, V261, P1591, DOI 10.1126/science.8372354; YOKOTA A, 1988, CELL, V55, P611, DOI 10.1016/0092-8674(88)90219-X	28	1235	1266	3	59	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 18	1996	380	6575					627	630		10.1038/380627a0	http://dx.doi.org/10.1038/380627a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UF741	8602263				2022-12-28	WOS:A1996UF74100046
J	Jeevaratnam, DR; Menon, DK				Jeevaratnam, DR; Menon, DK			Survey of intensive care of severely head injured patients in the United Kingdom	BRITISH MEDICAL JOURNAL			English	Article							CEREBRAL PERFUSION-PRESSURE; RANDOMIZED CLINICAL-TRIAL; INTRACRANIAL HYPERTENSION; COMATOSE PATIENTS; BRAIN INJURY; BLOOD-FLOW; MANAGEMENT; HYPERVENTILATION; STEROIDS	Objectives-To study practice in intensive care of patients with severe head injury in neurosurgical referral centres in United Kingdom. Design-Structured telephone interview of senior nursing staff in intensive care unit of adult neurosurgical referral centre. Setting-39 intensive care units in hospitals that accepted acute head injuries for specialist neurosurgical management, identified from Medical Directory and information from professional bodies. Main outcome measures-Details of organisation and administration of intensive care and patterns of monitoring and treatment for patients admitted with severe head injury. Results-Patients were managed in specialist neurosurgical intensive care units in 21 of the centres and in general intensive care units in 18. Their intensive care was coordinated by an anaesthetist in 25 units and by a neurosurgeon in 12. Annual caseload varied between units: 20 received >100 patients, 12 received 50-100, and seven received 25-49. Monitoring and treatment varied considerably between centres. Invasive arterial pressure monitoring was used routinely in 36 units, but central venous pressure monitoring was routinely used in 24 and intracranial pressure was routinely monitored in only 19. Corticosteroids were used to treat intracranial hypertension in 19 units. Seventeen units routinely aimed for arterial carbon dioxide pressure of 3.3-4.0 kPa, and one unit still used severe hyperventilation to a pressure of <3.3 kPa. Conclusion-The intensive care of patients with acute head injuries varied widely between the centres surveyed. Rationalisation of the intensive care of severe head injury with the production of widely accepted guidelines ought to improve the quality of care.	UNIV CAMBRIDGE,ADDENBROOKES HOSP,SCH CLIN,DEPT ANAESTHESIA,CAMBRIDGE CB2 2QQ,ENGLAND	Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge								BECKER DP, 1977, J NEUROSURG, V47, P491, DOI 10.3171/jns.1977.47.4.0491; BRAAKMAN R, 1983, J NEUROSURG, V58, P326, DOI 10.3171/jns.1983.58.3.0326; CHAN KH, 1993, NEUROSURGERY, V32, P547, DOI 10.1227/00006123-199304000-00009; CHANGARIS DG, 1987, J TRAUMA, V27, P1007, DOI 10.1097/00005373-198709000-00009; COLD GE, 1989, ACTA NEUROCHIR, V96, P100, DOI 10.1007/BF01456166; COOPER PR, 1979, J NEUROSURG, V51, P307, DOI 10.3171/jns.1979.51.3.0307; CRUZ J, 1993, J NEUROSURG, V79, P228, DOI 10.3171/jns.1993.79.2.0228; GHAJAR J, 1995, CRIT CARE MED, V23, P560, DOI 10.1097/00003246-199503000-00023; GIANNOTTA SL, 1984, NEUROSURGERY, V15, P497, DOI 10.1227/00006123-198410000-00004; GUDEMAN SK, 1979, J NEUROSURG, V51, P301, DOI 10.3171/jns.1979.51.3.0301; Jennett B., 1981, MANAGEMENT HEAD INJU; JONES PA, 1994, J NEUROSURG ANESTH, V6, P4; MARMAROU A, 1991, J NEUROSURG, V75, pS21, DOI 10.3171/sup.1991.75.1s.0s21; MARMAROU A, 1991, J NEUROSURG, V75, pS59, DOI 10.3171/sup.1991.75.1s.0s59; MARSHALL LF, 1979, J NEUROSURG, V50, P20, DOI 10.3171/jns.1979.50.1.0020; MILLER JD, 1977, J NEUROSURG, V47, P503, DOI 10.3171/jns.1977.47.4.0503; MILLER JD, 1993, J NEUROL NEUROSUR PS, V56, P440, DOI 10.1136/jnnp.56.5.440; MUIZELAAR JP, 1991, J NEUROSURG, V75, P731, DOI 10.3171/jns.1991.75.5.0731; NARAYAN RK, 1982, J NEUROSURG, V56, P650, DOI 10.3171/jns.1982.56.5.0650; OBRIST WD, 1984, J NEUROSURG, V61, P241, DOI 10.3171/jns.1984.61.2.0241; OSULLIVAN MG, 1994, J NEUROSURG, V80, P46, DOI 10.3171/jns.1994.80.1.0046; PICKARD JD, 1993, J NEUROL NEUROSUR PS, V56, P845, DOI 10.1136/jnnp.56.8.845; PIEK J, 1992, J NEUROSURG, V77, P901, DOI 10.3171/jns.1992.77.6.0901; ROBERTSON CS, 1992, J NEUROL NEUROSUR PS, V55, P594, DOI 10.1136/jnnp.55.7.594; ROBERTSON CS, 1985, J NEUROSURG, V63, P714, DOI 10.3171/jns.1985.63.5.0714; ROSNER MJ, 1990, J TRAUMA, V30, P933, DOI 10.1097/00005373-199008000-00001; SAUL TG, 1981, J NEUROSURG, V54, P596, DOI 10.3171/jns.1981.54.5.0596; SHEINBERG M, 1992, J NEUROSURG, V76, P212, DOI 10.3171/jns.1992.76.2.0212; Young B, 1991, Neurosurg Clin N Am, V2, P301	29	78	79	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 13	1996	312	7036					944	947						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UF659	8616307				2022-12-28	WOS:A1996UF65900019
J	Sadato, N; PascualLeone, A; Grafman, J; Ibanez, V; Deiber, MP; Dold, G; Hallett, M				Sadato, N; PascualLeone, A; Grafman, J; Ibanez, V; Deiber, MP; Dold, G; Hallett, M			Activation of the primary visual cortex by Braille reading in blind subjects	NATURE			English	Article							MONKEY; MACAQUE	PRIMARY visual cortex receives visual input from the eyes through the lateral geniculate nuclei, but is not known to receive input from other sensory modalities'. Its level of activity, both at rest and during auditory or tactile tasks, is higher in blind subjects than in normal controls(2), suggesting that it can subserve nonvisual functions; however, a direct effect of non-visual tasks on activation has not been demonstrated(2-4). To determine whether the visual cortex receives input from the somatosensory system(5-8), we used positron emission tomography (PET) to measure activation during tactile discrimination tasks in normal subjects and in Braille readers blinded in early life. Blind subjects showed activation of primary and secondary visual cortical areas during tactile tasks, whereas normal controls showed deactivation, A simple tactile stimulus that did not require discrimination produced no activation of visual areas in either group. Thus, in blind subjects, cortical areas normally reserved for vision may be activated by other sensory modalities.	NINCDS, HUMAN MOTOR CONTROL SECT, NIH, BETHESDA, MD 20892 USA; NINCDS, COGNIT NEUROSCI SECT, MED NEUROL BRANCH, NIH, BETHESDA, MD 20892 USA; FUKUI MED SCH, BIOMED IMAGING RES CTR, MATUOKA, FUKUI 91011, JAPAN	National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); NIH National Institute of Neurological Disorders & Stroke (NINDS); University of Fukui			Pascual-Leone, Alvaro/AAC-5101-2019; Deiber, Marie-Pierre/ABF-9026-2020; Pascual-Leone, Alvaro/G-6566-2011; Deiber, Marie-Pierre/M-5949-2014	Pascual-Leone, Alvaro/0000-0001-8975-0382; Sadato, Norihiro/0000-0002-9786-3907; Deiber, Marie-Pierre/0000-0002-4984-7363; Grafman, Jordan H./0000-0001-8645-4457				BRUCE C, 1981, J NEUROPHYSIOL, V46, P369, DOI 10.1152/jn.1981.46.2.369; Friston K J, 1994, Hum Brain Mapp, V1, P210, DOI 10.1002/hbm.460010306; FRISTON KJ, 1990, J CEREBR BLOOD F MET, V10, P458, DOI 10.1038/jcbfm.1990.88; FRISTON KJ, 1991, J CEREBR BLOOD F MET, V11, P690, DOI 10.1038/jcbfm.1991.122; HAXBY JV, 1994, J NEUROSCI, V14, P6336; Heller Morton, 1991, PSYCHOL TOUCH; Hollins M., 1989, UNDERSTANDING BLINDN; HYVARINEN J, 1981, NEUROSCI LETT, V26, P239, DOI 10.1016/0304-3940(81)90139-7; Kennedy John., 1993, DRAWING BLIND PICTUR; LEBIHAN D, 1993, P NATL ACAD SCI USA, V90, P11802, DOI 10.1073/pnas.90.24.11802; MEYER E, 1991, ANN NEUROL, V29, P440, DOI 10.1002/ana.410290418; Millar Susanna, 1994, UNDERSTANDING REPRES, DOI 10.1093/acprof:oso/9780198521426.001.0001; Morgan MichaelJ., 1977, MOLYNEUXS QUESTION V; RAUSCHECKER JP, 1993, J NEUROSCI, V13, P4538; RAUSCHECKER JP, 1995, TRENDS NEUROSCI, V18, P36, DOI 10.1016/0166-2236(95)93948-W; ROLAND PE, 1989, EUR J NEUROSCI, V1, P3, DOI 10.1111/j.1460-9568.1989.tb00769.x; SADATO N, 1995, NEUROLOGY, V45, pA426; SHIPP S, 1989, EUR J NEUROSCI, V1, P309, DOI 10.1111/j.1460-9568.1989.tb00798.x; Talairach J., 1988, APPROACH CEREBRAL IM; UHL F, 1994, ELECTROEN CLIN NEURO, V91, P249, DOI 10.1016/0013-4694(94)90188-0; UHL F, 1991, NEUROSCI LETT, V124, P256, DOI 10.1016/0304-3940(91)90107-5; WANETDEFALQUE MC, 1988, BRAIN RES, V446, P369, DOI 10.1016/0006-8993(88)90896-7; WORSLEY KJ, 1992, J CEREBR BLOOD F MET, V12, P900, DOI 10.1038/jcbfm.1992.127; ZEKI SM, 1978, NATURE, V274, P423, DOI 10.1038/274423a0	24	790	801	0	79	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 11	1996	380	6574					526	528		10.1038/380526a0	http://dx.doi.org/10.1038/380526a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UE663	8606771				2022-12-28	WOS:A1996UE66300049
J	Grant, GF				Grant, GF			My brain stem stroke	BRITISH MEDICAL JOURNAL			English	Editorial Material																			0	1	1	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 6	1996	312	7035					917	917						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UE371	8611912				2022-12-28	WOS:A1996UE37100072
J	Parkhouse, J				Parkhouse, J			Intake, output, and drop out in United Kingdom medical schools	BRITISH MEDICAL JOURNAL			English	Article											Parkhouse, J (corresponding author), UNIV OXFORD,MED CAREERS RES GRP,UNIT HLTH CARE EPIDEMIOL,S PARKS RD,OXFORD OX3 7LF,ENGLAND.							*DEP HLTH, 1989, 2ND ADV COMM MED MAN; *MED MANP STAND AD, 1992, 1 DEP HLTH MED MANP; *MED WORKF STAND A, 1995, 2 DEP HLTH MED WORKF; PARKHOUSE J, 1979, MED MANPOWER BRITAIN; *ROYAL COMM MED ED, 1988, CMND3569	5	24	24	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 6	1996	312	7035					885	885						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UE371	8611878				2022-12-28	WOS:A1996UE37100023
J	Joossens, L; Raw, M				Joossens, L; Raw, M			Are tobacco subsidies a misuse of public funds?	BRITISH MEDICAL JOURNAL			English	Article								The European Union spends about 1000m ecu (pound 800m, $1240m) a year subsidising tobacco production but only about 1.55m ecu (pound 1.2m, $1.85m) on smoking prevention. The subsidies, part of the common agriculutral policy, were originally intended to encourage farmers to grow commercially valued varieties of tobacco and thus reduce imports. But they also aimed to guarantee farmers' income, a goal in direct conflict with the first. The policy has failed to adapt production to demand or reduce imports, Since most tobacco grown in the union has little commercial value. Reforms introduced in 1992 have had a limited impact on expenditure, and data produced as a result of the reforms show that it would be much cheaper to give farmers direct income support than to subsidise them growing tobacco. Tobacco subsidies should be abolished and more should be spent on smoking prevention.	UNIV LONDON KINGS COLL,SCH MED & DENT,LONDON SE5,ENGLAND		Joossens, L (corresponding author), INT UNION AGAINST CANC,EUROPEAN UNION OFF,RUE PASCAL 33,B-1000 BRUSSELS,BELGIUM.							*COMM EUR COMM, 1993, 9371 COMM EUR COMM; JOOSSENS L, 1991, BRIT J ADDICT, V86, P1191, DOI 10.1111/j.1360-0443.1991.tb01699.x; SLAMA K, 1995, TOBACCO HLTH; 1994, OFFICIAL J EUROPEAN, V37; 1992, OFFICIAL J EUROPEA L, V215, P70; 1992, OFFICIAL J EUROPEA L, V351, P17	6	8	8	1	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 30	1996	312	7034					832	835						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UD378	8608295	Green Published			2022-12-28	WOS:A1996UD37800031
J	Gems, D; Riddle, DL				Gems, D; Riddle, DL			Longevity in Caenorhabditis elegans reduced by mating but not gamete production	NATURE			English	Article							FERTILIZATION-DEFECTIVE MUTANTS; FEMALE DROSOPHILA-MELANOGASTER; LIFE-SPAN; WILD-TYPE; SPERM; EVOLUTION; MALES; GENE	THEORIES Of life-history evolution propose that trade-offs occur between fitness components, including longevity and maximal reproduction(1-3). In Drosophila, female lifespan is shortened by increased egg production(4), receipt of male accessory fluid(5) and courting(6), Male lifespan is also reduced by courting and/or mating(7). Here we show that in the nematode Caenorhabditis elegans, mating with males reduces the lifespan of hermaphrodites by a mechanism independent of egg production or receipt of sperm, Conversely, males appear unaffected by mating, Thus, in C. elegans there is no apparent trade-off between longevity and increased egg or sperm production, but there is a substantial cost to hermaphrodites associated with copulation.	UNIV MISSOURI, DIV BIOL SCI, COLUMBIA, MO 65211 USA	University of Missouri System; University of Missouri Columbia	Gems, D (corresponding author), UNIV MISSOURI, PROGRAM MOLEC BIOL, COLUMBIA, MO 65211 USA.			Gems, David/0000-0002-6653-4676				ARGON Y, 1980, GENETICS, V96, P413; BRENNER S, 1974, GENETICS, V77, P71; CHAPMAN T, 1992, J INSECT PHYSIOL, V38, P223, DOI 10.1016/0022-1910(92)90070-T; CHAPMAN T, 1995, NATURE, V373, P241, DOI 10.1038/373241a0; CHEN PS, 1988, CELL, V54, P291, DOI 10.1016/0092-8674(88)90192-4; FRIEDMAN DB, 1988, GENETICS, V118, P75; HARSHMAN LG, 1994, EVOLUTION, V48, P758, DOI [10.2307/2410484, 10.1111/j.1558-5646.1994.tb01359.x]; HODGKIN J, 1983, GENETICS, V103, P43; KALB JM, 1993, P NATL ACAD SCI USA, V90, P8093, DOI 10.1073/pnas.90.17.8093; KENYON C, 1993, NATURE, V366, P461, DOI 10.1038/366461a0; Kimble J, 1988, NEMATODE CAENORHABDI, P191; KIRKWOOD TBL, 1977, NATURE, V270, P301, DOI 10.1038/270301a0; KLASS MR, 1977, MECH AGEING DEV, V6, P413, DOI 10.1016/0047-6374(77)90043-4; LHEMAULT SW, 1988, GENETICS, V120, P435; PARTRIDGE L, 1988, SCIENCE, V241, P1449, DOI 10.1126/science.241.4872.1449; PARTRIDGE L, 1987, J INSECT PHYSIOL, V33, P745, DOI 10.1016/0022-1910(87)90060-6; PARTRIDGE L, 1981, NATURE, V294, P580, DOI 10.1038/294580a0; SCHEDL T, 1988, GENETICS, V119, P43; SCOTT D, 1987, ANIM BEHAV, V35, P142, DOI 10.1016/S0003-3472(87)80219-1; VANVOORHIES WA, 1992, NATURE, V360, P456, DOI 10.1038/360456a0; WARD S, 1978, GENETICS, V88, P285; WARD S, 1981, J CELL BIOL, V91, P26, DOI 10.1083/jcb.91.1.26; WILKINSON L, 1989, SYSTAT SYSTEMS STATI; WILLIAMS GC, 1957, EVOLUTION, V11, P398, DOI 10.1111/j.1558-5646.1957.tb02911.x	24	152	158	1	27	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 22	1996	379	6567					723	725		10.1038/379723a0	http://dx.doi.org/10.1038/379723a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TW567	8602217				2022-12-28	WOS:A1996TW56700051
J	Snowdon, DA; Kemper, SJ; Mortimer, JA; Greiner, LH; Wekstein, DR; Markesbery, WR				Snowdon, DA; Kemper, SJ; Mortimer, JA; Greiner, LH; Wekstein, DR; Markesbery, WR			Linguistic ability in early life and cognitive function and Alzheimer's disease in late life - Findings from the Nun Study	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							EDUCATION; ADULTS; SENTENCES; AGE; POPULATION; PREVALENCE; DEMENTIA; SPAN	Objective.-To determine if linguistic ability in early life is associated with cognitive function and Alzheimer's disease in late life. Design.- Two measures of linguistic ability in early life, idea density and grammatical complexity, were derived from autobiographies written at a mean age of 22 yearr. Approximately 58 years later, the women who wrote these autobiographies participated in an assessment of cognitive function, and those who subsequently died were evaluated neuropathologically, Setting.-Convents in the United States participating in the Nun Study; primarily convents in the Milwaukee, Wis, area. Participants.-Cognitive function was investigated in 93 participants who were aged 75 to 95 years at the time of their assessments, and Alzheimer's disease was investigated in the 14 participants who died at 79 to 96 years of age. Main Outcome Measures.-Seven neuropsychological tests and neuropathologically confirmed Alzheimer's disease. Results.-Low idea density and low grammatical complexity in autobiographies written in early life were associated with low cognitive test scores in late life, Low idea density in early life had stronger and more consistent associations with poor cognitive function than did low grammatical complexity. Among the 14 sisters who died, neuropathologically confirmed Alzheimer's disease was present in all of those with low idea density in early life and in none of those with high idea density. Conclusions.-Low linguistic ability in early life was a strong predictor of poor cognitive function and Alzheimer's disease in late life.	UNIV KENTUCKY, DEPT PREVENT MED, COLL MED, LEXINGTON, KY 40536 USA; UNIV KENTUCKY, DEPT PHYSIOL, COLL MED, LEXINGTON, KY 40536 USA; UNIV KENTUCKY, DEPT NEUROL, COLL MED, LEXINGTON, KY 40536 USA; UNIV KENTUCKY, DEPT PATHOL, COLL MED, LEXINGTON, KY 40536 USA; UNIV KANSAS, DEPT PSYCHOL, LAWRENCE, KS USA; UNIV MINNESOTA, VET AFFAIRS MED CTR, MINNEAPOLIS, MN 55455 USA; UNIV MINNESOTA, DEPT NEUROL, MINNEAPOLIS, MN 55455 USA; UNIV MINNESOTA, DEPT EPIDEMIOL, MINNEAPOLIS, MN 55455 USA	University of Kentucky; University of Kentucky; University of Kentucky; University of Kentucky; University of Kansas; University of Minnesota System; University of Minnesota Twin Cities; US Department of Veterans Affairs; Veterans Health Administration (VHA); Minneapolis VA Health Care System; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities	Snowdon, DA (corresponding author), UNIV KENTUCKY, SANDERS BROWN CTR AGING, COLL MED, 101 SANDERS BROWN BLDG, LEXINGTON, KY 40536 USA.				NATIONAL INSTITUTE ON AGING [K04AG000553, K04AG000443, R01AG009862] Funding Source: NIH RePORTER; NIA NIH HHS [K04AG00443, K04AG00553, R01AG09862] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BIERER LM, 1995, ARCH NEUROL-CHICAGO, V52, P81, DOI 10.1001/archneur.1995.00540250089017; BOURAS C, 1994, CEREB CORTEX, V4, P138, DOI 10.1093/cercor/4.2.138; CHEUNG H, 1992, APPL PSYCHOLINGUIST, V13, P53, DOI 10.1017/S0142716400005427; CROPLEY AJ, 1977, LIFELONG ED PSYCHOL; DARCY C, 1994, NEUROBIOL AGING, V15, pS40; FRATIGLIONI L, 1991, NEUROLOGY, V41, P1886, DOI 10.1212/WNL.41.12.1886; GATZ M, 1994, GERONTOLOGIST, V34, P251, DOI 10.1093/geront/34.2.251; KEMPER S, 1993, ARCH NEUROL-CHICAGO, V50, P81, DOI 10.1001/archneur.1993.00540010075021; KEMPER S, 1989, APPL PSYCHOLINGUIST, V10, P49, DOI 10.1017/S0142716400008419; KEMPER S, 1990, DISCOURSE PROCESS, V13, P207, DOI 10.1080/01638539009544754; Kemper S., 1990, EUR J COGN PSYCHOL, V2, P205, DOI [10.1080/09541449008406205, DOI 10.1080/09541449008406205]; Kemper S., 1992, EVERYDAY MEMORY AGIN, P138, DOI [10.1007/978-1-4613-9151-7_9, DOI 10.1007/978-1-4613-9151-7_9]; KHACHATURIAN ZS, 1985, ARCH NEUROL-CHICAGO, V42, P1097, DOI 10.1001/archneur.1985.04060100083029; KINTSCH W, 1973, COGNITIVE PSYCHOL, V5, P257, DOI 10.1016/0010-0285(73)90036-4; KURIANSKY J, 1976, INT J AGING HUM DEV, V7, P343, DOI 10.2190/X45L-TWW7-WXXY-KA6K; LAZAR I, 1982, LASTING EFFECTS EARL; LYONS K, 1993, AGING COGNITION, V50, P81; MCKEOWN MG, 1987, NATURE VOCABULARY AC; MORRIS JC, 1989, NEUROLOGY, V39, P1159, DOI 10.1212/wnl.43.12.2457; Mortimer J. A., 1988, ETIOLOGY DEMENTIA AL, P39; MORTIMER JA, 1993, NEUROLOGY, V43, pS39; NAGY Z, 1995, DEMENTIA, V6, P21, DOI 10.1159/000106918; OHM TG, 1995, NEUROSCIENCE, V64, P209, DOI 10.1016/0306-4522(95)90397-P; PINCUS T, 1987, J CHRON DIS, V40, P865, DOI 10.1016/0021-9681(87)90186-X; POTVIN AR, 1972, ARCH PHYS MED REHAB, V53, P476; ROSENBERG S, 1987, APPL PSYCHOLINGUIST, V8, P19, DOI 10.1017/S0142716400000047; ROTH M, 1986, BRIT MED BULL, V42, P42, DOI 10.1093/oxfordjournals.bmb.a072097; Snedecor G.W., 1980, STAT METHODS, V7; SNOWDON DA, 1989, AM J EPIDEMIOL, V130, P999, DOI 10.1093/oxfordjournals.aje.a115433; SNOWDON DA, 1989, J CLIN EPIDEMIOL, V42, P1055, DOI 10.1016/0895-4356(89)90047-4; STERN Y, 1994, JAMA-J AM MED ASSOC, V271, P1004, DOI 10.1001/jama.271.13.1004; STERNBERG RJ, 1983, AM PSYCHOL, V38, P878, DOI 10.1037/0003-066X.38.8.878; Turner A., 1977, CONSTRUCTION USE PRO; WELSH KA, 1994, NEUROLOGY, V44, P609, DOI 10.1212/WNL.44.4.609; WOOLF B, 1955, ANN HUM GENET, V19, P251, DOI 10.1111/j.1469-1809.1955.tb01348.x; ZHANG MY, 1990, ANN NEUROL, V27, P428, DOI 10.1002/ana.410270412; 1985, SAS USERS GUIDE STAT	37	703	714	1	68	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 21	1996	275	7					528	532		10.1001/jama.275.7.528	http://dx.doi.org/10.1001/jama.275.7.528			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	TV569	8606473				2022-12-28	WOS:A1996TV56900029
J	Recht, A; Come, SE; Henderson, IC; Gelman, RS; Silver, B; Hayes, DF; Shulman, LN; Harris, JR				Recht, A; Come, SE; Henderson, IC; Gelman, RS; Silver, B; Hayes, DF; Shulman, LN; Harris, JR			The sequencing of chemotherapy and radiation therapy after conservative surgery for early-stage breast cancer	NEW ENGLAND JOURNAL OF MEDICINE			English	Article								Background. Patients with early-stage breast cancer who are at substantial risk for systemic metastases are increasingly treated with breast-conserving therapy and adjuvant chemotherapy. However, the optimal sequencing of chemotherapy and radiation therapy is not clear. Methods. Two hundred forty-four patients with stage I or II breast cancer who were at substantial risk for distant metastases were randomly assigned to receive a 12-week course of chemotherapy either before or after radiation therapy. All had had breast-conserving surgery. The median length of follow-up in surviving patients was 58 months (range, 10 to 124). Results. The five-year actuarial rates of cancer recurrence at any site and of distant metastases in the radiotherapy-first group and the chemotherapy-first group were 38 percent and 31 percent (P = 0.17) and 36 percent and 25 percent (P = 0.05), respectively. Overall survival was 73 percent and 81 percent (P = 0.11), respectively. The five-year crude rates of first recurrence according to site in the radiotherapy-first and chemotherapy-first groups, respectively, were 5 percent and 14 percent for local recurrence and 32 percent and 20 percent for distant or regional recurrence or both, This difference in the pattern of recurrence was of borderline statistical significance (P = 0.07). Conclusions. This study suggests that for patients at substantial risk for systemic metastases, it is preferable to give a le-week course of chemotherapy followed by radiation therapy, rather than radiation therapy followed by chemotherapy. (C) 1996, Massachusetts Medical Society.	BETH ISRAEL HOSP,DEPT MED,BOSTON,MA 02215; BETH ISRAEL HOSP,JOINT CTR RADIAT THERAPY,BOSTON,MA 02215; BETH ISRAEL HOSP,DEPT RADIAT ONCOL,BOSTON,MA 02215; DANA FARBER CANC INST,BREAST EVALUAT CTR,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA; BRIGHAM & WOMENS HOSP,DEPT MED,BOSTON,MA 02115; DANA FARBER CANC INST,DEPT BIOSTAT,BOSTON,MA 02115; HARVARD UNIV,SCH PUBL HLTH,BOSTON,MA 02115	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard T.H. Chan School of Public Health			Hayes, Daniel/ABE-1129-2020					*AM JOINT COMM CAN, 1993, MAN STAG CANC; ANTONIADES J, 1993, P AM SOC CLIN ONCOL, V12, P83; BUCHHOLZ TA, 1993, INT J RADIAT ONCOL, V26, P23, DOI 10.1016/0360-3016(93)90169-V; Buzdar A U, 1982, Breast Cancer Res Treat, V2, P163, DOI 10.1007/BF01806452; BUZDAR AU, 1993, CANCER-AM CANCER SOC, V71, P3680, DOI 10.1002/1097-0142(19930601)71:11<3680::AID-CNCR2820711134>3.0.CO;2-O; Dalton W. S., 1987, ADJUVANT THERAPY CAN, P263; FISHER B, 1990, J CLIN ONCOL, V8, P1483, DOI 10.1200/JCO.1990.8.9.1483; FOWBLE B, 1992, FRONT RADIAT THER ON, V26, P95; GELMAN R, 1990, J CLIN ONCOL, V8, P548, DOI 10.1200/JCO.1990.8.3.548; HARRIS JR, 1979, INT J RADIAT ONCOL, V5, P257, DOI 10.1016/0360-3016(79)90729-6; HARRIS JR, 1991, BREAST DISEASES, P388; HARTSELL WF, 1995, CANCER, V76, P2497, DOI 10.1002/1097-0142(19951215)76:12<2497::AID-CNCR2820761214>3.0.CO;2-6; Heimann Ruth, 1994, International Journal of Radiation Oncology Biology Physics, V30, P243, DOI 10.1016/0360-3016(94)90780-3; HOSMER DW, 1989, APPL LOGISTIC REGRES; LEONARD CE, 1995, J CLIN ONCOL, V13, P2906, DOI 10.1200/JCO.1995.13.12.2906; McCormick B, 1996, Cancer J Sci Am, V2, P39; Recht, 1992, Semin Radiat Oncol, V2, P107, DOI 10.1016/1053-4296(92)90014-C; RECHT A, 1991, J CLIN ONCOL, V9, P1662, DOI 10.1200/JCO.1991.9.9.1662; RECHT A, 1993, J CLIN ONCOL, V11, P192; Recht A, 1994, Oncology (Williston Park), V8, P19; SCHNITT SJ, 1994, CANCER, V74, P1746, DOI 10.1002/1097-0142(19940915)74:6<1746::AID-CNCR2820740617>3.0.CO;2-Y; SCHNITT SJ, 1992, AM J CLIN PATHOL, V98, P125, DOI 10.1093/ajcp/98.1.125; SERTOLI MR, 1995, J CLIN ONCOL, V13, P2712, DOI 10.1200/JCO.1995.13.11.2712; Wallgren A., 1995, International Journal of Radiation Oncology Biology Physics, V32, P148, DOI 10.1016/0360-3016(95)97678-T; WOOD WC, 1994, NEW ENGL J MED, V331, P139; WOOD WC, 1994, NEW ENGL J MED, V330, P1253, DOI 10.1056/NEJM199405053301801; 1988, NEW ENGL J MED, V319, P677	27	338	357	0	12	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 23	1996	334	21					1356	1361		10.1056/NEJM199605233342102	http://dx.doi.org/10.1056/NEJM199605233342102			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UL251	8614420				2022-12-28	WOS:A1996UL25100002
J	Cavallini, MC; Roman, MJ; Blank, SG; Pini, R; Pickering, TG; Devereux, RB				Cavallini, MC; Roman, MJ; Blank, SG; Pini, R; Pickering, TG; Devereux, RB			Association of the auscultatory gap with vascular disease in hypertensive patients	ANNALS OF INTERNAL MEDICINE			English	Article						hypertension; vascular diseases; blood pressure; auscultation; atherosclerosis	CAROTID-ARTERY ATHEROSCLEROSIS; BLOOD-PRESSURE; MEDIAL THICKNESS; ULTRASOUND; STIFFNESS; PULSE; POPULATIONS; VALIDATION; PREVALENCE; URBAN	Objective: To assess the relation of the auscultatory gap during blood pressure measurement to cardiovascular structure and function. Design: Cross-sectional study. Setting: A hypertension center in a university hospital. Patients: 168 persons with hypertension who were otherwise healthy and were not receiving medication. Measurements: Wideband external pulse recordings and ultrasonographic examination of the left ventricle and extracranial carotid arteries. Vascular stiffness was evaluated using simultaneous carotid pressure waveforms obtained by applanation tonometry of the contralateral carotid artery. Results: Classic auscultatory gaps were present in 21% of patients and were associated with older age (mean age +/- SD, 64 +/- 11 years for patients with gaps and 55 +/- 13 years for patients without gaps; P < 0.001), female sex (67% of patients with gaps and 44% of patients without gaps were female; P < 0.05), and increased arterial stiffness (arterial stiffness index, 8.5 +/- 4.6 in patients with gaps and 5.8 +/- 3.2 in patients without gaps; P < 0.005). The prevalence of atherosclerotic plaques was increased more than twofold among patients with gaps compared with patients without gaps (50% compared with 22%; P < 0.002). Patients with and without auscultatory gaps had similar blood pressures, left ventricular structure and function, serum cholesterol levels, and smoking history. Logistic regression analysis indicated that only female sex (P < 0.02), arterial stiffness (P < 0.002), and atherosclerotic plaque (P < 0.02) were independently associated with the presence of an auscultatory gap. Conclusions: This study provides strong evidence that auscultatory gaps are related to carotid atherosclerosis and to increased arterial stiffness in hypertensive patients, independent of age. Although these observations need to be confirmed prospectively, they suggest that auscultatory gaps may have prognostic relevance.	CORNELL UNIV, MED CTR, NEW YORK HOSP, DIV CARDIOL, NEW YORK, NY 10021 USA; UNIV FLORENCE, IST GERONTOL & GERIATR, I-50141 FLORENCE, ITALY; CORNELL UNIV, MED CTR, NEW YORK HOSP, HYPERTENS CTR, NEW YORK, NY 10021 USA	Cornell University; NewYork-Presbyterian Hospital; University of Florence; Cornell University; NewYork-Presbyterian Hospital				Pini, Riccardo/0000-0002-7940-7908	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL018323, P01HL047540] Funding Source: NIH RePORTER; NHLBI NIH HHS [P01 HL047540, HL 18323, HL 47540] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AVOLIO AP, 1985, CIRCULATION, V71, P202, DOI 10.1161/01.CIR.71.2.202; AVOLIO AP, 1983, CIRCULATION, V68, P50, DOI 10.1161/01.CIR.68.1.50; BLANK SG, 1991, HYPERTENSION, V17, P225, DOI 10.1161/01.HYP.17.2.225; BLANK SG, 1988, CIRCULATION, V77, P1297, DOI 10.1161/01.CIR.77.6.1297; Cook JE, 1917, J AMER MED ASSOC, V68, P1088; CRAVEN TE, 1990, CIRCULATION, V82, P1230, DOI 10.1161/01.CIR.82.4.1230; CROUSE JR, 1987, STROKE, V18, P990, DOI 10.1161/01.STR.18.6.990; DEVEREUX RB, 1993, CIRCULATION, V88, P1444, DOI 10.1161/01.CIR.88.4.1444; DEVEREUX RB, 1977, CIRCULATION, V55, P613, DOI 10.1161/01.CIR.55.4.613; FLORAS JS, 1988, HYPERTENSION, V11, P273, DOI 10.1161/01.HYP.11.3.273; Hamilton WF, 1939, AM J PHYSIOL, V125, P48, DOI 10.1152/ajplegacy.1938.125.1.48; HANDA N, 1990, STROKE, V21, P1567, DOI 10.1161/01.STR.21.11.1567; HIRAI T, 1989, CIRCULATION, V80, P78, DOI 10.1161/01.CIR.80.1.78; HOWARD G, 1993, STROKE, V24, P1297, DOI 10.1161/01.STR.24.9.1297; KAWASAKI T, 1987, CARDIOVASC RES, V21, P678, DOI 10.1093/cvr/21.9.678; KELLY R, 1992, J AM COLL CARDIOL, V20, P952, DOI 10.1016/0735-1097(92)90198-V; Kelly R, 1989, J VASC MED BIOL, V3, P142; Kelly R, 1989, J VASC MED BIOL, V1, P241; KOCHAR MS, 1992, POSTGRAD MED, V91, P393; KRYLOV DO, 1906, IZV VEN MED AKAD, V13, P221; KRYLOV DO, 1906, IZV VEN MED AKAD, V13, P319; KRYLOV DO, 1906, IZV VEN MED AKAD, V13, P113; LONDON G, 1992, HYPERTENSION, V20, P10, DOI 10.1161/01.HYP.20.1.10; Mudd SG, 1928, ARCH INTERN MED, V41, P249, DOI 10.1001/archinte.1928.00130140111008; OROURKE M, 1990, HYPERTENSION, V15, P339, DOI 10.1161/01.HYP.15.4.339; PARATI G, 1989, HYPERTENSION, V13, P647, DOI 10.1161/01.HYP.13.6.647; PETERSON LH, 1960, CIRC RES, V8, P622, DOI 10.1161/01.RES.8.3.622; PIGNOLI P, 1986, CIRCULATION, V74, P1399, DOI 10.1161/01.CIR.74.6.1399; Ragan C, 1941, B JOHNS HOPKINS HOSP, V69, P504; RODBARD S, 1957, CIRCULATION, V15, P850, DOI 10.1161/01.CIR.15.6.850; ROMAN MJ, 1992, J HYPERTENS, V10, pS115; ROMAN MJ, 1995, J AM COLL CARDIOL, V25, P83, DOI 10.1016/0735-1097(94)00316-I; ROMAN MJ, 1992, CIRCULATION, V86, P1909, DOI 10.1161/01.CIR.86.6.1909; SABA PS, 1993, J AM COLL CARDIOL, V22, P1873, DOI 10.1016/0735-1097(93)90772-S; SAFAR ME, 1989, J HYPERTENS, V7, P769, DOI 10.1097/00004872-198910000-00001; SAHN DJ, 1978, CIRCULATION, V58, P1072, DOI 10.1161/01.CIR.58.6.1072; SALONEN JT, 1993, CIRCULATION, V87, P56; SALONEN R, 1988, ARTERIOSCLEROSIS, V8, P788, DOI 10.1161/01.ATV.8.6.788; Schiller N B, 1989, J Am Soc Echocardiogr, V2, P358; SCHNABEL TG, 1952, CIRCULATION, V5, P257, DOI 10.1161/01.CIR.5.2.257; SESSLER GM, 1966, J ACOUST SOC AM, V40, P1433, DOI 10.1121/1.1910245; TAVEL ME, 1969, CIRCULATION, V39, P465, DOI 10.1161/01.CIR.39.4.465; TEICHHOLZ LE, 1976, AM J CARDIOL, V37, P7, DOI 10.1016/0002-9149(76)90491-4; WEST JE, 1983, J ACOUST SOC AM, V74, P680, DOI 10.1121/1.389852	44	36	36	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 15	1996	124	10					877	+		10.7326/0003-4819-124-10-199605150-00003	http://dx.doi.org/10.7326/0003-4819-124-10-199605150-00003			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UJ801	8610916				2022-12-28	WOS:A1996UJ80100003
J	Jacobson, AM				Jacobson, AM			Current concepts - The psychological care of patients with insulin-dependent diabetes mellitus	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							METABOLIC CONTROL; ADOLESCENTS; MANAGEMENT; DEPRESSION; CHILDREN; IDDM; INTERVENTIONS; PREVALENCE; EDUCATION; DISORDERS		HARVARD UNIV, SCH MED, DEPT PSYCHIAT, BOSTON, MA 02115 USA; JOSLIN DIABET CTR, BOSTON, MA 02215 USA	Harvard University; Harvard Medical School; Harvard University; Joslin Diabetes Center, Inc.					NIDDK NIH HHS [DK 27845, DK 42315] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK042315, R01DK027845] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		American Psychiatric Association, 1994, DIAGN STAT MAN MENT, VI; ANDERSON BJ, 1981, DIABETES CARE, V4, P586, DOI 10.2337/diacare.4.6.586; ANDERSON BJ, 1989, DIABETES CARE, V12, P179, DOI 10.2337/diacare.12.3.179; ANDERSON BJ, 1995, DIABETES SPECTRUM, V8, P69; [Anonymous], 1995, DIABETES, V44, P968; BECK AT, 1961, ARCH GEN PSYCHIAT, V4, P561, DOI 10.1001/archpsyc.1961.01710120031004; BERNBAUM M, 1988, DIABETES CARE, V11, P551, DOI 10.2337/diacare.11.7.551; Bernbaum M, 1989, Diabetes Educ, V15, P325, DOI 10.1177/014572178901500413; BERTAKIS KD, 1991, J FAM PRACTICE, V32, P175; BRINK S, 1995, DIABETES ED GOALS; Bryant L H, 1990, J S C Med Assoc, V86, P389; COHEN T, IN PRESS PSYCHOSOMAT; CONNELL JE, 1991, J AM DIET ASSOC, V91, P1556; COPELAND PM, 1995, HARVARD REV PSYCHIAT, V3, P36, DOI 10.3109/10673229509017162; COX D, 1995, DIABETES CARE, V18, P523, DOI 10.2337/diacare.18.4.523; DCCT Res Grp, 1988, DIABETES CARE, V11, P725; DECKERT T, 1978, DIABETOLOGIA, V14, P371, DOI 10.1007/BF01228131; DELAMATER AM, 1990, DIABETES CARE, V13, P492, DOI 10.2337/diacare.13.5.492; DELAMATER AM, 1990, DIABETES CARE, V13, P819; FEINGLOS MN, 1987, DIABETES CARE, V10, P72, DOI 10.2337/diacare.10.1.72; GALATZER A, 1982, DIABETES CARE, V5, P414, DOI 10.2337/diacare.5.4.414; GARNER DM, 1979, PSYCHOL MED, V9, P273, DOI 10.1017/S0033291700030762; GAVARD JA, 1993, DIABETES CARE, V16, P1167, DOI 10.2337/diacare.16.8.1167; GOODNICK PJ, 1995, J CLIN PSYCHIAT, V56, P128; HAMBURG BA, 1983, DIABETES CARE, V6, P409, DOI 10.2337/diacare.6.4.409; HAMBURG BA, 1982, PSYCHOSOM MED, V44, P321, DOI 10.1097/00006842-198209000-00002; HAMMERSLEY MS, 1985, BRIT MED J, V291, P1330, DOI 10.1136/bmj.291.6505.1330; HAUSER ST, 1985, FAM RELAT, V34, P99, DOI 10.2307/583762; HEMINGWAY E, 1987, SHORT STORIES E HEMI, P379; HERMIDA OG, 1994, BRIT J PHARMACOL, V111, P861, DOI 10.1111/j.1476-5381.1994.tb14817.x; HINKLE LAWRENCE E., 1952, JOUR MT SINAI HOSP, V19, P537; JACOBSON AM, 1991, DIABETES CARE, V14, P599, DOI 10.2337/diacare.14.7.599; JACOBSON AM, 1994, PSYCHOSOM MED, V56, P401, DOI 10.1097/00006842-199409000-00004; JACOBSON AM, 1994, PRINCIPLES PRACTICE, V5, P3179; JACOBSON AM, 1994, JOSLINS DIABETES MEL, P431; JACOBSON AM, 1996, PSYCHIAT SECRETS, P443; KAPLAN, 1989, MED CARE, V27, P679; KAPLAN SH, 1989, MED CARE, V27, pS110, DOI 10.1097/00005650-198903001-00010; KEMMER FW, 1986, NEW ENGL J MED, V314, P1078, DOI 10.1056/NEJM198604243141704; KOVACS M, 1995, AM J PSYCHIAT, V152, P523; KOVACS M, 1985, J PEDIATR-US, V106, P827, DOI 10.1016/S0022-3476(85)80368-1; KROLEWSKI AS, 1985, AM J MED, V78, P785, DOI 10.1016/0002-9343(85)90284-0; Lazare A., 1995, MED INTERVIEW CLIN C, P3; LUSTMAN PJ, 1988, PSYCHIAT CLIN N AM, V11, P419; LUSTMAN PJ, 1992, PSYCHOSOM MED, V54, P602, DOI 10.1097/00006842-199209000-00007; LUSTMAN PJ, 1986, J NERV MENT DIS, V174, P736, DOI 10.1097/00005053-198612000-00005; LUSTMAN PJ, 1995, DIABETES CARE, V18, P1133, DOI 10.2337/diacare.18.8.1133; MARRERO DG, 1982, PEDIATRIC ADOLESCENT, V10, P213; MCCULLOCH DK, 1986, DIABETIC MED, V3, P485, DOI 10.1111/j.1464-5491.1986.tb00800.x; MUHLHAUSER I, 1995, J INTERN MED, V237, P591; ORMEL J, 1991, ARCH GEN PSYCHIAT, V48, P700; PADGETT D, 1988, J CLIN EPIDEMIOL, V41, P1007, DOI 10.1016/0895-4356(88)90040-6; POLONSKY WH, 1995, DIABETES CARE, V18, P754, DOI 10.2337/diacare.18.6.754; POLONSKY WH, 1992, HEALTH PSYCHOL, V11, P199, DOI 10.1037/0278-6133.11.3.199; POLONSKY WH, 1994, DIABETES CARE, V17, P1178, DOI 10.2337/diacare.17.10.1178; POPKIN MK, 1988, ARCH GEN PSYCHIAT, V45, P64; RODIN GM, 1992, DIABETES CARE, V15, P1402, DOI 10.2337/diacare.15.10.1402; ROSSETTI L, 1990, DIABETES, V39, P1243, DOI 10.2337/diabetes.39.10.1243; RUBIN RR, 1989, DIABETES CARE, V12, P673, DOI 10.2337/diacare.12.10.673; RUBIN RR, 1992, DIABETES CARE, V15, P1640, DOI 10.2337/diacare.15.11.1640; RYDALL A, 1994, PSYCHOSOM MED, V56, P179; SCHADE DS, 1985, DIABETES CARE, V8, P12, DOI 10.2337/diacare.8.1.12; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; SURWIT RS, 1993, PSYCHOSOM MED, V55, P380, DOI 10.1097/00006842-199307000-00005; TATTERSALL R, 1991, BRIT MED J, V302, P1240, DOI 10.1136/bmj.302.6787.1240; WEINGER K, 1995, AM J MED, V98, P22, DOI 10.1016/S0002-9343(99)80077-1; WUISIN LR, 1993, DIABETES CARE, V16, P1061	67	100	103	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 9	1996	334	19					1249	1253		10.1056/NEJM199605093341907	http://dx.doi.org/10.1056/NEJM199605093341907			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	UJ054	8606721				2022-12-28	WOS:A1996UJ05400007
J	Stanley, SK; Ostrowski, MA; Justement, JS; Gantt, K; Hedayati, S; Mannix, M; Roche, K; Schwartzentruber, DJ; Fox, CH; Fauci, AS				Stanley, SK; Ostrowski, MA; Justement, JS; Gantt, K; Hedayati, S; Mannix, M; Roche, K; Schwartzentruber, DJ; Fox, CH; Fauci, AS			Effect of immunization with a common recall antigen on viral expression in patients infected with human immunodeficiency virus type 1	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HIV-INFECTION; LYMPHOCYTES; AIDS; DISEASE; CELLS; VIREMIA; AGENTS; MODEL	Background. Activation of the immune system is a normal response to antigenic stimulation, and such activation enhances the replication of human immunodeficiency virus type 1 (HIV-1). We studied the effect of immunization with a common recall antigen on viral expression in HIV-1-infected patients, on the ability to isolate virus, and on the susceptibility to HIV-1 infection of peripheral-blood mononuclear cells (PBMCs) from control subjects not infected with HIV-1. Methods. Thirteen HIV-1-infected patients and 10 uninfected adults were given a 0.5-ml booster dose of tetanus toroid. Studies were performed to evaluate changes in the degree of plasma viremia, proviral burden, the ability to isolate HIV-1, and the susceptibility of PBMCs to acute infection in vitro. Two patients underwent sequential lymph-node biopsies for the assessment of viral burden in these tissues. Results. All 13 HIV-1-infected patients had transient increases in plasma viremia after immunization, and the proviral burden increased in 11. These changes did not correlate with the base-line CD4+ T-cell counts. The lymph-node tissue also had increases in the proviral burden and viral RNA after immunization. The virus was more easily isolated from PBMCs from nine of the patients after immunization than before immunization. Despite considerable variability in the results, PBMCs from 7 of the 10 normal subjects were more easily infected in vitro with HIV-1 after immunization than before immunization. Conclusions. Activation of the immune system by an ongoing antigen-specific immune response to an exogenous stimulus transiently increases the expression of HIV-1 and may enhance the susceptibility of uninfected subjects to HIV-1. (C) 1996, Massachusetts Medical Society.	NCI,DEPT NURSING,WARREN GRANT MAGNUSON CLIN CTR,BETHESDA,MD 20892; NCI,DIV CANC TREATMENT,BETHESDA,MD 20892; MOL HISTOL INC,GAITHERSBURG,MD	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Stanley, SK (corresponding author), NIAID,IMMUNOREGULAT LAB,NIH,BLDG 30,RM 7A03,31 CTR DR,MSC-2520,BETHESDA,MD 20892, USA.			Hedayati, S Susan/0000-0001-8850-4729				BENTWICH Z, 1995, IMMUNOL TODAY, V16, P187, DOI 10.1016/0167-5699(95)80119-7; BRICHACEK B, 1995, 2 NAT C HUM RETR REL, P98; BUKRINSKY MI, 1991, SCIENCE, V254, P423, DOI 10.1126/science.1925601; BURKE AP, 1994, HUM PATHOL, V25, P248, DOI 10.1016/0046-8177(94)90196-1; CLAYDON EJ, 1991, AIDS, V5, P113, DOI 10.1097/00002030-199101000-00022; COHEN OJ, 1995, P NATL ACAD SCI USA, V92, P6017, DOI 10.1073/pnas.92.13.6017; COLEBUNDERS RL, 1991, AIDS, V5, pS103; EMBRETSON J, 1993, NATURE, V362, P359, DOI 10.1038/362359a0; FAUCI AS, 1993, SCIENCE, V262, P1011, DOI 10.1126/science.8235617; FOLKS T, 1986, J IMMUNOL, V136, P4049; FULTZ PN, 1992, AIDS RES HUM RETROV, V8, P313, DOI 10.1089/aid.1992.8.313; HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0; HO DD, 1992, LANCET, V339, P1549, DOI 10.1016/0140-6736(92)91321-X; JANOFF EN, 1991, J IMMUNOL, V147, P2130; LANE HC, 1985, NEW ENGL J MED, V313, P79, DOI 10.1056/NEJM198507113130204; MENZO S, 1992, J CLIN MICROBIOL, V30, P1752, DOI 10.1128/JCM.30.7.1752-1757.1992; NAGELKERKE NJD, 1990, AIDS, V4, P743, DOI 10.1097/00002030-199008000-00005; OBRIEN WA, 1995, BLOOD, V86, P1082; PANTALEO G, 1993, NATURE, V362, P355, DOI 10.1038/362355a0; POLI G, 1992, AIDS RES HUM RETROV, V8, P191, DOI 10.1089/aid.1992.8.191; POPOV J, 1992, J ACQ IMMUN DEF SYND, V5, P391; QUINN TC, 1987, JAMA-J AM MED ASSOC, V257, P2617, DOI 10.1001/jama.257.19.2617; ROSENBERG ZF, 1989, AIDS RES HUM RETROV, V5, P1, DOI 10.1089/aid.1989.5.1; SCHWIEBERT R, 1994, J VIROL, V68, P5538, DOI 10.1128/JVI.68.9.5538-5547.1994; STANLEY SK, 1993, J EXP MED, V178, P1151, DOI 10.1084/jem.178.4.1151; STAPRANS SI, 1995, J EXP MED, V182, P1727, DOI 10.1084/jem.182.6.1727; WACHTER H, 1986, LANCET, V2, P1216; WEI XP, 1995, NATURE, V373, P117, DOI 10.1038/373117a0; WILLEY RL, 1988, J VIROL, V62, P139, DOI 10.1128/JVI.62.1.139-147.1988; ZACK JA, 1990, CELL, V61, P213, DOI 10.1016/0092-8674(90)90802-L; ZAGURY D, 1986, SCIENCE, V231, P850, DOI 10.1126/science.2418502	31	320	324	0	3	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 9	1996	334	19					1222	1230		10.1056/NEJM199605093341903	http://dx.doi.org/10.1056/NEJM199605093341903			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UJ054	8606717				2022-12-28	WOS:A1996UJ05400003
J	Ishii, H; Jirousek, MR; Koya, D; Takagi, C; Xia, P; Clermont, A; Bursell, SE; Kern, TS; Ballas, LM; Heath, WF; Stramm, LE; Feener, EP; King, GL				Ishii, H; Jirousek, MR; Koya, D; Takagi, C; Xia, P; Clermont, A; Bursell, SE; Kern, TS; Ballas, LM; Heath, WF; Stramm, LE; Feener, EP; King, GL			Amelioration of vascular dysfunctions in diabetic rats by an oral PKC beta inhibitor	SCIENCE			English	Article							PROTEIN-KINASE-C; EPIDERMAL GROWTH-FACTOR; SMOOTH-MUSCLE CELLS; RETINAL CIRCULATION; PHORBOL ESTERS; ANGIOTENSIN-II; GLUCOSE; AUTOPHOSPHORYLATION; MICROALBUMINURIA; STAUROSPORINE	The vascular complications of diabetes mellitus have been correlated with enhanced activation of protein kinase C (PKC). LY333531, a specific inhibitor of the beta isoform of PKC, was synthesized and was shown to be a competitive reversible inhibitor of PKC beta(1) and beta(2), with a half-maximal inhibitory constant of similar to 5 nM; this value was one-fiftieth of that for other PKC isoenzymes and one-thousandth of that for non-PKC kinases. When administered orally, LY333531 ameliorated the glomerular filtration rate, albumin excretion rate, and retinal circulation in diabetic rats in a dose-responsive manner, in parallel with its inhibition of PKC activities.	BRIGHAM & WOMENS HOSP, DEPT MED, JOSLIN DIABET CTR, DIV RES, BOSTON, MA 02215 USA; HARVARD UNIV, SCH MED, BOSTON, MA 02215 USA; ELI LILLY & CO, LILLY RES LABS, INDIANAPOLIS, IN 46285 USA; UNIV WISCONSIN, DEPT OPHTHALMOL, MADISON, WI 53706 USA; SPHINX PHARMACEUT, DURHAM, NC 27707 USA	Harvard University; Brigham & Women's Hospital; Joslin Diabetes Center, Inc.; Harvard University; Harvard Medical School; Eli Lilly; University of Wisconsin System; University of Wisconsin Madison			Koya, Daisuke/J-3257-2014; Xia, Pu/G-3090-2010	Xia, Pu/0000-0003-4705-8878	NEI NIH HHS [EY05110-11] Funding Source: Medline; NIDDK NIH HHS [DK36836] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK036836] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDREJAUSKASBUCHDUNGER E, 1992, CANCER RES, V52, P5353; BURSELL SE, 1992, CURR EYE RES, V11, P287, DOI 10.3109/02713689209001782; CARAMELO C, 1988, BIOCHEM J, V254, P625, DOI 10.1042/bj2540625; CRAVEN PA, 1989, J CLIN INVEST, V83, P1667, DOI 10.1172/JCI114066; CRAVEN PA, 1990, DIABETES, V39, P667, DOI 10.2337/diabetes.39.6.667; DUTIL EM, 1994, J BIOL CHEM, V269, P29359; HANEDA M, 1993, KIDNEY INT, V44, P518, DOI 10.1038/ki.1993.276; HEASLEY LE, 1989, J BIOL CHEM, V264, P8646; HOSTETTER TH, 1982, AM J MED, V72, P375, DOI 10.1016/0002-9343(82)90490-9; HURST RD, 1995, DIABETES, V44, P759, DOI 10.2337/diabetes.44.7.759; INOGUCHI T, 1994, AM J PHYSIOL, V267, pE369, DOI 10.1152/ajpendo.1994.267.3.E369; INOGUCHI T, 1992, P NATL ACAD SCI USA, V89, P11059, DOI 10.1073/pnas.89.22.11059; ISHII H, UNPUB; JIROUSEK MR, IN PRESS BIOORG MED; MITCHELL FE, 1989, BIOCHEM J, V261, P131, DOI 10.1042/bj2610131; MOGENSEN CE, 1987, KIDNEY INT, V31, P673, DOI 10.1038/ki.1987.50; MOGENSEN CE, 1984, NEW ENGL J MED, V311, P89, DOI 10.1056/NEJM198407123110204; MOGENSEN CE, 1984, NEW ENGL J MED, V310, P356, DOI 10.1056/NEJM198402093100605; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; ODONNELL MP, 1988, FASEB J, V2, P2339, DOI 10.1096/fasebj.2.8.3282959; OHASHI H, 1993, REGUL PEPTIDES, V48, P9, DOI 10.1016/0167-0115(93)90331-2; OHNO S, 1990, J BIOL CHEM, V265, P6296; RASMUSSEN H, 1984, BIOCHEM BIOPH RES CO, V122, P776, DOI 10.1016/S0006-291X(84)80101-1; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; SHIBA T, 1993, AM J PHYSIOL, V265, pE783, DOI 10.1152/ajpendo.1993.265.5.E783; SMITH HW, 1945, J CLIN INVEST, V24, P388, DOI 10.1172/JCI101618; TAMAOKI T, 1986, BIOCHEM BIOPH RES CO, V135, P397, DOI 10.1016/0006-291X(86)90008-2; TOKER A, 1994, J BIOL CHEM, V269, P32358; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; WAUGH WH, 1977, CLIN CHEM, V23, P639; WILLIAMS B, 1992, DIABETES, V41, P1464, DOI 10.2337/diabetes.41.11.1464; XIA P, 1994, DIABETES, V43, P1122, DOI 10.2337/diabetes.43.9.1122; XIA P, 1995, J CLIN INVEST, V96, P733, DOI 10.1172/JCI118117; YASUDA I, 1990, BIOCHEM BIOPH RES CO, V166, P1220, DOI 10.1016/0006-291X(90)90996-Z; ZHANG J, 1994, J BIOL CHEM, V269, P19578; ZHANG J, 1993, P NATL ACAD SCI USA, V90, P6130, DOI 10.1073/pnas.90.13.6130	36	964	1016	1	30	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAY 3	1996	272	5262					728	731		10.1126/science.272.5262.728	http://dx.doi.org/10.1126/science.272.5262.728			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UJ051	8614835				2022-12-28	WOS:A1996UJ05100053
J	Echtenacher, B; Mannel, DN; Hultner, L				Echtenacher, B; Mannel, DN; Hultner, L			Critical protective role of mast cells in a model of acute septic peritonitis	NATURE			English	Article							TUMOR-NECROSIS-FACTOR; CONNECTIVE-TISSUE-TYPE; FACTOR-ALPHA; TNF-ALPHA; GRANULOCYTE INFILTRATION; DEFICIENT W/WV; MICE; MOUSE; CACHECTIN; RECRUITMENT	MAST cells play a detrimental role in IgE dependent allergic reactions, In contrast, a protective function for mast cells has been proposed on the basis of some worm infection models. No reports exist on the in vivo significance of these cells in bacterial infections(1,2). Here we use congenitally mast-cell-deficient W/W-v mice and normal +/+ littermates(3,4) to analyse the role of mast cells in a model of acute septic peritonitis (caecum ligation and puncture (CLP)), Following CLP, W/W-v mice showed a significantly increased mortality compared to +/+ mice, The selective reconstitution of W/W-v mice with cultured +/+ mast cells substantially protected them from the lethal effects of CLP, whereas an anti-tumour-necrosis-factor (TNF) antibody injected immediately after CLP completely suppressed this protection, Our results reveal a previously unrecognized protective role of mast cells and mast-cell-derived TNF in acute bacterial peritonitis.	GSF MUNICH,INST EXPT HAMATOL,D-81377 MUNICH,GERMANY; UNIV REGENSBURG,INST PATHOL TUMORIMMUNOL,D-93042 REGENSBURG,GERMANY	Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; University of Regensburg								ALEXANDER HR, 1991, J CLIN INVEST, V88, P34, DOI 10.1172/JCI115298; ANSEL JC, 1993, J IMMUNOL, V150, P4478; ECHTENACHER B, 1990, J IMMUNOL, V145, P3762; Echtenacher B, 1993, HOST DEFENSE DYSFUNC, P755; EGGER D, 1995, J IMMUNOL, V154, P1830; GALLI SJ, 1987, AM J PATHOL, V127, P191; GALLI SJ, 1993, NEW ENGL J MED, V328, P257; GORDON JR, 1990, IMMUNOL TODAY, V11, P458, DOI 10.1016/0167-5699(90)90176-A; GORDON JR, 1991, J EXP MED, V174, P103, DOI 10.1084/jem.174.1.103; GORDON JR, 1990, NATURE, V346, P274, DOI 10.1038/346274a0; HOLZHEIMER RG, 1991, INFECTION, V19, P447, DOI 10.1007/BF01726463; HULTNER L, 1989, J IMMUNOL, V142, P3440; LEALBERUMEN I, 1994, J IMMUNOL, V152, P5468; MALAVIYA R, 1994, J CLIN INVEST, V93, P1645, DOI 10.1172/JCI117146; MALAVIYA R, 1994, J IMMUNOL, V152, P1907; MATSUDA H, 1989, J IMMUNOL, V142, P927; MCCLEAN KL, 1994, CLIN INFECT DIS, V19, P100, DOI 10.1093/clinids/19.1.100; NAKANO T, 1985, J EXP MED, V162, P1025, DOI 10.1084/jem.162.3.1025; NAKANO T, 1987, J IMMUNOL, V138, P544; OTANI I, 1982, J IMMUNOL, V129, P2109; RAMOS BF, 1992, EUR J IMMUNOL, V22, P2381, DOI 10.1002/eji.1830220930; ROTHSTEIN JL, 1988, P NATL ACAD SCI USA, V85, P607, DOI 10.1073/pnas.85.2.607; SCHWARTZ LB, 1994, CURR OPIN IMMUNOL, V6, P91, DOI 10.1016/0952-7915(94)90039-6; SHER A, 1979, LAB INVEST, V41, P490; TRACEY KJ, 1986, SCIENCE, V234, P470, DOI 10.1126/science.3764421; VRANIAN G, 1981, J IMMUNOL, V126, P2302; WERSHIL BK, 1991, J CLIN INVEST, V87, P446, DOI 10.1172/JCI115016; WERSHIL BK, 1994, ADV EXP MED BIOL, V347, P39; YANO H, 1989, J CLIN INVEST, V84, P1276, DOI 10.1172/JCI114295; ZHANG Y, 1992, SCIENCE, V258, P1957, DOI 10.1126/science.1470922	30	756	784	0	19	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAY 2	1996	381	6577					75	77		10.1038/381075a0	http://dx.doi.org/10.1038/381075a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UJ053	8609992				2022-12-28	WOS:A1996UJ05300059
J	Omenn, GS; Goodman, GE; Thornquist, MD; Balmes, J; Cullen, MR; Glass, A; Keogh, JP; Meyskens, FL; Valanis, B; Williams, JH; Barnhart, S; Hammar, S				Omenn, GS; Goodman, GE; Thornquist, MD; Balmes, J; Cullen, MR; Glass, A; Keogh, JP; Meyskens, FL; Valanis, B; Williams, JH; Barnhart, S; Hammar, S			Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							EFFICACY TRIAL CARET; HIGH-RISK POPULATIONS; PREVENTION; VEGETABLES; FRUIT; DESIGN	Background. Lung cancer and cardiovascular disease are major causes of death in the United States, It has been proposed that carotenoids and retinoids are agents that may prevent these disorders. Methods. We conducted a multicenter, randomized, double-blind, placebo-controlled primary prevention trial - the Beta-Carotene and Retinol Efficacy Trial - involving a total of 18,314 smokers, former smokers, and workers exposed to asbestos. The effects of a combination of 30 mg of beta carotene per day and 25,000 IU of retinol (vitamin A) in the form of retinyl palmitate per day on the primary end point, the incidence of lung cancer, were compared with those of placebo. Results. A total of 388 new cases of lung cancer were diagnosed during the 73,135 person-years of follow-up (mean length of follow-up, 4.0 years). The active-treatment group had a relative risk of lung cancer of 1.28 (95 percent confidence interval, 1.04 to 1.57; P=0.02), as compared with the placebo group. There were no statistically significant differences in the risks of other types of cancer. in the active-treatment group, the relative risk of death from any cause was 1.17 (95 percent confidence interval, 1.03 to 1.33); of death from lung cancer, 1.46 (95 percent confidence interval, 1.07 to 2.00); and of death from cardiovascular disease, 1.26 (95 percent confidence interval, 0.99 to 1.61). On the basis of these findings, the randomized trial was stopped 21 months earlier than planned; follow-up will continue for another 5 years. Conclusions. After an average of four years of supplementation, the combination of beta carotene and vitamin A had no benefit and may have had an adverse effect on the incidence of lung cancer and on the risk of death from lung cancer, cardiovascular disease, and any cause in smokers and workers exposed to asbestos. (C) 1996, Massachusetts Medical Society.	UNIV WASHINGTON, DEPT ENVIRONM HLTH, SEATTLE, WA 98195 USA; UNIV WASHINGTON, DEPT MED, SEATTLE, WA 98195 USA; SWEDISH HOSP TUMOR INST, SEATTLE, WA USA; UNIV CALIF SAN FRANCISCO, DEPT MED, SAN FRANCISCO, CA 94143 USA; YALE UNIV, DEPT MED, NEW HAVEN, CT 06520 USA; KAISER PERMANENTE CTR HLTH RES, PORTLAND, OR USA; UNIV MARYLAND, DEPT MED, BALTIMORE, MD 21201 USA; UNIV CALIF IRVINE, DEPT MED, ORANGE, CA 92668 USA; UNIV CALIF IRVINE, CTR CANC, ORANGE, CA 92668 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Swedish Medical Center; University of California System; University of California San Francisco; Yale University; Kaiser Permanente; University System of Maryland; University of Maryland Baltimore; University of California System; University of California Irvine; University of California System; University of California Irvine	Omenn, GS (corresponding author), FRED HUTCHINSON CANC RES CTR, DIV PUBL HLTH SCI, 1124 COLUMBIA ST, MP859, SEATTLE, WA 98104 USA.		Balmes, John/L-6281-2019	Omenn, Gilbert S./0000-0002-8976-6074; cullen, mark/0000-0001-7996-1864	NATIONAL CANCER INSTITUTE [U01CA063674, U01CA063673, U01CA047989] Funding Source: NIH RePORTER; NCI NIH HHS [U01 CA47989, U01 CA63673, U01 CA63674] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alpha-Tocopherol Beta Carotene Cancer Prevention Study Group, 1994, N Engl J Med, V330, P1029, DOI 10.1056/NEJM199404143301501; [Anonymous], 1988, LANCET, V2, P349; [Anonymous], 1986, Lancet, V2, P57; BLOCK G, 1992, NUTR CANCER, V18, P1, DOI 10.1080/01635589209514201; BLOT WJ, 1993, JNCI-J NATL CANCER I, V85, P1483, DOI 10.1093/jnci/85.18.1483; Buring JE, 1992, J MYOCARDIAL ISCHEMI, V4, P27; BURTON GW, 1984, SCIENCE, V224, P569, DOI 10.1126/science.6710156; COLLINS R, 1995, LANCET, V345, P669; FLEMING TR, 1984, CONTROL CLIN TRIALS, V5, P348, DOI 10.1016/S0197-2456(84)80014-8; GOODMAN GE, 1994, CANCER EPIDEM BIOMAR, V3, P429; GOODMAN GE, 1993, CANCER EPIDEM BIOMAR, V2, P389; GREENWALD P, 1993, PREV MED, V22, P642, DOI 10.1006/pmed.1993.1058; Hennekens CH, 1996, NEW ENGL J MED, V334, P1145, DOI 10.1056/NEJM199605023341801; KRINSKY NI, 1993, ANNU REV NUTR, V13, P561, DOI 10.1146/annurev.nutr.13.1.561; LIPPMAN SM, 1994, CANCER RES, V54, pS2025; Manson Joann E., 1995, Annals of Epidemiology, V5, P261, DOI 10.1016/1047-2797(94)00091-7; MCLARTY JW, 1992, ADV EXP MED BIOL, V320, P141; *NAT CTR HLTH STAT, 1989, VIT HLTH STAT, V10; NICHOLSON W J, 1982, American Journal of Industrial Medicine, V3, P259, DOI 10.1002/ajim.4700030305; NIERENBERG DW, 1994, JNCI-J NATL CANCER I, V86, P117, DOI 10.1093/jnci/86.2.117; Omenn G S, 1995, Ann Epidemiol, V5, P333, DOI 10.1016/1047-2797(95)90014-4; OMENN GS, 1986, ENVIRON HEALTH PERSP, V70, P51, DOI 10.2307/3430342; OMENN GS, 1994, CANCER RES, V54, pS2038; OMENN GS, 1994, CANCER EPIDEM BIOMAR, V3, P711; OMENN GS, 1993, CANCER EPIDEM BIOMAR, V2, P381; PETO R, 1981, NATURE, V290, P201, DOI 10.1038/290201a0; PRENTICE RL, 1986, BIOMETRIKA, V73, P1; SCHOENBERGER JA, 1980, JAMA-J AM MED ASSOC, V243, P661; STEINMETZ KA, 1991, CANCER CAUSE CONTROL, V2, P325, DOI 10.1007/BF00051672; STEINMETZ KA, 1991, CANCER CAUSE CONTROL, V2, P427, DOI 10.1007/BF00054304; THORNQUIST MD, 1993, CONTROL CLIN TRIALS, V14, P308, DOI 10.1016/0197-2456(93)90228-6; WINGO PA, 1995, CA-CANCER J CLIN, V45, P8, DOI 10.3322/canjclin.45.1.8; WINGO PA, 1995, CA-CANCER J CLIN, V45, P127; XU MJ, 1992, J NATL CANCER I, V84, P1559, DOI 10.1093/jnci/84.20.1559; YUSUF S, 1983, CIRCULATION, V67, P32; 1993, MMWR-MORBID MORTAL W, V42, P230	36	2681	2768	5	260	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 2	1996	334	18					1150	1155		10.1056/NEJM199605023341802	http://dx.doi.org/10.1056/NEJM199605023341802			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UG831	8602180	Green Published			2022-12-28	WOS:A1996UG83100002
J	Ubel, PA; DeKay, ML; Baron, J; Asch, DA				Ubel, PA; DeKay, ML; Baron, J; Asch, DA			Cost-effectiveness analysis in a setting of budget constraints - Is it equitable?	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HEALTH-CARE PRIORITIES; OREGON	Background. One of the promises of cost-effectiveness analysis is that it can demonstrate how to maximize health benefits attainable within a specific limited budget. Many people argue, however, that when there are budget limitations, the use of cost-effectiveness analysis leads to health care policies that are inequitable. Methods. We asked prospective jurors, medical ethicists, and experts in medical decision making to choose between two screening tests for a population at low risk for colon cancer. One test was more cost effective than the other but because of budget constraints was too expensive to be given to everyone in the population. With the use of the more effective test for only half the population, 1100 lives could be saved at the same cost as that of saving 1000 lives with the use of the less effective test for the entire population. Results. Fifty-six percent of the prospective jurors, 53 percent of the medical ethicists, and 41 percent of the experts in medical decision making recommended offering the less effective screening test to everyone, even though 100 more lives would have been saved by offering the more expensive test to only a portion of the population, Most of the study participants justified this recommendation on the basis of equity, A smaller number stated either that it was not politically feasible to offer a test to only half the population or that the additional benefit of the more expensive test (100 more lives saved) was too small to justify offering it to only a portion of the public. Conclusions. People place greater importance on equity than is reflected by cost-effectiveness analysis, Even many experts in medical decision making - those often responsible for conducting cost-effectiveness analyses - expressed discomfort with some of its implications, Basing health care priorities on cost effectiveness may not be possible without incorporating explicit considerations of equity into cost-effectiveness analyses or the process used to develop health care policies on the basis of such analyses. (C) 1996, Massachusetts Medical Society.	VET AFFAIRS MED CTR,PHILADELPHIA,PA; UNIV PENN,LEONARD DAVIS INST HLTH ECON,PHILADELPHIA,PA 19104; UNIV PENN,WHARTON SCH,DEPT OPERAT & INFORMAT MANAGEMENT,PHILADELPHIA,PA 19104; UNIV PENN,DEPT PSYCHOL,PHILADELPHIA,PA 19104	University of Pennsylvania; Pennsylvania Medicine; US Department of Veterans Affairs; Veterans Health Administration (VHA); Philadelphia Veterans Affairs Medical Center; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania	Ubel, PA (corresponding author), UNIV PENN,SCH MED,DIV GEN INTERNAL MED,CTR BIOETH,3401 MKT ST,SUITE 320,PHILADELPHIA,PA 19104, USA.			Asch, David/0000-0002-7970-286X				AVORN J, 1984, NEW ENGL J MED, V310, P1294, DOI 10.1056/NEJM198405173102005; BARON J, 1992, J PERS SOC PSYCHOL, V63, P320, DOI 10.1037/0022-3514.63.2.320; BARON J, 1995, J BEHAV DECIS MAKING, V8, P71, DOI 10.1002/bdm.3960080202; Baron J., 1993, PSYCHOL PERSPECTIVES, P109, DOI DOI 10.1017/CBO9780511552069.007; Baron Jonathan, 1994, THINKING DECIDING; CANTOR SB, 1994, MED DECIS MAKING, V14, P259, DOI 10.1177/0272989X9401400308; CRAWSHAW R, 1985, JAMA-J AM MED ASSOC, V254, P3213, DOI 10.1001/jama.254.22.3213; EDDY DM, 1992, JAMA-J AM MED ASSOC, V267, P1669, DOI 10.1001/jama.267.12.1669; EMERY DD, 1989, HASTINGS CENT REP, V19, P8, DOI 10.2307/3562293; Garland M J, 1992, Law Med Health Care, V20, P67; HADORN DC, 1991, SOC SCI MED, V32, P773, DOI 10.1016/0277-9536(91)90303-T; HADORN DC, 1991, JAMA-J AM MED ASSOC, V265, P2218, DOI 10.1001/jama.265.17.2218; JOHANNESSON M, 1995, HEALTH POLICY, V31, P225, DOI 10.1016/0168-8510(95)98130-T; NORD E, 1993, J MED ETHICS, V19, P37, DOI 10.1136/jme.19.1.37; Nord E, 1993, Int J Technol Assess Health Care, V9, P463; NORD E, 1993, HEALTH POLICY, V24, P45, DOI 10.1016/0168-8510(93)90087-6; ROHRBAUGH J, 1980, J APPL PSYCHOL, V65, P34, DOI 10.1037/0021-9010.65.1.34; ROSS J, 1995, HEALTH POLICY, V31, P103, DOI 10.1016/0168-8510(94)00671-7; UBEL PA, 1995, HEALTH POLICY, V34, P145, DOI 10.1016/0168-8510(95)00714-4; UBEL PA, IN PRESS MED DECIS M; UBEL PA, IN PRESS SOC SCI MED	21	146	146	0	4	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 2	1996	334	18					1174	1177		10.1056/NEJM199605023341807	http://dx.doi.org/10.1056/NEJM199605023341807			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	UG831	8602185				2022-12-28	WOS:A1996UG83100007
J	deSemir, V				deSemir, V			What is newsworthy?	LANCET			English	Editorial Material								Why one event is deemed newsworthy while another is not seems to be one of the biggest puzzles to newspaper readers. A science story, just like any other story, must compete for space, and whether it is chosen depends on headline potential, the relationship between the journalist and section head, external social and cultural events. and sources of news. Although the choice of news is affected mainly by the desire to establish a certain complicity with the reader, ultimately, it is the journalist's intuition that influences what is published.			deSemir, V (corresponding author), POMPEU FABRA UNIV,SCI COMMUN OBSERV,LA RAMBLA 30-32,E-08002 BARCELONA,SPAIN.							[Anonymous], 1995, LANCET, V345, P669; ANTON T, 1995, NEW SCI JOURNALISTS, P6; CANNELL MB, 1995, SCIENCE, V268, P1045, DOI 10.1126/science.7754384; CANO RJ, 1995, SCIENCE, V268, P1060, DOI 10.1126/science.7538699; DIAMOND E, 1994, BEHIND TIMES; ELBERT T, 1995, SCIENCE, V270, P305, DOI 10.1126/science.270.5234.305; Fayard P., 1993, SCI QUOTIDIENS; FRANKEL DH, 1995, LANCET, V345, P1105, DOI 10.1016/S0140-6736(95)90836-6; GOULDEN JC, 1988, FIT PRINT AM ROSENTH; GUERRERO R, 1995, CIENCIA VIDA    1209, P2; Hansen A., 1994, PUBLIC UNDERST SCI, V3, P111, DOI DOI 10.1088/0963-6625/3/2/001; JABRI E, 1995, SCIENCE, V268, P998, DOI 10.1126/science.7754395; KENWARD, 1995, QUARK, V1, P55; LOPEZ M, 1994, ANAL SUPLEMENTO SALU; NELKIN D, 1995, SELLING SCI PRESS CO, pCH7; REUL J, 1995, LANCET, V345, P1403, DOI 10.1016/S0140-6736(95)92598-8; SALGADO A, 1995, REPTES CIENCIA PORTE, P104; 1995, FIGARO          0612, P14; 1995, EL PAIS         0923, P22; 1995, CIENCIA VIDA    1111, P6; 1995, CIENCIA VIDA    0722, P6; 1995, CIENCIA VIDA    0722, P10; 1993, LANCET, V342, P7; 1995, EL PAIS         0822, P20	24	29	29	0	6	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 27	1996	347	9009					1163	1166		10.1016/S0140-6736(96)90614-5	http://dx.doi.org/10.1016/S0140-6736(96)90614-5			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UG755	8609754				2022-12-28	WOS:A1996UG75500016
J	Visca, A; Bignamini, E				Visca, A; Bignamini, E			Concentration of inhaled amiloride in cystic fibrosis	LANCET			English	Letter											Visca, A (corresponding author), OSPED INFANTILE REGINA MARGHERITA,DIV PNEUMOL,I-10126 TURIN,ITALY.							GRAHAM A, 1993, EUR RESPIR J, V6, P1243; HUELS G, 1995, EUR RESPIR J, V8, P574; STUTTS MJ, 1995, SCIENCE, V269, P847, DOI 10.1126/science.7543698	3	7	7	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 20	1996	347	9008					1126	1126		10.1016/S0140-6736(96)90329-3	http://dx.doi.org/10.1016/S0140-6736(96)90329-3			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UG042	8602105				2022-12-28	WOS:A1996UG04200078
J	Aldaz, H; Schuster, E; Baker, TA				Aldaz, H; Schuster, E; Baker, TA			The interwoven architecture of the Mu transposase couples DNA synapsis to catalysis	CELL			English	Article							BACTERIOPHAGE-MU; TRANSPOSITIONAL ENHANCER; INVITRO TRANSPOSITION; STRAND TRANSFER; B-PROTEIN; A-PROTEIN; MINI-MU; SITE; RECOMBINATION; ENDS	Mu transposition occurs exclusively using a pair of recombination sites found at the ends of the phage genome. To address the mechanistic basis of this specificity, we have determined both where the individual subunits of the tetrameric transposase bind on the DNA and where they catalyze DNA joining. We demonstrate that subunits do not catalyze recombination at the site adjacent to where they are bound, but rather on the opposite end of the phage genome. Furthermore, subunits bound to two different sites contribute to catalysis of one reaction step. This interwoven subunit arrangement suggests a molecular explanation for the precision with which recombination occurs using a pair of DNA signals and provides an example of the way in which the architecture of a protein-DNA complex can define the reaction products.	MIT,HOWARD HUGHES MED INST,CAMBRIDGE,MA 02139	Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT)	Aldaz, H (corresponding author), MIT,DEPT BIOL,68-523,77 MASSACHUSETTS AVE,CAMBRIDGE,MA 02139, USA.			Schuster, Eugene/0000-0001-5076-2810	NIGMS NIH HHS [GM499224] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADZUMA K, 1991, J BIOL CHEM, V266, P6159; ALLISON RG, 1992, J BIOL CHEM, V267, P19963; ARCISZEWSKA LK, 1995, EMBO J, V14, P2112, DOI 10.1002/j.1460-2075.1995.tb07203.x; BAINTON R, 1991, CELL, V65, P805, DOI 10.1016/0092-8674(91)90388-F; BAKER TA, 1992, GENE DEV, V6, P2221, DOI 10.1101/gad.6.11.2221; BAKER TA, 1993, CELL, V74, P723, DOI 10.1016/0092-8674(93)90519-V; BAKER TA, 1994, P NATL ACAD SCI USA, V91, P6654, DOI 10.1073/pnas.91.14.6654; BAKER TA, 1994, GENE DEV, V8, P2416, DOI 10.1101/gad.8.20.2416; BAKER TA, 1991, CELL, V65, P1003, DOI 10.1016/0092-8674(91)90552-A; BENJAMIN HW, 1992, P NATL ACAD SCI USA, V89, P4648, DOI 10.1073/pnas.89.10.4648; Berg DE, 1989, MOBILE DNA; BOOCOCK MR, 1995, EMBO J, V14, P5129, DOI 10.1002/j.1460-2075.1995.tb00195.x; BUJACZ G, 1995, J MOL BIOL, V253, P333, DOI 10.1006/jmbi.1995.0556; CHACONAS G, 1985, J BIOL CHEM, V260, P2662; CHEN JW, 1993, J BIOL CHEM, V268, P14417; CHEN JW, 1992, CELL, V69, P647, DOI 10.1016/0092-8674(92)90228-5; CRAIG NL, 1995, SCIENCE, V270, P253, DOI 10.1126/science.270.5234.253; CRAIGIE R, 1986, CELL, V45, P793, DOI 10.1016/0092-8674(86)90554-4; CRAIGIE R, 1984, CELL, V39, P387, DOI 10.1016/0092-8674(84)90017-5; CRAIGIE R, 1987, CELL, V51, P493, DOI 10.1016/0092-8674(87)90645-3; DOAK TG, 1994, P NATL ACAD SCI USA, V91, P942, DOI 10.1073/pnas.91.3.942; DROGE P, 1990, P NATL ACAD SCI USA, V87, P5336, DOI 10.1073/pnas.87.14.5336; DYDA F, 1994, SCIENCE, V266, P1981, DOI 10.1126/science.7801124; FAYET O, 1990, MOL MICROBIOL, V4, P1771, DOI 10.1111/j.1365-2958.1990.tb00555.x; Grindley NDF, 1995, CELL, V83, P1063, DOI 10.1016/0092-8674(95)90132-9; GROENEN MAM, 1986, EMBO J, V5, P3687, DOI 10.1002/j.1460-2075.1986.tb04700.x; KAUFMAN PD, 1992, CELL, V69, P27, DOI 10.1016/0092-8674(92)90116-T; KIM K, 1995, NUCLEIC ACIDS RES, V23, P3937, DOI 10.1093/nar/23.19.3937; KIM K, 1995, J BIOL CHEM, V270, P1472, DOI 10.1074/jbc.270.3.1472; KIM S, 1992, SCIENCE, V256, P198, DOI 10.1126/science.1533056; KULKOSKY J, 1992, MOL CELL BIOL, V12, P2331, DOI 10.1128/MCB.12.5.2331; LAVOIE BD, 1991, EMBO J, V10, P3051, DOI 10.1002/j.1460-2075.1991.tb07856.x; LEE J, 1994, EMBO J, V13, P5346, DOI 10.1002/j.1460-2075.1994.tb06869.x; LEUNG PC, 1989, NATURE, V338, P656, DOI 10.1038/338656a0; LEVCHENKO I, 1995, GENE DEV, V9, P2399, DOI 10.1101/gad.9.19.2399; MIZUUCHI K, 1991, CELL, V66, P129, DOI 10.1016/0092-8674(91)90145-O; MIZUUCHI K, 1992, J BIOL CHEM, V267, P21273; MIZUUCHI K, 1992, ANNU REV BIOCHEM, V61, P1011; MIZUUCHI M, 1992, CELL, V70, P303, DOI 10.1016/0092-8674(92)90104-K; MIZUUCHI M, 1995, CELL, V83, P375, DOI 10.1016/0092-8674(95)90115-9; MIZUUCHI M, 1991, P NATL ACAD SCI USA, V88, P9031, DOI 10.1073/pnas.88.20.9031; MIZUUCHI M, 1989, CELL, V58, P399, DOI 10.1016/0092-8674(89)90854-4; NAKAYAMA C, 1987, P NATL ACAD SCI USA, V84, P1809, DOI 10.1073/pnas.84.7.1809; NUNESDUBY SE, 1994, EMBO J, V13, P4421, DOI 10.1002/j.1460-2075.1994.tb06762.x; PAN GH, 1993, MOL CELL BIOL, V13, P3167, DOI 10.1128/MCB.13.6.3167; QIAN XH, 1995, GENE DEV, V9, P2053, DOI 10.1101/gad.9.16.2053; RADSTROM P, 1994, J BACTERIOL, V176, P3257, DOI 10.1128/jb.176.11.3257-3268.1994; RICE P, 1995, CELL, V82, P209, DOI 10.1016/0092-8674(95)90308-9; ROBERTSON HM, 1993, NATURE, V362, P241, DOI 10.1038/362241a0; ROWLAND SJ, 1990, MOL MICROBIOL, V4, P961, DOI 10.1111/j.1365-2958.1990.tb00669.x; SAVILAHTI H, 1995, EMBO J, V14, P4893, DOI 10.1002/j.1460-2075.1995.tb00170.x; SCHUMM JW, 1981, VIROLOGY, V114, P429, DOI 10.1016/0042-6822(81)90224-5; STARK WM, 1992, TRENDS GENET, V8, P432, DOI 10.1016/0168-9525(92)90176-5; SURETTE MG, 1992, CELL, V68, P1101, DOI 10.1016/0092-8674(92)90081-M; SURETTE MG, 1987, CELL, V49, P253, DOI 10.1016/0092-8674(87)90566-6; SURETTE MG, 1991, J BIOL CHEM, V266, P3118; VANLUENEN HGAM, 1994, CELL, V79, P293, DOI 10.1016/0092-8674(94)90198-8; WILLIS MC, 1993, SCIENCE, V262, P1255, DOI 10.1126/science.7694369; WU ZG, 1995, EMBO J, V14, P3835, DOI 10.1002/j.1460-2075.1995.tb00053.x; WU ZG, 1994, J BIOL CHEM, V269, P28829; YANG JY, 1995, EMBO J, V14, P2374, DOI 10.1002/j.1460-2075.1995.tb07232.x; YANG SH, 1994, J BIOL CHEM, V269, P12789; YANG W, 1995, CELL, V82, P193, DOI 10.1016/0092-8674(95)90307-0; YANG W, 1995, STRUCTURE, V3, P131, DOI 10.1016/S0969-2126(01)00142-3; ZOU A, 1991, J BIOL CHEM, V266, P20476; ZOU AH, 1991, EMBO J, V10, P1585	66	79	82	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 19	1996	85	2					257	269		10.1016/S0092-8674(00)81102-2	http://dx.doi.org/10.1016/S0092-8674(00)81102-2			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UG255	8612278	Bronze			2022-12-28	WOS:A1996UG25500014
J	Musco, G; Stier, G; Joseph, C; Morelli, MAC; Nilges, M; Gibson, TJ; Pastore, A				Musco, G; Stier, G; Joseph, C; Morelli, MAC; Nilges, M; Gibson, TJ; Pastore, A			Three-dimensional structure and stability of the KH domain: Molecular insights into the fragile X syndrome	CELL			English	Article							FMR-1 GENE; PROTEIN; RECOGNITION; SEQUENCE	The KH module is a sequence motif found in a number of proteins that are known to be in close association with RNA. Experimental evidence suggests a direct involvement of KH in RNA binding. The human FMR1 protein, which has two KH domains, is associated with fragile X syndrome, the most common inherited cause of mental retardation. Here we present the three-dimensional solution structure of the KH module. The domain consists of a stable beta alpha alpha beta beta alpha fold. On the basis of our results, we suggest a potential surface for RNA binding centered on the loop between the first two helices. Substitution of a well-conserved hydrophobic residue located on the second helix destroys the KH fold; a mutation of this position in FMR1 leads to an aggravated fragile X phenotype.	UNIV BASILICATA, I-85100 POTENZA, ITALY	University of Basilicata	Musco, G (corresponding author), EUROPEAN MOLEC BIOL LAB, MEYERHOFSTR 1, D-69012 HEIDELBERG, GERMANY.		Musco, Giovanna/Q-2756-2019; musco, giovanna/I-7122-2012; Nilges, Michael/E-4803-2011	musco, giovanna/0000-0002-0469-2994; Nilges, Michael/0000-0002-1451-8092; Castiglione Morelli, Maria Antonietta/0000-0003-3967-3117; Gibson, Toby James/0000-0003-0657-5166				BIRNEY E, 1993, NUCLEIC ACIDS RES, V21, P5803, DOI 10.1093/nar/21.25.5803; BURD CG, 1994, SCIENCE, V265, P615, DOI 10.1126/science.8036511; BYCROFT M, 1995, EMBO J, V14, P3563, DOI 10.1002/j.1460-2075.1995.tb07362.x; CLUBB RT, 1994, STRUCTURE, V2, P1041, DOI 10.1016/S0969-2126(94)00107-3; DEBOULLE K, 1993, NAT GENET, V3, P31, DOI 10.1038/ng0193-31; DEVYS D, 1993, NAT GENET, V4, P335, DOI 10.1038/ng0893-335; EBERSOLE TA, 1995, IN PRESS NATURE GENE; FUMAGALLI S, 1994, NATURE, V368, P871, DOI 10.1038/368871a0; GIBSON TJ, 1993, FEBS LETT, V324, P361, DOI 10.1016/0014-5793(93)80152-K; GUENTERT P, 1991, Journal of Molecular Biology, V217, P517; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; ITO K, 1994, NUCLEIC ACIDS RES, V22, P53, DOI 10.1093/nar/22.1.53; JONES AR, 1995, GENE DEV, V9, P1491, DOI 10.1101/gad.9.12.1491; KHARRAT A, 1995, EMBO J, V14, P3563; KILEDJIAN M, 1995, EMBO J, V14, P4357, DOI 10.1002/j.1460-2075.1995.tb00110.x; LEFFERS H, 1995, EUR J BIOCHEM, V230, P447, DOI 10.1111/j.1432-1033.1995.tb20581.x; LIU K, 1995, J MOL BIOL, V247, P547, DOI 10.1016/S0022-2836(05)80136-6; LUYEBEEL KA, 1995, NAT GENET, V10, P483; MACIAS MJ, 1994, NATURE, V369, P675, DOI 10.1038/369675a0; MAHONE M, 1995, EMBO J, V14, P2043, DOI 10.1002/j.1460-2075.1995.tb07196.x; Mandel JL, 1992, CURR OPIN GENET DEV, V2, P422, DOI 10.1016/S0959-437X(05)80153-4; MATTAJ IW, 1993, CELL, V73, P837, DOI 10.1016/0092-8674(93)90265-R; MORELLI MAC, 1995, FEBS LETT, V358, P193, DOI 10.1016/0014-5793(94)01422-W; NANDABALAN K, 1993, CELL, V73, P407, DOI 10.1016/0092-8674(93)90239-M; NILGES M, 1995, J MOL BIOL, V245, P645, DOI 10.1006/jmbi.1994.0053; NILGES M, 1991, NATO ADV SCI I A-LIF, V225, P451; NUSSBAUM RL, 1995, METABOLIC BASIS INHE, P795; OUBRIDGE C, 1994, NATURE, V372, P432, DOI 10.1038/372432a0; PIERETTI M, 1991, CELL, V66, P817, DOI 10.1016/0092-8674(91)90125-I; REGNIER P, 1987, J BIOL CHEM, V262, P63; REISS AL, 1994, HUM MOL GENET, V3, P393, DOI 10.1093/hmg/3.3.393; SCHMIDT C, 1992, EUR J BIOCHEM, V206, P625, DOI 10.1111/j.1432-1033.1992.tb16967.x; SIEBEL CW, 1995, GENE DEV, V9, P269, DOI 10.1101/gad.9.3.269; SIOMI H, 1993, CELL, V74, P291, DOI 10.1016/0092-8674(93)90420-U; SIOMI H, 1994, CELL, V77, P33, DOI 10.1016/0092-8674(94)90232-1; SIOMI H, 1993, NUCLEIC ACIDS RES, V21, P1193, DOI 10.1093/nar/21.5.1193; SIOMI MC, 1995, EMBO J, V14, P2401, DOI 10.1002/j.1460-2075.1995.tb07237.x; SIPPL MJ, 1993, PROTEINS, V17, P355, DOI 10.1002/prot.340170404; THOMPSON JD, 1994, COMPUT APPL BIOSCI, V10, P19; URLAUB H, 1995, EMBO J, V14, P4578, DOI 10.1002/j.1460-2075.1995.tb00137.x; VERKERK AJMH, 1991, CELL, V65, P905, DOI 10.1016/0092-8674(91)90397-H; VRIEND G, 1990, J MOL GRAPHICS, V8, P52, DOI 10.1016/0263-7855(90)80070-V; ZHANG Y, 1995, EMBO J, V14, P5358, DOI 10.1002/j.1460-2075.1995.tb00220.x	43	255	260	1	9	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	APR 19	1996	85	2					237	245		10.1016/S0092-8674(00)81100-9	http://dx.doi.org/10.1016/S0092-8674(00)81100-9			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UG255	8612276	Bronze			2022-12-28	WOS:A1996UG25500012
J	ORiain, MJ; Jarvis, JUM; Faulkes, CG				ORiain, MJ; Jarvis, JUM; Faulkes, CG			A dispersive morph in the naked mole-rat	NATURE			English	Article							BEHAVIOR; COLONIES	Close inbreeding is known for a variety of small mammal species(1-4) for which a high probability of mortality during dispersal makes helping and delayed maturation a relatively secure fitness option(5). Prolonged inbreeding, however, is usually associated with lowered fitness(6,7), and it has been shown that most highly inbred small mammals(8) and social insects(9) have inbreeding-avoidance mechanisms that promote some degree of outbreeding. However, previous field and laboratory research on the naked mole-rat (Heterocephalus glaber) suggested that this cooperatively breeding rodent is highly inbred(10-12), with new colonies forming by fission(13). Here we report the discovery of a dispersal phenotype that may occasionally promote outbreeding in naked mole-rats. These dispersers are morphologically, physiologically and behaviourally distinct from other colony members. They are laden with fat, exhibit elevated levels of luteinizing hormone, have a strong urge to disperse, and only solicit matings with non-colony members. These findings suggest that, although rare, a dispersive morph exists within naked mole-rat colonies.	ZOOL SOC LONDON,INST ZOOL,CONSERVAT GENET GRP,LONDON NW1 4RY,ENGLAND	Zoological Society of London	ORiain, MJ (corresponding author), UNIV CAPE TOWN,DEPT ZOOL,RONDEBOSCH 7700,SOUTH AFRICA.		Faulkes, Chris/B-8377-2008; Faulkes, Chris/O-8101-2019	O'Riain, M. Justin/0000-0001-5233-8327				ARMITAGE KB, 1986, ECOLOGY, V67, P1186, DOI 10.2307/1938674; BENGTSSON BO, 1978, J THEOR BIOL, V73, P439, DOI 10.1016/0022-5193(78)90151-0; BLOUIN SF, 1988, TRENDS ECOL EVOL, V3, P230, DOI 10.1016/0169-5347(88)90164-4; Brett R.A., 1991, P97; CLARKE KR, 1994, USER GUIDE PRIMER VE; Dobzhansky T, 1970, GENETICS EVOLUTIONAR; FAULKES CG, 1990, J ZOOL, V221, P87, DOI 10.1111/j.1469-7998.1990.tb03778.x; Hamilton William D., 1993, P429; HOECK HN, 1982, Z TIERPSYCHOL, V59, P177; JARVIS JUM, 1994, TRENDS ECOL EVOL, V9, P47, DOI 10.1016/0169-5347(94)90267-4; Lacey E.A., 1991, P275; LOVEGROVE BG, 1991, BEHAV ECOL SOCIOBIOL, V28, P37; MYLES TG, 1978, Q REV BIOL, V63, P1; ORIAIN MJ, IN PRESS ANIM BEHAV; REEVE HK, 1990, P NATL ACAD SCI USA, V87, P2496, DOI 10.1073/pnas.87.7.2496; SELANDER RK, 1970, AM ZOOL, V10, P53; Sherman P. W., 1991, BIOL NAKED MOLE RAT; Smith Andrew T., 1993, P329; SMITH AT, 1987, BEHAV ECOL SOCIOBIOL, V13, P37; STENSETH NC, 1984, ECOLOGY ANIMAL MOVEM, P63	20	225	230	0	81	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	APR 18	1996	380	6575					619	621		10.1038/380619a0	http://dx.doi.org/10.1038/380619a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UF741	8602260				2022-12-28	WOS:A1996UF74100043
J	Kim, R; Rotnitzky, A; Sparrow, D; Weiss, ST; Wager, C; Hu, H				Kim, R; Rotnitzky, A; Sparrow, D; Weiss, ST; Wager, C; Hu, H			Longitudinal study of low-level lead exposure and impairment of renal function The normative aging study	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							BLOOD-PRESSURE; SERUM CREATININE; SMELTER WORKERS; HYPERTENSION; NEPHROPATHY; POPULATION; PARAMETERS; EXCRETION; FAILURE; PLASMA	Objective.-To determine whether low-level lead exposure is associated with impaired renal function. Design.-Retrospective cohort study. Setting and Participants.-Subjects were 459 men randomly selected from the participants of the Normative Aging Study who were originally recruited from healthy veterans in the greater Boston area in 1961 and were periodically examined at the Department of Veterans Affairs Outpatient Clinic every 3 to 5 years. We reconstructed blood lead concentrations for the period between 1979 and 1994 using samples of either archived red blood cells or fresh whole blood. Main Outcome Measures.-Serum creatinine concentration. Results.-After adjustment for age, body mass index, smoking, alcohol consumption, educational level, and hypertension, blood lead concentration was positively and significantly associated with concurrent concentration of serum creatinine (P=.005). A 10-fold increase in blood lead level predicted an increase of 7 mu mol/L (0.08 mg/dL) in serum creatinine concentration, which is roughly equivalent to the increase predicted by 20 years of aging. The association was also significant among subjects whose blood lead concentrations had never exceeded 0.48 mu mol/L (10 mu g/dL) throughout the study period. The age-related increase in serum creatinine level was earlier and faster in the group with the highest-quartile levels of long-term lead exposure than in the group with the lowest-quartile levels. Conclusions.-Low-level exposure to lead may impair renal function in middle-aged and older men. Longitudinal data suggest an acceleration of age-related impairment of renal function in association with long-term low-level lead exposure.	HARVARD UNIV, SCH PUBL HLTH, DEPT ENVIRONM HLTH, BOSTON, MA 02115 USA; HARVARD UNIV, SCH PUBL HLTH, DEPT EPIDEMIOL, BOSTON, MA 02115 USA; HARVARD UNIV, SCH PUBL HLTH, DEPT BIOSTAT, BOSTON, MA 02115 USA; DEPT VET AFFAIRS, OUTPATIENT CLIN, BOSTON, MA USA	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health	Kim, R (corresponding author), HARVARD UNIV, BRIGHAM & WOMENS HOSP,SCH MED,CHANNING LAB, DEPT MED, 180 LONGWOOD AVE, BOSTON, MA 02115 USA.				NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES005257, P42ES005947] Funding Source: NIH RePORTER; NIEHS NIH HHS [P42ES05947, ES05257] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BATUMAN V, 1983, NEW ENGL J MED, V309, P17, DOI 10.1056/NEJM198307073090104; BEHRINGER D, 1986, NEPHRON, V42, P323, DOI 10.1159/000183696; BELL B, 1972, AGING HUM DEVELOP, V3, P5, DOI 10.2190/GGVP-XLB5-PC3N-EF0G; BENNETT WM, 1985, KIDNEY INT, V28, P212, DOI 10.1038/ki.1985.143; BERNARD A, 1989, TOXICOL LETT, V46, P293, DOI 10.1016/0378-4274(89)90137-9; BROCHNERMORTENSEN J, 1977, SCAND J UROL NEPHROL, V11, P263, DOI 10.3109/00365597709179963; BRODY DJ, 1994, JAMA-J AM MED ASSOC, V272, P277, DOI 10.1001/jama.272.4.277; CAMPBELL BC, 1981, TOXICOL LETT, V9, P121, DOI 10.1016/0378-4274(81)90027-8; *CDC, 1985, PUBL CDC; Centers for Disease Control, 1991, PREV LEAD POIS YOUNG; CHASSON AL, 1961, AM J CLIN PATHOL, V35, P83, DOI 10.1093/ajcp/35.1_ts.83; CLEVELAND WS, 1979, J AM STAT ASSOC, V74, P829, DOI 10.2307/2286407; COCKCROFT DW, 1976, NEPHRON, V16, P31, DOI 10.1159/000180580; COLLEONI N, 1986, NEPHRON, V44, P32, DOI 10.1159/000183908; CRAMER K, 1974, BRIT J IND MED, V31, P113; DESILVA PE, 1981, BRIT J IND MED, V38, P209; DOSSANTOS AC, 1994, AM J IND MED, V26, P635; ERJJUKA J, 1992, BR J IND MED, V49, P631; FOWLER BA, 1991, ENVIRON HEALTH PERSP, V91, P77, DOI 10.2307/3430986; FRIEDMAN SA, 1972, ANN INTERN MED, V76, P41, DOI 10.7326/0003-4819-76-1-41; GERHARDSSON L, 1992, BRIT J IND MED, V49, P186; Goyer R A, 1971, Curr Top Pathol, V55, P147; GOYER RA, 1970, ARCH ENVIRON HEALTH, V20, P705, DOI 10.1080/00039896.1970.10665647; GOYER RA, 1985, DIETARY ENV LEAD HUM; HARLAN WR, 1985, JAMA-J AM MED ASSOC, V253, P530, DOI 10.1001/jama.253.4.530; HENDERSON D. A., 1958, MED JOUR AUSTRALIA I, V45, P377; Jaffe M., 1886, J PHYS CHEM-US, V10, P391, DOI [DOI 10.1515/BCHM1.1886.10.5.391, 10.1515/bchm1.1886.10.5.391]; LILIS R, 1968, BRIT J IND MED, V25, P196; LILIS R, 1979, J ENVIRON PATHOL TOX, V2, P1447; LIN JL, 1994, J RHEUMATOL, V21, P705; MANTON WI, 1984, BRIT J IND MED, V41, P313; MEYER BR, 1984, AM J MED, V76, P989, DOI 10.1016/0002-9343(84)90847-7; MULDOON SB, 1994, AM J EPIDEMIOL, V139, P599, DOI 10.1093/oxfordjournals.aje.a117049; *OCC SAF HLTH ADM, 1978, 29CFR19101025 OCC SA; PAYTON M, 1994, AM J EPIDEMIOL, V140, P821, DOI 10.1093/oxfordjournals.aje.a117330; PERNEGER TV, 1993, JAMA-J AM MED ASSOC, V269, P488, DOI 10.1001/jama.269.4.488; PIRKLE JL, 1985, AM J EPIDEMIOL, V121, P246, DOI 10.1093/oxfordjournals.aje.a113995; RABINOWITZ MB, 1976, J CLIN INVEST, V58, P260, DOI 10.1172/JCI108467; ROELS H, 1994, OCCUP ENVIRON MED, V51, P505, DOI 10.1136/oem.51.8.505; ROSE CL, 1976, GERONTOLOGIST, V16, P508, DOI 10.1093/geront/16.6.508; ROWE JW, 1979, J GERONTOL, V81, P155; SAUDIE E, 1984, J CHRON DIS, V37, P617; SHULMAN N B, 1989, Hypertension (Dallas), V13, pI80; SMITH DR, 1992, ENVIRON RES, V57, P190, DOI 10.1016/S0013-9351(05)80079-9; SPARROW D, 1986, AM J CARDIOL, V57, P218, DOI 10.1016/0002-9149(86)90894-5; STAESSEN J, 1990, BRIT J IND MED, V47, P442; STAESSEN JA, 1992, NEW ENGL J MED, V327, P151, DOI 10.1056/NEJM199207163270303; *TECHN, 1983, SG40011988 TECHN; VANDEVYVER FL, 1988, KIDNEY INT, V33, P601, DOI 10.1038/ki.1988.39; VERSCHOOR M, 1987, AM J IND MED, V12, P341, DOI 10.1002/ajim.4700120402; VICTERY W, 1982, J LAB CLIN MED, V99, P354; WEDEEN RP, 1986, AM J KIDNEY DIS, V8, P380, DOI 10.1016/S0272-6386(86)80113-5; WEDEEN RP, 1975, AM J MED, V59, P630, DOI 10.1016/0002-9343(75)90224-7; WEISS ST, 1986, AM J EPIDEMIOL, V123, P800, DOI 10.1093/oxfordjournals.aje.a114309; *WHO, 1980, WHO, V647	56	155	159	1	7	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 17	1996	275	15					1177	1181		10.1001/jama.275.15.1177	http://dx.doi.org/10.1001/jama.275.15.1177			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UE625	8609685				2022-12-28	WOS:A1996UE62500029
J	Armstrong, D; Reyburn, H; Jones, R				Armstrong, D; Reyburn, H; Jones, R			A study of general practitioners' reasons for changing their prescribing behaviour	BRITISH MEDICAL JOURNAL			English	Article								Objectives - To explore general practitioners' reasons for recent changes in their prescribing behaviour. Design - Qualitative analysis of semistructured interviews. Setting - General practice in south east London. Subjects - A heterogeneous sample of 18 general practitioners. Results - Interviewees were able to identify between two and five specific changes that had occurred in their prescribing in the preceding six months. The most frequently mentioned changes related to fluoxetine, angiotensin converting enzyme inhibitors, and the antibiotic treatment of Helicobacter pylori. Three models of change were identified: an accumulation model, in which the volume and authority of evidence were important; a challenge model, in which behaviour change followed a dramatic or conflictual clinical event; and a continuity model, in which change took place against a background of willingness to change, modulated by other factors such as cost pressures and the comprehensible therapeutic action of a drug. Behaviour change was reinforced and sustained by experiences with individual patients. Conclusions - Multiple factors are involved in general practitioners) decisions to change their prescribing habits. Three models of change can be identified which have important implications for the design and evaluation of interventions aimed at behaviour change.	UNITED MED & DENT SCH GUYS & ST THOMASS HOSP,DEPT GEN PRACTICE,LONDON SE11 6SP,ENGLAND	University of London; King's College London			Armstrong, David/AAI-4476-2021	Armstrong, David/0000-0003-3652-9662				[Anonymous], 1995, LANCET, V346, P785; DAVIDOFF F, 1995, BRIT MED J, V310, P1085, DOI 10.1136/bmj.310.6987.1085; DAVIS DA, 1992, JAMA-J AM MED ASSOC, V268, P1111, DOI 10.1001/jama.268.9.1111; GRIMSHAW JM, 1993, LANCET, V342, P1317, DOI 10.1016/0140-6736(93)92244-N; HAINES A, 1994, BMJ-BRIT MED J, V308, P1488, DOI 10.1136/bmj.308.6942.1488; SMITH R, 1995, BRIT MED J, V311, P961; TAYLOR RJ, 1991, BRIT J GEN PRACT, V41, P244	7	120	122	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 13	1996	312	7036					949	952						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UF659	8616310				2022-12-28	WOS:A1996UF65900022
J	Qadota, H; Python, CP; Inoue, SB; Arisawa, M; Anraku, Y; Zheng, Y; Watanabe, T; Levin, DE; Ohya, Y				Qadota, H; Python, CP; Inoue, SB; Arisawa, M; Anraku, Y; Zheng, Y; Watanabe, T; Levin, DE; Ohya, Y			Identification of yeast Rho1p GTPase as a regulatory subunit of 1,3-beta-glucan synthase	SCIENCE			English	Article							SACCHAROMYCES-CEREVISIAE; GENES	1,3-beta-D-Glucan synthase [also known as beta(1-->3)glucan synthase] is a multi-enzyme complex that catalyzes the synthesis of 1,8-beta-linked glucan, a major structural component of the yeast cell wall. Temperature-sensitive mutants in the essential Rho-type guanosine triphosphatase (GTPase), Rho1p, displayed thermolabile glucan synthase activity, which was restored by the addition of recombinant Rho1p. Glucan synthase from mutants expressing constitutively active Rho1p did not require exogenous guanosine triphosphate for activity. Rho1p copurified with beta(1-->3)glucan synthase and associated with the Fks1p subunit of this complex in vivo. Both proteins were localized predominantly at sites of cell wall remodeling. Therefore, it appears that Rho1p is a regulatory subunit of beta(1-->3)glucan synthase.	UNIV TOKYO, DEPT BIOL SCI, GRAD SCH SCI, BUNKYO KU, TOKYO 113, JAPAN; JOHNS HOPKINS UNIV, SCH PUBL HLTH, DEPT BIOCHEM, BALTIMORE, MD 21205 USA; NIPPON ROCHE RES CTR, DEPT MYCOL, KAMAKURA, KANAGAWA 247, JAPAN; UNIV TENNESSEE, DEPT BIOCHEM, MEMPHIS, TN 38163 USA	University of Tokyo; Johns Hopkins University; Roche Holding; University of Tennessee System; University of Tennessee Health Science Center			Zheng, Yi/J-7235-2015	Zheng, Yi/0000-0001-7089-6074; Levin, David/0000-0003-0696-2860	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM048533] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM48533] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CID VJ, 1995, MICROBIOL REV, V59, P345, DOI 10.1128/MMBR.59.3.345-386.1995; DER CJ, 1986, CELL, V44, P167, DOI 10.1016/0092-8674(86)90495-2; GARRETTENGELE P, 1995, MOL CELL BIOL, V15, P4103; Inoue S., UNPUB; INOUE SB, 1995, EUR J BIOCHEM, V231, P845, DOI 10.1111/j.1432-1033.1995.tb20770.x; Kamada Y, 1996, J BIOL CHEM, V271, P9193, DOI 10.1074/jbc.271.16.9193; KAMADA Y, 1995, GENE DEV, V9, P1559, DOI 10.1101/gad.9.13.1559; KLIS FM, 1994, YEAST, V10, P851, DOI 10.1002/yea.320100702; MADAULE P, 1987, P NATL ACAD SCI USA, V84, P779, DOI 10.1073/pnas.84.3.779; MAZUR P, 1995, MOL CELL BIOL, V15, P5671; MOL PC, 1994, J BIOL CHEM, V269, P31267; NONAKA H, 1995, EMBO J, V14, P5931, DOI 10.1002/j.1460-2075.1995.tb00281.x; PARAVICINI G, IN PRESS YEAST; PRINGLE JR, 1989, METHOD CELL BIOL, V31, P357; QADOTA H, 1994, P NATL ACAD SCI USA, V91, P9317, DOI 10.1073/pnas.91.20.9317; RAM AFJ, 1995, FEBS LETT, V358, P165, DOI 10.1016/0014-5793(94)01418-Z; SZANISZLO PJ, 1985, J BACTERIOL, V161, P1188, DOI 10.1128/JB.161.3.1188-1194.1985; TODA T, 1993, EMBO J, V12, P1987, DOI 10.1002/j.1460-2075.1993.tb05848.x; YAMOCHI W, 1994, J CELL BIOL, V125, P1077, DOI 10.1083/jcb.125.5.1077; YOSHIDA S, 1992, MOL GEN GENET, V231, P337, DOI 10.1007/BF00292700; ZHENG Y, 1994, J BIOL CHEM, V269, P2369	22	376	394	2	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 12	1996	272	5259					279	281		10.1126/science.272.5259.279	http://dx.doi.org/10.1126/science.272.5259.279			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UE729	8602515				2022-12-28	WOS:A1996UE72900045
J	Steriade, M				Steriade, M			Arousal: Revisiting the reticular activating system	SCIENCE			English	Editorial Material							NEURONS; CORTEX; BRAIN				Steriade, M (corresponding author), UNIV LAVAL, FAC MED, DEPT PHYSIOL, NEUROPHYSIOL LAB, QUEBEC CITY, PQ G1K 7P4, CANADA.							Amzica F, 1996, NEUROSCIENCE, V72, P309, DOI 10.1016/0306-4522(96)00012-7; CastroAlamancos MA, 1996, SCIENCE, V272, P274, DOI 10.1126/science.272.5259.274; FACON E, 1958, Rev Neurol (Paris), V98, P117; Jasper H. H., 1958, RETICULAR FORMATION, P319; Kinomura S, 1996, SCIENCE, V271, P512, DOI 10.1126/science.271.5248.512; LLINAS R, 1993, P NATL ACAD SCI USA, V90, P2078, DOI 10.1073/pnas.90.5.2078; MCCORMICK DA, 1992, PROG NEUROBIOL, V39, P337, DOI 10.1016/0301-0082(92)90012-4; Morison RS, 1942, AM J PHYSIOL, V135, P0281, DOI 10.1152/ajplegacy.1941.135.2.281; Morison RS, 1943, AM J PHYSIOL, V138, P0297, DOI 10.1152/ajplegacy.1943.138.2.297; MORUZZI G, 1949, ELECTROEN CLIN NEURO, V1, P455, DOI 10.1016/0013-4694(49)90066-8; MORUZZI GIUSEPPE, 1964, PROC AMER PHIL SOC, V108, P19; Munk MHJ, 1996, SCIENCE, V272, P271, DOI 10.1126/science.272.5259.271; PARE D, 1990, J NEUROSCI, V10, P20; Pare D, 1990, BRAIN CHOLINERGIC SY, P337; SEGARRA JM, 1970, ARCH NEUROL-CHICAGO, V22, P408, DOI 10.1001/archneur.1970.00480230026003; Soury J., 1899, SYSTEME NERVEUX CENT; SPENCER WA, 1961, J NEUROPHYSIOL, V24, P50, DOI 10.1152/jn.1961.24.1.50; STERIADE M, 1982, J NEUROPHYSIOL, V48, P352, DOI 10.1152/jn.1982.48.2.352; STERIADE M, 1987, J NEUROPHYSIOL, V57, P260, DOI 10.1152/jn.1987.57.1.260; Steriade M, 1996, J NEUROSCI, V16, P392, DOI 10.1523/jneurosci.16-01-00392.1996; Steriade M, 1996, J NEUROSCI, V16, P2788; STERIADE M, 1993, SCIENCE, V262, P679, DOI 10.1126/science.8235588; STERIADE M, 1974, J NEUROPHYSIOL, V37, P1093, DOI 10.1152/jn.1974.37.5.1093; WALSHE FMR, 1957, BRAIN, V80, P510, DOI 10.1093/brain/80.4.510; [No title captured]	25	239	248	1	24	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 12	1996	272	5259					225	226		10.1126/science.272.5259.225	http://dx.doi.org/10.1126/science.272.5259.225			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UE729	8602506				2022-12-28	WOS:A1996UE72900031
J	Bradley, C; Blenkinsopp, A				Bradley, C; Blenkinsopp, A			Over the counter drugs - The future for self medication	BRITISH MEDICAL JOURNAL			English	Article								The increasing trend towards deregulation of more medicines to over the counter status has implications for the primary health care team as well as for consumers and patients. Better information for patients could improve the safety of over the counter medicines, but better systems need to be devised for reporting adverse reactions. ''Collaborative care'' could bring financial benefits. Doctors, nurses, and pharmacists need to discuss how they will respond to self medication practices, and ways of rewarding pharmacists for advising patients need to be found. Improved communication between doctors and pharmacists and the involvement of nurses could bring health care professionals into a new and more constructive interaction with each other and with the patient-or the changes required could split the professions as they each try to keep control of medicines.	UNIV KEELE,DEPT PHARM POLICY & PRACTICE,KEELE ST5 5BG,STAFFS,ENGLAND	Keele University	Bradley, C (corresponding author), UNIV BIRMINGHAM,SCH MED,BIRMINGHAM B15 2TT,W MIDLANDS,ENGLAND.			Blenkinsopp, Alison/0000-0001-8872-2769				Blenkinsopp A, 1996, BRIT MED J, V312, P629; BRADLEY C, 1995, PRESCRIBER      0305, P75; DRIFE JO, 1993, BRIT MED J, V307, P695, DOI 10.1136/bmj.307.6906.695; GIBSON P, 1993, BRIT MED J, V306, P1514, DOI 10.1136/bmj.306.6891.1514; HERXHEIMER A, 1994, BRIT J GEN PRACT, V44, P339; *MED CONTR AG, 1992, CHANG LEG CLASS PRES; 1995, PHARM J, V254, P433; 1993, LANCET, V342, P565; 1992, OFFICIAL J EUROPEA L, P113	9	65	67	0	11	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 30	1996	312	7034					835	837						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UD378	8608296				2022-12-28	WOS:A1996UD37800032
J	Taylor, FC; Ramsay, ME; Renton, A; Cohen, H				Taylor, FC; Ramsay, ME; Renton, A; Cohen, H			Methods for managing the increased workload in anticoagulant clinic	BRITISH MEDICAL JOURNAL			English	Article									ST MARYS HOSP,SCH MED,DEPT PUBL HLTH,HLTH CARE DEV UNIT,LONDON W2 1PG,ENGLAND; ST MARYS HOSP,SCH MED,DEPT HAEMATOL,LONDON W2 1PG,ENGLAND	Imperial College London; Imperial College London	Taylor, FC (corresponding author), ROYAL COLL PHYSICIANS,RES UNIT,LONDON NW1 4LE,ENGLAND.							DUXBURY BM, 1982, BRIT MED J, V284, P702, DOI 10.1136/bmj.284.6317.702; LOWE GDO, 1992, BRIT MED J, V305, P1445, DOI 10.1136/bmj.305.6867.1445; POLLER L, 1993, J CLIN PATHOL, V46, P299, DOI 10.1136/jcp.46.4.299; Taylor F., 1994, British Journal of Haematology, V86, P68; VANDENBESSELAAR AMHP, 1990, THROMB HAEMOSTASIS, V63, P316	5	19	19	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 3	1996	312	7026					286	286						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TU507	8611786				2022-12-28	WOS:A1996TU50700024
J	Bollinger, ME; ArredondoVega, FX; Santisteban, I; Schwarz, K; Hershfield, MS; Lederman, HM				Bollinger, ME; ArredondoVega, FX; Santisteban, I; Schwarz, K; Hershfield, MS; Lederman, HM			Hepatic dysfunction as a complication of adenosine deaminase deficiency	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SEVERE COMBINED IMMUNODEFICIENCY; L-HOMOCYSTEINE HYDROLASE; S-ADENOSYLHOMOCYSTEINE; MUTATIONS; GENE; INACTIVATION; EXPRESSION; INHIBITOR; SEQUENCE; TOXICITY		JOHNS HOPKINS UNIV, SCH MED, EUDOWOOD DIV PEDIAT IMMUNOL, BALTIMORE, MD USA; JOHNS HOPKINS UNIV, SCH MED, DIV PEDIAT GASTROENTEROL, BALTIMORE, MD USA; DUKE UNIV, SCH MED, DEPT MED, DURHAM, NC 27706 USA; DUKE UNIV, SCH MED, DEPT BIOCHEM, DURHAM, NC 27706 USA	Johns Hopkins University; Johns Hopkins University; Duke University; Duke University					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK020902] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK20902] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AKESON AL, 1987, P NATL ACAD SCI USA, V84, P5947, DOI 10.1073/pnas.84.16.5947; AKESON AL, 1988, J BIOL CHEM, V263, P16291; ARREDONDOVEGA FX, 1990, J CLIN INVEST, V86, P444, DOI 10.1172/JCI114730; ARREDONDOVEGA FX, 1994, AM J HUM GENET, V54, P820; BENVENISTE P, 1995, P NATL ACAD SCI USA, V92, P8373, DOI 10.1073/pnas.92.18.8373; CHANDAR N, 1989, P NATL ACAD SCI USA, V86, P2703, DOI 10.1073/pnas.86.8.2703; COX DW, 1995, METABOLIC MOL BASES, V3, P4125; DROR Y, 1993, BLOOD, V81, P2021; GIBLETT ER, 1972, LANCET, V2, P1067; HERSHFIELD MS, 1980, P NATL ACAD SCI-BIOL, V77, P4292, DOI 10.1073/pnas.77.7.4292; HERSHFIELD MS, 1995, CLIN IMMUNOL IMMUNOP, V76, pS228, DOI 10.1016/S0090-1229(95)90306-2; HERSHFIELD MS, 1995, HUM MUTAT, V5, P107, DOI 10.1002/humu.1380050202; HERSHFIELD MS, 1979, J BIOL CHEM, V254, P22; HERSHFIELD MS, 1993, PEDIATR RES, V33, pS42; HERSHFIELD MS, 1987, NEW ENGL J MED, V316, P589, DOI 10.1056/NEJM198703053161005; Hershfield MS, 1995, METABOLIC MOL BASES, V2, P1725; HIRSCHHORN R, 1995, CLIN IMMUNOL IMMUNOP, V76, pS219, DOI 10.1016/S0090-1229(95)90288-0; HIRSCHHORN R, 1980, NEW ENGL J MED, V303, P377, DOI 10.1056/NEJM198008143030706; HIRSCHHORN R, 1990, Immunodeficiency Reviews, V2, P175; KREDICH NM, 1977, CELL, V12, P931, DOI 10.1016/0092-8674(77)90157-X; KREDICH NM, 1979, P NATL ACAD SCI USA, V76, P2450, DOI 10.1073/pnas.76.5.2450; MARKERT ML, 1989, AM J HUM GENET, V45, P354; MIGCHIELSEN AAJ, 1995, NAT GENET, V10, P279, DOI 10.1038/ng0795-279; O'Reilly R J, 1989, Immunodefic Rev, V1, P273; POIRIER LA, 1994, DRUG METAB REV, V26, P185, DOI 10.3109/03602539409029790; RATECH H, 1985, AM J PATHOL, V120, P157; ROSEN FS, 1995, NEW ENGL J MED, V333, P431, DOI 10.1056/NEJM199508173330707; SANTISTEBAN I, 1995, HUM MOL GENET, V4, P2081, DOI 10.1093/hmg/4.11.2081; SANTISTEBAN I, 1993, J CLIN INVEST, V92, P2291, DOI 10.1172/JCI116833; SANTISTEBAN I, 1995, HUM MUTAT, V5, P243, DOI 10.1002/humu.1380050309; STEPHAN JL, 1993, J PEDIATR-US, V123, P564, DOI 10.1016/S0022-3476(05)80951-5; WAINFAN E, 1989, CANCER RES, V49, P4094; WAKAMIYA M, 1995, P NATL ACAD SCI USA, V92, P3673, DOI 10.1073/pnas.92.9.3673; WEINBERG K, 1993, J CLIN INVEST, V92, P596, DOI 10.1172/JCI116626; WIGINTON DA, 1984, NUCLEIC ACIDS RES, V12, P2439, DOI 10.1093/nar/12.5.2439; WIGINTON DA, 1986, BIOCHEMISTRY-US, V25, P8234, DOI 10.1021/bi00373a017; WOLOS JA, 1993, J IMMUNOL, V150, P3264; WOLOS JA, 1993, J IMMUNOL, V151, P526	38	85	91	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 23	1996	334	21					1367	1371		10.1056/NEJM199605233342104	http://dx.doi.org/10.1056/NEJM199605233342104			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UL251	8614422				2022-12-28	WOS:A1996UL25100004
J	Olson, EN; Srivastava, D				Olson, EN; Srivastava, D			Molecular pathways controlling heart development	SCIENCE			English	Article							LEFT-RIGHT ASYMMETRY; MYOSIN HEAVY-CHAIN; HOMEO BOX GENES; RETINOIC ACID; DIGEORGE-SYNDROME; MUSCLE TRANSCRIPTION; CHICK-EMBRYO; NEURAL CREST; EXPRESSION; SPECIFICATION	Heart formation requires complex interactions among cells from multiple embryonic origins. Recent studies have begun to reveal the genetic pathways that control cardiac morphogenesis. Many of the genes within these pathways are conserved across vast phylogenetic distances, which has allowed cardiac development to be dissected in organisms ranging from flies to mammals. Studies of cardiac development have also revealed the molecular defects underlying several congenital cardiac malformations in humans and may ultimately provide opportunities for genetic testing and intervention.	UNIV TEXAS,SW MED CTR,DEPT PEDIAT,DIV CARDIOL,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Olson, EN (corresponding author), UNIV TEXAS,SW MED CTR,DEPT MOL BIOL & ONCOL,5323 HARRY HINES BLVD,DALLAS,TX 75235, USA.							ALTABA ARI, 1991, GENE DEV, V5, P175, DOI 10.1101/gad.5.2.175; AUBRY M, 1993, HUM MOL GENET, V2, P1583, DOI 10.1093/hmg/2.10.1583; AZPIAZU N, 1993, GENE DEV, V7, P1325, DOI 10.1101/gad.7.7b.1325; BALDWIN HS, 1994, TRENDS CARDIOVAS MED, V4, P178, DOI 10.1016/1050-1738(94)90055-8; BASSON CT, 1994, NEW ENGL J MED, V330, P885, DOI 10.1056/NEJM199403313301302; BIBEN C, UNPUB; BODMER R, 1993, DEVELOPMENT, V118, P719; BORG TK, 1995, DEVELOPMENTAL MECHANISMS OF HEART DISEASE, P175; BOUR BA, 1995, GENE DEV, V9, P730, DOI 10.1101/gad.9.6.730; BRANNAN CI, 1994, GENE DEV, V8, P1019, DOI 10.1101/gad.8.9.1019; BRITZCUNNINGHAM SH, 1995, NEW ENGL J MED, V332, P1323, DOI 10.1056/NEJM199505183322002; BROWN NA, 1990, DEVELOPMENT, V109, P1; BRUECKNER M, 1989, P NATL ACAD SCI USA, V86, P5035, DOI 10.1073/pnas.86.13.5035; BURN J, 1993, J MED GENET, V30, P822, DOI 10.1136/jmg.30.10.822; CHAMBERS AE, 1994, GENE DEV, V8, P1324, DOI 10.1101/gad.8.11.1324; CHISAKA O, 1991, NATURE, V350, P473, DOI 10.1038/350473a0; CHO KWY, 1990, GENE DEV, V4, P1910, DOI 10.1101/gad.4.11.1910; COLVIN EV, 1990, SCI PRACTICE PEDIAT, P71; CROSS JC, 1995, DEVELOPMENT, V121, P2513; CSERJESI P, 1995, DEV BIOL, V170, P664, DOI 10.1006/dbio.1995.1245; DEHAAN RL, 1963, J EMBRYOL EXP MORPH, V11, P65; DEHAAN RL, 1965, ORGANOGENESIS, P377; DRYSDALE TA, 1994, DEV BIOL, V165, P432, DOI 10.1006/dbio.1994.1265; DURSTON AJ, 1989, NATURE, V340, P140, DOI 10.1038/340140a0; EDMONDSON DG, 1994, DEVELOPMENT, V120, P1251; EISENBERG LM, 1995, CIRC RES, V77, P1, DOI 10.1161/01.RES.77.1.1; EPSTEIN DJ, 1993, P NATL ACAD SCI USA, V90, P532, DOI 10.1073/pnas.90.2.532; EVANS SM, 1995, DEVELOPMENT, V121, P3889; GASSMANN M, 1995, NATURE, V378, P390, DOI 10.1038/378390a0; GASSMANN M, 1995, NATURE, V378, P386; GOLDMUNTZ E, 1993, J MED GENET, V30, P807, DOI 10.1136/jmg.30.10.807; GOURDIE RG, 1995, DEVELOPMENT, V121, P1423; GREPIN C, 1995, MOL CELL BIOL, V15, P4095; HALFORD S, 1993, HUM MOL GENET, V2, P2099, DOI 10.1093/hmg/2.12.2099; HEIKINHEIMO M, 1994, DEV BIOL, V164, P361, DOI 10.1006/dbio.1994.1206; HOFFMAN JIE, 1995, PEDIATR CARDIOL, V16, P103, DOI 10.1007/BF00801907; HOFFMAN JIE, 1995, PEDIATR CARDIOL, V16, P155; HOLLENBERG SM, 1995, MOL CELL BIOL, V15, P3813; HOYLE C, 1992, DEVELOPMENT, V115, P1071; HUMMEL KP, 1959, J HERED, V50, P10; IP HS, 1994, MOL CELL BIOL, V14, P7517, DOI 10.1128/MCB.14.11.7517; JAN LY, 1993, CELL, V75, P1241; Jiang YM, 1996, DEV BIOL, V174, P258, DOI 10.1006/dbio.1996.0071; KASTNER P, 1994, CELL, V78, P987, DOI 10.1016/0092-8674(94)90274-7; KERN MJ, 1995, TRENDS CARDIOVAS MED, V5, P47, DOI 10.1016/1050-1738(94)00033-6; KIRBY ML, 1990, CIRCULATION, V82, P332, DOI 10.1161/01.CIR.82.2.332; KIRBY ML, 1995, CIRC RES, V77, P211, DOI 10.1161/01.RES.77.2.211; KOMURO I, 1993, P NATL ACAD SCI USA, V90, P8145, DOI 10.1073/pnas.90.17.8145; KORENBERG JR, 1995, DEVELOPMENTAL MECHANISMS OF HEART DISEASE, P581; KUBALAK SW, 1994, J BIOL CHEM, V269, P16961; KURIHARA H, UNPUB; KURIHARA Y, 1995, J CLIN INVEST, V96, P293, DOI 10.1172/JCI118033; LAVERRIERE AC, 1994, J BIOL CHEM, V269, P23177; LEE KF, 1995, NATURE, V378, P394, DOI 10.1038/378394a0; LEVIN M, 1995, CELL, V82, P803, DOI 10.1016/0092-8674(95)90477-8; LILLY B, 1995, SCIENCE, V267, P688, DOI 10.1126/science.7839146; LILLY B, 1994, P NATL ACAD SCI USA, V91, P562; LINTS TJ, 1993, DEVELOPMENT, V119, P419; LOWE LA, IN PRESS NATURE; LYONS GE, 1994, TRENDS CARDIOVAS MED, V4, P70, DOI 10.1016/1050-1738(94)90012-4; LYONS I, 1995, GENE DEV, V9, P1654, DOI 10.1101/gad.9.13.1654; MARINO B, 1992, AM J MED GENET, V42, P424, DOI 10.1002/ajmg.1320420404; MCGINNIS W, 1992, CELL, V68, P283, DOI 10.1016/0092-8674(92)90471-N; MIKAWA T, 1992, DEV DYNAM, V193, P11, DOI 10.1002/aja.1001930104; MILLERHANCE WC, 1993, J BIOL CHEM, V268, P25244; MYABARA S, 1994, CONGENITAL ANOM, V24, P283; NGUYEN HT, 1994, P NATL ACAD SCI USA, V91, P7520, DOI 10.1073/pnas.91.16.7520; OBERPRILLER JO, 1985, CARDIAC MORPHOGENESI, P12; OBRIEN TX, 1993, P NATL ACAD SCI USA, V90, P5157, DOI 10.1073/pnas.90.11.5157; OLSON EN, 1995, DEV BIOL, V172, P2, DOI 10.1006/dbio.1995.0002; OLSON EN, 1993, CIRC RES, V72, P1, DOI 10.1161/01.RES.72.1.1; OLSON EN, 1994, GENE DEV, V8, P1, DOI 10.1101/gad.8.1.1; OLSON EN, 1995, CARDIOVASCULAR MED, P741; OSMOND MK, 1991, DEVELOPMENT, V113, P1405; PAYNE RM, 1995, CIRCULATION, V91, P494, DOI 10.1161/01.CIR.91.2.494; POLLOCK R, 1991, GENE DEV, V5, P2327, DOI 10.1101/gad.5.12a.2327; RANGANAYAKULU G, 1995, DEV BIOL, V171, P169, DOI 10.1006/dbio.1995.1269; REAUME AG, 1995, SCIENCE, V267, P1831, DOI 10.1126/science.7892609; Rossant J, 1996, CIRC RES, V78, P349, DOI 10.1161/01.RES.78.3.349; SANCHEZ A, 1991, J BIOL CHEM, V266, P22419; SARTORELLI V, 1993, CIRC RES, V72, P925, DOI 10.1161/01.RES.72.5.925; Schultheiss TM, 1995, DEVELOPMENT, V121, P4203; SHIVDASANI RA, 1995, NATURE, V373, P432, DOI 10.1038/373432a0; SIVE HL, 1991, GENE DEV, V5, P1321, DOI 10.1101/gad.5.8.1321; SRIVASTAVA D, 1995, SCIENCE, V270, P1995, DOI 10.1126/science.270.5244.1995; STAINIER DYR, 1995, DEVELOPMENT, V121, P3141; STAINIER DYR, 1992, DEV BIOL, V153, P91, DOI 10.1016/0012-1606(92)90094-W; STAINIER DYR, IN PRESS DEVELOPMENT; SUCOV HM, 1994, GENE DEV, V8, P1007, DOI 10.1101/gad.8.9.1007; SUGI Y, 1994, DEV DYNAM, V200, P155, DOI 10.1002/aja.1002000207; SUNDIN O, 1992, DEVELOPMENT, V114, P841; VANMIEROP LHS, 1986, AM J CARDIOL, V58, P133, DOI 10.1016/0002-9149(86)90256-0; WEINSTEIN BM, 1995, NAT MED, V1, P1143, DOI 10.1038/nm1195-1143; WILSON DI, 1993, J MED GENET, V30, P852, DOI 10.1136/jmg.30.10.852; WONG MW, 1994, DEV BIOL, V166, P683, DOI 10.1006/dbio.1994.1347; YOKOYAMA T, 1993, SCIENCE, V260, P679, DOI 10.1126/science.8480178; YOST HJ, 1995, CELL, V82, P689, DOI 10.1016/0092-8674(95)90464-6; YU YT, 1992, GENE DEV, V6, P1783, DOI 10.1101/gad.6.9.1783; YUTZEY KE, 1995, CIRC RES, V77, P216, DOI 10.1161/01.RES.77.2.216; ZHANG Y, 1986, J CELL BIOL, V102, P1480, DOI 10.1083/jcb.102.4.1480	100	377	392	0	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 3	1996	272	5262					671	676		10.1126/science.272.5262.671	http://dx.doi.org/10.1126/science.272.5262.671			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UJ051	8614825				2022-12-28	WOS:A1996UJ05100033
J	Surprenant, A; Rassendren, F; Kawashima, E; North, RA; Buell, G				Surprenant, A; Rassendren, F; Kawashima, E; North, RA; Buell, G			The cytolytic P-2Z receptor for extracellular ATP identified as a P-2X receptor (P2X(7))	SCIENCE			English	Article								The P-2Z receptor is responsible for adenosine triphosphate (ATP)-dependent lysis of macrophages through the formation of membrane pores permeable to large molecules. Other ATP-gated channels, the P-2X receptors, are permeable only to small cations. Here, an ATP receptor, the P2X(7) receptor, was cloned from rat brain and exhibited both these properties. This protein is homologous to other P-2X receptors but has a unique carboxyl-terminal domain that was required for the lytic actions of ATP. Thus, the P2X(7) (or P-2Z) receptor is a bifunctional molecule that could function in both fast synaptic transmission and the ATP-mediated lysis of antigen-presenting cells.			Surprenant, A (corresponding author), GLAXO INST MOLEC BIOL SA,PLAN LES OUATES,CH-1228 GENEVA,SWITZERLAND.		North, Richard/GQA-6156-2022; Rassendren, Francois/AAA-6190-2021	Rassendren, Francois/0000-0003-3320-2461				ABBRACCHIO MP, 1994, PHARMACOL THERAPEUT, V64, P445, DOI 10.1016/0163-7258(94)00048-4; BLANCHARD DK, 1995, BLOOD, V85, P3173, DOI 10.1182/blood.V85.11.3173.bloodjournal85113173; BRAKE AJ, 1994, NATURE, V371, P519, DOI 10.1038/371519a0; Buell G, 1996, EMBO J, V15, P55, DOI 10.1002/j.1460-2075.1996.tb00333.x; BUISMAN HP, 1988, P NATL ACAD SCI USA, V85, P7988, DOI 10.1073/pnas.85.21.7988; CHEN CC, 1995, NATURE, V377, P428, DOI 10.1038/377428a0; CHOI DW, 1988, NEURON, V1, P623, DOI 10.1016/0896-6273(88)90162-6; Collo G, 1996, J NEUROSCI, V16, P2495; DIVIRGILIO F, 1990, IMMUNOL TODAY, V11, P274, DOI 10.1016/0167-5699(90)90111-L; EVANS RJ, 1995, MOL PHARMACOL, V48, P178; EVANS RJ, 1995, J PHYSIOL-LONDON, V487P, pP193; FENWICK EM, 1982, J PHYSIOL-LONDON, V331, P577, DOI 10.1113/jphysiol.1982.sp014393; HICKMAN SE, 1994, BLOOD, V84, P2452; KENNEDY C, 1995, TRENDS PHARMACOL SCI, V16, P168, DOI 10.1016/S0165-6147(00)89010-0; LEWIS C, 1995, NATURE, V377, P432, DOI 10.1038/377432a0; LIU CC, 1995, IMMUNOL TODAY, V16, P194, DOI 10.1016/0167-5699(95)80121-9; MURGIA M, 1993, J BIOL CHEM, V268, P8199; NUTTLE LC, 1994, J BIOL CHEM, V269, P13988; STEINBERG TH, 1987, J BIOL CHEM, V262, P8884; SURPRENANT A, 1995, TRENDS NEUROSCI, V18, P224, DOI 10.1016/0166-2236(95)93907-F; SURPRENANT A, UNPUB; VALERA S, 1994, NATURE, V371, P516, DOI 10.1038/371516a0; WILEY JS, 1994, BRIT J PHARMACOL, V112, P946, DOI 10.1111/j.1476-5381.1994.tb13172.x; ZAMBON A, 1994, CELL IMMUNOL, V156, P458, DOI 10.1006/cimm.1994.1190	24	1389	1453	0	43	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 3	1996	272	5262					735	738		10.1126/science.272.5262.735	http://dx.doi.org/10.1126/science.272.5262.735			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UJ051	8614837				2022-12-28	WOS:A1996UJ05100055
J	Skoog, I; Lernfelt, B; Landahl, S; Palmertz, B; Andreasson, LA; Nilsson, L; Persson, G; Oden, A; Svanborg, A				Skoog, I; Lernfelt, B; Landahl, S; Palmertz, B; Andreasson, LA; Nilsson, L; Persson, G; Oden, A; Svanborg, A			15-year longitudinal study of blood pressure and dementia	LANCET			English	Article							WHITE-MATTER LESIONS; ALZHEIMERS-DISEASE; VASCULAR DEMENTIA; CLINICAL-DIAGNOSIS; POPULATION; CT; ENCEPHALOPATHY; DISORDER; AGE	Background Vascular causes of dementia may be more common than supposed. Vascular factors may also have a role in late-onset Alzheimer's disease, but the role of hypertension in the development of dementia is unclear. Methods As part of the Longitudinal Population Study of 70-year-olds in Goteborg, Sweden, we analysed the relation between blood pressure and the development of dementia in the age intervals 70-75, 75-79, and 79-85 years in those non-demented at age 70 (n=382). The sample was followed up for 15 years and examined repeatedly with a comprehensive investigation, including a psychiatric and physical examination. Findings Participants who developed dementia at age 79-85 had higher systolic blood pressure at age 70 (mean 178 vs 164 mm Hg, p=0.034) and higher diastolic blood pressure at ages 70 (101 vs 92, p=0.004) and 75 (97 vs 90, p=0.022) than those who did not develop dementia, For subtypes of dementia, higher diastolic blood pressure was recorded at age 70 (101, p=0.019) for those developing Alzheimer's disease and at age 75 (101, p=0.015) for those developing vascular dementia than for those who did not develop dementia. Participants with white-matter lesions on computed tomography at age 85 had higher blood pressure at age 70 than those without such lesions. Blood pressure declined in the years before dementia onset and was then similar to or lower than that in non-demented individuals. Interpretation Previously increased blood pressure may increase the risk for dementia by inducing small-vessel disease and white-matter lesions. To what extent the decline in blood pressure before dementia onset is a consequence or a cause of the brain disease remains to be elucidated.	SAHLGRENS UNIV HOSP,SECT PSYCHIAT,DEPT CLIN NEUROSCI,GOTHENBURG,SWEDEN; OSTRA HOSP,DEPT RADIOL,GOTHENBURG,SWEDEN; VASA HOSP,DEPT GERIATR MED,GOTHENBURG,SWEDEN; GOTHENBURG UNIV,DEPT MATH,S-41124 GOTHENBURG,SWEDEN; UNIV ILLINOIS,DEPT MED,GERIATR MED SECT,CHICAGO,IL	Sahlgrenska University Hospital; Sahlgrenska University Hospital; University of Gothenburg; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital								American Psychiatric Association, 1987, DIAGN STAT MAN MENT; BLENNOW K, 1991, ACTA NEUROL SCAND, V83, P187, DOI 10.1111/j.1600-0404.1991.tb04675.x; BRENNER DE, 1993, NEUROLOGY, V43, P293, DOI 10.1212/WNL.43.2.293; BRUN A, 1986, ANN NEUROL, V19, P253, DOI 10.1002/ana.410190306; DELAMONTE SM, 1989, ANN NEUROL, V25, P450, DOI 10.1002/ana.410250506; DELSER T, 1990, J NEUROL SCI, V96, P1, DOI 10.1016/0022-510X(90)90052-O; ELIAS MF, 1993, AM J EPIDEMIOL, V138, P353, DOI 10.1093/oxfordjournals.aje.a116868; ERKINJUNTTI T, 1987, ACTA NEUROL SCAND, V75, P262, DOI 10.1111/j.1600-0404.1987.tb07931.x; ERKINJUNTTI T, 1988, J NEUROL NEUROSUR PS, V51, P1037, DOI 10.1136/jnnp.51.8.1037; FARMER ME, 1990, J CLIN EPIDEMIOL, V43, P475, DOI 10.1016/0895-4356(90)90136-D; FERRER I, 1990, J NEUROL SCI, V98, P37, DOI 10.1016/0022-510X(90)90180-U; Guo ZC, 1996, BRIT MED J, V312, P805, DOI 10.1136/bmj.312.7034.805; HACHINSKI V, 1992, LANCET, V340, P645; LANDAHL S, 1986, HYPERTENSION, V8, P1044, DOI 10.1161/01.HYP.8.11.1044; LARSON EB, 1993, NEW ENGL J MED, V328, P203, DOI 10.1056/NEJM199301213280308; LOTZ PR, 1986, AM J NEURORADIOL, V7, P817; MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939; NILSSON LV, 1984, ACTA PSYCHIAT SCAND, V70, P478, DOI 10.1111/j.1600-0447.1984.tb01237.x; PERSSON G, 1980, ACTA PSYCHIAT SCAND, V62, P119, DOI 10.1111/j.1600-0447.1980.tb00600.x; REIS DJ, 1988, ARCH NEUROL-CHICAGO, V45, P180, DOI 10.1001/archneur.1988.00520260066022; RINDER L, 1975, ACTA MED SCAND, V198, P397, DOI 10.1111/j.0954-6820.1975.tb19563.x; ROMAN GC, 1987, JAMA-J AM MED ASSOC, V258, P1782, DOI 10.1001/jama.258.13.1782; SCHEINBERG P, 1988, STROKE, V19, P1291, DOI 10.1161/01.STR.19.10.1291; SCHERR PA, 1991, AM J EPIDEMIOL, V134, P1303, DOI 10.1093/oxfordjournals.aje.a116033; SKOOG I, 1994, DEMENTIA, V5, P137, DOI 10.1159/000106711; SKOOG I, 1994, J GERIATR PSYCH NEUR, V7, P169, DOI 10.1177/089198879400700308; SKOOG I, 1993, NEW ENGL J MED, V328, P153, DOI 10.1056/NEJM199301213280301; STARR JM, 1992, J HYPERTENS, V10, pS31; STRANDGAARD S, 1994, LANCET, V344, P519, DOI 10.1016/S0140-6736(94)91903-8; TALMAN WT, 1985, ANN NEUROL, V18, P1, DOI 10.1002/ana.410180102	30	1324	1357	1	70	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 27	1996	347	9009					1141	1145		10.1016/S0140-6736(96)90608-X	http://dx.doi.org/10.1016/S0140-6736(96)90608-X			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UG755	8609748				2022-12-28	WOS:A1996UG75500010
J	Grammer, LC				Grammer, LC			Cefaclor serum sickness	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter											Grammer, LC (corresponding author), NORTHWESTERN UNIV,DEPT MED,CHICAGO,IL 60611, USA.			Grammer, Leslie/0000-0001-6860-2014				ACKLEY AM, 1981, SOUTHERN MED J, V74, P1550; HEBERT AA, 1991, J AM ACAD DERMATOL, V25, P805, DOI 10.1016/S0190-9622(08)80973-5; KEARNS GL, 1994, J PEDIATR-US, V125, P805, DOI 10.1016/S0022-3476(94)70112-1; LAWLEY TJ, 1993, ALLERGY PRINCIPLES P, P990; RIEDER MJ, 1991, CLIN PHARMACOL THER, V49, P13, DOI 10.1038/clpt.1991.3	5	7	7	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 17	1996	275	15					1152	1153						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UE625	8609672				2022-12-28	WOS:A1996UE62500009
J	Sablin, EP; Kull, FJ; Cooke, R; Vale, RD; Fletterick, RJ				Sablin, EP; Kull, FJ; Cooke, R; Vale, RD; Fletterick, RJ			Crystal structure of the motor domain of the kinesin-related motor ncd	NATURE			English	Article							PROTEIN; DROSOPHILA; MOVEMENT	MICROTUBULE-BASED ATPases of the kinesin superfamily(1,2) provide the motile force for many animated features of living cells. Kinesin motors differ in their direction of movement along microtubules. Kinesin(3) and ncd(4,5), a kinesin-related motor involved in formation and maintenance of mitotic and meiotic spindles, move in opposite directions along microtubules, even though their motor domains are 40% identical in amino-acid sequence. Here we report the crystal structure of the MgADP complex of the Drosophila ncd motor domain determined to 2.5 Angstrom by X-ray crystallography, and compare it to the kinesin structure. The ncd and kinesin motor domains are remarkably similar in structure, and the locations of conserved surface amino acids suggest these motors share a common microtubule-binding site, Moreover, structural and functional comparisons of ncd, kinesin, myosin and G proteins indicate that these NTPases may have a similar strategy of changing conformation between NTP and NDP states. We propose a general model for converting a common gamma-phosphate-sensing mechanism into opposite polarities of movement for kinesin and ncd.	UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM BIOPHYS,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT PHARMACOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,HOWARD HUGHES MED INST,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco; Howard Hughes Medical Institute; University of California System; University of California San Francisco								BOUME HR, 1990, NATURE, V348, P125; BOUME HR, 1991, NATURE, V349, P117; Brunger A. T., 1992, XPLOR VERSION 3 1 SY; ENDOW SA, 1992, ANNU REV CELL BIOL, V8, P29; ENDOW SA, 1994, EMBO J, V13, P2708, DOI 10.1002/j.1460-2075.1994.tb06561.x; FISHER AJ, 1995, BIOCHEMISTRY-US, V34, P8960, DOI 10.1021/bi00028a004; GOLDSTEIN LSB, 1993, ANNU REV GENET, V27, P319; HIROSE K, 1995, NATURE, V376, P277, DOI 10.1038/376277a0; Hoenger A., 1995, Molecular Biology of the Cell, V6, p157A; KJELDGAARD M, 1992, J MOL BIOL, V223, P721, DOI 10.1016/0022-2836(92)90986-T; KJELDGAARD M, 1993, STRUCTURE, V1, P35, DOI 10.1016/0969-2126(93)90007-4; Kull FJ, 1996, NATURE, V380, P550, DOI 10.1038/380550a0; KURIYAMA R, 1995, J CELL BIOL, V129, P1049, DOI 10.1083/jcb.129.4.1049; LAMBRIGHT DG, 1994, NATURE, V369, P621, DOI 10.1038/369621a0; Laskowski R. A., 1993, J APPL CRYSTALLOGR, V26, P282; LOCKHART A, 1995, J MOL BIOL, V249, P763, DOI 10.1006/jmbi.1995.0335; MCDONALD HB, 1990, CELL, V63, P1159, DOI 10.1016/0092-8674(90)90412-8; MCDONALD HB, 1990, CELL, V61, P991, DOI 10.1016/0092-8674(90)90064-L; MILBURN MV, 1990, SCIENCE, V247, P939, DOI 10.1126/science.2406906; NABER N, 1995, PROTEIN SCI, V4, P1824, DOI 10.1002/pro.5560040917; NOEL JP, 1993, NATURE, V366, P654, DOI 10.1038/366654a0; SABLIN EP, 1995, PROTEINS, V21, P68, DOI 10.1002/prot.340210108; SPRINZL M, 1994, TRENDS BIOCHEM SCI, V19, P245, DOI 10.1016/0968-0004(94)90149-X; STEWART RJ, 1993, P NATL ACAD SCI USA, V90, P5209, DOI 10.1073/pnas.90.11.5209; TONG L, 1991, J MOL BIOL, V217, P503, DOI 10.1016/0022-2836(91)90753-S; VALE RD, 1985, CELL, V43, P623, DOI 10.1016/0092-8674(85)90234-X; WALKER RA, 1990, NATURE, V347, P780, DOI 10.1038/347780a0; WITTINGHOFER A, 1994, CELL, V76, P201, DOI 10.1016/0092-8674(94)90327-1	28	318	324	0	13	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	APR 11	1996	380	6574					555	559		10.1038/380555a0	http://dx.doi.org/10.1038/380555a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UE663	8606780				2022-12-28	WOS:A1996UE66300058
J	Lambert, TW; Goldacre, MJ; Parkhouse, J; Edwards, C				Lambert, TW; Goldacre, MJ; Parkhouse, J; Edwards, C			Career destinations in 1994 of United Kingdom medical graduates of 1983: Results of a questionnaire survey	BRITISH MEDICAL JOURNAL			English	Article								Cohort studies of doctors' career choices and career progression since the mid-1970s have shown important changes in the medical workforce, in specialist training, and in employment. Examples of these changes are the increasing proportion of women doctors and of doctors who wish to work part time, the emigration patterns of doctors, and the development of vocational training for general practice. Studies enable the effects of longer term changes to be assessed, and sometimes they inform current debate.	UNIV OXFORD,DEPT PUBL HLTH & PRIMARY CARE,UNIT HLTH CARE EPIDEMIOL,OXFORD OX3 7LF,ENGLAND	University of Oxford				Lambert, Trevor/0000-0001-9688-3036				Allen I., 1994, DOCTORS THEIR CAREER; BAKER M, 1995, BRIT MED J, V310, P1301, DOI 10.1136/bmj.310.6990.1301; *DEP HLTH, 1992, 1 DEP HLTH MED WORKF; *DEP HLTH, 1995, 2 DEP HLTH MED WORKF; PARKHOUSE J, 1991, DOCTORS CAREERS AIMS; Report Todd, 1968, CMND3569; Wilson R, 1994, Health Trends, V26, P70	7	50	51	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 6	1996	312	7035					893	897						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UE371	8611884				2022-12-28	WOS:A1996UE37100030
J	Eccles, M; Clapp, Z; Grimshaw, J; Adams, PC; Higgins, B; Purves, I; Russell, I				Eccles, M; Clapp, Z; Grimshaw, J; Adams, PC; Higgins, B; Purves, I; Russell, I			North of England evidence based guidelines development project: Methods of guideline development .1.	BMJ-BRITISH MEDICAL JOURNAL			English	Article							ACUPUNCTURE; METAANALYSIS; TRIALS; PAIN		UNIV ABERDEEN, HLTH SERV RES UNIT, ABERDEEN AB9 2ZD, SCOTLAND; ROYAL VICTORIA INFIRM, NEWCASTLE UPON TYNE NE1 4LP, TYNE & WEAR, ENGLAND; FREEMAN RD HOSP, NEWCASTLE UPON TYNE NE7 7DN, TYNE & WEAR, ENGLAND; UNIV NEWCASTLE UPON TYNE, DEPT PRIMARY HLTH CARE, SOWERBY UNIT PRIMARY CARE INFORMAT, NEWCASTLE UPON TYNE NE2 4AA, TYNE & WEAR, ENGLAND; UNIV YORK, DEPT HLTH SCI & CLIN EVALUAT, YORK YO1 5DD, N YORKSHIRE, ENGLAND	University of Aberdeen; Newcastle University - UK; Newcastle Freeman Hospital; Newcastle University - UK; Newcastle University - UK; University of York - UK	Eccles, M (corresponding author), UNIV NEWCASTLE UPON TYNE, CTR HLTH SERV RES, NEWCASTLE UPON TYNE NE2 4AA, TYNE & WEAR, ENGLAND.		Eccles, Martin P/AAD-4029-2020; Russell, Ian T/H-1181-2012; Grimshaw, Jeremy/D-8726-2013	Grimshaw, Jeremy/0000-0001-8015-8243				[Anonymous], 1993, THORAX, V48, pS1; [Anonymous], 1979, J CANADIAN MED ASS, V121, P1193; *CLIN RES AUD GROU, 1993, CLIN GUID REP WORK P; Grimshaw J, 1993, Qual Health Care, V2, P243, DOI 10.1136/qshc.2.4.243; Grimshaw J, 1995, J Eval Clin Pract, V1, P37, DOI 10.1111/j.1365-2753.1995.tb00006.x; Grimshaw J M, 1994, Qual Health Care, V3, P45, DOI 10.1136/qshc.3.1.45; GRIMSHAW JM, 1993, LANCET, V342, P1317, DOI 10.1016/0140-6736(93)92244-N; GUYATT GH, 1994, JAMA-J AM MED ASSOC, V271, P59, DOI 10.1001/jama.271.1.59; Institute of Medicine, 1992, GUID CLIN PRACT DEV; JAESCHKE R, 1994, JAMA-J AM MED ASSOC, V271, P389, DOI 10.1001/jama.271.5.389; JAESCHKE R, 1994, JAMA-J AM MED ASSOC, V271, P703, DOI 10.1001/jama.271.9.703; KLEIJNEN J, 1991, THORAX, V46, P799, DOI 10.1136/thx.46.11.799; KLEIJNEN J, 1991, BRIT MED J, V302, P316, DOI 10.1136/bmj.302.6772.316; KOES BW, 1991, BRIT MED J, V302, P1572, DOI 10.1136/bmj.302.6792.1572; *N ENGL STAB ANG G, IN PRESS BMJ; *ROYAL COLL GEN PR, 1995, 26 ROYAL COLL GEN PR; TERRIET G, 1990, J CLIN EPIDEMIOL, V43, P1191, DOI 10.1016/0895-4356(90)90020-P; TERRIET G, 1990, BRIT J GEN PRACT, V40, P379; *U LEEDS, 1994, B U LEEDS, V8; 1996, BRIT MED J, V312, P762	20	129	144	0	5	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 23	1996	312	7033					760	762						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UC166	8605466				2022-12-28	WOS:A1996UC16600040
J	Khan, AS; Ksiazek, TG; Peters, CJ				Khan, AS; Ksiazek, TG; Peters, CJ			Hantavirus pulmonary syndrome	LANCET			English	Review											Khan, AS (corresponding author), CTR DIS CONTROL & PREVENT,SPECIAL PATHOGENS BRANCH,DIV VIRAL & RICKETTSIAL DIS,ATLANTA,GA 30333, USA.							ARMSTRONG LR, 1995, J INFECT DIS, V172, P1166, DOI 10.1093/infdis/172.4.1166; ARMSTRONG LR, 1995, IN PRESS PED INFECT; CHILDS JE, 1994, J INFECT DIS, V169, P1271, DOI 10.1093/infdis/169.6.1271; DUCHIN JS, 1994, NEW ENGL J MED, V330, P949, DOI 10.1056/NEJM199404073301401; ELLIOTT LH, 1994, AM J TROP MED HYG, V51, P102, DOI 10.4269/ajtmh.1994.51.102; FRAMPTON JW, 1995, LANCET, V346, P781, DOI 10.1016/S0140-6736(95)91542-7; FRANKLIN JF, 1990, BIOSCIENCE, V40, P509, DOI 10.2307/1311319; GLASS GE, 1994, NEPHRON, V68, P48, DOI 10.1159/000188086; GLASS GE, 1993, J INFECT DIS, V167, P614, DOI 10.1093/infdis/167.3.614; HJELLE B, 1995, VIROLOGY, V207, P452, DOI 10.1006/viro.1995.1104; Hjelle B, 1996, LANCET, V347, P57, DOI 10.1016/S0140-6736(96)91587-1; KETAI LH, 1994, RADIOLOGY, V191, P665, DOI 10.1148/radiology.191.3.8184043; KHAN AS, 1995, J MED VIROL, V46, P281, DOI 10.1002/jmv.1890460320; KHAN AS, IN PRESS AM J MED; KSIAZEK TG, 1995, AM J TROP MED HYG, V52, P117, DOI 10.4269/ajtmh.1995.52.117; LEE PW, 1982, LANCET, V2, P1405; MORZUNOV SP, 1995, J VIROL, V69, P1980, DOI 10.1128/JVI.69.3.1980-1983.1995; Musser Guy G., 1993, P501; NERURKAR VR, 1993, LANCET, V342, P1058, DOI 10.1016/0140-6736(93)92917-I; NOLTE KB, 1995, HUM PATHOL, V26, P110, DOI 10.1016/0046-8177(95)90123-X; ROLLIN PE, 1995, J MED VIROL, V46, P35, DOI 10.1002/jmv.1890460108; SONG JW, 1994, LANCET, V344, P1637, DOI 10.1016/S0140-6736(94)90430-8; SPIROPOULOU CF, 1994, VIROLOGY, V200, P715, DOI 10.1006/viro.1994.1235; TORREZMARTINEZ N, 1995, LANCET, V346, P780, DOI 10.1016/S0140-6736(95)91541-9; ZAKI SR, 1995, AM J PATHOL, V146, P552; ZAKI SR, 1996, IN PRESS ARCH VIROL; ZEITZ PS, 1995, J INFECT DIS, V171, P864, DOI 10.1093/infdis/171.4.864; 1994, CANADA COMMUNICABLE, V20, P121	28	48	50	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 16	1996	347	9003					739	741		10.1016/S0140-6736(96)90082-3	http://dx.doi.org/10.1016/S0140-6736(96)90082-3			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TZ982	8602007	Bronze			2022-12-28	WOS:A1996TZ98200015
J	Dubnau, J; Struhl, G				Dubnau, J; Struhl, G			RNA recognition and translational regulation by a homeodomain protein	NATURE			English	Article							HOMEOTIC GENE ANTENNAPEDIA; DROSOPHILA EMBRYO; BICOID PROTEIN; MESSENGER-RNA; ANTERIOR PATTERN; POLY(A) TAIL; BINDING-SITE; MAJOR GROOVE; FUSHI-TARAZU; EXPRESSION	In Drosophila, the primary determinant of anterior pattern is the gradient morphogen bicoid (bcd), a homeodomain protein that binds DNA and transcriptionally activates target genes at different threshold concentrations. Here we present evidence that bcd also binds RNA and acts as a translational repressor to generate an opposing gradient of the homeodomain protein caudal (cad). RNA binding by bcd seems to involve direct interactions between the bcd homeodomain and discrete target sequences within the 3' untranslated region of the cad messenger RNA and to block the initiation of cad translation.			Dubnau, J (corresponding author), COLUMBIA UNIV COLL PHYS & SURG,HOWARD HUGHES MED INST,DEPT GENET & DEV,701 W 168 ST,NEW YORK,NY 10032, USA.			Dubnau, Josh/0000-0002-9285-7444				ANDINO R, 1990, CELL, V63, P369, DOI 10.1016/0092-8674(90)90170-J; BASLER K, 1994, NATURE, V368, P208, DOI 10.1038/368208a0; BERLETH T, 1988, EMBO J, V7, P1749, DOI 10.1002/j.1460-2075.1988.tb03004.x; CURTIS D, 1995, CELL, V81, P171, DOI 10.1016/0092-8674(95)90325-9; DRIEVER W, 1989, NATURE, V340, P363, DOI 10.1038/340363a0; DRIEVER W, 1988, CELL, V54, P83, DOI 10.1016/0092-8674(88)90182-1; DRIEVER W, 1989, NATURE, V337, P138, DOI 10.1038/337138a0; DRIEVER W, 1988, CELL, V54, P95, DOI 10.1016/0092-8674(88)90183-3; DUBNAU J, 1995, THESIS COLUMBIA U; FISCHER JA, 1985, NUCLEIC ACIDS RES, V13, P6899, DOI 10.1093/nar/13.19.6899; FROHNHOFER HG, 1986, NATURE, V324, P120, DOI 10.1038/324120a0; GALLIE DR, 1991, GENE DEV, V5, P2108, DOI 10.1101/gad.5.11.2108; GILMARTIN GM, 1991, MOL CELL BIOL, V11, P2432, DOI 10.1128/MCB.11.5.2432; HANES SD, 1994, MOL CELL BIOL, V14, P3364, DOI 10.1128/MCB.14.5.3364; HANES SD, 1989, CELL, V57, P1275, DOI 10.1016/0092-8674(89)90063-9; KAUFMAN RJ, 1989, MOL CELL BIOL, V9, P946, DOI 10.1128/MCB.9.3.946; Kim S H, 1976, Prog Nucleic Acid Res Mol Biol, V17, P181, DOI 10.1016/S0079-6603(08)60070-7; KLAR A, 1992, CELL, V69, P95, DOI 10.1016/0092-8674(92)90121-R; KRAUSE HM, 1988, GENE DEV, V2, P1021, DOI 10.1101/gad.2.8.1021; LAWRENCE PA, 1987, NATURE, V328, P440, DOI 10.1038/328440a0; MACDONALD PM, 1986, NATURE, V324, P537, DOI 10.1038/324537a0; MICHEL F, 1989, NATURE, V342, P391, DOI 10.1038/342391a0; MLODZIK M, 1990, DEVELOPMENT, V109, P271; MLODZIK M, 1987, CELL, V48, P465, DOI 10.1016/0092-8674(87)90197-8; MLODZIK M, 1985, EMBO J, V4, P2961, DOI 10.1002/j.1460-2075.1985.tb04030.x; MUNROE D, 1990, MOL CELL BIOL, V10, P3441, DOI 10.1128/MCB.10.7.3441; OH SK, 1992, GENE DEV, V6, P1643, DOI 10.1101/gad.6.9.1643; PUGLISI JD, 1992, SCIENCE, V257, P76, DOI 10.1126/science.1621097; REBAGLIATI M, 1989, CELL, V58, P231, DOI 10.1016/0092-8674(89)90834-9; RUBIN GM, 1983, NUCLEIC ACIDS RES, V11, P6341, DOI 10.1093/nar/11.18.6341; RUFF M, 1991, SCIENCE, V252, P1682, DOI 10.1126/science.2047877; SACHS AB, 1989, CELL, V58, P857, DOI 10.1016/0092-8674(89)90938-0; SCHNEUWLY S, 1986, EMBO J, V5, P733, DOI 10.1002/j.1460-2075.1986.tb04275.x; SCHRODER C, 1988, EMBO J, V7, P2881, DOI 10.1002/j.1460-2075.1988.tb03145.x; SEEMAN NC, 1976, P NATL ACAD SCI USA, V73, P804, DOI 10.1073/pnas.73.3.804; STJOHNSTON D, 1989, DEVELOPMENT, V107, P13; STRUHL G, 1989, CELL, V57, P1259, DOI 10.1016/0092-8674(89)90062-7; TAN RY, 1993, CELL, V73, P1031, DOI 10.1016/0092-8674(93)90280-4; THEURKAUF WE, 1986, P NATL ACAD SCI USA, V83, P8477, DOI 10.1073/pnas.83.22.8477; WEEKS KM, 1991, CELL, V66, P577, DOI 10.1016/0092-8674(81)90020-9; WEEKS KM, 1993, SCIENCE, V261, P1574, DOI 10.1126/science.7690496; YARUS M, 1991, J MOL BIOL, V222, P995, DOI 10.1016/0022-2836(91)90590-3	42	286	290	0	13	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	FEB 22	1996	379	6567					694	699		10.1038/379694a0	http://dx.doi.org/10.1038/379694a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TW567	8602214				2022-12-28	WOS:A1996TW56700042
J	Glynn, RJ; Buring, JE				Glynn, RJ; Buring, JE			Ways of measuring rates of recurrent events	BMJ-BRITISH MEDICAL JOURNAL			English	Article							MODELS; EYES	Recurrent events are common in medical research, yet the best ways to measure their occurrence remain controversial. Moreover, the correct statistical techniques to compare the occurrence of such events across populations or treatment groups are not widely known. In both observational studies and randomised clinical trials one natural and intuitive measure of occurrence is the event rate, defined as the number of events (possibly including multiple events per person) divided by the total person-years of experience, This is often a more relevant and clinically interpretable measure of disease burden in a population than considering only the first event that occurs. Appropriate statistical tests to compare such event rates among treatment groups or populations require the recognition that some individuals may be especially likely to experience recurrent events. Straightforward approaches are available to account for this tendency in crude and stratified analyses. Recently developed regression models can appropriately examine the association of several variables with rates of recurrent events.			Glynn, RJ (corresponding author), HARVARD UNIV, BRIGHAM & WOMENS HOSP, SCH MED, DIV PREVENT MED, DEPT MED, BOSTON, MA 02215 USA.				NCI NIH HHS [CA40360] Funding Source: Medline; NEI NIH HHS [EY06633, EY08103] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA040360] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [R01EY006633, R01EY008103] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ALTMAN DG, 1994, JAMA-J AM MED ASSOC, V272, P129, DOI 10.1001/jama.272.2.129; [Anonymous], 1955, ARCH OPHTHALMOL-CHIC, V54, P462; [Anonymous], 1976, Am J Ophthalmol, V81, P383; ANSCOMBE FJ, 1950, BIOMETRIKA, V37, P358, DOI 10.1093/biomet/37.3-4.358; AVORN J, 1994, JAMA-J AM MED ASSOC, V271, P751, DOI 10.1001/jama.271.10.751; BECKMAN H, 1990, OPHTHALMOLOGY, V97, P1403; BRESLOW NE, 1993, J AM STAT ASSOC, V88, P9, DOI 10.1080/01621459.1993.10594284; CLAYTON D, 1985, J R STAT SOC A STAT, V148, P82, DOI 10.2307/2981943; COOIL B, 1991, J AM STAT ASSOC, V86, P285, DOI 10.2307/2290560; Cumming Robert G., 1990, Annals of Epidemiology, V1, P49; EDERER F, 1973, ARCH OPHTHALMOL-CHIC, V89, P1; FISHER ES, 1994, NEW ENGL J MED, V331, P989, DOI 10.1056/NEJM199410133311506; Fisher RA, 1941, ANN EUGENIC, V11, P182, DOI 10.1111/j.1469-1809.1941.tb02284.x; GAIL MH, 1980, BIOMETRICS, V36, P255, DOI 10.2307/2529977; GLYNN RJ, 1994, STAT MED, V13, P1023, DOI 10.1002/sim.4780131005; GLYNN RJ, 1994, ARCH INTERN MED, V154, P2649, DOI 10.1001/archinte.1994.00420230032005; GLYNN RJ, 1993, AM J EPIDEMIOL, V137, P776, DOI 10.1093/oxfordjournals.aje.a116738; GLYNN RJ, 1992, ARCH OPHTHALMOL-CHIC, V110, P381, DOI 10.1001/archopht.1992.01080150079033; Greenwood, 1920, J R STAT SOC, V83, P255; LAWLESS JF, 1987, J AM STAT ASSOC, V82, P808, DOI 10.2307/2288790; LIN JS, 1992, J AM STAT ASSOC, V87, P1091, DOI 10.2307/2290646; Lindsey J.K., 1993, MODELS REPEATED MEAS; OAKES D, 1989, J AM STAT ASSOC, V84, P487, DOI 10.2307/2289934; ROSNER B, 1984, BIOMETRICS, V40, P1025, DOI 10.2307/2531153; STUKEL TA, 1994, STAT MED, V13, P1781, DOI 10.1002/sim.4780131709; THALL PF, 1988, BIOMETRICS, V44, P197, DOI 10.2307/2531907; THOMPSON JR, 1993, BRIT J OPHTHALMOL, V77, P115, DOI 10.1136/bjo.77.2.115; WINDELER J, 1995, BRIT MED J, V310, P454, DOI 10.1136/bmj.310.6977.454; ZEGER SL, 1986, BIOMETRICS, V42, P121, DOI 10.2307/2531248	29	154	155	4	9	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 10	1996	312	7027					364	367						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TV698	8611837				2022-12-28	WOS:A1996TV69800030
J	Meraz, MA; White, JM; Sheehan, KCF; Bach, EA; Rodig, SJ; Dighe, AS; Kaplan, DH; Riley, JK; Greenlund, AC; Campbell, D; CarverMoore, K; DuBois, RN; Clark, R; Aguet, M; Schreiber, RD				Meraz, MA; White, JM; Sheehan, KCF; Bach, EA; Rodig, SJ; Dighe, AS; Kaplan, DH; Riley, JK; Greenlund, AC; Campbell, D; CarverMoore, K; DuBois, RN; Clark, R; Aguet, M; Schreiber, RD			Targeted disruption of the STAT1 gene in mice reveals unexpected physiologic specificity in the JAK-STAT signaling pathway	CELL			English	Article							INTERFERON-GAMMA RECEPTOR; PROTEIN-TYROSINE KINASE; TRANSCRIPTION; TRANSDUCTION; BINDING; ALPHA; IRF-1; IFN; PHOSPHORYLATION; COMPLEMENTATION	The JAK-STAT signaling pathway has been implicated in mediating biologic responses induced by many cytokines. However, cytokines that promote distinct cellular responses often activate identical STAT proteins, thereby raising the question of how specificity is manifest within this signaling pathway. Here we report the generation and characterization of mice deficient in STAT1. STAT1-deficient mice show no overt developmental abnormalities, but display a complete lack of responsiveness to either IFN alpha or IFN gamma and are highly sensitive to infection by microbial pathogens and viruses. In contrast, these mice respond normally to several other cytokines that activate STAT1 in vitro. These observations document that STAT1 plays an obligate and dedicated role in mediating IFN-dependent biologic responses and reveal an unexpected level of physiologic specificity for STAT1 action.	WASHINGTON UNIV,SCH MED,DEPT PATHOL,CTR IMMUNOL,ST LOUIS,MO 63110; UNIV ZURICH,INST MOLEC BIOL 1,CH-8093 ZURICH,SWITZERLAND; VANDERBILT UNIV,MED CTR,DEPT MED,NASHVILLE,TN 37232; VANDERBILT UNIV,MED CTR,DEPT CELL BIOL,NASHVILLE,TN 37232; GENENTECH INC,DEPT MOLEC BIOL,S SAN FRANCISCO,CA 92080	Washington University (WUSTL); University of Zurich; Vanderbilt University; Vanderbilt University; Roche Holding; Genentech			Schreiber, Robert D/A-1276-2013; Kaplan, Daniel H/N-2779-2013; Schreiber, Robert/Q-7550-2019; DuBois, Raymond N./AAX-8869-2020; MERAZ RIOS, MARCO ANTONIO/F-4194-2016; Rodig, Scott/Y-3889-2019; Dighe, Anand/AAP-9640-2020	Schreiber, Robert D/0000-0001-6311-0432; Kaplan, Daniel H/0000-0002-7851-7320; MERAZ RIOS, MARCO ANTONIO/0000-0001-6748-8117; Bach, Erika/0000-0002-5997-4489; White, James Michael/0000-0001-5110-6567; Dighe, Anand/0000-0003-4130-0758; Schreiber, Robert/0000-0003-1590-2341				BHAT GJ, 1994, J BIOL CHEM, V269, P31443; BRONOWSKI AM, 1995, MOL ENDOCRINOL, V9, P171; BUCHMEIER NA, 1985, P NATL ACAD SCI USA, V82, P7404, DOI 10.1073/pnas.82.21.7404; CELADA A, 1984, J EXP MED, V160, P55, DOI 10.1084/jem.160.1.55; DALTON DK, 1993, SCIENCE, V259, P1739, DOI 10.1126/science.8456300; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DIGHE AS, 1995, IMMUNITY, V3, P657, DOI 10.1016/1074-7613(95)90136-1; DUBOIS RN, 1995, CELL GROWTH DIFFER, V6, P523; FARRAR MA, 1991, J BIOL CHEM, V266, P19626; FARRAR MA, 1992, P NATL ACAD SCI USA, V89, P11706, DOI 10.1073/pnas.89.24.11706; FINBLOOM DS, 1995, J IMMUNOL, V155, P1079; FU XY, 1992, P NATL ACAD SCI USA, V89, P7840, DOI 10.1073/pnas.89.16.7840; FU XY, 1993, CELL, V74, P1135, DOI 10.1016/0092-8674(93)90734-8; FUJITA T, 1989, P NATL ACAD SCI USA, V86, P9936, DOI 10.1073/pnas.86.24.9936; GLIMCHER LH, 1992, ANNU REV IMMUNOL, V10, P13, DOI 10.1146/annurev.iy.10.040192.000305; GREENLUND AC, 1994, EMBO J, V13, P1591, DOI 10.1002/j.1460-2075.1994.tb06422.x; GREENLUND AC, 1995, IMMUNITY, V2, P677, DOI 10.1016/1074-7613(95)90012-8; GURNEY AL, 1995, P NATL ACAD SCI USA, V92, P5292, DOI 10.1073/pnas.92.12.5292; HARADA H, 1989, CELL, V58, P729, DOI 10.1016/0092-8674(89)90107-4; HARROCH S, 1994, EMBO J, V13, P1942, DOI 10.1002/j.1460-2075.1994.tb06463.x; HEIM MH, 1995, SCIENCE, V267, P1347, DOI 10.1126/science.7871432; HOU JZ, 1995, IMMUNITY, V2, P321, DOI 10.1016/1074-7613(95)90140-X; HOU JZ, 1994, SCIENCE, V265, P1701, DOI 10.1126/science.8085155; HUANG S, 1993, SCIENCE, V259, P1742, DOI 10.1126/science.8456301; IHLE JN, 1994, TRENDS BIOCHEM SCI, V19, P222, DOI 10.1016/0968-0004(94)90026-4; JACOBSON NG, 1995, J EXP MED, V181, P1755, DOI 10.1084/jem.181.5.1755; KERR IM, 1991, FEBS LETT, V285, P194, DOI 10.1016/0014-5793(91)80802-A; KUHN R, 1993, CELL, V75, P263, DOI 10.1016/0092-8674(93)80068-P; LARNER AC, 1993, SCIENCE, V261, P1730, DOI 10.1126/science.8378773; LEINIKKI PO, 1987, J IMMUNOL, V139, P3360; LEUNG S, 1995, MOL CELL BIOL, V15, P1312; MATSUYAMA T, 1993, CELL, V75, P83, DOI 10.1016/S0092-8674(05)80086-8; MCKENDRY R, 1991, P NATL ACAD SCI USA, V88, P11455, DOI 10.1073/pnas.88.24.11455; MIETTINEN PJ, 1995, NATURE, V376, P337, DOI 10.1038/376337a0; MULLER M, 1993, NATURE, V366, P129, DOI 10.1038/366129a0; MULLER U, 1994, SCIENCE, V264, P1918, DOI 10.1126/science.8009221; MULLER WJ, 1984, MOL CELL BIOL, V4, P2406, DOI 10.1128/MCB.4.11.2406; NATHAN C, 1994, CELL, V78, P915, DOI 10.1016/0092-8674(94)90266-6; REIS LFL, 1994, EMBO J, V13, P4798, DOI 10.1002/j.1460-2075.1994.tb06805.x; Sambrook J, 1989, MOL CLONING LABORATO; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; SCHINDLER C, 1992, P NATL ACAD SCI USA, V89, P7836, DOI 10.1073/pnas.89.16.7836; SCHINDLER U, 1995, J IMMUNOL, V2, P689; STAHL N, 1995, SCIENCE, V267, P1349, DOI 10.1126/science.7871433; STEIMLE V, 1993, CELL, V75, P135, DOI 10.1016/0092-8674(93)90685-J; VELAZQUEZ L, 1992, CELL, V70, P313, DOI 10.1016/0092-8674(92)90105-L; WATLING D, 1993, NATURE, V366, P166, DOI 10.1038/366166a0; WEBERNORDT RM, 1994, J IMMUNOL, V153, P3734; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; YAN RQ, 1995, NUCLEIC ACIDS RES, V23, P459, DOI 10.1093/nar/23.3.459; Yoshida K, 1996, P NATL ACAD SCI USA, V93, P407, DOI 10.1073/pnas.93.1.407	52	1357	1401	1	45	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 9	1996	84	3					431	442		10.1016/S0092-8674(00)81288-X	http://dx.doi.org/10.1016/S0092-8674(00)81288-X			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TV708	8608597	Bronze			2022-12-28	WOS:A1996TV70800012
J	Espinel, CH				Espinel, CH			On the trail of color	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																		1966, WHO PAHO EPIDEMIOL R, V138, P55	1	2	2	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 17	1996	275	3					168	168						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TP282	8604153				2022-12-28	WOS:A1996TP28200001
J	Hu, DJ; Dondero, TJ; Rayfield, MA; George, JR; Schochetman, G; Jaffe, HW; Luo, CC; Kalish, ML; Weniger, BG; Pau, CP; Schable, CA; Curran, JW				Hu, DJ; Dondero, TJ; Rayfield, MA; George, JR; Schochetman, G; Jaffe, HW; Luo, CC; Kalish, ML; Weniger, BG; Pau, CP; Schable, CA; Curran, JW			The emerging genetic diversity of HIV - The importance of global surveillance for diagnostics, research, and prevention	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							HUMAN-IMMUNODEFICIENCY-VIRUS; ENVELOPE PROTEIN; ZIDOVUDINE AZT; INFECTION; TYPE-1; AIDS; TRANSMISSION; SEQUENCE; RISK; RETROVIRUS	The discovery of highly divergent strains of human immunodeficiency virus (HIV) not reliably detected by a number of commonly used diagnostic tests has underscored the need for effective surveillance to track HIV variants and to direct research and prevention activities. Pathogens such as HIV that mutate extensively present significant challenges to effective monitoring of pathogens and to disease control, To date, relatively few systematic large-scale attempts have been made to characterize and sequence HIV isolates. For most of the world, including the United States, information an the distribution of HIV strains among different population groups Is limited. We describe herein the implications resulting from the rapid evolution of HIV and the need for systematic surveillance integrated with laboratory science and applied research. General surveillance guidelines are provided to assist in Identifying population groups for screening, in applying descriptive epidemiology and systematic sampling, and in developing and evaluating efficient laboratory testing algorithms. Timely reporting and dissemination of data is also an important element of surveillance efforts, Ultimately, the success of a global surveillance network depends on collaboration and on coordination of clinical laboratory, and epidemiologic efforts.	CTR DIS CONTROL & PREVENT, NATL CTR INFECT DIS, DIV AIDS STD & TB LAB RES, ATLANTA, GA 30333 USA	Centers for Disease Control & Prevention - USA	Hu, DJ (corresponding author), CTR DIS CONTROL & PREVENT, NATL CTR HIV STD & TB PREVENT, DIV HIV AIDS PREVENT, MAILSTOP E-50, ATLANTA, GA 30333 USA.			Hu, Dale/0000-0002-0519-1032; Weniger, Bruce/0000-0002-5450-5464				ADJORLOLOJOHNSON G, 1994, JAMA-J AM MED ASSOC, V272, P462, DOI 10.1001/jama.272.6.462; ANDREASSON PA, 1993, AIDS, V7, P989, DOI 10.1097/00002030-199307000-00013; ARTENSTEIN AW, 1995, LANCET, V346, P1197, DOI 10.1016/S0140-6736(95)92900-2; ARTENSTEIN AW, 1995, J INFECT DIS, V171, P805, DOI 10.1093/infdis/171.4.805; ASHTON LJ, 1994, LANCET, V344, P718, DOI 10.1016/S0140-6736(94)92210-1; BARRESINOUSSI F, 1983, SCIENCE, V220, P868, DOI 10.1126/science.6189183; BOBKOV A, 1994, AIDS, V8, P1649, DOI 10.1097/00002030-199412000-00002; BOBKOV A, 1994, AIDS, V8, P619, DOI 10.1097/00002030-199405000-00007; BRODINE SK, 1995, LANCET, V346, P1198, DOI 10.1016/S0140-6736(95)92901-0; Centers for Disease Control and Prevention, 1994, ADDRESSING EMERGING; CHAKRABARTI L, 1987, NATURE, V328, P543, DOI 10.1038/328543a0; CHANT K, 1993, LANCET, V342, P1548, DOI 10.1016/S0140-6736(05)80112-6; CHEINGSONGPOPOV R, 1994, AIDS RES HUM RETROV, V10, P1379, DOI 10.1089/aid.1994.10.1379; CHENGMAYER C, 1988, SCIENCE, V240, P80, DOI 10.1126/science.2832945; CLAVEL F, 1986, SCIENCE, V233, P343, DOI 10.1126/science.2425430; CLOYD MW, 1990, VIROLOGY, V174, P103, DOI 10.1016/0042-6822(90)90059-Z; CONNOR RI, 1993, J VIROL, V67, P1772, DOI 10.1128/JVI.67.4.1772-1777.1993; COURPOTIN C, 1994, PEDIATR INFECT DIS J, V13, P502; DECOCK KM, 1993, JAMA-J AM MED ASSOC, V270, P2083, DOI 10.1001/jama.270.17.2083; DECOCK KM, 1990, AIDS, V4, P443, DOI 10.1097/00002030-199005000-00010; DELAPORTE E, 1988, AIDS, V2, P136, DOI 10.1097/00002030-198804000-00013; DELEYS R, 1990, J VIROL, V64, P1207, DOI 10.1128/JVI.64.3.1207-1216.1990; DELWART EL, 1993, SCIENCE, V262, P1257, DOI 10.1126/science.8235655; DEWOLF F, 1994, AIDS RES HUM RETROV, V10, P1387, DOI 10.1089/aid.1994.10.1387; DONDERO TJ, 1994, LANCET, V343, P1376, DOI 10.1016/S0140-6736(94)92517-8; DOOLITTLE RF, 1989, NATURE, V339, P338, DOI 10.1038/339338a0; DUMITRESCU O, 1994, J INFECT DIS, V169, P281, DOI 10.1093/infdis/169.2.281; ERICE A, 1993, NEW ENGL J MED, V328, P1163, DOI 10.1056/NEJM199304223281605; ESSEX M, 1995, 3RD INT C AIDS AS PA; FELSENSTEIN J, 1988, ANNU REV GENET, V22, P521, DOI 10.1146/annurev.ge.22.120188.002513; FENYO EM, 1988, J VIROL, V62, P4414; FITZGIBBON JE, 1993, NEW ENGL J MED, V329, P1835, DOI 10.1056/NEJM199312163292502; GAO F, 1994, AIDS RES HUM RETROV, V10, P625, DOI 10.1089/aid.1994.10.625; GAO F, 1994, J VIROL, V68, P7433, DOI 10.1128/JVI.68.11.7433-7447.1994; GURTLER LG, 1994, J VIROL, V68, P1581; HAHN BH, 1986, SCIENCE, V232, P1548, DOI 10.1126/science.3012778; HENEINE W, 1995, J INFECT DIS, V171, P1210, DOI 10.1093/infdis/171.5.1210; HILLIS DM, 1994, SCIENCE, V264, P671, DOI 10.1126/science.8171318; HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0; HOLLAND J, 1982, SCIENCE, V215, P1577, DOI 10.1126/science.7041255; HOLMES EC, 1995, J INFECT DIS, V171, P45, DOI 10.1093/infdis/171.1.45; HU WS, 1990, SCIENCE, V250, P1227, DOI 10.1126/science.1700865; JAFFE HW, 1994, ANN INTERN MED, V121, P855, DOI 10.7326/0003-4819-121-11-199412010-00005; KALISH ML, 1994, AIDS RES HUM RETROV, V10, P1573, DOI 10.1089/aid.1994.10.1573; KANKI PJ, 1994, LANCET, V343, P943, DOI 10.1016/S0140-6736(94)90065-5; KESTENS L, 1992, AIDS, V6, P803, DOI 10.1097/00002030-199208000-00006; KLIKS SC, 1993, P NATL ACAD SCI USA, V90, P11518, DOI 10.1073/pnas.90.24.11518; KORBER B, 1992, AIDS RES HUM RETROV, V8, P1549, DOI 10.1089/aid.1992.8.1549; KORBER BTM, 1994, J VIROL, V68, P7467, DOI 10.1128/JVI.68.11.7467-7481.1994; KOSTRIKIS LG, 1995, J VIROL, V69, P6122, DOI 10.1128/JVI.69.10.6122-6130.1995; KOYANAGI Y, 1987, SCIENCE, V236, P819, DOI 10.1126/science.3646751; KUIKEN CL, 1993, P NATL ACAD SCI USA, V90, P9061, DOI 10.1073/pnas.90.19.9061; KUNANUSONT C, 1995, LANCET, V345, P1078, DOI 10.1016/S0140-6736(95)90818-8; LARDER BA, 1989, SCIENCE, V243, P1731, DOI 10.1126/science.2467383; LARDER BA, 1989, SCIENCE, V246, P1155, DOI 10.1126/science.2479983; LEARMONT J, 1992, LANCET, V340, P863, DOI 10.1016/0140-6736(92)93281-Q; Lederberg J., 1992, EMERGING INFECTIONS; LEGUENNO BM, 1991, J ACQ IMMUN DEF SYND, V4, P421; LI WH, 1988, MOL BIOL EVOL, V5, P313; LI WH, 1989, MOL BIOL EVOL, V6, P424; LOUSSERTAJAKA I, 1994, LANCET, V343, P1393, DOI 10.1016/S0140-6736(94)92524-0; LOUWAGIE J, 1993, AIDS, V7, P769, DOI 10.1097/00002030-199306000-00003; LOUWAGIE J, 1994, AIDS RES HUM RETROV, V10, P561, DOI 10.1089/aid.1994.10.561; LOUWAGIE J, 1992, AIDS RES HUM RETROV, V8, P1467, DOI 10.1089/aid.1992.8.1467; LOVEDAY C, 1995, LANCET, V345, P820, DOI 10.1016/S0140-6736(95)92963-0; LUKASHOV VV, 1995, AIDS, V9, P435, DOI 10.1097/00002030-199509050-00004; LUO CC, 1995, LANCET, V345, P1051, DOI 10.1016/S0140-6736(95)90792-0; LURIE P, 1994, JAMA-J AM MED ASSOC, V271, P295, DOI 10.1001/jama.271.4.295; MARLINK R, 1994, SCIENCE, V265, P1587, DOI 10.1126/science.7915856; MOHRI H, 1993, P NATL ACAD SCI USA, V90, P25, DOI 10.1073/pnas.90.1.25; Myers G, 1994, HUMAN RETROVIRUSES A; NKENGASONG JN, 1993, AIDS, V7, P1536, DOI 10.1097/00002030-199311000-00026; NZILAMBI N, 1988, NEW ENGL J MED, V318, P276, DOI 10.1056/NEJM198802043180503; OBRIEN TR, 1991, AIDS, V5, P85, DOI 10.1097/00002030-199101000-00012; OSMANOV S, 1994, AIDS RES HUM RETROV, V10, P1327, DOI 10.1089/aid.1994.10.1327; OU CY, 1993, LANCET, V341, P1171, DOI 10.1016/0140-6736(93)91001-3; OU CY, 1988, SCIENCE, V239, P295, DOI 10.1126/science.3336784; OU CY, 1990, AIDS RES HUM RETROV, V6, P1323, DOI 10.1089/aid.1990.6.1323; OU CY, 1992, AIDS RES HUM RETROV, V8, P1471, DOI 10.1089/aid.1992.8.1471; OU CY, 1992, SCIENCE, V256, P1165, DOI 10.1126/science.256.5060.1165; PANTALEO G, 1993, NEW ENGL J MED, V328, P327, DOI 10.1056/NEJM199302043280508; PAU CP, 1994, AIDS RES HUM RETROV, V10, P1369, DOI 10.1089/aid.1994.10.1369; PAU CP, 1993, AIDS, V7, P337, DOI 10.1097/00002030-199303000-00005; PEETERS M, 1989, AIDS, V3, P625, DOI 10.1097/00002030-198910000-00001; PEPIN J, 1991, AIDS, V5, P1165, DOI 10.1097/00002030-199110000-00002; PFUTZNER A, 1992, J ACQ IMMUN DEF SYND, V5, P972; PIATAK M, 1993, SCIENCE, V259, P1749, DOI 10.1126/science.8096089; PIENIAZEK D, 1995, EMERG INFECT DIS, V1, P86, DOI 10.3201/eid0103.950303; POPOVIC M, 1984, SCIENCE, V224, P497, DOI 10.1126/science.6200935; QUINN TC, 1994, P NATL ACAD SCI USA, V91, P2407, DOI 10.1073/pnas.91.7.2407; RICHMAN DD, 1994, J INFECT DIS, V169, P968, DOI 10.1093/infdis/169.5.968; ROBERTSON DL, 1995, NATURE, V374, P124, DOI 10.1038/374124b0; RUBSAMENWAIGMANN H, 1994, AIDS RES HUM RETROV, V10, P1401, DOI 10.1089/aid.1994.10.1401; SABINO EC, 1994, J VIROL, V68, P6340, DOI 10.1128/JVI.68.10.6340-6346.1994; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; SAKAI K, 1988, J VIROL, V62, P4078, DOI 10.1128/JVI.62.11.4078-4085.1988; SCHABLE C, 1994, LANCET, V344, P1333, DOI 10.1016/S0140-6736(94)90695-5; Schochetman G., 1994, AIDS TESTING COMPREH; SCHUITEMAKER H, 1992, J VIROL, V66, P1354, DOI 10.1128/JVI.66.3.1354-1360.1992; Sharp P.M., 1994, AIDS S1, V8, pS27; SHPAER EG, 1993, J MOL EVOL, V37, P57; SIEGRIST CA, 1994, LANCET, V344, P1771, DOI 10.1016/S0140-6736(94)92911-4; SMITH JD, 1994, AIDS RES HUM RETROV, V10, P577, DOI 10.1089/aid.1994.10.577; TSUCHIE H, 1995, INT J STD AIDS, V6, P117, DOI 10.1177/095646249500600211; WEI XP, 1995, NATURE, V373, P117, DOI 10.1038/373117a0; WENIGER BG, 1994, AIDS, V8, pS13; WENIGER BG, 1994, 10TH INT C AIDS YOK; WESTERVELT P, 1992, J VIROL, V66, P2577, DOI 10.1128/JVI.66.4.2577-2582.1992; WHITTLE H, 1994, AIDS, V8, P1617, DOI 10.1097/00002030-199411000-00015; WIKE CM, 1992, AIDS RES HUM RETROV, V8, P1297, DOI 10.1089/aid.1992.8.1297; WILLIAMSON C, 1995, LANCET, V346, P782, DOI 10.1016/S0140-6736(95)91543-5; WOLINSKY SM, 1992, SCIENCE, V255, P1134, DOI 10.1126/science.1546316; ZEKENG L, 1994, AIDS, V8, P1626, DOI 10.1097/00002030-199411000-00020; ZHONG P, 1995, AIDS RES HUM RETROV, V11, P239, DOI 10.1089/aid.1995.11.239; 1993, MMWR-MORBID MORTAL W, V42, P948; 1995, MMWR-MORBID MORTAL W, V44, P603; 1981, MMWR-MORBID MORTAL W, V30, P305; 1993, MMWR-MORBID MORTAL W, V42, P329; 1990, MMWR-MORBID MORTAL W, V39, P489	119	224	227	0	14	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 17	1996	275	3					210	216		10.1001/jama.275.3.210	http://dx.doi.org/10.1001/jama.275.3.210			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TP282	8604174				2022-12-28	WOS:A1996TP28200029
J	Groettrup, M; Soza, A; Eggers, M; Kuehn, L; Dick, TP; Schild, H; Rammensee, HG; Koszinowski, UH; Kloetzel, PM				Groettrup, M; Soza, A; Eggers, M; Kuehn, L; Dick, TP; Schild, H; Rammensee, HG; Koszinowski, UH; Kloetzel, PM			A role for the proteasome regulator PA28 alpha in antigen presentation	NATURE			English	Article							MURINE CYTOMEGALO-VIRUS; PEPTIDES	CYTOTOXIC T cells recognize viral proteins as peptide fragments which are produced in the cytosol and transported on major histocompatibility complex (MHC) class I proteins to the cell surface(1). Viral peptides that meet the stringent binding characteristics of class I proteins are generated by the 20S proteasome(2,3), The interferon (IFN)-gamma-inducible activator of the 20S proteasome, PA28 (refs 4-6), strongly influences the proteasomal cleavage pattern in vitro(7), This led us to investigate whether changes in cellular levels of PA28 affect the efficiency of viral antigen processing, A mouse fibroblast line expressing the murine cytomegalovirus pp89 protein was transfected with either the human or murine gene encoding the PA28 alpha subunit, which is sufficient to activate the peptide-hydrolysing activity of the 20S proteasome in vitro. Here we report that enhanced expression of PA28 alpha at a level similar to that obtained after IFN-gamma induction resulted in a marked enhancement of recognition by pp89-specific cytotoxic T cells; the presentation of influenza nucleoprotein was also significantly improved, These results demonstrate a fundamental in vivo function for PA28 alpha in antigen processing.	HUMBOLDT UNIV BERLIN,FAC MED CHARITE,INST BIOCHEM,D-10115 BERLIN,GERMANY; UNIV HEIDELBERG,DEPT VIROL,D-69120 HEIDELBERG,GERMANY; DIABET RES INST,D-40225 DUSSELDORF,GERMANY; GERMAN CANC RES CTR,D-69009 HEIDELBERG,GERMANY	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Ruprecht Karls University Heidelberg; Helmholtz Association; German Cancer Research Center (DKFZ)				Eggers, Maren/0000-0001-8485-9485; Soza, Andrea/0000-0003-3783-5231				AHN JY, 1995, FEBS LETT, V366, P37, DOI 10.1016/0014-5793(95)00492-R; BOES B, 1994, J EXP MED, V179, P901, DOI 10.1084/jem.179.3.901; CHU-PING M, 1992, Journal of Biological Chemistry, V267, P10515; DELVAL M, 1989, CELL, V58, P305, DOI 10.1016/0092-8674(89)90845-3; DELVAL M, 1991, J VIROL, V65, P3641, DOI 10.1128/JVI.65.7.3641-3646.1991; DUBIEL W, 1992, J BIOL CHEM, V267, P22369; GRAY CW, 1994, J MOL BIOL, V236, P7, DOI 10.1006/jmbi.1994.1113; GROETTRUP M, 1992, EMBO J, V11, P2735, DOI 10.1002/j.1460-2075.1992.tb05339.x; GROETTRUP M, 1995, J BIOL CHEM, V270, P23808, DOI 10.1074/jbc.270.40.23808; HONORE B, 1993, EUR J BIOCHEM, V218, P421, DOI 10.1111/j.1432-1033.1993.tb18392.x; KEIL GM, 1985, J VIROL, V54, P422, DOI 10.1128/JVI.54.2.422-428.1985; KOSZINOWSKI UH, 1986, J VIROL, V58, P59, DOI 10.1128/JVI.58.1.59-66.1986; MOTT JD, 1994, J BIOL CHEM, V269, P31466; RAMMENSEE HG, 1993, ANNU REV IMMUNOL, V11, P213, DOI 10.1146/annurev.iy.11.040193.001241; REALINI C, 1994, FEBS LETT, V348, P109, DOI 10.1016/0014-5793(94)00569-9; REALINI C, 1994, J BIOL CHEM, V269, P20727; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; ROTZSCHKE O, 1991, J EXP MED, V174, P1059, DOI 10.1084/jem.174.5.1059; ROTZSCHKE O, 1990, NATURE, V348, P252, DOI 10.1038/348252a0; SEELIG A, 1993, ENZYME PROTEIN, V47, P330, DOI 10.1159/000468691; YUKAWA M, 1991, BIOCHEM BIOPH RES CO, V178, P256, DOI 10.1016/0006-291X(91)91807-O	21	302	319	1	14	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAY 9	1996	381	6578					166	168		10.1038/381166a0	http://dx.doi.org/10.1038/381166a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UK139	8610016				2022-12-28	WOS:A1996UK13900053
J	Gibbons, GH; Dzau, VJ				Gibbons, GH; Dzau, VJ			Molecular therapies for vascular diseases	SCIENCE			English	Article							CELL; INVIVO	Vascular disease is the most common cause of death in the industrialized world. Although significant progress has been made in treating these disorders, more therapeutic agents must be developed that effectively prevent, arrest, or reverse this disease. Recent insights into the pathogenesis of vascular disease have opened up a new frontier of molecular therapies that target molecules as diverse as adhesion molecules and transcription factors. The biological rationale for these new therapies and their prospects for success are discussed.	STANFORD UNIV,SCH MED,FALK CARDIOVASC RES CTR,STANFORD,CA 94305	Stanford University					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL035610, R37HL035610, P01HL048638, R01HL035252] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-35610, HL-35252, HL-48638] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AIELLO LP, 1995, P NATL ACAD SCI USA, V92, P10457, DOI 10.1073/pnas.92.23.10457; ALEXANDER RW, 1995, HYPERTENSION, V25, P155, DOI 10.1161/01.HYP.25.2.155; ANDRES V, 1995, MOL CELL BIOL, V15, P4272; ASAHARA T, 1995, CIRCULATION, V91, P2793, DOI 10.1161/01.CIR.91.11.2793; ASHKENAZI A, 1991, P NATL ACAD SCI USA, V88, P10535, DOI 10.1073/pnas.88.23.10535; BENNETT MR, 1995, J CLIN INVEST, V95, P2266, DOI 10.1172/JCI117917; BIRO S, 1993, P NATL ACAD SCI USA, V90, P654, DOI 10.1073/pnas.90.2.654; BROOKS PC, 1994, CELL, V79, P1157, DOI 10.1016/0092-8674(94)90007-8; CAYATTE AJ, 1994, ARTERIOSCLER THROMB, V14, P753, DOI 10.1161/01.ATV.14.5.753; CHANG MW, 1995, J CLIN INVEST, V96, P2260, DOI 10.1172/JCI118281; CHANG MW, 1995, SCIENCE, V267, P518, DOI 10.1126/science.7824950; COLLER BS, 1995, CIRCULATION, V92, P2373, DOI 10.1161/01.CIR.92.9.2373; COLLINS T, 1995, FASEB J, V9, P899, DOI 10.1096/fasebj.9.10.7542214; COOKE JP, 1994, ARTERIOSCLER THROMB, V14, P653, DOI 10.1161/01.ATV.14.5.653; Daub H, 1996, NATURE, V379, P557, DOI 10.1038/379557a0; DECATERINA R, 1995, J CLIN INVEST, V96, P60, DOI 10.1172/JCI118074; FAXON DP, 1995, J AM COLL CARDIOL, V25, P362, DOI 10.1016/0735-1097(94)00368-Z; FERGUSON JJ, 1994, CIRCULATION, V90, P4, DOI 10.1161/01.CIR.90.1.4; Firulli AB, 1996, CIRC RES, V78, P196, DOI 10.1161/01.RES.78.2.196; GEARY RL, 1994, HUM GENE THER, V5, P1211, DOI 10.1089/hum.1994.5.10-1211; GENG YJ, 1995, AM J PATHOL, V147, P251; GIBBONS GH, 1994, NEW ENGL J MED, V330, P1431; GREGORY CR, 1995, TRANSPLANTATION, V59, P655, DOI 10.1097/00007890-199503150-00002; GRIENDLING KK, 1994, CIRC RES, V74, P1141, DOI 10.1161/01.RES.74.6.1141; HAN DKM, 1995, AM J PATHOL, V147, P267; HEERY JM, 1995, J CLIN INVEST, V96, P2322, DOI 10.1172/JCI118288; INDOLFI C, 1995, NAT MED, V1, P541, DOI 10.1038/nm0695-541; ISNER JM, 1995, CIRCULATION, V91, P2687, DOI 10.1161/01.CIR.91.11.2687; ISOBE M, 1992, SCIENCE, V255, P1125, DOI 10.1126/science.1347662; Khachigian LM, 1996, SCIENCE, V271, P1427, DOI 10.1126/science.271.5254.1427; KONDO S, 1994, EXP CELL RES, V213, P428, DOI 10.1006/excr.1994.1219; Laird JR, 1996, CIRCULATION, V93, P529, DOI 10.1161/01.CIR.93.3.529; LIAO F, 1994, J CLIN INVEST, V94, P877, DOI 10.1172/JCI117409; LIAW L, 1995, J CLIN INVEST, V95, P713, DOI 10.1172/JCI117718; LINSEMAN DA, 1995, J BIOL CHEM, V270, P12563, DOI 10.1074/jbc.270.21.12563; LOVICH MA, 1995, CIRC RES, V77, P1143, DOI 10.1161/01.RES.77.6.1143; MANN MJ, 1995, P NATL ACAD SCI USA, V92, P4502, DOI 10.1073/pnas.92.10.4502; MARRERO MB, 1995, NATURE, V375, P247, DOI 10.1038/375247a0; MARRERO MB, 1995, J BIOL CHEM, V270, P15734, DOI 10.1074/jbc.270.26.15734; MARUI N, 1993, J CLIN INVEST, V92, P1866, DOI 10.1172/JCI116778; MARX SO, 1995, CIRC RES, V76, P412, DOI 10.1161/01.RES.76.3.412; MATSUNO H, 1994, CIRCULATION, V90, P2203, DOI 10.1161/01.CIR.90.5.2203; MORISHITA R, 1995, P NATL ACAD SCI USA, V92, P5855, DOI 10.1073/pnas.92.13.5855; MORISHITA R, 1993, P NATL ACAD SCI USA, V90, P8474, DOI 10.1073/pnas.90.18.8474; NATHAN A, 1995, P NATL ACAD SCI USA, V92, P8130, DOI 10.1073/pnas.92.18.8130; OHARA Y, 1995, CIRCULATION, V92, P898, DOI 10.1161/01.CIR.92.4.898; OHNO T, 1994, SCIENCE, V265, P781, DOI 10.1126/science.8047883; PENG HB, 1995, J BIOL CHEM, V270, P14214, DOI 10.1074/jbc.270.23.14214; POLLMAN M, 1995, FASEB J, V9, pA351; POLLMAN MJ, 1995, CIRCULATION S1, V92, P101; ROSS R, 1995, ANNU REV PHYSIOL, V57, P791, DOI 10.1146/annurev.ph.57.030195.004043; SCHMIDT AM, 1995, J CLIN INVEST, V96, P1395, DOI 10.1172/JCI118175; SCHWARTZ SM, 1995, CIRC RES, V77, P445, DOI 10.1161/01.RES.77.3.445; SHI Y, 1994, CIRCULATION, V90, P944, DOI 10.1161/01.CIR.90.2.944; SIMONS M, 1992, NATURE, V359, P67, DOI 10.1038/359067a0; SPRINGER TA, 1995, ANNU REV PHYSIOL, V57, P827, DOI 10.1146/annurev.ph.57.030195.004143; STEINBERG D, 1995, ADV EXP MED BIOL, V369, P39; SUNDARESAN M, 1995, SCIENCE, V270, P296, DOI 10.1126/science.270.5234.296; TOPOL EJ, 1994, LANCET, V343, P881, DOI 10.1016/S0140-6736(94)90007-8; Tsai JC, 1996, J BIOL CHEM, V271, P3667; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; VONDERLEYEN HE, 1995, P NATL ACAD SCI USA, V92, P1137, DOI 10.1073/pnas.92.4.1137; WALSH K, 1996, KEYST S KEYST CO 29; WEIR L, 1995, J BIOL CHEM, V270, P5457, DOI 10.1074/jbc.270.10.5457; WEYRICH AS, 1995, J CLIN INVEST, V95, P2297, DOI 10.1172/JCI117921; WEYRICH AS, 1993, J CLIN INVEST, V91, P2620, DOI 10.1172/JCI116501; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324; Zempo N, 1996, ARTERIOSCL THROM VAS, V16, P28, DOI 10.1161/01.ATV.16.1.28; ZOHN IE, 1995, MOL CELL BIOL, V15, P6160	70	162	178	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 3	1996	272	5262					689	693		10.1126/science.272.5262.689	http://dx.doi.org/10.1126/science.272.5262.689			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UJ051	8614829				2022-12-28	WOS:A1996UJ05100037
J	Argy, O				Argy, O			Standards of care	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	7	7	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 1	1996	275	17					1296	1296		10.1001/jama.275.17.1296	http://dx.doi.org/10.1001/jama.275.17.1296			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UG612	8614098				2022-12-28	WOS:A1996UG61200001
J	Harris, JM				Harris, JM			Disease management: New wine in new bottles?	ANNALS OF INTERNAL MEDICINE			English	Article							COST	Cost pressures are driving the reorganization of the health care delivery system in the United States, causing health care delivery organizations to become larger and more diversified. These new health care delivery entities are arriving at the same time as a new approach to clinical care: commercial population-based medicine. This approach is sharing an increasing amount of space with the traditional physician-patient-based approach and offers strategies for managing a population's risk, demand, diseases, and outcomes. Although commercial population-based medicine strategies such as disease management may use many of the same tools as traditional public health approaches, they focus on the relatively short-term health needs of defined populations because of the underlying economic incentives facing payers. Population-based medicine promises better use of resources and a systems approach to health care delivery, but it also presents the pitfalls of subversion by the needs of commercial companies, unanticipated adverse effects, and wide application without adequate preparation.			Harris, JM (corresponding author), MED DIRECT INC, 6400 E TANQUE VERDE RD, SUITE A, TUCSON, AZ 85715 USA.							ANDERS G, 1995, WALL STREET J   0317, pA1; BATES DW, 1995, JAMA-J AM MED ASSOC, V274, P29, DOI 10.1001/jama.274.1.29; BODENHEIMER T, 1995, JAMA-J AM MED ASSOC, V274, P85, DOI 10.1001/jama.274.1.85; DEVEREUX RB, 1994, AM J CARDIOL, V74, P1024, DOI 10.1016/0002-9149(94)90853-2; DRUMMOND N, 1994, BRIT MED J, V308, P559, DOI 10.1136/bmj.308.6928.559; EDDY DM, 1991, JAMA-J AM MED ASSOC, V265, P2399, DOI 10.1001/jama.265.18.2399; EDDY DM, 1991, JAMA-J AM MED ASSOC, V265, P105, DOI 10.1001/jama.265.1.105; EDDY DM, 1993, JAMA-J AM MED ASSOC, V269, P1849, DOI 10.1001/jama.269.14.1849; GABLE CB, 1990, JAMA-J AM MED ASSOC, V264, P2910, DOI 10.1001/jama.264.22.2910; Graham A V, 1992, Fam Med, V24, P439; HARBERT GM, 1994, AM J OBSTET GYNECOL, V171, P329, DOI 10.1016/S0002-9378(94)70031-1; HUNTINGTON J, 1994, NEW ENGL J MED, V331, P1303, DOI 10.1056/NEJM199411103311910; KAHN KL, 1995, JAMA-J AM MED ASSOC, V274, P75, DOI 10.1001/jama.274.1.75; KASTE M, 1995, STROKE, V26, P249, DOI 10.1161/01.STR.26.2.249; LEAPE LL, 1995, JAMA-J AM MED ASSOC, V274, P35, DOI 10.1001/jama.1995.03530010049034; MANDEL EM, 1995, PEDIATRICS, V96, P5; MARWICK C, 1995, JAMA-J AM MED ASSOC, V274, P1416, DOI 10.1001/jama.274.18.1416; MULLOOLY JP, 1994, ANN INTERN MED, V121, P947, DOI 10.7326/0003-4819-121-12-199412150-00008; NICHOL KL, 1994, NEW ENGL J MED, V331, P778, DOI 10.1056/NEJM199409223311206; PAGE L, 1995, AMA NEWS        0304, P4; RANKIN K, 1995, DRUG STORE NEWS  MAR, P17; TANOUYE E, 1995, WALL STREET J   0712, pB6; TENNISON M, 1994, NEW ENGL J MED, V330, P1407, DOI 10.1056/NEJM199405193302002; Terry K, 1995, Med Econ, V72, P79; TERRY K, 1995, MED ECON, V72, P79; TERRY K, 1995, MED ECON, V72, P76; TOUGAARD L, 1992, LANCET, V339, P1517, DOI 10.1016/0140-6736(92)91274-C; VILLAR J, 1992, NEW ENGL J MED, V327, P1266, DOI 10.1056/NEJM199210293271803; ZOOK CJ, 1980, NEW ENGL J MED, V302, P996, DOI 10.1056/NEJM198005013021804	29	64	64	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 1	1996	124	9					838	842		10.7326/0003-4819-124-9-199605010-00009	http://dx.doi.org/10.7326/0003-4819-124-9-199605010-00009			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UG254	8610954				2022-12-28	WOS:A1996UG25400009
J	Hensch, TK; Stryker, MP				Hensch, TK; Stryker, MP			Ocular dominance plasticity under metabotropic glutamate receptor blockade	SCIENCE			English	Article							CATS VISUAL-CORTEX; KITTEN STRIATE CORTEX; LONG-TERM DEPRESSION; MONOCULAR DEPRIVATION; HIPPOCAMPAL-NEURONS; ANTAGONISM; INDUCTION; NEOCORTEX; ARBORS	Occluding vision through one eye during a critical period in early life nearly abolishes responses to that eye in visual cortex. This phenomenon is mimicked by long-term depression of synaptic transmission in vitro, which may require metabotropic glutamate receptors (mGluRs) and is age-dependent. Peaks in mGluR expression and glutamate stimulated phosphoinositide turnover during visual cortical development have been proposed as biochemical bases for the critical period. Pharmacological blockade of mGluRs specifically prevented synapse weakening in mouse visual cortical slices but did not alter kitten ocular dominance plasticity in vivo. Thus, a heightened mGluR response does not account for the critical period in development.	UNIV CALIF SAN FRANCISCO,DEPT PHYSIOL,CTR INTEGRATED NEUROSCI,WM KECK FDN,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco			Hensch, Takao/L-4182-2019	Stryker, Michael/0000-0003-1546-5831	NATIONAL EYE INSTITUTE [R37EY002874, R01EY002874] Funding Source: NIH RePORTER; NEI NIH HHS [EY02874, R01 EY002874] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		AIBA A, 1994, CELL, V79, P365, DOI 10.1016/0092-8674(94)90204-6; AIBA A, 1994, CELL, V79, P377, DOI 10.1016/0092-8674(94)90204-6; ANTONINI A, 1993, J NEUROSCI, V13, P3549; ANTONINI A, 1993, SCIENCE, V260, P1819, DOI 10.1126/science.8511592; ANTONINI A, IN PRESS J COMP NEUR; BASHIR ZI, 1993, EUR J PHARMACOL, V239, P265, DOI 10.1016/0014-2999(93)91009-C; BASHIR ZI, 1993, NATURE, V363, P347, DOI 10.1038/363347a0; BASHIR ZI, 1994, EXP BRAIN RES, V100, P437, DOI 10.1007/BF02738403; BASKYS A, 1992, TRENDS NEUROSCI, V15, P92, DOI 10.1016/0166-2236(92)90018-4; BIRSE EF, 1993, NEUROSCIENCE, V52, P481, DOI 10.1016/0306-4522(93)90400-A; BLAKEMORE C, 1982, J PHYSIOL-LONDON, V327, P489, DOI 10.1113/jphysiol.1982.sp014244; BOLSHAKOV VY, 1994, SCIENCE, V264, P1148, DOI 10.1126/science.7909958; BORTOLOTTO ZA, 1994, NATURE, V368, P740, DOI 10.1038/368740a0; BRABETI, 1995, NEUROPHARMACOLOGY, V34, P895; CAHUSAC PMB, 1994, EUR J NEUROSCI, V6, P1505, DOI 10.1111/j.1460-9568.1994.tb01012.x; CATANIA MV, 1994, NEUROSCIENCE, V61, P481, DOI 10.1016/0306-4522(94)90428-6; CHARPAK S, 1990, NATURE, V347, P765, DOI 10.1038/347765a0; CHINESTRA P, 1993, J NEUROPHYSIOL, V70, P2684, DOI 10.1152/jn.1993.70.6.2684; CONQUET F, 1994, NATURE, V372, P237, DOI 10.1038/372237a0; DRAGER UC, 1978, J NEUROPHYSIOL, V41, P28, DOI 10.1152/jn.1978.41.1.28; DUDEK SM, 1989, SCIENCE, V246, P673, DOI 10.1126/science.2573152; DUDEK SM, 1993, J NEUROSCI, V13, P2910; DUDEK SM, 1994, SOC NEUR ABSTR, V20; EATON SA, 1993, EUR J PHARM-MOLEC PH, V244, P195, DOI 10.1016/0922-4106(93)90028-8; FAGIOLINI M, 1994, VISION RES, V34, P709, DOI 10.1016/0042-6989(94)90210-0; GEREAU RW, 1995, J NEUROPHYSIOL, V74, P122, DOI 10.1152/jn.1995.74.1.122; GORDON JA, IN PRESS J NEUROSCI; HARTELL NA, 1994, NEUROREPORT, V5, P913, DOI 10.1097/00001756-199404000-00015; HARUTA H, 1994, NEUROREPORT, V5, P1829, DOI 10.1097/00001756-199409080-00036; HAYASHI Y, 1994, J NEUROSCI, V14, P3370; HENSCH TK, 1995, SOC NEUR ABSTR, V21; HSIA AY, 1995, NEUROPHARMACOLOGY, V34, P1567, DOI 10.1016/0028-3908(95)00115-M; JANE DE, 1993, NEUROPHARMACOLOGY, V32, P725, DOI 10.1016/0028-3908(93)90088-K; JANE DE, 1994, BRIT J PHARMACOL, V112, P809; JIA WWG, 1995, DEV BRAIN RES, V85, P109, DOI 10.1016/0165-3806(94)00181-X; JOLY C, 1995, J NEUROSCI, V15, P3970; KATO N, 1993, P NATL ACAD SCI USA, V90, P3650, DOI 10.1073/pnas.90.8.3650; KIRKWOOD A, 1994, J NEUROSCI, V14, P3404; KIRKWOOD A, 1995, NATURE, V375, P328, DOI 10.1038/375328a0; KIRKWOOD A, 1993, SCIENCE, V260, P1518, DOI 10.1126/science.8502997; LEVAY S, 1978, J COMP NEUROL, V179, P223, DOI 10.1002/cne.901790113; LINGENHOHL K, 1993, NEUROSCI RES, V18, P229, DOI 10.1016/0168-0102(93)90058-X; MANZONI OJ, 1994, EUR J NEUROSCI, V6, P1050, DOI 10.1111/j.1460-9568.1994.tb00599.x; MANZONI OJ, 1995, NEUROPHARMACOLOGY, V34, P965, DOI 10.1016/0028-3908(95)00060-J; MCCORMICK DA, 1985, J NEUROPHYSIOL, V54, P782, DOI 10.1152/jn.1985.54.4.782; MIOCHE L, 1989, J NEUROPHYSIOL, V62, P185, DOI 10.1152/jn.1989.62.1.185; NAKANISHI S, 1994, ANNU REV BIOPH BIOM, V23, P319, DOI 10.1146/annurev.bb.23.060194.001535; OLSON CR, 1975, J NEUROPHYSIOL, V38, P26, DOI 10.1152/jn.1975.38.1.26; OMARA SM, 1995, NEUROPHARMACOLOGY, V34, P983, DOI 10.1016/0028-3908(95)00062-B; PIN JP, 1995, NEUROPHARMACOLOGY, V34, P1, DOI 10.1016/0028-3908(94)00129-G; REID SNM, 1995, J COMP NEUROL, V355, P470, DOI 10.1002/cne.903550311; REID SNM, 1995, SOC NEUR ABSTR, V21; REITER HO, 1986, EXP BRAIN RES, V65, P182; RICHTER-LEVIN G, 1994, NEUROPHARMACOLOGY, V33, P853, DOI 10.1016/0028-3908(94)90181-3; RIEDEL G, 1995, J NEUROSCI, V15, P87; RIEDEL G, 1994, NEUROSCI LETT, V167, P141, DOI 10.1016/0304-3940(94)91047-2; SAUGSTAD JA, 1995, EUR J PHARM-MOLEC PH, V289, P395, DOI 10.1016/0922-4106(95)90120-5; SELIG DK, 1995, J NEUROPHYSIOL, V74, P1075, DOI 10.1152/jn.1995.74.3.1075; SHATZ CJ, 1978, J PHYSIOL-LONDON, V281, P267, DOI 10.1113/jphysiol.1978.sp012421; SHATZ CJ, 1990, NEURON, V5, P745, DOI 10.1016/0896-6273(90)90333-B; SHIGEMOTO R, 1994, NEURON, V12, P1245, DOI 10.1016/0896-6273(94)90441-3; STRATTON KR, 1990, EUR J PHARMACOL, V186, P357, DOI 10.1016/0014-2999(90)90461-E; THOMSEN C, 1994, EUR J PHARM-MOLEC PH, V267, P77, DOI 10.1016/0922-4106(94)90227-5; WIESEL TN, 1963, J NEUROPHYSIOL, V26, P1003, DOI 10.1152/jn.1963.26.6.1003; YANG XD, 1994, J NEUROPHYSIOL, V71, P1586, DOI 10.1152/jn.1994.71.4.1586; YI PL, 1995, NEUROSCI LETT, V185, P207, DOI 10.1016/0304-3940(95)11264-W	66	50	51	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 26	1996	272	5261					554	557		10.1126/science.272.5261.554	http://dx.doi.org/10.1126/science.272.5261.554			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UG826	8614806				2022-12-28	WOS:A1996UG82600046
J	Gordon, RD				Gordon, RD			Calcium antagonists and gastrointestinal haemorrhage: The balancing act	LANCET			English	Editorial Material											Gordon, RD (corresponding author), UNIV QUEENSLAND,GREENSLOPES HOSP,DEPT MED,HYPERTENS UNIT,BRISBANE,QLD,AUSTRALIA.		Gordon, Richard D/K-2555-2012						0	4	4	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 20	1996	347	9008					1056	1056		10.1016/S0140-6736(96)90269-X	http://dx.doi.org/10.1016/S0140-6736(96)90269-X			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UG042	8602049				2022-12-28	WOS:A1996UG04200002
J	Kleyn, PW; Fan, W; Kovats, SG; Lee, JJ; Pulido, JC; Wu, Y; Berkemeier, LR; Misumi, DJ; Holmgren, L; Charlat, O; Woolf, EA; Tayber, O; Brody, T; Shu, P; Hawkins, F; Kennedy, B; Baldini, L; Ebeling, C; Alperin, GD; Deeds, J; Lakey, ND; Culpepper, J; Chen, H; GlucksmannKuis, MA; Carlson, GA; Duyk, GM; Moore, KJ				Kleyn, PW; Fan, W; Kovats, SG; Lee, JJ; Pulido, JC; Wu, Y; Berkemeier, LR; Misumi, DJ; Holmgren, L; Charlat, O; Woolf, EA; Tayber, O; Brody, T; Shu, P; Hawkins, F; Kennedy, B; Baldini, L; Ebeling, C; Alperin, GD; Deeds, J; Lakey, ND; Culpepper, J; Chen, H; GlucksmannKuis, MA; Carlson, GA; Duyk, GM; Moore, KJ			Identification and characterization of the mouse obesity gene tubby: A member of a novel gene family	CELL			English	Article							NEUROPEPTIDE-Y; FOOD-INTAKE; WEIGHT; MICE	The mutated gene responsible for the tubby obesity phenotype has been identified by positional cloning. A single base change within a splice donor site results in the incorrect retention of a single intron in the mature tub mRNA transcript. The consequence of this mutation is the substitution of the carboxy-terminal 44 amino acids with 24 intron-encoded amino acids. The normal transcript appears to be abundantly expressed in the hypothalamus, a region of the brain involved in body weight regulation. Variation in the relative abundance of alternative splice products is observed between inbred mouse strains and appears to correlate with an intron length polymorphism. This allele of tub is a candidate for a previously reported diet-induced obesity quantitative trait locus on mouse chromosome 7.	MCLAUGHLIN RES INST BIOMED SCI,GREAT FALLS,MT 59405	McLaughlin Research Institute for Biomedical Sciences, Inc.	Kleyn, PW (corresponding author), MILLENNIUM PHARMACEUT INC,640 MEMORIAL DR,CAMBRIDGE,MA 02139, USA.							ALLISON DB, 1994, HEALTH PSYCHOL, V13, P362, DOI 10.1037/0278-6133.13.4.362; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; [Anonymous], 1995, CELL, V81, P289; BAI FL, 1985, BRAIN RES, V331, P172, DOI 10.1016/0006-8993(85)90730-9; BOEHM T, 1991, P NATL ACAD SCI USA, V88, P4367, DOI 10.1073/pnas.88.10.4367; BRAY GA, 1984, INT J OBES S8, V1, P119; BUCKLER AJ, 1991, P NATL ACAD SCI USA, V88, P4005, DOI 10.1073/pnas.88.9.4005; CAMPFIELD LA, 1995, SCIENCE, V269, P546, DOI 10.1126/science.7624778; Chen H, 1996, CELL, V84, P491, DOI 10.1016/S0092-8674(00)81294-5; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLAVERIE JM, 1994, GENOMICS, V23, P575, DOI 10.1006/geno.1994.1545; COLEMAN DL, 1973, DIABETOLOGIA, V9, P294, DOI 10.1007/BF01221857; COLEMAN DL, 1990, J HERED, V81, P424, DOI 10.1093/oxfordjournals.jhered.a111019; Considine RV, 1996, NEW ENGL J MED, V334, P292, DOI 10.1056/NEJM199602013340503; Dietrich WF, 1996, NATURE, V380, P149, DOI 10.1038/380149a0; FRIEDMAN JM, 1991, MAMM GENOME, V1, P130, DOI 10.1007/BF00351059; GOLD RM, 1977, PHYSIOL BEHAV, V18, P1111, DOI 10.1016/0031-9384(77)90019-1; GRUNDY SM, 1990, DM-DIS MON, V36, P641; HARRIS RBS, 1990, FASEB J, V4, P3310, DOI 10.1096/fasebj.4.15.2253845; HEWITT JK, 1991, ACTA GENET MED GEMEL, V40, P133, DOI 10.1017/S0001566000002567; JONES JM, 1992, GENOMICS, V14, P197, DOI 10.1016/S0888-7543(05)80308-8; KLEYN PW, 1993, P NATL ACAD SCI USA, V90, P6801, DOI 10.1073/pnas.90.14.6801; KNOLL JHM, 1993, AM J MED GENET, V46, P2, DOI 10.1002/ajmg.1320460103; KWITEKBLACK AE, 1993, NAT GENET, V5, P392, DOI 10.1038/ng1293-392; LEVINE AS, 1984, PEPTIDES, V5, P1025, DOI 10.1016/0196-9781(84)90165-7; LICHY JH, 1992, CELL GROWTH DIFFER, V3, P541; MAYER J, 1955, AM J PHYSIOL, V182, P75, DOI 10.1152/ajplegacy.1955.182.1.75; MILLER MW, 1993, GENE DEV, V7, P454, DOI 10.1101/gad.7.3.454; MORLEY JE, 1987, ENDOCR REV, V8, P256, DOI 10.1210/edrv-8-3-256; NAGGERT JK, 1995, NAT GENET, V10, P135, DOI 10.1038/ng0695-135; NISHINA PM, 1994, METABOLISM, V43, P554, DOI 10.1016/0026-0495(94)90195-3; NISHINA PM, 1994, METABOLISM, V43, P549, DOI 10.1016/0026-0495(94)90194-5; PRICE RA, 1987, AM J PSYCHIAT, V144, P1003; PRICE RA, 1990, INT J OBESITY, V14, P185; RILEY J, 1990, NUCLEIC ACIDS RES, V18, P2887, DOI 10.1093/nar/18.10.2887; SELDIN MF, 1994, J CLIN INVEST, V94, P269, DOI 10.1172/JCI117317; SHORPOSNER G, 1985, PHYSIOL BEHAV, V35, P883, DOI 10.1016/0031-9384(85)90255-0; STANLEY BG, 1985, LIFE SCI, V33, P2635; Tartaglia LA, 1995, CELL, V83, P1263, DOI 10.1016/0092-8674(95)90151-5; VAMBUTAS V, 1994, BBA-GENE STRUCT EXPR, V1217, P203, DOI 10.1016/0167-4781(94)90036-1; WARDEN CH, 1995, J CLIN INVEST, V95, P1545, DOI 10.1172/JCI117827; XU Y, 1994, ISMB, V2, P376; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0; 1994, HUM MOL GENET, V3, P621	44	274	293	1	9	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 19	1996	85	2					281	290		10.1016/S0092-8674(00)81104-6	http://dx.doi.org/10.1016/S0092-8674(00)81104-6			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UG255	8612280	Bronze			2022-12-28	WOS:A1996UG25500016
J	Lewis, MJ; Pelham, HRB				Lewis, MJ; Pelham, HRB			SNARE-mediated retrograde traffic from the Golgi complex to the endoplasmic reticulum	CELL			English	Article							INTEGRAL MEMBRANE-PROTEIN; LUMINAL ER PROTEINS; SECRETORY PATHWAY; SACCHAROMYCES-CEREVISIAE; VESICULAR TRANSPORT; SHUTTLE VECTORS; YEAST GENES; ENCODES; FUSION; RETRIEVAL	Operation of the secretory pathway in eukaryotic cells requires the selective docking and fusion of transport vesicles with the appropriate target organelle. This is mediated in part by integral membrane proteins termed v-SNAREs (on vesicles) and t-SNAREs (on the target membranes). We describe a novel yeast t-SNARE that resides on the endoplasmic reticulum and mediates retrograde traffic from the Golgi complex. Mutation of this protein prevents both the HDEL receptor and a membrane protein bearing a dibasic retrieval signal from recycling to the endoplasmic reticulum. Forward traffic is also blocked, but only indirectly. Comparison with other yeast mutants indicates that Sec21p (gamma-COP) and Sec20p (an endoplasmic reticulum membrane protein) are also involved primarily, if not exclusively, in retrograde transport.			Lewis, MJ (corresponding author), MRC, MOLEC BIOL LAB, HILLS RD, CAMBRIDGE CB2 2QH, ENGLAND.							ACHARYA U, 1995, CELL, V82, P895, DOI 10.1016/0092-8674(95)90269-4; ARIDOR M, 1995, J CELL BIOL, V131, P875, DOI 10.1083/jcb.131.4.875; BANFIELD DK, 1995, NATURE, V375, P806, DOI 10.1038/375806a0; BANFIELD DK, 1994, J CELL BIOL, V127, P357, DOI 10.1083/jcb.127.2.357; BARLOWE C, 1994, CELL, V77, P895, DOI 10.1016/0092-8674(94)90138-4; BECHERER KA, 1994, GUIDEBOOK SECRETORY, P253; Bednarek SY, 1995, CELL, V83, P1183, DOI 10.1016/0092-8674(95)90144-2; BENNETT MK, 1993, CELL, V74, P863, DOI 10.1016/0092-8674(93)90466-4; BENNETT MK, 1995, CURR OPIN CELL BIOL, V7, P581, DOI 10.1016/0955-0674(95)80016-6; COSSON P, 1994, SCIENCE, V263, P1629, DOI 10.1126/science.8128252; DEAN N, 1990, J CELL BIOL, V111, P369, DOI 10.1083/jcb.111.2.369; FERRONOVICK S, 1994, NATURE, V370, P191, DOI 10.1038/370191a0; GAYNOR EC, 1994, J CELL BIOL, V127, P653, DOI 10.1083/jcb.127.3.653; GRAHAM TR, 1991, J CELL BIOL, V114, P207, DOI 10.1083/jcb.114.2.207; Guthrie C, 1991, GUIDE YEAST GENETICS; HARDWICK KG, 1992, J CELL BIOL, V119, P513, DOI 10.1083/jcb.119.3.513; HILL J, 1991, NUCLEIC ACIDS RES, V19, P529; HORAZDOVSKY BF, 1993, J BIOL CHEM, V268, P4953; HOSOBUCHI M, 1992, NATURE, V360, P603, DOI 10.1038/360603a0; IKONEN E, 1995, CELL, V81, P571, DOI 10.1016/0092-8674(95)90078-0; JACKSON MR, 1993, J CELL BIOL, V121, P317, DOI 10.1083/jcb.121.2.317; JOHNSON LM, 1987, CELL, V48, P875, DOI 10.1016/0092-8674(87)90084-5; KAISER CA, 1990, CELL, V61, P723, DOI 10.1016/0092-8674(90)90483-U; LATTERICH M, 1995, CELL, V82, P885, DOI 10.1016/0092-8674(95)90268-6; LETOURNEUR F, 1994, CELL, V79, P1199, DOI 10.1016/0092-8674(94)90011-6; LEWIS MJ, 1992, CELL, V68, P353, DOI 10.1016/0092-8674(92)90476-S; LIAN JP, 1993, CELL, V73, P735, DOI 10.1016/0092-8674(93)90253-M; LIAN JP, 1994, NATURE, V372, P698, DOI 10.1038/372698a0; Lippincott-Schwartz Jennifer, 1993, Trends in Cell Biology, V3, P81, DOI 10.1016/0962-8924(93)90078-F; MUHLRAD D, 1992, YEAST, V8, P79, DOI 10.1002/yea.320080202; NASMYTH K, 1990, CELL, V62, P631, DOI 10.1016/0092-8674(90)90110-Z; NEWMAN AP, 1990, MOL CELL BIOL, V10, P3405, DOI 10.1128/MCB.10.7.3405; NOVICK P, 1981, CELL, V25, P461, DOI 10.1016/0092-8674(81)90064-7; PELHAM HRB, 1994, CELL, V79, P1125, DOI 10.1016/0092-8674(94)90002-7; PELHAM HRB, 1988, EMBO J, V7, P913, DOI 10.1002/j.1460-2075.1988.tb02896.x; PELHAM HRB, 1993, CELL, V73, P425, DOI 10.1016/0092-8674(93)90128-D; RABOUILLE C, 1995, CELL, V82, P905, DOI 10.1016/0092-8674(95)90270-8; ROTHBLATT J, 1989, METHOD CELL BIOL, V32, P3; ROTHMAN JE, 1994, CURR BIOL, V4, P220, DOI 10.1016/S0960-9822(00)00051-8; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; SCHIMMOLLER F, 1995, EMBO J, V14, P1329, DOI 10.1002/j.1460-2075.1995.tb07119.x; SCHRODER S, 1995, J CELL BIOL, V131, P895, DOI 10.1083/jcb.131.4.895; SEMENZA JC, 1990, CELL, V61, P1349, DOI 10.1016/0092-8674(90)90698-E; SIKORSKI RS, 1989, GENETICS, V122, P19; SOGAARD M, 1994, CELL, V78, P937, DOI 10.1016/0092-8674(94)90270-4; SOLLNER T, 1993, CELL, V75, P409, DOI 10.1016/0092-8674(93)90376-2; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; STAMNES MA, 1995, P NATL ACAD SCI USA, V92, P8011, DOI 10.1073/pnas.92.17.8011; SWEET DJ, 1993, EMBO J, V12, P2831, DOI 10.1002/j.1460-2075.1993.tb05944.x; SWEET DJ, 1992, EMBO J, V11, P423, DOI 10.1002/j.1460-2075.1992.tb05071.x; TOWNSLEY FM, 1994, EUR J CELL BIOL, V64, P211; WARD AC, 1990, NUCLEIC ACIDS RES, V18, P5319, DOI 10.1093/nar/18.17.5319	52	178	179	0	7	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 19	1996	85	2					205	215		10.1016/S0092-8674(00)81097-1	http://dx.doi.org/10.1016/S0092-8674(00)81097-1			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UG255	8612273	Bronze			2022-12-28	WOS:A1996UG25500009
J	Logothetis, NK; Leopold, DA; Sheinberg, DL				Logothetis, NK; Leopold, DA; Sheinberg, DL			What is rivalling during binocular rivalry?	NATURE			English	Article							SPATIAL-FREQUENCY; SUPPRESSION; PERCEPTION; DURATION; STIMULI	When different images are presented to the two eyes, they compete for perceptual dominance, such that one image is visible while the other is suppressed. This binocular rivalry is thought to reflect competition between monocular neurons within the primary visual cortex(1). However, neurons whose activity correlates with perception during rivalry are found mainly in higher cortical areas, and respond to input from both eyes(2,3). Thus rivalry may involve competition between alternative perceptual interpretations at a higher level of analysis. To investigate this, we tested the effect of rapidly alternating the rival stimuli between the two eyes. Under these conditions, the perceptual alternations exhibit the same temporal dynamics as with static patterns, and a single phase of perceptual dominance can span multiple alternations of the stimuli. Thus neural representations of the two stimuli compete for visual awareness independently of the eye through which they reach the higher visual areas. This finding places binocular rivalry in the general category of multistable phenomena, such as ambiguous figures, and provides a new way to study the neural cause and resolution of perceptual ambiguities.			Logothetis, NK (corresponding author), BAYLOR COLL MED,DIV NEUROSCI,1 BAYLOR PLAZA,HOUSTON,TX 77030, USA.		Logothetis, Nikos/U-9282-2019	Leopold, David/0000-0002-1345-6360				BLAKE R, 1980, PERCEPTION, V9, P223, DOI 10.1068/p090223; BLAKE R, 1989, PSYCHOL REV, V96, P145, DOI 10.1037/0033-295X.96.1.145; BLAKE R, 1979, J EXP PSYCHOL HUMAN, V5, P315, DOI 10.1037/0096-1523.5.2.315; BLAKE R, 1974, VISION RES, V14, P687, DOI 10.1016/0042-6989(74)90065-0; BORSELLINO A, 1972, KYBERNETIK, V10, P139, DOI 10.1007/BF00290512; CAMPBELL FW, 1972, J PHYSIOL-LONDON, V225, pP19; CRAIN K, 1961, J GEN PSYCHOL, V64, P259, DOI 10.1080/00221309.1961.9920444; FOX R, 1972, J EXP PSYCHOL, V93, P283, DOI 10.1037/h0032455; FOX R, 1969, PERCEPT PSYCHOPHYS, V5, P215, DOI 10.3758/BF03210542; FOX R, 1967, PERCEPT PSYCHOPHYS, V2, P432, DOI 10.3758/BF03208783; KULIKOWSKI JJ, 1992, OPHTHAL PHYSL OPT, V12, P168, DOI 10.1111/j.1475-1313.1992.tb00283.x; LATHROP RG, 1966, J EXP PSYCHOL, V72, P120, DOI 10.1037/h0023314; Leopold DA, 1996, NATURE, V379, P549, DOI 10.1038/379549a0; LEVELT WJM, 1966, BRIT J PSYCHOL, V57, P225, DOI 10.1111/j.2044-8295.1966.tb01023.x; Levelt WJM, 1965, BINOCULAR RIVALRY; LOGOTHETIS NK, 1989, SCIENCE, V245, P761, DOI 10.1126/science.2772635; POGGIO GF, 1977, J NEUROPHYSIOL, V40, P1392, DOI 10.1152/jn.1977.40.6.1392; TRIESMAN A, 1962, Q J EXP PSYCHOL, V14, P23; WALES R, 1970, PERCEPT PSYCHOPHYS, V8, P90, DOI 10.3758/BF03210180; WALKER P, 1975, PERCEPT PSYCHOPHYS, V18, P467, DOI 10.3758/BF03204122; WHITTLE P, 1968, PERCEPT PSYCHOPHYS, V4, P183, DOI 10.3758/BF03210465; WOLFE JM, 1983, PERCEPTION, V12, P447, DOI 10.1068/p120447	22	421	427	0	46	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	APR 18	1996	380	6575					621	624		10.1038/380621a0	http://dx.doi.org/10.1038/380621a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	UF741	8602261				2022-12-28	WOS:A1996UF74100044
J	Majeed, AW; Troy, G; Nicholl, JP; Smythe, A; Reed, MWR; Stoddard, CJ; Peacock, J; Johnson, AG				Majeed, AW; Troy, G; Nicholl, JP; Smythe, A; Reed, MWR; Stoddard, CJ; Peacock, J; Johnson, AG			Randomised, prospective, single-blind comparison of laparoscopic versus small-incision cholecystectomy	LANCET			English	Article							CONTROLLED TRIAL; MINI	Background We report a prospective randomised comparison between laparoscopic and small-incision cholecystectomy in 200 patients which was designed to eliminate bias for or against either technique. Methods Patients were randomised in the operating theatre and anaesthetic technique and pain-control methods were standardised. Four experienced surgeons did both types of procedure. Identical wound dressings were applied in both groups so that carers could be kept blind to the type of operation. Findings There was no significant difference between the groups for age, sex, body mass index, and American Society of Anaesthesiologists grade. Laparoscopic cholecystectomy took significantly longer than small-incision cholecystectomy (median 65 [range 27-140] min vs 40 [18-142] min, p<0.001). The operating time included operative cholangiography which was attempted in all patients. We found no significant difference between the groups for hospital stay (postoperative nights in hospital, median 3.0 [1-17] nights for laparoscopic vs 3.0 [1-14] nights for small-incision, p=0.74), time back to work for employed persons (median 5.0 weeks vs 4.0 weeks; p=0.39), and time to full activity (median 3.0 weeks vs 30 weeks; p=0.15). Interpretation Laparoscopic cholecystectomy takes longer to do than small-incision cholecystectomy and does not have any significant advantages in terms of hospital stay or postoperative recovery.	ROYAL HALLAMSHIRE HOSP, SHEFFIELD CTR HLTH & RELATED RES, SHEFFIELD S10 2JF, S YORKSHIRE, ENGLAND	University of Sheffield	Majeed, AW (corresponding author), ROYAL HALLAMSHIRE HOSP, DEPT SURG & ANAESTHET SCI, K-FLOOR, SHEFFIELD S10 2JF, S YORKSHIRE, ENGLAND.		Reed, Malcolm Walter/AAG-9219-2020; Nicholl, Jon/B-8257-2008	Reed, Malcolm Walter/0000-0001-7442-2132; 				ALTMAN LK, 1992, NY TIMES        0614, P4; BARKUN JS, 1992, LANCET, V340, P1116, DOI 10.1016/0140-6736(92)93148-G; CAMERON JL, 1991, ANN SURG, V213, P1; Chan A C, 1994, J R Coll Surg Edinb, V39, P26; DUBOIS F, 1982, NOUV PRESSE MED, V11, P1139; EMBERTON M, 1992, BRIT MED J, V304, P777, DOI 10.1136/bmj.304.6829.777-a; FLOWERS JL, 1992, ANN SURG, V215, P209, DOI 10.1097/00000658-199203000-00004; FULLARTON GM, 1994, GUT, V35, P1121, DOI 10.1136/gut.35.8.1121; GADACZ TR, 1993, AM J SURG, V165, P450, DOI 10.1016/S0002-9610(05)80939-0; Good P., 1993, PERMUTATION TESTS; GRACE PA, 1991, BRIT J SURG, V78, P160, DOI 10.1002/bjs.1800780209; GRAVES HA, 1991, ANN SURG, V213, P655, DOI 10.1097/00000658-199106000-00017; HUNTER JG, 1992, AM J SURG, V163, P53, DOI 10.1016/0002-9610(92)90252-M; LEDET WP, 1990, ARCH SURG-CHICAGO, V125, P1434; MAJEED AW, 1995, BRIT MED J, V311, P296, DOI 10.1136/bmj.311.7000.296; MAJEED AW, 1992, IR J MED SCI S11, V161, P23; MCGINN FP, 1995, BRIT J SURG, V82, P1374, DOI 10.1002/bjs.1800821027; MCMAHON AJ, 1994, LANCET, V343, P135, DOI 10.1016/S0140-6736(94)90932-6; MERRILL JR, 1988, AM SURGEON, V54, P256; MESSAHEL FM, 1995, ANAESTHESIA, V50, P901, DOI 10.1111/j.1365-2044.1995.tb05861.x; MEYERS WC, 1995, AM J SURG, V170, P55; MEYERS WC, 1991, NEW ENGL J MED, V324, P1073; MOSS G, 1986, ARCH SURG-CHICAGO, V121, P1159; NATHANSON LK, 1991, BRIT J SURG, V78, P155, DOI 10.1002/bjs.1800780208; NEUGEBAUER E, 1991, BRIT J SURG, V78, P150, DOI 10.1002/bjs.1800780207; ODWYER PJ, 1990, BRIT J SURG, V77, P1189, DOI 10.1002/bjs.1800771034; OLSEN DO, 1993, AM J SURG, V165, P440, DOI 10.1016/S0002-9610(05)80937-7; Pocock SJ., 2013, CLIN TRIALS PRACTICA; SCHIRMER BD, 1991, ANN SURG, V213, P665, DOI 10.1097/00000658-199106000-00018; SMITH R, 1991, BRIT MED J, V302, P593; STEELE RJC, 1995, BRIT J SURG, V82, P968, DOI 10.1002/bjs.1800820736; STEPHENSON BM, 1993, ANN ROY COLL SURG, V75, P249; TATE JJT, 1993, LANCET, V341, P1214, DOI 10.1016/0140-6736(93)91042-K; TYAGI NS, 1994, ANN SURG, V220, P617, DOI 10.1097/00000658-199411000-00004; VITALE GC, 1991, AM J SURG, V161, P396, DOI 10.1016/0002-9610(91)90606-E; WILLIAMS LF, 1993, AM J SURG, V165, P459, DOI 10.1016/S0002-9610(05)80941-9	36	329	332	0	6	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	APR 13	1996	347	9007					989	994		10.1016/S0140-6736(96)90143-9	http://dx.doi.org/10.1016/S0140-6736(96)90143-9			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UF380	8606612				2022-12-28	WOS:A1996UF38000008
J	Kull, FJ; Sablin, EP; Lau, R; Fletterick, RJ; Vale, RD				Kull, FJ; Sablin, EP; Lau, R; Fletterick, RJ; Vale, RD			Crystal structure of the kinesin motor domain reveals a structural similarity to myosin	NATURE			English	Article							ACTIVE-SITE; MICROTUBULES; MOLECULES; MOVEMENT; RELEASE; COMPLEX	KINESIN is the founding member of a superfamily of microtubule-based motor proteins that perform force-generating tasks such as organelle transport and chromosome segregation(1,2). It has two identical similar to 960-amino-acid chains containing an amino-terminal globular motor domain, a central alpha-helical region that enables dimer formation through a coiled coil, and a carboxy-terminal tail domain that binds light chains and possibly an organelle receptor(1). The kinesin motor domain of similar to 340 amino acids, which can produce movement in vitro(3), is much smaller than that of myosin (similar to 850 amino acids) and dynein (1,000 amino acids), and is the smallest known molecular motor. Here, we report the crystal structure of the human kinesin motor domain with bound ADP determined to 1.8-Angstrom resolution by X-ray crystallography. The motor consists primarily of a single alpha/beta arrowhead-shaped domain with dimensions of 70x45x45 Angstrom. Unexpectedly, it has a striking structural similarity to the core of the catalytic domain of the actin-based motor myosin. Although kinesin and myosin have virtually no amino-acid sequence identity, and exhibit distinct enzymatic(4-6) and motile(7-10) properties, our results suggest that these two classes of mechanochemical enzymes evolved from a common ancestor and share a similar force-generating strategy.	UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM BIOPHYS,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT PHARMACOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,HOWARD HUGHES MED INST,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco; Howard Hughes Medical Institute; University of California System; University of California San Francisco					Howard Hughes Medical Institute Funding Source: Medline; NIAMS NIH HHS [P01 AR042895-040005, P01 AR042895] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P01AR042895] Funding Source: NIH RePORTER	Howard Hughes Medical Institute(Howard Hughes Medical Institute); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		[Anonymous], 1994, ACTA CRYSTALLOGR D, V50, P760; BAGSHAW CR, 1974, BIOCHEM J, V141, P331, DOI 10.1042/bj1410331; BERLINER E, 1995, NATURE, V373, P718, DOI 10.1038/373718a0; BLOCK SM, 1990, NATURE, V348, P348, DOI 10.1038/348348a0; BLOOM G, 1994, MOTOR PROTEINS, V1; Brunger A. T., 1992, XPLOR VERSION 3 1 SY; COPPIN CM, IN PRESS P NATL ACAD; FISHER AJ, 1995, BIOCHEMISTRY-US, V34, P8960, DOI 10.1021/bi00028a004; FUJIWARA S, 1995, BIOPHYS J, V69, P1563, DOI 10.1016/S0006-3495(95)80028-7; GILBERT SP, 1995, NATURE, V373, P671, DOI 10.1038/373671a0; GOLDSTEIN LSB, 1993, ANNU REV GENET, V27, P319; GRAMMAR JC, 1993, BIOCHEMISTRY-US, V32, P5752; HACKNEY DD, 1988, P NATL ACAD SCI USA, V85, P6314, DOI 10.1073/pnas.85.17.6314; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; HOWARD J, 1989, NATURE, V342, P154, DOI 10.1038/342154a0; JONTES JD, 1995, NATURE, V378, P751, DOI 10.1038/378751a0; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; MA YZ, 1995, BIOCHEMISTRY-US, V34, P13233, DOI 10.1021/bi00040a039; McRee D.E., 1999, PRACTICAL PROTEIN CR, V2nd ed., P91; NABER N, 1995, PROTEIN SCI, V4, P1824, DOI 10.1002/pro.5560040917; NAVONE F, 1992, J CELL BIOL, V117, P1263, DOI 10.1083/jcb.117.6.1263; PESKIN CS, 1995, BIOPHYS J, V68, pS202; RAYMENT I, 1993, SCIENCE, V261, P58, DOI 10.1126/science.8316858; Sablin EP, 1996, NATURE, V380, P555, DOI 10.1038/380555a0; SPUDICH JA, 1994, NATURE, V372, P515, DOI 10.1038/372515a0; STORY RM, 1992, NATURE, V355, P374, DOI 10.1038/355374a0; SVOBODA K, 1993, NATURE, V365, P721, DOI 10.1038/365721a0; TAYLOR EW, 1992, HEART CARDIOVASCULAR, P1281; Vale RD, 1996, NATURE, V380, P451, DOI 10.1038/380451a0; WELLS JA, 1979, P NATL ACAD SCI USA, V76, P4966, DOI 10.1073/pnas.76.10.4966; WHITTAKER M, 1995, NATURE, V378, P748, DOI 10.1038/378748a0; YANG JT, 1990, SCIENCE, V249, P42, DOI 10.1126/science.2142332; YOUNT RG, 1992, PHILOS T ROY SOC B, V336, P55, DOI 10.1098/rstb.1992.0044	34	564	577	1	60	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	APR 11	1996	380	6574					550	555		10.1038/380550a0	http://dx.doi.org/10.1038/380550a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UE663	8606779	Green Accepted			2022-12-28	WOS:A1996UE66300057
J	DeLeo, GA; Dobson, AP				DeLeo, GA; Dobson, AP			Allometry and simple epidemic models for microparasites	NATURE			English	Article							POPULATION-DYNAMICS; TRANSMISSION; DENSITY	SIMPLE mathematical models for microparasites offer a useful way to examine the population dynamics of different viral and bacterial pathogens, One constraint in applying these models in free-living host populations is the paucity of data with which to estimate transmission rates. Here we recast a standard epidemiological model by setting the birth and death rates of the host population and its density as simple allometric functions of host body weight. We then use standard threshold theorems for the model in order to estimate the minimum rate of transmission for the parasite to establish itself in a mammalian host population, Transmission rates that produce different comparable values of the parasites' basic reproductive number, R(o), are themselves allometric functions of host body size. We have extended the model to show that hosts having different body sizes suffer epidemic outbreaks whose frequency scales,vith body size. The expected epidemic periods for pathogens in different mammalian populations correspond to cycles observed in free-living populations.			DeLeo, GA (corresponding author), PRINCETON UNIV, PRINCETON, NJ 08544 USA.		De Leo, Giulio/AAC-5098-2019	De Leo, Giulio/0000-0002-4186-3369; Dobson, Andy/0000-0002-9678-1694				ANDERSON R M, 1991; ANDERSON RM, 1979, NATURE, V280, P361, DOI 10.1038/280361a0; ANDERSON RM, 1985, PHILOS T R SOC B, V310, P327, DOI 10.1098/rstb.1985.0123; ANDERSON RM, 1981, PHILOS T R SOC B, V291, P451, DOI 10.1098/rstb.1981.0005; ANTONOVICS J, 1995, AM NAT, V145, P661, DOI 10.1086/285761; Calder WA., 1984, SIZE FUNCTION LIFE H; Chamov E. L., 1993, LIFE HIST INVARIANTS; FOWLER CW, 1981, ECOLOGY, V62, P602, DOI 10.2307/1937727; GRENFELL BT, 1995, INFECT DIS; Kermack WO, 1927, P R SOC LOND A-CONTA, V115, P700, DOI 10.1098/rspa.1927.0118; MOLLISON D, 1984, NATURE, V310, P224, DOI 10.1038/310224a0; PETERSON RO, 1984, SCIENCE, V224, P1350, DOI 10.1126/science.224.4655.1350; Portner HO, 2008, SCIENCE, V322, P690, DOI 10.1126/science.1163156; SILVA M, 1995, AM NAT, V145, P704, DOI 10.1086/285764; THRALL PH, 1995, AM NAT, V145, P43, DOI 10.1086/285727	15	68	69	1	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 22	1996	379	6567					720	722		10.1038/379720a0	http://dx.doi.org/10.1038/379720a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TW567	8602216				2022-12-28	WOS:A1996TW56700050
J	Phull, PS; Halliday, D; Price, AB; Jacyna, MR				Phull, PS; Halliday, D; Price, AB; Jacyna, MR			Absence of dyspeptic symptoms as a test for Helicobacter pylori eradication	BRITISH MEDICAL JOURNAL			English	Article											Phull, PS (corresponding author), NORTHWICK PK HOSP & CLIN RES CTR,HARROW HA1 3UJ,MIDDX,ENGLAND.							ATHERTON JC, 1994, GUT, V35, P723, DOI 10.1136/gut.35.6.723; LOGAN RPH, 1991, EUR J GASTROEN HEPAT, V3, P915; PHULL PS, 1995, POSTGRAD MED J, V71, P413, DOI 10.1136/pgmj.71.837.413; RAUWS EAJ, 1990, LANCET, V335, P1233, DOI 10.1016/0140-6736(90)91301-P; SVEDLUND J, 1988, DIGEST DIS SCI, V33, P129, DOI 10.1007/BF01535722	5	39	39	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 10	1996	312	7027					349	350						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TV698	8611832	Green Published			2022-12-28	WOS:A1996TV69800024
J	Pinner, RW; Teutsch, SM; Simonsen, L; Klug, LA; Graber, JM; Clarke, MJ; Berkelman, RL				Pinner, RW; Teutsch, SM; Simonsen, L; Klug, LA; Graber, JM; Clarke, MJ; Berkelman, RL			Trends in infectious diseases mortality in the United States	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							EPIDEMIOLOGY	Objective.-To evaluate recent trends in infectious diseases mortality in the United States. Design.-Descriptive study of infectious disease mortality, classifying International Classification of Diseases, Ninth Revision codes as infectious diseases, consequence of infectious diseases, or not infectious diseases. Multiple cause-of-death tapes from the National Center for Health Statistics for the years 1980 through 1992 were used, with a focus on underlying cause-of-death data and on codes that exclusively represent infectious diseases. Setting.-United States. Subjects.-All persons who died between 1980 and 1992. Main Outcome Measure.-Death. Results.-Between 1980 and 1992, the death rate due to infectious diseases as the underlying cause of death increased 58%, from 41 to 65 deaths per 100 000 population in the United States. Age-adjusted mortality from infectious diseases increased 39% during the same period. Infectious diseases mortality increased 25% among those aged 65 years and older (from 271 to 338 per 100 000), and 6.3 times among 25- to 44-year-olds (from six to 38 deaths per 100 000). Mortality due to respiratory tract infections increased 20%, from 25 to 30 deaths per 100 000, deaths attributed to human immunodeficiency virus increased from virtually none to 13 per 100 000 in 1992, and the rate of death due to septicemia increased 83% from 4.2 to 7.7 per 100 000. Conclusions.-Despite historical predictions that infectious diseases would wane in the United States, these data show that infectious diseases mortality in the United States has been increasing in recent years.	CTR DIS CONTROL & PREVENT,NATL CTR INFECT DIS,ATLANTA,GA 30341; CTR DIS CONTROL & PREVENT,EPIDEMIOL PROGRAM OFF,ATLANTA,GA 30341; TRANDES CORP,ATLANTA,GA; KLEMM ANAL GRP,ATLANTA,GA	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA			Simonsen, Lone/K-4531-2014	Simonsen, Lone/0000-0003-1535-8526				Bennett J. V., 1987, CLOSING GAP BURDEN U, P102; BONNEZ W, 1995, MANDELL DOUGLAS BENN, P1387; BUTLER JC, 1994, CLIN INFECT DIS, V19, P387, DOI 10.1093/clinids/19.3.387; CAMPBELL GL, 1995, ANN INTERN MED, V122, P151, DOI 10.7326/0003-4819-122-2-199501150-00014; Centers for Disease Control and Prevention, 1994, ADDRESSING EMERGING; COHEN ML, 1992, SCIENCE, V257, P1050, DOI 10.1126/science.257.5073.1050; Desenclos Jean-Claude A., 1992, Morbidity and Mortality Weekly Report, V41, P13; EWBANK D, 1986, MARCY ROSENAU PUBLIC, P75; FOHLMAN J, 1993, ANN MED, V25, P569; HADDIX A, 1996, PREVENTIVE EFFECTIVE; HELFAND RF, 1995, J INFECT DIS, V172, P1206, DOI 10.1093/infdis/172.5.1206; HERRINGTON CS, 1994, J CLIN PATHOL, V47, P1066, DOI 10.1136/jcp.47.12.1066; KOCHANEK KD, 1995, MONTHLY VITAL STATIS, V43, P70; Levins R., 1995, ECOSYST HEALTH, V1, P47; MACKENZIE WR, 1994, NEW ENGL J MED, V331, P161, DOI 10.1056/NEJM199407213310304; MORRISON EA, 1995, CLIN INFECT DIS, V18, P172; REEVES WC, 1989, REV INFECT DIS, V11, P426; SOLL AH, 1993, GASTROINTESTINAL DIS, P580; WISE RP, 1988, AM J PREV MED, V4, P268, DOI 10.1016/S0749-3797(18)31160-7; 1994, MONTHLY VITAL STAT R, V42; 1992, EMERGING INFECTIONS; 1995, MMWR-MORBID MORTAL W, V44, P468; [No title captured]; 1992, VITAL STATISTICS MOR; 1995, WORLD DEV REPORT 199; 1995, MMWR-MORBID MORTAL W, V44, P381; 1995, MMWR-MORBID MORTAL W, V44, P535; 1995, MMWR-MORBID MORTAL W, V44, P475; 1993, MMWR-MORBID MORTAL W, V42, P869	29	401	414	0	19	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 17	1996	275	3					189	193		10.1001/jama.275.3.189	http://dx.doi.org/10.1001/jama.275.3.189			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TP282	8604170				2022-12-28	WOS:A1996TP28200025
J	Gaziano, JM; Hebert, PR; Hennekens, CH				Gaziano, JM; Hebert, PR; Hennekens, CH			Cholesterol reduction: Weighing the benefits and risks	ANNALS OF INTERNAL MEDICINE			English	Editorial Material							CORONARY HEART-DISEASE; SERUM-CHOLESTEROL; LOWERING CHOLESTEROL; TOTAL MORTALITY; TRIALS		HARVARD UNIV, SCH PUBL HLTH, BOSTON, MA 02115 USA; VET AFFAIRS MED CTR, BOSTON, MA USA	Harvard University; Harvard T.H. Chan School of Public Health; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Gaziano, JM (corresponding author), HARVARD UNIV, SCH MED, BRIGHAM & WOMENS HOSP, DIV PREVENT MED, 900 COMMONWEALTH AVE E, BOSTON, MA 02215 USA.							BERNSTEIN MJ, 1985, JAMA-J AM MED ASSOC, V253, P2080; CHEN ZM, 1991, BRIT MED J, V303, P276, DOI 10.1136/bmj.303.6797.276; CLEEMAN JI, 1988, ARCH INTERN MED, V148, P36, DOI 10.1001/archinte.148.1.36; COLLINS R, 1992, BRIT MED J, V304, P1689, DOI 10.1136/bmj.304.6843.1689; DAYTON S, 1969, CIRCULATION S2, V39, P1; ENGELBERG H, 1992, LANCET, V339, P727, DOI 10.1016/0140-6736(92)90609-7; FRICK MH, 1987, NEW ENGL J MED, V317, P1237, DOI 10.1056/NEJM198711123172001; GOLDMAN L, 1984, ANN INTERN MED, V101, P825, DOI 10.7326/0003-4819-101-6-825; Gordon DS, 1995, LOWERING CHOLESTEROL, P33; GOULD AL, 1995, CIRCULATION, V91, P2274, DOI 10.1161/01.CIR.91.8.2274; GRUNDY SM, 1993, JAMA-J AM MED ASSOC, V269, P3015, DOI 10.1001/jama.269.23.3015; HEADY JA, 1992, LANCET, V340, P1405, DOI 10.1016/0140-6736(92)92588-7; HOLME I, 1990, CIRCULATION, V82, P1916, DOI 10.1161/01.CIR.82.6.1916; LAROSA JC, 1990, CIRCULATION, V81, P1721, DOI 10.1161/01.CIR.81.5.1721; LAW MR, 1994, BMJ-BRIT MED J, V308, P367, DOI 10.1136/bmj.308.6925.367; LAW MR, 1994, BMJ-BRIT MED J, V308, P363, DOI 10.1136/bmj.308.6925.363; LAW MR, 1994, BRIT MED J, V308, P373, DOI 10.1136/bmj.308.6925.373; MULDOON MF, 1990, BMJ-BRIT MED J, V301, P309, DOI 10.1136/bmj.301.6747.309; OLIVER M F, 1978, British Heart Journal, V40, P1069, DOI 10.1136/hrt.40.10.1069; OLIVER MF, 1984, LANCET, V2, P600; OLIVER MF, 1991, LANCET, V337, P1529, DOI 10.1016/0140-6736(91)93208-Q; PEDERSEN TR, 1994, LANCET, V344, P1383; PETO R, 1985, CIRCULATION, V72, P451; RAVNSKOV U, 1992, BMJ-BRIT MED J, V305, P15, DOI 10.1136/bmj.305.6844.15; RIFKIND BM, 1984, JAMA-J AM MED ASSOC, V251, P351; ROSSOUW JE, 1990, NEW ENGL J MED, V323, P1112, DOI 10.1056/NEJM199010183231606; SHEPHERD J, 1995, NEW ENGL J MED, V333, P1301, DOI 10.1056/NEJM199511163332001; SMITH GD, 1992, BMJ-BRIT MED J, V304, P431, DOI 10.1136/bmj.304.6824.431; 1987, JAMA-J AM MED ASSOC, V257, P937	29	29	29	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 15	1996	124	10					914	918		10.7326/0003-4819-124-10-199605150-00009	http://dx.doi.org/10.7326/0003-4819-124-10-199605150-00009			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UJ801	8610922				2022-12-28	WOS:A1996UJ80100009
J	Meno, C; Saijoh, Y; Fujii, H; Ikeda, M; Yokoyama, T; Yokoyama, M; Toyoda, Y; Hamada, H				Meno, C; Saijoh, Y; Fujii, H; Ikeda, M; Yokoyama, T; Yokoyama, M; Toyoda, Y; Hamada, H			Left-right asymmetric expression of the TGF beta-family member lefty in mouse embryos	NATURE			English	Article							REVERSAL; GENE	EXAMPLES Of lateral asymmetry are often found in vertebrates, such as the heart being on the left side, but the molecular mechanism governing the establishment of this left-right (LR) handedness is unknown(1). A diffusible morphogen may determine L-R polarity(2), but a likely molecule has not so far been identified. Here we report on the gene lefty, a member of the transforming growth factor-beta family, which may encode a morphogen for L-R determination. Lefty protein contains the cysteine-knot motif(3) characteristic of this superfamily(4,5) and is secreted as a processed form of relative molecular mass 25K-32K. Surprisingly, lefty is expressed in the left half of gastrulating mouse embryos. This asymmetric expression is very transient and occurs just before the first sign of lateral asymmetry appears. In the mouse mutants iv and inv, which cause situs inversus, the sites of lefty expression are inverted, indicating that lefty is downstream of iv and inv. These results suggest that lefty may be involved in setting up L-R asymmetry in the organ systems of mammals.	TOKYO METROPOLITAN INST MED SCI, BUNKYO KU, TOKYO 113, JAPAN; OSAKA UNIV, INST MOLEC & CELLULAR BIOL, SUITA, OSAKA 565, JAPAN; MBL CO LTD, INA LAB, INA, NAGANO 396, JAPAN; TOKYO WOMENS MED COLL, DEPT ANAT & DEV BIOL, SHINJUKU KU, TOKYO 162, JAPAN; MITSUBISHI KASEI INST LIFE SCI, MACHIDA, TOKYO 194, JAPAN; UNIV TOKYO, INST MED SCI, MINATO KU, TOKYO 108, JAPAN	Tokyo Metropolitan Institute of Medical Science; Osaka University; Tokyo Women's Medical University; University of Tokyo			Hamada, Hiroshi/N-6374-2015	Hamada, Hiroshi/0000-0002-7196-5948; Saijoh, Yukio/0000-0002-7548-4789				BROWN NA, 1991, CIBA F SYMP, V162, P182; BROWN NA, 1993, NATURE, V363, P303, DOI 10.1038/363303a0; BROWN NA, 1990, DEVELOPMENT, V109, P1; BRUECKNER M, 1989, P NATL ACAD SCI USA, V86, P5035, DOI 10.1073/pnas.86.13.5035; HOGAN BLM, 1994, DEVELOPMENT, P53; Hummel K. P., 1959, Journal of Heredity, V50, P9; KINGSLEY DM, 1994, GENE DEV, V8, P133, DOI 10.1101/gad.8.2.133; LAYTON WM, 1976, J HERED, V67, P336, DOI 10.1093/oxfordjournals.jhered.a108749; LEVIN M, 1995, CELL, V82, P803, DOI 10.1016/0092-8674(95)90477-8; MCBURNEY MW, 1982, DEV BIOL, V89, P503, DOI 10.1016/0012-1606(82)90338-4; MCDONALD NQ, 1993, CELL, V73, P421, DOI 10.1016/0092-8674(93)90127-C; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; SAIJOH Y, IN PRESS GENES CELLS; THEILER K, 1989, HOUSE MOUSE ATLAS EM, P40; WILKINSON DG, 1992, IN SITU HYBRIDIZATIO, P75; YOKOYAMA T, 1993, SCIENCE, V260, P679, DOI 10.1126/science.8480178; ZHOU XL, 1993, NATURE, V361, P543, DOI 10.1038/361543a0	18	366	378	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 9	1996	381	6578					151	155		10.1038/381151a0	http://dx.doi.org/10.1038/381151a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UK139	8610011				2022-12-28	WOS:A1996UK13900048
J	Brennick, J; Mattia, A				Brennick, J; Mattia, A			Strongyloides stercoralis Infestation	NEW ENGLAND JOURNAL OF MEDICINE			English	Article											Brennick, J (corresponding author), MASSACHUSETTS GEN HOSP,BOSTON,MA 02114, USA.								0	0	0	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 2	1996	334	18					1173	1173		10.1056/NEJM199605023341806	http://dx.doi.org/10.1056/NEJM199605023341806			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UG831	8602184				2022-12-28	WOS:A1996UG83100006
J	Doyle, JJ; Hnatiuk, OW; Torrington, KG; Slade, AR; Howard, RS				Doyle, JJ; Hnatiuk, OW; Torrington, KG; Slade, AR; Howard, RS			Necessity of routine chest roentgenography after thoracentesis	ANNALS OF INTERNAL MEDICINE			English	Article							COMPLICATIONS; THORACOCENTESIS	Objective: To determine the necessity of posteroanterior chest roentgenography for the identification of pneumothorax and other complications after thoracentesis. Design: Prospective cohort study. Setting: Tertiary care teaching hospital. Patients: 67 men and 43 women (mean age +/- SD, 62.4 +/- 13.2 years). Exclusion criteria included age younger than 18 years, concurrent pleural biopsy, ultrasound guidance, and use of mechanical ventilation. Measurements: 174 thoracenteses done between March 1991 and June 1993. Results: 2 hemothoraces (1.2%) occurred, and 8 patients had a total of 9 pneumothoraces (5.2%). The roentgenograms obtained immediately after the procedures identified 8 pneumothoraces; the other pneumothorax was seen incidentally on a delayed roentgenogram obtained 3 days later. Pneumothorax was suspected in 5 of the 8 cases, and tube thoracostomy was done in 4 of these 5 cases. Patients with unsuspected pneumothorax identified on the roentgenogram obtained immediately after the procedure did not receive treatment for their pneumothoraces. Univariate analysis showed that the variables that correlated significantly with pneumothorax were aspiration of air during the procedure (relative risk ratio, 12.3; 95% CI, 3.7 to 41.4), number of passes with the thoracentesis needle (relative risk ratio, 6.1; CI, 1.6 to 23.3), history of thoracic radiation therapy (relative risk ratio, 10.5; CI, 2.5 to 44.4), and operator suspicion of pneumothorax (relative risk ratio, 25.9; CI, 8.6 to 78.5). Conclusion: Among hospitalized patients with pleural effusions, we identified a subgroup of patients in whom the risk for pneumothorax is low enough (approximately 1%) with sufficiently minimal clinical consequences to justify the avoidance of about 60% of chest roentgenograms obtained after thoracentesis. These patients are clinically stable, have not previously received chest irradiation, had only one pass at thoracentesis attempted without the aspiration of any air, and give no other indication of pneumothorax.	WALTER REED ARMY MED CTR, PULM & CRIT CARE MED SERV, WASHINGTON, DC 20307 USA; UNIFORMED SERV UNIV HLTH SCI, BETHESDA, MD 20814 USA	United States Department of Defense; United States Army; Walter Reed National Military Medical Center; Uniformed Services University of the Health Sciences - USA								BARTTER T, 1993, CHEST, V103, P1873, DOI 10.1378/chest.103.6.1873; BRANDSTETTER RD, 1994, HEART LUNG, V23, P67; COLLINS TR, 1987, CHEST, V91, P817, DOI 10.1378/chest.91.6.817; Gerardi D., 1994, Chest, V106, p83S; GROGAN DR, 1990, ARCH INTERN MED, V150, P873, DOI 10.1001/archinte.150.4.873; Kleinbaum DG, 1982, EPIDEMIOLOGIC RES PR, P296; RAPTOPOULOS V, 1991, AM J ROENTGENOL, V156, P917, DOI 10.2214/ajr.156.5.2017951; ROTH BJ, 1991, ARCH INTERN MED, V151, P2095; SENEFF MG, 1986, CHEST, V90, P97, DOI 10.1378/chest.90.1.97; SOKOLOWSKI JW, 1989, AM REV RESPIR DIS, V140, P257, DOI 10.1164/ajrccm/140.1.257; SWINBURNE AJ, 1991, ARCH INTERN MED, V151, P2095, DOI 10.1001/archinte.1991.00400100147025; WALSHE ADP, 1992, THORAX, V47, P734, DOI 10.1136/thx.47.9.734	12	57	61	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 1	1996	124	9					816	820		10.7326/0003-4819-124-9-199605010-00005	http://dx.doi.org/10.7326/0003-4819-124-9-199605010-00005			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UG254	8610950				2022-12-28	WOS:A1996UG25400005
J	Martyn, C				Martyn, C			Blood pressure and dementia	LANCET			English	Editorial Material											Martyn, C (corresponding author), MRC,ENVIRONM EPIDEMIOL UNIT,SOUTHAMPTON,HANTS,ENGLAND.							BRUN A, 1986, ANN NEUROL, V19, P253, DOI 10.1002/ana.410190306; DELAMONTE SM, 1989, ANN NEUROL, V25, P450, DOI 10.1002/ana.410250506; ELIAS MF, 1993, AM J EPIDEMIOL, V138, P353, DOI 10.1093/oxfordjournals.aje.a116868; FARMER ME, 1987, AM J EPIDEMIOL, V126, P1103, DOI 10.1093/oxfordjournals.aje.a114749; Gale CR, 1996, BRIT MED J, V312, P608; Guo ZC, 1996, BRIT MED J, V312, P805, DOI 10.1136/bmj.312.7034.805; MIRSEN TR, 1991, ARCH NEUROL-CHICAGO, V48, P1015, DOI 10.1001/archneur.1991.00530220031015; SCHERR PA, 1991, AM J EPIDEMIOL, V134, P1303, DOI 10.1093/oxfordjournals.aje.a116033; Thomas T, 1996, NATURE, V380, P168, DOI 10.1038/380168a0; WALLACE RB, 1985, J CHRON DIS, V38, P475, DOI 10.1016/0021-9681(85)90031-1	10	7	8	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 27	1996	347	9009					1130	1131		10.1016/S0140-6736(96)90603-0	http://dx.doi.org/10.1016/S0140-6736(96)90603-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UG755	8609743				2022-12-28	WOS:A1996UG75500005
J	Tracey, KJ				Tracey, KJ			Repairing the broken heart of dilated cardiomyopathy	LANCET			English	Editorial Material							TUMOR-NECROSIS-FACTOR; SEPTIC SHOCK; CACHECTIN; ENDOTOXIN		PICOWER INST MED RES,MANHASSET,NY	Northwell Health	Tracey, KJ (corresponding author), CORNELL UNIV,MED CTR,N SHORE UNIV HOSP,MANHASSET,NY 11030, USA.			Tracey, Kevin J/0000-0003-1884-6314				ABRAHAM E, 1995, JAMA-J AM MED ASSOC, V273, P934, DOI 10.1001/jama.273.12.934; BEUTLER B, 1986, J EXP MED, V164, P1791, DOI 10.1084/jem.164.5.1791; BIANCHI M, 1996, J EXP MED, V181, P927; CALANDRA T, 1995, NATURE, V377, P68, DOI 10.1038/377068a0; FINKEL MS, 1992, SCIENCE, V257, P387, DOI 10.1126/science.1631560; KAPADIA S, 1995, AM J PHYSIOL-HEART C, V268, pH517, DOI 10.1152/ajpheart.1995.268.2.H517; NATANSON C, 1989, J EXP MED, V169, P823, DOI 10.1084/jem.169.3.823; SUFFREDINI AF, 1989, NEW ENGL J MED, V321, P280, DOI 10.1056/NEJM198908033210503; TRACEY KJ, 1990, J CLIN INVEST, V86, P2014, DOI 10.1172/JCI114937; TRACEY KJ, 1986, SCIENCE, V234, P470, DOI 10.1126/science.3764421; TRACEY KJ, 1987, SURG GYNECOL OBSTET, V164, P415; TRACEY KJ, 1987, NATURE, V330, P662, DOI 10.1038/330662a0; VANDERPOLL T, 1990, NEW ENGL J MED, V322, P1622, DOI 10.1056/NEJM199006073222302; YOKOYAMA T, 1993, J CLIN INVEST, V92, P2303, DOI 10.1172/JCI116834	14	1	1	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 27	1996	347	9009					1129	1130		10.1016/S0140-6736(96)90601-7	http://dx.doi.org/10.1016/S0140-6736(96)90601-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UG755	8609741				2022-12-28	WOS:A1996UG75500003
J	Carter, BD; Kaltschmidt, C; Kaltschmidt, B; Offenhauser, N; BohmMatthaei, R; Baeuerle, PA; Barde, YA				Carter, BD; Kaltschmidt, C; Kaltschmidt, B; Offenhauser, N; BohmMatthaei, R; Baeuerle, PA; Barde, YA			Selective activation of NF-kappa B by nerve growth factor through the neurotrophin receptor p75	SCIENCE			English	Article							AFFINITY NGF RECEPTOR; SCHWANN-CELLS; SCIATIC-NERVE; DIFFERENTIAL EXPRESSION; MESSENGER-RNA; GENE-TRANSFER; BINDING; AXOTOMY; LEADS	Nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF), and neurotrophin-3 (NT-3) selectively bind to distinct members of the Trk family of tyrosine kinase receptors, but all three bind with similar affinities to the neurotrophin receptor p75 (p75(NTR)). The biological significance of neurotrophin binding to p75(NTR) in cells that also express Trk receptors has been difficult to ascertain. In the absence of TrkA, NGF binding to p75(NTR) activated the transcription factor nuclear factor kappa B (NF-kappa B) in rat Schwann cells. This activation was not observed in Schwann cells isolated from mice that lacked p75(NTR). The effect was selective for NGF; NF-kappa B was not activated by BDNF or NT-3.	MAX PLANCK INST PSYCHIAT, DEPT NEUROBIOCHEM, W-8033 MARTINSRIED, GERMANY; UNIV FREIBURG, INST BIOCHEM, W-7800 FREIBURG, GERMANY; MAX PLANCK INST PSYCHIAT, DEPT NEUROCHEM, W-8033 MARTINSRIED, GERMANY	Max Planck Society; University of Freiburg; Max Planck Society			Barde, Yves/F-6019-2011	Offenhauser, Nina/0000-0002-3316-3047; Barde, Yves/0000-0002-7627-461X				ANTON ES, 1994, P NATL ACAD SCI USA, V91, P2795, DOI 10.1073/pnas.91.7.2795; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; BARBACID M, 1994, J NEUROBIOL, V25, P1386, DOI 10.1002/neu.480251107; BATTLEMAN DS, 1993, J NEUROSCI, V13, P941; BENEDETTI M, 1993, P NATL ACAD SCI USA, V90, P7859, DOI 10.1073/pnas.90.16.7859; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DOBROWSKY RT, 1994, SCIENCE, V265, P1596, DOI 10.1126/science.8079174; DOBROWSKY RT, 1995, J BIOL CHEM, V270, P22135, DOI 10.1074/jbc.270.38.22135; FUNAKOSHI H, 1993, J CELL BIOL, V123, P455, DOI 10.1083/jcb.123.2.455; HEMPSTEAD BL, 1991, NATURE, V350, P678, DOI 10.1038/350678a0; HEUMANN R, 1987, P NATL ACAD SCI USA, V84, P8735, DOI 10.1073/pnas.84.23.8735; ITOH K, 1995, J NEUROSCI, V15, P2504, DOI 10.1523/JNEUROSCI.15-03-02504.1995; KALTSCHMIDT C, 1993, MECH DEVELOP, V43, P135, DOI 10.1016/0925-4773(93)90031-R; KALTSCHMIDT C, 1994, MOL CELL BIOL, V14, P3981, DOI 10.1128/MCB.14.6.3981; KALTSCHMIDT C, 1995, P NATL ACAD SCI USA, V92, P9618, DOI 10.1073/pnas.92.21.9618; KAPLAN DR, 1994, J NEUROBIOL, V25, P1404, DOI 10.1002/neu.480251108; LEE KF, 1992, CELL, V69, P737, DOI 10.1016/0092-8674(92)90286-L; LEON A, 1994, P NATL ACAD SCI USA, V91, P3739, DOI 10.1073/pnas.91.9.3739; LEWIN GR, 1995, SEMIN NEUROSCI, V7, P227, DOI 10.1006/smns.1995.0026; LEWIN GR, 1993, TRENDS NEUROSCI, V16, P353, DOI 10.1016/0166-2236(93)90092-Z; MATSUOKA I, 1991, J NEUROSCI, V11, P3165; OFFENHAUSER N, 1995, EUR J NEUROSCI, V7, P2005, DOI 10.1111/j.1460-9568.1995.tb00722.x; OTTEN U, 1995, INT J DEV NEUROSCI, V13, P147, DOI 10.1016/0736-5748(95)00016-A; RABIZADEH S, 1994, DEV NEUROSCI-BASEL, V16, P207, DOI 10.1159/000112108; RADEKE MJ, 1987, NATURE, V325, P593, DOI 10.1038/325593a0; RODRIGUEZTEBAR A, 1990, NEURON, V4, P487, DOI 10.1016/0896-6273(90)90107-Q; RODRIGUEZTEBAR A, 1992, EMBO J, V11, P917, DOI 10.1002/j.1460-2075.1992.tb05130.x; SEBERT ME, 1993, J NEUROSCI RES, V36, P357, DOI 10.1002/jnr.490360402; SEILHEIMER B, 1987, EMBO J, V6, P1611, DOI 10.1002/j.1460-2075.1987.tb02408.x; TANIUCHI M, 1986, P NATL ACAD SCI USA, V83, P4094, DOI 10.1073/pnas.83.11.4094; TARTAGLIA LA, 1992, IMMUNOL TODAY, V13, P151, DOI 10.1016/0167-5699(92)90116-O; TARTAGLIA LA, 1993, CELL, V74, P845, DOI 10.1016/0092-8674(93)90464-2; VERDI JM, 1994, NEURON, V12, P733, DOI 10.1016/0896-6273(94)90327-1; WOOD JN, 1995, NEUROSCI LETT, V192, P41, DOI 10.1016/0304-3940(95)11603-T; WOOLF CJ, 1994, NEUROSCIENCE, V62, P327, DOI 10.1016/0306-4522(94)90366-2; ZHOU J, 1994, P NATL ACAD SCI USA, V91, P3824, DOI 10.1073/pnas.91.9.3824	36	593	614	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 26	1996	272	5261					542	545		10.1126/science.272.5261.542	http://dx.doi.org/10.1126/science.272.5261.542			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UG826	8614802				2022-12-28	WOS:A1996UG82600042
J	Peat, TS; Frank, EG; McDonald, JP; Levine, AS; Woodgate, R; Hendrickson, WA				Peat, TS; Frank, EG; McDonald, JP; Levine, AS; Woodgate, R; Hendrickson, WA			Structure of the UmuD' protein and its regulation in response to DNA damage	NATURE			English	Article							RECA-MEDIATED CLEAVAGE; MUTANT LEXA PROTEINS; ANOMALOUS DIFFRACTION; DEPENDENT CLEAVAGE; ESCHERICHIA-COLI; SOS MUTAGENESIS; AUTODIGESTION; POLYMERASE	FOR life to be sustained, mistakes in DNA repair must be tolerated when damage obscures the genetic information. In bacteria such as Escherichia coli, DNA damage elicits the well regulated 'SOS response' (reviewed in ref. 1). For the extreme case of damage that cannot be repaired by conventional enzymes, there are proteins that allow the replication of DNA through such lesions, but with a reduction in the fidelity of replication(2). Essential proteins in this mutagenic process are RecA, DNA polymerase III, UmuD, UmuD' and UmuC (umu: UV mutagenesis)(1-3). Regulation of this response involves a RecA-mediated self-cleavage of UmuD to produce UmuD'. To understand this system in more detail, we have determined the crystal structure of the E. coli UmuD' mutagenesis protein at 2.5 Angstrom resolution. Globular heads folded in an unusual beta-structure associate to form molecular dimers, and extended amino-terminal tails associate to produce crystallized filaments. The structure provides insight into the mechanism of the self-cleavage reaction that UmuD-like proteins undergo as part of the global SOS response(4-8).	COLUMBIA UNIV,DEPT BIOCHEM & MOLEC BIOPHYS,NEW YORK,NY 10032; COLUMBIA UNIV,HOWARD HUGHES MED INST,NEW YORK,NY 10032; NICHHD,SECT DNA REPLICAT REPAIR & MUTAGENESIS,NIH,BETHESDA,MD 20892	Columbia University; Columbia University; Howard Hughes Medical Institute; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)			Peat, Thomas S/F-9817-2010	Peat, Thomas S/0000-0002-6488-0831; Woodgate, Roger/0000-0001-5581-4616				[Anonymous], 1994, ACTA CRYSTALLOGR D, V50, P760; BATTISTA JR, 1990, P NATL ACAD SCI USA, V87, P7190, DOI 10.1073/pnas.87.18.7190; Brunger A. T., 1992, XPLOR VERSION 3 1 SY; BURCKHARDT SE, 1988, P NATL ACAD SCI USA, V85, P1811, DOI 10.1073/pnas.85.6.1811; DEBAERDEMAEKER T, 1988, ACTA CRYSTALLOGR A, V44, P353, DOI 10.1107/S0108767388000017; EVANS R, 1990, VIA, V11, P134; FRIEDBERG EC, 1995, DNA REPAIR; GIMBLE FS, 1986, J MOL BIOL, V192, P39, DOI 10.1016/0022-2836(86)90462-6; GIMBLE FS, 1989, J MOL BIOL, V206, P29, DOI 10.1016/0022-2836(89)90521-4; HENDRICKSON WA, 1990, EMBO J, V9, P1665, DOI 10.1002/j.1460-2075.1990.tb08287.x; HENDRICKSON WA, 1991, SCIENCE, V254, P51, DOI 10.1126/science.1925561; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kleywegt GJ, 1994, 1 MAP FINAL MODEL, P59; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LIN LL, 1989, J MOL BIOL, V210, P439, DOI 10.1016/0022-2836(89)90121-6; LITTLE JW, 1984, P NATL ACAD SCI-BIOL, V81, P1375, DOI 10.1073/pnas.81.5.1375; LITTLE JW, 1993, J BACTERIOL, V175, P4939; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; NOHMI T, 1988, P NATL ACAD SCI USA, V85, P1816, DOI 10.1073/pnas.85.6.1816; Otwinowski Z., 1993, DATA COLLECTION PROC, P56; PEAT TS, IN PRESS PROTEINS; RAJAGOPALAN M, 1992, P NATL ACAD SCI USA, V89, P10777, DOI 10.1073/pnas.89.22.10777; ROLAND KL, 1992, J MOL BIOL, V228, P395, DOI 10.1016/0022-2836(92)90829-9; SHAPIRO L, 1995, NATURE, V374, P327, DOI 10.1038/374327a0; SHINAGAWA H, 1988, P NATL ACAD SCI USA, V85, P1806, DOI 10.1073/pnas.85.6.1806; STORY RM, 1992, NATURE, V355, P318, DOI 10.1038/355318a0; STRYNADKA NCJ, 1992, NATURE, V359, P700, DOI 10.1038/359700a0; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; WOODGATE R, 1992, MOL MICROBIOL, V6, P2213, DOI 10.1111/j.1365-2958.1992.tb01397.x	30	140	142	0	4	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	APR 25	1996	380	6576					727	730		10.1038/380727a0	http://dx.doi.org/10.1038/380727a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UG827	8614470				2022-12-28	WOS:A1996UG82700056
J	Espinel, CH				Espinel, CH			de Kooning's late colours and forms: Dementia, creativity, and the healing power of art	LANCET			English	Article									GEORGETOWN UNIV, SCH MED, ARLINGTON, VA 22205 USA	Georgetown University	Espinel, CH (corresponding author), BLOOD PRESSURE CTR, 1715 N GEORGE MASON DR, SUITE 401, ARLINGTON, VA 22205 USA.							AM. PSYCHIATRIC ASS'N, 1994, DIAGN STAT MAN MENT, P123; BACON F, 1878, NOVUM ORGANUM, V1, P19; Campion EW, 1996, NEW ENGL J MED, V334, P791, DOI 10.1056/NEJM199603213341209; CICERO MT, 1984, SELECTED WORKS, P211; CLARFIELD AM, 1988, ANN INTERN MED, V109, P476, DOI 10.7326/0003-4819-109-6-476; ELSDORFER C, 1994, MED CLIN N AM, V78, P773; ESPINEL CH, 1994, LANCET, V344, P1750, DOI 10.1016/S0140-6736(94)92891-6; Espinel CH, 1995, LANCET, V346, P1684, DOI 10.1016/S0140-6736(95)92846-4; ESPINEL CH, 1996, JAMA-J AM MED ASSOC, V275, P168; FERRARA T, 1995, COMMUNICATION; Garrels G., 1995, W DEKOONING LATE PAI, P9; GROWDON JH, 1994, CLIN NEUROLOGY AGING, P102; HAUW JJ, 1991, PATHOLOGY AGING HUMA, P113; KATZ R, 1991, ESQIRE, V115, P111; LARSON K, 1994, VILLAGE VOICE, V39, P41; Mortimer JA, 1981, EPIDEMIOLOGY DEMENTI, P3; PRATHER M, 1994, W DEKOONING PAINTING, P75; SCHJELDAHL P, 1989, ART J, V48, P247, DOI 10.1080/00043249.1989.10792631; Storr R., 1995, W DEKOONING LATE PAI, P39; SULTZER DL, 1994, CLIN NEUROLOGY AGING, P379; SYLVESTER D, 1994, W DEKOONING PAINTING, P15	21	59	60	0	13	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	APR 20	1996	347	9008					1096	1098		10.1016/S0140-6736(96)90285-8	http://dx.doi.org/10.1016/S0140-6736(96)90285-8			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UG042	8602064	hybrid			2022-12-28	WOS:A1996UG04200018
J	Macnaughton, RJ				Macnaughton, RJ			Numbers, scales, and qualitative research	LANCET			English	Editorial Material											Macnaughton, RJ (corresponding author), UNIV GLASGOW,WOODSIDE HLTH CTR,DEPT GEN PRACTICE,GLASGOW G20 7LR,LANARK,SCOTLAND.							BRITTEN N, 1995, FAM PRACT, V12, P104, DOI 10.1093/fampra/12.1.104; Cohen M., 1934, INTRO LOGIC SCI METH; HENBEST RJ, 1989, FAM PRACT, V6, P249, DOI 10.1093/fampra/6.4.249; KINMONTH AL, 1995, FAM PRACT, V12, P1, DOI 10.1093/fampra/12.1.1; LAW SAT, 1995, BRIT J GEN PRACT, V45, P520; Likert R.A., 1932, ARCH PSYCHOL, V22, P5, DOI DOI 10.1111/J.1540-5834.2010.00585.X; MCKINSTRY B, 1991, BRIT J GEN PRACT, V41, P275; Nagel E., 1960, PHILOS SCI; PEACOCK JL, 1995, BRIT MED J, V311, P531, DOI 10.1136/bmj.311.7004.531; SYLVESTER SHH, 1993, BRIT MED J, V307, P912, DOI 10.1136/bmj.307.6909.912; WINEFIELD HR, 1995, SOC SCI MED, V41, P969, DOI 10.1016/0277-9536(94)00403-G	11	35	35	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 20	1996	347	9008					1099	1100		10.1016/S0140-6736(96)90286-X	http://dx.doi.org/10.1016/S0140-6736(96)90286-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	UG042	8602065				2022-12-28	WOS:A1996UG04200019
J	DeGroote, MA; Testerman, T; Xu, YS; Stauffer, G; Fang, FC				DeGroote, MA; Testerman, T; Xu, YS; Stauffer, G; Fang, FC			Homocysteine antagonism of nitric oxide-related cytostasis in Salmonella typhimurium	SCIENCE			English	Article							ESCHERICHIA-COLI; NUCLEOTIDE-SEQUENCE; CLONING VEHICLES; THRA GENE; CONSTRUCTION; DERIVATIVES; ACTIVATION; NITROGEN; DISEASE	Nitric oxide (NO) is associated with broad-spectrum antimicrobial activity of particular importance in infections caused by intracellular pathogens. An insertion mutation in the metL gene of Salmonella typhimurium conferred specific hypersusceptibility to S-nitrosothiol NO-donor compounds and attenuated virulence of the organism in mice. The metL gene product catalyzes two proximal metabolic steps required for homocysteine biosynthesis. S-Nitrosothiol resistance was restored by exogenous homocysteine or introduction of the metL gene on a plasmid. Measurement of expression of the homocysteine-sensitive metH gene indicated that S-nitrosothiols may directly deplete intracellular homocysteine. Homocysteine may act as an endogenous NO antagonist in diverse processes including infection, atherosclerosis, and neurologic disease.	UNIV COLORADO,HLTH SCI CTR,DEPT MED,DENVER,CO 80262; UNIV COLORADO,HLTH SCI CTR,DEPT PATHOL,DENVER,CO 80262; UNIV COLORADO,HLTH SCI CTR,DEPT MICROBIOL,DENVER,CO 80262; UNIV IOWA,DEPT MICROBIOL,IOWA CITY,IA 52242	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Iowa			Testerman, Traci L/AAI-1506-2020	Testerman, Traci L/0000-0002-3883-6407; Fang, Ferric/0000-0002-3243-110X	NIAID NIH HHS [AI32463] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI032463] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BAUER AW, 1966, AM J CLIN PATHOL, V45, P493; BOERS GHJ, 1985, NEW ENGL J MED, V313, P709, DOI 10.1056/NEJM198509193131201; BOLIVAR F, 1977, GENE, V2, P75, DOI 10.1016/0378-1119(77)90074-9; BYERLY KA, 1991, J BACTERIOL, V173, P3547, DOI 10.1128/jb.173.11.3547-3553.1991; CASTILHO BA, 1984, J BACTERIOL, V158, P488, DOI 10.1128/JB.158.2.488-495.1984; CHAN J, 1995, INFECT IMMUN, V63, P736, DOI 10.1128/IAI.63.2.736-740.1995; CHANG ACY, 1978, J BACTERIOL, V134, P1141, DOI 10.1128/JB.134.3.1141-1156.1978; CLARKE R, 1991, NEW ENGL J MED, V324, P1149, DOI 10.1056/NEJM199104253241701; DEGROOTE MA, 1995, P NATL ACAD SCI USA, V92, P6399, DOI 10.1073/pnas.92.14.6399; DEGROOTE MA, 1995, CLIN INFECT DIS, V21, pS162, DOI 10.1093/clinids/21.Supplement_2.S162; DEGROOTE MA, UNPUB; EVANS TG, 1993, J IMMUNOL, V151, P907; FINLAY BB, 1989, MOL MICROBIOL, V3, P1833, DOI 10.1111/j.1365-2958.1989.tb00170.x; FORMICA S, 1994, IMMUNOLOGY, V82, P42; GASTON B, 1993, P NATL ACAD SCI USA, V90, P10957, DOI 10.1073/pnas.90.23.10957; KATINKA M, 1980, P NATL ACAD SCI-BIOL, V77, P5730, DOI 10.1073/pnas.77.10.5730; MCCULLY KS, 1969, AM J PATHOL, V56, P111; Miller J.H., 1972, EXPT MOL GENETICS; MULLIGAN JT, 1982, J BACTERIOL, V151, P609, DOI 10.1128/JB.151.2.609-619.1982; NATHAN C, 1995, CELL, V82, P873, DOI 10.1016/0092-8674(95)90019-5; NAUCIEL C, 1992, INFECT IMMUN, V60, P450, DOI 10.1128/IAI.60.2.450-454.1992; ROCKETT KA, 1991, INFECT IMMUN, V59, P3280, DOI 10.1128/IAI.59.9.3280-3283.1991; SAINTGIRONS I, 1984, J BIOL CHEM, V259, P4282; SANDERSON KE, 1995, MICROBIOL REV, V59, P241, DOI 10.1128/MMBR.59.2.241-303.1995; SELHUB J, 1995, NEW ENGL J MED, V332, P286, DOI 10.1056/NEJM199502023320502; STAMLER JS, 1993, J CLIN INVEST, V91, P308, DOI 10.1172/JCI116187; STAMPFER MJ, 1995, NEW ENGL J MED, V332, P328, DOI 10.1056/NEJM199502023320511; TSAI JC, 1994, P NATL ACAD SCI USA, V91, P6369, DOI 10.1073/pnas.91.14.6369; URBANOWSKI ML, 1989, J BACTERIOL, V171, P3277, DOI 10.1128/jb.171.6.3277-3281.1989; ZAKIN MM, 1983, J BIOL CHEM, V258, P3028	30	153	167	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 19	1996	272	5260					414	417		10.1126/science.272.5260.414	http://dx.doi.org/10.1126/science.272.5260.414			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UG252	8602531				2022-12-28	WOS:A1996UG25200048
J	Hegde, RS; Lingappa, VR				Hegde, RS; Lingappa, VR			Sequence-specific alteration of the ribosome-membrane junction exposes nascent secretory proteins to the cytosol	CELL			English	Article							ENDOPLASMIC-RETICULUM MEMBRANE; APOLIPOPROTEIN-B; ER MEMBRANE; TRANSLOCATION; POLYPEPTIDE; PROTEOLIPOSOMES; ENVIRONMENT; COMPLEX	Tight docking of the ribosome at the translocation channel ensures that nascent secretory proteins are shielded from the cytoplasm during transfer into the endoplasmic reticulum. Discrete pause transfer sequences mediate the transient stopping of translocation in certain proteins. Here we show that during a translocational pause, the junction between the ribosome and translocation channel is opened, exposing the nascent chain to the cytosol. While transient, this opening is sufficient to demonstrate macromolecular interactions between the translocating chain and molecules added to the cytosol, such as antibodies and site-specific proteases. Moreover, this opening is accompanied by alterations in the proteins that neighbor the nascent chain. These results demonstrate that specific sequences within a translocating nascent chain can elicit dramatic and reversible structural changes in the translocation machinery. Thus, the translocon is dynamic and can be regulated.	UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco	Hegde, RS (corresponding author), UNIV CALIF SAN FRANCISCO,DEPT PHYSIOL,SAN FRANCISCO,CA 94143, USA.			Lingappa, Vishwanath R./0000-0003-0962-6571; Hegde, Ramanujan/0000-0001-8338-852X	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045480] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG002132] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 45480] Funding Source: Medline; NIA NIH HHS [AG 02132] Funding Source: Medline; NIGMS NIH HHS [GM 07618] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BERGERON JJM, 1994, TRENDS BIOCHEM SCI, V19, P124, DOI 10.1016/0968-0004(94)90205-4; CHUCK SL, 1992, CELL, V68, P9, DOI 10.1016/0092-8674(92)90202-N; CHUCK SL, 1990, NATURE, V346, P382, DOI 10.1038/346382a0; CONNOLLY T, 1989, J CELL BIOL, V108, P299, DOI 10.1083/jcb.108.2.299; CROWLEY KS, 1993, CELL, V73, P1101, DOI 10.1016/0092-8674(93)90640-C; CROWLEY KS, 1994, CELL, V78, P461, DOI 10.1016/0092-8674(94)90424-3; EVANS EA, 1986, P NATL ACAD SCI USA, V83, P581, DOI 10.1073/pnas.83.3.581; FRYDMAN J, 1994, NATURE, V370, P111, DOI 10.1038/370111a0; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GILMORE R, 1985, CELL, V42, P497, DOI 10.1016/0092-8674(85)90107-2; GORLICH D, 1992, NATURE, V357, P47, DOI 10.1038/357047a0; GORLICH D, 1993, CELL, V75, P615, DOI 10.1016/0092-8674(93)90483-7; Harlow E., 1988, ANTIBODIES LAB MANUA; KALIES KU, 1994, J CELL BIOL, V126, P925, DOI 10.1083/jcb.126.4.925; KELLARIS KV, 1991, J CELL BIOL, V114, P21, DOI 10.1083/jcb.114.1.21; KELLEHER DJ, 1992, CELL, V69, P55, DOI 10.1016/0092-8674(92)90118-V; KOIVU J, 1987, J BIOL CHEM, V262, P6447; LINGAPPA VR, 1991, CELL, V65, P527, DOI 10.1016/0092-8674(91)90081-9; MALKIN LI, 1967, J MOL BIOL, V26, P329, DOI 10.1016/0022-2836(67)90301-4; MATLACK KES, 1995, J BIOL CHEM, V270, P6170, DOI 10.1074/jbc.270.11.6170; MOTHES W, 1994, EMBO J, V13, P3973, DOI 10.1002/j.1460-2075.1994.tb06713.x; NICCHITTA CV, 1990, CELL, V60, P259, DOI 10.1016/0092-8674(90)90741-V; OOI CE, 1992, CELL, V71, P87, DOI 10.1016/0092-8674(92)90268-H; RAPOPORT TA, 1992, SCIENCE, V258, P931, DOI 10.1126/science.1332192; Sambrook J., 2002, MOL CLONING LAB MANU; SIEGEL V, 1995, CELL, V82, P167, DOI 10.1016/0092-8674(95)90301-1; WALTER P, 1983, METHOD ENZYMOL, V96, P682; WANG S, 1995, J CELL BIOL, V130, P519, DOI 10.1083/jcb.130.3.519; WETTERAU JR, 1990, J BIOL CHEM, V265, P9801; WIEDMANN M, 1987, NATURE, V328, P830, DOI 10.1038/328830a0	30	66	66	0	1	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 19	1996	85	2					217	228		10.1016/S0092-8674(00)81098-3	http://dx.doi.org/10.1016/S0092-8674(00)81098-3			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UG255	8612274	Bronze			2022-12-28	WOS:A1996UG25500010
J	Brunner, E; Smith, GD; Marmot, M; Canner, R; Beksinska, M; OBrien, J				Brunner, E; Smith, GD; Marmot, M; Canner, R; Beksinska, M; OBrien, J			Childhood social circumstances and psychosocial and behavioural factors as determinants of plasma fibrinogen	LANCET			English	Article							ISCHEMIC-HEART-DISEASE; BRITISH CIVIL-SERVANTS; RISK-FACTORS; CARDIOVASCULAR-DISEASE; INSULIN-RESISTANCE; EMPLOYMENT GRADE; CLOTTING FACTORS; WHITEHALL-II; ADULT LIFE; MORTALITY	Background High plasma fibrinogen concentration is associated with an increased risk of coronary heart disease. We have investigated associations between plasma fibrinogen and factors operating in childhood and in adulthood, including the psychosocial characteristics of work. Methods In a cross-sectional study of Civil Servants in London, UK, 2095 men and 1202 women aged 45-55 years provided blood samples for fibrinogen measurement at the time of the Whitehall II study baseline. The participants completed a questionnaire on demographic characteristics, education, employment grade, parents' occupation, health behaviours, and work characteristics. Findings Measures of childhood environment (adult height, father's social class, and participant's education) were inversely associated with adult plasma fibrinogen concentration in both sexes. Lower socioeconomic status (as shown by employment grade) was associated with higher fibrinogen concentrations, with differences from top to bottom grade of 0.22 g/L (95% CI 0.13-0.31) in men and 0.37 g/L (0.18-0.56) in women (p<0.0001, both sexes). This association was not accounted for by measures of childhood circumstances. Control over work, assessed by personnel managers, was inversely related to fibrinogen in both sexes, and a similar relation was seen for self-rated control over work among men but not women. Men in the bottom third of the distribution for self-rated and externally assessed control over work had higher fibrinogen concentrations than those in the top third for both measures (difference 0.16 g/L [0.07-0.26]; p<0.001). There was no difference between these extremes among women (0.02 g/L [-0.16 to 0.19]). Current smokers had higher fibrinogen concentrations than non-smokers, and moderate alcohol consumers had lower concentrations than those who drank occasionally or never. Interpretation Although our study was cross-sectional, it provides evidence that adult fibrinogen concentration is determined by factors operating throughout life. Fibrinogen may be a marker of the biological pathways that mediate the inverse socioeconomic gradient in coronary disease.	UNIV BRISTOL, DEPT SOCIAL MED, BRISTOL, AVON, ENGLAND; ST MARYS HOSP, PORTSMOUTH PO3 6AQ, HANTS, ENGLAND	University of Bristol	Brunner, E (corresponding author), UCL, SCH MED, DEPT EPIDEMIOL & PUBL HLTH, LONDON WC1E 6BT, ENGLAND.		Brunner, Eric/H-2114-2011; Davey Smith, George/A-7407-2013; Marmot, M G/Y-3920-2019	Brunner, Eric/0000-0002-0595-4474; Davey Smith, George/0000-0002-1407-8314; Marmot, M G/0000-0002-2431-6419	Medical Research Council [G8802774] Funding Source: Medline; NHLBI NIH HHS [2 ROI HL36310] Funding Source: Medline; Wellcome Trust Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL036310] Funding Source: NIH RePORTER	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); Wellcome Trust(Wellcome Trust); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALTERMAN T, 1994, AM J EPIDEMIOL, V139, P620, DOI 10.1093/oxfordjournals.aje.a117051; BAKER IA, 1988, INT J EPIDEMIOL, V17, P759, DOI 10.1093/ije/17.4.759; BARKER DJP, 1992, BMJ-BRIT MED J, V304, P148, DOI 10.1136/bmj.304.6820.148; BARKER DJP, 1986, LANCET, V1, P1077; BARTLEY M, 1994, BMJ-BRIT MED J, V309, P1475, DOI 10.1136/bmj.309.6967.1475; BRUNNER EJ, 1993, ATHEROSCLEROSIS, V102, P195, DOI 10.1016/0021-9150(93)90162-N; BULLERS S, 1994, WOMEN HEALTH, V22, P11; ELIASSON M, 1994, J CLIN EPIDEMIOL, V47, P513, DOI 10.1016/0895-4356(94)90298-4; ESCHWEGE E, 1985, HORM METAB RES, V15, P41; FERRARA A, 1994, AM J EPIDEMIOL, V140, P857, DOI 10.1093/oxfordjournals.aje.a117174; FOLSOM AR, 1993, AM J EPIDEMIOL, V138, P1023, DOI 10.1093/oxfordjournals.aje.a116821; FOLSOM AR, 1991, ATHEROSCLEROSIS, V191, P205; HEIN HO, 1992, J INTERN MED, V231, P477, DOI 10.1111/j.1365-2796.1992.tb00963.x; HEINRICH J, 1994, ARTERIOSCLER THROMB, V14, P54, DOI 10.1161/01.ATV.14.1.54; JUHANVAGUE I, 1993, ARTERIOSCLER THROMB, V13, P1865, DOI 10.1161/01.ATV.13.12.1865; KANNEL WB, 1987, JAMA-J AM MED ASSOC, V258, P1183, DOI 10.1001/jama.258.9.1183; KARASEK R, 1981, AM J PUBLIC HEALTH, V71, P694, DOI 10.2105/AJPH.71.7.694; LEE AJ, 1990, J CLIN EPIDEMIOL, V43, P913, DOI 10.1016/0895-4356(90)90075-Z; MARKOWE HLJ, 1985, BMJ-BRIT MED J, V291, P1312, DOI 10.1136/bmj.291.6505.1312; MARMOT M, 1995, J EPIDEMIOL COMMUN H, V49, P124, DOI 10.1136/jech.49.2.124; MARMOT M, 1991, BMJ-BRIT MED J, V303, P565, DOI 10.1136/bmj.303.6802.565; MARMOT MG, 1991, LANCET, V337, P1387, DOI 10.1016/0140-6736(91)93068-K; MARMOT MG, 1978, J EPIDEMIOL COMMUN H, V32, P244, DOI 10.1136/jech.32.4.244; MEADE TW, 1993, LANCET, V342, P1076, DOI 10.1016/0140-6736(93)92062-X; MEADE TW, 1987, HAEMOSTASIS THROMBOS, P697; PATEL P, 1995, BRIT MED J, V311, P711, DOI 10.1136/bmj.311.7007.711; PECK MN, 1995, SOC SCI MED, V41, P733, DOI 10.1016/0277-9536(94)00379-8; Power C., 1991, HLTH CLASS EARLY YEA; RABBANI LE, 1994, ATHEROSCLEROSIS, V105, P1, DOI 10.1016/0021-9150(94)90002-7; REAVEN GM, 1988, DIABETES, V37, P1595, DOI 10.2337/diabetes.37.12.1595; ROSENGREN A, 1990, BRIT MED J, V300, P634, DOI 10.1136/bmj.300.6725.634; SMITH GD, 1992, BRIT MED J, V304, P638, DOI 10.1136/bmj.304.6827.638-b; SMITH GD, 1990, J EPIDEMIOL COMMUN H, V44, P265, DOI 10.1136/jech.44.4.265; WILHELMSEN L, 1984, NEW ENGL J MED, V311, P501, DOI 10.1056/NEJM198408233110804; WILSON TW, 1993, AM J EPIDEMIOL, V137, P292, DOI 10.1093/oxfordjournals.aje.a116676; YARNELL JWG, 1991, CIRCULATION, V83, P836, DOI 10.1161/01.CIR.83.3.836	36	205	210	0	5	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	APR 13	1996	347	9007					1008	1013		10.1016/S0140-6736(96)90147-6	http://dx.doi.org/10.1016/S0140-6736(96)90147-6			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UF380	8606563				2022-12-28	WOS:A1996UF38000012
J	Pittrof, R; Lees, C; Thompson, C; Pickles, A; Martin, JF; Campbell, S				Pittrof, R; Lees, C; Thompson, C; Pickles, A; Martin, JF; Campbell, S			Crossover study of glyceryl trinitrate patches for controlling pain in women with severe dysmenorrhoea	BRITISH MEDICAL JOURNAL			English	Article									INST PSYCHIAT,MRC,CHILD PSYCHIAT UNIT,LONDON SE5 8AF,ENGLAND; UNIV LONDON KINGS COLL,SCH MED & DENT,DEPT MED,LONDON SE5 8RX,ENGLAND; ST GEORGE HOSP,LONDON,ENGLAND	University of London; King's College London; University of London; King's College London; St Georges University London	Pittrof, R (corresponding author), UNIV LONDON KINGS COLL,SCH MED & DENT,DEPT OBSTET & GYNAECOL,LONDON SE5 8RX,ENGLAND.		Pickles, Andrew/A-9625-2011	Pickles, Andrew/0000-0003-1283-0346				DAWOOD MY, 1990, CLIN OBSTET GYNECOL, V33, P168, DOI 10.1097/00003081-199003000-00023; LEES C, 1994, LANCET, V343, P1325, DOI 10.1016/S0140-6736(94)92468-6; MILSOM I, 1994, AM J OBSTET GYNECOL, V170, P123; NOONAN PK, 1985, J PHARMACOKINET BIOP, V13, P143, DOI 10.1007/BF01059395; PULKKINEN M, 1992, ACTA OBSTET GYN SCAN, V71, P181, DOI 10.3109/00016349209009915	5	27	27	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 6	1996	312	7035					884	884						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UE371	8611877				2022-12-28	WOS:A1996UE37100022
J	Kodandapani, R; Pio, F; Ni, CZ; Piccialli, G; Klemsz, M; McKercher, S; Maki, RA; Ely, KR				Kodandapani, R; Pio, F; Ni, CZ; Piccialli, G; Klemsz, M; McKercher, S; Maki, RA; Ely, KR			A new pattern for helix-turn-helix recognition revealed by the PU.1 ETS-domain-DNA complex	NATURE			English	Article							CRYSTAL-STRUCTURE; ONCOGENE; BINDING; MOTIF	THE Ets family of transcription factors, of which there are now about 35 members(1,2), regulate gene expression during growth and development. They share a conserved domain of around 85 amino acids(3) which binds as a monomer to the DNA sequence 5'-C/ AGGAA/T-3'. We have determined the crystal structure of an ETS domain complexed with DNA, at 2.3-Angstrom resolution. The domain is similar to alpha + beta (winged) 'helix-turn-helix' proteins and interacts with a ten-base-pair region of duplex DNA which takes up a uniform curve of 8 degrees. The domain contacts the DNA by a novel loop-helix-loop architecture, Four of the amino acids that directly interact with the DNA are highly conserved: two arginines from the recognition helix lying in the major groove, one lysine from the 'wing' that binds upstream of the core GGAA sequence, and another lysine, from the 'turn' of the 'helix-turn-helix' motif, which binds downstream and on the opposite strand.	BURNHAM INST,LA JOLLA CANC RES CTR,LA JOLLA,CA 92037; UNIV NAPLES FEDERICO II,DIPARTIMENTO CHIM ORGAN & BIOL,I-80134 NAPLES,ITALY; NEUROCRINE BIOSCI,SAN DIEGO,CA 92121	Sanford Burnham Prebys Medical Discovery Institute; University of Naples Federico II; Neurocrine Biosciences				Piccialli, Gennaro/0000-0002-1313-2091; pio, frederic/0000-0003-2050-847X				BABCOCK MS, 1994, J MOL BIOL, V237, P98, DOI 10.1006/jmbi.1994.1212; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRUNGER AT, 1990, ACTA CRYSTALLOGR A, V46, P585, DOI 10.1107/S0108767390002355; BRUNGER AT, 1992, X PLOR MANUAL VERSIO; CLARK KL, 1993, NATURE, V364, P412, DOI 10.1038/364412a0; Donaldson LW, 1996, EMBO J, V15, P125, DOI 10.1002/j.1460-2075.1996.tb00340.x; ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071; FUREY W, 1990, AM CRYSTALLOGR ASS 2, V18, P73; HARRISON CJ, 1994, SCIENCE, V263, P224, DOI 10.1126/science.8284672; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; JONES TA, 1985, METHOD ENZYMOL, V115, P157; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KARIM FD, 1990, GENE DEV, V4, P1451, DOI 10.1101/gad.4.9.1451; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; LIANG H, 1994, NAT STRUCT BIOL, V1, P871, DOI 10.1038/nsb1294-871; MAVROTHALASSITIS G, 1994, ONCOGENE, V9, P425; MOREAUGACHELIN F, 1989, ONCOGENE, V4, P1449; MOREAUGACHELIN F, 1994, BBA-REV CANCER, V1198, P149, DOI 10.1016/0304-419X(94)90011-6; Parkinson G, 1996, ACTA CRYSTALLOGR D, V52, P57, DOI 10.1107/S0907444995011115; PIO F, 1995, J BIOL CHEM, V270, P24258, DOI 10.1074/jbc.270.41.24258; Ramachandran G N, 1968, Adv Protein Chem, V23, P283, DOI 10.1016/S0065-3233(08)60402-7; RAMAKRISHNAN V, 1993, NATURE, V362, P219, DOI 10.1038/362219a0; SCHULTZ SC, 1991, SCIENCE, V253, P1001, DOI 10.1126/science.1653449; WANG BC, 1985, METHOD ENZYMOL, V115, P90; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; WEMER MH, 1995, CELL, V83, P761; WERNER MH, 1994, FEBS LETT, V345, P125, DOI 10.1016/0014-5793(94)00401-3	27	266	270	0	13	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	APR 4	1996	380	6573					456	460		10.1038/380456a0	http://dx.doi.org/10.1038/380456a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UD590	8602247				2022-12-28	WOS:A1996UD59000067
J	Drubin, DG; Nelson, WJ				Drubin, DG; Nelson, WJ			Origins of cell polarity	CELL			English	Review							BUD-SITE-SELECTION; SACCHAROMYCES-CEREVISIAE GENE; EPITHELIAL MDCK CYSTS; CANINE KIDNEY-CELLS; PLASMA-MEMBRANE; TYROSINE PHOSPHORYLATION; BINDING PROTEIN; YEAST; MORPHOGENESIS; SURFACE		STANFORD UNIV,SCH MED,BECKMAN CTR MOLEC & GENET MED,DEPT MOLEC & CELLULAR PHYSIOL,STANFORD,CA 94305	Stanford University	Drubin, DG (corresponding author), UNIV CALIF BERKELEY,DEPT MOLEC & CELL BIOL,229 STANLEY HALL,BERKELEY,CA 94720, USA.							ADAMS AEM, 1990, J CELL BIOL, V111, P131, DOI 10.1083/jcb.111.1.131; ADAMSON P, 1992, J CELL BIOL, V119, P617, DOI 10.1083/jcb.119.3.617; AROETI B, 1993, J CELL BIOL, V123, P1149, DOI 10.1083/jcb.123.5.1149; BACALLAO R, 1989, J CELL BIOL, V109, P2817, DOI 10.1083/jcb.109.6.2817; BAUER F, 1993, MOL CELL BIOL, V13, P5070, DOI 10.1128/MCB.13.8.5070; BEHRENS J, 1993, J CELL BIOL, V120, P757, DOI 10.1083/jcb.120.3.757; BENDER A, 1993, P NATL ACAD SCI USA, V90, P9926, DOI 10.1073/pnas.90.21.9926; BENDER A, 1989, P NATL ACAD SCI USA, V86, P9976, DOI 10.1073/pnas.86.24.9976; BENNETT V, 1992, J BIOL CHEM, V267, P8703; BENNETT V, 1990, PHYSIOL REV, V70, P1029, DOI 10.1152/physrev.1990.70.4.1029; BRADYKALNAY SM, 1995, J CELL BIOL, V130, P977, DOI 10.1083/jcb.130.4.977; CHANG F, 1991, THESIS U CALIFORNIA; CHANT J, 1995, J CELL BIOL, V129, P751, DOI 10.1083/jcb.129.3.751; CHANT J, 1991, CELL, V65, P1213, DOI 10.1016/0092-8674(91)90016-R; CHANT J, 1995, J CELL BIOL, V129, P767, DOI 10.1083/jcb.129.3.767; CHENEVERT J, 1994, GENETICS, V136, P1287; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; CVRCKOVA F, 1995, GENE DEV, V9, P1817, DOI 10.1101/gad.9.15.1817; DEBEUREGARD C, 1995, EMBO J, V14, P409; DORER R, 1995, J CELL BIOL, V131, P845, DOI 10.1083/jcb.131.4.845; DRUBIN DG, 1993, MOL BIOL CELL, V4, P1277, DOI 10.1091/mbc.4.12.1277; FATH KR, 1994, J CELL BIOL, V126, P661, DOI 10.1083/jcb.126.3.661; FIEDLER K, 1995, CELL, V81, P309, DOI 10.1016/0092-8674(95)90380-1; FLESCHER EG, 1993, J CELL BIOL, V122, P373, DOI 10.1083/jcb.122.2.373; FRIEDERICH E, 1989, CELL, V59, P461, DOI 10.1016/0092-8674(89)90030-5; FUJITA A, 1994, NATURE, V372, P567, DOI 10.1038/372567a0; GIMENO CJ, 1990, SCIENCE, V257, P626; GOVINDAN B, 1995, J CELL BIOL, V128, P1055, DOI 10.1083/jcb.128.6.1055; GRAVOTTA D, 1990, J CELL BIOL, V111, P2893, DOI 10.1083/jcb.111.6.2893; GUMBINER BM, 1993, NEURON, V11, P551, DOI 10.1016/0896-6273(93)90068-3; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; HAMMERTON RW, 1991, SCIENCE, V254, P847, DOI 10.1126/science.1658934; HEALY AM, 1991, MOL CELL BIOL, V11, P5767, DOI 10.1128/MCB.11.11.5767; HEINTZELMAN MB, 1992, CURR TOP DEV BIOL, V26, P93, DOI 10.1016/S0070-2153(08)60442-1; HERSKOWITZ I, 1995, IN PRESS COLD SPRING, V60; HU RJ, 1995, J CELL BIOL, V128, P1069, DOI 10.1083/jcb.128.6.1069; HUBER LA, 1993, J CELL BIOL, V123, P35, DOI 10.1083/jcb.123.1.35; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; IKONEN E, 1995, CELL, V81, P571, DOI 10.1016/0092-8674(95)90078-0; JACKSON CL, 1991, CELL, V67, P389, DOI 10.1016/0092-8674(91)90190-A; KELLOGG DR, 1995, J CELL BIOL, V130, P675, DOI 10.1083/jcb.130.3.675; Kemler R, 1992, Semin Cell Biol, V3, P149; KNUDSEN KA, 1995, J CELL BIOL, V130, P67, DOI 10.1083/jcb.130.1.67; KRON SJ, 1994, MOL BIOL CELL, V5, P1003, DOI 10.1091/mbc.5.9.1003; LAFONT F, 1994, NATURE, V372, P801; LEW DJ, 1995, CURR OPIN GENET DEV, V5, P17, DOI 10.1016/S0959-437X(95)90048-9; LEWIS JE, 1994, J CELL SCI, V107, P3615; LI R, 1995, J CELL BIOL, V128, P599, DOI 10.1083/jcb.128.4.599; LILLIE SH, 1994, J CELL BIOL, V125, P825, DOI 10.1083/jcb.125.4.825; LISANTI MP, 1990, TRENDS BIOCHEM SCI, V15, P113, DOI 10.1016/0968-0004(90)90195-H; Lombardo C. R., 1994, Molecular Biology of the Cell, V5, p47A; MADDEN K, 1992, MOL BIOL CELL, V3, P1025, DOI 10.1091/mbc.3.9.1025; MARRS JA, 1995, J CELL BIOL, V129, P507, DOI 10.1083/jcb.129.2.507; MATTER K, 1994, J CELL BIOL, V126, P991, DOI 10.1083/jcb.126.4.991; MAYS RW, 1994, CURR OPIN CELL BIOL, V6, P16, DOI 10.1016/0955-0674(94)90111-2; MAYS RW, 1995, J CELL BIOL, V130, P1105, DOI 10.1083/jcb.130.5.1105; MAZZONI C, 1993, J CELL BIOL, V123, P1821, DOI 10.1083/jcb.123.6.1821; MCNEILL H, 1990, CELL, V62, P309, DOI 10.1016/0092-8674(90)90368-O; Nelson W J, 1990, Semin Cell Biol, V1, P359; PALMER RE, 1992, J CELL BIOL, V119, P583, DOI 10.1083/jcb.119.3.583; PARK HO, 1993, NATURE, V365, P269, DOI 10.1038/365269a0; PREUSS D, 1992, MOL BIOL CELL, V3, P789, DOI 10.1091/mbc.3.7.789; PRINGLE JR, 1995, IN PRESS COLD SPRING, V60; READ EB, 1992, MOL BIOL CELL, V3, P429, DOI 10.1091/mbc.3.4.429; RIMM DL, 1995, P NATL ACAD SCI USA, V92, P8813, DOI 10.1073/pnas.92.19.8813; RODRIGUEZBOULAN E, 1992, ANNU REV CELL BIOL, V8, P395, DOI 10.1146/annurev.cb.08.110192.002143; RUGGIERI R, 1992, MOL CELL BIOL, V12, P758, DOI 10.1128/MCB.12.2.758; SANDERS SL, 1994, CURR BIOL, V4, P907, DOI 10.1016/S0960-9822(00)00201-3; SEGALL JE, 1993, P NATL ACAD SCI USA, V90, P8332, DOI 10.1073/pnas.90.18.8332; SIMON MN, 1995, NATURE, V376, P702, DOI 10.1038/376702a0; SIMON VR, 1995, J CELL BIOL, V130, P345, DOI 10.1083/jcb.130.2.345; TERBUSH DR, 1995, J CELL BIOL, V130, P299, DOI 10.1083/jcb.130.2.299; TSUKITA S, 1991, J CELL BIOL, V113, P867, DOI 10.1083/jcb.113.4.867; VALTZ N, 1995, J CELL BIOL, V131, P863, DOI 10.1083/jcb.131.4.863; VEGASALAS DE, 1987, J CELL BIOL, V104, P905, DOI 10.1083/jcb.104.4.905; WACKER IU, 1992, J CELL BIOL, V117, P813, DOI 10.1083/jcb.117.4.813; WALKER RA, 1993, ANNU REV BIOCHEM, V62, P429; WANG AZ, 1990, J CELL SCI, V95, P137; WANG AZ, 1990, J CELL SCI, V95, P153; WANG TT, 1995, MOL BIOL CELL, V6, P1011, DOI 10.1091/mbc.6.8.1011; Warren G, 1996, CELL, V84, P395, DOI 10.1016/S0092-8674(00)81284-2; WELCH MD, 1994, CURR OPIN CELL BIOL, V6, P110, DOI 10.1016/0955-0674(94)90124-4; YAMOCHI W, 1994, J CELL BIOL, V125, P1077, DOI 10.1083/jcb.125.5.1077; YEH E, 1995, J CELL BIOL, V130, P687, DOI 10.1083/jcb.130.3.687; ZHAO ZS, 1995, MOL CELL BIOL, V15, P5246; ZHENG Y, 1995, J BIOL CHEM, V270, P626, DOI 10.1074/jbc.270.2.626; ZIMAN M, 1993, MOL BIOL CELL, V4, P1307, DOI 10.1091/mbc.4.12.1307; ZIMAN M, 1991, MOL CELL BIOL, V11, P3537, DOI 10.1128/MCB.11.7.3537	89	869	881	1	75	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 9	1996	84	3					335	344		10.1016/S0092-8674(00)81278-7	http://dx.doi.org/10.1016/S0092-8674(00)81278-7			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TV708	8608587	Bronze			2022-12-28	WOS:A1996TV70800002
J	Bakken, JS; Krueth, J; WilsonNordskog, C; Tilden, RL; Asanovich, K; Dumler, JS				Bakken, JS; Krueth, J; WilsonNordskog, C; Tilden, RL; Asanovich, K; Dumler, JS			Clinical and laboratory characteristics of human granulocytic ehrlichiosis	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								Objective.-To characterize the clinical and laboratory features observed in patients with human granulocytic ehrlichiosis (HGE) and evaluate the utility of the diagnostic tools used to confirm the diagnosis. Design.-Retrospective case study of 41 patients with laboratory-diagnosed HGE. Setting.-A total of 228 patients from Minnesota and Wisconsin were evaluated between June 1990 and May 1995. Methods.-Cases were presumptively identified by a history of an influenzalike illness acquired in an area known to be endemic for ticks. Diagnostic laboratory testing included microscopic examination of Wright-stained peripheral blood smears for presence of neutrophilic morulae, polymerase chain reaction (PCR) analysis of acute-phase blood samples for the Ehrlichia phagocytophila/Ehrlichia equi group DNA, and evaluation of serological responses by indirect immunofluorescent antibody assay (IFA), using E equi as antigen. Results.-All patients presented with a temperature of at least 37.6 degrees C, and most had headache, myalgias, chills, and varying combinations of leukopenia, anemia, and thrombocytopenia. Eighty percent of the patients tested demonstrated morulae in the cytoplasm of peripheral blood neutrophils. Only 16 of 37 patients tested by PCR were positive for HGE, whereas serum IFA assays of acute or convalescent blood samples detected antibodies against E equi in 38 of 40 patients tested. Two patients died, and the calculated case fatality rate was 4.9%. Conclusions.-Human granulocytic ehrlichiosis is being increasingly recognized in Wisconsin and Minnesota. A more severe illness is associated with increased age, anemia, increased percentage of neutrophils and decreased percentage of lymphocytes in peripheral blood, and presence of morulae in neutrophils. The differential diagnosis for patients who develop an influenzalike illness following a tick bite should include HGE. Microscopic examination of the acute-phase blood smear to detect neutrophilic morulae is currently the quickest and most practical screening method for diagnosing HGE in the upper Midwest.	DULUTH CLIN LTD, DIV LAB MED, DULUTH, MN 55805 USA; DULUTH CLIN LTD, DIV EDUC & RES, DULUTH, MN 55805 USA; UNIV MARYLAND, SCH MED, DEPT PATHOL, BALTIMORE, MD 21201 USA	University System of Maryland; University of Maryland Baltimore	Bakken, JS (corresponding author), DULUTH CLIN LTD, INFECT DIS SECT, 400 E 3RD ST, DULUTH, MN 55805 USA.							ANDERSON BE, 1991, J CLIN MICROBIOL, V29, P2838, DOI 10.1128/JCM.29.12.2838-2842.1991; BAKKEN JS, 1994, JAMA-J AM MED ASSOC, V272, P212, DOI 10.1001/jama.272.3.212; BAKKEN JS, 1995, 33RD ANN M INF DIS S; BARLOUGH JE, 1995, J CLIN MICROBIOL, V33, P3333, DOI 10.1128/JCM.33.12.3333-3334.1995; BROUQUI P, 1995, LANCET, V346, P782, DOI 10.1016/S0140-6736(95)91544-3; Centers for Disease Control and Prevention (CDC), 1995, MMWR Morb Mortal Wkly Rep, V44, P593; CHEN SM, 1994, J CLIN MICROBIOL, V32, P589, DOI 10.1128/JCM.32.3.589-595.1994; DAWSON JE, 1990, J INFECT DIS, V162, P91, DOI 10.1093/infdis/162.1.91; DUMLER JS, 1995, CLIN INFECT DIS, V20, P1102, DOI 10.1093/clinids/20.5.1102; DUMLER JS, 1995, J CLIN MICROBIOL, V33, P1098, DOI 10.1128/JCM.33.5.1098-1103.1995; DUMLER JS, 1995, 35TH INT C ANT CHEM; DUMLER JS, 1995, NOV ASS MOL PATH ANN; EVERETT ED, 1994, ANN INTERN MED, V120, P730, DOI 10.7326/0003-4819-120-9-199405010-00002; FISH D, 1995, AM J MED, V98, pS2, DOI 10.1016/S0002-9343(99)80038-2; FISHBEIN DB, 1994, ANN INTERN MED, V120, P736, DOI 10.7326/0003-4819-120-9-199405010-00003; FOGGIE A, 1951, J PATHOL BACTERIOL, V63, P1, DOI 10.1002/path.1700630103; HARDALO CJ, 1995, CLIN INFECT DIS, V21, P910, DOI 10.1093/clinids/21.4.910; MADIGAN JE, 1995, J INFECT DIS, V172, P1141, DOI 10.1093/infdis/172.4.1141; MAEDA K, 1987, NEW ENGL J MED, V316, P853, DOI 10.1056/NEJM198704023161406; MAGNARELLI LA, 1995, J CLIN MICROBIOL, V33, P2710, DOI 10.1128/JCM.33.10.2710-2714.1995; PANCHOLI P, 1995, J INFECT DIS, V172, P1007, DOI 10.1093/infdis/172.4.1007; PANCHOLI P, 1995, 33RD ANN M INF DIS S; REED K, 1995, MARSHFIELD LAB NEWS, V18, P1; REED KD, 1995, JAMA-J AM MED ASSOC, V273, P23, DOI 10.1001/jama.273.1.23b; RICHTER PJ, IN PRESS J MED ENTOM; TELFORD SR, 1995, ANN INTERN MED, V123, P277, DOI 10.7326/0003-4819-123-4-199508150-00006; TELFORD SR, 1995, 35TH INT C ANT CHEM; 1993, US 1990 CENSUS W E N	28	366	385	0	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 17	1996	275	3					199	205		10.1001/jama.275.3.199	http://dx.doi.org/10.1001/jama.275.3.199			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TP282	8604172				2022-12-28	WOS:A1996TP28200027
J	ODell, JR; Haire, CE; Erikson, N; Drymalski, W; Palmer, W; Eckhoff, PJ; Garwood, V; Maloley, P; Klassen, LW; Wees, S; Klein, H; Moore, GF				ODell, JR; Haire, CE; Erikson, N; Drymalski, W; Palmer, W; Eckhoff, PJ; Garwood, V; Maloley, P; Klassen, LW; Wees, S; Klein, H; Moore, GF			Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine and hydroxychloroquine, or a combination of all three medications	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CONTROLLED CLINICAL-TRIAL; GOLD SODIUM THIOMALATE; DOUBLE-BLIND; PRELIMINARY CRITERIA; PULSE METHOTREXATE; D-PENICILLAMINE; 2ND-LINE DRUGS; PLACEBO; EFFICACY; AURANOFIN	mon disease that causes substantial morbidity and mortality. The responses of patients with rheumatoid arthritis to treatment with a single so-called disease-modifying drug, such as methotrexate, are often suboptimal. Despite limited data, many patients are treated with combinations of these drugs. Methods. We enrolled 102 patients with rheumatoid arthritis and poor responses to at least one disease-modifying drug in a two-year, double-blind, randomized study of treatment with methotrexate alone (7.5 to 17.5 mg per week), the combination of sulfasalazine (500 mg twice daily) and hydroxychloroquine (200 mg twice dally), or all three drugs. The dose of methotrexate was adjusted in an attempt to achieve remission in all patients. The primary end point of the study was the successful completion of two years of treatment with 50 percent improvement in composite symptoms of arthritis and no evidence of drug toxicity. Results. Fifty of the 102 patients had 50 percent improvement at nine months and maintained at least that degree of improvement for two years without evidence of major drug toxicity. Among them were 24 of 31 patients treated with all three drugs (77 percent), 12 of 36 patients treated with methotrexate alone (33 percent, P<0.001 for the comparison with the three-drug group), and 14 of 35 patients treated with sulfasalazine and hydroxychloroquine (40 percent, P=0.003 for the comparison with the three-drug group). Seven patients in the methotrexate group and three patients in each of the other two groups discontinued treatment because of drug toxicity. Conclusions. In patients with rheumatoid arthritis, combination therapy with methotrexate, sulfasalazine, and hydroxychloroquine is more effective than either methotrexate alone or a combination of sulfasalazine and hydroxychloroquine.	OMAHA VET AFFAIRS MED CTR,OMAHA,NE 68105	US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Nebraska-Western Iowa Health Care System	ODell, JR (corresponding author), UNIV NEBRASKA,MED CTR,DEPT INTERNAL MED,600 S 42ND ST,OMAHA,NE 68198, USA.							ALARCON GS, 1989, ARTHRITIS RHEUM, V32, P671, DOI 10.1002/anr.1780320603; ALARCON GS, 1987, J RHEUMATOL, V14, P93; ANDERSEN PA, 1985, ANN INTERN MED, V103, P489, DOI 10.7326/0003-4819-103-4-489; ARNETT FC, 1988, ARTHRITIS RHEUM, V31, P315, DOI 10.1002/art.1780310302; CASH JM, 1994, NEW ENGL J MED, V330, P1368; DIXON ASJ, 1975, ANN RHEUM DIS, V34, P416, DOI 10.1136/ard.34.5.416; EGGER MJ, 1985, ARTHRITIS RHEUM, V28, P613, DOI 10.1002/art.1780280603; FELSON DT, 1993, ARTHRITIS RHEUM-US, V36, P729, DOI 10.1002/art.1780360601; FELSON DT, 1992, ARTHRITIS RHEUM, V35, P1117, DOI 10.1002/art.1780351003; FELSON DT, 1990, ARTHRITIS RHEUM, V33, P1449, DOI 10.1002/art.1780331001; FELSON DT, 1994, ARTHRITIS RHEUM, V37, P1487, DOI 10.1002/art.1780371012; GIBSON T, 1987, BRIT J RHEUMATOL, V26, P279; HANNONEN P, 1993, ARTHRITIS RHEUM-US, V36, P1501, DOI 10.1002/art.1780361104; HOCHBERG MC, 1981, EPIDEMIOL REV, V3, P27, DOI 10.1093/oxfordjournals.epirev.a036238; KREMER JM, 1992, ARTHRITIS RHEUM, V35, P138, DOI 10.1002/art.1780350203; MORAND EF, 1992, J RHEUMATOL, V19, P1998; O'Dell J., 1995, Arthritis and Rheumatism, V38, pS366; PAULUS HE, 1990, ARTHRITIS RHEUM, V33, P477, DOI 10.1002/art.1780330403; PINALS RS, 1981, ARTHRITIS RHEUM, V24, P1308, DOI 10.1002/art.1780241012; PINALS RS, 1986, ARTHRITIS RHEUM, V29, P1427, DOI 10.1002/art.1780291202; PINALS RS, 1987, ARTHRITIS RHEUM, V30, P459; PINCUS T, 1994, ANN INTERN MED, V120, P26, DOI 10.7326/0003-4819-120-1-199401010-00005; SCOTT DL, 1987, LANCET, V1, P1108; SIGLER JW, 1974, ANN INTERN MED, V80, P21, DOI 10.7326/0003-4819-80-1-21; STEINBROCKER O, 1949, JAMA-J AM MED ASSOC, V140, P659, DOI 10.1001/jama.1949.02900430001001; TAGGART AJ, 1987, BRIT J RHEUMATOL, V26, P32; WARD JR, 1983, ARTHRITIS RHEUM, V26, P1303, DOI 10.1002/art.1780261102; WEINBLATT ME, 1993, ARTHRITIS RHEUM, V36, pS79; WEINBLATT ME, 1994, ARTHRITIS RHEUM, V37, P1492, DOI 10.1002/art.1780371013; WEINBLATT ME, 1985, NEW ENGL J MED, V312, P818, DOI 10.1056/NEJM198503283121303; WILLIAMS HJ, 1985, ARTHRITIS RHEUM-US, V28, P721, DOI 10.1002/art.1780280702; WILLIAMS HJ, 1988, ARTHRITIS RHEUM, V31, P702, DOI 10.1002/art.1780310602; WILLIAMS HJ, 1992, ARTHRITIS RHEUM, V35, P259, DOI 10.1002/art.1780350304; WILLKENS RF, 1992, ARTHRITIS RHEUM-US, V35, P849, DOI 10.1002/art.1780350802; WOLFE F, 1990, J RHEUMATOL, V17, P994; WOLFE F, 1994, ARTHRITIS RHEUM-US, V37, P481, DOI 10.1002/art.1780370408; Zar JH., 1999, BIOSTAT ANAL; [No title captured]	38	519	562	0	19	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 16	1996	334	20					1287	1291		10.1056/NEJM199605163342002	http://dx.doi.org/10.1056/NEJM199605163342002			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UK880	8609945				2022-12-28	WOS:A1996UK88000002
J	Sandlund, JT; Downing, JR; Crist, WM				Sandlund, JT; Downing, JR; Crist, WM			Medical progress - Non-Hodgkin's lymphoma in childhood	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							ACUTE LYMPHOBLASTIC-LEUKEMIA; PEDIATRIC-ONCOLOGY-GROUP; T-CELL LEUKEMIA; BONE-MARROW TRANSPLANTATION; HIGH-DOSE METHOTREXATE; C-MYC ONCOGENE; BURKITT-LYMPHOMA; RANDOMIZED TRIAL; DNA-BINDING; STAGE-III		ST JUDE CHILDRENS RES HOSP, DEPT LAB MED & PATHOL, MEMPHIS, TN 38105 USA; ST JUDE CHILDRENS RES HOSP, DEPT TUMOR CELL BIOL, MEMPHIS, TN 38105 USA; UNIV TENNESSEE, COLL MED, MEMPHIS, TN USA	St Jude Children's Research Hospital; St Jude Children's Research Hospital; University of Tennessee System; University of Tennessee Health Science Center	Sandlund, JT (corresponding author), ST JUDE CHILDRENS RES HOSP, DEPT HEMATOL ONCOL, 332 N LAUDERDALE ST, MEMPHIS, TN 38105 USA.		Downing, James R./N-8102-2018		NATIONAL CANCER INSTITUTE [P01CA023099, P30CA021765, P01CA020180] Funding Source: NIH RePORTER; NCI NIH HHS [P30 CA-21765, P01 CA-23099, P01 CA-20180] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMS JM, 1985, NATURE, V318, P533, DOI 10.1038/318533a0; ANAGNOSTOPOULOS I, 1989, BLOOD, V74, P810; ANDERSON JR, 1983, NEW ENGL J MED, V308, P559, DOI 10.1056/NEJM198303103081003; ANDERSON JR, 1993, J CLIN ONCOL, V11, P1024, DOI 10.1200/JCO.1993.11.6.1024; [Anonymous], 1982, CANCER, V49, P2112; AYER DE, 1993, CELL, V72, P211, DOI 10.1016/0092-8674(93)90661-9; BASH RO, 1993, BLOOD, V81, P2110; BERNARD A, 1982, BLOOD, V59, P549; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BLEYER WA, 1990, CA-CANCER J CLIN, V40, P355, DOI 10.3322/canjclin.40.6.355; BOEHM T, 1991, P NATL ACAD SCI USA, V88, P4367, DOI 10.1073/pnas.88.10.4367; BOWMAN WP, 1992, P AN M AM SOC CLIN, V11, P277; BRECHER M, 1992, P AN M AM SOC CLIN, V11, P430; CAIRO MS, 1994, P AN M AM SOC CLIN, V13, P392; CHILCOTE RR, 1991, P AN M AM SOC CLIN, V10, P289; COSSMAN J, 1983, CANCER RES, V43, P4486; CRIST WM, 1981, CANCER, V48, P2070, DOI 10.1002/1097-0142(19811101)48:9<2070::AID-CNCR2820480925>3.0.CO;2-U; CROCE CM, 1984, P NATL ACAD SCI-BIOL, V81, P3170, DOI 10.1073/pnas.81.10.3170; DAHL GV, 1985, BLOOD, V66, P1110; DALLAFAVERA R, 1982, P NATL ACAD SCI-BIOL, V79, P7824, DOI 10.1073/pnas.79.24.7824; ELLAURIE M, 1989, PEDIATR RES, V25, pA150; GORDON BG, 1992, BLOOD, V11, P2938; GU W, 1994, SCIENCE, V264, P251, DOI 10.1126/science.8146655; GU W, 1993, P NATL ACAD SCI USA, V90, P2935, DOI 10.1073/pnas.90.7.2935; GUTIERREZ MI, 1992, BLOOD, V79, P3261; HADDY TB, 1991, J CLIN ONCOL, V9, P1973, DOI 10.1200/JCO.1991.9.11.1973; HADDY TB, 1989, MED PEDIATR ONCOL, V17, P418; HATANO M, 1991, SCIENCE, V253, P79, DOI 10.1126/science.1676542; HENDERSON S, 1991, CELL, V65, P1107, DOI 10.1016/0092-8674(91)90007-L; HSU HL, 1994, P NATL ACAD SCI USA, V91, P3181, DOI 10.1073/pnas.91.8.3181; HUTCHISON RE, 1989, CANCER-AM CANCER SOC, V64, P23, DOI 10.1002/1097-0142(19890701)64:1<23::AID-CNCR2820640105>3.0.CO;2-T; HUTCHISON RE, 1995, J CLIN ONCOL, V13, P2023, DOI 10.1200/JCO.1995.13.8.2023; HVIZDALA EV, 1991, J CLIN ONCOL, V9, P1189, DOI 10.1200/JCO.1991.9.7.1189; HVIZDALA EV, 1988, J CLIN ONCOL, V6, P26, DOI 10.1200/JCO.1988.6.1.26; KADIN ME, 1991, J CLIN ONCOL, V9, P533, DOI 10.1200/JCO.1991.9.4.533; KADIN ME, 1994, J CLIN ONCOL, V12, P884, DOI 10.1200/JCO.1994.12.5.884; KENNEDY MA, 1991, P NATL ACAD SCI USA, V88, P8900, DOI 10.1073/pnas.88.20.8900; LINK MP, 1983, BLOOD, V61, P838; LINK MP, 1990, NEW ENGL J MED, V322, P1169, DOI 10.1056/NEJM199004263221701; LINK MP, 1993, MED PEDIATR ONCOL, V21, P532; LIPSHULTZ SE, 1991, NEW ENGL J MED, V324, P808, DOI 10.1056/NEJM199103213241205; LU M, 1991, EMBO J, V10, P2905, DOI 10.1002/j.1460-2075.1991.tb07840.x; Magrath I, 1996, J CLIN ONCOL, V14, P925, DOI 10.1200/JCO.1996.14.3.925; MAGRATH I, 1991, HEMATOL ONCOL, V9, P267; MAGRATH IT, 1984, BLOOD, V63, P1102; MAGRATH IT, 1993, PRINCIPLES PRACTICE, P537; MEADOWS AT, 1989, J CLIN ONCOL, V7, P92, DOI 10.1200/JCO.1989.7.1.92; MELLENTIN JD, 1989, CELL, V58, P77, DOI 10.1016/0092-8674(89)90404-2; MORRIS SW, 1994, SCIENCE, V263, P1281, DOI 10.1126/science.8122112; MORRIS SW, 1995, SCIENCE, V267, P316, DOI 10.1126/science.267.5196.316-b; MULLERWEIHRICH S, 1985, MALIGNANT LYMPHOMAS, V32, P633; MURPHY SB, 1980, CANCER, V45, P630, DOI 10.1002/1097-0142(19800215)45:4<630::AID-CNCR2820450403>3.0.CO;2-5; MURPHY SB, 1989, J CLIN ONCOL, V7, P186, DOI 10.1200/JCO.1989.7.2.186; MURPHY SB, 1986, J CLIN ONCOL, V4, P1732, DOI 10.1200/JCO.1986.4.12.1732; MURPHY SB, 1983, J CLIN ONCOL, V1, P326, DOI 10.1200/JCO.1983.1.5.326; MURPHY SB, 1978, NEW ENGL J MED, V299, P1446, DOI 10.1056/NEJM197812282992606; MURPHY SB, 1980, SEMIN ONCOL, V7, P332; PACKHAM G, 1995, BBA-REV CANCER, V1242, P11, DOI 10.1016/0304-419X(94)00015-T; PACKHAM G, 1994, MOL CELL BIOL, V14, P5741, DOI 10.1128/MCB.14.9.5741; Parker SL, 1996, CA-CANCER J CLIN, V46, P5, DOI 10.3322/canjclin.46.1.5; PATTE C, 1991, J CLIN ONCOL, V9, P123, DOI 10.1200/JCO.1991.9.1.123; PATTE C, 1986, J CLIN ONCOL, V4, P1219, DOI 10.1200/JCO.1986.4.8.1219; PATTE C, 1992, MED PEDIATR ONCOL, V20, P105, DOI 10.1002/mpo.2950200204; PATTE C, 1993, P 5 INT C MAL LYMPH, P52; PEDROSA F, 1993, MED PEDIATR ONCOL, V21, P532; Perel Y, 1990, MED PEDIATR ONCOL, V18, P397; PHILIP T, 1986, EUR J CANCER CLIN ON, V22, P1015, DOI 10.1016/0277-5379(86)90070-2; PHILIP T, 1988, J CLIN ONCOL, V6, P1118, DOI 10.1200/JCO.1988.6.7.1118; Poplack D.G, 1993, PRINCIPLES PRACTICE, V2nd, P3; PRENDERGAST GC, 1991, CELL, V65, P395, DOI 10.1016/0092-8674(91)90457-A; PUI CH, 1991, NEW ENGL J MED, V325, P1682, DOI 10.1056/NEJM199112123252402; PUI CH, 1992, LEUKEMIA LYMPHOMA, V7, P259, DOI 10.3109/10428199209049777; Razzouk BI, 1996, J INFECT DIS, V173, P529, DOI 10.1093/infdis/173.3.529; REITER A, 1995, J CLIN ONCOL, V13, P359, DOI 10.1200/JCO.1995.13.2.359; REITER A, 1992, BLOOD, V80, P2471; REITER A, 1994, J CLIN ONCOL, V12, P899, DOI 10.1200/JCO.1994.12.5.899; Ries L, 1994, NIH PUBLICATION, V94-2789; ROONEY CM, 1995, LANCET, V345, P9, DOI 10.1016/S0140-6736(95)91150-2; ROPER M, 1983, BLOOD, V61, P830; SANDLUND JT, 1991, LEUKEMIA, V5, P71; SANDLUND JT, 1994, MED PEDIATR ONCOL, V23, P350, DOI 10.1002/mpo.2950230406; SANDLUND JT, 1994, BLOOD, V84, P2467, DOI 10.1182/blood.V84.8.2467.bloodjournal8482467; SANDLUND JT, 1994, LEUKEMIA, V8, P30; SANDLUND JT, 1994, J CLIN ONCOL, V12, P895, DOI 10.1200/JCO.1994.12.5.895; SANDLUND JT, 1993, CANCER RES, V52, P127; SANDLUND JT, 1991, CLIN PEDIAT ONCOLOGY, P337; SANTANA VM, 1993, LEUKEMIA, V7, P187; SCHWENN MR, 1991, J CLIN ONCOL, V9, P133, DOI 10.1200/JCO.1991.9.1.133; SHIOTA M, 1995, BLOOD, V86, P1954, DOI 10.1182/blood.V86.5.1954.bloodjournal8651954; STANSFELD AG, 1988, LANCET, V1, P292; STANSFELD AG, 1988, LANCET, V1, P372; STEIN H, 1985, BLOOD, V66, P848; SULLIVAN MP, 1985, CANCER-AM CANCER SOC, V55, P323, DOI 10.1002/1097-0142(19850115)55:2<323::AID-CNCR2820550204>3.0.CO;2-9; SYNOLD TW, 1994, J CLIN INVEST, V94, P1996, DOI 10.1172/JCI117552; Taylor AMR, 1996, BLOOD, V87, P423, DOI 10.1182/blood.V87.2.423.bloodjournal872423; TUBERGEN DG, 1995, J CLIN ONCOL, V13, P1368, DOI 10.1200/JCO.1995.13.6.1368; UCKUN FM, 1995, LEUKEMIA LYMPHOMA, V18, P195, DOI 10.3109/10428199509059607; WEINSTEIN HJ, 1984, BLOOD, V64, P422; WEINSTEIN HJ, 1983, J CLIN ONCOL, V1, P537, DOI 10.1200/JCO.1983.1.9.537; WOLLNER N, 1976, CANCER, V37, P123, DOI 10.1002/1097-0142(197601)37:1<123::AID-CNCR2820370119>3.0.CO;2-7; XIA Y, 1991, P NATL ACAD SCI USA, V88, P11416, DOI 10.1073/pnas.88.24.11416; YOUNG J L JR, 1986, Cancer, V58, P598, DOI 10.1002/1097-0142(19860715)58:2+<598::AID-CNCR2820581332>3.0.CO;2-C; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A; ZERVOS AS, 1994, CELL, V79, P388	105	290	303	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 9	1996	334	19					1238	1248		10.1056/NEJM199605093341906	http://dx.doi.org/10.1056/NEJM199605093341906			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UJ054	8606720				2022-12-28	WOS:A1996UJ05400006
J	Wilson, JM				Wilson, JM			Adenoviruses as gene-delivery vehicles	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CYSTIC-FIBROSIS		UNIV PENN,DEPT MOL & CELLULAR ENGN,PHILADELPHIA,PA 19104	University of Pennsylvania	Wilson, JM (corresponding author), UNIV PENN,WISTAR INST 204,INST HUMAN GENE THERAPY,3601 SPRUCE ST,PHILADELPHIA,PA 19104, USA.		Wilson, James M/F-9220-2011	Wilson, James M/0000-0002-9630-3131				CRYSTAL RG, 1994, NAT GENET, V8, P42, DOI 10.1038/ng0994-42; HAY JG, 1995, HUM GENE THER, V6, P1487, DOI 10.1089/hum.1995.6.11-1487; KNOWLES MR, 1995, NEW ENGL J MED, V333, P823, DOI 10.1056/NEJM199509283331302; ROSENFELD MA, 1992, CELL, V68, P143, DOI 10.1016/0092-8674(92)90213-V; Wilson JM, 1995, J CLIN INVEST, V96, P2547, DOI 10.1172/JCI118318; YANG YP, 1994, NAT GENET, V7, P362, DOI 10.1038/ng0794-362; YANG YP, 1995, NAT MED, V1, P890, DOI 10.1038/nm0995-890; ZABNER J, 1993, CELL, V75, P207, DOI 10.1016/0092-8674(93)80063-K	8	392	413	0	10	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 2	1996	334	18					1185	1187		10.1056/NEJM199605023341809	http://dx.doi.org/10.1056/NEJM199605023341809			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UG831	8602187				2022-12-28	WOS:A1996UG83100009
J	Luft, BJ; Dattwyler, RJ; Johnson, RC; Luger, SW; Bosler, EM; Rahn, DW; Masters, EJ; Grunwaldt, E; Gadgil, SD				Luft, BJ; Dattwyler, RJ; Johnson, RC; Luger, SW; Bosler, EM; Rahn, DW; Masters, EJ; Grunwaldt, E; Gadgil, SD			Azithromycin compared with amoxicillin in the treatment of erythema migrans - A double-blind, randomized, controlled trial	ANNALS OF INTERNAL MEDICINE			English	Article						erythema chronicum migrans; Lyme disease; azithromycin; amoxicillin; Borrelia burgdorferi	EARLY LYME-DISEASE; BORRELIA-BURGDORFERI; DOXYCYCLINE	Objective: To determine whether azithromycin or amoxicillin is more efficacious for the treatment of erythema migrans skin lesions, which are characteristic of Lyme disease. Design: Randomized, double-blind, double-dummy, multicenter study. Acute manifestations and sequelae were assessed using a standardized format. Baseline clinical characteristics and response were correlated with serologic results. Patients were followed for 180 days. Setting: 12 outpatient centers in eight states. Patients: 246 adult patients with erythema migrans lesions at least 5 cm in diameter were enrolled and were stratified by the presence of flu-like symptoms (such as fever, chills, headache, malaise, fatigue, arthralgias, and myalgias) before randomization. Intervention: Oral treatment with either amoxicillin, 500 mg three times daily for 20 days, or azithromycin, 500 mg once daily for 7 days. Patients who received azithromycin also received a dummy placebo so that the dosing schedules were identical. Results: Of 217 evaluable patients, those treated with amoxicillin were significantly more likely than those treated with azithromycin to achieve complete resolution of disease at day 20, the end of therapy (88% compared with 76%; P = 0.024). More azithromycin recipients (16%) I than amoxicillin recipients (4%) had relapse (P = 0.005). A partial response at day 20 was highly predictive of relapse (27% of partial responders had relapse compared with 6% of complete responders; P < 0.001). For patients treated with azithromycin, development of an antibody response increased the possibility of achieving a complete response (81% of seropositive patients achieved a complete response compared with 60% of seronegative patients; P = 0.043). Patients with multiple erythema migrans lesions were more likely than patients with single erythema migrans lesions (P < 0.001) to have a positive antibody titer at baseline (63% compared with 17% for IgM; 39% compared with 16% for IgG). Fifty-seven percent of patients who had relapse were seronegative at the time of relapse. Conclusions: A 20-day course of amoxicillin was found to be an effective therapeutic regimen for erythema migrans. Most patients were seronegative for Borrelia burgdorferi at the time of presentation with erythema migrans (65%) and at the time of relapse (57%).	UNIV MINNESOTA, DEPT MICROBIOL, MINNEAPOLIS, MN 55455 USA; KAISER PERMANENTE, ROCKY HILL, CT 06067 USA; FAMILY PHYSICIANS GRP, CAPE GIRARDEAU, MO 63703 USA; YALE UNIV, NEW HAVEN, CT USA; PFIZER INC, GROTON, CT USA	University of Minnesota System; University of Minnesota Twin Cities; Kaiser Permanente; Yale University; Pfizer	Luft, BJ (corresponding author), SUNY STONY BROOK, DEPT MED, HSC T-16, ROOM 020, STONY BROOK, NY 11794 USA.		Dattwyler, Raymond/ABH-2292-2021	Dattwyler, Raymond/0000-0002-1983-1301; Luft, Benjamin/0000-0001-9008-7004	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI032454] Funding Source: NIH RePORTER; NIAID NIH HHS [AI32454] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BARANTON G, 1992, INT J SYST BACTERIOL, V42, P378, DOI 10.1099/00207713-42-3-378; BERGER BW, 1988, ANN NY ACAD SCI, V539, P346, DOI 10.1111/j.1749-6632.1988.tb31868.x; BOERLIN P, 1992, INFECT IMMUN, V60, P1677, DOI 10.1128/IAI.60.4.1677-1683.1992; DATTWYLER RJ, 1988, NEW ENGL J MED, V319, P1441, DOI 10.1056/NEJM198812013192203; DATTWYLER RJ, 1990, LANCET, V336, P1404, DOI 10.1016/0140-6736(90)93103-V; DYKHUIZEN DE, 1993, P NATL ACAD SCI USA, V90, P10163, DOI 10.1073/pnas.90.21.10163; ENGSTROM SM, 1995, J CLIN MICROBIOL, V33, P419, DOI 10.1128/JCM.33.2.419-427.1995; FEIR D, 1994, AM J TROP MED HYG, V51, P475, DOI 10.4269/ajtmh.1994.51.475; LUFT BJ, 1989, REV INFECT DIS, V11, pS1518; LUFT BJ, 1992, JAMA-J AM MED ASSOC, V267, P1364, DOI 10.1001/jama.267.10.1364; MASSAROTTI EM, 1992, AM J MED, V92, P396, DOI 10.1016/0002-9343(92)90270-L; NADELMAN RB, 1992, ANN INTERN MED, V117, P273, DOI 10.7326/0003-4819-117-4-273; PREACMURSIC V, 1989, EUR J CLIN MICROBIOL, V8, P651, DOI 10.1007/BF01968150; RAHN DW, 1991, ANN INTERN MED, V114, P472, DOI 10.7326/0003-4819-114-6-472; STRLE F, 1992, J ANTIMICROB CHEMOTH, V30, P543, DOI 10.1093/jac/30.4.543; STRLE F, 1993, INFECTION, V21, P83, DOI 10.1007/BF01710737; WALLICH R, 1992, INFECT IMMUN, V60, P4856, DOI 10.1128/IAI.60.11.4856-4866.1992; WEBER K, 1986, Zentralblatt fuer Bakteriologie Mikrobiologie und Hygiene Series A, V263, P377; 1993, MMWR-MORBID MORTAL W, V42, P345; 1992, MED LETT DRUG THER, V34, P95	20	147	149	0	7	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 1	1996	124	9					785	+		10.7326/0003-4819-124-9-199605010-00002	http://dx.doi.org/10.7326/0003-4819-124-9-199605010-00002			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UG254	8610947				2022-12-28	WOS:A1996UG25400002
J	Hall, DT; Feldman, PD; Holberg, JB; McGrath, MA				Hall, DT; Feldman, PD; Holberg, JB; McGrath, MA			Fluorescent hydroxyl emissions from Saturn's ring atmosphere	SCIENCE			English	Article							IRRADIANCE COMPARISON EXPERIMENT-1; MICROMETEORITE EROSION; PLASMA TRANSPORT; MAGNETOSPHERE; TORUS; MODEL; HYDROGEN; ORIGIN; CLOUD; WATER	Just before Earth passed through Saturn's ring plane on 10 August 1995, the Hubble Space Telescope Faint Object Spectrograph detected ultraviolet fluorescent emissions from a tenuous atmosphere of OH molecules enveloping the rings. Brightnesses decrease with increasing distance above the rings, implying a scale height of about 0.45 Saturn radii (R(S)). A spatial scan 0.28R(S) above the A and B rings indicates OH column densities of about 10(13) cm(-2) and number densities of up to 700 cm(-3). Saturn's rings must produce roughly 10(25) to 10(29) OH molecules per second to maintain the observed OH distribution.	UNIV ARIZONA,LUNAR & PLANETARY LAB,TUCSON,AZ 85716; SPACE TELESCOPE SCI INST,BALTIMORE,MD 21218	University of Arizona; Space Telescope Science Institute	Hall, DT (corresponding author), JOHNS HOPKINS UNIV,CTR ASTROPHYS SCI,DEPT PHYS & ASTRON,BALTIMORE,MD 21218, USA.							BLAMONT J, 1974, NASA SP, P125; BROADFOOT AL, 1981, SCIENCE, V212, P206, DOI 10.1126/science.212.4491.206; BUDZIEN SA, 1994, ICARUS, V107, P164, DOI 10.1006/icar.1994.1014; CARLSON RW, 1980, NATURE, V283, P461, DOI 10.1038/283461a0; CHENG AF, 1982, J GEOPHYS RES-SPACE, V87, P4567, DOI 10.1029/JA087iA06p04567; CLARK RN, 1980, ICARUS, V44, P388, DOI 10.1016/0019-1035(80)90033-0; CONNERNEY JEP, 1984, NATURE, V312, P136, DOI 10.1038/312136a0; CONNERNEY JEP, 1986, GEOPHYS RES LETT, V13, P773, DOI 10.1029/GL013i008p00773; Cuzzi J.N., 1984, PLANETARY RINGS, V75, P73; CUZZI JN, 1990, ICARUS, V84, P467, DOI 10.1016/0019-1035(90)90049-F; DENNEFELD M, 1974, IAU S, V65, P471; DONES L, 1991, ICARUS, V92, P194, DOI 10.1016/0019-1035(91)90045-U; EVIATAR A, 1990, ANN GEOPHYS, V8, P725; GANBARUCH Z, 1994, J GEOPHYS RES-SPACE, V99, P11063, DOI 10.1029/93JA03143; HAFF PK, 1986, ICARUS, V66, P258, DOI 10.1016/0019-1035(86)90156-9; HAMILTON DP, 1993, NATURE, V365, P498, DOI 10.1038/365498c0; HAMILTON DP, 1994, SCIENCE, V264, P550, DOI 10.1126/science.264.5158.550; HARRISON H, 1967, SCIENCE, V157, P1175, DOI 10.1126/science.157.3793.1175; HILTON DA, 1988, ICARUS, V73, P248, DOI 10.1016/0019-1035(88)90096-6; IP WH, 1995, ICARUS, V115, P295, DOI 10.1006/icar.1995.1098; IP WH, 1983, J GEOPHYS RES-SPACE, V88, P819, DOI 10.1029/JA088iA02p00819; IP WH, 1984, J GEOPHYS RES-SPACE, V89, P8843, DOI 10.1029/JA089iA10p08843; Ip WH, 1996, ASTROPHYS J, V457, P922, DOI 10.1086/176785; JOHNSON RE, 1989, ICARUS, V77, P311, DOI 10.1016/0019-1035(89)90092-4; JOHNSON RE, 1993, EOS, V74, P569; JUDGE DL, 1980, SCIENCE, V207, P431, DOI 10.1126/science.207.4429.431; LAZARUS AJ, 1983, J GEOPHYS RES-SPACE, V88, P8831, DOI 10.1029/JA088iA11p08831; MORFILL GE, 1983, ICARUS, V55, P439, DOI 10.1016/0019-1035(83)90114-8; MORFILL GE, 1993, J GEOPHYS RES-SPACE, V98, P11285, DOI 10.1029/93JA00308; NORTHROP TG, 1982, J GEOPHYS RES-SPACE, V87, P6045, DOI 10.1029/JA087iA08p06045; NORTHROP TG, 1987, ICARUS, V70, P124, DOI 10.1016/0019-1035(87)90079-0; PILCHER CB, 1970, SCIENCE, V167, P1372, DOI 10.1126/science.167.3923.1372; POSPIESZALSKA MK, 1991, ICARUS, V93, P45, DOI 10.1016/0019-1035(91)90162-M; RICHARDSON JD, 1986, J GEOPHYS RES, V91, P8749, DOI 10.1029/JA091iA08p08749; RICHARDSON JD, 1992, J GEOPHYS RES-SPACE, V97, P13705, DOI 10.1029/92JA00920; ROTTMAN GJ, 1993, J GEOPHYS RES-ATMOS, V98, P10667, DOI 10.1029/93JD00462; SCHLEICHER DG, 1988, ASTROPHYS J, V331, P1058, DOI 10.1086/166622; SCHLEICHER DG, 1983, THESIS U MARYLAND CO; SHEMANSKY DE, 1992, J GEOPHYS RES-SPACE, V97, P4143, DOI 10.1029/91JA02805; SHEMANSKY DE, 1993, NATURE, V363, P329, DOI 10.1038/363329a0; SHEMANSKY DE, 1995, CALIBRATING HUBBLE S, P88; Shi M, 1995, J GEOPHYS RES-PLANET, V100, P26387, DOI 10.1029/95JE03099; SMYTH WH, 1993, ICARUS, V101, P18, DOI 10.1006/icar.1993.1002; WEISER H, 1977, SCIENCE, V197, P755, DOI 10.1126/science.197.4305.755-a; WOODS TN, 1993, J GEOPHYS RES-ATMOS, V98, P10679, DOI 10.1029/93JD00463	45	36	36	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 26	1996	272	5261					516	518		10.1126/science.272.5261.516	http://dx.doi.org/10.1126/science.272.5261.516			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UG826	8614798				2022-12-28	WOS:A1996UG82600033
J	Kaplan, GA; Pamuk, ER; Lynch, JW; Cohen, RD; Balfour, JL				Kaplan, GA; Pamuk, ER; Lynch, JW; Cohen, RD; Balfour, JL			Inequality in income and mortality in the United States: Analysis of mortality and potential pathways	BRITISH MEDICAL JOURNAL			English	Article							ISCHEMIC-HEART-DISEASE	Objective-To examine the relation between health outcomes and the equality with which income is distributed in the United States. Design-The degree of income inequality, defined as the percentage of total household income received by the less well off 50% of households, and changes in income inequality were calculated for the 50 states in 1980 and 1990. These measures were then examined in relation to all cause mortality adjusted for age for each state, age specific deaths, changes in mortalities, and other health outcomes and potential pathways for 1980, 1990, and 1989-91. Main outcome measure-Age adjusted mortality from all causes. Results-There was a significant correlation (r = 0 . 62, P < 0 . 001) between the percentage of total household income received by the less well off 50% in each state and all cause mortality, unaffected by adjustment for state median incomes. Income inequality was also significantly associated with age specific mortalities and rates of low birth weight, homicide, violent crime, work disability, expenditures on medical care and police protection, smoking, and sedentary activity. Rates of unemployment, imprisonment, recipients of income assistance and food stamps, lack of medical insurance, and educational outcomes were also worse as income inequality increased. Income inequality was also associated with mortality trends, and there was a suggestion of an impact of inequality trends on mortality trends. Conclusions-Variations between states in the inequality of the distribution of income are significantly associated with variations between states in a large number of health outcomes and social indicators and with mortality trends. These differences parallel relative investments in human and social capital. Economic policies that influence income and wealth inequality may have an important impact on the health of countries.	CTR DIS CONTROL & PREVENT,NATL CTR HLTH STAT,HYATTSVILLE,MD 20782	Centers for Disease Control & Prevention - USA; CDC National Center for Health Statistics (NCHS)	Kaplan, GA (corresponding author), CALIF DEPT HLTH SERV,HUMAN POPULAT LAB,BERKELEY,CA 94704, USA.		Lynch, John W/A-4797-2008; Kaplan, George/AAJ-2398-2020	Lynch, John W/0000-0003-2781-7902; 				Amler RW, 1987, CLOSING GAP BURDEN U; *CDC, 1990, BRFSS SUMM PREV REP; Cliff AD, 1988, ATLAS DIS DISTRIBUTI; DANZIGER S, 1989, AM ECON REV, V79, P310; FRITZELL J, 1993, ACTA SOCIOL, V36, P47, DOI 10.1177/000169939303600104; HAAN MN, 1989, PATHWAYS HLTH ROLE S, P76; HOLLAND WW, 1992, EUROPEAN COMMUNITY A; JUDGE K, 1995, BRIT MED J, V311, P1282, DOI 10.1136/bmj.311.7015.1282; KAPLAN GA, 1988, AM J EPIDEMIOL, V127, P1131, DOI 10.1093/oxfordjournals.aje.a114907; KAPLAN GA, 1995, PSYCHOSOM MED, V57, P208, DOI 10.1097/00006842-199505000-00002; KAWACHI I, 1994, INCOME INEQUALITY LI; MARMOT MG, 1987, ANNU REV PUBL HEALTH, V8, P111, DOI 10.1146/annurev.pu.08.050187.000551; MASON TJ, 1973, DHEW PUBLICATION NIH; MORGENSTERN H, 1982, AM J PUBLIC HEALTH, V72, P1336, DOI 10.2105/AJPH.72.12.1336; *NAT CTR ED STAT, 1994, DIG ED STAT STAT 199; *NAT CTR HLTH STAT, 1991, DHHS PUB; PERRY HM, 1994, J HYPERTENS, V12, P315; SCHWARTZ S, 1994, AM J PUBLIC HEALTH, V84, P819, DOI 10.2105/AJPH.84.5.819; STALLONES RA, 1980, SCI AM, V243, P53, DOI 10.1038/scientificamerican1180-53; SUSSER M, 1994, AM J PUBLIC HEALTH, V84, P825, DOI 10.2105/AJPH.84.5.825; SYME SL, 1976, AM J EPIDEMIOL, V104, P1; THUROW LC, 1980, ZERO-SUM SOC; *US BUR CENS, 1992, CURR POP REP P60, V184; *US BUR CENS, 1992, 1990 CENS POP; *US BUR CENS, 1992, GOV FIN 1990 GF; *US BUR CENS, 1992, 1994 STAT ABSTR US; *US BUR JUST STAT, 1992, PRIS STAT FED I 1990; *US BUR LAB STAT, 1993, GEOGR PROF EMPL UN 1; WILKINSON RG, 1992, BRIT MED J, V304, P165, DOI 10.1136/bmj.304.6820.165; WILKINSON RG, 1993, HLTH WEALTH POVERTY; Wilkinson RG, 1986, CLASS HLTH RES LONGI; WOLFF E, 1995, TOP HEAVY STUDY INCR	32	774	792	1	150	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 20	1996	312	7037					999	1003						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	UG610	8616393				2022-12-28	WOS:A1996UG61000021
J	Gong, SC; Nussenzweig, MC				Gong, SC; Nussenzweig, MC			Regulation of an early developmental checkpoint in the B cell pathway by Ig beta	SCIENCE			English	Article							IMMUNOGLOBULIN GENE REARRANGEMENT; ANTIGEN RECEPTOR; ALLELIC EXCLUSION; TRANSGENIC MICE; LYMPHOCYTES-B; BONE-MARROW; LIGHT-CHAIN; PRE-B; HEAVY; MU	Many of the cell fate decisions in precursor B cells and more mature B cells are controlled by membrane immunoglobulin (Ig) M heavy chain (m mu) and the Ig alpha-Ig beta signal transducers. The role of Ig beta in regulating early B cell development was examined in mice that lack Ig beta (Ig beta(-/-)). These mice had a complete block in B cell development at the immature CD43(+)B220(+) stage. Immunoglobulin heavy chain diversity (D-H) and joining (J(H)) segments rearranged, but variable (V-H) to DJ(H) recombination and Immunoglobulin messenger RNA expression were compromised. These experiments define an unexpected, early requirement for Ig beta to produce B cells that can complete VDJ(H) recombination.	ROCKEFELLER UNIV,HOWARD HUGHES MED INST,NEW YORK,NY 10021	Howard Hughes Medical Institute; Rockefeller University			Nussenzweig, Michel/AAE-7292-2019					ALT FW, 1984, EMBO J, V3, P1209, DOI 10.1002/j.1460-2075.1984.tb01955.x; ALT FW, 1987, SCIENCE, V238, P1079, DOI 10.1126/science.3317825; CHEN C, 1995, NATURE, V373, P252, DOI 10.1038/373252a0; COSTA TE, 1992, J EXP MED, V175, P1669, DOI 10.1084/jem.175.6.1669; COSTA TEF, 1992, P NATL ACAD SCI USA, V89, P2205, DOI 10.1073/pnas.89.6.2205; EHLICH A, 1994, CURR BIOL, V4, P573, DOI 10.1016/S0960-9822(00)00129-9; EHLICH A, 1993, CELL, V72, P695, DOI 10.1016/0092-8674(93)90398-A; FERRIER P, 1990, EMBO J, V9, P117, DOI 10.1002/j.1460-2075.1990.tb08087.x; GOLD MR, 1994, ADV IMMUNOL, V55, P221; GRAWUNDER U, 1993, INT IMMUNOL, V5, P1609, DOI 10.1093/intimm/5.12.1609; HARDY RR, 1991, J EXP MED, V173, P1213, DOI 10.1084/jem.173.5.1213; HARTLEY SB, 1991, NATURE, V353, P765, DOI 10.1038/353765a0; HERMANSON GG, 1988, P NATL ACAD SCI USA, V85, P6890, DOI 10.1073/pnas.85.18.6890; HOMBACH J, 1990, NATURE, V343, P760, DOI 10.1038/343760a0; KARASUYAMA H, 1993, J EXP MED, V178, P469, DOI 10.1084/jem.178.2.469; KARASUYAMA H, 1994, CELL, V77, P133, DOI 10.1016/0092-8674(94)90241-0; KITAMURA D, 1992, NATURE, V356, P154, DOI 10.1038/356154a0; KUDO A, 1987, EMBO J, V6, P103, DOI 10.1002/j.1460-2075.1987.tb04725.x; LENNON GG, 1985, NATURE, V318, P475, DOI 10.1038/318475a0; LIN HH, 1995, NATURE, V376, P263, DOI 10.1038/376263a0; LOFFERT D, 1994, IMMUNOL REV, V137, P135, DOI 10.1111/j.1600-065X.1994.tb00662.x; MANZ J, 1988, J EXP MED, V168, P1363, DOI 10.1084/jem.168.4.1363; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MOMBAERTS P, 1992, CELL, V68, P869, DOI 10.1016/0092-8674(92)90030-G; NEMAZEE DA, 1989, NATURE, V337, P562, DOI 10.1038/337562a0; NUSSENZWEIG MC, 1987, SCIENCE, V236, P816, DOI 10.1126/science.3107126; OKADA A, 1994, J EXP MED, V180, P261, DOI 10.1084/jem.180.1.261; OKAMOTO M, 1992, J EXP MED, V175, P71, DOI 10.1084/jem.175.1.71; PAPAVASILIOU F, 1995, J EXP MED, V182, P1389, DOI 10.1084/jem.182.5.1389; PAPAVASILIOU F, 1995, SCIENCE, V268, P408, DOI 10.1126/science.7716544; PETRIE HT, 1995, J EXP MED, V182, P121, DOI 10.1084/jem.182.1.121; PLEIMAN CM, 1994, IMMUNOL TODAY, V15, P393, DOI 10.1016/0167-5699(94)90267-4; RADIC MZ, 1993, J EXP MED, V177, P1165, DOI 10.1084/jem.177.4.1165; RETH M, 1994, CURR OPIN IMMUNOL, V6, P3, DOI 10.1016/0952-7915(94)90026-4; RETH M, 1989, NATURE, V338, P383, DOI 10.1038/338383b0; ROLINK A, 1991, CELL, V66, P1081, DOI 10.1016/0092-8674(91)90032-T; SCHLISSEL MS, 1991, J EXP MED, V173, P711, DOI 10.1084/jem.173.3.711; SCHLISSEL MS, 1989, CELL, V58, P1001, DOI 10.1016/0092-8674(89)90951-3; SPANOPOULOU E, 1994, GENE DEV, V8, P1030, DOI 10.1101/gad.8.9.1030; SUN XH, 1994, CELL, V79, P893, DOI 10.1016/0092-8674(94)90078-7; SWIATEK PJ, 1993, GENE DEV, V7, P2071, DOI 10.1101/gad.7.11.2071; TIEGS SL, 1993, J EXP MED, V177, P1009, DOI 10.1084/jem.177.4.1009; URBANEK P, 1994, CELL, V79, P901, DOI 10.1016/0092-8674(94)90079-5; VENKITARAMAN AR, 1991, NATURE, V352, P777, DOI 10.1038/352777a0; YOUNG F, 1994, GENE DEV, V8, P1043, DOI 10.1101/gad.8.9.1043; ZHUANG Y, 1994, CELL, V79, P875, DOI 10.1016/0092-8674(94)90076-0	47	232	236	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 19	1996	272	5260					411	414		10.1126/science.272.5260.411	http://dx.doi.org/10.1126/science.272.5260.411			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UG252	8602530				2022-12-28	WOS:A1996UG25200047
J	Hodel, AE; Gershon, PD; Shi, XN; Quiocho, FA				Hodel, AE; Gershon, PD; Shi, XN; Quiocho, FA			The 1.85 angstrom structure of vaccinia protein VP39: A bifunctional enzyme that participates in the modification of both mRNA ends	CELL			English	Article							TRANSFER RNA-SYNTHETASE; VIRUS POLY(A) POLYMERASE; HNRNP-C-PROTEINS; CRYSTAL-STRUCTURE; BINDING DOMAIN; CATALYTIC SUBUNIT; RESOLUTION; POLYADENYLATION; PURIFICATION; PROGRAM	VP39 is a bifunctional vaccinia virus protein that acts as both an mRNA cap-specific RNA 2'-O-methyltransferase and a poly(A) polymerase processivity factor. Here, we report the 1.85 Angstrom crystal structure of a VP39 variant complexed with its AdoMet cofactor. VP39 comprises a single core domain with structural similarity to the catalytic domains of other methyltransferases. Surface features and mutagenesis data suggest two possible RNA-binding sites with novel underlying architecture, one of which forms a cleft spanning the region adjacent to the methyltransferase active site. This report provides a prototypic structure for an RNA methyltransferase, a protein that interacts with the mRNA 5' cap, and an intact poxvirus protein.	BAYLOR COLL MED,DEPT BIOCHEM,HOUSTON,TX 77030; TEXAS A&M UNIV,INST BIOSCI & TECHNOL,DEPT BIOCHEM & BIOPHYS,HOUSTON,TX 77030	Baylor College of Medicine; Texas A&M University System	Hodel, AE (corresponding author), BAYLOR COLL MED,HOWARD HUGHES MED INST,HOUSTON,TX 77030, USA.				NIGMS NIH HHS [1 RO1 GM51953-01A1] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051953] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BANNER DW, 1987, J MOL BIOL, V196, P657, DOI 10.1016/0022-2836(87)90039-8; BARBOSA E, 1978, J BIOL CHEM, V253, P7692; BELRHALI H, 1994, SCIENCE, V263, P1432, DOI 10.1126/science.8128224; BIOU V, 1994, SCIENCE, V263, P1404, DOI 10.1126/science.8128220; BRUNGER AT, 1992, XPLOR VERSION 3 1; BYCROFT M, 1995, EMBO J, V14, P3563, DOI 10.1002/j.1460-2075.1995.tb07362.x; CAVARELLI J, 1993, NATURE, V362, P181, DOI 10.1038/362181a0; CHENG XD, 1995, ANNU REV BIOPH BIOM, V24, P293, DOI 10.1146/annurev.bb.24.060195.001453; CHENG XD, 1993, CELL, V74, P299, DOI 10.1016/0092-8674(93)90421-L; EKLUND H, 1981, J MOL BIOL, V146, P561, DOI 10.1016/0022-2836(81)90047-4; FUREY W, 1990, AM CRYST ASS M SUMM; GERSHON PD, 1993, EMBO J, V12, P4705, DOI 10.1002/j.1460-2075.1993.tb06159.x; GERSHON PD, 1993, J BIOL CHEM, V268, P2203; GERSHON PD, 1991, CELL, V66, P1269, DOI 10.1016/0092-8674(91)90048-4; GERSHON PD, 1992, GENE DEV, V6, P1575, DOI 10.1101/gad.6.8.1575; GORLACH M, 1992, EMBO J, V11, P3289, DOI 10.1002/j.1460-2075.1992.tb05407.x; KANG CH, 1995, SCIENCE, V268, P1170, DOI 10.1126/science.7761833; KHARRAT A, 1995, EMBO J, V14, P3572, DOI 10.1002/j.1460-2075.1995.tb07363.x; KLIMASAUSKAS S, 1994, CELL, V76, P357, DOI 10.1016/0092-8674(94)90342-5; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KURIYAN J, 1993, J MOL BIOL, V234, P915, DOI 10.1006/jmbi.1993.1644; LABAHN J, 1994, P NATL ACAD SCI USA, V91, P10957, DOI 10.1073/pnas.91.23.10957; LEIJONMARCK M, 1980, NATURE, V286, P824, DOI 10.1038/286824a0; LINDAHL M, 1994, EMBO J, V13, P1249, DOI 10.1002/j.1460-2075.1994.tb06376.x; MORELLI MAC, 1995, FEBS LETT, V358, P193, DOI 10.1016/0014-5793(94)01422-W; MOSS B, 1991, J BIOL CHEM, V266, P1355; MOSS B, 1975, J BIOL CHEM, V250, P4722; MOSS B, 1990, ANNU REV BIOCHEM, V59, P661, DOI 10.1146/annurev.biochem.59.1.661; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; OUBRIDGE C, 1994, NATURE, V372, P432, DOI 10.1038/372432a0; PREDKI PF, 1995, CELL, V80, P41, DOI 10.1016/0092-8674(95)90449-2; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; REINISCH KM, 1995, CELL, V82, P143, DOI 10.1016/0092-8674(95)90060-8; ROBERTS RJ, 1995, CELL, V82, P9, DOI 10.1016/0092-8674(95)90046-2; ROSSMANN MG, 1974, NATURE, V250, P194, DOI 10.1038/250194a0; ROULD MA, 1989, SCIENCE, V246, P1135, DOI 10.1126/science.2479982; RUFF M, 1991, SCIENCE, V252, P1682, DOI 10.1126/science.2047877; SACK JS, 1988, J MOL GRAPHICS, V6, P224, DOI 10.1016/S0263-7855(98)80040-4; SCHINDELIN H, 1994, P NATL ACAD SCI USA, V91, P5119, DOI 10.1073/pnas.91.11.5119; SCHINDELIN H, 1993, NATURE, V364, P164, DOI 10.1038/364164a0; SCHLUCKEBIER G, 1995, J MOL BIOL, V247, P16, DOI 10.1006/jmbi.1994.0117; SCHNIERLE BS, 1994, J BIOL CHEM, V269, P20700; SCHNIERLE BS, 1992, P NATL ACAD SCI USA, V89, P2897, DOI 10.1073/pnas.89.7.2897; SHAMOO Y, 1995, NATURE, V376, P362, DOI 10.1038/376362a0; SHARMA A, 1994, STRUCTURE, V2, P767, DOI 10.1016/S0969-2126(94)00077-8; SHI X, 1996, RNA, V2, P80; SHUMAN S, 1990, METHOD ENZYMOL, V181, P170; SKINNER MM, 1994, P NATL ACAD SCI USA, V91, P2071, DOI 10.1073/pnas.91.6.2071; TUCKER PA, 1994, EMBO J, V13, P2994, DOI 10.1002/j.1460-2075.1994.tb06598.x; VALEGARD K, 1994, NATURE, V371, P623, DOI 10.1038/371623a0; VIDGREN J, 1994, NATURE, V368, P354, DOI 10.1038/368354a0; WILSON KS, 1986, P NATL ACAD SCI USA, V83, P7251, DOI 10.1073/pnas.83.19.7251; WITTEKIND M, 1992, BIOCHEMISTRY-US, V31, P6254, DOI 10.1021/bi00142a013; WU JC, 1987, J BIOL CHEM, V262, P4778	54	144	146	3	7	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 19	1996	85	2					247	256		10.1016/S0092-8674(00)81101-0	http://dx.doi.org/10.1016/S0092-8674(00)81101-0			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UG255	8612277	Bronze			2022-12-28	WOS:A1996UG25500013
J	Dawson, C; Whitfield, H				Dawson, C; Whitfield, H			ABC of urology - Urinary incontinence and urinary infection	BRITISH MEDICAL JOURNAL			English	Article									CENT MIDDLESEX HOSP,LONDON NW10 7NS,ENGLAND; INST UROL & NEPHROL,LONDON,ENGLAND	Imperial College London; University of London; University College London	Dawson, C (corresponding author), EDITH CAVELL HOSP,PETERBOROUGH,ENGLAND.								0	8	8	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 13	1996	312	7036					961	964						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UF659	8616315				2022-12-28	WOS:A1996UF65900027
J	Hopper, J				Hopper, J			Genes for osteoarthritis: Interpreting twin data - Commentary	BRITISH MEDICAL JOURNAL			English	Editorial Material											Hopper, J (corresponding author), UNIV MELBOURNE,NATL HLTH & MED RES COUNCIL TWIN REGISTRY,DEPT PUBL HLTH & COMMUNITY MED,MELBOURNE,VIC 3053,AUSTRALIA.							CHRISTIAN JC, 1995, GENET EPIDEMIOL, V12, P27, DOI 10.1002/gepi.1370120104; CLIFFORD C A, 1984, Genetic Epidemiology, V1, P63, DOI 10.1002/gepi.1370010109; DOYLE AC, 1892, ADVENTURES OF SHERLO; EISMAN JA, 1995, J BONE MINER RES, V10, P1289; HASEMAN JK, 1972, BEHAV GENET, V2, P3, DOI 10.1007/BF01066731; HOPPER JL, 1983, AM J EPIDEMIOL, V117, P344, DOI 10.1093/oxfordjournals.aje.a113547; HOPPER JL, 1992, ACTA GENET MED GEMEL, V41, P261, DOI 10.1017/S0001566000002129; Hopper JL., 1994, AUST J STAT, V36, P153, DOI [10.1111/j.1467-842X.1994.tb00859.x, DOI 10.1111/J.1467-842X.1994.TB00859.X]; PEACOCK M, 1995, J BONE MINER RES, V10, P1294; PENROSE LS, 1953, ANN EUGENIC, V18, P120	10	12	14	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 13	1996	312	7036					943	944						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UF659	8616306				2022-12-28	WOS:A1996UF65900018
J	Yu, CE; Oshima, J; Fu, YH; Wijsman, EM; Hisama, F; Alisch, R; Matthews, S; Nakura, J; Miki, T; Ouais, S; Martin, GM; Mulligan, J; Schellenberg, GD				Yu, CE; Oshima, J; Fu, YH; Wijsman, EM; Hisama, F; Alisch, R; Matthews, S; Nakura, J; Miki, T; Ouais, S; Martin, GM; Mulligan, J; Schellenberg, GD			Positional cloning of the Warner's syndrome gene	SCIENCE			English	Article							VARIEGATED TRANSLOCATION MOSAICISM; WERNERS SYNDROME; XERODERMA-PIGMENTOSUM; FIBROBLAST-CULTURES; PUTATIVE HELICASES; DNA HELICASE; REPAIR; RECOMBINATION; CHROMOSOME-8; LYMPHOCYTES	Werner's syndrome (WS) is an inherited disease with clinical symptoms resembling premature aging. Early susceptibility to a number of major age-related diseases is a key feature of this disorder. The gene responsible for WS (known as WRN) was identified by positional cloning. The predicted protein is 1432 amino acids in length and shows significant similarity to DNA helicases. Four mutations in WS patients were identified. Two of the mutations are splice-junction mutations, with the predicted result being the exclusion of exons from the final messenger RNA. One of these mutations, which results in a frameshift and a predicted truncated protein, was found in the homozygous state in 60 percent of Japanese WS patients examined. The other two mutations are nonsense mutations. The identification of a mutated putative helicase as the gene product of the WS gene suggests that defective DNA metabolism is involved in the complex process of aging in WS patients.	VET AFFAIRS PUGET SOUND HLTH CARE SYST, CTR GERIATR RES EDUC & CLIN, SEATTLE, WA 98108 USA; UNIV WASHINGTON, DEPT NEUROL, SEATTLE, WA 98195 USA; UNIV WASHINGTON, DEPT PHARMACOL, SEATTLE, WA 98195 USA; UNIV WASHINGTON, DEPT PATHOL, SEATTLE, WA 98195 USA; UNIV WASHINGTON, DEPT BIOSTAT, SEATTLE, WA 98195 USA; UNIV WASHINGTON, DIV MED GENET, DEPT MED, SEATTLE, WA 98195 USA; DARWIN MOLEC CORP, BOTHELL, WA 98021 USA; YALE UNIV, SCH MED, DEPT NEUROL, NEW HAVEN, CT 06510 USA; DAMASCUS CITY HOSP, ENDOCRINOL SECT, DAMASCUS, SYRIA; OSAKA UNIV, SCH MED, DEPT GERIATR MED, SUITA, OSAKA 565, JAPAN	Geriatric Research Education & Clinical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); Vet Affairs Puget Sound Health Care System; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Yale University; Osaka University			Hisama, Fuki M./I-7323-2019	Hisama, Fuki M./0000-0001-7772-7855	NATIONAL INSTITUTE ON AGING [R01AG012019, P01AG001751, T32AG000057] Funding Source: NIH RePORTER; NIA NIH HHS [P01 AG01751, T32 AG00057, R01 AG12019] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BUCKLER AJ, 1991, P NATL ACAD SCI USA, V88, P4005, DOI 10.1073/pnas.88.9.4005; CERIMELE D, 1982, HUM GENET, V62, P25, DOI 10.1007/BF00295600; CHANG M, 1994, AM J PATHOL, V144, P1; CHENG RZ, 1990, MUTAT RES, V237, P259, DOI 10.1016/0921-8734(90)90008-F; CHURCH DM, 1994, NAT GENET, V6, P98, DOI 10.1038/ng0194-98; ELLIS NA, 1995, CELL, V83, P655, DOI 10.1016/0092-8674(95)90105-1; EPSTEIN CJ, 1966, MEDICINE, V45, P177, DOI 10.1097/00005792-196605000-00001; FREJTER WL, 1992, P NATL ACAD SCI USA, V89, P261; FUJIWARA Y, 1977, J CELL PHYSIOL, V92, P365, DOI 10.1002/jcp.1040920305; FUJIWARA Y, 1993, CANCER RES, V53, P1172; FUKUCHI K, 1985, SOMAT CELL MOLEC GEN, V11, P303, DOI 10.1007/BF01534688; FUKUCHI K, 1990, HUM GENET, V84, P249; FUKUCHI K, 1989, P NATL ACAD SCI USA, V86, P5893, DOI 10.1073/pnas.86.15.5893; GANGLOFF S, 1994, MOL CELL BIOL, V14, P8391, DOI 10.1128/MCB.14.12.8391; GEBHART E, 1988, HUM GENET, V80, P135, DOI 10.1007/BF00702855; GODDARD KAB, IN PRESS AM J HUM GE; GORBALENYA AE, 1989, NUCLEIC ACIDS RES, V17, P4713, DOI 10.1093/nar/17.12.4713; GOTO M, 1978, J AM GERIATR SOC, V26, P341, DOI 10.1111/j.1532-5415.1978.tb03681.x; GOTO M, 1992, NATURE, V355, P735, DOI 10.1038/355735a0; GOTO M, 1981, CLIN GENET, V19, P8; HOEHN H, 1975, CYTOGENET CELL GENET, V15, P282, DOI 10.1159/000130526; KAGAN J, 1995, ONCOGENE, V11, P2121; KERANGUEVEN F, 1995, ONCOGENE, V10, P1023; KIHARA K, 1994, JPN J HUM GENET, V39, P403, DOI 10.1007/BF01892385; KRUK PA, 1995, P NATL ACAD SCI USA, V92, P258, DOI 10.1073/pnas.92.1.258; Martin G M, 1978, Birth Defects Orig Artic Ser, V14, P5; MARTIN GM, 1970, LAB INVEST, V23, P86; MENDONCA VM, 1995, J BACTERIOL, V177, P1326, DOI 10.1128/jb.177.5.1326-1335.1995; MULLIGAN J, UNPUB; MUNROE DJ, 1995, P NATL ACAD SCI USA, V92, P2209, DOI 10.1073/pnas.92.6.2209; NAKURA J, 1994, GENOMICS, V23, P600, DOI 10.1006/geno.1994.1548; NAKURA J, 1993, GERONTOLOGY, V39, P11; OSHIMA J, 1994, GENOMICS, V23, P100, DOI 10.1006/geno.1994.1464; PARIMOO S, 1991, P NATL ACAD SCI USA, V88, P9623, DOI 10.1073/pnas.88.21.9623; PYKETT MJ, 1994, CANCER GENET CYTOGEN, V76, P23, DOI 10.1016/0165-4608(94)90064-7; RUNGER TM, 1994, J INVEST DERMATOL, V102, P45, DOI 10.1111/1523-1747.ep12371730; SALK D, 1981, CYTOGENET CELL GENET, V30, P92, DOI 10.1159/000131596; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SCAPPATICCI S, 1982, HUM GENET, V62, P16, DOI 10.1007/BF00295599; SCHELLENBERG GD, 1992, LANCET, V339, P1002, DOI 10.1016/0140-6736(92)91590-5; SCHULZ VP, IN PRESS HUM GENET; STEFANINI M, 1989, MUTAT RES, V219, P179, DOI 10.1016/0921-8734(89)90013-1; SUNG P, 1993, NATURE, V365, P852, DOI 10.1038/365852a0; TAKEUCHI F, 1982, HUM GENET, V60, P365, DOI 10.1007/BF00569220; THANNHAUSER SJ, 1945, ANN INTERN MED, V23, P559, DOI 10.7326/0003-4819-23-4-559; TOLLEFSBOL TO, 1984, AGE, V7, P75, DOI 10.1007/BF02432205; TROELSTRA C, 1992, CELL, V71, P939, DOI 10.1016/0092-8674(92)90390-X; UBERBACHER EC, 1991, P NATL ACAD SCI USA, V88, P11261, DOI 10.1073/pnas.88.24.11261; WANG JC, 1991, J BIOL CHEM, V266, P6659; WATT PM, 1995, CELL, V81, P253, DOI 10.1016/0092-8674(95)90335-6; WEBER CA, 1990, EMBO J, V9, P1437, DOI 10.1002/j.1460-2075.1990.tb08260.x; WEEDA G, 1990, CELL, V62, P777, DOI 10.1016/0092-8674(90)90122-U; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0; WINSTON W, 1993, GENOMICS, V16, P685; YE L, 1995, GENOMICS, V28, P566, DOI 10.1006/geno.1995.1189; YU CE, 1994, AM J HUM GENET, V55, P356; YU CH, UNPUB	58	1388	1441	1	47	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 12	1996	272	5259					258	262		10.1126/science.272.5259.258	http://dx.doi.org/10.1126/science.272.5259.258			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UE729	8602509				2022-12-28	WOS:A1996UE72900039
J	Dawson, C; Whitfield, H				Dawson, C; Whitfield, H			ABC of urology - Subfertility and male sexual dysfunction	BRITISH MEDICAL JOURNAL			English	Article									CENT MIDDLESEX HOSP,LONDON NW10 7NS,ENGLAND; INST UROL & NEPHROL,LONDON,ENGLAND	Imperial College London; University of London; University College London	Dawson, C (corresponding author), EDITH CAVEL HOSP,PETERBOROUGH,CAMBS,ENGLAND.							MILLER MAW, 1994, PROSTAG LEUKOTR ESS, V51, P1, DOI 10.1016/0952-3278(94)90171-6; SCHLEGEL PN, 1994, CURR OPIN UROL, V4, P328; SIGMAN M, 1992, CAMPBELLS UROLOGY	3	7	8	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 6	1996	312	7035					902	905						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UE371	8611887				2022-12-28	WOS:A1996UE37100033
J	Trenque, T; Choisy, H; Germain, ML				Trenque, T; Choisy, H; Germain, ML			Pravastatin: Interaction with oral anticoagulant?	BRITISH MEDICAL JOURNAL			English	Letter											Trenque, T (corresponding author), HOP MAISON BLANCHE,CTR REG PHARMACOVIGILENCE,PHARMACOL LAB,F-51092 REIMS,FRANCE.		Thierry, TRENQUE/AAN-9125-2020					MCTAVISH D, 1991, DRUGS, V42, P65, DOI 10.2165/00003495-199142010-00005; REYNOLDS JEF, 1993, XTRAPHARMACOPOEIA, P979; TOBERT JA, 1990, AM J CARDIOL, V65, P23; WALKER JF, 1989, AM J MED S4A, V87, P445; WOLTERBEEK R, 1993, NED TIJDSCHR GENEESK, V13, P973	5	12	12	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 6	1996	312	7035					886	886						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UE371	8611880				2022-12-28	WOS:A1996UE37100026
J	Ferrara, N; CarverMoore, K; Chen, H; Dowd, M; Lu, L; OShea, KS; PowellBraxton, L; Hillan, KJ; Moore, MW				Ferrara, N; CarverMoore, K; Chen, H; Dowd, M; Lu, L; OShea, KS; PowellBraxton, L; Hillan, KJ; Moore, MW			Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene	NATURE			English	Article							ENDOTHELIAL GROWTH-FACTOR; ES CELLS; ANGIOGENESIS; DIFFERENTIATION; EXPRESSION; RECEPTOR; VASCULOGENESIS; DISRUPTION; SUGGESTS; ONCOGENE	ANGIOGENESIS is required for a wide variety of physiological and pathological processes(1). The endothelial cell-specific mitogen vascular endothelial growth factor (VEGF)(2,3) is a major mediator of pathological angiogenesis(4-6). Also, the expression of VEGF and its two receptors, Flt-1 and Flk-1/KDR, is related to the formation of blood vessels in mouse and rat embryos(7-10). Mice homozygous for mutations that inactivate either receptor die in utero between days 8.5 and 9.5 (refs 11,12). However, ligand(s) other than VEGF might activate such receptors(13,14). To assess the role of VEGF directly, we disrupted the VEGF gene in embryonic stem cells. Here we report the unexpected finding that loss of a single VEGF allele is lethal in the mouse embryo between days 11 and 12. Angiogenesis and blood-island formation were impaired, resulting in several developmental anomalies. Furthermore, VEGF-null embryonic stem cells exhibit a dramatically reduced ability to form tumours in nude mice.	GENENTECH INC,DEPT MOLEC BIOL,S SAN FRANCISCO,CA 94080; GENENTECH INC,DEPT BIOANALYT TECHNOL,S SAN FRANCISCO,CA 94080; UNIV MICHIGAN,DEPT ANAT & CELL BIOL,ANN ARBOR,MI 48109	Roche Holding; Genentech; Roche Holding; Genentech; University of Michigan System; University of Michigan	Ferrara, N (corresponding author), GENENTECH INC,DEPT CARDIOVASC RES,4600 POINT SAN BRUNO BLVD,S SAN FRANCISCO,CA 94080, USA.							ADAMIS AP, 1994, AM J OPHTHALMOL, V118, P445, DOI 10.1016/S0002-9394(14)75794-0; AIELLO LP, 1994, NEW ENGL J MED, V331, P1480, DOI 10.1056/NEJM199412013312203; Bradley A, 1987, TERATOCARCINOMAS EMB, P113; BRANDON EP, 1995, CURR BIOL, V5, P625, DOI 10.1016/S0960-9822(95)00127-8; BREIER G, 1992, DEVELOPMENT, V114, P521; DAMATO RJ, 1994, P NATL ACAD SCI USA, V91, P4082, DOI 10.1073/pnas.91.9.4082; DVORAK HF, 1995, AM J PATHOL, V146, P1029; FERRARA N, 1992, ENDOCR REV, V13, P18, DOI 10.1210/er.13.1.18; FOLKMAN J, 1992, J BIOL CHEM, V267, P10931; FONG GH, 1995, NATURE, V376, P66, DOI 10.1038/376066a0; HILBERG F, 1992, ONCOGENE, V7, P2371; Hogan B, 1994, MANIPULATING MOUSE E; JAKEMAN LB, 1993, ENDOCRINOLOGY, V133, P848, DOI 10.1210/en.133.2.848; KIM KJ, 1993, NATURE, V362, P841, DOI 10.1038/362841a0; LU LH, 1994, CELL VISION, V1, P169; MAGLIONE D, 1991, P NATL ACAD SCI USA, V88, P9267, DOI 10.1073/pnas.88.20.9267; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MCBRIDE WG, 1961, LANCET, V2, P1358; MORTENSEN RM, 1992, MOL CELL BIOL, V12, P2391, DOI 10.1128/MCB.12.5.2391; PARK JE, 1994, J BIOL CHEM, V269, P25646; PETERS KG, 1993, P NATL ACAD SCI USA, V90, P8915, DOI 10.1073/pnas.90.19.8915; Pugh RCB, 1976, PATHOLOGY TESTIS; QUINN TP, 1993, P NATL ACAD SCI USA, V90, P7533, DOI 10.1073/pnas.90.16.7533; RISAU W, 1988, DEVELOPMENT, V102, P471; Sambrook J., 2002, MOL CLONING LAB MANU; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; THEILER K, 1989, HOUSE MOUSE; Tisher E, 1991, J BIOL CHEM, V266, P11947; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; VIGON I, 1992, P NATL ACAD SCI USA, V89, P5640, DOI 10.1073/pnas.89.12.5640	30	2792	2929	5	89	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	APR 4	1996	380	6573					439	442		10.1038/380439a0	http://dx.doi.org/10.1038/380439a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UD590	8602242	Green Submitted			2022-12-28	WOS:A1996UD59000062
J	Moore, RD; Chaisson, RE				Moore, RD; Chaisson, RE			Natural history of opportunistic disease in an HIV-infected urban clinical cohort	ANNALS OF INTERNAL MEDICINE			English	Article						AIDS-related opportunistic infections; human immunodeficiency virus infection; urban health services; pneumonia, Pneumocystis carinii; acquired immunodeficiency syndrome	HUMAN-IMMUNODEFICIENCY-VIRUS; PNEUMOCYSTIS-CARINII PNEUMONIA; IMMUNE-DEFICIENCY SYNDROME; SAN-FRANCISCO; TRIMETHOPRIM-SULFAMETHOXAZOLE; AEROSOLIZED PENTAMIDINE; CONTROLLED TRIAL; UNITED-STATES; AIDS; PROPHYLAXIS	Objective: To determine the effect of contemporary clinical care on the natural history of opportunistic disease in an urban population infected with the human immunodeficiency virus (HIV). Setting: Urban university HIV clinic. Design: Retrospective and prospective observational study. Patients: 1246 HIV-infected patients with CD4(+) counts of 300 cells/mm(3) or less. Measurements: Incidence rates and Kaplan-Meier estimates of the probability of developing opportunistic disease with time, distribution of the CD4(+) counts at which opportunistic disease develops, survival after the development of opportunistic disease, and the association between preventive drug therapies and the occurrence of opportunistic infection. Results: The most common opportunistic disease was Candida esophagitis, which had an incidence of 13.3 events per 100 person-years and a 3-year Kaplan-Meier probability of 0.30. Pneumocystis carinii pneumonia, Mycobacterium avium complex bacteremia, cytomegalovirus, and the acquired immunodeficiency syndrome dementia complex occurred at rates of 5 to 9 events per 100 person-years and 3-year Kaplan-Meier probabilities of 0.15 to 0.22. Toxoplasmosis, cryptococcal meningitis, herpes zoster, the wasting syndrome, and Kaposi sarcoma occurred at rates of about 2 to 4 events per 100 person-years and with 3-year Kaplan-Meier probabilities of 0.05 to 0.10. Non-Hodgkin lymphoma, M. tuberculosis infection, progressive multifocal leukoencephalopathy, and cryptosporidiosis were the least common disorders, with an incidence of about 1 to 2 events per 100 person-years and a 3-year Kaplan-Meier probability less than 0.05. Only the incidences of cryptococcal meningitis, secondary P. carinii pneumonia, and herpes tester decreased (P < 0.05) between 1989-1992 and 1993-1995. Fluconazole use was associated with a decreased relative rate of 0.49 (P = 0.06) for cryptococcal meningitis and a decreased relative rate of 0.61 (P = 0.005) for esophageal candidiasis. Rifabutin use was associated with a decreased relative rate of 0.37 (P = 0.002) for M. avium complex bacteremia, and trimethoprim-sulfamethoxazole use was associated with decreased relative rates of 0.33 (P = 0.02) for secondary P. carinii pneumonia and 0.55 (P = 0.08) for primary P. carinii pneumonia. Candidiasis, herpes tester, and M. tuberculosis infection first occurred at a median CD4(+) count greater than 100 cells/mm(3), but all other opportunistic diseases first occurred at a median CD4(+) count less than 50 cells/mm(3). Median survival after diagnosis varied from 35 days for non-Hodgkin lymphoma to 680 days for herpes zoster. Conclusions: In the patients studied, the-incidences of secondary P. carinii pneumonia, cryptococcal meningitis, and herpes tester have declined in the past 5 years. The incidences of primary P. carinii pneumonia and Kaposi sarcoma appear to be declining compared with historical estimates. However, although these and other opportunistic diseases continue to be relatively frequent complications of HIV infection, they are first occurring at more advanced immunosuppression than in the past. Continued efforts are needed to develop effective strategies for preventing opportunistic disease in very advanced HIV infection.			Moore, RD (corresponding author), JOHNS HOPKINS UNIV, SCH MED, 1830 E MONUMENT ST, ROOM 8059, BALTIMORE, MD 21205 USA.				AHRQ HHS [R01 HS07809] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		ALWOOD K, 1994, AIDS, V8, P1103, DOI 10.1097/00002030-199408000-00010; [Anonymous], 1992, MMWR Recomm Rep, V41, P1; BACCHETTI P, 1988, J INFECT DIS, V157, P1044, DOI 10.1093/infdis/157.5.1044; BACELLAR H, 1994, NEUROLOGY, V44, P1892, DOI 10.1212/WNL.44.10.1892; BARTLETT JG, 1994, MED MANAGEMENT HIV I; BOZZETTE SA, 1995, NEW ENGL J MED, V332, P693, DOI 10.1056/NEJM199503163321101; CARR A, 1992, ANN INTERN MED, V117, P106, DOI 10.7326/0003-4819-117-2-106; Centers for Disease Control (CDC), 1982, MMWR Morb Mortal Wkly Rep, V31, P507; CESARMAN E, 1995, NEW ENGL J MED, V332, P1186, DOI 10.1056/NEJM199505043321802; CHAISSON RE, 1995, NEW ENGL J MED, V333, P751, DOI 10.1056/NEJM199509213331202; CHAISSON RE, 1992, AM REV RESPIR DIS, V146, P285, DOI 10.1164/ajrccm/146.2.285; CHAISSON RE, 1992, ARCH INTERN MED, V152, P2009, DOI 10.1001/archinte.152.10.2009; CHAULK CP, 1995, JAMA-J AM MED ASSOC, V274, P945, DOI 10.1001/jama.274.12.945; COX DR, 1972, J R STAT SOC B, V34, P187; CROWE SM, 1991, J ACQ IMMUN DEF SYND, V4, P770; FISCHL MA, 1988, JAMA-J AM MED ASSOC, V259, P1185, DOI 10.1001/jama.259.8.1185; GALLANT JE, 1994, ARCH INTERN MED, V154, P566, DOI 10.1001/archinte.154.5.566; GALLANT JE, 1994, ANN INTERN MED, V120, P932, DOI 10.7326/0003-4819-120-11-199406010-00006; GALLANT JE, 1992, J INFECT DIS, V166, P1223, DOI 10.1093/infdis/166.6.1223; GILLESPIE SM, 1991, ANN NEUROL, V30, P597, DOI 10.1002/ana.410300413; GLESBY MJ, 1995, CLIN INFECT DIS, V21, P370, DOI 10.1093/clinids/21.2.370; HAMILTONDUTOIT SJ, 1991, AM J PATHOL, V138, P149; HANSON DL, 1995, ARCH INTERN MED, V155, P1537, DOI 10.1001/archinte.155.14.1537; HARDY WD, 1992, NEW ENGL J MED, V327, P1842, DOI 10.1056/NEJM199212243272604; HOLMBERG SD, 1995, AM J EPIDEMIOL, V141, P395, DOI 10.1093/oxfordjournals.aje.a117441; JAFFE HW, 1983, J INFECT DIS, V148, P339, DOI 10.1093/infdis/148.2.339; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; LEOUNG GS, 1990, NEW ENGL J MED, V323, P769, DOI 10.1056/NEJM199009203231201; LILIENFELD AM, 1980, F EPIDEMIOLOGY, P336; MASUR H, 1989, ANN INTERN MED, V111, P223, DOI 10.7326/0003-4819-111-3-223; MCARTHUR JC, 1993, NEUROLOGY, V43, P2245, DOI 10.1212/WNL.43.11.2245; MOORE PS, 1995, NEW ENGL J MED, V332, P1181, DOI 10.1056/NEJM199505043321801; MOORE RD, 1994, NEW ENGL J MED, V330, P763, DOI 10.1056/NEJM199403173301107; MOORE RD, 1992, AIDS, V6, P671, DOI 10.1097/00002030-199207000-00009; MOORE RD, 1991, JAMA-J AM MED ASSOC, V265, P2208, DOI 10.1001/jama.265.17.2208; NIGHTINGALE SD, 1993, NEW ENGL J MED, V329, P828, DOI 10.1056/NEJM199309163291202; PAPE JW, 1993, LANCET, V342, P268, DOI 10.1016/0140-6736(93)91817-6; PHAIR J, 1990, NEW ENGL J MED, V322, P161, DOI 10.1056/NEJM199001183220304; PLUDA JM, 1990, ANN INTERN MED, V113, P276, DOI 10.7326/0003-4819-113-4-276; PORTER SB, 1992, NEW ENGL J MED, V327, P1643, DOI 10.1056/NEJM199212033272306; POWDERLY WG, 1995, NEW ENGL J MED, V332, P700, DOI 10.1056/NEJM199503163321102; RUTHERFORD GW, 1989, J INFECT DIS, V159, P569, DOI 10.1093/infdis/159.3.569; SCHNEIDER MME, 1992, NEW ENGL J MED, V327, P1836, DOI 10.1056/NEJM199212243272603; SELIK RM, 1984, AM J MED, V76, P493, DOI 10.1016/0002-9343(84)90669-7; SIDTIS JJ, 1993, ANN NEUROL, V33, P343, DOI 10.1002/ana.410330403; SPECTOR SA, 1995, 2 NAT C HUM RETR WAS; Van Loon Frederik P. L., 1995, Morbidity and Mortality Weekly Report, V44, P1; ZANGERLE R, 1991, LANCET, V337, P1232, DOI 10.1016/0140-6736(91)92910-T; 1994, MMWR-MORBID MORTAL W, V43, P644; 1994, NEW ENGL J MED, V44, P81	50	229	239	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 1	1996	124	7					633	+		10.7326/0003-4819-124-7-199604010-00003	http://dx.doi.org/10.7326/0003-4819-124-7-199604010-00003			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UB513	8607591				2022-12-28	WOS:A1996UB51300003
J	Varvarigou, A; Bardin, CL; Beharry, K; Chemtob, S; Papageorgiou, A; Aranda, JV				Varvarigou, A; Bardin, CL; Beharry, K; Chemtob, S; Papageorgiou, A; Aranda, JV			Early ibuprofen administration to prevent patent ductus arteriosus in premature newborn infants	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CEREBRAL BLOOD-FLOW; BIRTH-WEIGHT INFANTS; INTRAVENTRICULAR HEMORRHAGE; PROPHYLACTIC INDOMETHACIN; PRETERM INFANTS; EARLY CLOSURE; PROSTANOIDS; VELOCITY; PROSTAGLANDINS; THERAPY	Objective.-To test whether early postnatal (0 to 3 hours) intravenous administration of ibuprofen will prevent patent ductus arteriosus (PDA) in preterm neonates. Design.-Prospective sequential controlled trial with three treatment arms. Setting.-Level 3 perinatal-neonatal intensive care nursery. Patients.-Thirty-four premature newborn infants born from February to August 1993 with a mean birth weight of 913 g (range, 565 to 1460 g) and gestational age of 26.9 weeks (range, 22.4 to 31.0). Intervention.-Infants were consecutively assigned within 3 hours of age to treatment with either one dose of ibuprofen lysine (10 mg/kg intravenously) followed by 5 mg/kg per dose intravenously at 24 and 48 hours of age (n=12), one dose of ibuprofen lysine (10 mg/kg intravenously; n=11), or saline (n=11). Outcome Variables.-Primary outcome variable was the presence of ductus arteriosus by echocardiography and clinical assessments at 3, 7, and 21 days of life. Secondary outcome variables included presence of intraventricular hemorrhage, renal function, ventilatory and oxygen needs, hematologic changes, gastrointestinal function, time to full enteral feeding, duration of hospitalization, and age at discharge. Results.-The three groups of patients were comparable in birth weight, gestational age, antenatal administration of betamethasone, and other perinatal characteristics. Ibuprofen treatment significantly reduced plasma levels of prostaglandins, and the levels remained low for 72 hours in newborns who received three doses of the drug. The incidence of PDA and other variables did not differ between patients who received a single dose of ibuprofen and those given saline. However, compared with the saline-treated newborns, babies who received three doses of ibuprofen had no PDA (0/12 vs 7/11 for saline; P<.02), had lower daily mean airway pressures (mean+/-SD, 5.2+/-1.1 cm H2O vs 8.3+/-2.8 cm H2O for saline; P<.02) and better oxygenation index (2.6+/-0.6 vs 4.7+/-1.8 for saline; P<.02) at the end of the first week of life, and required fewer days of ventilation (25+/-14 days vs 44+/-26 days for saline; P<.03). Babies given three doses of ibuprofen tended to tolerate full oral feedings earlier (35+/-19 days vs 56+/-34 days for saline; P=.09), had shorter duration of hospitalization (71.2+/-22.6 days vs 127.3+/-74.7 days for saline; P<.05), and were discharged to home at an earlier postconceptional age (37.8+/-2.0 weeks vs 44.8+/-9.8 weeks for saline; P<.05). Ibuprofen treatment in this phase I trial was not associated with any apparent early neurological, intestinal, renal, hepatic, or hematologic complications. Conclusions.-Administration of three doses of ibuprofen within 3 hours after birth in preterm neonates reduced the incidence of PDA without causing notable early adverse drug reactions in this phase I trial. Early closure of the ductus arteriosus was also associated with better respiratory outcome and earlier discharge from the hospital.	MCGILL UNIV,LADY DAVIS INST MED RES,DEPT NEONATOL,MONTREAL,PQ H3T 1E2,CANADA; MCGILL UNIV,CTR PERINATAL & DEV PHARMACOL RES,LADY DAVIS INST,SMBD JEWISH GEN HOSP,DEPT PEDIAT,MONTREAL,PQ H3T 1E2,CANADA; MCGILL UNIV,DEPT THERAPEUT & PHARMACOL,MONTREAL,PQ,CANADA; UNIV MONTREAL,DEPT PEDIAT,MONTREAL,PQ H3C 3J7,CANADA; UNIV MONTREAL,DEPT PHARMACOL,MONTREAL,PQ H3C 3J7,CANADA	Lady Davis Institute; McGill University; Lady Davis Institute; McGill University; McGill University; Universite de Montreal; Universite de Montreal				Varvarigou, Anastasia/0000-0003-4558-0136				ARANDA JV, 1994, PEDIATR RES, V35, pA81; ARAVIND MK, 1984, J CHROMATOGR, V308, P350, DOI 10.1016/0378-4347(84)80229-7; BADA HS, 1989, J PEDIATR-US, V115, P631, DOI 10.1016/S0022-3476(89)80300-2; BANDSTRA ES, 1988, PEDIATRICS, V82, P533; BETKERUR MV, 1981, PEDIATRICS, V68, P99; BROTHWOOD M, 1986, ARCH DIS CHILD, V61, P559, DOI 10.1136/adc.61.6.559; CHEMTOB S, 1993, PEDIATR RES, V33, P336; CHEMTOB S, 1991, PEDIATR RES, V30, P106, DOI 10.1203/00006450-199107000-00021; CHEMTOB S, 1990, STROKE, V21, P777, DOI 10.1161/01.STR.21.5.777; CHEMTOB S, 1990, DEV PHARMACOL THERAP, V14, P1; CLYMAN RI, 1990, FETAL NEONATAL CARDI, P682; COCEANI F, 1979, CAN J PHYSIOL PHARM, V57, P825, DOI 10.1139/y79-126; COTTON RB, 1978, J PEDIATR-US, V93, P647, DOI 10.1016/S0022-3476(78)80910-X; COTTON RB, 1991, BIOL NEONATE, V60, P273; COTTON RB, 1979, J PEDIATR, V2, P467; FERGUSON GA, 1971, STATISTICAL ANAL PSY, P276; GALLO JM, 1986, J CLIN PHARMACOL, V26, P65, DOI 10.1002/j.1552-4604.1986.tb02905.x; GERSONY WM, 1983, J PEDIATR-US, V102, P895, DOI 10.1016/S0022-3476(83)80022-5; KAUFFMAN RE, 1992, J PEDIATR-US, V121, P969, DOI 10.1016/S0022-3476(05)80354-3; KRUEGER E, 1987, J PEDIATR-US, V111, P749, DOI 10.1016/S0022-3476(87)80262-7; LAUDIGNON N, 1988, BIOL NEONATE, V54, P254; LEFFLER CW, 1987, AM J PHYSIOL, V252, pH687, DOI 10.1152/ajpheart.1987.252.4.H687; MAHONY L, 1982, NEW ENGL J MED, V306, P506, DOI 10.1056/NEJM198203043060903; MALCOLM DD, 1993, J APPL PHYSIOL, V74, P1672, DOI 10.1152/jappl.1993.74.4.1672; MENT LR, 1994, PEDIATRICS, V93, P543; MERRITT TA, 1981, J PEDIATR-US, V99, P281, DOI 10.1016/S0022-3476(81)80479-9; NAULTY CM, 1978, J PEDIATR-US, V93, P682, DOI 10.1016/S0022-3476(78)80917-2; ORTIZ RM, 1987, PEDIATR CLIN N AM, V34, P39; PAPILE LA, 1978, J PEDIATR-US, V92, P529, DOI 10.1016/S0022-3476(78)80282-0; PERLMAN JM, 1985, NEW ENGL J MED, V312, P1353, DOI 10.1056/NEJM198505233122104; RENNIE JM, 1986, ARCH DIS CHILD, V61, P233, DOI 10.1136/adc.61.3.233; SHENNAN AT, 1988, PEDIATRICS, V82, P527; Sokal R R, 1981, BIOMETRY, P232; VANBEL F, 1991, J PEDIATR-US, V118, P621, DOI 10.1016/S0022-3476(05)83391-8; YEH TF, 1981, J PEDIATR-US, V98, P137, DOI 10.1016/S0022-3476(81)80560-4; 1984, ARCH OPHTHALMOL-CHIC, V102, P1130	36	125	130	0	6	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 21	1996	275	7					539	544		10.1001/jama.275.7.539	http://dx.doi.org/10.1001/jama.275.7.539			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TV569	8606475				2022-12-28	WOS:A1996TV56900031
J	Lucas, SB; Peacock, CS; Hounnou, A; Brattegaard, K; Koffi, K; Honde, M; Andoh, J; Bell, J; DeCock, KM				Lucas, SB; Peacock, CS; Hounnou, A; Brattegaard, K; Koffi, K; Honde, M; Andoh, J; Bell, J; DeCock, KM			Disease in children infected with HIV in Abidjan, Cote d'Ivoire	BRITISH MEDICAL JOURNAL			English	Article							VIRUS; DIAGNOSIS; MORTALITY; UTILITY; INFANTS	Objective-To document the range of disease in African children infected with HIV. Design-Necropsy results in consecutive children aged 1 month or more who were HIV positive and in children who were HIV negative for comparison; IgA western blots on serum samples from children under 2 years of age who were positive for HIV-1 to test the validity of routine HIV serology. Setting-Largest hospital in Abidjan, Cote d'Ivoire. Subjects-78 children who were HIV positive and 77 children who were HIV negative on whom a necropsy was performed; their median ages at death were 18 and 21 months respectively. 36 HIV positive children and 29 HIV negative children mere 1-14 months old; 42 HIV positive and 48 HIV negative children were greater than or equal to 15 months old. Main outcome measures-Cause of death and prevalence of diseases confirmed pathologically. Results-Respiratory tract infections were more common in HIV positive than in HIV negative children (73 (94%) v 52 (68%); P<0.05), and were aetiologically heterogeneous. Pneumocystis carinii pneumonia was found in 11 out of 36 (31%) HIV positive children aged <15 months, but in no HIV negative children. Among older children measles was more common in HIV positive children (8/42 (19%) v 2/48 (4%); P < 0.06). Pyogenic meningitis was present in similar proportions of HIV positive and HIV negative children aged < 15 months (7/36 (19%) and 7/29 (24%)). In HIV positive children tuberculosis (1/78), lymphocytic interstitial pneumonitis (1/78), and HIV encephalitis (2/78) were rare. Conclusions-There is greater overlap between diseases associated with HIV infection and other common health problems in African children than there is in adults. Compared with adults, HIV positive children had a high prevalence of P carinii pneumonia and a low prevalence of tuberculosis. Measles, but not malaria, was associated with HIV infection.	UNIV LONDON UNIV COLL,LONDON MED SCH,DEPT HISTOPATHOL,LONDON WC1E 6JJ,ENGLAND; PROJET RETRO CI,ABIDJAN,COTE IVOIRE; UNIV HOSP,ABIDJAN,COTE IVOIRE; UNIV EDINBURGH,SCH MED,DEPT PATHOL,DEPT NEUROPATHOL,EDINBURGH EH4 2XU,MIDLOTHIAN,SCOTLAND	University of London; University College London; University of Edinburgh			Peacock, Christopher/A-4052-2012					BLANCHE S, 1990, AM J DIS CHILD, V144, P1210, DOI 10.1001/archpedi.1990.02150350042021; Chin J, 1991, AIDS, V5 Suppl 2, pS57, DOI 10.1097/00002030-199101001-00009; CHINTU C, 1993, PEDIATR INFECT DIS J, V12, P499, DOI 10.1097/00006454-199306000-00008; DABIS F, 1993, AIDS, V7, P1139, DOI 10.1097/00002030-199308000-00027; DECOCK KM, 1990, AIDS, V4, P875, DOI 10.1097/00002030-199009000-00007; DOWELL SF, 1993, AIDS, V7, P1255, DOI 10.1097/00002030-199309000-00016; EMBREE JE, 1992, J INFECT DIS, V165, P262, DOI 10.1093/infdis/165.2.262; GIBB D, 1994, AIDS S1, V8, pS275; GIBB DM, 1994, ARCH DIS CHILD, V70, P241, DOI 10.1136/adc.70.3.241; Kozlowski PB, 1995, PEDIAT NEUROPATHOLOG, P435; LANDESMAN S, 1991, JAMA-J AM MED ASSOC, V266, P3443, DOI 10.1001/jama.266.24.3443; LEPAGE P, 1991, AIDS, V5, pS117; LUCAS SB, 1993, AIDS, V7, P1569, DOI 10.1097/00002030-199312000-00005; MGONE CS, 1991, J ACQ IMMUN DEF SYND, V4, P910; MIOTTI PG, 1992, INT J EPIDEMIOL, V21, P792; MULLER O, 1990, J TROP PEDIATRICS, V36, P283, DOI 10.1093/tropej/36.6.283; Nelson A M, 1992, Prog AIDS Pathol, V3, P1; NICOLL A, 1994, AIDS, V8, P995, DOI 10.1097/00002030-199407000-00019; PAN LX, 1993, J PATHOL, V170, P137, DOI 10.1002/path.1711700207; SASSANMOROKRO M, 1994, T ROY SOC TROP MED H, V88, P178, DOI 10.1016/0035-9203(94)90285-2; SCHULZ DM, 1962, ARCH PATHOL, V74, P244; SENSION MG, 1988, AM J DIS CHILD, V142, P1271, DOI 10.1001/archpedi.1988.02150120025021; SIMONDS RJ, 1993, JAMA-J AM MED ASSOC, V270, P470, DOI 10.1001/jama.270.4.470; WILLIAMS A. O., 1970, Ghana Medical Journal, V9, P23; 1987, MMWR-MORBID MORTAL W, V36, P1	25	140	140	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 10	1996	312	7027					335	338						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TV698	8611829	Green Published			2022-12-28	WOS:A1996TV69800020
J	Plouffe, JF; Breiman, RF; Facklam, RR				Plouffe, JF; Breiman, RF; Facklam, RR			Bacteremia with Streptococcus pneumoniae - Implications for therapy and prevention	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							COMMUNITY-ACQUIRED PNEUMONIA; PNEUMOCOCCAL BACTEREMIA; INFECTIONS; RESISTANCE; COUNTY	Objective.-To determine the incidence and mortality rates of patients with bacteremic infections with Streptococcus pneumoniae, and to determine the serotypes and antimicrobial susceptibilities of the pneumococcal isolates. Design.-Prospective case ascertainment and procurement of S pneumoniae isolates between January 1991 and April 1994, Setting.-Ten adult care hospitals in Franklin County, Ohio. Patients.-Patients (N=590) in whom S pneumoniae was isolated from blood cultures. Measurements.-Demographic data from patients with pneumococcal bacteremia were obtained by chart review. Pneumococcal serotyping and antimicrobial susceptibility testing were performed on 499 bacteremic isolates. Results.-Among residents of Franklin County, the annual incidence of pneumococcal bacteremia was higher in patients at least 65 years old (83.0 per 100 000 population) compared with younger adults (9.6 per 100 000 population) (odds ratio [OR], 8.74; 95% confidence interval [CI], 7.19 to 10.62) and more common among African Americans than whites (OR, 1.36; 954;, CI, 1.05 to 1.75), The relative risk of pneumococcal bacteremia among persons infected with the human immunodeficiency virus was 41.8 times (CI, 19.0 to 92.0) that of county residents 18 to 64 years of age. The overall mortality rate was 19% and was age-dependent, reaching 38% in patients at least 85 years old, The distribution of pneumococcal serotypes causing bacteremia was remarkably consistent over time. The incidence of drug-resistant strains increased during the study period; by 1994 14% were resistant to penicillin, 12% to ceftazidime, and 24% to trimethoprim-sulfamethoxazole. The resistant strains included several serotypes of S pneumoniae. Most serotypes (89.8%) of S pneumoniae causing bacteremia are contained in the pneumococcal vaccine. Conclusions.-Increased use of pneumococcal vaccine and recognition of antimicrobial resistance patterns may assist physicians in treating patients with S pneumoniae bacteremia. Educational programs to discourage unnecessary antimicrobial drug use should be developed for patients and physicians.	CTR DIS CONTROL & PREVENT,ATLANTA,GA 30341	Centers for Disease Control & Prevention - USA	Plouffe, JF (corresponding author), OHIO STATE UNIV,MED CTR,DEPT INTERNAL MED,N-1135 DOAN HALL,COLUMBUS,OH 43210, USA.							APPELBAUM PC, 1987, EUR J CLIN MICROBIOL, V6, P367, DOI 10.1007/BF02013089; BENNETT NM, 1992, AM J PUBLIC HEALTH, V82, P1513, DOI 10.2105/AJPH.82.11.1513; BREIMAN RF, 1990, ARCH INTERN MED, V150, P1401, DOI 10.1001/archinte.150.7.1401; BREIMAN RF, 1994, JAMA-J AM MED ASSOC, V271, P1831, DOI 10.1001/jama.271.23.1831; BROOME CV, 1981, REV INFECT DIS, V3, P277; CAPUTO GM, 1993, ARCH INTERN MED, V153, P1301, DOI 10.1001/archinte.153.11.1301; DOUGLAS RM, 1975, MED J AUSTRALIA, V1, P82, DOI 10.5694/j.1326-5377.1975.tb111243.x; FANG GD, 1990, MEDICINE, V69, P307, DOI 10.1097/00005792-199009000-00004; FRIEDLAND IR, 1994, NEW ENGL J MED, V331, P377, DOI 10.1056/NEJM199408113310607; GREENLAND S, 1985, BIOMETRICS, V41, P55, DOI 10.2307/2530643; HOFMANN J, 1995, NEW ENGL J MED, V333, P481, DOI 10.1056/NEJM199508243330803; JORGENSEN JH, 1991, J INFECT DIS, V163, P644, DOI 10.1093/infdis/163.3.644; KLUGMAN KP, 1990, CLIN MICROBIOL REV, V3, P171, DOI 10.1128/CMR.3.2.171-196.1990; MARRIE TJ, 1989, REV INFECT DIS, V11, P586; MARSTON BJ, 1993, LEGIONELLA, P36; MUNOZ R, 1991, J INFECT DIS, V164, P302, DOI 10.1093/infdis/164.2.302; MUSHER DM, 1992, CLIN INFECT DIS, V14, P801, DOI 10.1093/clinids/14.4.801; NARAQI S, 1974, J PEDIATR-US, V85, P671, DOI 10.1016/S0022-3476(74)80513-5; PALLARES R, 1995, NEW ENGL J MED, V333, P474, DOI 10.1056/NEJM199508243330802; PLOUFFE JF, 1994, J CLIN MICROBIOL, V32, P1606, DOI 10.1128/JCM.32.6.1606-1607.1994; PLOUFFE JF, 1994, 94TH GEN M AM SOC MI; SCHAPPERT SM, 1992, ADV DATA US DEP HLTH, V214; WOODHEAD MA, 1987, LANCET, V1, P671; 1994, MMWR-MORBID MORTAL W, V43, P31; 1994, MMWR-MORBID MORTAL W, V43, P216; 1994, M7A3 NAT COMM LAB ST; 1989, MMWR-MORBID MORTAL W, V38, P64; 1993, MMWR-MORBID MORTAL W, V44, P33; 1984, MMWR-MORBID MORTAL W, V33, P281; 1987, Q J MED, V62, P195; 1995, MMWR-MORBID MORTAL W, V44, P24; 1994, MMWR-MORBID MORTAL W, V43, P23; 1984, MMWR-MORBID MORTAL W, V33, P273; 1993, AM REV RESPIR DIS, V148, P1418; 1994, MMWR-MORBID MORTAL W, V43, P223	35	244	249	0	7	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 17	1996	275	3					194	198		10.1001/jama.275.3.194	http://dx.doi.org/10.1001/jama.275.3.194			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TP282	8604171				2022-12-28	WOS:A1996TP28200026
J	Zou, HY; Niswander, L				Zou, HY; Niswander, L			Requirement for BMP signaling in interdigital apoptosis and scale formation	SCIENCE			English	Article							INTERNUCLEOSOMAL DNA FRAGMENTATION; PROGRAMMED CELL-DEATH; MOUSE; MORPHOGENESIS; EXPRESSION	Interdigital cell death leads to regression of soft tissue between embryonic digits in many vertebrates. Although the signals that regulate interdigital apoptosis are not known, BMPs-signaling molecules of the transforming growth factor-beta superfamily-are expressed interdigitally. A dominant negative type I BMP receptor (dnBMPR-IB) was used here to block BMP signaling. Expression of dnBMPR in chicken embryonic hind limbs greatly reduced interdigital apoptosis and resulted in webbed feet. In addition, scales were transformed into feathers. The similarity of the webbing to webbed duck feet led to studies that indicate that BMPs are not expressed in the duck interdigit. These results indicate BMP signaling actively mediates cell death in the embryonic limb.	MEM SLOAN KETTERING CANC CTR,PROGRAM MOLEC BIOL,NEW YORK,NY 10021; CORNELL UNIV,GRAD SCH MED SCI,NEW YORK,NY 10021	Memorial Sloan Kettering Cancer Center; Cornell University			Niswander, Lee/D-3976-2013	Niswander, Lee/0000-0002-9959-0594; Zou, Hongyan/0000-0003-4216-5607				CARCAMO J, 1994, MOL CELL BIOL, V14, P3810, DOI 10.1128/MCB.14.6.3810; DHOUAILLY D, 1980, J EMBRYOL EXP MORPH, V58, P63; FRANCIS PH, 1994, DEVELOPMENT, V120, P209; FRANCISWEST PH, 1995, DEV DYNAM, V203, P187, DOI 10.1002/aja.1002030207; GARCIAMARTINEZ V, 1993, J CELL SCI, V106, P201; GRAHAM A, 1994, NATURE, V372, P684, DOI 10.1038/372684a0; HAMBURGER V, 1951, J MORPHOL, V88, P49, DOI 10.1002/jmor.1050880104; HOUSTON B, 1994, J MOL ENDOCRINOL, V13, P289, DOI 10.1677/jme.0.0130289; HUGHES SH, 1987, J VIROL, V61, P3004, DOI 10.1128/JVI.61.10.3004-3012.1987; ISHIDOU Y, 1995, J BONE MINER RES, V10, P1651; IZPISUABELMONTE JC, 1991, NATURE, V350, P585, DOI 10.1038/350585a0; JONES CM, 1991, DEVELOPMENT, V111, P531; KINGSLEY DM, 1992, CELL, V71, P399, DOI 10.1016/0092-8674(92)90510-J; KOENIG BB, 1994, MOL CELL BIOL, V14, P5961, DOI 10.1128/MCB.14.9.5961; KORSMEYER SJ, 1995, TRENDS GENET, V11, P101, DOI 10.1016/S0168-9525(00)89010-1; LIU F, 1995, MOL CELL BIOL, V15, P3479; LYONS KM, 1990, DEVELOPMENT, V109, P833; LYONS KM, 1995, MECH DEVELOP, V50, P71, DOI 10.1016/0925-4773(94)00326-I; MILLIGAN CE, 1995, NEURON, V15, P385, DOI 10.1016/0896-6273(95)90042-X; PAULOU MP, 1975, J EMBRYOL EXP MORPH, V34, P511; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; ROBERT B, 1991, GENE DEV, V5, P2363, DOI 10.1101/gad.5.12b.2363; ROS MA, 1994, ANAT EMBRYOL, V190, P375; ROSENZWEIG BL, 1995, P NATL ACAD SCI USA, V92, P7632, DOI 10.1073/pnas.92.17.7632; RUOSLAHTI E, 1994, CELL, V77, P477, DOI 10.1016/0092-8674(94)90209-7; Saunders J.W., 1967, MAJOR PROBLEMS DEV B, P289; STORM EE, 1994, NATURE, V368, P639, DOI 10.1038/368639a0; TENDIJKE P, 1994, J BIOL CHEM, V269, P16985; VAINIO S, 1993, CELL, V75, P45, DOI 10.1016/S0092-8674(05)80083-2; WHYTE M, 1995, NATURE, V376, P17, DOI 10.1038/376017a0; WILKINSON DG, 1993, IN SITU HYBRIDIZATIO, P75; WINNIER G, 1995, GENE DEV, V9, P2105, DOI 10.1101/gad.9.17.2105; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; ZAKERI ZF, 1993, FASEB J, V7, P470, DOI 10.1096/fasebj.7.5.8462789; ZOU H, UNPUB	35	488	499	1	26	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 3	1996	272	5262					738	741		10.1126/science.272.5262.738	http://dx.doi.org/10.1126/science.272.5262.738			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UJ051	8614838				2022-12-28	WOS:A1996UJ05100056
J	Florence, SL; Jain, N; Pospichal, MW; Beck, PD; Sly, DL; Kaas, JH				Florence, SL; Jain, N; Pospichal, MW; Beck, PD; Sly, DL; Kaas, JH			Central reorganization of sensory pathways following peripheral nerve regeneration in fetal monkeys	NATURE			English	Article							MACAQUE; CORTEX; MECHANISM	TRANSECTION Of a sensory nerve in adults results in profound abnormalities in sensory perception, even if the severed nerve is surgically repaired to facilitate accurate nerve regeneration, In marked contrast, fewer perceptual errors follow nerve transection and surgical repair in children(1-3), The basis for this superior recovery in children was unknown. Here rye show that there is little or no topographic order in the median nerve to the hand after median nerve section and surgical repair in immature macaque monkeys, Remarkably, however, in the same animals the representation of the reinnervated hand in primary somatosensory cortex (area 3b) is quite orderly, This indicates that there are mechanisms in the developing brain that can create cortical topography, despite disordered sensory inputs. Presumably the superior recovery of perceptual abilities after peripheral nerve transection in children depends on this restoration of somatotopy in the central sensory maps.	VANDERBILT UNIV,DEPT PATHOL,NASHVILLE,TN 37240	Vanderbilt University	Florence, SL (corresponding author), VANDERBILT UNIV,DEPT PSYCHOL,NASHVILLE,TN 37240, USA.		Jain, Neeraj/B-2882-2010	Jain, Neeraj/0000-0002-3672-5850				BUCHTHAL F, 1979, J NEUROL NEUROSUR PS, V42, P436, DOI 10.1136/jnnp.42.5.436; BUNNELL S, 1956, SURG HAND; CHANGEUX JP, 1976, NATURE, V264, P705, DOI 10.1038/264705a0; CLINE HT, 1991, VISION VISUAL DYSFUN, V11; DARIANSMITH C, 1990, J COMP NEUROL, V299, P47, DOI 10.1002/cne.902990104; Dellon AL, 2015, EVALUATION SENSIBILI, V4th; FITZGERALD M, 1985, J COMP NEUROL, V240, P407, DOI 10.1002/cne.902400408; FLORENCE SL, 1994, CEREB CORTEX, V4, P391, DOI 10.1093/cercor/4.4.391; HALLIN RG, 1981, EXP NEUROL, V73, P90, DOI 10.1016/0014-4886(81)90047-9; HEBB DO, 1949, ORG BEHAVIOR; HUBEL DH, 1977, PROC R SOC SER B-BIO, V198, P1, DOI 10.1098/rspb.1977.0085; Jain N, 1995, DEV BRAIN RES, V90, P24, DOI 10.1016/0165-3806(96)83483-3; KAAS JH, 1983, ANNU REV NEUROSCI, V6, P325, DOI 10.1146/annurev.ne.06.030183.001545; KILLACKEY HP, 1995, TRENDS NEUROSCI, V18, P402, DOI 10.1016/0166-2236(95)93937-S; O'Leary D D, 1994, Curr Opin Neurobiol, V4, P535, DOI 10.1016/0959-4388(94)90054-X; PONS TP, 1987, SOMATOSENS MOT RES, V4, P309, DOI 10.3109/07367228709144612; SHATZ CJ, 1986, ANNU REV NEUROSCI, V9, P171, DOI 10.1146/annurev.ne.09.030186.001131; STENT GS, 1973, P NATL ACAD SCI USA, V70, P997, DOI 10.1073/pnas.70.4.997; Woolsey TA, 1990, DEV SENSORY SYSTEMS	19	75	77	0	2	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAY 2	1996	381	6577					69	71		10.1038/381069a0	http://dx.doi.org/10.1038/381069a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UJ053	8609990				2022-12-28	WOS:A1996UJ05300057
J	Ewan, PW				Ewan, PW			Clinical study of peanut and nut allergy in 62 consecutive patients: New features and associations	BRITISH MEDICAL JOURNAL			English	Article							FOOD HYPERSENSITIVITY; NATURAL-HISTORY; ANAPHYLAXIS; PATTERNS; OIL	Objective-To investigate clinical features of acute allergic reactions to peanuts and other nuts. Design-Analysis of data from consecutive patients seen by one doctor over one year in an allergy clinic at a regional referral centre. Subjects-62 patients aged 11 months to 53 years seen between October 1993 and September 1994. Main outcome measures-Type and severity of allergic reactions, age at onset of symptoms, type of nut causing allergy, results of skin prick tests, and incidence of other allergic diseases and associated allergies. Results-Peanuts were the commonest cause of allergy (47) followed by Brazil nut (18), almond (14), and hazelnut (13). Onset of allergic symptoms occurred by the age of 2 years in 33/60 and by the age of 7 in 55/60. Peanuts accounted for all allergies in children sensitised in the first year of life and for 82% (27/33) of allergies in children sensitised by the third year of life. Multiple allergies appeared progressively with age. The commonest symptom was facial angioedema, and the major feature accounting for life threatening reactions was laryngeal oedema. Hypotension was uncommon. Of 55 patients, 53 were atopic-that is, had positive skin results of tests to common inhaled allergens-and all 53 had other allergic disorders (asthma, rhinitis, eczema) due to several inhaled allergens and other foods. Conclusions-Sensitisation, mainly to peanuts, is occurring in very young children, and multiple peanut/nut allergies appear progressively. Peanut and nut allergy is becoming common and can cause life threatening reactions. The main danger is laryngeal oedema. Young atopic children should avoid peanuts and nuts to prevent the development of this allergy.			Ewan, PW (corresponding author), UNIV CAMBRIDGE,SCH CLIN,ADDENBROOKES HOSP NHS TRUST,ALLERGY CLIN,CAMBRIDGE CB2 2QH,ENGLAND.							ARSHAD SH, 1991, CLIN EXP ALLERGY, V21, P373, DOI 10.1111/j.1365-2222.1991.tb01671.x; ASSEM ESK, 1990, BRIT MED J, V300, P1377, DOI 10.1136/bmj.300.6736.1377; ATKINS FM, 1985, J ALLERGY CLIN IMMUN, V75, P356, DOI 10.1016/0091-6749(85)90072-7; BOCK SA, 1989, J ALLERGY CLIN IMMUN, V83, P900, DOI 10.1016/0091-6749(89)90103-6; BOCK SA, 1990, J PEDIATR-US, V117, P561, DOI 10.1016/S0022-3476(05)80689-4; BURKS AW, 1989, ALLERGY PROC, V10, P256; DONOVAN KL, 1990, BRIT MED J, V300, P1378, DOI 10.1136/bmj.300.6736.1378; FRIES JH, 1982, ANN ALLERGY, V48, P220; MONERETVAUTRIN DA, 1991, LANCET, V338, P1149, DOI 10.1016/0140-6736(91)92008-P; PLATTSMILLS TAE, 1982, CLIN ASPECTS IMMUNOL, P570; SAMPSON HA, 1989, J PEDIATR-US, V115, P23, DOI 10.1016/S0022-3476(89)80323-3; SAMPSON HA, 1990, J ALLERGY CLIN IMMUN, V86, P1, DOI 10.1016/S0091-6749(05)80115-0; SMITH T, 1990, BRIT MED J, V300, P1354, DOI 10.1136/bmj.300.6736.1354; TAYLOR SL, 1981, J ALLERGY CLIN IMMUN, V68, P372, DOI 10.1016/0091-6749(81)90135-4; WARREN JB, 1986, CLIN PHARMACOL THER, V40, P673, DOI 10.1038/clpt.1986.243; YUNGINGER JW, 1988, JAMA-J AM MED ASSOC, V260, P1450, DOI 10.1001/jama.260.10.1450	16	261	269	0	9	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 27	1996	312	7038					1074	1078						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UH816	8616415				2022-12-28	WOS:A1996UH81600026
J	Mellon, I; Rajpal, DK; Koi, M; Boland, CR; Champe, GN				Mellon, I; Rajpal, DK; Koi, M; Boland, CR; Champe, GN			Transcription-coupled repair deficiency and mutations in human mismatch repair genes	SCIENCE			English	Article							NONPOLYPOSIS COLORECTAL-CANCER; NUCLEOTIDE EXCISION REPAIR; ESCHERICHIA-COLI; COCKAYNE-SYNDROME; DNA DAMAGE; PREFERENTIAL REPAIR; SELECTIVE REPAIR; STRAND; YEAST; MECHANISM	Deficiencies in mismatch repair have been linked to a common cancer predisposition syndrome in humans, hereditary nonpolyposis colorectal cancer (HNPCC), and a subset of sporadic cancers. Here, several mismatch repair-deficient tumor cell lines and HNPCC-derived lymphoblastoid cell lines were found to be deficient in an additional DNA repair process termed transcription-coupled repair (TCR). The TCR defect was corrected in a mutant cell line whose mismatch repair deficiency had been corrected by chromosome transfer. Thus, the connection between excision repair and mismatch repair previously described in Escherichia coli extends to humans. These results imply that deficiencies in TCR and exposure to carcinogens present in the environment may contribute to the etiology of tumors associated with genetic defects in mismatch repair.	NIEHS,MOLEC CARCINOGENESIS LAB,RES TRIANGLE PK,NC 27706; UNIV CALIF SAN DIEGO,DEPT MED,LA JOLLA,CA 92093	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); University of California System; University of California San Diego	Mellon, I (corresponding author), UNIV KENTUCKY,MARKEY CANC CTR,TOXICOL PROGRAM,DEPT PATHOL,LEXINGTON,KY 40536, USA.		Koi, Minoru/C-3489-2012; Koi, Minoru/G-9197-2014		NIGMS NIH HHS [GM45535-03] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045535, R29GM045535] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; BAKER SM, 1995, CELL, V82, P309, DOI 10.1016/0092-8674(95)90318-6; BHATTACHARYYA NP, 1994, P NATL ACAD SCI USA, V91, P6319, DOI 10.1073/pnas.91.14.6319; BORRESEN AL, 1995, HUM MOL GENET, V4, P2065, DOI 10.1093/hmg/4.11.2065; BOYER JC, 1995, CANCER RES, V55, P6063; BRONNER CE, 1994, NATURE, V368, P258, DOI 10.1038/368258a0; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; HANAWALT PC, 1994, CURR BIOL, V4, P518, DOI 10.1016/S0960-9822(00)00112-3; HOEIJMAKERS JHJ, 1993, TRENDS GENET, V9, P173, DOI 10.1016/0168-9525(93)90164-D; HOEIJMAKERS JHJ, 1993, TRENDS GENET, V9, P211, DOI 10.1016/0168-9525(93)90121-W; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; KOI M, 1994, CANCER RES, V54, P4308; KOLODNER RD, 1995, TRENDS BIOCHEM SCI, V20, P397, DOI 10.1016/S0968-0004(00)89087-8; KUNKEL TA, 1995, CURR BIOL, V5, P1091, DOI 10.1016/S0960-9822(95)00218-1; LEACH FS, 1993, CELL, V75, P1215, DOI 10.1016/0092-8674(93)90330-S; LEADON SA, 1992, J BIOL CHEM, V267, P23175; LEADON SA, 1993, P NATL ACAD SCI USA, V90, P10499, DOI 10.1073/pnas.90.22.10499; LLOYD RS, 1995, DNA REPAIR MECH IMPA, P25; LOMMEL L, 1993, MOL CELL BIOL, V13, P970, DOI 10.1128/MCB.13.2.970; LYNCH HT, 1993, GASTROENTEROLOGY, V104, P1535, DOI 10.1016/0016-5085(93)90368-M; MAYNE LV, 1992, CANCER RES, V42, P1493; MELLON I, 1987, CELL, V51, P241, DOI 10.1016/0092-8674(87)90151-6; MELLON I, 1989, NATURE, V342, P95, DOI 10.1038/342095a0; Mellon I, 1996, P NATL ACAD SCI USA, V93, P1292, DOI 10.1073/pnas.93.3.1292; MELLON I, UNPUB; MODRICH P, 1991, ANNU REV GENET, V25, P229, DOI 10.1146/annurev.ge.25.120191.001305; NANCE MA, 1992, AM J MED GENET, V42, P68, DOI 10.1002/ajmg.1320420115; NICOLAIDES NC, 1994, NATURE, V371, P75, DOI 10.1038/371075a0; OLLER AR, 1992, P NATL ACAD SCI USA, V89, P11036, DOI 10.1073/pnas.89.22.11036; ORTH K, 1994, P NATL ACAD SCI USA, V91, P9495, DOI 10.1073/pnas.91.20.9495; PAPADOPOULOS N, 1994, SCIENCE, V263, P1625, DOI 10.1126/science.8128251; PARSONS R, 1995, SCIENCE, V268, P738, DOI 10.1126/science.7632227; PARSONS R, 1993, CELL, V75, P1227, DOI 10.1016/0092-8674(93)90331-J; REITMAIR AH, 1995, NAT GENET, V11, P64, DOI 10.1038/ng0995-64; RISINGER JI, 1995, J BIOL CHEM, V270, P18183, DOI 10.1074/jbc.270.31.18183; SELBY CP, 1993, SCIENCE, V260, P53, DOI 10.1126/science.8465200; SELBY CP, 1991, P NATL ACAD SCI USA, V88, P11574, DOI 10.1073/pnas.88.24.11574; SMERDON MJ, 1990, CELL, V61, P675, DOI 10.1016/0092-8674(90)90479-X; SWEDER KS, 1992, P NATL ACAD SCI USA, V89, P10696, DOI 10.1073/pnas.89.22.10696; SWEDER KS, IN PRESS GENETICS; TERLETH C, 1989, NUCLEIC ACIDS RES, V17, P4433, DOI 10.1093/nar/17.12.4433; UMAR A, 1994, J BIOL CHEM, V269, P14367; VENEMA J, 1990, P NATL ACAD SCI USA, V87, P4707, DOI 10.1073/pnas.87.12.4707; VENEMA J, 1991, MOL CELL BIOL, V11, P4128, DOI 10.1128/MCB.11.8.4128; WATSON P, 1993, CANCER, V71, P677, DOI 10.1002/1097-0142(19930201)71:3<677::AID-CNCR2820710305>3.0.CO;2-#; XIAO W, 1995, CARCINOGENESIS, V16, P1933, DOI 10.1093/carcin/16.8.1933	46	252	252	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 26	1996	272	5261					557	560		10.1126/science.272.5261.557	http://dx.doi.org/10.1126/science.272.5261.557			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UG826	8614807	Green Submitted			2022-12-28	WOS:A1996UG82600047
J	Szekeres, M; Nemeth, K; KonczKalman, Z; Mathur, J; Kauschmann, A; Altmann, T; Redei, GP; Nagy, F; Schell, J; Koncz, C				Szekeres, M; Nemeth, K; KonczKalman, Z; Mathur, J; Kauschmann, A; Altmann, T; Redei, GP; Nagy, F; Schell, J; Koncz, C			Brassinosteroids rescue the deficiency of CYP90, a cytochrome P450, controlling cell elongation and de-etiolation in arabidopsis	CELL			English	Article							GENES; SEQUENCES; THALIANA	The cpd mutation localized by T-DNA tagging on Arabidopsis chromosome 5-14.3 inhibits cell elongation controlled by the ecdysone-like brassinosteroid hormone brassinolide. The cpd mutant displays de-etiolation and derepression of light-induced genes in the dark, as well as dwarfism, male sterility, and activation of stress-regulated genes in the light. The CPD gene encodes a cytochrome P450 (CYP90) sharing homologous domains with steroid hydroxylases. The phenotype of the cpd mutant is restored to wild type both by feeding with C23-hydroxylated brassinolide precursors and by ectopic overexpression of the CPD cDNA. Brassinosteroids also compensate for different cell elongation defects of Arabidopsis dot, cop, fus, and axr2 mutants, indicating that these steroids play an essential role in the regulation of plant development.	HUNGARIAN ACAD SCI, BIOL RES CTR, INST PLANT BIOL, H-6701 SZEGED, HUNGARY; MAX PLANCK INST ZUCHTUNGSFORSCH, D-50829 COLOGNE, GERMANY; MAX PLANCK INST MOLEK PFLANZENPHYSIOL, D-14476 GOLM, GERMANY	Eotvos Lorand Research Network; Hungarian Academy of Sciences; Hungarian Biological Research Center; Max Planck Society; Max Planck Society			Nagy, Ferenc/D-3532-2015	Nagy, Ferenc/0000-0002-6157-9269; Altmann, Thomas/0000-0002-3759-360X; Koncz, Csaba/0000-0003-4422-9993; Szekeres, Miklos/0000-0002-6354-1790				ADAM G, 1986, PHYTOCHEMISTRY, V25, P1787, DOI 10.1016/S0031-9422(00)81151-6; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ARMER EE, 1994, PLANT MOL BIOL, V26, P1423; CASTLE LA, 1994, PLANT CELL, V6, P25, DOI 10.1105/tpc.6.1.25; CHORY J, 1991, PLANT CELL, V3, P445, DOI 10.1105/tpc.3.5.445; CHORY J, 1994, PLANT PHYSIOL, V104, P339, DOI 10.1104/pp.104.2.339; CHORY J, 1994, ARABIDOPSIS, P579; CRANE FL, 1993, OXIDOREDUCTION PLASM, V2; Davies P. J., 1987, PLANT HORMONES THEIR; DENG XW, 1994, CELL, V76, P423, DOI 10.1016/0092-8674(94)90107-4; DENG XW, 1992, CELL, V71, P791, DOI 10.1016/0092-8674(92)90555-Q; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; ECKER JR, 1995, SCIENCE, V268, P667, DOI 10.1126/science.7732375; ESTELLE M, 1994, ARABIDOPSIS, P555; FEDER N, 1968, AM J BOT, V55, P123, DOI 10.2307/2440500; FINKELSTEIN RR, 1994, ARABIDOPSIS, P523; FREY M, 1995, MOL GEN GENET, V246, P100, DOI 10.1007/BF00290138; FUJIIKURIYAMA Y, 1982, P NATL ACAD SCI-BIOL, V79, P2793, DOI 10.1073/pnas.79.9.2793; FUJIOKA S, 1995, BIOSCI BIOTECH BIOCH, V59, P1543, DOI 10.1271/bbb.59.1543; GOTOH O, 1992, J BIOL CHEM, V267, P83; GROVE MD, 1979, NATURE, V281, P216, DOI 10.1038/281216a0; HAUGE BM, 1993, PLANT J, V3, P745, DOI 10.1111/j.1365-313X.1993.00745.x; Kendrick RE, 1994, PHOTOMORPHOGENESIS P; KONCZ C, 1992, PLANT MOL BIOL, V20, P963, DOI 10.1007/BF00027166; KONCZ C, 1989, P NATL ACAD SCI USA, V86, P8467, DOI 10.1073/pnas.86.21.8467; Koncz C., 1992, METHODS ARABIDOPSIS; KONCZ C, 1994, PLANT MOL BIOL MAN B, V2, P1; MANDAVA NB, 1988, ANNU REV PLANT PHYS, V39, P23, DOI 10.1146/annurev.arplant.39.1.23; MCNELLIS TW, 1994, PLANT CELL, V6, P487, DOI 10.1105/tpc.6.4.487; MEHDY MC, 1994, PLANT PHYSIOL, V105, P467, DOI 10.1104/pp.105.2.467; MILLAR AJ, 1994, ANNU REV GENET, V28, P325, DOI 10.1146/annurev.ge.28.120194.001545; MISERA S, 1994, MOL GEN GENET, V244, P242, DOI 10.1007/BF00285451; NEBERT DW, 1987, ANNU REV BIOCHEM, V56, P945, DOI 10.1146/annurev.biochem.56.1.945; NELSON DR, 1993, DNA CELL BIOL, V12, P1, DOI 10.1089/dna.1993.12.1; PAN ZQ, 1995, J BIOL CHEM, V270, P8487, DOI 10.1074/jbc.270.15.8487; QUAIL PH, 1995, SCIENCE, V268, P675, DOI 10.1126/science.7732376; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; TAKAHASHI T, 1995, GENE DEV, V9, P97, DOI 10.1101/gad.9.1.97; TREZZINI GF, 1993, PLANT MOL BIOL, V21, P385, DOI 10.1007/BF00019954; UKNES S, 1992, PLANT CELL, V4, P645, DOI 10.1105/tpc.4.6.645; WHITE PC, 1986, P NATL ACAD SCI USA, V83, P5111, DOI 10.1073/pnas.83.14.5111; WINKLER RG, 1995, PLANT CELL, V7, P1307, DOI 10.1105/tpc.7.8.1307	42	781	853	11	142	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 19	1996	85	2					171	182		10.1016/S0092-8674(00)81094-6	http://dx.doi.org/10.1016/S0092-8674(00)81094-6			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UG255	8612270	Bronze			2022-12-28	WOS:A1996UG25500006
J	Taylor, PJ; Monahan, J				Taylor, PJ; Monahan, J			Dangerous patients or dangerous diseases? Commentary	BRITISH MEDICAL JOURNAL			English	Editorial Material							OUTPATIENT TREATMENT; CIVIL COMMITMENT; SCHIZOPHRENIA; VIOLENCE; BEHAVIOR; PSYCHOPATHOLOGY; PREDICTION; PSYCHOSIS; DISORDER; CRIME		UNIV VIRGINIA,SCH LAW,CHARLOTTESVILLE,VA 22903	University of Virginia	Taylor, PJ (corresponding author), INST PSYCHIAT,DE CRESPIGNY PK, DENMARK HILL,LONDON SE5 8AF,ENGLAND.			Monahan, John/0000-0003-4431-3028				Bottoms A., 1987, HOWARD J, V26, P117, DOI 10.1111/j.1468-2311.1987.tb00584.x; CHAIKEN J, 1994, UNDERSTANDING PREVEN, V4; COID B, 1993, BRIT J PSYCHIAT, V162, P87, DOI 10.1192/bjp.162.1.87; Department of Health, 1992, STAT B, V2, P92; DOHRENWEND BP, 1980, ARCH GEN PSYCHIAT, V37, P1229; DVOSKIN JA, 1994, HOSP COMMUNITY PSYCH, V45, P679; Gabrielsen G, 1992, STUDIES CRIME CRIME, V1, P106; GELLER JL, 1990, HOSP COMMUNITY PSYCH, V41, P749; Hafner H, 1973, CRIMES VIOLENCE MENT; HARRY B, 1988, HOSP COMMUNITY PSYCH, V39, P862; Haxby D., 1978, PROBATION CHANGING S; HODGINS S, 1992, ARCH GEN PSYCHIAT, V49, P476, DOI 10.1001/archpsyc.1992.01820060056009; HUMPHREYS MS, 1992, BRIT J PSYCHIAT, V161, P501, DOI 10.1192/bjp.161.4.501; JAFFE D, 1994, INNOVATIONS RES, V3, P1; JOHNSTONE EC, 1986, BRIT J PSYCHIAT, V148, P115, DOI 10.1192/bjp.148.2.115; JONES K, 1980, INT J LAW PSYCHIAT, V3, P1, DOI 10.1016/0160-2527(80)90016-3; KRAKOWSKI M, 1988, COMPR PSYCHIAT, V29, P174, DOI 10.1016/0010-440X(88)90011-9; LAMB HR, 1992, HOSP COMMUNITY PSYCH, V43, P669; LIDZ CW, 1993, JAMA-J AM MED ASSOC, V269, P1007, DOI 10.1001/jama.269.8.1007; LINDQVIST P, 1990, BRIT J PSYCHIAT, V157, P345, DOI 10.1192/bjp.157.3.345; Link B.G., 1994, VIOLENCE MENTAL DISO, P137; LINK BG, 1992, AM SOCIOL REV, V57, P275, DOI 10.2307/2096235; LINK BG, 1995, EPIDEMIOL REV, V17, P1; May T., 1994, OXFORD HDB CRIMINOLO, P861; MCNEIL DE, 1995, AM J PSYCHIAT, V152, P901; MILLER RD, 1992, HOSP COMMUNITY PSYCH, V43, P79; MOSSMAN D, 1994, J CONSULT CLIN PSYCH, V62, P783, DOI 10.1037/0022-006X.62.4.783; MURRAY LS, 1993, LANCET, V341, P1487, DOI 10.1016/0140-6736(93)90631-P; ORTMANN J, 1981, PSYKISK AFRIGSLE KRI; ROBERTSON G, 1985, PSYCHOL MED, V15, P297, DOI 10.1017/S0033291700023576; ROBERTSON G, 1985, PSYCHOL MED, V15, P81, DOI 10.1017/S003329170002095X; ROFMAN ES, 1980, AM J PSYCHIAT, V137, P1061; Sowers W. E., 1993, CRIM BEHAV MENT HEAL, V3, P403; SWAITZ MS, 1995, PSYCHIAT SERVICES, V46, P381; SWANSON J, IN PRESS CRIMINAL BE; SWANSON JW, 1990, HOSP COMMUNITY PSYCH, V41, P761; Taylor P. J., 1995, P163; TAYLOR PJ, 1987, BRIT MED BULL, V43, P718, DOI 10.1093/oxfordjournals.bmb.a072211; TAYLOR PJ, 1988, BRIT J PSYCHIAT, V152, P340, DOI 10.1192/bjp.152.3.340; TAYLOR PJ, 1985, BRIT J PSYCHIAT, V147, P491, DOI 10.1192/bjp.147.5.491; Taylor PJ, 1994, CRIM BEHAV MENT HEAL, V4, P266; Taylor PJ, 1994, VIOLENCE MENTAL DISO, P161; Taylor PJ, 1993, FORENSIC PSYCHIAT CL, P329; TAYLOR PJ, 1993, CRIME MENTAL DISORDE, P63; TORREY EF, 1994, HOSP COMMUNITY PSYCH, V45, P653; TORREY EF, 1995, PSYCHIAT SERVICES, V46, P780; Walker N., 1973, CRIME INSANITY ENGLA, V2; WERNER PD, 1984, AM J PSYCHIAT, V141, P263; WESSELY S, 1993, BRIT J PSYCHIAT, V163, P69, DOI 10.1192/bjp.163.1.69; WESSELY S, 1994, PSYCHOL MED, V24, P483, DOI 10.1017/S0033291700027458; [No title captured]	51	25	25	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 13	1996	312	7036					967	969						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	UF659	8616317				2022-12-28	WOS:A1996UF65900029
J	Weintraub, MS; Grosskopf, I; Rassin, T; Miller, H; Charach, G; Rotmensch, HH; Liron, M; Rubinstein, A; Iaina, A				Weintraub, MS; Grosskopf, I; Rassin, T; Miller, H; Charach, G; Rotmensch, HH; Liron, M; Rubinstein, A; Iaina, A			Clearance of chylomicron remnants in normolipidaemic patients with coronary artery disease: Case control study over three years	BRITISH MEDICAL JOURNAL			English	Article							POSTPRANDIAL LIPOPROTEIN METABOLISM; HIGH-DENSITY LIPOPROTEIN; TRIGLYCERIDE-RICH LIPOPROTEINS; CHOLESTEROL-FED RABBITS; APOLIPOPROTEIN-E; PLASMA; RECEPTOR; CANINE; HYPERTRIGLYCERIDEMIA; ATHEROSCLEROSIS	Objective-To test the hypothesis that subjects who clear chylomicron remnants slowly from plasma may be at higher risk of coronary artery disease than indicated by their fasting plasma lipid concentrations. Design-Case control study over three years. Setting-An 800 bed general municipal hospital. Subjects-85 normolipidaemic patients with coronary artery disease selected prospectively and matched with 85 normolipidaemic subjects with normal coronary arteries on angiography. Interventions-All subjects were given a vitamin A fat loading test which specifically labels intestinal lipoproteins with retinyl palmitate. Main outcome measure-Postprandial lipoprotein metabolism. Results-The area below the chylomicron remnant retinyl palmitate curve was significantly increased in the coronary artery disease group as compared with the controls (mean 23.4 (SD 15.0) v 15.3 (8.9) mu mol/l.h; 95% confidence interval of difference 4.37 to 11.82). Conclusions-Normolipidaemic patients with coronary artery disease had significantly higher concentrations of chylomicron remnants in plasma than normolipidaemic subjects with normal coronary vessels. This may explain the mechanism underlying the susceptibility to atherosclerosis of coronary artery disease patients with normal fasting lipid values. As diet and drugs can ameliorate the accumulation of postprandial lipoproteins in plasma, the concentration of chylomicron remnants should be measured in patients at high risk of coronary artery disease.	TEL AVIV SOURASKY MED CTR,DEPT MED C,TEL AVIV,ISRAEL; TEL AVIV SOURASKY MED CTR,DEPT MED E,TEL AVIV,ISRAEL; TEL AVIV SOURASKY MED CTR,CORONARY CATHETERISAT UNIT,TEL AVIV,ISRAEL; TEL AVIV SOURASKY MED CTR,UNIT LIPID METAB,TEL AVIV,ISRAEL; TEL AVIV SOURASKY MED CTR,DEPT NEPHROL,TEL AVIV,ISRAEL; TEL AVIV UNIV,SACKLER FAC MED,IL-69978 TEL AVIV,ISRAEL	Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv Sourasky Medical Center; Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv Sourasky Medical Center; Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv Sourasky Medical Center; Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv Sourasky Medical Center; Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv Sourasky Medical Center; Tel Aviv University; Sackler Faculty of Medicine	Weintraub, MS (corresponding author), TEL AVIV SOURASKY MED CTR,DEPT INTERNAL MED C,TEL AVIV,ISRAEL.							BERR F, 1985, J LIPID RES, V26, P852; BERR F, 1984, J LIPID RES, V25, P805; BERR F, 1986, J LIPID RES, V27, P645; BLANCHET.EJ, 1971, J CELL BIOL, V51, P1, DOI 10.1083/jcb.51.1.1; CORTNER JA, 1987, J LIPID RES, V28, P195; DALE VP, 1962, PHYSIOL REV, V42, P674; DEMACKER PNM, 1991, EUR J CLIN INVEST, V21, P197, DOI 10.1111/j.1365-2362.1991.tb01809.x; EISENBERG S, 1984, J LIPID RES, V25, P1017; FLOREN CH, 1981, BIOCHIM BIOPHYS ACTA, V663, P336, DOI 10.1016/0005-2760(81)90219-8; GIANTURCO SH, 1988, J CLIN INVEST, V82, P1633, DOI 10.1172/JCI113775; GOLDSTEIN JL, 1980, J BIOL CHEM, V255, P1839; GOODMAN DS, 1962, J CLIN INVEST, V41, P1886, DOI 10.1172/JCI104645; GORDON T, 1977, AM J MED, V62, P707, DOI 10.1016/0002-9343(77)90874-9; GROOT PHE, 1991, ARTERIOSCLER THROMB, V11, P653, DOI 10.1161/01.ATV.11.3.653; GRUNDY SM, 1976, METABOLISM, V25, P1225, DOI 10.1016/S0026-0495(76)80006-6; HAZARD WR, 1976, METABOLISM, V25, P777; HOLLANDER D, 1981, J LAB CLIN MED, V97, P449; HUI DY, 1986, J BIOL CHEM, V261, P4256; HUI DY, 1981, J BIOL CHEM, V256, P5646; KANE JP, 1983, ARTERIOSCLEROSIS, V3, P47, DOI 10.1161/01.ATV.3.1.47; KARPE F, 1995, ARTERIOSCL THROM VAS, V15, P199, DOI 10.1161/01.ATV.15.2.199; KORN ED, 1955, J BIOL CHEM, V215, P1; KRAINSKI SD, 1990, METABOLISM, V39, P357; LINDGREN FT, 1972, BLOOD LIPIDS LIPOPRO, P181; LIPPEL K, 1981, ARTERIOSCLEROSIS, V1, P406, DOI 10.1161/01.ATV.1.6.406; MATTHEWS JNS, 1990, BRIT MED J, V300, P230, DOI 10.1136/bmj.300.6719.230; MILLER NE, 1981, BRIT MED J, V282, P1741, DOI 10.1136/bmj.282.6278.1741; MORGANROTH J, 1975, ANN INTERN MED, V82, P158, DOI 10.7326/0003-4819-82-2-158; NESTEL PJ, 1982, NEW ENGL J MED, V307, P327; PATSCH JR, 1983, P NATL ACAD SCI-BIOL, V80, P1449, DOI 10.1073/pnas.80.5.1449; REDGRAVE T G, 1970, Journal of Clinical Investigation, V49, P465, DOI 10.1172/JCI106255; SCHOEFL GI, 1968, PROC R SOC SER B-BIO, V169, P153, DOI 10.1098/rspb.1968.0003; STENDER S, 1982, ARTERIOSCLEROSIS, V2, P493, DOI 10.1161/01.ATV.2.6.493; STENDER S, 1981, ATHEROSCLEROSIS, V39, P97; THOMPSON KH, 1983, J NUTR, V113, P2002, DOI 10.1093/jn/113.10.2002; WEINTRAUB M, 1992, J GERONTOL, V47, pB209, DOI 10.1093/geronj/47.6.B209; WEINTRAUB MS, 1989, CIRCULATION, V79, P1007, DOI 10.1161/01.CIR.79.5.1007; WEINTRAUB MS, 1987, J CLIN INVEST, V79, P1110, DOI 10.1172/JCI112926; WEINTRAUB MS, 1987, J CLIN INVEST, V80, P1571, DOI 10.1172/JCI113243; WEINTRAUB MS, 1988, J CLIN INVEST, V82, P1884, DOI 10.1172/JCI113806; WILSON DE, 1985, METABOLISM, V34, P551, DOI 10.1016/0026-0495(85)90193-3; WILSON DE, 1983, METABOLISM, V32, P514, DOI 10.1016/0026-0495(83)90016-1; ZILVERSMIT DB, 1979, CIRCULATION, V60, P473, DOI 10.1161/01.CIR.60.3.473; 1984, JAMA-J AM MED ASSOC, V251, P365	44	161	161	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 13	1996	312	7036					935	939						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UF659	8616304	Green Published			2022-12-28	WOS:A1996UF65900016
J	Bussey, H				Bussey, H			Cell shape determination: A pivotal role for Rho	SCIENCE			English	Editorial Material											Bussey, H (corresponding author), MCGILL UNIV,DEPT BIOL,MONTREAL,PQ H3A 1B1,CANADA.							CHANT J, 1995, CELL, V81, P1, DOI 10.1016/0092-8674(95)90363-1; Drgonova J, 1996, SCIENCE, V272, P277, DOI 10.1126/science.272.5259.277; Imai J, 1996, GENETICS, V142, P359; MAZUR P, 1995, MOL CELL BIOL, V15, P5671; MOL PC, 1994, J BIOL CHEM, V269, P31267; NONAKA H, 1995, EMBO J, V14, P5931, DOI 10.1002/j.1460-2075.1995.tb00281.x; PARAVICINI G, 1992, MOL CELL BIOL, V12, P4896, DOI 10.1128/MCB.12.11.4896; Qadota H, 1996, SCIENCE, V272, P279, DOI 10.1126/science.272.5259.279; QADOTA H, 1994, P NATL ACAD SCI USA, V91, P9317, DOI 10.1073/pnas.91.20.9317; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; TAKAI Y, 1995, TRENDS BIOCHEM SCI, V20, P227, DOI 10.1016/S0968-0004(00)89022-2; YAMOCHI W, 1994, J CELL BIOL, V125, P1077, DOI 10.1083/jcb.125.5.1077	12	40	44	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 12	1996	272	5259					224	225		10.1126/science.272.5259.224	http://dx.doi.org/10.1126/science.272.5259.224			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UE729	8602505				2022-12-28	WOS:A1996UE72900030
J	Richardson, A; Parsons, JT				Richardson, A; Parsons, JT			A mechanism for regulation of the adhesion-associated protein tyrosine kinase pp125(FAK)	NATURE			English	Article							FOCAL ADHESIONS; EXPRESSION; PP125FAK	FOCAL adhesion kinase(1,2) (pp125(FAK)) is a member of a growing family of structurally distinct protein tyrosine kinases that includes the recently identified FakB(3) and PYK2/CAK beta/RAFTK(4,6). Activation of pp125(FAK) has been functionally linked to the formation of focal adhesions, integrin-mediated sites of contact between the cell and the extracellular matrix(7,8). The carboxy-terminal domain of pp125(FAK) is also expressed as a separate protein called pp41/43(FRNK) (where FRNK represents pp125(FAK)-related non-kinase)(9). Here we show that pp41/43(FRNK) acts as an inhibitor of pp125(FAK) by transiently blocking the formation of focal adhesions on fibronectin and constitutively reducing tyrosine phosphorylation of both pp125(FAK) and of two focal adhesion proteins, tensin and paxillin. These inhibitory effects of pp41/43(FRNK) are reversed by co-expression of pp125(FAK), suggesting that pp125(FAK) and pp41/43(FRNK) compete for a common binding protein(s) whose association with pp125(FAK) is necessary for signalling by pp125(FAK). We propose that pp41/43F RNK functions as an endogenous regulator of pp125(FAK), thus providing an unusual means to regulate both tyrosine kinase activity and cellular adhesion to the extracellular matrix.	UNIV VIRGINIA,HLTH SCI CTR,DEPT MICROBIOL,CHARLOTTESVILLE,VA 22908	University of Virginia			Richardson, Alan/I-4631-2015; Richardson, Alan/E-7615-2010	Richardson, Alan/0000-0003-1825-3375; 				ABRAHAM S, 1995, J BIOL CHEM, V270, P27742; ANDRE E, 1993, BIOCHEM BIOPH RES CO, V190, P140, DOI 10.1006/bbrc.1993.1022; COLINGE M, 1992, MOL CELL BIOL, V12, P2359; GALLAGHER PJ, 1991, J BIOL CHEM, V266, P23945; HANKS SK, 1992, P NATL ACAD SCI USA, V89, P8487, DOI 10.1073/pnas.89.18.8487; HILDEBRAND JD, 1993, J CELL BIOL, V123, P993, DOI 10.1083/jcb.123.4.993; Ilic Dusko, 1995, Nature (London), V377, P539, DOI 10.1038/377539a0; KANNER SB, 1994, P NATL ACAD SCI USA, V91, P10484, DOI 10.1073/pnas.91.22.10484; KANNER SB, 1990, P NATL ACAD SCI USA, V87, P3328, DOI 10.1073/pnas.87.9.3328; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; MOLINA CA, 1993, CELL, V75, P875, DOI 10.1016/0092-8674(93)90532-U; MOSSELMAN S, 1994, CANCER RES, V54, P220; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; RICHARDSON A, 1995, BIOESSAYS, V17, P229, DOI 10.1002/bies.950170309; SASAKI H, 1995, J BIOL CHEM, V270, P21206, DOI 10.1074/jbc.270.36.21206; SCHALLER MD, 1993, MOL CELL BIOL, V13, P785, DOI 10.1128/MCB.13.2.785; SCHALLER MD, 1995, MOL CELL BIOL, V15, P2635; SCHALLER MD, 1994, CURR OPIN CELL BIOL, V6, P705, DOI 10.1016/0955-0674(94)90097-3; SCHALLER MD, 1994, MOL CELL BIOL, V14, P1680, DOI 10.1128/MCB.14.3.1680; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; SHIRINSKY VP, 1993, J BIOL CHEM, V268, P16578; SUN ZM, 1995, MOL CELL BIOL, V15, P561, DOI 10.1128/MCB.15.1.561	22	442	454	0	6	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	APR 11	1996	380	6574					538	540		10.1038/380538a0	http://dx.doi.org/10.1038/380538a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UE663	8606775				2022-12-28	WOS:A1996UE66300053
J	Endress, M; Zinner, E; Bischoff, A				Endress, M; Zinner, E; Bischoff, A			Early aqueous activity on primitive meteorite parent bodies	NATURE			English	Article							EARLY SOLAR-SYSTEM; INTERSTELLAR GRAINS; ISOTOPE SYSTEMATICS	THE interstellar material from which the Solar System formed has been modified by many processes(1): evaporation and condensation in the solar nebula, accretion into protoplanetary bodies and post-accretion processes within these bodies, Meteorites provide a record of these events and their chronology(2), Carbonaceous CI chondrites are among the most primitive, undifferentiated meteorites(3-6), but nevertheless show evidence of post-accretion alteration(7); they contain carbonates that are believed to have formed by reactions between anhydrous CI precursor materials and circulating fluids in the meteorite parent body (or bodies), yet little is known about the nature of these reactions or the timescale on which they occurred, Here we report measurements of excess Cr-53-formed by the decay of short-lived Mn-53-in five carbonate fragments from the CI chondrites Orgueil and Ivuna. Our results show that aqueous alteration on small protoplanetary bodies must have begun less than 20 Myr after the time of formation of the oldest known solar-nebula condensates(2) (Allende refractory inclusions). This upper limit is much shorter than that of 50 Myr inferred from previous studies(8), and clearly establishes aqueous alteration as one of the earliest processes in the chemical evolution of the Solar System.	WASHINGTON UNIV,MCDONNELL CTR SPACE SCI,ST LOUIS,MO 63130; UNIV MUNSTER,INST PLANETOL,D-48149 MUNSTER,GERMANY	Washington University (WUSTL); University of Munster								ANDERS E, 1993, METEORITICS, V28, P490, DOI 10.1111/j.1945-5100.1993.tb00274.x; BIRCK JL, 1988, NATURE, V331, P579, DOI 10.1038/331579a0; ENDRESS M, 1994, METEORITICS, V29, P463; Endress M, 1996, GEOCHIM COSMOCHIM AC, V60, P489, DOI 10.1016/0016-7037(95)00399-1; FREDRIKSSON K, 1988, METEORITICS, V23, P35, DOI 10.1111/j.1945-5100.1988.tb00894.x; Kerridge JF., 1988, METEORITES EARLY SOL; Lugmair G. W., 1992, LUNAR PLANET SCI, VXXIII, P823; LUGMAIR GW, 1994, LPS, V25, P813; MACDOUGALL JD, 1984, NATURE, V307, P249, DOI 10.1038/307249a0; MACDOUGALL JD, 1989, METEORITICS, V24, P297; MACPHERSON GJ, 1995, METEORITICS, V30, P365, DOI 10.1111/j.1945-5100.1995.tb01141.x; MANHES G, 1988, COMPTES RENDUS ATP P, P323; OTT U, 1993, NATURE, V364, P25, DOI 10.1038/364025a0; PODOSEK FA, 1991, GEOCHIM COSMOCHIM AC, V55, P1083, DOI 10.1016/0016-7037(91)90165-2; Richardson S. M., 1978, Meteoritics, V13, P141, DOI 10.1111/j.1945-5100.1978.tb00803.x; SCATENAWACHEL DE, 1984, LUNAR PLANET SCI, V15, P718; Scott E. R. D., 1988, METEORITES EARLY SOL, P718; Tilton G. G., 1988, METEORITES EARLY SOL, P259; Zinner E., 1988, METEORITES EARLY SOL; [No title captured]; [No title captured]	21	128	132	0	15	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	FEB 22	1996	379	6567					701	703		10.1038/379701a0	http://dx.doi.org/10.1038/379701a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TW567	8602215				2022-12-28	WOS:A1996TW56700043
J	Koo, D; Maloney, K; Tauxe, R				Koo, D; Maloney, K; Tauxe, R			Epidemiology of diarrheal disease outbreaks on cruise ships, 1986 through 1993	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SHIGELLOSIS; ABOARD	Objective.-To describe the epidemiology of cruise-associated diarrheal disease outbreaks from 1986 through 1993, to determine if the incidence had changed since 1985, and to determine the preventability of outbreaks that continue to occur. Design.-The numerator data were collated from Centers for Disease Control and Prevention (CDC) outbreak investigation reports from 1986 through 1993. The denominator data were summations of cruise ship data on the number of passengers and length of cruises collected during routine diarrheal illness surveillance, available only for the period 1989 through 1993. Setting.-Cruise ships with outbreaks of diarrheal disease. Participants.-Cruise ship passengers and crew or staff who participated in the original investigations. Main Outcome Measures.-The incidence of outbreaks during the study period, pathogens isolated, and vehicles of transmission implicated in investigations. Results.-Among cruises of 3 to 15 days, CDC staff investigated 1.4 outbreaks per 1000 cruises, or 2.3 outbreaks per 10 million passenger-days. An etiologic agent was implicated in 21 (68%) of 31 investigated outbreaks: bacterial in 12, viral in nine. A specific vehicle of transmission was identified in 16. The most common vehicles of transmission were undercooked scallops (three outbreaks caused by enterotoxigenic Escherichia coli), eggs (two outbreaks caused by Salmonella serotype Enteritidis, one by Norwalk-like virus), and food items provided by caterers during onshore excursions (three outbreaks, one caused by Shigella sonnei). Conclusions.-Observance of two simple precautions could have prevented almost one third (5/16, or 31%) of the investigated outbreaks on cruise ships. Cruise lines have been reminded to cook seafoods thoroughly and to use pasteurized eggs for menu items calling for pooled eggs. Preventing food handlers from working while ill and riot using onshore caterers for offship excursions might have prevented at least an additional one third (5/16) of these outbreaks.	CTR DIS CONTROL & PREVENT,FOODBORNE & DIARRHEAL DIS BRANCH,DIV BACTERIAL & MYCOT DIS,ATLANTA,GA 30333; CTR DIS CONTROL & PREVENT,NATL CTR INFECT DIS,DIV BACTERIAL & MYCOT DIS,ATLANTA,GA 30333	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA								ADDISS DG, 1989, EPIDEMIOL INFECT, V103, P63, DOI 10.1017/S0950268800030363; DAVIES JW, 1977, CAN MED ASSOC J, V106, P877; LEW JF, 1991, AM J EPIDEMIOL, V134, P413, DOI 10.1093/oxfordjournals.aje.a116103; MERSON MH, 1975, JAMA-J AM MED ASSOC, V231, P723, DOI 10.1001/jama.231.7.723; MERSON MH, 1976, J MILK FOOD TECHNOL, V39, P285, DOI 10.4315/0022-2747-39.4.285; MERSON MH, 1975, AM J EPIDEMIOL, V101, P165, DOI 10.1093/oxfordjournals.aje.a112081; 1980, VESSEL SANITATION PR	7	45	47	0	5	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 21	1996	275	7					545	547		10.1001/jama.275.7.545	http://dx.doi.org/10.1001/jama.275.7.545			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TV569	8606476				2022-12-28	WOS:A1996TV56900032
J	Chen, H; Charlat, O; Tartaglia, LA; Woolf, EA; Weng, X; Ellis, SJ; Lakey, ND; Culpepper, J; Moore, KJ; Breitbart, RE; Duyk, GM; Tepper, RI; Morgenstern, JP				Chen, H; Charlat, O; Tartaglia, LA; Woolf, EA; Weng, X; Ellis, SJ; Lakey, ND; Culpepper, J; Moore, KJ; Breitbart, RE; Duyk, GM; Tepper, RI; Morgenstern, JP			Evidence that the diabetes gene encodes the leptin receptor: Identification of a mutation in the leptin receptor gene in db/db mice	CELL			English	Article							OBESE	OB-R is a high affinity receptor for leptin, an important circulating signal for the regulation of body weight. We identified an alternatively spliced transcript that encodes a form of mouse OB-R with a long intracellular domain, db/db mice also produce this alternatively spliced transcript, but with a 106 nt insertion that prematurely terminates the intracellular domain. We further identified a G-->T point mutation in the genomic OB-R sequence in db/db mice. This mutation generates a donor splice site that converts the 106 nt region to a novel exon retained in the OB-R transcript. We predict that the long intracellular domain form of OB-R is crucial for initiating intracellular signal transduction, and as a corollary, the inability to produce this form of OB-R leads to the severe obese phenotype found in db/db mice.			Chen, H (corresponding author), MILLENNIUM PHARMACEUT INC,640 MEM DR,CAMBRIDGE,MA 02139, USA.							BAUMANN H, 1994, MOL CELL BIOL, V14, P138, DOI 10.1128/MCB.14.1.138; CAMPFIELD LA, 1995, SCIENCE, V269, P546, DOI 10.1126/science.7624778; COLEMAN DL, 1973, DIABETOLOGIA, V9, P294, DOI 10.1007/BF01221857; COLEMAN DL, 1978, DIABETOLOGIA, V14, P141, DOI 10.1007/BF00429772; FRIEDMAN JM, 1992, CELL, V69, P217, DOI 10.1016/0092-8674(92)90402-X; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; HALAAS JL, 1995, SCIENCE, V269, P543, DOI 10.1126/science.7624777; KISHIMOTO T, 1994, CELL, V76, P253, DOI 10.1016/0092-8674(94)90333-6; LEE CC, 1988, SCIENCE, V239, P1288, DOI 10.1126/science.3344434; NARAZAKI M, 1994, P NATL ACAD SCI USA, V91, P2285, DOI 10.1073/pnas.91.6.2285; PELLEYMOUNTER MA, 1995, SCIENCE, V269, P540, DOI 10.1126/science.7624776; SMITH CWJ, 1993, MOL CELL BIOL, V13, P4939, DOI 10.1128/MCB.13.8.4939; STAHL N, 1995, SCIENCE, V267, P1349, DOI 10.1126/science.7871433; STEPHENS TW, 1995, NATURE, V377, P530, DOI 10.1038/377530a0; Tartaglia LA, 1995, CELL, V83, P1263, DOI 10.1016/0092-8674(95)90151-5; VALCARCEL J, 1995, PREMRNA PROCESSING, P97; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0; [No title captured]	18	1821	1923	1	76	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 9	1996	84	3					491	495		10.1016/S0092-8674(00)81294-5	http://dx.doi.org/10.1016/S0092-8674(00)81294-5			5	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TV708	8608603	Bronze			2022-12-28	WOS:A1996TV70800018
J	Peel, MR				Peel, MR			Effects on asylum seekers of ill treatment in Zaire	BRITISH MEDICAL JOURNAL			English	Article								To describe the health effects of the political system in Zaire on asylum seekers seen at the Medical Foundation for the Care of Victims of Torture a retrospective study was performed of the records of 92 asylum seekers from Zaire who were seen for medical reports at the medical foundation in 1993 and 1994. Eighty one had been imprisoned; the others had been severely ill treated at home by the security services. Sixty six had been detained for up to one year. Prison conditions were invariably insanitary, and food of poor quality when provided. All had been beaten on arrest, and all but two had been beaten repeatedly in prison. Nearly all the women and some of the men described sexual abuse. Almost all left prison through bribery or because a guard had a similar background. Seventy two asylum seekers had scarring, considered to be consistent with the history, and 70 were considered to have suffered persistent psychological damage. Asylum seekers from Zaire will have health effects hom experiences unimaginable to the ordinary Briton. An understanding of the background will help clinicians manage them.	UNITED MED & DENT SCH,GUYS & ST THOMAS HOSP,LONDON SE1 9RT,ENGLAND	Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London	Peel, MR (corresponding author), MED FDN CARE VICTIMS TORTURE,LONDON NW5 3EJ,ENGLAND.							ASKIN A, 1994, NEW INT, V259, P23; FORREST D, 1995, LANCET, V345, P225, DOI 10.1016/S0140-6736(95)90225-2; MONTGOMERY E, 1994, DAN MED BULL, V41, P588; WRONG M, 1995, FINANCIAL TIMES 0307; 1995, ANN INTERN MED, V122, P607; 1994, CAIRE COLLAPSING CRI; 1993, ECN4199449 WHO; 1994, 1994 HUM RIGHTS WATC, P57	8	8	8	1	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 3	1996	312	7026					293	294						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TU507	8611788				2022-12-28	WOS:A1996TU50700027
J	Asch, DA				Asch, DA			The role of critical care nurses in euthanasia and assisted suicide	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							VOLUNTARY EUTHANASIA; ATTITUDES	Background. Euthanasia and assisted suicide have received considerable attention recently in medical literature, public discussion, and proposed state legislation. Almost all the discussion in this area has focused on the role of physicians. However, nurses - especially critical care nurses - may be in a special position to understand the wishes of patients and to act on this understanding. Methods. I mailed a survey to 1600 critical care nurses in the United States, asking them to describe anonymously any requests from patients, family members or others acting for patients (surrogates), or physicians to perform euthanasia or assisted suicide, as well as their own practices. Results. Of the 1139 nurses who responded (71 percent), 852 said they practiced exclusively in intensive care units for adults in the United States. Of these 852 nurses, 141 (17 percent) reported that they had received requests from patients or family members to perform euthanasia or assist in suicide; 129 (16 percent of those for whom data were available) reported that they had engaged in such practices; and an additional 35 (4 percent) reported that they had hastened a patient's death by only pretending to provide life-sustaining treatment ordered by a physician. Some nurses reported engaging in these practices without the request or advance knowledge of physicians or others. The method of euthanasia most commonly described was the administration of a high dose of an opiate to a terminally ill patient. Conclusions. As public debate continues about euthanasia and assisted suicide, some critical care nurses in the United States are engaging in such practices. (C) 1995, Massachusetts Medical Society.	VET AFFAIRS MED CTR,PHILADELPHIA,PA; UNIV PENN,LEONARD DAVIS INST HLTH ECON,PHILADELPHIA,PA 19104; UNIV PENN,CTR BIOETH,DIV GEN INTERNAL MED,PHILADELPHIA,PA 19104	US Department of Veterans Affairs; Veterans Health Administration (VHA); University of Pennsylvania; Philadelphia Veterans Affairs Medical Center; University of Pennsylvania; University of Pennsylvania				Asch, David/0000-0002-7970-286X				*AM NURS ASS, 1994, POS STAT ACT EUTH; ANDERSON JG, 1993, SOC SCI MED, V37, P105, DOI 10.1016/0277-9536(93)90323-V; ANGELL M, 1988, NEW ENGL J MED, V319, P1348, DOI 10.1056/NEJM198811173192010; ASCH DA, 1995, CRIT CARE MED, V151, P288; Back AL, 1996, JAMA-J AM MED ASSOC, V275, P919, DOI 10.1001/jama.275.12.919; BAUME P, 1994, MED J AUSTRALIA, V161, P137, DOI 10.5694/j.1326-5377.1994.tb127345.x; BAUME P, 1994, MED J AUSTRALIA, V161, P142; BAUME P, 1994, MED J AUSTRALIA, V161, P140; BENRUBI GI, 1992, NEW ENGL J MED, V326, P197, DOI 10.1056/NEJM199201163260311; BLACKSHER EA, 1995, HASTINGS CENT REP, V25, P47; BLENDON RJ, 1992, JAMA-J AM MED ASSOC, V267, P2658, DOI 10.1001/jama.267.19.2658; CASSEL CK, 1990, NEW ENGL J MED, V323, P750, DOI 10.1056/NEJM199009133231110; COHEN JS, 1994, NEW ENGL J MED, V331, P89, DOI 10.1056/NEJM199407143310206; EMANUEL EJ, 1994, ARCH INTERN MED, V154, P1890, DOI 10.1001/archinte.154.17.1890; FRIED TR, 1993, ARCH INTERN MED, V153, P722, DOI 10.1001/archinte.153.6.722; KUHSE H, 1993, INT J NURS STUD, V30, P311, DOI 10.1016/0020-7489(93)90103-2; KUHSE H, 1988, MED J AUSTRALIA, V148, P623, DOI 10.5694/j.1326-5377.1988.tb116334.x; Kuhse H, 1992, Aust Nurses J, V21, P21; MILLER FG, 1994, NEW ENGL J MED, V331, P119, DOI 10.1056/NEJM199407143310211; SHAPIRO RS, 1994, ARCH INTERN MED, V154, P575, DOI 10.1001/archinte.154.5.575; SINGER PA, 1990, NEW ENGL J MED, V322, P1881, DOI 10.1056/NEJM199006283222610; Stevens C A, 1994, Med Law, V13, P541; WARD BJ, 1994, BRIT MED J, V308, P1332, DOI 10.1136/bmj.308.6940.1332; Wolf S M, 1989, Hastings Cent Rep, V19, P13, DOI 10.2307/3561964; Young A, 1993, Oncol Nurs Forum, V20, P445; 1988, JAMA-J AM MED ASSOC, V259, P272; 1995, JAMA-J AM MED ASSOC, V274, P1591	27	174	178	0	7	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 23	1996	334	21					1374	1379		10.1056/NEJM199605233342106	http://dx.doi.org/10.1056/NEJM199605233342106			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	UL251	8614424				2022-12-28	WOS:A1996UL25100006
J	Miller, G; Rigsby, MO; Heston, L; Grogan, E; Sun, R; Metroka, C; Levy, JA; Gao, SJ; Chang, Y; Moore, P				Miller, G; Rigsby, MO; Heston, L; Grogan, E; Sun, R; Metroka, C; Levy, JA; Gao, SJ; Chang, Y; Moore, P			Antibodies to butyrate-inducible antigens of Kaposi's sarcoma-associated herpesvirus in patients with HIV-1 infection	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							EPSTEIN-BARR-VIRUS; CYTOMEGALO-VIRUS; CELLS; EXPRESSION; DNA; ACTIVATION; SEQUENCES; PROTEINS; AIDS; GENE	Background. The recent identification in patients with Kaposi's sarcoma of DNA sequences with homology to gammaherpesviruses has led to the hypothesis that a newly identified virus, Kaposi's sarcoma-associated herpeslike virus (KSHV), has a role in the pathogenesis of Kaposi's sarcoma. We developed serologic markers for KSHV infection. Methods. KSHV antigens were prepared from a cell line (BC-1) that contains the genomes of both KSHV and the Epstein-Barr virus (EBV). We used immunoblot and immunofluorescence assays to examine serum samples from 102 patients with human immunodeficiency virus type 1 (HIV-1) infection for antibodies to KSHV-associated proteins and to distinguish these antibodies from antibodies to EBV antigens. A positive serologic response was defined by the recognition of an antigenic polypeptide, p40, in n-butyrate-treated BC-1 cells and by the absence of p40 recognition in untreated BC-1 cells or EBV-infected, KSHV-negative cells. The detection by the immunofluorescence assay of 10 to 20 times more antigen-positive cells in n-butyrate-treated BC-1 cells than in untreated cells was considered a positive response. Results. Antibodies to the p40 antigen expressed by chemically treated BC-1 cells were identified in 32 of 48 HIV-1-infected patients with Kaposi's sarcoma (67 percent), as compared with only 7 of 54 HIV-1-infected patients without Kaposi's sarcoma (13 percent). These results were confirmed by an immunofluorescence assay. The positive predictive value of the serologic tests for Kaposi's sarcoma was 82 percent, and the negative predictive value 75 percent. Conclusions. The presence of antibodies to a KSHV antigenic peptide correlates with the presence of Kaposi's sarcoma in a high-risk population and provides further evidence of an etiologic role for KSHV.	YALE UNIV, SCH MED, DEPT INTERNAL MED, NEW HAVEN, CT 06520 USA; YALE UNIV, SCH MED, DEPT EPIDEMIOL & PUBL HLTH, NEW HAVEN, CT 06520 USA; YALE UNIV, SCH MED, DEPT MOLEC BIOPHYS & BIOCHEM, NEW HAVEN, CT 06520 USA; YALE UNIV, SCH MED, DEPT GENET, NEW HAVEN, CT 06520 USA; ST LUKES ROOSEVELT HOSP, NEW YORK, NY USA; UNIV CALIF SAN FRANCISCO, SCH MED, SAN FRANCISCO, CA 94143 USA; COLUMBIA UNIV COLL PHYS & SURG, NEW YORK, NY 10032 USA; COLUMBIA UNIV, SCH PUBL HLTH, NEW YORK, NY USA	Yale University; Yale University; Yale University; Yale University; Mount Sinai St. Luke's; Mount Sinai West; University of California System; University of California San Francisco; Columbia University; Columbia University	Miller, G (corresponding author), YALE UNIV, SCH MED, DEPT PEDIAT, 333 CEDAR ST, RM 420 LSOG, NEW HAVEN, CT 06520 USA.		Moore, Patrick/GVR-8294-2022; Chang, Yuan/F-4146-2011; Gao, Shou-Jiang/B-8641-2012; Moore, Patrick S./F-3960-2011	Chang, Yuan/0000-0003-1125-4041; Moore, Patrick S./0000-0002-8132-858X; Gao, Shou-Jiang/0000-0001-6194-1742	NATIONAL CANCER INSTITUTE [R01CA070036] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI022959] Funding Source: NIH RePORTER; NCI NIH HHS [CA 70036] Funding Source: Medline; NIAID NIH HHS [AI 22959] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALBRECHT JC, 1992, J VIROL, V66, P5047, DOI 10.1128/JVI.66.8.5047-5058.1992; AMBINDER RF, 1987, J INFECT DIS, V156, P193, DOI 10.1093/infdis/156.1.193; AMBROZIAK JA, 1995, SCIENCE, V268, P582, DOI 10.1126/science.7725108; BERAL V, 1991, CANCER SURV, V10, P5; BERAL V, 1992, CANCER SURV, V12, pA225; BOSHOFF C, 1995, LANCET, V345, P1043; BURNS LJ, 1988, BLOOD, V72, P1536; CALENDER A, 1987, P NATL ACAD SCI USA, V84, P8060, DOI 10.1073/pnas.84.22.8060; CESARMAN E, 1995, BLOOD, V86, P2708, DOI 10.1182/blood.V86.7.2708.bloodjournal8672708; CESARMAN E, 1995, NEW ENGL J MED, V332, P1186, DOI 10.1056/NEJM199505043321802; CHANG Y, 1994, SCIENCE, V266, P1865, DOI 10.1126/science.7997879; Chang Y, 1996, ARCH INTERN MED, V156, P202, DOI 10.1001/archinte.156.2.202; DUPIN N, 1995, LANCET, V345, P761, DOI 10.1016/S0140-6736(95)90642-8; FRIEDMANKIEN AE, 1982, ANN INTERN MED, V96, P693, DOI 10.7326/0003-4819-96-6-693; GALLANT JE, 1994, ARCH INTERN MED, V154, P566, DOI 10.1001/archinte.154.5.566; GIRALDO G, 1980, INT J CANCER, V26, P23, DOI 10.1002/ijc.2910260105; GORDON JA, 1972, CENT AFR J MED, V19, P1; HUANG YQ, 1992, LANCET, V339, P515, DOI 10.1016/0140-6736(92)90338-4; JAHAN N, 1989, AIDS RES HUM RETROV, V5, P225, DOI 10.1089/aid.1989.5.225; Kaposi M., 1872, ARCH DERMATOL SYPHIL, V4, P265, DOI 10.1007/BF01830024; KNOWLES DM, 1989, BLOOD, V73, P792; LEDER A, 1975, CELL, V5, P319, DOI 10.1016/0092-8674(75)90107-5; LISITSYN N, 1993, SCIENCE, V259, P946, DOI 10.1126/science.8438152; LOETHE F, 1963, ACTA PATHOL MIC SC, V161, P1; LUKA J, 1979, VIROLOGY, V94, P228, DOI 10.1016/0042-6822(79)90455-0; MILLER G, 1973, P NATL ACAD SCI USA, V70, P190, DOI 10.1073/pnas.70.1.190; Moore PS, 1996, J VIROL, V70, P549, DOI 10.1128/JVI.70.1.549-558.1996; MOORE PS, 1995, NEW ENGL J MED, V332, P1181, DOI 10.1056/NEJM199505043321801; PENN I, 1979, TRANSPLANTATION, V27, P8, DOI 10.1097/00007890-197901000-00003; RABSON M, 1983, P NATL ACAD SCI-BIOL, V80, P2762, DOI 10.1073/pnas.80.9.2762; SAFAI B, 1980, CLIN BULL, V10, P62; SCHALLING M, 1995, NAT MED, V1, P705; SOULIER J, 1995, BLOOD, V86, P1276, DOI 10.1182/blood.V86.4.1276.bloodjournal8641276; SU IJ, 1995, LANCET, V345, P722, DOI 10.1016/S0140-6736(95)90893-5; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VANGRUNSVEN WMJ, 1993, J VIROL, V67, P3908, DOI 10.1128/JVI.67.7.3908-3916.1993; WANG RYH, 1993, CLIN INFECT DIS, V17, P724, DOI 10.1093/clinids/17.4.724; ZURHAUSEN H, 1978, NATURE, V272, P373; 1981, MMWR-MORBID MORTAL W, V30, P305	39	222	234	0	4	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 16	1996	334	20					1292	1297		10.1056/NEJM199605163342003	http://dx.doi.org/10.1056/NEJM199605163342003			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UK880	8609946				2022-12-28	WOS:A1996UK88000003
J	Pestotnik, SL; Classen, DC; Evans, RS; Burke, JP				Pestotnik, SL; Classen, DC; Evans, RS; Burke, JP			Implementing antibiotic practice guidelines through computer-assisted decision support: Clinical and financial outcomes	ANNALS OF INTERNAL MEDICINE			English	Article						practice guidelines; antibiotics; outcome and process assessment (health care); decision making, computer-assisted; cost-benefit analysis	EDUCATIONAL ORDER FORM; ANTIMICROBIAL AGENTS; PRESCRIBING PATTERNS; SURVEILLANCE; INFECTIONS; QUALITY; SYSTEM; REMINDERS; MISUSE; CARE	Objective: To determine the clinical and financial outcomes of antibiotic practice guidelines implemented through computer-assisted decision support. Design: Descriptive epidemiologic study and financial analysis. Setting: 520-bed community teaching hospital in Salt Lake City, Utah. Patients: All 162 196 patients discharged from LDS Hospital between 1 January 1988 and 31 December 1994. Intervention: An antibiotic management program that used local clinician-derived consensus guidelines embedded in computer-assisted decision support programs. Prescribing guidelines were developed for inpatient prophylactic, empiric, and therapeutic uses of antibiotics. Measurements: Measures of antibiotic use included timing of preoperative antibiotic administration and duration of postoperative antibiotic use. Clinical outcomes included rates of adverse drug events, patterns of antimicrobial resistance, mortality, and length of hospital stay. Financial and use outcomes were expressed as yearly expenditures for antibiotics and defined daily doses per 100 occupied bed-days. Results: During the 7-year study period, 63 759 hospitalized patients (39.3%) received antibiotics. The proportion of the hospitalized patients who received antibiotics increased each year, from 31.8% in 1988 to 53.1% in 1994. Use of broad-spectrum antibiotics increased from 24% of all antibiotic use in 1988 to 47% in 1994. The annual Medicare case-mix index increased from 1.7481 in 1988 to 2.0520 in 1993. Total acquisition costs of antibiotics (adjusted for inflation) decreased from 24.8% ($987 547) of the pharmacy drug expenditure budget in 1988 to 12.9% ($612 500) in 1994. Antibiotic costs per treated patient (adjusted for inflation) decreased from $122.66 per patient in 1988 to $51.90 per patient in 1994. Analysis using a standardized method (defined daily doses) to compare antibiotic use showed that antibiotic use decreased by 22.8% overall. Measures of antibiotic use and clinical outcomes improved during the study period. The percentage of patients having surgery who received appropriately timed preoperative antibiotics increased from 40% in 1988 to 99.1% in 1994. The average number of antibiotic doses administered for surgical prophylaxis was reduced from 19 doses in the base year to 5.3 doses in 1994. Antibiotic-associated adverse drug events decreased by 30%. During the study, antimicrobial resistance patterns were stable, and length of stay remained the same. Mortality rates decreased from 3.65% in 1988 to 2.65% in 1994 (P < 0.001). Conclusions: Computer-assisted decision support programs that use local clinician-derived practice guidelines can improve antibiotic use, reduce associated costs, and stabilize the emergence of antibiotic-resistant pathogens.	LATTER DAY ST HOSP, DEPT CLIN EPIDEMIOL, SALT LAKE CITY, UT 84143 USA				Young, Alexander/A-1523-2009	Young, Alexander/0000-0002-9367-9213				AVORN J, 1988, ARCH INTERN MED, V148, P1720, DOI 10.1001/archinte.148.8.1720; AVORN J, 1983, NEW ENGL J MED, V308, P1457, DOI 10.1056/NEJM198306163082406; BERMAN JR, 1992, AM J HOSP PHARM, V49, P1701, DOI 10.1093/ajhp/49.7.1701; BERWICK DM, 1994, JAMA-J AM MED ASSOC, V272, P797, DOI 10.1001/jama.272.10.797; BLUMENTHAL D, 1993, JAMA-J AM MED ASSOC, V269, P2775, DOI 10.1001/jama.269.21.2775; BURKE JP, 1991, J HOSP INFECT, V18, P424, DOI 10.1016/0195-6701(91)90052-A; BURKE JP, 1995, CURR OPIN INFECT DIS, V8, P269, DOI 10.1097/00001432-199508000-00009; BURKE JP, 1992, ASSESSING QUALITY HL, P509; CLASSEN D, 1993, THESIS U UTAH SALT L; CLASSEN DC, 1992, NEW ENGL J MED, V326, P281, DOI 10.1056/NEJM199201303260501; CLASSEN DC, 1991, JAMA-J AM MED ASSOC, V266, P2847, DOI 10.1001/jama.266.20.2847; COHEN ML, 1992, SCIENCE, V257, P1050, DOI 10.1126/science.257.5073.1050; COL NF, 1987, REV INFECT DIS, V9, pS232; DUNAGAN WC, 1991, REV INFECT DIS, V13, P405; DUNAGAN WC, 1993, DIAGN MICR INFEC DIS, V16, P265, DOI 10.1016/0732-8893(93)90120-V; EAST TD, 1991, INT J CLIN MONIT COM, V8, P263, DOI 10.1007/BF01739127; ECHOLS RM, 1984, J INFECT DIS, V150, P803, DOI 10.1093/infdis/150.6.803; EDDY DM, 1993, JAMA-J AM MED ASSOC, V270, P520; EISENBERG JM, 1981, JAMA-J AM MED ASSOC, V246, P2195, DOI 10.1001/jama.246.19.2195; Evans R S, 1993, Proc Annu Symp Comput Appl Med Care, P161; EVANS RS, 1986, JAMA-J AM MED ASSOC, V256, P1007, DOI 10.1001/jama.256.8.1007; EVANS RS, 1993, M D COMPUT, V10, P17; EVANS RS, 1994, ARCH INTERN MED, V154, P878, DOI 10.1001/archinte.154.8.878; EVANS RS, 1994, ANN PHARMACOTHER, V28, P523, DOI 10.1177/106002809402800417; EVANS RS, 1990, DICP ANN PHARMAC, V24, P351, DOI 10.1177/106002809002400401; GRECO PJ, 1993, NEW ENGL J MED, V329, P1271, DOI 10.1056/NEJM199310213291714; GROSSKOPF S, 1993, MED CARE, V31, P525, DOI 10.1097/00005650-199306000-00006; HIRSCHMAN SZ, 1988, ARCH INTERN MED, V148, P2001, DOI 10.1001/archinte.148.9.2001; HUTH TS, 1991, INFECT CONT HOSP EP, V12, P525; James B C, 1993, Front Health Serv Manage, V10, P3; KASSIRER JP, 1993, NEW ENGL J MED, V329, P1263, DOI 10.1056/NEJM199310213291710; KUNIN CM, 1990, REV INFECT DIS, V12, P12; LARSEN RA, 1989, INFECT CONT HOSP EP, V10, P316, DOI 10.2307/30146474; LEE KR, 1994, INFECT CONT HOSP EP, V15, P710, DOI 10.2307/30148337; MAKI DG, 1978, AM J MED SCI, V275, P271, DOI 10.1097/00000441-197805000-00005; MARR JJ, 1988, J INFECT DIS, V157, P869, DOI 10.1093/infdis/157.5.869; MAXWELL M, 1993, BRIT MED J, V307, P1190, DOI 10.1136/bmj.307.6913.1190; MCDONALD CJ, 1976, NEW ENGL J MED, V295, P1351, DOI 10.1056/NEJM197612092952405; McDonald CJ, 1996, ANN INTERN MED, V124, P56, DOI 10.7326/0003-4819-124-1_Part_1-199601010-00009; MCDONALD CJ, 1994, JAMA-J AM MED ASSOC, V271, P872, DOI 10.1001/jama.271.11.872; McDonald CJ, 1996, ANN INTERN MED, V124, P170, DOI 10.7326/0003-4819-124-1_Part_2-199601011-00018; MCGOWAN JE, 1994, INFECT CONT HOSP EP, V15, P478; MIWA LJ, 1992, PHARMACOL THERAPEUT, V17, P993; MIWA LJ, 1992, PHARMACOL THERAPEUT, V17, P989; MIWA LJ, 1992, PHARMACOL THERAPEUT, V17, P983; MURRAY BE, 1994, NEW ENGL J MED, V330, P1229, DOI 10.1056/NEJM199404283301710; PESTOTNIK SL, 1993, ANN PHARMACOTHER, V27, P497, DOI 10.1177/106002809302700418; PESTOTNIK SL, 1990, AM J MED, V88, P43, DOI 10.1016/0002-9343(90)90126-X; PESTOTNIK SL, 1993, THESIS U UTAH SALT L; Pryor T A, 1983, J Med Syst, V7, P87, DOI 10.1007/BF00995116; PRYOR TA, 1990, INT J CLIN MONIT COM, V7, P137, DOI 10.1007/BF02915578; RILEY DK, 1994, 4 ANN M SOC HOSP EP; RYAN BA, 1993, AM J HOSP PHARM, V50, pS3, DOI 10.1093/ajhp/50.8_Suppl_4.S3; SANTELL JP, 1995, AM J HEALTH-SYST PH, V52, P151, DOI 10.1093/ajhp/52.2.151; SHULKIN DJ, 1993, AM J HOSP PHARM, V50, pS8, DOI 10.1093/ajhp/50.8_Suppl_4.S8; SLOAN FA, 1993, MED CARE, V31, P851, DOI 10.1097/00005650-199310000-00001; SOUMERAI SB, 1993, MED CARE, V31, P552, DOI 10.1097/00005650-199306000-00009; SWARTZ MN, 1994, P NATL ACAD SCI USA, V91, P2420, DOI 10.1073/pnas.91.7.2420; TIERNEY WM, 1995, J AM MED INFORM ASSN, V2, P316, DOI 10.1136/jamia.1995.96073834; TIERNEY WM, 1993, JAMA-J AM MED ASSOC, V269, P379, DOI 10.1001/jama.269.3.379; Volpp K G, 1994, JAMA, V271, P1370, DOI 10.1001/jama.271.17.1370; WALKER RD, 1994, WESTERN J MED, V161, P39; Wilson C N, 1994, Hosp Pharm, V29, P961; WILSON CN, 1994, HOSP PHARM, V29, P961; WILSON CN, 1994, HOSP PHARM, V29, P964	65	457	462	0	21	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 15	1996	124	10					884	+		10.7326/0003-4819-124-10-199605150-00004	http://dx.doi.org/10.7326/0003-4819-124-10-199605150-00004			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UJ801	8610917				2022-12-28	WOS:A1996UJ80100004
J	Collignon, J; Varlet, I; Robertson, EJ				Collignon, J; Varlet, I; Robertson, EJ			Relationship between asymmetric nodal expression and the direction of embryonic turning	NATURE			English	Article							MOUSE EMBRYO; AUTORADIOGRAPHIC ANALYSIS; GASTRULATION; MUTATION; ECTODERM; POTENCY; FATE	GROWTH factors related to TGF-beta provide important signals for patterning the vertebrate body plan(1-3), One such family member, nodal, is required for formation of the primitive streak during mouse gastrulation(4-6), Here we have used a nodal-lacZ reporter allele to demonstrate asymmetric nodal expression in the mouse node, a structure thought to be the functional equivalent of the frog and chick 'organizer'(7), and in lateral plate mesoderm cells, We have also identified two additional genes acting with nodal in a pathway determining the left-right body axis. Thus we observe in inv mutant embryos(8) that the sidedness of nodal expression correlates with the direction of heart looping and embryonic turning, In contrast, HNF3-beta(+/-) nodal(lacZ/+) double-heterozygous embryos display LacZ staining on both left and right sides, and frequently exhibit defects in body situs, Taken together, these experiments, along with similar findings in chick(9), demonstrate that elements of the genetic pathway that establish the left-right body axis are conserved in vertebrates.	HARVARD UNIV,DEPT MOLEC & CELLULAR BIOL,CAMBRIDGE,MA 02138	Harvard University			collignon, jerome/K-8148-2017	Collignon, Jerome/0000-0002-1212-4006				ANG SL, 1994, CELL, V78, P561, DOI 10.1016/0092-8674(94)90522-3; BEDDINGTON RSP, 1981, J EMBRYOL EXP MORPH, V64, P87; BEDDINGTON RSP, 1982, J EMBRYOL EXP MORPH, V69, P265; BEDDINGTON RSP, 1994, DEVELOPMENT, V120, P613; CHANG DT, 1994, DEVELOPMENT, V120, P3339; CONLON FL, 1991, DEVELOPMENT, V111, P969; CONLON FL, 1994, DEVELOPMENT, V120, P1919; Conlon Frank, 1995, Seminars in Developmental Biology, V6, P249, DOI 10.1016/S1044-5781(06)80050-2; COOKE J, 1995, NATURE, V374, P681, DOI 10.1038/374681a0; ECHELARD Y, 1993, CELL, V75, P1417, DOI 10.1016/0092-8674(93)90627-3; Hogan B, 1994, MANIPULATING MOUSE E; IANNACCONE PM, 1992, DEV DYNAM, V194, P198, DOI 10.1002/aja.1001940305; Kaufman M.H., 1992, ATLAS MOUSE DEV; KESSLER DS, 1994, SCIENCE, V266, P596, DOI 10.1126/science.7939714; KINGSLEY DM, 1994, GENE DEV, V8, P133, DOI 10.1101/gad.8.2.133; LAWSON KA, 1991, DEVELOPMENT, V113, P891; LEVIN M, 1995, CELL, V82, P803, DOI 10.1016/0092-8674(95)90477-8; MARTI E, 1995, DEVELOPMENT, V121, P2537; MOUNTFORD P, 1994, P NATL ACAD SCI USA, V91, P4303, DOI 10.1073/pnas.91.10.4303; NEITO MA, 1992, DEVELOPMENT, V116, P227; PARAMESWARAN M, 1995, DEV GENET, V17, P16, DOI 10.1002/dvg.1020170104; POIRIER F, 1993, DEVELOPMENT, V119, P1229; SMITH DE, 1992, DEVELOPMENT, V116, P1033; SMITH JL, 1994, DEV DYNAM, V201, P279, DOI 10.1002/aja.1002010310; TAM PPL, 1987, DEVELOPMENT, V99, P109; WEINSTEIN DC, 1994, CELL, V78, P575, DOI 10.1016/0092-8674(94)90523-1; WILKINSON DG, 1992, IN SITU HYBRIDIZATIO, P75; YOKOYAMA T, 1993, SCIENCE, V260, P679, DOI 10.1126/science.8480178; ZHOU XL, 1993, NATURE, V361, P543, DOI 10.1038/361543a0	29	478	496	0	24	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAY 9	1996	381	6578					155	158		10.1038/381155a0	http://dx.doi.org/10.1038/381155a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UK139	8610012				2022-12-28	WOS:A1996UK13900049
J	Chin, YE; Kitagawa, M; Su, WCS; You, ZH; Iwamoto, Y; Fu, XY				Chin, YE; Kitagawa, M; Su, WCS; You, ZH; Iwamoto, Y; Fu, XY			Cell growth arrest and induction of cyclin-dependent kinase inhibitor p21(WAF1/CIP1) mediated by STAT1	SCIENCE			English	Article							GAMMA SIGNAL-TRANSDUCTION; PROTEIN-TYROSINE KINASE; INTERFERON-ALPHA; TRANSCRIPTION FACTOR; C-FOS; STIMULATED TRANSCRIPTION; ACTIVATION; ISGF3; PHOSPHORYLATION; EGF	Signal transducers and activators of transcription (STAT) proteins can be conditionally activated in response to epidermal growth factor (EGF) and interferon (IFN)-gamma. STAT activation was correlated with cell growth inhibition in response to EGF and IFN-gamma. Activated STAT proteins' specifically recognized the conserved STAT-responsive elements in the promoter of the gene encoding the cyclin-dependent kinase (CDK) inhibitor p21(WAF1/CIP1) and regulated the induction of p21 messenger RNA. IFN-gamma did not inhibit the growth of U3A cells, which are deficient in STAT1, but did inhibit the growth of U3A cells into which STAT1 alpha was reintroduced. Thus, STAT1 protein is essential for cell growth suppression in response to IFN-gamma. The STAT signaling pathway appears to negatively regulate the cell cycle by inducing CDK inhibitors in response to cytokines.	YALE UNIV,SCH MED,DEPT PATHOL,NEW HAVEN,CT 06520	Yale University			You, Zhu-Hong/AAI-6862-2020; Kitagawa, Motoo/W-8468-2019	Kitagawa, Motoo/0000-0003-1036-840X; Su, Wu-Chou/0000-0003-2953-4105	NIAID NIH HHS [R01 AI34522] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI034522] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BRAVO R, 1985, EMBO J, V4, P1193, DOI 10.1002/j.1460-2075.1985.tb03759.x; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FAN Z, 1995, J CELL BIOL, V131, P235, DOI 10.1083/jcb.131.1.235; FU XY, 1992, P NATL ACAD SCI USA, V89, P7840, DOI 10.1073/pnas.89.16.7840; FU XY, 1992, CELL, V70, P323, DOI 10.1016/0092-8674(92)90106-M; FU XY, 1995, J LEUKOCYTE BIOL, V57, P529, DOI 10.1002/jlb.57.4.529; FU XY, 1990, P NATL ACAD SCI USA, V87, P8555, DOI 10.1073/pnas.87.21.8555; FU XY, 1993, CELL, V74, P1135, DOI 10.1016/0092-8674(93)90734-8; FU XY, 1995, INDUCIBLE GENE EXPRE, V2, P99; GILL GN, 1981, NATURE, V293, P305, DOI 10.1038/293305a0; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; GUTCH MJ, 1992, P NATL ACAD SCI USA, V89, P11411, DOI 10.1073/pnas.89.23.11411; HAMBURGER AW, 1977, SCIENCE, V197, P461, DOI 10.1126/science.560061; HARPER JW, 1995, MOL BIOL CELL, V6, P387, DOI 10.1091/mbc.6.4.387; HARPER JW, 1993, CELL, V75, P805; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; IHLE JN, 1995, NATURE, V377, P591, DOI 10.1038/377591a0; KARIN M, 1995, CURR BIOL, V5, P747, DOI 10.1016/S0960-9822(95)00151-5; KATOH K, 1987, CELL STRUCT FUNCT, V12, P575, DOI 10.1247/csf.12.575; KESSLER DS, 1990, GENE DEV, V4, P1753, DOI 10.1101/gad.4.10.1753; KITAGAWA M, UNPUB; KWOK TT, 1994, CANCER RES, V54, P2834; LAMER AC, 1993, SCIENCE, V261, P1730; LEVY DE, 1989, GENE DEV, V3, P1362, DOI 10.1101/gad.3.9.1362; MCKENDRY R, 1991, P NATL ACAD SCI USA, V88, P11455, DOI 10.1073/pnas.88.24.11455; MULLER M, 1993, NATURE, V366, P129, DOI 10.1038/366129a0; MULLER M, 1993, EMBO J, V12, P4221, DOI 10.1002/j.1460-2075.1993.tb06106.x; RESNITZKY D, 1992, P NATL ACAD SCI USA, V89, P402, DOI 10.1073/pnas.89.1.402; RUFFJAMISON S, 1993, SCIENCE, V261, P1733, DOI 10.1126/science.8378774; RUFFJAMISON S, 1994, J BIOL CHEM, V269, P21933; SADOWSKI HB, 1993, NATURE, V362, P79, DOI 10.1038/362079a0; SADOWSKI HB, 1993, SCIENCE, V261, P1739, DOI 10.1126/science.8397445; SCHINDLER C, 1992, SCIENCE, V257, P809, DOI 10.1126/science.1496401; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; VELAZQUEZ L, 1992, CELL, V70, P313, DOI 10.1016/0092-8674(92)90105-L; WAGNER BJ, 1990, EMBO J, V9, P4477, DOI 10.1002/j.1460-2075.1990.tb07898.x; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; YOU Z, UNPUB; ZHANG H, 1994, GENE DEV, V8, P1750, DOI 10.1101/gad.8.15.1750; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422; [No title captured]	44	712	740	0	20	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 3	1996	272	5262					719	722		10.1126/science.272.5262.719	http://dx.doi.org/10.1126/science.272.5262.719			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UJ051	8614832				2022-12-28	WOS:A1996UJ05100050
J	LaSalle, JM; Lalande, M				LaSalle, JM; Lalande, M			Homologous association of oppositely imprinted chromosomal domains	SCIENCE			English	Article							INSITU HYBRIDIZATION; NUCLEI; TRANSVECTION; REPLICATION; DROSOPHILA	Human chromosome 15q11-q13 encompasses the Prader-Willi syndrome (PWS) and the Angelman syndrome (AS) loci, which are subject to parental imprinting, a process that marks the parental origin of certain chromosomal subregions. A temporal and spatial association between maternal and paternal chromosomes 15 was observed in human T lymphocytes by three-dimensional fluorescence in situ hybridization. This association occurred specifically at the imprinted 15q11-q13 regions only during the late S phase of the cell-cycle. Cells from PWS and AS patients were deficient in association, which suggests that normal imprinting involves mutual recognition and preferential association of maternal and paternal chromosomes 15.	HARVARD UNIV,CHILDRENS HOSP,SCH MED,HOWARD HUGHES MED INST,GENET DIV,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02115	Harvard University; Boston Children's Hospital; Harvard Medical School; Howard Hughes Medical Institute; Harvard University; Harvard Medical School			LaSalle, Janine M./A-4643-2008	LaSalle, Janine M./0000-0002-3480-2031	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS030628] Funding Source: NIH RePORTER; NINDS NIH HHS [R01 NS30628] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BOTTANI A, 1994, AM J MED GENET, V51, P35, DOI 10.1002/ajmg.1320510109; BUITING K, 1995, NAT GENET, V9, P395, DOI 10.1038/ng0495-395; CROUSE HV, 1960, GENETICS, V45, P1429; EMMERICH P, 1989, EXP CELL RES, V181, P126, DOI 10.1016/0014-4827(89)90188-2; FERGUSON M, 1992, CHROMOSOMA, V101, P557, DOI 10.1007/BF00660315; GUNARATNE PH, 1995, GENE DEV, V9, P808, DOI 10.1101/gad.9.7.808; HAAF T, 1991, EXP CELL RES, V192, P325, DOI 10.1016/0014-4827(91)90048-Y; HIRAOKA Y, 1993, J CELL BIOL, V120, P591, DOI 10.1083/jcb.120.3.591; JUDD BH, 1988, CELL, V53, P841, DOI 10.1016/S0092-8674(88)90209-7; KITSBERG D, 1993, NATURE, V364, P459, DOI 10.1038/364459a0; KLECKNER N, 1993, COLD SPRING HARB SYM, V58, P553, DOI 10.1101/SQB.1993.058.01.062; KNOLL JHM, 1994, NAT GENET, V6, P41, DOI 10.1038/ng0194-41; LALANDE M, 1994, NAT GENET, V8, P5, DOI 10.1038/ng0994-5; LASALLE JM, 1995, NAT GENET, V9, P386, DOI 10.1038/ng0495-386; LASALLE JM, UNPUB; LEIGHTON PA, 1995, NATURE, V375, P34, DOI 10.1038/375034a0; LEIGHTON PA, 1995, GENE DEV, V9, P2079, DOI 10.1101/gad.9.17.2079; LESKO SA, 1995, EXP CELL RES, V219, P499, DOI 10.1006/excr.1995.1258; LEWIS JP, 1993, HUM GENET, V92, P577, DOI 10.1007/BF00420942; MALCOLM S, 1991, LANCET, V337, P694, DOI 10.1016/0140-6736(91)90278-W; MANUELIDIS L, 1985, HUM GENET, V71, P288, DOI 10.1007/BF00388453; MANUELIDIS L, 1990, SCIENCE, V250, P1533, DOI 10.1126/science.2274784; NICHOLLS RD, 1989, NATURE, V342, P281, DOI 10.1038/342281a0; OKEEFE RT, 1992, J CELL BIOL, V116, P1095, DOI 10.1083/jcb.116.5.1095; PIRROTTA V, 1990, BIOESSAYS, V12, P409, DOI 10.1002/bies.950120903; RAZIN A, 1994, CELL, V77, P473, DOI 10.1016/0092-8674(94)90208-9; Robinson W. P., 1993, European Journal of Human Genetics, V1, P280; SUTCLIFFE JS, 1994, NAT GENET, V8, P52, DOI 10.1038/ng0994-52; TARTOF KD, 1991, CELL, V65, P201, DOI 10.1016/0092-8674(91)90153-P; TSAI JY, 1991, GENETICS, V129, P1159; WEINER BM, 1994, CELL, V77, P977, DOI 10.1016/0092-8674(94)90438-3; ZEMEL S, 1992, NAT GENET, V2, P61, DOI 10.1038/ng0992-61	32	209	214	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 3	1996	272	5262					725	728		10.1126/science.272.5262.725	http://dx.doi.org/10.1126/science.272.5262.725			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UJ051	8614834				2022-12-28	WOS:A1996UJ05100052
J	Porte, D; Schwartz, MW				Porte, D; Schwartz, MW			Diabetes complications: Why is glucose potentially toxic?	SCIENCE			English	Editorial Material							INSULIN		UNIV WASHINGTON,SEATTLE,WA 98108	University of Washington; University of Washington Seattle	Porte, D (corresponding author), DEPT VET AFFAIRS PUGET SOUND HLTH CARE SYST,DEPT MED,DIV METAB ENDOCRINOL & NUTR,SEATTLE,WA 98108, USA.		Schwartz, Michael W/H-9950-2012					BROWNLEE M, 1986, SCIENCE, V232, P1629, DOI 10.1126/science.3487117; BROWNLEE M, 1990, DIABETES MELLITUS TH, P279; HACHIYA HL, 1987, J BIOL CHEM, V262, P6417; HANSONPAINTON O, 1993, MOL CHEM NEUROPATHOL, V20, P245, DOI 10.1007/BF03160077; Ishii H, 1996, SCIENCE, V272, P728, DOI 10.1126/science.272.5262.728; JUDZEWITSCH RG, 1983, NEW ENGL J MED, V308, P119, DOI 10.1056/NEJM198301203080302; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; PFEIFER MA, 1995, DIABETES, V44, P1355, DOI 10.2337/diabetes.44.12.1355; SCHWARTZ MW, 1992, ENDOCR REV, V13, P387, DOI 10.1210/er.13.3.387; STEVENS MJ, 1995, DIABETIC MED, V12, P566, DOI 10.1111/j.1464-5491.1995.tb00544.x; WILLIAMS B, 1995, J HYPERTENS, V13, P477, DOI 10.1097/00004872-199505000-00001; 1993, NEW ENGL J MED, V329, P683	12	183	194	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 3	1996	272	5262					699	700		10.1126/science.272.5262.699	http://dx.doi.org/10.1126/science.272.5262.699			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UJ051	8614830				2022-12-28	WOS:A1996UJ05100041
J	Condos, R; McClune, A; Rom, WN; Schluger, NW				Condos, R; McClune, A; Rom, WN; Schluger, NW			Peripheral-blood-based PCR assay to identify patients with active pulmonary tuberculosis	LANCET			English	Article							IMMUNODEFICIENCY-VIRUS INFECTION; POLYMERASE CHAIN-REACTION; MYCOBACTERIUM-TUBERCULOSIS; DIAGNOSIS; STRAINS	Background There is a need for rapid diagnosis of pulmonary tuberculosis. We have previously used a PCR to detect circulating Mycobacterium tuberculosis DNA in blood samples from patients (mostly HIV-infected) with pulmonary tuberculosis. We have now prospectively investigated the role of this blood-based PCR assay for diagnosis of this disease in a clinical setting. Methods Our PCR assay is specific for the IS6110 insertion element of the M tuberculosis complex of organisms. We used it to test peripheral blood from 88 consecutive patients admitted to a chest ward with suspected pulmonary tuberculosis. Personnel who carried out the assay did not know the results of any clinical investigations and ultimate diagnosis, and clinicians did not know the PCR results. Results of the PCR assay were compared with the final clinical diagnosis. A subgroup of 15 patients had blood samples assayed serially to track the PCR signal over time. Findings 41 patients had a final clinical diagnosis of tuberculosis, and the cases were typical of those seen at our hospital: HIV infection was common, and most cases were not sputum-smear positive for acid-fast bacilli. The PCR assay correctly identified 39 of 41 patients with proven pulmonary tuberculosis, 26 (63%) of whom were sputum-smear negative. There were five patients in whom a positive PCR result did not accord with the final clinical diagnosis, and two of the 44 negative PCR results were classified as false negatives. The overall sensitivity and specificity of the PCR assay for a diagnosis of tuberculosis was 95% and 89%, respectively. In 15 patients with pulmonary tuberculosis and a positive blood assay, the PCR result remained positive after 1 month of therapy, but had reverted to negative in 13 of the 15 by 4 months of therapy. Interpretation We conclude that peripheral-blood-based PCR detection for the diagnosis of tuberculosis is a technically feasible approach that has a potentially important role in the diagnosis of pulmonary tuberculosis.	NYU,MED CTR & SCH MED,BELLEVUE CHEST SERV,NEW YORK,NY; NYU,MED CTR & SCH MED,DIV PULM & CRIT CARE MED,NEW YORK,NY	New York University; New York University			Schluger, Neil/ABA-1793-2021	Rom, William/0000-0002-8793-7028	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K07HL003030] Funding Source: NIH RePORTER; NHLBI NIH HHS [K07 HL03030] Funding Source: Medline; PHS HHS [M01 00096] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ALUOCH JA, 1985, TUBERCLE, V66, P237, DOI 10.1016/0041-3879(85)90061-3; BOUZA E, 1993, ARCH INTERN MED, V153, P496, DOI 10.1001/archinte.153.4.496; CHIN DP, 1995, AM J RESP CRIT CARE, V151, P1872, DOI 10.1164/ajrccm.151.6.7767534; GODFREYFAUSSETT P, 1995, THORAX, V50, P709, DOI 10.1136/thx.50.7.709; GORDIN FM, 1983, AM REV RESPIR DIS, V139, P1090; HERMANS PWM, 1990, J CLIN MICROBIOL, V28, P1204, DOI 10.1128/JCM.28.6.1204-1213.1990; KENNEDY N, 1994, J INFECT DIS, V170, P713, DOI 10.1093/infdis/170.3.713; KLEIN NC, 1989, CHEST, V95, P1190, DOI 10.1378/chest.95.6.1190; LEVY H, 1989, CHEST, V95, P1193, DOI 10.1378/chest.95.6.1193; LONGO MC, 1990, GENE, V93, P125, DOI 10.1016/0378-1119(90)90145-H; NARDELL EA, 1993, MED CLIN N AM, V77, P1315, DOI 10.1016/S0025-7125(16)30196-1; SCHLUGER NW, 1994, LANCET, V344, P232, DOI 10.1016/S0140-6736(94)92999-8; SCHLUGER NW, 1994, CHEST, V105, P1116, DOI 10.1378/chest.105.4.1116; SCHLUGER NW, 1994, AM J RESP CRIT CARE, V149, P264, DOI 10.1164/ajrccm.149.1.8111591; SCHLUGERNW, 1995, AM J RESP CRIT CARE, V152, P11; SHAFER RW, 1991, MEDICINE, V70, P384, DOI 10.1097/00005792-199111000-00004; SMITH E, 1992, SCAND J INFECT DIS, V24, P109, DOI 10.3109/00365549209048409; WILSON SM, 1993, T ROY SOC TROP MED H, V87, P177, DOI 10.1016/0035-9203(93)90478-9; YAJKO DM, 1994, CLIN INFECT DIS, V19, P334, DOI 10.1093/clinids/19.2.334; YUEN LKW, 1993, J CLIN MICROBIOL, V31, P1615, DOI 10.1128/JCM.31.6.1615-1618.1993	20	80	83	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 20	1996	347	9008					1082	1085		10.1016/S0140-6736(96)90281-0	http://dx.doi.org/10.1016/S0140-6736(96)90281-0			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UG042	8602060	hybrid			2022-12-28	WOS:A1996UG04200014
J	Gale, CR; Martyn, CN				Gale, CR; Martyn, CN			Breastfeeding, dummy use, and adult intelligence	LANCET			English	Article							ESSENTIAL FATTY-ACIDS; PROVIDE BREAST-MILK; COGNITIVE-DEVELOPMENT; CHILD-DEVELOPMENT; MOTHERS CHOICE	Background Several studies show that children who were breastfed as babies gain higher scores on intelligence tests than those who were bottlefed. Although these findings suggest that breastfeeding in early life may promote cognitive development, their interpretation is complicated by the current association between breastfeeding and higher social class. We investigated the relation between method of feeding in infancy and adult intelligence in a setting where breastfeeding was not linked with socioeconomic advantage. Methods We followed up 994 men and women, born between 1920 and 1930 in Hertfordshire, UK, for whom information on infant feeding had been recorded by health visitors. Intelligence was measured by the AH4 IQ test, taken on a computer. Factors significantly linked with IQ were investigated by multivariate analysis. Findings Study participants who had been exclusively breastfed gained slightly higher scores on the IQ test than those who had been exclusively bottlefed, or fed with both breast and bottle. IQ was lower in participants who had used a dummy (pacifier) in infancy, in those whose fathers were in manual occupations at the time of their birth, and in those whose mothers were young at the time they were born. Scores on the IQ lest fell as the number of older siblings increased. In multivariate analysis, after adjustment for the effect of all other variables, no association was found between adult intelligence and method of feeding. Dummy use in infancy, number of older siblings, maternal age at birth of the participant, and father's occupational class remained independent predictors of adult intelligence. Interpretation The mechanisms that link type of feeding in early life with later intelligence may have more to do with the child's social environment than with the nutritional qualities of the milk.	UNIV SOUTHAMPTON, SOUTHAMPTON GEN HOSP, MRC, ENVIRONM EPIDEMIOL UNIT, SOUTHAMPTON SO16 6YD, HANTS, ENGLAND	University of Southampton			Gale, Catharine R/B-1653-2012					BAKRER DJP, 1994, MOTHERS BABIES DISEA; BELOL RQ, 1974, EFFECT INFANT ITS CA, P1; BRUNER JS, 1973, DEV PSYCHOBIOL, V6, P45, DOI 10.1002/dev.420060107; CRAWFORD MA, 1976, LANCET, V1, P452; Crawford Michael A., 1993, American Journal of Clinical Nutrition, V57, p703S, DOI 10.1093/ajcn/57.5.703S; FARQUHARSON J, 1992, LANCET, V340, P810, DOI 10.1016/0140-6736(92)92684-8; FERGUSSON DM, 1982, SOC SCI MED, V16, P1705, DOI 10.1016/0277-9536(82)90096-X; FILDES V, 1992, J BIOSOC SCI, V24, P53, DOI 10.1017/S0021932000006799; FLOREY CDV, 1995, INT J EPIDEMIOL, V24, pS21, DOI 10.1093/ije/24.Supplement_1.S21; GALE CR, 1995, SOC HIST MED, V8, P231, DOI 10.1093/shm/8.2.231; GREENE LC, 1995, BIOCHEM SOC T, V23, pS376, DOI 10.1042/bst023376s; HEIM A, 1968, AH 4 TEST; Hoefer C, 1929, J AMER MED ASSOC, V92, P615, DOI 10.1001/jama.1929.02700340015006; JACOBSON SW, 1992, LANCET, V339, P926, DOI 10.1016/0140-6736(92)90962-3; KORNER AF, 1971, AM J ORTHOPSYCHIAT, V41, P608, DOI 10.1111/j.1939-0025.1971.tb03220.x; LUCAS A, 1992, LANCET, V339, P261, DOI 10.1016/0140-6736(92)91329-7; MARTIN J, 1988, INFANT FEEDING 1985; Martin J., 1978, INFANT FEEDING 1975; MORLEY R, 1988, ARCH DIS CHILD, V63, P1382, DOI 10.1136/adc.63.11.1382; MORROWTLUCAK M, 1988, SOC SCI MED, V26, P635, DOI 10.1016/0277-9536(88)90028-7; NEURINGER M, 1993, NUTR REV, V51, P238, DOI 10.1111/j.1753-4887.1993.tb03112.x; POLLOCK JI, 1994, DEV MED CHILD NEUROL, V36, P429, DOI 10.1111/j.1469-8749.1994.tb11869.x; POLLOCK JI, 1989, ARCH DIS CHILD, V64, P763, DOI 10.1136/adc.64.5.763; RIGHARD L, 1992, BIRTH-ISS PERINAT C, V19, P185, DOI 10.1111/j.1523-536X.1992.tb00399.x; RODGERS B, 1978, DEV MED CHILD NEUROL, V20, P421, DOI 10.1111/j.1469-8749.1978.tb15242.x; ROGAN WJ, 1993, EARLY HUM DEV, V31, P181, DOI 10.1016/0378-3782(93)90194-Y; SILVA PA, 1978, AUST PAEDIATR J, V14, P265; TAYLOR B, 1984, DEV MED CHILD NEUROL, V26, P73; VICTORA CG, 1993, LANCET, V341, P404, DOI 10.1016/0140-6736(93)92991-2; Wright P., 1987, EATING HABITS, P75	30	87	88	1	12	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	APR 20	1996	347	9008					1072	1075		10.1016/S0140-6736(96)90278-0	http://dx.doi.org/10.1016/S0140-6736(96)90278-0			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	UG042	8602057				2022-12-28	WOS:A1996UG04200011
J	Zheng, C; Heintz, N; Hatten, ME				Zheng, C; Heintz, N; Hatten, ME			CNS gene encoding astrotactin, which supports neuronal migration along glial fibers	SCIENCE			English	Article							FETAL MONKEY NEOCORTEX; CEREBELLAR CORTEX; CELL MIGRATION; DIFFERENTIATION; SYSTEM; TIME	Vertebrate central nervous system (CNS) histogenesis depends on glia-guided migration of postmitotic neurons to form neuronal laminae. Previous studies have established that the neuronal protein astrotactin functions in murine cerebellar granule cell migration in vitro. The gene encoding astrotactin predicts a protein with three epidermal growth factor repeats and two fibronectin type III repeats. Astrotactin messenger RNA is expressed in postmitotic neuronal precursors in the cerebellum, hippocampus, cerebrum, and olfactory bulb, where migration establishes laminar structures. Fab fragments of antibodies to a recombinant astrotactin peptide blocked migration of cerebellar granule neurons in vitro along astroglial fibers. Transfection of astrotactin complementary DNA into 3T3 cells indicated that astrotactin acts as a ligand for neuron-glia binding during neuronal migration.	ROCKEFELLER UNIV,HOWARD HUGHES MED INST,NEW YORK,NY 10021	Howard Hughes Medical Institute; Rockefeller University					NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS015429] Funding Source: NIH RePORTER; NINDS NIH HHS [NS15429] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AUSUBEL FM, 1994, CURRENT PROTOCOL S27, V2; Cajal S. R., 1911, HISTOLOGIE SYSTEME N; CAVINESS VS, 1973, J COMP NEUROL, V148, P141, DOI 10.1002/cne.901480202; COOKE RM, 1987, NATURE, V327, P339, DOI 10.1038/327339a0; DARCANGELO G, 1995, NATURE, V374, P719, DOI 10.1038/374719a0; EDMONDSON JC, 1987, J NEUROSCI, V7, P1928; FISHELL G, 1991, DEVELOPMENT, V113, P755; FURLEY AJ, 1990, CELL, V61, P157, DOI 10.1016/0092-8674(90)90223-2; GAO WQ, 1992, CELL, V68, P841, DOI 10.1016/0092-8674(92)90028-B; GAO WQ, 1993, SCIENCE, V260, P367, DOI 10.1126/science.8469990; GREENWALD I, 1994, CURR OPIN GENET DEV, V4, P556, DOI 10.1016/0959-437X(94)90072-B; Hatten M E, 1993, Curr Opin Neurobiol, V3, P38, DOI 10.1016/0959-4388(93)90033-U; JESSELL TM, 1988, NEURON, V1, P3, DOI 10.1016/0896-6273(88)90204-8; KUHAR S, 1993, DEVELOPMENT, V112, P97; RAKIC P, 1971, J COMP NEUROL, V141, P283, DOI 10.1002/cne.901410303; RAKIC P, 1972, J COMP NEUROL, V145, P61, DOI 10.1002/cne.901450105; RAKIC P, 1971, BRAIN RES, V33, P471, DOI 10.1016/0006-8993(71)90119-3; SKORSTENGAARD K, 1986, EUR J BIOCHEM, V161, P441, DOI 10.1111/j.1432-1033.1986.tb10464.x; STITT TN, 1990, NEURON, V5, P639, DOI 10.1016/0896-6273(90)90218-5	19	192	195	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 19	1996	272	5260					417	419		10.1126/science.272.5260.417	http://dx.doi.org/10.1126/science.272.5260.417			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UG252	8602532				2022-12-28	WOS:A1996UG25200049
J	Naylor, CD; Sermer, M; Chen, EL; Sykora, K				Naylor, CD; Sermer, M; Chen, EL; Sykora, K			Cesarean delivery in relation to birth weight and gestational glucose tolerance - Pathophysiology or practice style?	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DIABETES-MELLITUS; SHOULDER DYSTOCIA; SCREENING-TESTS; PREGNANCY; COMPLICATIONS; CRITERIA; SECTION; REPRESENT; ONTARIO	Objectives.-To examine the relationship between birth weight and mode of delivery among women with untreated borderline gestational diabetes mellitus (GDM), treated overt GDM, and normoglycemia. Design.-Prospective cohort study. Setting.-Three Toronto, Ontario, teaching hospitals. Patients.-A total of 3778 volunteers aged 24 years or older. Interventions.-Subjects underwent a 3-hour, 100-g oral glucose tolerance test at 28 weeks' gestation, regardless of screening test results. Usual care was provided to 143 women who met the National Diabetes Data Group criteria for GDM, Physicians were blinded to glucose test results for all others, including 115 untreated women with borderline GDM by the broader criteria of Carpenter and Coustan. Main Outcome Measures.-Crude and adjusted rates of cesarean delivery and neonatal macrosomia (birth weight >4000 g). Results.-Compared with normoglycemic controls, the untreated borderline GDM group had increased rates of macrosomia (28.7% vs 13.7%, P<.001) and cesarean delivery (29.6% vs 20.2%, P=.02). Cesarean delivery in this subgroup was associated with macrosomia (45.5% vs 23.5%, P=.03). Usual care of known GDM normalized birth weights, but the cesarean delivery rate was about 33% whether macrosomia was present or absent. A clearly increased risk of cesarean delivery among treated patients compared with normoglycemic controls persisted after adjustment for multiple maternal risk factors (adjusted odds ratio, 2.1; 95% confidence interval, 1.3 to 3.6). Conclusions.-Infant macrosomia was a mediating factor in high cesarean delivery rates for women with untreated borderline GDM, While detection and treatment of GDM normalized birth weights, rates of cesarean delivery remained inexplicably high. Recognition of GDM may lead to a lower threshold for surgical delivery that mitigates the potential benefits of treatment.	UNIV TORONTO,DEPT MED,TORONTO,ON M5S 1A1,CANADA; UNIV TORONTO,DEPT SURG,TORONTO,ON M5S 1A1,CANADA; UNIV TORONTO,DEPT OBSTET & GYNECOL,TORONTO,ON M5S 1A1,CANADA; UNIV TORONTO,CLIN EPIDEMIOL & HLTH CARE RES PROGRAM,SUNNYBROOK UNIT,TORONTO,ON M5S 1A1,CANADA; INST CLIN EVALUAT SCI,TORONTO,ON,CANADA	University of Toronto; University of Toronto; University of Toronto; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto								ANDERSON GM, 1984, NEW ENGL J MED, V311, P887, DOI 10.1056/NEJM198410043111405; ANDERSON GM, 1989, CAN MED ASSOC J, V141, P1049; BUCHANAN TA, 1994, DIABETES CARE, V17, P275, DOI 10.2337/diacare.17.4.275; CARPENTER MW, 1982, AM J OBSTET GYNECOL, V144, P768, DOI 10.1016/0002-9378(82)90349-0; CATALANO PM, 1986, AM J OBSTET GYNECOL, V155, P1255, DOI 10.1016/0002-9378(86)90155-9; Freinkel N, 1985, Diabetes, V34 Suppl 2, P1; GABBE SG, 1986, NEW ENGL J MED, V315, P1025, DOI 10.1056/NEJM198610163151609; GOLDMAN M, 1991, DIABETES, V40, P79, DOI 10.2337/diab.40.2.S79; HARRIS MI, 1988, DIABETES CARE, V11, P402, DOI 10.2337/diacare.11.5.402; HOSMER DW, 1989, APPL LOGISTIC REGRES; HUNTER DS, 1991, EFFECTIVE CARE PREGN, P403; JACOBSON JD, 1989, AM J OBSTET GYNECOL, V161, P981, DOI 10.1016/0002-9378(89)90767-9; LANGER O, 1987, AM J OBSTET GYNECOL, V157, P758, DOI 10.1016/S0002-9378(87)80045-5; LANGER O, 1991, AM J OBSTET GYNECOL, V165, P831, DOI 10.1016/0002-9378(91)90424-P; LANGER O, 1994, AM J OBSTET GYNECOL, V170, P1036, DOI 10.1016/S0002-9378(94)70097-4; LEIKIN EL, 1987, OBSTET GYNECOL, V69, P570; LINDSAY MK, 1989, OBSTET GYNECOL, V73, P103; LOMAS J, 1991, JAMA-J AM MED ASSOC, V265, P2202, DOI 10.1001/jama.265.17.2202; LUCAS MJ, 1993, OBSTET GYNECOL, V82, P260; MAGEE MS, 1993, JAMA-J AM MED ASSOC, V269, P609, DOI 10.1001/jama.269.5.609; MEHTA CR, 1983, J AM STAT ASSOC, V78, P427, DOI 10.2307/2288652; Metzger B E, 1985, Diabetes, V34 Suppl 2, P111; MODANLOU HD, 1982, OBSTET GYNECOL, V60, P417; NAYLOR CD, 1989, DIABETES CARE, V12, P565, DOI 10.2337/diacare.12.8.565; O'Sullivan JB, 1979, CARBOHYD METABOL, P425; OSULLIVAN JB, 1964, DIABETES, V13, P278; SACKS DA, 1989, AM J OBSTET GYNECOL, V161, P638, DOI 10.1016/0002-9378(89)90369-4; SAS Institute Inc, 1990, SAS STAT US GUID VER, P1; SERMER M, 1995, AM J OBSTET GYNECOL, V173, P146, DOI 10.1016/0002-9378(95)90183-3; SERMER M, 1994, AM J OBSTET GYNECOL, V171, P607, DOI 10.1016/0002-9378(94)90072-8; TALLARIGO L, 1986, NEW ENGL J MED, V315, P989, DOI 10.1056/NEJM198610163151603; WALKINSHAW SA, 1993, PREGNANCY CHILDBIRTH; 1985, DIABETES S2, V34, P123; 1979, DIABETES, V28, P1039	34	262	269	0	8	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 17	1996	275	15					1165	1170		10.1001/jama.275.15.1165	http://dx.doi.org/10.1001/jama.275.15.1165			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UE625	8609683				2022-12-28	WOS:A1996UE62500027
J	Cuschieri, A; Fayers, P; Fielding, J; Craven, J; Bancewicz, J; Joypaul, V; Cook, P				Cuschieri, A; Fayers, P; Fielding, J; Craven, J; Bancewicz, J; Joypaul, V; Cook, P			Postoperative morbidity and mortality after D-1 and D-2 resections for gastric cancer: Preliminary results of the MRC randomised controlled surgical trial	LANCET			English	Article							CARCINOMA; SURGERY; GERMAN	Background In Japan the surgical approach to treatment of potentially curable gastric cancer, including extended lymphadenectomy, seems in retrospective surveys to give better results than the less radical procedures favoured in Western countries. There has, however, been no evidence from randomised trials that extended lymphadenectomy (D-2 gastric resection) confers a survival advantage. This question was addressed in a trial involving thirty-two surgeons in Europe. Methods In a prospective randomised controlled trial, D-1 resection (level 1 lymphadenectomy) was compared with D-2 resection (levels 1 and 2 lymphadenectomy). Central randomisation (200 patients in each arm) followed a staging laparotomy. Findings The D-2 group had greater postoperative hospital mortality (13% vs 6.5%; p=0.04 [95% CI 9-18% for D-2, 4-11% for D-1] and higher overall postoperative morbidity (46% vs 28%; p<0.001); their postoperative stay was also longer. The excess postoperative morbidity and mortality in the D-2 group was accounted for by distal pancreatico-splenectomy and splenectomy. In the whole group (400 patients), survival beyond three years was 30% in patients whose gastrectomy included en-bloc pancreatico-splenic resection versus 50% in the remainder. Interpretation D-2 gastric resections are followed by higher morbidity and mortality than D-1 resections. These disadvantages are consequent upon additional pancreatectomies and distal splenectomies, and in long-term follow-up the higher mortality when the pancreas and spleen are resected may prove to nullify any survival benefit from D-2 procedures.	MRC,CANC TRIALS OFF,LONDON W1N 4AL,ENGLAND; QUEEN ELIZABETH HOSP,BIRMINGHAM B15 2TH,W MIDLANDS,ENGLAND; KINGSTON GEN HOSP,ST VINCENTS,JAMAICA; HOPE HOSP,SALFORD M6 8HD,LANCS,ENGLAND	University of Birmingham	Cuschieri, A (corresponding author), UNIV DUNDEE,NINEWELLS HOSP & MED SCH,DEPT SURG,MRC,GASTR CANC WORKING PARTY,DUNDEE DD1 9SY,SCOTLAND.		Cuschieri, Alfred/A-7634-2013; Cuschieri, Alfred/O-4092-2019; Fayers, Peter M/A-5999-2010	Cuschieri, Alfred/0000-0003-0764-5947; Fayers, Peter/0000-0003-4778-1513				ALLUM WH, 1989, BRIT J SURG, V76, P535, DOI 10.1002/bjs.1800760604; BONENKAMP JJ, 1995, LANCET, V345, P745, DOI 10.1016/S0140-6736(95)90637-1; BONENKAMP JJ, 1993, WORLD J SURG, V17, P410, DOI 10.1007/BF01658714; DIGGORY RT, 1985, BRIT J SURG, V72, P146, DOI 10.1002/bjs.1800720226; FINDLAY M, 1994, ANN ONCOL, V5, P609, DOI 10.1093/oxfordjournals.annonc.a058932; KAJITANI T, 1981, JPN J SURG, V11, P127; MARUYAMA K, 1987, WORLD J SURG, V11, P418, DOI 10.1007/BF01655804; MIWA K, 1979, GANN MONOGR, V22, P61; NAKAJIMA T, 1989, HEPATO-GASTROENTEROL, V36, P79; RODER JD, 1993, CANCER-AM CANCER SOC, V72, P2089, DOI 10.1002/1097-0142(19931001)72:7<2089::AID-CNCR2820720706>3.0.CO;2-H; SMITH JW, 1991, ARCH SURG-CHICAGO, V126, P1469; SUELING HM, 1993, BMJ-BRIT MED J, V307, P591, DOI 10.1136/bmj.307.6904.591; YOSHINO K, 1995, INT GASTRIC CANC C B, V1, P91; 1989, CANC STAT REGISTRATI	14	801	843	0	14	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 13	1996	347	9007					995	999		10.1016/S0140-6736(96)90144-0	http://dx.doi.org/10.1016/S0140-6736(96)90144-0			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UF380	8606613				2022-12-28	WOS:A1996UF38000009
J	Arrow, KJ; Cropper, ML; Eads, GC; Hahn, RW; Lave, LB; Noll, RG; Portney, PR; Russell, M; Schmalensee, R; Smith, VK; Stavins, RN				Arrow, KJ; Cropper, ML; Eads, GC; Hahn, RW; Lave, LB; Noll, RG; Portney, PR; Russell, M; Schmalensee, R; Smith, VK; Stavins, RN			Is there a role for benefit-cost analysis in environmental, health, and safety regulation?	SCIENCE			English	Editorial Material									WORLD BANK,WASHINGTON,DC 20433; CHARLES RIVER ASSOCIATES INC,WASHINGTON,DC 20004; AMER ENTERPRISE INST PUBL POLICY RES,WASHINGTON,DC 20036; CARNEGIE MELLON UNIV,GRAD SCH IND ORG,PITTSBURGH,PA 15213; RESOURCES FUTURE INC,WASHINGTON,DC 20036; UNIV TENNESSEE,DEPT ECON,KNOXVILLE,TN 37996; MIT,ALFRED P SLOAN SCH MANAGEMENT,CAMBRIDGE,MA 02139; DUKE UNIV,DURHAM,NC 27708; HARVARD UNIV,JOHN F KENNEDY SCH GOVT,CAMBRIDGE,MA 02138	The World Bank; Charles River Associates; American Enterprise Institute for Public Policy Research; Carnegie Mellon University; Resources for the Future; University of Tennessee System; University of Tennessee Knoxville; Massachusetts Institute of Technology (MIT); Duke University; Harvard University	Arrow, KJ (corresponding author), STANFORD UNIV,DEPT ECON,STANFORD,CA 94305, USA.							Arrow KJ, 1996, BENEFIT COST ANAL EN; CHRISTIANSEN GB, 1985, HDB NATURAL RESOURCE, V1, P345; CROPPER ML, 1992, J ECON LIT, V30, P675; FRAAS A, 1991, LAW CONTEMP PROBL, V54, P113, DOI 10.2307/1191875; Freeman A.M., 1993, RESOURCES FUTURE, V1st ed.; Grubb W.Norton., 1984, ENV POLICY REAGANS E, P121; HAHN RW, IN PRESS RISKS COSTS; Hopkins T. D., 1992, COST REGULATION FILL; JAFFE AB, 1995, J ECON LIT, V33, P132; MORRALL JF, 1986, REGULATION, V10, P25; *OFF MAN BUDG, 1993, REG PROGR US GOV APR; *OFF MAN BUDG, 1995, BUDG US GOV FISC YEA; Schmalensee R, 1994, BALANCING EC GROWTH, P55	13	326	330	2	88	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 12	1996	272	5259					221	222		10.1126/science.272.5259.221	http://dx.doi.org/10.1126/science.272.5259.221			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	UE729	8602504				2022-12-28	WOS:A1996UE72900028
J	Rose, C; Vargas, F; Facchinetti, P; Bourgeat, P; Bambal, RB; Bishop, PB; Chan, SMT; Moore, ANJ; Ganellin, CR; Schwartz, JC				Rose, C; Vargas, F; Facchinetti, P; Bourgeat, P; Bambal, RB; Bishop, PB; Chan, SMT; Moore, ANJ; Ganellin, CR; Schwartz, JC			Characterization and Inhibition of a cholecystokinin-inactivating serine peptidase	NATURE			English	Article							SYNAPTIC-MEMBRANES; BRAIN-SLICES; GLYCOSYL-PHOSPHATIDYLINOSITOL; ENDOGENOUS CHOLECYSTOKININ; TETRAPEPTIDE DEGRADATION; ENKEPHALINASE INHIBITOR; SUBSTRATE-SPECIFICITY; OCTAPEPTIDE CCK-8; PROTEINS; AMINOPEPTIDASE	A cholecystokinin (CCK)-inactivating peptidase was purified and identified as a membrane-bound isoform of tripeptidyl peptidase II (EC 3.4. 14. 10), a cytosolic subtilisin-like peptidase of previously unknown functions. The peptidase was found in neurons responding to cholecystokinin, as well as in non-neuronal cells. Butabindide, a potent and specific inhibitor, was designed and shown to protect endogenous cholecystokinin from inactivation and to display pro-satiating effects mediated by the CCKA receptor.	UNIV LONDON UNIV COLL, CHRISTOPHER INGOLD LABS, DEPT CHEM, LONDON WC1H 0AJ, ENGLAND; UNIV PARIS 05, FAC PHARM, F-75006 PARIS, FRANCE	University of London; University College London; UDICE-French Research Universities; Universite Paris Cite	Rose, C (corresponding author), CTR PAUL BROCA, INSERM, U109, UNITE NEUROBIOL & PHARMACOL, 2TER RUE ALESIA, F-75014 PARIS, FRANCE.							BALOW RM, 1983, J BIOL CHEM, V258, P1622; BALOW RM, 1986, J BIOL CHEM, V261, P2409; BAUMER P, 1992, GUT, V33, P753, DOI 10.1136/gut.33.6.753; CAMUS A, 1989, NEUROSCIENCE, V29, P595, DOI 10.1016/0306-4522(89)90133-4; CHARIOT J, 1990, AM J PHYSIOL, V259, pG198, DOI 10.1152/ajpgi.1990.259.2.G198; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; DANIELSEN EM, 1977, BIOCHIM BIOPHYS ACTA, V494, P332, DOI 10.1016/0005-2795(77)90163-5; DESCHODTLANCKMAN M, 1984, PEPTIDES, V5, P649, DOI 10.1016/0196-9781(84)90098-6; DESCHODTLANCKMAN M, 1983, PEPTIDES, V4, P71, DOI 10.1016/0196-9781(83)90169-9; DOCKRAY GJ, 1976, NATURE, V264, P568, DOI 10.1038/264568a0; Dockray GJ, 1990, GASTROINTEST ENDOSC, P321; DURIEUX C, 1986, NEUROPEPTIDES, V7, P1, DOI 10.1016/0143-4179(86)90072-7; ELLMAN GL, 1961, BIOCHEM PHARMACOL, V7, P88, DOI 10.1016/0006-2952(61)90145-9; FERGUSON MAJ, 1988, ANNU REV BIOCHEM, V57, P285; GIROS B, 1987, J PHARMACOL EXP THER, V243, P666; HOKFELT T, 1980, NATURE, V285, P476, DOI 10.1038/285476a0; HUGHES J, 1990, P NATL ACAD SCI USA, V87, P6728, DOI 10.1073/pnas.87.17.6728; HUGHES J, 1989, NEUROPEPTIDE CHOLECY; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LLORENS C, 1980, BIOCHEM BIOPH RES CO, V96, P1710, DOI 10.1016/0006-291X(80)91371-6; LLORENSCORTES C, 1986, P NATL ACAD SCI USA, V83, P6226, DOI 10.1073/pnas.83.16.6226; LOTTI VJ, 1987, J PHARMACOL EXP THER, V241, P103; LOW MG, 1989, FASEB J, V3, P1600, DOI 10.1096/fasebj.3.5.2522071; LOW MG, 1988, J IMMUNOL METHODS, V113, P101, DOI 10.1016/0022-1759(88)90386-9; MALFROY B, 1987, BIOCHEM BIOPH RES CO, V144, P59, DOI 10.1016/S0006-291X(87)80475-8; MALFROY B, 1978, NATURE, V276, P523, DOI 10.1038/276523a0; MASSOULIE J, 1993, PROG NEUROBIOL, V41, P31, DOI 10.1016/0301-0082(93)90040-Y; MATSAS R, 1984, FEBS LETT, V175, P124, DOI 10.1016/0014-5793(84)80583-9; MCDERMOTT JR, 1983, NEUROCHEM INT, V5, P641, DOI 10.1016/0197-0186(83)90058-X; PATEY G, 1981, SCIENCE, V212, P113, DOI 10.1126/science.7015510; PERSSON H, 1989, P NATL ACAD SCI USA, V86, P6166, DOI 10.1073/pnas.86.16.6166; Powell J.L., 1986, PROTEINASE INHIBITOR, P55; ROQUES BP, 1980, NATURE, V288, P286, DOI 10.1038/288286a0; ROSE C, 1988, P NATL ACAD SCI USA, V85, P8326, DOI 10.1073/pnas.85.21.8326; ROSE C, 1989, NEUROSCIENCE, V29, P583, DOI 10.1016/0306-4522(89)90132-2; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; SCHWARTZ JC, 1981, LIFE SCI, V29, P1715, DOI 10.1016/0024-3205(81)90182-X; SMITH GP, 1994, ANN NY ACAD SCI, V713, P236, DOI 10.1111/j.1749-6632.1994.tb44071.x; SOKOLOFF P, 1990, NATURE, V347, P146, DOI 10.1038/347146a0; STEARDO L, 1985, J NEUROCHEM, V45, P784, DOI 10.1111/j.1471-4159.1985.tb04061.x; TARR GE, 1986, MICROCHARACTERIZATIO, P155; TOMKINSON B, 1994, BIOCHEM J, V304, P517, DOI 10.1042/bj3040517; TOMKINSON B, 1991, BIOCHEMISTRY-US, V30, P168, DOI 10.1021/bi00215a025; VANDERHAEGEN JJ, 1984, ANN NY ACAD SCI, V448, P1; Vanderhaeghen J.J., 1985, Handbook of Chemical Neuroanatomy, V4, P406; VANDERHAEGHEN JJ, 1975, NATURE, V257, P604, DOI 10.1038/257604a0; WHITTAKE.VP, 1966, ANN NY ACAD SCI, V137, P982, DOI 10.1111/j.1749-6632.1966.tb50211.x; WILSON C, 1993, NEUROCHEM RES, V18, P743, DOI 10.1007/BF00966768; WOODRUFF G, 1991, REV PHARM, V31, P469; ZUZEL KA, 1985, NEUROSCIENCE, V15, P149, DOI 10.1016/0306-4522(85)90129-0	50	141	147	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 4	1996	380	6573					403	409		10.1038/380403a0	http://dx.doi.org/10.1038/380403a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UD590	8602240				2022-12-28	WOS:A1996UD59000051
J	Goldblatt, D; Fairley, CK; Cartwright, K; Miller, E				Goldblatt, D; Fairley, CK; Cartwright, K; Miller, E			Interchangeability of conjugated Haemophilus influenzae type b vaccines during primary immunisation of infants	BRITISH MEDICAL JOURNAL			English	Article							IMMUNOGENICITY		PUBL HLTH LAB SERV,CTR COMMUNICABLE DIS SURVEILLANCE,IMMUNISAT DIV,LONDON NW9 5EQ,ENGLAND; GLOUCESTER ROYAL HOSP,PUBL HLTH LAB,GLOUCESTER GL1 3NN,ENGLAND	Public Health England	Goldblatt, D (corresponding author), INST CHILD HLTH,IMMUNOBIOL UNIT,LONDON WC1N 1EH,ENGLAND.		Goldblatt, David/C-5972-2008	Goldblatt, David/0000-0002-0769-5242; Christopher, Fairley/0000-0001-9081-1664	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BOOY R, 1992, ARCH DIS CHILD, V67, P475, DOI 10.1136/adc.67.4.475; BOOY R, 1994, LANCET, V344, P362, DOI 10.1016/S0140-6736(94)91400-1; *DEP HLTH, 1992, IMM INF DIS, P100; GRANOFF DM, 1992, J PEDIATR-US, V121, P187, DOI 10.1016/S0022-3476(05)81186-2; KAYHTY H, 1983, J INFECT DIS, V147, P1100	5	15	15	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 30	1996	312	7034					817	818						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UD378	8608290				2022-12-28	WOS:A1996UD37800025
J	Fowler, JS; Volkow, ND; Wang, GJ; Pappas, N; Logan, J; MacGregor, R; Alexoff, D; Shea, C; Schlyer, D; Wolf, AP; Warner, D; Zezulkova, I; Cilento, R				Fowler, JS; Volkow, ND; Wang, GJ; Pappas, N; Logan, J; MacGregor, R; Alexoff, D; Shea, C; Schlyer, D; Wolf, AP; Warner, D; Zezulkova, I; Cilento, R			Inhibition of monoamine oxidase B in the brains of smokers	NATURE			English	Article							L-DEPRENYL; PARKINSONS-DISEASE; CIGARETTE SMOKERS; TOBACCO-SMOKE; NEUROTOXICITY; STRIATUM; RATS	THE massive health problem associated with cigarette smoking is exacerbated by the addictive properties of tobacco smoke and the limited success of current approaches to cessation of smoking(1). Yet little is known about the neuropharmacological actions of cigarette smoke that contribute to smoking behaviour, or why smoking is so prevalent in psychiatric disorders(2) and is associated with a decreased risk of Parkinson's disease(3), Here we report that brains of living smokers show a 40% decrease in the level of monoamine oxidase B (MAO B; EC 1.4.3.4) relative to non-smokers or former smokers. MAO B is involved in the breakdown of dopamine, a neurotransmitter implicated in reinforcing and motivating behaviours as well as movement. MAO B inhibition is therefore associated with enhanced activity of dopamine(4), as well as with decreased production of hydrogen peroxide, a source of reactive oxygen species 5, We propose that reduction of MAO B activity may synergize with nicotine to produce the diverse behavioural and epidemiological effects of smoking.	SUNY STONY BROOK,DEPT PSYCHIAT,STONY BROOK,NY 11794	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Fowler, JS (corresponding author), BROOKHAVEN NATL LAB,DEPT CHEM,UPTON,NY 11973, USA.							BERLIN I, 1995, CLIN PHARMACOL THER, V58, P444, DOI 10.1016/0009-9236(95)90058-6; BERRY MD, 1994, PROG NEUROBIOL, V42, P375, DOI 10.1016/0301-0082(94)90081-7; BOULTON AA, 1988, LANCET, V1, P114; CARR LA, 1991, LIFE SCI, V48, P1173, DOI 10.1016/0024-3205(91)90455-K; CARR LA, 1990, NEUROPHARMACOLOGY, V29, P311, DOI 10.1016/0028-3908(90)90019-N; DICHIARA G, 1988, P NATL ACAD SCI USA, V85, P5274; DLUZEN DE, 1991, J NEURAL TRANSM-GEN, V85, P145, DOI 10.1007/BF01244706; Dougherty E. R., 1992, INTRO MORPHOLOGICAL; FOWLER JS, 1994, SYNAPSE, V18, P86, DOI 10.1002/syn.890180203; FOWLER JS, 1995, J NUCL MED, V36, P1255; FOWLER JS, 1988, J NEUROCHEM, V51, P1524, DOI 10.1111/j.1471-4159.1988.tb01121.x; Henningfield Jack E., 1995, P1715; HUGHES JR, 1986, AM J PSYCHIAT, V143, P993; JACKSON DM, 1994, PHARMACOL THERAPEUT, V64, P291, DOI 10.1016/0163-7258(94)90041-8; JOSSAN SS, 1987, BIOGENIC AMINES, V4, P371; KNOLL J, 1994, LIFE SCI, V54, P1047, DOI 10.1016/0024-3205(94)00415-3; MORENS DM, 1995, NEUROLOGY, V45, P1041, DOI 10.1212/WNL.45.6.1041; NORMAN TR, 1987, PSYCHIAT RES, V20, P199, DOI 10.1016/0165-1781(87)90079-5; ORELAND L, 1981, LIFE SCI, V29, P2511, DOI 10.1016/0024-3205(81)90706-2; PATERSON IA, 1991, J PHARMACOL EXP THER, V258, P1019; PATLAK CS, 1983, J CEREBR BLOOD F MET, V3, P1, DOI 10.1038/jcbfm.1983.1; Pavlin R, 1993, FARM VESTN, V44, P185; REITER RJ, 1995, FASEB J, V9, P526, DOI 10.1096/fasebj.9.7.7737461; RIEDERER P, 1986, J NEUROCHEM, V46, P1359, DOI 10.1111/j.1471-4159.1986.tb01747.x; STAPLETON JM, 1993, NIDA RES MONOGR, V132, P106; TARIOT PN, 1987, PSYCHOPHARMACOLOGY, V91, P489, DOI 10.1007/BF00216016; TETRUD JW, 1989, SCIENCE, V245, P519, DOI 10.1126/science.2502843; WANG GJ, 1994, J NUCL MED, V35, P1457; YAMASHITA K, 1988, GERONTOLOGY, V34, P199, DOI 10.1159/000212953; YONG VW, 1986, J NEUROL SCI, V72, P265, DOI 10.1016/0022-510X(86)90014-6; YU PH, 1987, LIFE SCI, V41, P675, DOI 10.1016/0024-3205(87)90446-2	31	520	539	0	35	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	FEB 22	1996	379	6567					733	736		10.1038/379733a0	http://dx.doi.org/10.1038/379733a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TW567	8602220				2022-12-28	WOS:A1996TW56700054
J	Bounameaux, H; Hicklin, L; Desmarais, S				Bounameaux, H; Hicklin, L; Desmarais, S			Seasonal variation in deep vein thrombosis	BMJ-BRITISH MEDICAL JOURNAL			English	Article											Bounameaux, H (corresponding author), UNIV HOSP GENEVA, DEPT INTERNAL MED, DIV ANGIOL & HAEMOSTASIS, CH-1211 GENEVA 4, SWITZERLAND.							COOKE EA, 1995, BRIT MED J, V310, P129, DOI 10.1136/bmj.310.6972.129b; GALLERANI M, 1992, EUR HEART J, V13, P661, DOI 10.1093/oxfordjournals.eurheartj.a060232; WILMSHURST P, 1994, BMJ-BRIT MED J, V309, P1029, DOI 10.1136/bmj.309.6961.1029; WOODHOUSE PR, 1994, LANCET, V343, P435, DOI 10.1016/S0140-6736(94)92689-1; WROBLEWSKI BM, 1992, CLIN ORTHOP RELAT R, P222	5	55	57	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 3	1996	312	7026					284	285						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TU507	8611784				2022-12-28	WOS:A1996TU50700022
J	Thompson, D; Oster, G				Thompson, D; Oster, G			Use of terfenadine and contraindicated drugs	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CONSEQUENCES	Objective.-To assess changes in concurrent use of products containing terfenadine and contraindicated macrolide antibiotics (erythromycin, clarithromycin, troleandomycin) and imidazole antifungals (ketoconazole, itraconazole) following reports of serious drug-drug interactions and changes in product labeling. Design.-Retrospective review of computerized pharmacy claims. Setting.-A large health insurer in New England. Patients.-Health plan members with 1 or more paid pharmacy claims for products containing terfenadine between January 1990 and June 1994. Main Outcome Measures.-Among persons with paid claims for terfenadine in any given month, percentage with a prescription for any contraindicated drug that alternatively was dispensed on the same day as (''same-day dispensing'') or had therapy days that overlapped those of (''overlapping use'') a prescription for terfenadine. Results.-Concurrent use of terfenadine and contraindicated drugs declined over the study period. The rate of same-day dispensing declined by 84%, from an average of 2.5 per 100 persons receiving terfenadine in 1990 to 0.4 per 100 persons during the first 6 months of 1994, while the rate of overlapping use declined by 57% (from 5.4 to 2.3 per 100 persons). Most cases involved erythromycin. Conclusions.-Despite substantial declines following reports of serious drug-drug interactions and changes in product labeling, concurrent use of terfenadine and contraindicated macrolide antibiotics and imidazole antifungals continues to occur.	POLICY ANAL INC,BROOKLINE,MA 02146	Policy Analysis Inc			Thompson, David/E-2431-2018	Thompson, David/0000-0001-8518-6307				[Anonymous], 1992, Med Lett Drugs Ther, V34, P9; Cavuto NJ, 1996, JAMA-J AM MED ASSOC, V275, P1086, DOI 10.1001/jama.275.14.1086; CRANE JK, 1993, AM J MED, V95, P445, DOI 10.1016/0002-9343(93)90317-I; HONIG PK, 1992, CLIN PHARMACOL THER, V52, P231, DOI 10.1038/clpt.1992.135; HONIG PK, 1993, JAMA-J AM MED ASSOC, V269, P1513, DOI 10.1001/jama.269.12.1513; HONIG PK, 1993, J CLIN PHARMACOL, V33, P1201, DOI 10.1002/j.1552-4604.1993.tb03920.x; *IMS AM LTD, 1995, 1995 NAT PRESCR AUD; MASHETER HC, 1993, CLIN REV ALLERG, V11, P5; *MM DOW INC, 1990, IMP DRUG WARN; *MM DOW INC, 1992, IMP DRUG WARN; *MM DOW INC, 1993, SELD PROD LAB; MONAHAN BP, 1990, JAMA-J AM MED ASSOC, V264, P2788, DOI 10.1001/jama.264.21.2788; NIGHTINGALE SL, 1992, JAMA-J AM MED ASSOC, V268, P705, DOI 10.1001/jama.268.6.705; PECK CC, 1993, JAMA-J AM MED ASSOC, V269, P1550, DOI 10.1001/jama.269.12.1550; Pulmonary-Allergy Drugs Advisory Committee, 1990, P PULM ALL DRUGS ADV; WOOSLEY RL, 1993, JAMA-J AM MED ASSOC, V269, P1535	16	88	88	1	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 1	1996	275	17					1339	1341		10.1001/jama.275.17.1339	http://dx.doi.org/10.1001/jama.275.17.1339			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UG612	8614120				2022-12-28	WOS:A1996UG61200031
J	Enari, M; Talanian, RV; Wong, WW; Nagata, S				Enari, M; Talanian, RV; Wong, WW; Nagata, S			Sequential activation of ICE-like and CPP32-like proteases during Fas-mediated apoptosis	NATURE			English	Article								BINDING of Fas ligand or an agonistic anti-Fas antibody induces apoptosis in Fas-bearing cells(1). The interleukin-1 beta-converting enzyme (ICE) is a cysteine protease(2) that is involved in apoptosis induced by various stimuli, including Fas-mediated apoptosis(3-8). Several ICE homologues have been identified, and these are subdivided into three groups (ICE-, CPP32- and Ich-1-like proteases)(9-18). We show here that specific inhibitors of ICE- or CPP32-like proteases can inhibit Fas-mediated apoptosis. Transient ICE-like activity was found in the cytosolic fraction of Fas-activated cells, whereas ICE-dependent, CPP32-like activity gradually accumulated in the cytosol. Cell lysates from mouse lymphoma supplemented with either recombinant ICE or CPP32 induced apoptosis of nuclei. The CPP32 inhibitor inhibited ICE- or CPP32-induced apoptosis in the cell-free system, whereas the ICE-inhibitor only inhibited ICE-induced apoptosis. Cell extracts from thymocytes from ICE-null mice induced apoptosis in the cell-free system when it was supplemented with CPP32. These results indicate that Fas sequentially activates ICE- and CPP32-like proteases, and that downstream CPP32, together with a component(s) in the cytoplasm, causes apoptosis of nuclei.	OSAKA BIOSCI INST,SUITA,OSAKA 565,JAPAN; BASF BIORES CORP,WORCESTER,MA 01605; OSAKA UNIV,SCH MED,DEPT GENET,SUITA,OSAKA 565,JAPAN	BASF; Osaka University			Nagata, Shigekazu/AAG-3203-2019; Enari, Masato/E-5507-2014	Nagata, Shigekazu/0000-0001-9758-8426; Enari, Masato/0000-0003-4293-3848				ALNEMRI ES, 1995, J BIOL CHEM, V270, P4312, DOI 10.1074/jbc.270.9.4312; BUMP NJ, 1995, SCIENCE, V269, P1885, DOI 10.1126/science.7569933; CHOW SC, 1995, FEBS LETT, V364, P134, DOI 10.1016/0014-5793(95)00370-O; Duan HJ, 1996, J BIOL CHEM, V271, P1621, DOI 10.1074/jbc.271.3.1621; ENARI M, 1995, NATURE, V375, P78, DOI 10.1038/375078a0; ENARI M, 1995, EMBO J, V14, P5201, DOI 10.1002/j.1460-2075.1995.tb00204.x; FAUCHEU C, 1995, EMBO J, V14, P1914, DOI 10.1002/j.1460-2075.1995.tb07183.x; FERNANDESALNEMRI T, 1995, CANCER RES, V55, P2737; FERNANDESALNEMRI T, 1994, J BIOL CHEM, V269, P30761; GAGLIARDINI V, 1994, SCIENCE, V263, P826, DOI 10.1126/science.8303301; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; KAMENS J, 1995, J BIOL CHEM, V270, P15250, DOI 10.1074/jbc.270.25.15250; KOMIYAMA T, 1994, J BIOL CHEM, V269, P19331; KUIDA K, 1995, SCIENCE, V267, P2000, DOI 10.1126/science.7535475; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; LI P, 1995, CELL, V80, P401, DOI 10.1016/0092-8674(95)90490-5; LOS M, 1995, NATURE, V375, P81, DOI 10.1038/375081a0; MARTIN SJ, 1995, EMBO J, V14, P5191, DOI 10.1002/j.1460-2075.1995.tb00203.x; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; MUNDAY NA, 1995, J BIOL CHEM, V270, P15870, DOI 10.1074/jbc.270.26.15870; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; NAKAJIMA H, 1995, J EXP MED, V181, P1905, DOI 10.1084/jem.181.5.1905; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; OGASAWARA J, 1993, NATURE, V364, P806, DOI 10.1038/364806a0; SCHULZEOSTHOFF K, 1994, J CELL BIOL, V127, P15, DOI 10.1083/jcb.127.1.15; TEWARI M, 1995, J BIOL CHEM, V270, P3255, DOI 10.1074/jbc.270.7.3255; THOMBERY N, 1995, PERSP DRUG DISC DES, V2, P389; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; TWARI M, 1995, CELL, V81, P801; WANG L, 1994, CELL, V78, P739, DOI 10.1016/S0092-8674(94)90422-7	30	953	979	1	9	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	APR 25	1996	380	6576					723	726		10.1038/380723a0	http://dx.doi.org/10.1038/380723a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UG827	8614469				2022-12-28	WOS:A1996UG82700055
J	Walcheck, B; Kahn, J; Fisher, JM; Wang, BB; Fisk, RS; Payan, DG; Feehan, C; Betageri, R; Darlak, K; Spatola, AF; Kishimoto, TK				Walcheck, B; Kahn, J; Fisher, JM; Wang, BB; Fisk, RS; Payan, DG; Feehan, C; Betageri, R; Darlak, K; Spatola, AF; Kishimoto, TK			Neutrophil rolling altered by inhibition of L-selectin shedding in vitro	NATURE			English	Article							ADHESION MOLECULE-1; CHEMOTACTIC FACTORS; ENDOTHELIAL-CELLS; PRECURSOR; INFLAMMATION; CLEAVAGE; PROTEIN; INVIVO; ALPHA	THE L-selectin adhesion molecule is involved in guiding leukocytes to sites of inflammation(1). L-selectin is cleaved by an unusual proteolytic activity at a membrane-proximal site resulting in rapid shedding from the cell surface(2-7). Although it has been demonstrated that L-selectin mediates, in part, the early event of leukocyte rolling under hydrodynamic flows(8-10), the contribution of shedding to L-selectin function has remained unknown. Here we show that hydroxamic acid-based metalloprotease inhibitors block L-selectin downregulation from the cell surface of stimulated neutrophils, without affecting Mac-1 mobilization or general neutrophil activation, and inhibit cleavage of L-selectin in a cell-free system. Unexpectedly, the hydroxamic acid-based inhibitors reduced neutrophil rolling velocity under hydrodynamic flow, resulting in increased neutrophil accumulation. These results suggest that L-selectin is cleaved in seconds-much faster than previously suspected-during the process of rolling under hydrodynamic flow, and that shedding of L-selectin may contribute significantly to the velocity of leukocyte rolling, L-selectin shedding during rolling interactions may be physiologically important for limiting leukocyte aggregation and accumulation at sites of inflammation.	BOEHRINGER INGELHEIM PHARMACEUT INC,DEPT IMMUNOL,RIDGEFIELD,CT 06877; BOEHRINGER INGELHEIM PHARMACEUT INC,DEPT INFLAMMATORY DIS,RIDGEFIELD,CT 06877; KHEPRI PHARMACEUT INC,S SAN FRANCISCO,CA 94080; UNIV LOUISVILLE,DEPT CHEM,LOUISVILLE,KY 40292; UNIV LOUISVILLE,DEPT BIOCHEM,LOUISVILLE,KY 40292	Boehringer Ingelheim; Boehringer Ingelheim; University of Louisville; University of Louisville								ALON R, 1995, NATURE, V374, P539, DOI 10.1038/374539a0; BARGATZE RF, 1994, J EXP MED, V180, P1785, DOI 10.1084/jem.180.5.1785; BAUMHUETER S, 1993, SCIENCE, V262, P436, DOI 10.1126/science.7692600; CHEN AJ, 1995, J EXP MED, V182, P519, DOI 10.1084/jem.182.2.519; CROWE PD, 1995, J EXP MED, V181, P1205, DOI 10.1084/jem.181.3.1205; Feehan C, 1996, J BIOL CHEM, V271, P7019, DOI 10.1074/jbc.271.12.7019; Finger EB, 1996, NATURE, V379, P266, DOI 10.1038/379266a0; GEARING AJH, 1994, NATURE, V370, P555, DOI 10.1038/370555a0; GRIFFIN JD, 1990, J IMMUNOL, V145, P576; HAMANN A, 1988, J IMMUNOL, V140, P737; KAHN J, 1994, J CELL BIOL, V125, P461, DOI 10.1083/jcb.125.2.461; KISHIMOTO TK, 1989, SCIENCE, V245, P1238, DOI 10.1126/science.2551036; KRIEGLER M, 1988, CELL, V53, P45, DOI 10.1016/0092-8674(88)90486-2; LASKY LA, 1992, SCIENCE, V258, P964, DOI 10.1126/science.1439808; LAWRENCE MB, 1995, EUR J IMMUNOL, V25, P1025, DOI 10.1002/eji.1830250425; LEY K, 1991, BLOOD, V77, P2553; MCGEEHAN GM, 1994, NATURE, V370, P558, DOI 10.1038/370558a0; MIGAKI GI, 1995, J EXP MED, V182, P549, DOI 10.1084/jem.182.2.549; MOHLER KM, 1994, NATURE, V370, P218, DOI 10.1038/370218a0; MULLBERG J, 1994, J IMMUNOL, V152, P4958; OLESEN SP, 1988, NATURE, V331, P168, DOI 10.1038/331168a0; PALECANDA A, 1992, EUR J IMMUNOL, V22, P1279, DOI 10.1002/eji.1830220524; PANDIELLA A, 1991, P NATL ACAD SCI USA, V88, P1726, DOI 10.1073/pnas.88.5.1726; PURI KD, 1995, J CELL BIOL, V131, P261, DOI 10.1083/jcb.131.1.261; RAMCHANDRAN R, 1994, J BIOL CHEM, V269, P2125; SCHLEIFFENBAUM B, 1992, J CELL BIOL, V119, P229, DOI 10.1083/jcb.119.1.229; SIMON SI, 1992, J IMMUNOL, V149, P2765; SISODIA SS, 1992, P NATL ACAD SCI USA, V89, P6075, DOI 10.1073/pnas.89.13.6075; SMITH CW, 1991, J CLIN INVEST, V87, P609, DOI 10.1172/JCI115037; SPATOLA AF, 1992, PEPTIDES CHEM BIOL, P820; VONANDRIAN UH, 1991, P NATL ACAD SCI USA, V88, P7538, DOI 10.1073/pnas.88.17.7538; WONG ST, 1989, CELL, V56, P495, DOI 10.1016/0092-8674(89)90252-3	32	260	269	1	7	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	APR 25	1996	380	6576					720	723		10.1038/380720a0	http://dx.doi.org/10.1038/380720a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UG827	8614468				2022-12-28	WOS:A1996UG82700054
J	Feldman, W; Feldman, ME				Feldman, W; Feldman, ME			The intelligence on infant feeding	LANCET			English	Editorial Material							COGNITIVE-DEVELOPMENT; LIFE		SCARBOROUGH GRACE HOSP,TORONTO,ON,CANADA	Scarborough Hospital	Feldman, W (corresponding author), UNIV TORONTO,HOSP SICK CHILDREN,DEPT PAEDIAT,TORONTO,ON M5G 1X8,CANADA.							DUV C, 1995, INT J EPIDMEIOL, V24, pS21; FERGUSSON DM, 1982, SOC SCI MED, V16, P1705, DOI 10.1016/0277-9536(82)90096-X; JACOBSON SW, 1992, LANCET, V339, P926, DOI 10.1016/0140-6736(92)90962-3; MORROWTLUCAK M, 1988, SOC SCI MED, V26, P635, DOI 10.1016/0277-9536(88)90028-7; SILVA PA, 1978, AUST PAEDIATR J, V4, P265; TAYLOR B, 1984, DEV MED CHILD NEUROL, V26, P73; TEMBOURY MC, 1994, J PEDIATR GASTR NUTR, V18, P32, DOI 10.1097/00005176-199401000-00005; WRIGHT P, 1992, LANCET, V339, P612, DOI 10.1016/0140-6736(92)90898-D	8	6	6	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 20	1996	347	9008					1057	1057		10.1016/S0140-6736(96)90270-6	http://dx.doi.org/10.1016/S0140-6736(96)90270-6			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	UG042	8602050				2022-12-28	WOS:A1996UG04200003
J	Turney, J				Turney, J			Public understanding of science	LANCET			English	Article								The scientist's lament about public understanding of science is often heard. But scientific understanding is not merely a matter of scientific literacy; it also embraces issues of trust in scientists, doctors, and sources of information. People have an appetite for scientific information, and they are good at sifting the information relevant to their lives. Nonetheless, the onus will increasingly be on the scientist to explain scientific findings in ways that a range of publics can use. So, we need to improve the scientist's understanding of the public.			Turney, J (corresponding author), UNIV LONDON UNIV COLL,DEPT SCI & TECHNOL STUDIES,GOWER ST,LONDON WC1E 6BT,ENGLAND.							DAVISON C, 1991, SOCIOL HEALTH ILL, V13, P1, DOI 10.1111/1467-9566.ep11340301; DURANT J, 1992, PUBLIC UNDERSTANDING, V0001; DURANT J, 1995, NEW AGENDA PUBLIC UN; FAYARD P, 1992, PUBLIC UNDERST SCI, V1, P15; FREWER L, 1995, PUBLIC UNDERSTABNDIN, V3, P385; IRWIN A, 1995, CITIZEN SCI, P131; IRWIN A, 1995, CITIZEN SCI, P14; Jasanoff S., 1995, HDB SCI TECHNOLOGY S, DOI [10.4135/9781412990127, DOI 10.4135/9781412990127]; Joss S, 1995, PUBLIC UNDERST SCI, V4, P195, DOI DOI 10.1088/0963-6625/4/2/006; LAETSCH WM, 1987, COMMUNICATING SCI PU, P1; Lambert H., 1996, MISUNDERSTOOD SCI PU; Layton D., 1993, INARTICULATE SCI PER; MADDOX J, 1995, NATURE, V378, P435, DOI 10.1038/378435a0; RICHARDS M, 1966, TROUBLED HELIX SOCIA; *ROYAL SOC, 1985, PUBL UND SCI REP ROY; SHAMOS MH, 1995, MYTH SCI LIT; Solomon J., 1992, GETTING KNOW ENERGY; Thomas G., 1987, SCI LITERACY PAPERS, P1; TREFIL J, 1992, 1001 THINGS EVERYONE; Turney J, 1995, GENET ENG BIOTECHNOL, V15, P181; TURNEY J, 1995, MOL MED TODAY, V1, P359, DOI 10.1016/S1357-4310(95)93815-X; TURNEY J, 1996, RES PRACTICE PUBLIC	22	46	49	0	9	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 20	1996	347	9008					1087	1090		10.1016/S0140-6736(96)90283-4	http://dx.doi.org/10.1016/S0140-6736(96)90283-4			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UG042	8602062				2022-12-28	WOS:A1996UG04200016
J	Kee, F				Kee, F			Patients' prerogatives and perceptions of benefit	BMJ-BRITISH MEDICAL JOURNAL			English	Article							CLINICAL-TRIALS; PREFERENCE; CANCER; HEALTH	Patients today demand more information about their treatment. Doctors, however, seem reluctant to cast aside ingrained habits of paternalism, believing they can best interpret therapeutic choices for their patients. Whether doctors can be more objective and effective than patients in interpreting the ''probabilities'' of medical evidence is open to question. On the other hand, the exercise of choice by patients may itself have a bearing on the probabilities of outcome. Involving patients more in making therapeutic choices is justified if doctors can present options in an unbiased and effective manner and if the process improves the outcome of the care delivered.			Kee, F (corresponding author), QUEENS UNIV BELFAST, ROYAL VICTORIA HOSP, DEPT EPIDEMIOL & PUBL HLTH, BELFAST BT12 6BJ, ANTRIM, NORTH IRELAND.							ADER R, 1995, LANCET, V345, P99, DOI 10.1016/S0140-6736(95)90066-7; ANTMAN EM, 1992, JAMA-J AM MED ASSOC, V268, P240, DOI 10.1001/jama.268.2.240; Becker MH, 1979, COMPLIANCE HLTH CARE; BOBBIO M, 1994, LANCET, V343, P1209, DOI 10.1016/S0140-6736(94)92407-4; CASSILETH BR, 1982, JAMA-J AM MED ASSOC, V248, P968, DOI 10.1001/jama.248.8.968; CHALMERS I, 1995, BRIT MED J, V310, P1315, DOI 10.1136/bmj.310.6990.1315; CHASSIN MR, 1993, MED CARE, V31, pYS37, DOI 10.1097/00005650-199305001-00006; DAWSON NV, 1993, MED DECIS MAKING, V13, P258, DOI 10.1177/0272989X9301300314; ENGLAND SL, 1992, SOC SCI MED, V34, P1217, DOI 10.1016/0277-9536(92)90314-G; FLOOD AB, 1993, MED CARE, V31, P1043, DOI 10.1097/00005650-199311000-00006; GLYNN RJ, 1994, ARCH INTERN MED, V154, P2649, DOI 10.1001/archinte.1994.00420230032005; Gulanick M, 1994, Am J Crit Care, V3, P368; HOROWITZ R, 1990, LANCET, V342, P1142; HORTON R, 1994, LANCET, V344, P211, DOI 10.1016/S0140-6736(94)92992-0; HUX JE, 1994, J GEN INTERN MED, V9, P195, DOI 10.1007/BF02600123; Kasper J F, 1992, QRB Qual Rev Bull, V18, P183; KASSIRER JP, 1989, AM J MED, V86, P433, DOI 10.1016/0002-9343(89)90342-2; KIMBALL BP, 1994, CAN J CARDIOL, V10, P815; KING KB, 1992, RES NURS HEALTH, V15, P327, DOI 10.1002/nur.4770150503; LAMB GC, 1994, ARCH INTERN MED, V154, P2753, DOI 10.1001/archinte.1994.00420230150018; LEVINE MN, 1992, ANN INTERN MED, V117, P53, DOI 10.7326/0003-4819-117-1-53; LLEWELLYNTHOMAS HA, 1991, SOC SCI MED, V32, P35, DOI 10.1016/0277-9536(91)90124-U; LLEWELLYNTHOMAS HA, 1992, MED DECIS MAKING, V12, P115, DOI 10.1177/0272989X9201200204; MALENKA DJ, 1993, J GEN INTERN MED, V8, P543, DOI 10.1007/BF02599636; MAZUR DJ, 1994, MED DECIS MAKING, V14, P255, DOI 10.1177/0272989X9401400307; MCNEIL BJ, 1982, NEW ENGL J MED, V306, P1259, DOI 10.1056/NEJM198205273062103; Meredith P, 1995, Qual Health Care, V4, P18, DOI 10.1136/qshc.4.1.18; NAYLOR CD, 1994, J CLIN EPIDEMIOL, V47, P787, DOI 10.1016/0895-4356(94)90176-7; NEASE RF, 1994, MED DECIS MAKING, V14, P382, DOI 10.1177/0272989X9401400409; OCONNOR A, 1994, MED DECIS MAKING, V14, P438; POSES RM, 1995, MED DECIS MAKING, V15, P65, DOI 10.1177/0272989X9501500110; PRATT L, 1957, AM J PUBLIC HEALTH N, V47, P1277, DOI 10.2105/AJPH.47.10.1277; Sackett DL, 1991, CLIN EPIDEMIOLOGY BA, V2nd; SCHEIER MF, 1987, J PERS, V55, P169, DOI 10.1111/j.1467-6494.1987.tb00434.x; SCHULMAN BA, 1979, MED CARE, V17, P267, DOI 10.1097/00005650-197903000-00004; SOX HC, 1981, ANN INTERN MED, V95, P680, DOI 10.7326/0003-4819-95-6-680; STEWART MA, 1995, CAN MED ASSOC J, V152, P1423; WISIEWSKI S, 1995, CONTROL CLIN TRIALS, V16, pS124; 1980, NEW ENGL J MED, V30, P1038; 1995, LANCET, V345, P1449	40	27	28	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	APR 13	1996	312	7036					958	960						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	UF659	8616314				2022-12-28	WOS:A1996UF65900026
J	Rothman, JE; Wieland, FT				Rothman, JE; Wieland, FT			Protein sorting by transport vesicles	SCIENCE			English	Review							ADP-RIBOSYLATION FACTOR; GTP-BINDING PROTEIN; COP-COATED VESICLES; LUMINAL ER PROTEINS; ENDOPLASMIC-RETICULUM; GOLGI-APPARATUS; INTRACELLULAR-TRANSPORT; TRANSMEMBRANE PROTEINS; VESICULAR TRANSPORT; GUANINE-NUCLEOTIDE	Eukaryotic life depends on the spatial and temporal organization of cellular membrane systems. Recent advances in understanding the machinery of vesicle transport have established general principles that underlie a broad variety of physiological processes, including cell surface growth, the biogenesis of distinct intracellular organelles, endocytosis, and the controlled release of hormones and neurotransmitters.	UNIV HEIDELBERG, INST BIOCHEM 1, HEIDELBERG, GERMANY	Ruprecht Karls University Heidelberg	Rothman, JE (corresponding author), MEM SLOAN KETTERING CANC CTR, CELLULAR BIOCHEM & BIOPHYS PROGRAM, 1275 YORK AVE, NEW YORK, NY 10021 USA.							AALTO MK, 1992, CELL, V68, P181, DOI 10.1016/0092-8674(92)90462-L; ACHARYA U, 1995, CELL, V82, P895, DOI 10.1016/0092-8674(95)90269-4; AHLE S, 1988, EMBO J, V7, P919, DOI 10.1002/j.1460-2075.1988.tb02897.x; ANDERSON RGW, 1977, CELL, V10, P351, DOI 10.1016/0092-8674(77)90022-8; BALCH WE, 1994, CELL, V76, P841, DOI 10.1016/0092-8674(94)90359-X; BALCH WE, 1992, J BIOL CHEM, V267, P13053; BANFIELD DK, 1995, NATURE, V375, P806, DOI 10.1038/375806a0; BARANSKI TJ, 1991, J BIOL CHEM, V266, P23365; BARLOWE C, 1994, CELL, V77, P895, DOI 10.1016/0092-8674(94)90138-4; BARLOWE C, 1993, NATURE, V365, P347, DOI 10.1038/365347a0; Bauerfeind R, 1993, CURR OPIN CELL BIOL, V5, P628, DOI 10.1016/0955-0674(93)90132-A; Bednarek SY, 1995, CELL, V83, P1183, DOI 10.1016/0092-8674(95)90144-2; BELL WD, 1995, NATURE, V373, P626; BENNETT MK, 1993, CELL, V74, P863, DOI 10.1016/0092-8674(93)90466-4; BENNETT MK, 1992, SCIENCE, V257, P255, DOI 10.1126/science.1321498; BERGMANN JE, 1983, J CELL BIOL, V97, P1777, DOI 10.1083/jcb.97.6.1777; BITTNER MA, 1992, J BIOL CHEM, V267, P16619; BLOBEL G, 1980, P NATL ACAD SCI-BIOL, V77, P1496, DOI 10.1073/pnas.77.3.1496; BLOCK MR, 1988, P NATL ACAD SCI USA, V85, P7852, DOI 10.1073/pnas.85.21.7852; BOS K, 1993, EMBO J, V12, P2219, DOI 10.1002/j.1460-2075.1993.tb05870.x; BRANDS R, 1985, J CELL BIOL, V101, P1724, DOI 10.1083/jcb.101.5.1724; BRENNWALD P, 1994, CELL, V79, P245, DOI 10.1016/0092-8674(94)90194-5; BRETSCHER MS, 1993, SCIENCE, V261, P1280, DOI 10.1126/science.8362242; BROADIE K, 1995, NEURON, V15, P663, DOI 10.1016/0896-6273(95)90154-X; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; BROWN HA, 1993, CELL, V75, P1137, DOI 10.1016/0092-8674(93)90323-I; BULLOUGH PA, 1994, NATURE, V371, P37, DOI 10.1038/371037a0; CALAKOS N, 1994, SCIENCE, V263, P1146, DOI 10.1126/science.8108733; CANFIELD WM, 1991, J BIOL CHEM, V266, P5682; CHAPMAN ER, 1994, J BIOL CHEM, V269, P27427; CLARY DO, 1990, CELL, V61, P709, DOI 10.1016/0092-8674(90)90482-T; COCKCROFT S, 1994, SCIENCE, V263, P523, DOI 10.1126/science.8290961; COSSON P, 1994, SCIENCE, V263, P1629, DOI 10.1126/science.8128252; CRAIG LC, 1956, TECHNIQUE ORGANIC CH, V13; DASCHER C, 1994, J BIOL CHEM, V269, P1437; DEAN N, 1990, J CELL BIOL, V111, P369, DOI 10.1083/jcb.111.2.369; DONALDSON JG, 1992, NATURE, V360, P350, DOI 10.1038/360350a0; DONALDSON JG, 1992, P NATL ACAD SCI USA, V89, P6408, DOI 10.1073/pnas.89.14.6408; DUNPHY WG, 1981, P NATL ACAD SCI-BIOL, V78, P7453, DOI 10.1073/pnas.78.12.7453; FIEDLER K, UNPUB; GAYNOR EC, 1994, J CELL BIOL, V127, P653, DOI 10.1083/jcb.127.3.653; GRIFFITHS G, 1986, SCIENCE, V234, P438, DOI 10.1126/science.2945253; GRIFFITHS G, 1983, J CELL BIOL, V96, P835, DOI 10.1083/jcb.96.3.835; GRIFFITHS G, 1994, J CELL BIOL, V127, P1557, DOI 10.1083/jcb.127.6.1557; GUO Q, 1994, J CELL BIOL, V125, P1213, DOI 10.1083/jcb.125.6.1213; HANSON PI, 1995, J BIOL CHEM, V270, P16955, DOI 10.1074/jbc.270.28.16955; HARRIS SL, IN PRESS J CELL BIOL; HAY JC, 1992, J CELL BIOL, V119, P139, DOI 10.1083/jcb.119.1.139; HAYASHI T, 1995, EMBO J, V14, P2317, DOI 10.1002/j.1460-2075.1995.tb07226.x; HELENIUS A, 1994, MOL BIOL CELL, V5, P253, DOI 10.1091/mbc.5.3.253; HELMS JB, 1992, NATURE, V360, P352, DOI 10.1038/360352a0; HINSHAW JE, 1995, NATURE, V374, P190, DOI 10.1038/374190a0; HOE MH, 1995, J BIOL CHEM, V270, P25057, DOI 10.1074/jbc.270.42.25057; HOSOBUCHI M, 1992, NATURE, V360, P603, DOI 10.1038/360603a0; HUGUENEY P, 1995, P NATL ACAD SCI USA, V92, P5630, DOI 10.1073/pnas.92.12.5630; HUMPHREY JS, 1993, J CELL BIOL, V120, P1123, DOI 10.1083/jcb.120.5.1123; JACKSON MR, 1993, J CELL BIOL, V121, P317, DOI 10.1083/jcb.121.2.317; JACKSON MR, 1990, EMBO J, V9, P3153, DOI 10.1002/j.1460-2075.1990.tb07513.x; JAMES DE, 1994, J CELL BIOL, V126, P1123, DOI 10.1083/jcb.126.5.1123; KANASEKI T, 1969, J CELL BIOL, V42, P202, DOI 10.1083/jcb.42.1.202; KARTENBECK J, 1978, CELL BIOL INT REP, V2, P457, DOI 10.1016/0309-1651(78)90097-8; King C. J., 1980, SEPARATION PROCESSES, V2nd; KLIONSKY DJ, 1990, J BIOL CHEM, V265, P5349; KORNFELD S, 1989, ANNU REV CELL BIOL, V5, P483, DOI 10.1146/annurev.cb.05.110189.002411; LATTERICH M, 1995, CELL, V82, P885, DOI 10.1016/0092-8674(95)90268-6; LETOURNEUR F, 1994, CELL, V79, P1199, DOI 10.1016/0092-8674(94)90011-6; LEWIS MJ, 1990, CELL, V61, P1359, DOI 10.1016/0092-8674(90)90699-F; LISANTI MP, 1989, J CELL BIOL, V109, P2145, DOI 10.1083/jcb.109.5.2145; Machamer CE, 1993, CURR OPIN CELL BIOL, V5, P606, DOI 10.1016/0955-0674(93)90129-E; MALHOTRA V, 1988, CELL, V54, P221, DOI 10.1016/0092-8674(88)90554-5; MALHOTRA V, 1989, CELL, V58, P329, DOI 10.1016/0092-8674(89)90847-7; MCINTYRE GF, 1994, J BIOL CHEM, V269, P567; MELLMAN I, 1992, CELL, V68, P829, DOI 10.1016/0092-8674(92)90027-A; MIESENBOCK G, 1995, J CELL BIOL, V129, P309, DOI 10.1083/jcb.129.2.309; MONTECUCCO C, 1994, MOL MICROBIOL, V13, P1, DOI 10.1111/j.1365-2958.1994.tb00396.x; MUNRO S, 1987, CELL, V48, P899, DOI 10.1016/0092-8674(87)90086-9; NILSSON T, 1994, CURR OPIN CELL BIOL, V6, P517, DOI 10.1016/0955-0674(94)90070-1; NILSSON T, 1989, CELL, V58, P707, DOI 10.1016/0092-8674(89)90105-0; NILSSON T, 1993, J CELL BIOL, V120, P5, DOI 10.1083/jcb.120.1.5; ORCI L, 1981, P NATL ACAD SCI-BIOL, V78, P293, DOI 10.1073/pnas.78.1.293; ORCI L, 1989, CELL, V56, P357, DOI 10.1016/0092-8674(89)90239-0; ORCI L, 1986, CELL, V46, P171, DOI 10.1016/0092-8674(86)90734-8; ORCI L, 1993, NATURE, V364, P732, DOI 10.1038/364732a0; OSTERMANN J, 1993, CELL, V75, P1015, DOI 10.1016/0092-8674(93)90545-2; OYLER GA, 1989, J CELL BIOL, V109, P3039, DOI 10.1083/jcb.109.6.3039; PALADE G, 1975, SCIENCE, V189, P347, DOI 10.1126/science.1096303; PALLANCK L, 1995, NATURE, V376, P25, DOI 10.1038/376025a0; PEARSE BMF, 1975, J MOL BIOL, V97, P93, DOI 10.1016/S0022-2836(75)80024-6; PEARSE BMF, 1988, EMBO J, V7, P3331, DOI 10.1002/j.1460-2075.1988.tb03204.x; PELLEGRINI LL, 1995, EMBO J, V14, P4705, DOI 10.1002/j.1460-2075.1995.tb00152.x; PEPPERKOK R, 1993, CELL, V74, P71, DOI 10.1016/0092-8674(93)90295-2; PETER F, 1993, J CELL BIOL, V122, P1155, DOI 10.1083/jcb.122.6.1155; Pettersson RF, 1995, COLD SPRING HARB SYM, V60, P147, DOI 10.1101/SQB.1995.060.01.018; PEVSNER J, 1994, P NATL ACAD SCI USA, V91, P1445, DOI 10.1073/pnas.91.4.1445; PFEFFER SR, 1987, ANNU REV BIOCHEM, V56, P829, DOI 10.1146/annurev.biochem.56.1.829; RABOUILLE C, 1995, J CELL SCI, V108, P1617; RABOUILLE C, 1995, CELL, V82, P905, DOI 10.1016/0092-8674(95)90270-8; ROBINSON M S, 1992, Trends in Cell Biology, V2, P293, DOI 10.1016/0962-8924(92)90118-7; ROTHMAN JE, 1986, CELL, V46, P5, DOI 10.1016/0092-8674(86)90852-4; ROTHMAN JE, 1981, SCIENCE, V213, P1212, DOI 10.1126/science.7268428; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; SALAMA NR, 1993, EMBO J, V12, P4073, DOI 10.1002/j.1460-2075.1993.tb06091.x; Sandoval Ignacio V., 1994, Trends in Cell Biology, V4, P292, DOI 10.1016/0962-8924(94)90220-8; SCHIAVO G, 1995, NATURE, V378, P733, DOI 10.1038/378733a0; SCHIMMOLLER F, 1995, EMBO J, V14, P1329, DOI 10.1002/j.1460-2075.1995.tb07119.x; SCHUTZE MP, 1994, EMBO J, V13, P1696, DOI 10.1002/j.1460-2075.1994.tb06434.x; SEMENZA JC, 1990, CELL, V61, P1349, DOI 10.1016/0092-8674(90)90698-E; SERAFINI T, 1991, CELL, V67, P239, DOI 10.1016/0092-8674(91)90176-Y; SIMONS K, 1993, NEURON, V11, P789, DOI 10.1016/0896-6273(93)90109-5; SOGAARD M, 1994, CELL, V78, P937, DOI 10.1016/0092-8674(94)90270-4; SOLLNER T, 1993, CELL, V75, P409, DOI 10.1016/0092-8674(93)90376-2; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; Stack JH, 1995, ANNU REV CELL DEV BI, V11, P1; STAMNES MA, 1993, CELL, V73, P999, DOI 10.1016/0092-8674(93)90277-W; STAMNES MA, 1995, P NATL ACAD SCI USA, V92, P8011, DOI 10.1073/pnas.92.17.8011; STEARNS T, 1990, P NATL ACAD SCI USA, V87, P1238, DOI 10.1073/pnas.87.3.1238; STENBECK G, 1992, FEBS LETT, V314, P195, DOI 10.1016/0014-5793(92)80973-K; STINCHCOMBE JC, 1995, J CELL BIOL, V131, P1387, DOI 10.1083/jcb.131.6.1387; SUDHOF TC, 1995, NATURE, V375, P645, DOI 10.1038/375645a0; SUDHOF TC, 1989, NEURON, V2, P1475, DOI 10.1016/0896-6273(89)90193-1; TAKEI K, 1995, NATURE, V374, P186, DOI 10.1038/374186a0; TANIGAWA G, 1993, J CELL BIOL, V123, P1365, DOI 10.1083/jcb.123.6.1365; THOMAS P, 1993, NEURON, V11, P93, DOI 10.1016/0896-6273(93)90274-U; TRAUB LM, 1993, J CELL BIOL, V123, P561, DOI 10.1083/jcb.123.3.561; TRIMBLE WS, 1988, P NATL ACAD SCI USA, V85, P4538, DOI 10.1073/pnas.85.12.4538; TROWBRIDGE IS, 1993, ANNU REV CELL BIOL, V9, P129, DOI 10.1146/annurev.cb.09.110193.001021; UNGEWICKELL E, 1995, NATURE, V378, P632, DOI 10.1038/378632a0; VALE RD, 1985, CELL, V43, P623, DOI 10.1016/0092-8674(85)90234-X; WATERS MG, 1991, NATURE, V349, P248, DOI 10.1038/349248a0; WEIDMANN M, 1984, NATURE, V309, P637, DOI 10.1038/309637a0; WHITNEY JA, 1995, CELL, V83, P703; Wieland F., UNPUB; WIELAND FT, 1987, CELL, V50, P289, DOI 10.1016/0092-8674(87)90224-8; WILSON DW, 1989, NATURE, V339, P355, DOI 10.1038/339355a0; WONG SH, 1993, J BIOL CHEM, V268, P22853; WOODWARD MP, 1978, P NATL ACAD SCI USA, V75, P4394, DOI 10.1073/pnas.75.9.4394; YOSHIHISA T, 1993, SCIENCE, V259, P1466, DOI 10.1126/science.8451644; ZHANG CJ, 1994, J CELL BIOL, V124, P289, DOI 10.1083/jcb.124.3.289	138	1005	1035	5	130	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 12	1996	272	5259					227	234		10.1126/science.272.5259.227	http://dx.doi.org/10.1126/science.272.5259.227			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UE729	8602507				2022-12-28	WOS:A1996UE72900032
J	Colas, P; Cohen, B; Jessen, T; Grishina, I; McCoy, J; Brent, R				Colas, P; Cohen, B; Jessen, T; Grishina, I; McCoy, J; Brent, R			Genetic selection of peptide aptamers that recognize and inhibit cyclin-dependent kinase 2	NATURE			English	Article							BINDING; LIBRARY; LIGANDS	A NETWORK of interacting proteins controls the activity of cyclin-dependent kinase 2 (Cdk2) (refs 1, 2) and governs the entry of higher eukaryotic cells into S phase. Analysis of this and other genetic regulatory networks would be facilitated by intracellular reagents that recognize specific targets and inhibit specific network connections. We report here the expression of a combinatorial library of constrained 20-residue peptides displayed by the active-site loop of Escherichia coli thioredoxin, and the use of a two-hybrid system to select those that bind human Cdk2. These peptide aptamers were designed to mimic the recognition function of the complementarity-determining regions of immunoglobulins. The aptamers recognized different epitopes on the Cdk2 surface with equilibrium dissociation constant in the nanomolar range; those tested inhibited Cdk2 activity. Our results show that peptide aptamers bear some analogies with monoclonal antibodies, with the advantages that they are isolated together with their coding genes, that their small sizes should allow their structures to be solved, and that they are designated to function inside cells.	MASSACHUSETTS GEN HOSP, DEPT BIOL MOLEC, BOSTON, MA 02114 USA; HARVARD UNIV, SCH MED, DEPT GENET, BOSTON, MA 02115 USA; GENET INST INC, CAMBRIDGE, MA 02142 USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School				Colas, Pierre/0000-0001-7436-3718				AUSUBEL FM, 1999, SHORT PROTOCOLS MOL; CWIRLA SE, 1990, P NATL ACAD SCI USA, V87, P6378, DOI 10.1073/pnas.87.16.6378; DESAI D, 1992, MOL BIOL CELL, V3, P571, DOI 10.1091/mbc.3.5.571; DEVLIN JJ, 1990, SCIENCE, V249, P404, DOI 10.1126/science.2143033; ESTOJAK J, 1995, MOL CELL BIOL, V15, P5820; FINLEY RL, 1994, P NATL ACAD SCI USA, V91, P12980, DOI 10.1073/pnas.91.26.12980; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; GOLEMIS EA, 1992, MOL CELL BIOL, V12, P3006, DOI 10.1128/MCB.12.7.3006; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; KATO J, 1993, GENE DEV, V7, P331; LAM KS, 1991, NATURE, V354, P82, DOI 10.1038/354082a0; LAVALLIE ER, 1993, BIO-TECHNOL, V11, P187, DOI 10.1038/nbt0293-187; LEE JW, 1995, NATURE, V374, P91, DOI 10.1038/374091a0; LU ZJ, 1995, BIO-TECHNOL, V13, P366, DOI 10.1038/nbt0495-366; MCCONNELL SJ, 1994, GENE, V151, P115, DOI 10.1016/0378-1119(94)90640-8; MCLAFFERTY MA, 1993, GENE, V128, P29, DOI 10.1016/0378-1119(93)90149-W; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; OLDENBURG KR, 1992, P NATL ACAD SCI USA, V89, P5393, DOI 10.1073/pnas.89.12.5393; OSHANNESSY DJ, 1993, ANAL BIOCHEM, V212, P457, DOI 10.1006/abio.1993.1355; REYMOND A, 1995, ONCOGENE, V11, P1173; RUDEN DM, 1991, NATURE, V350, P250, DOI 10.1038/350250a0; Scott Jamie K., 1994, Current Opinion in Biotechnology, V5, P40, DOI 10.1016/S0958-1669(05)80068-0; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SPOLAR RS, 1994, SCIENCE, V263, P777, DOI 10.1126/science.8303294; YANG MJ, 1995, NUCLEIC ACIDS RES, V23, P1152, DOI 10.1093/nar/23.7.1152; ZHOU SY, 1994, CURR BIOL, V4, P973, DOI 10.1016/S0960-9822(00)00221-9	26	336	410	2	39	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 11	1996	380	6574					548	550		10.1038/380548a0	http://dx.doi.org/10.1038/380548a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UE663	8606778				2022-12-28	WOS:A1996UE66300056
J	LaRosa, JC				LaRosa, JC			Cholesterol agonistics	ANNALS OF INTERNAL MEDICINE			English	Editorial Material							CORONARY HEART-DISEASE; ARTERY DISEASE; ATHEROSCLEROSIS-REGRESSION; SERUM-CHOLESTEROL; MECHANISMS; MEN; ASSOCIATION; DIET; PATHOGENESIS; CALIFORNIA	Considerable evidence links elevated blood cholesterol levels to the development of atherosclerosis. The National Cholesterol Education Program (NCEP) has recently published revised guidelines for detecting and treating hypercholesterolemia in adults. Included in these guidelines is the recommendation that all adults older than 20 years of age know their cholesterol levels. Under the NCEP guidelines, knowledge of cholesterol levels, even if the levels are elevated, does not automatically lead to drug therapy; on the other hand, under these guidelines, adults are not automatically excluded from treatment simply on the basis of age or sex. The guidelines presented by the American College of Physicians in this issue differ from the NCEP guidelines in that they recommend only limited screening, primarily for middle-aged men. This recommendation is based in part on the assumption that overuse of cholesterol-lowering drugs will otherwise become a problem. In fact, a major current problem is underuse of cholesterol-lowering medications, even in patients at high risk for coronary events. The guidelines proposed by the College minimize large elements of the database linking cholesterol to atherogenesis and make unwarranted and unproven assumptions about physician behavior. In its rationale, its potential consequences, and the process by which it was derived, this policy is in error and should be rejected.			LaRosa, JC (corresponding author), TULANE UNIV, MED CTR, 1430 TULANE AVE, SL-76, NEW ORLEANS, LA 70112 USA.							ALEXANDER RW, 1995, HYPERTENSION, V25, P155, DOI 10.1161/01.HYP.25.2.155; [Anonymous], 1993, Am J Cardiol, V72, P1031; ASCH DA, 1995, ANN INTERN MED, V122, P846, DOI 10.7326/0003-4819-122-11-199506010-00007; AUSTIN MA, 1994, INT J CLIN LAB RES, V24, P187, DOI 10.1007/BF02592460; BROWN BG, 1993, BRIT HEART J, V69, pS48; BYINGTON RP, 1995, CIRCULATION, V92, P2419, DOI 10.1161/01.CIR.92.9.2419; ELTON PJ, 1994, J EPIDEMIOL COMMUN H, V48, P22, DOI 10.1136/jech.48.1.22; FRICK MH, 1987, NEW ENGL J MED, V317, P1237, DOI 10.1056/NEJM198711123172001; FUSTER V, 1992, NEW ENGL J MED, V326, P242, DOI 10.1056/NEJM199201233260406; FUSTER V, 1992, NEW ENGL J MED, V326, P310; Garber AM, 1996, ANN INTERN MED, V124, P515, DOI 10.7326/0003-4819-124-5-199603010-00013; Garber AM, 1996, ANN INTERN MED, V124, P518, DOI 10.7326/0003-4819-124-5-199603010-00013; GILES WH, 1993, JAMA-J AM MED ASSOC, V269, P1133, DOI 10.1001/jama.269.9.1133; GOULD AL, 1995, CIRCULATION, V91, P2274, DOI 10.1161/01.CIR.91.8.2274; GREENWOOD P, 1995, AM J CARDIOL, V76, P570; GRUNDY SM, 1993, JAMA-J AM MED ASSOC, V269, P3015, DOI 10.1001/jama.269.23.3015; HARRIS T, 1992, J CLIN EPIDEMIOL, V45, P595, DOI 10.1016/0895-4356(92)90131-6; HIGGINS MW, 1988, TRENDS CORONARY HEAR, pR7; HULLEY SB, 1980, NEW ENGL J MED, V302, P1383, DOI 10.1056/NEJM198006193022503; IRIBARREN C, 1995, ARCH INTERN MED, V155, P695, DOI 10.1001/archinte.155.7.695; JOHNSON CL, 1993, JAMA-J AM MED ASSOC, V269, P3002, DOI 10.1001/jama.269.23.3002; KANE JP, 1990, JAMA-J AM MED ASSOC, V264, P3007, DOI 10.1001/jama.264.23.3007; KANNEL WB, 1985, J AM COLL CARDIOL, V5, pB141, DOI 10.1016/S0735-1097(85)80545-3; KATO H, 1973, AM J EPIDEMIOL, V97, P372, DOI 10.1093/oxfordjournals.aje.a121518; KEYS A, 1970, CIRCULATION, V41, pI1; KLAG MJ, 1993, NEW ENGL J MED, V328, P313, DOI 10.1056/NEJM199302043280504; LAROSA JC, 1990, CIRCULATION, V81, P1721, DOI 10.1161/01.CIR.81.5.1721; LAROSA JC, 1993, AM J CARDIOL, V72, P776, DOI 10.1016/0002-9149(93)91062-M; ORNISH D, 1990, LANCET, V336, P129, DOI 10.1016/0140-6736(90)91656-U; PEARSON TA, 1993, AM J CARDIOL, V72, P1072, DOI 10.1016/0002-9149(93)90864-9; PEDERSEN TR, 1994, LANCET, V344, P1383; PEDERSEN TR, 1995, CIRCULATION S1, V92, P672; RIFKIND BM, 1984, JAMA-J AM MED ASSOC, V251, P351; ROBERTSON TL, 1977, AM J CARDIOL, V39, P239, DOI 10.1016/S0002-9149(77)80197-5; RUDERMAN NB, 1992, DIABETES CARE, V15, P1787, DOI 10.2337/diacare.15.11.1787; SCHAEFER EJ, 1995, ARTERIOSCL THROM VAS, V15, P1079, DOI 10.1161/01.ATV.15.8.1079; SCHULER G, 1992, CIRCULATION, V86, P1, DOI 10.1161/01.CIR.86.1.1; SHEPHERD J, 1995, NEW ENGL J MED, V333, P1301, DOI 10.1056/NEJM199511163332001; STCLAIR RW, 1983, PROG CARDIOVASC DIS, V26, P109; TENKANEN L, 1994, ARCH INTERN MED, V154, P2714, DOI 10.1001/archinte.1994.00420230107012; WATERS D, 1995, CIRCULATION, V92, P2404, DOI 10.1161/01.CIR.92.9.2404; WATTS GF, 1992, LANCET, V339, P563, DOI 10.1016/0140-6736(92)90863-X	42	46	46	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 1	1996	124	5					505	508		10.7326/0003-4819-124-5-199603010-00008	http://dx.doi.org/10.7326/0003-4819-124-5-199603010-00008			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TW773	8602710				2022-12-28	WOS:A1996TW77300008
J	Pourquie, O; Fan, CM; Coltey, M; Hirsinger, E; Watanabe, Y; Breant, C; FrancisWest, P; Brickell, P; TessierLavigne, M; LeDouarin, NM				Pourquie, O; Fan, CM; Coltey, M; Hirsinger, E; Watanabe, Y; Breant, C; FrancisWest, P; Brickell, P; TessierLavigne, M; LeDouarin, NM			Lateral and axial signals involved in avian somite patterning: A role for BMP4	CELL			English	Article							BONE-MORPHOGENETIC PROTEIN-4; MINDED GENE ENCODES; DIFFERENTIATION; NOTOCHORD; EMBRYOS; MUSCLE; ORIGIN; CHICK; MUSCULATURE; LIMB	In vertebrates, muscles of the limbs and body wall derive from the lateral compartment of the embryonic somites, and axial muscles derive from the medial compartment. Whereas the mechanisms that direct patterning of somites along the dorsoventral axis are beginning to be understood, little is known about the tissue interactions and signaling molecules that direct somite patterning along the mediolateral axis. We report the identification of a specific marker for the lateral semitic compartment and its early derivatives, cSim1, an avian homolog of the Drosophila single minded gene. Using this marker, we provide evidence that specification of the lateral semitic lineage results from the antagonistic actions of a diffusible medializing signal from the neural tube and a diffusible lateralizing signal from the lateral plate mesoderm, and we implicate bone morphogenetic protein 4 (BMP4) in directing this lateralization.	COLL FRANCE, F-94736 NOGENT SUR MARNE, FRANCE; UCL, SCH MED, DEPT MOLEC PATHOL, LONDON W1P 6DB, ENGLAND; UNIV CALIF SAN FRANCISCO, HOWARD HUGHES MED INST, DEPT ANAT, SAN FRANCISCO, CA 94143 USA; UNITED MED & DENT SCH, GUYS HOSP, GUYS & ST THOMAS MED & DENT SCH, LONDON SE1 9RT, ENGLAND	UDICE-French Research Universities; PSL Research University Paris; College de France; University of London; University College London; UCL Medical School; Howard Hughes Medical Institute; University of California System; University of California San Francisco; Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London	Pourquie, O (corresponding author), CNRS, INST EMBRYOL, 49 AVE BELLE GABRIELLE, F-94736 NOGENT SUR MARNE, FRANCE.		Pourquié, Olivier/CAJ-5443-2022; Hirsinger, Estelle/K-2847-2017; WATANABE, YUJI/AAI-7750-2021	Pourquié, Olivier/0000-0001-5189-1227; Hirsinger, Estelle/0000-0002-5256-7741; 				AOYAMA H, 1988, DEVELOPMENT, V104, P15; BRANDSABERI B, 1993, ANAT EMBRYOL, V188, P239; BUCKINGHAM M, 1992, TRENDS GENET, V8, P144, DOI 10.1016/0168-9525(92)90373-C; CHEN H, 1995, NAT GENET, V10, P9, DOI 10.1038/ng0595-9; CHEVALLIER A, 1977, J EMBRYOL EXP MORPH, V41, P245; CHRIST B, 1977, ANAT EMBRYOL, V150, P171, DOI 10.1007/BF00316649; CHRIST B, 1983, ANAT EMBRYOL, V166, P87, DOI 10.1007/BF00317946; CHRIST B, 1992, ANAT EMBRYOL, V186, P505; CHRIST B, 1995, ANAT EMBRYOL, V191, P381, DOI 10.1007/BF00304424; CREWS ST, 1988, CELL, V52, P143, DOI 10.1016/0092-8674(88)90538-7; DAHMANE N, 1995, P NATL ACAD SCI USA, V92, P9191, DOI 10.1073/pnas.92.20.9191; DALE L, 1992, DEVELOPMENT, V115, P573; FAINSOD A, 1994, EMBO J, V13, P5015, DOI 10.1002/j.1460-2075.1994.tb06830.x; FAN CM, 1994, CELL, V79, P1175, DOI 10.1016/0092-8674(94)90009-4; FAN CM, IN PRESS MOL CELL NE; FRANCIS PH, 1994, DEVELOPMENT, V120, P209; GOULDING M, 1994, DEVELOPMENT, V120, P957; HAMBURGER V, 1951, J MORPHOL, V88, P49, DOI 10.1002/jmor.1050880104; HENRIQUE D, 1995, NATURE, V375, P787, DOI 10.1038/375787a0; HOGAN BLM, 1994, DEVELOPMENT, P53; HUGHES SH, 1987, J VIROL, V61, P3004, DOI 10.1128/JVI.61.10.3004-3012.1987; JOHNSON RL, 1995, CELL, V81, P313, DOI 10.1016/0092-8674(95)90381-X; JOHNSON RL, 1994, CELL, V79, P1165, DOI 10.1016/0092-8674(94)90008-6; JONES CM, 1991, DEVELOPMENT, V111, P531; KAEHN K, 1988, ANAT EMBRYOL, V177, P191, DOI 10.1007/BF00321131; LEDOUARIN N, 1970, CR ACAD SCI D NAT, V270, P1708; LEWIS JO, 1994, MECH DEVELOP, V48, P81, DOI 10.1016/0925-4773(94)90018-3; LIEM KF, 1995, CELL, V82, P969, DOI 10.1016/0092-8674(95)90276-7; NAMBU JR, 1991, CELL, V67, P1157, DOI 10.1016/0092-8674(91)90292-7; ORDAHL CP, 1992, DEVELOPMENT, V114, P339; ORDAHL CP, 1993, MOL BASIS MORPHOGENE, P165; POTTS WM, 1987, J GEN VIROL, V68, P3177, DOI 10.1099/0022-1317-68-12-3177; POURQUIE O, 1993, P NATL ACAD SCI USA, V90, P5242, DOI 10.1073/pnas.90.11.5242; POURQUIE O, 1995, P NATL ACAD SCI USA, V92, P3219, DOI 10.1073/pnas.92.8.3219; POWNALL ME, 1992, DEV BIOL, V151, P67, DOI 10.1016/0012-1606(92)90214-2; RONG PM, 1992, DEVELOPMENT, V115, P657; SAITOH O, 1993, NUCLEIC ACIDS RES, V21, P2503, DOI 10.1093/nar/21.10.2503; SELLECK MAJ, 1991, DEVELOPMENT, V112, P615; WILLIAMS BA, 1994, DEVELOPMENT, V120, P785	39	352	361	0	8	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 9	1996	84	3					461	471		10.1016/S0092-8674(00)81291-X	http://dx.doi.org/10.1016/S0092-8674(00)81291-X			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TV708	8608600	Bronze			2022-12-28	WOS:A1996TV70800015
J	Douglas, PS; Ginsburg, GS				Douglas, PS; Ginsburg, GS			The evaluation of chest pain in women	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							CORONARY-ARTERY DISEASE; GOOD CLINICAL JUDGMENT; HEART-DISEASE; BYPASS-SURGERY; FOLLOW-UP; MORTALITY; BIAS; RISK; MANAGEMENT; MENOPAUSE		HARVARD UNIV,SCH MED,BOSTON,MA	Harvard University; Harvard Medical School	Douglas, PS (corresponding author), BETH ISRAEL HOSP,HARVARD THORNDIKE LAB,DIV CARDIOVASC,330 BROOKLINE AVE,BOSTON,MA 02215, USA.			Douglas, Pamela/0000-0001-9876-4049				[Anonymous], 1994, Circulation, V89, P1333; AYANIAN JZ, 1991, NEW ENGL J MED, V325, P221, DOI 10.1056/NEJM199107253250401; BEARDEN D, 1994, J AM GERIATR SOC, V42, P1143, DOI 10.1111/j.1532-5415.1994.tb06979.x; BENGTSSON C, 1993, BMJ-BRIT MED J, V307, P1385, DOI 10.1136/bmj.307.6916.1385; BICKELL NA, 1992, ANN INTERN MED, V116, P791, DOI 10.7326/0003-4819-116-10-791; BIRDWELL BG, 1993, ARCH INTERN MED, V153, P1991, DOI 10.1001/archinte.153.17.1991; BITTNER V, 1993, CARDIOVASCULAR HLTH, P63; BLAIR SN, 1989, JAMA-J AM MED ASSOC, V262, P2395, DOI 10.1001/jama.262.17.2395; BULLEMER F, 1995, J AM COLL CARDIO FEB, pA267; CANNON RO, 1992, CIRCULATION, V85, P883, DOI 10.1161/01.CIR.85.3.883; CHAE SC, 1993, J AM COLL CARDIOL, V21, P1305, DOI 10.1016/0735-1097(93)90301-G; COLDITZ GA, 1987, NEW ENGL J MED, V316, P1105, DOI 10.1056/NEJM198704303161801; COLLINS L, IN PRESS ACUTE MYOCA; CORNONIHUNTLEY J, 1989, ARCH INTERN MED, V149, P780, DOI 10.1001/archinte.149.4.780; CREAN JM, 1994, J AM COLL CARDIOL, pA299; CRIQUI MH, 1993, NEW ENGL J MED, V328, P1220, DOI 10.1056/NEJM199304293281702; DOUGLAS P, 1993, CARDIOVASCULAR HLTH; DOUGLAS PS, IN PRESS HEART DIS T; EAGLE KA, 1994, J AM COLL CARDIOL, V23, P1091, DOI 10.1016/0735-1097(94)90596-7; ENGEL HJ, 1983, EUR HEART J, V4, P1; ERNST E, 1993, ANN INTERN MED, V118, P956, DOI 10.7326/0003-4819-118-12-199306150-00008; FRIED JP, 1993, CARDIOVASCULAR HLTH, P217; FURBERG CD, 1994, CIRCULATION, V90, P1679, DOI 10.1161/01.CIR.90.4.1679; GRADY D, 1992, ANN INTERN MED, V117, P1016, DOI 10.7326/0003-4819-117-12-1016; GREEN LA, 1994, J FAM PRACTICE, V39, P331; Haynes SG, 1993, CARDIOVASCULAR HLTH, P269; HEALY B, 1991, NEW ENGL J MED, V325, P274, DOI 10.1056/NEJM199107253250408; KHAN SS, 1990, ANN INTERN MED, V112, P561, DOI 10.7326/0003-4819-112-8-561; LASKEY WK, 1992, ANN INTERN MED, V116, P869, DOI 10.7326/0003-4819-116-10-869; LOBO RA, 1993, CARDIOVASCULAR HLTH, P153; MANSON JAE, 1990, NEW ENGL J MED, V322, P882, DOI 10.1056/NEJM199003293221303; MANSON JE, 1995, CIRCULATION, V91, P927; MARWICK TH, 1995, J AM COLL CARDIOL, V26, P335, DOI 10.1016/0735-1097(95)80004-Z; MATTHEWS KA, 1989, NEW ENGL J MED, V321, P641, DOI 10.1056/NEJM198909073211004; MAYNARD C, 1992, J MYOCARD ISCHEMIA, V4, P27; MELIN JA, 1985, CIRCULATION, V71, P535, DOI 10.1161/01.CIR.71.3.535; MILLER VT, 1994, ATHEROSCLEROSIS, V108, pS73, DOI 10.1016/0021-9150(94)90154-6; MORISE AP, 1993, AM J MED, V94, P491, DOI 10.1016/0002-9343(93)90083-2; PEPINE CJ, 1994, AM J CARDIOL, V74, P226, DOI 10.1016/0002-9149(94)90361-1; PILOTE L, 1995, AM HEART J, V129, P1237, DOI 10.1016/0002-8703(95)90426-3; RICHEDWARDS JW, 1995, NEW ENGL J MED, V332, P1758, DOI 10.1056/NEJM199506293322607; SAWADA SG, 1989, J AM COLL CARDIOL, V14, P1440, DOI 10.1016/0735-1097(89)90378-1; SHAW LJ, 1994, ANN INTERN MED, V120, P559, DOI 10.7326/0003-4819-120-7-199404010-00005; SPELSBERG A, 1993, CARDIOVASCULAR HLTH, P191; STAMPFER MJ, 1991, PREV MED, V20, P47, DOI 10.1016/0091-7435(91)90006-P; STEINGART RM, 1991, NEW ENGL J MED, V325, P226, DOI 10.1056/NEJM199107253250402; SULLIVAN AK, 1994, BRIT MED J, V308, P883, DOI 10.1136/bmj.308.6933.883; TOBIN JN, 1987, ANN INTERN MED, V107, P19, DOI 10.7326/0003-4819-107-1-19; WANG XL, 1994, CIRCULATION, V89, P1974, DOI 10.1161/01.CIR.89.5.1974; WEINER DA, 1979, NEW ENGL J MED, V301, P230, DOI 10.1056/NEJM197908023010502; Wenger NK, 1993, CARDIOVASCULAR HLTH, P67; WILLETT WC, 1987, NEW ENGL J MED, V317, P1303, DOI 10.1056/NEJM198711193172102; WILLICH SN, 1993, J AM COLL CARDIOL, V21, pA238; ZUANETTI G, 1993, J AM COLL CARDIOL, V22, P1788, DOI 10.1016/0735-1097(93)90758-S; 1995, JAMA-J AM MED ASSOC, V273, P199	55	239	248	0	5	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 16	1996	334	20					1311	1315		10.1056/NEJM199605163342007	http://dx.doi.org/10.1056/NEJM199605163342007			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UK880	8609950				2022-12-28	WOS:A1996UK88000007
J	Wolinsky, SM; Korber, BTM; Neumann, AU; Daniels, M; Kunstman, KJ; Whetsell, AJ; Furtado, MR; Cao, YZ; Ho, DD; Safrit, JT; Koup, RA				Wolinsky, SM; Korber, BTM; Neumann, AU; Daniels, M; Kunstman, KJ; Whetsell, AJ; Furtado, MR; Cao, YZ; Ho, DD; Safrit, JT; Koup, RA			Adaptive evolution of human immunodeficiency virus-type 1 during the natural course of infection	SCIENCE			English	Article							VESICULAR STOMATITIS-VIRUS; PRIMARY HIV-1 INFECTION; BIOLOGICAL PHENOTYPE; SYNDROME AIDS; CLONAL POOLS; POPULATIONS; TRANSMISSION; PROGRESSION; SEQUENCES; DIVERSITY	The rate of progression to disease varies considerably among individuals infected with human immunodeficiency virus-type 1 (HIV-1). Analyses of semiannual blood samples obtained from six infected men showed that a rapid rate of CD4 T cell loss was associated with relative evolutionary stasis of the HIV-1 quasispecies virus population. More moderate rates of CD4 T cell loss correlated with genetic evolution within three of four subjects. Consistent with selection by the immune constraints of these subjects, amino acid changes were apparent within the appropriate epitopes of human leukocyte antigen class I-restricted cytotoxic T lymphocytes. Thus, the evolutionary dynamics exhibited by the HIV-1 quasispecies virus populations under natural selection are compatible with adaptive evolution.	LOS ALAMOS NATL LAB, DIV THEORET, LOS ALAMOS, NM 87545 USA; AARON DIAMOND AIDS RES CTR, NEW YORK, NY 10016 USA; ROCKEFELLER UNIV, NEW YORK, NY 10016 USA	United States Department of Energy (DOE); Los Alamos National Laboratory; Rockefeller University	Wolinsky, SM (corresponding author), NORTHWESTERN UNIV, SCH MED, DEPT MED, 303 E CHICAGO AVE, CHICAGO, IL 60611 USA.		Wolinsky, Steven/B-2893-2012	Korber, Bette/0000-0002-2026-5757; Wolinsky, Steven/0000-0002-9625-6697; Furtado, Manohar/0000-0001-6016-1357	NIAID NIH HHS [AI45218, AI35522, AI32535] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI035522, R01AI035522] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AHMAD N, 1995, J VIROL, V69, P1001, DOI 10.1128/JVI.69.2.1001-1012.1995; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ASJO B, 1986, LANCET, V2, P660; AUTRAN B, 1996, 10 C CEUT GARD, P118; BONYHADI ML, 1993, NATURE, V363, P728, DOI 10.1038/363728a0; BUCHBINDER S, 1994, AIDS, V8, P393; BURNS DPW, 1993, J VIROL, V67, P4104, DOI 10.1128/JVI.67.7.4104-4113.1993; CAO YZ, 1995, NEW ENGL J MED, V332, P201, DOI 10.1056/NEJM199501263320401; CHEYNIER R, 1994, CELL, V78, P373, DOI 10.1016/0092-8674(94)90417-0; CLARK SJ, 1991, NEW ENGL J MED, V324, P954, DOI 10.1056/NEJM199104043241404; COFFIN JM, 1995, SCIENCE, V267, P483, DOI 10.1126/science.7824947; CONNOR RI, 1994, J VIROL, V68, P4400, DOI 10.1128/JVI.68.7.4400-4408.1994; CONNOR RI, 1993, J VIROL, V67, P1772, DOI 10.1128/JVI.67.4.1772-1777.1993; COUILLIN I, 1994, J EXP MED, V180, P1129, DOI 10.1084/jem.180.3.1129; DAAR ES, 1991, NEW ENGL J MED, V324, P961, DOI 10.1056/NEJM199104043241405; DELATORRE JC, 1990, J VIROL, V64, P664, DOI 10.1128/JVI.64.2.664-671.1990; DELWART E, UNPUB; DELWART EL, 1994, J VIROL, V68, P6672, DOI 10.1128/JVI.68.10.6672-6683.1994; DESROSIERS RC, 1992, AIDS RES HUM RETROV, V8, P411, DOI 10.1089/aid.1992.8.411; DEWOLF F, 1994, AIDS RES HUM RETROV, V10, P1387, DOI 10.1089/aid.1994.10.1387; EIGEN M, 1987, COLD SPRING HARB SYM, V52, P307, DOI 10.1101/SQB.1987.052.01.036; Eigen M., 1988, RNA GENETICS, V3, P211; EYSTER ME, 1989, ANN INTERN MED, V110, P963, DOI 10.7326/0003-4819-110-12-963; FAULKNER DV, 1988, TRENDS BIOCHEM SCI, V13, P321, DOI 10.1016/0968-0004(88)90129-6; Felsenstein J, 1993, PHYLIP PHYLOGENY INT; Felsenstein J., 2005, PHYLIP PHYLOGENY INF, DOI DOI 10.1111/J.1096-0031.1989.TB00562.X; FOUCHIER RAM, 1992, J VIROL, V66, P3183, DOI 10.1128/JVI.66.5.3183-3187.1992; FURTADO MR, 1995, J VIROL, V69, P2092, DOI 10.1128/JVI.69.4.2092-2100.1995; Ganeshan S., UNPUB; GIORGI JV, 1993, J ACQ IMMUN DEF SYND, V6, P904; GRASSBERGER P, 1983, PHYS LETT A, V97, P227, DOI 10.1016/0375-9601(83)90753-3; GRAZIOSI C, 1993, P NATL ACAD SCI USA, V90, P6405, DOI 10.1073/pnas.90.14.6405; GREENOUGH TC, 1994, AIDS RES HUM RETROV, V10, P395, DOI 10.1089/aid.1994.10.395; HENIKOFF S, 1991, NEW BIOL, V3, P1148; HOLLAND JJ, 1992, CURR TOP MICROBIOL, V176, P1; HOLMES EC, 1992, P NATL ACAD SCI USA, V89, P4835, DOI 10.1073/pnas.89.11.4835; IVERSEN AKN, 1995, J VIROL, V69, P5743, DOI 10.1128/JVI.69.9.5743-5753.1995; JOHNSON RP, 1993, J VIROL, V67, P438, DOI 10.1128/JVI.67.1.438-445.1993; KELT I, 1994, J INFECT DIS, V169, P1236; KIRCHHOFF F, 1995, NEW ENGL J MED, V332, P228, DOI 10.1056/NEJM199501263320405; KLEIN MR, 1995, J EXP MED, V181, P1365, DOI 10.1084/jem.181.4.1365; KOOT M, 1993, ANN INTERN MED, V118, P681, DOI 10.7326/0003-4819-118-9-199305010-00004; KORBER B, 1992, AIDS RES HUM RETROV, V8, P1461, DOI 10.1089/aid.1992.8.1461; KORBER B, UNPUB; KORBER BTM, 1995, NATURE, V378, P242, DOI 10.1038/378242a0; KORBER BTM, 1994, J VIROL, V68, P7467, DOI 10.1128/JVI.68.11.7467-7481.1994; KORBER BTM, 1994, J VIROL, V68, P6730, DOI 10.1128/JVI.68.10.6730-6744.1994; KOUP RA, 1994, J VIROL, V68, P4650, DOI 10.1128/JVI.68.7.4650-4655.1994; KOUP RA, UNPUB; KUIKEN CL, 1992, J VIROL, V66, P4622, DOI 10.1128/JVI.66.7.4622-4627.1992; KWOK S, 1989, NATURE, V339, P237, DOI 10.1038/339237a0; LANDE R, 1985, P NATL ACAD SCI USA, V82, P7641, DOI 10.1073/pnas.82.22.7641; LEARMONT J, 1993, LANCET, V341, P113; LUKASHOV VV, 1995, J VIROL, V69, P6911, DOI 10.1128/JVI.69.11.6911-6916.1995; MCMICHAEL AJ, 1994, AIDS S1, V8, pS155; MELLORS JW, 1995, ANN INTERN MED, V122, P573, DOI 10.7326/0003-4819-122-8-199504150-00003; MICHAEL NL, 1995, J VIROL, V69, P6758, DOI 10.1128/JVI.69.11.6758-6769.1995; MICHAEL NL, 1995, J VIROL, V69, P1868, DOI 10.1128/JVI.69.3.1868-1877.1995; MIEDEMA F, 1994, IMMUNOL REV, V140, P35, DOI 10.1111/j.1600-065X.1994.tb00864.x; MOORE JP, 1994, J VIROL, V68, P5142, DOI 10.1128/JVI.68.8.5142-5155.1994; MULLINS J, 1994, 9 C CENT GENT GARD, P77; MUNOZ A, 1995, J ACQ IMMUN DEF SYND, V8, P496, DOI 10.1097/00042560-199504120-00010; Myers G, 1994, HUMAN RETROVIRUSES A; NEWMAN CM, 1985, NATURE, V315, P400, DOI 10.1038/315400a0; NIELSEN C, 1993, AIDS, V7, P1035, DOI 10.1097/00002030-199308000-00002; NOWAK MA, 1991, SCIENCE, V254, P963, DOI 10.1126/science.1683006; NOWAK MA, 1995, SCI AM, V273, P58, DOI 10.1038/scientificamerican0895-58; NOWAK MA, 1995, NATURE, V375, P534; PANTALEO G, 1994, IMMUNOL REV, V140, P105, DOI 10.1111/j.1600-065X.1994.tb00867.x; PAU CP, 1994, AIDS RES HUM RETROV, V10, P1369, DOI 10.1089/aid.1994.10.1369; Renyi A., 1970, PROBABILITY THEORY; RICHMAN DD, 1994, J INFECT DIS, V169, P968, DOI 10.1093/infdis/169.5.968; RINALDO C, 1995, J VIROL, V69, P5838, DOI 10.1128/JVI.69.9.5838-5842.1995; RUTHERFORD GW, 1990, BRIT MED J, V301, P1183, DOI 10.1136/bmj.301.6762.1183; SAAG MS, 1991, J EXP MED, V172, P1055; SAFRIT JT, 1994, J IMMUNOL, V153, P3822; SCHRAGER LK, 1994, AIDS, V8, P895; SCHUITEMAKER H, 1992, J VIROL, V66, P1354, DOI 10.1128/JVI.66.3.1354-1360.1992; SHEPPARD HW, 1993, AIDS, V7, P1159, DOI 10.1097/00002030-199309000-00002; STEINHAUER DA, 1989, J VIROL, V63, P2063, DOI 10.1128/JVI.63.5.2063-2071.1989; STEINHAUER DA, 1989, J VIROL, V63, P2072, DOI 10.1128/JVI.63.5.2072-2080.1989; SWOFFEND D, 1988, THESIS U ILLINOIS UR; TERSMETTE M, 1988, J VIROL, V62, P2026, DOI 10.1128/JVI.62.6.2026-2032.1988; TERSMETTE M, 1989, J VIROL, V63, P2118, DOI 10.1128/JVI.63.5.2118-2125.1989; WAINHOBSON S, 1995, NATURE, V373, P102, DOI 10.1038/373102a0; WOLFS TFW, 1992, VIROLOGY, V189, P103, DOI 10.1016/0042-6822(92)90685-I; WOLINSKY S, UNPUB; WOLINSKY SM, 1992, SCIENCE, V255, P1134, DOI 10.1126/science.1546316; WOLINSKY SM, 1994, 9 C CENT GENT GARD, P95; WRIGHT S, 1982, EVOLUTION, V36, P427, DOI 10.1111/j.1558-5646.1982.tb05065.x; WRIGHT S, 1977, EVOLUTION GENETICS P, V1; ZHANG LQ, 1993, J VIROL, V67, P3345, DOI 10.1128/JVI.67.6.3345-3356.1993; ZHU TF, 1993, SCIENCE, V261, P1179, DOI 10.1126/science.8356453; ZINKERNAGEL RM, 1994, IMMUNOL TODAY, V15, P262, DOI 10.1016/0167-5699(94)90005-1	94	496	513	1	32	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 26	1996	272	5261					537	542		10.1126/science.272.5261.537	http://dx.doi.org/10.1126/science.272.5261.537			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UG826	8614801				2022-12-28	WOS:A1996UG82600041
J	Presti, JC				Presti, JC			Estrogen therapy for prostate carcinoma	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter							CANCER				Presti, JC (corresponding author), UNIV CALIF SAN FRANCISCO,DEPT UROL,SAN FRANCISCO,CA 94143, USA.							BYAR DP, 1973, CANCER, V32, P1126, DOI 10.1002/1097-0142(197311)32:5<1126::AID-CNCR2820320518>3.0.CO;2-C; HENRIKSSON P, 1986, BRIT MED J, V293, P413, DOI 10.1136/bmj.293.6544.413; JOHANSSON JE, 1991, J UROLOGY, V145, P519, DOI 10.1016/S0022-5347(17)38385-4; 1984, NEW ENGL J MED, V311, P1281	4	5	7	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 17	1996	275	15					1153	1153		10.1001/jama.275.15.1153	http://dx.doi.org/10.1001/jama.275.15.1153			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UE625	8609673				2022-12-28	WOS:A1996UE62500010
J	Chisholm, A; Mann, J; Sutherland, W; Duncan, A; Skeaff, M; Frampton, C				Chisholm, A; Mann, J; Sutherland, W; Duncan, A; Skeaff, M; Frampton, C			Effect on lipoprotein profile of replacing butter with margarine in a low fat diet: Randomised crossover study with hypercholesterolaemic subjects	BRITISH MEDICAL JOURNAL			English	Article							CORONARY HEART-DISEASE; SERUM-LIPIDS; ACIDS; PLASMA; CHOLESTEROL; DENSITY; HUMANS	Objective-To examine the effect on lipid and lipoprotein concentrations when butter or an unsaturated margarine is used for cooking or spreading in a reduced fat diet. Design-Randomised crossover study with two intervention periods of six weeks' duration separated by a five week washout. Setting-Community setting in New Zealand. Subjects-49 volunteers with polygenic hypercholesterolaemia and baseline total cholesterol concentration in the range 5.5-7.9 mmol/l. Main outcome measures-Concentrations of total and low density lipoprotein, Lp(a) lipoprotein, high density lipoprotein, apolipoprotein B 100, and apolipoprotein A I. Results-Concentrations of low density lipoprotein cholesterol and apolipoprotein B were about 10% lower with margarine than with butter. Lp(a) lipoprotein and high density lipoprotein cholesterol concentrations were similar with the two diets. Conclusion-Despite concerns about adverse effects on lipoproteins of trans fatty acids in margarines, the use of unsaturated margarine rather than butter by hypercholesterolaemic people is associated with a lipoprotein profile that would be expected to reduce cardiovascular risk.	UNIV OTAGO,DEPT HUMAN NUTR,DUNEDIN,NEW ZEALAND; UNIV OTAGO,DEPT MED,DUNEDIN,NEW ZEALAND; LINCOLN UNIV,CTR COMP & BIOMETR,CANTERBURY,NEW ZEALAND	University of Otago; University of Otago; Lincoln University - New Zealand			Skeaff, Clark/C-2713-2009					ASSMAN G, 1993, CLIN CHEM, V29, P2026; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BROOK JG, 1989, EUR HEART J, V10, P702, DOI 10.1093/oxfordjournals.eurheartj.a059554; CONNOR WE, 1989, ARTERIOSCLEROSIS S, V1, P91; FOLEY M, 1992, EUR J CLIN NUTR, V46, P429; FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499; FUMERON F, 1991, AM J CLIN NUTR, V53, P655, DOI 10.1093/ajcn/53.3.655; GRUNDY SM, 1990, J LIPID RES, V31, P1149; HOLUB BJ, 1987, METHOD ENZYMOL, V141, P234; MATTSON FH, 1985, J LIPID RES, V26, P194; MENSINK RP, 1990, NEW ENGL J MED, V323, P439, DOI 10.1056/NEJM199008163230703; MENSINK RP, 1992, J LIPID RES, V33, P1493; NESTEL P, 1992, J LIPID RES, V33, P1029; SACKS FM, 1986, ARCH INTERN MED, V146, P1573, DOI 10.1001/archinte.146.8.1573; THOLSTRUP T, 1994, AM J CLIN NUTR, V60, P919, DOI 10.1093/ajcn/60.6.919; WAHLE KWJ, 1993, EUR J CLIN NUTR, V47, P828; WILLETT WC, 1993, LANCET, V341, P581, DOI 10.1016/0140-6736(93)90350-P; WOOD R, 1993, J LIPID RES, V34, P1; ZOCK PL, 1992, J LIPID RES, V33, P399; 1994, CIRCULATION, V89, P1336; 1991, ARCH INTERN MED, V151, P1071; 1992, NUTR METAB, V2, P113	22	40	41	0	6	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 13	1996	312	7036					931	934						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UF659	8616303	Green Published			2022-12-28	WOS:A1996UF65900015
J	Becker, L; Poreda, RJ; Bada, JL				Becker, L; Poreda, RJ; Bada, JL			Extraterrestrial helium trapped in fullerenes in the sudbury impact structure	SCIENCE			English	Article							ION-MOLECULE REACTIONS; CIRCUMSTELLAR CHEMISTRY; ALLENDE METEORITE; ORGANIC-MOLECULES; INTERSTELLAR; CARBON; PARTICLES; DELIVERY; ORIGINS; GASES	Fullerenes (C-60 and C-70) in the Sudbury impact structure contain trapped helium with a He-3/He-4 ratio of 5.5 x 10(-4) to 5.9 x 10(-4). The He-3/He-4 ratio exceeds the accepted solar wind value by 20 to 30 percent and is higher by an order of magnitude than the maximum reported mantle value, Terrestrial nuclear reactions or cosmic-ray bombardment are not sufficient to generate such a high ratio. The He-3/He-4 ratios in the Sudbury fullerenes are similar to those found in meteorites and in some interplanetary dust particles. The implication is that the helium within the C-60 molecules at Sudbury is of extraterrestrial origin.	UNIV CALIF SAN DIEGO,SCRIPPS INST OCEANOG,LA JOLLA,CA 92093; UNIV ROCHESTER,DEPT EARTH & ENVIRONM SCI,ROCHESTER,NY 14627	University of California System; University of California San Diego; Scripps Institution of Oceanography; University of Rochester	Becker, L (corresponding author), NASA,AMES RES CTR,DIV SPACE SCI,MOFFETT FIELD,CA 94035, USA.							ALLAMANDOLA LJ, 1989, ASTROPHYS J SUPPL S, V71, P733, DOI 10.1086/191396; ALLEGRE CJ, 1983, NATURE, V303, P762, DOI 10.1038/303762a0; ANDERS E, 1975, SCIENCE, V190, P1262, DOI 10.1126/science.190.4221.1262; ANDERS E, 1993, METEORITICS, V28, P490, DOI 10.1111/j.1945-5100.1993.tb00274.x; BECKER L, 1994, NATURE, V372, P507, DOI 10.1038/372507a0; BECKER L, 1994, SCIENCE, V265, P642, DOI 10.1126/science.11536660; BENKERT JP, 1993, J GEOPHYS RES-PLANET, V98, P13147, DOI 10.1029/93JE01460; BLACK DC, 1969, EARTH PLANET SC LETT, V6, P395, DOI 10.1016/0012-821X(69)90190-3; BOHME DK, 1992, CHEM REV, V92, P1487, DOI 10.1021/cr00015a002; CERLING TE, 1994, ANNU REV EARTH PL SC, V22, P273, DOI 10.1146/annurev.ea.22.050194.001421; CHYBA C, 1992, NATURE, V355, P125, DOI 10.1038/355125a0; CHYBA CF, 1990, SCIENCE, V249, P366, DOI 10.1126/science.11538074; FARLEY KA, 1995, NATURE, V376, P153, DOI 10.1038/376153a0; FOING BH, 1994, NATURE, V369, P296, DOI 10.1038/369296a0; HARE JP, 1992, ACCOUNTS CHEM RES, V25, P106, DOI 10.1021/ar00015a002; HEYMANN D, 1986, J GEOPHYS RES, V91, P135; JIMENEZVASQUEZ HA, IN PRESS J CHEM PHYS; JIMENEZVAZQUEZ HA, 1994, CHEM PHYS LETT, V229, P111, DOI 10.1016/0009-2614(94)01028-5; KRATSCHMER W, 1990, NATURE, V347, P354, DOI 10.1038/347354a0; KROTO H, 1988, SCIENCE, V242, P1139, DOI 10.1126/science.242.4882.1139; KURZ MD, 1983, EARTH PLANET SC LETT, V66, P38; LAL D, 1989, EARTH PLANET SC LETT, V96, P1, DOI 10.1016/0012-821X(89)90118-0; LEWIS RS, 1976, METEORITICS, V11, P320; MAMYRIN BA, 1984, HELIUM ISOTOPESNATUR; MATSUDA JI, 1980, GEOCHIM COSMOCHIM AC, V44, P1861, DOI 10.1016/0016-7037(80)90235-5; NIEMEYER S, 1981, P LUNAR PLANET SCI, V12, P1177; NIER AO, 1992, METEORITICS, V27, P166, DOI 10.1111/j.1945-5100.1992.tb00744.x; NIER AO, 1990, GEOCHIM COSMOCHIM AC, V54, P173, DOI 10.1016/0016-7037(90)90205-Y; OTT U, 1981, GEOCHIM COSMOCHIM AC, V45, P1751, DOI 10.1016/0016-7037(81)90009-0; OZIMA M, 1984, NATURE, V311, P449; Ozima M., 1983, NOBLE GAS GEOCHEMIST; PETRIE S, 1993, ASTRON ASTROPHYS, V271, P662; POREDA RJ, 1992, EARTH PLANET SC LETT, V113, P129, DOI 10.1016/0012-821X(92)90215-H; RISON W, 1983, EARTH PLANET SC LETT, V66, P367; ROBL TL, 1993, ORG GEOCHEM, V20, P249, DOI 10.1016/0146-6380(93)90042-A; SAUNDERS M, 1993, SCIENCE, V259, P1428, DOI 10.1126/science.259.5100.1428; Saunders M, 1996, SCIENCE, V271, P1693, DOI 10.1126/science.271.5256.1693; SMALLEY RE, 1991, J PHYS CHEM-US, V95, P7564; SNOW TP, 1995, SCIENCE, V270, P1455, DOI 10.1126/science.270.5241.1455; SWART PK, 1983, SCIENCE, V220, P406, DOI 10.1126/science.220.4595.406; SWINDLE TD, 1988, METEORITES EARLY SOL, P535; TIELENS AGGM, 1990, NASA CONF P, V3061, P59; WEISKE T, 1991, CHEM PHYS LETT, V193, P97; ZINNER E, 1995, METEORITICS, V30, P209, DOI 10.1111/j.1945-5100.1995.tb01115.x; ZINNER E, 1990, LUNAR PLANET SCI, V21, P1379	45	78	84	0	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 12	1996	272	5259					249	252		10.1126/science.272.5259.249	http://dx.doi.org/10.1126/science.272.5259.249			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UE729	8602508	Green Published			2022-12-28	WOS:A1996UE72900036
J	Damasio, H; Grabowski, TJ; Tranel, D; Hichwa, RD; Damasio, AR				Damasio, H; Grabowski, TJ; Tranel, D; Hichwa, RD; Damasio, AR			A neural basis for lexical retrieval	NATURE			English	Article							BRAIN; SYSTEMS; ORGANIZATION; RECOGNITION; LANGUAGE; APHASIA; ANATOMY; SPEECH; NOUNS; VERBS	Two parallel studies using positron emission tomography, one conducted in neurological patients with brain lesions, the other in normal individuals, indicate that the normal process of retrieving words that denote concrete entities depends in part on multiple regions of the left cerebral hemisphere, located outside the classic language areas. Moreover, anatomically separable regions tend to process words for distinct kinds of items.	UNIV IOWA, COLL MED, DEPT NEUROL, DIV BEHAV NEUROL & COGNIT NEUROSCI, IOWA CITY, IA 52242 USA; UNIV IOWA, COLL MED, POSITRON EMISS TOMOG IMAGING CTR, IOWA CITY, IA 52242 USA; SALK INST BIOL STUDIES, LA JOLLA, CA 92186 USA	University of Iowa; University of Iowa; Salk Institute			Damasio, Antonio/AAD-1342-2019	Tranel, Daniel/0000-0002-1338-1389				ALBERT MS, 1979, ARCH NEUROL-CHICAGO, V36, P211, DOI 10.1001/archneur.1979.00500400065010; CARAMAZZA A, 1991, NATURE, V349, P788, DOI 10.1038/349788a0; Damasio A., 1994, LARGE SCALE NEURONAL, P61; DAMASIO AR, 1993, P NATL ACAD SCI USA, V90, P4957, DOI 10.1073/pnas.90.11.4957; DAMASIO AR, 1992, NEW ENGL J MED, V326, P531, DOI 10.1056/NEJM199202203260806; DAMASIO AR, 1982, NEUROLOGY, V32, P331, DOI 10.1212/WNL.32.4.331; DAMASIO AR, 1989, COGNITION, V33, P25, DOI 10.1016/0010-0277(89)90005-X; DAMASIO AR, 1992, SCI AM, V267, P89; DAMASIO AR, 1990, S QUANTITATIVE BIOL, V55, P1039; DAMASIO H, 1992, ARCH NEUROL-CHICAGO, V49, P137, DOI 10.1001/archneur.1992.00530260037016; DAMASIO H, 1993, INT CONGR SER, V1030, P465; DANIELE A, 1994, NEUROPSYCHOLOGIA, V32, P1325, DOI 10.1016/0028-3932(94)00066-2; DEHAENE S, 1995, NEUROREPORT, V6, P2153, DOI 10.1097/00001756-199511000-00014; DEMONET JF, 1992, BRAIN, V115, P1753, DOI 10.1093/brain/115.6.1753; Friston K J, 1994, Hum Brain Mapp, V1, P210, DOI 10.1002/hbm.460010306; FRISTON KJ, 1991, J CEREBR BLOOD F MET, V11, P690, DOI 10.1038/jcbfm.1991.122; GARRETT M, 1992, COGNITION, V42, P143, DOI 10.1016/0010-0277(92)90042-G; GOODGLASS H, 1986, CORTEX, V22, P87, DOI 10.1016/S0010-9452(86)80034-X; GRABOWSKI TJ, IN PRESS HUM BRAIN M; GRABOWSKI TJ, 1995, HUM BRAIN MAPP, V2, P123, DOI DOI 10.1002/HBM.460020302; HART J, 1992, NATURE, V359, P60, DOI 10.1038/359060a0; HART J, 1985, NATURE, V316, P439, DOI 10.1038/316439a0; HERSCOVITCH P, 1983, J NUCL MED, V24, P782; HICHWA RD, 1995, CHEMISTS' VIEWS OF IMAGING CENTERS, P401; HILLIS AE, 1991, BRAIN, V114, P2081, DOI 10.1093/brain/114.5.2081; HILLIS AE, 1995, J COGNITIVE NEUROSCI, V7, P396, DOI 10.1162/jocn.1995.7.3.396; Kosslyn S. M., 1994, IMAGE BRAIN; LEVELT WJM, 1992, COGNITION, V42, P1, DOI 10.1016/0010-0277(92)90038-J; MARTIN A, 1995, SCIENCE, V270, P102, DOI 10.1126/science.270.5233.102; Martin A, 1996, NATURE, V379, P649, DOI 10.1038/379649a0; MAZOYER BM, 1993, J COGNITIVE NEUROSCI, V5, P467, DOI 10.1162/jocn.1993.5.4.467; MCCARTHY RA, 1988, NATURE, V334, P428, DOI 10.1038/334428a0; MCKENNA P, 1994, NEUROPSYCHOL REHABIL, V4, P255; NOBRE AC, 1994, NATURE, V372, P260, DOI 10.1038/372260a0; OJEMANN GA, 1991, J NEUROSCI, V11, P2281; Ono M, 1990, ATLAS CEREBRAL SULCI; Perani D., 1995, Society for Neuroscience Abstracts, V21, P1498; PETERSEN SE, 1988, NATURE, V331, P585, DOI 10.1038/331585a0; RAICHLE ME, 1994, CEREB CORTEX, V4, P8, DOI 10.1093/cercor/4.1.8; SEMENZA C, 1989, NATURE, V342, P678, DOI 10.1038/342678a0; SERGENT J, 1992, BRAIN, V115, P15, DOI 10.1093/brain/115.1.15; Smith EE, 1981, CATEGORIES CONCEPTS; SNODGRASS JG, 1980, J EXP PSYCHOL-HUM L, V6, P174, DOI 10.1037/0278-7393.6.2.174; Talairach J., 1988, COPLANAR STEREOTAXIC; TRANEL D, 1995, J COGNITIVE NEUROSCI, V7, P425, DOI 10.1162/jocn.1995.7.4.425; Tranel D., 1995, Society for Neuroscience Abstracts, V21, P1497; WARRINGTON EK, 1983, BRAIN, V106, P859, DOI 10.1093/brain/106.4.859; WOODS RP, 1993, J COMPUT ASSIST TOMO, V17, P536, DOI 10.1097/00004728-199307000-00004; WORSLEY KJ, 1994, ADV APPL PROBAB, V26, P13, DOI 10.2307/1427576	49	1092	1111	1	142	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	APR 11	1996	380	6574					499	505		10.1038/380499a0	http://dx.doi.org/10.1038/380499a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UE663	8606767				2022-12-28	WOS:A1996UE66300041
J	Deckert, T; Yokoyama, H; Mathiesen, E; Ronn, B; Jensen, T; FeldtRasmussen, B; BorchJohnsen, K; Jensen, JS				Deckert, T; Yokoyama, H; Mathiesen, E; Ronn, B; Jensen, T; FeldtRasmussen, B; BorchJohnsen, K; Jensen, JS			Cohort study of predictive value of urinary albumin excretion for atherosclerotic vascular disease in patients with insulin dependent diabetes	BRITISH MEDICAL JOURNAL			English	Article							INCIPIENT NEPHROPATHY; DENSITY-LIPOPROTEIN; BLOOD-PRESSURE; RISK-FACTORS; MICROALBUMINURIA; MORTALITY; MELLITUS; HYPERTENSION; PREVALENCE; NIDDM	Objective-To examine whether slightly elevated urinary albumin excretion precedes development of atherosclerotic vascular disease in patients with insulin dependent diabetes independently of conventional atherogenic risk factors and of diabetic nephropathy. Design-Cohort study with 11 year follow up. Setting-Diabetes centre in Denmark. Subjects-259 patients aged 19-51 with insulin dependent diabetes of 6-34 years' duration and without atherosclerotic vascular disease or diabetic nephropathy at baseline. Main outcome measures-Baseline variables: urinary albumin excretion, blood pressure, smoking habits, and serum concentrations of total cholesterol, high density lipoprotein cholesterol, sialic acid, and von Willebrand factor. End point: atherosclerotic vascular disease assessed by death certificates, mailed questionnaires, and hospital records. Results-Thirty patients developed atherosclerotic vascular disease during follow up of 2457 person years. Elevated urinary albumin excretion was significantly predictive of atherosclerotic vascular disease (hazard ratio 1.06 (95% confidence interval 1.02 to 1.18) per 5 mg increase in 24 hour urinary albumin excretion, P=0.002). Predictive effect was independent of age; sex; blood pressure; smoking; serum concentrations of total cholesterol, high density lipoprotein cholesterol, sialic acid, and von Willebrand factor; level of haemoglobin A(1c); insulin dose; duration of diabetes; and diabetic nephropathy (hazard ratio 1.04 (1.01 to 1.08) per 5 mg increase in 24 hour urinary albumin excretion, P=0.03). Conclusion-Slightly elevated urinary albumin excretion independently predicted atherosclerotic vascular disease in patients with insulin dependent diabetes.	STENO DIABET CTR,DK-2820 GENTOFTE,DENMARK	Steno Diabetes Center				Mathiesen, elisabeth/0000-0003-3279-0863; Feldt-Rasmussen, Bo/0000-0002-8267-3027				BORCHJOHNSEN K, 1985, DIABETOLOGIA, V28, P590, DOI 10.1007/BF00281993; BORCHJOHNSEN K, 1987, BRIT MED J, V294, P1561; CASTELLO M, 1979, NATURE, V281, P677; CHASE HP, 1991, JAMA-J AM MED ASSOC, V265, P614, DOI 10.1001/jama.265.5.614; CROOK MA, 1994, DIABETES CARE, V17, P305, DOI 10.2337/diacare.17.4.305; DAMSGAARD EM, 1992, KIDNEY INT, V41, P731; DAMSGAARD EM, 1990, BRIT MED J, V300, P297, DOI 10.1136/bmj.300.6720.297; DECKERT T, 1989, DIABETOLOGIA, V32, P219, DOI 10.1007/BF00285287; DECKERT T, 1991, CARDIOVASCULAR RISK, V1, P154; Feldt-Rasmussen B, 1984, DIABETIC NEPHROPATHY, V3, P101; FELDTRASMUSSEN B, 1986, LANCET, V2, P1300; FELDTRASMUSSEN B, 1987, DIABETOLOGIA, V30, P610; INGERSLEV J, 1987, SCAND J CLIN LAB INV, V47, P143; Jarrett R J, 1984, Diabet Med, V1, P17; JARRETT RJ, 1989, DIABETES METAB REV, V5, P547, DOI 10.1002/dmr.5610050702; JENSEN G, 1983, ACTA MED SCAND S682, V214, P1; JENSEN T, 1988, DIABETOLOGIA, V31, P142, DOI 10.1007/BF00276846; JENSEN T, 1989, BRIT MED J, V298, P27, DOI 10.1136/bmj.298.6665.27-a; JENSEN T, 1987, DIABETOLOGIA, V30, P144, DOI 10.1007/BF00274218; JENSEN T, 1989, SCAND J CLIN LAB INV, V49, P589, DOI 10.3109/00365518909089140; JENSEN T, 1989, LANCET, V1, P461; JENSEN T, 1989, NEW ENGL J MED, V321, P1572, DOI 10.1056/NEJM198912073212304; JONES SL, 1989, BRIT MED J, V298, P487, DOI 10.1136/bmj.298.6672.487; LINDBERG G, 1991, BRIT MED J, V302, P143, DOI 10.1136/bmj.302.6769.143; Mancini G, 1965, Immunochemistry, V2, P235, DOI 10.1016/0019-2791(65)90004-2; MATHIESEN ER, 1990, DIABETES, V39, P245, DOI 10.2337/diabetes.39.2.245; MATHIESEN ER, 1984, DIABETOLOGIA, V26, P406; MATTOCK MB, 1992, DIABETES, V41, P736, DOI 10.2337/diabetes.41.6.736; MESSENT JWC, 1992, KIDNEY INT, V41, P836, DOI 10.1038/ki.1992.128; MORRISH NJ, 1990, DIABETOLOGIA, V33, P538, DOI 10.1007/BF00404141; NEIL A, 1993, DIABETES CARE, V16, P996, DOI 10.2337/diacare.16.7.996; NORGAARD K, 1990, DIABETOLOGIA, V33, P407, DOI 10.1007/BF00404089; OREKHOV AN, 1991, ATHEROSCLEROSIS, V86, P153, DOI 10.1016/0021-9150(91)90211-K; PARVING HH, 1988, BMJ-BRIT MED J, V296, P156, DOI 10.1136/bmj.296.6616.156; ROSE GA, 1962, B WORLD HEALTH ORGAN, V27, P546; SCHAUER R, 1982, ADV CARBOHYD CHEM BI, V40, P131, DOI 10.1016/S0065-2318(08)60109-2; SCHMITZ A, 1988, DIABETIC MED, V5, P1126; SCHNITZER JE, 1992, AM J PHYSIOL, V32, pH48; SCHROLL M, 1982, DAN MED BULL, V29, P213; SIMPSON H, 1993, BRIT J BIOMED SCI, V50, P164; SVENDSEN PA, 1980, DIABETOLOGIA, V19, P130, DOI 10.1007/BF00421859; TELMER S, 1984, ACTA MED SCAND, V215, P63; Torffvit Ole, 1993, Journal of Diabetes and its Complications, V7, P49, DOI 10.1016/1056-8727(93)90024-S; WISEMAN M, 1984, DIABETOLOGIA, V26, P401; YOKOYAMA H, 1995, J INTERN MED, V237, P519, DOI 10.1111/j.1365-2796.1995.tb00878.x; YUDKIN JS, 1988, LANCET, V2, P530	46	156	159	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 6	1996	312	7035					871	874						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UE371	8611873				2022-12-28	WOS:A1996UE37100017
J	Kalluri, R; Petrides, S; Wilson, CB; Tomaszewski, JE; Palevsky, HI; Grippi, MA; Madaio, MP; Neilson, EG				Kalluri, R; Petrides, S; Wilson, CB; Tomaszewski, JE; Palevsky, HI; Grippi, MA; Madaio, MP; Neilson, EG			Anti-alpha 1(IV) collagen autoantibodies associated with lung adenocarcinoma presenting as the Goodpasture syndrome	ANNALS OF INTERNAL MEDICINE			English	Article									UNIV PENN, PENN CTR MOL STUDIES KIDNEY DIS, RENAL ELECTROLYTE & HYPERTENS DIV, DEPT MED, PHILADELPHIA, PA 19104 USA; Scripps Res Inst, DEPT IMMUNOL, LA JOLLA, CA 92037 USA	University of Pennsylvania; Scripps Research Institute			Kalluri, Raghu/E-2677-2015	Kalluri, Raghu/0000-0002-2190-547X	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007006, R01DK030280, P50DK045191, R37DK030280] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-45191, DK-30280, DK-07006] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AZNAVOORIAN S, 1993, CANCER-AM CANCER SOC, V71, P1368, DOI 10.1002/1097-0142(19930215)71:4<1368::AID-CNCR2820710432>3.0.CO;2-L; BAILEY RR, 1981, CLIN NEPHROL, V15, P211; Isobe H, 1993, Nihon Hinyokika Gakkai Zasshi, V84, P457; KALLURI R, 1994, P NATL ACAD SCI USA, V91, P6201, DOI 10.1073/pnas.91.13.6201; KALLURI R, 1994, J AM SOC NEPHROL, V6, P1199; MEYERS CM, IN PRESS IMMUNOLOGIC; NEILSON EG, 1993, J BIOL CHEM, V268, P8402; WILSON CB, 1991, KIDNEY, V1, P1062; WILSON CB, 1980, MANUAL CLIN IMMUNOLO, P376; YUDOH K, 1994, JPN J CANCER RES, V85, P1263, DOI 10.1111/j.1349-7006.1994.tb02939.x	10	23	25	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 1	1996	124	7					651	653		10.7326/0003-4819-124-7-199604010-00005	http://dx.doi.org/10.7326/0003-4819-124-7-199604010-00005			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UB513	8607593				2022-12-28	WOS:A1996UB51300005
J	Pedrini, MT; Levey, AS; Lau, J; Chalmers, TC; Wang, PH				Pedrini, MT; Levey, AS; Lau, J; Chalmers, TC; Wang, PH			The effect of dietary protein restriction on the progression of diabetic and nondiabetic renal diseases: A meta-analysis	ANNALS OF INTERNAL MEDICINE			English	Article						dietary proteins; meta-analysis; kidney failure, chronic; diabetic nephropathies; albuminuria	CLINICAL-TRIALS; NEPHROPATHY; FAILURE; INSUFFICIENCY; METAANALYSIS	Background: Dietary protein has long been thought to play a role in the progression of chronic renal disease, but clinical trials to date have not consistently shown that dietary protein restriction is beneficial. Purpose: To use meta-analysis to assess the efficacy of dietary protein restriction in previously published studies of diabetic and nondiabetic renal diseases, including the recently completed Modification of Diet in Renal Disease Study. Data Sources: The English-language medical literature published from January 1966 through December 1994 was searched for studies examining the effect of low-protein diets in humans with chronic renal disease. A total of 1413 patients in five studies of nondiabetic renal disease (mean length of follow-up, 18 to 36 months) and 108 patients in five studies of type I diabetes mellitus (mean length of follow-up, 9 to 35 months) were included. Study Selection: Randomized, controlled studies were selected for nondiabetic renal disease; randomized, controlled studies or time-controlled stud ies with non randomized crossover design were selected for diabetic nephropathy. Data Extraction: Data in tables, figures, or text were independently extracted by two of the authors. Data Synthesis: The relative risk for progression of renal disease in patients receiving a low-protein diet compared with patients receiving a usual-protein diet was calculated by using a random-effects model. In five studies of nondiabetic renal disease, a low-protein diet significantly reduced the risk for renal failure or death (relative risk, 0.67 [95% CI, 0.50 to 0.89]). In five studies of insulin-dependent diabetes mellitus, a low-protein diet significantly slowed the increase in urinary albumin level or the decline in glomerular filtration rate or creatinine clearance (relative risk, 0.56 [CI, 0.40 to 0.77]). Tests for heterogeneity showed no significant differences in relative risk among studies of either diabetic or nondiabetic renal disease. No significant differences were seen between diet groups in pooled mean arterial blood pressure (diabetic and nondiabetic patients) or glycosylated hemoglobin level (diabetic patients only). Conclusion: Dietary protein restriction effectively slows the progression of both diabetic and nondiabetic renal diseases.	TUFTS UNIV NEW ENGLAND MED CTR, DEPT MED, DIV NEPHROL, BOSTON, MA 02111 USA; TUFTS UNIV NEW ENGLAND MED CTR, DIV CLIN CARE RES, BOSTON, MA 02111 USA; UNIV CALIF IRVINE, DEPT BIOL CHEM, IRVINE, CA 92717 USA	Tufts Medical Center; Tufts Medical Center; University of California System; University of California Irvine								BARSOTTI G, 1988, CLIN NEPHROL, V29, P280; BRENNER BM, 1983, KIDNEY INT, V23, P647, DOI 10.1038/ki.1983.72; CLAVARELLA A, 1987, DIABETES CARE, V10, P407; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; DONNER A, 1984, STAT MED, V3, P199, DOI 10.1002/sim.4780030302; DULLAART RPF, 1993, DIABETES CARE, V16, P483, DOI 10.2337/diacare.16.2.483; FOUQUE D, 1992, BMJ-BRIT MED J, V304, P216, DOI 10.1136/bmj.304.6821.216; IHLE BU, 1989, NEW ENGL J MED, V321, P1773, DOI 10.1056/NEJM198912283212601; JUNGERS P, 1987, KIDNEY INT, V32, pS67; KLAHR S, 1994, NEW ENGL J MED, V330, P877, DOI 10.1056/NEJM199403313301301; LAU J, 1992, NEW ENGL J MED, V327, P248, DOI 10.1056/NEJM199207233270406; LEVEY AS, 1990, KIDNEY INT, V38, P167, DOI 10.1038/ki.1990.182; LEVEY AS, 1996, IN PRESS AM J KIDNEY; LEWIS EJ, 1993, NEW ENGL J MED, V329, P1456, DOI 10.1056/NEJM199311113292004; LOCATELLI F, 1991, LANCET, V337, P1299, DOI 10.1016/0140-6736(91)92977-A; PARVING HH, 1985, HYPERTENSION, V7, P114; ROBINS J, 1986, AM J EPIDEMIOL, V124, P719, DOI 10.1093/oxfordjournals.aje.a114447; ROSMAN JB, 1989, KIDNEY INT, V36, pS96; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; STRIKER G, 1995, J AM SOC NEPHROL, V5, P1537; VIBERTI G, 1994, JAMA-J AM MED ASSOC, V271, P275, DOI 10.1001/jama.271.4.275; WALKER JD, 1989, LANCET, V2, P1411; WANG PH, 1993, LANCET, V341, P1306, DOI 10.1016/0140-6736(93)90816-Y; WILLIAMS PS, 1991, Q J MED, V81, P837; ZELLER K, 1991, NEW ENGL J MED, V324, P78, DOI 10.1056/NEJM199101103240202	25	487	519	0	11	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 1	1996	124	7					627	+		10.7326/0003-4819-124-7-199604010-00002	http://dx.doi.org/10.7326/0003-4819-124-7-199604010-00002			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UB513	8607590				2022-12-28	WOS:A1996UB51300002
J	Guo, ZC; Viitanen, M; Fratiglioni, L; Winblad, B				Guo, ZC; Viitanen, M; Fratiglioni, L; Winblad, B			Low blood pressure and dementia in elderly people: The Kungsholmen project	BRITISH MEDICAL JOURNAL			English	Article							ALZHEIMERS-DISEASE; POPULATION SURVEY; SENILE DEMENTIA; FLOW; DISORDER; GLUCOSE; SCALE; AGE	Objective-To examine the relation between blood pressure and dementia in elderly people. Design-Cross sectional, population based study. Setting-Kungsholmen district of Stockholm, Sweden. Subjects-1642 subjects aged 75-101 years. Main outcome measures-Prevalence and adjusted odds ratio of dementia by blood pressure. Results-People with systolic pressure less than or equal to 140 mmHg were more often diagnosed as demented than those with systolic pressure >140 mmHg: odds ratios (95% confidence interval) adjusted for age, sex, and education were 2.98 (2.17 to 4.08) for all dementias, 2.91 (1.93 to 4.38) for Alzheimer's disease, 2.00 (1.09 to 3.65) for vascular dementia, and 5.07 (2.65 to 9.70) for other dementias. Similar results were seen in subjects with diastolic pressure less than or equal to 75 mmHg compared with those with higher diastolic pressure. When severity and duration of dementia were taken into account, only moderate and severe dementia were found to be significantly related to relatively low blood pressure, and the association was stronger in subjects with longer disease duration. Use of hypotensive drugs and comorbidity with cardiovascular disease did not modify the results for all dementias, Alzheimer's disease, and other dementias but slightly reduced the association between vascular dementia and diastolic blood pressure. Conclusions-Both systolic and diastolic blood pressure were inversely related to prevalence of dementia in elderly people. We think that relatively low blood pressure is probably a complication of the dementia process, particularly Alzheimer's disease, although it is possible that low blood pressure may predispose a subpopulation to developing dementia.	KAROLINSKA INST,DEPT GERIATR MED,S-11382 STOCKHOLM,SWEDEN	Karolinska Institutet	Guo, ZC (corresponding author), STOCKHOLM GERONTOL RES CTR,DALAGATAN 9-11,S-11382 STOCKHOLM,SWEDEN.		Viitanen, Matti/AAY-5163-2020	Landin-Wilhelmsen, Kerstin/0000-0003-1998-5105				American Psychiatric Association, 1987, DIAGN STAT MAN MENT; [Anonymous], 1990, GUID ATC CLASS; ARONSON MK, 1993, ALZHEIMERS DIS ADV C, P55; BOTS ML, 1991, EPIDEMIOL REV, V13, P294, DOI 10.1093/oxfordjournals.epirev.a036073; BROWN WD, 1991, ALZ DIS ASSOC DIS, V5, P131, DOI 10.1097/00002093-199100520-00010; BUCHT G, 1983, ACTA MED SCAND, V213, P387; BURKE WJ, 1994, J AUTONOM NERV SYST, V48, P65, DOI 10.1016/0165-1838(94)90160-0; ELMSTAHL S, 1992, AGE AGEING, V21, P301, DOI 10.1093/ageing/21.4.301; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; FORETTE F, 1991, AM J MED, V90, pS14, DOI 10.1016/0002-9343(91)90430-6; FORSELL Y, 1992, ACTA PSYCHIAT SCAND, V86, P49, DOI 10.1111/j.1600-0447.1992.tb03225.x; FRATIGLIONI L, 1991, NEUROLOGY, V41, P1886, DOI 10.1212/WNL.41.12.1886; FRATIGLIONI L, 1992, ARCH NEUROL-CHICAGO, V49, P927, DOI 10.1001/archneur.1992.00530330049015; FRATIGLIONI L, 1992, NEUROEPIDEMIOLOGY, V11, P29, DOI 10.1159/000110958; HACHINSKI VC, 1975, ARCH NEUROL-CHICAGO, V32, P632, DOI 10.1001/archneur.1975.00490510088009; HARDY J, 1985, NEUROCHEM INT, V7, P545, DOI 10.1016/0197-0186(85)90050-6; HUGHES CP, 1982, BRIT J PSYCHIAT, V140, P566, DOI 10.1192/bjp.140.6.566; LANDIN K, 1993, J INTERN MED, V233, P357, DOI 10.1111/j.1365-2796.1993.tb00684.x; OBRIEN JT, 1992, J NEUROL NEUROSUR PS, V55, P1182, DOI 10.1136/jnnp.55.12.1182; OBRIEN MD, 1994, DEMENTIA, V5, P133, DOI 10.1159/000106710; ROMAN GC, 1987, JAMA-J AM MED ASSOC, V258, P1782, DOI 10.1001/jama.258.13.1782; SCHEINBERG P, 1988, STROKE, V19, P1291, DOI 10.1161/01.STR.19.10.1291; *SPSS, 1994, SPSS ADV STAT 6 1; STRANDGAARD S, 1994, LANCET, V344, P519, DOI 10.1016/S0140-6736(94)91903-8; SULKAVA R, 1987, ACTA NEUROL SCAND, V76, P123, DOI 10.1111/j.1600-0404.1987.tb03555.x; VANDUIJN CM, 1991, BRIT MED J, V302, P1491, DOI 10.1136/bmj.302.6791.1491	26	233	239	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 30	1996	312	7034					805	808		10.1136/bmj.312.7034.805	http://dx.doi.org/10.1136/bmj.312.7034.805			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UD378	8608286	Green Published			2022-12-28	WOS:A1996UD37800021
J	Prince, MJ; Bird, AS; Blizard, RA; Mann, AH				Prince, MJ; Bird, AS; Blizard, RA; Mann, AH			Is the cognitive function of older patients affected by antihypertensive treatment? Results from 54 months of the Medical Research Council's treatment trial of hypertension in older adults	BMJ-BRITISH MEDICAL JOURNAL			English	Article							BLOOD-PRESSURE LEVEL; PERFORMANCE; INTELLIGENCE; REDUCTION; DECLINE	Objective-To establish whether initiation of treatment with diuretic or beta blocker is associated over 54 months with change in cognitive function. Design-A cognitive substudy, nested within a randomised, placebo controlled, single blind trial. Setting-226 general practices hom the Medical Research Council's general practice research framework. Subjects-A subset of 2584 subjects sequentially recruited from among the 4396 participants aged 65-74 in the trial of treatment of hypertension in older adults. The 4396 subjects were randomised to receive diuretic, beta blocker, or placebo. Subjects had mean systolic pressures of 160-209 mm Hg and mean diastolic pressures <115 mm Hg during an eight week run in. Outcome measures-The rate of change in paired associate learning test (PALT) and trail making test part A (TMT) scores (administered at entry and at 1, 9, 21, and 54 months) over time. Results-There was no difference in the mean learning test coefficients (rate of change of score over time) between the three treatments: diuretic -0.31 (95% confidence interval -0.23 to -0.39), beta blocker -0.33 (-0.25 to -0.41), placebo -0.30, (-0.24 to -0.36). There was also no difference in the mean trail making coefficients (rate of change in time taken to complete over time) between the three groups: diuretic -2.73 (95% confidence interval -3.57 to -1.88), beta blocker -2.08 (-3.29 to -0.87), placebo -3.01, (-3.69 to -2.32). A less conservative protocol analysis confirmed this negative finding. Conclusion-Treating moderate hypertension in older people is unlikely to influence, for better or for worse, subsequent cognitive function.	ROYAL FREE HOSP, ACAD DEPT PSYCHIAT, LONDON NW3 2QG, ENGLAND	University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School	Prince, MJ (corresponding author), INST PSYCHIAT, SECT EPIDEMIOL & GEN PRACTICE, LONDON SE5 8AF, ENGLAND.		Prince, Martin J/A-9170-2010; mann, anthony/A-8911-2011	Prince, Martin J/0000-0003-1379-7146; 	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		[Anonymous], 1991, JAMA, V265, P3255; BIRD AS, 1990, J HYPERTENS, V8, P147, DOI 10.1097/00004872-199002000-00008; BIRD AS, 1987, INT J GERIATR PSYCH, V2, P31, DOI 10.1002/gps.930020106; BRETELER MMB, 1994, STROKE, V25, P1109, DOI 10.1161/01.STR.25.6.1109; ELIAS MF, 1993, AM J EPIDEMIOL, V138, P353, DOI 10.1093/oxfordjournals.aje.a116868; FARMER ME, 1990, J CLIN EPIDEMIOL, V43, P475, DOI 10.1016/0895-4356(90)90136-D; FARMER ME, 1987, AM J EPIDEMIOL, V126, P1103, DOI 10.1093/oxfordjournals.aje.a114749; FARNETT L, 1991, JAMA-J AM MED ASSOC, V265, P489, DOI 10.1001/jama.265.4.489; INGLIS J, 1959, J MENT SCI, V105, P440, DOI 10.1192/bjp.105.439.440; LITTLE A, 1987, BRIT J PSYCHIAT, V150, P808, DOI 10.1192/bjp.150.6.808; McWhinney IR, 1989, TXB FAMILY MED; MEADE TW, 1992, BMJ-BRIT MED J, V304, P405; *NAT CTR HLTH STAT, 1991, DHHS PHS PUBL, P85; NELSON HE, 1978, CORTEX, V14, P234, DOI 10.1016/S0010-9452(78)80049-5; Raven John C, 1940, Ment Health (Lond), V1, P10; Reltan R., 1959, PERCEPT MOTOR SKILL, V8, P271; SCHMIDT R, 1993, NEUROLOGY, V43, P2490, DOI 10.1212/WNL.43.12.2490; VANSWIETEN JC, 1991, ANN NEUROL, V30, P825, DOI 10.1002/ana.410300612; WAKLSTEIN SR, 1991, J CONSULT CLIN PSYCH, V59, P513; WILKIE F, 1971, SCIENCE, V172, P959, DOI 10.1126/science.172.3986.959; 1979, JAMA-J AM MED ASSOC, V242, P2572; 1981, MED J AUSTRALIA, V2, P398	22	246	257	0	6	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAR 30	1996	312	7034					801	805						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UD378	8608285				2022-12-28	WOS:A1996UD37800020
J	Bland, JM; Altman, DG				Bland, JM; Altman, DG			Statistics notes - Transforming data .17.	BRITISH MEDICAL JOURNAL			English	Article									INST HLTH SCI,CTR STAT MED,IMPERIAL CANC RES FUND,MED STAT GRP,OXFORD OX3 7LF,ENGLAND	University of Oxford	Bland, JM (corresponding author), UNIV LONDON ST GEORGES HOSP,SCH MED,DEPT PUBL HLTH SCI,LONDON SW17 0RE,ENGLAND.							ALTMAN DG, 1995, BRIT MED J, V310, P298, DOI 10.1136/bmj.310.6975.298; Bland JM, 1996, BRIT MED J, V312, P700	2	221	224	0	14	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 23	1996	312	7033					770	770						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UC166	8605469				2022-12-28	WOS:A1996UC16600043
J	Lahdensuo, A; Haahtela, T; Herrala, J; Kava, T; Kiviranta, K; Kuusisto, P; Peramaki, E; Poussa, T; Saarelainen, S; Svahn, T				Lahdensuo, A; Haahtela, T; Herrala, J; Kava, T; Kiviranta, K; Kuusisto, P; Peramaki, E; Poussa, T; Saarelainen, S; Svahn, T			Randomised comparison of guided self management and traditional treatment of asthma over one year	BRITISH MEDICAL JOURNAL			English	Article							GENERAL-PRACTICE; ADULT ASTHMA; PEAK FLOW; EDUCATION; TRIAL	Objective-To compare the efficacy of self management of asthma with traditional treatment. Design-12 month prospective randomised trial. Setting-Outpatient clinics in Finland. Subjects-115 patients with mild to moderately severe asthma. Interventions-Patient education and adjustment of anti-inflammatory therapy guided by peak flow measurements. Main outcome measures-Unscheduled admissions to hospital and outpatient visits, days off work, courses of antibiotics and prednisolone, lung function, and quality of life. Results-The mean number of unscheduled visits to ambulatory care facilities (0.5 v 1.0), days off work (2.8 v 4.8), and courses of antibiotics (0.4 v 0.9) and prednisolone (0.4 v 1.0) per patient were lower and the quality of life score (16.6 v 8.4 at 12 months) higher in the self management group than in the traditionally treated group. In both groups admissions for asthma were rare. Conclusions-Self management reduces incidents caused by asthma and improves quality of life.	UNIV HELSINKI,CENT HOSP,SKIN & ALLERGY HOSP,SF-00250 HELSINKI,FINLAND; CENT HOSP NO KARELIA,DEPT PULM DIS,SF-80780 KONTIONIEMI,FINLAND; STAT CONSULTING,SF-33300 TAMPERE,FINLAND; SUOMEN ASTRA OY,SF-02430 MASALA,FINLAND	University of Helsinki; Helsinki University Central Hospital	Lahdensuo, A (corresponding author), TAMPERE UNIV HOSP,DEPT PULM DIS,SF-36280 PIKONLINNA,FINLAND.		Herrala, Jaakko/L-9797-2013	Herrala, Jaakko/0000-0002-6524-1759				[Anonymous], 1993, THORAX, V48, pS1; Averill B.A., 1980, CIENC BIOL COIMBRA, V5, P167; BAILEY WC, 1990, ARCH INTERN MED, V150, P1664, DOI 10.1001/archinte.150.8.1664; BEASLEY R, 1989, THORAX, V44, P200, DOI 10.1136/thx.44.3.200; BLAINEY AD, 1991, HLTH TRENDS, V22, P151; British Thoracic Association, 1982, BR MED J CLIN RES ED, V285, P1251; CHARLTON I, 1990, BRIT MED J, V301, P1355, DOI 10.1136/bmj.301.6765.1355; DSOUZA W, 1994, EUR RESPIR J, V7, P1260, DOI 10.1183/09031936.94.07071260; HAAHTELA T, 1994, NEW ENGL J MED, V331, P700, DOI 10.1056/NEJM199409153311103; HAAHTELA T, 1991, NEW ENGL J MED, V325, P388, DOI 10.1056/NEJM199108083250603; HARGREAVE FE, 1990, J ALLERGY CLIN IMMUN, V85, P1098, DOI 10.1016/0091-6749(90)90056-A; HILTON S, 1986, LANCET, V1, P26; HUDGEL DW, 1979, AM REV RESPIR DIS, V120, P393; JAMISON JP, 1990, THORAX, V45, pP341; JOHNSON AJ, 1984, BRIT MED J, V288, P1870, DOI 10.1136/bmj.288.6434.1870; JONES PW, 1992, AM REV RESPIR DIS, V145, P1321, DOI 10.1164/ajrccm/145.6.1321; KENDRICK AH, 1993, BRIT MED J, V307, P422, DOI 10.1136/bmj.307.6901.422; KINSMAN RA, 1980, J PSYCHOSOM RES, V24, P97, DOI 10.1016/0022-3999(80)90059-8; KLEIGER JH, 1979, J ASTHMA RES, V16, P93, DOI 10.3109/02770907909106618; MAYO PH, 1990, ANN INTERN MED, V112, P864, DOI 10.7326/0003-4819-112-11-864; *NAT HEART LUNG BL, 1992, NIH PUBL; NICHOLSON KG, 1993, BRIT MED J, V307, P982, DOI 10.1136/bmj.307.6910.982; OSMAN LM, 1994, BRIT MED J, V308, P568, DOI 10.1136/bmj.308.6928.568; PARTRIDGE MR, 1993, RES CLIN FORUMS, V15, P65; REEDER KP, 1990, J ASTHMA, V27, P219, DOI 10.3109/02770909009073330; WILSON SR, 1993, AM J MED, V94, P564, DOI 10.1016/0002-9343(93)90206-5; 1994, BRIT MED J, V308, P564	27	257	264	1	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 23	1996	312	7033					748	752						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UC166	8605463				2022-12-28	WOS:A1996UC16600030
J	Rimm, EB; Klatsky, A; Grobbee, D; Stampfer, MJ				Rimm, EB; Klatsky, A; Grobbee, D; Stampfer, MJ			Review of moderate alcohol consumption and reduced risk of coronary heart disease: Is the effect due to beer, wine, or spirits?	BRITISH MEDICAL JOURNAL			English	Review							HIGH-DENSITY-LIPOPROTEIN; MYOCARDIAL-INFARCTION; ARTERY DISEASE; CARDIOVASCULAR MORTALITY; MEN; CHOLESTEROL; BEVERAGES; WOMEN; RESVERATROL; DRINKERS	Objectives-To review the effect of specific types of alcoholic drink on coronary risk. Design-Systematic review of ecological, case-control, and cohort studies in which specific associations were available for consumption of beer, wine, and spirits and risk of coronary heart disease. Subjects-12 ecological, three case-control, and 10 separate prospective cohort studies. Main outcome measures-Alcohol consumption and relative risk of morbidity and mortality from coronary heart disease. Results-Most ecological studies suggested that wine was more effective in reducing risk of mortality from heart disease than beer or spirits. Taken together, the three case-control studies did not suggest that one type of drink was more cardioprotective than the others. Of the 10 prospective cohort studies, four found a significant inverse association between risk of heart disease and moderate wine drinking, four found such an association for beer, and four for spirits. Conclusions-Results from observational studies, where alcohol consumption can be linked directly to an individual's risk of coronary heart disease, provide strong evidence that all alcoholic drinks are linked with lower risk. Thus, a substantial portion of the benefit is from alcohol rather than other components of each type of drink.	KAISER PERMANENTE MED CTR,OAKLAND,CA; DIV RES GRP,OAKLAND,CA; ERASMUS UNIV ROTTERDAM,SCH MED,DEPT EPIDEMIOL & BIOSTAT,3000 DR ROTTERDAM,NETHERLANDS	Kaiser Permanente; Erasmus University Rotterdam	Rimm, EB (corresponding author), HARVARD UNIV,SCH PUBL HLTH,DEPT NUTR,665 HUNTINGTON AVE,BOSTON,MA 02115, USA.		Grobbee, Diederick/C-7651-2014	Grobbee, Diederick/0000-0003-4472-4468				ARTAUDWILD SM, 1993, CIRCULATION, V88, P2771, DOI 10.1161/01.CIR.88.6.2771; Barboriak J J, 1981, Curr Alcohol, V8, P293; BARNARD MJ, 1992, LANCET, V340, P313; CRIQUI MH, 1987, AM J EPIDEMIOL, V126, P629, DOI 10.1093/oxfordjournals.aje.a114702; CRIQUI MH, 1994, LANCET, V344, P1719, DOI 10.1016/S0140-6736(94)92883-5; DUCIMETIERE P, 1993, EUR HEART J, V14, P727, DOI 10.1093/eurheartj/14.6.727; DUNBABIN DW, 1990, STROKE, V21, P36; FARCHI G, 1992, INT J EPIDEMIOL, V21, P74, DOI 10.1093/ije/21.1.74; FITZPATRICK DF, 1993, AM J PHYSIOL, V265, pH774; FRANKEL EN, 1993, LANCET, V341, P1103, DOI 10.1016/0140-6736(93)92472-6; FRIEDMAN LA, 1986, AM J EPIDEMIOL, V124, P481, DOI 10.1093/oxfordjournals.aje.a114418; GAZIANO JM, 1993, NEW ENGL J MED, V329, P1829, DOI 10.1056/NEJM199312163292501; GIOVANNUCCI E, 1991, AM J EPIDEMIOL, V133, P810; GIOVANNUCCI E, 1993, AM J EPIDEMIOL, V137, P502, DOI 10.1093/oxfordjournals.aje.a116703; GRONBAEK M, 1995, BRIT MED J, V310, P1165, DOI 10.1136/bmj.310.6988.1165; HEGSTED DM, 1988, J NUTR, V118, P1184, DOI 10.1093/jn/118.10.1184; HENNEKENS CH, 1979, JAMA-J AM MED ASSOC, V242, P1973, DOI 10.1001/jama.242.18.1973; HULLEY SB, 1981, CIRCULATION, V64, P57; KAGAN A, 1981, CIRCULATION, V64, P27; KAUFMAN DW, 1985, AM J EPIDEMIOL, V121, P548, DOI 10.1093/oxfordjournals.aje.a114032; KITTNER SJ, 1983, AM J EPIDEMIOL, V117, P538, DOI 10.1093/oxfordjournals.aje.a113576; KLATSKY AL, 1986, AM J CARDIOL, V58, P710, DOI 10.1016/0002-9149(86)90342-5; KLATSKY AL, 1990, BRIT J ADDICT, V85, P1279; KLATSKY AL, 1993, AM J CARDIOL, V71, P467, DOI 10.1016/0002-9149(93)90460-T; KLATSKY AL, 1990, AM J CARDIOL, V66, P1237, DOI 10.1016/0002-9149(90)91107-H; KLATSKY AL, 1992, ANN INTERN MED, V117, P646, DOI 10.7326/0003-4819-117-8-646; KLUFT C, 1990, FIBRINOLYSIS, V4, P69, DOI 10.1016/0268-9499(90)90363-O; KOZARAREVIC DJ, 1980, LANCET, V1, P613; LANGER RD, 1992, CIRCULATION, V85, P910, DOI 10.1161/01.CIR.85.3.910; LAPORTE RE, 1981, LANCET, V1, P105; LAPORTE RE, 1980, PREV MED, V9, P22, DOI 10.1016/0091-7435(80)90057-2; LEGER AS, 1979, LANCET, V1, P1017; MACLURE M, 1993, EPIDEMIOL REV, V15, P328, DOI 10.1093/oxfordjournals.epirev.a036124; MANSON JE, 1992, NEW ENGL J MED, V326, P1406, DOI 10.1056/NEJM199205213262107; MAXWELL S, 1994, LANCET, V344, P193, DOI 10.1016/S0140-6736(94)92795-2; MOORE RD, 1986, MEDICINE, V65, P242, DOI 10.1097/00005792-198607000-00004; NANJI AA, 1985, INT J CARDIOL, V8, P487, DOI 10.1016/0167-5273(85)90126-3; NANJI AA, 1986, ATHEROSCLEROSIS, V60, P197, DOI 10.1016/0021-9150(86)90011-0; RENAUD S, 1992, LANCET, V339, P1523, DOI 10.1016/0140-6736(92)91277-F; RENAUD SC, 1992, AM J CLIN NUTR, V55, P1012, DOI 10.1093/ajcn/55.5.1012; RIDKER PM, 1994, JAMA-J AM MED ASSOC, V272, P929, DOI 10.1001/jama.272.12.929; RIMM EB, 1991, LANCET, V338, P464, DOI 10.1016/0140-6736(91)90542-W; ROSENBERG L, 1981, AM J PUBLIC HEALTH, V71, P82, DOI 10.2105/AJPH.71.1.82; Rothman K, 1986, MODERN EPIDEMIOLOGY; SALONEN JT, 1983, J CHRON DIS, V36, P533, DOI 10.1016/0021-9681(83)90131-5; SCHMIDT W, 1981, BRIT J ADDICT, V76, P407; SEGALL JJ, 1992, LANCET, V340, P313; SIEMANN EH, 1992, AM J ENOL VITICULT, V43, P49; STAMPFER MJ, 1991, NEW ENGL J MED, V325, P373, DOI 10.1056/NEJM199108083250601; STAMPFER MJ, 1993, AM J PUBLIC HEALTH, V83, P801, DOI 10.2105/AJPH.83.6.801; STAMPFER MJ, 1988, NEW ENGL J MED, V319, P267, DOI 10.1056/NEJM198808043190503; SUH I, 1992, ANN INTERN MED, V116, P881, DOI 10.7326/0003-4819-116-11-881; THORNTON J, 1983, LANCET, V2, P819; Verschuren PM, 1993, HLTH ISSUES RELATED; WERTH J, 1980, LANCET, V2, P1141; WILLETT WC, 1987, NEW ENGL J MED, V317, P1303, DOI 10.1056/NEJM198711193172102; YANO K, 1977, NEW ENGL J MED, V297, P405, DOI 10.1056/NEJM197708252970801	57	763	776	1	97	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 23	1996	312	7033					731	736						6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UC166	8605457	Green Published			2022-12-28	WOS:A1996UC16600023
J	Kaplan, SH; Greenfield, S; Gandek, B; Rogers, WH; Ware, JE				Kaplan, SH; Greenfield, S; Gandek, B; Rogers, WH; Ware, JE			Characteristics of physicians with participatory decision-making styles	ANNALS OF INTERNAL MEDICINE			English	Article							PATIENT SATISFACTION; INTERNAL MEDICINE; FAMILY-PRACTICE; INTERVIEWING SKILLS; PSYCHOSOCIAL DOMAIN; PRIMARY CARE; OUTCOMES; COMMUNICATION; SPECIALTIES; SYSTEMS	Objectives: To identify physician and practice characteristics associated with a physician's propensity to involve patients in diagnostic and treatment decisions, or participatory decision-making style. Design: A representative cross-sectional sample of patients participating in the Medical Outcomes Study characterized each physician's style by using a self-reported questionnaire. A single averaged style score was generated for each physician. Style scores were compared among physicians who differed in age, sex, minority status, specialty, primary care training or training in interviewing skills, satisfaction with professional autonomy, and practice volume. Settings: Solo practices, multispecialty groups, and health maintenance organizations in Boston, Chicago, and Los Angeles. Participants: 7730 patients sampled over 9 days from the practices of 300 physicians. Physicians were practicing general internal medicine, family medicine, cardiology, and endocrinology. Measurements: Participatory decision-making style was measured using a three-item scale on a questionnaire that was completed by patients after their office visit. Physician and practice characteristics were reported by physicians on self-administered questionnaires. Results: Among patients of physicians who were rated in the lowest (least participatory) quartile, one third changed physicians in the following year; among patients of physicians who were rated in the highest quartile, only 15% changed physicians. Higher scores were associated with greater patient satisfaction. Physicians who had had primary care training or training in interviewing skills scored higher than those without such training. Physicians in higher-volume practices were rated as less participatory than those in lower-volume practices. Physicians who were satisfied with their level of professional autonomy were rated as more participatory than those who were dissatisfied. Conclusion: Participatory decision-making style is influenced by physicians' background, training, practice volume, and professional autonomy. Because participatory decision-making style is related to patient satisfaction and loyalty to the physician, cost-containment strategies that reduce time with patients and decrease physician autonomy may result in suboptimal patient outcomes.	TUFTS UNIV NEW ENGLAND MED CTR, HLTH INST, BOSTON, MA 02111 USA	Tufts Medical Center	Kaplan, SH (corresponding author), TUFTS UNIV NEW ENGLAND MED CTR, PRIMARY CARE OUTCOMES RES INST, 750 WASHINGTON ST, BOX 345, BOSTON, MA 02111 USA.			Greenfield, Sheldon/0000-0003-4628-1998; Kaplan, Sherrie/0000-0002-8644-5849	NATIONAL INSTITUTE ON AGING [R01AG008409] Funding Source: NIH RePORTER; NIA NIH HHS [AG8409] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ADAMSON TE, 1989, J FAM PRACTICE, V29, P93; [Anonymous], 1990, JAMA-J AM MED ASSOC, V263, P2344; BARRY MJ, 1988, JAMA-J AM MED ASSOC, V259, P3010, DOI 10.1001/jama.259.20.3010; BASS MJ, 1986, J FAM PRACTICE, V23, P43; BECKMAN H, 1990, J GEN INTERN MED, V5, P42, DOI 10.1007/BF02602308; BEISECKER AE, 1990, MED CARE, V28, P19, DOI 10.1097/00005650-199001000-00004; BERTAKIS KD, 1987, J FAM PRACTICE, V24, P305; BULLER MK, 1987, J HEALTH SOC BEHAV, V28, P375, DOI 10.2307/2136791; CHERKIN DC, 1988, J FAM PRACTICE, V26, P543; GREENFIELD S, 1994, DIABETES CARE, V17, P32; GREENFIELD S, 1995, JAMA-J AM MED ASSOC, V274, P1436; GREENFIELD S, 1992, JAMA-J AM MED ASSOC, V267, P1624, DOI 10.1001/jama.267.12.1624; GREENFIELD S, 1985, ANN INTERN MED, V102, P520, DOI 10.7326/0003-4819-102-4-520; GREENFIELD S, 1988, J GEN INTERN MED, V3, P448, DOI 10.1007/BF02595921; HAMBURGER S, 1982, J FAM PRACTICE, V14, P719; HEMENWAY D, 1990, NEW ENGL J MED, V322, P1059, DOI 10.1056/NEJM199004123221507; HESZENKLEMENS I, 1984, SOC SCI MED, V19, P9, DOI 10.1016/0277-9536(84)90132-1; Janis I. L., 1977, DECISION MAKING; Kaplan S, 1989, COMMUNICATING MED PA; KAPLAN SH, 1993, CLIN RES, V41, pA541; KAPLAN SH, 1995, MED CARE, V33, P1176, DOI 10.1097/00005650-199512000-00002; KAPLAN SH, 1989, MED CARE, V27, pS110, DOI 10.1097/00005650-198903001-00010; KAPLAN SH, 1992, CLIN RES, V40, pA614; KERN DE, 1989, J GEN INTERN MED, V4, P421, DOI 10.1007/BF02599696; KRAVITZ RL, 1992, JAMA-J AM MED ASSOC, V267, P1617, DOI 10.1001/jama.267.12.1617; LEVY DR, 1985, PEDIATRICS, V75, P639; LIKE R, 1987, SOC SCI MED, V24, P351, DOI 10.1016/0277-9536(87)90153-5; LIPKIN M, 1984, ANN INTERN MED, V100, P277, DOI 10.7326/0003-4819-100-2-277; MCWHINNEY IR, 1986, HEADACHE, V26, P285; MURPHYCULLEN CL, 1984, SOC SCI MED, V19, P163, DOI 10.1016/0277-9536(84)90283-1; NOREN J, 1980, NEW ENGL J MED, V302, P11, DOI 10.1056/NEJM198001033020103; ORTH JE, 1987, HEALTH PSYCHOL, V6, P29, DOI 10.1037/0278-6133.6.1.29; RADECKI SE, 1988, J AM GERIATR SOC, V36, P713, DOI 10.1111/j.1532-5415.1988.tb07173.x; ROST KM, 1991, DIABETES CARE, V14, P881, DOI 10.2337/diacare.14.10.881; ROTER DL, 1990, J GEN INTERN MED, V5, P347, DOI 10.1007/BF02600404; SCHERGER JE, 1980, J FAM PRACTICE, V10, P95; SHEA S, 1990, J GEN INTERN MED, V5, P327, DOI 10.1007/BF02600401; STARFIELD B, 1981, AM J PUBLIC HEALTH, V71, P127, DOI 10.2105/AJPH.71.2.127; STEWART MA, 1979, J R COLL GEN PRACT, P77; STILES WB, 1979, MED CARE, V17, P667, DOI 10.1097/00005650-197906000-00010; STREET RL, 1987, J NONVERBAL BEHAV, V11, P234, DOI 10.1007/BF00987255; TARLOV AR, 1989, JAMA-J AM MED ASSOC, V262, P925, DOI 10.1001/jama.262.7.925; Ware J E Jr, 1983, Eval Program Plann, V6, P291, DOI 10.1016/0149-7189(83)90009-5; WAYLAND MT, 1988, J MED EDUC, V63, P921; WENNEKER MB, 1989, JAMA-J AM MED ASSOC, V261, P253, DOI 10.1001/jama.261.2.253; WOOLLEY FR, 1978, SOC SCI MED-MED SOC, V12, P123, DOI 10.1016/0160-7979(78)90034-6	46	470	472	0	14	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 1	1996	124	5					497	504		10.7326/0003-4819-124-5-199603010-00007	http://dx.doi.org/10.7326/0003-4819-124-5-199603010-00007			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	TW773	8602709				2022-12-28	WOS:A1996TW77300007
J	Lau, JYN; Davis, GL; Prescott, LE; Maertens, G; Lindsay, KL; Qian, KP; Mizokami, M; Simmonds, P; Perrillo, RP; Schiff, ER; Bodenheimer, HC; Balart, LA; Regenstein, F; Dienstag, JL; Katkov, WN; Tamburro, CH; Goff, JS; Everson, GT; Goodman, Z; Albrecht, J				Lau, JYN; Davis, GL; Prescott, LE; Maertens, G; Lindsay, KL; Qian, KP; Mizokami, M; Simmonds, P; Perrillo, RP; Schiff, ER; Bodenheimer, HC; Balart, LA; Regenstein, F; Dienstag, JL; Katkov, WN; Tamburro, CH; Goff, JS; Everson, GT; Goodman, Z; Albrecht, J			Distribution of hepatitis C virus genotypes determined by line probe assay in patients with chronic hepatitis C seen at tertiary referral centers in the United States	ANNALS OF INTERNAL MEDICINE			English	Article						hepatitis C viruses; genotype; hepatitis C; assay, line probe; serotyping	SEQUENCE; REGION; VARIABILITY; INFECTION; DISTINCT; SUBTYPES; GENOMES	Objective: To 1) verify the validity of a new line probe assay for hepatitis C virus (HCV) genotyping and 2) determine the distribution of HCV genotypes and the association between HCV genotype and clinical variables in patients with chronic hepatitis C seen in tertiary referral centers in the United States. Design: Retrospective cross-sectional analysis. Patients: 438 patients with chronic hepatitis C from 10 tertiary referral centers. Measurements: The validity of the line probe assay was first verified against a panel of serum specimens that had previously been characterized by six different HCV genotyping methods. Specimens from all 438 patients were then genotyped using this line probe assay. The associations between HCV genotype and clinical variables were examined using analysis of variance. Pairwise testing was used when the F test showed a statistically significant difference. Nonparametric alternatives were used for variables for which normality could not be assumed. Results: The line probe assay was quick and reproducible, and it showed good concordance with other tests. In our sample, the proportions of patients with HCV types 1, 2, 3, and 4 were 71.5%, 13.5%, 5.5%, and 1.1%, respectively. Subtypes la and Ib were seen in approximately equal proportions of patients with HCV type 1. Mixed infection was detected in 3.7% of specimens, and 4.8% of specimens either had negative results on polymerase chain reaction or could not be typed. A higher proportion of patients with HCV type 1 than of patients with HCV-type 1 had acquired HCV through transfusion of blood products (50% compared with 25%; P < 0.001). Patients with HCV type 1 also had a longer estimated duration of infection compared with patients with HCV type 3 (P = 0.004) and type 4 (P = 0.049). Disease activity did not differ among patients infected with HCV types 1, 2, or 3. Levels of viremia were similar in patients with HCV types 1, 2, or 3, but patients with HCV type 4 had a lower level of viremia than did patients with HCV type 1 (P = 0.047). Conclusions: The line probe assay can be used in patients with chronic HCV infection in the United States. In patients with chronic hepatitis C referred to tertiary centers in the United States, type 1 is the most common HCV genotype. Disease activity and viremia levels do not differ among patients chronically infected with HCV types 1, 2, or 3.	UNIV EDINBURGH, DEPT MICROBIOL, EDINBURGH EH8 9AG, MIDLOTHIAN, SCOTLAND; INNOGENET, B-9052 GHENT, BELGIUM; UNIV SO CALIF, DEPT MED, DIV GASTROINTESTINAL & LIVER DIS, LOS ANGELES, CA 90033 USA; NAGOYA CITY UNIV, SCH MED, DEPT INTERNAL MED 2, NAGOYA, AICHI 467, JAPAN; VET AFFAIRS MED CTR, ST LOUIS, MO USA; UNIV MIAMI, MIAMI, FL 33152 USA; RHODE ISL HOSP, PROVIDENCE, RI 02902 USA; BROWN UNIV, PROVIDENCE, RI 02912 USA; ALTON OCHSNER MED FDN & OCHSNER CLIN, NEW ORLEANS, LA 70121 USA; MASSACHUSETTS GEN HOSP, BOSTON, MA 02114 USA; UNIV LOUISVILLE, LOUISVILLE, KY 40292 USA; UNIV COLORADO, DENVER, CO 80202 USA; ARMED FORCES INST PATHOL, WASHINGTON, DC 20306 USA; SCHERING PLOUGH CORP, RES INST, KENILWORTH, NJ 07033 USA	University of Edinburgh; Innogenetics NV; University of Southern California; Nagoya City University; US Department of Veterans Affairs; Veterans Health Administration (VHA); University of Miami; Lifespan Health Rhode Island; Rhode Island Hospital; Brown University; Ochsner Health System; Harvard University; Massachusetts General Hospital; University of Louisville; University of Colorado System; University of Colorado Denver; United States Department of Defense; Merck & Company; Schering Plough Corporation	Lau, JYN (corresponding author), UNIV FLORIDA, J HILLIS MILLER HLTH CTR, DEPT MED, DIV GASTROENTEROL HEPATOL & NUTR, GAINESVILLE, FL 32610 USA.			Simmonds, Peter/0000-0002-7964-4700	NCRR NIH HHS [5M01RR00082, M01RR01066, RR-00865] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000082, M01RR001066, M01RR000865] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		BUKH J, 1993, P NATL ACAD SCI USA, V90, P8234, DOI 10.1073/pnas.90.17.8234; CHA TA, 1992, P NATL ACAD SCI USA, V89, P7144, DOI 10.1073/pnas.89.15.7144; CHAN SW, 1992, J GEN VIROL, V73, P1131, DOI 10.1099/0022-1317-73-5-1131; CHAYAMA K, 1993, J GASTROEN HEPATOL, V8, P150, DOI 10.1111/j.1440-1746.1993.tb01507.x; CHEMELLO L, 1995, HEPATOLOGY, V22, P700, DOI 10.1016/0270-9139(95)90286-4; COLLINS ML, 1995, ANAL BIOCHEM, V226, P120, DOI 10.1006/abio.1995.1199; DAVIS GL, 1994, HEPATOLOGY, V19, P1337, DOI 10.1002/hep.1840190603; ENOMOTO N, 1990, BIOCHEM BIOPH RES CO, V170, P1021, DOI 10.1016/0006-291X(90)90494-8; HOUGHTON M, 1991, HEPATOLOGY, V14, P381, DOI 10.1016/0270-9139(91)91430-9; KNODELL RG, 1981, HEPATOLOGY, V1, P431, DOI 10.1002/hep.1840010511; LAU JYN, 1993, J HEPATOL, V17, P253, DOI 10.1016/S0168-8278(05)80047-9; LAU JYN, 1995, LANCET, V346, P425, DOI 10.1016/S0140-6736(95)92786-7; LAU JYN, 1995, J INFECT DIS, V171, P281, DOI 10.1093/infdis/171.2.281; LAU JYN, 1993, LANCET, V341, P1501, DOI 10.1016/0140-6736(93)90635-T; MARTINOTPEIGNOUX M, 1995, HEPATOLOGY, V22, P1050, DOI 10.1016/0270-9139(95)90608-8; MCOMISH F, 1993, TRANSFUSION, V33, P7, DOI 10.1046/j.1537-2995.1993.33193142314.x; MIZOKAMI M, 1994, GASTROENTEROLOGY, V107, P1181, DOI 10.1016/0016-5085(94)90245-3; MORI S, 1992, BIOCHEM BIOPH RES CO, V183, P334, DOI 10.1016/0006-291X(92)91648-A; NAKAO T, 1991, J GEN VIROL, V72, P2105, DOI 10.1099/0022-1317-72-9-2105; NGUYEN TT, 1994, GASTROENTEROLOGY, V106, pA950; NOUSBAUM JB, 1995, ANN INTERN MED, V122, P161, DOI 10.7326/0003-4819-122-3-199502010-00001; OGATA N, 1991, P NATL ACAD SCI USA, V88, P3392, DOI 10.1073/pnas.88.8.3392; OKAMOTO H, 1992, J GEN VIROL, V73, P673, DOI 10.1099/0022-1317-73-3-673; OKAMOTO H, 1992, VIROLOGY, V188, P331, DOI 10.1016/0042-6822(92)90762-E; OKAMOTO H, 1992, VIROLOGY, V190, P894, DOI 10.1016/0042-6822(92)90933-G; ORITO E, 1994, J HEPATOL, V21, P130, DOI 10.1016/S0168-8278(94)80149-5; SIMMONDS P, 1993, J GEN VIROL, V74, P661, DOI 10.1099/0022-1317-74-4-661; SIMMONDS P, 1993, J GEN VIROL, V74, P2391, DOI 10.1099/0022-1317-74-11-2391; SIMMONDS P, 1993, J CLIN MICROBIOL, V31, P1493, DOI 10.1128/JCM.31.6.1493-1503.1993; SIMMONDS P, 1994, HEPATOLOGY, V19, P1321, DOI 10.1016/0270-9139(94)90887-7; Smith DB, 1996, J INFECT DIS, V173, P727, DOI 10.1093/infdis/173.3.727; SMITH DB, 1995, J GEN VIROL, V76, P1749, DOI 10.1099/0022-1317-76-7-1749; STUYVER L, 1993, J GEN VIROL, V74, P1093, DOI 10.1099/0022-1317-74-6-1093; TAKADA N, 1992, J HEPATOL, V14, P35, DOI 10.1016/0168-8278(92)90128-C; TSUKIYAMAKOHARA K, 1991, VIRUS GENES, V5, P243, DOI 10.1007/BF00568974; VANDOORN LJ, 1994, J HEPATOL, V21, P122, DOI 10.1016/S0168-8278(94)80148-7	36	168	171	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 15	1996	124	10					868	+		10.7326/0003-4819-124-10-199605150-00002	http://dx.doi.org/10.7326/0003-4819-124-10-199605150-00002			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UJ801	8610915				2022-12-28	WOS:A1996UJ80100002
J	Robinson, M; Lanza, F; Avner, D; Haber, M				Robinson, M; Lanza, F; Avner, D; Haber, M			Effective maintenance treatment of reflux esophagitis with low-dose lansoprazole - A randomized, double-blind, placebo-controlled trial	ANNALS OF INTERNAL MEDICINE			English	Article						antacids; esophagitis, peptic; lansoprazole; gastric acid; endoscopy, digestive system	TERM TREATMENT; OMEPRAZOLE; RELAPSE; CISAPRIDE	Objective: To compare the efficacy of two doses of lansoprazole with that of placebo in preventing recurrence of erosive esophagitis in a 12-month period. Design: Randomized, double-blind, parallel, placebo-controlled trial. Setting: 25 U.S. medical centers. Patients: 173 patients with documented healing of erosive esophagitis after 8 weeks of acid-suppressing therapy. Intervention: Lansoprazole, 15 mg or 30 mg, or placebo once daily for as long as 12 months. Measurements: Endoscopy and symptom evaluation after 1, 2, 3, 6, 9, and 12 months of treatment. Endoscopy was also done whenever symptoms suggested erosive changes. Results: Lansoprazole was significantly superior to placebo in maintaining healing and preventing recurrence of symptoms. By month 1, 45% of placebo recipients remained healed compared with more than 90% of patients in either lansoprazole group. By month 12, only 24% of placebo recipients remained healed compared with 79% of patients receiving 15 mg of lansoprazole and 90% of patients receiving 30 mg of lansoprazole. During the same period, 35% of placebo recipients remained asymptomatic compared with 72% of recipients of 15 mg of lansoprazole and 67% of recipients of 30 mg of lansoprazole. The 15-mg and 30-mg lansoprazole doses did not differ significantly in maintaining healing and controlling symptoms. Follow-up after recurrence of erosion indicated that during the 12 months, 35% of placebo recipients and 2% of lansoprazole recipients had three or more recurrences. Conclusion: Lansoprazole effectively maintains healing of erosive esophagitis. The 15-mg and 30-mg lansoprazole doses did not differ significantly for use as maintenance treatment.	BAYLOR COLL MED, HOUSTON INST CLIN RES, HOUSTON, TX 77074 USA; MED COLL PENN & HAHNEMANN UNIV, DEPT PATHOL & LAB MED, PHILADELPHIA, PA 19129 USA	Baylor College of Medicine; Drexel University	Robinson, M (corresponding author), UNIV OKLAHOMA, COLL MED, OKLAHOMA FDN DIGEST RES, 711 STANTON L YOUNG BLVD, SUITE 501, OKLAHOMA CITY, OK 73104 USA.							ARMSTRONG D, 1989, GUT, V30, pA1494; BARDHAN K O, 1991, Gastroenterology, V100, pA30; BARRADELL LB, 1992, DRUGS, V44, P225, DOI 10.2165/00003495-199244020-00007; BENHAIM M C, 1990, Gastroenterology, V98, pA20; BERLIN R, 1989, Gastroenterology, V96, pA39; DEVAULT KR, 1994, MAYO CLIN PROC, V69, P867, DOI 10.1016/S0025-6196(12)61790-X; HATLEBAKK JG, 1993, SCAND J GASTROENTERO, V28, P224, DOI 10.3109/00365529309096076; HETZEL DJ, 1992, DIGESTION, V51, P35, DOI 10.1159/000200913; HETZEL DJ, 1988, GASTROENTEROLOGY, V95, P903, DOI 10.1016/0016-5085(88)90162-X; JANSEN JBMJ, 1990, GASTROENTEROLOGY, V99, P621, DOI 10.1016/0016-5085(90)90946-X; KAUL B, 1986, SCAND J GASTROENTERO, V21, P139, DOI 10.3109/00365528609034638; KOCH GG, 1984, AM J MED, V77, P43; KOELZ HR, 1986, GASTROENTEROLOGY, V91, P1198, DOI 10.1016/S0016-5085(86)80017-8; KOOP H, 1991, DIGEST DIS SCI, V36, P552, DOI 10.1007/BF01297018; LAMBERTS R, 1988, DIGESTION, V39, P126, DOI 10.1159/000199615; LAURSEN L S, 1992, Gastroenterology, V102, pA109; ROBINSON M, 1995, ALIMENT PHARM THERAP, V9, P25; SOLCIA E, 1992, DIGESTION, V51, P82, DOI 10.1159/000200921; SOLCIA E, 1988, DIGESTION, V41, P185, DOI 10.1159/000199786; TOUSSAINT J, 1991, GUT, V32, P1280, DOI 10.1136/gut.32.11.1280; TYTGAT GNJ, 1990, SCAND J GASTROENTERO, V25, P1, DOI 10.3109/00365529009093121; TYTGAT GNJ, 1992, SCAND J GASTROENTERO, V27, P175, DOI 10.3109/00365529208999945	22	118	122	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 15	1996	124	10					859	+		10.7326/0003-4819-124-10-199605150-00001	http://dx.doi.org/10.7326/0003-4819-124-10-199605150-00001			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UJ801	8610914				2022-12-28	WOS:A1996UJ80100001
J	Amarenco, P; Heinzlef, O; Lucas, C; Touboul, PJ; Gerard, JL; Adrai, V; Rougemont, D; Bousser, MG; Chauvel, C; Benhalima, B; Albo, C; Abergel, E; Besson, G; Vercueil, L; Bertrand, B; Chavot, D; Tatu, L; Bernard, Y; Rondepierre, P; Goulard, L; Deklunder, G; Chamas, E; Falcon, S; Wolf, JE; Giroud, M; Tzourio, C				Amarenco, P; Heinzlef, O; Lucas, C; Touboul, PJ; Gerard, JL; Adrai, V; Rougemont, D; Bousser, MG; Chauvel, C; Benhalima, B; Albo, C; Abergel, E; Besson, G; Vercueil, L; Bertrand, B; Chavot, D; Tatu, L; Bernard, Y; Rondepierre, P; Goulard, L; Deklunder, G; Chamas, E; Falcon, S; Wolf, JE; Giroud, M; Tzourio, C			Atherosclerotic disease of the aortic arch as a risk factor for recurrent ischemic stroke	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							TRANSESOPHAGEAL ECHOCARDIOGRAPHY; CHOLESTEROL EMBOLIZATION; CARDIOPULMONARY BYPASS; SYSTEMIC EMBOLIZATION; CEREBRAL INFARCTION; COMPLICATION; ATHEROMAS; PLAQUE	Background. Atherosclerotic disease of the aortic arch is found in 60 percent of patients 60 years of age or older who have had brain infarction. The aim of this study was to determine whether atherosclerotic plaques in the aortic arch are a risk factor for recurrent brain infarction and for vascular events in general (i.e., brain infarction, myocardial infarction, peripheral embolism, and death from vascular causes). Methods. For a period of two to four years, we followed a cohort of 331 patients 60 years of age or older who were consecutively admitted to the hospital with brain infarction (a total of 788 person-years of follow-up). All patients underwent transesophageal echocardiography to determine whether atherosclerotic plaques were present in the aortic arch proximal to the ostium of the left subclavian artery. The patients were divided into three groups according to the thickness of the wall of the aortic arch (<1 mm, 1 to 3.9 mm, and greater than or equal to 4 mm). Results. The incidence of recurrent brain infarction was 11.9 per 100 person-years in patients with an aortic-wall thickness of greater than or equal to 4 mm, as compared with 3.5 per 100 person-years in patients with a wall thickness of 1 to 3.9 mm and 2.8 per 100 person-years in patients with a wall thickness of <1 mm (P<0.001). The overall incidence of vascular events was 26.0, 9.1, and 5.9 per 100 person-years of follow-up in the respective groups (P<0.001). After adjustment for the presence of carotid stenosis, atrial fibrillation, peripheral arterial disease, and other risk factors, aortic plaques greater than or equal to 4 mm thick (including the thickness of the aortic wall) were found to be independent predictors of recurrent brain infarction (relative risk, 3.8; 95 percent confidence interval, 1.8 to 7.8; P=0.0012) and of all vascular events (relative risk, 3.5; 95 percent confidence interval, 2.1 to 5.9; P<0.001). Conclusions. Atherosclerotic plaques greater than or equal to 4 mm thick in the aortic arch are significant predictors of recurrent brain infarction and other vascular events. (C) 1996, Massachusetts Medical Society.			Amarenco, P (corresponding author), HOP ST ANTOINE, SERV NEUROL, 184 RUE FAUBOURG ST ANTOINE, F-75571 PARIS 12, FRANCE.		Tzourio, Christophe I/B-7459-2008; Tzourio, christophe/L-6344-2019; Tzourio, christophe/B-4015-2009; VERCUEIL, Laurent/AAN-2941-2021	Tzourio, christophe/0000-0002-6517-2984; Tzourio, christophe/0000-0002-6517-2984; VERCUEIL, Laurent/0000-0003-3323-0091; Moulin, thierry/0000-0002-6639-8117				ALTMAN R, 1994, BMJ-BRIT MED J, V308, P81, DOI 10.1136/bmj.308.6921.81; AMARENCO P, 1992, STROKE, V23, P1005, DOI 10.1161/01.STR.23.7.1005; AMARENCO P, 1994, NEW ENGL J MED, V331, P1474, DOI 10.1056/NEJM199412013312202; AMARENCO P, 1992, NEW ENGL J MED, V326, P221, DOI 10.1056/NEJM199201233260402; BEAL MF, 1981, NEUROLOGY, V31, P860, DOI 10.1212/WNL.31.7.860; BRUNS FJ, 1978, AM J MED SCI, V275, P105, DOI 10.1097/00000441-197801000-00013; CASTLEMA B, 1967, NEW ENGL J MED, V276, P1368, DOI 10.1056/NEJM196706152762410; COGAN DG, 1964, ARCH OPHTHALMOL-CHIC, V71, P308; DAVID NJ, 1963, NEUROLOGY, V13, P708, DOI 10.1212/WNL.13.8.708; DAVILAROMAN VG, 1994, STROKE, V25, P2010, DOI 10.1161/01.STR.25.10.2010; DIXON WJ, 1992, BMDP STATISTICAL SOF; FEDER W, 1961, ANN INTERN MED, V55, P911, DOI 10.7326/0003-4819-55-6-911; GARDNER TJ, 1985, ANN THORAC SURG, V40, P574, DOI 10.1016/S0003-4975(10)60352-9; GORE I, 1960, AM J CLIN PATHOL, V33, P416; HOLLENHORST RW, 1966, AM J OPHTHALMOL, V61, P1159, DOI 10.1016/0002-9394(66)90238-8; HOROWITZ DR, 1992, NEUROLOGY, V42, P1602, DOI 10.1212/WNL.42.8.1602; JONES EF, 1995, STROKE, V26, P218; KARALIS DG, 1991, J AM COLL CARDIOL, V17, P73, DOI 10.1016/0735-1097(91)90706-F; KATZ ES, 1992, J AM COLL CARDIOL, V20, P70, DOI 10.1016/0735-1097(92)90139-E; MCKIBBIN DW, 1976, J THORAC CARDIOV SUR, V71, P741; NIHOYANNOPOULOS P, 1993, AM J CARDIOL, V71, P1208, DOI 10.1016/0002-9149(93)90647-U; PRICE DL, 1970, NEUROLOGY, V20, P1209, DOI 10.1212/WNL.20.12.1209; RAMIREZ G, 1978, ARCH INTERN MED, V138, P1430, DOI 10.1001/archinte.138.9.1430; *SAS I, 1989, SAS US GUID, V1; SOLOWAY HB, 1964, ARCH NEUROL-CHICAGO, V11, P657, DOI 10.1001/archneur.1964.00460240089012; STURGILL BC, 1963, ARCH PATHOL, V76, P189; TAYLOR DW, 1991, NEW ENGL J MED, V325, P445; TOYODA K, 1992, STROKE, V23, P1056, DOI 10.1161/01.STR.23.8.1056; TUNICK PA, 1990, AM HEART J, V120, P658, DOI 10.1016/0002-8703(90)90024-R; TUNICK PA, 1994, J AM COLL CARDIOL, V23, P1085, DOI 10.1016/0735-1097(94)90595-9; TUNICK PA, 1991, ANN INTERN MED, V115, P423, DOI 10.7326/0003-4819-115-6-423; TUNICK PA, 1992, AM HEART J, V124, P239; WINTER WJ, 1957, ARCH PATHOL, V64, P137; 1993, LANCET, V342, P1255; 1994, BRIT MED J, V308, P1540; 1972, NEW ENGL J MED, V286, P1146	36	457	466	0	8	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 9	1996	334	19					1216	1221						6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UJ054	8606716				2022-12-28	WOS:A1996UJ05400002
J	Hubbard, R; Lewontin, RC				Hubbard, R; Lewontin, RC			Pitfalls of genetic testing	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							ATTITUDES				Hubbard, R (corresponding author), HARVARD UNIV,CAMBRIDGE,MA 02138, USA.							BABUL R, 1993, JAMA-J AM MED ASSOC, V270, P2321, DOI 10.1001/jama.270.19.2321; Collins FS, 1996, NEW ENGL J MED, V334, P186, DOI 10.1056/NEJM199601183340311; GELLER G, 1995, NAT GENET, V11, P364, DOI 10.1038/ng1295-364; GIANNELLI F, 1990, NUCLEIC ACIDS RES, V18, P4053, DOI 10.1093/nar/18.14.4053; HOSKINS KF, 1995, JAMA-J AM MED ASSOC, V273, P577, DOI 10.1001/jama.273.7.577; HUMPHRIES P, 1992, SCIENCE, V256, P804, DOI 10.1126/science.1589761; KOLATA G, 1996, NY TIMES        0401, pA15; KOLATA G, 1996, NY TIMES        0617, pA1; PAPERMASTER DS, 1995, NAT MED, V1, P874, DOI 10.1038/nm0995-874; Seachrist Lisa, 1995, Sci News, V148, P394, DOI 10.2307/4018302; SIEBERT C, 1995, NY TIMES MAGAZI 0917, P93; SIEBERT C, 1995, NY TIMES MAGAZI 0917, P50; SIEBERT C, 1995, NY TIMES MAGAZI 0917, P74; SIEBERT C, 1995, NY TIMES MAGAZI 0917, P104; SIEBERT C, 1995, NY TIMES MAGAZI 0917, P64; WERTZ DC, 1992, AM J HUM GENET, V50, P1077; 1993, NEW ENGL J MED, V329, P1308	17	84	84	0	3	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 2	1996	334	18					1192	1194		10.1056/NEJM199605023341812	http://dx.doi.org/10.1056/NEJM199605023341812			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UG831	8602190				2022-12-28	WOS:A1996UG83100012
J	Kushi, LH; Folsom, AR; Prineas, RJ; Mink, PJ; Wu, Y; Bostick, RM				Kushi, LH; Folsom, AR; Prineas, RJ; Mink, PJ; Wu, Y; Bostick, RM			Dietary antioxidant vitamins and death from coronary heart disease in postmenopausal women	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							LOW-DENSITY-LIPOPROTEIN; E CONSUMPTION; ATHEROSCLEROSIS; RISK; QUESTIONNAIRE; PROGRESSION; POPULATION; RABBIT; MEN	Background. The role of dietary antioxidant vitamins in preventing coronary heart disease has aroused considerable interest because of the knowledge that oxidative modification of low-density lipoprotein may promote atherosclerosis. Methods. We studied 34,486 postmenopausal women with no cardiovascular disease who in early 1986 completed a questionnaire that assessed, among other factors, their intake of vitamins A, E, and C from food sources and supplements. During approximately seven years of follow-up (ending December 31, 1992), 242 of the women died of coronary heart disease. Results. In analyses adjusted for age and dietary energy intake, vitamin E consumption appeared to be inversely associated with the risk of death from coronary heart disease, This association was particularly striking in the subgroup of 21,809 women who did not consume vitamin supplements (relative risks from lowest to highest quintile of vitamin E intake, 1.0, 0.68, 0.71, 0.42, and 0.42; P for trend=0.008), After adjustment for possible confounding variables, this inverse association remained (relative risks from lowest to highest quintile, 1.0, 0.70, 0.76, 0.32, and 0.38; P for trend=0.004). There was little evidence that the intake of vitamin E from supplements was associated with a decreased risk of death from coronary heart disease, but the effects of high-dose supplementation and the duration of supplement use could not be definitively addressed, Intake of vitamins A and C did not appear to be associated with the risk of death from coronary heart disease. Conclusions. These results suggest that in postmenopausal women the intake of vitamin E from food is inversely associated with the risk of death from coronary heart disease and that such women can lower their risk without using vitamin supplements. By contrast, the intake of vitamins A and C was not associated with lower risks of dying from coronary disease. (C) 1996, Massachusetis Medical Society.	UNIV MIAMI, DEPT EPIDEMIOL & PUBL HLTH, MIAMI, FL 33152 USA; UNIV PITTSBURGH, DEPT EPIDEMIOL, PITTSBURGH, PA 15261 USA; WAKE FOREST UNIV, BOWMAN GRAY SCH MED, WINSTON SALEM, NC USA	University of Miami; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Wake Forest University; Wake Forest Baptist Medical Center	Kushi, LH (corresponding author), UNIV MINNESOTA, SCH PUBL HLTH, DIV EPIDEMIOL, 1300 S 2ND ST, SUITE 300, MINNEAPOLIS, MN 55454 USA.			Kushi, Lawrence/0000-0001-9136-1175	NATIONAL CANCER INSTITUTE [R01CA039742] Funding Source: NIH RePORTER; NCI NIH HHS [CA-39742] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ASCHERIO A, 1992, J NUTR, V122, P1792, DOI 10.1093/jn/122.9.1792; AVIRAM M, 1993, ATHEROSCLEROSIS, V98, P1, DOI 10.1016/0021-9150(93)90217-I; BEATON GH, 1994, AM J CLIN NUTR, V59, p253S, DOI 10.1093/ajcn/59.1.253S; BISGARD KM, 1994, AM J EPIDEMIOL, V139, P990, DOI 10.1093/oxfordjournals.aje.a116948; BJORKHEM I, 1991, ARTERIOSCLER THROMB, V11, P15, DOI 10.1161/01.ATV.11.1.15; Buring JE, 1992, J MYOCARDIAL ISCHEMI, V4, P27; ENSTROM JE, 1992, EPIDEMIOLOGY, V3, P194, DOI 10.1097/00001648-199205000-00003; FRASER GE, 1992, ARCH INTERN MED, V152, P1416, DOI 10.1001/archinte.152.7.1416; Gaziano J. Michael, 1995, Annals of Epidemiology, V5, P255, DOI 10.1016/1047-2797(94)00090-G; HEINONEN OP, 1994, NEW ENGL J MED, V330, P1029; KIRCHER T, 1985, NEW ENGL J MED, V313, P1263, DOI 10.1056/NEJM198511143132005; KITA T, 1987, P NATL ACAD SCI USA, V84, P5928, DOI 10.1073/pnas.84.16.5928; KNEKT P, 1994, AM J EPIDEMIOL, V139, P1180, DOI 10.1093/oxfordjournals.aje.a116964; MEYER F, 1994, CIRCULATION, V89, P932; MUNGER RG, 1992, AM J EPIDEMIOL, V136, P192, DOI 10.1093/oxfordjournals.aje.a116485; Prineas R J, 1993, Ann Epidemiol, V3, P35, DOI 10.1016/1047-2797(93)90007-Q; PRINEAS RJ, 1993, NEW ENGL J MED, V329, P359; RIMM EB, 1993, NEW ENGL J MED, V328, P1450, DOI 10.1056/NEJM199305203282004; SALONEN JT, 1992, LANCET, V339, P883, DOI 10.1016/0140-6736(92)90926-T; SELHUB J, 1993, JAMA-J AM MED ASSOC, V270, P2693, DOI 10.1001/jama.270.22.2693; SELHUB J, 1995, NEW ENGL J MED, V332, P286, DOI 10.1056/NEJM199502023320502; STAMPFER MJ, 1993, NEW ENGL J MED, V328, P1444, DOI 10.1056/NEJM199305203282003; STAMPFER MJ, 1992, JAMA-J AM MED ASSOC, V268, P877, DOI 10.1001/jama.268.7.877; STEINBERG D, 1992, CIRCULATION, V85, P2338, DOI 10.1161/01.CIR.85.6.2337; STEINBERG D, 1989, NEW ENGL J MED, V320, P915; VERLANGIERI AJ, 1992, J AM COLL NUTR, V11, P131; WHITE AD, IN PRESS J CLIN EPID; WILLETT WC, 1988, AM J EPIDEMIOL, V127, P188, DOI 10.1093/oxfordjournals.aje.a114780; WILLETT WC, 1993, LANCET, V341, P581, DOI 10.1016/0140-6736(93)90350-P; YLAHERTTUALA S, 1989, J CLIN INVEST, V84, P1086, DOI 10.1172/JCI114271	30	696	721	0	18	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 2	1996	334	18					1156	1162		10.1056/NEJM199605023341803	http://dx.doi.org/10.1056/NEJM199605023341803			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UG831	8602181				2022-12-28	WOS:A1996UG83100003
J	Schalk, I; Zeng, K; Wu, SK; Stura, EA; Matteson, J; Huang, MD; Tandon, A; Wilson, IA; Balch, WE				Schalk, I; Zeng, K; Wu, SK; Stura, EA; Matteson, J; Huang, MD; Tandon, A; Wilson, IA; Balch, WE			Structure and mutational analysis of Rab GDP-dissociation inhibitor	NATURE			English	Article							PARA-HYDROXYBENZOATE HYDROXYLASE; GTP-BINDING PROTEIN; CHOROIDEREMIA GENE; CRYSTAL-STRUCTURE; MACROMOLECULAR CRYSTALLOGRAPHY; GERANYLGERANYL TRANSFERASE; PURIFICATION; RESOLUTION; SUBSTRATE; HOMOLOG	The crystal structure of the bovine alpha-isoform of Rab GDP-dissociation inhibitor (GDI), which functions in vesicle-membrane transport to recycle and regulate Rab GTPases, has been determined to a resolution of 1.81 Angstrom. GDI is constructed of two main structural units, a large complex multisheet domain I and a smaller alpha-helical domain II. The structural organization of domain I is surprisingly closely related to FAD-containing monooxygenases and oxidases. Sequence-conserved regions common to GDI and the choroideraemia gene product, which delivers Rab to catalytic subunits of Rab geranylgeranyltransferase II, are clustered on one face of the molecule. The two most sequence-conserved regions, which form a compact structure at the apex of GDI, are shown by site-directed mutagenesis to play a critical role in the binding of Rab proteins.	SCRIPPS RES INST, DEPT MOL, LA JOLLA, CA 92037 USA; Scripps Res Inst, DEPT CELL BIOL, LA JOLLA, CA 92037 USA	Scripps Research Institute; Scripps Research Institute			Stura, Enrico A./A-2793-2010	Stura, Enrico A./0000-0001-6718-2118				ALEXANDROV K, 1994, EMBO J, V13, P5262, DOI 10.1002/j.1460-2075.1994.tb06860.x; ANDRES DA, 1993, CELL, V73, P1091, DOI 10.1016/0092-8674(93)90639-8; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRUNGER AT, 1992, THESIS YALE U; CREMERS FPM, 1994, J BIOL CHEM, V269, P2111; Cremers Frans P. M., 1992, Human Molecular Genetics, V1, P71, DOI 10.1093/hmg/1.2.71; DASCHER C, 1994, J BIOL CHEM, V269, P1437; DEKKER LV, 1991, J NEUROCHEM, V54, P205; ENTSCH B, 1995, FASEB J, V9, P476, DOI 10.1096/fasebj.9.7.7737455; FERRIN TE, 1988, J MOL GRAPHICS, V6, P13, DOI 10.1016/0263-7855(88)80054-7; FUJIMURA K, 1994, J BIOL CHEM, V269, P9205; FUREY W, 1990, AM CRYSTALLOGR ASS 4; HARRISON SC, 1968, J APPL CRYSTALLOGR, V1, P84, DOI 10.1107/S0021889868005054; HECHT HJ, 1993, J MOL BIOL, V229, P153, DOI 10.1006/jmbi.1993.1015; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; HOWARD AJ, 1987, J APPL CRYSTALLOGR, V20, P383, DOI 10.1107/S0021889887086436; JIANG Y, 1994, P NATL ACAD SCI USA, V91, P4377, DOI 10.1073/pnas.91.10.4377; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Lambright DG, 1996, NATURE, V379, P311, DOI 10.1038/379311a0; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LI JY, 1993, BIOCHEMISTRY-US, V32, P11507, DOI 10.1021/bi00094a006; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; McRee D.E., 1993, PRACTICAL PROTEIN CR, P1; McRee DE, 1992, J MOL GRAPHICS, V10, P44, DOI DOI 10.1016/0263-7855(92)80022-6; NASSAR M, 1995, NATURE, V375, P554, DOI 10.1038/375554a0; NUOFFER C, 1994, J CELL BIOL, V125, P225, DOI 10.1083/jcb.125.2.225; NUOFFER C, 1994, ANNU REV BIOCHEM, V63, P949, DOI 10.1146/annurev.bi.63.070194.004505; NUOFFER C, 1995, METHOD ENZYMOL, V257, P3; PETER F, 1994, J CELL BIOL, V126, P1393, DOI 10.1083/jcb.126.6.1393; PFEFFER SR, 1995, J BIOL CHEM, V270, P17057, DOI 10.1074/jbc.270.29.17057; SASAKI T, 1990, J BIOL CHEM, V265, P2333; SCHALK IJ, 1994, J MOL BIOL, V244, P469, DOI 10.1006/jmbi.1994.1744; SCHREUDER HA, 1989, J MOL BIOL, V208, P679, DOI 10.1016/0022-2836(89)90158-7; SEABRA MC, 1992, CELL, V70, P1049, DOI 10.1016/0092-8674(92)90253-9; SEABRA MC, 1993, SCIENCE, V259, P377, DOI 10.1126/science.8380507; SHAPIRO AD, 1995, J BIOL CHEM, V270, P11085, DOI 10.1074/jbc.270.19.11085; SOLDATI T, 1993, MOL BIOL CELL, V4, P425, DOI 10.1091/mbc.4.4.425; STOTT K, 1993, J BIOL CHEM, V268, P6097; STURA EA, 1994, ACTA CRYSTALLOGR D, V50, P448, DOI 10.1107/S0907444994001794; ULLRICH O, 1994, NATURE, V368, P157, DOI 10.1038/368157a0; ULLRICH O, 1993, J BIOL CHEM, V268, P18143; VANBOKHOVEN H, 1994, HUM MOL GENET, V3, P1041, DOI 10.1093/hmg/3.7.1041; VANDENHURK JAJM, 1992, AM J HUM GENET, V50, P1195; VONMOLLARD GF, 1991, NATURE, V349, P79, DOI 10.1038/349079a0; WALDHERR M, 1993, NAT GENET, V3, P193, DOI 10.1038/ng0393-193; WALL MA, 1995, CELL, V83, P1047, DOI 10.1016/0092-8674(95)90220-1; WANG BC, 1985, METHOD ENZYMOL, V115, P90; WIERENGA RK, 1979, J MOL BIOL, V131, P55, DOI 10.1016/0022-2836(79)90301-2; WIERENGA RK, 1986, J MOL BIOL, V187, P101, DOI 10.1016/0022-2836(86)90409-2; WILSON AL, 1993, J BIOL CHEM, V268, P14561	52	141	144	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 2	1996	381	6577					42	48		10.1038/381042a0	http://dx.doi.org/10.1038/381042a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UJ053	8609986				2022-12-28	WOS:A1996UJ05300048
J	Paterson, C				Paterson, C			Measuring outcomes in primary care: A patient generated measure, MYMOP, compared with the SF-36 health survey	BRITISH MEDICAL JOURNAL			English	Article							SURVEY QUESTIONNAIRE; FUNCTIONAL STATUS; INSTRUMENTS; QUALITY; LIFE	Objective-To assess the sensitivity to within person change over time of an outcome measure for practitioners in primary care that is applicable to a wide range of illness. Design-Comparison of a new patient generated instrument, the measure yourself medical outcome profile (MYMOP), with the SF-36 health profile and a five point change score; all scales were completed during the consultation with practitioners and repeated after four weeks. 103 patients were followed up for 16 weeks and their results charted; seven practitioners were interviewed. Setting-Established practice of the four NHS general practitioners and four of the private complementary practitioners working in one medical centre. Subjects-Systematic sample of 218 patients from general practice and all 47 patients of complementary practitioners; patients had had symptoms for more than seven days. Outcome measures-Standardised response mean and index of responsiveness; views of practitioners. Results-The index of responsiveness, relating to the minimal clinically important difference, was high for MYMOP: 1.14 for the first symptom, 1.33 for activity, and 0.85 for the profile compared with <0.45 for SF-36. MYMOP's validity was supported by significant correlation between the change score and the change in the MYMOP score and the ability of this instrument to detect more improvement in acute than in chronic conditions. Practitioners found that MYMOP was practical and applicable to all patients with symptoms and that its use increased their awareness of patients' priorities. Conclusion-MYMOP shows promise as an outcome measure for primary care and for complementary treatment. It is more sensitive to change than the SF-36 and has the added bonus of improving patient-practitioner communication.			Paterson, C (corresponding author), WARWICK HOUSE MED CTR,TAUNTON TA1 2YJ,SOMERSET,ENGLAND.							BRAZIER JE, 1992, BMJ-BRIT MED J, V305, P160, DOI 10.1136/bmj.305.6846.160; Garratt A M, 1993, Qual Health Care, V2, P5, DOI 10.1136/qshc.2.1.5; GARRATT AM, 1993, BMJ-BRIT MED J, V306, P1440, DOI 10.1136/bmj.306.6890.1440; GUYATT G, 1987, J CHRON DIS, V40, P171, DOI 10.1016/0021-9681(87)90069-5; GUYATT GH, 1993, J CLIN EPIDEMIOL, V46, P1433, DOI 10.1016/0895-4356(93)90143-O; GUYATT GH, 1992, J CLIN EPIDEMIOL, V45, P1341, DOI 10.1016/0895-4356(92)90194-R; GUYATT GH, 1987, THORAX, V42, P773, DOI 10.1136/thx.42.10.773; HOWIE JGR, 1984, BRIT MED J, V289, P1770, DOI 10.1136/bmj.289.6460.1770; KATZ JN, 1992, MED CARE, V30, P917, DOI 10.1097/00005650-199210000-00004; KINNERSLEY P, 1994, BRIT J GEN PRACT, V44, P545; MACKENZIE CR, 1986, J CHRON DIS, V39, P429, DOI 10.1016/0021-9681(86)90110-4; MCGOURTY H, 1993, LIVERPOOL PUBLIC HLT, V13; OBOYLE CA, 1992, LANCET, V339, P1088, DOI 10.1016/0140-6736(92)90673-Q; PATERSON C, 1995, BRIT J GEN PRACT, V45, P255; Phillips R C, 1992, J Heart Valve Dis, V1, P42; RUTA DA, 1994, MED CARE, V32, P1109, DOI 10.1097/00005650-199411000-00004; WILKIN D, 1992, MEASURES NEED OUTCOM; WONGCHUNG D, 1991, FAM PRACT, V8, P404, DOI 10.1093/fampra/8.4.404; YODFAT Y, 1991, FAM PRACT, V8, P409, DOI 10.1093/fampra/8.4.409	19	268	272	1	16	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 20	1996	312	7037					1016	1020						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UG610	8616351				2022-12-28	WOS:A1996UG61000029
J	Johnson, LN; Noble, MEM; Owen, DJ				Johnson, LN; Noble, MEM; Owen, DJ			Active and inactive protein kinases: Structural basis for regulation	CELL			English	Review							MICROTUBULE-ASSOCIATED PROTEIN-2; CATALYTIC SUBUNIT; INHIBITOR PEPTIDE; GAMMA-SUBUNIT; PHOSPHORYLATION; BINDING; SITES		UNIV OXFORD,OXFORD CTR MOLEC SCI,OXFORD OX1 3QU,ENGLAND	University of Oxford	Johnson, LN (corresponding author), UNIV OXFORD,LAB MOLEC BIOPHYS,OXFORD OX1 3QU,ENGLAND.			Noble, Martin/0000-0002-3595-9807				ADAMS JA, 1995, BIOCHEMISTRY-US, V34, P2447, DOI 10.1021/bi00008a007; ADAMS JA, 1993, PROTEIN SCI, V2, P2177, DOI 10.1002/pro.5560021217; AHN NG, 1991, J BIOL CHEM, V266, P4220; BOSSEMEYER D, 1993, EMBO J, V12, P849, DOI 10.1002/j.1460-2075.1993.tb05725.x; BROWN NR, 1995, STRUCTURE, V3, P1235, DOI 10.1016/S0969-2126(01)00259-3; CARMEL G, 1994, J BIOL CHEM, V269, P7304; COX S, 1994, CURR OPIN STRUC BIOL, V4, P893, DOI 10.1016/0959-440X(94)90272-0; Cox S, 1995, BIOCHEMISTRY-US, V34, P16203, DOI 10.1021/bi00049a036; COX S, 1992, PROTEIN ENG, V5, P811, DOI 10.1093/protein/5.8.811; DASGUPTA M, 1995, J BIOL CHEM, V270, P22283, DOI 10.1074/jbc.270.38.22283; DASGUPTA M, 1989, J BIOL CHEM, V264, P17156; DEBONDT HL, 1993, NATURE, V363, P592; Goldberg J, 1996, CELL, V84, P875, DOI 10.1016/S0092-8674(00)81066-1; GOULD KL, 1991, EMBO J, V10, P3297, DOI 10.1002/j.1460-2075.1991.tb04894.x; Hardie G., 1995, PROTEIN KINASE FACTS; HU SH, 1994, NATURE, V369, P581, DOI 10.1038/369581a0; HUANG WD, 1994, P NATL ACAD SCI USA, V91, P8960, DOI 10.1073/pnas.91.19.8960; HUBBARD SR, 1994, NATURE, V372, P746, DOI 10.1038/372746a0; JEFFREY PD, 1995, NATURE, V376, P313, DOI 10.1038/376313a0; KEMP BE, 1991, BIOCHIM BIOPHYS ACTA, V1094, P67, DOI 10.1016/0167-4889(91)90027-U; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; KNIGHTON DR, 1991, SCIENCE, V253, P414, DOI 10.1126/science.1862343; LEVIN LR, 1990, MOL CELL BIOL, V10, P1066, DOI 10.1128/MCB.10.3.1066; LONGENECKER KL, 1995, IN PRESS J MOL BIOL; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; OLAH GA, 1993, BIOCHEMISTRY-US, V32, P3649, DOI 10.1021/bi00065a018; ORR JW, 1994, J BIOL CHEM, V269, P27715; OWEN DJ, 1995, STRUCTURE, V3, P467, DOI 10.1016/S0969-2126(01)00180-0; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; SHOJI S, 1979, J BIOL CHEM, V254, P6211; STEINBERG RA, 1993, MOL CELL BIOL, V13, P2332, DOI 10.1128/MCB.13.4.2332; STURGILL TW, 1986, BIOCHEM BIOPH RES CO, V134, P565, DOI 10.1016/S0006-291X(86)80457-0; TAYLOR SS, 1994, STRUCTURE, V2, P345, DOI 10.1016/S0969-2126(00)00036-8; TIMMS JF, 1995, BIOCHEM J, V308, P219, DOI 10.1042/bj3080219; WHITE MF, 1994, J BIOL CHEM, V269, P1; XU RM, 1995, EMBO J, V14, P1015, DOI 10.1002/j.1460-2075.1995.tb07082.x; ZHANG FM, 1994, NATURE, V367, P704, DOI 10.1038/367704a0; ZHANG JD, 1995, STRUCTURE, V3, P299, DOI 10.1016/S0969-2126(01)00160-5	38	1142	1189	1	51	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 19	1996	85	2					149	158		10.1016/S0092-8674(00)81092-2	http://dx.doi.org/10.1016/S0092-8674(00)81092-2			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UG255	8612268	Bronze			2022-12-28	WOS:A1996UG25500004
J	Hoeksema, J				Hoeksema, J			Vasectomy reversal	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter							VASOVASOSTOMY				Hoeksema, J (corresponding author), RUSH PRESBYTERIAN ST LUKES MED CTR,DEPT UROL,CHICAGO,IL 60612, USA.							BELKER AM, 1991, J UROLOGY, V145, P505, DOI 10.1016/S0022-5347(17)38381-7; BELKER AM, 1988, ADV UROLOGY, P193; MEINERTZ H, 1990, FERTIL STERIL, V54, P315	3	2	2	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 17	1996	275	15					1152	1152						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UE625	8609671				2022-12-28	WOS:A1996UE62500008
J	Antia, NH				Antia, NH			Laparoscopic cholecystectomy	LANCET			English	Editorial Material											Antia, NH (corresponding author), FDN MED RES,BOMBAY,MAHARASHTRA,INDIA.								0	5	5	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 13	1996	347	9007					985	985		10.1016/S0140-6736(96)90138-5	http://dx.doi.org/10.1016/S0140-6736(96)90138-5			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UF380	8606607				2022-12-28	WOS:A1996UF38000003
J	Elwyn, GJ; Williams, LA; Barry, S; Kinnersley, P				Elwyn, GJ; Williams, LA; Barry, S; Kinnersley, P			Waiting list management in general practice: A review of orthopaedic patients	BMJ-BRITISH MEDICAL JOURNAL			English	Article							PRACTITIONERS; REFERRALS	Objective-To review all patients on a current general practice orthopaedic waiting list for outpatient appointments with regard to accuracy of the list, clinical priority, and need for further radiological investigation before hospital attendance. Design-Record review by one general practitioner and a radiologist, and discussion with patients of management alternatives. Setting-Six partner city centre urban fund-holding general practice, list size 8651 (29% low deprivation payment status). Subjects-116 adults on an orthopaedic waiting list. Main outcome measures-List accuracy (patient details and status on waiting list); clinical priority (severity of condition); further investigations (results of tests after radiological review). Results-32 patients (28%) were removed from the waiting list because of inaccuracies. 14 patients were considered to be high priority and referred to other hospitals by utilising waiting list initiative funds. Of these patients, five agreed to referral to another hospital (treatment completed on average within three months of rereferral), six did not wish to be rereferred, and two did not attend to discuss the offer and remained on the original waiting list. One prioritised patient had further radiological investigations, was reassured, and was taken off the waiting List. 10 patients had further investigations. These resulted in six patients being referred to other hospitals, three being taken off the waiting list, and one seeking private care. Conclusions-Systematic review of patients on an orthopaedic waiting list of one general practice, though time consuming, led to the identification of inaccuracies in the list and changes in management. Costs need further evaluation, but if the findings occur widely substantial benefits could be achieved for patients.	CARDIFF ROYAL INFIRM, CARDIFF CF2 1SZ, S GLAM, WALES; DEPT GEN PRACTICE, CARDIFF CF3 7PN, S GLAM, WALES	Cardiff Royal Infirmary	Elwyn, GJ (corresponding author), FOUR ELMS MED CTR, CARDIFF CF1 2AF, S GLAM, WALES.		Elwyn, G./L-4292-2015; Elwyn, Glyn/B-4798-2009	Elwyn, Glyn/0000-0002-0917-6286				CHADDA D, 1993, HLTH SERVICE J, V103, P12; DIETCH R, 1984, LANCET, V1, P1419; ELLIOT J, 1995, LIFE SLOW LANE EXPER; HEMINGWAY H, 1995, BRIT MED J, V310, P818, DOI 10.1136/bmj.310.6983.818; Martin M, 1995, Health Serv J, V105, P24; MCGLADE KJ, 1988, BRIT MED J, V297, P1246, DOI 10.1136/bmj.297.6658.1246; MILLS RP, 1991, J ROY SOC MED, V84, P405, DOI 10.1177/014107689108400709; Ovretveit J, 1995, PURCHASING HLTH; ROBINSON R, 1993, HLTH SERVICE J, V103, P24; ROLAND MO, 1991, BRIT MED J, V302, P1124, DOI 10.1136/bmj.302.6785.1124; STEWART M, 1991, BRIT J GEN PRACT, V41, P508; STEWART M, 1991, BR J GEN PRACT, V41, P353; STODDART PGP, 1989, CLIN RADIOL, V40, P183, DOI 10.1016/S0009-9260(89)80088-1; WEST R, 1991, J MANAGEMENT MED, V5, P19; 1993, HLTH SERVICE J, V103, P16	15	11	12	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	APR 6	1996	312	7035					887	888						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UE371	8611882				2022-12-28	WOS:A1996UE37100027
J	Pisacane, A; deLuca, U; Criscuolo, L; Vaccaro, F; Valiante, A; Inglese, A; Caracciolo, G; Pinto, L				Pisacane, A; deLuca, U; Criscuolo, L; Vaccaro, F; Valiante, A; Inglese, A; Caracciolo, G; Pinto, L			Breast feeding and hypertrophic pyloric stenosis: Population based case-control study	BRITISH MEDICAL JOURNAL			English	Article									SANTOBONO PAEDIAT HOSP,NAPLES,ITALY		Pisacane, A (corresponding author), UNIV NAPLES,DEPT PAEDIAT,I-80131 NAPLES,ITALY.							DODGE JA, 1975, ARCH DIS CHILD, V50, P171, DOI 10.1136/adc.50.3.171; JEDD MB, 1986, AM J DIS CHILD, V142, P334; MARCHINI G, 1994, ACTA PAEDIATR, V83, P374, DOI 10.1111/j.1651-2227.1994.tb18122.x; SPENCE MA, 1978, GENETIC EPIDEMIOLOGY, P331; WEBB AR, 1983, ARCH DIS CHILD, V58, P586, DOI 10.1136/adc.58.8.586	5	19	19	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 23	1996	312	7033					745	746						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UC166	8605461	Green Published			2022-12-28	WOS:A1996UC16600027
J	Naylor, CD; Guyatt, GH				Naylor, CD; Guyatt, GH			Users' guides to the medical literature .10. How to use an article reporting variations in the outcomes of health services	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							IN-HOSPITAL MORTALITY; BYPASS GRAFT-SURGERY; RISK-FACTORS; VOLUME; PROSTATECTOMY; RESECTION		MCMASTER UNIV,HLTH SCI CTR,DEPT CLIN EPIDEMIOL & BIOSTAT,HAMILTON,ON L8N 3Z5,CANADA; UNIV TORONTO,DEPT MED,TORONTO,ON,CANADA; UNIV TORONTO,DEPT SURG,TORONTO,ON,CANADA; UNIV TORONTO,SUNNYBROOK UNIT,CLIN EPIDEMIOL & HLTH CARE RES PROGRAM,TORONTO,ON,CANADA; INST CLIN EVALUAT SCI,N YORK,ON,CANADA	McMaster University; University of Manitoba; Children's Hospital Research Institute of Manitoba; University of Toronto; University of Toronto; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center								ANDERSEN TF, 1990, MED CARE, V28, P870, DOI 10.1097/00005650-199010000-00002; CONCATO J, 1992, JAMA-J AM MED ASSOC, V267, P1077, DOI 10.1001/jama.267.8.1077; DALEY J, 1994, RISK ADJUSTMENT MEAS, P199; EDWARDS FH, 1994, ANN THORAC SURG, V57, P12, DOI 10.1016/0003-4975(94)90358-1; GUYATT GH, 1993, JAMA-J AM MED ASSOC, V270, P2598, DOI 10.1001/jama.270.21.2598; HANNAN EL, 1992, MED CARE, V30, P892, DOI 10.1097/00005650-199210000-00002; HANNAN EL, 1992, HEALTH SERV RES, V27, P517; HANNAN EL, 1991, MED CARE, V29, P1094, DOI 10.1097/00005650-199111000-00003; HIGGINS TL, 1992, JAMA-J AM MED ASSOC, V267, P2344, DOI 10.1001/jama.267.17.2344; JOLLIS JG, 1993, ANN INTERN MED, V119, P844, DOI 10.7326/0003-4819-119-8-199310150-00011; JOLLIS JG, 1994, NEW ENGL J MED, V331, P1625, DOI 10.1056/NEJM199412153312406; LEVINE M, 1994, JAMA-J AM MED ASSOC, V271, P1615, DOI 10.1001/jama.271.20.1615; LOCALIO AR, 1995, ANN INTERN MED, V122, P125, DOI 10.7326/0003-4819-122-2-199501150-00009; MALENKA DJ, 1990, J UROLOGY, V144, P224, DOI 10.1016/S0022-5347(17)39416-8; MALENKA DJ, 1994, J CLIN EPIDEMIOL, V47, P1027, DOI 10.1016/0895-4356(94)90118-X; MARK DB, 1994, NEW ENGL J MED, V331, P1130, DOI 10.1056/NEJM199410273311706; MEYHOFF HH, 1987, SCAND J UROL NE S102, V4, P1; OCONNOR GT, 1992, CIRCULATION, V85, P2110, DOI 10.1161/01.CIR.85.6.2110; ROOS NP, 1989, NEW ENGL J MED, V320, P1120, DOI 10.1056/NEJM198904273201705; SHOWSTACK JA, 1987, JAMA-J AM MED ASSOC, V257, P785, DOI 10.1001/jama.257.6.785; TU JV, 1995, CIRCULATION, V91, P677, DOI 10.1161/01.CIR.91.3.677; WHITE KL, 1967, PUBLIC HEALTH REP, V82, P847, DOI 10.2307/4593149; WU AW, 1995, ANN INTERN MED, V122, P149, DOI 10.7326/0003-4819-122-2-199501150-00013	23	84	86	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 21	1996	275	7					554	558		10.1001/jama.275.7.554	http://dx.doi.org/10.1001/jama.275.7.554			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	TV569	8606478				2022-12-28	WOS:A1996TV56900034
J	Sheldon, TA; Raffle, A; Watt, I				Sheldon, TA; Raffle, A; Watt, I			Controversies in management - Department of health shoots itself in the hip - Why the report of the Advisory Group on Osteoporosis undermines evidence based purchasing	BRITISH MEDICAL JOURNAL			English	Article									AVON HLTH,BRISTOL BS2 8EE,AVON,ENGLAND; BRISTOL ROYAL INFIRM & GEN HOSP,DIRECTORATE CLIN RADIOL,BRISTOL BS2 8HW,AVON,ENGLAND	Bristol Royal Infirmary	Sheldon, TA (corresponding author), UNIV YORK,NHS CTR REVIEWS & DISSEMINAT,YORK YO1 5DD,N YORKSHIRE,ENGLAND.			Sheldon, Trevor Andrew/0000-0002-7479-5913				BARLOW DM, 1994, ADVISORY GROUP OSTEO; Calman K, 1994, J Med Screen, V1, P101; CAULEY JA, 1995, ANN INTERN MED, V122, P9, DOI 10.7326/0003-4819-122-1-199501010-00002; Chalmers I, 1995, SYSTEMATIC REV; ETTINGER B, 1993, NEW ENGL J MED, V329, P1192, DOI 10.1056/NEJM199310143291610; EVANS NJB, 1995, REV DEPT HLTH ARRANG; PECKHAM M, 1993, RES HLTH; Sox H. C., 1989, ASSESSMENT DIAGNOSTI; TORGERSON DJ, 1995, EUR J OBSTET GYN R B, V59, P57, DOI 10.1016/0028-2243(94)02002-V; 1995, MEASUREMENT BONE DEN	10	15	15	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 3	1996	312	7026					296	297						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TU507	8611790				2022-12-28	WOS:A1996TU50700030
J	Takeshita, A; Shibata, Y; Shinjo, K; Yanagi, M; Tobita, T; Ohnishi, K; Miyawaki, S; Shudo, K; Ohno, R				Takeshita, A; Shibata, Y; Shinjo, K; Yanagi, M; Tobita, T; Ohnishi, K; Miyawaki, S; Shudo, K; Ohno, R			Successful treatment of relapse of acute promyelocytic leukemia with a new synthetic retinoid, Am80	ANNALS OF INTERNAL MEDICINE			English	Article							ACID		SAISEIKAI HOSP, MAEBASHI, GUMMA 371, JAPAN; UNIV TOKYO, FAC PHARMACEUT SCI, BUNKYO KU, TOKYO 113, JAPAN	University of Tokyo	Takeshita, A (corresponding author), HAMAMATSU UNIV SCH MED, DEPT MED 3, DIV HEMATOL, 3600 HANDA CHO, HAMAMATSU, SHIZUOKA 43131, JAPAN.							CORNIC M, 1994, LEUKEMIA, V8, pS16; DEGOS L, 1995, BLOOD, V85, P2643, DOI 10.1182/blood.V85.10.2643.bloodjournal85102643; HASHIMOTO Y, 1995, J CANCER RES CLIN, V121, P696, DOI 10.1007/BF01218530; HUANG ME, 1988, BLOOD, V72, P567, DOI 10.1182/blood.V72.2.567.567; KAGECHIKA H, 1988, J MED CHEM, V31, P2182, DOI 10.1021/jm00119a021; KANAMARU A, 1995, BLOOD, V85, P1202, DOI 10.1182/blood.V85.5.1202.bloodjournal8551202; MILLER WH, 1995, BLOOD, V85, P3021, DOI 10.1182/blood.V85.11.3021.bloodjournal85113021; MUINDI J, 1992, BLOOD, V79, P299; OHNO R, 1994, LEUKEMIA, V8, pS64; WARRELL RP, 1991, NEW ENGL J MED, V324, P1385, DOI 10.1056/NEJM199105163242002; WARRELL RP, 1993, NEW ENGL J MED, V329, P177, DOI 10.1056/NEJM199307153290307; Yamada O, 1994, Gan To Kagaku Ryoho, V21, P1981; ZELENT A, 1989, NATURE, V339, P714, DOI 10.1038/339714a0	13	35	38	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 15	1996	124	10					893	896		10.7326/0003-4819-124-10-199605150-00006	http://dx.doi.org/10.7326/0003-4819-124-10-199605150-00006			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UJ801	8610919				2022-12-28	WOS:A1996UJ80100006
J	Kizer, KW				Kizer, KW			Geriatrics in the VA: Providing experience for the nation	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											Kizer, KW (corresponding author), DEPT VET AFFAIRS,WASHINGTON,DC 20422, USA.							1996, JAMA-J AM MED ASSOC, V275, P1069	1	6	6	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 1	1996	275	17					1303	1303		10.1001/jama.275.17.1303	http://dx.doi.org/10.1001/jama.275.17.1303			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UG612	8614102				2022-12-28	WOS:A1996UG61200005
J	Mendall, MA; Patel, P; Ballam, L; Strachan, D; Northfield, TC				Mendall, MA; Patel, P; Ballam, L; Strachan, D; Northfield, TC			C Reactive protein and its relation to cardiovascular risk factors: A population based cross sectional study	BRITISH MEDICAL JOURNAL			English	Article							ACUTE PHASE; MYOCARDIAL-INFARCTION; INSULIN-RESISTANCE; LIPIDS; SERUM; INFECTION; DISEASE	Objective-To test the hypothesis that minor chronic insults such as smoking, chronic bronchitis, and two persistent bacterial infections may be associated with increases in C reactive protein concentration within the normal range and that variations in the C reactive protein concentration in turn may be associated with levels of cardiovascular risk factors and chronic coronary heart disease. Design-Population based cross sectional study. Setting-General practices in Merton, Sutton, and Wandsworth. Subjects-A random sample of 388 men aged 50-69 years from general practice registers. 612 men were invited to attend and 413 attended, of whom 25 non-white men were excluded. The first 303 of the remaining 388 men had full risk factor profiles determined. Interventions-Measurements of serum C reactive protein concentrations by in house enzyme linked immunosorbent assay (ELISA); other determinations by standard methods. Coronary heart disease was sought by the Rose angina questionnaire and Minnesota coded electrocardiograms. Main outcome measures-Serum C reactive protein concentrations, cardiovascular risk factor levels, and the presence of coronary heart disease. Results-Increasing age, smoking, symptoms of chronic bronchitis, Helicobacter pylori and Chlamydia pneumoniae infections, and body mass index were all associated with raised concentrations of C reactive protein. C Reactive protein concentration was associated with raised serum fibrinogen, sialic acid, total cholesterol, triglyceride, glucose, and apolipoprotein B values. C Reactive protein concentration was negatively associated with high density lipoprotein cholesterol concentration. There was a weaker positive relation with low density lipoprotein cholesterol concentration and no relation with apolipoprotein A I value. C Reactive protein concentration was also strongly associated with coronary heart disease. Conclusion-The body's response to inflammation may play an important part in influencing the progression of atherosclerosis. The association of C reactive protein concentration with coronary heart disease needs testing in prospective studies.			Mendall, MA (corresponding author), ST GEORGES MED SCH,DIV BIOCHEM MED,LONDON SW17 0RE,ENGLAND.							AKIRA S, 1993, ADV IMMUNOL, V54, P1, DOI 10.1016/S0065-2776(08)60532-5; ALVAREZ C, 1986, CLIN CHEM, V32, P142; BAUMANN H, 1994, IMMUNOL TODAY, V15, P74, DOI 10.1016/0167-5699(94)90137-6; CABANA VG, 1989, J LIPID RES, V30, P39; COOMBES EJ, 1980, J TRAUMA, V20, P971, DOI 10.1097/00005373-198011000-00012; DEBEER FC, 1982, J IMMUNOL METHODS, V50, P299, DOI 10.1016/0022-1759(82)90168-5; FAHIEWILSON M, 1987, CLIN CHIM ACTA, V167, P197, DOI 10.1016/0009-8981(87)90372-X; FEINGOLD KR, 1992, DIABETES, V41, P97, DOI 10.2337/diab.41.2.S97; GAULDIE J, 1989, ANN NY ACAD SCI, V557, P46; HELDENBERG D, 1980, ATHEROSCLEROSIS, V35, P433, DOI 10.1016/0021-9150(80)90184-7; HOTAMISLIGIL GS, 1995, J CLIN INVEST, V95, P2409, DOI 10.1172/JCI117936; JUHANVAGUE I, 1993, ARTERIOSCLER THROMB, V13, P1865, DOI 10.1161/01.ATV.13.12.1865; KAHN C, 1995, SCIENCE, V373, P384; LINDBERG G, 1991, BRIT MED J, V302, P143, DOI 10.1136/bmj.302.6769.143; LIUZZO G, 1994, NEW ENGL J MED, V331, P417, DOI 10.1056/NEJM199408183310701; MACKIEWICZ A, 1991, J IMMUNOL, V146, P3032; MATTILA KJ, 1989, BRIT MED J, V298, P779, DOI 10.1136/bmj.298.6676.779; MENDALL MA, 1994, BRIT HEART J, V71, P437; NAITO H K, 1987, Comprehensive Therapy, V13, P43; PALOSUO T, 1986, ACTA MED SCAND, V220, P175; PATEL P, 1995, BRIT MED J, V311, P711, DOI 10.1136/bmj.311.7007.711; REAVEN GM, 1988, DIABETES, V37, P1595, DOI 10.2337/diabetes.37.12.1595; RYDER REJ, 1984, BRIT MED J, V289, P1651, DOI 10.1136/bmj.289.6459.1651; SAIKKU P, 1992, ANN INTERN MED, V116, P273, DOI 10.7326/0003-4819-116-4-273; STEEL DM, 1994, IMMUNOL TODAY, V15, P81, DOI 10.1016/0167-5699(94)90138-4; THOMPSON SG, 1995, NEW ENGL J MED, V332, P635, DOI 10.1056/NEJM199503093321003; WOODHOUSE PR, 1994, LANCET, V343, P435, DOI 10.1016/S0140-6736(94)92689-1	27	709	740	1	41	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 27	1996	312	7038					1061	1065						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UH816	8616412				2022-12-28	WOS:A1996UH81600023
J	Stein, MB				Stein, MB			How shy is too shy?	LANCET			English	Editorial Material							SOCIAL PHOBIA				Stein, MB (corresponding author), UNIV CALIF SAN DIEGO,DEPT PSYCHIAT,LA JOLLA,CA 92093, USA.							DAVIDSON JRT, 1993, PSYCHOL MED, V23, P709, DOI 10.1017/S0033291700025484; Juster H R, 1996, Prog Behav Modif, V30, P74; KATZELNICK DJ, 1995, AM J PSYCHIAT, V152, P1368; Magee WJ, 1996, ARCH GEN PSYCHIAT, V53, P159; SCHNEIER FR, 1992, ARCH GEN PSYCHIAT, V49, P282; Stein MB, 1996, ARCH GEN PSYCHIAT, V53, P169; STEIN MB, 1994, AM J PSYCHIAT, V151, P408; STEIN MB, IN PRESS J CLIN PSYC; Sutherland SM, 1995, SOCIAL PHOBIA CLIN R, P323; VANVLIET IM, 1994, PSYCHOPHARMACOLOGY, V115, P128, DOI 10.1007/BF02244762; VERSIANI M, 1992, BRIT J PSYCHIAT, V161, P353, DOI 10.1192/bjp.161.3.353; Weiller E., 1996, British Journal of Psychiatry, V168, P169, DOI 10.1192/bjp.168.2.169	12	43	43	0	5	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 27	1996	347	9009					1131	1132		10.1016/S0140-6736(96)90604-2	http://dx.doi.org/10.1016/S0140-6736(96)90604-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	UG755	8609744				2022-12-28	WOS:A1996UG75500006
J	Craigie, R				Craigie, R			Quality control in Mu DNA transposition	CELL			English	Review							RECOMBINATION				Craigie, R (corresponding author), NIDDK,NIH,BLDG 5,ROOM 301,BETHESDA,MD 20892, USA.							CHEN JW, 1992, CELL, V69, P647, DOI 10.1016/0092-8674(92)90228-5; CRAIG NL, 1995, SCIENCE, V270, P253, DOI 10.1126/science.270.5234.253; ECHOLS H, 1986, SCIENCE, V233, P1050, DOI 10.1126/science.2943018; LAVOIE BD, 1995, CURR TOP MICROBIOL I, V204, P83; MIZUUCHI K, 1992, ANNU REV BIOCHEM, V61, P1011; Rice P, 1996, CURR OPIN STRUC BIOL, V6, P76, DOI 10.1016/S0959-440X(96)80098-4; vanGent DC, 1996, SCIENCE, V271, P1592, DOI 10.1126/science.271.5255.1592; WATSON MA, 1996, IN PRESS CELL, V85; YANG JY, 1995, EMBO J, V14, P2374, DOI 10.1002/j.1460-2075.1995.tb07232.x	9	17	17	0	0	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	APR 19	1996	85	2					137	140		10.1016/S0092-8674(00)81089-2	http://dx.doi.org/10.1016/S0092-8674(00)81089-2			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UG255	8612265	Bronze			2022-12-28	WOS:A1996UG25500001
J	May, EW; Craig, NL				May, EW; Craig, NL			Switching from cut-and-paste to replicative Tn7 transposition	SCIENCE			English	Article							BACTERIOPHAGE-MU; MICROSCOPIC ANALYSIS; MECHANISM; DNA; RECOMBINATION; INTERMEDIATE; INSERTION; PROTEIN; COINTEGRATION; PURIFICATION	The bacterial transposon Tn7 usually moves through a cut-and-paste mechanism whereby the transposon is excised from a donor site and joined to a target site io form a simple insertion. The transposon was converted to a replicative element that generated plasmid fusions in vitro and cointegrate products in vivo. This switch was a consequence of the separation of 5'- and 3'-end processing reactions of Tn7 transposition as demonstrated by the consequences of a single amino acid alteration in an element-encoded protein essential for normal cut-and-paste transposition. The mutation specifically blocked cleavage of the 5' strand at each transposon end without disturbing the breakage and joining or! the 3' strand, producing a fusion (the Shapiro Intermediate) that resulted in replicative transposition. The ability of Tn7 recombination products to serve as substrates for both the limited gap repair required to complete cut-and-paste transposition and the extensive DNA replication involved in cointegrate formation suggests a remarkable plasticity in Tn7's recruitment of host repair and replication functions.	JOHNS HOPKINS UNIV,SCH MED,DEPT MOLEC BIOL & GENET,HOWARD HUGHES MED INST,BALTIMORE,MD 21205	Howard Hughes Medical Institute; Johns Hopkins University								ARCISZEWSKA LK, 1991, J BIOL CHEM, V266, P21736; ARCISZEWSKA LK, 1989, J MOL BIOL, V207, P35, DOI 10.1016/0022-2836(89)90439-7; ARTHUR A, 1979, MOL GEN GENET, V175, P267, DOI 10.1007/BF00397226; BAINTON R, 1991, CELL, V65, P805, DOI 10.1016/0092-8674(91)90388-F; BAINTON RJ, 1993, CELL, V72, P931, DOI 10.1016/0092-8674(93)90581-A; BENDER J, 1986, CELL, V45, P801, DOI 10.1016/0092-8674(86)90555-6; Berg DE, 1989, MOBILE DNA; BIEL SW, 1984, GENETICS, V108, P319; BIERY M, UNPUB; CHALMERS RM, 1994, J BIOL CHEM, V269, P8029; CRAIG NL, 1991, MOL MICROBIOL, V5, P2569, DOI 10.1111/j.1365-2958.1991.tb01964.x; CRAIG NL, 1989, MOBILE DNA, P211; CRAIG NL, 1995, CURR TOP MICROBIOL I, V204, P27; CRAIGIE R, 1985, CELL, V41, P867, DOI 10.1016/S0092-8674(85)80067-2; DERBYSHIRE KM, 1986, CELL, V47, P325, DOI 10.1016/0092-8674(86)90586-6; GALAS DJ, 1989, MOBILE DNA, P109; GARY P, IN PRESS J MOL BIOL; HANIFORD DB, 1991, CELL, V64, P171; HANIFORD DB, 1989, CELL, V59, P385, DOI 10.1016/0092-8674(89)90299-7; KLECKNER N, 1995, CURR TOP MICROBIOL I, V204, P49; KUBO KM, 1990, J BACTERIOL, V172, P2774, DOI 10.1128/jb.172.5.2774-2778.1990; LAVOIE BD, 1990, J BIOL CHEM, V265, P1623; MAY E, UNPUB; MILLER JL, 1986, GENE, V48, P101, DOI 10.1016/0378-1119(86)90356-2; MIZUUCHI K, 1992, ANNU REV BIOCHEM, V61, P1011; NAKAI H, 1995, J BIOL CHEM, V270, P19591, DOI 10.1074/jbc.270.33.19591; OHTSUBO E, 1980, COLD SPRING HARB SYM, V45, P283, DOI 10.1101/SQB.1981.045.01.041; PEREZMORGA DL, 1993, NUCLEIC ACIDS RES, V21, P1327, DOI 10.1093/nar/21.5.1327; ROGERS M, 1986, MOL GEN GENET, V205, P550, DOI 10.1007/BF00338097; Sambrook J., 2002, MOL CLONING LAB MANU; SARNOVSKY R, UNPUB; SHAPIRO JA, 1979, P NATL ACAD SCI USA, V76, P1933, DOI 10.1073/pnas.76.4.1933; SHARPE PL, 1992, NUCLEIC ACIDS RES, V20, P2525; SHERRATT D, 1989, MOBILE DNA, P163; STELLWAGEN A, UNPUB; SURETTE MG, 1987, CELL, V49, P254; TANG Y, 1991, NUCLEIC ACIDS RES, V19, P3395, DOI 10.1093/nar/19.12.3395; WADDELL CS, 1988, GENE DEV, V2, P137, DOI 10.1101/gad.2.2.137; WEINERT TA, 1983, SCIENCE, V222, P755, DOI 10.1126/science.6314502	39	84	87	1	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 19	1996	272	5260					401	404		10.1126/science.272.5260.401	http://dx.doi.org/10.1126/science.272.5260.401			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UG252	8602527				2022-12-28	WOS:A1996UG25200044
J	Wolffe, AP				Wolffe, AP			Histone deacetylase: A regulator of transcription	SCIENCE			English	Editorial Material							DNA; ACETYLATION; INVITRO; YEAST				Wolffe, AP (corresponding author), NICHHD,MOLEC EMBRYOL LAB,NIH,BETHESDA,MD 20892, USA.							Alevizopoulos A, 1995, GENE DEV, V9, P3051, DOI 10.1101/gad.9.24.3051; ALLFREY VG, 1964, P NATL ACAD SCI USA, V51, P786, DOI 10.1073/pnas.51.5.786; BAUER WR, 1994, J MOL BIOL, V236, P685, DOI 10.1006/jmbi.1994.1180; BRAUNSTEIN M, 1993, GENE DEV, V7, P592, DOI 10.1101/gad.7.4.592; DURRIN LK, 1991, CELL, V65, P1023, DOI 10.1016/0092-8674(91)90554-C; GARCIARAMIREZ M, 1995, J BIOL CHEM, V270, P17923, DOI 10.1074/jbc.270.30.17923; HECHT A, 1995, CELL, V80, P583, DOI 10.1016/0092-8674(95)90512-X; LAYBOURN PJ, 1991, SCIENCE, V254, P238, DOI 10.1126/science.1718039; LEE DY, 1993, CELL, V72, P73, DOI 10.1016/0092-8674(93)90051-Q; LIN SY, 1975, CELL, V4, P107, DOI 10.1016/0092-8674(75)90116-6; SCHILD C, 1993, EMBO J, V12, P423, DOI 10.1002/j.1460-2075.1993.tb05674.x; Taunton J, 1996, SCIENCE, V272, P408, DOI 10.1126/science.272.5260.408; VIDAL M, 1991, MOL CELL BIOL, V11, P6317, DOI 10.1128/MCB.11.12.6317; VIDAL M, 1991, MOL CELL BIOL, V11, P6300; WANG HM, 1993, MOL CELL BIOL, V13, P1805, DOI 10.1128/MCB.13.3.1805; WANG HM, 1990, P NATL ACAD SCI USA, V87, P9761, DOI 10.1073/pnas.87.24.9761	16	263	287	0	14	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 19	1996	272	5260					371	372		10.1126/science.272.5260.371	http://dx.doi.org/10.1126/science.272.5260.371			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UG252	8602525	Green Submitted			2022-12-28	WOS:A1996UG25200036
J	Horton, R				Horton, R			Surgical research or comic opera: Questions, but few answers	LANCET			English	Editorial Material																		BEGG C, IN PRESS JAMA; KARRAN S, 1991, RECENT ADV SURG, V14, P221; Maddern GJ, 1996, BRIT J SURG, V83, P145, DOI 10.1046/j.1365-2168.1996.02185.x; Udelsman R, 1996, WORLD J SURG, V20, P88, DOI 10.1007/s002689900016; Way LW, 1996, AM J SURG, V171, P2, DOI 10.1016/S0002-9610(99)80064-6; 1981, MMWR-MORBID MORTAL W, V30, P250	6	433	443	0	17	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 13	1996	347	9007					984	985		10.1016/S0140-6736(96)90137-3	http://dx.doi.org/10.1016/S0140-6736(96)90137-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UF380	8606606				2022-12-28	WOS:A1996UF38000002
J	Bamji, AN				Bamji, AN			Brain injury rehabilitation: Jaw jaw not war war	BRITISH MEDICAL JOURNAL			English	Editorial Material																			0	2	2	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 6	1996	312	7035					916	917						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UE371	8611911				2022-12-28	WOS:A1996UE37100071
J	Darbar, D; Luck, J; Davidson, N; Pringle, T; Main, G; McNeill, G; Struthers, AD				Darbar, D; Luck, J; Davidson, N; Pringle, T; Main, G; McNeill, G; Struthers, AD			Sensitivity and specificity of QTc dispersion for identification of risk of cardiac death in patients with peripheral vascular disease	BRITISH MEDICAL JOURNAL			English	Article							VENTRICULAR ARRHYTHMIAS; RECOVERY	Objective-To determine whether QTc dispersion, which is easily obtained from a standard electrocardiogram, can predict those patients with peripheral vascular disease who will subsequently suffer a cardiac death, despite having no cardiac symptoms or signs. Design-Patients with peripheral vascular disease were followed up for five years after they had had coronary angiography, radionuclide ventriculography, and their QTc dispersion calculated from their 12 lead electrocardiogram. Subjects-49 such patients were then divided into three groups: survivors (34), cardiac death (12), and non-cardiac death (3). Main outcome measure-Survival. Results-The mean (SD; range) ejection fractions were similar in all three groups: survivors 45.9 (11.0; 27.0-52.0), cardiac death 44.0 (7.90; 28.5-59.0), and non-cardiac death 45.3 (4.55; 39.0-50.0). QTc dispersion was significantly prolonged in the cardiac death group compared with in the survivors (86.3 (23.9; 41.0-139) v 56.5 (25.4; 25.0-164); P=0.002). A QTc dispersion greater than or equal to 60 ms had a 92% sensitivity and 81% specificity in predicting cardiac death. QTc dispersion in patients with diffuse coronary artery disease was significantly (P<0.05) greater than in those with no disease or disease affecting one, two, or three vessels. Conclusions-There is a strong link between QTc dispersion and cardiac death in patients with peripheral vascular disease. QTc dispersion may therefore be a cheap and non-invasive way of assessing the risk of cardiac death in patients with peripheral vascular disease.	UNIV DUNDEE,NINEWELLS HOSP & MED SCH,DEPT CLIN PHARMACOL,DUNDEE DD1 9SY,SCOTLAND; UNIV DUNDEE,NINEWELLS HOSP & MED SCH,DEPT CARDIOL,DUNDEE DD1 9SY,SCOTLAND	University of Dundee; University of Dundee			Darbar, Dawood/C-9079-2015	Darbar, Dawood/0000-0002-4103-5977; Struthers, Allan/0000-0002-2926-2528				BARON JF, 1994, NEW ENGL J MED, V330, P663, DOI 10.1056/NEJM199403103301002; BARR CS, 1994, LANCET, V343, P327, DOI 10.1016/S0140-6736(94)91164-9; BELTRAMI CA, 1994, CIRCULATION, V89, P151, DOI 10.1161/01.CIR.89.1.151; BUJA G, 1993, AM J CARDIOL, V72, P973, DOI 10.1016/0002-9149(93)91118-2; DAVEY P, 1994, BRIT HEART J, V71, P268; HIGHAM P, 1994, BRIT HEART J, V71, P508; KAUTZNER J, 1994, PACE, V17, P928, DOI 10.1111/j.1540-8159.1994.tb01435.x; LEE HS, 1994, BR HEART J S5, V71, P98; MERX W, 1977, AM HEART J, V94, P603, DOI 10.1016/S0002-8703(77)80130-0; MORENO FL, 1994, CIRCULATION, V90, P94, DOI 10.1161/01.CIR.90.1.94; MURRAY A, 1994, BRIT HEART J, V71, P386; Potratz J., 1993, European Heart Journal, V14, P254; PYE M, 1994, BRIT HEART J, V71, P511; PYE MP, 1992, CARDIOVASC RES, V26, P740, DOI 10.1093/cvr/26.8.740; STOLETNIY LN, 1994, J AM COLL CARDIOL, pA178; WEBER KT, 1990, CIRCULATION, V82, P1387, DOI 10.1161/01.CIR.82.4.1387; WHITE HD, 1987, CIRCULATION, V76, P44, DOI 10.1161/01.CIR.76.1.44; YUNUS A, 1994, J AM COLL CARDIOL, pA179	18	78	82	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 6	1996	312	7035					874	878						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UE371	8611874				2022-12-28	WOS:A1996UE37100018
J	Towler, HMA; Lightman, S				Towler, HMA; Lightman, S			Recent advances - Ophthalmology	BRITISH MEDICAL JOURNAL			English	Article							SUBFOVEAL NEOVASCULAR MEMBRANES; MACULAR DEGENERATION		MOORFIELDS EYE HOSP,LONDON EC1V 2PD,ENGLAND; INST OPHTHALMOL,LONDON EC1V 2PD,ENGLAND	University of London; University College London; Moorfields Eye Hospital NHS Foundation Trust; University of London; University College London	Towler, HMA (corresponding author), WHIPPS CROSS HOSP & CHEST CLIN,FOREST HEALTHCARE,LONDON E11 1NR,ENGLAND.							ALGVERE PV, 1994, GRAEF ARCH CLIN EXP, V232, P707, DOI 10.1007/BF00184273; BIRD AC, 1995, AM J OPHTHALMOL, V119, P543, DOI 10.1016/S0002-9394(14)70212-0; BLUMENKRANZ MS, 1994, OPHTHALMOLOGY S, V101, P69; BRESSLER SB, 1982, AM J OPHTHALMOL, V93, P157, DOI 10.1016/0002-9394(82)90410-X; CHAKRAVARTHY U, 1993, BRIT J OPHTHALMOL, V77, P265, DOI 10.1136/bjo.77.5.265; CHAKRAVARTHY U, 1989, CURR EYE RES, V8, P337, DOI 10.3109/02713688908996381; CHAN CK, 1995, OPHTHALMOLOGY, V102, P757, DOI 10.1016/S0161-6420(95)30958-X; CHRISTMAS NJ, 1995, OPHTHALMOLOGY, V102, P263; DEBUSTROS S, 1994, OPHTHALMOLOGY, V101, P1055; FUNG WE, 1991, AM J OPHTHALMOL, V112, P349, DOI 10.1016/S0002-9394(14)76743-1; GARTRY DS, 1995, BRIT MED J, V310, P979, DOI 10.1136/bmj.310.6985.979; GLASER BM, 1992, OPHTHALMOLOGY, V99, P1162; Hingorani M, 1995, BRIT J OPHTHALMOL, V79, P1138, DOI 10.1136/bjo.79.12.1138; KELMAN CD, 1967, AM J OPHTHALMOL, V64, P23, DOI 10.1016/0002-9394(67)93340-5; LAMBERT HM, 1992, AM J OPHTHALMOL, V113, P257, DOI 10.1016/S0002-9394(14)71576-4; LIU C, 1993, EYE, V7, P550, DOI 10.1038/eye.1993.120; MARTIN DF, 1994, ARCH OPHTHALMOL-CHIC, V112, P1531, DOI 10.1001/archopht.1994.01090240037023; MCCLAUGHLIN M, 1993, NAT GENET, V4, P130; MORLEY MG, 1995, OPHTHALMOLOGY, V102, P388; MURRAY T, 1993, EYE, V7, P332, DOI 10.1038/eye.1993.71; Nason R J, 1994, J Am Optom Assoc, V65, P774; NEUHANN T, 1987, KLIN MONATSBL AUGENH, V190, P542, DOI 10.1055/s-2008-1050454; NEWSOME DA, 1988, ARCH OPHTHALMOL-CHIC, V106, P192; PARK SS, 1995, OPHTHALMOLOGY, V102, P775, DOI 10.1016/S0161-6420(95)30956-6; REPKA MX, 1994, ARCH OPHTHALMOL-CHIC, V112, P1320, DOI 10.1001/archopht.1994.01090220070025; Rubinstein MP, 1995, J BRIT CONT LENS A, V18, P95; SANBORN GE, 1992, ARCH OPHTHALMOL-CHIC, V110, P188, DOI 10.1001/archopht.1992.01080140044023; SCOTT A, 1990, OPHTHALMOLOGY, V97, P134; WROBLEWSKI JJ, 1994, BRIT J OPHTHALMOL, V78, P831, DOI 10.1136/bjo.78.11.831; 1991, ARCH OPHTHALMOL-CHIC, V109, P1220	30	3	3	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 6	1996	312	7035					889	892						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UE371	8611883				2022-12-28	WOS:A1996UE37100028
J	Scanziani, M; Malenka, RC; Nicoll, RA				Scanziani, M; Malenka, RC; Nicoll, RA			Role of intercellular interactions in heterosynaptic long-term depression	NATURE			English	Article							SYNAPTIC PLASTICITY; AREA CA1; HIPPOCAMPUS; POTENTIATION; RECEPTORS; INDUCTION; RAT; STIMULATION	BIDIRECTIONAL control of synaptic strength is thought to be important for the development of neuronal circuits and information storage. The demonstration of homosynaptic long-term depression(1) greatly enhances the usefulness of the synapse as a mnemonic device, but theoreticians have also seen the need for heterosynaptic decreases in synaptic efficacy, both in neuronal development(2-4) and information storage(5). Indeed, induction of long-term potentiation in one population of synapses can be associated with a modest depression at neighbouring inactive synapses in the same population of cells(6-10). Here we report that in the CA1 region of the hippocampus this heterosynaptic long-term depression has the property that its sites of induction and expression occur in different populations of cells and thus requires the spread of a signal between neurons. Such a mechanism ensures a widespread distribution of this form of plasticity.	UNIV CALIF SAN FRANCISCO,DEPT PHYSIOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT PSYCHIAT,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco	Scanziani, M (corresponding author), UNIV CALIF SAN FRANCISCO,DEPT MOLEC & CELLULAR PHARMACOL,SAN FRANCISCO,CA 94143, USA.							ARTOLA A, 1993, TRENDS NEUROSCI, V16, P480, DOI 10.1016/0166-2236(93)90081-V; BASKYS A, 1991, J PHYSIOL-LONDON, V444, P687, DOI 10.1113/jphysiol.1991.sp018901; Bear Mark F., 1994, Current Opinion in Neurobiology, V4, P389, DOI 10.1016/0959-4388(94)90101-5; BONHOEFFER T, 1989, P NATL ACAD SCI USA, V86, P8113, DOI 10.1073/pnas.86.20.8113; BOULTON CL, 1994, EUR J NEUROSCI, V6, P1528, DOI 10.1111/j.1460-9568.1994.tb00543.x; CASTILLO PE, 1994, NEURON, V12, P261, DOI 10.1016/0896-6273(94)90269-0; CASTROALAMANCOS MA, 1995, J NEUROSCI, V15, P5324; CHAN CP, 1988, P NATL ACAD SCI USA, V85, P6257, DOI 10.1073/pnas.85.17.6257; CHRISTIE BR, 1994, HIPPOCAMPUS, V4, P127, DOI 10.1002/hipo.450040203; COLLINGRIDGE GL, 1990, TRENDS PHARMACOL SCI, V11, P290, DOI 10.1016/0165-6147(90)90011-V; DESMOND NL, 1991, BRAIN RES, V552, P93, DOI 10.1016/0006-8993(91)90664-H; GROVER LM, 1993, NEUROSCI LETT, V154, P39, DOI 10.1016/0304-3940(93)90166-I; LINDEN DJ, 1995, ANNU REV NEUROSCI, V18, P319, DOI 10.1146/annurev.ne.18.030195.001535; LYNCH GS, 1977, NATURE, V266, P737, DOI 10.1038/266737a0; MANZONI OJ, 1994, SCIENCE, V265, P2098, DOI 10.1126/science.7916485; MARTIN KAC, 1988, Q J EXP PHYSIOL CMS, V73, P637, DOI 10.1113/expphysiol.1988.sp003190; MULKEY RM, 1992, NEURON, V9, P967, DOI 10.1016/0896-6273(92)90248-C; MULKEY RM, 1993, SCIENCE, V261, P1051, DOI 10.1126/science.8394601; MULLER D, 1995, NEURON, V14, P599, DOI 10.1016/0896-6273(95)90316-X; SAH P, 1989, SCIENCE, V246, P815, DOI 10.1126/science.2573153; SCHREURS BG, 1993, BRAIN RES, V631, P235, DOI 10.1016/0006-8993(93)91540-9; SCHUMAN EM, 1994, SCIENCE, V263, P532, DOI 10.1126/science.8290963; SEJNOWSKI IJ, 1977, J THEOR BIOL, V69, P385, DOI 10.1016/0022-5193(77)90146-1; STENT GS, 1973, P NATL ACAD SCI USA, V70, P997, DOI 10.1073/pnas.70.4.997; WICKENS JR, 1991, NEUROSCI LETT, V130, P128, DOI 10.1016/0304-3940(91)90244-N; WIGSTROM H, 1983, NATURE, V301, P603, DOI 10.1038/301603a0; WILSON MA, 1993, SCIENCE, V261, P1055, DOI 10.1126/science.8351520	27	89	90	0	6	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	APR 4	1996	380	6573					446	450		10.1038/380446a0	http://dx.doi.org/10.1038/380446a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UD590	8602244				2022-12-28	WOS:A1996UD59000064
J	[Anonymous]				[Anonymous]			Burdens of proof of misconduct	NATURE			English	Editorial Material																			0	0	0	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 4	1996	380	6573					367	367						1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UD590	8602225				2022-12-28	WOS:A1996UD59000001
J	Hein, HO; Suadicani, P; Gyntelberg, F				Hein, HO; Suadicani, P; Gyntelberg, F			Alcohol consumption, serum low density lipoprotein cholesterol concentration, and risk of ischaemic heart disease: Six year follow up in the Copenhagen male study	BRITISH MEDICAL JOURNAL			English	Article							MORTALITY; MEN	Objectives-To investigate the interplay between use of alcohol, concentration of low density lipoprotein cholesterol, and risk of ischaemic heart disease. Design-Prospective study with controlling for several relevant confounders, including concentrations of other lipid fractions. Setting-Copenhagen male study, Denmark. Subjects-2826 men aged 53-74 years without overt ischaemic heart disease. Main outcome measure-Incidence of ischaemic heart disease during a six year follow up period. Results-172 men (6.1%) had a first ischaemic heart disease event. There was an overall inverse association between alcohol intake and risk of ischaemic heart disease. The association was highly dependent on concentration of low density lipoprotein cholesterol. In men with a high concentration (greater than or equal to 5.25 mmol/l) cumulative incidence rates of ischaemic heart disease were 16.4% for abstainers, 8.7% for those who drank 1-21 beverages a week, and 4.4% for those who drank 22 or more beverages a week. With abstainers as reference and after adjust ment for confounders, corresponding relative risks (95% confidence interval) were 0.4 (0.2 to 1.0; P<0.05) and 0.2 (0.1 to 0.8; P<0.01). In men with a concentration <3.63 mmol/l use of alcohol was not associated with risk. The attributable risk (95% confidence interval) of ischaemic heart disease among men with concentrations greater than or equal to 3.63 mmol/l who abstained from drinking alcohol was 43% (10% to 64%). Conclusions-In middle aged and elderly men the inverse association between alcohol consumption and risk of ischaemic heart disease is highly dependent on the concentration of low density lipoprotein cholesterol. These results support the suggestion that use of alcohol may in part explain the French paradox.			Hein, HO (corresponding author), STATE UNIV HOSP,RIGSHOSP 7122,EPIDEMIOL RES UNIT,DK-2200 COPENHAGEN N,DENMARK.							BURSTEIN M, 1970, J LIPID RES, V11, P583; CASTELLI WP, 1977, LANCET, V2, P153; CASTELLI WP, 1984, AM J MED, V76, P2; CRIQUI MH, 1987, AM J EPIDEMIOL, V126, P629, DOI 10.1093/oxfordjournals.aje.a114702; CRIQUI MH, 1994, LANCET, V344, P1719, DOI 10.1016/S0140-6736(94)92883-5; FOLSOM AR, 1955, EUR HEART J SA, V16, P21; FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499; GAZIANO JM, 1993, NEW ENGL J MED, V329, P1829, DOI 10.1056/NEJM199312163292501; GYNTELBERG F, 1973, DAN MED BULL, V20, P1; GYNTELBERG F, 1975, DAN MED BULL, V22, P81; HEIN HO, 1992, J INTERN MED, V232, P481, DOI 10.1111/j.1365-2796.1992.tb00620.x; HEIN HO, 1993, LANCET, V341, P392, DOI 10.1016/0140-6736(93)92987-5; HEINRICH J, 1994, ARTERIOSCLER THROMB, V14, P54, DOI 10.1161/01.ATV.14.1.54; HENDRIKS HFJ, 1994, BRIT MED J, V308, P1003, DOI 10.1136/bmj.308.6935.1003; KIECHL S, 1994, STROKE, V25, P1593, DOI 10.1161/01.STR.25.8.1593; KLEINBAUM DG, 1982, EPIDEMIOLOGIC RES; LOPESVIRELLA MF, 1977, CLIN CHEM, V23, P882; NORUSIS MJ, 1988, SPSS PC PLUS BASE MA; NORUSIS MJ, 1988, SPSS PC PLUS ADV STA; RENAUD S, 1992, LANCET, V339, P1523, DOI 10.1016/0140-6736(92)91277-F; RIDKER PM, 1994, JAMA-J AM MED ASSOC, V272, P929, DOI 10.1001/jama.272.12.929; RIMM EB, 1991, LANCET, V338, P464, DOI 10.1016/0140-6736(91)90542-W; Rose G, 1982, CARDIOVASCULAR SURVE; ROSE GA, 1964, LANCET, V1, P296; SHAPER AG, 1990, BRIT J ADDICT, V85, P837; SHAPER AG, 1988, LANCET, V2, P1267; SIEDEL J, 1981, J CLIN CHEM CLIN BIO, V19, P838; Stahler F, 1977, Med Lab (Stuttg), V30, P29; SUADICANI P, 1994, INT J EPIDEMIOL, V23, P293, DOI 10.1093/ije/23.2.293; SUH I, 1992, ANN INTERN MED, V116, P881, DOI 10.7326/0003-4819-116-11-881; Svalastoga Kaare, 1959, PRESTIGE CLASS MOBIL; TUNSTALLPEDOE H, 1994, CIRCULATION, V90, P583, DOI 10.1161/01.CIR.90.1.583; YANO K, 1977, NEW ENGL J MED, V297, P405, DOI 10.1056/NEJM197708252970801; 1960, BRIT MED J, V2, P1665	34	98	99	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 23	1996	312	7033					736	741						8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UC166	8605458	Green Published			2022-12-28	WOS:A1996UC16600024
J	McCabe, ERB; Fine, BA; Golbus, MS; Greenhouse, JB; McGrath, GL; New, M; OBrien, WE; Rowley, PT; Sly, WS; Spence, MA; Stockman, JA; Whyte, M; Wilson, W; Wolf, B; Aerts, JMFG; Barranger, JA; Barton, NW; Beutler, E; Brady, RO; Cox, TM; Ekstein, J; Eng, CM; Erikson, A; Findling, DM; Garber, AM; Ginns, EI; Grabowski, GA; Hill, SC; Hollack, CEM; Kaback, MM; Lee, RE; Mankin, HJ; Mistry, PK; Moscicki, RA; Murray, GJ; Natowicz, M; Pastores, GM; Miranda, MCS; Sidransky, E; Ware, JE; Willemsen, R; Zaizov, R; Zimran, A; Beitins, IZ; Berman, RE; Elliott, JM; Ferguson, JH; Hall, WH; McKeon, C; Nitkin, RM; Schlesinger, SL; Sheridan, PH; Weeks, M; Cowdry, RW; Alexander, DF; Gorden, P; Hall, ZW; Vaitukaitis, JL; Collins, FS; Groft, S				McCabe, ERB; Fine, BA; Golbus, MS; Greenhouse, JB; McGrath, GL; New, M; OBrien, WE; Rowley, PT; Sly, WS; Spence, MA; Stockman, JA; Whyte, M; Wilson, W; Wolf, B; Aerts, JMFG; Barranger, JA; Barton, NW; Beutler, E; Brady, RO; Cox, TM; Ekstein, J; Eng, CM; Erikson, A; Findling, DM; Garber, AM; Ginns, EI; Grabowski, GA; Hill, SC; Hollack, CEM; Kaback, MM; Lee, RE; Mankin, HJ; Mistry, PK; Moscicki, RA; Murray, GJ; Natowicz, M; Pastores, GM; Miranda, MCS; Sidransky, E; Ware, JE; Willemsen, R; Zaizov, R; Zimran, A; Beitins, IZ; Berman, RE; Elliott, JM; Ferguson, JH; Hall, WH; McKeon, C; Nitkin, RM; Schlesinger, SL; Sheridan, PH; Weeks, M; Cowdry, RW; Alexander, DF; Gorden, P; Hall, ZW; Vaitukaitis, JL; Collins, FS; Groft, S			Gaucher disease - Current issues in diagnosis and treatment	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								Objective.-To provide physicians with a responsible assessment of the diagnosis and treatment of Gaucher disease. Participants.-A nonfederal, nonadvocate, 14-member panel representing the fields of pediatrics, obstetrics and gynecology, genetics, endocrinology, molecular biology, internal medicine, and biostatistics. In addition, 30 experts in genetics, pediatrics, neurology, obstetrics and gynecology, orthopedics, hematology, genetic counseling, clinical pathology, and epidemiology presented data to the panel and a conference audience of 230 during a 1 1/2-day public session. Questions and statements from conference attendees were considered during the open session. Closed deliberations by the panel occurred during the remainder of the second day and the morning of the third. Evidence.-The literature was searched through MEDLINE, and an extensive bibliography of references was provided to the panel and the conference audience. Experts prepared abstracts with relevant citations from the literature. Scientific evidence was given precedence over clinical anecdotal experience. Consensus Process.-The panel, answering predefined questions, developed their conclusions based on the scientific evidence presented in open forum and on the scientific literature. The panel composed a draft statement that was read in its entirety and circulated to the experts and the audience for comment. Thereafter, the panel resolved conflicting recommendations and released a revised statement at the end of the conference. The panel finalized the revisions within a few weeks after the conference. Conclusions.-Despite the success of enzyme therapy, treatment is limited by the cost of the agent. This makes it imperative to determine the lowest effective initial and maintenance doses, to define the appropriate clinical indications for treatment, and to establish uniform methods to optimize outcome assessment. The value of treatment for asymptomatic individuals has not been determined. General population screening for affected individuals and for carriers is not appropriate at this time. As a prototype for all rare diseases, the plight of patients with Gaucher disease raises difficult financial and ethical issues, which we as a society must address.	NORTHWESTERN UNIV,SCH MED,GRAD PROGRAM GENET COUNSELING,DEPT OBSTET & GYNECOL,CHICAGO,IL; UNIV CALIF SAN FRANCISCO,DEPT OBSTET GYNECOL & REPROD SCI,SAN FRANCISCO,CA 94143; CARNEGIE MELLON UNIV,DEPT STAT,PITTSBURGH,PA 15213; NEW YORK HOSP,CORNELL MED CTR,DEPT PEDIAT,NEW YORK,NY; BAYLOR COLL MED,DEPT MOLEC & HUMAN GENET,HOUSTON,TX; UNIV ROCHESTER,SCH MED,DEPT MED,DIV GENET,ROCHESTER,NY; ST LOUIS UNIV,SCH MED,DEPT BIOCHEM & MOLEC BIOL,ST LOUIS,MO 63104; UNIV CALIF IRVINE,DIV HUMAN GENET,DEPT PEDIAT,IRVINE,CA; DUKE UNIV,MED CTR,DURHAM,NC; UNIV N CAROLINA,SCH MED,CHAPEL HILL,NC; WASHINGTON UNIV,SCH MED,ST LOUIS,MO; WESTERN MONTANA CLIN,MISSOULA,MT; VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DEPT HUMAN GENET,RICHMOND,CA; VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DEPT PEDIAT,RICHMOND,CA	Northwestern University; University of California System; University of California San Francisco; Carnegie Mellon University; Cornell University; NewYork-Presbyterian Hospital; Baylor College of Medicine; University of Rochester; Saint Louis University; University of California System; University of California Irvine; Duke University; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; Washington University (WUSTL); Virginia Commonwealth University; Virginia Commonwealth University	McCabe, ERB (corresponding author), UNIV CALIF LOS ANGELES,SCH MED,DEPT PEDIAT,LOS ANGELES,CA 90024, USA.		Garber, Alan M/F-1476-2010; Greenhouse, Joel/W-2132-2019; Stockman, James/ABG-6085-2021; Pastores, Gregory M./AAE-8647-2020; Aerts, Johannes/A-1028-2009	Greenhouse, Joel/0000-0001-5087-9648; Aerts, Johannes/0000-0001-8168-2565					0	85	92	0	8	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 21	1996	275	7					548	553		10.1001/jama.1996.03530310054033	http://dx.doi.org/10.1001/jama.1996.03530310054033			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TV569	8606477	Green Submitted			2022-12-28	WOS:A1996TV56900033
J	Mitchison, TJ; Cramer, LP				Mitchison, TJ; Cramer, LP			Actin-based cell motility and cell locomotion	CELL			English	Review							NEURONAL GROWTH CONE; HEAVY-CHAIN GENE; MYOSIN-I; LIVING FIBROBLASTS; NERVE GROWTH; CENTRIPETAL TRANSPORT; DICTYOSTELIUM; FILAMENTS; ORGANIZATION; LAMELLIPODIA				Mitchison, TJ (corresponding author), UNIV CALIF SAN FRANCISCO, DEPT CELLULAR & MOLEC PHARMACOL, SAN FRANCISCO, CA 94143 USA.				NIGMS NIH HHS [GM48027] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAINES IC, 1992, J CELL BIOL, V119, P1193, DOI 10.1083/jcb.119.5.1193; BILOZUR ME, 1989, CELL MOTIL CYTOSKEL, V14, P469, DOI 10.1002/cm.970140405; BRAY D, 1988, SCIENCE, V239, P883, DOI 10.1126/science.3277283; BRAY D, 1979, J CELL SCI, V37, P391; BRAY D, 1985, J NEUROSCI, V5, P3204; BRIDGMAN PC, 1989, J CELL BIOL, V108, P95, DOI 10.1083/jcb.108.1.95; CONDEELIS J, 1992, CELL MOTIL CYTOSKEL, V22, P1, DOI 10.1002/cm.970220102; CORTESE JD, 1989, P NATL ACAD SCI USA, V86, P5773, DOI 10.1073/pnas.86.15.5773; COSSART P, 1995, CURR OPIN CELL BIOL, V7, P94, DOI 10.1016/0955-0674(95)80050-6; COUCHMAN JR, 1979, J CELL SCI, V39, P149; COX D, 1995, J CELL BIOL, V128, P819, DOI 10.1083/jcb.128.5.819; CRAMER L, 1993, J CELL BIOL, V122, P833, DOI 10.1083/jcb.122.4.833; CRAMER LP, 1994, CURR OPIN CELL BIOL, V6, P82, DOI 10.1016/0955-0674(94)90120-1; CRAMER LP, 1995, J CELL BIOL, V131, P179, DOI 10.1083/jcb.131.1.179; CUDMORE S, 1995, NATURE, V378, P636, DOI 10.1038/378636a0; DELOZANNE A, 1987, SCIENCE, V236, P1086, DOI 10.1126/science.3576222; DOOLITTLE KW, 1995, DEV BIOL, V167, P118, DOI 10.1006/dbio.1995.1011; FISHER GW, 1988, CELL MOTIL CYTOSKEL, V11, P235, DOI 10.1002/cm.970110403; FORSCHER P, 1988, J CELL BIOL, V107, P1505, DOI 10.1083/jcb.107.4.1505; FUKUI Y, 1989, NATURE, V341, P328, DOI 10.1038/341328a0; GREBECKI A, 1994, INT REV CYTOL, V148, P37; HARRIS A, 1972, EXP CELL RES, V73, P519, DOI 10.1016/0014-4827(72)90084-5; Hartwig JH, 1991, CURR OPIN CELL BIOL, V3, P87, DOI 10.1016/0955-0674(91)90170-4; HEIDEMANN SR, 1991, J CELL SCI, P35; HEINZEN RA, 1993, INFECT IMMUN, V61, P1926, DOI 10.1128/IAI.61.5.1926-1935.1993; Hotani H, 1990, Adv Biophys, V26, P135, DOI 10.1016/0065-227X(90)90010-Q; HUXLEY HE, 1973, NATURE, V244, P445, DOI 10.1038/243445a0; INOUE S, 1995, MOL BIOL CELL, V6, P1619, DOI 10.1091/mbc.6.12.1619; Italiano JE, 1996, CELL, V84, P105, DOI 10.1016/S0092-8674(00)80997-6; JAY PY, 1992, NATURE, V356, P438, DOI 10.1038/356438a0; JAY PY, 1995, J CELL SCI, V108, P387; JUNG G, 1990, J CELL BIOL, V110, P1955, DOI 10.1083/jcb.110.6.1955; KNECHT DA, 1987, SCIENCE, V236, P1081, DOI 10.1126/science.3576221; KOLEGA J, 1993, MOL BIOL CELL, V4, P819, DOI 10.1091/mbc.4.8.819; KUCIK DF, 1989, NATURE, V340, P315, DOI 10.1038/340315a0; KURODA K, 1990, INT REV CYTOL, P121; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; LEE J, 1993, NATURE, V362, P167, DOI 10.1038/362167a0; LEE J, 1994, J CELL BIOL, V127, P1957, DOI 10.1083/jcb.127.6.1957; LEWIS AK, 1992, J CELL BIOL, V119, P1219, DOI 10.1083/jcb.119.5.1219; LIN CH, 1995, NEURON, V14, P763, DOI 10.1016/0896-6273(95)90220-1; Matsudaira Paul, 1994, Seminars in Cell Biology, V5, P165, DOI 10.1006/scel.1994.1021; MCGOLDRICK CA, 1995, J CELL BIOL, V128, P577, DOI 10.1083/jcb.128.4.577; MCKENNA NM, 1989, J CELL BIOL, V109, P1163, DOI 10.1083/jcb.109.3.1163; MITCHISON T, 1988, NEURON, V1, P761, DOI 10.1016/0896-6273(88)90124-9; MITCHISON TJ, 1995, PHILOS T ROY SOC B, V349, P299, DOI 10.1098/rstb.1995.0117; MOON A, 1995, MOL BIOL CELL, V6, P1423, DOI 10.1091/mbc.6.11.1423; Oliver Tim, 1994, Seminars in Cell Biology, V5, P139, DOI 10.1006/scel.1994.1018; PASTERNAK C, 1989, NATURE, V341, P549, DOI 10.1038/341549a0; PESKIN CS, 1993, BIOPHYS J, V65, P316, DOI 10.1016/S0006-3495(93)81035-X; POLLARD TD, 1986, ANNU REV BIOCHEM, V55, P987, DOI 10.1146/annurev.bi.55.070186.005011; RIDLEY AJ, 1995, CURR OPIN GENET DEV, V5, P24, DOI 10.1016/S0959-437X(95)90049-7; ROBERTS TM, 1995, CURR OPIN CELL BIOL, V7, P13, DOI 10.1016/0955-0674(95)80039-5; SCHMIDT CE, 1994, BIOPHYS J, V67, P461, DOI 10.1016/S0006-3495(94)80502-8; Sheetz Michael P., 1994, Seminars in Cell Biology, V5, P149, DOI 10.1006/scel.1994.1019; SHEETZ MP, 1989, NATURE, V340, P284, DOI 10.1038/340284a0; SHEETZ MP, 1990, CELL, V61, P231, DOI 10.1016/0092-8674(90)90804-N; SHEETZ MP, 1992, CELL MOTIL CYTOSKEL, V22, P160, DOI 10.1002/cm.970220303; Small J V, 1988, Electron Microsc Rev, V1, P155; Small J. Victor, 1994, Seminars in Cell Biology, V5, P157, DOI 10.1006/scel.1994.1020; SMALL JV, 1995, J CELL BIOL, V129, P1275, DOI 10.1083/jcb.129.5.1275; SMITH SJ, 1988, SCIENCE, V242, P708, DOI 10.1126/science.3055292; SUN HQ, 1995, CURR OPIN CELL BIOL, V7, P102, DOI 10.1016/0955-0674(95)80051-4; TEMMGROVE C, 1992, J CELL SCI, V101, P599; THERIOT JA, 1992, J CELL BIOL, V119, P367, DOI 10.1083/jcb.119.2.367; THERIOT JA, 1991, NATURE, V352, P126, DOI 10.1038/352126a0; Theriot JA, 1995, ANNU REV CELL DEV BI, V11, P213, DOI 10.1146/annurev.cb.11.110195.001241; TILNEY LG, 1982, J CELL BIOL, V93, P820, DOI 10.1083/jcb.93.3.820; TILNEY LG, 1989, J CELL BIOL, V109, P1597, DOI 10.1083/jcb.109.4.1597; TITUS MA, 1993, MOL BIOL CELL, V4, P233, DOI 10.1091/mbc.4.2.233; TOMASEK JJ, 1982, DEV BIOL, V92, P107, DOI 10.1016/0012-1606(82)90155-5; VASILIEV JM, 1991, J CELL SCI, V98, P1; WAGNER MC, 1992, J CELL BIOL, V119, P163, DOI 10.1083/jcb.119.1.163; WANG YL, 1985, J CELL BIOL, V101, P597, DOI 10.1083/jcb.101.2.597; WESSELS D, 1991, CELL MOTIL CYTOSKEL, V20, P301, DOI 10.1002/cm.970200406; ZHUKAREV V, 1995, CELL MOTIL CYTOSKEL, V30, P229, DOI 10.1002/cm.970300307; ZIGMOND SH, 1993, CELL MOTIL CYTOSKEL, V25, P309, DOI 10.1002/cm.970250402	77	1275	1293	1	93	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 9	1996	84	3					371	379		10.1016/S0092-8674(00)81281-7	http://dx.doi.org/10.1016/S0092-8674(00)81281-7			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TV708	8608590	Bronze			2022-12-28	WOS:A1996TV70800005
J	Barlow, D; Cooper, C; Reeve, J; Reid, D				Barlow, D; Cooper, C; Reeve, J; Reid, D			Controversies in management - Department of health shoots itself in the hip - Department of health is fair to patients with osteoporosis	BRITISH MEDICAL JOURNAL			English	Article									SOUTHAMPTON GEN HOSP,MRC,ENVIRONM EPIDEMIOL UNIT,SOUTHAMPTON SO16 6YD,HANTS,ENGLAND; JOHN RADCLIFFE HOSP,NUFFIELD DEPT OBSTET & GYNAECOL,OXFORD OX3 9DU,ENGLAND; UNIV CAMBRIDGE,ADDENBROOKES HOSP,DEPT MED,CAMBRIDGE CB2 2QQ,ENGLAND; ABERDEEN ROYAL INFIRM,ABERDEEN AB9 2ZB,SCOTLAND	University of Southampton; University of Oxford; Addenbrooke's Hospital; University of Cambridge; University of Aberdeen			Reeve, Jonathan/C-7551-2012	Reeve, Jonathan/0000-0002-4364-2682				[Anonymous], 1994, WHO TECH REP SER, V843; BLACK DM, 1993, OSTEOPOROSIS INT, V3, P29; COMPSTON JE, 1995, BRIT MED J, V310, P1507, DOI 10.1136/bmj.310.6993.1507; COMPSTON JE, 1995, BRIT MED J, V311, P687, DOI 10.1136/bmj.311.7006.687a; COOPER C, 1995, NEW ENGL J MED, V332, P814, DOI 10.1056/NEJM199503233321210; CUMMINGS SR, 1995, NEW ENGL J MED, V332, P767, DOI 10.1056/NEJM199503233321202; LIBERMANN WA, 1995, NEW ENGL J MED, V333, P1437; 1989, J BONE MINER RES S2, V4, P1; 1994, ADVISORY GROUP OSTEO	9	8	8	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 3	1996	312	7026					297	298						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TU507	8611791				2022-12-28	WOS:A1996TU50700031
J	Patz, JA; Epstein, PR; Burke, TA; Balbus, JM				Patz, JA; Epstein, PR; Burke, TA; Balbus, JM			Global climate change and emerging infectious diseases	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							AEDES-AEGYPTI DIPTERA; SUB-SAHARAN AFRICA; CONTACT HYPERSENSITIVITY; SCHISTOSOMA-HAEMATOBIUM; ULTRAVIOLET-IRRADIATION; IMMUNE-SYSTEM; UV-RADIATION; SEA-LEVEL; TEMPERATURE; SUPPRESSION	Climatic factors influence the emergence and reemergence of infectious diseases, in addition to multiple human, biological, and ecological determinants. Climatologists have identified upward trends in global temperatures and now estimate an unprecedented rise of 2.0 degrees C by the year 2100. Of major concern is that these changes can affect the introduction and dissemination of many serious infectious diseases. The incidence of mosquito-borne diseases, including malaria, dengue, and viral encephalitides, are among those diseases most sensitive to climate. Climate change would directly affect disease transmission by shifting the vector's geographic range and increasing reproductive and biting rates and by shortening the pathogen incubation period. Climate-related increases in sea surface temperature and sea level can lead to higher incidence of water-borne infectious and toxin-related illnesses, such as cholera and shellfish poisoning. Human migration and damage to health infrastructures from the projected increase in climate variability could indirectly contribute to disease transmission. Human susceptibility to infections might be further compounded by malnutrition due to climate stress on agriculture and potential alterations in the human immune system caused by increased flux of ultraviolet radiation. Analyzing the role of climate in the emergence of human infectious diseases will require interdisciplinary cooperation among physicians, climatologists, biologists, and social scientists. Increased disease surveillance; integrated modeling, and use of geographically based data systems wilt afford more anticipatory measures by the medical community. Understanding the linkages between climatological and ecological change as determinants of disease emergence and redistribution will ultimately help optimize preventive strategies.	JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,DEPT HLTH POLICY,BALTIMORE,MD 21205; HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA; GEORGE WASHINGTON UNIV,SCH MED & HLTH SCI,DIV ENVIRONM & OCCUPAT MED,WASHINGTON,DC 20052	Johns Hopkins University; Harvard University; Harvard Medical School; George Washington University	Patz, JA (corresponding author), JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,DEPT MOLEC MICROBIOL & IMMUNOL,615 N WOLFE ST,BALTIMORE,MD 21205, USA.							ALONSO PL, 1994, LANCET, V344, P1175, DOI 10.1016/S0140-6736(94)90505-3; ANDERSON DM, 1992, HARMFUL ALGAE NEWS, V2, P4; [Anonymous], 1995, ECOSYST HEALLTH; [Anonymous], 1993, BRUCE CHWATTS ESSENT; [Anonymous], 1992, IARC MONOGRAPHS EVAL, V55; [Anonymous], 1991, MALARIA OBSTACLES OP; BAADSGAARD O, 1991, ARCH DERMATOL, V127, P99, DOI 10.1001/archderm.127.1.99; BARNOLA JM, 1994, TRENDS 93 COMPENDIUM, V65; Benenson AS, 1990, CONTROL COMMUNICABLE, V15th; BOUMA MJ, 1994, LANCET, V343, P1440, DOI 10.1016/S0140-6736(94)92569-0; BOWEN SG, 1980, ST LOUIS ENCEPHALITI; Brown A. W. A., 1983, Integrated mosquito control methodologies. Volume 1. Experience and components from conventional chemical control, P161; BRUCE JP, 1994, B AM METEOROL SOC, V75, P1831, DOI 10.1175/1520-0477(1994)075<1831:NDRAGC>2.0.CO;2; Centers for Disease Control and Prevention, 1994, ADDRESSING EMERGING; CESTARI TF, 1995, J INVEST DERMATOL, V105, P8, DOI 10.1111/1523-1747.ep12312309; CHANDLER AC, 1945, AM J TROP MED, V25, P145; CIAIS P, 1995, SCIENCE, V269, P1098, DOI 10.1126/science.269.5227.1098; COOPER KD, 1992, P NATL ACAD SCI USA, V89, P8497, DOI 10.1073/pnas.89.18.8497; CRUZ PD, 1988, PHOTODERMATOLOGY, V5, P151; DAYNES RA, 1990, GLOBAL ATMOSPHERIC C; DEFABO EC, 1983, J EXP MED, V157, P84; DOBSON A, 1993, LANCET, V342, P1096, DOI 10.1016/0140-6736(93)92069-6; DOBSON A, 1992, GLOBAL WARMING BIOL; EPSTEIN PR, 1995, AM J PUBLIC HEALTH, V85, P168, DOI 10.2105/AJPH.85.2.168; EPSTEIN PR, 1994, DIS EVOLUTION GLOBAL, P423; Figueroa M, 1982, Bull Pan Am Health Organ, V16, P130; FLAVIN C, 1994, WORLD WATCH, V7, P10; FOCKS DA, 1995, AM J TROP MED HYG, V53, P489, DOI 10.4269/ajtmh.1995.53.489; GIANNINI MS, 1990, GLOBAL ATMOSPHERIC C; GILLETT JD, 1974, EFFECTS METEOROLOGIC, P79; Glantz M.H., 1991, TELECONNECTIONS LINK; GLASS GE, 1993, APPLICATIONS GIS TEC; GREENWOOD BM, 1984, LANCET, V1, P1339; GUBLER DJ, 1995, EMERG INFECT DIS, V1, P55; GUBLER DJ, 1994, INFECT AGENT DIS, V2, P383; Haile D.G., 1989, POTENTIAL EFFECTS GL; HAINES A, 1991, J PUBLIC HEALTH MED, V13, P69; HALSTEAD SB, 1988, HDB VIRAL RICKETTSIA, P85; Halstead Scott B., 1993, Tropical Medicine, V35, P137; HARDY JL, 1988, ARBOVIRUSES EPIDEMIO, V1; HERRERABASTO E, 1992, AM J TROP MED HYG, V46, P649, DOI 10.4269/ajtmh.1992.46.649; HERSEY P, 1983, J IMMUNOL, V31, P171; Houghton J.T., 1990, CLIMATE CHANGE IPCC; Houghton J.T., 1992, CLIMATE CHANGE 1992; HUQ A, 1990, APPL ENVIRON MICROB, V56, P2370, DOI 10.1128/AEM.56.8.2370-2373.1990; JEEVAN A, 1990, CELL IMMUNOL, V130, P32, DOI 10.1016/0008-8749(90)90159-O; JETTEN TH, 1994, CHANGE, V18, P10; KARL TR, 1993, B AM METEOROL SOC, V74, P1007, DOI 10.1175/1520-0477(1993)074<1007:ANPORG>2.0.CO;2; KARL TR, 1995, NATURE, V377, P217, DOI 10.1038/377217a0; Karl TR, 1995, CONSEQUENCES, V1, P3; KERR JB, 1993, SCIENCE, V262, P1032, DOI 10.1126/science.262.5136.1032; Kiladis GN, 1989, J CLIMATE, V2, P1069, DOI 10.1175/1520-0442(1989)002<1069:GCAAWE>2.0.CO;2; KOOPMAN JS, 1991, AM J EPIDEMIOL, V133, P1168, DOI 10.1093/oxfordjournals.aje.a115829; KRIPKE ML, 1986, J INVEST DERMATOL, V86, P543, DOI 10.1111/1523-1747.ep12355000; KRIPKE ML, 1992, EFFECTS HUMAN HLTH U; LARCOM LL, 1990, J NATL CANCER I, V82, P1361, DOI 10.1093/jnci/82.16.1361; LEAF A, 1989, NEW ENGL J MED, V321, P1577, DOI 10.1056/NEJM198912073212305; Lederberg J., 1992, EMERGING INFECTIONS; Lembeye G., 1992, HARMFUL ALGAE NEWS, V2, P1; LEVINS R, 1994, AM SCI, V82, P52; LOEVINSOHN ME, 1994, LANCET, V343, P714, DOI 10.1016/S0140-6736(94)91586-5; LONGSTRETH JA, 1989, POTENTIAL EFFECTS GL; MACDONALD G, 1954, TROPICAL DIS B, V50, P871; MACDONALD W W, 1956, Ann Trop Med Parasitol, V50, P399; MARTENS WJM, 1995, ENVIRON HEALTH PERSP, V103, P458, DOI 10.2307/3432584; MARTENS WJM, 1994, GLOBAL DYNAMICS SUST, V3; MARTENS WJM, 1995, GLOBO REPORT SERIES, V10; MASKELL K, 1993, LANCET, V342, P1027, DOI 10.1016/0140-6736(93)92883-U; Matsuoka Y., 1995, J GLOBAL ENV ENG, V1, P43; MCMICHAEL AJ, 1993, INT J EPIDEMIOL, V22, P1, DOI 10.1093/ije/22.1.1; MEARNS LO, 1993, DROUGHT ASSESSMENT M, P109; Mills D., 1995, PUBLICATIONS CLIMATO, V48, P1; MITCHELL JFB, 1995, NATURE, V376, P501, DOI 10.1038/376501a0; MOLINA MJ, 1974, NATURE, V249, P810, DOI 10.1038/249810a0; MONATH TP, 1987, AM J TROP MED HYG, V37, pS40, DOI 10.4269/ajtmh.1987.37.40S; MONATH TP, 1990, PRINCIPLES PRACTICE; MOORE PS, 1992, CLIN INFECT DIS, V14, P515, DOI 10.1093/clinids/14.2.515; MORISON WL, 1989, PHOTOCHEM PHOTOBIOL, V50, P515, DOI 10.1111/j.1751-1097.1989.tb05557.x; MORSE SS, 1995, EMERG INFECT DIS, V1, P7, DOI 10.3201/eid0101.950102; NICHOLLS N, 1993, LANCET, V342, P1284, DOI 10.1016/0140-6736(93)92368-4; Nicholls N., 1991, TELECONNECTIONS LINK, P493; NODEN BH, IN PRESS PARASITOLOG; NOONAN FP, 1981, PHOTOCHEM PHOTOBIOL, V34, P683, DOI 10.1111/j.1751-1097.1981.tb09425.x; PANT CP, 1973, J MED ENTOMOL, V10, P219, DOI 10.1093/jmedent/10.2.219; PARRILLA G, 1994, NATURE, V369, P204; PARRY ML, 1993, LANCET, V342, P1345, DOI 10.1016/0140-6736(93)92251-N; PATZ JA, 1995, WORLD RESOURCE REV, V7, P104; PATZ JA, IN PRESS CLIMATE RES; RAPER SCB, 1995, RISING SEA LEVEL SUB; REEVES WC, 1994, J MED ENTOMOL, V31, P323, DOI 10.1093/jmedent/31.3.323; REISEN WK, 1993, J MED ENTOMOL, V30, P151, DOI 10.1093/jmedent/30.1.151; REITER P, 1988, ARBOVIRUSES EPIDEMIO, P245; ROGERS DJ, 1991, NATURE, V351, P739, DOI 10.1038/351739a0; ROGERS DJ, 1993, LANCET, V342, P1282, DOI 10.1016/0140-6736(93)92367-3; ROGERS DJ, 1993, PARASITOL TODAY, V9, P266, DOI 10.1016/0169-4758(93)90074-P; RUEDA LM, 1990, J MED ENTOMOL, V27, P892, DOI 10.1093/jmedent/27.5.892; Schneider S.H., 1990, GLOBAL WARMING ARE W; SCOTT TW, 1993, J MED ENTOMOL, V30, P922, DOI 10.1093/jmedent/30.5.922; SHIFF CJ, 1979, T ROY SOC TROP MED H, V73, P375, DOI 10.1016/0035-9203(79)90157-3; SHIFF CJ, 1975, INT J PARASITOL, V5, P119; SHOPE R, 1991, ENVIRON HEALTH PERSP, V96, P171, DOI 10.2307/3431227; Shope R.E., 1990, GLOBAL ATMOSPHERIC C; SHOPE RE, 1980, YALE J BIOL MED, V53, P93; STONE R, 1993, SCIENCE, V262, P833, DOI 10.1126/science.8235603; TAYLOR HR, 1988, NEW ENGL J MED, V319, P1429, DOI 10.1056/NEJM198812013192201; TAYLOR P, 1986, T ROY SOC TROP MED H, V80, P12, DOI 10.1016/0035-9203(86)90185-9; Tegart W.J. McG., 1990, CLIMATE CHANGE IPCC; TESTER P, 1991, HLTH ENV DIGEST, V5, P4; Titus J. G., 1995, PROBABILITY SEA LEVE; TRENT DW, 1983, VIROLOGY, V128, P271, DOI 10.1016/0042-6822(83)90255-6; VALERO MV, 1993, LANCET, V341, P705, DOI 10.1016/0140-6736(93)90483-W; Valiela I., 1984, MARINE ECOLOGICAL PR, DOI 10.1007/978-1-4757-4125-4; VANDERLEUN JC, 1991, ENV EFFECTS OZONE DE; WASHINO RK, 1994, AM J TROP MED HYG, V50, P134, DOI 10.4269/ajtmh.1994.50.134; WATTS DM, 1987, AM J TROP MED HYG, V36, P143, DOI 10.4269/ajtmh.1987.36.143; WENZEL RP, 1994, NEW ENGL J MED, V330, P1004, DOI 10.1056/NEJM199404073301410; WHETTON PH, 1993, CLIMATIC CHANGE, V25, P289, DOI 10.1007/BF01098378; WIGLEY TML, 1992, NATURE, V357, P293, DOI 10.1038/357293a0; WOLFF K, 1983, J INVEST DERMATOL, V80, pS17, DOI 10.1111/1523-1747.ep12536750; ZULUETA J, 1980, T R SOC TROP MED HYG, V74, P624; 1985, 10 YEARS ONCHOCERCIA; 1992, 9404 SCRIPPS I OC RE; 1989, MMWR-MORBID MORTAL W, V38, P440; 1994, RAD FORCING CLIMATE; 1990, POTENTIAL HLTH EFFEC; 1994, DENGUE DENGUE HEMORR, P98; IN PRESS CLIMATE CHA; 1991, 1991 ENSO CLIM CHANG	128	419	450	9	328	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 17	1996	275	3					217	223		10.1001/jama.275.3.217	http://dx.doi.org/10.1001/jama.275.3.217			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TP282	8604175				2022-12-28	WOS:A1996TP28200030
J	Weinberger, M; Hendeles, L				Weinberger, M; Hendeles, L			Drug therapy - Theophylline in asthma	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							EXERCISE-INDUCED BRONCHOSPASM; SLOW-RELEASE THEOPHYLLINE; INHALED ALBUTEROL; BRONCHIAL HYPERRESPONSIVENESS; MAINTENANCE THERAPY; SODIUM CROMOGLYCATE; PRESCHOOL-CHILDREN; NEDOCROMIL SODIUM; DISTILLED WATER; CROMOLYN SODIUM		UNIV IOWA, COLL MED, DEPT PEDIAT, IOWA CITY, IA USA; UNIV FLORIDA, COLL PHARM, GAINESVILLE, FL USA; UNIV FLORIDA, COLL MED, DEPT PEDIAT, GAINESVILLE, FL USA	University of Iowa; State University System of Florida; University of Florida; State University System of Florida; University of Florida								AVITAL A, 1991, J PEDIATR-US, V119, P979, DOI 10.1016/S0022-3476(05)83062-8; BACHMANN K, 1987, THER DRUG MONIT, V9, P279, DOI 10.1097/00007691-198709000-00005; BARNES PJ, 1995, NEW ENGL J MED, V332, P868, DOI 10.1056/NEJM199503303321307; BARNES PJ, 1995, EUR RESPIR J, V8, P457, DOI 10.1183/09031936.95.08030457; BARNES PJ, 1994, EUR RESPIR J, V7, P579, DOI 10.1183/09031936.94.07030579; BENDER B, 1992, JAMA-J AM MED ASSOC, V267, P2621; BIERMAN CW, 1977, PEDIATRICS, V60, P845; BILLING B, 1982, EUR J RESPIR DIS, V63, P399; BONFIGLIO MF, 1991, PHARMACOTHERAPY, V11, P85; BOWTON DL, 1988, CHEST, V94, P371, DOI 10.1378/chest.94.2.371; BRENNER M, 1988, CLIN ALLERGY, V18, P143, DOI 10.1111/j.1365-2222.1988.tb02853.x; Brown EA, 1940, NEW ENGL J MED, V223, P843, DOI 10.1056/NEJM194011212232103; CARTER E, 1993, J PEDIATR-US, V122, P470, DOI 10.1016/S0022-3476(05)83443-2; CHANG KC, 1978, LANCET, V1, P1132; CHEUNG D, 1992, NEW ENGL J MED, V327, P1198, DOI 10.1056/NEJM199210223271703; COTROMANES E, 1985, CHEST, V88, P194, DOI 10.1378/chest.88.2.194; CRESCIOLI S, 1992, EUR J PHARM-ENVIRON, V228, P45, DOI 10.1016/0926-6917(92)90010-A; DAWOOD AG, 1977, CLIN ALLERGY, V7, P161, DOI 10.1111/j.1365-2222.1977.tb01437.x; DERBY LE, 1990, PHARMACOTHERAPY, V10, P112; DIGIULIO GA, 1993, J PEDIATR-US, V122, P464, DOI 10.1016/S0022-3476(05)83442-0; DOLL DC, 1979, ANESTH ANALG, V58, P139; DUSDIEKER L, 1982, J PEDIATR-US, V101, P281; EASTON PA, 1988, J APPL PHYSIOL, V64, P1445, DOI 10.1152/jappl.1988.64.4.1445; ERJEFALT I, 1986, ACTA PHYSIOL SCAND, V128, P653, DOI 10.1111/j.1748-1716.1986.tb08027.x; FABBRI LM, 1986, ANN ALLERGY, V56, P171; FJELLBIRKELAND L, 1994, RESP MED, V88, P599, DOI 10.1016/S0954-6111(05)80008-3; GIANNINI D, 1995, AM J RESP CRIT CARE, V151, pA39; GINCHANSKY E, 1977, J PEDIATR-US, V91, P655, DOI 10.1016/S0022-3476(77)80527-1; GREENING AP, 1994, LANCET, V344, P219, DOI 10.1016/S0140-6736(94)92996-3; GROOT CAR, 1992, EUR RESPIR J, V5, P1075; HAMBLETON G, 1977, LANCET, V1, P381; HEINS M, 1988, EUR RESPIR J, V1, P306; HENDELES L, 1978, CLIN PHARMACOKINET, V3, P294, DOI 10.2165/00003088-197803040-00003; HENDELES L, 1992, J PEDIATR-US, V120, P177, DOI 10.1016/S0022-3476(05)80423-8; HENDELES L, 1977, DRUG INTEL CLIN PHAR, V11, P12, DOI 10.1177/106002807701100101; HENDELES L, 1995, PHARMACOTHERAPY, V15, P409; HENDELES L, 1995, J ALLERGY CLIN IMMUN, V95, P505, DOI 10.1016/S0091-6749(95)70312-8; Hendeles L, 1986, APPLIED PHARMACOKINE, P1105; Herrmann G, 1938, J LAB CLIN MED, V23, P135; HILLER EJ, 1975, BRIT J DIS CHEST, V69, P103; HIRSHMAN CA, 1982, ANESTHESIOLOGY, V56, P464, DOI 10.1097/00000542-198206000-00012; HOLGATE ST, 1984, J ALLERGY CLIN IMMUN, V74, P302, DOI 10.1016/0091-6749(84)90262-8; HOWELL LL, 1990, J PHARMACOL EXP THER, V254, P786; HOWELL RE, 1990, J PHARMACOL EXP THER, V255, P1008; HOWELL RE, 1990, LIFE SCI, V46, P563, DOI 10.1016/0024-3205(90)90123-9; HUANG D, 1993, ANN INTERN MED, V119, P1155, DOI 10.7326/0003-4819-119-12-199312150-00001; ISRAEL E, 1993, ANN INTERN MED, V119, P1059, DOI 10.7326/0003-4819-119-11-199312010-00001; JENNE JW, 1972, CLIN PHARMACOL THER, V13, P349; JOAD JP, 1986, J ALLERGY CLIN IMMUN, V78, P1147, DOI 10.1016/0091-6749(86)90264-2; JOAD JP, 1987, J ALLERGY CLIN IMMUN, V79, P78, DOI 10.1016/S0091-6749(87)80020-9; KELLOWAY JS, 1994, ARCH INTERN MED, V154, P1349, DOI 10.1001/archinte.154.12.1349; KIDNEY J, 1995, AM J RESP CRIT CARE, V151, P1907, DOI 10.1164/ajrccm.151.6.7767539; KOENIG JQ, 1992, J ALLERGY CLIN IMMUN, V89, P789, DOI 10.1016/0091-6749(92)90432-2; KRAEMER MJ, 1982, PEDIATRICS, V69, P476; KRAFT M, IN PRESS J ALLERGY C; LAGENTE V, 1995, AM J RESP CRIT CARE, V151, P1720, DOI 10.1164/ajrccm.151.6.7539326; LINDGREN S, 1992, NEW ENGL J MED, V327, P926, DOI 10.1056/NEJM199209243271305; MAGNUSSEN H, 1987, AM REV RESPIR DIS, V136, P1163, DOI 10.1164/ajrccm/136.5.1163; MATSUNGA SK, 1989, CLIN PHARMACOL THER, V46, P399, DOI 10.1038/clpt.1989.158; MATTHAY RA, 1976, THORAX, V31, P470, DOI 10.1136/thx.31.4.470; MATTHYS H, 1994, RESPIRATION, V61, P241; MILAVETZ G, 1987, CLIN PHARMACOL THER, V41, P388, DOI 10.1038/clpt.1987.46; MILAVETZ G, 1986, J PEDIATR-US, V109, P351, DOI 10.1016/S0022-3476(86)80403-6; MOLEMA J, 1989, EUR RESPIR J, V2, P308; MURCIANO D, 1984, NEW ENGL J MED, V311, P349, DOI 10.1056/NEJM198408093110601; MURPHY DG, 1993, ARCH INTERN MED, V153, P1784, DOI 10.1001/archinte.153.15.1784; MUSLOW HA, 1992, J PEDIATR-US, V121, P466, DOI 10.1016/S0022-3476(05)81806-2; NASSIF E, 1987, J ALLERGY CLIN IMMUN, V80, P518, DOI 10.1016/0091-6749(87)90002-9; NASSIF EG, 1981, NEW ENGL J MED, V304, P71, DOI 10.1056/NEJM198101083040202; NEIJENS HJ, 1985, J PEDIATR-US, V107, P811, DOI 10.1016/S0022-3476(85)80426-1; OHICKEY SP, 1994, RESP MED, V88, P499, DOI 10.1016/S0954-6111(05)80330-0; PATEL KR, 1986, EUR J RESPIR DIS, V69, P256; PATEL KR, 1986, BRIT J CLIN PHARMACO, V21, P231, DOI 10.1111/j.1365-2125.1986.tb05181.x; POLLOCK J, 1977, PEDIATRICS, V60, P840; RABE KF, 1993, AM REV RESPIR DIS, V147, pA184; RABE KF, 1995, AM J RESP CRIT CAR S, V151, pA388; RAMAGE L, 1994, RESP MED, V88, P363, DOI 10.1016/0954-6111(94)90042-6; RIVINGTON RN, 1995, AM J RESP CRIT CARE, V151, P325, DOI 10.1164/ajrccm.151.2.7842186; SARKAR MA, 1992, DRUG METAB DISPOS, V20, P31; SARRAZIN E, 1980, J PEDIATR-US, V97, P825, DOI 10.1016/S0022-3476(80)80280-0; SCHIFF GD, 1991, ANN INTERN MED, V114, P748, DOI 10.7326/0003-4819-114-9-748; SCORDAMAGLIA A, 1988, CLIN IMMUNOL IMMUNOP, V48, P238, DOI 10.1016/0090-1229(88)90087-6; SELF TH, 1990, CHEST, V98, P1317, DOI 10.1378/chest.98.6.1317; SESSLER CN, 1990, AM J MED, V88, P567, DOI 10.1016/0002-9343(90)90519-J; SHANNON M, 1993, ANN INTERN MED, V119, P1161, DOI 10.7326/0003-4819-119-12-199312150-00002; SHAPIRO GG, 1985, PHARMACOTHERAPY, V5, P156; SIMONS FER, 1982, AM J DIS CHILD, V136, P790, DOI 10.1001/archpedi.1982.03970450032008; SPECTOR SL, 1994, AM J RESP CRIT CARE, V150, P618, DOI 10.1164/ajrccm.150.3.8087328; STEIN MA, 1993, ANN ALLERGY, V70, P135; STIRT JA, 1981, ANESTH ANALG, V60, P517; SULLIVAN P, 1994, LANCET, V343, P1006, DOI 10.1016/S0140-6736(94)90127-9; SULLIVAN P, 1994, LANCET, V343, P1512; SVENDSEN UG, 1991, EUR RESPIR J, V4, P992; TINKELMAN DG, 1993, PEDIATRICS, V92, P64; TOOGOOD JH, 1981, J ALLERGY CLIN IMMUN, V67, P317, DOI 10.1016/0091-6749(81)90028-2; WEINBERG.MM, 1974, J PEDIATR-US, V84, P421; WEINBERGER M, 1975, CLIN PHARMACOL THER, V17, P585; WEINBERGER M, 1995, ANN ALLERG ASTHMA IM, V75, P209; WEINBERGER M, 1978, NEW ENGL J MED, V299, P852, DOI 10.1056/NEJM197810192991603; WEINBERGER M, 1993, ALLERGY PRINCIPLES P, V1, P816; WELTON AF, 1980, BIOCHEM PHARMACOL, V29, P1085, DOI 10.1016/0006-2952(80)90400-1	101	186	188	1	9	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 23	1996	334	21					1380	1388		10.1056/NEJM199605233342107	http://dx.doi.org/10.1056/NEJM199605233342107			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UL251	8614425				2022-12-28	WOS:A1996UL25100007
J	Svoboda, K; Tank, DW; Denk, W				Svoboda, K; Tank, DW; Denk, W			Direct measurement of coupling between dendritic spines and shafts	SCIENCE			English	Article							LONG-TERM POTENTIATION; SERIAL ELECTRON-MICROSCOPY; BIOPHYSICAL CHARACTERISTICS; FLUORESCENCE MICROSCOPY; HIPPOCAMPAL SLICES; RAT HIPPOCAMPUS; PURKINJE-CELLS; CALCIUM; VARIABILITY; AMPLITUDE	Characterization of the diffusional and electrotonic coupling of spines to the dendritic shaft is crucial to understanding neuronal integration and synaptic plasticity. Two-photon photobleaching and photorelease of fluorescein dextran were used to generate concentration gradients between spines and shafts in rat CAI pyramidal neurons. Diffusional reequilibration was monitored with two-photon fluorescence imaging. The time course of reequilibration was exponential, with time constants in the range of 20 to 100 milliseconds, demonstrating chemical compartmentalization on such time scales. These values imply that electrical spine neck resistances are unlikely to exceed 150 megohms and more likely range from 4 to 50 megohms.	AT&T BELL LABS,LUCENT TECHNOL,BIOL COMPUTAT RES DEPT,MURRAY HILL,NJ 07974	Alcatel-Lucent; Lucent Technologies; AT&T; Nokia Corporation; Nokia Bell Labs			denk, winfried/I-6627-2012					ALLBRITTON NL, 1992, SCIENCE, V258, P1812, DOI 10.1126/science.1465619; AXELROD D, 1976, BIOPHYS J, V16, P1055, DOI 10.1016/S0006-3495(76)85755-4; BARBOUR B, 1993, NEURON, V11, P759, DOI 10.1016/0896-6273(93)90085-6; Baudry M., 1994, LONG TERM POTENTIATI, V2; BEKKERS JM, 1990, P NATL ACAD SCI USA, V87, P5359, DOI 10.1073/pnas.87.14.5359; Berg, 2018, RANDOM WALKS BIOL; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; BROWN TH, 1992, SINGLE NEURON COMPUT, P81; CAUCHETEUXSILBERZAN I, 1993, BIOPHYS J, V64, pA109; CHANG HT, 1952, COLD SPRING HARB SYM, V17, P189, DOI 10.1101/SQB.1952.017.01.019; CRICK F, 1982, TRENDS NEUROSCI, V5, P44, DOI 10.1016/0166-2236(82)90020-0; DENK W, 1990, SCIENCE, V248, P73, DOI 10.1126/science.2321027; DENK W, 1994, J NEUROSCI METH, V54, P151, DOI 10.1016/0165-0270(94)90189-9; DENK W, 1995, P NATL ACAD SCI USA, V92, P8279, DOI 10.1073/pnas.92.18.8279; DENK W, UNPUB; Denk Winfried, 1995, P445; FROMHERZ P, 1994, P NATL ACAD SCI USA, V91, P4604, DOI 10.1073/pnas.91.10.4604; GAMBLE E, 1987, SCIENCE, V236, P1311, DOI 10.1126/science.3495885; HARRIS KM, 1989, J NEUROSCI, V9, P2982; HARRIS KM, 1992, J NEUROSCI, V12, P2685; HARRIS KM, 1988, J NEUROSCI, V8, P4455; HOLMES WR, 1990, BRAIN RES, V519, P338, DOI 10.1016/0006-8993(90)90098-V; JAFFE DB, 1994, J NEUROBIOL, V25, P220, DOI 10.1002/neu.480250303; KOCH C, 1983, PROC R SOC SER B-BIO, V218, P455, DOI 10.1098/rspb.1983.0051; KULLMANN DM, 1992, NATURE, V357, P240, DOI 10.1038/357240a0; LANNI F, 1985, J CELL BIOL, V100, P1091, DOI 10.1083/jcb.100.4.1091; LINDEN DJ, 1993, NEURON, V11, P1093, DOI 10.1016/0896-6273(93)90222-D; LISMAN JE, 1993, TRENDS NEUROSCI, V16, P141, DOI 10.1016/0166-2236(93)90122-3; MAJOR G, 1994, J NEUROSCI, V14, P4613; MALENKA RC, 1994, LONG TERM POTENTIATI, V2, P121; MULLER W, 1991, NATURE, V354, P73, DOI 10.1038/354073a0; NEHER E, 1992, J PHYSIOL-LONDON, V450, P273, DOI 10.1113/jphysiol.1992.sp019127; Peters A., 1991, FINE STRUCTURE NERVO; PETROZZINO JJ, 1995, NEURON, V14, P1223, DOI 10.1016/0896-6273(95)90269-4; POPOV S, 1992, J NEUROSCI, V12, P77; RAASTAD M, 1992, EUR J NEUROSCI, V4, P113, DOI 10.1111/j.1460-9568.1992.tb00114.x; Rall W., 1978, STUDIES NEUROPHYSIOL, P203; SEJNOWSKI TJ, 1992, SINGLE NEURON COMPUT, P117; SVOBODA K, UNPUB; Tank DW, 1995, J NEUROSCI, V15, P7940; WILSON CJ, 1984, J NEUROSCI, V4, P281; YUSTE R, 1995, NATURE, V375, P682, DOI 10.1038/375682a0; ZADOR A, 1990, P NATL ACAD SCI USA, V87, P6718, DOI 10.1073/pnas.87.17.6718	43	387	396	0	17	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 3	1996	272	5262					716	719		10.1126/science.272.5262.716	http://dx.doi.org/10.1126/science.272.5262.716			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UJ051	8614831				2022-12-28	WOS:A1996UJ05100049
J	Emsley, P; Charles, IG; Fairweather, NF; Isaacs, NW				Emsley, P; Charles, IG; Fairweather, NF; Isaacs, NW			Structure of Bordetella pertussis virulence factor P.69 pertactin	NATURE			English	Article							PROTEIN; IDENTIFICATION; MOTIF	A NEW generation of whooping-cough vaccines contain P.69 pertactin, a surface-exposed domain of an outer membrane protein expressed by the virulent bacterium Bordetella pertussis(1-3). This protein is a virulence factor that mediates adhesion to target mammalian cells, a reaction that is in part mediated by an RGD sequence, The X-ray crystal structure of P.69 pertactin has been determined to 2.5 Angstrom. The protein fold consists of a 16-stranded parallel beta-helix with a V-shaped cross-section, and is the largest beta-helix known to date, Several between-strand weakly conserved amino-acid repeats form internal and external ladders, The structure appears as a helix from which several loops protrude, which contain sequence motifs associated with the biological activity of the protein. One particular (GGXXP)(5) sequence is located directly after the RGD motif, and may mediate interaction with epithelial cells. The carboxy-terminal region of P.69 pertactin incorporates a (PQP)(5) motif loop containing the major immunoprotective epitope.	UNIV GLASGOW, DEPT CHEM, GLASGOW G12 8QQ, LANARK, SCOTLAND; UCL, CRUCIFORM PROJECT, LONDON W1P 9LN, ENGLAND; GLAXO WELLCOME RES LABS, DEPT CELL BIOL, BECKENHAM BR3 385, KENT, ENGLAND	University of Glasgow; University of London; University College London; GlaxoSmithKline; Wellcome Research Laboratories					Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		[Anonymous], 1994, ACTA CRYSTALLOGR D, V50, P760; BAUMANN U, 1993, EMBO J, V12, P3357, DOI 10.1002/j.1460-2075.1993.tb06009.x; BRUNGRE AT, 1988, X PLOR REFERENCE MAN; CHARLES I, 1994, MICROBIOL-SGM, V140, P3301, DOI 10.1099/13500872-140-12-3301; CHARLES IG, 1989, P NATL ACAD SCI USA, V86, P3554, DOI 10.1073/pnas.86.10.3554; CHARLES IG, 1991, EUR J IMMUNOL, V21, P1147, DOI 10.1002/eji.1830210509; Cowtan K., 1994, JOINT CCP4 ESF EACBM, V31, P34; EMSLEY P, 1994, J MOL BIOL, V235, P772, DOI 10.1006/jmbi.1994.1029; Greco D, 1996, NEW ENGL J MED, V334, P341, DOI 10.1056/NEJM199602083340601; Gustafsson L, 1996, NEW ENGL J MED, V334, P349, DOI 10.1056/NEJM199602083340602; HYNES RO, 1987, CELL, V48, P547; ISHIBASHI Y, 1994, J EXP MED, V180, P1225, DOI 10.1084/jem.180.4.1225; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LEININGER E, 1991, P NATL ACAD SCI USA, V88, P345, DOI 10.1073/pnas.88.2.345; MAKOFF AJ, 1990, BIO-TECHNOL, V8, P1030, DOI 10.1038/nbt1190-1030; MONTARAZ JA, 1985, INFECT IMMUN, V47, P744, DOI 10.1128/IAI.47.3.744-751.1985; Otwinowski Z., 1991, ISOMORPHOUS REPLACEM, P80; OTWINOWSKI Z, 1992, DATA COLLECTION PROC, P56; RAMAKRISHNAN C, 1965, BIOPHYS J, V5, P909, DOI 10.1016/S0006-3495(65)86759-5; SHELDRICK GM, 1990, ACTA CRYSTALLOGR A, V46, P467, DOI 10.1107/S0108767390000277; STEINBACHER S, 1994, SCIENCE, V265, P383, DOI 10.1126/science.8023158; WANG BC, 1985, METHOD ENZYMOL, V115, P90; WILLIAMSON MP, 1994, BIOCHEM J, V297, P249, DOI 10.1042/bj2970249; YODER MD, 1993, STRUCTURE, V1, P241, DOI 10.1016/0969-2126(93)90013-7; YODER MD, 1993, SCIENCE, V260, P1503, DOI 10.1126/science.8502994; 1988, LANCET, V8592, P955	28	254	271	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	MAY 2	1996	381	6577					90	92		10.1038/381090a0	http://dx.doi.org/10.1038/381090a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UJ053	8609998				2022-12-28	WOS:A1996UJ05300064
J	Owens, DK; Holodniy, M; McDonald, TW; Scott, J; Sonnad, S				Owens, DK; Holodniy, M; McDonald, TW; Scott, J; Sonnad, S			A meta-analytic evaluation of the polymerase chain reaction for the diagnosis of HIV infection in infants	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							HUMAN-IMMUNODEFICIENCY-VIRUS; INVITRO ANTIBODY-PRODUCTION; SEROPOSITIVE MOTHERS; HIGH-RISK; PEDIATRIC-PATIENTS; ANTIGEN-DETECTION; CLINICAL UTILITY; TYPE-1 INFECTION; CHILDREN BORN; CULTURE	Objective.-To evaluate the sensitivity and specificity of the polymerase chain reaction (PCR) for the diagnosis of infection with human immunodeficiency Virus (HIV) in infants. Data Sources.-We used studies published between 1988 and 1994 identified in a literature search of 17 databases, including MEDLINE. Study Selection.-Studies were included if DNA amplification by PCR was performed on peripheral blood mononuclear cells from infants or children. Data Extraction.-Two investigators independently extracted data, The study design was assessed independently by 2 investigators who were blinded to study results. Data Synthesis.-Thirty-two studies met the inclusion criteria and were analyzed. The median reported sensitivity was 91.6% (range, 31%-100%), and the median specificity was 100% (range, 50%-100%), A summary receiver operating characteristic curve based on all 32 studies indicated that PCR has a maximum joint sensitivity and specificity between 93.2% and 94.9%. Subgroup analysis indicated that the joint sensitivity and specificity was significantly (P=.04) higher in older infants (98.2%) than in neonates (aged less than or equal to 30 days; 93.3%). For infants at low risk of perinatal transmission (probability of transmission, 8.3%), the positive predictive value for PCR is 55.8% in neonates and 83.2% in older infants. A negative PCR result reduces the probability of HIV infection to less than 3%. No studies met all criteria for study design. Conclusions.-Although PCR is one of the best available tests for diagnosis of HIV infection in neonates and infants, it is not definitive. Therefore, PCR should be interpreted with the aid of careful clinical follow-up examinations. The sensitivity and specificity of PCR in neonates is lower than in older infants, which results in a low positive predictive value; however, negative tests are informative, Delaying the use of PCR until after the neonatal period or repeating PCR on independent samples obtained 30 to 60 days later will reduce test errors.	STANFORD UNIV,DEPT STAT,STANFORD,CA 94305; STANFORD UNIV,DIV GEN INTERNAL MED,STANFORD,CA 94305; STANFORD UNIV,DIV INFECT DIS & GEOG MED,STANFORD,CA 94305; STANFORD UNIV,DEPT MED,STANFORD,CA 94305; STANFORD UNIV,DEPT HLTH RES & POLICY,STANFORD,CA 94305	Stanford University; Stanford University; Stanford University; Stanford University; Stanford University	Owens, DK (corresponding author), VET AFFAIRS PALO ALTO HLTH CARE SYST,GEN INTERNAL MED SECT 111A,3801 MIRANDA AVE,PALO ALTO,CA 94304, USA.			Holodniy, Mark/0000-0002-6655-7982	PHS HHS [A1 27762-04] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ARKIN CF, 1990, JAMA-J AM MED ASSOC, V263, P275, DOI 10.1001/jama.263.2.275; BLANCHE S, 1989, NEW ENGL J MED, V320, P1643, DOI 10.1056/NEJM198906223202502; BLANCHE S, 1990, AM J DIS CHILD, V144, P1210, DOI 10.1001/archpedi.1990.02150350042021; BORGHI V, 1993, MICROBIOLOGICA, V16, P181; BORKOWSKY W, 1992, J INFECT DIS, V166, P616, DOI 10.1093/infdis/166.3.616; BRANDT CD, 1994, ARCH PEDIAT ADOL MED, V148, P250, DOI 10.1001/archpedi.1994.02170030020004; BRANDT CD, 1992, J CLIN MICROBIOL, V30, P36, DOI 10.1128/JCM.30.1.36-40.1992; BURGARD M, 1992, NEW ENGL J MED, V327, P1192, DOI 10.1056/NEJM199210223271702; CASSOL SA, 1992, J ACQ IMMUN DEF SYND, V5, P113; CHADWICK EG, 1989, J INFECT DIS, V160, P954, DOI 10.1093/infdis/160.6.954; COMEAU AM, 1992, NEW ENGL J MED, V326, P1703; COMEAU AM, 1992, J ACQ IMMUN DEF SYND, V5, P271; CONNOR EM, 1994, NEW ENGL J MED, V331, P1173, DOI 10.1056/NEJM199411033311801; DENAMUR E, 1993, AIDS, V7, P897, DOI 10.1097/00002030-199306000-00026; DEROSSI A, 1991, AIDS, V5, P15, DOI 10.1097/00002030-199101000-00002; DEROSSI A, 1988, LANCET, V2, P278; DEROSSI A, 1992, AIDS, V6, P1117, DOI 10.1097/00002030-199210000-00008; DULIEGE AM, 1992, PEDIATR INFECT DIS J, V11, P630; DULIEGE AM, 1995, J PEDIATR-US, V126, P625, DOI 10.1016/S0022-3476(95)70365-9; EDWARDS JR, 1989, J PEDIATR-US, V115, P200, DOI 10.1016/S0022-3476(89)80065-4; ELSADR W, 1994, EVALUATION MANAGEMEN, V7; ESCAICH S, 1991, J ACQ IMMUN DEF SYND, V4, P130; FLEISS JL, 1981, STATISTICAL METHODS, P13; GARBARGCHENON A, 1993, J VIROL METHODS, V42, P117, DOI 10.1016/0166-0934(93)90183-R; GOEDERT JJ, 1991, LANCET, V338, P1471, DOI 10.1016/0140-6736(91)92297-F; GUETTARI N, 1993, AIDS, V7, P1269, DOI 10.1097/00002030-199309000-00019; GUPTA P, 1991, J ACQ IMMUN DEF SYND, V4, P1004; HOFFMAN RM, 1991, SPINE, V16, P623, DOI 10.1097/00007632-199106000-00005; JACKSON JB, 1993, J CLIN MICROBIOL, V31, P3123, DOI 10.1128/JCM.31.12.3123-3128.1993; KAPLAN JE, 1995, CLIN INFECT DIS, V21, pS12, DOI 10.1093/clinids/21.Supplement_1.S12; KELSEY J, 1986, METHOIDS OBSERVATION, P366; KENT DL, 1992, AM J ROENTGENOL, V158, P1135, DOI 10.2214/ajr.158.5.1533084; KENT DL, 1992, INVEST RADIOL, V27, P245, DOI 10.1097/00004424-199203000-00014; KRIVINE A, 1990, J PEDIATR-US, V116, P372, DOI 10.1016/S0022-3476(05)82823-9; KRIVINE A, 1992, LANCET, V339, P1187, DOI 10.1016/0140-6736(92)91131-Q; LANDESMAN S, 1991, JAMA-J AM MED ASSOC, V266, P3443, DOI 10.1001/jama.266.24.3443; LAURE F, 1988, LANCET, V2, P538; MANAK MM, 1993, ANN NY ACAD SCI, V693, P255, DOI 10.1111/j.1749-6632.1993.tb26275.x; MATHESON PB, 1995, J INFECT DIS, V172, P353, DOI 10.1093/infdis/172.2.353; MOK JQ, 1987, LANCET, V1, P1164; MOSES L, 1986, THINK EXPLAIN STAT, P250; MOSES LE, 1993, STAT MED, V12, P1293, DOI 10.1002/sim.4780121203; Owens DK, 1996, ANN INTERN MED, V124, P803, DOI 10.7326/0003-4819-124-9-199605010-00004; OWENS DK, 1990, MED INFORMATICS COMP, P70; PALUMBO PE, 1995, J PEDIATR-US, V126, P592, DOI 10.1016/S0022-3476(95)70357-8; Paul MO, 1996, J INFECT DIS, V173, P68, DOI 10.1093/infdis/173.1.68; PETRU A, 1992, PEDIATR INFECT DIS J, V11, P30, DOI 10.1097/00006454-199201000-00008; PHILBRICK JT, 1980, AM J CARDIOL, V46, P807, DOI 10.1016/0002-9149(80)90432-4; POLLACK H, 1993, J ACQ IMMUN DEF SYND, V6, P582; PUCHHAMMERSTOCKL E, 1993, WIEN KLIN WOCHENSCHR, V105, P429; QUINN TC, 1991, JAMA-J AM MED ASSOC, V266, P3439, DOI 10.1001/jama.266.24.3439; RANSOHOFF DF, 1978, NEW ENGL J MED, V299, P926, DOI 10.1056/NEJM197810262991705; REID MC, 1995, JAMA-J AM MED ASSOC, V274, P645, DOI 10.1001/jama.274.8.645; ROBINS J, 1986, BIOMETRICS, V42, P311, DOI 10.2307/2531052; ROGERS MF, 1989, NEW ENGL J MED, V320, P1649, DOI 10.1056/NEJM198906223202503; RUDIN C, 1991, EUR J CLIN MICROBIOL, V10, P146, DOI 10.1007/BF01964447; RYDER RW, 1988, AIDS, V2, pS83, DOI 10.1097/00002030-198800001-00012; RYDER RW, 1989, NEW ENGL J MED, V320, P1637, DOI 10.1056/NEJM198906223202501; SCARLATTI G, 1991, AIDS, V5, P1173, DOI 10.1097/00002030-199110000-00003; SCHWARTZ JS, 1988, JAMA-J AM MED ASSOC, V259, P2574, DOI 10.1001/jama.259.17.2574; SIMON F, 1993, J ACQ IMMUN DEF SYND, V6, P201; VANDEPERRE P, 1991, NEW ENGL J MED, V325, P593, DOI 10.1056/NEJM199108293250901; WEINTRUB PS, 1991, AIDS, V5, P881, DOI 10.1097/00002030-199107000-00014; *WHO, 1994, HIST TYP FEM GEN TRA, P13; WILLIAMS P, 1990, AIDS, V4, P393, DOI 10.1097/00002030-199005000-00003; YOURNO J, 1992, J CLIN MICROBIOL, V30, P2887, DOI 10.1128/JCM.30.11.2887-2892.1992; 1988, LANCET, V2, P1039; 1994, MMWR-MORBID MORTAL W, V43, P1; 1995, CLIN INFECT DIS   S1, V21, pS32; 1987, MMWR-MORBID MORTAL W, V36, P225	70	76	81	1	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 1	1996	275	17					1342	1348		10.1001/jama.275.17.1342	http://dx.doi.org/10.1001/jama.275.17.1342			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UG612	8614121				2022-12-28	WOS:A1996UG61200032
J	Robertson, JM; Burtt, DS; Edmonds, KL; Molina, PL; Kiefe, CI; Ellner, JJ				Robertson, JM; Burtt, DS; Edmonds, KL; Molina, PL; Kiefe, CI; Ellner, JJ			Delayed tuberculin reactivity in persons of Indochinese origin: Implications for preventive therapy	ANNALS OF INTERNAL MEDICINE			English	Article						tuberculin test; tuberculosis; Vietnam; ethnic groups; lymphocyte transformation	SKIN-TEST; LYMPHOCYTE-RESPONSES; SUPPRESSION; REACTORS	Objectives: To 1) study a variant delayed reaction to tuberculin testing as a way to enhance screening for tuberculosis among high-risk persons and 2) correlate the delayed reaction with lymphocyte blastogenesis. Design: Cross-sectional study. Setting: 2 public health department clinics in North Carolina. Participants: 121 adults who had recently emigrated from Vietnam to North Carolina and who were ethnic Vietnamese and ethnic Dega, a minority population group from the central highlands region of Vietnam. Measurements: Medical history, physical examination, laboratory evaluation, and standard purified protein derivative (PPD) testing (Mantoux method). Skin test results were read at 72 hours and again at 6 days. Variant reactivity was defined as induration of less than 10 mm at 72 hours that, when reassessed at 6 days, had increased in size to 10 mm or greater. Persons with negative (n = 54) and variant (n = 32) PPD results also had booster testing at 10 to 12 weeks. Serum samples were obtained from 57 participants for lymphocyte blastogenesis studies. Results: 26% of participants had variant tuberculin reactivity. Variant reactivity was strongly associated with booster positivity: Sixty-five percent of persons with variant PPD results had booster positivity compared with 16% of persons with negative PPD results (P < 0.001). The lymphocyte blastogenesis response of persons with variant PPD results was between the response of persons with negative PPD results and that of persons with positive PPD results. Conclusions: Variant reactivity in this high-risk group was a predictor of booster positivity. Together with the blastogenic response pattern, this association strongly-suggests that variant reactivity has a high positive predictive value for tuberculous infection. Clinicians should incorporate these findings into their approach for choosing candidates for preventive therapy.	CASE WESTERN RESERVE UNIV, SCH MED, DEPT MED, DIV INFECT DIS, CLEVELAND, OH 44106 USA; UNIV N CAROLINA, SCH MED, DEPT RADIOL, CHAPEL HILL, NC 27599 USA; UNIV ALABAMA, DEPT MED, DIV PREVENT MED, BIRMINGHAM, AL 35205 USA	Case Western Reserve University; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of Alabama System; University of Alabama Birmingham	Robertson, JM (corresponding author), UNIV NEW MEXICO, DEPT MED, SCH MED, ACC 5TH FLOOR, 2211 LOMAS NE, ALBUQUERQUE, NM 87131 USA.			Ellner, Jerrold/0000-0001-6150-0082				*AM SOC HLTH SYST, 1995, AHFS DRUG INF, P1722; [Anonymous], 1990, MMWR Recomm Rep, V39, P1; [Anonymous], 1992, MMWR Recomm Rep, V41, P1; BASS JB, 1994, AM J RESP CRIT CARE, V149, P1359, DOI 10.1164/ajrccm.149.5.8173779; BASS JB, 1993, TUBERCULOSIS COMPREH, P139; BURTT DS, 1992, EVALUATING ALTERNATI; ELLNER JJ, 1979, CELL IMMUNOL, V45, P213, DOI 10.1016/0008-8749(79)90379-4; HAVLIR DV, 1991, CHEST, V99, P1172, DOI 10.1378/chest.99.5.1172; HUEBNER RE, 1993, CLIN INFECT DIS, V17, P968, DOI 10.1093/clinids/17.6.968; KLEINHENZ ME, 1981, J CLIN INVEST, V68, P153, DOI 10.1172/JCI110231; KLEINHENZ ME, 1983, J LAB CLIN MED, V102, P751; MAHMOUDI A, 1993, JAMA-J AM MED ASSOC, V270, P65, DOI 10.1001/jama.270.1.65; MCANULTY JM, 1995, ARCH INTERN MED, V155, P713, DOI 10.1001/archinte.155.7.713; MCKENNA MT, 1995, NEW ENGL J MED, V332, P1071, DOI 10.1056/NEJM199504203321606; MILLER WT, 1993, SEMIN ROENTGENOL, V28, P109, DOI 10.1016/S0037-198X(05)80100-2; MORSE DL, 1985, AM REV RESPIR DIS, V132, P516; RAVIGLIONE MC, 1995, JAMA-J AM MED ASSOC, V273, P220, DOI 10.1001/jama.273.3.220; *STAT CORP, 1993, STAT VERS 3 1; *US BUR CENS, 1995, STAT ABSTR US, P11; *USD, 1990, EPI INFO VERS 5 0 WO; Van Loon Frederik P. L., 1995, Morbidity and Mortality Weekly Report, V44, P1; Wenzel M, 1991, Nurse Pract, V16, P25; 1990, MMWR-MORBID MORTAL W, V39, P9; 1993, MMWR-MORBID MORTAL W, V42, P696; 1993, MMWR-MORBID MORTAL W, V42, P961; 1993, MMWR-MORBID MORTAL W, V42, P628	26	12	13	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 1	1996	124	9					779	+		10.7326/0003-4819-124-9-199605010-00001	http://dx.doi.org/10.7326/0003-4819-124-9-199605010-00001			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UG254	8610946				2022-12-28	WOS:A1996UG25400001
J	Schilham, MW; Oosterwegel, MA; Moerer, P; Ya, J; deBoer, PAJ; vandeWetering, M; Verbeek, S; Lamers, WH; Kruisbeek, AM; Cumano, A; Clevers, H				Schilham, MW; Oosterwegel, MA; Moerer, P; Ya, J; deBoer, PAJ; vandeWetering, M; Verbeek, S; Lamers, WH; Kruisbeek, AM; Cumano, A; Clevers, H			Defects in cardiac outflow tract formation and pro-B-lymphocyte expansion in mice lacking Sox-4	NATURE			English	Article							SEX-DETERMINING REGION; CELL DEVELOPMENT; BONE-MARROW; GENE; PROTEIN; FAMILY	A STRIKING example of the relationship between regulation of transcription and phenotype is the central role of the Y-chromo somal gene Sry in mammalian sex determination(1,2). Sry is the founding member of a large family of so-called Sox genes(1,3). During murine embryogenesis, the transcriptional activator Sox-4 is expressed at several sites, hut in adult mice expression is restricted to immature B and T lymphocytes(4). Using targeted genedisruption, we have found that Sox-4(-/-) embryos succumb to circulatory failure at day E14. This was a result of impaired development of the endocardial ridges (a specific site of Sox-4 expression) into the semilunar valves and the outlet portion of the muscular ventricular septum. The observed range of septation defects is known as 'common arterial trunk' in man. We studied haemopoiesis in lethally irradiated mice reconstituted with Sox-4(-/-) fetal liver cells acid found that a specific block occurred in B-cell development at the pro-B cell stage. In line with this, the frequency and proliferative capacity of IL-7-responsive B cell progenitors in fetal liver were severely decreased in vitro.	UNIV UTRECHT HOSP,DEPT IMMUNOL,3508 GA UTRECHT,NETHERLANDS; UNIV UTRECHT HOSP,TRANSGEN MOUSE FACIL,3508 GA UTRECHT,NETHERLANDS; NETHERLANDS CANC INST,DIV IMMUNOL,1066 CX AMSTERDAM,NETHERLANDS; UNIV AMSTERDAM,ACAD MED CTR,DEPT ANAT & EMBRYOL,1105 A2 AMSTERDAM,NETHERLANDS; INST PASTEUR,UNITE BIOL MOL GENE,F-75024 PARIS 15,FRANCE	Utrecht University; Utrecht University Medical Center; Utrecht University; Utrecht University Medical Center; Netherlands Cancer Institute; University of Amsterdam; Academic Medical Center Amsterdam; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris			Lamers, Wouter H./D-2965-2012; Schilham, Marco W./AAL-7223-2021	Schilham, Marco W./0000-0003-4391-6003; Cumano, Ana/0000-0002-4578-959X				ANGELINI P, 1974, EUR J CARDIOL, V2, P11; BAIN G, 1994, CELL, V79, P885, DOI 10.1016/0092-8674(94)90077-9; BRANNAN CI, 1994, GENE DEV, V8, P1019, DOI 10.1101/gad.8.9.1019; BRITZCUNNINGHAM SH, 1995, NEW ENGL J MED, V332, P1323, DOI 10.1056/NEJM199505183322002; CHEN Z, 1994, GENE DEV, V8, P2293, DOI 10.1101/gad.8.19.2293; CUMANO A, 1992, NATURE, V356, P612, DOI 10.1038/356612a0; DISANTO JP, 1995, P NATL ACAD SCI USA, V92, P377, DOI 10.1073/pnas.92.2.377; EHLICH A, 1993, CELL, V72, P695, DOI 10.1016/0092-8674(93)90398-A; GEORGOPOULOS K, 1994, CELL, V79, P143, DOI 10.1016/0092-8674(94)90407-3; GUBBAY J, 1990, NATURE, V346, P245, DOI 10.1038/346245a0; HARDY RR, 1991, J EXP MED, V173, P1213, DOI 10.1084/jem.173.5.1213; HAWLEY RG, 1993, J EXP MED, V178, P1175, DOI 10.1084/jem.178.4.1175; KIRBY ML, 1995, CIRC RES, V77, P211, DOI 10.1161/01.RES.77.2.211; KITAMURA D, 1992, CELL, V69, P823, DOI 10.1016/0092-8674(92)90293-L; LIN HH, 1995, NATURE, V376, P263, DOI 10.1038/376263a0; MOORMAN AFM, 1995, CIRC RES, V76, P616, DOI 10.1161/01.RES.76.4.616; MORRISONGRAHAM K, 1992, DEVELOPMENT, V115, P133; PESCHON JJ, 1994, J EXP MED, V180, P1955, DOI 10.1084/jem.180.5.1955; REAUME AG, 1995, SCIENCE, V267, P1831, DOI 10.1126/science.7892609; ROLINK A, 1993, EUR J IMMUNOL, V23, P1284, DOI 10.1002/eji.1830230614; SCHILHAM MW, 1993, NUCLEIC ACIDS RES, V21, P2009, DOI 10.1093/nar/21.8.2009; SINCLAIR AH, 1990, NATURE, V346, P240, DOI 10.1038/346240a0; SUCOV HM, 1994, GENE DEV, V8, P1007, DOI 10.1101/gad.8.9.1007; URBANEK P, 1994, CELL, V79, P901, DOI 10.1016/0092-8674(94)90079-5; VANMIEROP LHS, 1969, CIBA COLLECTION MEDI, V5, P112; VERBEEK S, 1995, NATURE, V374, P70, DOI 10.1038/374070a0; VONDEWETERING M, 1993, EMBO J, V12, P3847; WRIGHT EM, 1993, NUCLEIC ACIDS RES, V21, P744, DOI 10.1093/nar/21.3.744; YOUNG F, 1994, GENE DEV, V8, P1043, DOI 10.1101/gad.8.9.1043; ZHUANG Y, 1994, CELL, V79, P875, DOI 10.1016/0092-8674(94)90076-0	30	375	382	0	12	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	APR 25	1996	380	6576					711	714		10.1038/380711a0	http://dx.doi.org/10.1038/380711a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UG827	8614465				2022-12-28	WOS:A1996UG82700051
J	Kennedy, BP; Kawachi, I; ProthrowStith, D				Kennedy, BP; Kawachi, I; ProthrowStith, D			Income distribution and mortality: Cross sectional ecological study of the Robin Hood index in the United States	BRITISH MEDICAL JOURNAL			English	Article							INTERNATIONAL COMPARISONS; MEDICAL INTERVENTION; HEALTH; DETERMINANTS; INEQUALITY	Objective-To determine the effect of income inequality as measured by the Robin Hood index and the Gini coefficient on all cause and cause specific mortality in the United States. Design-Cross sectional ecological study. Setting-Households in the United States. Main outcome measures-Disease specific mortality, income, household size, poverty, and smoking rates for each state. Results-The Robin Hood index was positively correlated with total mortality adjusted for age (r = 0 . 54; P < 0 . 05). This association remained after adjustment for poverty (P < 0 . 007), where each percentage increase in the index was associated with an increase in the total mortality of 21 . 68 deaths per 100000. Effects of the index were also found for infant mortality (P = 0 . 013); coronary heart disease (P = 0 . 004); malignant neoplasms (P = 0 . 023); and homicide (P < 0 . 001). Strong associations were also found between the index and causes of death amenable to medical intervention. The Gini coefficient showed very little correlation with any of the causes of death. Conclusion-Variations between states in the inequality of income were associated with increased mortality from several causes. The size of the gap between the wealthy and less well off-as distinct from the absolute standard of living enjoyed by the poor-seems to matter in its own right. The findings suggest that policies that deal with the growing inequities in income distribution may have an important impact on the health of the population.	HARVARD UNIV,SCH PUBL HLTH,DEPT HLTH & SOCIAL BEHAV,BOSTON,MA 02115	Harvard University; Harvard T.H. Chan School of Public Health	Kennedy, BP (corresponding author), HARVARD UNIV,SCH PUBL HLTH,DEPT HLTH POLICY & MANAGEMENT,BOSTON,MA 02115, USA.							Atkinson A B, 1992, EC TRANSFORMATION EE; BIRDSALL N, 1994, INEQUALITY GROWTH RE; Black D., 1982, INEQUALITIES HLTH BL; BUHMANN B, 1988, REV INCOME WEALTH, V34, P115; CHARLTON JRH, 1986, BRIT MED J, V292, P295, DOI 10.1136/bmj.292.6516.295; FLEGG AT, 1982, POP STUD-J DEMOG, V36, P441, DOI 10.2307/2174055; FRIEDE A, 1993, AM J PUBLIC HEALTH, V83, P1289, DOI 10.2105/AJPH.83.9.1289; JUDGE K, 1995, BRIT MED J, V311, P1282, DOI 10.1136/bmj.311.7015.1282; KAWACHI I, 1994, 942 HLTH I NEW ENGL; KONDOR Y, 1971, ECONOMETRICA, V39, P1041, DOI 10.2307/1909676; LEGRAND J, 1987, EUR ECON REV, V31, P182, DOI 10.1016/0014-2921(87)90030-4; MACKENBACH JP, 1990, J EPIDEMIOL COMMUN H, V44, P106, DOI 10.1136/jech.44.2.106; MARSHALL SW, 1993, INT J EPIDEMIOL, V22, P255, DOI 10.1093/ije/22.2.255; MORGENSTERN H, 1982, AM J PUBLIC HEALTH, V72, P1336, DOI 10.2105/AJPH.72.12.1336; RODGERS GB, 1979, POP STUD-J DEMOG, V33, P343, DOI 10.2307/2173539; *US BUR CENS, 1993, CD ROM INC POV; WILKINSON RG, 1990, SOCIOL HEALTH ILL, V12, P391, DOI 10.1111/1467-9566.ep11340405; WILKINSON RG, 1994, DAEDALUS, V123, P61; WILKINSON RG, 1992, BRIT MED J, V304, P165, DOI 10.1136/bmj.304.6820.165; Wilkinson RG, 1986, CLASS HLTH RES LONGI	20	532	535	2	61	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 20	1996	312	7037					1004	1007		10.1136/bmj.312.7037.1004	http://dx.doi.org/10.1136/bmj.312.7037.1004			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	UG610	8616345	Green Published, Green Submitted			2022-12-28	WOS:A1996UG61000022
J	Cobb, JP; Danner, RL				Cobb, JP; Danner, RL			Nitric oxide and septic shock	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							VASCULAR SMOOTH-MUSCLE; METHYL-L-ARGININE; INDUCED HYPOTENSION; HEMODYNAMIC-CHANGES; INHIBITION; SYNTHASE; SEPSIS; ENDOTOXIN; EXPRESSION; REVERSAL		NIH,DEPT CRIT CARE MED,WARREN G MAGNUSON CLIN CTR,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA								AISAKA K, 1992, JPN J PHARMACOL, V56, P245; COBB JP, 1993, CRIT CARE MED, V21, P1261; COBB JP, 1992, J EXP MED, V176, P1175, DOI 10.1084/jem.176.4.1175; COBB JP, 1995, AM J PHYSIOL-HEART C, V268, pH1634, DOI 10.1152/ajpheart.1995.268.4.H1634; DANNER RL, 1995, ROLE NITRIC OXIDE SE, V24, P155; EVANS T, 1994, J INFECT DIS, V169, P343, DOI 10.1093/infdis/169.2.343; FINKEL MS, 1992, SCIENCE, V257, P387, DOI 10.1126/science.1631560; GELLER DA, 1993, P NATL ACAD SCI USA, V90, P3491, DOI 10.1073/pnas.90.8.3491; GEROULANOS S, 1992, LANCET, V339, P435; GROSS SS, 1990, BIOCHEM BIOPH RES CO, V170, P96, DOI 10.1016/0006-291X(90)91245-N; HARBRECHT BG, 1992, CRIT CARE MED, V20, P1568, DOI 10.1097/00003246-199211000-00015; HAYNES WG, 1993, J HYPERTENS, V11, P1375, DOI 10.1097/00004872-199312000-00009; HIBBS JB, 1992, J CLIN INVEST, V89, P867, DOI 10.1172/JCI115666; HOLLENBERG SM, 1993, AM J PHYSIOL, V264, pH60; HUTCHESON IR, 1990, BRIT J PHARMACOL, V101, P815, DOI 10.1111/j.1476-5381.1990.tb14163.x; KILBOURN RG, 1990, BIOCHEM BIOPH RES CO, V172, P1132, DOI 10.1016/0006-291X(90)91565-A; KILBOURN RG, 1995, CRIT CARE MED, V23, P1018, DOI 10.1097/00003246-199506000-00005; KILBOURN RG, 1992, J NATL CANCER I, V84, P1008, DOI 10.1093/jnci/84.13.1008; KILBOURN RG, 1990, P NATL ACAD SCI USA, V87, P3629, DOI 10.1073/pnas.87.9.3629; KILBOURN RG, 1994, J APPL PHYSIOL, V76, P1130, DOI 10.1152/jappl.1994.76.3.1130; KILBOURN RG, 1995, ENDOTHELIUM, V3, pS15; KLABUNDE RE, 1991, BIOCHEM BIOPH RES CO, V178, P1135, DOI 10.1016/0006-291X(91)91010-A; KLEMM P, 1995, BRIT J PHARMACOL, V114, P363, DOI 10.1111/j.1476-5381.1995.tb13235.x; KUBES P, 1991, P NATL ACAD SCI USA, V88, P4651, DOI 10.1073/pnas.88.11.4651; LANDIN L, 1994, CHEST, V106, P250, DOI 10.1378/chest.106.1.250; LAUBACH VE, 1995, P NATL ACAD SCI USA, V92, P10688, DOI 10.1073/pnas.92.23.10688; LECHEVALIER T, 1994, J APPL PHYSIOL, V77, P471, DOI 10.1152/jappl.1994.77.1.471; LORENTE JA, 1993, CRIT CARE MED, V21, P759, DOI 10.1097/00003246-199305000-00021; LORENTE JA, 1993, CRIT CARE MED, V21, P1287, DOI 10.1097/00003246-199309000-00010; MACMICKING JD, 1995, CELL, V81, P641, DOI 10.1016/0092-8674(95)90085-3; MACNAUL KL, 1993, BIOCHEM BIOPH RES CO, V196, P1330, DOI 10.1006/bbrc.1993.2398; MEYER J, 1994, CRIT CARE MED, V22, P306, DOI 10.1097/00003246-199402000-00023; MEYER J, 1993, ANESTH ANALG, V77, P1215; MEYER J, 1992, J APPL PHYSIOL, V73, P824; MINNARD EA, 1994, ARCH SURG-CHICAGO, V129, P142; MORRIS SM, 1994, AM J PHYSIOL, V266, pE829, DOI 10.1152/ajpendo.1994.266.6.E829; NATANSON C, 1994, ANN INTERN MED, V120, P771, DOI 10.7326/0003-4819-120-9-199405010-00009; NATHAN C, 1994, CELL, V78, P915, DOI 10.1016/0092-8674(94)90266-6; NATHAN C, 1992, FASEB J, V6, P3051, DOI 10.1096/fasebj.6.12.1381691; NATHAN CF, 1990, J NATL CANCER I, V82, P726, DOI 10.1093/jnci/82.9.726; NAVA E, 1991, LANCET, V338, P1555, DOI 10.1016/0140-6736(91)92375-C; OCHOA JB, 1992, J NATL CANCER I, V84, P864, DOI 10.1093/jnci/84.11.864; OCHOA JB, 1991, ANN SURG, V214, P621, DOI 10.1097/00000658-199111000-00013; PERRELLA MA, 1991, AM J PHYSIOL, V261, pR323, DOI 10.1152/ajpregu.1991.261.2.R323; PETROS A, 1991, LANCET, V338, P1557, DOI 10.1016/0140-6736(91)92376-D; PETROS A, 1994, CARDIOVASC RES, V28, P34, DOI 10.1093/cvr/28.1.34; PREISER JC, 1994, EUR SURG RES, V26, P10, DOI 10.1159/000129313; REES DD, 1995, ENDOTHELIUM, V3, pS116; ROBERTSON FM, 1994, ARCH SURG-CHICAGO, V129, P149; SHEN WQ, 1994, CIRC RES, V75, P1086, DOI 10.1161/01.RES.75.6.1086; SPAIN DA, 1994, SURGERY, V116, P322; STAMLER JS, 1994, CELL, V78, P931, DOI 10.1016/0092-8674(94)90269-0; STATMAN R, 1994, J SURG RES, V57, P93, DOI 10.1006/jsre.1994.1116; TEALE DM, 1992, J ANTIMICROB CHEMOTH, V30, P839, DOI 10.1093/jac/30.6.839; VANDERVORT AL, 1994, J IMMUNOL, V152, P4102; WEI XQ, 1995, NATURE, V375, P408, DOI 10.1038/375408a0; WEITZBERG E, 1995, CRIT CARE MED, V23, P909, DOI 10.1097/00003246-199505000-00020; YAN L, 1994, J IMMUNOL, V153, P1825; ZENI F, 1996, 24TH ANN M FRENCH I	59	140	147	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 17	1996	275	15					1192	1196		10.1001/jama.275.15.1192	http://dx.doi.org/10.1001/jama.275.15.1192			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UE625	8609688				2022-12-28	WOS:A1996UE62500032
J	Loeb, JM; Buck, AS				Loeb, JM; Buck, AS			Framework for selection of performance measurement systems: Attributes of conformance	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									JOINT COMMISS ACCREDITAT HEALTHCARE ORG,MEASUREMENT & RES,OAKBROOK TERRACE,IL 60181		Loeb, JM (corresponding author), JOINT COMMISS ACCREDITAT HEALTHCARE ORG,RES & EVALUAT,1 RENAISSANCE BLVD,OAKBROOK TERRACE,IL 60181, USA.							1995, JAMA-J AM MED ASSOC, V273, P1405	1	3	3	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 21	1996	275	7					508	508						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TV569	8606459				2022-12-28	WOS:A1996TV56900006
J	Wetzel, FT				Wetzel, FT			Surgery for herniated vertebral disks	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter											Wetzel, FT (corresponding author), UNIV CHICAGO,DEPT SURG,SECT ORTHOPAED SURG & REHABIL MED,CHICAGO,IL 60637, USA.							BODEN SD, 1990, ORTHOP T, V14, P66; BUSH K, 1992, SPINE, V17, P1205, DOI 10.1097/00007632-199210000-00013; Mixter W.J., 1934, NEW ENGL J MED, V211, P210, DOI [10.1056/NEJM193408022110506, DOI 10.1056/NEJM193408022110506]; MORRIS EW, 1986, SPINE, V11, P436, DOI 10.1097/00007632-198606000-00007; MORRIS J, 1988, ORTHOPEDICS, V11, P1483; WEBER H, 1983, SPINE, V8, P131, DOI 10.1097/00007632-198303000-00003; WIESEL SW, 1984, SPINE, V9, P549, DOI 10.1097/00007632-198409000-00003; WILLIAMS RW, 1986, SPINE, V11, P851, DOI 10.1097/00007632-198610000-00023	8	2	2	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 21	1996	275	7					513	514						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TV569	8606464				2022-12-28	WOS:A1996TV56900011
J	Hyman, AA; Karsenti, E				Hyman, AA; Karsenti, E			Morphogenetic properties of microtubules and mitotic spindle assembly	CELL			English	Review							REAL-TIME OBSERVATIONS; DYNAMIC INSTABILITY; CYTOPLASMIC DYNEIN; GTP HYDROLYSIS; LIVING CELLS; XENOPUS EGGS; INVITRO; KINETOCHORE; PROTEIN; MICROSCOPY				Hyman, AA (corresponding author), EUROPEAN MOLEC BIOL LAB, CELL BIOL PROGRAM, MEYERHOFSTR 1, D-69012 HEIDELBERG, GERMANY.		Hyman, Anthony A/B-3917-2017; Hyman, Tony/F-1923-2011	Hyman, Anthony A/0000-0003-3664-154X; 				AMOS LA, 1974, J CELL SCI, V14, P523; ANDERSEN SSL, 1994, J CELL BIOL, V127, P1289, DOI 10.1083/jcb.127.5.1289; ARNAL I, 1995, CURR BIOL, V5, P900, DOI 10.1016/S0960-9822(95)00180-1; BAJER AS, 1981, COLD SPRING HARB SYM, V46, P263; BELMONT LD, 1990, CELL, V62, P579, DOI 10.1016/0092-8674(90)90022-7; BERGEN LG, 1980, J CELL BIOL, V84, P151, DOI 10.1083/jcb.84.1.151; CARLIER MF, 1989, INT REV CYTOL, V115, P139; CASSIMERIS L, 1988, J CELL BIOL, V107, P2223, DOI 10.1083/jcb.107.6.2223; CHRETIEN D, 1995, J CELL BIOL, V129, P1311, DOI 10.1083/jcb.129.5.1311; COUE M, 1991, J CELL BIOL, V112, P1165, DOI 10.1083/jcb.112.6.1165; DOGTEROM AM, 1994, THESIS U PARIS ORSAY; DRECHSEL DN, 1994, CURR BIOL, V4, P1053, DOI 10.1016/S0960-9822(00)00243-8; DRECHSEL DN, 1992, MOL BIOL CELL, V3, P1141, DOI 10.1091/mbc.3.10.1141; ENDOW SA, 1994, J CELL SCI, V107, P859; ERICKSON HP, 1992, ANNU REV BIOPH BIOM, V21, P145, DOI 10.1146/annurev.bb.21.060192.001045; EUTENEUER U, 1981, J CELL BIOL, V89, P338, DOI 10.1083/jcb.89.2.338; EVANS L, 1985, J CELL BIOL, V100, P1185, DOI 10.1083/jcb.100.4.1185; GARD DL, 1992, DEV BIOL, V151, P516, DOI 10.1016/0012-1606(92)90190-R; GEUENS G, 1989, J CELL BIOL, V108, P939, DOI 10.1083/jcb.108.3.939; GORBSKY GJ, 1987, J CELL BIOL, V104, P9, DOI 10.1083/jcb.104.1.9; HOLY TE, 1994, P NATL ACAD SCI USA, V91, P5682, DOI 10.1073/pnas.91.12.5682; HYMAN AA, 1990, J CELL BIOL, V110, P1607, DOI 10.1083/jcb.110.5.1607; HYMAN AA, 1991, NATURE, V351, P206, DOI 10.1038/351206a0; HYMAN AA, 1992, MOL BIOL CELL, V3, P1155, DOI 10.1091/mbc.3.10.1155; HYMAN AA, 1995, J CELL BIOL, V128, P117, DOI 10.1083/jcb.128.1.117; KARSENTI E, 1984, J CELL BIOL, V99, pS47, DOI 10.1083/jcb.99.1.47s; Karsenti E, 1991, Semin Cell Biol, V2, P251; KIRSCHNER M, 1986, CELL, V45, P329, DOI 10.1016/0092-8674(86)90318-1; KOSHLAND DE, 1988, NATURE, V331, P499, DOI 10.1038/331499a0; Lambert Anne Marie, 1994, V13, P325; LOMBILLO VA, 1995, J CELL BIOL, V128, P107, DOI 10.1083/jcb.128.1.107; MANDELKOW E, 1995, CURR OPIN CELL BIOL, V7, P72, DOI 10.1016/0955-0674(95)80047-6; MANDELKOW EM, 1991, J CELL BIOL, V114, P977, DOI 10.1083/jcb.114.5.977; MANIOTIS A, 1991, CELL, V67, P495, DOI 10.1016/0092-8674(91)90524-3; MARGOLIS RL, 1990, EMBO J, V9, P4095, DOI 10.1002/j.1460-2075.1990.tb07631.x; MASTRONARDE DN, 1993, J CELL BIOL, V123, P1475, DOI 10.1083/jcb.123.6.1475; McIntosh J. Richard, 1994, V13, P413; MCNIVEN MA, 1988, J CELL BIOL, V106, P1593, DOI 10.1083/jcb.106.5.1593; MELKI R, 1989, BIOCHEMISTRY-US, V28, P9143, DOI 10.1021/bi00449a028; MERDES A, 1990, EUR J CELL BIOL, V53, P313; MICKEY B, 1995, J CELL BIOL, V130, P909, DOI 10.1083/jcb.130.4.909; MITCHISON T, 1986, CELL, V45, P515, DOI 10.1016/0092-8674(86)90283-7; MITCHISON T, 1984, NATURE, V312, P237, DOI 10.1038/312237a0; MITCHISON TJ, 1988, ANNU REV CELL BIOL, V4, P527, DOI 10.1146/annurev.cellbio.4.1.527; MITCHISON TJ, 1985, J CELL BIOL, V101, P766, DOI 10.1083/jcb.101.3.766; MITCHISON TJ, 1992, J CELL BIOL, V119, P569, DOI 10.1083/jcb.119.3.569; MITCHISON TJ, 1989, J CELL BIOL, V109, P637, DOI 10.1083/jcb.109.2.637; PFARR CM, 1990, NATURE, V345, P263, DOI 10.1038/345263a0; PRYER NK, 1992, J CELL SCI, V103, P965; PURICH DL, 1984, ADV PROTEIN CHEM, V36, P133, DOI 10.1016/S0065-3233(08)60297-1; RIEDER CL, 1990, J CELL BIOL, V110, P81, DOI 10.1083/jcb.110.1.81; SAMMAK PJ, 1988, NATURE, V332, P724, DOI 10.1038/332724a0; SAWIN KE, 1991, J CELL BIOL, V112, P941, DOI 10.1083/jcb.112.5.941; SAWIN KE, 1991, J CELL BIOL, V112, P925, DOI 10.1083/jcb.112.5.925; SAWIN KE, 1993, BIOESSAYS, V15, P399, DOI 10.1002/bies.950150606; SCHULZE E, 1986, J CELL BIOL, V102, P1020, DOI 10.1083/jcb.102.3.1020; SHIINA N, 1992, EMBO J, V11, P3977, DOI 10.1002/j.1460-2075.1992.tb05491.x; SIMON JR, 1992, CELL MOTIL CYTOSKEL, V21, P1, DOI 10.1002/cm.970210102; SIMON JR, 1990, J CELL SCI, V96, P571; THEURKAUF WE, 1992, J CELL BIOL, V116, P1167, DOI 10.1083/jcb.116.5.1167; URRUTIA R, 1991, P NATL ACAD SCI USA, V88, P6701, DOI 10.1073/pnas.88.15.6701; VASQUEZ RJ, 1994, J CELL BIOL, V127, P985, DOI 10.1083/jcb.127.4.985; VERDE F, 1992, J CELL BIOL, V118, P1097, DOI 10.1083/jcb.118.5.1097; VERDE F, 1991, J CELL BIOL, V112, P1177, DOI 10.1083/jcb.112.6.1177; VERDE F, 1990, NATURE, V343, P233, DOI 10.1038/343233a0; VERNOS I, 1995, TRENDS CELL BIOL, V5, P297, DOI 10.1016/S0962-8924(00)89045-5; VERNOS I, 1995, CELL, V81, P117, DOI 10.1016/0092-8674(95)90376-3; WALKER RA, 1988, J CELL BIOL, V107, P1437, DOI 10.1083/jcb.107.4.1437; Wilson EB., 1925, CELL DEV HEREDITY, V3rd edition; ZHANG DH, 1995, J CELL BIOL, V129, P1287, DOI 10.1083/jcb.129.5.1287	70	249	252	0	11	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 9	1996	84	3					401	410		10.1016/S0092-8674(00)81285-4	http://dx.doi.org/10.1016/S0092-8674(00)81285-4			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TV708	8608594	Bronze			2022-12-28	WOS:A1996TV70800009
J	Packer, M; Bristow, MR; Cohn, JN; Colucci, WS; Fowler, MB; Gilbert, EM; Shusterman, NH				Packer, M; Bristow, MR; Cohn, JN; Colucci, WS; Fowler, MB; Gilbert, EM; Shusterman, NH			The effect of carvedilol on morbidity and mortality in patients with chronic heart failure	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							IDIOPATHIC DILATED CARDIOMYOPATHY; BETA-ADRENOCEPTOR ANTAGONIST; CONGESTIVE CARDIOMYOPATHY; PLASMA NOREPINEPHRINE; RECEPTOR BLOCKADE; CLINICAL-TRIALS; SURVIVAL; VASODILATOR; METOPROLOL	Background. Controlled clinical trials have shown that beta-blockers can produce hemodynamic and symptomatic improvement in chronic heart failure, but the effect of these drugs on survival has not been determined. Methods. We enrolled 1094 patients with chronic heart failure in a double-blind, placebo-controlled, stratified program, in which patients were assigned to one of four treatment protocols on the basis of their exercise capacity. Within each of the four protocols patients with mild, moderate, or severe heart failure with left ventricular ejection fractions less than or equal to 0.35 were randomly assigned to receive either placebo (n = 398) or the beta-blocker carvedilol (n = 696); background therapy with digoxin, diuretics, and an angiotensin-converting-enzyme inhibitor remained constant. Patients were observed for the occurrence of death or hospitalization for cardiovascular reasons during the following 6 months (12 months for the group with mild heart failure). Results. The overall mortality rate was 7.8 percent in the placebo group and 3.2 percent in the carvedilol group; the reduction in risk attributable to carvedilol was 65 percent (95 percent confidence interval, 39 to 80 percent; P < 0.001). This finding led the Data and Safety Monitoring Board to recommend termination of the study before its scheduled completion. in addition, as compared with placebo, carvedilol therapy was accompanied by a 27 percent reduction in the risk of hospitalization for cardiovascular causes (19.6 percent vs. 14.1 percent, P = 0.036), as well as a 38 percent reduction in the combined risk of hospitalization or death (24.5 percent vs. 15.8 percent, P < 0.001). Worsening heart failure as an adverse reaction during treatment was less frequent in the carvedilol group than in the placebo group. Conclusions. Carvedilol reduces the risk of death as well as the risk of hospitalization for cardiovascular causes in patients with heart failure who are receiving treatment with digoxin, diuretics, and an angiotensin-converting-enzyme inhibitor. (C) 1996, Massachusetts Medical Society.	UNIV COLORADO,HLTH SCI CTR,DENVER,CO; UNIV MINNESOTA,SCH MED,MINNEAPOLIS,MN 55455; STANFORD UNIV,SCH MED,PALO ALTO,CA 94304; BOSTON UNIV,SCH MED,BOSTON,MA 02118; SMITHKLINE BEECHAM PHARMACEUT,KING OF PRUSSIA,PA 19406; UNIV UTAH,SCH MED,SALT LAKE CITY,UT	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Minnesota System; University of Minnesota Twin Cities; Stanford University; Boston University; GlaxoSmithKline; Utah System of Higher Education; University of Utah	Packer, M (corresponding author), COLUMBIA UNIV,COLL PHYS & SURG,DIV CIRCULATORY PHYSIOL,630 W 168TH ST,NEW YORK,NY 10032, USA.		bristow, michael r/G-7850-2011	Colucci, Wilson/0000-0002-0576-9420				[Anonymous], 1994, CIRCULATION, V90, P1765; BRIL A, 1992, CARDIOVASC RES, V26, P518, DOI 10.1093/cvr/26.5.518; BRISTOW M R, 1992, Journal of the American College of Cardiology, V19, p146A; BRISTOW MR, 1994, CIRCULATION, V89, P1632, DOI 10.1161/01.CIR.89.4.1632; BRISTOW MR, 1993, AM J CARDIOL, V71, pC12, DOI 10.1016/0002-9149(93)90082-N; COHN JN, 1986, NEW ENGL J MED, V314, P1547, DOI 10.1056/NEJM198606123142404; COHN JN, 1984, NEW ENGL J MED, V311, P819, DOI 10.1056/NEJM198409273111303; COX DR, 1972, J R STAT SOC B, V34, P187; DHALLA AK, 1994, CIRCULATION, V90, P491; DONCK LV, 1991, J CARDIOVASC PHARM, V18, P1, DOI 10.1097/00005344-199107000-00001; EICHHORN EJ, 1994, J AM COLL CARDIOL, V24, P1310, DOI 10.1016/0735-1097(94)90114-7; EPSTEIN SE, 1966, ANN INTERN MED, V65, P20, DOI 10.7326/0003-4819-65-1-20; FELDMAN AM, 1993, NEW ENGL J MED, V329, P149, DOI 10.1056/NEJM199307153290301; FISHER ML, 1994, J AM COLL CARDIOL, V23, P943, DOI 10.1016/0735-1097(94)90641-6; GILBERT EM, 1993, AM J CARDIOL, V71, pC23, DOI 10.1016/0002-9149(93)90083-O; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KRUM H, 1995, CIRCULATION, V92, P1499, DOI 10.1161/01.CIR.92.6.1499; MANN DL, 1992, CIRCULATION, V85, P790, DOI 10.1161/01.CIR.85.2.790; METRA M, 1994, J AM COLL CARDIOL, V24, P1678, DOI 10.1016/0735-1097(94)90174-0; NEWTON GE, 1995, CIRCULATION S1, V92, P395; OBRIEN PC, 1979, BIOMETRICS, V35, P549, DOI 10.2307/2530245; OLSEN SL, 1995, J AM COLL CARDIOL, V25, P1225, DOI 10.1016/0735-1097(95)00012-S; PACKER M, 1993, CIRCULATION, V88, P301; PACKER M, 1991, NEW ENGL J MED, V325, P1468, DOI 10.1056/NEJM199111213252103; PACKER M, 1992, J AM COLL CARDIOL, V20, P248, DOI 10.1016/0735-1097(92)90167-L; PETO R, 1976, BRIT J CANCER, V34, P585, DOI 10.1038/bjc.1976.220; RUFFOLO RR, 1990, EUR J CLIN PHARMACOL, V38, pS82, DOI 10.1007/BF01409471; SABBAH HN, 1994, CIRCULATION, V89, P2852, DOI 10.1161/01.CIR.89.6.2852; SACKNERBERNSTEI.J, 1995, CIRCULATION S1, V92, P395; SWEDBERG K, 1979, LANCET, V1, P1374; THOMAS JA, 1978, AM J CARDIOL, V41, P233, DOI 10.1016/0002-9149(78)90162-5; WAAGSTEIN F, 1975, BRIT HEART J, V37, P1022; WAAGSTEIN F, 1989, CIRCULATION, V80, P551, DOI 10.1161/01.CIR.80.3.551; WAAGSTEIN F, 1993, LANCET, V342, P1441, DOI 10.1016/0140-6736(93)92930-R; WOODLEY SL, 1991, CIRCULATION, V84, P2426, DOI 10.1161/01.CIR.84.6.2426; YATES JC, 1981, AM HEART J, V102, P210, DOI 10.1016/S0002-8703(81)80012-9; YOSHIKAWA T, IN PRESS EUR HEART J; YUE TL, 1992, J PHARMACOL EXP THER, V263, P92; 1991, NEW ENGL J MED, V325, P293; 1987, NEW ENGL J MED, V316, P1429	40	3441	3566	0	118	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 23	1996	334	21					1349	1355		10.1056/NEJM199605233342101	http://dx.doi.org/10.1056/NEJM199605233342101			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UL251	8614419				2022-12-28	WOS:A1996UL25100001
J	[Anonymous]				[Anonymous]			Reductionists lay claim to the mind	NATURE			English	Editorial Material																			0	0	0	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	MAY 9	1996	381	6578					97	97						1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UK139	8610018				2022-12-28	WOS:A1996UK13900001
J	Bigbee, WL; Jensen, RH; Veidebaum, T; Tekkel, M; Rahu, M; Stengrevics, A; Kesminiene, A; Kurtinaitis, J; Auvinen, A; Hakulinen, T; Servomaa, E; Rytomaa, T; Obrams, GI; Boice, JD				Bigbee, WL; Jensen, RH; Veidebaum, T; Tekkel, M; Rahu, M; Stengrevics, A; Kesminiene, A; Kurtinaitis, J; Auvinen, A; Hakulinen, T; Servomaa, E; Rytomaa, T; Obrams, GI; Boice, JD			Glycophorin A biodosimetry in Chernobyl cleanup workers from the Baltic countries	BRITISH MEDICAL JOURNAL			English	Article									UNIV PITTSBURGH,INST CANC,MOL CARCINOGENESIS PROGRAM,PITTSBURGH,PA 15238; UNIV CALIF SAN FRANCISCO,DEPT LAB MED,SAN FRANCISCO,CA 94143; INST EXPT & CLIN MED,DEPT EPIDEMIOL & BIOSTAT,TALLINN,ESTONIA; LATVIA CANC REGISTRY,RIGA,LATVIA; LITHUANIAN CHERNOBYL MED CTR,VILNIUS,LITHUANIA; LITHUANIAN CANC REGISTRY,MITHUANIAN ONCOL CTR,VILNIUS,LITHUANIA; FINNISH CTR RADIAT & NUCL SAFETY,HELSINKI,FINLAND; FINNISH CANC REGISTRY,SF-00170 HELSINKI,FINLAND; NCI,EXTRAMURAL PROGRAMS BRANCH,BETHESDA,MD 20892; NCI,RADIAT EPIDEMIOL BRANCH,BETHESDA,MD 20892	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of California System; University of California San Francisco; National Cancer Institute - Lithuania; Radiation & Nuclear Safety Authority (STUK); Finnish Cancer Registry; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Bigbee, WL (corresponding author), UNIV PITTSBURGH,CTR ENVIRONM & OCCUPAT HLTH & TOXICOL,GRAD SCH PUBL HLTH,PITTSBURGH,PA 15238, USA.		Auvinen, Anssi/AAL-2111-2020; Auvinen, Anssi/AAD-9311-2020; Rahu, Mati/A-9981-2008	Auvinen, Anssi/0000-0003-1125-4818; 	NCI NIH HHS [N01-CP-50520] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		JENSEN RH, 1995, RADIAT RES, V141, P129, DOI 10.2307/3579040; JENSEN RH, IN PRESS CYTOMETRY; LANGLOIS RG, 1993, RADIAT RES, V136, P111, DOI 10.2307/3578647; STRAUME T, 1991, HEALTH PHYS, V60, P71, DOI 10.1097/00004032-199101000-00011; *UN SCI COMM EFF A, 1988, SOURC EFF RISK ION R	5	23	23	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 27	1996	312	7038					1078	1079						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UH816	8616416				2022-12-28	WOS:A1996UH81600027
J	Boxma, H; Broekhuizen, T; Patka, P; Oosting, H				Boxma, H; Broekhuizen, T; Patka, P; Oosting, H			Randomised controlled trial of single-dose antibiotic prophylaxis in surgical treatment of closed fractures: The Dutch Trauma Trial	LANCET			English	Article							WOUND-INFECTION; MULTICENTER; CEFAZOLIN	Background The efficacy of prophylactic antibiotics in fracture surgery remains controversial for lack of well-documented prospective studies. We report here the findings of the Dutch Trauma Trial, a prospective, randomised, double-blind, placebo-controlled study of antibiotic prophylaxis in the primary operative treatment of limb fractures. Ceftriaxone was chosen because of its broad spectrum of activity and because its pharmacokinetic profile, including high serum levels, high tissue penetration, and long elimination half-life, makes it suitable for single-dose prophylaxis. Methods Patients aged 18 years or more, attending one of fourteen Dutch centres for acute treatment of closed fractures, were randomly allocated to a single preoperative dose of ceftriaxone 2 g or placebo, and evaluated for development of wound infection and nosocomial infection at 10 days, 30 days, and 120 days, To assess the effects of drop-outs and withdrawals, best-case and worst-case analyses were performed. Findings A total of 2195 patients were included, The incidence of superficial and deep wound infections after placebo was 8.3%, compared with 3.6% in the ceftriaxone group (p<0.001, Pearson chi(2)-test), The rate of nosocomial infection in the first month was 10.2% with placebo and 2.3% with ceftriaxone (p<0.001, Pearson chi(2)-test). Gram-positive bacteria were found in 74.5% of wound infections and 13.4% of nosocomial infections. Interpretation Adequate single-dose prophylaxis with a long-acting broad-spectrum antibiotic substantially reduces the incidence of wound infection and early nosocomial infection after surgery for closed fractures.	UNIV AMSTERDAM,ACAD MED CTR,DEPT SURG,1105 AZ AMSTERDAM,NETHERLANDS; FREE UNIV AMSTERDAM HOSP,DEPT SURG,1081 HV AMSTERDAM,NETHERLANDS; UNIV AMSTERDAM,ACAD MED CTR,DEPT CLIN EPIDEMIOL & BIOSTAT,1105 AZ AMSTERDAM,NETHERLANDS	University of Amsterdam; Academic Medical Center Amsterdam; Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER; University of Amsterdam; Academic Medical Center Amsterdam	Boxma, H (corresponding author), ZUIDERZIEKENHUIS,DEPT SURG,GROENE HILLEDIJK 315,3075 EA ROTTERDAM,NETHERLANDS.							ALBERS BA, 1994, UNFALLCHIRURG, V97, P625; ALLGOWER M, 1980, SURG CLIN N AM, V60, P133; ARENS S, 1994, HYG MED, V19, P85; BERGAN T, 1988, INSIGHTS TREAT SERIO, V2, P15; BODOKY A, 1993, J BONE JOINT SURG AM, V75A, P61, DOI 10.2106/00004623-199301000-00009; BOYD RJ, 1973, J BONE JOINT SURG AM, VA 55, P1251, DOI 10.2106/00004623-197355060-00012; BUCKLEY R, 1990, CAN J SURG, V33, P122; BURKE JF, 1961, SURGERY, V50, P161; BURNETT JW, 1980, J BONE JOINT SURG AM, V62, P457, DOI 10.2106/00004623-198062030-00017; CULVER DH, 1991, AM J MED, V91, pS152, DOI 10.1016/0002-9343(91)90361-Z; CUSHING RD, 1977, SURG CLIN N AM, V57, P165; DIPIRO JT, 1986, AM J SURG, V152, P552, DOI 10.1016/0002-9610(86)90228-X; ERICSON C, 1973, J BONE JOINT SURG AM, VA 55, P808, DOI 10.2106/00004623-197355040-00015; GATELL JM, 1984, J BONE JOINT SURG AM, V66A, P1219, DOI 10.2106/00004623-198466080-00009; GATELL JM, 1987, J BONE JOINT SURG AM, V69A, P1189, DOI 10.2106/00004623-198769080-00012; HENLEY MB, 1986, CLIN ORTHOP RELAT R, V209, P249; HILL C, 1981, LANCET, V1, P795; MCQUEEN MM, 1990, INJURY, V21, P104, DOI 10.1016/0020-1383(90)90065-3; NICHOLS RL, 1991, AM J MED, V91, pS54, DOI 10.1016/0002-9343(91)90344-W; OESTERN HJ, 1983, ORTHOPADE, V2, P2; PAIEMENT GD, 1994, J ORTHOP TRAUMA, V8, P64, DOI 10.1097/00005131-199402000-00014; PATZAKIS MJ, 1974, J BONE JOINT SURG AM, VA 56, P532, DOI 10.2106/00004623-197456030-00010; PAVEL A, 1974, J BONE JOINT SURG AM, VA 56, P777, DOI 10.2106/00004623-197456040-00011; POLLOCK AA, 1982, ANTIMICROB AGENTS CH, V22, P816, DOI 10.1128/AAC.22.5.816; ROTH AI, 1986, J TRAUMA, V26, P757, DOI 10.1097/00005373-198608000-00013; Stolle D, 1980, Hefte Unfallheilkd, V143, P1; WITTMANN DH, 1985, RECENT ADV CHEMOTHER, P189; WYMENGA A, 1992, ACTA ORTHOP SCAND, V63, P19, DOI 10.3109/17453679209154842; 1964, ANN SURG S2, V160, P1	29	178	181	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 27	1996	347	9009					1133	1137		10.1016/S0140-6736(96)90606-6	http://dx.doi.org/10.1016/S0140-6736(96)90606-6			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UG755	8609746				2022-12-28	WOS:A1996UG75500008
J	AlMohammad, A; Scott, J; Beatt, KJ; MacDermot, J; Davies, K; Aitman, T; Clutterbuck, E; Beynon, H; Noble, MIM				AlMohammad, A; Scott, J; Beatt, KJ; MacDermot, J; Davies, K; Aitman, T; Clutterbuck, E; Beynon, H; Noble, MIM			Grand Rounds - Hammersmith Hospital - A physiology classic revisited after 60 years	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							HYPERTENSION				AlMohammad, A (corresponding author), HAMMERSMITH HOSP NHS TRUST, CHARING CROSS HOSP, DEPT CARDIOL, LONDON W6 8AF, ENGLAND.							Goldblatt H, 1934, J EXP MED, V59, P347, DOI 10.1084/jem.59.3.347; Goldblatt H, 1938, J EXP MED, V67, P809, DOI 10.1084/jem.67.5.809; GOLDBLATT H, 1932, B ACAD MED CLEVELAND, V16, P6; GOLDBLATT H, 1938, HARVEY LECT 33, P237; GRUNTZIG A, 1978, LANCET, V1, P801; LARAGH JH, 1975, AM J MED, V58, P4, DOI 10.1016/0002-9343(75)90527-6; PICKERING TG, 1990, HYPERTENSION PATHOPH, V2; REIDY JF, 1990, CLIN RADIOL, V42, P299, DOI 10.1016/S0009-9260(05)82142-7; TOBIAN L, 1969, AM J PHYSIOL, V217, P458, DOI 10.1152/ajplegacy.1969.217.2.458; Wilson C, 1941, Q J MED, V10, P65; Wilson C, 1939, LANCET, V1, P136	11	1	1	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	APR 20	1996	312	7037					1029	1031						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UG610	8616354				2022-12-28	WOS:A1996UG61000033
J	CarrHill, RA; Rice, N; Roland, M				CarrHill, RA; Rice, N; Roland, M			Socioeconomic determinants of rates of consultation in general practice based on fourth national morbidity survey of general practices	BRITISH MEDICAL JOURNAL			English	Article							HEALTH; UNEMPLOYMENT; PRACTITIONER; DEPRIVATION; MORTALITY; ENGLAND; CARE	Objective-To identify the socioeconomic determinants of consultation rates in general practice. Design-Analysis of data from the fourth national morbidity survey of general practices (MSGP4) including sociodemographic details of individual patients and small area statistics from the 1991 census. Multilevel modelling techniques were used to take account of both individual patient data and small area statistics to relate socioeconomic and health status factors directly to a measure of general practitioner workload. Results-Higher rates of consultations were found in patients who were classified as permanently sick, unemployed (especially those who became unemployed during the study year), living in rented accommodation, from the Indian subcontinent, living with a spouse or partner (women only), children living with two parents (girls only), and living in urban areas, especially those living relatively near the practice. When characteristics of individual patients are known and controlled for the role of ''indices of deprivation'' is considerably reduced. The effect of individual sociodemographic characteristics were shown to vary between different areas. Conclusions-Demographic and socioeconomic factors can act as powerful predictors of consultation patterns. Though it will always be necessary to retain some local planning discretion, the sets of coefficients estimated for individual level factors, area level characteristics, and for practice groupings may be sufficient to provide an indicative level of demand for general medical services. Although the problems in using socioeconomic data from individual patients would be substantial, these results are relevant to the development of a resource allocation formula for general practice.	UNIV YORK,CTR HLTH ECON,YORK YO1 5DD,N YORKSHIRE,ENGLAND; UNIV MANCHESTER,NATL PRIMARY CARE RES & DEV CTR,MANCHESTER M13 9PL,LANCS,ENGLAND	University of York - UK; University of Manchester								BALARAJAN R, 1989, BRIT MED J, V299, P958, DOI 10.1136/bmj.299.6705.958; BALARAJAN R, 1987, J EPIDEMIOL COMMUN H, V41, P196, DOI 10.1136/jech.41.3.196; BALARAJAN R, 1992, BRIT MED J, V304, P529, DOI 10.1136/bmj.304.6826.529; BEALE N, 1988, J ROY COLL GEN PRACT, V38, P197; BEALE N, 1988, J ROY COLL GEN PRACT, V38, P200; Blaxter M., 1990, HLTH LIFESTYLES; BURGHES L, 1994, BRIT MED J, V308, P1114, DOI 10.1136/bmj.308.6937.1114; Carr-Hill R., 1994, DETERMINANTS GMS UTI; CARRHILL RA, 1994, BRIT MED J, V309, P1046, DOI 10.1136/bmj.309.6961.1046; CARSTAIRS V, 1989, COMMUNITY MED, V11, P210, DOI 10.1093/oxfordjournals.pubmed.a042469; Goldstein H., 1987, MULTILEVEL MODELS ED; *HLTH ED AUTH, 1994, BLACK MIN ETHN GROUP; Jarman B., 1983, BRIT MED J, V286, P705; JENKINSCLARKE S, 1995, SKILL MIX PRIMARY HL; JUDGE K, 1993, BRIT MED J, V306, P677, DOI 10.1136/bmj.306.6879.677; MAYS N, 1989, J EPIDEMIOL COMMUN H, V43, P191, DOI 10.1136/jech.43.2.191; MCCULLAGH P, 1986, GENERALIZED LINEAR M; MORGAN M, 1987, J EPIDEMIOL COMMUN H, V41, P269, DOI 10.1136/jech.41.4.269; MORRIS JK, 1991, BRIT J IND MED, V48, P1; MORTONJONES T, 1993, BRIT MED J, V306, P1731, DOI 10.1136/bmj.306.6894.1731; Oakley A, 1993, EUROPEAN J PUBLIC HL, V3, P220; Patterson L., 1991, BRIT EDUC RES J, V17, P387; PHILLIMORE P, 1993, LOCATING HLTH SOCIOL; Robinson WS, 1950, AM SOCIOL REV, V15, P351, DOI 10.2307/2087176; Royal College of General Practitioners Office of Population Consensus & Survey. Department of Health, 1995, MORB STAT GEN PRACT; SELVIN HC, 1958, AM J SOCIOL, V63, P607, DOI 10.1086/222356; SHELDON TA, 1994, BRIT MED J, V309, P1059, DOI 10.1136/bmj.309.6961.1059; SUCKLING J, 1994, INTERFACE PRIMARY SE; WILSON SH, 1993, PUBLIC HEALTH, V107, P153, DOI 10.1016/S0033-3506(05)80436-6; YUEN P, 1989, BRIT MED J, V298, P1212, DOI 10.1136/bmj.298.6682.1212	30	163	165	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 20	1996	312	7037					1008	1012						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UG610	8616346				2022-12-28	WOS:A1996UG61000024
J	Coggon, D; Winter, P; Martyn, C; Inskip, H				Coggon, D; Winter, P; Martyn, C; Inskip, H			Contrasting epidemiology of aortic aneurysm and peripheral vascular disease in England and Wales	BRITISH MEDICAL JOURNAL			English	Article											Coggon, D (corresponding author), UNIV SOUTHAMPTON,SOUTHAMPTON GEN HOSP,MRC,ENVIRONM EPIDEMIOL UNIT,SOUTHAMPTON SO16 6YD,HANTS,ENGLAND.		Inskip, Hazel/L-5467-2018	Inskip, Hazel/0000-0001-8897-1749				BEGNTSSON H, 1992, EUR J SURG, V158, P19; FOWKES FGR, 1989, BRIT MED J, V298, P33, DOI 10.1136/bmj.298.6665.33; MARMOT M, 1992, CORONARY HEART DIS E, P3; REED D, 1992, CIRCULATION, V85, P205, DOI 10.1161/01.CIR.85.1.205; VANLAARHOVEN CJHM, 1993, EUR J VASCULAR SURG, V7, P386, DOI 10.1016/S0950-821X(05)80254-3	5	12	12	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 13	1996	312	7036					948	948						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UF659	8616309				2022-12-28	WOS:A1996UF65900021
J	Humar, A; Keystone, J				Humar, A; Keystone, J			Fortnightly review - Evaluating fever in travellers returning from tropical countries	BMJ-BRITISH MEDICAL JOURNAL			English	Article							MALARIA		UNIV TORONTO, TORONTO HOSP,DEPT MED,DIV INFECT DIS, TROP DIS UNIT, TORONTO, ON M5G 2C4, CANADA	University of Toronto; University Toronto Affiliates; University Health Network Toronto								BEADLE C, 1994, LANCET, V343, P564, DOI 10.1016/S0140-6736(94)91520-2; BRADLEY DJ, 1995, BRIT MED J, V310, P709, DOI 10.1136/bmj.310.6981.709; CLEMENS R, 1995, J INFECT DIS, V171, pS44, DOI 10.1093/infdis/171.Supplement_1.S44; DOHERTY JF, 1995, QJM-INT J MED, V88, P277; Goldberg M B, 1988, Infect Dis Clin North Am, V2, P571; GUBLER DJ, 1993, INFECT AGENT DIS, V2, P383; KUMAR BKA, 1993, J TROP MED HYG, V96, P245; MACLEAN JD, 1994, TRAVEL MED ADVISOR, V5; MCDONALD JC, 1988, AM J MED, V85, P799, DOI 10.1016/S0002-9343(88)80024-X; MILNE LM, 1994, J CLIN PATHOL, V47, P740, DOI 10.1136/jcp.47.8.740; MOLYNEUX M, 1993, BRIT MED J, V306, P1175, DOI 10.1136/bmj.306.6886.1175; RAMIREZRONDA CH, 1994, INFECT DIS CLIN N AM, V8, P107; RAOULT D, 1991, ANTIMICROB AGENTS CH, V35, P2457, DOI 10.1128/AAC.35.12.2457; SAXE SE, 1992, INFECT DIS CLIN N AM, V6, P427; Strickland G. T., 1991, HUNTERS TROPICAL MED; STRICKLAND GT, 1992, MED CLIN N AM, V76, P1375, DOI 10.1016/S0025-7125(16)30292-9; SVENSON JE, 1995, ARCH INTERN MED, V155, P861, DOI 10.1001/archinte.155.8.861; TINDALL B, 1988, ARCH INTERN MED, V148, P945, DOI 10.1001/archinte.148.4.945; VISSER LG, 1995, CLIN INFECT DIS, V20, P280, DOI 10.1093/clinids/20.2.280; WILSON M, 1991, WORLD GUIDE INFECTIO; WOLFE MS, 1995, J INFECT DIS, V171, pS29, DOI 10.1093/infdis/171.Supplement_1.S29; WOODRUFF BA, 1991, JAMA-J AM MED ASSOC, V265, P756, DOI 10.1001/jama.265.6.756; WU RG, 1994, CHEMOTHERAPY, V40, P61, DOI 10.1159/000239172; WYLER DJ, 1993, CLIN INFECT DIS, V16, P449, DOI 10.1093/clind/16.4.449; 1995, MMWR-MORBID MORTAL W, V44, P353	25	37	39	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	APR 13	1996	312	7036					953	956						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UF659	8616312	Green Published			2022-12-28	WOS:A1996UF65900024
J	Drgonova, J; Drgon, T; Tanaka, K; Kollar, R; Chen, GC; Ford, RA; Chan, CSM; Takai, Y; Cabib, E				Drgonova, J; Drgon, T; Tanaka, K; Kollar, R; Chen, GC; Ford, RA; Chan, CSM; Takai, Y; Cabib, E			Rho1p, a yeast protein at the interface between cell polarization and morphogenesis	SCIENCE			English	Article							RAS SUPERFAMILY GENES; SACCHAROMYCES-CEREVISIAE; BETA-(1->3)GLUCAN SYNTHETASE; WALL; BIOSYNTHESIS; GROWTH; DEFECT; GTP	The enzyme that catalyzes the synthesis of the major structural component of the yeast cell wall, beta(1-->3)-D-glucan synthase (also known as 1,3-beta-glucan synthase), requires a guanosine triphosphate (GTP) binding protein for activity. The GTP binding protein was identified as Rho1p. The rho1 mutants were defective in GTP stimulation of glucan synthase, and the defect was corrected by addition of purified or recombinant Rho1p. A protein missing in purified preparations from a rho1 strain was identified as Rho1p. Rho1p also regulates protein kinase C, which controls a mitogen-activated protein kinase cascade. Experiments with a dominant positive PKC1 gene showed that the two effects of Rho1p are independent of each other. The colocalization of Rho1p with actin patches at the site of bud emergence and the role of Rho1p in cell wall synthesis emphasize the importance of Rho1p in polarized growth and morphogenesis.	NIDDKD,BIOCHEM & METAB LAB,BETHESDA,MD 20892; OSAKA UNIV,SCH MED,DEPT MOLEC BIOL & BIOCHEM,SUITA,OSAKA 565,JAPAN; UNIV TEXAS,DEPT MICROBIOL,AUSTIN,TX 78712	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); Osaka University; University of Texas System; University of Texas Austin			chan, cherry/GQY-4591-2022; Drgonova, Jana/B-2903-2008; Chen, Guang-Chao/P-1262-2019	Chen, Guang-Chao/0000-0002-4980-4718; Drgonova, Jana/0000-0002-4623-8466				CABIB E, 1983, P NATL ACAD SCI-BIOL, V80, P3318, DOI 10.1073/pnas.80.11.3318; CABIB E, 1982, ANNU REV BIOCHEM, V51, P763, DOI 10.1146/annurev.bi.51.070182.003555; CABIB E, UNPUB; CHANT J, 1995, CELL, V81, P1, DOI 10.1016/0092-8674(95)90363-1; DRGONOVA J, UNPUB; DRUBIN DG, 1991, CELL, V65, P1093, DOI 10.1016/0092-8674(91)90001-F; Errede B, 1993, CURR OPIN CELL BIOL, V5, P254, DOI 10.1016/0955-0674(93)90112-4; HALL A, 1994, ANNU REV CELL BIOL, V10, P31, DOI 10.1146/annurev.cb.10.110194.000335; KANG MS, 1986, P NATL ACAD SCI USA, V83, P5808, DOI 10.1073/pnas.83.16.5808; LEVIN DE, 1992, J CELL BIOL, V116, P1221, DOI 10.1083/jcb.116.5.1221; MADAULE P, 1987, P NATL ACAD SCI USA, V84, P779, DOI 10.1073/pnas.84.3.779; MATSUI Y, 1992, GENE, V114, P43, DOI 10.1016/0378-1119(92)90705-T; MATSUI Y, 1992, MOL CELL BIOL, V12, P5690, DOI 10.1128/MCB.12.12.5690; MAZUR P, 1995, MOL CELL BIOL, V15, P5671; MIZUNO T, 1991, P NATL ACAD SCI USA, V88, P6442, DOI 10.1073/pnas.88.15.6442; MOL PC, 1994, J BIOL CHEM, V269, P31267; MULHOLLAND J, 1994, J CELL BIOL, V125, P381, DOI 10.1083/jcb.125.2.381; NONAKA H, 1995, EMBO J, V14, P5931, DOI 10.1002/j.1460-2075.1995.tb00281.x; ROEMER T, 1994, J CELL BIOL, V127, P567, DOI 10.1083/jcb.127.2.567; SHEMATEK EM, 1980, J BIOL CHEM, V255, P895; SHEMATEK EM, 1980, J BIOL CHEM, V255, P888; TAKAI Y, 1995, TRENDS BIOCHEM SCI, V20, P227, DOI 10.1016/S0968-0004(00)89022-2; YAMOCHI W, 1994, J CELL BIOL, V125, P1077, DOI 10.1083/jcb.125.5.1077	24	301	316	2	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 12	1996	272	5259					277	279		10.1126/science.272.5259.277	http://dx.doi.org/10.1126/science.272.5259.277			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UE729	8602514				2022-12-28	WOS:A1996UE72900044
J	Munk, MHJ; Roelfsema, PR; Konig, P; Engel, AK; Singer, W				Munk, MHJ; Roelfsema, PR; Konig, P; Engel, AK; Singer, W			Role of reticular activation in the modulation of intracortical synchronization	SCIENCE			English	Article							CAT VISUAL-CORTEX; OSCILLATORY NEURONAL RESPONSES; CROSS-CORRELATION; CONNECTIONS; MONKEY; HZ	During aroused states of the brain, electroencephalographic activity is characterized by fast, irregular fluctuations of low amplitude, which are thought to reflect desynchronization of neuronal activity. This phenomenon seems at odds with the proposal that synchronization of cortical responses may play an important role in the processing of sensory signals. Here, activation of the mesencephalic reticular formation (MRF), an effective way to ''desynchronize the electroencephalogram,'' was shown to facilitate oscillatory activity in the gamma frequency range and to enhance the stimulus-specific synchronization of neuronal spike responses in the visual cortex of cats.			Munk, MHJ (corresponding author), MAX PLANCK INST HIRNFORSCH,ABT NEUROPHYSIOL,DEUTSCHORDENSTR 46,D-60528 FRANKFURT,GERMANY.		Singer, Wolf/D-6874-2012; Roelfsema, Pieter/J-6903-2013; König, Peter/ABB-2380-2020; Engel, Andreas K./AAH-6384-2019; Engel, Andreas K/C-7781-2012	Roelfsema, Pieter/0000-0002-1625-0034; König, Peter/0000-0003-3654-5267; Engel, Andreas K./0000-0003-4899-8466; Engel, Andreas K/0000-0003-4899-8466				Abeles M., 1982, LOCAL CORTICAL CIRCU; BOUYER JJ, 1981, ELECTROEN CLIN NEURO, V51, P244, DOI 10.1016/0013-4694(81)90138-3; COPE TC, 1987, J PHYSIOL-LONDON, V390, P161, DOI 10.1113/jphysiol.1987.sp016692; ECKHORN R, 1993, NEUROREPORT, V4, P243, DOI 10.1097/00001756-199303000-00004; ECKHORN R, 1988, BIOL CYBERN, V60, P121, DOI 10.1007/BF00202899; ENGEL A K, 1992, Current Biology, V2, P332, DOI 10.1016/0960-9822(92)90898-K; ENGEL AK, 1991, P NATL ACAD SCI USA, V88, P6048, DOI 10.1073/pnas.88.14.6048; ENGEL AK, 1991, SCIENCE, V252, P1177, DOI 10.1126/science.252.5009.1177; ENGEL AK, 1991, P NATL ACAD SCI USA, V88, P9136, DOI 10.1073/pnas.88.20.9136; GRAY C M, 1987, Neuroscience, V22, pS434; GRAY CM, 1989, P NATL ACAD SCI USA, V86, P1698, DOI 10.1073/pnas.86.5.1698; GRAY CM, 1989, NATURE, V338, P334, DOI 10.1038/338334a0; KONIG P, 1993, EUR J NEUROSCI, V5, P501, DOI 10.1111/j.1460-9568.1993.tb00516.x; KONIG P, 1995, P NATL ACAD SCI USA, V92, P290, DOI 10.1073/pnas.92.1.290; KONIG P, 1994, J NEUROSCI METH, V54, P31, DOI 10.1016/0165-0270(94)90157-0; KREITER AK, 1992, EUR J NEUROSCI, V4, P369, DOI 10.1111/j.1460-9568.1992.tb00884.x; KREITER AK, IN PRESS J NEUROSCI; MORUZZI G, 1949, ELECTROEN CLIN NEURO, V1, P455, DOI 10.1016/0013-4694(49)90066-8; Munk MHJ, 1995, J NEUROPHYSIOL, V74, P2401, DOI 10.1152/jn.1995.74.6.2401; MURTHY VN, 1992, P NATL ACAD SCI USA, V89, P5670, DOI 10.1073/pnas.89.12.5670; NELSON JI, 1992, VISUAL NEUROSCI, V9, P21, DOI 10.1017/S0952523800006349; Nowak LG, 1995, J NEUROPHYSIOL, V74, P2379, DOI 10.1152/jn.1995.74.6.2379; SCHWARZ C, 1991, J NEUROSCI, V11, P2995; SINGER W, 1993, ANNU REV PHYSIOL, V55, P349, DOI 10.1146/annurev.physiol.55.1.349; SINGER W, 1995, ANNU REV NEUROSCI, V18, P555, DOI 10.1146/annurev.neuro.18.1.555; SINGER W, 1995, SCIENCE, V270, P758, DOI 10.1126/science.270.5237.758; SINGER W, 1990, BRAIN CHOLINERGIC SY, P314; Steriade M, 1996, J NEUROSCI, V16, P392, DOI 10.1523/jneurosci.16-01-00392.1996; STERIADE M, 1993, SCIENCE, V262, P679, DOI 10.1126/science.8235588; STERIADE M, 1991, P NATL ACAD SCI USA, V88, P4396, DOI 10.1073/pnas.88.10.4396	30	344	347	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 12	1996	272	5259					271	274		10.1126/science.272.5259.271	http://dx.doi.org/10.1126/science.272.5259.271			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UE729	8602512				2022-12-28	WOS:A1996UE72900042
J	Johnson, SR; Pavord, ID; Tatersfield, AE; Macfarlane, JT; Donald, FE; Ahsan, AJ; Banks, DC; Loudon, M				Johnson, SR; Pavord, ID; Tatersfield, AE; Macfarlane, JT; Donald, FE; Ahsan, AJ; Banks, DC; Loudon, M			Grand rounds - City Hospital, Nottingham - A complicated case of community acquired pneumonia - Beware of drug induced side effects in critically ill people	BRITISH MEDICAL JOURNAL			English	Discussion							INTENSIVE-CARE TREATMENT; ERYTHROMYCIN; OTOTOXICITY; SALBUTAMOL				Johnson, SR (corresponding author), CITY HOSP,DIV RESP MED,NOTTINGHAM NG5 1PB,ENGLAND.			Pavord, Ian/0000-0002-4288-5973; Johnson, Simon/0000-0002-9837-2763				ACOCELLA G, 1983, REV INFECT DIS, V5, pS428; ACOCELLA G, 1972, EUR J CLIN PHARMACOL, V5, P111, DOI 10.1007/BF00561755; ALKHAYER M, 1990, RESP MED, V84, P13, DOI 10.1016/S0954-6111(08)80087-X; GALLAGHER KL, 1979, ANN INTERN MED, V91, P744, DOI 10.7326/0003-4819-91-5-744; HAEFELI WE, 1992, INTENS CARE MED, V18, P469, DOI 10.1007/BF01708583; HUBBARD RB, 1993, Q J MED, V86, P327; LIPWORTH BJ, 1990, CLIN SCI, V78, P255, DOI 10.1042/cs0780255; Macfarlane J, 1994, Semin Respir Infect, V9, P153; Ortqvist A, 1994, Semin Respir Infect, V9, P166; ORTQVIST A, 1985, SCAND J INFECT DIS, V17, P377; SMYTH ET, 1993, BRIT MED J, V306, P543, DOI 10.1136/bmj.306.6877.543; SORENSEN J, 1989, SCAND J INFECT DIS, V21, P33, DOI 10.3109/00365548909035678; SORENSEN J, 1986, SCAND J INFECT DIS, V18, P329, DOI 10.3109/00365548609032344; TEBOEKHORST T, 1988, J HEPATOL, V7, P111, DOI 10.1016/S0168-8278(88)80514-2; UMSTEAD GS, 1986, ARCH INTERN MED, V146, P897, DOI 10.1001/archinte.146.5.897; WOODHEAD MA, 1985, J INFECTION, V10, P204, DOI 10.1016/S0163-4453(85)92463-6; Wreghitt T, 1993, Commun Dis Rep CDR Rev, V3, pR119; 1992, RESP MED, V86, P7	18	4	4	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 6	1996	312	7035					899	901						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UE371	8611886				2022-12-28	WOS:A1996UE37100032
J	Bridger, S; Cairns, SR				Bridger, S; Cairns, SR			Survey of general practitioners' views of consultants' non-urgent referral of outpatients to other consultants	BRITISH MEDICAL JOURNAL			English	Article									ROYAL SUSSEX CTY HOSP,BRIGHTON BN2 5BE,E SUSSEX,ENGLAND	University of Brighton								AMSTRONG D, 1995, BRIT MED J, V310, P581; BOWLING A, 1991, BRIT MED J, V303, P292, DOI 10.1136/bmj.303.6797.292; Morrell D C, 1971, J R Coll Gen Pract, V21, P77; SAMANTA A, 1991, J ROY COLL PHYS LOND, V25, P33; WOOLEY B, 1992, REFERRAL MED OUTPATI, P43	5	4	4	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 30	1996	312	7034					821	822						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UD378	8608292				2022-12-28	WOS:A1996UD37800027
J	Gill, P; Dowell, AC; Neal, RD; Smith, N; Heywood, P; Wilson, AE				Gill, P; Dowell, AC; Neal, RD; Smith, N; Heywood, P; Wilson, AE			Evidence based general practice: A retrospective study of interventions in one training practice	BRITISH MEDICAL JOURNAL			English	Article							DOUBLE-BLIND; CONTROLLED TRIAL; HYPERTENSION	Objective-To estimate the proportion of interventions in general practice that are based on evidence from clinical trials and to assess the appropriateness of such an evaluation. Design-Retrospective review of case notes. Setting-One suburban training general practice. Subjects-122 consecutive doctor-patient consultations over two days. Main outcome measures-Proportions of interventions based on randomised controlled trials (from literature search with Medline, pharmaceutical databases, and standard textbooks), on convincing non-experimental evidence, and without substantial evidence. Results-21 of the 122 consultations recorded were excluded due to insufficient data; 31 of the interventions were based on randomised controlled trial evidence and 51 based on convincing nonexperimental evidence. Hence 82/101 (81%) of interventions were based on evidence meeting our criteria. Conclusions-Most interventions within general practice are based on evidence from clinical trials, but the methods used in such trials may not be the most appropriate to apply to this setting.	UNIV LEEDS,CTR RES PRIMARY CARE,LEEDS LS2 9LN,W YORKSHIRE,ENGLAND	University of Leeds								AGNEW RAL, 1977, CLIN ALLERGY, V7, P183, DOI 10.1111/j.1365-2222.1977.tb01440.x; [Anonymous], 1995, LANCET, V346, P785; AVEYARD P, 1995, LANCET, V346, P838; BRADLEY F, 1995, LANCET, V346, P838; Bridges-Webb Charles, 1992, Medical Journal of Australia, V157, pS1; BROGDEN RN, 1976, DRUGS, V12, P249, DOI 10.2165/00003495-197612040-00001; *C US OFF TECHN AS, 1978, ASS EFF SAF MED TECH; CIPRANDI G, 1991, J INVEST ALLERG CLIN, V1, P368; CIPRANDI G, 1990, ANN ALLERGY, V65, P156; CORNE SJ, 1989, INT CLIN PSYCHOPHARM, V4, P245, DOI 10.1097/00004850-198907000-00007; Cullen S I, 1976, Cutis, V17, P1208; CULLEN SI, 1977, CUTIS, V19, P126; DAVIDOFF F, 1995, BRIT MED J, V310, P1085, DOI 10.1136/bmj.310.6987.1085; DICKERSIN K, 1994, BMJ-BRIT MED J, V309, P1286, DOI 10.1136/bmj.309.6964.1286; DRAYER JIM, 1983, HYPERTENSION, V5, P108; ELLIS J, 1995, LANCET, V346, P407, DOI 10.1016/S0140-6736(95)92781-6; Evans EGV, 1992, J DERMATOL TREAT, V3, P181; FITZPATRICK MF, 1990, BRIT MED J, V301, P1365, DOI 10.1136/bmj.301.6765.1365; FROST H, 1995, BRIT MED J, V310, P151, DOI 10.1136/bmj.310.6973.151; GELBACH S, 1979, J MED EDUC, V54, P730; HALLIN L, 1983, J CARDIOVASC PHARM, V5, P1083, DOI 10.1097/00005344-198311000-00025; HANSSON L, 1975, BRIT MED J, V2, P367, DOI 10.1136/bmj.2.5967.367; HASHAM F, 1981, ARCH DIS CHILD, V56, P722, DOI 10.1136/adc.56.9.722; Howie J G, 1972, J R Coll Gen Pract, V22, P310; LACEY RW, 1980, LANCET, V1, P1270; Low R A, 1975, Curr Med Res Opin, V3, P211, DOI 10.1185/03007997509113674; Marsland DW, 1980, CONTENT FAMILY PRACT; MORLEY CA, 1983, BRIT J CLIN PHARMACO, V15, P715, DOI 10.1111/j.1365-2125.1983.tb01555.x; PETRI M, 1987, ARTHRITIS RHEUM-US, V30, P1040, DOI 10.1002/art.1780300911; RICHARDS JG, 1980, CURR MED RES OPIN, V6, P393, DOI 10.1185/03007998009109457; RICKELS K, 1980, J CLIN PHARMACOL, V20, P581, DOI 10.1002/j.1552-4604.1980.tb01673.x; SILAS JH, 1982, BRIT MED J, V284, P1602, DOI 10.1136/bmj.284.6329.1602; SMITH EB, 1977, SOUTHERN MED J, V70, P47, DOI 10.1097/00007611-197701000-00021; SMITH R, 1995, BRIT MED J, V311, P961; WHEATLEY D, 1986, ACTA PSYCHIAT SCAN S, V332, P142; 1985, BRIT MED J, V291, P97; 1989, J ANTIMICROB CHEMOTH, V23, P261; 1992, LANCET, V340, P1131	38	125	128	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 30	1996	312	7034					819	821						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UD378	8608291				2022-12-28	WOS:A1996UD37800026
J	Goodfellow, J; Ramsey, MW; Luddington, LA; Jones, CJH; Coates, PA; Dunstan, F; Lewis, MJ; Owens, DR; Henderson, AH				Goodfellow, J; Ramsey, MW; Luddington, LA; Jones, CJH; Coates, PA; Dunstan, F; Lewis, MJ; Owens, DR; Henderson, AH			Endothelium and inelastic arteries: An early marker of vascular dysfunction in noninsulin dependent diabetes	BRITISH MEDICAL JOURNAL			English	Article							INSULIN		UNIV WALES COLL MED,DIABET RES UNIT,CARDIFF CF4 4XN,S GLAM,WALES; UNIV WALES COLL MED,DEPT MED STAT & COMP,CARDIFF CF4 4XN,S GLAM,WALES	Cardiff University; Cardiff University	Goodfellow, J (corresponding author), UNIV WALES COLL MED,CARDIOVASC SCI RES GRP,CARDIFF CF4 4XN,S GLAM,WALES.							COATES PA, 1993, DIABETES, V42, P1635, DOI 10.2337/diabetes.42.11.1635; OROURKE MF, 1989, J HUM HYPERTEN, V10, P47; RAMSEY MW, 1995, CIRCULATION, V92, P3212, DOI 10.1161/01.CIR.92.11.3212; STEHOUWER CDA, 1992, LANCET, V340, P319, DOI 10.1016/0140-6736(92)91401-S	4	116	117	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 23	1996	312	7033					744	745						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UC166	8605460				2022-12-28	WOS:A1996UC16600026
J	Lands, RH; Ridge, O				Lands, RH; Ridge, O			Epiphany	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	0	0	1	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 21	1996	275	7					564	564						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TV569	8606481				2022-12-28	WOS:A1996TV56900037
J	Pope, HG; YurgelunTodd, D				Pope, HG; YurgelunTodd, D			The residual cognitive effects of heavy marijuana use in college students	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							AIRCRAFT PILOT PERFORMANCE; CANNABIS USE	Objective.-To assess whether frequent marijuana use is associated with residual neuropsychological effects. Design.-Single-blind comparison of regular users vs infrequent users of marijuana. Participants.-Two samples of college undergraduates: 65 heavy users, who had smoked marijuana a median of 29 days in the past 30 days (range, 22 to 30 days) and who also displayed cannabinoids in their urine, and 64 light users, who had smoked a median of 1 day in the last 30 days (range, 0 to 9 days) and who displayed no urinary cannabinoids. Intervention.-Subjects arrived at 2 PM On day 1 of their study visit, then remained at our center overnight under supervision. Neuropsychological tests were administered to all subjects starting at 9 AM On day 2. Thus, all subjects were abstinent from marijuana and other drugs for a minimum of 19 hours before testing. Main Outcome Measures.-Subjects received a battery of standard neuropsychological tests to assess general intellectual functioning, abstraction ability, sustained attention, verbal fluency, and ability to learn and recall new verbal and visuospatial information. Results.-Heavy users displayed significantly greater impairment than light users on attentional/executive functions, as evidenced particularly by greater perseverations on card sorting and reduced learning of word lists. These differences remained after controlling for potential confounding variables, such as estimated levels of premorbid cognitive functioning, and for use of alcohol and other substances in the two groups. Conclusions.-Heavy marijuana use is associated with residual neuropsychological effects even after a day of supervised abstinence from the drug. However, the question remains open as to whether this impairment is due to a residue of drug in the brain, a withdrawal effect from the drug, or af rank neurotoxic effect of the drug.	MCLEAN HOSP,BRAIN IMAGING CTR,BELMONT,MA 02178; HARVARD UNIV,SCH MED,DEPT PSYCHIAT,BOSTON,MA 02115	Harvard University; McLean Hospital; Harvard University; Harvard Medical School	Pope, HG (corresponding author), MCLEAN HOSP,BIOL PSYCHIAT LAB,115 MILL ST,BELMONT,MA 02178, USA.				NIDA NIH HHS [R01 DA06522] Funding Source: Medline; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA006522] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		Benton A, 1978, PSYCHOL ASSESSMENT R; Benton A.L., 1994, CONTRIBUTIONS NEUROP; BLOCK RI, 1993, PSYCHOPHARMACOLOGY, V110, P219, DOI 10.1007/BF02246977; CHAIT LD, 1990, PSYCHOPHARMACOLOGY, V100, P328, DOI 10.1007/BF02244601; DELIS D, 1987, CALIFORNIA VERBAL LE; Heaton, 1981, WISCONSIN CARD SORTI; HEISHMAN SJ, 1990, PHARMACOL BIOCHEM BE, V37, P561, DOI 10.1016/0091-3057(90)90028-G; JONES RT, 1981, J CLIN PHARMACOL, V21, pS143, DOI 10.1002/j.1552-4604.1981.tb02589.x; KOURI E, 1995, BIOL PSYCHIAT, V38, P475, DOI 10.1016/0006-3223(94)00325-W; LEIRER VO, 1991, AVIAT SPACE ENVIR MD, V62, P221; LEVIN S, 1989, J ABNORM PSYCHOL, V98, P341, DOI 10.1037/0021-843X.98.4.341; Loring D W, 1990, Arch Clin Neuropsychol, V5, P1, DOI 10.1016/0887-6177(90)90002-7; MACLEOD CM, 1991, PSYCHOL BULL, V109, P163, DOI 10.1037/0033-2909.109.2.163; MEHTA CR, 1984, BIOMETRICS, V40, P819, DOI 10.2307/2530927; MENDELSON JH, 1984, AM J PSYCHIAT, V141, P1289; MENDHIRATTA SS, 1988, BRIT J ADDICT, V83, P749; MESULAM MM, 1985, PRINCIPLES BEHAVIORA; MILNER B, 1963, ARCH NEUROL-CHICAGO, V9, P90, DOI 10.1001/archneur.1963.00460070100010; MUELLER JH, 1979, TEST ANXIETY THEORY; PAGANO M, 1981, J AM STAT ASSOC, V76, P931, DOI 10.2307/2287590; PAGE JB, 1988, J PSYCHOACTIVE DRUGS, V20, P57, DOI 10.1080/02791072.1988.10524372; POPE HG, 1995, DRUG ALCOHOL DEPEN, V38, P25, DOI 10.1016/0376-8716(95)01097-I; POPE HG, 1990, AM J PSYCHIAT, V147, P998; ROHR JM, 1989, INT J ADDICT, V24, P627, DOI 10.3109/10826088909047302; RUBIN V, 1975, GANJA JAMAICA MED AN, P111; SCHWARTZ RH, 1989, AM J DIS CHILD, V143, P1214, DOI 10.1001/archpedi.1989.02150220110030; Seth R, 1991, Prog Drug Res, V36, P71; SOIOWIJ N, 1995, LIFE SCI, V56, P2119; SOLOWIJ N, 1995, BIOL PSYCHIAT, V37, P731, DOI 10.1016/0006-3223(94)00178-6; SPITZ HH, 1972, PSYCHOL BULL, V78, P183, DOI 10.1037/h0032954; Spitzer RL, 1990, STRUCTURED CLIN INTE; VARMA VK, 1988, DRUG ALCOHOL DEPEN, V21, P147, DOI 10.1016/0376-8716(88)90061-0; Wechsler D., 2008, WECHSLER ADULT INTEL, P257; Wechsler D, 1945, J PSYCHOL, V19, P87, DOI 10.1080/00223980.1945.9917223; YESAVAGE JA, 1985, AM J PSYCHIAT, V142, P1325; 1987, DIAGNOSTIC STATISTIC; 1988, SCORING MANUAL ADULT	37	378	383	1	72	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 21	1996	275	7					521	527		10.1001/jama.275.7.521	http://dx.doi.org/10.1001/jama.275.7.521			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	TV569	8606472				2022-12-28	WOS:A1996TV56900028
J	Kemp, R; Hayward, P; Applewhaite, G; Everitt, B; David, A				Kemp, R; Hayward, P; Applewhaite, G; Everitt, B; David, A			Compliance therapy in psychotic patients: Randomised controlled trial	BRITISH MEDICAL JOURNAL			English	Article							SCHIZOPHRENIC-PATIENTS; INSIGHT; SCALE; NONCOMPLIANCE; MEDICATION; MANAGEMENT; REFUSAL	Objective-To determine whether compliance therapy, a cognitive-behavioural intervention, could improve compliance with treatment and hence social adjustment in acutely psychotic inpatients, and if so, whether the effect persisted six months later. Design-Randomised controlled trial of compliance therapy and non-specific counselling, each comprising 4-6 sessions lasting 10-60 minutes. Setting-Acute psychiatric admissions ward serving an inner London catchment area. Subjects-47 patients with psychosis. Main outcome measures-Informant and observer reported measure of compliance; observer assessed global functioning after intervention and three and six months later; self rated attitudes to drug treatment after the intervention and one month later symptom scores after intervention and six months later. Results-25 patients received compliance therapy and showed significantly greater improvements in their attitudes to drug treatment and in their insight into illness and compliance with treatment compared with the control group. These gains persisted for six months. The intervention group was 5.2 times more likely than the control group to reach a criterion level of compliance (95% confidence interval 1.5 to 18.3). Global functioning showed a tendency to improve more in the intervention group after a delay (odds ratio 3.0 (0.8 to 11.5) to reach the criterion level at six months). Four subjects given compliance therapy and six in the control group were readmitted during follow up (odds ratio 2.0 (0.48 to 8.2)). Conclusions-Compliance therapy is a pragmatic method for improving compliance with drug treatment in psychotic inpatients and its gains persist for at least six months. Overall functioning may also be enhanced.	INST PSYCHIAT,LONDON SE5 8AZ,ENGLAND; INST PSYCHIAT,DEPT PSYCHOL,LONDON SE5 8AF,ENGLAND; INST PSYCHIAT,DEPT BIOSTAT & COMP,LONDON SE5 8AF,ENGLAND	University of London; King's College London; University of London; King's College London; University of London; King's College London	Kemp, R (corresponding author), UNIV LONDON KINGS COLL HOSP,DEPT PSYCHOL MED,LONDON SE5 8AZ,ENGLAND.		David, Anthony/O-1750-2019; David, Anthony S/C-1315-2011	David, Anthony/0000-0003-0967-774X; David, Anthony S/0000-0003-0967-774X				BABIKER IE, 1986, PSYCHIAT DEV, V4, P329; BARNES TRE, 1989, BRIT J PSYCHIAT, V154, P672, DOI 10.1192/bjp.154.5.672; BOCZKOWSKI JA, 1985, J CONSULT CLIN PSYCH, V53, P666, DOI 10.1037/0022-006X.53.5.666; Churchill DN, 1985, MODERN MED CANADA, V40, P1068; Coid JW, 1994, PSYCHIAT B, V18, P449, DOI 10.1192/pb.18.8.449; CORRIGAN PW, 1990, HOSP COMMUNITY PSYCH, V41, P1203; DAVID A, 1992, BRIT J PSYCHIAT, V161, P599, DOI 10.1192/bjp.161.5.599; DAVID AS, 1990, BRIT J PSYCHIAT, V156, P798, DOI 10.1192/bjp.156.6.798; DAVIS JM, 1986, J CLIN PSYCHOPHARM, V6, P2; ECKMAN TA, 1990, J CLIN PSYCHOPHARM, V10, P33, DOI 10.1097/00004714-199002000-00006; ECKMAN TA, 1992, AM J PSYCHIAT, V149, P1549; ENDICOTT J, 1976, ARCH GEN PSYCHIAT, V33, P766; EVERITT BS, 1995, J ROY STAT SOC D-STA, V44, P113, DOI 10.2307/2348622; FALLOON IRH, 1984, SCHIZOPHRENIA BULL, V10, P412, DOI 10.1093/schbul/10.3.412; FRISON L, 1992, STAT MED, V11, P1685, DOI 10.1002/sim.4780111304; GARETY PA, 1994, BRIT J MED PSYCHOL, V67, P259, DOI 10.1111/j.2044-8341.1994.tb01795.x; GOLDSTEIN MJ, 1992, PSYCHOPHARMACOL BULL, V28, P237; Hayward P, 1995, J MENTAL HLTH, V4, P511, DOI DOI 10.1080/09638239550037343; HOGAN TP, 1983, PSYCHOL MED, V13, P177, DOI 10.1017/S0033291700050182; HOGE SK, 1990, ARCH GEN PSYCHIAT, V47, P949; KANE JM, 1983, J CLIN PSYCHIAT, V44, P3; KELLY GR, 1987, SOC SCI MED, V25, P1205, DOI 10.1016/0277-9536(87)90367-4; KEMP R, IN PRESS COMPLIANCE; LUKOFF D, 1986, SCHIZOPHRENIA BULL, V12, P578, DOI 10.1093/schbul/12.4.578; MARDER SR, 1983, AM J PSYCHIAT, V140, P470; MCEVOY JP, 1989, COMPR PSYCHIAT, V30, P13, DOI 10.1016/0010-440X(89)90113-2; Miller W, 2002, MOTIVATIONAL INTERVI, V2nd; Nelson H.E., 1982, NATIONAL ADULT READI; Rollnick S, 1992, J MENT HEALTH, V1, P25, DOI DOI 10.3109/09638239209034509; SELLWOOD W, 1994, SOC PSYCH PSYCH EPID, V29, P172; SELTZER A, 1980, CAN J PSYCHIAT, V25, P638, DOI 10.1177/070674378002500807; Simpson G M, 1970, Acta Psychiatr Scand Suppl, V212, P11; STREICKER SK, 1986, PSYCHOSOC REHABIL J, V4, P15; VANPUTTEN T, 1976, ARCH GEN PSYCHIAT, V33, P1443; VANPUTTEN T, 1974, ARCH GEN PSYCHIAT, V31, P67	35	421	430	0	13	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 10	1996	312	7027					345	349						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	TV698	8611831				2022-12-28	WOS:A1996TV69800023
J	Aitken, DA; Wallace, EM; Crossley, JA; Swanston, IA; vanPareren, Y; vanMaarle, M; Groome, NP; Macri, JN; Connor, JM				Aitken, DA; Wallace, EM; Crossley, JA; Swanston, IA; vanPareren, Y; vanMaarle, M; Groome, NP; Macri, JN; Connor, JM			Dimeric inhibin a as a marker for Down's syndrome in early pregnancy	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HUMAN CHORIONIC-GONADOTROPIN; SERUM ALPHA-FETOPROTEIN; CHROMOSOMALLY ABNORMAL PREGNANCIES; MATERNAL SERUM; UNCONJUGATED ESTRIOL; IMMUNOREACTIVE INHIBIN; RISK; AGE; CHORIOGONADOTROPIN; TRISOMY-18	Background. In screening for Down's syndrome in the second trimester of pregnancy, the concentrations of alpha-fetoprotein, the beta subunit of human chorionic gonadotropin, and intact human chorionic gonadotropin in maternal serum are widely used markers. We investigated a new marker, dimeric inhibin A, and compared its predictive value with that of the established markers. Methods. Serum samples were obtained at 7 to 18 weeks of gestation from 58 women whose fetuses were known to be affected by Down's syndrome, 32 whose fetuses were affected by trisomy 18, and 438 whose fetuses were normal, and the samples were analyzed for each marker. Individual serum concentrations of each marker were converted to multiples of the median value at the appropriate length of gestation in the women with normal pregnancies, and rates of detection of Down's syndrome by screening for inhibin A in various combinations with the other markers were estimated by multivariate analysis. Results. In the women with fetuses affected by Down's syndrome, the serum inhibin A concentrations were 2.06 times the median value in the women with normal pregnancies (P<0.001). This compared with 2.00 times the median for the beta subunit of human chorionic gonadotropin, 1.82 times the median for intact human chorionic gonadotropin, and 0.72 times the median for alphafetoprotein. The serum concentrations of inhibin A in the women with fetuses affected by Down's syndrome did not appear to be significantly elevated above normal until the end of the first trimester and were not significantly different from normal in the women with fetuses affected by trisomy 18 (P=0.17). The rate of detection of Down's syndrome was 53 percent and the false positive rate was 5 percent when alpha-fetoprotein, the beta subunit of human chorionic gonadotropin, and maternal age were used together as predictors. The detection rate increased to 75 percent when inhibin A was added (P=0.002). Conclusions. In the second trimester of pregnancy, measuring inhibin A in maternal serum, in combination with measurements of alpha-fetoprotein and the beta subunit of human chorionic gonadotropin, significantly improved the rate of detection of Down's syndrome. (C) 1996, Massachusetts Medical Society.	UNIV EDINBURGH,CTR REPROD BIOL,DEPT OBSTET & GYNAECOL,EDINBURGH EH3 9EW,MIDLOTHIAN,SCOTLAND; MRC,CTR REPROD BIOL,REPROD BIOL UNIT,EDINBURGH EH3 9EW,MIDLOTHIAN,SCOTLAND; OXFORD BROOKES UNIV,SCH BIOL & MOLEC SCI,OXFORD,ENGLAND; NTD LABS,HUNTINGTON STN,NEW YORK,NY	University of Edinburgh; Oxford Brookes University	Aitken, DA (corresponding author), DUNCAN GUTHRIE INST MED GENET,GLASGOW G3 8SJ,LANARK,SCOTLAND.		Wallace, Euan M/K-6774-2015	Wallace, Euan M/0000-0002-4506-5233				AITKEN DA, 1993, PRENATAL DIAG, V13, P681, DOI 10.1002/pd.1970130804; BOGART MH, 1987, PRENATAL DIAG, V7, P623, DOI 10.1002/pd.1970070904; BROCK DJH, 1990, PRENATAL DIAG, V10, P245, DOI 10.1002/pd.1970100406; Canick J. A., 1994, American Journal of Human Genetics, V55, pA9; CANICK JA, 1988, BRIT J OBSTET GYNAEC, V95, P330, DOI 10.1111/j.1471-0528.1988.tb06601.x; Crossley J A, 1994, J Med Screen, V1, P180; CROSSLEY JA, 1991, PRENATAL DIAG, V11, P83, DOI 10.1002/pd.1970110204; CROSSLEY JA, 1993, PRENATAL DIAG, V13, P271, DOI 10.1002/pd.1970130406; CUCKLE HS, 1987, BRIT J OBSTET GYNAEC, V94, P387, DOI 10.1111/j.1471-0528.1987.tb03115.x; CUCKLE HS, 1994, PRENATAL DIAG, V14, P387, DOI 10.1002/pd.1970140508; CUCKLE HS, 1995, PRENATAL DIAG, V15, P385, DOI 10.1002/pd.1970150416; GOODBURN SF, 1994, PRENATAL DIAG, V14, P391, DOI 10.1002/pd.1970140509; GRAHAM GW, 1992, PRENATAL DIAG, V12, P505, DOI 10.1002/pd.1970120605; GROOME N, 1993, J IMMUNOL METHODS, V165, P167, DOI 10.1016/0022-1759(93)90342-5; GROOME NP, 1994, CLIN ENDOCRINOL, V40, P717, DOI 10.1111/j.1365-2265.1994.tb02504.x; HADDOW JE, 1992, NEW ENGL J MED, V327, P588, DOI 10.1056/NEJM199208273270902; MACINTOSH MCM, 1993, PRENATAL DIAG, V13, P563, DOI 10.1002/pd.1970130705; MACRI JN, 1990, AM J OBSTET GYNECOL, V163, P1248, DOI 10.1016/0002-9378(90)90700-H; MACRI JN, 1993, ANN CLIN BIOCHEM, V30, P94, DOI 10.1177/000456329303000117; MACRI JN, 1993, PRENATAL DIAG, V13, P557, DOI 10.1002/pd.1970130704; MACRI JN, 1994, PRENATAL DIAG, V14, P97, DOI 10.1002/pd.1970140204; MCLACHLAN RI, 1987, CLIN ENDOCRINOL, V27, P663, DOI 10.1111/j.1365-2265.1987.tb02949.x; MERKATZ IR, 1984, AM J OBSTET GYNECOL, V148, P886, DOI 10.1016/0002-9378(84)90530-1; MIYAMOTO K, 1985, BIOCHEM BIOPH RES CO, V129, P396, DOI 10.1016/0006-291X(85)90164-0; PALOMAKI GE, 1992, PRENATAL DIAG, V12, P925, DOI 10.1002/pd.1970121112; QU JP, 1991, J CLIN ENDOCR METAB, V72, P862, DOI 10.1210/jcem-72-4-862; REYNOLDS TM, 1990, ANN CLIN BIOCHEM, V27, P452, DOI 10.1177/000456329002700506; ROBERTSON DM, 1995, J ENDOCRINOL, V144, P261, DOI 10.1677/joe.0.1440261; SCHNEYER AL, 1990, J CLIN ENDOCR METAB, V70, P1208, DOI 10.1210/jcem-70-4-1208; SPENCER K, 1994, ANN CLIN BIOCHEM, V31, P447, DOI 10.1177/000456329403100504; SPENCER K, 1993, BRIT MED J, V307, P764, DOI 10.1136/bmj.307.6907.764; SPENCER K, 1992, ANN CLIN BIOCHEM, V29, P506, DOI 10.1177/000456329202900504; SPENCER K, 1991, CLIN CHEM, V37, P809; SPENCER K, 1993, BRIT MED J, V307, P1455, DOI 10.1136/bmj.307.6917.1455; SPENCER K, 1993, ANN CLIN BIOCHEM, V30, P219, DOI 10.1177/000456329303000226; TOVANABUTRA S, 1993, CLIN ENDOCRINOL, V38, P101, DOI 10.1111/j.1365-2265.1993.tb00979.x; VANLITH JMM, 1994, OBSTET GYNECOL, V83, P661; VANLITH JMM, 1992, PRENATAL DIAG, V12, P801, DOI 10.1002/pd.1970121005; WALD NJ, 1988, BRIT MED J, V297, P1029; WALD NJ, 1988, BRIT J OBSTET GYNAEC, V95, P334, DOI 10.1111/j.1471-0528.1988.tb06602.x; WALD NJ, 1988, BRIT MED J, V297, P883, DOI 10.1136/bmj.297.6653.883; WALD NJ, 1992, BMJ-BRIT MED J, V305, P391, DOI 10.1136/bmj.305.6850.391; WALLACE EM, 1994, CLIN ENDOCRINOL, V41, P483, DOI 10.1111/j.1365-2265.1994.tb02579.x; WALLACE EM, 1995, PRENATAL DIAG, V15, P359, DOI 10.1002/pd.1970150410; ZEITUNE M, 1991, PRENATAL DIAG, V11, P847, DOI 10.1002/pd.1970111106	45	132	135	0	3	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 9	1996	334	19					1231	1236		10.1056/NEJM199605093341904	http://dx.doi.org/10.1056/NEJM199605093341904			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UJ054	8606718				2022-12-28	WOS:A1996UJ05400004
J	Enger, C; Graham, N; Peng, Y; Chmiel, JS; Kingsley, LA; Detels, R; Munoz, A				Enger, C; Graham, N; Peng, Y; Chmiel, JS; Kingsley, LA; Detels, R; Munoz, A			Survival from early, intermediate, and late stages of HIV infection	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ACQUIRED-IMMUNODEFICIENCY-SYNDROME; MULTICENTER AIDS COHORT; PNEUMOCYSTIS-CARINII PNEUMONIA; PLACEBO-CONTROLLED TRIAL; VIRUS INFECTION; CUBIC MILLIMETER; TERM SURVIVAL; DOUBLE-BLIND; ZIDOVUDINE; PROPHYLAXIS	Objective.-To estimate expected survival time among homosexual men infected with the human immunodeficiency virus type 1 (HIV-1) by (1) the calendar period before (1985-1988) and after (1989-1993) the widespread availability of acquired immunodeficiency syndrome (AIDS) treatments with antiretroviral and prophylactic interventions, acid (2) stage of HIV disease. Design.-A prospective cohort study. A group of HIV-1-infected homosexual men were followed from July 1985 through June 1993 and evaluated every 6 months for the presence of clinical symptoms and measurement of the CD4 cell count, To measure the effectiveness of AIDS therapies in this nonrandomized study, we used 2 calendar periods as proxy measures of relative intensity of exposure to antiretroviral therapy. Stage of infection was defined by CD4 cell count and presence of HIV-related clinical symptoms or AIDS. Setting and Study Participants.-Homosexual men infected with HIV-1 from the Multicenter AIDS Cohort Study. Main Outcome Measure.-Survival time based on stage of HIV infection. Results.-The percentage of HIV-1-infected individuals free of AIDS and clinical symptoms at baseline who survived 2.5 years according to baseline CD4 cell counts of 0 to 0.100, 0.101 to 0.200, and 0.201 to 0.350 x 10(9)/L was 22%, 53%, and 83%, respectively, for the 1985-1988 calendar period, compared with 54%, 71%, and 91%, respectively, for men in the 1989-1993 calendar period. Among men free of AIDS with CD4 cell counts of greater than 0.350 x 10(9)/L, the relative hazard of mortality was 1.6 to 2.3 times higher for those with clinical symptoms compared with those free of clinical symptoms. Conclusions.-Survival of AIDS-free HIV-1-infected individuals with CD4 cell counts of less than 0.350 x 10(9)/L has improved since antiretroviral and HIV prophylactic treatments have become available, but the long-term prognosis remains poor.	JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,DEPT EPIDEMIOL,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT ONCOL,BALTIMORE,MD 21205; NORTHWESTERN UNIV,SCH MED,DEPT PREVENT MED,CHICAGO,IL; UNIV PITTSBURGH,DEPT INFECT DIS & MICROBIOL,PITTSBURGH,PA 15260; UNIV CALIF LOS ANGELES,SCH PUBL HLTH,DEPT EPIDEMIOL,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,GRAD SCH PUBL HLTH,LOS ANGELES,CA 90024	Johns Hopkins University; Johns Hopkins University; Northwestern University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles				Kingsley, Lawrence/0000-0002-7000-8556	NCRR NIH HHS [5-MO1-RR-00722] Funding Source: Medline; NIAID NIH HHS [UO1-AI-35043, UO1-AI-35042] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000722] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI035043, U01AI035042] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALCABES P, 1993, EPIDEMIOL REV, V15, P303, DOI 10.1093/oxfordjournals.epirev.a036122; BACCHETTI P, 1988, J INFECT DIS, V157, P1044, DOI 10.1093/infdis/157.5.1044; BUIRA E, 1992, J ACQ IMMUN DEF SYND, V5, P737; COOPER DA, 1993, NEW ENGL J MED, V329, P297, DOI 10.1056/NEJM199307293290501; Cox D. R., 1984, ANAL SURVIVAL DATA; FISCHL MA, 1990, ANN INTERN MED, V112, P727, DOI 10.7326/0003-4819-112-10-727; FISCHL MA, 1987, NEW ENGL J MED, V317, P185, DOI 10.1056/NEJM198707233170401; GAIL MH, 1995, AIDS CLIN TRIALS, P403; GIORGI JV, 1990, CLIN IMMUNOL IMMUNOP, V55, P173, DOI 10.1016/0090-1229(90)90096-9; GRAHAM NMH, 1992, NEW ENGL J MED, V326, P1037, DOI 10.1056/NEJM199204163261601; GRAHAM NMH, 1991, LANCET, V338, P265, DOI 10.1016/0140-6736(91)90414-K; GRAHAM NMH, 1991, J ACQ IMMUN DEF SYND, V4, P267; GRAHAM NMH, 1994, J CLIN EPIDEMIOL, V47, P1003, DOI 10.1016/0895-4356(94)90115-5; HAMILTON JD, 1992, NEW ENGL J MED, V326, P437, DOI 10.1056/NEJM199202133260703; HARRIS JE, 1990, JAMA-J AM MED ASSOC, V263, P397, DOI 10.1001/jama.263.3.397; HOOVER DR, 1993, NEW ENGL J MED, V329, P1922, DOI 10.1056/NEJM199312233292604; JACOBSON LP, 1993, AM J EPIDEMIOL, V138, P952, DOI 10.1093/oxfordjournals.aje.a116815; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KASLOW RA, 1987, AM J EPIDEMIOL, V126, P310, DOI 10.1093/aje/126.2.310; KIRBY AJ, 1994, J ACQ IMMUN DEF SYND, V7, P1242; LEMP GF, 1990, JAMA-J AM MED ASSOC, V263, P402, DOI 10.1001/jama.263.3.402; LUNDGREN JD, 1994, JAMA-J AM MED ASSOC, V271, P1088, DOI 10.1001/jama.271.14.1088; MOORE RD, 1991, NEW ENGL J MED, V324, P1412, DOI 10.1056/NEJM199105163242006; MUNOZ A, 1992, STAT MED, V11, P939, DOI 10.1002/sim.4780110711; MUNOZ A, 1993, AM J EPIDEMIOL, V137, P423, DOI 10.1093/oxfordjournals.aje.a116691; MUNOZ A, 1992, J ACQ IMMUN DEF SYND, V5, P694; MUNOZ A, 1995, AIDS CLIN TRIALS, P423; OSMOND D, 1994, JAMA-J AM MED ASSOC, V271, P1083, DOI 10.1001/jama.271.14.1083; PHILLIPS AN, 1993, AM J EPIDEMIOL, V138, P870, DOI 10.1093/oxfordjournals.aje.a116789; ROTHENBERG R, 1987, NEW ENGL J MED, V317, P1297, DOI 10.1056/NEJM198711193172101; SAAH AJ, 1994, J ACQ IMMUN DEF SYND, V7, P287; VELLA S, 1992, JAMA-J AM MED ASSOC, V267, P1232, DOI 10.1001/jama.267.9.1232; VELLA S, 1994, J ACQ IMMUN DEF SYND, V7, P31; VOLBERDING PA, 1994, JAMA-J AM MED ASSOC, V272, P437, DOI 10.1001/jama.272.6.437; VOLBERDING PA, 1990, NEW ENGL J MED, V322, P941, DOI 10.1056/NEJM199004053221401; ZEGER SL, 1986, BIOMETRICS, V42, P121, DOI 10.2307/2531248; 1994, LANCET, V343, P871	37	103	103	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 1	1996	275	17					1329	1334		10.1001/jama.275.17.1329	http://dx.doi.org/10.1001/jama.275.17.1329			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UG612	8614118				2022-12-28	WOS:A1996UG61200029
J	Malonek, D; Grinvald, A				Malonek, D; Grinvald, A			Interactions between electrical activity and cortical microcirculation revealed by imaging spectroscopy: Implications for functional brain mapping	SCIENCE			English	Article							CEREBRAL BLOOD-FLOW; HUMAN VISUAL-CORTEX; ISO-ORIENTATION DOMAINS; SENSORY STIMULATION; HIPPOCAMPAL SLICES; INTRINSIC SIGNALS; NEURAL ACTIVITY; STRIATE CORTEX; ARCHITECTURE; ORGANIZATION	Modern neuroimaging techniques use signals originating from microcirculation to map brain function. In this study, activity-dependent changes in oxyhemoglobin, deoxyhemoglobin, and light scattering were characterized by an imaging spectroscopy approach that offers high spatial, temporal, and spectral resolution. Sensory stimulation of cortical columns initiates tissue hypoxia and vascular responses that occur within the first 3 seconds and are highly localized to individual cortical columns. However, the later phase of the vascular response is less localized, spreading over distances of 3 to 5 millimeters.			Malonek, D (corresponding author), WEIZMANN INST SCI, DEPT NEUROBIOL, IL-76100 REHOVOT, ISRAEL.							BELLIVEAU JW, 1991, SCIENCE, V254, P716, DOI 10.1126/science.1948051; BLASDEL GG, 1992, J NEUROSCI, V12, P3139, DOI 10.1523/JNEUROSCI.12-08-03139.1992; BONHOEFFER T, 1993, J NEUROSCI, V13, P4157; BONHOEFFER T, 1991, NATURE, V353, P429, DOI 10.1038/353429a0; CHANCE B, 1962, SCIENCE, V137, P499, DOI 10.1126/science.137.3529.499; COHEN LB, 1973, PHYSIOL REV, V53, P373; COHEN LB, 1968, NATURE, V218, P438, DOI 10.1038/218438a0; DIRNAGL U, COMMUNICATION; FOX PT, 1986, NATURE, V323, P806, DOI 10.1038/323806a0; FOX PT, 1985, ANN NEUROL, V17, P303, DOI 10.1002/ana.410170315; FOX PT, 1988, SCIENCE, V241, P462, DOI 10.1126/science.3260686; FOX PT, 1986, P NATL ACAD SCI USA, V83, P1140, DOI 10.1073/pnas.83.4.1140; FROSTIG RD, 1990, P NATL ACAD SCI USA, V87, P6082, DOI 10.1073/pnas.87.16.6082; Godecke I, 1996, NATURE, V379, P251, DOI 10.1038/379251a0; GREENBERG J, 1979, Acta Neurologica Scandinavica Supplementum, V60, P12; GRINVALD A, 1982, J PHYSIOL-LONDON, V333, P269, DOI 10.1113/jphysiol.1982.sp014453; GRINVALD A, 1986, NATURE, V324, P361, DOI 10.1038/324361a0; HEINRICH U, 1987, PFLUG ARCH EUR J PHY, V409, P152, DOI 10.1007/BF00584764; HENNIG T, 1994, MAGNET RESON MED, V31, P85, DOI 10.1002/mrm.1910310115; HUBEL DH, 1962, J PHYSIOL-LONDON, V160, P106, DOI 10.1113/jphysiol.1962.sp006837; IADECOLA C, 1993, TRENDS NEUROSCI, V16, P206, DOI 10.1016/0166-2236(93)90156-G; JOBSIS FF, 1977, J APPL PHYSIOL, V43, P858; KATO M, 1974, EXP NEUROL, V42, P65, DOI 10.1016/0014-4886(74)90006-5; KUSCHINSKY W, 1992, CEREBROVAS BRAIN MET, V4, P261; KWONG KK, 1992, P NATL ACAD SCI USA, V89, P5675, DOI 10.1073/pnas.89.12.5675; LASSEN NA, 1961, EXPERIENTIA, V17, P42, DOI 10.1007/BF02157946; MACVICAR BA, 1991, J NEUROSCI, V11, P1458; MENON RS, 1994, P SOC MAGN RES, V1, P68; OGAWA S, 1990, P NATL ACAD SCI USA, V87, P9868, DOI 10.1073/pnas.87.24.9868; OGAWA S, 1992, P NATL ACAD SCI USA, V89, P5951, DOI 10.1073/pnas.89.13.5951; OLESEN J, 1971, BRAIN, V94, P635, DOI 10.1093/brain/94.4.635; RAICHLE ME, 1994, SCI AM, V270, P58, DOI 10.1038/scientificamerican0494-58; RATZLAFF EH, 1991, J NEUROSCI METH, V36, P127, DOI 10.1016/0165-0270(91)90038-2; RISBERG J, 1973, BRAIN, V96, P737, DOI 10.1093/brain/96.4.737; Roy C S, 1890, J Physiol, V11, P85; SALZBERG BM, 1983, NATURE, V306, P36, DOI 10.1038/306036a0; Silver I A, 1978, Ciba Found Symp, P49; SOKOLOFF L, 1977, J NEUROCHEM, V28, P897, DOI 10.1111/j.1471-4159.1977.tb10649.x; TASAKI I, 1968, P NATL ACAD SCI USA, V61, P883, DOI 10.1073/pnas.61.3.883; TSO DY, 1990, SCIENCE, V249, P417, DOI 10.1126/science.2165630; TURNER R, 1993, MAGNET RESON MED, V29, P277, DOI 10.1002/mrm.1910290221; Turner R, 1994, P SOC MAGN RESON, V1, P430; WATANABE M, 1994, J CEREBR BLOOD F MET, V14, P75, DOI 10.1038/jcbfm.1994.12; WELIKY M, 1995, NEURON, V15, P541, DOI 10.1016/0896-6273(95)90143-4	44	850	859	2	47	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 26	1996	272	5261					551	554		10.1126/science.272.5261.551	http://dx.doi.org/10.1126/science.272.5261.551			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UG826	8614805				2022-12-28	WOS:A1996UG82600045
J	Miedema, F; Klein, MR				Miedema, F; Klein, MR			AIDS pathogenesis: A finite immune response to blame?	SCIENCE			English	Editorial Material							HUMAN-IMMUNODEFICIENCY-VIRUS; PROGRESSION; INFECTION; HIV				Miedema, F (corresponding author), NETHERLANDS RED CROSS,BLOOD TRANSFUS SERV,CENT LAB,DEPT CLIN VIROIMMUNOL,PLESMANLAAN 125,1066 CX AMSTERDAM,NETHERLANDS.							ASJO B, 1986, LANCET, V2, P660; CONNOR RI, 1993, J VIROL, V67, P1772, DOI 10.1128/JVI.67.4.1772-1777.1993; DELWART EL, 1994, J VIROL, V68, P6672, DOI 10.1128/JVI.68.10.6672-6683.1994; FERBAS J, 1995, J INFECT DIS, V172, P329, DOI 10.1093/infdis/172.2.329; HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0; KLEIN MR, 1995, J EXP MED, V181, P1365, DOI 10.1084/jem.181.4.1365; KOOT M, 1993, ANN INTERN MED, V118, P681, DOI 10.7326/0003-4819-118-9-199305010-00004; LUKASHOV VV, 1995, J VIROL, V69, P6911, DOI 10.1128/JVI.69.11.6911-6916.1995; MIEDEMA F, 1990, IMMUNOL TODAY, V11, P293, DOI 10.1016/0167-5699(90)90116-Q; NOWAK MA, 1995, NATURE, V375, P606, DOI 10.1038/375606a0; NOWAK MA, 1991, SCIENCE, V254, P963, DOI 10.1126/science.1683006; NOWAK MA, 1995, SCI AM, V273, P58, DOI 10.1038/scientificamerican0895-58; PANTALEO G, 1993, NEW ENGL J MED, V328, P327, DOI 10.1056/NEJM199302043280508; PHILLIPS RE, 1991, NATURE, V354, P453, DOI 10.1038/354453a0; RINALDO C, 1995, J VIROL, V69, P5838, DOI 10.1128/JVI.69.9.5838-5842.1995; ROOS MTL, 1995, J INFECT DIS, V171, P531, DOI 10.1093/infdis/171.3.531; Wolinsky SM, 1996, SCIENCE, V272, P537, DOI 10.1126/science.272.5261.537; ZINKERNAGEL RM, 1995, CURR OPIN IMMUNOL, V7, P462, DOI 10.1016/0952-7915(95)80089-1	18	34	34	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 26	1996	272	5261					505	506		10.1126/science.272.5261.505	http://dx.doi.org/10.1126/science.272.5261.505			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UG826	8614796				2022-12-28	WOS:A1996UG82600029
J	Lazarovits, AI; Poppema, S; Zhang, Z; Khandaker, M; LeFeuvre, CE; Singhal, SK; Garcia, BM; Ogasa, N; Jevnikar, AM; White, MJ; Singh, G; Stiller, CR; Zhong, RZ				Lazarovits, AI; Poppema, S; Zhang, Z; Khandaker, M; LeFeuvre, CE; Singhal, SK; Garcia, BM; Ogasa, N; Jevnikar, AM; White, MJ; Singh, G; Stiller, CR; Zhong, RZ			Prevention and reversal of renal allograft rejection by antibody against CD45RB	NATURE			English	Article								REJECTION continues to be the single largest impediment to successful organ transplantation(1). Antilymphocyte globulin, which contains antibodies that react with the leukocyte common antigen known as CD45 (refs 2-6), has proved to be one of the most effective agents for preventing rejection. We have shown earlier that a monoclonal antibody directed against the RB isoform of CD45 substantially inhibits the alloreactivity of human CD4(+) lymphocytes in vitro(7). Here we investigate whether CD45RB could be an appropriate target for preventing renal allograft rejection in mice. Mice treated with two injections of a monoclonal antibody (MB23G2) (ref. 8) raised against CD45RB protein all survived and had normal renal function. Furthermore, this antibody reversed acute rejection when therapy was delayed until day 4, and the mice survived for their natural lifespan. The immunosuppression achieved may find application in the prevention and treatment of transplant rejection in man.	UNIV WESTERN ONTARIO,FAC MED,DEPT MED,LONDON,ON N6A 5A5,CANADA; UNIV WESTERN ONTARIO,FAC MED,DEPT SURG,LONDON,ON N6A 5A5,CANADA; UNIV WESTERN ONTARIO,FAC MED,DEPT MICROBIOL & IMMUNOL,LONDON,ON N6A 5A5,CANADA; UNIV WESTERN ONTARIO,FAC MED,DEPT PATHOL,LONDON,ON N6A 5A5,CANADA; UNIV GRONINGEN,DEPT PATHOL,9713 EZ GRONINGEN,NETHERLANDS	Western University (University of Western Ontario); Western University (University of Western Ontario); Western University (University of Western Ontario); Western University (University of Western Ontario); University of Groningen	Lazarovits, AI (corresponding author), JOHN P ROBARTS RES INST,LONDON HLTH SCI CTR,MULTIORGAN TRANSPLANT SERV,UNIV CAMPUS,LONDON,ON N6A 5A5,CANADA.		Jevnikar, Anthony M./G-3309-2011; Poppema, Sibrand/D-1204-2012					BIRKELAND ML, 1989, P NATL ACAD SCI USA, V86, P6734, DOI 10.1073/pnas.86.17.6734; BONNEFOYBERARD N, 1991, TRANSPLANTATION, V51, P669, DOI 10.1097/00007890-199103000-00024; FABRE JW, 1977, TRANSPLANTATION, V23, P349, DOI 10.1097/00007890-197704000-00009; FABRE JW, 1980, TRANSPLANTATION, V30, P167, DOI 10.1097/00007890-198009000-00003; GAJEWSKI TF, 1994, P NATL ACAD SCI USA, V91, P38, DOI 10.1073/pnas.91.1.38; IBRAHIM S, 1995, TRANSPLANTATION, V59, P724, DOI 10.1097/00007890-199503150-00015; LAZAROVITS AI, 1992, TRANSPLANTATION, V54, P724, DOI 10.1097/00007890-199210000-00030; LAZAROVITS AI, 1994, J IMMUNOL, V153, P3956; LAZAROVITS AI, 1993, J IMMUNOL, V150, P5163; QUAN D, 1994, TRANSPLANTATION, V58, P808, DOI 10.1097/00007890-199410150-00011; REBELLATO LM, 1994, TRANSPLANTATION, V57, P685, DOI 10.1097/00007890-199403150-00010; SUTHANTHIRAN M, 1994, NEW ENGL J MED, V331, P365, DOI 10.1056/NEJM199408113310606; TROWBRIDGE IS, 1994, ANNU REV IMMUNOL, V12, P85, DOI 10.1146/annurev.iy.12.040194.000505; WARR GW, 1976, IMMUNOCHEMISTRY, V13, P753, DOI 10.1016/0019-2791(76)90196-8; ZHANG Z, 1995, MICROSURG, V16, P103, DOI 10.1002/micr.1920160212	15	135	149	0	7	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	APR 25	1996	380	6576					717	720		10.1038/380717a0	http://dx.doi.org/10.1038/380717a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UG827	8614467				2022-12-28	WOS:A1996UG82700053
J	Majeed, A				Majeed, A			Commentary: The basis of a more rational method of funding primary medical care?	BRITISH MEDICAL JOURNAL			English	Editorial Material											Majeed, A (corresponding author), UNIV LONDON ST GEORGES HOSP,SCH MED,DEPT PUBL HLTH SCI,LONDON SW17 0RE,ENGLAND.			Majeed, Azeem/0000-0002-2357-9858				CHARLTON J, 1995, BRIT J GEN PRACT, V45, P565; DIXON J, 1994, BRIT MED J, V309, P30, DOI 10.1136/bmj.309.6946.30; JUDGE K, 1994, BRIT MED J, V308, P1363, DOI 10.1136/bmj.308.6940.1363; MAJEED FA, 1995, BRIT MED J, V310, P1373, DOI 10.1136/bmj.310.6991.1373; SCRIVENER G, 1995, BRIT MED J, V311, P163, DOI 10.1136/bmj.311.6998.163	5	1	1	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 20	1996	312	7037					1012	1013						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UG610	8616347				2022-12-28	WOS:A1996UG61000025
J	Wang, Y; Reen, DJ; Puri, P				Wang, Y; Reen, DJ; Puri, P			Is a histologically normal appendix following emergency appendicectomy always normal?	LANCET			English	Article								Background Appendixes removed from patients with suspected appendicitis often appear normal on histological examination. We examined appendix specimens for expression of abnormal amounts of cytokines, an indicator of an inflammatory response. Methods Tumour necrosis factor alpha (TNF alpha) and interleukin-2 (IL-2) expression was measured by in-situ hybridisation in ten specimens from patients with acute appendicitis, 12 normal appendix specimens removed from patients undergoing elective abdominal surgery, and 31 appendix specimens from patients with a clinical diagnosis of appendicitis but an appendix histologically classified as normal. Cytokine-specific RNA antisense probes were prepared by in-vitro transcription and digoxigenin (DIG) labelled. In-situ hybridisation was done on 5 mu m paraffin sections. Tissue sections hybridised by sense probes acted as negative control for each cytokine. Following hybridisation, the probes were detected by alkaline phosphatase labelled anti-DIG monoclonal antibody and visualised by nitroblue tetrazolium staining. Findings All histologically proven acute appendicitis specimens demonstrated intense cellular TNF alpha mRNA expression in germinal centres and moderate levels of expression throughout the mucosa. IL-2 mRNA was strongly expressed in the lamina propria and only moderately expressed in germinal centres. Normal appendixes all showed almost complete absence of TNF alpha and IL-2 mRNA expression. Seven of the 31 histologically classified normal appendix specimens from patients with a clinical diagnosis of appendicitis demonstrated TNF alpha and IL-2 mRNA expression similar to acute appendicitis specimens in germinal centres, submucosa, and lamina propria layers. Interpretation TNF alpha and IL-2 mRNA expression is sensitive marker of inflammation in appendicitis. A substantial proportion of histologically normal appendixes showed clear evidence of an inflammatory response in the form of increased cytokine expression.	OUR LADYS HOSP SICK CHILDREN,CHILDRENS RES CTR,CRUMLIN 12,DUBLIN,IRELAND	Our Ladys Children Hospital Crumlin								BRAEGGER CP, 1994, ANN ALLERGY, V72, P135; COMMINIELLO C, 1994, ANGIOLOGY, V45, P1015; DAHLSTROM JE, 1994, AUST NZ J SURG, V64, P692, DOI 10.1111/j.1445-2197.1994.tb02059.x; DISEBASTIANO P, 1995, DIGEST DIS SCI, V40, P366, DOI 10.1007/BF02065423; Ferreira S H, 1993, Drugs, V46 Suppl 1, P1; FINE G, 1995, ANDERSONS PATHOLOGY, P1055; GURBINDO C, 1993, J PEDIATR GASTR NUTR, V17, P247, DOI 10.1097/00005176-199310000-00003; KARTTUNEN R, 1995, GUT, V36, P341, DOI 10.1136/gut.36.3.341; KONTAKOU M, 1994, GUT, V35, P1037, DOI 10.1136/gut.35.8.1037; Levine J.D., 1994, TXB PAIN, P45; MACDONALD TT, 1990, CLIN EXP IMMUNOL, V81, P301; MAHUMMUD N, 1995, EUR J GASTROEN HEPAT, V7, P215; PARDUE ML, 1983, NUCLEIC ACID HYBRIDI, P179; PURI P, 1995, PEDIATR SURG INT, V10, P61; SHER ME, 1995, AM J SURG, V169, P133, DOI 10.1016/S0002-9610(99)80121-4; SIEGEL MJ, 1995, PEDIATR SURG INT, V10, P62; TSUJI M, 1993, J PEDIATR GASTR NUTR, V16, P43, DOI 10.1097/00005176-199301000-00008; WATKINS LR, 1994, BRAIN RES, V654, P15, DOI 10.1016/0006-8993(94)91566-0	18	64	65	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 20	1996	347	9008					1076	1079		10.1016/S0140-6736(96)90279-2	http://dx.doi.org/10.1016/S0140-6736(96)90279-2			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UG042	8602058				2022-12-28	WOS:A1996UG04200012
J	Russell, DW				Russell, DW			Green light for steroid hormones	SCIENCE			English	Editorial Material											Russell, DW (corresponding author), UNIV TEXAS,SW MED CTR,DEPT MOLEC GENET,DALLAS,TX 75235, USA.			Russell, David/0000-0002-0277-403X				CHORY J, 1993, TRENDS GENET, V9, P167, DOI 10.1016/0168-9525(93)90163-C; CHORY J, 1991, PLANT CELL, V3, P445, DOI 10.1105/tpc.3.5.445; Li JM, 1996, SCIENCE, V272, P398, DOI 10.1126/science.272.5260.398; LIAO SS, 1995, BIOCHEM BIOPH RES CO, V214, P833, DOI 10.1006/bbrc.1995.2362; MANGELSDORF DJ, COMMUNICATION; RUSSELL DW, 1994, ANNU REV BIOCHEM, V63, P25, DOI 10.1146/annurev.bi.63.070194.000325; SZEKERES M, 1996, CELL            0419	7	10	11	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 19	1996	272	5260					370	371		10.1126/science.272.5260.370	http://dx.doi.org/10.1126/science.272.5260.370			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UG252	8602524				2022-12-28	WOS:A1996UG25200035
J	Kizer, KW				Kizer, KW			Progress on posttraumatic stress disorder	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											Kizer, KW (corresponding author), VET HLTH ADM,WASHINGTON,DC 20422, USA.							American Psychiatric Association, 2000, DSM 4 DIAGN STAT MAN, V4th ed., DOI DOI 10.1001/JAMA.1994.03520100096	1	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 17	1996	275	15					1149	1149						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UE625	8609668				2022-12-28	WOS:A1996UE62500004
J	Mulholland, K; Suara, RO; Siber, G; Roberton, D; Jaffar, S; NJie, J; Baden, L; Thompson, C; Anwaruddin, R; Dinan, L; Glezen, WP; Francis, N; Fritzell, B; Greenwood, BM				Mulholland, K; Suara, RO; Siber, G; Roberton, D; Jaffar, S; NJie, J; Baden, L; Thompson, C; Anwaruddin, R; Dinan, L; Glezen, WP; Francis, N; Fritzell, B; Greenwood, BM			Maternal immunization with Haemophilus influenzae type b polysaccharide-tetanus protein conjugate vaccine in the Gambia	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HEMOPHILUS-INFLUENZAE; PREGNANT-WOMEN; CAPSULAR POLYSACCHARIDE; SERUM ANTIBODIES; CHILDREN; INFANTS; MENINGITIS; PROTECTION	Objective.-To evaluate maternal responses to Haemophilus influenzae type b (Hib) polysaccharide-tetanus protein conjugate vaccine (polyribosylribitol phosphate-tetanus or PRP-T) given to pregnant Gambian women, the transplacental transfer of antibody, and the effect of maternal immunization on infant responses to the vaccine. Design.-An open, randomized immunogenicity study. Setting.-A busy urban health center in The Gambia. Study participants.-A total of 451 pregnant women enrolled during the third trimester of pregnancy. Intervention.-Study participants were randomized to three groups. In one group, mothers were given PRP-T during the third trimester and their infants were given PRP-T at 2, 3, and 4 months of age, In the second group, mothers received PRP-T and infants were given inactivated poliovirus vaccine. In the third group, mothers received meningococcal A and C vaccine, and their infants received PRP-T. Main Outcome Measures.-Anti-PRP antibody measurements of maternal, cord, and infant blood. Results.-Vaccinated women had a marked increase in total anti-PRP antibody (geometric mean titer, 9.0 mu g/mL), which was greatest in women in their first or second pregnancy, Previous tetanus vaccination during the same pregnancy and high concentrations of antitetanus antibody were associated with lower anti-PRP responses. In infants of PRP-T recipients, cord blood anti-PRP IgG concentrations were 61% of simultaneous maternal concentrations, In vaccinated infants of vaccinated mothers, geometric mean anti-PRP antibody concentrations at birth, 2 months of age, and 5 months of age were 1.92, 0.35, and 2.84 mu g/mL, respectively, while in vaccinated infants of unvaccinated mothers, the corresponding concentrations were 0.29, 0.12, and 3.91 mu g/mL. At 2 months of age, 60% of infants of vaccinated mothers and 26% of infants of unvaccinated mothers had anti-PRP antibody concentrations considered to be protective (>0.15 mu g/mL). Conclusions.-In areas where much invasive Hib disease occurs in infants younger than 6 months, maternal immunization may help to reduce the risk of Hib disease in infants too young for immunization.	MRC LABS,FAJARA,GAMBIA; DANA FARBER CANC INST,BOSTON,MA 02115; UNIV ADELAIDE,DEPT PAEDIAT,ADELAIDE,SA 5001,AUSTRALIA; BAYLOR COLL MED,DEPT MICROBIOL & IMMUNOL,HOUSTON,TX 77030; CHARING CROSS & WESTMINSTER MED SCH,DEPT HISTOPATHOL,LONDON W6 8RF,ENGLAND; PASTEUR MERIEUX SERUMS & VACCINS,MARNES COQUETTE,FRANCE	MRC Laboratory Molecular Biology; Harvard University; Dana-Farber Cancer Institute; University of Adelaide; Baylor College of Medicine; Imperial College London				Jaffar, Shabbar/0000-0002-9615-1588	NIAID NIH HHS [AI 15126] Funding Source: Medline	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABDULRAUF A, 1990, PEDIATR INFECT DIS J, V9, P918, DOI 10.1097/00006454-199012000-00012; ADAMS WG, 1993, JAMA-J AM MED ASSOC, V269, P221, DOI 10.1001/jama.269.2.221; AMSTEY MS, 1985, AM J OBSTET GYNECOL, V153, P607, DOI 10.1016/S0002-9378(85)80243-X; BAKER CJ, 1988, NEW ENGL J MED, V319, P1180, DOI 10.1056/NEJM198811033191802; BIJLMER HA, 1990, J INFECT DIS, V161, P1210, DOI 10.1093/infdis/161.6.1210; BIJLMER HA, 1994, DEV USES HAEMOPHILUS, P247; BLACK RE, 1980, B WORLD HEALTH ORGAN, V58, P927; BULMER JN, 1993, HISTOPATHOLOGY, V22, P211, DOI 10.1111/j.1365-2559.1993.tb00110.x; Burkhardt AE., 1879, DTSCH ARCH KLIN MED, V24, P506; CLAESSON BA, 1989, J PEDIATR-US, V114, P97, DOI 10.1016/S0022-3476(89)80611-0; Cohen P, 1943, J AMER MED ASSOC, V121, P656, DOI 10.1001/jama.1943.02840090026008; DEJOHN D, 1989, LANCET, V2, P1415; DRAPER NR, 1981, APPLIED REGRESSION A; ENGLUND JA, 1995, J INFECT DIS, V171, P99, DOI 10.1093/infdis/171.1.99; ENGLUND JA, 1993, J INFECT DIS, V168, P647, DOI 10.1093/infdis/168.3.647; FUNKHOUSER A, 1991, REV INFECT DIS, V13, pS542; GILL TJ, 1983, J CLIN INVEST, V72, P987, DOI 10.1172/JCI111071; GLEZEN WP, 1992, J INFECT DIS, V165, pS134, DOI 10.1093/infdis/165-Supplement_1-S134; HERZENBERG LA, 1980, NATURE, V285, P664, DOI 10.1038/285664a0; INSEL RA, 1986, MANUAL CLIN LABORATO, P379; KAYHTY H, 1983, J INFECT DIS, V147, P1100; KURIKKA S, 1995, PEDIATRICS, V95, P815; MAKELA PH, 1992, J INFECT DIS, V165, pS2, DOI 10.1093/infdis/165.Supplement_1-S2; Montgomery D. C., 2021, INTRO LINEAR REGRESS; MULHOLLAND EK, 1994, LANCET, V343, P794, DOI 10.1016/S0140-6736(94)91870-8; MULHOLLAND EK, 1994, ANN TROP PAEDIATR, V14, P83; MURPHY TV, 1993, J PEDIATR-US, V122, P517, DOI 10.1016/S0022-3476(05)83529-2; SANTOSHAM M, 1991, NEW ENGL J MED, V324, P1767, DOI 10.1056/NEJM199106203242503; SHAPIRO ED, 1993, JAMA-J AM MED ASSOC, V269, P264, DOI 10.1001/jama.269.2.264; SIBER GR, 1990, NEW ENGL J MED, V323, P1387, DOI 10.1056/NEJM199011153232005; TAKALA AK, 1993, PEDIATR INFECT DIS J, V12, P593, DOI 10.1097/00006454-199307000-00010; TAKALA AK, 1991, J INFECT DIS, V164, P982, DOI 10.1093/infdis/164.5.982; TALL FR, 1992, MED MALADIES INFECT, V22, P1173, DOI 10.1016/S0399-077X(05)81433-7; VINCENTBALLEREAU F, 1985, PATHOL BIOL, V33, P764; ZAJAC BA, 1986, J INFECTION, V13, P39, DOI 10.1016/S0163-4453(86)92668-X; ZOLLINGER WD, 1981, J IMMUNOL METHODS, V46, P129, DOI 10.1016/0022-1759(81)90130-7	36	68	70	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 17	1996	275	15					1182	1188						7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UE625	8609686				2022-12-28	WOS:A1996UE62500030
J	Verrilli, D; Welch, HG				Verrilli, D; Welch, HG			The impact of diagnostic testing on therapeutic interventions	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HEALTH; CARE	Objective.-To gain insight into the usefulness of managing the earlier phase of decision making, we examined the relationship between selected diagnostic tests and the therapeutic interventions they might trigger. Design.-Medicare's National Claims History and Part B files were used to obtain summary information on 100% of all physician claims submitted from 1987 through 1993. We regressed the annual rates of selected therapeutic interventions on selected diagnostic tests, which had been previously paired based on the clinical expectation that the test might drive subsequent intervention. Population and Setting.-These data represent the physician services received by approximately 30 million elderly Americans in each of 7 years. Main Outcome Measure.-Coefficient of determination (R(2)). Results.-The annual rate for the diagnostic tests increased rapidly during the period (range, 1.4- to 3.0-fold increase) and accounted for the bulk of the variance in therapeutic intervention rates (R(2)>0.80, P<.01) for five diagnostic-therapeutic pairs: cardiac catheterization with cardiac revascularization procedures, imaging of the spine with back surgery, swallowing studies with percutaneous gastrostomy, mammography with breast biopsy and excision, and prostate biopsy with prostatectomy. Although the rate of abdominal ultrasound increased during the period, it was not related with either cholecystectomy or abdominal aortic aneurysm repair. Conclusion.-There has been a substantial increase in diagnostic testing in the United States that closely tracked the increase of clinically relevant downstream procedures. Managing diagnostic testing could be an important strategy for controlling the increase of therapeutic interventions.	DEPT VET AFFAIRS MED CTR,WHITE RIVER JCT,VT; DARTMOUTH COLL,DARTMOUTH MED SCH,CTR EVALUAT CLIN SCI,HANOVER,NH 03756	Dartmouth College					NHLBI NIH HHS [HCFA-17-C-90044/3-01] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BARSKY AJ, 1988, NEW ENGL J MED, V318, P414, DOI 10.1056/NEJM198802183180705; BLACK WC, 1993, NEW ENGL J MED, V328, P1237, DOI 10.1056/NEJM199304293281706; Bouhaddou O, 1993, Proc Annu Symp Comput Appl Med Care, P258; DEVESA SS, 1995, JNCI-J NATL CANCER I, V87, P175, DOI 10.1093/jnci/87.3.175; GWALTNEY JM, 1994, NEW ENGL J MED, V330, P25, DOI 10.1056/NEJM199401063300105; JENSEN MC, 1994, NEW ENGL J MED, V331, P69, DOI 10.1056/NEJM199407143310201; JOHNSON J, 1992, HOSPITALS, V66, P26; MOLD JW, 1986, NEW ENGL J MED, V314, P512, DOI 10.1056/NEJM198602203140809; PARK RE, 1986, AM J PUBLIC HEALTH, V76, P766, DOI 10.2105/AJPH.76.7.766; Schieber G J, 1991, Health Aff (Millwood), V10, P106, DOI 10.1377/hlthaff.10.1.106; *US DEP HHS, 1992, HLTH US 1991; VERRILLI D, 1995, TRENDS VOLUME INTENS; WELCH HG, 1989, NEW ENGL J MED, V321, P1261, DOI 10.1056/NEJM198911023211809; WENNBERG J, 1973, SCIENCE, V182, P1102, DOI 10.1126/science.182.4117.1102	14	68	71	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 17	1996	275	15					1189	1191		10.1001/jama.275.15.1189	http://dx.doi.org/10.1001/jama.275.15.1189			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UE625	8609687				2022-12-28	WOS:A1996UE62500031
J	Alvarez, FJ; DelRio, MC				Alvarez, FJ; DelRio, MC			Alcohol and driving	LANCET			English	Editorial Material											Alvarez, FJ (corresponding author), UNIV VALLADOLID,FAC MED,DEPT PHARMACOL & THERAPEUT,DRUGS & ALCOHOL RES GRP,VALLADOLID,SPAIN.		Alvarez, Francisco/GZL-1953-2022; Alvarez, F. Javier/X-2294-2019; Alvarez, F. Javier/E-7204-2016	Alvarez, F. Javier/0000-0002-7566-5678; Alvarez, F. Javier/0000-0002-7566-5678				BIECHELER MB, 1995, 9403CN0130 EURICPALD; *DIR GEN TRANSP CO, 1995, VII3921995 DIR GEN T; DUNBAR JA, 1987, BRIT MED J, V295, P1458, DOI 10.1136/bmj.295.6611.1458; *EUR TRANSP SAF CO, 1995, RED TRAFF INJ RES AL; GUPPY A, 1994, BRIT MED J, V308, P1056; POLEN M R, 1988, Journal of the American Medical Association, V259, P77; WELLSPARKER E, 1995, ADDICTION, V90, P907, DOI 10.1046/j.1360-0443.1995.9079074.x; 1995, 9403CN01 EURICPALDT	8	12	12	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 13	1996	347	9007					985	986						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UF380	8606608				2022-12-28	WOS:A1996UF38000004
J	Munroe, PB; Rapola, J; Mitchison, HM; Mustonen, A; Mole, SE; Gardiner, RM; Jarvela, I				Munroe, PB; Rapola, J; Mitchison, HM; Mustonen, A; Mole, SE; Gardiner, RM; Jarvela, I			Prenatal diagnosis of Batten's disease	LANCET			English	Article							NEURONAL CEROID-LIPOFUSCINOSIS	Background Batten's disease is the most common progressive encephalopathy of childhood in Western countries. The major mutation is a 1 kb deletion, which is carried by 81% of Batten's disease patients. We report on the use of direct gene analysis in the prenatal diagnosis of this disease. Methods and findings A Finnish woman with a son with Batten's disease came for genetic counselling for her current pregnancy. Electron microscopy of a chorionic villus sample gave suggestive findings. We used PCR to look for the intragenic microsatellite marker D16S298; 96% of Finnish Batten's disease patients carry allele 6 at this marker. The fetus and the affected son both carried the same high-risk genotype, 6/6. Both were homozygous for the 1 kb deletion. The pregnancy was terminated. Electron microscopy of the fetus showed typical Batten's disease changes. Interpretation We have successfully used direct gene analysis in the prenatal diagnosis of Batten's disease.	NATL PUBL HLTH INST, LAB HUMAN MOLEC GENET, SF-00300 HELSINKI, FINLAND; UCL, SCH MED, RAYNE INST, DEPT PAEDIAT, LONDON, ENGLAND; UNIV HELSINKI, CHILDRENS HOSP, HELSINKI, FINLAND; TAMPERE UNIV HOSP, DEPT CLIN GENET, TAMPERE, FINLAND	Finland National Institute for Health & Welfare; University of London; King's College London; University College London; UCL Medical School; University of Helsinki; Tampere University; Tampere University Hospital			Jarvela, Irma E/L-5836-2013; Mitchison, Hannah M./C-1891-2008; Mole, Sara/C-2024-2008	Jarvela, Irma E/0000-0002-1770-6187; Mole, Sara/0000-0003-4385-4957; Munroe, Patricia/0000-0002-4176-2947; Mitchison, Hannah/0000-0002-3163-6293	NINDS NIH HHS [NS28722] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS028722] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		CARPENTER S, 1977, BRAIN, V100, P137, DOI 10.1093/brain/100.1.137; GARDINER M, 1990, GENOMICS, V8, P387, DOI 10.1016/0888-7543(90)90297-8; LAKE BD, 1995, 41 ANN M PAED PATH S; LERNER TJ, 1995, CELL, V82, P949, DOI 10.1016/0092-8674(95)90274-0; MITCHISON HM, 1994, GENOMICS, V22, P465, DOI 10.1006/geno.1994.1412; MITCHISON HM, 1995, AM J HUM GENET, V56, P654; RAPOLA J, 1990, PRENATAL DIAG, V10, P553, DOI 10.1002/pd.1970100902; SANTAVUORI P, 1988, BRAIN DEV-JPN, V10, P80, DOI 10.1016/S0387-7604(88)80075-5; SYVANEN AC, 1992, GENOMICS, V12, P590, DOI 10.1016/0888-7543(92)90452-X	9	35	35	0	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	APR 13	1996	347	9007					1014	1015		10.1016/S0140-6736(96)90148-8	http://dx.doi.org/10.1016/S0140-6736(96)90148-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UF380	8606564				2022-12-28	WOS:A1996UF38000013
J	Metherall, P; Barber, DC; Smallwood, RH; Brown, BH				Metherall, P; Barber, DC; Smallwood, RH; Brown, BH			Three-dimensional electrical impedance tomography	NATURE			English	Article							APPLIED POTENTIAL TOMOGRAPHY	THE electrical resistivity of mammalian tissues varies widely(1-5) and is correlated with physiological function(6-8). Electrical impedance tomography (EIT) can be used to probe such variations in vivo, and offers a non-invasive means of imaging the internal conductivity distribution of the human body(9-11). But the computational complexity of EIT has severe practical limitations, and previous work has been restricted to considering image reconstruction as an essentially two-dimensional problem(10,12). This simplification can limit significantly the imaging capabilities of EIT, as the electric currents used to determine the conductivity variations will not in general be confined to a two-dimensional plane(13), A few studies have attempted three-dimensional EIT image reconstruction(14,15), but have not yet succeeded in generating images of a quality suitable for clinical applications. Here we report the development of a three-dimensional EIT system with greatly improved imaging capabilities, which combines our 64-electrode data-collection apparatus(16) with customized matrix inversion techniques. Our results demonstrate the practical potential of EIT for clinical applications, such as lung or brain imaging and diagnostic screenings.			Metherall, P (corresponding author), UNIV SHEFFIELD, ROYAL HALLAMSHIRE HOSP, DEPT MED PHYS & CLIN ENGN, GLOSSUP RD, SHEFFIELD S10 2JF, S YORKSHIRE, ENGLAND.		Smallwood, Rod/C-5583-2011	Smallwood, Rod/0000-0003-0134-0632				ALBERT A, 1972, REGRESSION MOOREPENR; BARBER CC, 1983, ELECTRON LETT, V19, P933, DOI 10.1049/el:19830637; BARBER DC, 1989, CLIN PHYS PHYSIOL M, V10, P368, DOI 10.1088/0143-0815/10/4/011; BARBER DC, 1990, SIAM PROC S, P151; BARBER DC, 1984, J PHYS E SCI INSTRUM, V17, P723, DOI 10.1088/0022-3735/17/9/002; BARBER DC, 1993, CLINICAL AND PHYSIOLOGICAL APPLICATIONS OF ELECTRICAL IMPEDANCE TOMOGRAPHY, P47; Brown B H, 1987, Clin Phys Physiol Meas, V8 Suppl A, P91, DOI 10.1088/0143-0815/8/4A/012; BROWN BH, 1994, INNOV TECH BIOL MED, V15, P1; Dawids S G, 1987, Clin Phys Physiol Meas, V8 Suppl A, P175, DOI 10.1088/0143-0815/8/4A/022; DIJKSTRA AM, 1993, J MED ENG TECHNOL, V17, P89, DOI 10.3109/03091909309016213; Duck FA., 1990, PHYS PROPERTIES TISS, P167; GEDDES LA, 1967, MED BIOL ENG, V5, P271, DOI 10.1007/BF02474537; GESELOWITZ DB, 1971, IEEE T BIO-MED ENG, VBM18, P38, DOI 10.1109/TBME.1971.4502787; Goble J., 1992, Applied Computational Electromagnetics Society Journal, V7, P128; GOLUB GH, 1970, NUMER MATH, V14, P403, DOI 10.1007/BF02163027; Hansen P. C., 1994, Numerical Algorithms, V6, P1, DOI 10.1007/BF02149761; HOLDER DS, 1993, CLIN PHYSL APPL ELEC, P47; KOTRE CJ, 1989, CLIN PHYS PHYSIOL M, V10, P275, DOI 10.1088/0143-0815/10/3/008; MCADAMS ET, 1995, PHYSIOL MEAS, V16, pA1, DOI 10.1088/0967-3334/16/3A/001; MORUCCI JP, 1995, PHYSIOL MEAS, V16, pA123, DOI 10.1088/0967-3334/16/3A/012; Pethig R, 1987, Clin Phys Physiol Meas, V8 Suppl A, P5, DOI 10.1088/0143-0815/8/4A/002; RABBANI KS, 1991, CLIN PHYS PHYSIOL M, V12, P393, DOI 10.1088/0143-0815/12/4/009; STOY RD, 1982, PHYS MED BIOL, V27, P501, DOI 10.1088/0031-9155/27/4/002; WITSOE DA, 1967, MED BIOL ENG, V5, P239, DOI 10.1007/BF02474533	24	320	332	2	62	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 11	1996	380	6574					509	512		10.1038/380509a0	http://dx.doi.org/10.1038/380509a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UE663	8606768	Green Accepted			2022-12-28	WOS:A1996UE66300043
J	Durand, JM; Suchet, L				Durand, JM; Suchet, L			Ranitidine and aseptic meningitis	BRITISH MEDICAL JOURNAL			English	Letter									HOP ST MARGUERITE,DEPT NEUROL,MARSEILLE 9,FRANCE	UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille	Durand, JM (corresponding author), HOP ST MARGUERITE,DEPT INTERNAL MED,BP 29,MARSEILLE 9,FRANCE.		Suchet, Laurent/AAK-1698-2020					JOFFE AM, 1989, AM J MED, V87, P332, DOI 10.1016/S0002-9343(89)80160-3; RIVER Y, 1994, J NEUROL NEUROSUR PS, V57, P705, DOI 10.1136/jnnp.57.6.705	2	8	8	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 6	1996	312	7035					886	886						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UE371	8611881				2022-12-28	WOS:A1996UE37100025
J	Mira, M; Alperstein, G; Karr, M; Ranmuthugala, G; Causer, J; Niec, A; Lilburne, AM				Mira, M; Alperstein, G; Karr, M; Ranmuthugala, G; Causer, J; Niec, A; Lilburne, AM			Haem iron intake in 12-36 month old children depleted in iron: Case-control study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							DEFICIENCY ANEMIA; INFANTS; RISK; MILK	Objective-To compare the intakes of haem and non-haem iron in iron depleted and iron replete children. Design-Case-control study. Setting-Early Childhood Centres and a long day care centre in Sydney, Australia. Subjects-Children aged 12-36 months depleted in iron and controls matched for age and sex. Mean outcome measures-Iron status by using plasma ferritin concentration. A three day weighed dietary intake record completed by the parents. Risk factors for iron deficiency assessed by questionnaire. Results-Fifty six iron depleted and 68 iron replete children participated. The average daily intake of haem iron was significantly lower in the iron depleted group (t=2.392, P=0.018); there was a tendency towards a lower average daily intake of non-haem iron (t=1 724, P=0.086) and vitamin C (t=1.921, P=0.057) for iron depleted children. Low intake of haem iron (<0 71 mg/day) was significantly associated with iron depletion with an odds ratio of 3.0 (P=0.005). The proportion of iron depleted children who were given whole cows' milk before 12 months of age was almost double that of iron replete children; multivariate analysis showed that both haem iron intake and age of introduction of cows' milk were independently associated with iron depletion. Conclusions-The results of this study show that, in young children in developed countries, a lower haem iron intake is a major risk factor for iron depletion; the introduction of whole cows' milk before 12 months is further confirmed as a risk factor. Parental education on nutrition should now focus on these two aspects of nutrition for infants and young children.	ROYAL PRINCE ALFRED HOSP, CENT SYDNEY AREA HLTH SERV, COMMUNITY HLTH SERV, CAMPERDOWN, NSW 2050, AUSTRALIA; AUSTRALIAN NATL UNIV, NATL CTR EPIDEMIOL & POPULAT HLTH, CANBERRA, ACT, AUSTRALIA	University of Sydney; Australian National University	Mira, M (corresponding author), CENT SYDNEY AREA HLTH SERV, DIV GEN PRACTICE, BALMAIN, NSW 2041, AUSTRALIA.		Ranmuthugala, Geetha/P-5041-2019; Ranmuthugala, Geetha/F-5938-2012	Ranmuthugala, Geetha/0000-0002-4893-5775; Ranmuthugala, Geetha/0000-0002-4893-5775				BJORNRASMUSSEN E, 1974, J CLIN INVEST, V53, P237; CALVO EB, 1992, PEDIATRICS, V90, P375; DALLMAN P, 1989, AM J CLIN NUTR, V50, P575; DALLMAN PR, 1980, AM J CLIN NUTR, V33, P86, DOI 10.1093/ajcn/33.1.86; Dean A. G., 1990, EPI INFO VERSION 5 W; FRIEL JK, 1990, CAN MED ASSOC J, V143, P733; GEBSKI V, 1992, STAT PACKAGE INTERAC; HALLBERG L, 1984, AM J CLIN NUTR, V39, P577, DOI 10.1093/ajcn/39.4.577; HERCBERG S, 1987, NUTR REP INT, V35, P307; LOZOFF B, 1991, NEW ENGL J MED, V325, P687, DOI 10.1056/NEJM199109053251004; MACPHAIL AP, 1989, ACTA PAEDIATR SCAND, P114; MILLS AF, 1990, ARCH DIS CHILD, V65, P428, DOI 10.1136/adc.65.4.428; MONSEN ER, 1978, AM J CLIN NUTR, V31, P134, DOI 10.1093/ajcn/31.1.134; *NAT HLTH MED RES, 1991, NH MRC REC DIET INT; OSKI FA, 1983, PEDIATRICS, V71, P877; SIIMES MA, 1984, J PEDIATR-US, V104, P196, DOI 10.1016/S0022-3476(84)80991-9; TUNNESSEN WW, 1987, J PEDIATR-US, V111, P813, DOI 10.1016/S0022-3476(87)80193-2; VAZQUEZSEOANE P, 1985, NEW ENGL J MED, V313, P1239, DOI 10.1056/NEJM198511073131936; WALTER T, 1989, PEDIATRICS, V84, P7; *XYR, 1989, DIET 1 VERS 3 00; [No title captured]	21	33	33	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	APR 6	1996	312	7035					881	883						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UE371	8611876	Green Published			2022-12-28	WOS:A1996UE37100021
J	Sabroe, RA; Staughton, RCD; Bunker, CB				Sabroe, RA; Staughton, RCD; Bunker, CB			Bronchospasm induced by isotretinoin	BRITISH MEDICAL JOURNAL			English	Letter											Sabroe, RA (corresponding author), CHELSEA & WESTMINSTER HOSP,DEPT DERMATOL,LONDON SW10 9NH,ENGLAND.			Bunker, Christopher/0000-0002-6693-7483				BUNKER CB, 1989, LANCET, V1, P435; BUNKER CB, 1991, CLIN EXP DERMATOL, V16, P11, DOI 10.1111/j.1365-2230.1991.tb00284.x; BUNKER CB, 1991, BR J DERMATOL S38, V125, P29; FISHER DA, 1985, J AM ACAD DERMATOL, V13, P524, DOI 10.1016/S0190-9622(85)80374-1	4	10	10	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 6	1996	312	7035					886	886						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UE371	8611879				2022-12-28	WOS:A1996UE37100024
J	Lerner, BH				Lerner, BH			Can stress cause disease? Revisiting the tuberculosis research of Thomas Holmes, 1949-1961	ANNALS OF INTERNAL MEDICINE			English	Article							LIFE EVENTS; MEDICINE; SURVIVAL; SUPPORT; CANCER; MODEL	The increasing emphasis in medicine on treating the whole patient has focused attention on the association between emotions and disease. However, physicians have long studied the connection between mind and body. One particularly interesting researcher in this area was Thomas Holmes, a charismatic and iconoclastic Seattle physician who studied the association between stress and tuberculosis in the 1950s. Although lacking the sophistication of modern biostatistics, several of Holmes' studies suggested that persons who had experienced stressful situations, such as divorce, death of a spouse, or loss of a job, were more likely to develop tuberculosis and less likely to recover from it. Holmes consciously used the same scientific methods as his peers, devising a numeric scale that quantified stressful events and doing prospective studies with control groups. Yet, he also emphasized the need to understand each patient's story and to view his or her tuber culosis as the culmination of a life of emotional hardship. Although Holmes' work was rudimentary, his basic supposition may have been correct. Recent research, benefiting from advances in both immunology and biostatistics. suggests that stress may lead to decreased immune function and thus to clinical disease. As studies of stress and disease become more statistically sophisticated, it will be important to retain Holmes' emphasis on understanding the lives of individual patients.			Lerner, BH (corresponding author), COLUMBIA UNIV COLL PHYS & SURG, DEPT MED, BLACK BLDG 101, 630 W 168TH ST, NEW YORK, NY 10032 USA.							ACKERKNECHT EH, 1982, PSYCHOL MED, V12, P17, DOI 10.1017/S0033291700043245; Alexander F, 1950, PSYCHOSOMATIC MED IT; AMUNDSON M, 1960, COMMUNICATION   0316; ANGELL M, 1985, NEW ENGL J MED, V312, P1570, DOI 10.1056/NEJM198506133122411; [Anonymous], 1994, HDB HUMAN STRESS IMM; [Anonymous], 1915, BODILY CHANGES PAIN; ARONOWITZ R, 1988, J CLIN GASTROENTEROL, V10, P298, DOI 10.1097/00004836-198806000-00013; ARTHUR RJ, 1979, LIFE STRESS ILLNESS, P195; BARLEY BG, 1987, LADIES HOME J    MAY, V104, P38; BAUER SM, 1994, J ADV NURS, V19, P1114, DOI 10.1111/j.1365-2648.1994.tb01195.x; BERKMAN LF, 1992, ANN INTERN MED, V117, P1003, DOI 10.7326/0003-4819-117-12-1003; BOVBJERG DH, 1991, CANCER-AM CANCER SOC, V67, P828, DOI 10.1002/1097-0142(19910201)67:3+<828::AID-CNCR2820671413>3.0.CO;2-A; BREWER LA, 1954, AM REV TUBERC PULM, V69, P554; CHARON R, 1995, ANN INTERN MED, V122, P599, DOI 10.7326/0003-4819-122-8-199504150-00008; CLARKE ER, 1954, AM REV TUBERC PULM, V69, P351; COHEN S, 1991, NEW ENGL J MED, V325, P606, DOI 10.1056/NEJM199108293250903; DEVITO PL, 1994, USA TODAY        JUL, V123, P27; Dohrenwend BS, 1981, STRESSFUL LIFE EVENT, P1; DUBOS R, 1987, WHITE PLAGUE TUBERCU, P128; Dunbar H. F., 1947, MIND BODY PSYCHOSOMA; ENGEL GL, 1980, AM J PSYCHIAT, V137, P535; ENGEL GL, 1977, SCIENCE, V196, P129, DOI 10.1126/science.847460; FELDBERG GD, 1955, DIS CLASS TUBERCULOS, P51; FLACH J, 1994, J NATL CANCER I, V86, P256, DOI 10.1093/jnci/86.4.256; GRANT I, 1987, J BEHAV MED, V10, P231, DOI 10.1007/BF00846537; GROB GN, 1991, ASYLUM COMMUNITY MEN, P134; HART JE, 1959, THESIS U WASHINGTON; HAWKINS NG, 1957, AM REV TUBERC PULM, V75, P768; HAWKINS NG, 1956, THESIS U WASHINGTON, P48; HAWKINS NG, 1953, THESIS U WASHINGTON, P41; HAWKINS NG, 1954, T NATL TUBERCULOSIS, V50, P233; HAWKINS NG, 1956, THESIS U WASHINGTON, pR1; HOLMES TH, 1978, PSYCHOSOMATICS, V19, P747; HOLMES TH, 1961, J PSYCHOSOM RES, V5, P235, DOI 10.1016/0022-3999(61)90001-0; HOLMES TH, 1950, NOSE EXPT STUDY REAC, P62; HOLMES TH, 1956, PERSONALITY STRESS T, P145; HOLMES TH, 1956, PERSONALITY STRESS T, P92; HOLMES TH, 1960, COMMUNICATION   1228; KAPLAN HB, 1991, SOC SCI MED, V33, P909, DOI 10.1016/0277-9536(91)90262-B; Keller S. E., 1994, HDB HUMAN STRESS IMM, P217, DOI [DOI 10.1016/B978-0-12-285960-1.50013-7, 10.1016/B978-0-12-285960-1, DOI 10.1016/B978-0-12-285960-1]; KERR L, 1955, COMMUNICATION   0519; KOOME AF, 1965, COMMUNICATION   0927; LERNER BH, 1993, AM J PUBLIC HEALTH, V83, P758, DOI 10.2105/AJPH.83.5.758; Levenson Dorothy., 1994, MIND BODY MED HIST A; LIPOWSKI ZJ, 1986, CAN J PSYCHIAT, V31, P2, DOI 10.1177/070674378603100102; MCDANIEL JS, 1992, SOUTHERN MED J, V85, P388, DOI 10.1097/00007611-199204000-00013; MCDANIEL JS, 1992, SOUTH MED J, V85, P402; PELOSI AJ, 1992, BRIT MED J, V304, P1295, DOI 10.1136/bmj.304.6837.1295; PLOTNIKOFF PN, 1991, STRESS IMMUNITY; Powell R C, 1977, Psychiatr Q, V49, P133, DOI 10.1007/BF01071661; RAHE RH, 1990, PSYCHOSOM MED, V52, P373, DOI 10.1097/00006842-199007000-00001; ROSENGREN A, 1993, BRIT MED J, V307, P1102, DOI 10.1136/bmj.307.6912.1102; ROZANSKI A, 1988, NEW ENGL J MED, V318, P1005, DOI 10.1056/NEJM198804213181601; Ryan F., 1993, GLOTTA; SCHWARZ MR, 1964, COMMUNICATION   0605; SELYE H, 1956, PERSONALITY STRESS T, P45; SMITH RC, 1991, ANN INTERN MED, V115, P470, DOI 10.7326/0003-4819-115-6-470; SONTAG S, 1989, ILLNESS AS METAPHOR; SPIEGEL D, 1989, LANCET, V2, P888; STARR P, 1982, SOCIAL TRANSFORMATIO, P189; TELLER ME, 1988, TUBERCULOSIS MOVEMEN, P109; THEORELL T, 1992, PSYCHOTHER PSYCHOSOM, V57, P108, DOI 10.1159/000288583; Thoits P.A., 1983, PSYCHOSOCIAL STRESS, P33; Tishler P V, 1992, Pharos Alpha Omega Alpha Honor Med Soc, V55, P32; TOFFLER A, 1970, FUTURE SHOCK, P327; TOTMAN R, 1979, SOCIAL CAUSES ILLNES, P107; TRACY SW, 1992, B HIST MED, V66, P53; WOLFF HG, 1962, PSYCHOSOM MED, V24, P25, DOI 10.1097/00006842-196201000-00005; 1971, TIME            0301, V97, P54	69	37	37	0	5	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 1	1996	124	7					673	680		10.7326/0003-4819-124-7-199604010-00008	http://dx.doi.org/10.7326/0003-4819-124-7-199604010-00008			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UB513	8607596				2022-12-28	WOS:A1996UB51300008
J	Brown, J; Bryan, S; Warren, R				Brown, J; Bryan, S; Warren, R			Mammography screening: An incremental cost effectiveness analysis of double versus single reading of mammograms	BRITISH MEDICAL JOURNAL			English	Article							BREAST-CANCER; MORTALITY; REDUCTION	Objective-To compare mammography reading by one radiologist with independent reading by two radiologists. Design-An observational non-randomised trial at St Margaret's Hospital, Epping. Subjects-33 734 consecutive attenders for breast screening in the main trial and a sample of 132 attenders for assessment who provided data on private costs. Interventions-Three reporting policies were compared: single reading, consensus double reading, and non-consensus double reading. Main outcome measures-Numbers of cancers detected, recall rates, screening and assessment costs, and cost effectiveness ratios. Results-A policy of double reading followed by consensus detected an additional nine cancers per 10 000 women screened (95% confidence interval 5 to 13) compared with single reading. A non-consensus double reading policy detected an additional 10 cancers per 10 000 women screened (95% confidence interval 6 to 14). The difference in numbers of cancers detected between the consensus and nonconsensus double reading policies was not significant (95% confidence interval -0.2 to 2.2). The proportion of women recalled for assessment after consensus double reading was significantly lower than after single reading (difference 2.7%; 95% confidence interval 2.4% to 3.0%). The recall rate with the nonconsensus policy was significantly higher than with single reading (difference 3.0%; 2.5% to 3.5%). Consensus double reading cost less than single reading (saving pound 4853 per 10000 women screened). Non-consensus double reading cost more than single reading (difference pound 19259 per 10000 women screened). Conclusions-In the screening unit studied a consensus double reading policy was more effective and less costly than a single reading policy.	ST MARGARETS HOSP,BREAST SCREENING SERV,EPPING CM16 6TN,ESSEX,ENGLAND		Brown, J (corresponding author), BRUNEL UNIV,HLTH ECON RES GRP,UXBRIDGE UB8 3PH,MIDDX,ENGLAND.							ANDERSON EDC, 1994, CLIN RADIOL, V49, P248, DOI 10.1016/S0009-9260(05)81850-1; ANDERSSON I, 1988, BRIT MED J, V297, P943, DOI 10.1136/bmj.297.6654.943; ASHBY J, 1989, 6 BRUN U HLTH EC RES; Bryan S, 1995, J Med Screen, V2, P62; BRYAN S, 1995, J EPIDEMIOL COMMUN H, V49, P70, DOI 10.1136/jech.49.1.70; CHAMBERLAIN J, 1993, BRIT MED J, V307, P353, DOI 10.1136/bmj.307.6900.353; CLARKE PR, 1990, EC ANAL SCREENING BR; DAY NE, 1991, BRIT MED BULL, V47, P400, DOI 10.1093/oxfordjournals.bmb.a072479; GARDNER MJ, 1989, STAT CONFIDENCE CONF; MILLER AB, 1988, SCREENING BREAST CAN, P51; Sculpher M J, 1992, Health Econ, V1, P39, DOI 10.1002/hec.4730010107; TABAR L, 1985, LANCET, V1, P829, DOI 10.1016/S0140-6736(85)92204-4; THURFJELL EL, 1994, RADIOLOGY, V191, P241, DOI 10.1148/radiology.191.1.8134580; VERBEEK ALM, 1984, LANCET, V1, P1222; Wald NJ, 1993, BREAST, V2, P209; WARREN RML, 1995, BRIT J RADIOL, V68, P958, DOI 10.1259/0007-1285-68-813-958; WOODMAN CBJ, 1995, BRIT MED J, V310, P224, DOI 10.1136/bmj.310.6974.224; *WORK GROUP, 1986, BREAST CANC SCREEN R	18	104	106	0	6	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 30	1996	312	7034					809	812						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UD378	8608287				2022-12-28	WOS:A1996UD37800022
J	Garber, AM; Browner, WS; Mazzaferri, EL; Feussner, JR; Kerby, GR; Friesinger, GC; Marton, KI; Mushlin, AI; Palda, VA; Thibault, GE; Sox, H; Barker, J; Hart, I; Blonde, L; Mazzaferri, EL; Carravallah, L; Noble, J; Duffy, D; Feinberg, A; Wallace, E; Fryhofer, S; Waxman, H				Garber, AM; Browner, WS; Mazzaferri, EL; Feussner, JR; Kerby, GR; Friesinger, GC; Marton, KI; Mushlin, AI; Palda, VA; Thibault, GE; Sox, H; Barker, J; Hart, I; Blonde, L; Mazzaferri, EL; Carravallah, L; Noble, J; Duffy, D; Feinberg, A; Wallace, E; Fryhofer, S; Waxman, H			Guidelines for using serum cholesterol, high-density lipoprotein cholesterol, and triglyceride levels as screening tests for preventing coronary heart disease in adults	ANNALS OF INTERNAL MEDICINE			English	Article											Garber, AM (corresponding author), AMER COLL PHYSICIANS, DEPT SCI POLICY, INDEPENCE MALL W, 6TH ST RACE, PHILADELPHIA, PA 19106 USA.							[Anonymous], COMMON SCREENING TES; CLEEMAN JI, 1988, ARCH INTERN MED, V148, P36, DOI 10.1001/archinte.148.1.36; Garber AM, 1996, ANN INTERN MED, V124, P518, DOI 10.7326/0003-4819-124-5-199603010-00013; LOGAN AG, 1993, CAN MED ASSOC J, V148, P521; 1993, 2ND REPORT EXPERT PA; [No title captured]; 1995, GUIDE CLIN PREVENTIV; 1990, J CLIN EPIDEMIOL, V43, P1028	8	150	151	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 1	1996	124	5					515	517		10.7326/0003-4819-124-5-199603010-00013	http://dx.doi.org/10.7326/0003-4819-124-5-199603010-00013			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TW773	8602714				2022-12-28	WOS:A1996TW77300012
J	Weliky, M; Bosking, WH; Fitzpatrick, D				Weliky, M; Bosking, WH; Fitzpatrick, D			A systematic map of direction preference in primary visual cortex	NATURE			English	Article							MONKEY STRIATE CORTEX; ISO-ORIENTATION DOMAINS; FUNCTIONAL ARCHITECTURE; ORGANIZATION; SELECTIVITY; GEOMETRY; COLUMNS; AREA-18	NEURONS in the primary visual cortex respond selectively to the orientation of edges and their direction of motion. Orientation preference is mapped in a systematic fashion across the cortical surface, such that neurons in adjacent columns have similar but slightly shifted preferred orientations(1-7), Microelectrode studies have suggested that direction preference is also arranged in a systematic fashion(8-10), but exactly how this response property is mapped remains unclear. Here we show by optical imaging(4-5) of intrinsic signals(6-7,11-14) in ferret cortical area 17 that there is a mosaic-like map of direction preference, This map consists of numerous regions within which direction preference changes in a slow, continuous fashion, These regions are separated by winding boundaries (fractures) across which direction preference shifts abruptly, often by 180 degrees, Comparison of direction and orientation preference maps shows that these fractures subdivide iso-orientation domains into regions selective for opposite directions of motion.			Weliky, M (corresponding author), DUKE UNIV,MED CTR,DEPT NEUROBIOL,BOX 3209,DURHAM,NC 27710, USA.							BLASDEL GG, 1986, NATURE, V321, P579, DOI 10.1038/321579a0; BLASDEL GG, 1992, J NEUROSCI, V12, P3115, DOI 10.1523/JNEUROSCI.12-08-03115.1992; BONHOEFFER T, 1993, J NEUROSCI, V13, P4157; BONHOEFFER T, 1991, NATURE, V353, P429, DOI 10.1038/353429a0; BRAITENBERG V, 1979, BIOL CYBERN, V33, P179, DOI 10.1007/BF00337296; FITZPATRICK D, 1994, J SOC NEUR ABSTR, V20, P837; FROSTIG RD, 1990, P NATL ACAD SCI USA, V87, P6082, DOI 10.1073/pnas.87.16.6082; HUBEL DH, 1968, J PHYSIOL-LONDON, V195, P215, DOI 10.1113/jphysiol.1968.sp008455; HUBEL DH, 1977, PROC R SOC SER B-BIO, V198, P1, DOI 10.1098/rspb.1977.0085; HUBEL DH, 1974, J COMP NEUROL, V158, P267, DOI 10.1002/cne.901580304; MALONEK D, 1994, P ROY SOC B-BIOL SCI, V258, P109, DOI 10.1098/rspb.1994.0150; PAYNE BR, 1981, BRAIN RES, V211, P445, DOI 10.1016/0006-8993(81)90971-9; SWINDALE NV, 1982, PROC R SOC SER B-BIO, V215, P211, DOI 10.1098/rspb.1982.0038; SWINDALE NV, 1987, J NEUROSCI, V7, P1414; TOLHURST DJ, 1981, EXP BRAIN RES, V44, P340; WELIKY M, 1994, J NEUROSCI, V14, P7291; WELIKY M, 1995, NEURON, V15, P541, DOI 10.1016/0896-6273(95)90143-4	17	194	194	2	10	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	FEB 22	1996	379	6567					725	728		10.1038/379725a0	http://dx.doi.org/10.1038/379725a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	TW567	8602218				2022-12-28	WOS:A1996TW56700052
J	Gerasimenko, OV; Gerasimenko, JV; Belan, PV; Petersen, OH				Gerasimenko, OV; Gerasimenko, JV; Belan, PV; Petersen, OH			Inositol trisphosphate and cyclic ADP-ribose-mediated release of Ca2+ from single isolated pancreatic zymogen granules	CELL			English	Article							EXOCRINE PANCREAS; ACINAR-CELLS; SUBCELLULAR-DISTRIBUTION; ENDOPLASMIC-RETICULUM; PROTEIN-SYNTHESIS; CALCIUM; SECRETION; OSCILLATIONS; THAPSIGARGIN; INHIBITION	In pancreatic acinar cells low (physiological) agonist concentrations evoke cytosolic Ca2+ spikes specifically in the apical secretory pole that contains a high density of secretory (zymogen) granules (ZGs). Inositol 1,4,5-trisphosphate (IP3) is believed to release Ca2+ from the endoplasmic reticulum, but we have now tested whether the Ca2+-releasing messengers IP3 and cyclic ADP-ribose (cADPr) can liberate Ca2+ from ZGs. In experiments on single isolated ZGs, we show using confocal microscopy that IP3 and cADPr evoke a marked decrease in the free intragranular Ca2+ concentration. Using a novel high resolution method, we have measured changes in the Ca2+ concentration in the vicinity of an isolated ZG and show that IP3 and cADPr cause rapid Ca2+ release from the granule, explaining the agonist-evoked cytosolic Ca2+ rise in the secretory pole.	UNIV LIVERPOOL,PHYSIOL LAB,MRC SECRETORY CONTROL,RES GRP,LIVERPOOL L69 3BX,MERSEYSIDE,ENGLAND	University of Liverpool			Gerasimenko, Oleg/A-6622-2010; Petersen, Ole H/E-8708-2010; Gerasimenko, Julia/A-7688-2010; Belan, Pavel/AAV-3522-2021	Gerasimenko, Oleg/0000-0003-2573-8258; Belan, Pavel/0000-0001-5429-3716; Gerasimenko, Julia/0000-0002-2262-2543; Petersen, Ole/0000-0002-6998-0380	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BLONDEL O, 1995, TRENDS NEUROSCI, V18, P157, DOI 10.1016/0166-2236(95)93894-4; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; CLEMENTE F, 1975, J CELL BIOL, V65, P88, DOI 10.1083/jcb.65.1.88; FASOLATO C, 1991, J BIOL CHEM, V266, P20159; FULLER CM, 1989, PFLUG ARCH EUR J PHY, V415, P29, DOI 10.1007/BF00373138; GERASIMENKO OV, 1995, CELL, V80, P439, DOI 10.1016/0092-8674(95)90494-8; Gorelick Frederick S., 1994, P1353; HOFER AM, 1993, P NATL ACAD SCI USA, V90, P2598, DOI 10.1073/pnas.90.7.2598; KASAI H, 1994, TRENDS NEUROSCI, V17, P95, DOI 10.1016/0166-2236(94)90112-0; KASAI H, 1993, CELL, V74, P669, DOI 10.1016/0092-8674(93)90514-Q; KASAI H, 1990, NATURE, V348, P735, DOI 10.1038/348735a0; KASAI H, 1995, CIBA F SYMP, V188, P104; Kern Horst F., 1993, P9; MARTY A, 1991, J MEMBRANE BIOL, V124, P189, DOI 10.1007/BF01994353; MARUYAMA Y, 1994, CELL CALCIUM, V16, P419, DOI 10.1016/0143-4160(94)90035-3; MARUYAMA Y, 1993, EMBO J, V12, P3017, DOI 10.1002/j.1460-2075.1993.tb05970.x; NAKAGAKI I, 1984, PFLUG ARCH EUR J PHY, V401, P340, DOI 10.1007/BF00584333; NATHANSON MH, 1994, J BIOL CHEM, V269, P4693; NICAISE G, 1992, BIOL CELL, V75, P89, DOI 10.1016/0248-4900(92)90128-N; PALADE G, 1975, SCIENCE, V189, P347, DOI 10.1126/science.1096303; PAREKH AB, 1993, J PHYSIOL-LONDON, V469, P653, DOI 10.1113/jphysiol.1993.sp019836; PETERSEN OH, 1994, ANNU REV PHYSIOL, V56, P297, DOI 10.1146/annurev.ph.56.030194.001501; POZZAN T, 1994, PHYSIOL REV, V74, P595, DOI 10.1152/physrev.1994.74.3.595; ROGERS J, 1987, BIOCHIM BIOPHYS ACTA, V897, P217, DOI 10.1016/0005-2736(87)90418-4; STREB H, 1984, J MEMBRANE BIOL, V81, P241, DOI 10.1007/BF01868717; TEPIKIN AV, 1992, J BIOL CHEM, V267, P3569; TEPIKIN AV, 1992, J BIOL CHEM, V267, P14073; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; THORN P, 1993, CELL, V74, P661, DOI 10.1016/0092-8674(93)90513-P; THORN P, 1994, EMBO J, V13, P2038, DOI 10.1002/j.1460-2075.1994.tb06478.x; TOESCU EC, 1995, J BIOL CHEM, V270, P8528, DOI 10.1074/jbc.270.15.8528; TOESCU EC, 1992, EMBO J, V11, P1623, DOI 10.1002/j.1460-2075.1992.tb05208.x; TOESCU EC, 1994, PFLUG ARCH EUR J PHY, V427, P325, DOI 10.1007/BF00374541; TSE FW, 1994, P NATL ACAD SCI USA, V91, P9750, DOI 10.1073/pnas.91.21.9750; WILCOX RA, 1994, J BIOL CHEM, V269, P26815; WILEMAN T, 1991, J BIOL CHEM, V266, P4500; WONG WL, 1993, BIOCHEM J, V289, P71, DOI 10.1042/bj2890071; YOO SH, 1990, J BIOL CHEM, V265, P13446; ZHANG BX, 1992, J BIOL CHEM, V267, P15419	40	207	217	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 9	1996	84	3					473	480		10.1016/S0092-8674(00)81292-1	http://dx.doi.org/10.1016/S0092-8674(00)81292-1			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TV708	8608601	Bronze			2022-12-28	WOS:A1996TV70800016
J	Lee, K; Collinson, S; Walt, G; Gilson, L				Lee, K; Collinson, S; Walt, G; Gilson, L			Who should be doing what in international health: A confusion of mandates in the United Nations?	BRITISH MEDICAL JOURNAL			English	Article								Since 1945 at least five United Nations organisations have become substantially involved in international health activities. This has led to considerable confusion among policy makers, scholars, and UN staff over their distinct and appropriate mandates. Interviews with staff and a historical analysis have shown that while formal mandates have been complementary, effective mandates have led to an unclear delineation of activities. The processes of translating formal into effective mandates have been influenced by the decentralised nature of the UN, lack of a master plan for its activities, the considerable growth in the policy agenda, and the shift towards a multisectoral approach to health. The identification of each organisation's comparative advantage, at both the global and country levels, is one way of understanding what each organisation does best and perhaps should be doing. There is a need for improved mechanisms to define effective mandates, taking into account comparative advantages, if the mandates of UN organisations are appropriate to meet future challenges in international health.	LONDON SCH HYG & TROP MED,HLTH POLICY UNIT,HLTH ECON & FINANCING PROGRAMME,LONDON WC1E 7HT,ENGLAND	University of London; London School of Hygiene & Tropical Medicine	Lee, K (corresponding author), LONDON SCH HYG & TROP MED,HLTH POLICY UNIT,INT HLTH POLICY PROGRAMME,LONDON WC1E 7HT,ENGLAND.		Gilson, Lucy/R-8846-2019	Gilson, Lucy/0000-0002-2775-7703				[Anonymous], 1993, WORLD DEV REPORT INV; [Anonymous], 1946, CONSTITUTION WHO; GODIEE F, 1994, BRIT MED J, V309, P1424; HART C, 1993, CONTRIBUTIONS UN DEV; JEAN F, 1993, LIFE DEATH AID; MICHAUD C, 1994, B WORLD HEALTH ORGAN, V72, P161; NAIM M, 1994, BRETTON WOODS LOOKIN, pC273; NAKAJIMA H, 1995, WHO A48DIV42; VAUGHAN JP, 1995, COOPERATION HLTH DEV, P27; WALT G, 1994, HEALTH POLICY PLANN, V9, P353, DOI 10.1093/heapol/9.4.353; 1964, ARTICLES AGREEMENT; 1995, 2ND M COMM A GEN; 1994, 1994 WORLD BANK ANN; 1993, EICEF1993L5 UNICEF; 1995, WHA A48109 WHO; 1995, WORLD HLTH REPORT; 1995, INVESTING PEOPLE; 1993, UNFPA1993 REP; 1946, ESTABLISHMENT INT CH	19	38	38	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 3	1996	312	7026					302	307						6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TU507	8611793	Green Published			2022-12-28	WOS:A1996TU50700034
J	Hennekens, CH; Buring, JE; Manson, JE; Stampfer, M; Rosner, B; Cook, NR; Belanger, C; LaMotte, F; Gaziano, JM; Ridker, PM; Willett, W; Peto, R				Hennekens, CH; Buring, JE; Manson, JE; Stampfer, M; Rosner, B; Cook, NR; Belanger, C; LaMotte, F; Gaziano, JM; Ridker, PM; Willett, W; Peto, R			Lack of effect of long-term supplementation with beta carotene on the incidence of malignant neoplasms and cardiovascular disease	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							VITAMIN-E CONSUMPTION; PHYSICIANS HEALTH; CANCER; RISK; TRIAL	Background. Observational studies suggest that people who consume more fruits and vegetables containing beta carotene have somewhat lower risks of cancer and cardiovascular disease, and earlier basic research suggested plausible mechanisms. Because large randomized trials of long duration were necessary to test this hypothesis directly, we conducted a trial of beta carotene supplementation. Methods. In a randomized, double-blind, placebo-controlled trial of beta carotene (50 mg on alternate days), we enrolled 22,071 male physicians, 40 to 84 years of age, in the United States; 11 percent were current smokers and 39 percent were former smokers at the beginning of the study in 1982. By December 31, 1995, the scheduled end of the study, fewer than 1 percent had been lost to follow-up, and compliance was 78 percent in the group that received beta carotene. Results. Among 11,036 physicians randomly assigned to receive beta carotene and 11,035 assigned to receive placebo, there were virtually no early or late differences in the overall incidence of malignant neoplasms or cardiovascular disease, or in overall mortality. In the beta carotene group, 1273 men had any malignant neoplasm (except nonmelanoma skin cancer), as compared with 1293 in the placebo group (relative risk, 0.98; 95 percent confidence interval, 0.91 to 1.06). There were also no significant differences in the number of cases of lung cancer (82 in the beta carotene group vs. 88 in the placebo group); the number of deaths from cancer (386 vs. 380), deaths from any cause (979 vs. 968), or deaths from cardiovascular disease (338 vs. 313); the number of men with myocardial infarction (468 vs. 489); the number with stroke (367 vs. 382); or the number with any one of the previous three end points (967 vs. 972). Among current and former smokers, there were also no significant early or late differences in any of these end points. Conclusions. In this trial among healthy men, 12 years of supplementation with beta carotene produced neither benefit nor harm in terms of the incidence of malignant neoplasms, cardiovascular disease, or death from all causes. (C) 1996, Massachusetts Medical Society.	BRIGHAM & WOMENS HOSP, DEPT MED, CHANNING LAB, BOSTON, MA 02115 USA; BRIGHAM & WOMENS HOSP, DEPT MED, DIV PREVENT MED, BOSTON, MA 02115 USA; BRIGHAM & WOMENS HOSP, DEPT MED, DIV CARDIOVASC MED, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT AMBULATORY CARE & PREVENT, BOSTON, MA USA; HARVARD UNIV, SCH PUBL HLTH, DEPT EPIDEMIOL, BOSTON, MA 02115 USA; HARVARD UNIV, SCH PUBL HLTH, DEPT BIOSTAT, BOSTON, MA 02115 USA; HARVARD UNIV, SCH PUBL HLTH, DEPT NUTR, BOSTON, MA 02115 USA; UNIV OXFORD, IMPERIAL CANC RES FUND, CLIN TRIAL SERV UNIT, OXFORD, ENGLAND	Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; University of Oxford					NCI NIH HHS [CA-34944, CA-40360] Funding Source: Medline; NHLBI NIH HHS [HL-26490] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA040360] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		[Anonymous], 1988, NEW ENGL J MED; [Anonymous], 1989, NEW ENGL J MED, V321, P129; BLOT WJ, 1993, JNCI-J NATL CANCER I, V85, P1483, DOI 10.1093/jnci/85.18.1483; BURING JE, 1993, CANC PRINCIPLES PRAC, P464; Buring JE, 1992, J MYOCARDIAL ISCHEMI, V4, P27; BURTON GW, 1984, SCIENCE, V224, P569, DOI 10.1126/science.6710156; FRANCESCHI S, 1991, INT J CANCER, V48, P395, DOI 10.1002/ijc.2910480315; GAZIANO JM, 1994, NATURAL ANTIOXIDANTS, P387; GAZIANO JM, 1992, ANN NY ACAD SCI, V669, P249; GREENBERG ER, 1990, NEW ENGL J MED, V323, P789, DOI 10.1056/NEJM199009203231204; GREENBERG ER, 1994, NEW ENGL J MED, V331, P141, DOI 10.1056/NEJM199407213310301; GREENBERG ER, 1991, NEW ENGL J MED, V325, P1324; Hennekens C.H., 1987, EPIDEMIOLOGY MED; HENNEKENS CH, 1986, NEW ENGL J MED, V315, P1288, DOI 10.1056/NEJM198611133152009; HENNEKENS CH, 1994, NEW ENGL J MED, V330, P1080, DOI 10.1056/NEJM199404143301510; HENNEKENS CH, 1993, ANN NY ACAD SCI, V703, P18, DOI 10.1111/j.1749-6632.1993.tb26330.x; MANSON JE, 1991, AM J PREV MED, V7, P150, DOI 10.1016/S0749-3797(18)30931-0; MENKES MS, 1986, NEW ENGL J MED, V315, P1250, DOI 10.1056/NEJM198611133152003; NOMURA AMY, 1991, INT J CANCER, V48, P199, DOI 10.1002/ijc.2910480208; Omenn GS, 1996, NEW ENGL J MED, V334, P1150, DOI 10.1056/NEJM199605023341802; PETO R, 1981, NATURE, V290, P201, DOI 10.1038/290201a0; RIMM EB, 1993, NEW ENGL J MED, V328, P1450, DOI 10.1056/NEJM199305203282004; SATTERFIELD S, 1990, AM J PREV MED, V6, P290, DOI 10.1016/S0749-3797(18)30997-8; STAMPFER MJ, 1993, NEW ENGL J MED, V328, P1444, DOI 10.1056/NEJM199305203282003; STEINBERG D, 1989, NEW ENGL J MED, V320, P915; STICH HF, 1984, LANCET, V1, P1204; *WHO, 1971, ISCH HEART DIS REG R; 1994, NEW ENGL J MED, V330, P1029	28	1805	1847	1	75	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 2	1996	334	18					1145	1149		10.1056/NEJM199605023341801	http://dx.doi.org/10.1056/NEJM199605023341801			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UG831	8602179	Bronze			2022-12-28	WOS:A1996UG83100001
J	Monini, P; deLellis, L; Fabris, M; Rigolin, F; Cassai, E				Monini, P; deLellis, L; Fabris, M; Rigolin, F; Cassai, E			Kaposi's sarcoma-associated herpesvirus DNA sequences in prostate tissue and human semen	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							AIDS; CYTOKINES; GROWTH; CELLS	Background. Sequences of a novel herpesvirus, Kaposi's sarcoma-associated herpesvirus (KSHV), have been identified in Kaposi's sarcoma tissue, but it is not known whether the virus is transmitted by sexual contact. Methods. Using the polymerase chain reaction (PCR), we searched for KSHV DNA sequences in ejaculates from 43 healthy men and tissue from the urogenital tract or prostate of 100 immunocompetent adults. Results. In an unblinded analysis, we identified KSHV DNA sequences in 2 of 20 tissue specimens from the urinary tract (10 percent; 15 men and 5 women), 3 of 46 specimens from the female genital tract (6.5 percent), 4 of 18 specimens from the glans or foreskin (22 percent), 7 of 16 specimens from the prostate (44 percent), and 30 of 33 ejaculates (91 percent), By contrast, such sequences were present in 1 of 18 samples of normal skin (5.5 percent) and 1 of 14 samples of peripheral-blood mononuclear cells (PBMCs; 7.1 percent), Ejaculates and PBMC samples from each of 10 study subjects were analyzed in a blinded, coded fashion, along with PBMCs and biopsy specimens of normal skin from 4 and 8 other patients, respectively. This analysis confirmed the presence of KSHV DNA sequences in semen, Viral DNA was not found in the sperm heads but was present in the fraction of the ejaculates that contained urothelial and other types of cells. Point mutations were found in PCR products amplified from both prostate tissue and sperm samples. Conclusions. KSHV infects a large proportion of healthy adults and is probably transmitted by sexual contact. (C) 1996, Massachusetts Medical Society.	ST ANNA HOSP,LAB ANAL,FERRARA,ITALY	University of Ferrara; Arcispedale Sant'Anna	Monini, P (corresponding author), UNIV FERRARA,INST MICROBIOL,VIA L BORSARI 46,I-44100 FERRARA,ITALY.		Monini, Paolo/K-1429-2016	Monini, Paolo/0000-0002-4941-6854				BARILLARI G, 1992, J IMMUNOL, V149, P3727; BERAL V, 1990, LANCET, V335, P123, DOI 10.1016/0140-6736(90)90001-L; BERAL V, 1992, LANCET, V339, P632, DOI 10.1016/0140-6736(92)90793-3; BROOKS JJ, 1986, LANCET, V2, P1309; CESARMAN E, 1995, NEW ENGL J MED, V332, P1186, DOI 10.1056/NEJM199505043321802; CHANG Y, 1994, SCIENCE, V266, P1865, DOI 10.1126/science.7997879; COUTURIER E, 1990, LANCET, V335, P1105, DOI 10.1016/0140-6736(90)92685-B; DELELLIS L, 1995, J INFECT DIS, V172, P1605, DOI 10.1093/infdis/172.6.1605; ENSOLI B, 1994, NATURE, V371, P674, DOI 10.1038/371674a0; ENSOLI B, 1989, SCIENCE, V243, P223, DOI 10.1126/science.2643161; HUANG YQ, 1995, LANCET, V345, P759, DOI 10.1016/S0140-6736(95)90641-X; KYO S, 1994, J INFECT DIS, V170, P682, DOI 10.1093/infdis/170.3.682; MOORE PS, 1995, NEW ENGL J MED, V332, P1181, DOI 10.1056/NEJM199505043321801; PETERMAN TA, 1993, AIDS, V7, P605, DOI 10.1097/00002030-199305000-00001; REAL FX, 1985, NEW ENGL J MED, V313, P1659; ROIZMAN B, 1995, NEW ENGL J MED, V332, P1227, DOI 10.1056/NEJM199505043321810; SU IJ, 1995, LANCET, V345, P722, DOI 10.1016/S0140-6736(95)90893-5; VONBEROLDINGEN CH, 1989, PCR TECHNOLOGY PRINC, P209	18	217	225	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 2	1996	334	18					1168	1172		10.1056/NEJM199605023341805	http://dx.doi.org/10.1056/NEJM199605023341805			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UG831	8602183	Bronze			2022-12-28	WOS:A1996UG83100005
J	Epstein, RS; Sherwood, LM				Epstein, RS; Sherwood, LM			From outcomes research to disease management: A guide for the perplexed	ANNALS OF INTERNAL MEDICINE			English	Article							QUALITY-OF-LIFE; MEDICAL-CARE; USERS GUIDES; HEALTH; TECHNOLOGY; THERAPY; ADULTS; ASTHMA; COSTS	Outcomes research is a rapidly evolving field that incorporates epidemiology, health services research, health economics, and psychometrics. Measurement of clinical and other outcomes has become increasingly important to the stakeholders in a rapidly changing health care environment. The desire to improve outcomes and control costs has stimulated greater interest in cost-effectiveness studies, which determine how well effective therapies work in the usual practice setting and how much they cost. The application of outcomes principles to the practices of health care providers has resulted in efforts to implement disease management programs. Unlike traditional programs carried out by physicians, these new efforts are based on systematic population-based approaches to identifying persons at risk, intervening with specific programs of care, and measuring clinical and other outcomes. The new efforts depend heavily on modern information systems.	MERCK & CO INC, W POINT, PA 19486 USA	Merck & Company								A Donabedian, 1980, EXPLORATIONS QUALITY, VI; ANDERSON GM, 1990, CLIN PHARMACOL THER, V48, P111, DOI 10.1038/clpt.1990.125; BROOK RH, 1983, NEW ENGL J MED, V309, P1426, DOI 10.1056/NEJM198312083092305; BROOK RH, 1985, MED CARE, V23, P710, DOI 10.1097/00005650-198505000-00030; CLEELAND CS, 1990, ADV PAIN RES THER, V16, P47; Corrigan J M, 1993, Jt Comm J Qual Improv, V19, P566; CROOG SH, 1986, NEW ENGL J MED, V314, P1657, DOI 10.1056/NEJM198606263142602; DEYO RA, 1995, MED CARE, V33, pAS286; DIAMOND GA, 1993, ANN INTERN MED, V118, P455, DOI 10.7326/0003-4819-118-6-199303150-00010; DONABEDIAN A, 1966, MILBANK FUND Q, V44, P166, DOI 10.2307/3348969; DONABEDIAN A, 1978, SCIENCE, V200, P856, DOI 10.1126/science.417400; EAKER E, 1994, NEW ENGL J MED, V330, P70, DOI 10.1056/NEJM199401063300121; ELLWOOD PM, 1988, NEW ENGL J MED, V318, P1549, DOI 10.1056/NEJM198806093182329; GUESS HA, 1996, MED CARE, V33, pAS26; GUYATT GH, 1994, JAMA-J AM MED ASSOC, V271, P59, DOI 10.1001/jama.271.1.59; GUYATT GH, 1993, JAMA-J AM MED ASSOC, V270, P2598, DOI 10.1001/jama.270.21.2598; HYLAND ME, 1991, RESP MED, V85, P13, DOI 10.1016/S0954-6111(06)80163-0; JAESCHKE R, 1989, CONTROL CLIN TRIALS, V10, P407, DOI 10.1016/0197-2456(89)90005-6; JONES PW, 1994, EUR RESPIR J, V7, P55, DOI 10.1183/09031936.94.07010055; JUNIPER EF, 1992, THORAX, V47, P76, DOI 10.1136/thx.47.2.76; KIRSHNER B, 1985, J CHRON DIS, V38, P27, DOI 10.1016/0021-9681(85)90005-0; KRAKAUER H, 1991, STAT MED, V10, P521, DOI 10.1002/sim.4780100405; LYDICK E, 1993, QUAL LIFE RES, V2, P221, DOI 10.1007/BF00435226; Maimonides, 1904, GUIDE PERPLEXED; MAKLAN CW, 1994, MED CARE, V32, pJS13; MARKS GB, 1992, J CLIN EPIDEMIOL, V45, P461, DOI 10.1016/0895-4356(92)90095-5; OSTER G, 1995, CONTROL CLIN TRIALS, V16, P3, DOI 10.1016/0197-2456(94)00028-2; OSTER G, IN PRESS ARCH INTERN; OXMAN AD, 1993, JAMA-J AM MED ASSOC, V270, P2093; PEDERSEN TR, 1994, LANCET, V344, P1383; PERFETTO EM, IN PRESS PHARMACOEPI; Revicki D A, 1992, Pharmacoeconomics, V1, P394; ROGERS WJ, 1994, J AM COLL CARDIOL, V23, P393, DOI 10.1016/0735-1097(94)90426-X; ROPER WL, 1988, NEW ENGL J MED, V319, P1197, DOI 10.1056/NEJM198811033191805; SIMON G, 1995, J CLIN EPIDEMIOL, V48, P363, DOI 10.1016/0895-4356(94)00141-C; SOGHIKIAN K, 1992, MED CARE, V30, P855, DOI 10.1097/00005650-199209000-00009; STEINWACHS DM, 1994, HEALTH AFFAIR, V13, P153, DOI 10.1377/hlthaff.13.4.153; TANKE ED, 1994, MED CARE, V32, P380, DOI 10.1097/00005650-199404000-00006; TENGS TO, 1995, RISK ANAL, V15, P369, DOI 10.1111/j.1539-6924.1995.tb00330.x	39	210	216	1	8	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 1	1996	124	9					832	837		10.7326/0003-4819-124-9-199605010-00008	http://dx.doi.org/10.7326/0003-4819-124-9-199605010-00008			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	UG254	8610953				2022-12-28	WOS:A1996UG25400008
J	Geli, MI; Riezman, H				Geli, MI; Riezman, H			Role of type I myosins in receptor-mediated endocytosis in yeast	SCIENCE			English	Article							SACCHAROMYCES-CEREVISIAE; TRANSPORT; ACTIN; CELLS	Type I myosins are thought to drive actin-dependent membrane motility, but the direct demonstration in vivo of their involvement in specific cellular processes has been difficult. Deletion of the genes MYO3 and MYO5, which encode the yeast type I myosins, almost abolished growth. A double-deleted mutant complemented with a MYO5 temperature-sensitive allele (myo5-1) showed a strong defect in the internalization step of receptor-mediated endocytosis, whereas the secretory pathway remained apparently unaffected. Thus, myosin I activity is required for a budding event in endocytosis but not for several other aspects of membrane traffic.	UNIV BASEL, BIOZENTRUM, CH-4056 BASEL, SWITZERLAND	University of Basel			Geli, Maria Isabel/L-3246-2014	Geli, Maria Isabel/0000-0002-3452-6700; Riezman, Howard/0000-0003-4680-9422				BAINES IC, 1995, J CELL BIOL, V130, P591, DOI 10.1083/jcb.130.3.591; BEMENT WM, 1994, J MOL BIOL, V243, P356, DOI 10.1006/jmbi.1994.1662; BEMENT WM, 1994, P NATL ACAD SCI USA, V91, P6549, DOI 10.1073/pnas.91.14.6549; BENEDETTI H, 1994, MOL BIOL CELL, V5, P1023, DOI 10.1091/mbc.5.9.1023; CHENEY R E, 1992, Current Opinion in Cell Biology, V4, P27, DOI 10.1016/0955-0674(92)90055-H; DULIC V, 1991, METHOD ENZYMOL, V194, P697; GOODSON HV, 1995, CELL MOTIL CYTOSKEL, V30, P73, DOI 10.1002/cm.970300109; GOTTLIEB TA, 1993, J CELL BIOL, V120, P695, DOI 10.1083/jcb.120.3.695; HAMMER JA, 1994, J MUSCLE RES CELL M, V15, P1, DOI 10.1007/BF00123827; HASSON T, 1995, CURR OPIN CELL BIOL, V7, P587, DOI 10.1016/0955-0674(95)80017-4; HICKE L, UNPUB; JOHNSTON GC, 1991, J CELL BIOL, V113, P539, DOI 10.1083/jcb.113.3.539; JUNG G, 1990, J CELL BIOL, V110, P1955, DOI 10.1083/jcb.110.6.1955; KUBLER E, 1994, EMBO J, V13, P5539, DOI 10.1002/j.1460-2075.1994.tb06891.x; KUBLER E, 1993, EMBO J, V12, P2855, DOI 10.1002/j.1460-2075.1993.tb05947.x; LAMAZE C, 1995, CURR OPIN CELL BIOL, V7, P573, DOI 10.1016/0955-0674(95)80015-8; MANIAK M, 1995, CELL, V83, P915, DOI 10.1016/0092-8674(95)90207-4; MCGOLDRICK CA, 1995, J CELL BIOL, V128, P577, DOI 10.1083/jcb.128.4.577; MULHOLLAND J, 1994, J CELL BIOL, V125, P381, DOI 10.1083/jcb.125.2.381; MUNN AL, 1995, MOL BIOL CELL, V6, P1721, DOI 10.1091/mbc.6.12.1721; NOVAK KD, 1995, J CELL BIOL, V131, P1205, DOI 10.1083/jcb.131.5.1205; RATHS S, 1993, J CELL BIOL, V120, P55, DOI 10.1083/jcb.120.1.55; SANDVIG K, 1990, J BIOL CHEM, V265, P6382; STEVENS T, 1982, CELL, V30, P439, DOI 10.1016/0092-8674(82)90241-0; STOFFLER HE, 1995, J CELL BIOL, V129, P819, DOI 10.1083/jcb.129.3.819; TAN JL, 1992, ANNU REV BIOCHEM, V61, P721, DOI 10.1146/annurev.bi.61.070192.003445; ZANOLARI B, 1992, CELL, V71, P755, DOI 10.1016/0092-8674(92)90552-N; 1988, GENE, V74, P527	28	219	225	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 26	1996	272	5261					533	535		10.1126/science.272.5261.533	http://dx.doi.org/10.1126/science.272.5261.533			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UG826	8614799				2022-12-28	WOS:A1996UG82600039
J	Chaliasos, N; Bourantas, C; Kritikou, E; Lapatsanis, P				Chaliasos, N; Bourantas, C; Kritikou, E; Lapatsanis, P			A 7-month-old girl with fever and bleeding	LANCET			English	Article							LEISHMANIASIS		UNIV IOANNINA,DEPT CHILD HLTH,GR-45110 IOANNINA,GREECE	University of Ioannina								BADARO R, 1990, NEW ENGL J MED, V322, P16, DOI 10.1056/NEJM199001043220104; EVANS TG, 1993, INFECT DIS CLIN N AM, V7, P527; SENGUPTA PC, 1972, DISEASES CHILDREN SU, P831	3	2	2	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 20	1996	347	9008					1086	1086		10.1016/S0140-6736(96)90282-2	http://dx.doi.org/10.1016/S0140-6736(96)90282-2			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UG042	8602061				2022-12-28	WOS:A1996UG04200015
J	Lygerou, Z; Allmang, C; Tollervey, D; Seraphin, B				Lygerou, Z; Allmang, C; Tollervey, D; Seraphin, B			Accurate processing of a eukaryotic precursor ribosomal RNA by ribonuclease MRP in vitro	SCIENCE			English	Article							SACCHAROMYCES-CEREVISIAE; SCHIZOSACCHAROMYCES-POMBE; U1 SNRNA; SUBSTRATE; INVITRO; CONTAINS; MUTANT; GENE	Very few of the enzymes required for eukaryotic precursor ribosomal RNA (pre-rRNA) processing have been identified, Ribonuclease (RNase) MRP was characterized as a nuclease that cleaves mitochondrial replication primers, but it is predominantly nucleolar, Previous genetic evidence revealed that this ribonucleoprotein is required, directly or indirectly, for cleavage of the yeast pre-rRNA in vivo at site A(3). Here, an in vitro processing system that accurately reproduces this cleavage is described. Biochemical purification and the use of extracts depleted of the MRP RNA demonstrate that endonucleolytic cleavage of the pre-rRNA is directly mediated by RNase MRP, This establishes a role for RNase MRP in the nucleolus.	EUROPEAN MOLEC BIOL LAB,D-69117 HEIDELBERG,GERMANY	European Molecular Biology Laboratory (EMBL)			Tollervey, David/AAR-6662-2020	Tollervey, David/0000-0003-2894-2772; Allmang, Christine/0000-0001-8883-0874; Seraphin, Bertrand/0000-0002-5168-1921				ALTMAN S, 1993, FASEB J, V7, P7, DOI 10.1096/fasebj.7.1.7916700; CHANG DD, 1989, CELL, V56, P131, DOI 10.1016/0092-8674(89)90991-4; CHANG DD, 1987, SCIENCE, V235, P1178, DOI 10.1126/science.2434997; CHU S, 1994, P NATL ACAD SCI USA, V91, P659, DOI 10.1073/pnas.91.2.659; COTE J, 1993, SCIENCE, V261, P765, DOI 10.1126/science.7688144; DARR SC, 1992, TRENDS BIOCHEM SCI, V17, P178, DOI 10.1016/0968-0004(92)90262-8; DRAINAS D, 1989, FEBS LETT, V251, P84, DOI 10.1016/0014-5793(89)81433-4; HANNON GJ, 1989, MOL CELL BIOL, V9, P4422, DOI 10.1128/MCB.9.10.4422; HENRY Y, 1994, EMBO J, V13, P2452, DOI 10.1002/j.1460-2075.1994.tb06530.x; KASS S, 1990, CELL, V60, P897, DOI 10.1016/0092-8674(90)90338-F; KISS T, 1992, CELL, V70, P11, DOI 10.1016/0092-8674(92)90528-K; KRUPP G, 1991, J MOL BIOL, V217, P637, DOI 10.1016/0022-2836(91)90522-8; LEE JY, 1991, MOL CELL BIOL, V11, P721, DOI 10.1128/MCB.11.2.721; LIN RJ, 1985, J BIOL CHEM, V260, P4780; LINDAHL L, 1992, NUCLEIC ACIDS RES, V20, P295, DOI 10.1093/nar/20.2.295; LYGEROU Z, 1994, GENE DEV, V8, P1423, DOI 10.1101/gad.8.12.1423; LYGEROU Z, UNPUB; MORRISSEY JP, 1995, TRENDS BIOCHEM SCI, V20, P78, DOI 10.1016/S0968-0004(00)88962-8; PEARSON D, 1985, MOL CELL BIOL, V5, P808, DOI 10.1128/MCB.5.4.808; POTUSCHAK T, 1993, NUCLEIC ACIDS RES, V21, P3239, DOI 10.1093/nar/21.14.3239; Sambrook J., 1989, MOL CLONING; SCHMITT ME, 1993, MOL CELL BIOL, V13, P7935, DOI 10.1128/MCB.13.12.7935; SERAPHIN B, 1989, CELL, V59, P349, DOI 10.1016/0092-8674(89)90296-1; SERAPHIN B, 1988, EMBO J, V7, P2533, DOI 10.1002/j.1460-2075.1988.tb03101.x; SHUAI K, 1991, NUCLEIC ACIDS RES, V19, P5059, DOI 10.1093/nar/19.18.5059; TOPPER JN, 1992, CELL, V70, P16, DOI 10.1016/0092-8674(92)90529-L; TRANGUCH AJ, 1994, BIOCHEMISTRY-US, V33, P1778, DOI 10.1021/bi00173a022; Venema J, 1995, YEAST, V11, P1629, DOI 10.1002/yea.320111607; YIP MT, 1989, J BIOL CHEM, V264, P4045	29	211	211	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 12	1996	272	5259					268	270		10.1126/science.272.5259.268	http://dx.doi.org/10.1126/science.272.5259.268			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UE729	8602511				2022-12-28	WOS:A1996UE72900041
J	Wan, Y; Kurosaki, T; Huang, XY				Wan, Y; Kurosaki, T; Huang, XY			Tyrosine kinases in activation of the MAP kinase cascade by G-protein-coupled receptors	NATURE			English	Article							GENE-PRODUCT; PHOSPHORYLATES; FIBROBLASTS; CLONING; RAS	THE mitogen-activated protein kinase (MAPK) signalling cascade is a prominent cellular pathway used by many growth factors, hormones and neurotransmitters to regulate physiological responses(1,2). Although activation of the MAPK pathway by receptors with tyrosine kinase activity is well defined(3), the mechanism used by heterotrimeric G-protein-coupled receptors to activate this pathway is less clear. Here we show that in cells deficient in the Src-related tyrosine kinase Lyn, stimulation of MAPK kinase and MAPK by G(q)-coupled mi muscarinic acetylcholine receptors (mAChR) is blocked, whereas G(i)-coupled m2 mAChR-mediated stimulation is unaffected. In cells deficient in the tyrosine kinase SyK, both m(1) and m2 mAChRs failed to stimulate MAPK kinase and MAPK. This result indicates that Syk is essential for the G(i)-coupled pathway and that Lyn and Syk are necessary for the G(q)-coupled pathway.	CORNELL UNIV,COLL MED,DEPT PHYSIOL,NEW YORK,NY 10021; WYETH AYERST RES,DEPT ONCOL & IMMUNOL,PEARL RIVER,NY 10965	Cornell University; Pfizer								ALESSANDRINI A, 1992, P NATL ACAD SCI USA, V89, P8200, DOI 10.1073/pnas.89.17.8200; BOULTON TG, 1990, SCIENCE, V249, P64, DOI 10.1126/science.2164259; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; COOK SJ, 1993, EMBO J, V12, P3475, DOI 10.1002/j.1460-2075.1993.tb06022.x; CRESPO P, 1994, NATURE, V369, P418, DOI 10.1038/369418a0; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; FAURE M, 1994, J BIOL CHEM, V269, P7851; HAWES BE, 1995, J BIOL CHEM, V270, P17148, DOI 10.1074/jbc.270.29.17148; HUANG XY, 1993, CELL, V75, P1145, DOI 10.1016/0092-8674(93)90324-J; KOCH WJ, 1994, P NATL ACAD SCI USA, V91, P12706, DOI 10.1073/pnas.91.26.12706; KUROSAKI T, 1995, J EXP MED, V182, P1815, DOI 10.1084/jem.182.6.1815; LANGHANSRAJASEKARAN SA, 1995, P NATL ACAD SCI USA, V92, P8601, DOI 10.1073/pnas.92.19.8601; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; MATSUDA S, 1992, EMBO J, V11, P973, DOI 10.1002/j.1460-2075.1992.tb05136.x; PERALTA EG, 1987, EMBO J, V6, P3923, DOI 10.1002/j.1460-2075.1987.tb02733.x; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; SEGER R, 1992, J BIOL CHEM, V267, P14373; SHIUE L, 1995, MOL CELL BIOL, V15, P272, DOI 10.1128/MCB.15.1.272; TAKATA M, 1995, FEBS LETT, V374, P407, DOI 10.1016/0014-5793(95)01160-G; TAKATA M, 1994, EMBO J, V13, P1341, DOI 10.1002/j.1460-2075.1994.tb06387.x; TANIGUCHI T, 1991, J BIOL CHEM, V266, P15790; VANBIESEN T, 1995, NATURE, V376, P781, DOI 10.1038/376781a0; VANCORVEN EJ, 1993, P NATL ACAD SCI USA, V90, P1257, DOI 10.1073/pnas.90.4.1257; WINITZ S, 1993, J BIOL CHEM, V268, P19196; ZHENG CF, 1993, J BIOL CHEM, V268, P11435	27	264	268	0	6	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	APR 11	1996	380	6574					541	544		10.1038/380541a0	http://dx.doi.org/10.1038/380541a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UE663	8606776				2022-12-28	WOS:A1996UE66300054
J	Dixon, MS; Jones, DA; Keddie, JS; Thomas, CM; Harrison, K; Jones, JDG				Dixon, MS; Jones, DA; Keddie, JS; Thomas, CM; Harrison, K; Jones, JDG			The tomato Cf-2 disease resistance locus comprises two functional genes encoding leucine-rich repeat proteins	CELL			English	Article							CLADOSPORIUM-FULVUM; CLONING; KINASE	In plants, resistance to pathogens is frequently determined by dominant resistance genes, whose products are proposed to recognize pathogen-encoded avirulence gene (Avr) products. The tomato resistance locus Cf-2 was isolated by positional cloning and found to contain two almost identical genes, each conferring resistance to isolates of tomato leaf mould (C. fulvum) expressing the corresponding Avr2 gene. The two Cf-2 genes encode protein products that differ from each other by only three amino acids and contain 38 leucine-rich repeat (LRR) motifs. Of the LRRs, 20 show extremely conserved alternating repeats. The C-terminus of Cf-2 carries regions of pronounced homology to the protein encoded by the unlinked Cf-9 gene. We suggest that this conserved region interacts with other proteins involved in activating plant defense mechanisms.	JOHN INNES CTR,SAINSBURY LAB,NORWICH NR4 7UH,NORFOLK,ENGLAND	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); John Innes Center			Jones, David A/C-9507-2009; Jones, Jonathan DG/J-5129-2012	Jones, David A/0000-0001-8809-5822; Jones, Jonathan DG/0000-0002-4953-261X				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ASHFIELD T, 1994, MOL PLANT MICROBE IN, V7, P645, DOI 10.1094/MPMI-7-0645; BENT AF, 1994, SCIENCE, V265, P1856, DOI 10.1126/science.8091210; BOWLING SA, 1994, PLANT CELL, V6, P1845, DOI 10.1105/tpc.6.12.1845; CARROLL BJ, 1995, GENETICS, V139, P407; CHANG C, 1992, PLANT CELL, V4, P1263, DOI 10.1105/tpc.4.10.1263; DICKINSON MJ, 1993, MOL PLANT MICROBE IN, V6, P341, DOI 10.1094/MPMI-6-341; DIETRICH RA, 1994, CELL, V77, P565, DOI 10.1016/0092-8674(94)90218-6; DIXON MS, 1995, MOL PLANT MICROBE IN, V8, P200, DOI 10.1094/MPMI-8-0200; ELLIS JG, 1995, P NATL ACAD SCI USA, V92, P4185, DOI 10.1073/pnas.92.10.4185; FILLATTI JJ, 1987, BIO-TECHNOL, V5, P726, DOI 10.1038/nbt0787-726; Flor H. H., 1946, JOUR AGRIC RES, V73, P335; GRANT MR, 1995, SCIENCE, V269, P843, DOI 10.1126/science.7638602; GREENBERG JT, 1994, CELL, V77, P551, DOI 10.1016/0092-8674(94)90217-8; HAMMONDKOSACK KE, 1994, PLANT CELL, V6, P361, DOI 10.2307/3869756; HAMMONDKOSACK KE, 1994, MOL PLANT MICROBE IN, V7, P58, DOI 10.1094/MPMI-7-0058; JOHAL GS, 1995, BIOESSAYS, V17, P685, DOI 10.1002/bies.950170805; JONES DA, 1993, MOL PLANT MICROBE IN, V6, P348, DOI 10.1094/MPMI-6-348; JONES DA, 1994, SCIENCE, V266, P789, DOI 10.1126/science.7973631; JONES JDG, 1994, CURR BIOL, V4, P749, DOI 10.1016/S0960-9822(00)00168-8; JOOSTEN MHAJ, 1994, NATURE, V367, P384, DOI 10.1038/367384a0; KOBE B, 1994, TRENDS BIOCHEM SCI, V19, P415, DOI 10.1016/0968-0004(94)90090-6; KOBE B, 1993, NATURE, V366, P751, DOI 10.1038/366751a0; LAMB CJ, 1994, CELL, V76, P419, DOI 10.1016/0092-8674(94)90106-6; LANGFORD AN, 1948, CAN J RES C, V26, P35, DOI 10.1139/cjr48c-006; LAWRENCE GJ, 1995, PLANT CELL, V7, P1195, DOI 10.1105/tpc.7.8.1195; LEVINE A, 1994, CELL, V79, P583, DOI 10.1016/0092-8674(94)90544-4; MARTIN GB, 1993, SCIENCE, V262, P1432, DOI 10.1126/science.7902614; MAY MJ, 1996, IN PRESS PLANT PHYSL; MINDRINOS M, 1994, CELL, V78, P1069; NASRALLAH JB, 1993, PLANT CELL, V5, P1325, DOI 10.2307/3869785; OLIVER RP, 1993, MOL PLANT MICROBE IN, V6, P521, DOI 10.1094/MPMI-6-521; SALMERON JM, 1994, PLANT CELL, V6, P511, DOI 10.1105/tpc.6.4.511; Sambrook J, 1989, MOL CLONING LABORATO; SCONFIEDL S, 1992, PLANT CELL, V4, P573; SONG WY, 1995, SCIENCE, V270, P1804, DOI 10.1126/science.270.5243.1804; STASKAWICZ BJ, 1995, SCIENCE, V268, P661, DOI 10.1126/science.7732374; Stevens MA, 1988, THE TOMATO CROP, P35; VANKAN JAL, 1991, MOL PLANT MICROBE IN, V4, P52, DOI 10.1094/MPMI-4-052; VERAESTRELLA R, 1992, PLANT PHYSIOL, V99, P1208, DOI 10.1104/pp.99.3.1208; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WALKER JC, 1994, PLANT MOL BIOL, V26, P1599, DOI 10.1007/BF00016492; WARD ER, 1991, PLANT CELL, V3, P1085, DOI 10.1105/tpc.3.10.1085; WHITHAM S, 1994, CELL, V78, P1101, DOI 10.1016/0092-8674(94)90283-6	44	449	505	2	34	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 9	1996	84	3					451	459		10.1016/S0092-8674(00)81290-8	http://dx.doi.org/10.1016/S0092-8674(00)81290-8			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	TV708	8608599	Bronze			2022-12-28	WOS:A1996TV70800014
J	Jernigan, DB; Cetron, MS; Breiman, RF				Jernigan, DB; Cetron, MS; Breiman, RF			Minimizing the impact of drug-resistant Streptococcus pneumoniae (DRSP) - A strategy from the DRSP Working Group	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DAY-CARE-CENTER; PENICILLIN-RESISTANT; MICRODILUTION SYSTEM; MENINGITIS; FAILURE; SUSCEPTIBILITY; PNEUMOCOCCI; MEDIA	Emergence of drug-resistant Streptococcus pneumoniae (DRSP) presents a challenge to the medical and public health communities since the magnitude of the problem is not known, the clinical impact of DRSP infections is not well described, national vaccination rates are low, and antimicrobial drugs are often used excessively and inappropriately. To address the problem of DRSP, a working group sponsored by Centers for Disease Control and Prevention was formed in June 1994 consisting of public health practitioners, health care providers, and clinical laboratorians representing state and federal agencies and various professional organizations. Through periodic open meetings, the working group has developed a strategy for surveillance, investigation, prevention, and control of infections due to DRSP, The strategy focuses on (1) implementing an electronic laboratory-based surveillance (ELBS) system for reporting invasive DRSP infections and providing clinically relevant feedback to clinicians, (2) identifying risk factors and outcomes of DRSP infection, (3) increasing pneumococcal vaccination, and (4) promoting judicious antimicrobial drug use. Data received through ELBS will be used to make timely estimates of the community-specific prevalence of drug-resistant pneumococci. National, regional, and local trends will be made available to health care providers and clinicians to promote optimal antimicrobial drug use and increased vaccination in targeted areas. Once in operation, the ELBS network will be adaptable to other diseases, improving the comprehensiveness and timeliness of public health surveillance. The intended outcome of the strategy is to reduce complications of DRSP infection, such as long-ten sequelae of infection, health care expenditures, morbidity, and mortality.	CTR DIS CONTROL & PREVENT,NATL CTR INFECT DIS,CHILDHOOD & RESP DIS BRANCH,ATLANTA,GA 30333	Centers for Disease Control & Prevention - USA								APPLEBAUM PC, 1992, CLIN INFECT DIS, V15, P77; BAQUERO F, 1991, J ANTIMICROB CHEMOTH, V28, P31, DOI 10.1093/jac/28.suppl_C.31; BLOCK SL, 1995, PEDIATR INFECT DIS J, V14, P751, DOI 10.1097/00006454-199509000-00005; BRADLEY JS, 1991, PEDIATR INFECT DIS J, V10, P871; BREIMAN RF, 1994, JAMA-J AM MED ASSOC, V271, P1831, DOI 10.1001/jama.271.23.1831; CAPUTO GM, 1993, ARCH INTERN MED, V153, P1301, DOI 10.1001/archinte.153.11.1301; CARROLL K, 1991, J CLIN MICROBIOL, V29, P2651, DOI 10.1128/JCM.29.11.2651-2652.1991; CHANDY CJ, 1994, CLIN INFECT DIS, V18, P188; DUCHIN JS, 1995, PEDIATR INFECT DIS J, V14, P745, DOI 10.1097/00006454-199509000-00004; FEDSON DS, 1994, VACCINES, P543; GARRETT L, 1994, COMING PLAGUE, P411; HOFMANN J, 1995, NEW ENGL J MED, V333, P481, DOI 10.1056/NEJM199508243330803; JACOBS MR, 1978, NEW ENGL J MED, V299, P735, DOI 10.1056/NEJM197810052991402; JERNIGAN DB, 1995, 35TH INT C ANT AG CH; JORGENSEN JH, 1994, J CLIN MICROBIOL, V32, P2448, DOI 10.1128/JCM.32.10.2448-2459.1994; MCCAIG LF, 1995, JAMA-J AM MED ASSOC, V273, P214, DOI 10.1001/jama.273.3.214; MCGOWAN JE, 1983, REV INFECT DIS, V5, P1033; PALLARES R, 1995, NEW ENGL J MED, V333, P474, DOI 10.1056/NEJM199508243330802; RADETSKY MS, 1981, LANCET, V2, P771; REICHLER MR, 1992, J INFECT DIS, V166, P1346, DOI 10.1093/infdis/166.6.1346; SHANHOLTZER CJ, 1986, AM J CLIN PATHOL, V85, P626, DOI 10.1093/ajcp/85.5.626; Shlaes D, 1991, ASM NEWS, V57, P455; SLOAS MM, 1992, PEDIATR INFECT DIS J, V11, P662; STOOL SE, 1989, PEDIATR INFECT DIS J, V8, pS11; Tilghman RC, 1937, ARCH INTERN MED, V59, P602, DOI 10.1001/archinte.1937.00170200044004; 1995, MMWR-MORBID MORTAL W, V44, P513; 1995, MMWR-MORBID MORTAL W, V44, P506; 1994, MMWR-MORBID MORTAL W, V43, P216; 1995, MMWR-MORBID MORTAL W, V44, P737; 1994, PERFORMANCE STAND S5; 1992, EMERGING INFECTIONS, P92; 1994, PERFORMANCE STANDARD, P14; 1990, DHHS PHS9150213 PUBL; 1994, TIME            0912, V144, P62; 1994, MMWR-MORBID MORTAL W, V43, P23; 1994, MMWR-MORBID MORTAL W, V43, P223	36	156	158	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 17	1996	275	3					206	209		10.1001/jama.275.3.206	http://dx.doi.org/10.1001/jama.275.3.206			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TP282	8604173				2022-12-28	WOS:A1996TP28200028
J	Schulman, KA; Rubenstein, LE; Abernethy, DR; Seils, DM; Sulmasy, DP				Schulman, KA; Rubenstein, LE; Abernethy, DR; Seils, DM; Sulmasy, DP			The effect of pharmaceutical benefits managers: Is it being evaluated?	ANNALS OF INTERNAL MEDICINE			English	Article							DRUG COSTS; FORMULARY	Over the last decade, the number of pharmaceutical benefits managers has increased, and their influence has expanded rapidly. These managers now provide prescription drug coverage to more than 100 million Americans. The effect of pharmaceutical benefits managers on health care delivery remains unclear. We review the development of these organizations, their current role in the delivery of pharmaceutical therapies to patients, and their relationship with pharmaceutical manufacturers. We discuss potential advantages and disadvantages of pharmaceutical benefits manager practices and suggest ways in which these organizations can be made more accountable to the employer groups that hire them.	GEORGETOWN UNIV, MED CTR, DIV CLIN PHARMACOL, WASHINGTON, DC 20007 USA; GEORGETOWN UNIV, MED CTR, CTR CLIN BIOETH, WASHINGTON, DC 20007 USA	Georgetown University; Georgetown University	Schulman, KA (corresponding author), GEORGETOWN UNIV, MED CTR,CLIN ECON RES UNIT,2233 WISCONSIN AVE,NW, SUITE 440, WASHINGTON, DC 20007 USA.			Seils, Damon/0000-0001-8257-745X				ABRAHAMS P, 1994, FINANCIAL TIMES 0612, P25; ALPER PR, 1993, WALL STREET J   1117, pA22; BEROD T, 1990, AM J HOSP PHARM, V47, P1751, DOI 10.1093/ajhp/47.8.1751a; BLACK L, 1994, INDEPENDENT     0505, P3; BLOOM BS, 1985, MED CARE, V23, P872, DOI 10.1097/00005650-198507000-00004; BLOOM BS, 1986, JAMA-J AM MED ASSOC, V256, P2523, DOI 10.1001/jama.256.18.2523; BOOTMAN JL, 1995, TOTAL DISEASE MANAGE, P79; BROWN JG, 1994, HOUSE SUBCOMM REG BU; BURTON T, 1994, WALL STREET J   0712, pA3; COHEN MB, 1990, ANN INTERN MED, V113, P160; COTTERELL CC, 1991, AM J HOSP PHARM, V48, P1712, DOI 10.1093/ajhp/48.8.1712; COUNSELL G, 1994, INDEPENDENT     0508, P3; CROMWELL DM, 1995, 1 ANN NAT RES SERV A; ETHEREDGE L, 1995, RES AGENDA BRIEF; FERRANDO C, 1987, DRUG INTEL CLIN PHAR, V21, P653, DOI 10.1177/1060028087021007-819; FLANIGAN J, 1994, LOS ANGELES TIM 0525, pBUS1; FREUDENHEIM M, 1994, NY TIMES        1010, pC3; FREUDENHEIM M, 1995, NY TIMES        0411, pD1; FREUDENHEIM M, 1994, NY TIMES        1104, pD1; FREUDENHEIM M, 1994, NY TIMES        0906, pA1; Freudenheim Milt, 1994, NEW YORK TIMES  0412, pD2; GIBALDI M, 1995, PHARMACOTHERAPY, V15, P265; GIBSON PG, 1995, ANN INTERN MED, V123, P488, DOI 10.7326/0003-4819-123-7-199510010-00002; GLICKMAN L, 1994, J AM GERIATR SOC, V42, P992, DOI 10.1111/j.1532-5415.1994.tb06594.x; GRASELA TH, 1994, PHARMACOEPIDEM DR S, P413; GREEN JA, 1985, AM J HOSP PHARM, V42, P1537, DOI 10.1093/ajhp/42.7.1537; GURWITZ JH, 1994, JAMA-J AM MED ASSOC, V272, P316, DOI 10.1001/jama.272.4.316; HILZENRATH D, 1994, WASHINGTON POST 1027, pB11; HILZENRATH D, 1994, WASHINGTON POST 0504, pD1; HILZENRATH DS, 1994, WASH POST       0712, pA1; KAPLAN MS, 1995, J ASTHMA, V32, P321, DOI 10.3109/02770909509082756; KESSLER DA, 1994, NEW ENGL J MED, V331, P1350, DOI 10.1056/NEJM199411173312007; KOLATA G, 1994, NY TIMES        0808, pD1; KRALEWSKI J, 1994, HEALTH CARE MANAGE R, V19, P62; KRELING DH, 1989, MED CARE, V27, P34, DOI 10.1097/00005650-198901000-00004; LEXCHIN J, 1992, INT J HEALTH SERV, V22, P471, DOI 10.2190/94N5-P2ML-CVP7-5WAG; *MERCK CO, 1994, ANN REP PURS SECT 13; MILLER LG, 1993, J FAM PRACTICE, V36, P33; MORGAN DJR, 1991, POSTGRAD MED J, V67, P165, DOI 10.1136/pgmj.67.784.165; MUIRHEAD G, 1995, DRUG TOPICS, V139, P40; OBRIEN KP, 1995, J ASTHMA, V32, P325, DOI 10.3109/02770909509082757; PEARCE MJ, 1994, NEW ZEAL MED J, V107, P101; ROSSDEGNAN D, 1993, JAMA-J AM MED ASSOC, V270, P1937, DOI 10.1001/jama.270.16.1937; SCHACHNER M, 1993, BUSINESS INSURANCE, V27, P11; SHALANSKY SJ, 1991, AM J HOSP PHARM, V48, P2655, DOI 10.1093/ajhp/48.12.2655; SLOAN FA, 1993, MED CARE, V31, P851, DOI 10.1097/00005650-199310000-00001; SMALLEY WE, 1995, NEW ENGL J MED, V332, P1612, DOI 10.1056/NEJM199506153322406; SOUMERAI SB, 1993, MILBANK Q, V71, P217, DOI 10.2307/3350399; SOUMERAI SB, 1994, NEW ENGL J MED, V331, P650, DOI 10.1056/NEJM199409083311006; SOUMERAI SB, 1995, NEW ENGL J MED, V332, P1641, DOI 10.1056/NEJM199506153322411; TUMULTY PA, 1973, EFFECTIVE CLINICIAN, P111; *US FED TRADE COMM, 1994, 9410102 US FED TRADE; WALTERS R, 1994, FINANCIAL TIMES 0511, P32; WILLCOX SM, 1994, JAMA-J AM MED ASSOC, V272, P292, DOI 10.1001/jama.272.4.292; 1994, CHICAGO TRIBUNE 0618, pS6; 1994, ATLANTA J CONST 0712, P13; 1995, NY TIMES        0201, pD3; 1995, WALL STREET J   0201, pB1; 1995, HEHS9645 US GEN ACC	59	35	35	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 15	1996	124	10					906	913		10.7326/0003-4819-124-10-199605150-00008	http://dx.doi.org/10.7326/0003-4819-124-10-199605150-00008			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UJ801	8610921				2022-12-28	WOS:A1996UJ80100008
J	Foulkes, NS; Duval, G; SassoneCorsi, P				Foulkes, NS; Duval, G; SassoneCorsi, P			Adaptive inducibility of CREM as transcriptional memory of circadian rhythms	NATURE			English	Article							PINEAL N-ACETYLTRANSFERASE; BETA-ADRENERGIC-RECEPTOR; GLAND; SPERMATOGENESIS; EXPRESSION; REPRESSOR; DIRECTS; SWITCH	THE CREM gene(1-4) encodes the transcriptional repressor ICER(3,5), which has been implicated in the molecular mechanisms controlling circadian rhythms in mammals(4-6). ICER is rhythmically expressed in the pineal gland, with peak levels occurring at night(5). ICER levels are regulated by light by means of the suprachiasmatic nucleus (SCN); transcription is induced during darkness by adrenergic input to the pineal gland from the SCN, which activates the ICER promoter using cyclic AMP and the transcriptional activator CREB. This induction is transient because ICER represses its own transcription(3), Here we show that the response of the CREM gene to adrenergic stimulation is determined by night length, Depending on the photoperiod of the prior entraining cycles, the CREM gene is either subsensitive or supersensitive to induction. This differential responsiveness is controlled by the changing balance between positive (CREB) and negative (ICER) transcriptional regulators. Thus, the transcriptional response of the CREM gene is determined by the memory of past photoperiods.	INST GENET & BIOL MOL & CELLULAIRE,F-67404 ILLKIRCH GRAFFENS,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm)			Jansen, Heiko T./A-5770-2008; Foulkes, Nicholas S/K-7003-2013	Jansen, Heiko T./0000-0003-0178-396X; Foulkes, Nicholas S/0000-0002-1794-9891				ARMSTRONG A, 1995, MOL CELL BIOL, V15, P1826; AXELROD J, 1974, SCIENCE, V184, P1341, DOI 10.1126/science.184.4144.1341; BORJIGIN J, 1995, NATURE, V378, P783, DOI 10.1038/378783a0; BOURTCHULADZE R, 1994, CELL, V79, P59, DOI 10.1016/0092-8674(94)90400-6; COON SL, 1995, SCIENCE, V270, P1681, DOI 10.1126/science.270.5242.1681; DEGUCHI T, 1972, P NATL ACAD SCI USA, V69, P2208, DOI 10.1073/pnas.69.8.2208; DEGUCHI T, 1973, P NATL ACAD SCI USA, V70, P2411, DOI 10.1073/pnas.70.8.2411; FOULKES NS, 1992, NATURE, V355, P80, DOI 10.1038/355080a0; FOULKES NS, 1991, CELL, V64, P739, DOI 10.1016/0092-8674(91)90503-Q; FOULKES NS, 1993, NATURE, V362, P264, DOI 10.1038/362264a0; GINTY DD, 1993, SCIENCE, V260, P238, DOI 10.1126/science.8097062; HUANG YY, 1994, CELL, V79, P69, DOI 10.1016/0092-8674(94)90401-4; ILLNEROVA H, 1985, J PINEAL RES, V2, P67, DOI 10.1111/j.1600-079X.1985.tb00628.x; ILLNEROVA H, 1988, PINEAL RES REV, V6, P173; ILNEROVA H, 1986, CIRCADIAN RHYTHMS MA, P1; LALLI E, 1995, P NATL ACAD SCI USA, V92, P9633, DOI 10.1073/pnas.92.21.9633; MOLINA CA, 1993, CELL, V75, P875, DOI 10.1016/0092-8674(93)90532-U; MONACO L, 1995, P NATL ACAD SCI USA, V92, P10673, DOI 10.1073/pnas.92.23.10673; REITER RJ, 1991, ENDOCR REV, V12, P151, DOI 10.1210/edrv-12-2-151; ROMERO JA, 1975, P NATL ACAD SCI USA, V72, P2107, DOI 10.1073/pnas.72.6.2107; ROMERO JA, 1974, SCIENCE, V184, P1091, DOI 10.1126/science.184.4141.1091; ROMERO JA, 1975, P NATL ACAD SCI USA, V72, P1661, DOI 10.1073/pnas.72.5.1661; SASSONECORSI P, 1994, CELL, V78, P361, DOI 10.1016/0092-8674(94)90415-4; SASSONECORSI PA, 1995, REV CELL DEV BIOL, V11, P355; STEHLE JH, 1993, NATURE, V365, P314, DOI 10.1038/365314a0; STEHLE JH, 1995, MOL ENDOCRINOL, V9, P706, DOI 10.1210/me.9.6.706; SUGDEN D, 1985, NATURE, V314, P359, DOI 10.1038/314359a0; SUMIOVA A, 1995, P NATL ACAD SCI USA, V92, P7754; TAKAHASHI JS, 1994, CURR BIOL, V4, P165, DOI 10.1016/S0960-9822(94)00040-0; YIN JCP, 1994, CELL, V79, P49, DOI 10.1016/0092-8674(94)90399-9	30	85	85	0	3	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAY 2	1996	381	6577					83	85		10.1038/381083a0	http://dx.doi.org/10.1038/381083a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UJ053	8609995				2022-12-28	WOS:A1996UJ05300062
J	Miyazaki, T; Dierich, A; Benoist, C; Mathis, D				Miyazaki, T; Dierich, A; Benoist, C; Mathis, D			Independent modes of natural killing distinguished in mice lacking Lag3	SCIENCE			English	Article							BONE-MARROW ALLOGRAFTS; KILLER-CELLS; T-CELLS; ANTIGEN RECOGNITION; GENE-COMPLEX; MOUSE NKR-P1; NK CLONES; EXPRESSION; SPECIFICITY; LY-49	The LAG3 protein has several features in common with CD4, suggesting that it may be important in controlling T cell reactivity. However, mice with a Lag3 null mutation have now been shown to exhibit a defect in the natural killer cell, rather than the T cell, compartment. Killing of certain tumor targets by natural killer cells from these mice was inhibited or even abolished, whereas lysis of cells displaying major histocompatibility complex class I disparities remained intact. It appears that LAG3 is a receptor or coreceptor that defines different modes of natural killing.	CU STRASBOURG,STRASBOURG,FRANCE	UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Miyazaki, T (corresponding author), ULP,CNRS,INSERM,INST GENET & BIOL MOL & CELLULAIRE,1 RUE LAURENT FRIES,F-67404 ILLKIRCH GRAFFENS,FRANCE.							BAIXERAS E, 1992, J EXP MED, V176, P327, DOI 10.1084/jem.176.2.327; BEZOUSKA K, 1994, NATURE, V372, P150, DOI 10.1038/372150a0; BYRNE BC, 1988, NUCLEIC ACIDS RES, V16, P4165, DOI 10.1093/nar/16.19.9342; CELLA M, 1994, J EXP MED, V180, P1235, DOI 10.1084/jem.180.4.1235; CEREDIG R, 1985, NATURE, V314, P98, DOI 10.1038/314098a0; CICCONE E, 1992, J EXP MED, V175, P709, DOI 10.1084/jem.175.3.709; CICCONE E, 1992, J EXP MED, V176, P963, DOI 10.1084/jem.176.4.963; COLONNA M, 1993, SCIENCE, V260, P1121, DOI 10.1126/science.8493555; DENNERT G, 1988, J IMMUNOL, V140, P2472; GIORDA R, 1991, J IMMUNOL, V147, P1701; HOGLUND P, 1991, P NATL ACAD SCI USA, V88, P10332, DOI 10.1073/pnas.88.22.10332; KARLHOFER FM, 1995, J EXP MED, V181, P1785, DOI 10.1084/jem.181.5.1785; KARLHOFER FM, 1992, NATURE, V358, P66, DOI 10.1038/358066a0; Karre K, 1993, Semin Immunol, V5, P127, DOI 10.1006/smim.1993.1016; Karre K, 1985, MECHANISMS CYTOTOXIC, P81; KILLEEN N, 1993, EMBO J, V12, P1547, DOI 10.1002/j.1460-2075.1993.tb05798.x; KOLLER BH, 1990, SCIENCE, V248, P1227, DOI 10.1126/science.2112266; LIAO NS, 1991, SCIENCE, V253, P199, DOI 10.1126/science.1853205; LITWIN V, 1993, J EXP MED, V178, P1321, DOI 10.1084/jem.178.4.1321; LJUNGGREN HG, 1994, P NATL ACAD SCI USA, V91, P6520, DOI 10.1073/pnas.91.14.6520; LJUNGGREN HG, 1990, IMMUNOL TODAY, V11, P7; LOCKSLEY RM, 1993, SCIENCE, V261, P1448, DOI 10.1126/science.8367726; MIYAZAKI T, IN PRESS INT IMMUNOL; Miyazaki T., UNPUB; MORETTA A, 1994, J EXP MED, V180, P545, DOI 10.1084/jem.180.2.545; MURPHY WJ, 1987, J EXP MED, V166, P1499, DOI 10.1084/jem.166.5.1499; PIONTEK GE, 1985, J IMMUNOL, V135, P4281; RAULET DH, 1995, CELL, V82, P697, DOI 10.1016/0092-8674(95)90466-2; RYAN JC, 1995, J EXP MED, V181, P1911, DOI 10.1084/jem.181.5.1911; SARMIENTO M, 1980, J IMMUNOL, V125, P2665; SENTMAN CL, 1994, J IMMUNOL, V153, P5482; SENTMAN CL, 1989, J IMMUNOL, V142, P1847; STONEMAN ER, 1995, J EXP MED, V182, P305, DOI 10.1084/jem.182.2.305; SYMINGTON FW, 1981, IMMUNOGENETICS, V14, P53, DOI 10.1007/BF00344299; TRIEBEL F, 1990, J EXP MED, V171, P1393, DOI 10.1084/jem.171.5.1393; TRIEBEL F, 1995, EUR J IMMUNOL, V25, P2718; TRINCHIERI G, 1994, J EXP MED, V180, P417, DOI 10.1084/jem.180.2.417; YOKOYAMA WM, 1990, J IMMUNOL, V145, P2353; YOKOYAMA WM, 1995, P NATL ACAD SCI USA, V92, P3081, DOI 10.1073/pnas.92.8.3081; YOKOYAMA WM, 1995, CURR OPIN IMMUNOL, V7, P110, DOI 10.1016/0952-7915(95)80036-0; YOKOYAMA WM, 1991, J IMMUNOL, V147, P3229; YOKOYAMA WM, 1993, ANNU REV IMMUNOL, V11, P613, DOI 10.1146/annurev.iy.11.040193.003145; YU YYL, 1992, ANNU REV IMMUNOL, V10, P189, DOI 10.1146/annurev.iy.10.040192.001201; ZAJAC AJ, 1995, INT IMMUNOL, V7, P1545, DOI 10.1093/intimm/7.10.1545; ZIEGLER SF, 1994, J IMMUNOL, V152, P1228	45	121	130	0	14	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	APR 19	1996	272	5260					405	408		10.1126/science.272.5260.405	http://dx.doi.org/10.1126/science.272.5260.405			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UG252	8602528				2022-12-28	WOS:A1996UG25200045
J	Heierhorst, J; Kobe, B; Feil, SC; Parker, MW; Benian, GM; Weiss, KR; Kemp, BE				Heierhorst, J; Kobe, B; Feil, SC; Parker, MW; Benian, GM; Weiss, KR; Kemp, BE			Ca2+/S100 regulation of giant protein kinases	NATURE			English	Article							CALCIUM-BINDING; PEPTIDE COMPLEX; CALMODULIN; ELEGANS	Protein phosphorylation by protein kinases plays a central regulatory role in cellular processes and these kinases are themselves tightly regulated(1). One common mechanism of regulation involves Ca2+-binding proteins (CaBP) such as calmodulin (CaM)(2). Here we report a Ca2+-effector mechanism for protein kinase activation by demonstrating the specific and >1,000-fold activation of the myosin-associated giant protein kinase twitchin by Ca2+/S100A1(2). S100A1(2) is a member of a large CaBP family that is implicated in various cellular processes, including cell growth, differentiation and motility, but whose molecular actions are largely unknown(3). The S100A1(2)-binding site is a part of the autoregulatory sequence positioned in the active site that is responsible for intrasteric autoinhibition of twitchin kinase; the mechanism of autoinhibition based on the crystal structures of two twitchin kinase fragments is described elsewhere(4). Ca2+/S100 represents a likely physiological activator for the entire family of giant protein kinases involved in muscle contractions and cytoskeletal structure(2,5-9).	ST VINCENTS INST MED RES,FITZROY,VIC 3065,AUSTRALIA; CUNY MT SINAI SCH MED,DEPT PHYSIOL & BIOPHYS,NEW YORK,NY 10029; EMORY UNIV,DEPT PATHOL,ATLANTA,GA 30322	St. Vincent's Institute of Medical Research; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; Emory University			Kobe, Bostjan/D-1292-2009; Parker, Michael W/F-9069-2013; Kemp, Bruce E/L-2633-2014; Kemp, Bruce/G-9602-2019	Kobe, Bostjan/0000-0001-9413-9166; Parker, Michael W/0000-0002-3101-1138; Kemp, Bruce E/0000-0001-6735-5082; Kemp, Bruce/0000-0001-6735-5082				AYMESOUTHGATE A, 1995, J CELL BIOL, V128, P393, DOI 10.1083/jcb.128.3.393; BABU YS, 1985, NATURE, V315, P37, DOI 10.1038/315037a0; BAUDIER J, 1986, J BIOL CHEM, V261, P8192; BENIAN GM, 1989, NATURE, V342, P45, DOI 10.1038/342045a0; ESCOBAR AL, 1994, NATURE, V367, P739, DOI 10.1038/367739a0; GAUTEL M, 1995, EUR J BIOCHEM, V230, P752; HEIERHORST J, 1994, J BIOL CHEM, V269, P21086; HEIERHORST J, 1995, EUR J BIOCHEM, V233, P426, DOI 10.1111/j.1432-1033.1995.426_2.x; HU SH, 1994, NATURE, V369, P581, DOI 10.1038/369581a0; IKURA M, 1992, SCIENCE, V256, P632, DOI 10.1126/science.1585175; KATO K, 1986, J NEUROCHEM, V46, P15555; KEMP BE, 1994, PROTEIN KINASES, P30; KOBE B, UNPUB NATURE STRUCTB; LABEIT S, 1995, SCIENCE, V270, P293, DOI 10.1126/science.270.5234.293; LAWRENCE MC, 1993, J MOL BIOL, V234, P946, DOI 10.1006/jmbi.1993.1648; LEI JY, 1994, J BIOL CHEM, V269, P21078; MEADOR WE, 1992, SCIENCE, V257, P1251, DOI 10.1126/science.1519061; MEADOR WE, 1993, SCIENCE, V262, P17185; MOERMAN DG, 1988, GENE DEV, V2, P93, DOI 10.1101/gad.2.1.93; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; POTTS BCM, 1995, NAT STRUCT BIOL, V2, P790, DOI 10.1038/nsb0995-790; PROBST WC, 1994, P NATL ACAD SCI USA, V91, P8487, DOI 10.1073/pnas.91.18.8487; SCHAFER BW, 1995, GENOMICS, V25, P638, DOI 10.1016/0888-7543(95)80005-7; STRYNADKA NCJ, 1989, ANNU REV BIOCHEM, V58, P951, DOI 10.1146/annurev.bi.58.070189.004511; TAYLOR SS, 1994, PROTEIN KINASES, P1; ZIMMER DB, 1995, BRAIN RES BULL, V37, P417, DOI 10.1016/0361-9230(95)00040-2	26	119	121	0	8	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	APR 18	1996	380	6575					636	639		10.1038/380636a0	http://dx.doi.org/10.1038/380636a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UF741	8602266				2022-12-28	WOS:A1996UF74100049
J	Coid, JW				Coid, JW			Dangerous patients with mental illness: Increased risks warrant new policies, adequate resources, and appropriate legislation	BRITISH MEDICAL JOURNAL			English	Article							DISORDER; BEHAVIOR; SCHIZOPHRENIA; VIOLENT; CRIME				Coid, JW (corresponding author), UNIV LONDON ST BARTHOLOMEWS HOSP & MED COLL,LONDON EC1A 7BE,ENGLAND.							BLOMCOOPER L, 1995, FALLING SHADOW ONE P; BUCHANAN A, 1993, PSYCHOL MED, V23, P123, DOI 10.1017/S0033291700038915; COID J, 1983, PSYCHOL MED, V13, P855, DOI 10.1017/S0033291700051576; *CONF ENQ HOM SUIC, 1994, PREL REP HOM; CRICHTON J, 1995, PSYCHIAT PATIENT VIO, P9; Department of Health, 1993, LEG POW CAR MENT ILL; Department of Health, 1994, GUID DISCH MENT DIS; Dolan Bridget, 1993, PSYCHOPATHIC ANTISOC; DROSKIN JA, 1994, HOSP COMMUNITY PSYCH, V45, P679; EASTMAN N, 1995, BRIT MED J, V310, P1081, DOI 10.1136/bmj.310.6987.1081; *HLTH SERV ADV COM, 1987, VIOL STAFF HLTH SERV; HODGINS S, 1992, ARCH GEN PSYCHIAT, V49, P476, DOI 10.1001/archpsyc.1992.01820060056009; HUMPHREYS MS, 1992, BRIT J PSYCHIAT, V161, P501, DOI 10.1192/bjp.161.4.501; LAGOS JM, 1977, AM J PSYCHIAT, V134, P1134; LINDQVIST P, 1990, BRIT J PSYCHIAT, V157, P345, DOI 10.1192/bjp.157.3.345; LINK BG, 1995, EPIDEMIOL REV, V17, P172, DOI 10.1093/oxfordjournals.epirev.a036173; LINK BG, 1992, AM SOCIOL REV, V57, P275, DOI 10.2307/2096235; MODESTIN J, 1995, BRIT J PSYCHIAT, V166, P667, DOI 10.1192/bjp.166.5.667; MONAHAN J, 1992, AM PSYCHOL, V47, P511, DOI 10.1037/0003-066X.47.4.511; MULVEY EP, 1994, HOSP COMMUNITY PSYCH, V45, P663; RABKIN JG, 1979, PSYCHOL BULL, V86, P1, DOI 10.1037/0033-2909.86.1.1; RITCHIE JH, 1994, REPORT ENQUIRY CARE; *ROYAL COLL PSYCH, 1993, COMM SUP ORD; SWANSON JW, 1990, HOSP COMMUNITY PSYCH, V41, P761; Taylor PJ, 1993, FORENSIC PSYCHIAT CL, P329; *UK HL, 1995, MENT HLTH PAT COMM; WESSELY S, 1993, VIOLENCE, P119; WESSELY S, 1994, PSYCHOL MED, V24, P483, DOI 10.1017/S0033291700027458; WESSELY S, 1991, CRIMINAL BEHAVIOUR M, V1, P193; WOODLEY L, 1995, WOODLEY TEAM REPORT	30	37	38	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 13	1996	312	7036					965	966						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	UF659	8616316				2022-12-28	WOS:A1996UF65900028
J	Smith, CB; Betz, WJ				Smith, CB; Betz, WJ			Simultaneous independent measurement of endocytosis and exocytosis	NATURE			English	Article							BOVINE CHROMAFFIN CELLS; CAPACITANCE MEASUREMENTS; SECRETION	STUDIES of membrane traffic between the cytoplasm and surface of a cell suggest that membrane internalization is tightly coupled to secretion. Studies using the capacitance technique show that endocytosis can follow evoked exocytosis within a second or less(1-3). The capacitance technique, however, measures only the net change in cell surface area, and thus separating exocytosis from endocytosis requires that the two events do not overlap in time. This condition is probably met with small, brief stimuli(1-5), but during prolonged stimulation it is more likely that exocytosis and endocytosis occur simultaneously(6). We used FM1-43 fluorescence, which provides a cumulative measure of exocytosis, independent of endocytosis, in combination with capacitance monitoring to track unidirectional movements of membrane simultaneously and in real time in bovine adrenal chromaffin cells. We confirm that, with relatively small stimuli, exocytosis ceases before endocytosis begins (no overlap). In contrast, during prolonged stimulation, the onset of endocytosis is delayed by 2-3 min, but then the rate of endocytosis quickly grows to equal that of exocytosis. The delayed onset of endocytosis may be an emergency defence against catastrophic cell swelling.	UNIV COLORADO,SCH MED,DEPT PHYSIOL,DENVER,CO 80262; UNIV COLORADO,SCH MED,PROGRAM NEUROSCI,DENVER,CO 80262	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver								Artalejo CR, 1996, NEURON, V16, P195, DOI 10.1016/S0896-6273(00)80036-7; ARTALEJO CR, 1995, P NATL ACAD SCI USA, V92, P8328, DOI 10.1073/pnas.92.18.8328; AUGUSTINE GJ, 1992, J PHYSIOL-LONDON, V450, P247, DOI 10.1113/jphysiol.1992.sp019126; BETZ WJ, 1994, J CELL BIOL, V124, P843, DOI 10.1083/jcb.124.5.843; BETZ WJ, 1992, SCIENCE, V255, P200, DOI 10.1126/science.1553547; BETZ WJ, 1992, J NEUROSCI, V12, P363, DOI 10.1523/jneurosci.12-02-00363.1992; BURGOYNE RD, 1995, PFLUG ARCH EUR J PHY, V430, P213, DOI 10.1007/BF00374652; DETOLEDO GA, 1993, NATURE, V363, P554, DOI 10.1038/363554a0; FIDLER N, 1989, BIOPHYS J, V56, P1153, DOI 10.1016/S0006-3495(89)82762-6; GREER MA, 1992, HORMONE METAB RES, V24; GRINVALD A, 1982, BIOPHYS J, V39, P301, DOI 10.1016/S0006-3495(82)84520-7; GRINVALD A, 1988, PHYSIOL REV, V68, P1285, DOI 10.1152/physrev.1988.68.4.1285; HARTMANN J, 1995, J PHYSIOL-LONDON, V483, P201, DOI 10.1113/jphysiol.1995.sp020578; HEIDELBERGER R, 1994, NATURE, V371, P513, DOI 10.1038/371513a0; HENKEL AW, IN PRESS P NATL ACAD; Hoffmann EK, 1995, INT REV CYTOL, V161, P173; HORRIGAN FT, 1994, NEURON, V13, P1119, DOI 10.1016/0896-6273(94)90050-7; JOSHI C, 1988, BIOPHYS J, V53, P885, DOI 10.1016/S0006-3495(88)83169-2; KRASZEWSKI K, 1995, NEUROSCIENCE, V15, P4328; MOLLARD P, 1995, P NATL ACAD SCI USA, V92, P3065, DOI 10.1073/pnas.92.7.3065; NEHER E, 1993, NEURON, V10, P21, DOI 10.1016/0896-6273(93)90238-M; NEHER E, 1988, J PHYSIOL-LONDON, V395, P193, DOI 10.1113/jphysiol.1988.sp016914; NEHER E, 1982, P NATL ACAD SCI-BIOL, V79, P6712, DOI 10.1073/pnas.79.21.6712; OBERHAUSER AF, 1995, BIOPHYS J, V69, P451, DOI 10.1016/S0006-3495(95)79918-0; PARSONS TD, 1994, NEURON, V13, P875, DOI 10.1016/0896-6273(94)90253-4; RIEKE F, 1994, NEURON, V13, P863, DOI 10.1016/0896-6273(94)90252-6; RYAN TA, 1995, NEURON, V14, P983, DOI 10.1016/0896-6273(95)90336-4; RYAN TA, 1993, NEURON, V11, P713, DOI 10.1016/0896-6273(93)90081-2; THOMAS P, 1994, J CELL BIOL, V124, P667, DOI 10.1083/jcb.124.5.667; VONGERSDORFF H, 1994, NATURE, V367, P735, DOI 10.1038/367735a0	30	202	204	2	10	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	APR 11	1996	380	6574					531	534		10.1038/380531a0	http://dx.doi.org/10.1038/380531a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UE663	8606773				2022-12-28	WOS:A1996UE66300051
J	Pisacane, A; Impagliazzo, N; DeCaprio, C; Criscuolo, L; Inglese, A; daSilva, MCMP				Pisacane, A; Impagliazzo, N; DeCaprio, C; Criscuolo, L; Inglese, A; daSilva, MCMP			Breast feeding and tonsillectomy	BRITISH MEDICAL JOURNAL			English	Article											Pisacane, A (corresponding author), UNIV NAPLES,DEPT PAEDIAT,I-80131 NAPLES,ITALY.							BISSET AF, 1994, BRIT MED J, V308, P1129, DOI 10.1136/bmj.308.6937.1129; BRODSKY L, 1989, PEDIATR CLIN N AM, V36, P1551; BURR ML, 1993, ARCH DIS CHILD, V68, P724, DOI 10.1136/adc.68.6.724; MAW AR, 1986, ARCH DIS CHILD, V61, P421, DOI 10.1136/adc.61.5.421; PISACANE A, 1995, BRIT MED J, V310, P836, DOI 10.1136/bmj.310.6983.836	5	11	11	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 23	1996	312	7033					746	747						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UC166	8605462	Green Published			2022-12-28	WOS:A1996UC16600028
J	Patel, V				Patel, V			Recognition of common mental disorders in primary care in African countries: Should ''mental'' be dropped?	LANCET			English	Article							HEALTH		INST PSYCHIAT,SECT EPIDEMIOL & GEN PRACTICE,LONDON SE5,ENGLAND									Chaturvedi Santosh K., 1993, International Review of Psychiatry, V5, P179, DOI 10.3109/09540269309028309; *CIT HAR HLTH DEP, 1994, 1993 HAR HLTH DEP; Goldberg DP., 1992, COMMON MENTAL DISORD; GUARNACCIA PJ, 1990, AM J PSYCHIAT, V147, P1449; HARDING TW, 1980, PSYCHOL MED, V10, P231, DOI 10.1017/S0033291700043993; LEWIS G, 1992, PSYCHOL MED, V22, P1011, DOI 10.1017/S0033291700038575; LITTLEWOOD R, 1990, BRIT J PSYCHIAT, V156, P308, DOI 10.1192/bjp.156.3.308; Mumford David B., 1993, International Review of Psychiatry, V5, P231, DOI 10.3109/09540269309028313; PARRY C, IN PRESS TRANSCULT P; PATEL V, 1995, PSYCHOL MED, V25, P1191, DOI 10.1017/S003329170003316X; PATEL V, 1995, ACTA PSYCHIAT SCAND, V92, P103, DOI 10.1111/j.1600-0447.1995.tb09551.x; PATEL V, 1995, PSYCHOL MED, V25, P485, DOI 10.1017/S0033291700033407; Patel V., 1995, Central African Journal of Medicine, V41, P209; PATEL V, 1995, SOC SCI MED, V40, P1291, DOI 10.1016/0277-9536(94)00231-H; PATEL V, IN PRESS SOC PSYCHIA; SELL H, 1988, P WORLD PSYCH ASS C; 1995, MENTAL ILLNESS GEN H	17	18	18	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 16	1996	347	9003					742	744		10.1016/S0140-6736(96)90083-5	http://dx.doi.org/10.1016/S0140-6736(96)90083-5			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	TZ982	8602008				2022-12-28	WOS:A1996TZ98200016
J	Engel, J				Engel, J			Recurrent afebrile flulike symptoms	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter							HERPES-SIMPLEX VIRUSES; INFECTIONS				Engel, J (corresponding author), E CAROLINA UNIV,SCH MED,DEPT MED,INFECT DIS SECT,GREENVILLE,NC 27834, USA.							BROOKS BO, 1991, J TOXICOL-CLIN TOXIC, V29, P315, DOI 10.3109/15563659109000363; COREY L, 1986, NEW ENGL J MED, V314, P686, DOI 10.1056/NEJM198603133141105; COREY L, 1986, NEW ENGL J MED, V314, P749, DOI 10.1056/NEJM198603203141205; LAURENCE J, 1993, ANN INTERN MED, V119, P55, DOI 10.7326/0003-4819-119-1-199307010-00010; SNELLER MC, 1993, ANN INTERN MED, V118, P720, DOI 10.7326/0003-4819-118-9-199305010-00011; YAMAMOTO LJ, 1991, NEW ENGL J MED, V325, P1082, DOI 10.1056/NEJM199110103251507; 1991, LANCET, V338, P1493	7	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 21	1996	275	7					514	514		10.1001/jama.275.7.514	http://dx.doi.org/10.1001/jama.275.7.514			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TV569	8606465				2022-12-28	WOS:A1996TV56900012
J	Annas, GJ; Caplan, A; Elias, S				Annas, GJ; Caplan, A; Elias, S			The politics of human-embryo research - Avoiding ethical gridlock	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									BOSTON UNIV,SCH PUBL HLTH,BOSTON,MA 02118; UNIV PENN,CTR BIOETH,PHILADELPHIA,PA 19104; BAYLOR COLL MED,HOUSTON,TX 77030	Boston University; University of Pennsylvania; Pennsylvania Medicine; Baylor College of Medicine	Annas, GJ (corresponding author), BOSTON UNIV,SCH MED,BOSTON,MA 02118, USA.			Annas, George/0000-0001-5836-7831				ANNAS GJ, 1989, NEW ENGL J MED, V320, P1079, DOI 10.1056/NEJM198904203201610; CAMPBELL CS, 1995, HASTINGS CENT REP, V25, P44, DOI 10.2307/3562495; CARSON SA, 1995, CONTEMP OBSTET GYNEC, V40, P71; CHARO A, 1995, STANFORD LAW POLICY, V6, P2; COREA G, 1985, MOTHER MACHINE, P178; COWLEY G, 1995, NEWSWEEK        0612, P66; HEALY BP, 1995, J WOMENS HLTH, V4, P609; MORGAN D, 1995, WASH POST       1103, pA1; National Institute of Health, 1994, REP HUM EMBR RES PAN; NIEBUHR G, 1996, NY TIMES        0417, pA19; Purdum Todd S, 1996, N Y Times Web, pB10; ROBERTSON JA, 1995, HASTINGS CENT REP, V25, P37, DOI 10.2307/3562492; Schwartz John, 1994, WASH POST       0803	13	47	47	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 16	1996	334	20					1329	1332		10.1056/NEJM199605163342012	http://dx.doi.org/10.1056/NEJM199605163342012			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	UK880	8609955	Green Published			2022-12-28	WOS:A1996UK88000012
J	Williams, PT				Williams, PT			High-density lipoprotein cholesterol and other risk factors for coronary heart disease in female runners	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PHYSICAL-ACTIVITY; CARDIOVASCULAR-DISEASE; DISTANCE RUNNERS; ALCOHOL INTAKE; UNITED-STATES; FOLLOW-UP; WOMEN; EXERCISE; PREMENOPAUSAL; SUBFRACTIONS	Background. Official guidelines from the Centers for Disease Control and Prevention assert that the majority of health benefits from physical activity are obtained by walking 2 miles (3.2 km) briskly most days of the week (the energy equivalent of running 8 to 12 km per week). The objective of our study was to examine the dose-response relation in women between risk factors for coronary heart disease, particularly the concentration of high-density lipoprotein (HDL) cholesterol, and vigorous exercise at levels that exceed the official guidelines. Methods. The number of kilometers run per week reported by 1837 female recreational runners in a national cross-sectional survey was compared with medical data provided by the women's physicians. Results. In these cross-sectional data, plasma HDL cholesterol concentrations were higher by an average (+/-SE) of 0.133+/-0.020 mg per deciliter (0.003+/-0.0005 mmol per liter) for every additional kilometer run per week, an amount nearly identical with that previously reported for men (0.136+/-0.006 mg per deciliter [0.004+/-0.0002 mmol per liter] per kilometer per week). Among women who ran less than 48 km per week, mean plasma HDL concentrations were significantly higher with each 16-km increment in distance. Women who ran more than 64 km per week had significantly higher mean concentrations of HDL cholesterol than did women who ran less than 48 km per week. They were also significantly more likely to have HDL cholesterol concentrations greater than 100, 90, or 80 mg per deciliter (2.6, 2.3, or 2.1 mmol per liter) than were women running less than 64 km per week. HDL cholesterol concentrations increased significantly in relation to the number of kilometers run per week in premenopausal women who were not using oral contraceptives and in postmenopausal women, whether they were receiving estrogen-replacement therapy or not. Conclusions. Substantial increases in HDL cholesterol concentrations were found in women who exercised at levels exceeding current guidelines; higher HDL cholesterol concentrations could provide added health benefits to these women.			Williams, PT (corresponding author), UNIV CALIF BERKELEY,LAWRENCE BERKELEY LAB,DIV LIFE SCI,BLDG 934,BERKELEY,CA 94720, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R55HL045652, R01HL045652, R03HL055640] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-45652, HL-55640] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		[Anonymous], 1991, GUID EX TEST PRESCR; BLUMENTHAL JA, 1991, ARTERIOSCLER THROMB, V11, P912, DOI 10.1161/01.ATV.11.4.912; BROWNELL KD, 1982, CIRCULATION, V65, P477, DOI 10.1161/01.CIR.65.3.477; BRUNNER D, 1987, AM J CARDIOL, V59, P1271, DOI 10.1016/0002-9149(87)90903-9; BUSH TL, 1987, CIRCULATION, V75, P1102, DOI 10.1161/01.CIR.75.6.1102; CASTELLI WP, 1988, AM J OBSTET GYNECOL, V158, P1553, DOI 10.1016/0002-9378(88)90189-5; FULLER WA, 1987, MEASUREMENT ERROR MO, P4; GORDON DJ, 1989, CIRCULATION, V79, P8, DOI 10.1161/01.CIR.79.1.8; HAHN RA, 1990, JAMA-J AM MED ASSOC, V264, P2654, DOI 10.1001/jama.264.20.2654; HARTING GH, 1984, EXP AGING RES, V10, P13, DOI 10.1080/03610738408258535; HARTUNG GH, 1986, AM J CARDIOL, V58, P148, DOI 10.1016/0002-9149(86)90259-6; HASKELL WL, 1984, NEW ENGL J MED, V310, P805, DOI 10.1056/NEJM198403293101301; KAISERAUER S, 1989, MED SCI SPORT EXER, V21, P120; KRUMMEL D, 1993, P SOC EXP BIOL MED, V204, P123; LAPIDUS L, 1986, BRIT HEART J, V55, P295, DOI 10.1136/hrt.55.3.295; LaRosa J C, 1992, Womens Health Issues, V2, P102, DOI 10.1016/S1049-3867(05)80278-6; LERNER DJ, 1986, AM HEART J, V111, P383, DOI 10.1016/0002-8703(86)90155-9; LINDHEIM SR, 1994, OBSTET GYNECOL, V83, P167; LOKEY EA, 1989, INT J SPORTS MED, V10, P424, DOI 10.1055/s-2007-1024937; MCGINNIS JM, 1993, JAMA-J AM MED ASSOC, V270, P2207, DOI 10.1001/jama.270.18.2207; Miller RG, 1986, ANOVA BASICS APPL ST; MOORE CE, 1983, METABOLISM, V32, P189, DOI 10.1016/0026-0495(83)90228-7; MORGAN DW, 1986, PHYSICIAN SPORTSMED, V14, P166, DOI 10.1080/00913847.1986.11709017; OWENS JF, 1990, PREV MED, V19, P147, DOI 10.1016/0091-7435(90)90016-D; PATE RR, 1995, JAMA-J AM MED ASSOC, V273, P402, DOI 10.1001/jama.273.5.402; PODL TR, 1994, METABOLISM, V43, P808, DOI 10.1016/0026-0495(94)90258-5; RAINVILLE S, 1984, INT J SPORTS MED, V5, P137, DOI 10.1055/s-2008-1025895; SALONEN JT, 1982, AM J EPIDEMIOL, V115, P526, DOI 10.1093/oxfordjournals.aje.a113334; SEIDELL JC, 1990, INT J EPIDEMIOL, V19, P303, DOI 10.1093/ije/19.2.303; STAMFORD BA, 1984, METABOLISM, V33, P585, DOI 10.1016/0026-0495(84)90053-2; SUTER E, 1992, J SPORT MED PHYS FIT, V32, P400; UPTON SJ, 1984, MED SCI SPORT EXER, V16, P67; WILLIAMS PT, 1982, JAMA-J AM MED ASSOC, V247, P2674, DOI 10.1001/jama.247.19.2674; WILLIAMS PT, 1992, ARTERIOSCLER THROMB, V12, P332, DOI 10.1161/01.ATV.12.3.332; WILLIAMS PT, 1993, ATHEROSCLEROSIS, V98, P251, DOI 10.1016/0021-9150(93)90134-G; WILLIAMS PT, 1994, METABOLISM, V43, P917, DOI 10.1016/0026-0495(94)90277-1; WILLIAMS PT, 1995, JAMA-J AM MED ASSOC, V274, P533, DOI 10.1001/jama.1995.03530070031016; WILLIAMS PT, 1994, CIRCULATION, V90, P471; Wood P D, 1977, Ann N Y Acad Sci, V301, P748, DOI 10.1111/j.1749-6632.1977.tb38244.x; 1995, MMWR-MORBID MORTAL W, V44, P105; 1995, MMWR-MORBID MORTAL W, V44, P113	41	129	131	0	4	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 16	1996	334	20					1298	1303		10.1056/NEJM199605163342004	http://dx.doi.org/10.1056/NEJM199605163342004			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UK880	8609947				2022-12-28	WOS:A1996UK88000004
J	Verghese, P; Stone, LS				Verghese, P; Stone, LS			Perceived visual speed constrained by image segmentation	NATURE			English	Article							RESPONSES; VELOCITY; MOTION; AREA; DISCRIMINATION; DIRECTION; CONTRAST; CORTEX; FIELD	LITTLE is known about how or where the visual system parses the visual scene into objects or surfaces. However, it is generally assumed that the segmentation and grouping of pieces of the image into discrete entities is due to 'later' processing stages, after the 'early' processing of the visual image by local mechanisms selective for attributes such as colour, orientation, depth, and motion(1). Speed perception is also thought to be mediated by early mechanisms tuned for speed(2-5). Here we show that manipulating the way in which an image is parsed changes the way in which local speed information is processed. Manipulations that cause multiple stimuli to appear as parts of a single patch degrade speed discrimination, whereas manipulations that perceptually divide a single large stimulus into parts improve discrimination. These results indicate that processes as early as speed perception may be constrained by the parsing of the visual image into discrete entities.	NASA,AMES RES CTR,MOFFETT FIELD,CA 94035	National Aeronautics & Space Administration (NASA); NASA Ames Research Center								ALBRIGHT TD, 1995, P NATL ACAD SCI USA, V92, P2433, DOI 10.1073/pnas.92.7.2433; ALLMAN J, 1985, PERCEPTION, V14, P105, DOI 10.1068/p140105; BORN RT, 1992, NATURE, V357, P497, DOI 10.1038/357497a0; BREGMAN AL, 1981, PERCEPTUAL ORG; BRITTEN KH, 1992, J NEUROSCI, V12, P4745; DeValois RL, 1990, SPATIAL VISION; DOWNING C J, 1989, Investigative Ophthalmology and Visual Science, V30, P72; GRAY CM, 1989, NATURE, V338, P334, DOI 10.1038/338334a0; HE ZJ, 1992, NATURE, V359, P231, DOI 10.1038/359231a0; HE ZJJ, 1994, NATURE, V367, P173, DOI 10.1038/367173a0; HEEGER DJ, 1992, VISUAL NEUROSCI, V9, P181, DOI 10.1017/S0952523800009640; JOHNSTON A, 1986, VISION RES, V26, P1099, DOI 10.1016/0042-6989(86)90044-1; KANIZSA G, 1979, ORG VISION ESSAYS GE; LEGGE GE, 1980, J OPT SOC AM A, V70, P1459; MAUNSELL JHR, 1983, J NEUROPHYSIOL, V49, P1127, DOI 10.1152/jn.1983.49.5.1127; MCKEE SP, 1986, VISION RES, V26, P609, DOI 10.1016/0042-6989(86)90009-X; MORRONE MC, 1995, NATURE, V376, P507, DOI 10.1038/376507a0; MOVSHON J A, 1988, Investigative Ophthalmology and Visual Science, V29, P327; PASTERNAK T, 1994, CEREB CORTEX, V4, P247, DOI 10.1093/cercor/4.3.247; ROBSON JG, 1981, VISION RES, V21, P409, DOI 10.1016/0042-6989(81)90169-3; VERGHESE P, 1995, VISION RES, V35, P2811, DOI 10.1016/0042-6989(95)00038-2; WATAMANIUK SNJ, 1992, VISION RES, V32, P2341, DOI 10.1016/0042-6989(92)90097-3; WATAMANIUK SNJ, 1995, NATURE, V377, P729, DOI 10.1038/377729a0; WATSON AB, 1994, J OPT SOC AM A, V11, P496, DOI 10.1364/JOSAA.11.000496; WELCH L, 1989, NATURE, V337, P734, DOI 10.1038/337734a0; WELCH L, 1990, PERCEPTION, V19, P425, DOI 10.1068/p190425; ZIPSER K, 1994, INVEST OPHTH VIS SCI, V34, P3171	27	59	59	0	9	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAY 9	1996	381	6578					161	163		10.1038/381161a0	http://dx.doi.org/10.1038/381161a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UK139	8610014				2022-12-28	WOS:A1996UK13900051
J	GeisterferLowrance, AAT; Christe, M; Conner, DA; Ingwall, JS; Schoen, FJ; Seidman, CE; Seidman, JG				GeisterferLowrance, AAT; Christe, M; Conner, DA; Ingwall, JS; Schoen, FJ; Seidman, CE; Seidman, JG			A mouse model of familial hypertrophic cardiomyopathy	SCIENCE			English	Article							EMBRYONIC STEM-CELLS; MYOSIN HEAVY-CHAIN	A mouse model of familial hypertrophic cardiomyopathy (FHC) was generated by the introduction of an Arg(403)-->Gln mutation into the alpha cardiac myosin heavy chain (Mwc) gene. Homozygous alpha MHC(403/403) mice died 7 days after birth, and sedentary heterozygous alpha MHC(403/+) mice survived for 1 year. Cardiac histopathology and dysfunction in the alpha MHC(403/+) mice resembled human FHC. Cardiac dysfunction preceded histopathologic changes, and myocyte disarray, hypertrophy, and fibrosis increased with age. Young male alpha MHC(403/+) mice showed more evidence of disease than did their female counterparts. Preliminary results suggested that exercise capacity may have been compromised in the alpha MHC(403/+) mice. This mouse model may help to define the natural history of FHC.	HARVARD UNIV,SCH MED,HOWARD HUGHES MED INST,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT GENET,BOSTON,MA 02115; BRIGHAM & WOMENS HOSP,DEPT MED,BOSTON,MA 02115; BRIGHAM & WOMENS HOSP,DEPT PATHOL,BOSTON,MA 02115; BRIGHAM & WOMENS HOSP,HOWARD HUGHES MED INST,BOSTON,MA 02115	Harvard University; Harvard Medical School; Howard Hughes Medical Institute; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Howard Hughes Medical Institute								CHRISTE M, UNPUB; CHRISTE ME, 1994, AM J PHYSIOL-HEART C, V267, pH2050, DOI 10.1152/ajpheart.1994.267.5.H2050; GEISTERFERLOWRA.AA, UNPUB; HASTY P, 1991, NATURE, V350, P243, DOI 10.1038/350243a0; HENDRICKSON BA, 1995, J EXP MED, V182, P1905, DOI 10.1084/jem.182.6.1905; JAENICKE T, 1990, GENOMICS, V8, P194, DOI 10.1016/0888-7543(90)90272-V; LEINWAND LA, 1983, SCIENCE, V221, P766, DOI 10.1126/science.6879174; MARON BJ, 1987, NEW ENGL J MED, V316, P780, DOI 10.1056/NEJM198703263161305; MARON BJ, 1982, CIRCULATION, V65, P1388, DOI 10.1161/01.CIR.65.7.1388; MCKENNA W, 1981, AM J CARDIOL, V47, P532, DOI 10.1016/0002-9149(81)90535-X; Seidman CE, 1995, MOL CARDIOVASCULAR M, P193; SOLARO RJ, 1971, BIOCHIM BIOPHYS ACTA, V245, P259, DOI 10.1016/0005-2728(71)90033-8; VALANCIUS V, 1991, MOL CELL BIOL, V11, P1402, DOI 10.1128/MCB.11.3.1402; WATKINS H, 1995, HUM MOL GENET, V4, P1721, DOI 10.1093/hmg/4.suppl_1.1721; WATKINS H, 1995, NAT GENET, V11, P434, DOI 10.1038/ng1295-434; WEIS JH, 1994, CURRENT PROTOCOLS MO, pCH5; WYNNE J, 1992, HEART DISEASE TXB CA, P1394; ZHANG W, 1996, J EXP MED, V183, P1	18	411	424	1	14	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAY 3	1996	272	5262					731	734		10.1126/science.272.5262.731	http://dx.doi.org/10.1126/science.272.5262.731			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UJ051	8614836				2022-12-28	WOS:A1996UJ05100054
J	Maldonado, E; Shiekhattar, R; Sheldon, M; Cho, H; Drapkin, R; Rickert, P; Lees, E; Anderson, CW; Linn, S; Reinberg, D				Maldonado, E; Shiekhattar, R; Sheldon, M; Cho, H; Drapkin, R; Rickert, P; Lees, E; Anderson, CW; Linn, S; Reinberg, D			A human RNA polymerase II complex associated with SRB and DNA-repair proteins	NATURE			English	Article							SACCHAROMYCES-CEREVISIAE; TRANSCRIPTION; GENE	WE report here the isolation of a human RNA polymerase II complex containing a subset of the basal transcription factors and the human homologues of the yeast SRB (for suppressors of RNA polymerase B) proteins(1-3). The complex contains transcriptional coactivators and increases the activation of transcription, In addition, some components of the RNA polymerase II complex participate in DNA repair.	UNIV MED & DENT NEW JERSEY,ROBERT WOOD JOHNSON MED SCH,DEPT BIOCHEM,HOWARD HUGHES MED INST,PISCATAWAY,NJ 08854; STANFORD UNIV,DNAX RES INST MOLEC & CELLULAR BIOL INC,DEPT CHEM,PALO ALTO,CA 94304; BROOKHAVEN NATL LAB,DEPT BIOL,UPTON,NY 11973; UNIV CALIF BERKELEY,DEPT BIOCHEM,BERKELEY,CA 94720	Howard Hughes Medical Institute; Rutgers State University New Brunswick; Rutgers State University Medical Center; Merck & Company; Dnax Research Institute Of Molecular & Cellular Biology Inc.; Stanford University; United States Department of Energy (DOE); Brookhaven National Laboratory; University of California System; University of California Berkeley			Drapkin, Ronny/E-9944-2016	Drapkin, Ronny/0000-0002-6912-6977; Reinberg, Danny/0000-0003-4288-2016				ABOUSSEKHRA A, 1992, MOL CELL BIOL, V12, P3224, DOI 10.1128/MCB.12.7.3224; ABOUSSEKHRA A, 1995, CELL, V80, P859, DOI 10.1016/0092-8674(95)90289-9; ADZUMA K, 1984, MOL CELL BIOL, V4, P2735, DOI 10.1128/MCB.4.12.2735; BARDWELL AJ, 1994, SCIENCE, V265, P2082, DOI 10.1126/science.8091230; BLUNT T, 1995, CELL, V80, P813, DOI 10.1016/0092-8674(95)90360-7; Chao DM, 1996, NATURE, V380, P82, DOI 10.1038/380082a0; DRAPKIN R, 1994, NATURE, V368, P769, DOI 10.1038/368769a0; FLORES O, 1989, J BIOL CHEM, V264, P8913; GE H, 1994, CELL, V78, P513, DOI 10.1016/0092-8674(94)90428-6; GERARD M, 1991, J BIOL CHEM, V266, P20940; HABRAKEN Y, 1994, NATURE, V371, P531, DOI 10.1038/371531a0; HUANG JC, 1992, P NATL ACAD SCI USA, V89, P3664, DOI 10.1073/pnas.89.8.3664; HWANG PI, 1995, FASEB J, V9, pA1398; IVANOV EL, 1995, MOL CELL BIOL, V15, P2245; KIM YJ, 1994, CELL, V77, P599, DOI 10.1016/0092-8674(94)90221-6; KIRCHGESSNER CU, 1995, SCIENCE, V267, P1178, DOI 10.1126/science.7855601; KOLESKE AJ, 1994, NATURE, V368, P466, DOI 10.1038/368466a0; KRETZSCHMAR M, 1994, CELL, V78, P525, DOI 10.1016/0092-8674(94)90429-4; LAI JS, 1992, P NATL ACAD SCI USA, V89, P6958, DOI 10.1073/pnas.89.15.6958; LESSMILLER SP, 1995, SCIENCE, V267, P1183; LU H, 1991, P NATL ACAD SCI USA, V88, P10004, DOI 10.1073/pnas.88.22.10004; NISHIDA C, 1988, J BIOL CHEM, V263, P501; OSSIPOW, 1995, CELL, V83, P137; SETO E, 1991, NATURE, V354, P241, DOI 10.1038/354241a0; SHINOHARA A, 1992, CELL, V69, P457, DOI 10.1016/0092-8674(92)90447-K; SMIDER V, 1994, SCIENCE, V266, P288, DOI 10.1126/science.7939667; TACCIOLI GE, 1994, SCIENCE, V265, P1442, DOI 10.1126/science.8073286; TASSAN JP, 1995, P NATL ACAD SCI USA, V92, P8871, DOI 10.1073/pnas.92.19.8871; THOMPSON GM, 1995, P NATL ACAD SCI USA, V92, P4587; VANVUUREN AJ, 1994, EMBO J, V13, P1645, DOI 10.1002/j.1460-2075.1994.tb06428.x; WANG ZG, 1994, NATURE, V368, P74, DOI 10.1038/368074a0	31	306	314	0	7	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAY 2	1996	381	6577					86	89		10.1038/381086a0	http://dx.doi.org/10.1038/381086a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UJ053	8609996				2022-12-28	WOS:A1996UJ05300063
J	Dawson, C; Whitfield, H				Dawson, C; Whitfield, H			ABC of urology - Urological malignancy .1. Prostate cancer	BRITISH MEDICAL JOURNAL			English	Article									CENT MIDDLESEX HOSP,LONDON NW10 7NS,ENGLAND; INST UROL & NEPHROL,LONDON,ENGLAND	Imperial College London; University of London; University College London	Dawson, C (corresponding author), EDITH CAVELL HOSP,PETERBOROUGH,CAMBS,ENGLAND.							ANDRIOLE GL, 1993, CURR OPIN UROL, V3, P373; BENTVELSEN FM, 1993, EUR J CANCER, V29A, P804, DOI 10.1016/S0959-8049(05)80413-7; BOYLE P, 1993, ADV UROLOGY ANDROLOG, V6; CATALONA WJ, 1994, NEW ENGL J MED, V331, P996; STEINER MS, 1995, EUR UROL, V27, P9	5	8	8	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 20	1996	312	7037					1032	1034						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UG610	8616355				2022-12-28	WOS:A1996UG61000034
J	Simske, JS; Kaech, SM; Harp, SA; Kim, SK				Simske, JS; Kaech, SM; Harp, SA; Kim, SK			LET-23 receptor localization by the cell junction protein LIN-7 during C-elegans vulval induction	CELL			English	Article							TUMOR SUPPRESSOR GENE; NEMATODE CAENORHABDITIS-ELEGANS; SEPTATE JUNCTIONS; MEMBRANE-PROTEIN; GUANYLATE KINASE; TYROSINE KINASE; DROSOPHILA; EXPRESSION; ENCODES; DISKS	In C. elegans, the anchor cell signal induces Pn.p cells to form the vulva by activating a conserved receptor tyrosine kinase pathway. lin-2 and lin-7 mutants exhibit a vulvaless phenotype similar to the phenotype observed when this signaling pathway is defective. We have found that LIN-7 is a cell junction-associated protein that binds to the LET-23 receptor tyrosine kinase. LET-23 is also localized to the cell junctions, and both LIN-2 and LIN-7 are required for this localization. LET-23 overexpression rescues the lin-2 or lin-7 vulvaless phenotype, suggesting that increased receptor density can compensate for mislocalization. These results suggest that proper localization of LET-23 receptor to the Pn.p cell junctions is required for signaling activity.			Simske, JS (corresponding author), STANFORD UNIV, SCH MED, DEPT DEV BIOL, STANFORD, CA 94305 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043977] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM043977-09] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Anderson JM, 1993, CURR OPIN CELL BIOL, V5, P772, DOI 10.1016/0955-0674(93)90024-K; AROIAN RV, 1991, GENETICS, V128, P251; AROIAN RV, 1990, NATURE, V348, P693, DOI 10.1038/348693a0; BANERJEE U, 1987, CELL, V51, P151, DOI 10.1016/0092-8674(87)90020-1; BEITEL GJ, 1990, NATURE, V348, P503, DOI 10.1038/348503a0; BRYANT PJ, 1992, CELL, V68, P621, DOI 10.1016/0092-8674(92)90136-Z; CHO KO, 1992, NEURON, V9, P929, DOI 10.1016/0896-6273(92)90245-9; CREPALDI T, 1994, J CELL BIOL, V125, P313, DOI 10.1083/jcb.125.2.313; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; EISENMANN DM, 1994, CURR OPIN GENET DEV, V4, P508, DOI 10.1016/0959-437X(94)90065-B; FEHON R, 1994, DEVELOPMENT, V103, P545; FEHON RG, 1991, J CELL BIOL, V113, P657, DOI 10.1083/jcb.113.3.657; FERGUSON EL, 1985, GENETICS, V110, P17; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FINNEY M, 1990, CELL, V63, P895, DOI 10.1016/0092-8674(90)90493-X; FRANCIS R, 1991, J CELL BIOL, V114, P465, DOI 10.1083/jcb.114.3.465; HAN M, 1990, CELL, V63, P921, DOI 10.1016/0092-8674(90)90495-Z; HERMAN RK, 1990, NATURE, V348, P169, DOI 10.1038/348169a0; HILL RJ, 1992, NATURE, V358, P470, DOI 10.1038/358470a0; HORVITZ HR, 1980, GENETICS, V96, P435; Hoskins R, 1996, DEVELOPMENT, V122, P97; JESAITIS LA, 1994, J CELL BIOL, V124, P949, DOI 10.1083/jcb.124.6.949; KATZ WS, 1995, CELL, V82, P297, DOI 10.1016/0092-8674(95)90317-8; KIM E, 1995, NATURE, V378, P85, DOI 10.1038/378085a0; KIM SK, 1995, CURR OPIN CELL BIOL, V7, P641, DOI 10.1016/0955-0674(95)80105-7; KIM SK, 1990, GENE DEV, V4, P357, DOI 10.1101/gad.4.3.357; KIMBLE J, 1981, DEV BIOL, V87, P286, DOI 10.1016/0012-1606(81)90152-4; KISTNER U, 1993, J BIOL CHEM, V268, P4580; KOERNER TJ, 1991, METHOD ENZYMOL, V194, P477; KOGA M, 1995, DEVELOPMENT, V121, P2655; KORNAU HC, 1995, SCIENCE, V269, P1737, DOI 10.1126/science.7569905; MARATOSFLIER E, 1987, J CELL BIOL, V105, P1595, DOI 10.1083/jcb.105.4.1595; PERRIMON N, 1988, DEV BIOL, V127, P392, DOI 10.1016/0012-1606(88)90326-0; RUFF P, 1991, P NATL ACAD SCI USA, V88, P6595, DOI 10.1073/pnas.88.15.6595; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SATO T, 1995, SCIENCE, V268, P411, DOI 10.1126/science.7536343; SIMSKE JS, 1995, NATURE, V375, P142, DOI 10.1038/375142a0; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STERNBERG PW, 1986, CELL, V44, P761, DOI 10.1016/0092-8674(86)90842-1; STRINGHAM EG, 1992, MOL BIOL CELL, V3, P221, DOI 10.1091/mbc.3.2.221; SULSTON JE, 1977, DEV BIOL, V56, P110, DOI 10.1016/0012-1606(77)90158-0; TOMLINSON A, 1987, CELL, V51, P143, DOI 10.1016/0092-8674(87)90019-5; WILLOTT E, 1993, P NATL ACAD SCI USA, V90, P7834, DOI 10.1073/pnas.90.16.7834; Wood WB, 1988, NEMATODE CAENORHABDI; WOODS DF, 1991, CELL, V66, P451, DOI 10.1016/0092-8674(81)90009-X; ZAK NB, 1992, DEV BIOL, V149, P448, DOI 10.1016/0012-1606(92)90299-V	46	227	240	0	7	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	APR 19	1996	85	2					195	204		10.1016/S0092-8674(00)81096-X	http://dx.doi.org/10.1016/S0092-8674(00)81096-X			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	UG255	8612272	Bronze			2022-12-28	WOS:A1996UG25500008
J	Casey, ATH; Crockard, HA; Bland, JM; Stevens, J; Moskovich, R; Ransford, AO				Casey, ATH; Crockard, HA; Bland, JM; Stevens, J; Moskovich, R; Ransford, AO			Surgery on the rheumatoid cervical spine for the non-ambulant myelopathic patient - Too much, too late?	LANCET			English	Article							ATLANTO-AXIAL SUBLUXATION; TRANSORAL DECOMPRESSION; NATURAL-HISTORY; ARTHRITIS; FUSION; FIXATION; STABILIZATION; PROGRESSION; INSTABILITY; DISEASE	Background Opinions differ on the timing of surgery for rheumatoid arthritis patients with atlanto-axial subluxation. Some clinicians wait for development of neurological signs; others favour prophylactic fusion and decompression. We examined the results of surgery in relation to neurological state at the time of operation. Methods 134 patients underwent surgery for rheumatoid involvement of the cervical spine, after development of objective signs of myelopathy. Surgical outcomes were examined prospectively in two groups-patients who were still ambulant at the time of presentation (Ranawat class III A) and patients who had lost the ability to walk (Ranawat class III B)-by means of neurological and functional grading systems in conjunction with standard measures of postoperative morbidity and mortality. Findings 58% of the ambulant patients attained Ranawat neurological grades I or II compared with only 20% of the non-ambulant patients (p<0.0001). The non-ambulant group also fared worse in terms of postoperative complication rate, length of hospital stay, functional outcome, and ultimately survival. Radiologically, the non-ambulant patients were characterised by a smaller cross-sectional spinal cord area. Interpretation The strong likelihood of surgical complications, the poor survival, and the limited prospects for functional recovery in non-ambulant patients make a strong case for earlier surgical intervention. At a late stage of disease most patients will have irreversible cord damage.	UCL NATL HOSP NEUROL & NEUROSURG, DEPT NEUROL SURG, LONDON WC1 N3BG, ENGLAND; UCL NATL HOSP NEUROL & NEUROSURG, DEPT RADIOL, LONDON WC1 N3BG, ENGLAND; UNIV LONDON ST GEORGES HOSP, SCH MED, DEPT PUBL HLTH SCI, LONDON, ENGLAND	University of London; University College London; UCL Medical School; University College London Hospitals NHS Foundation Trust; University of London; University College London; UCL Medical School; University College London Hospitals NHS Foundation Trust; St Georges University London								AGARWAL AK, 1992, J RHEUMATOL, V19, P1364; AGARWAL AK, 1993, BRIT MED J, V306, P79, DOI 10.1136/bmj.306.6870.79; BODEN SD, 1993, J BONE JOINT SURG AM, V75A, P1282, DOI 10.2106/00004623-199309000-00004; BREIG A, 1966, J NEUROSURG, V25, P177; CLARK CR, 1989, J BONE JOINT SURG AM, V71A, P381, DOI 10.2106/00004623-198971030-00012; CONATY JP, 1989, J BONE JOINT SURG AM, V71, P381; CROCKARD HA, 1990, J BONE JOINT SURG BR, V72, P682, DOI 10.1302/0301-620X.72B4.2380227; CROCKARD HA, 1986, J BONE JOINT SURG BR, V68, P350, DOI 10.1302/0301-620X.68B3.3733795; CUSCHIERI A, 1988, ESSENTIAL SURGICAL P, P150; FRIES JF, 1980, ARTHRITIS RHEUM, V23, P137, DOI 10.1002/art.1780230202; HENDERSON FC, 1993, ANN RHEUM DIS, V52, P629, DOI 10.1136/ard.52.9.629; HEYWOOD AWB, 1988, J BONE JOINT SURG BR, V70, P708, DOI 10.1302/0301-620X.70B5.3192565; KOURTOPOULOS H, 1988, ACTA NEUROCHIR, V91, P113, DOI 10.1007/BF01424564; Lang J., 1993, CLIN ANATOMY CERVICA; Magerl F., 1987, CERVICAL SPINE, P322; MARTEL W, 1961, AMER J ROENTGENOL RA, V86, P223; MATHEWS JA, 1974, ANN RHEUM DIS, V33, P526, DOI 10.1136/ard.33.6.526; MCCARRON RF, 1988, SOUTHERN MED J, V81, P474, DOI 10.1097/00007611-198804000-00016; MCRAE DL, 1961, RADIOLOGY, V76, P572; MOSKOVICH R, 1992, SPINE B, V73, P972; PAPADOPOULOS SM, 1991, J NEUROSURG, V74, P1, DOI 10.3171/jns.1991.74.1.0001; PAYNE EE, 1957, BRAIN, V80, P571, DOI 10.1093/brain/80.4.571; PELLICCI PM, 1981, J BONE JOINT SURG AM, V63, P342, DOI 10.2106/00004623-198163030-00003; PEPPELMAN WC, 1993, SPINE, V18, P2375, DOI 10.1097/00007632-199312000-00001; RANA NA, 1989, SPINE, V14, P1054, DOI 10.1097/00007632-198910000-00005; RANAWAT CS, 1979, J BONE JOINT SURG AM, V61, P1003, DOI 10.2106/00004623-197961070-00006; RANSFORD AO, 1986, J BONE JOINT SURG BR, V68, P173, DOI 10.1302/0301-620X.68B2.3514627; ROPES M W, 1958, Bull Rheum Dis, V9, P175; SANTAVIRTA S, 1991, J BONE JOINT SURG BR, V73, P116, DOI 10.1302/0301-620X.73B1.1991743; SANTAVIRTA S, 1988, J BONE JOINT SURG AM, V70A, P658, DOI 10.2106/00004623-198870050-00004; SMITH PH, 1972, ANN RHEUM DIS, V31, P431, DOI 10.1136/ard.31.6.431; STEINBROCKER O, 1949, JAMA-J AM MED ASSOC, V140, P659, DOI 10.1001/jama.1949.02900430001001; STIRRAT AN, 1993, CLIN ORTHOP RELAT R, P135; SYMMONS DPM, 1994, BRIT J RHEUMATOL, V33, P735; WEISSMAN BNW, 1982, RADIOLOGY, V144, P745, DOI 10.1148/radiology.144.4.7111719; WINFIELD J, 1981, ANN RHEUM DIS, V40, P109, DOI 10.1136/ard.40.2.109; YU YL, 1985, NEURORADIOLOGY, V27, P399, DOI 10.1007/BF00327602; ZOMA A, 1987, J BONE JOINT SURG BR, V69, P8, DOI 10.1302/0301-620X.69B1.3818739	38	101	103	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	APR 13	1996	347	9007					1004	1007		10.1016/S0140-6736(96)90146-4	http://dx.doi.org/10.1016/S0140-6736(96)90146-4			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UF380	8606562				2022-12-28	WOS:A1996UF38000011
J	NobenTrauth, K; Naggert, JK; North, MA; Nishina, PM				NobenTrauth, K; Naggert, JK; North, MA; Nishina, PM			A candidate gene for the mouse mutation tubby	NATURE			English	Article							PHOSPHODIESTERASE	A MUTATION in the tub gene causes maturity-onset obesity, insulin resistance(1), and sensory (d)eficits(2,3). In contrast to the rapid juvenile-onset weight gain seen in diabetes (db) and obese (ob) mice, obesity in tubby mice develops gradually, and strongly resembles the late-onset obesity seen in the human population. Excessive deposition of adipose tissue eventually leads to a twofold increase of body weight. Tubby mice also suffer retinal degeneration and neurosensory hearing loss(2,3). The tripartite character of the tubby phenotype shows striking similarity to human obesity syndromes, such as Alstrom(4) and Bardet-Biedl(5). Here we report the identification of a G --> T transversion in a candidate gene that abolishes a donor splice site in the 3' coding region and results in a larger transcript containing the unspliced intron. This alteration is predicted to replate the 44-carboxy-terminal amino acids with a 20-amino-acid sequence not found in the wild-type protein. Additionally, a second, prematurely truncated transcript with the unspliced intron is observed in testis messenger RNA and a 2-3-fold increase in brain mRNA is observed in tubby mice compared to B6. The phenotypic features of tubby mice may be the result of cellular apoptosis triggered by expression of the mutated tub gene.	JACKSON LAB,BAR HARBOR,ME 04609; SEQUANA THERAPEUT INC,LA JOLLA,CA 92037	Jackson Laboratory								ALSTROM C H, 1959, Acta Psychiatr Neurol Scand Suppl, V129, P1; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BEAVO JA, 1995, PHYSIOL REV, V75, P725, DOI 10.1152/physrev.1995.75.4.725; BOWES C, 1990, NATURE, V347, P677, DOI 10.1038/347677a0; BRAY GA, 1995, OBES RES, V3, P383, DOI 10.1002/j.1550-8528.1995.tb00164.x; COLEMAN DL, 1990, J HERED, V81, P424, DOI 10.1093/oxfordjournals.jhered.a111019; DIETRICH WF, 1994, NAT GENET, V7, P220, DOI 10.1038/ng0694supp-220; FARBER DB, 1994, PROG RETIN EYE RES, V13, P31, DOI 10.1016/1350-9462(94)90004-3; HECKENLIVELY JR, 1995, P NATL ACAD SCI USA, V92, P11100, DOI 10.1073/pnas.92.24.11100; JONES JM, 1992, GENOMICS, V14, P197, DOI 10.1016/S0888-7543(05)80308-8; LACOMBE ML, 1986, J BIOL CHEM, V261, P6811; LOVETT M, 1994, CURRENT PROTOCOLS HU; NAGGERT JK, 1995, NAT GENET, V10, P135, DOI 10.1038/ng0695-135; NORTH MA, 1993, MAMM GENOME, V4, P466, DOI 10.1007/BF00364779; OHLEMILLER KK, 1995, NEUROREPORT, V6, P845, DOI 10.1097/00001756-199504190-00005; SCHULER GD, 1991, PROTEINS, V9, P180, DOI 10.1002/prot.340090304; SEGRE JA, 1995, GENOMICS, V28, P549, DOI 10.1006/geno.1995.1187; VAMBUTAS V, 1994, BBA-GENE STRUCT EXPR, V1217, P203, DOI 10.1016/0167-4781(94)90036-1; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0; WONG P, 1994, BIOCHEM CELL BIOL, V72, P489, DOI 10.1139/o94-066	20	271	285	1	8	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	APR 11	1996	380	6574					534	538		10.1038/380534a0	http://dx.doi.org/10.1038/380534a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UE663	8606774				2022-12-28	WOS:A1996UE66300052
J	Eachus, J; Williams, M; Chan, P; Smith, GD; Grainge, M; Donovan, J; Frankel, S				Eachus, J; Williams, M; Chan, P; Smith, GD; Grainge, M; Donovan, J; Frankel, S			Deprivation and cause specific morbidity: Evidence from the Somerset and Avon survey of health	BMJ-BRITISH MEDICAL JOURNAL			English	Article							BRITISH CIVIL-SERVANTS; NEIGHBORHOOD DEPRIVATION; INDIVIDUAL MORBIDITY; GENERAL-PRACTICE; INEQUALITIES; MORTALITY; SCORES; INDICATORS; WHITEHALL; RESOURCES	Objective-To investigate the association between cause specific morbidity and deprivation in order to inform the debates on inequalities in health and health services resource allocation. Design-Cross sectional postal questionnaire survey ascertaining self reported health status, with validation of a 20% sample through general practitioner and hospital records. Setting-Inner city, urban, and rural areas of Avon and Somerset. Subjects-Stratified random sample of 28 080 people aged 35 and over from 40 general practices. Main outcome measures-Age and sex standardised prevalence of various diseases; Townsend deprivation scores were assigned by linking postcodes to enumeration districts. Relative indices of inequality were calculated to estimate the magnitude of the association between socioeconomic position and morbidity. Results-The response rate was 85.3%. The prevalence of most of the conditions rose with increasing material deprivation. The relative index of inequality, for both sexes combined, was greater than 1 for all conditions except diabetes. The conditions most strongly associated with deprivation were diabetic eye disease (relative index of inequality 3.21; 95% confidence interval 1.84 to 5.59), emphysema (2.72; 1.67 to 4.43) and bronchitis (2.27; 1.92 to 2.68). The relative index of inequality was significantly higher in women for asthma (P<0.05) and in men for depression (P<0.01). The mean reporting of prevalent conditions was 1.07 for the most deprived fifth of respondents and 0.77 in the most affluent fifth (P < 0.001). Conclusions-Material deprivation is strongly linked with many common diseases. NHS resource allocation should be modified to reflect such morbidity differentials.	UNIV BRISTOL, DEPT SOCIAL MED, BRISTOL BS8 2PR, AVON, ENGLAND	University of Bristol			Davey Smith, George/A-7407-2013	Davey Smith, George/0000-0002-1407-8314; Grainge, Matthew/0000-0001-7181-4042				ASHLEY J, 1985, MORTAL MORBID DIAGNO; BENSHLOMO Y, 1992, J EPIDEMIOL COMMUN H, V46, P532, DOI 10.1136/jech.46.5.532; Benzeval M, 1995, TACKLING INEQUALITIE; BICKLER G, 1993, BRIT MED J, V306, P1167, DOI 10.1136/bmj.306.6886.1167; BLANE D, IN PRESS J R STAT A; BLAXTER M, 1987, LANCET, V2, P30; BUCQUET D, 1986, SOC SCI MED, V23, P737, DOI 10.1016/0277-9536(86)90122-X; CARSTAIRS V, 1989, BRIT MED J, V299, P886, DOI 10.1136/bmj.299.6704.886; CURTIS SE, 1990, J EPIDEMIOL COMMUN H, V44, P62, DOI 10.1136/jech.44.1.62; FEATHERSTONE PI, 1992, BRIT J GEN PRACT, V42, P21; FOSTER K, 1993, GENERAL HOUSEHOLD SU; Gore, 1987, HLTH LIFESTYLE SURVE; GUNNELL DJ, 1995, BRIT MED J, V311, P226, DOI 10.1136/bmj.311.6999.226; HOPTON JL, 1992, BRIT J GEN PRACT, V42, P236; HUTCHINSON A, 1989, BRIT MED J, V299, P1142, DOI 10.1136/bmj.299.6708.1142; JESSOP EG, 1992, J EPIDEMIOL COMMUN H, V46, P543, DOI 10.1136/jech.46.5.543; KUNST AE, 1995, J EPIDEMIOL COMMUN H, V49, P117, DOI 10.1136/jech.49.2.117; Kunst AE, 1994, MEASURING SOCIOECONO; LOWY A, 1994, J PUBLIC HEALTH MED, V16, P113, DOI 10.1093/oxfordjournals.pubmed.a042912; MACKENBACH JP, 1994, BRIT MED J, V309, P1487, DOI 10.1136/bmj.309.6967.1487; MARMOT MG, 1991, LANCET, V337, P1387, DOI 10.1016/0140-6736(91)93068-K; MAYS N, 1989, J EPIDEMIOL COMMUN H, V43, P191, DOI 10.1136/jech.43.2.191; MCCARRON PG, 1994, BRIT MED J, V309, P1481, DOI 10.1136/bmj.309.6967.1481; MCCORMICK A, 1995, OPCS MORBIDITY STATI; MORRIS R, 1991, J PUBLIC HEALTH MED, V13, P318; ODONNELL O, 1991, J HEALTH ECON, V10, P1, DOI 10.1016/0167-6296(91)90014-E; PAYNE JN, 1993, J PUBLIC HEALTH MED, V15, P161; PAYNE JN, 1994, J EPIDEMIOL COMMUN H, V48, P74, DOI 10.1136/jech.48.1.74; PETERS TJ, 1995, PAEDIATR PERINAT EP, V9, P219, DOI 10.1111/j.1365-3016.1995.tb00135.x; PHILLIMORE P, 1994, BRIT MED J, V308, P1125, DOI 10.1136/bmj.308.6937.1125; PINCUS T, 1987, J CHRON DIS, V40, P865, DOI 10.1016/0021-9681(87)90186-X; READING R, 1994, J EPIDEMIOL COMMUN H, V48, P192, DOI 10.1136/jech.48.2.192; SHELDON TA, 1993, BRIT MED J, V306, P835, DOI 10.1136/bmj.306.6881.835; SHEWRY MC, 1992, BRIT J GEN PRACT, V42, P406; SMITH GD, 1991, BRIT MED J, V302, P359, DOI 10.1136/bmj.302.6773.359; SMITH GD, 1990, J EPIDEMIOL COMMUN H, V44, P265, DOI 10.1136/jech.44.4.265; SMITH GD, 1990, BMJ-BRIT MED J, V301, P373, DOI 10.1136/bmj.301.6748.373; Smith GD, 1994, EUROPEAN J PUBLIC HL, V4, P131, DOI DOI 10.1093/EURPUB/4.2.131; SORLIE PD, 1995, AM J PUBLIC HEALTH, V85, P949, DOI 10.2105/AJPH.85.7.949; STANSFELD SA, 1992, PSYCHOL MED, V22, P739, DOI 10.1017/S0033291700038186; TONSEND P, 1985, INT J HEALTH SERV, V15, P637, DOI 10.2190/AN09-8R52-UE6B-VWUU; Townsend P., 1988, INEQUALITIES HLTH; VICTOR CR, 1991, HLTH HLTH CARE LATER; WAGSTAFF A, 1991, SOC SCI MED, V33, P545, DOI 10.1016/0277-9536(91)90212-U; WAGSTAFF A, 1994, HEALTH ECON, V3, P281, DOI 10.1002/hec.4730030409; WILKINSON RG, 1986, CLASS HLTH, P1; WILLIAMSJOHNSON MM, 1994, HAZARDOUS WASTE AND PUBLIC HEALTH: INTERNATIONAL CONGRESS ON THE HEALTH EFFECTS OF HAZARDOUS WASTE, P448; 1993, EGRET EPIDEMIOLOGICA; 1986, REGISTRAR GENERALS D; 1995, OCCUPATIONAL HLTH DE; 1976, SHARING RESOURCES HL	51	163	163	0	11	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	FEB 3	1996	312	7026					287	292						6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	TU507	8611787				2022-12-28	WOS:A1996TU50700025
J	deQuadros, CA; Olive, JM; Hersh, BS; Strassburg, MA; Henderson, DA; BrandlingBennett, D; Alleyne, GAO				deQuadros, CA; Olive, JM; Hersh, BS; Strassburg, MA; Henderson, DA; BrandlingBennett, D; Alleyne, GAO			Measles elimination in the Americas - Evolving strategies	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							UNITED-STATES; ERADICATION; TRANSMISSION; OUTBREAK; PATTERNS; VACCINE	The strategy currently used to control measles in most countries has been to immunize each successive birth cohort through the routine health services delivery system. While measles vaccine coverage has increased markedly, significant measles outbreaks have continued to recur. During the past 5 years, experience in the Americas suggests that measles transmission has been interrupted in a number of countries (Cuba, Chile, and countries in the English-speaking Caribbean and successfully controlled in ail remaining countries, Since 1991 these countries have implemented one-time ''catch-up'' vaccination campaigns (conducted during short period, usually 1 week to 1 month, and targeting all children 9 months through 14 years of age, regardless of previous vaccination status or measles disease history). These campaigns have been followed by improvements in routine vaccination services and in surveillance systems, so that the progress of the measles elimination efforts can be sustained and monitored. follow-up mass vaccination campaigns for children younger than 5 years are planned to take place every 3 to 5 years.	PAN AMER HLTH ORG, OFF DEPUTY DIRECTOR, WASHINGTON, DC 20037 USA; PAN AMER HLTH ORG, OFF DIRECTOR, WASHINGTON, DC 20037 USA; WHO, GLOBAL PROGRAM VACCINES, CH-1211 GENEVA, SWITZERLAND; LOS ANGELES CTY DEPT HLTH SERV, LOS ANGELES, CA USA; JOHNS HOPKINS UNIV, SCH HYG & PUBL HLTH, DEPT INT HLTH & EPIDEMIOL, BALTIMORE, MD USA; PAN AMER HLTH ORG, EXPANDED PROGRAM IMMUNIZAT, WASHINGTON, DC 20037 USA	Pan American Health Organization; Pan American Health Organization; World Health Organization; Johns Hopkins University; Pan American Health Organization	deQuadros, CA (corresponding author), PAN AMER HLTH ORG, SPECIAL PROGRAM VACCINES & IMMUNIZAT, 525 E 23RD ST NW, WASHINGTON, DC 20037 USA.							ATKINSON WL, 1992, ANNU REV MED, V43, P451, DOI 10.1146/annurev.med.43.1.451; BART KJ, 1991, JAMA-J AM MED ASSOC, V266, P1547; BELLINI WJ, 1994, J INFECT DIS, V170, pS15, DOI 10.1093/infdis/170.Supplement_1.S15; BIANCHINE PJ, 1992, ALLERGY PROC, V13, P225, DOI 10.2500/108854192778817040; BORGONO JM, 1994, EPI NEWSLETTER   OCT, V16, P1; BRUNELL PA, 1983, JAMA-J AM MED ASSOC, V250, P1409, DOI 10.1001/jama.250.11.1409; CHEN RT, 1994, INT J EPIDEMIOL, V23, P185, DOI 10.1093/ije/23.1.185; CHEN RT, 1989, AM J EPIDEMIOL, V129, P173, DOI 10.1093/oxfordjournals.aje.a115106; Clements C. John, 1992, World Health Statistics Quarterly, V45, P285; Clements CJ, 1993, MEASLES POLIOMYELITI, P13; DELAJARA JJ, 1995, CONTROL SARAMPION CH; DEQUADROS CA, 1992, ANNU REV PUBL HEALTH, V13, P239, DOI 10.1146/annurev.publhealth.13.1.239; FINE PEM, 1993, EPIDEMIOL REV, V15, P265, DOI 10.1093/oxfordjournals.epirev.a036121; FINE PEM, 1982, INT J EPIDEMIOL, V11, P5, DOI 10.1093/ije/11.1.5; FOEGE WH, 1982, PUBLIC HEALTH REP, V97, P402; FOEGE WH, 1971, SCI PUBLICATION PAN, V226, P207; FOSTER S O, 1971, African Journal of Medical Sciences, V2, P151; HERSH BS, 1991, AM J PUBLIC HEALTH, V81, P360, DOI 10.2105/AJPH.81.3.360; HERSH BS, 1992, JAMA-J AM MED ASSOC, V267, P1936, DOI 10.1001/jama.267.14.1936; HINMAN AR, 1979, JAMA-J AM MED ASSOC, V242, P1157, DOI 10.1001/jama.242.11.1157; HOPESIMPSON RE, 1952, LANCET, V2, P549, DOI DOI 10.1016/S0140-6736(52)91357-3; HOPKINS DR, 1982, LANCET, V1, P1396; HOSPEDALES CJ, 1992, W INDIAN MED J, V41, P43; KRUGMAN S, 1963, PEDIATRICS, V31, P919; KRUGMAN S, 1985, INFECTIOUS DISEASES; MARKOWITZ LE, 1989, NEW ENGL J MED, V320, P75, DOI 10.1056/NEJM198901123200202; MARKOWITZ LE, 1990, PEDIATR INFECT DIS J, V9, P101, DOI 10.1097/00006454-199002000-00008; MCLEAN AR, 1988, EPIDEMIOL INFECT, V100, P111, DOI 10.1017/S0950268800065614; MOLINERT HT, 1993, PRINCIPALES ASPECTOS; PELTOLA H, 1994, NEW ENGL J MED, V331, P1397, DOI 10.1056/NEJM199411243312101; ROTA PA, 1994, VIROLOGY, V198, P724, DOI 10.1006/viro.1994.1086; SABIN AB, 1992, PEDIATRICS, V90, P162; SMITH EA, 1970, J NIGERIAN MED ASSOC, V7, P16; THACKER SB, 1991, AM J EPIDEMIOL, V133, P517, DOI 10.1093/oxfordjournals.aje.a115923; WILLIAMS PJ, 1983, REV INFECT DIS, V5, P391; 1995, MMWR-MORBID MORTAL W, V44, P486; 1995, EPI NEWSLETTER   FEB, V17, P1; 1995, MMWR-MORBID MORTAL W, V44, P613; 1995, MMWR-MORBID MORTAL W, V44, P619; 1995, MMWR-MORBID MORTAL W, V44, P493; 1994, EPI NEWSLETTER   DEC, V16, P8; 1995, WKLY B          1125, V1; 1994, J INFECT DIS S1, V170, pS63; 1993, MMWR-MORBID MORTAL W, V42, P925; 1994, WKLY EPIDEMIOL REC, V69, P229; 1993, WORLD DEV REPORT 199, P60; 1994, EPI NEWSLETTER   OCT, V16, P1; 1992, EPI NEWSLETTER   JUN, V14, P2; 1989, MMWR-MORBID MORTAL W, V38, pS9	49	208	214	0	19	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 17	1996	275	3					224	229		10.1001/jama.275.3.224	http://dx.doi.org/10.1001/jama.275.3.224			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TP282	8604176				2022-12-28	WOS:A1996TP28200031
J	Politano, L; Nigro, V; Nigro, G; Petretta, VR; Passamano, L; Papparella, S; DiSomma, S; Comi, LI				Politano, L; Nigro, V; Nigro, G; Petretta, VR; Passamano, L; Papparella, S; DiSomma, S; Comi, LI			Development of cardiomyopathy in female carriers of Duchenne and Becker muscular dystrophies	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							EXPRESSION; LOCUS; GENE	Objective.-To characterize the presence and behavior of the dystrophinopathic myocardial damage in female carriers of a gene defect at the Xp21 locus of the X chromosome that causes Duchenne and Becker muscular dystrophies (DMD and BMD). Design.-Cohort study from April 1, 1985, to April 30, 1995, with cardiologic follow-up performed yearly for a minimum of 3 to a maximum of 10 years. Setting.-Counseling center for genetic muscular disorders, Patients.-A total of 197 women and girls aged 5 to 60 years ascertained to be carriers of the DMD (n=152) or BMD (n=45) gene. Main Outcome Measures.-Cardiac status at yearly examinations as determined by 12-lead electrocardiogram (ECG), 24-hour ambulatory ECG, M-mode and 2-dimensional echocardiography, and carotid pulse tracing. Myocardial scintigram was performed on each individual at least twice during the study, Immunohistochemical analysis of dystrophin from myocardium and/or skeletal muscle biopsy was performed in 12 carriers. Results.-Preclinical or clinically evident myocardial involvement was found in 166 cases (84.3%), without significant differences in percentage and behavior between DMD and BMD carriers. Its occurrence increased significantly with age, from 54.5% (18 cases) in carriers aged between 5 and 16 years to 90.2% (148 cases) in carriers older than 16 years. Dystrophin anomalies were detected at the membrane level of the myocardial fibers in all endomyocardial biopsy specimens. Conclusions.-Genetic anomalies can be considered the primary cause of myocardial damage in carriers of dystrophinopathic myopathies; myocardial damage shows the same behavior already described in DMD and BMD patients and progresses from preclinical to dilated cardiomyopathy, passing through stages of myocardial hypertrophy or dysrhythmias.	UNIV NAPLES 2,DEPT INTERNAL & EXPT MED,CARDIOMYOL & GENET SECT,NAPLES,ITALY; UNIV NAPLES 2,INST GEN PATHOL & ONCOL,NAPLES,ITALY; UNIV NAPLES,ENVIRONM PATHOL INTERUNIV CTR,NAPLES,ITALY; UNIV NAPLES,INTERDEPT CTR GENET IMMUNOL & CARDIOVASC DIS,NAPLES,ITALY	Universita della Campania Vanvitelli; Universita della Campania Vanvitelli; University of Naples Federico II; University of Naples Federico II			Nigro, Vincenzo/AAB-2274-2022; POLITANO, LUISA/AAK-6885-2020	Nigro, Vincenzo/0000-0002-3378-5006	Telethon [287] Funding Source: Medline	Telethon(Fondazione Telethon)		BEGGS AH, 1990, HUM GENET, V86, P45; BERKO BA, 1987, NEW ENGL J MED, V316, P1186, DOI 10.1056/NEJM198705073161904; BRAUNWALD E, 1994, HEART DISEASE TXB CA; Chamberlain J.S., 1990, PCR PROTOCOLS GUIDE, P272; COMI LI, 1992, INT J CARDIOL, V34, P297, DOI 10.1016/0167-5273(92)90028-2; COMI LI, 1993, ACTA CARDIOMIOL, V1, P117; COMI LI, 1991, ACTA CARDIOMIOL, V3, P35; DEVISSER M, 1992, MUSCLE NERVE, V15, P591, DOI 10.1002/mus.880150510; Emery A.E.H., 1993, DUCHENNE MUSCULAR DY; EMERY AEH, 1969, BMJ-BRIT MED J, V2, P418, DOI 10.1136/bmj.2.5654.418; EMERY AH, 1990, PRINCIPLES PRACTICE; HOFFMAN EP, 1987, CELL, V51, P919, DOI 10.1016/0092-8674(87)90579-4; ISHIKAWA Y, 1995, SEMIN NEUROL, V15, P93, DOI 10.1055/s-2008-1041013; KAMAKURA K, 1990, J NEUROL, V237, P483, DOI 10.1007/BF00314767; LANE RJM, 1980, NEUROLOGY, V30, P497, DOI 10.1212/WNL.30.5.497; LIMONGELLI FM, 1982, CARDIOMYOLOGY, V1, P105; NICHOLSON LVB, 1990, ACTA NEUROPATHOL, V80, P239, DOI 10.1007/BF00294640; NIGRO G, 1983, MUSCLE NERVE, V6, P253, DOI 10.1002/mus.880060403; NIGRO G, 1995, MUSCLE NERVE, V18, P283, DOI 10.1002/mus.880180304; NIGRO G, 1990, INT J CARDIOL, V26, P271, DOI 10.1016/0167-5273(90)90082-G; NIGRO G, 1994, NEUROMUSCULAR DISORD, V4, P371, DOI 10.1016/0960-8966(94)90073-6; NIGRO G, 1995, ANN NY ACAD SCI, V752, P108, DOI 10.1111/j.1749-6632.1995.tb17412.x; NIGRO G, 1976, P 7 EUR C CARD AMST, P421; Nigro G., 1984, CARDIOMYOLOGY, V3, P45; NIGRO V, 1994, HUM MOL GENET, V3, P1907, DOI 10.1093/hmg/3.10.1907; NIGRO V, 1992, HUM MOL GENET, V1, P517, DOI 10.1093/hmg/1.7.517; PERLOFF JK, 1992, J CARDIOVASC ELECTR, V3, P394, DOI 10.1111/j.1540-8167.1992.tb00982.x; PERLOFF JK, 1966, CIRCULATION, V33, P625, DOI 10.1161/01.CIR.33.4.625; Politano L, 1986, CARDIOMYOLOGY, V5, P139; POLITANO L, 1993, 5EME C NAT MAL NEUR; SALZER HR, 1984, CARDIOMYOLOGY, V3, P23; STEARE SE, 1992, BRIT HEART J, V68, P304; TOWBIN JA, 1990, PEDIATR RES, V27, pA25; WIEGAND V, 1984, Z KARDIOL, V73, P188	34	148	151	0	8	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 1	1996	275	17					1335	1338		10.1001/jama.275.17.1335	http://dx.doi.org/10.1001/jama.275.17.1335			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UG612	8614119				2022-12-28	WOS:A1996UG61200030
J	Blackstone, MO				Blackstone, MO			Hospital admission for low-risk acute upper gastrointestinal bleeding	LANCET			English	Editorial Material							HEMORRHAGE				Blackstone, MO (corresponding author), UNIV CHICAGO,DEPT MED,GASTROENTEROL SECT,CHICAGO,IL 60637, USA.							GRIFFITHS WJ, 1979, NEW ENGL J MED, V300, P1411, DOI 10.1056/NEJM197906213002503; LAINE L, 1994, NEW ENGL J MED, V331, P717, DOI 10.1056/NEJM199409153311107; LONGSTRETH GF, 1995, LANCET, V345, P108, DOI 10.1016/S0140-6736(95)90068-3; WARA P, 1985, GASTROENTEROLOGY, V88, P1209, DOI 10.1016/S0016-5085(85)80081-0; ZIMMERMAN J, 1995, SCAND J GASTROENTERO, V30, P327, DOI 10.3109/00365529509093285	5	2	2	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 27	1996	347	9009					1130	1130		10.1016/S0140-6736(96)90602-9	http://dx.doi.org/10.1016/S0140-6736(96)90602-9			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UG755	8609742				2022-12-28	WOS:A1996UG75500004
J	Joynt, GM; Gomersall, CD; Buckley, TA; Oh, TE; Young, RJ; Freebairn, RC				Joynt, GM; Gomersall, CD; Buckley, TA; Oh, TE; Young, RJ; Freebairn, RC			Comparison of intrathoracic and intra-abdominal measurements of central venous pressure	LANCET			English	Article							CRITICALLY ILL ADULTS; INFERIOR VENA-CAVA; FEMORAL VEIN; CATHETERIZATION; ACCURACY; PATIENT; ACCESS	Background Complications can arise from standard intrathoracic central venous pressure (CVP) measurements in critically ill, mechanically ventilated patients. We have assessed the feasibility of catheterisation by the femoral route to measure CVP in the abdomen (ACVP). We compared measurements by the standard jugular or subclavian route (TCVP) with simultaneous ACVP measurements by the femoral route. Methods Between June, 1994 and May, 1995, we recruited 20 critically ill adult patients with various disorders; all patients already had a TCVP line in situ. We placed a femoral catheter in the inferior vena cava close to the right atrium under electrocardiographic guidance. The catheter position was confirmed (and corrected if necessary) by chest radiography. CVP was measured from both sites hourly for 6 h. Positive end-expiratory pressure, mean airway pressure, and intra-abdominal pressure were recorded simultaneously. Findings One patient was excluded because radiography showed that the catheter position was incorrect. For 133 paired measurements of ACVP and TCVP in the remaining 19 patients, the mean difference was 0.45 mm Hg (SD 0.89; 95% CI 0.30-0.60); the limits of agreement were -1.33 to 2.23 mm Hg (-1.63 to 2.53). We found a small tendency for the difference between ACVP and TCVP to increase as positive end-expiratory pressure and mean airway pressure increased; the difference was statistically, but not clinically, significant. Interpretation Our study showed that for clinical purposes CVP can be measured by a femoral catheter placed in the abdominal inferior vena cava near the right atrium. This approach can replace standard TCVP measurements in critically ill, mechanically ventilated patients.			Joynt, GM (corresponding author), CHINESE UNIV HONG KONG,PRINCE WALES HOSP,DEPT ANAESTHESIA & INTENS CARE,SHA TIN,NEW TERR,HONG KONG.		Joynt, Gavin M/C-7606-2009; Gomersall, Charles D/J-1540-2012; Freebairn, Ross C/F-4255-2010	Joynt, Gavin M/0000-0002-5823-3435; Gomersall, Charles D/0000-0002-8494-8063; Freebairn, Ross/0000-0002-1967-8183				AGEE KR, 1992, CRIT CARE CLIN, V8, P677, DOI 10.1016/S0749-0704(18)30218-5; BERG RA, 1992, J PEDIATR-US, V120, P67, DOI 10.1016/S0022-3476(05)80600-6; BLAND JM, 1986, LANCET, V1, P307, DOI 10.1016/s0140-6736(86)90837-8; GETZEN LC, 1979, AM J SURG, V138, P875, DOI 10.1016/0002-9610(79)90314-3; GUYTON AC, 1973, AM HEART J, V86, P431, DOI 10.1016/0002-8703(73)90132-4; IBERTI TJ, 1989, ANESTHESIOLOGY, V70, P47, DOI 10.1097/00000542-198901000-00011; KANTER RK, 1986, PEDIATRICS, V77, P842; LLOYD TR, 1992, PEDIATRICS, V89, P506; MANGIANTE EC, 1988, J TRAUMA, V28, P1644, DOI 10.1097/00005373-198812000-00005; MCGEE WT, 1993, CRIT CARE MED, V21, P1118, DOI 10.1097/00003246-199308000-00008; OTTO CW, 1985, MONITORING ANESTHESI, P121; Purdue G F, 1986, J Burn Care Rehabil, V7, P498, DOI 10.1097/00004630-198611000-00011; RUSSELL JA, 1983, CRIT CARE MED, V11, P936, DOI 10.1097/00003246-198312000-00007; SELDINGER SI, 1953, ACTA RADIOL, V39, P368, DOI 10.3109/00016925309136722; SENEFF M, 1991, INTENS CARE MED, P17; SWANSON RS, 1984, ANN EMERG MED, V13, P244, DOI 10.1016/S0196-0644(84)80471-0; WILLIAMS JF, 1991, CRIT CARE MED, V19, P550, DOI 10.1097/00003246-199104000-00016; 1989, FDA DRUG B       JUL, P15	18	37	39	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 27	1996	347	9009					1155	1157		10.1016/S0140-6736(96)90611-X	http://dx.doi.org/10.1016/S0140-6736(96)90611-X			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UG755	8609751				2022-12-28	WOS:A1996UG75500013
J	Mahon, J; Laupacis, A; Donner, A; Wood, T				Mahon, J; Laupacis, A; Donner, A; Wood, T			Randomised study of n of 1 trials versus standard practice	BRITISH MEDICAL JOURNAL			English	Article							CLINICAL-TRIALS; INDIVIDUAL PATIENTS; AMITRIPTYLINE; THEOPHYLLINE; EXPERIENCE; THERAPY; BENEFIT; DISEASE; QUALITY; LIFE	Objective-To compare outcomes between groups of patients with irreversible chronic airflow limitation given theophylline by n of 1 trials or standard practice. Design-Randomised controlled study of n of 1 trials versus standard practice. Setting-Tertiary care centre outpatient department. Subjects-31 patients with irreversible chronic airflow limitation who were unsure that theophylline was helpful after an open trial. Interventions-n Of 1 trials (single patient randomised multiple crossover comparisons of theophylline against placebo) followed published guidelines. For standard practice patients theophylline was stopped and resumed if their dyspnoea worsened; if their dyspnoea then improved theophylline was continued. For both groups a decision to continue or stop the drug was made within three months of randomisation. Main outcome measures-Exercise capacity as measured by six minute walking distance, quality of life as measured by the chronic respiratory disease questionnaire at baseline and six months after randomisation, and proportions of patients taking theophylline at six months. Results-26 patients completed follow up. 47% fewer n of 1 trial patients than standard practice patients were taking theophylline at six months (5/14 versus 10/12; 95% confidence interval of difference 14% to 80%) without differences in exercise capacity or quality of life. Conclusions-n Of 1 trials led to less theophylline use without adverse effects on exercise capacity or quality of life in patients with irreversible chronic airflow limitation, These data directly support the presence of a clinically important bias towards unnecessary treatment during open prescription of theophylline for irreversible chronic airflow limitation. Confirmation in a larger study and similar studies for other problems appropriate for n of 1 trials are needed before widespread use of n of 1 trials can be advocated in routine clinical practice.	UNIV WESTERN ONTARIO,DEPT MED & EPIDEMIOL,LONDON,ON,CANADA; UNIV WESTERN ONTARIO,DEPT BIOSTAT & EPIDEMIOL,LONDON,ON,CANADA; UNIV WESTERN ONTARIO,DEPT MED,LONDON,ON,CANADA	Western University (University of Western Ontario); Western University (University of Western Ontario); Western University (University of Western Ontario)			Mahon, Jeff/G-3324-2011					BRUERA E, 1992, J PAIN SYMPTOM MANAG, V7, P365, DOI 10.1016/0885-3924(92)90091-U; CHATELLIER G, 1995, HYPERTENSION, V25, P294, DOI 10.1161/01.HYP.25.2.294; Colton T., 1974, STAT MED, V1; DALES RE, 1992, PHARMACOTHERAPY, V12, P331; GUYATT G, 1988, CAN MED ASSOC J, V139, P497; GUYATT G, 1986, NEW ENGL J MED, V314, P889, DOI 10.1056/NEJM198604033141406; GUYATT GH, 1990, ANN INTERN MED, V112, P293, DOI 10.7326/0003-4819-112-4-293; GUYATT GH, 1987, AM REV RESPIR DIS, V135, P1069; GUYATT GH, 1990, CONTROL CLIN TRIALS, V11, P88, DOI 10.1016/0197-2456(90)90003-K; GUYATT GH, 1987, THORAX, V42, P773, DOI 10.1136/thx.42.10.773; HOOGWERF BJ, 1985, DIABETES CARE, V8, P526, DOI 10.2337/diacare.8.5.526; IRWIG L, 1995, LANCET, V345, P469, DOI 10.1016/S0140-6736(95)90578-2; JAESCHKE R, 1991, J RHEUMATOL, V18, P447; JAESCHKE R, 1989, CONTROL CLIN TRIALS, V10, P407, DOI 10.1016/0197-2456(89)90005-6; JOHANNESSEN T, 1992, SCAND J GASTROENTERO, V27, P189, DOI 10.3109/00365529208999947; JOHANNESSEN T, 1991, BMJ-BRIT MED J, V303, P173, DOI 10.1136/bmj.303.6795.173; LARSON EB, 1993, JAMA-J AM MED ASSOC, V270, P2708, DOI 10.1001/jama.270.22.2708; LARSON EB, 1990, WESTERN J MED, V152, P52; LEVITT AJ, 1990, CAN MED ASSOC J, V142, P341; LINKS PS, 1992, CAN J PSYCHIAT, V37, P148, DOI 10.1177/070674379203700223; MARCH L, 1994, BRIT MED J, V309, P1041, DOI 10.1136/bmj.309.6961.1041; MCLEOD RS, 1986, LANCET, V1, P726; MURCIANO D, 1989, NEW ENGL J MED, V320, P1521, DOI 10.1056/NEJM198906083202304; NEWHOUSE MT, 1990, CHEST, V98, P1, DOI 10.1378/chest.98.1.1; Nuovo J, 1992, J Am Board Fam Pract, V5, P137; PATEL A, 1991, AM REV RESPIR DIS, V44, P962; PETERSEN H, 1988, SCAND J GASTROE S147, V23, P7; PORTA MS, 1986, J GEN INTERN MED, V1, P418, DOI 10.1007/BF02596430; ROBIN ED, 1986, CHEST, V90, P888, DOI 10.1378/chest.90.6.888; WHITE JC, 1992, J CLIN PSYCHIAT, V53, P153; [No title captured]; 1986, LANCET, V1, P1254	32	67	69	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 27	1996	312	7038					1069	1074						6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UH816	8616414				2022-12-28	WOS:A1996UH81600025
J	Dubrova, YE; Nesterov, VN; Krouchinsky, NG; Ostapenko, VA; Neumann, R; Neil, DL; Jeffreys, AJ				Dubrova, YE; Nesterov, VN; Krouchinsky, NG; Ostapenko, VA; Neumann, R; Neil, DL; Jeffreys, AJ			Human minisatellite mutation rate after the Chernobyl accident	NATURE			English	Article							IONIZING-RADIATION; HUMAN DNA; CHILDREN; LENGTH; LOCI	Germline mutation at human minisatellite loci has been studied among children horn in heavily polluted areas of the Mogilev district of Belarus after the Chernobyl accident and in a control population. The frequency of mutation was found to be twice as high in the exposed families as in the control group. Mutation rate in the Mogilev families was correlated with the level of caesium-137 surface contamination, consistent with radiation induction of germline mutation.	UNIV LEICESTER, DEPT GENET, LEICESTER LE1 7RH, LEICS, ENGLAND; RES INST RADIAT MED, MOGILYOV 212004, BELARUS	University of Leicester			Dubrova, Yuri/ABA-7148-2020	Neil, David/0000-0002-9994-9536; Dubrova, Yuri/0000-0001-5281-7539	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ANSPAUGH LR, 1988, SCIENCE, V242, P1513, DOI 10.1126/science.3201240; BOCHKOV NP, 1993, VESTN ROS AKAD MED+, P51; CROMPTON NEA, 1990, RADIAT RES, V124, P300, DOI 10.2307/3577843; DROSDOVITCH VV, 1989, PROGNOSIS DOSES EXPO; DUBROVA YE, 1993, NAT GENET, V5, P92, DOI 10.1038/ng0993-92; FAN YF, 1995, NT J RAD BIOL, V68, P177; GIVER CR, 1995, CARCINOGENESIS, V16, P267, DOI 10.1093/carcin/16.2.267; JEFFREYS AJ, 1994, NAT GENET, V6, P136, DOI 10.1038/ng0294-136; JEFFREYS AJ, 1991, NATURE, V354, P204, DOI 10.1038/354204a0; JEFFREYS AJ, 1988, NATURE, V332, P278, DOI 10.1038/332278a0; JEFFREYS AJ, 1991, AM J HUM GENET, V48, P824; JEFFREYS AJ, 1985, NATURE, V314, P67, DOI 10.1038/314067a0; KAZAKOV VS, 1992, NATURE, V359, P21, DOI 10.1038/359021a0; KENIGSBERG YE, 1994, CHERNOBYL DISASTER M, P18; KIEFER J, 1988, RADIAT RES, V113, P71, DOI 10.2307/3577181; KODAIRA M, 1995, AM J HUM GENET, V57, P1275; LAZJUK GI, 1993, CHERNOBYL PAPERS, V1, P385; LAZYUK GI, 1994, GENETIKA+, V30, P1268; LIKHTAREV IA, 1995, NATURE, V375, P365, DOI 10.1038/375365a0; LUNING KG, 1971, MUTAT RES, V12, P291, DOI 10.1016/0027-5107(71)90017-0; MONCKTON DG, 1994, NAT GENET, V8, P162, DOI 10.1038/ng1094-162; NEEL JV, 1988, AM J HUM GENET, V42, P663; NEEL JV, 1990, AM J HUM GENET, V46, P1053; NEEL JV, 1980, P 14 INT C GEN MIR, V1, P235; NELSON SL, 1994, CARCINOGENESIS, V15, P495, DOI 10.1093/carcin/15.3.495; ORLOV MY, 1992, ATOM ENERGY+, V72, P334, DOI 10.1007/BF00760881; SADAMOTO S, 1994, INT J RADIAT BIOL, V65, P549, DOI 10.1080/09553009414550641; SOUTHERN EM, 1979, ANAL BIOCHEM, V100, P319, DOI 10.1016/0003-2697(79)90235-5; VERGNAUD G, 1991, GENOMICS, V11, P135, DOI 10.1016/0888-7543(91)90110-Z; WARD JF, 1990, INT J RADIAT BIOL, V57, P1141, DOI 10.1080/09553009014551251; WONG Z, 1987, ANN HUM GENET, V51, P269, DOI 10.1111/j.1469-1809.1987.tb01062.x	31	315	337	0	63	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 25	1996	380	6576					683	686		10.1038/380683a0	http://dx.doi.org/10.1038/380683a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UG827	8614461				2022-12-28	WOS:A1996UG82700040
J	Kobayashi, S; Yamada, M; Asaoka, M; Kitamura, T				Kobayashi, S; Yamada, M; Asaoka, M; Kitamura, T			Essential role of the posterior morphogen nanos for germline development in Drosophila	NATURE			English	Article							POLE CELL-FORMATION; MATERNAL GENE; BODY PATTERN; EMBRYO; PLASM; SEGMENTATION; ANTERIOR; OSKAR; ANTEROPOSTERIOR; MELANOGASTER	IN many animal groups, factors required for germline formation are localized in germ plasm(1), a region of the egg cytoplasm, In Drosophila embryos, germ plasm is located in the posterior pole region and is inherited in pole cells, the germline progenitors. Transplantation experiments have demonstrated that germ plasm contains factors that can form germline(2-4), and germ plasm also directs abdomen formation(5). Genetic analysis has shown that a common mechanism directs the localization of the abdomen and germline-forming factors to the posterior pole(6-12). The critical factor for abdomen formation is the nanos (nos) protein (nanos)(13-15). Here we show that nos is also essential for germline formation in Drosophila; pole cells lacking nanos activity fail to migrate into the gonads, and so do not become functional germ cells. In such pole cells, gene expression, which normally initiates within the gonad, begins prematurely during pole cell migration. Premature activation of genes in germline precursors may mean that these cells fail to develop normally. A function for nos protein in Drosophila germline formation is compatible with observations of its association with germ plasm in other animals(16-18).	UNIV TSUKUBA, CTR TSUKUBA ADV RES ALLIANCE, TSUKUBA, IBARAKI 305, JAPAN	University of Tsukuba	Kobayashi, S (corresponding author), UNIV TSUKUBA, INST BIOL SCI, GENE EXPT CTR, TSUKUBA, IBARAKI 305, JAPAN.		Yamada, Masashi/AAQ-1314-2021; Yamada, Masashi/AAI-1059-2020	Yamada, Masashi/0000-0002-8660-1653; Asaoka, Miho/0000-0001-5591-8626				BARKER DD, 1992, GENE DEV, V6, P2312, DOI 10.1101/gad.6.12a.2312; BOSWELL RE, 1985, CELL, V43, P97, DOI 10.1016/0092-8674(85)90015-7; BOSWELL RE, 1991, DEVELOPMENT, V113, P373; Campos-Ortega J.A., 2013, EMBRYONIC DEV DROSOP; CURTIS D, 1995, DEVELOPMENT, V121, P1899; EDDY EM, 1975, INT REV CYTOL, V43, P229; EPHRUSSI A, 1992, NATURE, V358, P387, DOI 10.1038/358387a0; FORRISTALL C, 1995, DEVELOPMENT, V121, P201; FROHNHOFER HG, 1986, J EMBRYOL EXP MORPH, V97, P169; HULSKAMP M, 1989, NATURE, V338, P629, DOI 10.1038/338629a0; ILLMENSEE K, 1974, P NATL ACAD SCI USA, V71, P1016, DOI 10.1073/pnas.71.4.1016; ILLMENSEE K, 1976, EXP CELL RES, V97, P127, DOI 10.1016/0014-4827(76)90662-5; IRISH V, 1989, NATURE, V338, P646, DOI 10.1038/338646a0; KOBAYASHI S, 1993, BIOTECH HISTOCHEM, V68, P237, DOI 10.3109/10520299309104704; KOBAYASHI S, 1993, DEVELOPMENT, V117, P885; LEHMANN R, 1991, DEVELOPMENT, V112, P679; LEHMANN R, 1986, CELL, V47, P141, DOI 10.1016/0092-8674(86)90375-2; LEHMANN R, 1987, DEV BIOL, V119, P402, DOI 10.1016/0012-1606(87)90045-5; MANSEAU LJ, 1989, GENE DEV, V3, P1437, DOI 10.1101/gad.3.9.1437; MOSQUERA L, 1993, DEVELOPMENT, V117, P377; OKADA M, 1974, DEV BIOL, V37, P43, DOI 10.1016/0012-1606(74)90168-7; OLIVER B, 1987, GENE DEV, V1, P913, DOI 10.1101/gad.1.9.913; SCHUEPBACH T, 1986, Wilhelm Roux's Archives of Developmental Biology, V195, P302; SMITH JL, 1992, CELL, V70, P849, DOI 10.1016/0092-8674(92)90318-7; STRUHL G, 1989, NATURE, V338, P741, DOI 10.1038/338741a0; WANG C, 1991, CELL, V66, P637, DOI 10.1016/0092-8674(91)90110-K; WANG C, 1994, DEV DYNAM, V199, P103, DOI 10.1002/aja.1001990204; WARRIOR R, 1994, DEV BIOL, V166, P180, DOI 10.1006/dbio.1994.1306; WHARTON RP, 1991, CELL, V67, P955, DOI 10.1016/0092-8674(91)90368-9	29	239	251	0	41	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	APR 25	1996	380	6576					708	711		10.1038/380708a0	http://dx.doi.org/10.1038/380708a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UG827	8614464				2022-12-28	WOS:A1996UG82700050
J	Watt, GCM				Watt, GCM			All together now: Why social deprivation matters to everyone	BRITISH MEDICAL JOURNAL			English	Article							CARDIOVASCULAR-DISEASE; GENERAL-PRACTICE; HEALTH; PREVENTION; DEPRESSION; EDINBURGH; GLASGOW; RISK	Inequalities in health in the United Kingdom are widening as a result of economic policy. By focusing on specific diseases, health policy fails to address why less prosperous groups die earlier from most major categories of death. By concentrating on actions which can be taken by individuals and local communities health policy ignores actions which require the support and involvement of society as a whole. Clinicians see the consequences of health and economic policy in their everyday practice and could contribute more effectively to public debate. There is a crying need to improve public and professional understanding of the links between health, education, and economic policy and the consequences for everyone of the increasing social and economic exclusion of a substantial proportion of the population.			Watt, GCM (corresponding author), UNIV GLASGOW,WOODSIDE HLTH CTR,GLASGOW G20 7LR,LANARK,SCOTLAND.							BALARAJAN R, 1992, BRIT MED J, V304, P529, DOI 10.1136/bmj.304.6826.529; Barker D. J. P., 1994, MOTHERS BABIES DIS L; BREMNER S, 1995, CALCULATION ABRIDGED; DELAMOTHE T, 1992, BRIT MED J, V305, P263, DOI 10.1136/bmj.305.6848.263; *DEP SOC SEC, 1993, HOUS AV INC 1979 199; Eachus J, 1996, BMJ-BRIT MED J, V312, P287; EBRAHIM S, 1995, BRIT J GEN PRACT, V45, P283; Goldberg DP., 1992, COMMON MENTAL DISORD; HART JT, 1971, LANCET, V1, P405, DOI 10.1016/S0140-6736(71)92410-X; HASTINGS A, 1993, BRIT J GEN PRACT, V43, P47; HOBBS R, 1993, BRIT MED J, V306, P534, DOI 10.1136/bmj.306.6877.534; JUDGE K, 1995, BRIT MED J, V311, P1282, DOI 10.1136/bmj.311.7015.1282; KENDELL RE, 1984, ALCOHOL ALCOHOLISM, V19, P271; KOTTKE TE, 1985, AM J EPIDEMIOL, V121, P697, DOI 10.1093/aje/121.5.697; MACINTYRE S, IN PRESS SOC SCI MED; MCCARRON PG, 1994, BRIT MED J, V309, P1481, DOI 10.1136/bmj.309.6967.1481; MOSER K, 1991, LONGITUDINAL STUDY M; *NHS CTR REV DISS, 1995, REV RES EFF HLTH SER; PAYKEL ES, 1992, BRIT MED J, V305, P1198, DOI 10.1136/bmj.305.6863.1198; PRIEST RG, 1991, BRIT J GEN PRACT, V41, P487; *PUBL HLTH POL UN, 1996, COR HEART DIS SCOTL; ROSE G, 1990, BRIT MED J, V301, P1031, DOI 10.1136/bmj.301.6759.1031; ROSE G, 1981, BMJ-BRIT MED J, V282, P1847, DOI 10.1136/bmj.282.6279.1847; Rose G., 1992, STRATEGY PREVENTIVE; Scott NC, 1979, J ROY COLL GEN PRACT, V29, P201; SMITH GD, 1993, BRIT MED J, V307, P1085, DOI 10.1136/bmj.307.6912.1085; SMITH GD, 1990, BMJ-BRIT MED J, V301, P373, DOI 10.1136/bmj.301.6748.373; SMITH GD, IN PRESS AM J PUB HL; SMITH WCS, 1990, J CLIN EPIDEMIOL, V43, P637, DOI 10.1016/0895-4356(90)90033-L; TOWNSEND P, 1994, BRIT MED J, V309, P1674, DOI 10.1136/bmj.309.6970.1674; TUNSTALLPEDOE H, 1989, SCOT MED J, V34, P556, DOI 10.1177/003693308903400604; Watt G C, 1993, Health Bull (Edinb), V51, P407; WATT GCM, 1992, J EPIDEMIOL COMMUN H, V46, P498, DOI 10.1136/jech.46.5.498; WATT GCM, 1994, BRIT MED J, V309, P1030, DOI 10.1136/bmj.309.6961.1030; WILKINSON R, 1992, BRIT MED J, V304, P164	35	39	39	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 20	1996	312	7037					1026	1029						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UG610	8616353				2022-12-28	WOS:A1996UG61000032
J	Ballard, CG; Eastwood, C; Gahir, M; Wilcock, G				Ballard, CG; Eastwood, C; Gahir, M; Wilcock, G			A follow up study of depression in the carers of dementia sufferers	BRITISH MEDICAL JOURNAL			English	Article									YARDLEY GREEN HOSP,BIRMINGHAM B9 5SS,W MIDLANDS,ENGLAND; REASIDE CLIN,BIRMINGHAM B45 9BE,W MIDLANDS,ENGLAND; FRENCHAY HOSP,BRISTOL BS16 1LE,AVON,ENGLAND		Ballard, CG (corresponding author), NEWCASTLE GEN HOSP,MRC,NEUROCHEM PATHOL UNIT,NEWCASTLE TYNE NE4 6BE,TYNE & WEAR,ENGLAND.			Ballard, Clive/0000-0003-0022-5632				BALLARD CG, 1995, INT J GERIATR PSYCH, V10, P477, DOI 10.1002/gps.930100607; COOPE B, 1995, INT J GERIATR PSYCH, V10, P237, DOI 10.1002/gps.930100310; COSTELLO CG, 1990, BR J PSYCH, V157, P612; MORRIS RG, 1988, BRIT J PSYCHIAT, V153, P147, DOI 10.1192/bjp.153.2.147; PEARLIN LI, 1990, GERONTOLOGIST, V30, P583, DOI 10.1093/geront/30.5.583	5	51	51	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 13	1996	312	7036					947	947						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	UF659	8616308				2022-12-28	WOS:A1996UF65900020
J	CastroAlamancos, MA; Connors, BW				CastroAlamancos, MA; Connors, BW			Short-term plasticity of a thalamocortical pathway dynamically modulated by behavioral state	SCIENCE			English	Article							AUGMENTING RESPONSES; NEURONS; CAT; RAT; NEOCORTEX; CORTEX; NOREPINEPHRINE; POTENTIALS	The neocortex receives information about the environment and the rest of the brain through pathways from the thalamus. These pathways have frequency-dependent properties that can strongly influence their effect on the neocortex. In 1943 Morison and Dempsey described "augmenting responses," a form of short-term plasticity in some thalamocortical pathways that is triggered by 8- to 15-hertz activation. Results from anesthetized rats showed that the augmenting response is initiated by pyramidal cells in layer V. The augmenting response was also observed in awake, unrestrained animals and was found to be dynamically modulated by their behavioral state.			CastroAlamancos, MA (corresponding author), BROWN UNIV, DEPT NEUROSCI, PROVIDENCE, RI 02912 USA.		Connors, Barry/AAX-1975-2020	Connors, Barry/0000-0002-3739-3157; Castro-Alamancos, Manuel/0000-0002-2916-9585	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS025983] Funding Source: NIH RePORTER; NIMH NIH HHS [MH19118] Funding Source: Medline; NINDS NIH HHS [NS25983] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AGMON A, 1992, J NEUROSCI, V12, P319; ASTONJONES G, 1981, J NEUROSCI, V1, P876; CASTROALAMANCOS MA, 1993, NEUROSCIENCE, V52, P637, DOI 10.1016/0306-4522(93)90412-9; CastroAlamancos MA, 1996, J NEUROSCI, V16, P2767; CASTROALAMANCOS MA, 1995, NEUROSCIENCE, V68, P793, DOI 10.1016/0306-4522(95)00178-L; CASTROALAMANCOS MA, 1995, J NEUROSCI, V15, P5324; CONNORS BW, 1988, J PHYSIOL-LONDON, V406, P443, DOI 10.1113/jphysiol.1988.sp017390; Cooper J.R., 1991, BIOCH BASIS NEUROPHA; Dempsey EW, 1943, AM J PHYSIOL, V138, P0283, DOI 10.1152/ajplegacy.1943.138.2.283; FERSTER D, 1985, J PHYSIOL-LONDON, V367, P217, DOI 10.1113/jphysiol.1985.sp015821; GLENN LL, 1982, NEUROSCIENCE, V7, P1861, DOI 10.1016/0306-4522(82)90003-3; HERKENHAM M, 1980, SCIENCE, V207, P532, DOI 10.1126/science.7352263; Herkenham M., 1986, CEREB CORTEX, V5, P403; JONES EG, 1986, CEREBRAL CORTEX, V5; MITZDORF U, 1985, PHYSIOL REV, V65, P37, DOI 10.1152/physrev.1985.65.1.37; MORIN D, 1981, BRAIN RES, V205, P49, DOI 10.1016/0006-8993(81)90719-8; Morison RS, 1943, AM J PHYSIOL, V138, P0297, DOI 10.1152/ajplegacy.1943.138.2.297; NICOLELIS MAL, 1995, SCIENCE, V268, P1353, DOI 10.1126/science.7761855; Paxinos G., 2004, J CHEM INF MODEL, V5th; PURPURA DP, 1964, J NEUROPHYSIOL, V27, P117, DOI 10.1152/jn.1964.27.2.117; SASAKI K, 1970, Experimental Neurology, V26, P369, DOI 10.1016/0014-4886(70)90133-0; SEMBA K, 1984, NEUROSCIENCE, V12, P761, DOI 10.1016/0306-4522(84)90168-4; SILVA LR, 1991, SCIENCE, V251, P432, DOI 10.1126/science.1824881; SOMOGYI P, 1990, NEURAL MECHANISMS VI, P35; SPENCER WA, 1961, J NEUROPHYSIOL, V24, P26, DOI 10.1152/jn.1961.24.1.26; STERIADE M, 1969, J NEUROPHYSIOL, V32, P251, DOI 10.1152/jn.1969.32.2.251; STERIADE M, 1981, BRAIN RES, V205, P67, DOI 10.1016/0006-8993(81)90720-4; Steriade M., 1990, THALAMIC OSCILLATION; VANDERWOLF CH, 1988, INT REV NEUROBIOL, V30, P225; WANG Z, 1993, J NEUROSCI, V13, P2199; ZUCKER RS, 1989, ANNU REV NEUROSCI, V12, P13, DOI 10.1146/annurev.neuro.12.1.13	31	81	81	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	APR 12	1996	272	5259					274	277		10.1126/science.272.5259.274	http://dx.doi.org/10.1126/science.272.5259.274			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UE729	8602513				2022-12-28	WOS:A1996UE72900043
J	Carr, CS; Ling, KDE; Boulos, P; Singer, M				Carr, CS; Ling, KDE; Boulos, P; Singer, M			Randomised trial of safety and efficacy of immediate postoperative enteral feeding in patients undergoing gastrointestinal resection	BRITISH MEDICAL JOURNAL			English	Article							INTESTINAL PERMEABILITY; COMPLICATIONS; NUTRITION; ENDOTOXIN; HUMANS; MUSCLE	Objectives-To assess whether immediate postoperative enteral feeding in patients who have undergone gastrointestinal resection is safe and effective. Design-Randomised trial of immediate postoperative enteral feeding through a nasojejunal tube v conventional postoperative intravenous fluids until the reintroduction of normal diet. Setting-Teaching hospitals in London. Subjects-30 patients under the care of the participating consultant surgeon who were undergoing elective laparotomies with a view to gastrointestinal resection for quiescent, chronic gastrointestinal disease. Two patients did not proceed to resection. Main outcome measures-Nutritional state, nutritional intake and nitrogen balance, gut mucosal permeability measured by lactulose-mannitol differential sugar absorption test, complications, and outcome. Results-Successful immediate enteral feeding was established in all 14 patients, with a mean (SD) daily intake of 6.78 (1.57) MJ (1622 (375) kcal before reintroduction of oral diet compared with 1.58 (0.14) MJ (377 (34) kcal) for those on intravenous fluids (P<0.0001). Urinary nitrogen balance on the first postoperative day was negative in those on intravenous fluids but positive in all 14 enterally fed patients (mean (SD) -13.2 (11.6) g v 5.3 (2.7) g; P<0 005). There was no difference by day 5. There was no change in gut mucosal permeability in the enterally fed group but a significant increase from the test ratios seen before the operation in those on intravenous fluids (0.11 (0.06) v 0.15 (0.12); P<0.005). There were also fewer postoperative complications in the enterally fed group (P< 0.005). Conclusions-Immediate postoperative enteral feeding in patients undergoing intestinal resection seems to be safe, prevents an increase in gut mucosal permeability, and produces a positive nitrogen balance.	UCL, DEPT MED, BLOOMSBURY INST INTENS CARE MED, LONDON WC1E 6JJ, ENGLAND; UCL, MIDDLESEX HOSP, SCH MED, DEPT CARDIOTHORAC SURG, LONDON W1N 8AA, ENGLAND; UCL, MIDDLESEX HOSP, SCH MED, DEPT SURG, LONDON W1N 8AA, ENGLAND; UCL, WHITTINGTON HOSP, SCH MED, DEPT MED, LONDON N19 5NF, ENGLAND	University of London; University College London; University of London; University College London; UCL Medical School; University of London; University College London; UCL Medical School; University of London; University College London; UCL Medical School			Singer, Mervyn/J-4425-2012	Singer, Mervyn/0000-0002-1042-6350				BUZBY G P, 1991, New England Journal of Medicine, V325, P525; CATCHPOLE BN, 1989, AUST NZ J SURG, V59, P199, DOI 10.1111/j.1445-2197.1989.tb01502.x; CHIARELLI A, 1990, AM J CLIN NUTR, V51, P1035, DOI 10.1093/ajcn/51.6.1035; ELEBUTE EA, 1983, BRIT J SURG, V70, P29, DOI 10.1002/bjs.1800700111; FONG YM, 1989, ANN SURG, V210, P449, DOI 10.1097/00000658-198910000-00005; HARRIS CE, 1992, INTENS CARE MED, V18, P38, DOI 10.1007/BF01706424; JOHNSON LR, 1975, GASTROENTEROLOGY, V68, P1177; KAPPERSKLUNNE MC, 1989, CANCER, V64, P1747, DOI 10.1002/1097-0142(19891015)64:8<1747::AID-CNCR2820640832>3.0.CO;2-F; KUDSK K, 1991, ANN SURG, V5, P503; MOORE EE, 1986, J TRAUMA, V26, P874, DOI 10.1097/00005373-198610000-00003; MOORE F, 1995, CLIN INTENSIVE CARE, V6, P1; ODWYER ST, 1988, ARCH SURG-CHICAGO, V123, P1459; ROUMEN RMH, 1993, J VASC SURG, V17, P734, DOI 10.1016/0741-5214(93)90118-6; SCHROEDER D, 1991, JPEN-PARENTER ENTER, V15, P376, DOI 10.1177/0148607191015004376; WEBB AR, 1989, JPEN-PARENTER ENTER, V13, P30, DOI 10.1177/014860718901300130; ZIEGLER TR, 1988, ARCH SURG-CHICAGO, V123, P1313	16	163	169	0	3	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	APR 6	1996	312	7035					869	871						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UE371	8611872	Green Published			2022-12-28	WOS:A1996UE37100016
J	Carmeliet, P; Ferreira, V; Breier, G; Pollefeyt, S; Kieckens, L; Gertsenstein, M; Fahrig, M; Vandenhoeck, A; Harpal, K; Eberhardt, C; Declercq, C; Pawling, J; Moons, L; Collen, D; Risau, W; Nagy, A				Carmeliet, P; Ferreira, V; Breier, G; Pollefeyt, S; Kieckens, L; Gertsenstein, M; Fahrig, M; Vandenhoeck, A; Harpal, K; Eberhardt, C; Declercq, C; Pawling, J; Moons, L; Collen, D; Risau, W; Nagy, A			Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele	NATURE			English	Article							ENDOTHELIAL GROWTH-FACTOR; TYROSINE KINASE; STEM-CELLS; MICE; ANGIOGENESIS; EXPRESSION; GENE; VASCULOGENESIS; RECEPTOR	THE endothelial cell-specific vascular endothelial growth factor (VEGF)(1-5) and its cellular receptors Flt-1 (refs 6,7) and Flk-1 (refs 8,9) have been implicated in the formation of the embryonic vasculature. This is suggested by their colocalized expression during embryogenesis(10,11) and the impaired vessel formation in Flk-1 (ref. 12) and Flt-1 (ref. 13) deficient embryos. However, because Flt-1 also binds placental growth factor(14,15), a VEGF homologue, the precise role of VEGF was unknown. Here we report that formation of blood vessels was abnormal, but not abolished, in heterozygous VEGF-deficient (VEGF(+/-)) embryos, generated by aggregation of embryonic stem (ES) cells with tetraploid embryos (T-ES)(16,17), and more impaired in homozygous VEGF-deficient (VEGF(-/-)) T-ES embryos, resulting in death at mid-gestation. Similar phenotypes were observed in F-1-VEGF(+/-) embryos, generated by germline transmission. We believe that this heterozygous lethal phenotype, which differs from the homozygous lethality in VEGF-receptor-deficient embryos, is unprecedented for a targeted autosomal gene inactivation, and is indicative of a tight dose-dependent regulation of embryonic vessel development by VEGF.	MAX PLANCK INST PHYSIOL & CLIN RES, WG KERCKHOFF INST, ABT MOL ZELLBIOL, BAD NAUHEIM, GERMANY; MT SINAI HOSP, SAMUEL LUNENFELD RES INST, TORONTO, ON M5G 1X5, CANADA; UNIV TORONTO, DEPT MED GENET, TORONTO, ON M5S 1A1, CANADA	Max Planck Society; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto	Carmeliet, P (corresponding author), CATHOLIC UNIV LEUVEN VIB, CTR TRANSGENE TECHNOL & GENE THERAPY, B-3000 LOUVAIN, BELGIUM.		Breier, Georg/E-3580-2016; Carmeliet, Peter/AAQ-5140-2020; Nagy, Andras/G-6465-2013	Breier, Georg/0000-0002-9467-780X; Carmeliet, Peter/0000-0001-7961-1821; Nagy, Andras/0000-0003-4311-0413; Moons, Lieve (Godelieve)/0000-0003-0186-1411				ALON T, 1995, NAT MED, V1, P1024, DOI 10.1038/nm1095-1024; BREIER G, 1992, DEVELOPMENT, V114, P521; BREIER G, 1995, DEV DYNAM, V204, P228, DOI 10.1002/aja.1002040303; CARMELIET P, 1993, J CLIN INVEST, V92, P2746, DOI 10.1172/JCI116892; CLAFFEY KP, 1995, BBA-PROTEIN STRUCT M, V1246, P1, DOI 10.1016/0167-4838(94)00144-6; DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256; DVORAK HF, 1995, AM J PATHOL, V146, P1029; FERRARA N, 1993, TRENDS CARDIOVAS MED, V3, P244, DOI 10.1016/1050-1738(93)90046-9; FONG GH, 1995, NATURE, V376, P66, DOI 10.1038/376066a0; FRIEDRICH G, 1991, GENE DEV, V5, P1513, DOI 10.1101/gad.5.9.1513; KLAGSBRUN M, 1993, CURR BIOL, V3, P699, DOI 10.1016/0960-9822(93)90073-W; MAGLIONE D, 1991, P NATL ACAD SCI USA, V88, P9276; MILLAUER B, 1993, CELL, V72, P835, DOI 10.1016/0092-8674(93)90573-9; MUSTONEN T, 1995, J CELL BIOL, V129, P895, DOI 10.1083/jcb.129.4.895; NAGY A, 1993, P NATL ACAD SCI USA, V90, P8424, DOI 10.1073/pnas.90.18.8424; NAGY A, 1994, GENE TARGETING PRACT, P147; Neufeld Gera, 1994, Progress in Growth Factor Research, V5, P89, DOI 10.1016/0955-2235(94)90019-1; PARK JE, 1994, J BIOL CHEM, V269, P25646; PLATE KH, 1994, BRAIN PATHOL, V4, P207, DOI 10.1111/j.1750-3639.1994.tb00835.x; POTGENS AJG, 1994, J BIOL CHEM, V269, P32879; PURI MC, 1995, EMBO J, V14, P5884, DOI 10.1002/j.1460-2075.1995.tb00276.x; RISAU W, 1988, DEVELOPMENT, V102, P471; Risau W, 1995, ANNU REV CELL DEV BI, V11, P73, DOI 10.1146/annurev.cb.11.110195.000445; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; SHIBUYA M, 1990, ONCOGENE, V5, P519; STAVRI GT, 1995, FEBS LETT, V358, P311, DOI 10.1016/0014-5793(94)01458-D; TISCHER E, 1991, J BIOL CHEM, V266, P11947; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M	28	3150	3324	2	147	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	APR 4	1996	380	6573					435	439		10.1038/380435a0	http://dx.doi.org/10.1038/380435a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UD590	8602241				2022-12-28	WOS:A1996UD59000061
J	Sawatari, A; Callaway, EM				Sawatari, A; Callaway, EM			Convergence of magno- and parvocellular pathways in layer 4B of macaque primary visual cortex	NATURE			English	Article							SLICES; PARALLEL	EARLY visual processing is characterized by two independent parallel pathways: the magnocellular stream, which carries information useful for motion analysis, and the parvocellular stream, which carries information useful for analyses of shape and colour(1-3). Although increasing anatomical and physiological evidence indicates some degree of convergence of the two streams, the pathway through layer 4B of primary visual cortex (V1) and on to higher cortical areas is usually considered to carry only magnocellular input(1-3). This is inferred from anatomical descriptions of local circuitry in V1, and functional studies of area MT, which receives input from layer 4B(4-7). We have directly measured the sources of local functional input to individual layer 4B neurons by combining intracellular recording and biocytin labelling with laser-scanning photostimulations(8-10). We found that most layer 4B neurons receive strong input from both magnocellular-stream-recipient layer 4C alpha neurons and parvocellular-stream-recipient layer 4C beta neurons. Thus higher cortical areas that receive input either directly or indirectly from layer 4B are likely to be more strongly influenced by the parvocellular pathway than previously believed.			Sawatari, A (corresponding author), SALK INST BIOL STUDIES,MOLEC NEUROBIOL LAB,10010 N TORREY PINES RD,LA JOLLA,CA 92037, USA.		Callaway, Edward/D-4336-2011	Callaway, Edward/0000-0002-6366-5267				ALLEN C, 1994, P NATL ACAD SCI USA, V91, P10380, DOI 10.1073/pnas.91.22.10380; BLANTON MG, 1989, J NEUROSCI METH, V30, P203, DOI 10.1016/0165-0270(89)90131-3; CALLAWAY EM, 1993, P NATL ACAD SCI USA, V90, P7661, DOI 10.1073/pnas.90.16.7661; DALVA MB, 1994, SCIENCE, V265, P255, DOI 10.1126/science.7912852; KATZ LC, 1994, J NEUROSCI METH, V54, P205, DOI 10.1016/0165-0270(94)90194-5; LACHICA EA, 1992, P NATL ACAD SCI USA, V89, P3566, DOI 10.1073/pnas.89.8.3566; LIVINGSTONE M, 1988, SCIENCE, V240, P740, DOI 10.1126/science.3283936; LUND JS, 1988, ANNU REV NEUROSCI, V11, P253, DOI 10.1146/annurev.ne.11.030188.001345; MAUNSELL JHR, 1990, J NEUROSCI, V10, P3323; MERIGAN WH, 1993, ANNU REV NEUROSCI, V16, P369, DOI 10.1146/annurev.ne.16.030193.002101; RAASTAD M, 1992, EUR J NEUROSCI, V4, P113, DOI 10.1111/j.1460-9568.1992.tb00114.x; STEVENS CF, 1995, NEURON, V14, P795, DOI 10.1016/0896-6273(95)90223-6; Van Essen D. C., 1994, COGNITIVE NEUROSCIEN; WIEBOLDT R, 1994, P NATL ACAD SCI USA, V91, P8752, DOI 10.1073/pnas.91.19.8752; YOSHIOKA T, 1994, VISUAL NEUROSCI, V11, P467, DOI 10.1017/S0952523800002406	15	129	133	0	8	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	APR 4	1996	380	6573					442	446		10.1038/380442a0	http://dx.doi.org/10.1038/380442a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UD590	8602243				2022-12-28	WOS:A1996UD59000063
J	Vale, RD; Funatsu, T; Pierce, DW; Romberg, L; Harada, Y; Yanagida, T				Vale, RD; Funatsu, T; Pierce, DW; Romberg, L; Harada, Y; Yanagida, T			Direct observation of single kinesin molecules moving along microtubules	NATURE			English	Article							HEAVY-CHAIN; MOVEMENT; DOMAIN; MOTOR; EXPRESSION	KINESIN is a two-headed motor protein that powers organelle transport along microtubules(1). Many ATP molecules are hydrolysed by kinesin for each diffusional encounter with the microtubule(2,3). Here we report the development of a new assay in which the processive movement of individual fluorescently labelled kinesin molecules along a microtubule can be visualized directly; this observation is achieved by low-background total internal reflection fluorescence microscopy(4) in the absence of attachment of the motor to a cargo (for example, an organelle or bead). The average distance travelled after a binding encounter with a microtubule is 600 nm, which reflects a similar to 1% probability of detachment per mechanical cycle, Surprisingly, processive movement could still be observed at salt concentrations as high as 0.3 M NaCl. Truncated kinesin molecules having only a single motor domain do not show detectable processive movement, which is consistent with a model in which kinesin's two force-generating heads operate by a hand-over-hand mechanism.	UNIV CALIF SAN FRANCISCO,HOWARD HUGHES MED INST,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT PHARMACOL,SAN FRANCISCO,CA 94143; OSAKA UNIV,DEPT BIOPHYS ENGN,TOYONAKA,OSAKA 560,JAPAN	Howard Hughes Medical Institute; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Osaka University	Vale, RD (corresponding author), RES DEV CORP JAPAN,ERATO,YANAGIDA BIOMOTRON PROJECT,SENBA HIGASHI 2-4-14,MINO,OSAKA 562,JAPAN.		Funatsu, Takashi/Q-1404-2015; Yanagida, Toshio/D-1919-2009	Funatsu, Takashi/0000-0002-9656-8308; 	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P01AR042895] Funding Source: NIH RePORTER; Howard Hughes Medical Institute Funding Source: Medline; NIAMS NIH HHS [P01 AR042895, P01 AR042895-040005] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); Howard Hughes Medical Institute(Howard Hughes Medical Institute); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BERLINER E, 1995, NATURE, V373, P718, DOI 10.1038/373718a0; BLOCK SM, 1990, NATURE, V348, P348, DOI 10.1038/348348a0; BLOOM G, 1994, MOTOR PROTEINS, V1; CORREIA JJ, 1995, BIOCHEMISTRY-US, V34, P4898, DOI 10.1021/bi00014a047; FUNATSU T, 1995, NATURE, V374, P555, DOI 10.1038/374555a0; GILBERT SP, 1995, NATURE, V373, P671, DOI 10.1038/373671a0; GILBERT SP, 1993, BIOCHEMISTRY-US, V32, P4677, DOI 10.1021/bi00068a028; HACKNEY DD, 1994, P NATL ACAD SCI USA, V91, P6865, DOI 10.1073/pnas.91.15.6865; HACKNEY DD, 1995, NATURE, V377, P448, DOI 10.1038/377448a0; HARADA Y, 1990, J MOL BIOL, V216, P49, DOI 10.1016/S0022-2836(05)80060-9; HIROKAWA N, 1989, CELL, V56, P867, DOI 10.1016/0092-8674(89)90691-0; HUANG TG, 1994, J BIOL CHEM, V269, P16493; HUANG TG, 1994, J BIOL CHEM, V269, P16502; HYMAN A, 1990, METHOD ENZYMOL, V196, P303; ITAKURA S, 1993, BIOCHEM BIOPH RES CO, V196, P1504, DOI 10.1006/bbrc.1993.2422; KAMIYA R, 1991, J CELL BIOL, V112, P441, DOI 10.1083/jcb.112.3.441; NAVONE F, 1992, J CELL BIOL, V117, P1263, DOI 10.1083/jcb.117.6.1263; SCHNAPP BJ, 1990, P NATL ACAD SCI USA, V87, P10053, DOI 10.1073/pnas.87.24.10053; SHIMIZU T, 1995, BIOCHEMISTRY-US, V34, P13259, DOI 10.1021/bi00040a042; STEWART RJ, 1993, P NATL ACAD SCI USA, V90, P5209, DOI 10.1073/pnas.90.11.5209; SVOBODA K, 1993, NATURE, V365, P721, DOI 10.1038/365721a0; VALE RD, 1985, CELL, V42, P39, DOI 10.1016/S0092-8674(85)80099-4; VALE RD, 1994, J BIOL CHEM, V269, P23769; YANG JT, 1989, CELL, V56, P879, DOI 10.1016/0092-8674(89)90692-2	24	579	617	0	108	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	APR 4	1996	380	6573					451	453		10.1038/380451a0	http://dx.doi.org/10.1038/380451a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	UD590	8602245	Green Accepted			2022-12-28	WOS:A1996UD59000065
J	Hanks, GW; deConno, F; Ripamonti, C; Ventafridda, V; Hanna, M; McQuay, HJ; Mercadante, S; Meynadier, J; Poulain, P; Casas, JRI; Sawe, J; Twycross, RG; Vainio, A; Zech, D				Hanks, GW; deConno, F; Ripamonti, C; Ventafridda, V; Hanna, M; McQuay, HJ; Mercadante, S; Meynadier, J; Poulain, P; Casas, JRI; Sawe, J; Twycross, RG; Vainio, A; Zech, D			Fortnightly review - Morphine in cancer pain: Modes of administration	BRITISH MEDICAL JOURNAL			English	Article							TRANSDERMAL FENTANYL; ORAL MORPHINE; BIOAVAILABILITY; CONTROVERSIES; MANAGEMENT; TABLETS; POTENCY		IST NAZL TUMORI,I-20133 MILAN,ITALY; UNIV LONDON,KINGS COLL SCH MED & DENT,LONDON,ENGLAND; UNIV OXFORD,OXFORD PAIN RELIEF UNIT,OXFORD,ENGLAND; SOC ASSISTENZA MALATO ONCOL TERMINALE,PALERMO,ITALY; CTR OSCAR LAMBRET,F-59020 LILLE,FRANCE; INST GUSTAVE ROUSSY,VILLEJUIF,FRANCE; HOSP SANTA CREU,BARCELONA,SPAIN; HUDDINGE UNIV HOSP,S-14186 HUDDINGE,SWEDEN; UNIV OXFORD,SIR MICHAEL SOBELL HOUSE,OXFORD,ENGLAND; HELSINKI UNIV,CENT HOSP,HELSINKI,FINLAND; UNIV COLOGNE,ANASTHESIOL KLIN,COLOGNE,GERMANY	Fondazione IRCCS Istituto Nazionale Tumori Milan; University of London; King's College London; University of Oxford; UNICANCER; Centre Oscar Lambret; UNICANCER; Gustave Roussy; Karolinska Institutet; University of Oxford; University of Helsinki; Helsinki University Central Hospital; University of Cologne	Hanks, GW (corresponding author), BRISTOL ONCOL CTR,DEPT PALLIAT MED,BRISTOL BS2 8ED,AVON,ENGLAND.		Ripamonti, Carla I/C-4557-2017	Ripamonti, Carla I/0000-0001-5495-5054				[Anonymous], [No title captured]; CHRUBASIK J, 1988, BRIT J ANAESTH, V61, P228, DOI 10.1093/bja/61.2.228; DECONNO F, 1995, J CLIN ONCOL, V13, P1004, DOI 10.1200/JCO.1995.13.4.1004; DOVER SB, 1987, BRIT MED J, V294, P553, DOI 10.1136/bmj.294.6571.553; FINN JW, 1993, J CLIN ONCOL, V11, P967, DOI 10.1200/JCO.1993.11.5.967; FOLEY KM, 1986, ADV PAIN RES THER, V8, P3; HANKS GW, 1989, CANCER, V63, P2378, DOI 10.1002/1097-0142(19890601)63:11<2378::AID-CNCR2820631150>3.0.CO;2-8; HANKS GW, 1987, LANCET, V2, P723; HANKS GW, 1982, LANCET, V2, P1410; HOGAN Q, 1991, PAIN, V46, P271, DOI 10.1016/0304-3959(91)90110-J; INTURRISI CE, 1993, OXFORD TXB PALLIATIV, P166; Kaiko R F, 1988, J Palliat Care, V4, P64; KAIKO RF, 1989, ROYAL SOC MED INT C, V149, P235; KALSO E, 1990, CLIN PHARMACOL THER, V47, P639, DOI 10.1038/clpt.1990.85; LASAGNA L, 1965, NARCOTICS, P53; LESLIE ST, 1980, BRIT J CLIN PHARMACO, V9, P531, DOI 10.1111/j.1365-2125.1980.tb05858.x; McQuay H J, 1990, J Pain Symptom Manage, V5, P75, DOI 10.1016/S0885-3924(05)80019-3; MCQUAY HJ, 1987, LANCET, V2, P1458; PLUMMER JL, 1991, PAIN, V44, P215, DOI 10.1016/0304-3959(91)90088-F; Portenoy R K, 1990, J Pain Symptom Manage, V5, P307, DOI 10.1016/0885-3924(90)90047-N; PORTENOY RK, 1993, ANESTHESIOLOGY, V78, P36, DOI 10.1097/00000542-199301000-00007; PORTENOY RK, 1993, OXFORD TXB PALLIATIV, P187; POULAIN P, 1988, BRIT J ANAESTH, V61, P569, DOI 10.1093/bja/61.5.569; Regnard C, 1987, PALLIATIVE MED, V1, P107; Ripamonti C, 1991, J Palliat Care, V7, P30; SAWE J, 1983, EUR J CLIN PHARMACOL, V24, P537, DOI 10.1007/BF00609900; SAWE J, 1986, CLIN PHARMACOKINET, V11, P87; SCHUG SA, 1992, J PAIN SYMPTOM MANAG, V7, P259, DOI 10.1016/0885-3924(92)90059-Q; SJOBERG M, 1991, ACTA ANAESTH SCAND, V35, P30; SWARM RA, 1993, OXFORD TXB PALLIATIV, P204; Twycross R G, 1988, J Palliat Care, V4, P67; TWYCROSS RG, 1988, CANCER SURV, V7, P29; TWYCROSS RG, 1984, J ROY COLL PHYS LOND, V18, P32; TWYCROSS RG, 1994, PAIN RELIEF ADV CANC, P255; TWYCROSS RG, 1983, SYMPTOM CONTROL FAR, P190; VAINIO A, 1995, LANCET, V346, P667, DOI 10.1016/S0140-6736(95)92281-4; VENTAFRIDDA V, 1987, CANCER, V59, P851; ZECH DFJ, 1995, PAIN, V63, P65, DOI 10.1016/0304-3959(95)00017-M; ZECH DFJ, 1992, PAIN, V50, P293, DOI 10.1016/0304-3959(92)90034-9	39	139	141	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 30	1996	312	7034					823	826						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UD378	8608293				2022-12-28	WOS:A1996UD37800029
J	Schulz, KF; Grimes, DA; Altman, DG; Hayes, RJ				Schulz, KF; Grimes, DA; Altman, DG; Hayes, RJ			Blinding and exclusions after allocation in randomised controlled trials: Survey of published parallel group trials in obstetrics and gynaecology	BRITISH MEDICAL JOURNAL			English	Article							CLINICAL-TRIALS	Objective-To assess the methodological quality of approaches to blinding and to handling of exclusions as reported in randomised trials from one medical specialty. Design-Survey of published, parallel group randomised controlled trials. Data sources-A random sample of 110 reports in which allocation was described as randomised from the 1990 and 1991 volumes of four journals of obstetrics and gynaecology. Main outcome measures-The adequacy of the descriptions of double blinding and exclusions after randomisation. Results-Though 31 trials reported being double blind, about twice as many could have been. Of the 31 trials only eight (26%) provided information on the protection of the allocation schedule and only five (16%) provided some written assurance of successful implemention of double blinding. Of 38 trials in which the authors provided sufficient information for readers to infer that no exclusions after randomisation had occurred, six (16%) reported adequate allocation concealment and none stated that an intention to treat analysis had been performed. That compared with 14 (27%) and six (12%), respectively, for the 52 trials that reported exclusions. Conclusions-Investigators could have double blinded more often. When they did double blind, they reported poorly and rarely evaluated it. Paradoxically, trials that reported exclusions seemed generally of a higher methodological standard than those that had no apparent exclusions. Exclusions from analysis may have been made in some of the trials in which no exclusions were reported. Editors and readers of reports of randomised trials should understand that flawed reporting of exclusions may often provide a misleading impression of the quality of the trial.	UNIV CALIF SAN FRANCISCO,DEPT OBSTET GYNECOL & REPROD SCI,SAN FRANCISCO,CA 94110; IMPERIAL CANC RES FUND,MED STAT GRP,CTR STAT MED,MED STAT LAB,OXFORD OX3 7LF,ENGLAND; LONDON SCH HYG & TROP MED,TROP HLTH EPIDEMIOL UNIT,LONDON WC1E 9HT,ENGLAND	University of California System; University of California San Francisco; University of Oxford; University of London; London School of Hygiene & Tropical Medicine	Schulz, KF (corresponding author), CTR DIS CONTROL & PREVENT,DIV SEXUALLY TRANSMITTED DIS PREVENT,ATLANTA,GA 30333, USA.			Hayes, Richard/0000-0002-1729-9892				Altman D.G., 1991, PRACTICAL STAT MED R; ALTMAN DG, 1990, LANCET, V335, P149, DOI 10.1016/0140-6736(90)90014-V; ARNETT RM, 1990, AM J OBSTET GYNECOL, V163, P1074, DOI 10.1016/0002-9378(90)91130-5; BULPITT CJ, 1983, RANDOMISED CONTROLLE; CHALMERS I, 1989, EFFECTIVE CARE PREGN, V1, P39; CHALMERS TC, 1987, STAT MED, V6, P315, DOI 10.1002/sim.4780060320; CHALMERS TC, 1981, CONTROL CLIN TRIALS, V2, P31, DOI 10.1016/0197-2456(81)90056-8; De Jonge H, 1983, Stat Med, V2, P155, DOI 10.1002/sim.4780020209; Dean A.G., 1994, EPI INFO VERSION 6 W; DERSIMONIAN R, 1982, NEW ENGL J MED, V306, P1332, DOI 10.1056/NEJM198206033062204; GXTZSCHE PC, 1989, EUR J CLIN PHARMACOL, V36, P429; GXTZSCHE PC, 1989, CONTROL CLIN TRIALS, V10, P31; KARLOWSKI TR, 1975, JAMA-J AM MED ASSOC, V231, P1038, DOI 10.1001/jama.231.10.1038; LEWIS JA, 1993, BRIT J CANCER, V68, P647, DOI 10.1038/bjc.1993.402; MAY GS, 1981, CIRCULATION, V4, P942; MEINERT CL, 1984, CONTROL CLIN TRIALS, V5, P328, DOI 10.1016/S0197-2456(84)80013-6; MOSTELLER F, 1980, CONTROL CLIN TRIALS, V1, P37, DOI 10.1016/S0197-2456(80)80006-7; POCOCK SJ, 1982, STATISTICIAN, V31, P1; Pocock SJ., 2013, CLIN TRIALS PRACTICA; SACKETT DL, 1979, NEW ENGL J MED, V301, P1410, DOI 10.1056/NEJM197912273012602; SCHULZ KF, 1994, JAMA-J AM MED ASSOC, V272, P125, DOI 10.1001/jama.272.2.125; SCHULZ KF, 1995, JAMA-J AM MED ASSOC, V273, P408, DOI 10.1001/jama.273.5.408; SONIS J, 1994, J FAM PRACTICE, V39, P225; WILLIAMS DH, 1994, CONTROL CLIN TRIALS, V15, P294, DOI 10.1016/0197-2456(94)90045-0; 1994, JAMA-J AM MED ASSOC, V272, P1926	25	106	109	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 23	1996	312	7033					742	744						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	UC166	8605459				2022-12-28	WOS:A1996UC16600025
J	Lidbrink, E; Elfving, J; Frisell, J; Jonsson, E				Lidbrink, E; Elfving, J; Frisell, J; Jonsson, E			Neglected aspects of false positive findings of mammography in breast cancer screening: Analysis of false positive cases from the Stockholm trial	BRITISH MEDICAL JOURNAL			English	Article							COST-EFFECTIVENESS; MORTALITY; WOMEN	Objectives-To examine the implications of false positive results of mammography in terms of the time lag from screening and complete mammography to the point when women with false positive results are declared free of cancer; the extra examinations, biopsies, and check ups required; and the cost of these extra procedures. Design-Review of women with false positive results from the Stockholm mammography screening trial. Setting-Department of Oncology, South Hospital, Stockholm. Subjects-352 and 150 women with false positive results of mammography from the first and second screening rounds of the Stockholm trial. Main outcome measures-Extra examinations and investigations required and the cost of these procedures. Results-The 352 women from the first screening round made 1112 visits to the physician and had 397 fine needle aspiration biopsies, 187 mammograms, and 90 surgical biopsies before being declared free of cancer. After six months 64% of the women (219/342) were declared cancer free. The 150 women in the second round made 427 visits to the physician and had 145 fine needle aspiration biopsies, 70 mammograms, and 28 surgical biopsies, and after six months 73% (107/147) were declared cancer free. The follow up costs of the false positive screening results were Kr2.54m (pound 250 000) in the first round and Kr0.85m (pound 84 000) in the second round. Women under 50 accounted for about 41% of these costs. Conclusions-The examinations and investigations carried out after false positive mammography-especially in women under 50-and the cost of these procedures are a neglected but substantial problem.	SODER SJUKHUSET,STOCKHOLM,SWEDEN; SWEDISH COUNCIL TECHNOL ASSESSMENT HLTH CARE,STOCKHOLM,SWEDEN; HUDDINGE UNIV HOSP,KAROLINSKA INST,DEPT MED,STOCKHOLM,SWEDEN	Sodersjukhuset Hospital; Karolinska Institutet								ANDERSSON I, 1988, BRIT MED J, V297, P943, DOI 10.1136/bmj.297.6654.943; ANDERSSON I, 1981, RADIOLOGY, V138, P59, DOI 10.1148/radiology.138.1.7455098; BROWN ML, 1992, J GERONTOL, V47, P51; BROWN ML, 1992, CANCER-AM CANCER SOC, V69, P1963, DOI 10.1002/1097-0142(19920401)69:7+<1963::AID-CNCR2820691717>3.0.CO;2-0; COCKBURN J, 1992, SOC SCI MED, V34, P1129, DOI 10.1016/0277-9536(92)90286-Y; DEKONING HJ, 1991, INT J CANCER, V49, P531, DOI 10.1002/ijc.2910490410; DEVITT JE, 1989, LANCET, V2, P1257; EDDY DM, 1988, JAMA-J AM MED ASSOC, V259, P1512, DOI 10.1001/jama.259.10.1512; Elixhauser A, 1991, Int J Technol Assess Health Care, V7, P604; Erichsen G G, 1990, Nord Med, V105, P64; FENTIMAN IS, 1988, LANCET, V1, P1041; FRISELL J, 1991, BREAST CANCER RES TR, V18, P49, DOI 10.1007/BF01975443; FRISELL J, 1989, BREAST CANCER RES TR, V13, P79, DOI 10.1007/BF01806553; FRISELL J, 1986, BREAST CANCER RES TR, V8, P45, DOI 10.1007/BF01805924; GRAM IT, 1990, BRIT J CANCER, V62, P1018, DOI 10.1038/bjc.1990.430; KOPANS DB, 1987, AJR AM J ROENTGENOL, V150, P785; Lerman C E, 1993, Oncology (Williston Park), V7, P67; LIDBRINK EK, 1994, ACTA ONCOL, V33, P353, DOI 10.3109/02841869409098428; MCLELLAND R, 1992, RADIOL CLIN N AM, V30, P235; MILLER AB, 1993, AM J PREV MED, V9, P175, DOI 10.1016/S0749-3797(18)30734-7; MUSHLIN AI, 1992, CANCER, V69, P1957, DOI 10.1002/1097-0142(19920401)69:7+<1957::AID-CNCR2820691716>3.0.CO;2-T; NIELSEN M, 1984, CANCER, V43, P107; NYSTROM L, 1993, LANCET, V341, P973, DOI 10.1016/0140-6736(93)91067-V; OKUBO I, 1991, CANCER, V67, P2021, DOI 10.1002/1097-0142(19910415)67:8<2021::AID-CNCR2820670802>3.0.CO;2-L; SHAPIRO S, 1982, JNCI-J NATL CANCER I, V69, P349; SHAPIRO S, 1971, J AMER MED ASSOC, V215, P1777; Skrabanek P, 1991, Int J Technol Assess Health Care, V7, P633; TABAR L, 1992, RADIOL CLIN N AM, V30, P187; TABAR L, 1981, RADIOLOGY, V138, P219, DOI 10.1148/radiology.138.1.7005939; TABAR L, 1985, LANCET, V1, P829, DOI 10.1016/S0140-6736(85)92204-4; Van Der Maas PJ, 1989, INT J CANCER, V43, P1055, DOI 10.1002/ijc.2910430617; WRIGHT CJ, 1986, SURGERY, V100, P594; 1986, MAMMOGRAFISCREENING, V3, P1	33	87	88	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 3	1996	312	7026					273	276						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TU507	8611781				2022-12-28	WOS:A1996TU50700019
